PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Waiter, J; Newport, JW				Waiter, J; Newport, JW			Regulation of replicon size in Xenopus egg extracts	SCIENCE			English	Article							DNA-REPLICATION; INITIATION; CHROMOSOMES; EMBRYOS; INVITRO; ORIGINS; NUCLEI; SYSTEM; UNITS	Once a specific number of cells have been produced in the early Xenopus laevis embryo, replicon size during the S phase of the cell cycle increases. Here, it is reported that similar increase in replicon size occurred when the concentration of nuclei in replication-competent Xenopus egg extracts exceeded a critical threshold. In this system, the origin recognition complex (ORC) did not become stoichiometrically limiting for initiation, and similar amounts of this complex bound to chromatin regardless of replicon size. These data suggest that in early development, an unidentified factor controls how many preformed ORC-DNA complexes initiate DNA replication.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego				Walter, Johannes/0000-0002-4186-7570	PHS HHS [1F32FM17980-01, R01FM44656] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1987, EMBO J, V6, P1997, DOI 10.1002/j.1460-2075.1987.tb02463.x; BLUMENTH.AB, 1973, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/SQB.1974.038.01.024; CALLAN HG, 1972, PROC R SOC SER B-BIO, V181, P19, DOI 10.1098/rspb.1972.0039; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; COZZARELLI NR, 1977, ANNU REV BIOCHEM, V46, P641, DOI 10.1146/annurev.bi.46.070177.003233; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2	21	145	147	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1997	275	5302					993	995		10.1126/science.275.5302.993	http://dx.doi.org/10.1126/science.275.5302.993			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020085				2022-12-01	WOS:A1997WH38800050
J	Studer, A; Hadida, S; Ferritto, R; Kim, SY; Jeger, P; Wipf, P; Curran, DP				Studer, A; Hadida, S; Ferritto, R; Kim, SY; Jeger, P; Wipf, P; Curran, DP			Fluorous synthesis: A fluorous-phase strategy for improving separation efficiency in organic synthesis	SCIENCE			English	Article							BIGINELLI DIHYDROPYRIMIDINE SYNTHESIS; COMBINATORIAL CHEMISTRY; DRUG DISCOVERY; LIBRARIES	Recovery and purification difficulties can limit the yield and utility of otherwise successful organic synthesis strategies. A ''fluorous synthesis'' approach is outlined in which organic molecules are rendered soluble in fluorocarbon solvents by attachment of a suitable fluorocarbon group. Fluorocarbon solvents are usually immiscible in organic solutions, and fluorous molecules partition out of an organic phase and into a fluorous phase in a standard liquid-liquid extraction. Simple yet substantive separations of organic reaction mixtures are achieved without resorting to chromatography. Because fluorous synthesis combines in many respects the favorable purification features of solid-phase synthesis with the favorable reaction, identification, and analysis features of traditional organic synthesis,it should prove valuable in the automated synthesis of libraries of individual pure organic compounds.	UNIV PITTSBURGH,DEPT CHEM,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Wipf, Peter/AAG-1771-2021	Wipf, Peter/0000-0001-7693-5863				Armstrong RW, 1996, ACCOUNTS CHEM RES, V29, P123, DOI 10.1021/ar9502083; Biginelli P., 1893, GAZZ CHIM ITAL, V23, P360; BIRR C, 1978, ASPECTS MERRIFIELD P; Boger DL, 1996, J AM CHEM SOC, V118, P2109, DOI 10.1021/ja9539711; Booth R A, UNPUB; BOUTEVIN B, 1993, J FLUORINE CHEM, V60, P211, DOI 10.1016/S0022-1139(00)80035-4; BROWN D, 1996, J AM CHEM SOC, V118, P6331; Caramella P, 1984, 13 DIPOLAR CYCLOADDI, V1, P291; CARELL T, 1995, CHEM BIOL, V2, P171, DOI 10.1016/1074-5521(95)90072-1; Cheng S, 1996, J AM CHEM SOC, V118, P2567, DOI 10.1021/ja9530681; Curran DP, 1996, J AM CHEM SOC, V118, P2531, DOI 10.1021/ja953287m; Curran DP, 1996, J ORG CHEM, V61, P6480, DOI 10.1021/jo961309x; CURRAN DP, 1996, CHEMTRACTS ORG CHEM, V9, P75; Dressman BA, 1996, TETRAHEDRON LETT, V37, P937, DOI 10.1016/0040-4039(95)02395-X; Ellman JA, 1996, ACCOUNTS CHEM RES, V29, P132, DOI 10.1021/ar950190w; Fruchtel JS, 1996, ANGEW CHEM INT EDIT, V35, P17, DOI 10.1002/anie.199600171; Gait M. J., 1984, OLIGONUCLEOTIDE SYNT; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GALLOP MA, 1994, J MED CHEM, V37, P1386; Gordeev MF, 1996, J ORG CHEM, V61, P924, DOI 10.1021/jo951706s; Gordeev MF, 1996, TETRAHEDRON LETT, V37, P4643, DOI 10.1016/0040-4039(96)00923-9; Gordon EM, 1996, ACCOUNTS CHEM RES, V29, P144, DOI 10.1021/ar950170u; GREENE TW, 1991, PROTECTIVE GROUPS OR; Hamper BC, 1996, TETRAHEDRON LETT, V37, P3671, DOI 10.1016/0040-4039(96)00659-4; HAN HS, 1995, P NATL ACAD SCI USA, V92, P6419, DOI 10.1073/pnas.92.14.6419; Hermkens PHH, 1996, TETRAHEDRON, V52, P4527, DOI 10.1016/0040-4020(96)00216-5; HILDEBRAND JH, 1949, J AM CHEM SOC, V71, P22, DOI 10.1021/ja01169a008; HORVATH IT, 1994, SCIENCE, V266, P72, DOI 10.1126/science.266.5182.72; HOUK KN, 1984, J AM CHEM SOC, V106, P3880, DOI 10.1021/ja00325a040; Hudlicky M., 1992, CHEM ORGANIC FLUORIN; HUTCHINS SM, 1995, TETRAHEDRON LETT, V36, P2583, DOI 10.1016/0040-4039(95)00345-D; Kaldor SW, 1996, TETRAHEDRON LETT, V37, P7193, DOI 10.1016/0040-4039(96)01636-X; KAPPE CO, 1993, TETRAHEDRON, V49, P6937; MITSCHER LA, 1995, CHEMTRACTS ORG CHEM, V8, P19; Mjalli AMM, 1996, TETRAHEDRON LETT, V37, P2943, DOI 10.1016/0040-4039(96)00365-6; Rinnova M, 1996, COLLECT CZECH CHEM C, V61, P171, DOI 10.1135/cccc19960171; SCOTT RL, 1948, J AM CHEM SOC, V70, P4090, DOI 10.1021/ja01192a036; SISIDO K, 1971, J ORGANOMET CHEM, V33, P337, DOI 10.1016/S0022-328X(00)87417-3; Tempest PA, 1996, ANGEW CHEM INT EDIT, V35, P640, DOI 10.1002/anie.199606401; TERRETT NK, 1995, TETRAHEDRON, V51, P8135, DOI 10.1016/0040-4020(95)00467-M; Thompson LA, 1996, CHEM REV, V96, P555, DOI 10.1021/cr9402081; UGI I, 1982, ANGEW CHEM INT EDIT, V21, P810, DOI 10.1002/anie.198208101; WIPF P, 1995, TETRAHEDRON LETT, V36, P7819, DOI 10.1016/0040-4039(95)01660-A; ZHU DW, 1993, SYNTHESIS-STUTTGART, P953	44	492	537	13	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					823	826		10.1126/science.275.5301.823	http://dx.doi.org/10.1126/science.275.5301.823			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012347				2022-12-01	WOS:A1997WG77700058
J	Naatanen, R; Lehtokoski, A; Lennes, M; Cheour, M; Huotilainen, M; Iivonen, A; Vainio, M; Alku, P; Ilmoniemi, RJ; Luuk, A; Allik, J; Sinkkonen, J; Alho, K				Naatanen, R; Lehtokoski, A; Lennes, M; Cheour, M; Huotilainen, M; Iivonen, A; Vainio, M; Alku, P; Ilmoniemi, RJ; Luuk, A; Allik, J; Sinkkonen, J; Alho, K			Language-specific phoneme representations revealed by electric and magnetic brain responses	NATURE			English	Article							LINGUISTIC EXPERIENCE; SENSORY MEMORY; PERCEPTION; INFANTS	There is considerable debate about whether the early processing of sounds depends on whether they form part of speech. Proponents of such speech specificity postulate the existence of language-dependent memory traces, which are activated in the processing of speech(1-3) but not when equally complex, acoustic non-speech stimuli are processed. Here we report the existence of these traces in the human brain, We presented to Finnish subjects the Finnish phoneme prototype /e/ as the frequent stimulus, and other Finnish phoneme prototypes or a non-prototype (the Estonian prototype /(o) over tilde/) as the infrequent stimulus. We found that the brain's automatic change-detection response, reflected electrically as the mismatch negativity (MMN)(4-10), was enhanced when the infrequent, deviant stimulus was a prototype (the Finnish /o/) relative to when it was a non-prototype (the Estonian /(o) over tilde/). These phonemic traces, revealed by MMN, are language-specific, as /(o) over tilde/ caused enhancement of MMN in Estonians. Whole-head magnetic recordings(11,12) located the source of this native-language, phoneme-related response enhancement, and thus the language-specific memory traces, in the auditory cortex of the left hemisphere.	UNIV HELSINKI, DEPT PHONET, FIN-00014 HELSINKI, FINLAND; UNIV HELSINKI, CENT HOSP, MED ENGN CTR, BIOMAG LAB, FIN-00014 HELSINKI, FINLAND; UNIV TURKU, DEPT APPL PHYS ELECT & INFORMAT TECHNOL, SF-20500 TURKU, FINLAND; HELSINKI UNIV TECHNOL, ACOUST LAB, FIN-02150 ESPOO, FINLAND; TARTU STATE UNIV, DEPT PSYCHOL, EE-202400 TARTU, ESTONIA	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Turku; Aalto University; University of Tartu	Naatanen, R (corresponding author), UNIV HELSINKI, DEPT PSYCHOL, COGNIT BRAIN RES UNIT, FIN-00014 HELSINKI, FINLAND.		Ilmoniemi, Risto/E-9704-2012; Allik, Jüri/D-5609-2009; Alho, Kimmo/G-2997-2013; Lennes, Mietta/M-2197-2016; Alku, Paavo/E-2400-2012; Allik, Jüri/N-3038-2019	Ilmoniemi, Risto/0000-0002-3340-2618; Allik, Jüri/0000-0002-8358-4747; Alho, Kimmo/0000-0001-8563-2792; Lennes, Mietta/0000-0003-4735-3017; Allik, Jüri/0000-0002-8358-4747; Huotilainen, Minna/0000-0002-7251-6984; Vainio, Martti/0000-0003-2570-0196; Alku, Paavo/0000-0002-8173-9418				AALTONEN O, IN PRESS J ACOUST SO; Alho K, 1996, PSYCHOPHYSIOLOGY, V33, P369, DOI 10.1111/j.1469-8986.1996.tb01061.x; ALKU P, 1992, SPEECH COMMUN, V11, P109, DOI 10.1016/0167-6393(92)90005-R; ANLANKO R, 1993, NEUROREPORT, V2, P1356; Fant G., 1960, ACOUSTIC THEORY SPEE; GIARD MH, 1995, J COGNITIVE NEUROSCI, V7, P133, DOI 10.1162/jocn.1995.7.2.133; HAMALAINEN M, 1993, REV MOD PHYS, V65, P413, DOI 10.1103/RevModPhys.65.413; Hari R., 1990, ADV AUDIOL, V6, P222; IIVONEN A, 1995, PHONETICA, V52, P221, DOI 10.1159/000262174; KNUUTILA JET, 1993, IEEE T MAGN, V29, P3315, DOI 10.1109/20.281163; Kraus N, 1996, SCIENCE, V273, P971, DOI 10.1126/science.273.5277.971; KUHL PK, 1993, J PHONETICS, V21, P125; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; KUHL PK, 1991, PERCEPT PSYCHOPHYS, V50, P93, DOI 10.3758/BF03212211; Levanen S, 1996, CEREB CORTEX, V6, P288, DOI 10.1093/cercor/6.2.288; LIBERMAN AM, 1957, J EXP PSYCHOL, V54, P358, DOI 10.1037/h0044417; LIIV G, 1970, SOV FINNO UGRIC STUD, V6, P7; NAATANEN R, 1978, ACTA PSYCHOL, V42, P313, DOI 10.1016/0001-6918(78)90006-9; NAATANEN R, 1994, TRENDS NEUROSCI, V17, P389, DOI 10.1016/0166-2236(94)90048-5; NAATANEN R, 1995, EAR HEARING, V16, P6; Naatanen R, 1995, EEG CL N SU, P179; Naatanen R., 1992, ATTENTION BRAIN FUNC; TIITINEN H, 1994, NATURE, V372, P90, DOI 10.1038/372090a0; WIIK K, 1965, ANN U TURKU, V94, P1	24	898	914	10	187	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 30	1997	385	6615					432	434		10.1038/385432a0	http://dx.doi.org/10.1038/385432a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WF007	9009189				2022-12-01	WOS:A1997WF00700051
J	Lebwohl, M				Lebwohl, M			New treatments for alopecia areata	LANCET			English	Editorial Material											Lebwohl, M (corresponding author), CUNY MT SINAI SCH MED,DEPT DERMATOL,NEW YORK,NY 10029, USA.							Schuttelaar ML, 1996, BRIT J DERMATOL, V135, P581, DOI 10.1046/j.1365-2133.1996.d01-1044.x; Taylor CR, 1995, BRIT J DERMATOL, V133, P914, DOI 10.1111/j.1365-2133.1995.tb06925.x; Vandenbark A A, 1995, J Invest Dermatol, V104, p10S; Weise K, 1996, DERMATOLOGY, V192, P129, DOI 10.1159/000246337	4	5	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					222	223		10.1016/S0140-6736(05)64857-X	http://dx.doi.org/10.1016/S0140-6736(05)64857-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014905				2022-12-01	WOS:A1997WD90600005
J	Huang, XM; Molema, G; King, S; Watkins, L; Edgington, TS; Thorpe, PE				Huang, XM; Molema, G; King, S; Watkins, L; Edgington, TS; Thorpe, PE			Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; SOLID TUMORS; EXPRESSION; SURFACE; PROCOAGULANT; RECEPTORS; ANTIGEN; CANCER; CELLS	Selective occlusion of tumor vasculature was tested as a therapy for solid tumors in a mouse model. The formation of blood clots (thrombosis) within the tumor Vessels was initiated by targeting the cell surface domain of human tissue factor, by means of a bispecific antibody, to an experimentally induced marker on tumor vascular endothelial cells. This truncated form of tissue factor (tTF) had limited ability to initiate thrombosis when free in the circulation, but became an effective and selective thrombogen when targeted to tumor endothelial cells. Intravenous administration of the antibody-tTF complex to mice with large neuroblastomas resulted incomplete tumor regressions in 38 percent of the mice.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HAMON CTR THERAPEUT ONCOL RES, DALLAS, TX 75235 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Scripps Research Institute; Scripps Research Institute				Molema, Grietje/0000-0002-4147-6676	NATIONAL CANCER INSTITUTE [R01CA059569, R01CA054168] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA59569, R01-CA54168] Funding Source: Medline; NHLBI NIH HHS [P01-HL16411] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BRENNAN M, 1985, SCIENCE, V229, P81, DOI 10.1126/science.3925553; BROWN LF, 1993, CANCER RES, V53, P4727; BRULAND OS, 1988, CANCER RES, V48, P5302; BURROWS FJ, 1993, P NATL ACAD SCI USA, V90, P8996, DOI 10.1073/pnas.90.19.8996; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; BURROWS FJ, 1994, PHARMACOL THERAPEUT, V64, P155, DOI 10.1016/0163-7258(94)90037-X; BURROWS FJ, 1992, CANCER RES, V52, P595; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DENEKAMP J, 1990, CANCER METAST REV, V9, P267, DOI 10.1007/BF00046365; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Folkman J, 1992, Semin Cancer Biol, V3, P65; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; KING SF, UNPUB; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; MURRAY JC, 1991, INT J RADIAT BIOL, V60, P273, DOI 10.1080/09553009114551991; PABORSKY LR, 1991, J BIOL CHEM, V266, P21911; PAULUS W, 1991, BRIT J CANCER, V63, P367, DOI 10.1038/bjc.1991.87; PLATE KH, 1993, CANCER RES, V53, P5822; RETTIG WJ, 1992, P NATL ACAD SCI USA, V89, P10832, DOI 10.1073/pnas.89.22.10832; RUF W, 1991, J BIOL CHEM, V266, P2158; SCHLINGEMANN RO, 1990, LAB INVEST, V62, P690; STONE MJ, 1995, BIOCHEM J, V310, P605, DOI 10.1042/bj3100605; TRUCCO M, 1981, IMMUNOLOGICAL METHOD, V2, P1; WANG JM, 1993, INT J CANCER, V54, P363, DOI 10.1002/ijc.2910540303; ZACHARSKI LR, 1993, JNCI-J NATL CANCER I, V85, P1225, DOI 10.1093/jnci/85.15.1225	28	403	492	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					547	550		10.1126/science.275.5299.547	http://dx.doi.org/10.1126/science.275.5299.547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999802				2022-12-01	WOS:A1997WE25700049
J	Lee, FS; Hagler, J; Chen, ZJJ; Maniatis, T				Lee, FS; Hagler, J; Chen, ZJJ; Maniatis, T			Activation of the I kappa B alpha kinase complex by MEKK1, a kinase of the JNK pathway	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE; C-JUN; ESCHERICHIA-COLI; VIRUS INDUCTION; MAMMALIAN-CELLS; BETA GENE; PHOSPHORYLATION; DOMAIN; PROTEOLYSIS	Both NF-kappa B and c-Jun are activated by cytokines such as TNF-alpha and by stresses such as UV irradiation. A key step in the activation of NF-kappa B is the phosphorylation of its inhibitor, I kappa B alpha, by a ubiquitination-inducible multiprotein kinase complex (I kappa B alpha kinase). A central kinase in the c-Jun activation pathway is mitogen-activated protein kinase/ERK kinase kinase-1 (MEKK1). Here, we show that MEKK1 induces the site-specific phosphorylation of I kappa B alpha in vivo and, most strikingly, can directly activate the I kappa B alpha kinase complex in vitro. Thus, MEKK1 is a critical component of both the c-Jun and NF-kappa B stress response pathways. Since the I kappa B alpha kinase complex can be independently activated by ubiquitination or MEKK1-dependent phosphorylation, it may be an integrator of multiple signal transduction pathways leading to the activation of NF-kappa B.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138; PROSCRIPT INC,CAMBRIDGE,MA 02139	Harvard University				Lee, Frank/0000-0003-2511-1834	NIAID NIH HHS [K08 AI01241, AI20642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001241, R01AI020642, R37AI020642] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHOI KY, 1994, CELL, V78, P499; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Sambrook J., 1989, MOL CLONING LAB MANU; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THEVENIN C, 1990, New Biologist, V2, P793; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAN MH, 1994, NATURE, V372, P798; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x	47	654	671	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1997	88	2					213	222		10.1016/S0092-8674(00)81842-5	http://dx.doi.org/10.1016/S0092-8674(00)81842-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008162	Bronze			2022-12-01	WOS:A1997WE97000010
J	Onrust, R; Herzmark, P; Chi, P; Garcia, PD; Lichtarge, O; Kingsley, C; Bourne, HR				Onrust, R; Herzmark, P; Chi, P; Garcia, PD; Lichtarge, O; Kingsley, C; Bourne, HR			Receptor and beta gamma binding sites in the alpha subunit of the retinal G protein transducin	SCIENCE			English	Article							NUCLEOTIDE EXCHANGE; CRYSTAL-STRUCTURE; GTP HYDROLYSIS; RHODOPSIN; ACTIVATION; GDP; FLUORESCENCE; MECHANISM; MUTATION; COMPLEX	Transmembrane receptors for hormones, neurotransmitters, light, and odorants mediate their cellular effects by activating heterotrimeric guanine nucleotide-binding proteins (G proteins), Crystal structures have revealed contact surfaces between G protein subunits, but not the surfaces or molecular mechanism through which G alpha beta gamma responds to activation by transmembrane receptors, Such a surface was identified from the results of testing 100 mutant alpha subunits of the retinal G protein transducin for their ability to interact with rhodopsin, Sites at which alanine substitutions impaired this interaction mapped to two distinct G alpha surfaces: a beta gamma-binding surface and a putative receptor-interacting surface. On the basis of these results a mechanism for receptor-catalyzed exchange of guanosine diphosphate for guanosine triphosphate is proposed.	UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,PROGRAM BIOMED SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA-54427] Funding Source: Medline; NIGMS NIH HHS [GM-27800] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027800, R01GM027800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOUME HR, 1991, NATURE, V349, P117; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DENKER BM, 1995, BIOCHEMISTRY-US, V34, P5544, DOI 10.1021/bi00016a028; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; QUILLIAM LA, 1995, P NATL ACAD SCI USA, V92, P1272, DOI 10.1073/pnas.92.5.1272; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	38	192	193	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					381	384		10.1126/science.275.5298.381	http://dx.doi.org/10.1126/science.275.5298.381			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994033				2022-12-01	WOS:A1997WC87300044
J	Estrada, J; Boronat, M; Mielgo, M; Magallon, R; Millan, I; Diez, S; Lucas, T; Barcelo, B				Estrada, J; Boronat, M; Mielgo, M; Magallon, R; Millan, I; Diez, S; Lucas, T; Barcelo, B			The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP; DIFFERENTIAL-DIAGNOSIS; ADENOMAS; MICROSURGERY; RADIOTHERAPY; THERAPY	Background Irradiation of the pituitary is widely considered the most appropriate treatment for patients with Cushing's disease in whom transsphenoidal microsurgery has been unsuccessful. However, there is little information about the long-term efficacy of this treatment. Methods We used external pituitary radiation to treat 30 adult patients with persistent or recurrent Cushing's disease after unsuccessful transsphenoidal surgery. The mean (+/-SD) dose of radiation was 50+/-1 Gy. Pituitary and adrenal function was assessed every six months after radiation therapy. Remission was defined as the regression of symptoms and signs of Cushing's syndrome, normal urinary cortisol excretion, and a low plasma cortisol concentration in the morning after the administration of 1 mg of dexamethasone at midnight. Results Twenty-five patients (83 percent) had remissions during a median follow-up of 42 months (range, 18 to 114). The remissions began 6 to 60 months after radiation therapy, but in most cases (22 patients) remission occurred during the first 2 years. None of the 25 patients had a relapse of Cushing's disease after remission was achieved. There was no relation between the response to radiotherapy and sex, age, urinary cortisol excretion before radiotherapy, the interval between surgery and radiotherapy, whether a pituitary adenoma was found by pathological examination, or tumor size. Seventeen patients had a deficiency of growth hormone after radiation therapy, 10 had a deficiency of gonadotropins, 4 had a deficiency of thyrotropin, and 1 had a deficiency of corticotropin. Conclusions Pituitary irradiation is an effective and well-tolerated treatment for patients with Cushing's disease in whom transsphenoidal surgery is unsuccessful. (C) 1997, Massachusetts Medical Society.	UNIV AUTONOMA MADRID, CLIN PUERTA DE HIERRO, DEPT RADIAT ONCOL, MADRID 28035, SPAIN; UNIV AUTONOMA MADRID, CLIN PUERTA DE HIERRO, DEPT BIOSTAT, MADRID 28035, SPAIN	Autonomous University of Madrid; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Autonomous University of Madrid; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Estrada, J (corresponding author), UNIV AUTONOMA MADRID, CLIN PUERTA DE HIERRO, SERV ENDOCRINOL, DEPT ENDOCRINOL, MADRID 28035, SPAIN.		Boronat, Mauro/I-2851-2017	Boronat, Mauro/0000-0001-8535-8543				BENEDETTI J, 1990, BMDP STATISTICAL SOF, V2, P739; BOCHICCHIO D, 1995, J CLIN ENDOCR METAB, V80, P3114, DOI 10.1210/jc.80.11.3114; BRADA M, 1993, CLIN ENDOCRINOL, V38, P571, DOI 10.1111/j.1365-2265.1993.tb02137.x; BURCH WM, 1985, ARCH INTERN MED, V145, P1106, DOI 10.1001/archinte.145.6.1106; CARPENTER PC, 1988, ENDOCRIN METAB CLIN, V17, P445, DOI 10.1016/S0889-8529(18)30412-2; FAHLBUSCH R, 1986, J ROY SOC MED, V79, P262, DOI 10.1177/014107688607900504; HOWLETT TA, 1989, CLIN ENDOCRINOL, V31, P309, DOI 10.1111/j.1365-2265.1989.tb01255.x; HUGHES MN, 1993, INT J RADIAT ONCOL, V27, P1035, DOI 10.1016/0360-3016(93)90520-6; JENNINGS AS, 1977, NEW ENGL J MED, V297, P957, DOI 10.1056/NEJM197711032971801; LAMBERTS SWJ, 1995, J CLIN ENDOCR METAB, V80, P3111, DOI 10.1210/jc.80.11.3111; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; LITTLEY MD, 1990, CLIN ENDOCRINOL, V33, P445, DOI 10.1111/j.1365-2265.1990.tb03883.x; MAMPALAM TJ, 1988, ANN INTERN MED, V109, P487, DOI 10.7326/0003-4819-109-6-487; MCCANCE DR, 1993, CLIN ENDOCRINOL, V38, P79, DOI 10.1111/j.1365-2265.1993.tb00976.x; MURAYAMA M, 1992, J CLIN ENDOCR METAB, V75, P935, DOI 10.1210/jc.75.3.935; NELSON JC, 1978, AM J MED SCI, V275, P165, DOI 10.1097/00000441-197803000-00006; NUGENT CA, 1965, ARCH INTERN MED, V116, P172, DOI 10.1001/archinte.1965.03870020012006; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; OLDFIELD EH, 1992, NEW ENGL J MED, V326, P1172; ORTH DN, 1971, NEW ENGL J MED, V285, P243, DOI 10.1056/NEJM197107292850501; ORTH DN, 1995, NEW ENGL J MED, V332, P791, DOI 10.1056/NEJM199503233321207; PIETERS GFFM, 1989, J CLIN ENDOCR METAB, V69, P1122, DOI 10.1210/jcem-69-6-1122; SCHTEINGART DE, 1980, ANN INTERN MED, V92, P613, DOI 10.7326/0003-4819-92-5-613; SHARPE GF, 1985, CLIN ENDOCRINOL, V22, P169, DOI 10.1111/j.1365-2265.1985.tb01078.x; TINDALL GT, 1990, J NEUROSURG, V72, P363, DOI 10.3171/jns.1990.72.3.0363; TRAINER PJ, 1993, CLIN ENDOCRINOL, V38, P73, DOI 10.1111/j.1365-2265.1993.tb00975.x; TYRRELL JB, 1994, ENDOCRIN METAB CLIN, V23, P925, DOI 10.1016/S0889-8529(18)30075-6; TYRRELL JB, 1986, ANN INTERN MED, V104, P180, DOI 10.7326/0003-4819-104-2-180; VICENTE A, 1991, ACTA ENDOCRINOL-COP, V125, P470, DOI 10.1530/acta.0.1250470; YOUNG WF, 1988, MAYO CLIN PROC, V63, P256, DOI 10.1016/S0025-6196(12)65099-X	30	243	247	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1997	336	3					172	177		10.1056/NEJM199701163360303	http://dx.doi.org/10.1056/NEJM199701163360303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC266	8988897				2022-12-01	WOS:A1997WC26600003
J	Cole, TJ				Cole, TJ			3-in-1 weight-monitoring chart	LANCET			English	Article							GAIN				Cole, TJ (corresponding author), MRC,DUNN NUTR CTR,CAMBRIDGE CB4 1XJ,ENGLAND.		Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200				COLE TJ, 1995, ARCH DIS CHILD, V73, P8, DOI 10.1136/adc.73.1.8; COLE TJ, 1994, STAT MED, V13, P2477, DOI 10.1002/sim.4780132311; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; WHITEHEAD R G, 1989, Journal of Human Nutrition and Dietetics, V2, P73, DOI 10.1111/j.1365-277X.1989.tb00012.x; WRIGHT CM, 1994, ACTA PAEDIATR, V83, P351, DOI 10.1111/j.1651-2227.1994.tb18118.x	5	18	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					102	103		10.1016/S0140-6736(05)60886-0	http://dx.doi.org/10.1016/S0140-6736(05)60886-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996428				2022-12-01	WOS:A1997WB80000019
J	Drobniewski, F				Drobniewski, F			Is death inevitable with multiresistant TB plus HIV infection?	LANCET			English	Editorial Material							MULTIDRUG-RESISTANT TUBERCULOSIS		UNIV LONDON KINGS COLL,SCH MED,DEPT MICROBIOL,LONDON SE22 8QF,ENGLAND	University of London; King's College London	Drobniewski, F (corresponding author), UNIV LONDON KINGS COLL,SCH MED,PHLS MYCOBACTERIUM REFERENCE UNIT,LONDON SE22 8QF,ENGLAND.							Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P330; DROBNIEWSKI FA, 1995, J MED MICROBIOL, V43, P85, DOI 10.1099/00222615-43-2-85; Drobniewski FA, 1996, BRIT J HOSP MED, V56, P204; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Miller R, 1996, LANCET, V348, P307, DOI 10.1016/S0140-6736(95)11037-2; SALOMON N, 1995, CLIN INFECT DIS, V21, P1245, DOI 10.1093/clinids/21.5.1245; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404; TURETT GS, 1995, CLIN INFECT DIS, V21, P1238, DOI 10.1093/clinids/21.5.1238; 1991, MMWR-MORBID MORTAL W, V40, P585	10	33	35	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					71	72		10.1016/S0140-6736(05)60878-1	http://dx.doi.org/10.1016/S0140-6736(05)60878-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996412				2022-12-01	WOS:A1997WB80000003
J	Hidalgo, E; Ding, HG; Demple, B				Hidalgo, E; Ding, HG; Demple, B			Redox signal transduction: Mutations shifting [2Fe-2S] centers of the SoxR sensor-regulator to the oxidized form	CELL			English	Article							SUPEROXIDE RESPONSE REGULON; ESCHERICHIA-COLI; OXIDATIVE-STRESS; POSITIVE CONTROL; TRANSCRIPTIONAL ACTIVATION; NITRIC-OXIDE; PROTEIN; GENES; PURIFICATION; MACROPHAGES	SoxR is a [2Fe-2S] transcription factor triggered by oxidative stress and activated in vitro by one-electron oxidation or assembly of the iron-sulfur centers. To distinguish which mechanism operates in cells, we studied constitutively active SoxR (SoxR(c)) proteins. Three SoxR(c) proteins contained [2Fe-2S] centers required for in vitro transcription and, like wild-type SoxR, were inactivated by chemical reduction. However, in vivo spectroscopy showed that even without oxidative stress, the three SoxR(c) proteins failed to accumulate with reduced [2Fe-2S] (less than or equal to 4% compared to greater than or equal to 40% for wild type). One SoxR(c) protein had a redox potential 65 mV lower than wild type, consistent with its accumulation in the oxidized (activated) form in vivo. These results link in vitro and in vivo approaches showing novel redox regulation that couples an iron-sulfur oxidation state to promoter activation.			Hidalgo, E (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT MOL & CELLULAR TOXICOL,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Hidalgo, Elena/K-2919-2014; Ding, Huangen/AAJ-8550-2020	Hidalgo, Elena/0000-0002-3768-6785; Ding, Huangen/0000-0002-4815-7336	NATIONAL CANCER INSTITUTE [R01CA037831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005726] Funding Source: NIH RePORTER; NCI NIH HHS [CA37831] Funding Source: Medline; NIEHS NIH HHS [F32 ES05726] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; Beinert H, 1996, FEBS LETT, V382, P218, DOI 10.1016/0014-5793(96)00140-8; CHOU JH, 1993, J BACTERIOL, V175, P1026, DOI 10.1128/JB.175.4.1026-1031.1993; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; Demple B., 1996, REGULATION GENE EXPR, P433; Ding HE, 1996, P NATL ACAD SCI USA, V93, P9449, DOI 10.1073/pnas.93.18.9449; Ding HG, 1996, J BIOL CHEM, V271, P33173, DOI 10.1074/jbc.271.52.33173; Dutton P L, 1978, Methods Enzymol, V54, P411; Fraenkel D., 1996, ESCHERICHIA COLI SAL, P189; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GREEN J, 1993, MOL MICROBIOL, V8, P61, DOI 10.1111/j.1365-2958.1993.tb01203.x; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HAUSLADEN A, 1996, OXYR CELL, V86, P719; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; Hidalgo E, 1996, J BIOL CHEM, V271, P7269, DOI 10.1074/jbc.271.13.7269; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; HIDALGO E, 1997, IN PRESS EMBO J; JAIR KW, 1995, J BACTERIOL, V177, P7100, DOI 10.1128/jb.177.24.7100-7104.1995; LI ZY, 1994, J BIOL CHEM, V269, P18371; Lin ECC, 1996, ESCHERICHIA COLI SAL, P1526; LIOCHEV SI, 1994, P NATL ACAD SCI USA, V91, P1328, DOI 10.1073/pnas.91.4.1328; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MoradasFerreira P, 1996, MOL MICROBIOL, V19, P651, DOI 10.1046/j.1365-2958.1996.403940.x; NAKAJIMA H, 1995, BIOSCI BIOTECH BIOCH, V59, P1323, DOI 10.1271/bbb.59.1323; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; NUNOSHIBA T, 1995, INFECT IMMUN, V63, P794, DOI 10.1128/IAI.63.3.794-798.1995; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; NUNOSHIBA T, 1994, NUCLEIC ACIDS RES, V22, P2958, DOI 10.1093/nar/22.15.2958; NUNOSHIBA T, 1993, CANCER RES, V53, P3250; PARKHILL J, 1993, EMBO J, V12, P413, DOI 10.1002/j.1460-2075.1993.tb05673.x; PRIVALLE CT, 1993, P NATL ACAD SCI USA, V90, P2310, DOI 10.1073/pnas.90.6.2310; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; TSANEVA IR, 1990, J BACTERIOL, V172, P4197, DOI 10.1128/jb.172.8.4197-4205.1990; WELSS B, 1997, DNA DAMAGE REPAIR; WU J, 1992, J BACTERIOL, V174, P3915, DOI 10.1128/jb.174.12.3915-3920.1992; WU J, 1995, J BIOL CHEM, V270, P10323, DOI 10.1074/jbc.270.17.10323; WU J, 1991, J BACTERIOL, V173, P2864, DOI 10.1128/JB.173.9.2864-2871.1991	43	121	124	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					121	129		10.1016/S0092-8674(00)81864-4	http://dx.doi.org/10.1016/S0092-8674(00)81864-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019397	Green Published, Bronze			2022-12-01	WOS:A1997WC56900015
J	Svoboda, K; Denk, W; Kleinfeld, D; Tank, DW				Svoboda, K; Denk, W; Kleinfeld, D; Tank, DW			In vivo dendritic calcium dynamics in neocortical pyramidal neurons	NATURE			English	Article							ACTION-POTENTIALS; SYNAPTIC ACTIVATION; HIPPOCAMPAL-NEURONS; CORTICAL-NEURONS; CELL DENDRITES; RAT; CA1; PROPAGATION; MICROSCOPY; FREQUENCY	THE dendrites of mammalian pyramidal neurons contain a rich collection of active conductances that can support Na+ and Ca2+ action potentials (for a review see ref, 1), The presence, site of initiation, and direction of propagation of Na+ and Ca2+ action potentials are, however, controversial(2), and seem to be sensitive to resting membrane potential, ionic composition, and degree of channel inactivation, and depend on the intensity and pattern of synaptic stimulation, This makes it difficult to extrapolate from in vitro experiments to the situation in the intact brain, Here we show that two-photon excitation laser scanning microscopy(3) can penetrate the highly scattering tissue of the intact brain. We used this property to measure sensory stimulus-induced dendritic [Ca2+] dynamics of layer 2/3 pyramidal neurons of the rat primary vibrissa (Sm1) cortex in vivo. Simultaneous recordings of intracellular voltage and dendritic [Ca2+] dynamics during whisker stimulation or current injection showed increases in [Ca2+] only in coincidence with Na+ action potentials, The amplitude of these [Ca2+] transients at a given location was approximately proportional to the number of Na+ action potentials in a short burst, The amplitude for a given number of action potentials was greatest in the proximal apical dendrite rand declined steeply,vith increasing distance from the soma, with little Ca2+ accumulation in the most distal branches, in layer 1.	AT&T BELL LABS,LUCENT TECHNOL,BIOL COMPUTAT RES DEPT,MURRAY HILL,NJ 07974	Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs			denk, winfried/I-6627-2012					ANDREASEN M, 1993, J NEUROPHYSIOL, V69, P1966, DOI 10.1152/jn.1993.69.6.1966; ANDREASEN M, 1995, J PHYSIOL-LONDON, V483, P421, DOI 10.1113/jphysiol.1995.sp020595; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; Buzsaki G, 1996, P NATL ACAD SCI USA, V93, P9921, DOI 10.1073/pnas.93.18.9921; CALLAWAY JC, 1995, J NEUROPHYSIOL, V74, P1395, DOI 10.1152/jn.1995.74.4.1395; CARVELL GE, 1988, BRAIN RES, V448, P186, DOI 10.1016/0006-8993(88)91118-3; CARVELL GE, 1990, J NEUROSCI, V10, P2638; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DENK W, 1994, J NEUROSCI METH, V54, P151, DOI 10.1016/0165-0270(94)90189-9; Feller MB, 1996, J NEUROPHYSIOL, V76, P381, DOI 10.1152/jn.1996.76.1.381; GUTFREUND Y, 1995, J PHYSIOL-LONDON, V483, P621, DOI 10.1113/jphysiol.1995.sp020611; Helmchen F, 1996, BIOPHYS J, V70, P1069, DOI 10.1016/S0006-3495(96)79653-4; HIRSCH JA, 1995, NATURE, V378, P612, DOI 10.1038/378612a0; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; KIM HG, 1995, J NEUROPHYSIOL, V74, P1810, DOI 10.1152/jn.1995.74.4.1810; KIM HG, 1993, J NEUROSCI, V13, P5301, DOI 10.1523/JNEUROSCI.13-12-05301.1993; Kleinfeld D, 1996, J COMP NEUROL, V375, P89, DOI 10.1002/(SICI)1096-9861(19961104)375:1<89::AID-CNE6>3.0.CO;2-K; MAGEE JC, 1995, SCIENCE, V268, P301, DOI 10.1126/science.7716525; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; REGEHR WG, 1994, CURR BIOL, V4, P436, DOI 10.1016/S0960-9822(00)00096-8; REUVENI I, 1993, J NEUROSCI, V13, P4609; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; Tsubokawa H, 1996, J NEUROPHYSIOL, V76, P2896, DOI 10.1152/jn.1996.76.5.2896; TURNER RW, 1991, J NEUROSCI, V11, P2270; WONG RKS, 1979, P NATL ACAD SCI USA, V76, P986, DOI 10.1073/pnas.76.2.986; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4	30	595	610	2	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					161	165		10.1038/385161a0	http://dx.doi.org/10.1038/385161a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990119				2022-12-01	WOS:A1997WB72800055
J	Kern, D; Kern, G; Neef, H; Tittmann, K; KillenbergJabs, M; Wikner, C; Schneider, G; Hubner, G				Kern, D; Kern, G; Neef, H; Tittmann, K; KillenbergJabs, M; Wikner, C; Schneider, G; Hubner, G			How thiamine diphosphate is activated in enzymes	SCIENCE			English	Article							YEAST PYRUVATE DECARBOXYLASE; DEPENDENT ENZYME; 3-DIMENSIONAL STRUCTURE; TRANSKETOLASE; CATALYSIS; C(2)-PROTON; RESOLUTION; PYROPHOSPHATE; EXCHANGE; OXIDASE	The controversial question of how thiamine diphosphate, the biologically active form of vitamin B-1, is activated in different enzymes has been addressed. Activation of the coenzyme was studied by measuring thermodynamics and kinetics of deprotonation at the carbon in the 2-position (C2) of thiamine diphosphate in the enzymes pyruvate decarboxylase and transketolase by use of nuclear magnetic resonance spectroscopy, proton/deuterium exchange, coenzyme analogs, and site-specific mutant enzymes. Interaction of a glutamate with the nitrogen in the 1'-position in the pyrimidine ring activated the 4'-amino group to act as an efficient proton acceptor for the C2 proton. The protein component accelerated the deprotonation of the C2 atom by several orders of magnitude, beyond the rate of the overall enzyme reaction. Therefore, the earlier proposed concerted mechanism or stabilization of a C2 carbanion can be excluded.	UNIV HALLE WITTENBERG,INST BIOCHEM,D-06120 HALLE,GERMANY; KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN	Martin Luther University Halle Wittenberg; Karolinska Institutet				Schneider, Gunter/0000-0003-0622-5713				ALVAREZ FJ, 1991, J AM CHEM SOC, V113, P8402, DOI 10.1021/ja00022a030; Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; BOITEUX A, 1970, FEBS LETT, V9, P293, DOI 10.1016/0014-5793(70)80381-7; BRESLOW R, 1958, J AM CHEM SOC, V80, P3719, DOI 10.1021/ja01547a064; BRINGERMEYER S, 1986, ARCH MICROBIOL, V146, P105, DOI 10.1007/BF00402334; CRANE EJ, 1993, J AM CHEM SOC, V115, P8912, DOI 10.1021/ja00073a004; CROSBY J, 1970, J AM CHEM SOC, V92, P5707, DOI 10.1021/ja00722a027; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; GOLBIK R, 1991, BIOORG CHEM, V19, P10, DOI 10.1016/0045-2068(91)90039-R; HARRIS TK, 1995, BIOCHEMISTRY-US, V34, P13994, DOI 10.1021/bi00043a005; HARRIS TK, 1995, BIOCHEMISTRY-US, V34, P14001, DOI 10.1021/bi00043a006; HOLZER H, 1959, ANGEW CHEM INT EDIT, V71, P776, DOI 10.1002/ange.19590712406; HUBNER G, 1978, EUR J BIOCHEM, V92, P175, DOI 10.1111/j.1432-1033.1978.tb12735.x; JORDAN F, 1982, ANN NY ACAD SCI, V378, P14; JORDAN F, 1978, J AM CHEM SOC, V100, P2532; KEMP DS, 1970, J AM CHEM SOC, V92, P2554, DOI 10.1021/ja00711a062; KOGA J, 1995, BBA-PROTEIN STRUCT M, V1249, P1, DOI 10.1016/0167-4838(95)00011-I; KONIG S, 1994, J BIOL CHEM, V269, P10879; KONIG S, IN PRESS BIOCHEMISTR; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; MULLER YA, 1994, J MOL BIOL, V237, P315, DOI 10.1006/jmbi.1994.1233; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; NEEF H, 1973, J PRAKT CHEM, V315, P701, DOI 10.1002/prac.19733150415; NIKKOLA M, 1994, J MOL BIOL, V238, P387, DOI 10.1006/jmbi.1994.1299; PETZOLD DR, 1976, STUD BIOPHYS, V54, P159; SCHELLENBERGER A, 1967, ANGEW CHEM INT EDIT, V6, P1024, DOI 10.1002/anie.196710241; SCHELLENBERGER A, 1967, H-S Z PHYSIOL CHEM, V348, P501, DOI 10.1515/bchm2.1967.348.1.501; SCHELLENBERGER A, 1970, CHEM BER, V123, P1489; SCHELLENBERGER A, 1985, BIOCHEM EDUC, V13, P160; SCHNEIDER G, 1993, BIOORG CHEM, V21, P109, DOI 10.1006/bioo.1993.1012; WASHABAUGH MW, 1988, BIOCHEMISTRY-US, V27, P5044, DOI 10.1021/bi00414a015; WIKNER C, 1994, J BIOL CHEM, V269, P32144; WIKNER C, UNPUB; ZEHENDER H, 1985, FEBS LETT, V180, P51, DOI 10.1016/0014-5793(85)80228-3	34	235	237	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					67	70		10.1126/science.275.5296.67	http://dx.doi.org/10.1126/science.275.5296.67			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974393				2022-12-01	WOS:A1997WA90300049
J	Birdsall, MA; Farquhar, CM; White, HD				Birdsall, MA; Farquhar, CM; White, HD			Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization	ANNALS OF INTERNAL MEDICINE			English	Article							HEART-DISEASE; CARDIOVASCULAR-DISEASE; INSULIN RESISTANCE; FOLLOW-UP; RISK; FRAMINGHAM; PREVALENCE; EXCESS	Background: Women with polycystic ovaries have associated risk factors for coronary artery disease. It is unknown whether women with more extensive coronary artery disease are more likely to have polycystic ovaries. Objective: To determine whether women who have more extensive coronary artery disease as seen on coronary angiography are more likely to have polycystic ovaries appearing on ultrasonography than are women with less severe coronary disease. Design: Prevalence study of women who had had coronary angiography. Setting: Women referred for coronary angiography for assessment of chest pain or valvular disease in Auckland, New Zealand, during a 2-year period. Patients: 143 women 60 years of age or younger who had had coronary angiography. Women who had previously had bilateral oophorectomy were excluded. Measurements: The extent of coronary artery disease assessed by quantitative angiography was compared with the presence or absence of polycystic ovaries. Pelvic ultrasonography was done without knowledge of the extent of coronary artery disease. Assessment of angiograms was blinded. Insulin resistance and gonadotropin, testosterone, and serum lipid levels were also measured. Results: Polycystic ovaries were found in 42% of women and were associated with hirsutism; previous hysterectomy; higher free testosterone, triglyceride, and C-peptide levels; and lower high-density lipoprotein cholesterol levels. Women with polycystic ovaries had more extensive coronary artery disease than women with normal ovaries (number of segments with >50% stenosis, 1.7 [95% CI, 1.1 to 2.3] compared with 0.82 [CI, 0.54 to 1.1]; P < 0.01). On logistic regression analysis, the extent of coronary artery disease (P = 0.032) and family history of heart disease (P = 0.022) were predictors of the presence of polycystic ovaries. Conclusions: In women having coronary angiography, those with more extensive coronary artery disease were more likely to have polycystic ovaries on ultrasonography than were those with less extensive disease. Visualization of polycystic ovaries by sonography was associated with distinct metabolic and endocrine abnormalities. Further study is required to evaluate whether surgery or hormone replacement therapy can modify the risk.	GREEN LANE HOSP, DEPT CARDIOL, AUCKLAND 1003, NEW ZEALAND; NATL WOMENS HOSP, AUCKLAND 1003, NEW ZEALAND; UNIV AUCKLAND, AUCKLAND 1, NEW ZEALAND	University of Auckland				Farquhar, Cynthia/0000-0002-3685-3553				ADAMS J, 1986, BRIT MED J, V293, P355, DOI 10.1136/bmj.293.6543.355; Birdsall MA, 1996, CLIN ENDOCRINOL, V44, P269, DOI 10.1046/j.1365-2265.1996.676498.x; CASTELLI WP, 1984, AM J MED, V76, P4, DOI 10.1016/0002-9343(84)90952-5; CASTELLI WP, 1986, AM HEART J, V112, P432, DOI 10.1016/0002-8703(86)90296-6; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; CONWAY GS, 1989, CLIN ENDOCRINOL, V30, P459, DOI 10.1111/j.1365-2265.1989.tb00446.x; DAHLGREN E, 1992, FERTIL STERIL, V57, P505; DUNAIF A, 1989, DIABETES, V38, P1165, DOI 10.2337/diabetes.38.9.1165; FARQUHAR CM, 1994, AUST NZ J OBSTET GYN, V34, P67, DOI 10.1111/j.1479-828X.1994.tb01041.x; FERRIMAN D, 1961, J CLIN ENDOCR METAB, V21, P1440, DOI 10.1210/jcem-21-11-1440; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; POLSON DW, 1988, LANCET, V1, P870; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; VLIETSTRA RE, 1982, ARTERIOSCLEROSIS, V2, P208, DOI 10.1161/01.ATV.2.3.208; WILD RA, 1985, J CLIN ENDOCR METAB, V61, P946, DOI 10.1210/jcem-61-5-946; WILD RA, 1990, FERTIL STERIL, V54, P255; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102	18	238	250	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					32	35		10.7326/0003-4819-126-1-199701010-00005	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992921				2022-12-01	WOS:A1997WA16500005
J	Steele, A; Gowrishankar, M; Abrahamson, S; Mazer, CD; Feldman, RD; Halperin, ML				Steele, A; Gowrishankar, M; Abrahamson, S; Mazer, CD; Feldman, RD; Halperin, ML			Postoperative hyponatremia despite near-isotonic saline infusion: A phenomenon of desalination	ANNALS OF INTERNAL MEDICINE			English	Article							ANTI-DIURETIC HORMONE; PLASMA SODIUM CONCENTRATION; INAPPROPRIATE SECRETION; SURGERY; WOMEN	Background: It is widely presumed that the development of postoperative hyponatremia (which may be severe) results from administration of hypotonic fluids while antidiuretic hormone is acting. Objective: To show that hyponatremia would occur in patients 24 hours after surgery if only near-isotonic solutions are given and to evaluate the mechanisms responsible for hyponatremia in this setting. Design: Prospective cohort study. Setting: University medical center. Patients: 22 women who were having uncomplicated gynecologic surgery with infusion of near-isotonic solutions only (sodium chloride, 154 mmol/L, or Ringer lactate [sodium, 130 mmol/L, and potassium, 4 mmol/L]). Measurements: Plasma electrolyte levels were measured at the time of induction of anesthesia and 24 hours later. Data on the balance of water and electrolytes were obtained for the same 24-hour period. Results: At the time of induction of anesthesia, the plasma sodium concentration was 140 +/- 1 mmol/L; 24 hours later, it decreased in 21 of 22 patients (mean decrease, 4.2 +/- 0.4 mmol/L [P < 0.001]; lowest level, 131 mmol/L in 2 patients). The urine remained hypertonic (peak sodium plus potassium concentration in urine, 294 +/- 9 mmol/L) in all patients for the first 16 hours after induction of anesthesia. Conclusions: Postoperative hyponatremia occurred within 24 hours of induction of anesthesia when only near-isotonic fluids were infused. Hyponatremia was generally caused by generation of electrolyte-free water during excretion of hypertonic urine-a desalination process. This electrolyte-free water was retained in the body because of the actions of antidiuretic hormone. If the pathophysiology of this hyponatremic state is understood, recommendations for its prevention and treatment can be deduced.	UNIV TORONTO, ST MICHAELS HOSP, TORONTO, ON M5B 1A6, CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto			Feldman, Ross/G-3293-2011	Mazer, Cyril David/0000-0003-2566-4308				ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; Ayus JC, 1996, NEUROLOGY, V46, P323, DOI 10.1212/WNL.46.2.323; AYUS JC, 1992, ANN INTERN MED, V117, P891, DOI 10.7326/0003-4819-117-11-891; CHUNG HM, 1986, ARCH INTERN MED, V146, P333, DOI 10.1001/archinte.146.2.333; COWLEY D M, 1988, Australian and New Zealand Journal of Surgery, V58, P485, DOI 10.1111/j.1445-2197.1988.tb06240.x; DECAUX G, 1980, AM J MED, V69, P99, DOI 10.1016/0002-9343(80)90506-9; DECAUX G, 1981, NEW ENGL J MED, V304, P329, DOI 10.1056/NEJM198102053040605; EDELMAN IS, 1958, J CLIN INVEST, V37, P1236, DOI 10.1172/JCI103712; GOLDBERG M, 1981, MED CLIN N AM, V65, P251, DOI 10.1016/S0025-7125(16)31523-1; Gowrishankar M, 1996, KIDNEY INT, V50, P1490, DOI 10.1038/ki.1996.463; GOWRISHANKAR M, 1997, IN PRESS J AM SOC NE; GUY AJ, 1987, BRIT J SURG, V74, P1027, DOI 10.1002/bjs.1800741123; HALPERIN ML, 1985, AM J PHYSIOL, V248, pF607, DOI 10.1152/ajprenal.1985.248.4.F607; HALPERIN ML, 1986, AM J NEPHROL, V6, P241, DOI 10.1159/000167170; HANTMAN D, 1973, ANN INTERN MED, V78, P870, DOI 10.7326/0003-4819-78-6-870; Harrigan MR, 1996, NEUROSURGERY, V38, P152, DOI 10.1097/00006123-199601000-00035; IRVIN TT, 1972, LANCET, V2, P1159; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; NELSON PB, 1981, J NEUROSURG, V55, P938, DOI 10.3171/jns.1981.55.6.0938; Oh MS, 1995, FLUID ELECTROLYTE AC, P1; Robertson Gary L., 1993, P99; ROSCOE JM, 1975, CAN MED ASSOC J, V112, P452; ROSE BD, 1986, AM J MED, V81, P1033, DOI 10.1016/0002-9343(86)90401-8; THOMAS TH, 1979, BRIT J SURG, V66, P540, DOI 10.1002/bjs.1800660806; TINDALL SF, 1981, BRIT J SURG, V68, P639, DOI 10.1002/bjs.1800680911; WRIGHT HK, 1962, SURG GYNECOL OBSTET, V115, P553	26	182	192	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					20	25		10.7326/0003-4819-126-1-199701010-00003	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992919				2022-12-01	WOS:A1997WA16500003
J	Connolly, JB; Roberts, IJH; Armstrong, JD; Kaiser, K; Forte, M; Tully, T; OKane, CJ				Connolly, JB; Roberts, IJH; Armstrong, JD; Kaiser, K; Forte, M; Tully, T; OKane, CJ			Associative learning disrupted by impaired G(s) signaling in Drosophila mushroom bodies	SCIENCE			English	Article							CYCLIC-AMP PHOSPHODIESTERASE; STIMULATORY G-PROTEIN; ADENYLYL-CYCLASE; PREFERENTIAL EXPRESSION; GENE-EXPRESSION; ALPHA-SUBUNIT; MEMORY; MELANOGASTER; RUTABAGA; MUTANT	Disruptions in mushroom body (MB) or central complex (CC) brain structures impair Drosophila associative olfactory learning. Perturbations in adenosine 3',5' monophosphate signaling also disrupt learning. To integrate these observations, expression of a constitutively activated stimulatory heterotrimeric guanosine triphosphate-binding protein alpha subunit (G alpha(s)(star)) was targeted to these brain structures. The ability to associate odors with electroshock was abolished when G alpha(s)(star) was targeted to MB, but not CC, structures, whereas sensorimotor responses to these stimuli remained normal, Expression of G alpha(s)(star) did not affect gross MB morphology, and wild-type G alpha(s) expression did not affect learning, Thus, olfactory learning depends on regulated G(s) signaling in Drosophila MBs.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND; UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV MOL GENET,GLASGOW G11 6NU,LANARK,SCOTLAND; OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201	University of Cambridge; University of Glasgow; Oregon Health & Science University	Connolly, JB (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.		O'Kane, Cahir/Q-6681-2019	O'Kane, Cahir/0000-0002-3488-2078; Connolly, John B./0000-0002-7033-3463; Armstrong, Douglas/0000-0002-5397-3864	NICHD NIH HHS [HD 32245] Funding Source: Medline; Wellcome Trust Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032245] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMSTRONG JD, 1995, THESIS U GLASGOW SCO; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYNTON S, 1992, GENETICS, V131, P655; BRAND AH, 1993, DEVELOPMENT, V118, P401; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; deBelle JS, 1996, P NATL ACAD SCI USA, V93, P9875, DOI 10.1073/pnas.93.18.9875; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; HAMMER M, 1995, J NEUROSCI, V15, P1617, DOI 10.1523/JNEUROSCI.15-03-01617.1995; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; KANDEL E, 1995, SCIENCE, V268, P825, DOI 10.1126/science.7754367; KANDEL ER, 1987, SYNAPTIC FUNCTION, P471; KKAISER K, UNPUB; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; Li W, 1996, LEARN MEMORY, V2, P320, DOI 10.1101/lm.2.6.320; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; NEER E, 1995, CELL, V60, P249; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; ODELL KMC, 1995, NEURON, V15, P55, DOI 10.1016/0896-6273(95)90064-0; QUAN F, 1989, P NATL ACAD SCI USA, V86, P4321, DOI 10.1073/pnas.86.11.4321; QUAN F, 1991, P NATL ACAD SCI USA, V88, P1898, DOI 10.1073/pnas.88.5.1898; Schreibmayer W, 1996, NATURE, V380, P624, DOI 10.1038/380624a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; SOKAL RR, 1981, BIOMETRY PRINCIPLES, P229; SPRADLING A, 1986, DROSOPHILA PRACTICAL, P75; SWEENEY ST, 1995, NEURON, V14, P341, DOI 10.1016/0896-6273(95)90290-2; TANG W, 1994, PROTEINS, P19; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; URBAN J, 1994, GENE DEV, V8, P1787; WOLFGANG WJ, 1990, J NEUROSCI, V10, P1014; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; YANG MY, 1995, NEURON, V15, P45; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036	41	408	412	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2104	2107		10.1126/science.274.5295.2104	http://dx.doi.org/10.1126/science.274.5295.2104			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953046				2022-12-01	WOS:A1996VY97400056
J	Saffran, JR; Aslin, RN; Newport, EL				Saffran, JR; Aslin, RN; Newport, EL			Statistical learning by 8-month-old infants	SCIENCE			English	Article							ACQUISITION; EXPERIENCE; PATTERNS; SPEECH; WORDS	Learners rely on a combination of experience-independent and experience-dependent mechanisms to extract information from the environment, Language acquisition involves both types of mechanisms, but most theorists emphasize the relative importance of experience-independent mechanisms. The present study shows that a fundamental task of language acquisition, segmentation of words from fluent speech, can be accomplished by 8-month-old infants based solely on the statistical relationships between neighboring speech sounds. Moreover, this word segmentation was based on statistical learning from only 2 minutes of exposure, suggesting that infants have access to a powerful mechanism for the computation of statistical properties of the language input.			Saffran, JR (corresponding author), UNIV ROCHESTER,DEPT BRAIN & COGNIT SCI,601 ELMWOOD AVE,ROCHESTER,NY 14627, USA.		Galantucci, Bruno/E-5770-2010		NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000167] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC00167, R01 DC000167, R01 DC000167-26] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		[Anonymous], 1980, PERCEPTION PRODUCTIO; BICKERTON D, 1984, BEHAV BRAIN SCI, V7, P173, DOI 10.1017/S0140525X00044149; Brent MR, 1996, COGNITION, V61, P93, DOI 10.1016/S0010-0277(96)00719-6; Brown R., 1973, 1 LANGUAGE; Chomsky N., 1965, ASPECTS THEORY SYNTA; Chomsky Noam, 1980, RULES REPRESENTATION; CHRISTOPHE A, 1994, J ACOUST SOC AM, V95, P1570, DOI 10.1121/1.408544; CRAIN S, 1991, BEHAV BRAIN SCI, V14, P597, DOI 10.1017/S0140525X00071491; Cutler A., 1987, Computer Speech and Language, V2, P133, DOI 10.1016/0885-2308(87)90004-0; DECASPER AJ, 1994, INFANT BEHAV DEV, V17, P159, DOI 10.1016/0163-6383(94)90051-5; Erbaugh MS., 1992, CROSSLINGUISTIC STUD, P373, DOI [10.4324/9781315808208, DOI 10.4324/9781315808208]; Fodor JA., 1983, MODULARITY MIND; Gleitman LR, 1995, LANGUAGE INVITATION, P1; GOULD E, 1975, DEV PSYCHOBIOL, V8, P33; Harris ZS, 1955, LANGUAGE, V31, P190, DOI 10.2307/411036; Hayes J. R., 1970, COGNITION DEV LANGUA; Hess E. H., 1973, IMPRINTING; HOY RR, 1974, AM ZOOL, V14, P1067; JUSCZYK P, 1993, J MEM LANG, V32, P401; JUSCZYK PW, 1993, CHILD DEV, V64, P675, DOI 10.2307/1131210; JUSCZYK PW, 1995, COGNITIVE PSYCHOL, V29, P1, DOI 10.1006/cogp.1995.1010; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; LENNEBERG EH, 1967, BIOL F LANGUAGE; LEON M, 1975, PHYSIOL BEHAV, V14, P311, DOI 10.1016/0031-9384(75)90039-6; MEHLER J, 1988, COGNITION, V29, P149; SAFFRAN J, IN PRESS PSYCHOL SCI; Saffran JR, 1996, J MEM LANG, V35, P606, DOI 10.1006/jmla.1996.0032; SLOBIN D, 1987, CROSSLINGUISTIC STUD, V2; Slobin D I, 1985, CROSSLINGUISTIC STUD, V1; TEICHER MH, 1977, SCIENCE, V198, P635, DOI 10.1126/science.918660	30	2964	2992	22	404	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1926	1928		10.1126/science.274.5294.1926	http://dx.doi.org/10.1126/science.274.5294.1926			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VY200	8943209				2022-12-01	WOS:A1996VY20000049
J	Yamagata, K; Furuta, H; Oda, N; Kaisaki, PJ; Menzel, S; Cox, NJ; Fajans, SS; Signorini, S; Stoffel, M; Bell, GI				Yamagata, K; Furuta, H; Oda, N; Kaisaki, PJ; Menzel, S; Cox, NJ; Fajans, SS; Signorini, S; Stoffel, M; Bell, GI			Mutations In the hepatocyte nuclear factor-4 alpha gene in maturity-onset diabetes of the young (MODY1)	NATURE			English	Article							LIGAND-BINDING DOMAIN; RECEPTOR SUPERFAMILY; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; HORMONE RECEPTOR; LIVER; HNF-4; MELLITUS; SUBTYPE	THE disease maturity-onset diabetes of the young (MODY) is a genetically heterogeneous monogenic form of non-insulin-dependent (type 2) diabetes mellitus (NIDDM), characterized by early onset, usually before 25 years of age and often in adolescence or childhood, and by autosomal dominant inheritance(1). It has been estimated that 2-5% of patients with NIDDM may have this form of diabetes mellitus(2,3). Clinical studies have shown that prediabetic MODY subjects have normal insulin sensitivity but suffer from a defect in glucose-stimulated insulin secretion, suggesting that pancreatic beta-cell dysfunction rather than insulin resistance is the primary defect in this disorder(4,5). Linkage studies have localized the genes that are mutated in MODY on human chromosomes 20 (MODY1)(6), 7 (MODY2)(2) and 12 (MODY3)(7), with MODY2 and MODY3 being allelic with the genes encoding glucokinase(2), a key regulator of insulin secretion, and hepatocyte nuclear factor-1 alpha (HNF-1 alpha)(8), a transcription factor involved in tissue-specific regulation of liver genes but also expressed in pancreatic islets, insulinoma cells and other tissues. Here we show that MODY1 is the gene encoding HNF-4 alpha (gene symbol, TCF14), a member of the steroid/thyroid hormone receptor superfamily and an upstream regulator of HNF-1 alpha expressiong-(9,11).	UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; ROCKEFELLER UNIV,LAB METAB DIS,NEW YORK,NY 10021	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Michigan System; University of Michigan; Rockefeller University			Menzel, Stephan/U-6906-2019	Stoffel, Markus/0000-0003-1304-5817; Menzel, Stephan/0000-0002-1590-9108				BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BYME MM, 1995, DIABETES, V44, P699; Byrne MM, 1996, DIABETES, V45, P1503, DOI 10.2337/diabetes.45.11.1503; CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Drewes T, 1996, MOL CELL BIOL, V16, P925; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; FAJANS SS, 1994, LIFE SCI, V55, P413, DOI 10.1016/0024-3205(94)90052-3; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; HERMAN WH, 1994, DIABETES, V43, P40, DOI 10.2337/diabetes.43.1.40; HERMAN WH, 1994, DIABETES, V43, P1171; IRWIN M, 1994, P NATL ACAD SCI USA, V91, P11684, DOI 10.1073/pnas.91.24.11684; Iwasaki Naoki, 1996, Journal of the Japan Diabetes Society, V39, P409; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LEDERMANN HM, 1995, LANCET, V345, P648, DOI 10.1016/S0140-6736(95)90548-0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STOFFEL M, 1996, P NATL ACAD SCI USA, V93, P3939; TAVAVIRAS S, 1994, MECH DEVELOP, V48, P67; VAXILLAIRE M, 1995, NAT GENET, V9, P418, DOI 10.1038/ng0495-418; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311	30	922	955	1	27	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					458	460		10.1038/384458a0	http://dx.doi.org/10.1038/384458a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945471	Green Submitted			2022-12-01	WOS:A1996VW68700061
J	Kuida, K; Zheng, TS; Na, SQ; Kuan, CY; Yang, D; Karasuyama, H; Rakic, P; Flavell, RA				Kuida, K; Zheng, TS; Na, SQ; Kuan, CY; Yang, D; Karasuyama, H; Rakic, P; Flavell, RA			Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice	NATURE			English	Article							PROGRAMMED CELL-DEATH; CHICK-EMBRYO; SPINAL-CORD; PHOSPHATIDYLSERINE; INHIBITION; MIGRATION; PROTEASE; ELEGANS	PROGRAMMED cell death (apoptosis) is a prominent feature of the development of the immune and nervous systems(1,2). The identification of the Caenorhabditis elegans cell death gene, ced-3, as a prototype of the interleukin-1 beta converting enzyme (ICE) protease family has led to extensive evidence implicating these enzymes in apoptosis(3,4). Among the ten or more members of the ICE protease family, CPP32/yama/apopain(5-7) exhibits the highest similarity to CED-3 in both sequence homolog and substrate specificity(8). To analyse its function in vivo, we generated CPP32-deficient mice by homologous recombination, These mice, horn at a frequency lower than expected by mendelian genetics, mere smaller than their Littermates and died at 1-3 weeks of age, Although their thymocytes retained normal susceptibility to various apoptotic stimuli, brain development in CPP32-deficient mice was profoundly affected, and discernible by embryonic day 12, resulting in a variety of hyperplasias and disorganized cell deployment, These supernumerary cells were postmitotic and terminally differentiated by the postnatal stage, Pyknotic clusters at sites of major morphogenetic change during normal brain development(9) were not observed in the mutant embryos, indicating decreased apoptosis in the absence of CPP32. Thus CPP32 is shown to play a critical role during morphogenetic cell death(9,10) in the mammalian brain.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510; TOKYO METROPOLITAN INST MED SCI,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	Howard Hughes Medical Institute; Yale University; Yale University; Tokyo Metropolitan Institute of Medical Science			Karasuyama, Hajime/A-7966-2011	Karasuyama, Hajime/0000-0003-0689-0836				Chinnaiyan AM, 1996, CURR BIOL, V6, P555; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; Eksioglu YZ, 1996, NEURON, V16, P77, DOI 10.1016/S0896-6273(00)80025-2; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; HAMBURGER V, 1958, AM J ANAT, V102, P265; HOMMA S, 1994, J COMP NEUROL, V345, P377, DOI 10.1002/cne.903450305; HORVITZ HR, 1983, COLD SPRING HARB SYM, V48, P453, DOI 10.1101/SQB.1983.048.01.050; KALLEN B, 1955, J ANAT, V89, P153; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Osborne BA, 1996, CURR OPIN IMMUNOL, V8, P245, DOI 10.1016/S0952-7915(96)80063-X; PITTMAN R, 1979, J COMP NEUROL, V187, P425, DOI 10.1002/cne.901870210; RAKIC P, 1968, J COMP NEUROL, V132, P45, DOI 10.1002/cne.901320103; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; SILVER J, 1973, J MORPHOL, V140, P159, DOI 10.1002/jmor.1051400204; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Whyte M, 1996, TRENDS CELL BIOL, V6, P245, DOI 10.1016/0962-8924(96)20025-X; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073	30	1655	1686	2	66	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					368	372		10.1038/384368a0	http://dx.doi.org/10.1038/384368a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934524				2022-12-01	WOS:A1996VV27100052
J	Petrov, DA; Lozovskaya, ER; Hartl, DL				Petrov, DA; Lozovskaya, ER; Hartl, DL			High intrinsic: Rate of DNA loss in Drosophila	NATURE			English	Article							TRANSPOSABLE ELEMENTS; PROCESSED PSEUDOGENES; SEQUENCE EVOLUTION; GENES; MECHANISM	PSEUDOGENES are common in mammals but virtually absent in Drosophila(1). All putative Drosophila pseudogenes show patterns of molecular evolution that are inconsistent with the lack of functional constraints(2-5). The absence of bona fide pseudogenes is not only puzzling it also hampers attempts to estimate rates and patterns of neutral DNA change. The estimation problem is especially acute in the case of deletions and insertions, which are likely to have large effects when they occur in functional genes and are therefore subject to strong purifying selection. We propose a solution to this problem by taking advantage of the propensity of retrotransposable elements, without long terminal repeats (non-LTR) to: create non-functional, 'dead-on-arrival' copies of themselves as a common by-product of their transpositional cycle(6-8). Phylogenetic analysis of a non-LTR element, Helena, demonstrates that copies lose DNA at an unusually high rate, suggesting that lack of pseudogenes in Drosophila is the product of rampant deletion of DNA in unconstrained regions, This finding has important implications for the study of genome evolution in general and the 'C-value paradox'(9) in particular.			Petrov, DA (corresponding author), HARVARD UNIV, DEPT ORGANISM & EVOLUTIONARY BIOL, 16 DIVINITY AVE, CAMBRIDGE, MA 02138 USA.			Petrov, Dmitri/0000-0002-3664-9130				BEBENEK K, 1993, REVERSE TRANSCRIPTAS; Bernard J., 1988, EUKARYOTE GENOME DEV, DOI [10.1007/978-94-011-5991-3, DOI 10.1007/978-94-011-5991-3]; CURRIE PD, 1994, GENETICS, V138, P353; deSouza SJ, 1996, GENES CELLS, V1, P493, DOI 10.1046/j.1365-2443.1996.d01-264.x; EICKBUSH DG, 1995, GENETICS, V139, P685; FINNEGAN DJ, 1989, MOBILE DNA, P503; GRAUR D, 1989, J MOL EVOL, V28, P279, DOI 10.1007/BF02103423; HUGHES AL, 1995, NATURE, V377, P391, DOI 10.1038/377391a0; JEFFS P, 1991, P ROY SOC B-BIOL SCI, V244, P151, DOI 10.1098/rspb.1991.0064; JONES CW, 1982, J MOL EVOL, V19, P87, DOI 10.1007/BF02100227; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LONG MY, 1993, SCIENCE, V260, P91, DOI 10.1126/science.7682012; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MADDISON WP, 1992, VERSION 3; MCCLURE M, 1993, REVERSE TRANSCRIPTAS; PETROV DA, 1995, P NATL ACAD SCI USA, V92, P8050, DOI 10.1073/pnas.92.17.8050; SHARP PM, 1989, J MOL EVOL, V28, P398, DOI 10.1007/BF02603075; SPRINGER MS, 1995, MOL BIOL EVOL, V12, P219; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; SULLIVAN DT, 1994, MOL BIOL EVOL, V11, P443; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.biochem.55.1.631; [No title captured]	23	295	300	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					346	349		10.1038/384346a0	http://dx.doi.org/10.1038/384346a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934517				2022-12-01	WOS:A1996VV27100045
J	Bugge, TH; Kombrinck, KW; Flick, MJ; Daugherty, CC; Danton, MJS; Degen, JL				Bugge, TH; Kombrinck, KW; Flick, MJ; Daugherty, CC; Danton, MJS; Degen, JL			Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency	CELL			English	Article							TUMOR-CELL INVASION; UROKINASE RECEPTOR; DEGRADATION PRODUCTS; ACTIVATOR; MOUSE; GROWTH; INHIBITION; EMBRYOGENESIS; DISSEMINATION; LOCALIZATION	Plasmin(ogen) is an extracellular serine protease implicated in the activation of latent growth factors and procollagenase, degradation of extracellular matrix components, and fibrin clearance. Plasminogen (Plg) deficiency in mice results in high mortality, wasting, spontaneous gastrointestinal ulceration, rectal prolapse, and severe thrombosis. Furthermore, Plg-deficient mice display delayed wound healing following skin injury, a defect partly related to impaired keratinocyte migration. We generated mice deficient in Pig and fibrinogen (Fib) and show that removal of fibrin(ogen) from the extracellular environment alleviates the diverse spontaneous pathologies previously associated with Pig deficiency and corrects healing times. Mice deficient in Pig and Fib are phenotypically indistinguishable from Fib-deficient mice. These data suggest that the fundamental and possibly only essential physiological role of Pig is fibronolysis.	RIGSHOSP,FINSEN LAB,DK-2100 COPENHAGEN 0,DENMARK; CHILDRENS HOSP RES FDN,DIV PATHOL,CINCINNATI,OH 45229	Rigshospitalet; University of Copenhagen; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Bugge, TH (corresponding author), CHILDRENS HOSP RES FDN,DIV DEV BIOL,CINCINNATI,OH 45229, USA.				NHLBI NIH HHS [HL47826] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047826] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BODE VC, 1979, DEV BIOL, V73, P272, DOI 10.1016/0012-1606(79)90067-8; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; BUGGE TH, 1995, J BIOL CHEM, V270, P16886, DOI 10.1074/jbc.270.28.16886; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; Clark R. A. F., 1988, MOL CELLULAR BIOL WO; COLLEN D, 1994, MOL BASIS BLOOD DIS, P725; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Dewerchin M, 1996, J CLIN INVEST, V97, P870, DOI 10.1172/JCI118489; DONALDSON DJ, 1988, J INVEST DERMATOL, V90, P623, DOI 10.1111/1523-1747.ep12560762; DUMLER I, 1993, FEBS LETT, V322, P37, DOI 10.1016/0014-5793(93)81106-A; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; Gyetko MR, 1996, J CLIN INVEST, V97, P1818, DOI 10.1172/JCI118611; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Leonardsson G, 1995, P NATL ACAD SCI USA, V92, P12446, DOI 10.1073/pnas.92.26.12446; MAROTTI KR, 1982, DEV BIOL, V90, P154, DOI 10.1016/0012-1606(82)90220-2; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OSSOWSKI L, 1991, CANCER RES, V51, P274; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PEPPER MS, 1987, J CELL BIOL, V105, P2435; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; PLOW EF, 1986, J IMMUNOL, V137, P1910; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; ROBSON SC, 1993, BLOOD, V81, P3006; ROBSON SC, 1994, BRIT J HAEMATOL, V86, P322, DOI 10.1111/j.1365-2141.1994.tb04733.x; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; ROMER J, 1991, J INVEST DERMATOL, V97, P803, DOI 10.1111/1523-1747.ep12486833; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; SKOGEN WF, 1988, BLOOD, V71, P1475; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; THOMPSON WD, 1993, BLOOD COAGUL FIBRIN, V4, P113, DOI 10.1097/00001721-199304010-00019; TRUDEL M, 1994, BLOOD, V84, P3189; VALINSKY JE, 1981, CELL, V25, P471, DOI 10.1016/0092-8674(81)90065-9; VASSALLI JD, 1994, FIBRINOLYSIS, V8, P172, DOI 10.1016/0268-9499(94)90715-3; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801	54	321	333	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					709	719		10.1016/S0092-8674(00)81390-2	http://dx.doi.org/10.1016/S0092-8674(00)81390-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929539	Bronze			2022-12-01	WOS:A1996VU03500013
J	Bycroft, M; Hubbard, TJP; Proctor, M; Freund, SMV; Murzin, AG				Bycroft, M; Hubbard, TJP; Proctor, M; Freund, SMV; Murzin, AG			The solution structure of the S1 RNA binding domain: A member of an ancient nucleic acid-binding fold	CELL			English	Article							RIBOSOMAL-PROTEIN S1; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MESSENGER-RNA; POLYNUCLEOTIDE PHOSPHORYLASE; THERMUS-THERMOPHILUS; SECONDARY STRUCTURE; NUSA PROTEIN; SEQUENCE; RECOGNITION	The S1 domain, originally identified in ribosomal protein S1, is found in a large number of RNA-associated proteins. The structure of the S1 RNA-binding domain from the E. coli polynucleotide phosphorylase has been determined using NMR methods and consists of a five-stranded antiparallel beta barrel. Conserved residues on one face of the barrel and adjacent loops form the putative RNA-binding site. The structure of the S1 domain is very similar to that of cold shock protein, suggesting that they are both derived from an ancient nucleic acid-binding protein. Enhanced sequence searches reveal hitherto unidentified S1 domains in RNase E, RNase II, NusA, EMB-5, and other proteins.	UNIV CAMBRIDGE, CTR MRC, CAMBRIDGE CB2 2QH, ENGLAND	University of Cambridge	Bycroft, M (corresponding author), UNIV CAMBRIDGE, CTR PROT ENGN, DEPT CHEM, LENSFIELD RD, CAMBRIDGE CB2 1EW, ENGLAND.		Hubbard, Tim J/C-2567-2008; Bycroft, Mark/D-9446-2017; Hubbard, Tim J.P./AAT-4571-2020	Hubbard, Tim J/0000-0002-1767-9318; Hubbard, Tim J.P./0000-0002-1767-9318; Bycroft, Mark/0000-0002-0673-2216				BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; BLEASBY AJ, 1994, NUCLEIC ACIDS RES, V22, P3574; BONI IV, 1991, NUCLEIC ACIDS RES, V19, P155, DOI 10.1093/nar/19.1.155; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; Brunger A. T., 1993, X PLOR MANUAL VERSIO; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CLEMENS MJ, 1994, MOL BIOL REP, V19, P201, DOI 10.1007/BF00986962; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; EKLUND EA, 1995, GENE, V155, P231, DOI 10.1016/0378-1119(94)00898-3; Fuchs TM, 1996, J BACTERIOL, V178, P4445, DOI 10.1128/jb.178.15.4445-4452.1996; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GRIBSKOV M, 1992, GENE, V119, P107, DOI 10.1016/0378-1119(92)90073-X; Hubbard EJA, 1996, SCIENCE, V273, P112, DOI 10.1126/science.273.5271.112; HUBBARD TJ, 1995, PROTEINS, V23, P398, DOI 10.1002/prot.340230313; ITO K, 1991, J BACTERIOL, V173, P1492, DOI 10.1128/jb.173.4.1492-1501.1991; Jaishree TN, 1996, BIOCHEMISTRY-US, V35, P2845, DOI 10.1021/bi951062i; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANGER D, 1994, NUCLEIC ACIDS RES, V22, P694, DOI 10.1093/nar/22.4.694; LIU K, 1995, J MOL BIOL, V247, P547, DOI 10.1016/S0022-2836(05)80136-6; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MATTAJ IW, 1995, NAT STRUCT BIOL, V2, P518, DOI 10.1038/nsb0795-518; MOSYAK L, 1995, NAT STRUCT BIOL, V2, P537, DOI 10.1038/nsb0795-537; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Nierlich DP, 1996, PROG NUCLEIC ACID RE, V52, P153, DOI 10.1016/S0079-6603(08)60967-8; OKADA Y, 1994, J BACTERIOL, V176, P917, DOI 10.1128/jb.176.3.917-922.1994; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; REGNIER P, 1987, J BIOL CHEM, V262, P63; RINGQUIST S, 1995, BIOCHEMISTRY-US, V34, P3640, DOI 10.1021/bi00011a019; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; RUCKMAN J, 1994, J BIOL CHEM, V269, P26655; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STONEHOUSE J, 1995, J MAGN RESON SER A, V112, P43, DOI 10.1006/jmra.1995.1008; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; TEPLYAKOV A, 1994, PROTEIN SCI, V3, P1098, DOI 10.1002/pro.5560030713; TOBE T, 1992, J BACTERIOL, V174, P6359, DOI 10.1128/JB.174.20.6359-6367.1992; VENKATESH TV, 1993, J BACTERIOL, V175, P1844, DOI 10.1128/JB.175.6.1844-1846.1993; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; ZILHAO R, 1993, MOL MICROBIOL, V8, P43, DOI 10.1111/j.1365-2958.1993.tb01201.x	66	347	354	2	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1997	88	2					235	242		10.1016/S0092-8674(00)81844-9	http://dx.doi.org/10.1016/S0092-8674(00)81844-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008164	Bronze			2022-12-01	WOS:A1997WE97000012
J	Freed, EO; Englund, G; Maldarelli, F; Martin, MA				Freed, EO; Englund, G; Maldarelli, F; Martin, MA			Phosphorylation of residue 131 of HIV-1 matrix is not required for macrophage infection	CELL			English	Letter							IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEAR-LOCALIZATION SIGNAL; NONDIVIDING CELLS; PRODUCTIVE INFECTION; PROTEIN; INVITRO; DOMAIN				Freed, EO (corresponding author), NIAID,MOL MICROBIOL LAB,NIH,BETHESDA,MD 20892, USA.		Maldarelli, Frank/O-2428-2016					Berthold E, 1996, J VIROL, V70, P4667, DOI 10.1128/JVI.70.7.4667-4682.1996; Bukrinskaya AG, 1996, P NATL ACAD SCI USA, V93, P367, DOI 10.1073/pnas.93.1.367; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; ENGLUND G, 1995, J VIROL, V69, P3216, DOI 10.1128/JVI.69.5.3216-3219.1995; FREED EO, 1994, J VIROL, V68, P5311, DOI 10.1128/JVI.68.8.5311-5320.1994; FREED EO, 1995, J VIROL, V69, P3949, DOI 10.1128/JVI.69.6.3949-3954.1995; FREED EO, 1994, NATURE, V369, P107, DOI 10.1038/369107b0; FREUNDLICH B, 1983, J IMMUNOL METHODS, V62, P31, DOI 10.1016/0022-1759(83)90107-2; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; KORNBLUTH RS, 1989, J EXP MED, V169, P1137, DOI 10.1084/jem.169.3.1137; LAZDINS JK, 1991, J IMMUNOL, V147, P1201; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; SCHUITEMAKER H, 1994, EMBO J, V13, P5929, DOI 10.1002/j.1460-2075.1994.tb06938.x; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992	16	61	61	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1997	88	2					171	173		10.1016/S0092-8674(00)81836-X	http://dx.doi.org/10.1016/S0092-8674(00)81836-X			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008157	Bronze			2022-12-01	WOS:A1997WE97000004
J	Hale, CA; deBoer, PAJ				Hale, CA; deBoer, PAJ			Direct binding of FtsZ to ZipA, an essential component of the septal ring structure that mediates cell division in E-coli	CELL			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; PROTEIN FTSZ; GENE; IDENTIFICATION; INHIBITION; INTERACTS; MEMBRANE; REGIONS; RATIO	FtsZ is a soluble, tubulin-like GTPase that forms a membrane-associated ring at the division site of bacterial cells. While this ring is thought to drive cell constriction, it is not well understood how it is assembled or how it affects cell wall invagination. Here we report that FtsZ binds directly to a novel integral inner-membrane protein in E. coli that we call ZipA. We present genetic and morphological evidence indicating that this interaction is required for cell division, and show that a fluorescent ZipA-Gfp fusion protein is located in a ring structure at the division site, both before and during cell wall invagination. ZipA is an essential component of the division machinery, and, by binding to both FtsZ and the cytoplasmic membrane, is likely to be directly involved in the assembly and/or function of the FtsZ ring.			Hale, CA (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.			de Boer, Piet/0000-0002-5375-6317				Addinall SG, 1996, J BACTERIOL, V178, P3877, DOI 10.1128/jb.178.13.3877-3884.1996; Baumann P, 1996, P NATL ACAD SCI USA, V93, P6726, DOI 10.1073/pnas.93.13.6726; BEGG KJ, 1995, J BACTERIOL, V177, P6211, DOI 10.1128/jb.177.21.6211-6222.1995; BI E, 1993, J BACTERIOL, V175, P1118, DOI 10.1128/JB.175.4.1118-1125.1993; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BYRNE CR, 1988, J BACTERIOL, V170, P3150, DOI 10.1128/jb.170.7.3150-3157.1988; DAI K, 1992, J BACTERIOL, V174, P6145, DOI 10.1128/JB.174.19.6145-6151.1992; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1990, ANNU REV GENET, V24, P249, DOI 10.1146/annurev.genet.24.1.249; DEBOER PAJ, 1992, J BACTERIOL, V174, P63, DOI 10.1128/jb.174.1.63-70.1992; DEBOER PAJ, 1990, P NATL ACAD SCI USA, V87, P1129, DOI 10.1073/pnas.87.3.1129; DESCOTEAUX A, 1987, J BACTERIOL, V169, P1938, DOI 10.1128/jb.169.5.1938-1942.1987; DEWAR SJ, 1992, J BACTERIOL, V174, P6314, DOI 10.1128/JB.174.19.6314-6316.1992; DONACHIE WD, 1993, ANNU REV MICROBIOL, V47, P199, DOI 10.1146/annurev.mi.47.100193.001215; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; ERICKSON HP, 1995, CELL, V80, P367, DOI 10.1016/0092-8674(95)90486-7; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HIGASHITANI A, 1995, BIOCHEM BIOPH RES CO, V209, P198, DOI 10.1006/bbrc.1995.1489; Huang J, 1996, J BACTERIOL, V178, P5080, DOI 10.1128/jb.178.17.5080-5085.1996; HUISMAN O, 1984, P NATL ACAD SCI-BIOL, V81, P4490, DOI 10.1073/pnas.81.14.4490; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; ISHINO Y, 1986, MOL GEN GENET, V204, P1, DOI 10.1007/BF00330179; KHATTAR MM, 1994, J BACTERIOL, V176, P7140, DOI 10.1128/JB.176.23.7140-7147.1994; LUTKENHAUS J, 1993, MOL MICROBIOL, V9, P403, DOI 10.1111/j.1365-2958.1993.tb01701.x; LUTKENHAUS J, 1996, ESCHERICHIA COLI SAL, P1615; Margolin W, 1996, J BACTERIOL, V178, P1320, DOI 10.1128/jb.178.5.1320-1327.1996; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; OSTERYOUNG KW, 1995, NATURE, V376, P473, DOI 10.1038/376473b0; Park JT, 1996, ESCHERICHIA COLI SAL, P48; PLA J, 1991, MOL MICROBIOL, V5, P1681, DOI 10.1111/j.1365-2958.1991.tb01915.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; SANCHEZ M, 1994, EMBO J, V13, P4919, DOI 10.1002/j.1460-2075.1994.tb06819.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Wang X, 1996, MOL MICROBIOL, V21, P313, DOI 10.1046/j.1365-2958.1996.6421360.x; WARD JE, 1985, CELL, V42, P941, DOI 10.1016/0092-8674(85)90290-9; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; ZHAO CR, 1995, P NATL ACAD SCI USA, V92, P4314	46	391	402	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1997	88	2					175	185		10.1016/S0092-8674(00)81838-3	http://dx.doi.org/10.1016/S0092-8674(00)81838-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008158	Bronze			2022-12-01	WOS:A1997WE97000006
J	Jonas, EA; Knox, RJ; Smith, TCM; Wayne, NL; Connor, JA; Karzmarek, LK				Jonas, EA; Knox, RJ; Smith, TCM; Wayne, NL; Connor, JA; Karzmarek, LK			Regulation by insulin of a unique neuronal Ca2+ pool and of neuropeptide secretion	NATURE			English	Article							EGG-LAYING HORMONE; BAG CELL NEURONS; ELECTRICAL AFTERDISCHARGE; INOSITOL TRISPHOSPHATE; NEUROENDOCRINE CELLS; APLYSIA; CALCIUM; CHANNELS; RELEASE; THAPSIGARGIN	The insulin receptor is a tyrosine kinase receptor that is found in mammalian brain(1) and at high concentrations in the bag cell neurons of Aplysia(2). We show here that insulin causes an acute rise in intracellular Ca2+ concentration ([Ca2+](i)) in these neurons and triggers release of neuropeptide. The insulin-sensitive intracellular Ca2+ pool differs pharmacologically from previously described Ca2+ stores that are sensitive to inositol trisphosphate and from mitochondrial Ca2+ stores(3-7). Insulin, but not thapsigargin, stimulates Ca2+ release at the distal tips of neurites, the presumed site of neuropeptide secretion(8,9). The effects of insulin on intracellular Ca2+ release and neuropeptide secretion occur without triggering spontaneous action potentials. The insulin-sensitive rise in [Ca2+](i) moves into the distal tips of neurites after exposure to a cyclic AMP analogue, a treatment that causes a similar translocation of neuronal vesicles(10-12). Our data indicate that Ca2+ release from a distinct intracellular pool associated with secretory vesicles may contribute to secretion of neuropeptide in the absence of neuronal discharge.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90025; LOVELACE BIOMED & ENVIRONM RES INST,ALBUQUERQUE,NM 87108	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Lovelace Respiratory Research Institute	Jonas, EA (corresponding author), YALE UNIV,SCH MED,DEPT PHARMACOL,333 CEDAR ST,NEW HAVEN,CT 06520, USA.							ARCH S, 1976, J GEN PHYSIOL, V68, P197, DOI 10.1085/jgp.68.2.197; AZHDERIAN EM, 1994, NEURON, V12, P1223, DOI 10.1016/0896-6273(94)90439-1; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; FINK LA, 1988, J NEUROSCI, V8, P2544; FORSCHER P, 1987, J NEUROSCI, V7, P3600; FRAZIER WT, 1967, J NEUROPHYSIOL, V30, P1288, DOI 10.1152/jn.1967.30.6.1288; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; HASKINS JT, 1981, J NEUROCYTOL, V10, P729, DOI 10.1007/BF01262650; HAVRANKOVA J, 1978, NATURE, V272, P827, DOI 10.1038/272827a0; Jonas EA, 1996, J NEUROSCI, V16, P1645; KNOX RJ, 1992, NEURON, V8, P883, DOI 10.1016/0896-6273(92)90202-O; Knox RJ, 1996, J PHYSIOL-LONDON, V494, P627, DOI 10.1113/jphysiol.1996.sp021520; LOECHNER KJ, 1990, J NEUROPHYSIOL, V63, P738, DOI 10.1152/jn.1990.63.4.738; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MAYERI E, 1985, J NEUROSCI, V5, P2060; MEECH RW, 1980, J PHYSIOL-LONDON, V298, P111, DOI 10.1113/jphysiol.1980.sp013070; PerezTerzic CM, 1995, BIOCHEM J, V312, P955, DOI 10.1042/bj3120955; STUART DK, 1980, J NEUROPHYSIOL, V43, P488, DOI 10.1152/jn.1980.43.2.488; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WAYNE NL, 1994, ENDOCRINOLOGY, V134, P1046, DOI 10.1210/en.134.3.1046; WAYNE NL, 1995, ENDOCRINOLOGY, V136, P369, DOI 10.1210/en.136.1.369; YAMAMOTO H, 1990, N-S ARCH PHARMACOL, V341, P273	25	105	108	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					343	346		10.1038/385343a0	http://dx.doi.org/10.1038/385343a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002519				2022-12-01	WOS:A1997WD91400051
J	Schwartz, DA; Doebbeling, BN; Merchant, JA; Barrett, DH; Black, DW; Burmeister, LF; Clarke, WR; Falter, KH; Hall, DB; Jones, MF; Saag, KG; Snyders, TL; Thorne, PS; Torner, JC; Wolson, RF; Ballas, ZK; Barrash, J; Casale, TB; Chrischilles, E; Falk, H; Hansen, MD; Kathol, RG; Kelly, JR; Pfohl, BM; Piette, WW; Quinlisk, P; Rohrer, JE; Sprince, NL; Talby, PM; Zwerling, C				Schwartz, DA; Doebbeling, BN; Merchant, JA; Barrett, DH; Black, DW; Burmeister, LF; Clarke, WR; Falter, KH; Hall, DB; Jones, MF; Saag, KG; Snyders, TL; Thorne, PS; Torner, JC; Wolson, RF; Ballas, ZK; Barrash, J; Casale, TB; Chrischilles, E; Falk, H; Hansen, MD; Kathol, RG; Kelly, JR; Pfohl, BM; Piette, WW; Quinlisk, P; Rohrer, JE; Sprince, NL; Talby, PM; Zwerling, C			Self-reported illness and health status among gulf war veterans - A population-based study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIFFERENTIAL RECALL; BIAS; QUESTIONNAIRE; IMPACT; SCALE	Objective.-To assess the prevalence of self-reported symptoms and illnesses among military personnel deployed during the Persian Gulf War (PGW) and to compare the prevalence of these conditions with the prevalence among military personnel on active duly at the same time, but not deployed to the Persian Gulf (non-PGW). Design.-Cross-sectional telephone interview survey of PGW and non-PGM, military personnel. The study instrument consisted of validated questions, validated questionnaires, and investigator-derived questions designed to assess relevant medical and psychiatric conditions. Setting.-Population-based sample of military personnel from Iowa. Study Participants.-A total of 4886 study subjects were randomly selected from 1 of 4 study domains (PGW regular military, PGW National Guard/Reserve, non-PGW regular military, and non-PGW National Guard/Reserve), stratifying for age, sex, race, rank, and branch of military service. Main Outcome Measures.-Self-reported symptoms and symptoms of medical illnesses and psychiatric conditions. Results.-Overall, 3695 eligible study subjects (76%) and 91% of the located subjects completed the telephone interview. Compared with non-PGW military personnel, PGW military personnel reported a significantly higher prevalence of symptoms of depression (17.0% vs 10.9%; Cochran-Mantel-Haenszel test statistic, P<.001), posttraumatic stress disorder (PTSD) (1.9% vs 0.8%, P=.007), chronic fatigue (1.3% vs 0.3%, P<.001), cognitive dysfunction (18.7% vs 7.6%, P<.001), bronchitis (3.7% vs 2.7%, P<.001), asthma (7.2% vs 4.1%, P=.004), fibromyalgia (19.2% vs 9.6%, P<.001), alcohol abuse (17.4% vs 12.6%, P=.02), anxiety (4.0% vs 1.8%, P<.001), and sexual discomfort (respondent, 1.5% vs 1.1%, P=.009; respondent's female partner, 5.1% vs 2.4%, P<.001). Assessment of health-related quality of life demonstrated diminished mental and physical functioning scores for PGW military personnel. In almost all cases, larger differences between PGW and non-PGW military personnel were observed in the National Guard/Reserve comparison. Within the PGW military study population, compared with veterans in the regular military, Veterans in the National Guard/Reserve only reported more symptoms of chronic fatigue (2.9% vs 1.0%, P=.03) and alcohol abuse (19.4% vs 17.0%, P=.004). Conclusions.-Military personnel who participated in the PGW have a higher self-reported prevalence of medical and psychiatric conditions than contemporary military personnel who were not deployed to the Persian Gulf. These findings establish the need to further investigate the potential etiologic, clinical, pathogenic, and public health implications of the increased prevalence of multiple medical and psychiatric conditions in populations of military personnel deployed to the Persian Gulf.	CTR DIS CONTROL & PREVENT, NATL CTR ENVIRONM HLTH, ATLANTA, GA 30333 USA; IOWA DEPT PUBL HLTH, DES MOINES, IA 50319 USA	Centers for Disease Control & Prevention - USA	Schwartz, DA (corresponding author), UNIV IOWA, COLL MED, DEPT INTERNAL MED, SE318 GH, IOWA CITY, IA 52242 USA.		Doebbeling, Bradley/C-6620-2009; Casale, Thomas B/K-4334-2013; Doebbeling, Bradley/AAC-1063-2022; Doebbeling, Bradley/L-9155-2019	Casale, Thomas B/0000-0002-3149-7377; Doebbeling, Bradley/0000-0003-3504-3468; 	PHS HHS [U50/CCU711513] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AbouDonia MB, 1996, J TOXICOL ENV HEALTH, V48, P35, DOI 10.1080/009841096161456; [Anonymous], 1988, JAMA, V259, P2701; [Anonymous], 1994, JAMA, V272, P391; [Anonymous], 1995, Arch Intern Med, V155, P262; BERGNER M, 1976, INT J HEALTH SERV, V6, P393, DOI 10.2190/RHE0-GGH4-410W-LA17; BOYLE CA, 1987, JAMA-J AM MED ASSOC, V257, P790; CALLE EE, 1988, JAMA-J AM MED ASSOC, V259, P2715, DOI 10.1001/jama.1988.03720180041030; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P443; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; CHOUINARD E, 1995, J CLIN EPIDEMIOL, V48, P245, DOI 10.1016/0895-4356(94)00132-A; *COMM REV HLTH CON, 1994, HLTH CONS SERV PERS; COUGHLIN SS, 1990, J CLIN EPIDEMIOL, V43, P87, DOI 10.1016/0895-4356(90)90060-3; *CTR DIS CONTR PRE, 1995, BEH RISK FACT SURV S; *CTR ENV HLTH INJ, 1989, HLTH  STAT VIETN VET, V2; DECOUFLE P, 1992, AM J EPIDEMIOL, V135, P312, DOI 10.1093/oxfordjournals.aje.a116285; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; DREWS CD, 1990, INT J EPIDEMIOL, V19, P1107, DOI 10.1093/ije/19.4.1107; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FLEISS JL, 1991, STATISTICAL METHODS; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Gray GC, 1996, NEW ENGL J MED, V335, P1505, DOI 10.1056/NEJM199611143352007; Greenland S, 1982, Stat Med, V1, P217, DOI 10.1002/sim.4780010304; Hyams KC, 1996, ANN INTERN MED, V125, P398, DOI 10.7326/0003-4819-125-5-199609010-00007; Kang HK, 1996, NEW ENGL J MED, V335, P1498, DOI 10.1056/NEJM199611143352006; MAGILL AJ, 1993, NEW ENGL J MED, V328, P1383, DOI 10.1056/NEJM199305133281904; MCHORNEY CA, 1994, MED CARE, V32, P551, DOI 10.1097/00005650-199406000-00002; *NAT CTR HLTH SERV, 1989, PUBL PHS; *NAT CTR INF DIS C, 1994, ILLN PERS GULF VET L; NEUGEBAUER R, 1990, J CLIN EPIDEMIOL, V43, P1337, DOI 10.1016/0895-4356(90)90100-4; *OFF ASS SECR DEF, 1996, COMPR CLIN EV PROGR; *OFF UND SECR DEF, 1994, REP DEF SCI BOARD TA; Penman AD, 1996, MIL MED, V161, P1; *PRES ADV COMM GUL, 1996, INT REP; REYNOLDS CF, 1988, PSYCHIAT RES, V24, P231, DOI 10.1016/0165-1781(88)90106-0; *SAS I INC, 1990, SAS IML SOFTW US REF; SATO T, 1990, ENVIRON HEALTH PERSP, V87, P95, DOI 10.2307/3431011; SHAH BV, 1992, SUDAAN USERS MANUAL; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; STRAHAN R, 1972, J CLIN PSYCHOL, V28, P191, DOI 10.1002/1097-4679(197204)28:2<191::AID-JCLP2270280220>3.0.CO;2-G; *U CAL, 1994, COMP ASS SURV EX SYS; *U IOW, 1993, FEM FAM HLTH QUEST A; Ware J.E., 1993, SCORING SF 36 SF 36, DOI DOI 10.6-10.7; Weathers FW, 1993, ANN M INT SOC, V1, P548; WOLFE F, 1995, ARTHRITIS RHEUM-US, V38, P19, DOI 10.1002/art.1780380104; 1993, VITAL HLTH STAT, V1	47	410	413	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1997	277	3					238	245						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WB446	9005274				2022-12-01	WOS:A1997WB44600026
J	Stark, H; Orlova, EV; RinkeAppel, J; Junke, N; Mueller, F; Rodnina, M; Wintermeyer, W; Brimacombe, R; vanHeel, M				Stark, H; Orlova, EV; RinkeAppel, J; Junke, N; Mueller, F; Rodnina, M; Wintermeyer, W; Brimacombe, R; vanHeel, M			Arrangement of tRNAs in pre- and posttranslocational ribosomes revealed by electron cryomicroscopy	CELL			English	Article							ESCHERICHIA-COLI RIBOSOMES; FLUORESCENCE ENERGY-TRANSFER; PHENYLALANINE TRANSFER-RNA; MESSENGER-RNA; P-SITE; ANGULAR RECONSTITUTION; DECODING REGION; CROSS-LINKING; EXIT SITE; 16S RNA	The three-dimensional structure of the translating 70S E. coli ribosome is presented in its two main conformations: the pretranslocational and the posttranslocational states. Using electron cryomicroscopy and angular reconstitution, structures at 20 Angstrom resolution were obtained, which, when compared with our earlier reconstruction of ''empty'' ribosomes, showed densities corresponding to tRNA molecules-at the P and E sites for posttranslocational ribosomes and at the A and P sites for pretranslocational ribosomes. The P-site tRNA lies directly above the bridge connecting the two ribosomal subunits, with the A-site tRNA fitted snugly against it at an angle of similar to 50 degrees, toward the L7/L12 side of the ribosome. The E-site tRNA appears to lie between the side robe of the 30S subunit and the L1 protuberance.	MAX PLANCK INST MOL GENET, D-14195 BERLIN, GERMANY; UNIV WITTEN HERDECKE, INST MOL BIOL, D-58453 WITTEN, GERMANY; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND	Max Planck Society; Witten Herdecke University; Imperial College London	Stark, H (corresponding author), MAX PLANCK GESELL, FRITZ HABER INST, FARADAYWEG 4-6, D-14195 BERLIN, GERMANY.		Rodnina, Marina V./AAD-4667-2019; Orlova, Elena/CAF-8290-2022	Rodnina, Marina V./0000-0003-0105-3879; Holger, Stark/0000-0002-6161-1118; Orlova, Elena/0000-0003-3371-415X				Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; CALOGERO RA, 1988, P NATL ACAD SCI USA, V85, P6427, DOI 10.1073/pnas.85.17.6427; CHIU W, 1986, ANNU REV BIOPHYS BIO, V15, P237; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GNIRKE A, 1989, J BIOL CHEM, V264, P7291; GORNICKI P, 1984, J BIOL CHEM, V259, P493; HARAUZ G, 1986, OPTIK, V73, P146; Hawkes P W., 1980, COMPUTER PROCESSING, P1; HENDERSON R, 1995, Q REV BIOPHYS, V28, P171, DOI 10.1017/S003358350000305X; JOHNSON AE, 1982, J MOL BIOL, V156, P113, DOI 10.1016/0022-2836(82)90462-4; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; LILL R, 1987, J MOL BIOL, V196, P137, DOI 10.1016/0022-2836(87)90516-X; LILL R, 1988, J MOL BIOL, V203, P699, DOI 10.1016/0022-2836(88)90203-3; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOORE PB, 1995, STRUCTURE, V3, P851, DOI 10.1016/S0969-2126(01)00219-2; Mueller F, 1995, BIOCHEM CELL BIOL, V73, P767, DOI 10.1139/o95-085; NOLLER HF, 1990, RIBOSOME, P73; OAKES M, 1986, STRUCTURE FUNCTION G, P47; OFVERSTEDT LG, 1994, CELL, V79, P629, DOI 10.1016/0092-8674(94)90548-7; PAULSEN H, 1986, BIOCHEMISTRY-US, V25, P2749, DOI 10.1021/bi00358a002; PAULSEN H, 1983, J MOL BIOL, V167, P411, DOI 10.1016/S0022-2836(83)80342-8; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; REMME J, 1989, EUR J BIOCHEM, V183, P281, DOI 10.1111/j.1432-1033.1989.tb14925.x; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; RHEINBERGER HJ, 1986, FEBS LETT, V204, P97, DOI 10.1016/0014-5793(86)81393-X; RinkeAppel J, 1995, RNA, V1, P1018; ROBERTSON JM, 1987, J MOL BIOL, V196, P525, DOI 10.1016/0022-2836(87)90030-1; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; SCHATZ M, 1995, J STRUCT BIOL, V114, P28, DOI 10.1006/jsbi.1995.1003; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; SIRDESHMUKH R, 1985, NUCLEIC ACIDS RES, V13, P1185, DOI 10.1093/nar/13.4.1185; SMITH D, 1989, P NATL ACAD SCI USA, V86, P4397, DOI 10.1073/pnas.86.12.4397; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STOFFLER G, 1986, STRUCTURE FUNCTION G, P28; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; VANHEEL M, 1985, EMBO J, V4, P2389, DOI 10.1002/j.1460-2075.1985.tb03944.x; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/S0304-3991(81)80197-0; VANHEEL M, 1989, OPTIK, V82, P114; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VANHEEL M, 1992, SCANNING MICROSCOPY, V6, P23; WALLECZEK J, 1990, J BIOL CHEM, V265, P11338; WOWER J, 1993, EMBO J, V12, P617, DOI 10.1002/j.1460-2075.1993.tb05694.x; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232; YONATH A, 1993, CURR OPIN STRUC BIOL, V3, P175, DOI 10.1016/S0959-440X(05)80149-6	54	216	217	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1997	88	1					19	28		10.1016/S0092-8674(00)81854-1	http://dx.doi.org/10.1016/S0092-8674(00)81854-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019401	Bronze			2022-12-01	WOS:A1997WC56900005
J	Bell, SA; Schaller, M; Rocken, M				Bell, SA; Schaller, M; Rocken, M			Occlusive paromomycin for cutaneous leishmaniasis	LANCET			English	Article											Bell, SA (corresponding author), UNIV MUNICH,DEPT DERMATOL,D-80337 MUNICH,GERMANY.			Rocken, Martin/0000-0003-3795-7001				ELON J, 1992, J AM ACAD DERMATOL, V27, P227, DOI 10.1016/0190-9622(92)70175-F; ELON J, 1988, PARASITOL TODAY, V4, P76, DOI 10.1016/0169-4758(88)90200-1; KOFF AB, 1994, J AM ACAD DERMATOL, V31, P693, DOI 10.1016/S0190-9622(94)70229-2; ROCKEN M, 1995, DERMATOL VENEROL, P261	4	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					29	29		10.1016/S0140-6736(05)62161-7	http://dx.doi.org/10.1016/S0140-6736(05)62161-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988124				2022-12-01	WOS:A1997WA72500018
J	Bundey, S				Bundey, S			Few psychological consequences of presymptomatic testing for Huntington disease	LANCET			English	Editorial Material							DUTCH PROGRAM				Bundey, S (corresponding author), BIRMINGHAM WOMENS HOSP,CLIN GENET UNIT,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND.							CODORI AM, 1994, AM J MED GENET, V54, P167, DOI 10.1002/ajmg.1320540303; *COMM INT HUNT ASS, 1994, J MED GENET, V31, P555; *HUNT DIS COLL RES, 1993, CELL, V72, P971; Lawson K, 1996, J MED GENET, V33, P856, DOI 10.1136/jmg.33.10.856; TIBBEN A, 1993, AM J MED GENET, V48, P103, DOI 10.1002/ajmg.1320480209; TIBBEN A, 1994, PSYCHOSOM MED, V56, P526, DOI 10.1097/00006842-199411000-00008	6	21	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					4	4		10.1016/S0140-6736(05)62155-1	http://dx.doi.org/10.1016/S0140-6736(05)62155-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988110				2022-12-01	WOS:A1997WA72500004
J	Wolffers, I				Wolffers, I			Culture, media, and HIV/AIDS in Asia	LANCET			English	Editorial Material							AIDS				Wolffers, I (corresponding author), VRIJE UNIV AMSTERDAM, FAC MED, SECT HLTH CARE DEV COUNTRIES, VAN DE BOECHORSTSTR 7, NL-1081 BT AMSTERDAM, NETHERLANDS.							Baker A. J., 1986, SOCIAL DIMENSIONS AI, P179; Clatts M C, 1989, Med Anthropol, V10, P105; DEBRUYN M, 1994, ALTERING IMAGE AIDS; FORD N, 1991, SOC SCI MED, V33, P405, DOI 10.1016/0277-9536(91)90321-3; Geertz C., 1973, INTERPRETATIONS CULT; Geertz Clifford, 1983, LOCAL KNOWLEDGE; HARRIS M, 1979, CULTURAL MATERIALISM; KEESING RM, 1987, CURR ANTHROPOL, V28, P161, DOI 10.1086/203508; KING D, 1990, WOMEN HEALTH, V16, P155, DOI 10.1300/J013v16n03_09; Lear D, 1990, INT Q COMMUN HLTH ED, V10, P253; Mann J., 1992, AIDS WORLD GLOBAL RE; NELKIN D, 1991, MILBANK Q, V69, P293, DOI 10.2307/3350206; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; Osteria T, 1991, AIDS Educ Prev, V3, P133; PINS M, 1989, AIDS CARE, V1, P77; REID E, 1995, HIV AIDS GLOBAL INTE; SANDFORT T, 1992, 8 INT C AIDS AMST; Shilts Randy., 1987, BAND PLAYED; THANHDAM T, 1983, DEV CHANGE, V14, P533, DOI 10.1111/j.1467-7660.1983.tb00165.x; Weniger BG, 1996, NEW ENGL J MED, V335, P343, DOI 10.1056/NEJM199608013350510; Wolffers I, 1994, Ned Tijdschr Geneeskd, V138, P307; WOLFFERS I, 1995, HIV AIDS MASS MEDIA; WOLFFERS I, 1992, AIDS PRIMARY HLTH CA; WOLFFERS I, 1994, ALTERING IMAGE AIDS, P15	24	16	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 4	1997	349	9044					52	54		10.1016/S0140-6736(96)07032-8	http://dx.doi.org/10.1016/S0140-6736(96)07032-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WA725	8988132				2022-12-01	WOS:A1997WA72500047
J	Holmes, TC; Fadool, DA; Ren, RB; Levitan, IB				Holmes, TC; Fadool, DA; Ren, RB; Levitan, IB			Association of Src tyrosine kinase with a human potassium channel mediated by SH3 domain	SCIENCE			English	Article							ACETYLCHOLINE-RECEPTOR; HIPPOCAMPAL-NEURONS; PROTEIN; BINDING; MEMBRANE; FAMILY; KV1.5; IDENTIFICATION; LOCALIZATION; MODULATION	The human Kv1.5 potassium channel (hKv1.5) contains proline-rich sequences identical to those that bind to src homology 3 (SH3) domains. Direct association of the Src tyrosine kinase with cloned hKv1.5 and native hKv1.5 in human myocardium was observed. This interaction was mediated by the proline-rich motif of hKv1.5 and the SH3 domain of Src. Furthermore, hKv1.5 was tyrosine phosphorylated, and the channel current was suppressed, in cells coexpressing v-Src. These results provide direct biochemical evidence for a signaling complex composed of a potassium channel and a protein tyrosine kinase.	BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254; BRANDEIS UNIV,VOLEN CTR COMPLEX SYST,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	Brandeis University; Brandeis University; Brandeis University; Brandeis University				Holmes, Todd/0000-0001-8152-8832	NINDS NIH HHS [F32 NS009952] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009952] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BIELEFELDT K, 1994, BIOPHYS J, V66, P1904, DOI 10.1016/S0006-3495(94)80984-1; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FUHRER C, IN PRESS J BIOL CHEM; Holmes TC, 1996, J NEUROSCI, V16, P1581; HOLMES TJ, UNPUB; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KOMAU HC, 1995, SCIENCE, V269, P1737; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; MALETICSAVATIC M, 1995, J NEUROSCI, V15, P3840; MAYS DJ, 1995, J CLIN INVEST, V96, P282, DOI 10.1172/JCI118032; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; OVERTURF KE, 1994, AM J PHYSIOL-CELL PH, V267, pC1231, DOI 10.1152/ajpcell.1994.267.5.C1231; PHILIPSON LH, 1993, BIOCHIM BIOPHYS ACTA, V1153, P111, DOI 10.1016/0005-2736(93)90282-5; REINHART PH, 1995, J NEUROSCI, V15, P4572; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SASAKI Y, 1995, FEBS LETT, V372, P20, DOI 10.1016/0014-5793(95)00954-8; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; SWOPE SL, 1994, J BIOL CHEM, V269, P29817; TAMKUN MM, 1991, FASEB J, V5, P331, DOI 10.1096/fasebj.5.3.2001794; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	31	240	244	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2089	2091		10.1126/science.274.5295.2089	http://dx.doi.org/10.1126/science.274.5295.2089			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953041				2022-12-01	WOS:A1996VY97400051
J	Brewer, TF; Heymann, SJ; Colditz, GA; Wilson, ME; Auerbach, K; Kane, D; Fineberg, HV				Brewer, TF; Heymann, SJ; Colditz, GA; Wilson, ME; Auerbach, K; Kane, D; Fineberg, HV			Evaluation of tuberculosis control policies using computer simulation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; DRUG-RESISTANT TUBERCULOSIS; HIV-INFECTED PATIENTS; UNITED-STATES; DECISION-ANALYSIS; EPIDEMIOLOGY; TRANSMISSION; MODEL; RISK	Objective.-To develop more effective methods to assess tuberculosis (TB) control strategies so we can meet national goals for the elimination of TB in the United States. Design.-Using a semi-Markov model that divided the US population into 3 age groups and 18 clinical states based on disease status and risk for TB and human immunodeficiency virus (HIV) infection, we measured the effects of 5 changes in TB policy, introduced singly and in combination: (1) increased coverage and (2) improved efficacy of preventive therapy, (3) increased coverage and (4) improved efficacy of treatment, and (5) introduction of BCG vaccination. Results.-A BCG Vaccination program that reached 10% of eligible children and 1% or eligible adults each year would produce a 17% reduction in cases and an 11% decline in deaths over 10 years. Preventive therapy programs among the general population would have little effect on the number of TB cases, but a program targeting HIV-infected patients would reduce HIV-associated TB cases and deaths 14% to 20%. A 10% improvement in the coverage and efficacy of both preventive therapy and treatment, coupled with the BCG vaccination program, would lead to a 47% decline in TB cases and a 50% decline in TB deaths relative to baseline over 10 years. Conclusions.-Improvements in treatment coverage or effectiveness alone are unlikely to reach established national goals for the elimination of TB. These goals can be achieved through a combination of improvements in current programs with targeted preventive therapy and BCG vaccination programs.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT HLTH CARE POLICY, BOSTON, MA 02115 USA; HARVARD UNIV, JOHN F KENNEDY SCH GOVT, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT POPULAT & INT HLTH, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, TECHNOL ASSESSMENT GRP, BOSTON, MA 02115 USA; MT AUBURN HOSP, DIV INFECT DIS, CAMBRIDGE, MA 02238 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Mount Auburn Hospital	Brewer, TF (corresponding author), BRIGHAM & WOMENS HOSP, CHANNING LAB, 181 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	AHRQ HHS [1 F32 HS00079] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BARRETTCONNOR E, 1981, PREV MED, V10, P69, DOI 10.1016/0091-7435(81)90007-4; BASS J, 1992, AM REV RESPIR DIS, V146, P1623; BELLIN E, 1994, JAMA-J AM MED ASSOC, V271, P708, DOI 10.1001/jama.271.9.708; BESNARD M, 1993, PEDIATR INFECT DIS J, V12, P993, DOI 10.1097/00006454-199312000-00006; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; BRAUN MM, 1993, JAMA-J AM MED ASSOC, V269, P2865, DOI 10.1001/jama.269.22.2865; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BURWEN D, 1993, P INT C AIDS JUN 6 1; BUSILLO CP, 1992, CHEST, V102, P797, DOI 10.1378/chest.102.3.797; Carter E J, 1992, R I Med, V75, P449; *CDCP, 1992, 7221 CDCP US DEP HLT; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P481; *CDCP, 1992, MMWR-MORBID MORTAL W, V41; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P301; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P395; *CDCP, 1993, TUB STAT US 1991, P14; *CDCP, 1994, NAT HIV SER SUMM RES, P3; *CDCP, 1993, 7215 CDCP US DEP HLT; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P387; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; COMSTOCK GW, 1976, PUBLIC HEALTH REP, V91, P276; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; DUTT AK, 1984, AM J MED, V77, P233, DOI 10.1016/0002-9343(84)90697-1; *ENC BRIT, 1993, ENC BRIT, P741; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GRAHAM NMH, 1993, ANN ALLERGY, V71, P421; GREENBERG PD, 1991, AM REV RESPIR DIS, V143, P490, DOI 10.1164/ajrccm/143.3.490; GUTMAN LT, 1994, PEDIATR INFECT DIS J, V13, P963, DOI 10.1097/00006454-199411000-00006; HAMBURG MA, 1992, NEW YORK STATE J MED, V92, P291; HART PD, 1977, BRIT MED J, V2, P293, DOI 10.1136/bmj.2.6082.293; HOBBY GL, 1974, AM REV RESPIR DIS, V110, P95; JAIN RK, 1989, COMPUT BIOMED RES, V22, P209, DOI 10.1016/0010-4809(89)90001-3; Karon J M, 1992, MMWR Recomm Rep, V41, P1; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; Lotte A, 1988, Bull Int Union Tuberc Lung Dis, V63, P47; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MOULDING T, 1971, ANN INTERN MED, V74, P761, DOI 10.7326/0003-4819-74-5-761; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; RIEDER HL, 1991, CHEST, V100, P678, DOI 10.1378/chest.100.3.678; ROSE DN, 1992, J GEN INTERN MED, V7, P589, DOI 10.1007/BF02599196; ROSE DN, 1988, AM J PREV MED, V4, P102, DOI 10.1016/S0749-3797(18)31204-2; ROSE DN, 1986, JAMA-J AM MED ASSOC, V256, P2709, DOI 10.1001/jama.256.19.2709; Rouillon A, 1976, Adv Tuberc Res, V19, P64; SALOMON N, 1995, CLIN INFECT DIS, V21, P1245, DOI 10.1093/clinids/21.5.1245; SEAHOLM SK, 1988, INT J BIOMED COMPUT, V23, P97, DOI 10.1016/0020-7101(88)90067-0; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; Stokey E., 1978, PRIMER POLICY ANAL; TAYLOR WC, 1981, ANN INTERN MED, V94, P808, DOI 10.7326/0003-4819-94-6-808; *US BUR CENS, 1993, 1993 STAT ABSTR US; *US IMM NAT SERV S, 1994, IMM ADM COUNTR BIRTH; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; Wharton M, 1990, MMWR Recomm Rep, V39, P1; *WHO EXP PROGR IMM, 1993, INF SYST SUMM WHO AM; *WHO EXP PROGR IMM, 1993, INF SYST SUMM WHO W	69	36	36	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1996	276	23					1898	1903		10.1001/jama.276.23.1898	http://dx.doi.org/10.1001/jama.276.23.1898			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX522	8968016				2022-12-01	WOS:A1996VX52200038
J	Palermo, GD; Colombero, LT; Schattman, GL; Davis, OK; Rosenwaks, Z				Palermo, GD; Colombero, LT; Schattman, GL; Davis, OK; Rosenwaks, Z			Evolution of pregnancies and initial follow-up of newborns delivered after intracytoplasmic sperm injection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MALE-FACTOR INFERTILITY; CHROMOSOME-ABNORMALITIES; ASSISTED FERTILIZATION; SUBZONAL INSEMINATION; INVITRO FERTILIZATION; MATERNAL AGE; SPERMATOGENESIS; ABSENCE; RATES	Objective.-To analyze the in vivo development of embryos conceived after intracytoplasmic sperm injection (ICSI), as well as obstetric outcome, occurrence of chromosomal abnormalities, and rate of congenital malformations in neonates born as a result of this treatment. Design.-Retrospective study. Setting.-University-based in vitro fertilization (IVF) clinic. Patients.-A total of 751 couples in whom the male partners were presumed to be the cause of repeated failed IVF attempts or whose semen parameters were unacceptable for conventional IVF treatment. Interventions.-Analysis of pregnancies resulting from 987 ICSI cycles; pregnancy outcome data were obtained from the records of obstetrician-gynecologists and/or pediatricians. Main Outcome Measures.-Pregnancy rates, obstetric outcome, and frequency of chromosomal abnormalities and congenital malformations. Results.-The overall clinical pregnancy (fetal heartbeat) rate was 44.3%, with a resultant delivery rate per ICSI cycle of 38.7% (n=382). In 8 of 11 miscarriages for which cytogenetic data were available, an autosomal trisomy was found, and 7 additional pregnancies were terminated because of a chromosomal abnormality after prenatal diagnosis. There was an equal distribution of vaginal vs cesarean deliveries (n=192 and n=190, respectively). Of the 578 neonates resulting from treatment by ICSI, 15 (2.6%) presented with congenital abnormalities (9 major and 6 minor abnormalities). However, this frequency of malformations is lower than that observed in offspring born after standard IVF at our institution. Furthermore, when pregnancy outcome of ICSI vs IVF was analyzed in terms of semen origin, no differences were found in the frequency of miscarriages or in the rate of congenital malformations. Conclusions.-The evolution of pregnancies and occurrence of congenital malformations following treatment by ICSI were within the range observed with standard in vitro fertilization.			Palermo, GD (corresponding author), NEW YORK HOSP, CORNELL MED CTR, CTR REPROD MED & INFERTIL, DEPT OBSTET & GYNECOL, 505 E 70TH ST, NEW YORK, NY 10021 USA.							BIGGERS JD, 1981, NEW ENGL J MED, V304, P336, DOI 10.1056/NEJM198102053040607; BONDUELLE M, 1994, HUM REPROD, V9, P1765, DOI 10.1093/oxfordjournals.humrep.a138791; BONDUELLE M, 1994, HUM REPROD S4, V9, P38; BONDUELLE M, 1995, HUM REPROD UPDATE, V1, P3; COHEN J, 1992, J ASSIST REPROD GEN, V9, P197, DOI 10.1007/BF01203813; COHEN J, 1988, ANN NY ACAD SCI, V541, P1, DOI 10.1111/j.1749-6632.1988.tb22236.x; DEJONGE CJ, 1995, HUM REPROD, V10, P2518, DOI 10.1093/oxfordjournals.humrep.a135733; DOYLE PE, 1991, J EPIDEMIOL COMMUN H, V45, P43, DOI 10.1136/jech.45.1.43; GOVAERTS I, 1995, LANCET, V346, P1095; HARTZ SC, 1992, FERTIL STERIL, V57, P15; HASSOLD T, 1985, HUM GENET, V70, P11, DOI 10.1007/BF00389450; HOLMES LB, 1976, NEW ENGL J MED, V295, P204, DOI 10.1056/NEJM197607222950406; KOBAYASHI K, 1994, HUM MOL GENET, V3, P1965, DOI 10.1093/hmg/3.11.1965; LANCASTER PAL, 1987, LANCET, V2, P110; LIEBAERS I, 1995, LANCET, V346, P1095, DOI 10.1016/S0140-6736(95)91768-3; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; MUNNE S, 1995, FERTIL STERIL, V64, P382, DOI 10.1016/S0015-0282(16)57739-5; MUNNE S, 1995, HUM REPROD, V10, P1014, DOI 10.1093/oxfordjournals.humrep.a136027; *NEW YORK STAT DEP, 1990, CONG MALF REG ANN RE; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; PALERMO G, 1993, FERTIL STERIL, V59, P826; Palermo GD, 1996, HUM REPROD, V11, P172; Palermo GD, 1996, FERTIL STERIL, V65, P899; PALERMO GD, 1995, SEMIN REPROD ENDOCR, V13, P39, DOI 10.1055/s-2007-1016341; PALERMO GD, 1995, FERTIL STERIL, V63, P1231, DOI 10.1016/S0015-0282(16)57603-1; PATRIZIO P, 1993, HUM REPROD, V8, P215, DOI 10.1093/oxfordjournals.humrep.a138025; PATRIZIO P, 1995, HUM REPROD, V10, P2520, DOI 10.1093/oxfordjournals.humrep.a135734; SCHLESSELMAN JJ, 1979, AM J OBSTET GYNECOL, V135, P135; SCHOYSMAN R, 1994, J ANDROL, V15, pS10; SILBER SJ, 1994, HUM REPROD, V9, P1705, DOI 10.1093/oxfordjournals.humrep.a138778; SMITH DW, 1975, J PEDIATR-US, V87, P162, DOI 10.1016/S0022-3476(75)80111-9; Svendsen TO, 1996, FERTIL STERIL, V65, P561, DOI 10.1016/S0015-0282(16)58154-0; TESARIK J, 1995, LANCET, V346, P1096; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1055, DOI 10.1093/oxfordjournals.humrep.a138191; VELD PI, 1995, LANCET, V346, P773, DOI 10.1016/S0140-6736(95)91531-1; Warburton D, 1986, PERINATAL GENETICS D, P133; WISANTO A, 1995, HUM REPROD, V10, P2713, DOI 10.1093/oxfordjournals.humrep.a135773	37	129	131	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1996	276	23					1893	1897		10.1001/jama.276.23.1893	http://dx.doi.org/10.1001/jama.276.23.1893			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX522	8968015				2022-12-01	WOS:A1996VX52200037
J	Adamson, DC; Wildemann, B; Sasaki, M; Glass, JD; McArthur, JC; Christov, VI; Dawson, TM; Dawson, VL				Adamson, DC; Wildemann, B; Sasaki, M; Glass, JD; McArthur, JC; Christov, VI; Dawson, TM; Dawson, VL			Immunologic NO synthase: Elevation in severe AIDS dementia and induction by HIV-1 gp41	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; BLOOD-BRAIN-BARRIER; NERVOUS-SYSTEM; COAT PROTEIN; CYTOKINE EXPRESSION; CORTICAL CULTURES; ENVELOPE PROTEIN; NEURONAL INJURY	Indirect mechanisms are implicated in the pathogenesis of the dementia associated with human immunodeficiency virus-typo 1 (HIV-1) infection. Proinflammatory molecules such as tumor necrosis factor alpha and eicosanoids are elevated in the central nervous system of patients with HIV-1-related dementia. Nitric oxide (NO) is a potential mediator of neuronal injury, because cytokines may activate the immunologic (type II) isoform of No synthase (iNOS). The levels of iNOS in severe HIV-1-associated dementia coincided with increased expression of the HIV-1 coat protein gp41. Furthermore, gp41 induced iNOS in primary cultures of mixed rat neuronal and glial cells and killed neurons through a NO-dependent mechanism. Thus, gp41-induced NO formation may contribute to the severe cognitive dysfunction associated with HIV-1 infection.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Dawson, Valina/Y-9757-2019	Dawson, Valina/0000-0002-2915-3970	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035042] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35042] Funding Source: Medline; NINDS NIH HHS [NS07392, NS22643] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adamson DC, 1996, MOL MED, V2, P417, DOI 10.1007/BF03401901; ADAMSON DR, UNPUB; ADLEBIASSETTE H, 1995, NEUROPATH APPL NEURO, V21, P218, DOI 10.1111/j.1365-2990.1995.tb01053.x; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BONOFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; BREW BJ, 1995, ANN NEUROL, V38, P563, DOI 10.1002/ana.410380404; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAWSON VL, 1993, P NATL ACAD SCI USA, V90, P3256, DOI 10.1073/pnas.90.8.3256; DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0; Dickson D W, 1996, J NeuroAIDS, V1, P57; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2; GELBARD HA, 1995, NEUROPATH APPL NEURO, V21, P208, DOI 10.1111/j.1365-2990.1995.tb01052.x; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GLASS JD, 1993, NEUROLOGY, V43, P2230, DOI 10.1212/WNL.43.11.2230; GLASS JD, 1995, ANN NEUROL, V38, P755, DOI 10.1002/ana.410380510; GRIFFIN DE, 1994, ANN NEUROL, V35, P592, DOI 10.1002/ana.410350513; HARRISON MJG, 1995, AIDS NEUROLOGY, P32; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; HILL JM, 1993, BRAIN RES, V603, P222, DOI 10.1016/0006-8993(93)91241-J; JANSSEN RS, 1991, NEUROLOGY, V41, P778; Johnson RT, 1996, ANN NEUROL, V39, P392, DOI 10.1002/ana.410390319; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOKA P, 1995, J NEUROIMMUNOL, V57, P179, DOI 10.1016/0165-5728(94)00184-P; KOKA P, 1995, J EXP MED, V182, P941, DOI 10.1084/jem.182.4.941; Lane TE, 1996, MOL MED, V2, P27, DOI 10.1007/BF03402200; LIPTON SA, 1992, TRENDS NEUROSCI, V15, P75, DOI 10.1016/0166-2236(92)90013-X; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; LIPTON SA, 1991, NEURON, V7, P111, DOI 10.1016/0896-6273(91)90079-F; MACKENZIEGRAHAM AJ, 1994, DEV NEUROSCI-BASEL, V16, P162, DOI 10.1159/000112103; MASLIAH E, 1992, LAB INVEST, V66, P285; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; MOLLACE V, 1993, BIOCHEM BIOPH RES CO, V194, P439, DOI 10.1006/bbrc.1993.1839; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PETITO CK, 1992, ANN NEUROL, V32, P658, DOI 10.1002/ana.410320509; PETITO CK, 1995, AM J PATHOL, V146, P1121; PIETRAFORTE D, 1994, J LEUKOCYTE BIOL, V55, P175, DOI 10.1002/jlb.55.2.175; POWER C, 1994, J VIROL, V68, P4643, DOI 10.1128/JVI.68.7.4643-4649.1994; POWER C, 1993, ANN NEUROL, V34, P339, DOI 10.1002/ana.410340307; PRICE RW, 1988, J INFECT DIS, V158, P1079, DOI 10.1093/infdis/158.5.1079; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474; SAVIO T, 1993, J NEUROSCI RES, V34, P265, DOI 10.1002/jnr.490340303; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Takahashi K, 1996, ANN NEUROL, V39, P705, DOI 10.1002/ana.410390606; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; TOMATORE C, 1994, NEUROLOGY, V44, P481; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; TYOR WR, 1993, NEUROLOGY, V43, P1002, DOI 10.1212/WNL.43.5.1002; VAZEUX R, 1992, AM J PATHOL, V140, P137; WAHL LM, 1989, P NATL ACAD SCI USA, V86, P621, DOI 10.1073/pnas.86.2.621; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; WILDEMANN B, UNPUB; WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613; WILEY CA, 1994, ANN NEUROL, V36, P673, DOI 10.1002/ana.410360422; Wong ML, 1996, NAT MED, V2, P581, DOI 10.1038/nm0596-581	69	372	379	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1917	1921		10.1126/science.274.5294.1917	http://dx.doi.org/10.1126/science.274.5294.1917			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943206				2022-12-01	WOS:A1996VY20000046
J	Yamaguchi, H; Hendrickson, WA				Yamaguchi, H; Hendrickson, WA			Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; DOMAINS; P56LCK; CD4; ICK	REGULATION through phosphorylation is a characteristic of signalling pathways(1,2), and the lymphocyte kinase Lck (p56(lck)) both performs phosphorylation and is affected by it. Lck is a Src-family tyrosine kinase expressed in T lymphocytes, where it participates in the cellular immune response(3). Like all Src homologues, it comprises SH3, SH2 and kinase domains. Lck associates through its distinctive amino-terminal segment with the cytoplasmic tails of either T cell co-receptor, CD4 or CD8-alpha(4,5) Activated Lck phosphorylates T-cell receptor zeta-chains, which then recruit the ZAP70 kinase to promote T cell activation(6). Lck is activated by autophosphorylation at Tyr 394 in the activation loop(7) and it is inactive when Tyr 505 near the carboxy terminus is phosphorylated and interacts with its own SH2 domain(8). Here we report the crystal structure of the Lck tyrosine kinase domain (LCKK) in its activated state at 1.7 Angstrom resolution. The structure reveals how a phosphoryl group at Tyr 394 generates a competent active site. Comparisons with other kinase structures indicate that tyrosine phophophorylation and ligand binding may in general elicit two distinct hinge-like movements between the kinase subdomains. From modelling studies, we suggest a basis for inhibition by phosphorylation at Tyr 505.	COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT BIOCHEM & MOL BIOPHYS,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute; Columbia University								Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FISCHER EH, 1955, J BIOL CHEM, V216, P121; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; *SERC, 1979, 4 SERC DAR LAB; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHOJI S, 1979, J BIOL CHEM, V254, P6211; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1992, ONCOGENE, V7, P971; VEILLETTE A, 1990, ONCOGENE, V5, P1455; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	28	421	430	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					484	489		10.1038/384484a0	http://dx.doi.org/10.1038/384484a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945479				2022-12-01	WOS:A1996VW68700069
J	Quinn, TC; Gaydos, C; Shepherd, M; Bobo, L; Hook, EW; Viscidi, R; Rompalo, A				Quinn, TC; Gaydos, C; Shepherd, M; Bobo, L; Hook, EW; Viscidi, R; Rompalo, A			Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; PELVIC INFLAMMATORY DISEASE; FIRST-VOID URINE; REACTION ASSAY; MONOCLONAL-ANTIBODIES; NEISSERIA-GONORRHOEAE; ENZYME-IMMUNOASSAY; ASYMPTOMATIC MEN; DIAGNOSIS; WOMEN	Objectives.-To determine the frequency of Chlamydia trachomatis genital infection within sexual partnerships using highly sensitive polymerase chain reaction (PCR) amplification and to identify the variables that might modify transmission. Design.-Cross-sectional study of sexual partnerships comparing in vitro culture and PCR amplification for C trachomatis. Setting.-Two outpatient sexually transmitted disease clinics. Participants.-Four hundred ninety-four people in sexual partnerships attending sexually transmitted disease clinics. Main Outcome Measure.-Genital infection with C trachomatis. Methods.-DNA sequencing was performed to examine specific genotypes within and between partnerships. Cross-sectional analysis was performed to determine characteristics associated with concordance or discordance of infection with partnerships. Results.-Cultures were positive for C trachomatis in 8.5% of males and 12.9% of females (P=.03), Using PCR, more infections were identified both in males (14.2%) and in females (15.8%), and the difference in infection rates analyzed by sex was no longer significant. In 20.4% of 494 couples, at least 1 partner had PCR results positive for C trachomatis, with a concordant infection rate of 10.7%, significantly higher than the 5.5% concordant infection rate demonstrable by culture (P<.01). Male-female and female-male transmission frequencies were equal (68%). The nucleotide sequences of the major outer membrane protein gene products were identical and unique for each of 15 culture-negative, PCR-positive concordant partnerships. In concordant infections, factors associated with infection in female partners were age less than 20 years, more than 1 partner in the past 6 months, and cervical ectopy greater than 25%. Conclusions.-Using PCR, the frequency of chlamydia transmission by infected males and females was nearly identical. The high rate of concordant infection, high frequency of infection among asymptomatic individuals, and high frequency of transmission regardless of sex underscore the importance of routine screening for chlamydia in both males and females, along with provision of treatment to all sexual partners of chlamydia-infected individuals.	NIAID, NIH, BETHESDA, MD 20892 USA; BALTIMORE CITY DEPT HLTH, BALTIMORE, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Quinn, TC (corresponding author), JOHNS HOPKINS UNIV, DIV INFECT DIS, DEPT MED, ROSS 1159, 720 RUTLAND AVE, BALTIMORE, MD 21205 USA.		Quinn, Thomas/A-2494-2010; Gaydos, Charlotte A./E-9937-2010	Viscidi, Raphael/0000-0002-7906-8002	NIAID NIH HHS [5R01 AI29508-02, 5R01 AI27727-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027727, R01AI029508] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1991, MMWR Recomm Rep, V40, P1; ARNO JN, 1994, SEX TRANSM DIS, V21, P47, DOI 10.1097/00007435-199401000-00010; BARNES RC, 1985, J CLIN MICROBIOL, V22, P609, DOI 10.1128/JCM.22.4.609-613.1985; BOBO L, 1991, LANCET, V338, P847, DOI 10.1016/0140-6736(91)91502-L; BRUNHAM RC, 1994, SEX TRANSM DIS, V21, P353, DOI 10.1097/00007435-199411000-00010; CATES W, 1990, EPIDEMIOL REV, V12, P199, DOI 10.1093/oxfordjournals.epirev.a036054; CHERNESKY MA, 1994, J CLIN MICROBIOL, V32, P2682, DOI 10.1128/JCM.32.11.2682-2685.1994; CHERNESKY MA, 1994, J INFECT DIS, V170, P1308, DOI 10.1093/infdis/170.5.1308; DUNLOP EMC, 1985, SEX TRANSM DIS, V12, P68, DOI 10.1097/00007435-198504000-00003; *GLOB PROGR AIDS W, 1995, OV SEL CUR SEX TRANS; HARRISON HR, 1985, AM J OBSTET GYNECOL, V153, P244, DOI 10.1016/S0002-9378(85)80105-8; Herrera J. L., 1993, Morbidity and Mortality Weekly Report, V42, P1; HOOK EW, 1992, AM J EPIDEMIOL, V136, P662, DOI 10.1093/oxfordjournals.aje.a116546; JASCHEK G, 1993, J CLIN MICROBIOL, V31, P1209, DOI 10.1128/JCM.31.5.1209-1212.1993; JONES RB, 1986, J CLIN MICROBIOL, V24, P1029, DOI 10.1128/JCM.24.6.1029-1033.1986; Katz BP, 1990, CHLAMYDIA INFECT, P567; KUNIMOTO D, 1985, REV INFECT DIS, V7, P665; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H; LYCKE E, 1980, SEX TRANSM DIS, V7, P6, DOI 10.1097/00007435-198001000-00002; MAHONY JB, 1992, J CLIN MICROBIOL, V30, P2241, DOI 10.1128/JCM.30.9.2241-2245.1992; PAAVONEN J, 1978, SEX TRANSM DIS, V5, P93, DOI 10.1097/00007435-197807000-00003; PAAVONEN J, 1979, SEX TRANSM DIS, V6, P69, DOI 10.1097/00007435-197904000-00005; QUINN TC, 1994, SEX TRANSM DIS, V21, pS19; QUINN TC, 1992, ADV HOST DEFENSE MEC, V8, P1; RAMSTEDT K, 1991, SEX TRANSM DIS, V18, P205, DOI 10.1097/00007435-199110000-00002; ROLFS RT, 1992, AM J OBSTET GYNECOL, V166, P983, DOI 10.1016/0002-9378(92)91377-M; RYS PN, 1990, J CLIN MICROBIOL, V28, P1968; SCHACHTER J, 1989, NEW ENGL J MED, V320, P802, DOI 10.1056/NEJM198903233201210; SCHACHTER J, 1990, WESTERN J MED, V153, P523; SCHACHTER J, 1994, J CLIN MICROBIOL, V32, P2540, DOI 10.1128/JCM.32.10.2540-2543.1994; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; SHAFER MA, 1987, J INFECT DIS, V156, P223, DOI 10.1093/infdis/156.1.223; STAMM WE, 1983, J CLIN MICROBIOL, V17, P666, DOI 10.1128/JCM.17.4.666-668.1983; STAMM WE, 1988, ANN INTERN MED, V108, P710, DOI 10.7326/0003-4819-108-5-710; UPCHURCH DM, 1991, AM J EPIDEMIOL, V134, P1159, DOI 10.1093/oxfordjournals.aje.a116019; VISCIDI RP, 1993, J INFECT DIS, V168, P488, DOI 10.1093/infdis/168.2.488; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2070, DOI 10.1001/jama.257.15.2070; WOLCOTT MJ, 1992, CLIN MICROBIOL REV, V5, P370, DOI 10.1128/CMR.5.4.370-386.1992; WORM AM, 1987, GENITOURIN MED, V63, P19; YUAN Y, 1989, INFECT IMMUN, V57, P1040, DOI 10.1128/IAI.57.4.1040-1049.1989	41	167	168	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1737	1742		10.1001/jama.276.21.1737	http://dx.doi.org/10.1001/jama.276.21.1737			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940322				2022-12-01	WOS:A1996VV56600031
J	Tinker, A; Jan, YN; Jan, LY				Tinker, A; Jan, YN; Jan, LY			Regions responsible for the assembly of inwardly rectifying potassium channels	CELL			English	Article							RECTIFIER K+ CHANNEL; FUNCTIONAL EXPRESSION; ACETYLCHOLINE-RECEPTOR; MOLECULAR-CLONING; PROTEINS; MG2+; RECTIFICATION; MUTATIONS; AGONISTS; NEURONS	Inwardly rectifying potassium channels have an important role in determining the resting potential of the cell. They are tetrameric proteins with two transmembrane segments (M1 and M2), a pore-forming loop (H5), a cytoplasmic N-terminal, and longer C-terminal domain. We have used biochemical and electrophysiological methods to identify regions required for homotypic interactions and those responsible for the incompatibility between IRK1 and two other members of the same subfamily (IRK2 and IRK3) and two members from other subfamilies (ROMK1 and 6.1\uK(ATP)). The data indicate that, in contrast to the voltage-gated class of potassium channel, the proximal C-terminus and the transmembrane segment M2 determine homo- and heteromultimerization and that heteromultimerization between members of the same or different subfamilies is case specific.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048200] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48200] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; BOND CT, 1994, RECEPTOR CHANNEL, V2, P183; Collins A, 1996, J NEUROSCI, V16, P1; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Fink M, 1996, FEBS LETT, V378, P64, DOI 10.1016/0014-5793(95)01388-1; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V261, P251, DOI 10.1098/rspb.1995.0145; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Isomoto S, 1996, BIOCHEM BIOPH RES CO, V218, P286, DOI 10.1006/bbrc.1996.0050; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KIM KM, 1995, NEUROSCIENCE, V69, P1145, DOI 10.1016/0306-4522(95)00326-E; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1995, AM J PHYSIOL-CELL PH, V269, pC821, DOI 10.1152/ajpcell.1995.269.4.C821; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIAO YJ, 1996, IN PRESS J NEUROSCI; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, J GEN PHYSIOL, V104, P477, DOI 10.1085/jgp.104.3.477; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MCNICHOLAS CM, 1996, IN PRESS AM J PHYSL; MORISHIGE KI, 1994, FEBS LETT, V346, P251, DOI 10.1016/0014-5793(94)00483-8; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; Pessia M, 1996, EMBO J, V15, P2980, DOI 10.1002/j.1460-2075.1996.tb00661.x; PREMKUMAR LS, 1994, J NEUROPHYSIOL, V71, P2570, DOI 10.1152/jn.1994.71.6.2570; Reuveny E, 1996, BIOPHYS J, V70, P754, DOI 10.1016/S0006-3495(96)79615-7; SHEN NV, 1993, NEURON, V11, P67; Slesinger PA, 1996, NEURON, V16, P321, DOI 10.1016/S0896-6273(00)80050-1; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; TAKAHASHI N, 1994, J BIOL CHEM, V269, P23274; Tucker SJ, 1996, J BIOL CHEM, V271, P5866, DOI 10.1074/jbc.271.10.5866; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7	52	134	138	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					857	868		10.1016/S0092-8674(00)81993-5	http://dx.doi.org/10.1016/S0092-8674(00)81993-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945513	Bronze			2022-12-01	WOS:A1996VV77400012
J	Offermanns, S; Mancino, V; Revel, JP; Simon, MI				Offermanns, S; Mancino, V; Revel, JP; Simon, MI			Vascular system defects and impaired cell chemokinesis as a result of G alpha(13) deficiency	SCIENCE			English	Article							G-PROTEINS; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; ENDOTHELIUM; PATHWAY; MICE; ACTIVATION; RECEPTORS; KINASE; RHO	Heterotrimeric GTP-binding proteins (G proteins) participate in cellular signaling and regulate a variety of physiological processes. Disruption of the gene encoding the G protein subunit alpha(13) (G alpha(13)) in mice impaired the ability of endothelial cells to develop into an organized Vascular system, resulting in intrauterine death. In addition, G alpha(13) (-/-) embryonic fibroblasts showed greatly impaired migratory responses to thrombin. These results demonstrate that G alpha(13) participates in the regulation of cell movement in response to specific-ligands, as well as in developmental angiogenesis.			Offermanns, S (corresponding author), CALTECH,DIV BIOL 14775,PASADENA,CA 91125, USA.		Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805	NIA NIH HHS [AG 12288] Funding Source: Medline; NIGMS NIH HHS [GM 34236] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034236, R01GM034236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012288] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; BIMBAUMER L, 1992, CELL, V71, P1068; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; DAVIS CA, 1993, METHOD ENZYMOL, V225, P502; DELPOZO MA, 1995, J CELL BIOL, V131, P495, DOI 10.1083/jcb.131.2.495; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGGINS T, 1994, CELL BIOL LAB HDB, P294; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; OFFERMANNS S, UNPUB; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; SA G, 1994, J BIOL CHEM, V269, P3219; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SOZZANI S, 1991, J IMMUNOL, V147, P2215; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; YANG JT, 1993, DEVELOPMENT, V119, P1093; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0; [No title captured]	41	281	287	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					533	536		10.1126/science.275.5299.533	http://dx.doi.org/10.1126/science.275.5299.533			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999798				2022-12-01	WOS:A1997WE25700045
J	Nulman, I; Rovet, J; Stewart, DE; Wolpin, J; Gardner, HA; Theis, JGW; Kulin, N; Koren, G				Nulman, I; Rovet, J; Stewart, DE; Wolpin, J; Gardner, HA; Theis, JGW; Kulin, N; Koren, G			Neurodevelopment of children exposed in utero to antidepressant drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANCY; FLUOXETINE; IMIPRAMINE; DEPRESSION; THERAPY	Background Many women of reproductive age have depression, necessitating therapy with either a tricyclic antidepressant drug or a drug, such as fluoxetine, that inhibits the reuptake of serotonin. Whether these drugs affect fetal neurodevelopment is not known. Methods We studied the children of 80 mothers who had received a tricyclic antidepressant drug during pregnancy, 55 children whose mothers had received fluoxetine during pregnancy, and 84 children whose mothers had not been exposed during pregnancy to any agent known to affect the fetus adversely. The children's global IQ and language development were assessed between 16 and 86 months of postnatal age by age-appropriate Bayley Scales of Infant Development or the McCarthy Scales of Children's Abilities (for IQ) and the Reynell Developmental Language Scales. Results The mean (+/-SD) global 10 scores were 118+/-17 in the children of mothers who received a tricyclic antidepressant drug, 117+/-17 in those whose mothers received fluoxetine, and 115+/-14 in those in the control group. The language scores were similar in all three groups. The results were similar in children exposed to a tricyclic antidepressant drug or fluoxetine during the first trimester and those exposed throughout pregnancy. There were also no significant differences in temperament, mood, arousability, activity level, distractibility, or behavior problems in the three groups of children. Conclusions In utero exposure to either tricyclic antidepressant drugs or fluoxetine does not affect global 10, language development, or behavioral development in preschool children. (C) 1997, Massachusetis Medical Society.	HOSP SICK CHILDREN,DIV CLIN PHARMACOL,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,MOTHERISK PROGRAM,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DEPT PEDIAT,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DEPT PSYCHOL,TORONTO,ON M5G 1X8,CANADA; TORONTO HOSP,WOMENS HLTH PROGRAM,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,TORONTO,ON,CANADA; OSHAWA GEN HOSP,OSHAWA,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto			Theis, Jochen Goar Walther/AAB-5884-2020; Stewart, Donna Eileen E/J-2844-2016	Stewart, Donna Eileen E/0000-0002-8157-7746				ACHENBACH TM, 1991, MANUAL CHILD BEHAVIO; Bayley N., 1993, BAYLEY SCALES INFANT; BORYS DJ, 1992, AM J EMERG MED, V10, P115, DOI 10.1016/0735-6757(92)90041-U; Chambers CD, 1996, NEW ENGL J MED, V335, P1010, DOI 10.1056/NEJM199610033351402; COHEN LS, 1989, PSYCHOSOMATICS, V30, P25, DOI 10.1016/S0033-3182(89)72314-8; CROMBIE DL, 1972, BRIT MED J, V1, P745, DOI 10.1136/bmj.1.5802.745; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; Fullard W., 1978, TODDLER TEMPERAMENT; Goodman S H, 1992, Prog Exp Pers Psychopathol Res, V15, P47; Gram L, 1994, NEW ENGL J MED, V332, P343; GRAM LF, 1994, NEW ENGL J MED, V331, P1354; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Hudson WW, 1982, CLIN MEASUREMENT PAC; IDANPAAN.J, 1973, LANCET, V2, P282; KESSLER RC, 1993, J AFFECT DISORDERS, V29, P85, DOI 10.1016/0165-0327(93)90026-G; KOREN G, 1989, AM J OBSTET GYNECOL, V160, P1190, DOI 10.1016/0002-9378(89)90186-5; KOREN G, 1994, MATERNAL FETAL TOXIC; KUENSSBERG EV, 1972, BMJ-BRIT MED J, V2, P292, DOI 10.1136/bmj.2.5808.292-b; McCarthy D., 1972, MCCARTHY SCALES CHIL; MCDEVITT SC, 1978, J CHILD PSYCHOL PSYC, V19, P245, DOI 10.1111/j.1469-7610.1978.tb00467.x; MISRI S, 1991, INT J PSYCHIAT MED, V21, P157, DOI 10.2190/JDTX-BYC3-K3VP-LWAH; MORRISON HL, 1983, CHILDREN DEPRESSED P; Nulman I, 1996, TERATOLOGY, V53, P304; PANDE AC, 1993, INT CLIN PSYCHOPHARM, V8, P267, DOI 10.1097/00004850-199300840-00010; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; POTTER WZ, 1991, NEW ENGL J MED, V325, P633; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; REYNELL J, 1985, REYNELL DEV LANGUAGE; Shepard TH, 1986, CATALOG TERATOGENIC; SIM M, 1972, BRIT MED J, V2, P45, DOI 10.1136/bmj.2.5804.45; VORHEES CV, 1994, FUND APPL TOXICOL, V23, P194, DOI 10.1006/faat.1994.1098; Wechsler D, 1981, ADULT INTELLIGENCE S; Weissman MM., 1991, PSYCHIAT DISORDERS A, P53; 1972, LANCET, V1, P838	34	399	404	0	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1997	336	4					258	262		10.1056/NEJM199701233360404	http://dx.doi.org/10.1056/NEJM199701233360404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WE632	8995088	Bronze			2022-12-01	WOS:A1997WE63200004
J	Ichijo, H; Nishida, E; Irie, K; tenDijke, P; Saitoh, M; Moriguchi, T; Takagi, M; Matsumoto, K; Miyazono, K; Gotoh, Y				Ichijo, H; Nishida, E; Irie, K; tenDijke, P; Saitoh, M; Moriguchi, T; Takagi, M; Matsumoto, K; Miyazono, K; Gotoh, Y			Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways	SCIENCE			English	Article							PROTEIN-KINASE CASCADES; C-JUN; TRANSDUCTION PATHWAYS; STRESS; PHOSPHORYLATION; CLONING; CDNA; THREONINE; BETA; RECEPTORS	Mitogen-activated protein (MAP) kinase cascades are activated in response to various extracellular stimuli, including growth factors and environmental stresses. A MAP kinase kinase kinase (MAPKKK), termed ASK1, was identified that activated two different subgroups of MAP kinase kinases (MAPKK), SEK1 (or MKK4) and MKK3/MAPKK6 (or MKK6), which in turn activated stress-activated protein kinase (SAPK, also known as JNK; c-Jun amino-terminal kinase) and p38 subgroups of MAP kinases, respectively. Overexpression of ASK1 induced apoptotic cell death, and ASK1 was activated in cells treated with tumor necrosis factor-alpha (TNF-alpha), Moreover, TNF-alpha-induced apoptosis was inhibited by a catalytically inactive form of ASK1. ASK1 may be a key element in the mechanism of stress- and cytokine-induced apoptosis.	KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOL BIOL,SAKYO KU,KYOTO 60601,JAPAN; NAGOYA UNIV,FAC SCI,DEPT MOL BIOL,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; BIOMED CTR,LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN; TOKYO MED & DENT UNIV,DEPT ORAL PATHOL,BUNKYO KU,TOKYO 113,JAPAN	Kyoto University; Nagoya University; Ludwig Institute for Cancer Research; Tokyo Medical & Dental University (TMDU)	Ichijo, H (corresponding author), JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOSHIMA KU,1-37-1 KAMI IKEBUKURO,TOKYO 170,JAPAN.		Dijke, Peter ten/AAG-4660-2021; Moriguchi, Tetsuo/D-7061-2012	Dijke, Peter ten/0000-0002-7234-342X; Moriguchi, Tetsuo/0000-0002-9598-4991; Ichijo, Hidenori/0000-0002-5005-6438				Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; GOTOH Y, UNPUB; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ICHIJO H, 1993, J BIOL CHEM, V268, P14505; ICHIJO H, UNPUB; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PONCZ M, 1987, BLOOD, V69, P219; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SELINS KS, 1987, J IMMUNOL, V139, P3199; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798	43	1949	2041	6	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					90	94		10.1126/science.275.5296.90	http://dx.doi.org/10.1126/science.275.5296.90			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974401				2022-12-01	WOS:A1997WA90300057
J	Iyengar, R				Iyengar, R			Signal transduction - There are GAPS and there are GAPS	SCIENCE			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; MECHANISM; GTPASE; ACTIVATION; HYDROLYSIS; MUTANTS; SUBUNIT				Iyengar, R (corresponding author), CUNY MT SINAI SCH MED,DEPT PHARMACOL,BOX 1215,NEW YORK,NY 10029, USA.							Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HUNT TW, 1996, NATURE, V383, P178; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KURJAN J, 1993, ANNU REV GENET, V27, P147; KUTUZOV M, 1994, EUR J BIOCHEM, V220, P963, DOI 10.1111/j.1432-1033.1994.tb18700.x; LINDER ME, 1987, J BIOL CHEM, V265, P8283; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Roush W, 1996, SCIENCE, V271, P1056, DOI 10.1126/science.271.5252.1056; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TAUSSIG R, 1994, J BIOL CHEM, V269, P6039; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WANG J, IN PRESS J BIOL CHEM; WATSON N, 1996, NATURE, V383, P175	25	27	27	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					42	43		10.1126/science.275.5296.42	http://dx.doi.org/10.1126/science.275.5296.42			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8999536				2022-12-01	WOS:A1997WA90300039
J	Vikkula, M; Boon, LM; Carraway, KL; Calvert, JT; Diamonti, AJ; Goumnerov, B; Pasyk, KA; Marchuk, DA; Warman, ML; Cantley, LC; Mulliken, JB; Olsen, BR				Vikkula, M; Boon, LM; Carraway, KL; Calvert, JT; Diamonti, AJ; Goumnerov, B; Pasyk, KA; Marchuk, DA; Warman, ML; Cantley, LC; Mulliken, JB; Olsen, BR			Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2	CELL			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR-BETA; VENOUS MALFORMATIONS; ENDOTHELIAL-CELLS; MOUSE EMBRYO; GENE; EXPRESSION; PROTEIN; VASCULOGENESIS; ANGIOGENESIS	Venous malformations (VMs), the most common errors of vascular morphogenesis in humans, are composed of dilated, serpiginous channels. The walls of the channels have a variable thickness of smooth muscle; some mural regions lack smooth muscle altogether. A missense mutation resulting in an arginine-to-tryptophan substitution at position 849 in the kinase domain of the receptor tyrosine kinase TIE2 segregates with dominantly inherited VM in two unrelated families. Using proteins expressed in insect cells, we demonstrate that the mutation results in increased activity of TIE2. We conclude that an activating mutation in TlE2 causes inherited VMs in the two families and that the TIE2 signaling pathway is critical for endothelial cell-smooth muscle cell communication in venous morphogenesis.	HARVARD UNIV,SCH DENT MED,HARVARD FORSYTH DEPT ORAL BIOL,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV PLAST SURG,BOSTON,MA 02115; DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC 27710; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV MICHIGAN,INST GERONTOL,ANN ARBOR,MI 48109; HARVARD UNIV,BETH ISRAEL DEACONESS HOSP,SCH MED,DEPT CELL BIOL,DIV SIGNAL TRANSDUCT,BOSTON,MA 02115	Harvard University; Harvard School of Dental Medicine; Harvard University; Boston Children's Hospital; Harvard Medical School; Duke University; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Michigan System; University of Michigan; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Vikkula, M (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Vikkula, Miikka/Q-1038-2018; Boon, Laurence/HCI-3629-2022; Cantley, Lewis C/D-1800-2014	Vikkula, Miikka/0000-0002-6236-338X; Cantley, Lewis C/0000-0002-1298-7653; Marchuk, Douglas/0000-0002-3110-6671	NHLBI NIH HHS [HL33014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN KE, 1994, J VASC SURG, V19, P577, DOI 10.1016/S0741-5214(94)70029-X; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; BELLUS GA, 1995, AM J HUM GENET, V56, P368; BETSHOLTZ C, 1993, BIOL PLATELET DERIVE, P11; BONIN LR, 1994, AM J PHYSIOL-HEART C, V267, pH1698, DOI 10.1152/ajpheart.1994.267.5.H1698; BOON LM, 1994, HUM MOL GENET, V3, P1583, DOI 10.1093/hmg/3.9.1583; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAMORE PA, 1993, GROWTH FACTORS, V8, P61, DOI 10.3109/08977199309029135; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1994, GENOMICS, V23, P512, DOI 10.1006/geno.1994.1536; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FILLINGER MF, 1993, J VASC SURG, V17, P1058, DOI 10.1016/0741-5214(93)90676-D; GALLIONE CJ, 1995, J MED GENET, V32, P197, DOI 10.1136/jmg.32.3.197; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; GROTENDORST GR, 1982, J CELL PHYSIOL, V113, P261, DOI 10.1002/jcp.1041130213; GUY PM, 1992, J BIOL CHEM, V267, P13851; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; Kraling BM, 1996, AM J PATHOL, V148, P1181; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MERWIN JR, 1991, AM J PATHOL, V138, P37; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MULLIKEN JB, 1988, HEMANGIOMAS MALFORMA; NAKAMURA H, 1988, AM J ANAT, V181, P406, DOI 10.1002/aja.1001810409; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; Powell RJ, 1996, J VASC SURG, V24, P51, DOI 10.1016/S0741-5214(96)70144-1; Powell RJ, 1996, ANN VASC SURG, V10, P4, DOI 10.1007/BF02002334; RISAU W, 1988, DEVELOPMENT, V102, P471; RISAU W, 1988, DEV BIOL, V125, P441, DOI 10.1016/0012-1606(88)90225-4; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SHINBROT E, 1994, DEV DYNAM, V199, P169, DOI 10.1002/aja.1001990302; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; Webster MK, 1996, MOL CELL BIOL, V16, P4081; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128	45	530	555	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1181	1190		10.1016/S0092-8674(00)81814-0	http://dx.doi.org/10.1016/S0092-8674(00)81814-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980225	Bronze			2022-12-01	WOS:A1996WA54100007
J	Nichol, KL				Nichol, KL			Booster doses of influenza vaccine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PLACEBO-CONTROLLED TRIAL; ELDERLY PERSONS; COST-EFFECTIVENESS; ANTIBODY-RESPONSE; ADVERSE REACTIONS; EFFICACY; ADULTS; PEOPLE				Nichol, KL (corresponding author), UNIV MINNESOTA, SCH MED, VA MED CTR, DEPT MED, MINNEAPOLIS, MN 55455 USA.							[Anonymous], 1996, MMWR Recomm Rep, V45, P1; CATE TR, 1983, REV INFECT DIS, V5, P737; COUCH RB, 1983, ANNU REV MICROBIOL, V37, P529, DOI 10.1146/annurev.mi.37.100183.002525; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; FOY HM, 1973, JAMA-J AM MED ASSOC, V226, P758, DOI 10.1001/jama.226.7.758; GOVAERT TME, 1993, BMJ-BRIT MED J, V307, P988, DOI 10.1136/bmj.307.6910.988; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GROSS PA, 1987, J CLIN MICROBIOL, V25, P1763, DOI 10.1128/JCM.25.9.1763-1765.1987; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; LO W, 1993, EUR J CLIN MICROBIOL, V12, P778, DOI 10.1007/BF02098469; MARGOLIS KL, 1990, JAMA-J AM MED ASSOC, V264, P1139, DOI 10.1001/jama.264.9.1139; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; Nichol KL, 1996, ARCH INTERN MED, V156, P1546, DOI 10.1001/archinte.156.14.1546; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; RASTOGI S, 1995, CLIN DIAGN LAB IMMUN, V2, P120, DOI 10.1128/CDLI.2.1.120-121.1995	17	4	5	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1996	276	23					1857	1857		10.1001/jama.1996.03540230007002	http://dx.doi.org/10.1001/jama.1996.03540230007002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX522	8967994				2022-12-01	WOS:A1996VX52200001
J	McMaster, P				McMaster, P			More radical surgical excision for hepatocellular cancer?	LANCET			English	Article											McMaster, P (corresponding author), UNIV HOSP,LIVER & HEPATOBILIARY UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							Grellier L, 1996, LANCET, V348, P1212, DOI 10.1016/S0140-6736(96)04444-3; ROMANI F, 1994, J AM COLL SURGEONS, V178, P379; WU HC, 1996, SURGERY, V120, P34; Yamamoto J, 1996, BRIT J SURG, V83, P1219	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1601	1602		10.1016/S0140-6736(05)65689-9	http://dx.doi.org/10.1016/S0140-6736(05)65689-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961985				2022-12-01	WOS:A1996VX87600004
J	Chew, SJ; Vicario, DS; Nottebohm, F				Chew, SJ; Vicario, DS; Nottebohm, F			Quantal duration of auditory memories	SCIENCE			English	Article							ZEBRA FINCHES; ANISOMYCIN; PERIODS; SONG	Neuronal responses in the caudomedial neostriatum (NCM) of adult zebra finches (Taeniopygia guttata) decreased upon repeated, unreinforced presentations of conspecific song, calls, or other complex sounds. This ''stimulus-specific habituation'' is a form of learning, and its spontaneous loss, a form of ''forgetting,'' Spontaneous forgetting occurred only at narrowly defined times (2 to 3, 6 to 7, 14 to 15, 17 to 18.5, 46 to 48, or 85 to 89 hours after first exposure to a stimulus), determined by stimulus class, number of presentations, and interval between presentations. The first five forgetting times coincided with periods when gene expression and protein; synthesis in NCM were required for maintenance of the longer lasting (85 to 89 hours) habituation. The number of successive episodes of gene expression induced by a stimulus, but occurring long after stimulus presentation, appears to determine the quantal duration of auditory memories.	ROCKEFELLER UNIV,LAB ANIM BEHAV,NEW YORK,NY 10021	Rockefeller University					NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040900, R37MH018343, R01MH018343] Funding Source: NIH RePORTER; NIMH NIH HHS [MH40900, MH18343] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		CHEW SJ, 1995, P NATL ACAD SCI USA, V92, P3406, DOI 10.1073/pnas.92.8.3406; Chew SJ, 1996, P NATL ACAD SCI USA, V93, P1950, DOI 10.1073/pnas.93.5.1950; FREEMAN FM, 1995, NEUROBIOL LEARN MEM, V63, P291, DOI 10.1006/nlme.1995.1034; GRECKSCH G, 1980, PHARMACOL BIOCHEM BE, V12, P663, DOI 10.1016/0091-3057(80)90145-8; Kroodsma DE., 1982, ACOUSTIC COMMUNICATI; MATTHIES H, 1994, LONG TERM POTENTIATI, P233; SIMPSON HB, 1990, J NEUROSCI, V10, P1541; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; Vates GE, 1996, J COMP NEUROL, V366, P613, DOI 10.1002/(SICI)1096-9861(19960318)366:4<613::AID-CNE5>3.0.CO;2-7; ZANN R, 1990, ANIM BEHAV, V40, P811, DOI 10.1016/S0003-3472(05)80982-0	10	57	58	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1909	1914		10.1126/science.274.5294.1909	http://dx.doi.org/10.1126/science.274.5294.1909			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943204				2022-12-01	WOS:A1996VY20000044
J	Son, H; Hawkins, RD; Martin, K; Kiebler, M; Huang, PL; Fishman, MC; Kandel, ER				Son, H; Hawkins, RD; Martin, K; Kiebler, M; Huang, PL; Fishman, MC; Kandel, ER			Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthase	CELL			English	Article							PLATELET-ACTIVATING-FACTOR; HIPPOCAMPAL PYRAMIDAL CELLS; RAT HIPPOCAMPUS; SYNAPTIC TRANSMISSION; RETROGRADE MESSENGER; INHIBITORS; ENHANCEMENT; SYNAPSES; SLICES; CA1	Nitric oxide (NO) has been implicated in hippocampal long-term potentiation (LTP), but LTP is normal in mice with a targeted mutation in the neuronal form of NO synthase (nNOS(-)). LTP was also normal in mice with a targeted mutation in endothelial NOS (eNOS(-)), but LTP in stratum radiatum of CA1 was significantly reduced in doubly mutant mice (nNOS(-)/eNOS(-)). By contrast, LTP in stratum oriens was normal in the doubly mutant mice. These results provide the first genetic evidence that NOS is involved in LTP in stratum radiatum and suggest that the neuronal and endothelial forms can compensate for each other in mice with a single mutation. They further suggest that there is also a NOS-independent component of LTP in stratum radiatum and that LTP in stratum oriens is largely NOS independent.	COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,CHARLESTOWN,MA 02129	Columbia University; Harvard University; Massachusetts General Hospital; Harvard University	Son, H (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.			Kiebler, Michael/0000-0002-8850-6297	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS010828, P01NS010828, R01NS033335] Funding Source: NIH RePORTER; NIMH NIH HHS [MH50733] Funding Source: Medline; NINDS NIH HHS [NS33335, NS10828] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAI A, 1994, HIPPOCAMPUS, V4, P1, DOI 10.1002/hipo.450040103; ARAI A, 1992, EUR J NEUROSCI, V4, P411, DOI 10.1111/j.1460-9568.1992.tb00890.x; BANNERMAN DM, 1994, J NEUROSCI, V14, P7415; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BOULTON CL, 1995, NEUROSCIENCE, V69, P699, DOI 10.1016/0306-4522(95)00349-N; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; CUMMINGS JA, 1994, NEUROSCI LETT, V176, P110, DOI 10.1016/0304-3940(94)90883-4; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; Doyle C, 1996, J NEUROSCI, V16, P418; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRIBKOFF VK, 1992, J NEUROPHYSIOL, V68, P639, DOI 10.1152/jn.1992.68.2.639; Haley J. E., 1995, Society for Neuroscience Abstracts, V21, P1809; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HALEY JE, 1993, NEUROSCI LETT, V160, P85, DOI 10.1016/0304-3940(93)90919-C; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; IZUMI Y, 1993, NEUROREPORT, V4, P1131; KAIBARA T, 1993, J NEUROSCI, V13, P2391, DOI 10.1523/JNEUROSCI.13-06-02391.1993; Kantor D. B., 1996, Society for Neuroscience Abstracts, V22, P1511; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LUMRAGAN JT, 1993, NEUROSCIENCE, V57, P973, DOI 10.1016/0306-4522(93)90042-E; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; OUARDOUZ M, 1995, J NEUROPHYSIOL, V73, P810, DOI 10.1152/jn.1995.73.2.810; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; WENDLAND B, 1994, P NATL ACAD SCI USA, V91, P2151, DOI 10.1073/pnas.91.6.2151; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; WILLIAMS JH, 1993, NEURON, V11, P877, DOI 10.1016/0896-6273(93)90117-A; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	41	362	376	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1015	1023		10.1016/S0092-8674(00)81796-1	http://dx.doi.org/10.1016/S0092-8674(00)81796-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978606	hybrid			2022-12-01	WOS:A1996VY44700007
J	Srajer, V; Teng, TY; Ursby, T; Pradervand, C; Ren, Z; Adachi, S; Schildkamp, W; Bourgeois, D; Wulff, M; Moffat, K				Srajer, V; Teng, TY; Ursby, T; Pradervand, C; Ren, Z; Adachi, S; Schildkamp, W; Bourgeois, D; Wulff, M; Moffat, K			Photolysis of the carbon monoxide complex of myoglobin: Nanosecond time-resolved crystallography	SCIENCE			English	Article							MOLECULAR-DYNAMICS SIMULATION; LIGAND-BINDING; LAUE DIFFRACTION; PROTEIN CRYSTALS; SINGLE-CRYSTALS; MACROMOLECULAR CRYSTALLOGRAPHY; CONFORMATIONAL RELAXATION; RESONANCE RAMAN; HEME-PROTEINS; DOCKING SITE	The biological activity of macromolecules is accompanied by rapid structural changes. The photosensitivity of the carbon monoxide complex of myoglobin was used al the European Synchrotron Radiation Facility to obtain pulsed, Laue x-ray diffraction data with nanosecond time resolution during the process of heme and protein relaxation after carbon monoxide photodissociation and during rebinding. These time-resolved experiments reveal the structures of myoglobin photoproducts, provide a structural foundation to spectroscopic results and molecular dynamics calculations, and demonstrate that time-resolved macromolecular crystallography can elucidate the structural bases of biochemical mechanisms on the nanosecond time scale.	UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,CONSORTIUM ADV RADIAT SOURCES,CHICAGO,IL 60637; EUROPEAN SYNCHROTRON RADIAT FACIL,F-38043 GRENOBLE,FRANCE; INST PHYS & CHEM RES,BIOPHYS CHEM LAB,WAKO,SAITAMA 35101,JAPAN; IBS,UPR 9015,F-38027 GRENOBLE,FRANCE	University of Chicago; University of Chicago; European Synchrotron Radiation Facility (ESRF); RIKEN; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)			, Bourgeois/AAI-2337-2020; Pradervand, Claude P/I-8114-2013; Pradervand, Claude/GPF-4155-2022	Pradervand, Claude/0000-0001-5251-3930; Adachi, Shin-ichi/0000-0002-3676-1165	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036452, R01GM036452] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 07707] Funding Source: Medline; NIGMS NIH HHS [GM 36452] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; ANSARI A, 1992, SCIENCE, V256, P1796, DOI 10.1126/science.1615323; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; Bourgeois D, 1996, J SYNCHROTRON RADIAT, V3, P65, DOI 10.1107/S090904959501661X; CHEN Y, 1994, REV SCI INSTRUM, V65, P1506, DOI 10.1063/1.1144883; Cruickshank D. W. J., 1992, TIME RESOLVED MACROM; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; FRANZEN S, 1995, BIOCHEMISTRY-US, V34, P1224, DOI 10.1021/bi00004a016; GENBERG L, 1991, SCIENCE, V251, P1051, DOI 10.1126/science.1998121; GENICK U, UNPUB; GIBSON QH, 1986, J BIOL CHEM, V261, P228; HAGEN SJ, 1995, SCIENCE, V269, P959, DOI 10.1126/science.7638618; HARTMANN, 1996, P NATL ACAD SCI USA, V93, P7013; HENRY ER, 1986, P NATL ACAD SCI USA, V83, P8982, DOI 10.1073/pnas.83.23.8982; IBEN IET, 1989, BIOPHYS J, V56, P459, DOI 10.1016/S0006-3495(89)82693-1; JANES SM, 1988, BIOPHYS J, V54, P545, DOI 10.1016/S0006-3495(88)82987-4; KENDREW JC, 1956, P ROY SOC          A, V238, P305; KUCZERA K, 1993, P NATL ACAD SCI USA, V90, P5805, DOI 10.1073/pnas.90.12.5805; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LI HY, 1993, J BIOL CHEM, V268, P17908; LI P, 1992, J CHEM PHYS, V97, P3214, DOI 10.1063/1.463008; LIM M, 1995, SCIENCE, V269, P962, DOI 10.1126/science.7638619; LIM MH, 1995, J CHEM PHYS, V102, P4355, DOI 10.1063/1.469484; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; LINGLE R, 1991, J AM CHEM SOC, V113, P3992, DOI 10.1021/ja00010a052; MARTIN JL, 1992, ANNU REV BIOPH BIOM, V21, P199, DOI 10.1146/annurev.biophys.21.1.199; MOFFAT K, 1984, SCIENCE, V223, P1423, DOI 10.1126/science.223.4643.1423; MOFFAT K, 1995, CURR OPIN STRUC BIOL, V5, P656, DOI 10.1016/0959-440X(95)80059-X; MOFFAT K, 1989, ANNU REV BIOPHYS BIO, V18, P309, DOI 10.1146/annurev.biophys.18.1.309; MORIKIS D, 1988, J AM CHEM SOC, V110, P6341, DOI 10.1021/ja00227a011; NG K, 1995, BIOCHEMISTRY-US, V34, P879, DOI 10.1021/bi00003a022; PHILLIPS SEV, 1981, BROOKHAVEN PROTEIN D; REN Z, 1995, J APPL CRYSTALLOGR, V28, P461, DOI 10.1107/S0021889895003207; REN Z, 1995, J APPL CRYSTALLOGR, V28, P482, DOI 10.1107/S0021889895003219; SCHAAD O, 1993, P NATL ACAD SCI USA, V90, P9547, DOI 10.1073/pnas.90.20.9547; SCHLICHTING, 1994, NATURE, V317, P808; SIKORA S, 1994, BIOCHEMISTRY-US, V33, P4454, DOI 10.1021/bi00181a004; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TIAN WD, 1992, PHYS REV LETT, V68, P408, DOI 10.1103/PhysRevLett.68.408; XIE XL, 1991, BIOCHEMISTRY-US, V30, P3682, DOI 10.1021/bi00229a013; ZHU L, 1992, J MOL BIOL, V224, P207, DOI 10.1016/0022-2836(92)90584-7	42	448	455	3	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1726	1729		10.1126/science.274.5293.1726	http://dx.doi.org/10.1126/science.274.5293.1726			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939867				2022-12-01	WOS:A1996VW71200066
J	Robb, DL; Heasman, J; Raats, J; Wylie, C				Robb, DL; Heasman, J; Raats, J; Wylie, C			A kinesin-like protein is required for germ plasm aggregation in Xenopus	CELL			English	Article							MATERNAL MESSENGER-RNA; VEGETAL CORTEX; MESODERM INDUCTION; OOCYTES; EMBRYOS; EGGS; LOCALIZATION; DROSOPHILA; TRANSLOCATION; MICROTUBULES	In embryos of X. laevis, and many other species, early development requires targeted movements of molecules and molecular aggregates within the oocyte or egg cytoplasm. One well-known example in Xenopus is the aggregation of germ plasm, a group of cytoplasmic islands that become distributed during the first few cell cycles to cells that will give rise to the germ line. Nothing is known about the cytoskeletal motor proteins that may drive these movements. We show here that a recently identified Xenopus kinesin-like protein, Xklp1, is required for the aggregation of germ plasm in early Xenopus embryos, thus assigning this protein a role in a developmentally important cytoplasmic localization.	UNIV MINNESOTA, SCH MED, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT CELL BIOL & NEUROANAT, MINNEAPOLIS, MN 55455 USA; KATHOLIEKE UNIV, DEPT BIOCHEM, NIJMEGEN, NETHERLANDS	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Radboud University Nijmegen	Robb, DL (corresponding author), UNIV MINNESOTA, SCH MED, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA.							AKITA Y, 1985, J EMBRYOL EXP MORPH, V90, P251; BLACKLER AW, 1958, J EMBRYOL EXP MORPH, V6, P491; Boleti H, 1996, CELL, V84, P49, DOI 10.1016/S0092-8674(00)80992-7; BOUNOURE LOUIS, 1934, ANN SCI NAT ZOOL, V17, P67; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; COLE DG, 1995, TRENDS CELL BIOL, V5, P259, DOI 10.1016/S0962-8924(00)89028-5; Conklin E, 1905, BIOL BULL-US, V8, P205, DOI 10.2307/1535879; Conklin E.G., 1905, J ACAD NAT SCI PHILA, V12, P1, DOI DOI 10.5962/BHL.TITLE.4801; CZOLOWSKA R, 1969, J EMBRYOL EXP MORPH, V22, P229; CZOLOWSKA R, 1972, ROUX ARCH DEV BIOL, V169, P335, DOI 10.1007/BF00580253; DIXON KE, 1981, NETH J ZOOL, V31, P5; ELINSON RP, 1988, DEV BIOL, V128, P185, DOI 10.1016/0012-1606(88)90281-3; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GARD DL, 1994, DEV BIOL, V161, P131, DOI 10.1006/dbio.1994.1015; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; GURURAJAN R, 1994, P NATL ACAD SCI USA, V91, P2056, DOI 10.1073/pnas.91.6.2056; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HEASMAN J, 1991, METHOD CELL BIOL, V36, P213; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HOLWILL S, 1987, DEVELOPMENT, V100, P735; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; HOULISTON E, 1994, DEVELOPMENT, V120, P1213; IKENISHI K, 1982, DEV GROWTH DIFFER, V24, P205; IKENISHI K, 1986, DEV BIOL, V113, P259, DOI 10.1016/0012-1606(86)90128-4; ILLMENSEE K, 1976, DEV BIOL, V49, P40, DOI 10.1016/0012-1606(76)90257-8; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; KLOC M, 1995, DEVELOPMENT, V121, P287; KLOC M, 1994, SCIENCE, V265, P1101, DOI 10.1126/science.7520603; LEHMANN R, 1995, CELL, V83, P353, DOI 10.1016/0092-8674(95)90111-6; LINNEN JM, 1993, GENE, V128, P181, DOI 10.1016/0378-1119(93)90561-G; MAHOWALD AP, 1968, J EXP ZOOL, V167, P237, DOI 10.1002/jez.1401670211; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; Micklem DR, 1995, DEV BIOL, V172, P377, DOI 10.1006/dbio.1995.8048; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; RESSOM RE, 1988, DEVELOPMENT, V103, P507; Reverberi G., 1946, Pubblicazioni della Stazione Zoologica di Napoli, V20, P199; SAVAGE RM, 1993, DEV BIOL, V157, P371, DOI 10.1006/dbio.1993.1142; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; SMITH LD, 1966, DEV BIOL, V14, P330, DOI 10.1016/0012-1606(66)90019-4; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; TORPEY NP, 1992, J CELL SCI, V101, P151; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VERNOS I, 1993, DEV BIOL, V157, P232, DOI 10.1006/dbio.1993.1127; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; VINCENT JP, 1986, DEV BIOL, V113, P484, DOI 10.1016/0012-1606(86)90184-3; WAKAHARA M, 1977, J EMBRYOL EXP MORPH, V39, P221; WEEKS DL, 1987, P NATL ACAD SCI USA, V84, P2798, DOI 10.1073/pnas.84.9.2798; WHITINGTON PM, 1975, J EMBRYOL EXP MORPH, V33, P57; Wilson EB, 1904, J EXP ZOOL, V1, P1, DOI 10.1002/jez.1400010102; WYLIE CC, 1986, J CELL SCI, P329; YISRAELI JK, 1989, DEVELOPMENT, V107, P31; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	58	64	64	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					823	831		10.1016/S0092-8674(00)81990-X	http://dx.doi.org/10.1016/S0092-8674(00)81990-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945510	Bronze			2022-12-01	WOS:A1996VV77400009
J	Wolthers, KC; Wisman, GBA; Otto, SA; Husman, AMD; Schaft, N; deWolf, F; Goudsmit, J; Coutinho, RA; vanderZee, AGJ; Meyaard, L; Miedema, F				Wolthers, KC; Wisman, GBA; Otto, SA; Husman, AMD; Schaft, N; deWolf, F; Goudsmit, J; Coutinho, RA; vanderZee, AGJ; Meyaard, L; Miedema, F			T cell telomere length in HIV-1 infection: No evidence for increased CD4(+) T cell turnover	SCIENCE			English	Article							HUMAN FIBROBLASTS; TERMINAL TRANSFERASE; HUMAN-LYMPHOCYTES; IMMORTAL CELLS; MITOTIC CLOCK; IN-VITRO; AIDS; INDIVIDUALS; PROGRESSION; MEMORY	Progression to acquired immunodeficiency syndrome (AIDS) has been related to exhaustion of the regenerative capacity of the immune system resulting from high T cell turnover. Analysis of telomeric terminal restriction fragment (TRF) length, a marker for cellular replicative history, showed that CD8(+) T cell TRF length decreased but CD4(+) T cell TRF length was stable during the course of human immunodeficiency Virus type-1 (HIV-1) infection, which was not explained by differential telomerase activity. This observation provides evidence that turnover in the course of HIV-1 infection can be increased considerably in CD8(+) T cells, but not in CD4(+) T cells. These results are compatible with CD4(+) T cell decline in HIV-1 infection caused by interference with cell renewal.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, DEPT CLIN VIROIMMUNOL, NL-1066 CX AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, EXPT & CLIN IMMUNOL LAB, AMSTERDAM, NETHERLANDS; UNIV GRONINGEN, ACAD HOSP GRONINGEN, DEPT OBSTET & GYNAECOL, GRONINGEN, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT HUMAN RETROVIROL, NL-1105 AZ AMSTERDAM, NETHERLANDS; MUNICIPAL HLTH SERV, DEPT PUBL HLTH, AMSTERDAM, NETHERLANDS	University of Amsterdam; University of Groningen; University of Amsterdam; Academic Medical Center Amsterdam			Wolthers, Katja C./E-5140-2018; Schaft, Niels/H-3713-2011	Wolthers, Katja C./0000-0003-1617-7049; Schaft, Niels/0000-0001-8236-9298; Meyaard, Linde/0000-0003-0707-4793				Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bofill M, 1996, AIDS, V10, P827, DOI 10.1097/00002030-199607000-00005; Boudet F, 1996, J IMMUNOL, V156, P2282; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Effros RB, 1996, AIDS, V10, pF17, DOI 10.1097/00002030-199607000-00001; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; GIORGI JV, 1987, J IMMUNOL, V138, P3725; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GRUTERS RA, 1991, AIDS, V5, P837, DOI 10.1097/00002030-199107000-00007; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HIYAMA K, 1995, J IMMUNOL, V155, P3711; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO HN, 1993, J IMMUNOL, V150, P3070; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOSLER DE, 1995, NATURE, V375, P193, DOI 10.1038/375193b0; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; Ohyashiki JH, 1996, JPN J CANCER RES, V87, P329, DOI 10.1111/j.1349-7006.1996.tb00225.x; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PHILLIPS AN, 1995, NATURE, V375, P195, DOI 10.1038/375195a0; ROOS MTL, 1995, J INFECT DIS, V171, P531, DOI 10.1093/infdis/171.3.531; SCHELLEKENS PTA, 1992, AIDS, V6, P665, DOI 10.1097/00002030-199207000-00008; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SLAGBOOM PE, 1994, AM J HUM GENET, V55, P876; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; TANCHOT C, 1995, EUR J IMMUNOL, V25, P2127, DOI 10.1002/eji.1830250802; Tough DF, 1996, IMMUNOL REV, V150, P129, DOI 10.1111/j.1600-065X.1996.tb00699.x; VAZIRI H, 1993, AM J HUM GENET, V52, P661; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091	54	245	259	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1543	1547		10.1126/science.274.5292.1543	http://dx.doi.org/10.1126/science.274.5292.1543			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929418				2022-12-01	WOS:A1996VV77500053
J	Siegler, EL				Siegler, EL			April may be cruel, but November's pretty lousy, too	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Siegler, EL (corresponding author), BROOKLYN HOSP CTR, 121 DEKALB AVE, BROOKLYN, NY 11201 USA.			Siegler, Eugenia/0000-0001-9449-5873					0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					774	775		10.7326/0003-4819-125-9-199611010-00014	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929014				2022-12-01	WOS:A1996VQ07200012
J	Adams, MD; Venter, JC				Adams, MD; Venter, JC			Should non-peer-reviewed raw DNA sequence data release be forced on the scientific community?	SCIENCE			English	Editorial Material							GENOME				Adams, MD (corresponding author), INST GENOM RES,MED CTR DR,ROCKVILLE,MD 20850, USA.							ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P151; ANDERSON C, 1993, SCIENCE, V259, P1685, DOI 10.1126/science.259.5102.1685; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; LIPMAN D, COMMUNICATION; Marshall E, 1996, SCIENCE, V272, P477; WHITE O, 1993, NUCLEIC ACIDS RES, V21, P3829, DOI 10.1093/nar/21.16.3829	9	18	29	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					534	536		10.1126/science.274.5287.534	http://dx.doi.org/10.1126/science.274.5287.534			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VN919	8928007				2022-12-01	WOS:A1996VN91900035
J	Giordano, C; Stassi, G; DeMaria, R; Todaro, M; Richiusa, P; Papoff, G; Ruberti, G; Bagnasco, M; Testi, R; Galluzzo, A				Giordano, C; Stassi, G; DeMaria, R; Todaro, M; Richiusa, P; Papoff, G; Ruberti, G; Bagnasco, M; Testi, R; Galluzzo, A			Potential involvement of fas and its ligand in the pathogenesis of Hashimoto's thyroiditis	SCIENCE			English	Article							INDUCED APOPTOSIS; RECEPTOR; DISEASE; CELLS; EXPRESSION; APO-1; DOG	The mechanisms responsible for thyrocyte destruction in Hashimoto's thyroiditis (HT) are poorly understood. Thyrocytes from HT glands, but not from nonautoimmune thyroids, expressed Fas. Interleukin-1 beta (IL-1 beta), abundantly produced in HT glands, induced Fas expression in normal thyrocytes, and cross-linking of Fas resulted in massive thyrocyte apoptosis. The ligand for Fas (FasL) was shown to be constitutively expressed both in normal and HT thyrocytes and was able to kill Fas-sensitive targets. Exposure to IL-1 beta induced thyrocyte apoptosis, which was prevented by antibodies that block Fas, suggesting that IL-1 beta-induced Fas expression serves as a limiting factor for thyrocyte destruction. Thus, Fas-FasL interactions among HT thyrocytes may contribute to clinical hypothyroidism.	UNIV ROMA TOR VERGATA,DEPT EXPT MED & BIOCHEM SCI,ROME,ITALY; UNIV PALERMO,IMMUNOL LAB,ENDOCRINOL SECT,INST CLIN MED,PALERMO,ITALY; CNR,INST CELL BIOL,DEPT IMMUNOBIOL,ROME,ITALY; UNIV GENOA,GENOA,ITALY	University of Rome Tor Vergata; University of Palermo; Consiglio Nazionale delle Ricerche (CNR); University of Genoa			De Maria, Ruggero/S-6385-2019; PAPOFF, GIULIANA/AAX-9520-2020; GIORDANO, Carla/R-4296-2017	De Maria, Ruggero/0000-0003-2255-0583; PAPOFF, GIULIANA/0000-0003-2251-8794; GIORDANO, Carla/0000-0003-1731-9395; RUBERTI, Giovina/0000-0003-2367-9709	Telethon [A.066] Funding Source: Medline	Telethon(Fondazione Telethon)		BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Cascino I, 1996, J IMMUNOL, V156, P13; CHAMPION BR, 1992, CURR OPIN IMMUNOL, V4, P770, DOI 10.1016/0952-7915(92)90060-R; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; COCLET J, 1989, CLIN ENDOCRINOL, V31, P655, DOI 10.1111/j.1365-2265.1989.tb01290.x; DAVIES TF, 1992, J CLIN INVEST, V89, P157, DOI 10.1172/JCI115556; DEMARIA R, 1996, J CLIN INVEST, V97, P1; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DREMIER S, 1994, BIOCHEM BIOPH RES CO, V200, P52, DOI 10.1006/bbrc.1994.1412; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; GRUBECKLOEBENSTEIN B, 1989, CLIN EXP IMMUNOL, V77, P324; KOTANI T, 1995, AUTOIMMUNITY, V20, P231, DOI 10.3109/08916939508995700; KRAMMER PH, 1994, IMMUNOL REV, V14, P2175; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; WEETMAN AP, 1994, ENDOCR REV, V15, P788, DOI 10.1210/er.15.6.788; WU Z, 1994, CLIN EXP IMMUNOL, V98, P470	23	492	522	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					960	963		10.1126/science.275.5302.960	http://dx.doi.org/10.1126/science.275.5302.960			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020075				2022-12-01	WOS:A1997WH38800040
J	Johannesson, M; Jonsson, B; Kjekshus, J; Olsson, AG; Pedersen, TR; Wedel, H				Johannesson, M; Jonsson, B; Kjekshus, J; Olsson, AG; Pedersen, TR; Wedel, H			Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; HEALTH-CARE; HYPERTENSION; PREVENTION; THERAPY	Background The Scandinavian Simvastatin Survival Study (4S) showed that lowering cholesterol levels with simvastatin reduces mortality and morbidity in patients with angina pectoris or previous acute myocardial infarction. Before the widespread use of cholesterol-lowering drugs in such patients is recommended, its cost effectiveness should be demonstrated. We estimated the cost effectiveness of simvastatin treatment to lower cholesterol levels in relation to the age, sex, and cholesterol level before treatment of patients with coronary heart disease. Methods We estimated the cost per year of life gained with simvastatin therapy. To model the increased life expectancy, hazard functions from 4S were used. The costs studied included those of the intervention and the direct and indirect costs associated with morbidity from coronary causes. We prepared separate estimates for men and women at various ages (from 35 to 70 years) and total cholesterol levels before treatment (213 to 309 mg per deciliter). Results In the analysis limited to direct costs, the cost of each year of life gained ranged from $3,800 for 70-year-old men with 309 mg of cholesterol per deciliter to $27,400 for 35-year-old women with 213 mg of cholesterol per deciliter, When we included indirect costs, the results ranged from a savings in the youngest patients to a cost of $13,300 per year of life gained in 70-year-old women with 213 mg of cholesterol per deciliter. Conclusions In patients with coronary heart disease, simvastatin therapy is cost effective among both men and women at the ages and cholesterol levels studied. (C) 1997, Massachusetts Medical Society.	UNIV OSLO, RIKSHOSP, CARDIOL SECT, N-0027 OSLO, NORWAY; FAC HLTH SCI, DEPT INTERNAL MED, LINKOPING, SWEDEN; AKER HOSP, DEPT MED, CARDIOL SECT, OSLO, NORWAY; NORD SCH PUBL HLTH, GOTHENBURG, SWEDEN	University of Oslo; National Hospital Norway; University of Oslo	Johannesson, M (corresponding author), STOCKHOLM SCH ECON, CTR HLTH ECON, BOX 6501, S-11383 STOCKHOLM, SWEDEN.		Johannesson, Magnus/E-9680-2011	Johannesson, Magnus/0000-0001-8759-6393				Breslow NE., 1987, IARC SCI PUBL, VII, P131; *DRG, 1995, 395 DRG; *FASS, 1995, LAK SVER; GERDTHAM UG, 1993, HEALTH POLICY, V24, P1, DOI 10.1016/0168-8510(93)90083-2; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; HAY JW, 1991, AM J CARDIOL, V67, P789, DOI 10.1016/0002-9149(91)90609-O; Johannesson M, 1996, J INTERN MED, V240, P23, DOI 10.1046/j.1365-2796.1996.491830000.x; JOHANNESSON M, 1991, MED INFORM, V16, P355, DOI 10.3109/14639239109067657; JOHANNESSON M, 1993, SCAND J CLIN LAB INV, V53, P725, DOI 10.3109/00365519309092577; JOHANNESSON M, 1991, HEALTH POLICY, V19, P55, DOI 10.1016/0168-8510(91)90074-8; Jonsson B, 1996, EUR HEART J, V17, P1001; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; PEDERSEN TR, 1995, LANCET, V345, P1274; Pedersen TR, 1996, CIRCULATION, V93, P1796, DOI 10.1161/01.CIR.93.10.1796; PEDERSEN TR, 1994, LANCET, V344, P1383; RUSSELL LB, 1986, PREVENTION BETTER CU; *STAT CENTR, 1995, STAT ARSB 96; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; Weinstein M C, 1990, Int J Technol Assess Health Care, V6, P93; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; 1992, LANCET, V340, P148; 1995, NEW ENGL J MED, V333, P267	25	320	322	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1997	336	5					332	336		10.1056/NEJM199701303360503	http://dx.doi.org/10.1056/NEJM199701303360503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG233	9011785				2022-12-01	WOS:A1997WG23300003
J	Freymann, DM; Keenan, RJ; Stroud, RM; Walter, P				Freymann, DM; Keenan, RJ; Stroud, RM; Walter, P			Structure of the conserved GTPase domain of the signal recognition particle	NATURE			English	Article							CRYSTAL-STRUCTURE; PROTEIN TRANSLOCATION; BINDING DOMAIN; HYDROLYSIS; MECHANISM; SUBUNIT; CONFORMATION; RECEPTOR; SEQUENCE; ERRORS	The signal-recognition particle (SRP) and its receptor (SR) function in the co-translational targeting of nascent protein-ribosome complexes to the membrane translocation apparatus(1). The SRP protein subunit (termed Ffh in bacteria) that recognizes the signal sequence of nascent polypeptides is a GTPase, as is the SR-alpha subunit (termed FtsY)(2,3). Ffh. and FtsY interact directly, each stimulating the GTP hydrolysis activity of the other(4). The sequence of Ffh suggests three domains: an amino-terminal N domain of unknown function, a central GTPase G domain, and a methionine-rich M domain that binds both SRP RNA and signal peptides(5,6). Sequence conservation suggests that structurally similar N and G domains are present in FtsY(7,8). Here we report the structure of the nucleotide-free form of the NG fragment of Ffh. Consistent with a role for apo Ffh in protein targeting, the side chains of the empty active-site pocket form a tight network of interactions which map stabilize the nucleotide-free protein. The structural relationship between the two domains suggests that the N domain senses or controls the nucleotide occupancy of the GTPase domain. A structural subdomain unique to these evolutionarily conserved GTPases constitutes them as a distinct subfamily in the GTPase superfamily(9).			Freymann, DM (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.		Stroud, Rhonda/GQZ-0151-2022; Stroud, Rhonda M./C-5503-2008	Stroud, Rhonda/0000-0001-5242-8015; Stroud, Rhonda M./0000-0001-5242-8015; Freymann, Douglas/0000-0002-5231-8841; Keenan, Robert/0000-0003-1466-0889				Al-Karadaghi S, 1996, STRUCTURE, V4, P555, DOI 10.1016/S0969-2126(96)00061-5; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Evarsson A., 1994, EMBO J, V13, P3669; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KUSTERS R, 1995, FEBS LETT, V372, P253, DOI 10.1016/0014-5793(95)00997-N; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87; ZOPF D, 1993, J CELL BIOL, V120, P1113, DOI 10.1083/jcb.120.5.1113	30	201	204	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					361	364		10.1038/385361a0	http://dx.doi.org/10.1038/385361a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002524				2022-12-01	WOS:A1997WD91400056
J	Lasmezas, CI; Deslys, JP; Robain, O; Jaegly, A; Beringue, V; Peyrin, JM; Fournier, JG; Hauw, JJ; Rossier, J; Dormont, D				Lasmezas, CI; Deslys, JP; Robain, O; Jaegly, A; Beringue, V; Peyrin, JM; Fournier, JG; Hauw, JJ; Rossier, J; Dormont, D			Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein	SCIENCE			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; JAKOB-DISEASE AGENT; SCRAPIE AGENT; PRP; REPLICATION; STRAIN; NEURODEGENERATION; ACCUMULATION; MECHANISMS; RESISTANT	The agent responsible for transmissible spongiform encephalopathies (TSEs) is thought to be a malfolded, protease-resistant version (PrPres) of the normal cellular prion protein (PrP). The interspecies transmission of bovine spongiform encephalopathy (BSE) to mice was studied. Although all of the mice injected with homogenate from BSE-infected cattle brain exhibited neurological symptoms and neuronal death, more than 55 percent had no detectable PrPres. During serial passage, PrPres appeared after the agent became adapted to the new host. Thus, PrPres may be involved in species adaptation, but a further unidentified agent may actually transmit BSE.	HOP ST VINCENT DE PAUL,INSERM,U29,F-75674 PARIS 14,FRANCE; HOP LA PITIE SALPETRIERE,INSERM,U153,F-75651 PARIS 13,FRANCE; HOP LA PITIE SALPETRIERE,INSERM,U360,LAB ESCOUROLLE,F-75651 PARIS 13,FRANCE; ECOLE SUPER PHYS & CHIM IND VILLE PARIS,CNRS,URA 2054,F-75231 PARIS 5,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Lasmezas, CI (corresponding author), CEA,SERV NEUROVIROL,DSV,DRM,SSA,BP 6,60-68 AVE GEN LECLERC,F-92265 FONTENAY ROSES,FRANCE.			Peyrin, Jean-Michel/0000-0002-0108-1266; Peyrin, Jean-Michel/0000-0002-8705-8672				Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; DAWSON M, 1990, VET REC, V127, P338; Dickinson A. G., 1976, Slow virus diseases of animals and man,, P209; DICKINSON AG, 1989, UNCONVENTIONAL VIRUS, P446; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; FOSTER JD, 1993, VET REC, V133, P339, DOI 10.1136/vr.133.14.339; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; KIMBERLIN RH, 1987, J GEN VIROL, V68, P1875, DOI 10.1099/0022-1317-68-7-1875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; Lasmezas CI, 1996, J GEN VIROL, V77, P1601, DOI 10.1099/0022-1317-77-7-1601; MANUELIDIS L, 1994, ANN NY ACAD SCI, V724, P259, DOI 10.1111/j.1749-6632.1994.tb38916.x; Manuelidis L, 1996, VIROLOGY, V216, P46, DOI 10.1006/viro.1996.0033; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Riesner D, 1996, J VIROL, V70, P1714, DOI 10.1128/JVI.70.3.1714-1722.1996; SAKAGUCHI S, 1995, J VIROL, V69, P7586, DOI 10.1128/JVI.69.12.7586-7592.1995; SKLAVIADIS TK, 1989, J VIROL, V63, P1212, DOI 10.1128/JVI.63.3.1212-1222.1989; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; WELLS GAH, 1995, BRAIN PATHOL, V5, P91, DOI 10.1111/j.1750-3639.1995.tb00580.x; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WYATT JM, 1990, VET REC, V126, P513; XI YG, 1992, NATURE, V356, P598, DOI 10.1038/356598a0	34	486	496	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					402	405		10.1126/science.275.5298.402	http://dx.doi.org/10.1126/science.275.5298.402			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994041				2022-12-01	WOS:A1997WC87300052
J	Musti, AM; Treier, M; Bohmann, D				Musti, AM; Treier, M; Bohmann, D			Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases	SCIENCE			English	Article							PROTEIN-DEGRADATION; ACTIVATION DOMAIN; HA-RAS; PATHWAY; PROTEASOME; AUGMENTS	The proto-oncogene-encoded transcription factor c-Jun activates genes in response to a number of inducers that act through mitogen-activated protein kinase (MAPK) signal transduction pathways. The activation of c-Jun after phosphorylation by MAPK is accompanied by a reduction in c-Jun ubiquitination and consequent stabilization of the protein. These results illustrate the relevance of regulated protein degradation in the signal-dependent central oi gene expression.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Musti, Anna Maria/M-2520-2019; Treier, Mathias/AAD-6388-2021	MUSTI, Anna Maria/0000-0003-1443-2739				BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; ISAKSSON A, 1996, BIOCHIM BIOPHYS ACTA, V1288, P21; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Peverali FA, 1996, EMBO J, V15, P3943, DOI 10.1002/j.1460-2075.1996.tb00768.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Treier Mathias, 1996, P297, DOI 10.1002/9783527615032.ch11; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6	17	405	411	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					400	402		10.1126/science.275.5298.400	http://dx.doi.org/10.1126/science.275.5298.400			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994040				2022-12-01	WOS:A1997WC87300051
J	Bateson, MC				Bateson, MC			Bile acid research and applications	LANCET			English	Editorial Material											Bateson, MC (corresponding author), GEN HOSP,BISHOP AUCKLAND DL14 6AD,DURHAM,ENGLAND.								0	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					5	6		10.1016/S0140-6736(05)62157-5	http://dx.doi.org/10.1016/S0140-6736(05)62157-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988112				2022-12-01	WOS:A1997WA72500006
J	Pajarinen, J; Laippala, P; Penttila, A; Karhunen, PJ				Pajarinen, J; Laippala, P; Penttila, A; Karhunen, PJ			Incidence of disorders of spermatogenesis in middle aged Finnish men, 1981-91: Two necropsy series	BRITISH MEDICAL JOURNAL			English	Article							SEMEN QUALITY; SPERM COUNTS; CIGARETTE-SMOKING; TESTICULAR CANCER; ALCOHOL; DECLINE	Objective: To investigate if the incidence of disorders of spermatogenesis and testicular tissue morphology have changed in middle aged Finnish men over 10 years. Design: Two necropsy series completed in 1981 and in 1991. Setting: Department of Forensic Medicine, University of Helsinki, Finland. Subjects: 528 men, aged 35 to 69 years, subjected to medicolegal necropsy. Main outcome measures: Scoring of spermatogenesis and morphometric analysis of testicular tissue components. Individual risk factors for testicular disorders obtained by postmortem blind interviews with acquaintances. Results: Normal spermatogenesis was found in 41.7% of the men (mean age 53.1 years). Between 1981 and 1991, the ratio of normal spermatogenesis decreased significantly (odds ratio 3.5; 95% confidence interval 2.5 to 5.1) from 56.4% to 26.9%, with a parallel increase in the incidence of partial and complete spermatogenic arrest (2.1; 1.4 to 2.9 and 2.9; 1.7 to 5.0, respectively). During this period, the size of seminiferous tubules decreased, the amount of fibrotic tissue increased, and the weight of testicles decreased significantly Alterations in testicular characteristics over time could not be explained by changes in body mass index smoking, alcohol drinking, or exposure to drugs. Conclusions: The incidence of normal spermatogenesis decreased among middle aged Finnish men from 1981 to 1991, and the incidence of disorders of spermatogenesis and pathological alterations in testicles increased. Deteriorating spermatogenesis may thus be one important factor in the explanation of declining sperm counts observed worldwide.	UNIV TAMPERE,DEPT BIOMETR,FIN-33101 TAMPERE,FINLAND; UNIV TAMPERE,SCH MED,TAMPERE,FINLAND	Tampere University; Tampere University	Pajarinen, J (corresponding author), UNIV HELSINKI,DEPT FORENS MED,POB 40,FIN-00014 HELSINKI,FINLAND.							ADLERCREUTZ H, 1990, ANN NY ACAD SCI, V595, P281, DOI 10.1111/j.1749-6632.1990.tb34302.x; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; BOIESEN PT, 1979, ACTA PATH MICRO IM A, V87, P139; BROMWICH P, 1994, BRIT MED J, V309, P19, DOI 10.1136/bmj.309.6946.19; Bujan L, 1996, BRIT MED J, V312, P471, DOI 10.1136/bmj.312.7029.471; CARLSEN E, 1995, ENVIRON HEALTH PERSP, V103, P137, DOI 10.2307/3432523; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; CHIA SE, 1994, ARCH ANDROLOGY, V33, P163, DOI 10.3109/01485019408987820; Comhaire F, 1995, INT J ANDROL, V18, P1; DIKSHIT RK, 1987, FERTIL STERIL, V48, P334; DRIFE JO, 1987, DRUGS, V33, P610, DOI 10.2165/00003495-198733060-00004; FIELD B, 1990, SEMIN REPROD ENDOCR, V8, P44, DOI 10.1055/s-2007-1021422; *FINN STAT ALC CO, 1993, ALC STAT YB; Fisch H, 1996, FERTIL STERIL, V65, P1009, DOI 10.1016/S0015-0282(16)58278-8; Hakulinen T, 1986, Acta Pathol Microbiol Immunol Scand Suppl, V288, P1; Irvine S, 1996, BMJ-BRIT MED J, V312, P467, DOI 10.1136/bmj.312.7029.467; JACKSON MB, 1988, HORM RES, V30, P153, DOI 10.1159/000181052; JEGOU B, 1992, CELL BIOL TOXICOL, V8, P49, DOI 10.1007/BF00130510; Joffe M, 1996, LANCET, V347, P1519, DOI 10.1016/S0140-6736(96)90673-X; KARHUNEN PJ, 1990, ALCOHOL ALCOHOLISM, V25, P25; KULLER LH, 1978, AM J EPIDEMIOL, V108, P192, DOI 10.1093/oxfordjournals.aje.a112611; MEINHARD E, 1973, BRIT MED J, V3, P577, DOI 10.1136/bmj.3.5880.577; OLSEN GW, 1995, FERTIL STERIL, V63, P887, DOI 10.1016/S0015-0282(16)57498-6; OSTERLIND A, 1986, BRIT J CANCER, V53, P501, DOI 10.1038/bjc.1986.79; Pajarinen J, 1996, ALCOHOL CLIN EXP RES, V20, P332, DOI 10.1111/j.1530-0277.1996.tb01648.x; Pajarinen J, 1996, INT J ANDROL, V19, P155, DOI 10.1111/j.1365-2605.1996.tb00456.x; PAJARINEN JT, 1994, INT J ANDROL, V17, P292, DOI 10.1111/j.1365-2605.1994.tb01259.x; Paulsen CA, 1996, FERTIL STERIL, V65, P1015; ROSENBLUM E, 1985, ENDOCRINOLOGY, V115, P311; Sharpe RM, 1995, ENVIRON HEALTH PERSP, V103, P1136, DOI 10.2307/3432610; SHARPE RM, 1993, J ENDOCRINOL, V136, P357, DOI 10.1677/joe.0.1360357; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SUOMINEN J, 1993, BRIT MED J, V306, P1579, DOI 10.1136/bmj.306.6892.1579; VERMA AK, 1993, DIAGN CYTOPATHOL, V9, P37, DOI 10.1002/dc.2840090108; Vierula M, 1996, INT J ANDROL, V19, P11, DOI 10.1111/j.1365-2605.1996.tb00427.x; Wanderas EH, 1995, EUR J CANCER, V31A, P2044, DOI 10.1016/0959-8049(95)00321-5; WIDENIUS TV, 1987, J STEROID BIOCHEM, V28, P185, DOI 10.1016/0022-4731(87)90375-X; YAMADA K, 1993, BIOL PHARM BULL, V16, P425	41	45	46	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					13	18		10.1136/bmj.314.7073.13	http://dx.doi.org/10.1136/bmj.314.7073.13			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB684	9001473	Green Published			2022-12-01	WOS:A1997WB68400017
J	Helfand, M; Marton, KI; ZimmerGembeck, MJ; Sox, HC				Helfand, M; Marton, KI; ZimmerGembeck, MJ; Sox, HC			History of visible rectal bleeding in a primary care population - Initial assessment and 10-year follow-up	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTRAST BARIUM ENEMA; FLEXIBLE SIGMOIDOSCOPY; COLORECTAL-CANCER; GENERAL-PRACTICE; SYMPTOMS; COLONOSCOPY; PREVALENCE; DIAGNOSIS; SYSTEMS	Objective.-To determine whether a complaint of visible rectal bleeding that is elicited by a screening review of systems merits investigation and to assess the accuracy of a defined protocol to evaluate bleeding, Design.-Prospective cohort study. Setting.-Primary care clinics in a veterans medical center. Patients.-We used an 8-item review of systems to identify 297 individuals with visible rectal bleeding; 201 (68%) of these individuals completed a specified protocol consisting of double-contrast barium enema (DCBE) examination, rigid sigmoidoscopy, and follow-up visit after 6 to 12 months. Ten years later we ve rifled the diagnosis in 131 (93%) of 141 patients whose initial evaluation suggested no cause, or a benign anorectal cause, of bleeding. Main Outcome Measures.-Final diagnoses after 2 and 10 years; sensitivity and specificity of symptoms, DCBE, and rigid sigmoidoscopy. Results.-We diagnosed serious disease in 48 (24%) of the 201 patients; 26 had polyps, 9 had inflammatory bowel disease, and 13 (6.5%) had colon cancer. Symptoms did not predict the diagnosis. Neither DCBE nor rigid sigmoidoscopy atone was sufficiently sensitive to be used alone, but the combination of DCBE and rigid sigmoidoscopy had a sensitivity of 0.96 and a specificity of 0.76 for the diagnosis of polyps, cancer, or inflammatory bowel disease. Conclusions.-Self-reported rectal bleeding detected by means of a review of systems was associated with a high likelihood of important pathology. Physicians should ask all adults about visible rectal bleeding and should visualize the entire colon in those who report bleeding.	VET AFFAIRS MED CTR,DEPT MED,PORTLAND,OR; ST MARYS HOSP,DEPT MED,SAN FRANCISCO,CA; DARTMOUTH COLL SCH MED,DEPT MED,HANOVER,NH	US Department of Veterans Affairs; Veterans Health Administration (VHA); Dartmouth College	Helfand, M (corresponding author), OREGON HLTH SCI UNIV,CTR BIOMED INFORMAT COMMUN,BICC-504,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.		Zimmer-Gembeck, Melanie/H-3031-2015	Zimmer-Gembeck, Melanie/0000-0001-9100-010X				BOLAND BJ, 1995, AM J MED SCI, V309, P194, DOI 10.1097/00000441-199504000-00002; BREWSTER NT, 1994, BRIT J SURG, V81, P445, DOI 10.1002/bjs.1800810341; CROSLAND A, 1995, BRIT MED J, V311, P486, DOI 10.1136/bmj.311.7003.486; DENT OF, 1986, DIS COLON RECTUM, V29, P243, DOI 10.1007/BF02553027; EDDY DM, 1991, COMMON SCREENING TES, P286; FIJTEN GH, 1995, FAM PRACT, V12, P279, DOI 10.1093/fampra/12.3.279; FIJTEN GH, 1994, BRIT J GEN PRACT, V44, P320; FIJTEN GH, 1993, FAM PRACT, V10, P283, DOI 10.1093/fampra/10.3.283; FOUTCH PG, 1995, AM J GASTROENTEROL, V90, P564; GOULSTON KJ, 1986, LANCET, V2, P261; IRVINE EJ, 1988, GUT, V29, P1188, DOI 10.1136/gut.29.9.1188; MANT A, 1989, DIS COLON RECTUM, V32, P191, DOI 10.1007/BF02554525; MITCHELL TL, 1992, J GEN INTERN MED, V7, P393, DOI 10.1007/BF02599154; RANSOHOFF DF, 1990, JAMA-J AM MED ASSOC, V264, P76, DOI 10.1001/jama.264.1.76; REX DK, 1990, GASTROENTEROLOGY, V98, P855, DOI 10.1016/0016-5085(90)90007-N; Sackett D, 1991, CLIN EPIDEMIOLOGY BA; SILMAN AJ, 1983, BRIT J SURG, V70, P721, DOI 10.1002/bjs.1800701209	17	61	63	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1997	277	1					44	48		10.1001/jama.277.1.44	http://dx.doi.org/10.1001/jama.277.1.44			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ767	8980209				2022-12-01	WOS:A1997VZ76700028
J	Stenson, B				Stenson, B			Promoting attachment, providing memories	BRITISH MEDICAL JOURNAL			English	Article											Stenson, B (corresponding author), ROYAL EDINBURGH INFIRM,SIMPSON MEM MATERN PAVIL,NEONATAL UNIT,EDINBURGH EH3 9YN,MIDLOTHIAN,SCOTLAND.								0	0	0	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1615	1615		10.1136/bmj.313.7072.1615	http://dx.doi.org/10.1136/bmj.313.7072.1615			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991007	Green Published			2022-12-01	WOS:A1996VZ81100038
J	Otipoby, KL; Andersson, KB; Draves, KE; Klaus, SJ; Farr, AG; Kerner, JD; Perlmutter, RM; Law, CL; Clark, EA				Otipoby, KL; Andersson, KB; Draves, KE; Klaus, SJ; Farr, AG; Kerner, JD; Perlmutter, RM; Law, CL; Clark, EA			CD22 regulates thymus-independent responses and the lifespan of B cells	NATURE			English	Article							TYROSINE-PHOSPHATASE 1C; ANTIGEN RECEPTOR; T-CELLS; ADHESION MOLECULE; STEM-CELLS; ACTIVATION; ASSOCIATION; LIGANDS; MARROW; GENE	THE B-lymphocyte-restricted glycoprotein CD22 is expressed on mature IgM(+) IgD(+) B cells(1-3), and is capable of binding to ligands on T and B cells(2,4-7). CD22 can interact with both the B-cell antigen receptor (BCR) complex(8,9) and signalling molecules, including the protein tyrosine phosphatase SHP1 (PTP1C, SHP)(10-12), a putative negative regulator of BCR signalling(13,14). Thus CD22 may facilitate interactions with lymphocytes and regulate the threshold of BCR signalling(1,11,13). To define the in vivo function of CD22, we generated CD22-deficient mice. Here we show that CD22 is required for normal antibody responses to thymus-independent antigens and regulates the lifespan of mature B cells.	UNIV WASHINGTON,MED CTR,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT BIOL STRUCT,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT BIOCHEM & MED,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle				Clark, Edward A/0000-0001-8061-5475				ALLMAN DM, 1993, J IMMUNOL, V151, P4431; ANDERSSON KB, IN PRESS EUR J IMMUN; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; Cyster JG, 1995, IMMUNITY, V3, P691, DOI 10.1016/1074-7613(95)90059-4; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; FULCHER DA, 1994, J EXP MED, V179, P125, DOI 10.1084/jem.179.1.125; Fulcher DA, 1996, J EXP MED, V183, P2313, DOI 10.1084/jem.183.5.2313; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; LAW CL, 1993, J IMMUNOL, V151, P175; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; LAW CL, 1995, J IMMUNOL, V155, P3368; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; RAMTHELL JC, 1996, CELL, V87, P319; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TORRES RM, 1992, J IMMUNOL, V149, P2641; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	31	338	342	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 19	1996	384	6610					634	637		10.1038/384634a0	http://dx.doi.org/10.1038/384634a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VZ296	8967951				2022-12-01	WOS:A1996VZ29600031
J	Burgess, R; Rawls, A; Brown, D; Bradley, A; Olson, EN				Burgess, R; Rawls, A; Brown, D; Bradley, A; Olson, EN			Requirement of the paraxis gene for somite formation and musculoskeletal patterning	NATURE			English	Article							LOOP-HELIX PROTEIN; MOUSE EMBRYOGENESIS; BOX GENE; MESODERM; EXPRESSION; TRANSCRIPTION; SEGMENTATION; LINEAGES; MEMBER; FAMILY	THE segmental organization of the vertebrate embryo is first apparent when somites form in a rostrocaudal progression from the paraxial mesoderm adjacent to the neural tube. Newly formed somites appear as paired epithelial spheres that become patterned to form vertebrae, ribs, skeletal muscle and derms(1-3). Paraxis is a basic helix-loop-helix transcription factor expressed in paraxial mesoderm and somites(4). Here we show that in mice homozygous for a paraxis null mutation, cells from the paraxial mesoderm are unable to form epithelia and so somite formation is disrupted. In the absence of normal somites, the axial skeleton and skeletal muscle form but are improperly patterned. Unexpectedly, however, we found that formation of epithelial somites was not required for segmentation of the embryo or for the establishment of somitic cell lineages. These results demonstrate that paraxis regulates somite morphogenesis, and that the function of somites is to pattern the axial skeleton and skeletal muscles.	UNIV TEXAS,SW MED CTR,HAMON CTR BASIC CANC RES,DEPT MOL BIOL & ONCOL,DALLAS,TX 75235; LEXICON GENET INC,THE WOODLANDS,TX 77381; BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Lexicon Pharmaceuticals; Baylor College of Medicine; Howard Hughes Medical Institute				Bradley, Allan/0000-0002-2349-8839				BLANAR MA, 1995, P NATL ACAD SCI USA, V92, P5870, DOI 10.1073/pnas.92.13.5870; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; COULY GF, 1993, DEVELOPMENT, V117, P409; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; GOULDING M, 1993, GENOMICS, V17, P355, DOI 10.1006/geno.1993.1332; JACOBSON AG, 1988, DEVELOPMENT, V104, P209; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Muller M, 1996, DEVELOPMENT, V122, P2071; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; TAM PPL, 1982, AM J ANAT, V164, P209, DOI 10.1002/aja.1001640303; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; YAMAGUCHI TP, 1992, DEV BIOL, V152, P75, DOI 10.1016/0012-1606(92)90157-C	26	190	194	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1996	384	6609					570	573		10.1038/384570a0	http://dx.doi.org/10.1038/384570a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955271				2022-12-01	WOS:A1996VX76900061
J	McEvilly, RJ; Erkman, L; Luo, L; Sawchenko, PE; Ryan, AF; Rosenfeld, MG				McEvilly, RJ; Erkman, L; Luo, L; Sawchenko, PE; Ryan, AF; Rosenfeld, MG			Requirement for Brn-3.0 In differentiation and survival of sensory and motor neurons	NATURE			English	Article							NERVOUS-SYSTEM; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; CNS NEURONS; POU FAMILY; CELLS; EXPRESSION; RAT; HOMEODOMAIN; PROTEIN	SPECIFIC families of transcription factors mediate events in the sequential maturation of distinct neuronal phenotypes. Members of one such family, the class IV POU domain transcription factor Brn-3.0, and two highly related factors Brn-3.1 and Brn-3.2, are differentially expressed in the developing and mature mammalian nervous system(1-11). The expression pattern of Brn-3.0 suggested that it has an important role in the development of sensory ganglia, as well as red nucleus, inferior olive, and nucleus ambiguus. Analysis of mice null for the Brn-3.0 locus shows that Brn-3.0 is required for the survival of subpopulations of proprioceptive, mechanoreceptive and nociceptive sensory neurons, where deletion of the gene affects neurotrophin and neurotrophin-receptor gene expression. Deletion of Brn-3.0 also alters either differentiation, migration or survival of specific central neuronal populations.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT SURG, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT OTOLARYNGOL & NEUROSCI, LA JOLLA, CA 92093 USA; VET AFFAIRS MED CTR, LA JOLLA, CA 92093 USA; SALK INST BIOL STUDIES, NEURONAL STRUCT & FUNCT LAB, SAN DIEGO, CA 92186 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Salk Institute					Veterans Affairs [I01BX001205] Funding Source: NIH RePORTER; BLRD VA [I01 BX001205] Funding Source: Medline	Veterans Affairs(US Department of Veterans Affairs); BLRD VA		ALTMAN J, 1982, ADV ANAT EMBRYOL CEL, V74, P1; ALTMAN J, 1987, J COMP NEUROL, V257, P490, DOI 10.1002/cne.902570403; BHARGAVA AK, 1993, P NATL ACAD SCI USA, V90, P10260, DOI 10.1073/pnas.90.21.10260; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; COLLUM RG, 1992, NUCLEIC ACIDS RES, V20, P4919, DOI 10.1093/nar/20.18.4919; CONOVER JC, 1995, NATURE, V375, P235, DOI 10.1038/375235a0; CUNNINGHAM ET, 1989, J NEUROSCI, V9, P1668; DIENER PS, 1994, NEUROREPORT, V5, P1913, DOI 10.1097/00001756-199410000-00018; EMFORS P, 1994, NATURE, V368, P147; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; Jiang YH, 1996, J BIOL CHEM, V271, P10723, DOI 10.1074/jbc.271.18.10723; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SCHWARTZ IR, 1990, J ELECTRON MICR TECH, V15, P225, DOI 10.1002/jemt.1060150304; SHER AE, 1971, ACTA OTO-LARYNGOL, P1; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7; XIANG MQ, 1995, J NEUROSCI, V15, P4762	30	216	217	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 12	1996	384	6609					574	577		10.1038/384574a0	http://dx.doi.org/10.1038/384574a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955272				2022-12-01	WOS:A1996VX76900062
J	Chertow, GM; Milford, EL; Mackenzie, HS; Brenner, BM				Chertow, GM; Milford, EL; Mackenzie, HS; Brenner, BM			Antigen-independent determinants of cadaveric kidney transplant failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL-TRANSPLANTATION; AGE; GLOMERULI; SURVIVAL; MASS; RECIPIENTS; REJECTION; RATS; SIZE	Objective.-To determine the association of various antigen-independent factors with long-term cadaveric kidney transplant failure. Design.-Cohort analytic study. Setting.-Kidney transplant centers (N=131) in the United States. Patients.-A total of 31 515 patients who received cadaveric kidney transplants between October 1987 and December 1991. Patients with unknown or uninterpretable vital status or graft survival time (n=264 [0.8%]) were excluded. Main Outcome Measure.-Graft failure, estimated at 2 extremes, depending on whether the death of a patient with a functioning graft was censored ("censored graft failure") or not ("uncensored graft failure"). Results.-During the 62-month study period, 5883 patients required the reinstitution of dialysis because of graft failure, 2404 patients died with graft failure, and 2041 patients died with a functioning graft. The relative risks of censored and uncensored graft failure were significantly associated with donor age, sex, and race and recipient body surface area, after adjusting for recipient age, sex, race, diabetes, cold ischemia time, panel cross-reactivity, pretransplant blood transfusions, previous renal transplantation, functional status, and HLA antigen mismatch. Conclusions.-In cadaveric kidney transplantation, selected demographic and anthropometric factors are significantly related to long-term graft outcomes, even after adjusting for well-known antigen-dependent risk factors. These results support the hypothesis that the supply of viable donor nephrons and the physiologic demands of the transplant recipient are important determinants of long-term graft failure. Antigen-independent factors such as donor age should be incorporated into organ allocation algorithms to optimize equity and efficiency.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,RENAL DIV,DEPT MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School				Chertow, Glenn/0000-0002-7599-0534				BRENNER BM, 1988, AM J HYPERTENS, V1, P335, DOI 10.1093/ajh/1.4.335; BRENNER BM, 1992, J AM SOC NEPHROL, V3, P162; BUTKUS DE, 1992, NEW ENGL J MED, V327, P840, DOI 10.1056/NEJM199209173271203; Cecka J M, 1994, Clin Transpl, P1; Collett, 2014, MODELLING SURVIVAL D; COX DR, 1972, J R STAT SOC B, V34, P187; Gaston RS, 1996, TRANSPLANTATION, V61, P383, DOI 10.1097/00007890-199602150-00010; HEEMANN UW, 1995, TRANSPLANT P, V27, P549; HEEMANN UW, 1994, TRANSPLANT P, V26, P2047; HOWARD RJ, 1990, CLIN TRANSPLANT, V4, P181; KAPLAN C, 1975, AM J PATHOL, V80, P227; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPPEL B, 1980, VIRCHOWS ARCH A, V387, P271, DOI 10.1007/BF00454830; KUPIN W, 1994, J AM SOC NEPHROL, V5, P1019; Kupin Warren L., 1993, Journal of the American Society of Nephrology, V4, P945; Mackay EM, 1932, ARCH INTERN MED, V50, P590, DOI 10.1001/archinte.1932.00150170082008; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; NYENGAARD JR, 1992, ANAT REC, V232, P194, DOI 10.1002/ar.1092320205; OPELZ G, 1991, TRANSPLANT P, V23, P373; RENNKE HG, 1986, PROGR NATURE RENAL D, P111; ROTH D, 1994, J AM SOC NEPHROL, V5, P1035; SAS Institute Inc, 1990, SAS STAT US GUID VER, V4; TAUCHI H, 1971, GERONTOLOGY, V17, P87, DOI 10.1159/000211811; TERASAKI PI, 1994, TRANSPLANTATION, V57, P1450, DOI 10.1097/00007890-199405270-00008; TESI RJ, 1994, LANCET, V343, P461, DOI 10.1016/S0140-6736(94)92698-0; THERNEAU TM, 1990, BIOMETRIKA, V77, P147, DOI 10.2307/2336057; *UNOS, 1994, 1994 REP CTR SPEC GR; Walter F, 1939, J EXP MED, V69, P467, DOI 10.1084/jem.69.3.467	28	119	119	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1732	1736		10.1001/jama.276.21.1732	http://dx.doi.org/10.1001/jama.276.21.1732			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940321				2022-12-01	WOS:A1996VV56600030
J	Janda, KD; Lo, LC; Lo, CHL; Sim, MM; Wang, R; Wong, CH; Lerner, RA				Janda, KD; Lo, LC; Lo, CHL; Sim, MM; Wang, R; Wong, CH; Lerner, RA			Chemical selection for catalysis in combinatorial antibody libraries	SCIENCE			English	Article							GLYCOSIDASE INHIBITORS; GENERATION; GLUCOPYRANOSYL; INTERMEDIATE; MECHANISM; SYSTEM	For the past decade the immune system has been exploited as a rich source of de novo catalysts. Catalytic antibodies have been shown to have chemoselectivity, enantioselectivity, large rate accelerations, and even an ability to reroute chemical reactions. In many instances catalysts have been made for reactions for which these are no known natural or man-made enzymes. Yet, the full power of this combinatorial system can only be exploited if there was a system that allows for the direct selection of a particular function. A method that allows for the direct chemical selection for catalysis from antibody libraries was so devised, whereby the positive aspects of hybridoma technology were preserved and re-formatted in the filamentous phage system to allow direct selection of catalysis. This methodology is based on a purely chemical selection process, making it more general than biologically based selection systems because of its not limited to reaction products that perturb cellular machinery.	SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	Janda, KD (corresponding author), Scripps Res Inst, DEPT CHEM, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Lo, Lee-Chiang Lo/G-9165-2015	Lo, Lee-Chiang Lo/0000-0002-5821-1690	NIGMS NIH HHS [GM-43858, GM-44154] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043858, R37GM044154, R01GM043858, R01GM044154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen H. J., 1992, GLYCOCONJUGATES COMP; AMYES TL, 1989, J AM CHEM SOC, V111, P78; Barbas Carlos F. Iii, 1995, Methods (Orlando), V8, P94, DOI 10.1006/meth.1995.9997; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; COLLET TA, 1992, P NATL ACAD SCI USA, V89, P10026, DOI 10.1073/pnas.89.21.10026; FENNIRI H, 1995, P NATL ACAD SCI USA, V92, P2278, DOI 10.1073/pnas.92.6.2278; GONG B, 1992, J AM CHEM SOC, V114, P1486, DOI 10.1021/ja00030a056; HALAZY S, 1990, BIOORG CHEM, V18, P330, DOI 10.1016/0045-2068(90)90007-R; HORTON HR, 1969, BIOCHIM BIOPHYS ACTA, V194, P272; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; ICHIKAWA Y, 1995, TETRAHEDRON LETT, V36, P4585, DOI 10.1016/0040-4039(95)00870-I; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P10779, DOI 10.1073/pnas.91.23.10779; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P2532, DOI 10.1073/pnas.91.7.2532; JANDA KD, 1994, PHARM MONOCLONAL ANT; JANDA KD, 1996, COMPREHENSIVE SUPRAM, V4, P43; Jeong JH, 1996, J AM CHEM SOC, V118, P4227, DOI 10.1021/ja951602z; Kirby AJ, 1996, NAT STRUCT BIOL, V3, P107, DOI 10.1038/nsb0296-107; Kirby AJ, 1994, ADV PHYS ORG CHEM, V29, P87, DOI 10.1016/S0065-3160(08)60076-3; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KUAPP S, 1994, J AM CHEM SOC, V116, P7461; KUROKI R, 1993, SCIENCE, V262, P2030, DOI 10.1126/science.8266098; LAMPEN JO, 1946, J BIOL CHEM, V164, P789; LESLEY SA, 1993, P NATL ACAD SCI USA, V90, P1160, DOI 10.1073/pnas.90.4.1160; LIU KKC, 1991, J ORG CHEM, V56, P6280, DOI 10.1021/jo00022a013; LO CHL, 1996, OSR J CHEM, V36, P195; LOOK GC, 1993, ACCOUNTS CHEM RES, V26, P182, DOI 10.1021/ar00028a008; MACBEATH G, 1994, J AM CHEM SOC, V116, P6101, DOI 10.1021/ja00093a006; Matsumura I, 1996, BIOCHEMISTRY-US, V35, P1890, DOI 10.1021/bi951672i; MOLE JE, 1973, BIOCHEMISTRY-US, V12, P5278, DOI 10.1021/bi00750a009; PAPANDREOU G, 1993, J AM CHEM SOC, V115, P11682, DOI 10.1021/ja00078a004; PAUL WE, 1992, FUNDAMENTAL IMMUNOLO; PEARSON B, 1961, P SOC EXP BIOL MED, V108, P619; REYMOND JL, 1991, ANGEW CHEM INT EDIT, V30, P1711, DOI 10.1002/anie.199117111; Roepke RR, 1944, J BACTERIOL, V48, P401, DOI 10.1128/JB.48.4.401-412.1944; SCHRAMM VL, 1994, J BIOL CHEM, V269, P18259; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; Seiler N, 1978, ENZYME ACTIVATED IRR; SILVERMAN RB, 1988, MECH BASED ENZYME IN, V1; SILVERMAN RB, 1988, MECH BASED ENZYME IN, V2; Sinnott M. L., 1987, ENZYME MECHANISMS, P259; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SMILEY JA, 1994, P NATL ACAD SCI USA, V91, P8319, DOI 10.1073/pnas.91.18.8319; SUGA H, 1994, J AM CHEM SOC, V116, P11197, DOI 10.1021/ja00103a061; TANG Y, 1991, P NATL ACAD SCI USA, V88, P8784, DOI 10.1073/pnas.88.19.8784; TAWFIK DS, 1993, P NATL ACAD SCI USA, V90, P373, DOI 10.1073/pnas.90.2.373; TRAUT RR, 1973, BIOCHEMISTRY-US, V12, P3266, DOI 10.1021/bi00741a019; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; WINCHESTER B, 1992, GLYCOBIOLOGY, V2, P199, DOI 10.1093/glycob/2.3.199; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775; WITHERS SG, 1988, J AM CHEM SOC, V110, P8551, DOI 10.1021/ja00233a045; YU JH, 1994, ANGEW CHEM INT EDIT, V33, P339, DOI 10.1002/anie.199403391; ZHANG YL, 1994, J AM CHEM SOC, V116, P7557, DOI 10.1021/ja00096a012	52	170	213	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					945	948		10.1126/science.275.5302.945	http://dx.doi.org/10.1126/science.275.5302.945			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	WH388	9020070				2022-12-01	WOS:A1997WH38800035
J	Newman, EA; Zahs, KR				Newman, EA; Zahs, KR			Calcium waves in retinal glial cells	SCIENCE			English	Article							ASTROCYTES IN-SITU; FREE AMINO-ACIDS; GAP-JUNCTIONS; GLUTAMATE; THAPSIGARGIN; ACTIVATION; RECEPTORS; NETWORKS; NEURONS; RELEASE	Calcium signals were recorded from glial cells in acutely isolated rat retina to determine whether Ca2+ waves occur in glial cells of intact central nervous system tissue. Chemical (adenosine triphosphate), electrical, and mechanical stimulation of astrocytes initiated increases in the intracellular concentration of Ca2+ that propagated at similar to 23 micrometers per second through astrocytes and Muller cells as intercellular waves. The Ca2+ waves persisted in the absence of extracellular Ca2+ but were largely abolished by thapsigargin and intracellular heparin, indicating that Ca2+ was released from intracellular stores. The waves did not evoke changes in cell membrane potential but traveled synchronously in astrocytes and Muller cells, suggesting a functional linkage between these two types of glial cells. Such glial Ca2+ waves may constitute an extraneuronal signaling pathway in the central nervous system.			Newman, EA (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL,435 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.				NEI NIH HHS [R01 EY004077-19, EY04077, R01 EY004077, EY10383] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004077, R01EY010383] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BARRES BA, 1990, NEURON, V5, P527, DOI 10.1016/0896-6273(90)90091-S; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHARLES AC, 1993, GLIA, V7, P134, DOI 10.1002/glia.440070203; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CORNELLBELL AH, 1991, CELL CALCIUM, V12, P185, DOI 10.1016/0143-4160(91)90020-F; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DUFFY S, 1995, J NEUROSCI, V15, P5535; ENKVIST MOK, 1992, J NEUROCHEM, V59, P519, DOI 10.1111/j.1471-4159.1992.tb09401.x; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; FINKBEINER SM, 1993, GLIA, V9, P83, DOI 10.1002/glia.440090202; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GUNNARSON G, 1987, EXP EYE RES, V44, P235, DOI 10.1016/S0014-4835(87)80008-8; HASSINGER TD, 1995, J NEUROBIOL, V28, P159, DOI 10.1002/neu.480280204; HEINAMAKI AA, 1986, NEUROCHEM RES, V11, P535, DOI 10.1007/BF00965323; Kettenmann H., 1995, NEUROGLIA; KIM WT, 1994, GLIA, V11, P173, DOI 10.1002/glia.440110211; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PARPURA V, 1995, J NEUROSCI, V15, P5831; PORTER JT, 1995, J NEUROCHEM, V65, P1515, DOI 10.1046/j.1471-4159.1995.65041515.x; PORTER JT, 1995, GLIA, V13, P101, DOI 10.1002/glia.440130204; ROBINSON SR, 1993, SCIENCE, V262, P1072; SHAO Y, 1995, CELL CALCIUM, V17, P187, DOI 10.1016/0143-4160(95)90033-0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466	26	352	359	2	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					844	847		10.1126/science.275.5301.844	http://dx.doi.org/10.1126/science.275.5301.844			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012354	Green Accepted			2022-12-01	WOS:A1997WG77700065
J	Nightingale, SL				Nightingale, SL			FDA proposes to withdraw terfenadine approval	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1997, FED REGISTER, V62, P1889	1	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					370	370						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE771	9010159				2022-12-01	WOS:A1997WE77100008
J	Mattingley, JB; Davis, G; Driver, J				Mattingley, JB; Davis, G; Driver, J			Preattentive filling-in of visual surfaces in parietal extinction	SCIENCE			English	Article							FEATURE-INTEGRATION; NEGLECT; ATTENTION; PERCEPTION; PATIENT; LESIONS; HUMANS; FIELD; LOBE	Unilateral brain damage frequently produces ''extinction,'' in which patients can detect brief single visual stimuli on either side but are unaware of a contralesional stimulus if presented concurrently with an ipsilesional stimulus. Explanations for extinction have invoked deficits in initial processes that operate before the focusing of visual attention or in later attentive stages of vision, Preattentive vision was preserved in a parietally damaged patient, whose extinction was less severe when bilateral stimuli formed a common surface, even if this required visual filling-in to yield illusory Kanizsa figures or completion of partially occluded figures. These results show that parietal extinction arises only after substantial processing has generated visual surfaces, supporting recent claims that visual attention is surface-based.	UNIV LONDON BIRKBECK COLL,DEPT PSYCHOL,LONDON WC1E 7HX,ENGLAND	University of London; Birkbeck University London	Mattingley, JB (corresponding author), UNIV CAMBRIDGE,DEPT EXPT PSYCHOL,DOWNING ST,CAMBRIDGE CB2 3EB,ENGLAND.		Mattingley, Jason/J-1537-2014; Driver, Jon/A-4779-2010; Davis, Gregory/G-9954-2012	Mattingley, Jason/0000-0003-0929-9216; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAYLIS GC, 1993, J COGNITIVE NEUROSCI, V5, P453, DOI 10.1162/jocn.1993.5.4.453; Bender M.B., 1952, DISORDERS PERCEPTION; BERTI A, 1992, J COGNITIVE NEUROSCI, V4, P345, DOI 10.1162/jocn.1992.4.4.345; COHEN A, 1991, PSYCHOL SCI, V2, P106, DOI 10.1111/j.1467-9280.1991.tb00109.x; Critchley M, 1966, PARIETAL LOBES; DAVIS G, 1994, NATURE, V371, P79; DIPELLEGRINO G, 1995, NEUROPSYCHOLOGIA, V33, P153, DOI 10.1016/0028-3932(94)00111-2; DRIVER J, 1992, NATURE, V360, P73, DOI 10.1038/360073a0; Duncan J., 1996, ATTENTION PERFORM, P549; ENNS JT, 1992, VSCOPE SOFTWARE MANU; ENNS JT, 1994, VISUAL SEARCH, V3; FRIEDMANHILL SR, 1995, SCIENCE, V269, P853, DOI 10.1126/science.7638604; HE ZJ, 1992, NATURE, V359, P231, DOI 10.1038/359231a0; HE ZJ, 1995, P NATL ACAD SCI USA, V92, P11155, DOI 10.1073/pnas.92.24.11155; HUMPHREYS GW, 1994, NATURE, V372, P357, DOI 10.1038/372357a0; Jackendoff R., 1987, EXPLOR COGN SCI, P356; KANIZSA, 1979, ORG VISION; Kanizsa G., 1955, RIV PSICOL, V49, P7; KARNATH HO, 1988, NEUROPSYCHOLOGIA, V26, P27, DOI 10.1016/0028-3932(88)90028-0; Kinsbourne M., 1993, UNILATERAL NEGLECT C, P63; LADAVAS E, 1993, NEUROPSYCHOLOGIA, V31, P1307, DOI 10.1016/0028-3932(93)90100-E; MARSHALL JC, 1988, NATURE, V336, P766, DOI 10.1038/336766a0; MICHOTTE A, 1964, STUDIA PSYCHOL LOUVA; NAKAYAMA K, 1995, INVITATION COGNITIVE, V2, P1; Ramachandran V. S., 1987, PERCEPTION ILLUSORY, P93, DOI 10.1007/978-1-4612-4760-9_10; RAPCSAK SZ, 1987, J NEUROL NEUROSUR PS, V50, P1117, DOI 10.1136/jnnp.50.9.1117; SHIPLEY TF, 1992, J EXP PSYCHOL HUMAN, V18, P106, DOI 10.1037/0096-1523.18.1.106; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; VALLAR G, 1994, J NEUROL NEUROSUR PS, V57, P464, DOI 10.1136/jnnp.57.4.464; VOLPE BT, 1979, NATURE, V282, P722, DOI 10.1038/282722a0; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; VONDERHEYDT R, 1989, J NEUROSCI, V9, P1731; Ward R, 1996, PSYCHOL SCI, V7, P177, DOI 10.1111/j.1467-9280.1996.tb00353.x; Ward R., 1994, VIS COGN, V1, P101, DOI DOI 10.1080/13506289408402295	34	192	194	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					671	674		10.1126/science.275.5300.671	http://dx.doi.org/10.1126/science.275.5300.671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WF077	9005854				2022-12-01	WOS:A1997WF07700041
J	Stone, EM; Fingert, JH; Alward, WLM; Nguyen, TD; Polansky, JR; Sunden, SLF; Nishimura, D; Clark, AF; Nystuen, A; Nichols, BE; Mackey, DA; Ritch, R; Kalenak, JW; Craven, ER; Sheffield, VC				Stone, EM; Fingert, JH; Alward, WLM; Nguyen, TD; Polansky, JR; Sunden, SLF; Nishimura, D; Clark, AF; Nystuen, A; Nichols, BE; Mackey, DA; Ritch, R; Kalenak, JW; Craven, ER; Sheffield, VC			Identification of a gene that causes primary open angle glaucoma	SCIENCE			English	Article							DOMINANT JUVENILE GLAUCOMA; RECEPTOR; PROTEINS; LINKAGE; BLINDNESS; FAMILY	Glaucoma is a major cause of blindness and is characterized by progressive degeneration of the optic nerve and is usually associated with elevated intraocular pressure. Analyses of sequence tagged site (STS) content and haplotype sharing between families affected with chromosome 1q-linked open angle glaucoma (GLC1A) were used to prioritize candidate genes for mutation screening. A gene encoding a trabecular mesh-work protein (TIGR) mapped to the narrowest disease interval by STS content and radiation hybrid mapping. Thirteen glaucoma patients were found to have one of three mutations in this gene (3.9 percent of the population studied). One of these mutations was also found in a control individual (0.2 percent). Identification of these mutations will aid in early diagnosis, which is essential for optimal application of existing therapies.	UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT OPHTHALMOL,IOWA CITY,IA 52242; UNIV CALIF SAN FRANCISCO,DEPT OPHTHALMOL,SAN FRANCISCO,CA 94143; ALCON LABS INC,FT WORTH,TX 76134; UNIV MELBOURNE,DEPT OPHTHALMOL,MELBOURNE,VIC 3002,AUSTRALIA; UNIV TASMANIA,MENZIES CTR,HOBART,TAS,AUSTRALIA; NEW YORK EYE & EAR INFIRM,DEPT OPHTHALMOL,NEW YORK,NY 10003; MED COLL WISCONSIN,DEPT OPHTHALMOL,MILWAUKEE,WI 53226; UNIV COLORADO,SCH MED,DEPT OPHTHALMOL,DENVER,CO 80262	University of Iowa; University of Iowa; University of California System; University of California San Francisco; Novartis; Alcon; University of Melbourne; University of Tasmania; New York Eye & Ear Infirmary of Mount Sinai; Medical College of Wisconsin; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Fingert, John/F-8787-2012; Alward, Wallace/AAY-4149-2020; Mackey, David A/H-5340-2014; Fingert, John/AAX-4750-2021	Fingert, John/0000-0002-0377-0479; Mackey, David A/0000-0001-7914-4709; Fingert, John/0000-0002-0377-0479; Alward, Wallace/0000-0001-6368-9018; Sheffield, Val/0000-0002-6282-0835; Stone, Edwin M./0000-0003-3343-4414; Craven, Earl/0000-0002-2077-659X	NEI NIH HHS [EY08905, EY10564, EY02477] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002477, R01EY010564, R01EY008905] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; ESCRIBANO J, 1995, J BIOCHEM-TOKYO, V118, P921, DOI 10.1093/jb/118.5.921; HILLER R, 1975, AM J OPHTHALMOL, V80, P62, DOI 10.1016/0002-9394(75)90870-3; JOHNSON AT, 1993, OPHTHALMOLOGY, V100, P524; KAHN HA, 1973, US PHS PUBL NIH, P120; LANGE K, 1995, GENOME RES, V5, P136, DOI 10.1101/gr.5.2.136; LOWE DG, 1990, GENOMICS, V8, P304, DOI 10.1016/0888-7543(90)90286-4; MAO LK, 1991, AM J OPHTHALMOL, V111, P51, DOI 10.1016/S0002-9394(14)76896-5; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; MORISSETTE J, 1995, AM J HUM GENET, V56, P1431; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NGUYEN TD, 1996, Patent No. 14024; NGUYEN TV, UNPUB; Polansky J R, 1989, Prog Clin Biol Res, V312, P113; Polansky JR, 1993, BASIC ASPECTS GLAUCO, P307; QUIGLEY HA, 1979, AM J OPHTHALMOL, V87, P519, DOI 10.1016/0002-9394(79)90241-1; RICHARDS JE, 1994, AM J HUM GENET, V54, P62; SHEFFIELD VC, 1993, NAT GENET, V4, P47, DOI 10.1038/ng0593-47; SHEFFIELD VC, UNPUB; Sunden SLF, 1996, GENOME RES, V6, P862, DOI 10.1101/gr.6.9.862; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TIELSCH JM, 1993, T N ORL ACA, P61; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; WATKINS HC, 1993, HUM MOL GENET, V2, P1084, DOI 10.1093/hmg/2.7.1084-a; WIGGS JL, 1994, GENOMICS, V21, P299, DOI 10.1006/geno.1994.1269	27	1109	1202	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					668	670		10.1126/science.275.5300.668	http://dx.doi.org/10.1126/science.275.5300.668			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005853				2022-12-01	WOS:A1997WF07700040
J	VanEssen, DC				VanEssen, DC			A tension-based theory of morphogenesis and compact wiring in the central nervous system	NATURE			English	Article							RETINAL GANGLION-CELLS; RHESUS-MONKEY; CEREBRAL-CORTEX; STRIATE CORTEX; MIGRATING NEURONS; TISSUE-CULTURE; CORTICAL AREAS; CALLOSAL AXONS; MACAQUE MONKEY; ORGANIZATION	Many structural features of the mammalian central nervous system can be explained by a morphogenetic mechanism that involves mechanical tension along axons, dendrites and glial processes. In the cerebral cortex, for example, tension along axons in the white matter can explain how and why the cortex folds in a characteristic species-specific pattern. in the cerebellum, tension along parallel fibres can explain why the cortex is highly elongated but folded like an accordion. By keeping the aggregate length of axonal and dendritic wiring low, tension should contribute to the compactness of neural circuitry throughout the adult brain.			VanEssen, DC (corresponding author), WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.							ALLMAN JM, 1974, BRAIN RES, V76, P247, DOI 10.1016/0006-8993(74)90458-2; AULADELL C, 1995, NEUROSCIENCE, V64, P1091, DOI 10.1016/0306-4522(94)00393-J; BARBAS H, 1989, J COMP NEUROL, V286, P353, DOI 10.1002/cne.902860306; BARBAS H, 1987, J COMP NEUROL, V256, P211, DOI 10.1002/cne.902560203; BARBAS H, 1988, J COMP NEUROL, V276, P353; BARLOW HB, 1986, VISION RES, V26, P81, DOI 10.1016/0042-6989(86)90072-6; BARRON DH, 1950, J EXP ZOOL, V113, P553, DOI 10.1002/jez.1401130304; Bok ST, 1959, HISTONOMY CEREBRAL C; BRAY D, 1979, J CELL SCI, V37, P391; Burke R., 2011, COMPR PHYSIOL, DOI [10.1002/cphy.cp010210, DOI 10.1002/CPHY.CP010210]; Cajal S.R., 1911, HISTOLOGIE SYSTEME N; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; CHERNIAK C, 1995, TRENDS NEUROSCI, V18, P522, DOI 10.1016/0166-2236(95)98373-7; CHERNIAK C, 1992, BIOL CYBERN, V66, P503, DOI 10.1007/BF00204115; Coogan TA, 1996, J COMP NEUROL, V372, P327, DOI 10.1002/(SICI)1096-9861(19960826)372:3<327::AID-CNE1>3.0.CO;2-4; COULOMBRE AJ, 1956, J EXP ZOOL, V133, P211, DOI 10.1002/jez.1401330202; COWEY A, 1979, Q J EXP PSYCHOL, V31, P1, DOI 10.1080/14640747908400703; DECARLOS JA, 1992, J NEUROSCI, V12, P1194; Dehay C, 1996, J COMP NEUROL, V367, P70, DOI 10.1002/(SICI)1096-9861(19960325)367:1<70::AID-CNE6>3.0.CO;2-G; DENNERLL TJ, 1989, J CELL BIOL, V109, P3073, DOI 10.1083/jcb.109.6.3073; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; DESMOND ME, 1977, DEV BIOL, V57, P188, DOI 10.1016/0012-1606(77)90364-5; Drury HA, 1996, J COGNITIVE NEUROSCI, V8, P1, DOI 10.1162/jocn.1996.8.1.1; DRURY HA, UNPUB J NEUROSCI; Enlow D. H., 1990, FACIAL GROWTH; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FINLAY BL, 1995, SCIENCE, V268, P1578, DOI 10.1126/science.7777856; FRAHM HD, 1982, J HIRNFORSCH, V23, P375; FRIEDMAN DP, 1980, J COMP NEUROL, V192, P21, DOI 10.1002/cne.901920103; Fuller R. B., 1979, SYNERGETICS; GALABURDA AM, 1983, J COMP NEUROL, V221, P169, DOI 10.1002/cne.902210206; Goldman-Rakic PS, 1980, PROG BRAIN RES, V53, P3; Harrison RG, 1935, PROC R SOC SER B-BIO, V118, P155, DOI 10.1098/rspb.1935.0053; HENDRICKSON AE, 1984, OPHTHALMOLOGY, V91, P603; HOFMAN MA, 1989, PROG NEUROBIOL, V32, P137, DOI 10.1016/0301-0082(89)90013-0; HOPFIELD JJ, 1985, BIOL CYBERN, V52, P141; Ingber D. E, 1989, CELL SHAPE DETERMINA, P3; JONES EG, 1978, J COMP NEUROL, V181, P291, DOI 10.1002/cne.901810206; Jouandet M L, 1989, J Cogn Neurosci, V1, P88, DOI 10.1162/jocn.1989.1.1.88; KIRBY MA, 1992, VISUAL NEUROSCI, V9, P603, DOI 10.1017/S095252380000184X; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAMOUREUX P, 1992, J CELL BIOL, V118, P655, DOI 10.1083/jcb.118.3.655; LAMOUREUX P, 1989, Nature (London), V340, P159, DOI 10.1038/340159a0; LEGROSCLARK WE, 1945, ESSAYS GROWTH FORM, P1; Mead C., 1978, INTRO VLSI SYSTEMS; MILLER J D, 1987, Neurological Research, V9, P193; MITCHISON G, 1991, P ROY SOC B-BIOL SCI, V245, P151, DOI 10.1098/rspb.1991.0102; MOREST DK, 1969, Z ANAT ENTWICKLUNGS, V128, P290, DOI 10.1007/BF00522529; ODELL GM, 1981, DEV BIOL, V85, P446, DOI 10.1016/0012-1606(81)90276-1; Ono M, 1990, ATLAS CEREBRAL SULCI; Polyak S, 1957, VERTEBRATE SYSTEM; PONS TP, 1986, J COMP NEUROL, V248, P313, DOI 10.1002/cne.902480303; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1995, TRENDS NEUROSCI, V18, P383, DOI 10.1016/0166-2236(95)93934-P; Ramon y Cajal S, 1960, STUDIES VERTEBRATE N; RICHMAN DP, 1975, SCIENCE, V189, P18, DOI 10.1126/science.1135626; Sauer FC, 1935, J COMP NEUROL, V62, P377, DOI 10.1002/cne.900620207; SCANNELL JW, 1995, J NEUROSCI, V15, P1463; SCHWARTZ ML, 1991, P NATL ACAD SCI USA, V88, P1354, DOI 10.1073/pnas.88.4.1354; SELTZER B, 1980, BRAIN RES, V192, P339, DOI 10.1016/0006-8993(80)90888-4; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; SOUSA APB, 1991, J COMP NEUROL, V308, P665, DOI 10.1002/cne.903080411; STEINEKE TC, 1993, DEV BRAIN RES, V74, P151, DOI 10.1016/0165-3806(93)90001-Q; STEWART RM, 1975, ACTA NEUROPATHOL, V31, P1, DOI 10.1007/BF00696881; STOPAK D, 1982, DEV BIOL, V90, P383, DOI 10.1016/0012-1606(82)90388-8; Sultan Fahad, 1993, Journal fuer Hirnforschung, V34, P79; TAKADA K, 1988, CLIN NEUROPATHOL, V7, P111; Thompson DW., 1917, GROWTH FORM, DOI [10.5962/bhl.title.11332, DOI 10.5962/BHL.TITLE.11332]; TOGA AW, 1996, DEV NEUROIMAGING MAP, P15; TUSA RJ, 1979, J COMP NEUROL, V185, P657, DOI 10.1002/cne.901850405; VANESSEN DC, 1984, VISION RES, V24, P429, DOI 10.1016/0042-6989(84)90041-5; VANESSEN DC, 1986, J COMP NEUROL, V244, P451, DOI 10.1002/cne.902440405; Wainwright S. A., 1988, AXIS CIRCUMFERENCE C; Welker W, 1990, CEREB CORTEX, P3, DOI DOI 10.1007/978-1-4615-3824-0; WELKER WI, 1990, ARCH ITAL BIOL, V128, P87; Whittaker V.P., 1984, HDB NEUROCHEMISTRY, V7, P1; YOUNG MP, 1992, NATURE, V358, P152, DOI 10.1038/358152a0	77	1210	1216	3	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					313	318		10.1038/385313a0	http://dx.doi.org/10.1038/385313a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002514				2022-12-01	WOS:A1997WD91400042
J	Bates, DW; Spell, N; Cullen, DJ; Burdick, E; Laird, N; Petersen, LA; Small, SD; Sweitzer, BJ; Leape, LL				Bates, DW; Spell, N; Cullen, DJ; Burdick, E; Laird, N; Petersen, LA; Small, SD; Sweitzer, BJ; Leape, LL			The costs of adverse drug events in hospitalized patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADMISSIONS; MORBIDITY	Objective.-To assess the additional resource utilization associated with an adverse drug event (ADE). Design.-Nested case-control study within a prospective cohort study, Participants.-The cohort included 4108 admissions to a stratified random sample of 11 medical and surgical units in 2 tertiary-care hospitals over a 6-month period. Cases were patients with an ADE, and the control for each case was the patient on the same unit as the case with the most similar pre-event length of stay. Main Outcome Measures.-Postevent length of stay and total costs. Methods.-Incidents were detected by self-report stimulated by nurses and pharmacists and by daily chart review, and were classified as to whether they represented ADEs. Information on length of stay and charges was obtained from billing data, and costs were estimated by multiplying components of charges times hospital-specific ratios of costs to charges. Results.-During the study period, there were 247 ADEs among 207 admissions. After outliers and multiple episodes were excluded, there were 190 ADEs, of which 60 were preventable. In paired regression analyses adjusting for multiple factors, including severity, comorbidity, and case mix, the additional length of stay associated with an ADE was 2.2 days (P=.04), and the increase in cost associated with an ADE was $3244 (P=.04). For preventable ADEs, the increases were 4.6 days in length of stay (P=.03) and $5857 in total cost (P=.07). After adjusting for our sampling strategy, the estimated postevent costs attributable to an ADE were $2595 for all ADEs and $4685 for preventable ADEs. Based on these costs and data about the incidence of ADEs, we estimate that the annual costs attributable to all ADEs and preventable ADEs for a 700-bed teaching hospital are $5.6 million and $2.8 million, respectively. Conclusions.-The substantial costs of ADEs to hospitals justify investment in efforts to prevent these events. Moreover, these estimates are conservative because they do not include the costs of injuries to patients or malpractice costs.	BRIGHAM & WOMENS HOSP, DIV GEN MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT ANESTHESIA, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, HLTH SERV RES & DEV, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University					AHRQ HHS [R01-HS07107-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM HOSP ASS, 1993, HOSP STAT; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CULLEN DJ, 1989, PROBL CRIT CARE, V3, P545; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; EVANS RS, 1993, P ANN S COMPUT APPL, V17, P161; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KORIN J, 1993, HOSP FORMUL, V28, P59; KOSKA MT, 1989, HOSPITALS, V63, P24; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MCKENNEY JM, 1976, AM J HOSP PHARM, V33, P792, DOI 10.1093/ajhp/33.8.792; *NAT ASS INS COMM, 1980, MED MALPR CLOS CLAIM; Rogowski J R, 1990, Health Care Financ Rev, V12, P87; SANDRICK K, 1995, HOSP HEALTH NETWORK, V69, P46; SANDRICK K, 1995, HOSP HEALTH NETWORK, V69, P36; *SAS, 1988, SAS PROC GUID REL 6; THORPE KE, 1992, HEALTH AFFAIR, V11, P41, DOI 10.1377/hlthaff.11.2.41; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; 1996, US NEWS WORLD R 0812, P67	24	1189	1228	2	52	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1997	277	4					307	311		10.1001/jama.277.4.307	http://dx.doi.org/10.1001/jama.277.4.307			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WC458	9002493				2022-12-01	WOS:A1997WC45800030
J	Antz, C; Geyer, M; Fakler, B; Schott, MK; Guy, HR; Frank, R; Ruppersberg, JP; Kalbitzer, HR				Antz, C; Geyer, M; Fakler, B; Schott, MK; Guy, HR; Frank, R; Ruppersberg, JP; Kalbitzer, HR			NMR structure of inactivation gates from mammalian voltage-dependent potassium channels	NATURE			English	Article							SHAKER K-CHANNELS; IK(A) CHANNELS; BALL PEPTIDE; SPECTROSCOPY; PROTEINS; SPECTRA; BRAIN	The electrical signalling properties of neurons originate largely from the gating properties of their ion channels, N-type inactivation of voltage-gated potassium (K-v) channels is the best-understood gating transition in ion channels, and occurs by a 'ball-and-chain' type mechanism. In this mechanism an N-terminal domain (inactivation gate), which is tethered to the cytoplasmic side of the channel protein by a protease-cleavable chain, binds to its receptor at the inner vestibule of the channel, thereby physically blocking the pore(1,2). Even when synthesized as a peptide, ball domains restore inactivation in K-v channels whose inactivation domains have been deleted(2,3), Using high-resolution nuclear magnetic resonance (NMR) spectroscopy, we analysed the three-dimensional structure of the ball peptides from two rapidly inactivating mammalian K-v channels (Raw3 (K(v)3.4) and RCK4 (K(v)1.4)). The inactivation peptide of Raw3 (Raw3-IP) has a compact structure that exposes two phosphorylation sites and allows the formation of an intramolecular disulphide bridge between two spatially close cysteine residues. Raw3-IP exhibits a characteristic surface charge pattern with a positively charged, a hydrophobic, and a negatively charged region, The RCK4 inactivation peptide (RCK4-IP) shows a similar spatial distribution of charged and uncharged regions, but is more flexible and less ordered in its amino-terminal part.	MAX PLANCK INST MED RES,DEPT BIOPHYS,D-69120 HEIDELBERG,GERMANY; NIH,MATH BIOL LAB,BETHESDA,MD 20892; ZENTRUM MOL BIOL,D-69120 HEIDELBERG,GERMANY; UNIV TUBINGEN,INST PHYSIOL,D-72076 TUBINGEN,GERMANY	Max Planck Society; National Institutes of Health (NIH) - USA; Ruprecht Karls University Heidelberg; Eberhard Karls University of Tubingen				Kalbitzer, Hans Robert/0000-0002-6514-2355; Geyer, Matthias/0000-0002-7718-5002				AUER WP, 1976, J CHEM PHYS, V64, P2229; BRUNGER AT, 1992, X PLOR VERSION 3 1; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; FERNANDEZBALLESTER G, 1995, BIOPHYS J, V68, P858, DOI 10.1016/S0006-3495(95)80262-6; FRANK R, 1988, MODERN METHODS PROTE; GUY HR, 1992, BIOPHYS J, V62, P238; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEE CWB, 1993, BIOPHYS J, V61, pA379; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P977, DOI 10.1085/jgp.102.6.977; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; NEIDIG KP, 1995, J BIOMOL NMR, V6, P255, DOI 10.1007/BF00197807; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; OTTING G, 1993, BIOCHEMISTRY-US, V32, P3571, DOI 10.1021/bi00065a008; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; STEPHENS GJ, 1995, J PHYSIOL-LONDON, V484, P1; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	24	97	101	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1997	385	6613					272	275		10.1038/385272a0	http://dx.doi.org/10.1038/385272a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000078				2022-12-01	WOS:A1997WC71100053
J	Magee, JC; Johnston, D				Magee, JC; Johnston, D			A synaptically controlled, associative signal for Hebbian plasticity in hippocampal neurons	SCIENCE			English	Article							LONG-TERM POTENTIATION; DEPOLARIZING CURRENT PULSES; PYRAMIDAL CELL DENDRITES; CA2+ CHANNELS; CALCIUM; CA1; ACTIVATION; SYNAPSES; SPINES; INFLUX	The role of back-propagating dendritic action potentials in the induction of long-term potentiation (LTP) was investigated in CA1 neurons by means of dendritic patch recordings and simultaneous calcium imaging. Pairing of subthreshold excitatory postsynaptic potentials (EPSPs) with back-propagating action potentials resulted in an amplification of dendritic action potentials and evoked calcium influx near the site of synaptic input. This pairing also induced a robust LTP, which was reduced when EPSPs were paired with non-back-propagating action potentials or when stimuli were unpaired. Action potentials thus provide a synaptically controlled, associative signal to the dendrites for Hebbian modifications of synaptic strength.			Magee, JC (corresponding author), BAYLOR COLL MED,DIV NEUROSCI,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH044754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011535, P50NS011535] Funding Source: NIH RePORTER; NIMH NIH HHS [MH44754] Funding Source: Medline; NINDS NIH HHS [NS09482, NS11535] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREASEN M, 1995, J PHYSIOL-LONDON, V483, P421, DOI 10.1113/jphysiol.1995.sp020595; BLISS T V P, 1988, P3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; CALLAWAY JC, 1995, J NEUROPHYSIOL, V74, P1395, DOI 10.1152/jn.1995.74.4.1395; Christie BR, 1996, LEARN MEMORY, V3, P160, DOI 10.1101/lm.3.2-3.160; CHRISTIE BR, 1995, J NEUROPHYSIOL, V73, P2553, DOI 10.1152/jn.1995.73.6.2553; Colbert CM, 1996, J NEUROSCI, V16, P6676; Denk W, 1996, CURR OPIN NEUROBIOL, V6, P372, DOI 10.1016/S0959-4388(96)80122-X; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; HEBB DO, 1949, ORG BEHAVIOR; Hoffman Dax, 1996, Society for Neuroscience Abstracts, V22, P793; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JAFFE DB, 1994, J NEUROBIOL, V25, P220, DOI 10.1002/neu.480250303; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; Johnston D, 1996, ANNU REV NEUROSCI, V19, P165, DOI 10.1146/annurev.ne.19.030196.001121; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KOCH C, 1982, PHILOS T R SOC B, V298, P227, DOI 10.1098/rstb.1982.0084; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; LASSERROSS N, 1991, J NEUROSCI METH, V36, P253, DOI 10.1016/0165-0270(91)90051-Z; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MAGEE JC, 1995, J PHYSIOL-LONDON, V487, P67, DOI 10.1113/jphysiol.1995.sp020862; MAGEE JC, 1995, J NEUROPHYSIOL, V74, P1335, DOI 10.1152/jn.1995.74.3.1335; Magee JC, 1996, J NEUROPHYSIOL, V76, P3460, DOI 10.1152/jn.1996.76.5.3460; MAGEE JC, 1995, SCIENCE, V268, P301, DOI 10.1126/science.7716525; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MILLS LR, 1994, J NEUROSCI, V14, P6815; MONTAGUE PR, 1994, LEARN MEMORY, V1, P1; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; REGEHR WG, 1992, J NEUROSCI, V12, P4202; SCHARFMAN HE, 1985, BRAIN RES, V331, P267, DOI 10.1016/0006-8993(85)91552-5; SCHWINDT PC, 1995, J NEUROPHYSIOL, V74, P2220, DOI 10.1152/jn.1995.74.5.2220; SEJNOWSKI TJ, 1989, NEURAL MODELS PLASTI, P105; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; STUART G, 1995, NEURON, V15, P1065, DOI 10.1016/0896-6273(95)90095-0; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; TEYLER TJ, 1994, HIPPOCAMPUS, V4, P623, DOI 10.1002/hipo.450040602; Tsubokawa H, 1996, J NEUROPHYSIOL, V76, P2896, DOI 10.1152/jn.1996.76.5.2896; TURNER RW, 1991, J NEUROSCI, V11, P2270; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; ZADOR A, 1990, P NATL ACAD SCI USA, V87, P6718, DOI 10.1073/pnas.87.17.6718	49	943	963	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					209	213		10.1126/science.275.5297.209	http://dx.doi.org/10.1126/science.275.5297.209			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985013				2022-12-01	WOS:A1997WC02200037
J	Natoli, G; Costanzo, A; Ianni, A; Templeton, DJ; Woodgett, JR; Balsano, C; Levrero, M				Natoli, G; Costanzo, A; Ianni, A; Templeton, DJ; Woodgett, JR; Balsano, C; Levrero, M			Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; PROGRAMMED CELL-DEATH; NF-KAPPA-B; C-JUN; PROTEIN-KINASE; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAIN; INTERACTS; FAMILY; CD40	Interaction oi the p55 tumor necrosis factor receptor 1 (TNF-R1)-associated signal transducer TRADD with FADD signals apoptosis, whereas the TNF receptor-associated factor 2 protein (TRAF2) is required for activation of the nuclear transcription factor nuclear factor kappa B. TNF-induced activation of the stress-activated protein kinase (SAPK) was shown to occur through a noncytotoxic TRAF2-dependent pathway. TRAF2 was both sufficient and necessary for activation of SAPK by TNF-R1; conversely, expression of a dominant-negative FADD mutant, which blocks apoptosis, did not interfere with SAPK activation. Therefore, SAPK activation occurs through a pathway that is not required for TNF-R1-induced apoptosis.	POLICLIN UMBERTO 1,IST CLIN MED 1,I-00161 ROME,ITALY; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106; PRINCESS MARGARET HOSP,ONTARIO CANC INST,TORONTO,ON M5G 2M9,CANADA; UNIV AQUILA,DEPT MED INTERNA,I-67100 LAQUILA,ITALY	Sapienza University Rome; University Hospital Sapienza Rome; Case Western Reserve University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of L'Aquila	Natoli, G (corresponding author), POLICLIN UMBERTO 1,FDN ANDREA CESALPINO,VIALE POLICLIN 155,I-00161 ROME,ITALY.		Costanzo, Antonio/D-3896-2012; Costanzo, Antonio/GZG-2433-2022; Woodgett, Jim/F-1087-2010; Natoli, gioacchino/J-2100-2018; Templeton, Dennis J/F-7695-2011; Balsano, Clara/AAK-9870-2020; Natoli, gioacchino/ABB-8679-2020; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; Woodgett, Jim/0000-0003-3731-5797; Balsano, Clara/0000-0002-9615-7031; Levrero, Massimo/0000-0002-4978-0875; Natoli, Gioacchino/0000-0003-0711-2411				ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Baker SJ, 1996, ONCOGENE, V12, P1; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERBERICH I, 1996, EMBO J, V14, P5338; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; NATOLI G, UNPUB; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAUCHI N, 1989, CANCER RES, V49, P1671; YAN MH, 1994, NATURE, V372, P798; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644	52	403	411	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					200	203		10.1126/science.275.5297.200	http://dx.doi.org/10.1126/science.275.5297.200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985011				2022-12-01	WOS:A1997WC02200034
J	Rodnina, MV; Savelsbergh, A; Katunin, VI; Wintermeyer, W				Rodnina, MV; Savelsbergh, A; Katunin, VI; Wintermeyer, W			Hydrolysis of GTP by elongation factor G drives tRNA movement on the ribosome	NATURE			English	Article							CRYSTAL-STRUCTURE; TRANSFER-RNA; FACTOR TU; ESCHERICHIA-COLI; EF-TU; STEADY-STATE; FACTOR-II; TRANSLOCATION; TRANSLATION; MECHANISM	Elongation factor G (EF-G) is a GTPase that is involved in the translocation of bacterial ribosomes along messenger RNA during protein biosynthesis. In contrast to current models, EF-G-dependent GTP hydrolysis is shown to precede, and greatly accelerate, the rearrangement of the ribosome that leads to translocation. Domain IV of the EF-G structure is crucial for both rapid translocation and subsequent release of the factor from the ribosome. By coupling the free energy of GTP hydrolysis to translocation, EF-G serves as a motor protein to drive the directional movement of transfer and messenger RNAs on the ribosome.	UNIV WITTEN HERDECKE,INST MOL BIOL,D-58448 WITTEN,GERMANY; RUSSIAN ACAD SCI,ST PETERSBURG NUCL PHYS INST,GATCHINA 188350,RUSSIA	Witten Herdecke University; National Research Centre - Kurchatov Institute; Petersburg Nuclear Physics Institute; Russian Academy of Sciences			Rodnina, Marina V./AAD-4667-2019	Rodnina, Marina V./0000-0003-0105-3879; Savelsbergh, Andreas/0000-0002-6136-3230				Abel K, 1996, STRUCTURE, V4, P229, DOI 10.1016/S0969-2126(96)00027-5; Aevarsson A, 1995, J MOL EVOL, V41, P1096; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Al-Karadaghi S, 1996, STRUCTURE, V4, P555, DOI 10.1016/S0969-2126(96)00061-5; BACA OG, 1976, BIOCHEMISTRY-US, V15, P4570, DOI 10.1021/bi00666a004; BELITSINA NV, 1975, FEBS LETT, V54, P35, DOI 10.1016/0014-5793(75)81062-3; Bemasconi C. F., 1976, RELAXATION KINETICS; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; Borowski C, 1996, P NATL ACAD SCI USA, V93, P4202, DOI 10.1073/pnas.93.9.4202; CUNDLIFFE E, 1990, RIBOSOME, P479; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; GAVRILOVA LP, 1976, J MOL BIOL, V101, P537, DOI 10.1016/0022-2836(76)90243-6; HOU Y, 1994, J BACTERIOL, V176, P123, DOI 10.1128/JB.176.1.123-129.1994; INOUEYOKOSAWA N, 1974, J BIOL CHEM, V249, P4321; Johanson U, 1996, J MOL BIOL, V258, P420, DOI 10.1006/jmbi.1996.0259; JOHANSON U, 1994, GENE, V143, P55, DOI 10.1016/0378-1119(94)90604-1; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; Liljas A, 1995, BIOCHEM CELL BIOL, V73, P1209, DOI 10.1139/o95-130; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MODOLELL J, 1977, EUR J BIOCHEM, V81, P491, DOI 10.1111/j.1432-1033.1977.tb11974.x; MODOLELL J, 1975, FEBS LETT, V60, P109, DOI 10.1016/0014-5793(75)80429-7; MOORE PB, 1995, SCIENCE, V270, P1453, DOI 10.1126/science.270.5241.1453; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Nyborg J, 1996, TRENDS BIOCHEM SCI, V21, P81, DOI 10.1016/0968-0004(96)30008-X; NYGARD O, 1985, BIOCHIM BIOPHYS ACTA, V824, P152, DOI 10.1016/0167-4781(85)90092-2; OMURA F, 1989, EUR J BIOCHEM, V180, P1, DOI 10.1111/j.1432-1033.1989.tb14607.x; PAULSEN H, 1986, BIOCHEMISTRY-US, V25, P2749, DOI 10.1021/bi00358a002; ROBERTSON JM, 1987, J MOL BIOL, V196, P525, DOI 10.1016/0022-2836(87)90030-1; ROBERTSON JM, 1986, J MOL BIOL, V189, P653, DOI 10.1016/0022-2836(86)90495-X; ROBERTSON JM, 1986, J MOL BIOL, V192, P351, DOI 10.1016/0022-2836(86)90370-0; RODNINA MV, 1995, EMBO J, V14, P2613, DOI 10.1002/j.1460-2075.1995.tb07259.x; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; Rodnina MV, 1996, J BIOL CHEM, V271, P646, DOI 10.1074/jbc.271.2.646; RODNINA MV, 1994, BIOCHEMISTRY-US, V33, P12267, DOI 10.1021/bi00206a033; ROSENDAHL G, 1995, NUCLEIC ACIDS RES, V23, P2396, DOI 10.1093/nar/23.13.2396; RYAN PC, 1991, J MOL BIOL, V221, P1257, DOI 10.1016/0022-2836(91)90932-V; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SCHLICHTING I, 1989, P NATL ACAD SCI USA, V86, P7687, DOI 10.1073/pnas.86.20.7687; Semenkov YP, 1996, P NATL ACAD SCI USA, V93, P12183, DOI 10.1073/pnas.93.22.12183; SERDYUK I, 1992, BIOCHIMIE, V74, P299, DOI 10.1016/0300-9084(92)90107-P; SPIRIN A, 1987, BIOCHIMIE, V69, P949, DOI 10.1016/0300-9084(87)90228-8; SPIRIN AS, 1969, COLD SPRING HARB SYM, V34, P197, DOI 10.1101/SQB.1969.034.01.026; SPIRIN AS, 1985, PROG NUCLEIC ACID RE, V32, P75, DOI 10.1016/S0079-6603(08)60346-3; SPIRIN AS, 1984, FEBS LETT, V165, P280, DOI 10.1016/0014-5793(84)80186-6; STARK H, IN PRESS CELL; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653	49	385	394	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					37	41		10.1038/385037a0	http://dx.doi.org/10.1038/385037a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985244				2022-12-01	WOS:A1997WA73100040
J	Bellefroid, EJ; Bourguignon, C; Hollemann, T; Ma, QF; Anderson, DJ; Kintner, C; Pieler, T				Bellefroid, EJ; Bourguignon, C; Hollemann, T; Ma, QF; Anderson, DJ; Kintner, C; Pieler, T			X-MyT1, a Xenopus C2HC-type zinc finger protein with a regulatory function in neuronal differentiation	CELL			English	Article							NEUROGENIC GENE-DELTA; ACHAETE-SCUTE COMPLEX; NEURAL INDUCTION; BINDING-PROTEIN; CELL FATE; DROSOPHILA; EXPRESSION; EMBRYOS; NOTCH; ENHANCER	X-MyT1 is a C2HC-type zinc finger protein that we find to be involved in the primary selection of neuronal precursor cells in Xenopus. Expression of this gene is positively regulated by the bHLH protein X-NGNR-1 and negatively regulated by the Notch/Delta signal transduction pathway. X-MyT1 is able to promote ectopic neuronal differentiation and to confer insensitivity to lateral inhibition, but only in cooperation with bHLH transcription factors. Inhibition of X-MyT1 function inhibits normal neurogenesis as well as ectopic neurogenesis caused by overexpression of X-NGNR-1. On the basis of these findings, we suggest that X-MyT1 is a novel, essential element in the cascade of events that allows cells to escape lateral inhibition and to enter the pathway that leads to terminal neuronal differentiation.	SALK INST BIOL STUDIES,SAN DIEGO,CA 92186; CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125	Salk Institute; California Institute of Technology; Howard Hughes Medical Institute	Bellefroid, EJ (corresponding author), INST BIOCHEM & MOL ZELLBIOL,HUMBOLDTALLEE 23,D-37073 GOTTINGEN,GERMANY.							BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; Chitnis A, 1996, DEVELOPMENT, V122, P2295; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; FEDOROFF NV, 1977, COLD SPRING HARB SYM, V42, P1195; FERREIRO B, 1994, DEVELOPMENT, V120, P3649; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Heitzler P, 1996, DEVELOPMENT, V122, P161; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; JENNINGS B, 1995, DEVELOPMENT, V121, P3745; KIM JG, 1992, MOL CELL BIOL, V12, P5632, DOI 10.1128/MCB.12.12.5632; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KUNISCH M, 1994, P NATL ACAD SCI USA, V91, P10139, DOI 10.1073/pnas.91.21.10139; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; MARKMEYER P, 1990, GENE, V93, P129, DOI 10.1016/0378-1119(90)90146-I; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MUSCAVITCH MA, 1994, DEV BIOL, V166, P415; NIETFELD W, 1990, EMBO J, V9, P3699, DOI 10.1002/j.1460-2075.1990.tb07582.x; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OSCHWALD R, 1991, International Journal of Developmental Biology, V35, P399; SAHIN M, 1993, J NEUROSCI, V13, P4968; SKEATH JB, 1994, FASEB J, V8, P714, DOI 10.1096/fasebj.8.10.8050670; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	37	190	197	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1191	1202		10.1016/S0092-8674(00)81815-2	http://dx.doi.org/10.1016/S0092-8674(00)81815-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980226	Bronze			2022-12-01	WOS:A1996WA54100008
J	Pfeifer, A; Aszodi, A; Seidler, U; Ruth, P; Hofmann, F; Fassler, R				Pfeifer, A; Aszodi, A; Seidler, U; Ruth, P; Hofmann, F; Fassler, R			Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II	SCIENCE			English	Article							HEAT-STABLE ENTEROTOXIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; MOUSE MODEL; ACTIVATION; EXPRESSION; CLONING; RAT; RECEPTOR; GUANYLIN; SEQUENCE	Cyclic guanosine 3',5'-monophosphate (cGMP)-dependent protein kinases (cGKs) mediate cellular signaling induced by nitric oxide and cGMP. Mice deficient in the type II cGK were resistant to Escherichia coli STa, an enterotoxin that stimulates cGMP accumulation and intestinal fluid secretion. The cGKII-deficient mice also developed dwarfism that was caused by a severe defect in endochondral ossification at the growth plates. These results indicate that cGKII plays a central role in diverse physiological processes.	UNIV TUBINGEN,MED KLIN 1,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen	Pfeifer, A (corresponding author), TECH UNIV MUNICH,INST PHARMACOL & TOXICOL,BIEDERSTEINER STR 29,D-80802 MUNICH,GERMANY.							CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; FELTS WJL, 1957, TRANSPLAN B, V4, P5; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRENCH PJ, 1995, J BIOL CHEM, V270, P26626, DOI 10.1074/jbc.270.44.26626; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GIANNELLA RA, 1976, INFECT IMMUN, V14, P95, DOI 10.1128/IAI.14.1.95-99.1976; GIANNELLA RA, 1981, ANNU REV MED, V32, P341, DOI 10.1146/annurev.me.32.020181.002013; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; HUNZIKER EB, 1987, J BONE JOINT SURG AM, V69A, P162, DOI 10.2106/00004623-198769020-00002; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCIAKY D, 1994, GENOMICS, V24, P583, DOI 10.1006/geno.1994.1670; SHABB JB, 1992, J BIOL CHEM, V267, P5723; UHLER MD, 1993, J BIOL CHEM, V268, P13586; USSING HH, 1951, ACTA PHYSIOL SCAND, V23, P110, DOI 10.1111/j.1748-1716.1951.tb00800.x; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X	27	314	341	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2082	2086		10.1126/science.274.5295.2082	http://dx.doi.org/10.1126/science.274.5295.2082			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953039				2022-12-01	WOS:A1996VY97400049
J	Bannister, AJ; Kouzarides, T				Bannister, AJ; Kouzarides, T			The CBP co-activator is a histone acetyltransferase	NATURE			English	Article							E1A	THE CBP protein acts as a transcriptional adaptor for many different transcription factors by directly contacting DNA-bound activators(1-7). One mechanism by which CBP is thought to stimulate transcription is by recruiting the histone acetyltransferase (HAT) P/CAF to the promoters(8). Here we show that CBP has intrinsic HAT activity. The HAT domain of CBP is adjacent to the binding site for the transcriptional activator E1A. Although E1A displaces P/CAF from CBP, it does not disrupt the CBP-associated HAT activity. Thus E1A carries HAT activity when complexed with CBP. Targeting CBP-associated HAT activity to specific promoters may therefore be a mechanism by which E1A acts as a transcriptional activator.	UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge; University of Cambridge				Bannister, Andrew/0000-0002-6312-4436; Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Hagmeyer BM, 1996, ONCOGENE, V12, P1025; Janknecht R, 1996, ONCOGENE, V12, P1961; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/S0968-0004(06)80020-4; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; WONG HK, 1994, J VIROL, V68, P4910, DOI 10.1128/JVI.68.8.4910-4920.1994; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	13	1479	1512	0	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 19	1996	384	6610					641	643		10.1038/384641a0	http://dx.doi.org/10.1038/384641a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VZ296	8967953				2022-12-01	WOS:A1996VZ29600033
J	Bikah, G; Carey, J; Ciallella, JR; Tarakhovsky, A; Bondada, S				Bikah, G; Carey, J; Ciallella, JR; Tarakhovsky, A; Bondada, S			CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells	SCIENCE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; NF-KAPPA-B; LYMPHOCYTES-B; CROSS-LINKING; SH2 DOMAIN; T-CELLS; ACTIVATION; MICE; CD5; STIMULATION	A subset of B lymphocytes present primarily in the peritoneal and pleural cavities is defined by the expression of GD5 and is elevated in autoimmune diseases. Upon signaling through membrane immunoglobulin M (mIgM), splenic B lymphocytes (B-2) proliferate, whereas peritoneal B cells (B-1) undergo apoptosis, However, in CD5-deficient mice, B-1 cells responded to mlgM crosslinking by developing a resistance to apoptosis and entering the cell cycle, In wild-type B-1 cells, prevention of association between CD5 and mlgM rescued their growth response to mlgM crosslinking, Thus the B cell receptor-mediated signaling is negatively regulated by CD5 in normal B-1 cells.	UNIV KENTUCKY, DEPT MICROBIOL & IMMUNOL, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, CTR AGING, LEXINGTON, KY 40536 USA; UNIV COLOGNE, INST GENET, D-50937 COLOGNE, GERMANY	University of Kentucky; University of Kentucky; University of Cologne					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005731] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21490] Funding Source: Medline; NIA NIH HHS [AG05731] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BELLOC F, 1988, CYTOMETRY, V9, P19, DOI 10.1002/cyto.990090104; BIKAH G, UNPUB; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; DALE LM, 1993, J EXP MED, V177, P857; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HAYAKAWA K, 1984, P NATL ACAD SCI-BIOL, V81, P2494, DOI 10.1073/pnas.81.8.2494; HAYAKAWA K, 1983, J EXP MED, V157, P202, DOI 10.1084/jem.157.1.202; HEATH AW, 1994, EUR J IMMUNOL, V24, P1828, DOI 10.1002/eji.1830240816; HERZENBERG LA, 1992, ANN NY ACAD SCI, V651, P1; ILLERA VA, 1993, J IMMUNOL, V151, P2965; JAKWAY JP, 1986, J IMMUNOL, V137, P2225; Jamin C, 1996, SCAND J IMMUNOL, V43, P73, DOI 10.1046/j.1365-3083.1996.d01-8.x; KEARNEY JF, 1986, IMMUNOL REV, V94, P39, DOI 10.1111/j.1600-065X.1986.tb01163.x; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P812, DOI 10.1002/eji.1830240406; LIOU LB, 1992, INT IMMUNOL, V4, P15, DOI 10.1093/intimm/4.1.15; LIU JL, 1991, J IMMUNOL, V146, P1685; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCEVOY L, 1988, J LEUKOCYTE BIOL, V44, P337, DOI 10.1002/jlb.44.5.337; MORRIS DL, 1993, J EXP MED, V177, P857, DOI 10.1084/jem.177.3.857; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; MUTHUKKUMAR S, 1995, INT IMMUNOL, V7, P305, DOI 10.1093/intimm/7.2.305; MUTHUSAMY N, 1991, J IMMUNOL, V147, P2483; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; O'Garra A, 1992, Int Rev Immunol, V8, P219, DOI 10.3109/08830189209055575; PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.iy.11.040193.001555; PENNELL CA, 1985, P NATL ACAD SCI USA, V82, P3799, DOI 10.1073/pnas.82.11.3799; PLAS DR, 1996, SCIENCE, V272, P117; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAJEWSKY K, 1987, SCIENCE, V238, P1088, DOI 10.1126/science.3317826; Reid S, 1996, J IMMUNOL METHODS, V192, P43, DOI 10.1016/0022-1759(96)00004-X; ROONEY JW, 1991, EUR J IMMUNOL, V21, P2993, DOI 10.1002/eji.1830211214; ROTHSTEIN TL, 1988, J IMMUNOL, V141, P4089; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; TARAKHOVSKY A, 1994, EUR J IMMUNOL, V24, P1678, DOI 10.1002/eji.1830240733; TARAKHOVSKY A, 1995, SCIENCE, V269, P535, DOI 10.1126/science.7542801; TSUBATA T, 1994, CURR BIOL, V4, P8, DOI 10.1016/S0960-9822(00)00003-8; UDHAYAKUMAR V, 1991, J IMMUNOL, V146, P4120; VAN DE VELDE H, 1991, NATURE, V351, P662; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	43	248	250	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1906	1909		10.1126/science.274.5294.1906	http://dx.doi.org/10.1126/science.274.5294.1906			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943203				2022-12-01	WOS:A1996VY20000043
J	Garcia, KC; Scott, CA; Brunmark, A; Carbone, FR; Peterson, PA; Wilson, IA; Teyton, L				Garcia, KC; Scott, CA; Brunmark, A; Carbone, FR; Peterson, PA; Wilson, IA; Teyton, L			CD8 enhances formation of stable T-cell receptor MHC class I molecule complexes	NATURE			English	Article							TOXIC LYMPHOCYTES-T; ANTIGEN RECEPTOR; PEPTIDE; AFFINITY; BINDING; KINETICS; ANTIBODY; PROTEIN; RECOGNITION; ASSOCIATION	T-CELL antigen receptors (TCR) generally interact with moderate affinity with the complex formed by major histocompatibility complex (MHC) molecules and foreign peptides(1-7), MHC/TCR recognition is followed by the generation of a signal to the T cell through a monomorphic multicomponent system that includes the CD3 complex and accessory molecules such as CD4 and CD8, The interaction between the extracellular domains of MHC and TCR molecules(1-7), and the interaction of MHC and CD4/CD8 molecules(8-10), have been considered to occur independently of one another. We report here that the affinity of CD8 dimers for MHC class I molecules is independent of haplotype and peptide content, and that the affinity of the TCR for its specific ligand is enhanced through a reduced 'off' rate in the presence of either CD8 alpha alpha homo- or CD8 alpha beta heterodimers. Moreover, CD8 seems to help recognition of the specific MHC-peptide complex either by guiding an energetically favourable docking of TCR onto MHC, or by inducing conformational changes in the MHC complex that can augment the TCR/MHC-peptide interaction. CD8 should therefore be considered as an active participant in the T-cell recognition complex, rather than simply as an accessory molecule.	RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA; SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA; MONASH UNIV, ALFRED HOSP, MELBOURNE, VIC 3181, AUSTRALIA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute; Scripps Research Institute; Florey Institute of Neuroscience & Mental Health; Monash University			Carbone, Francis/ABF-2141-2020					AJITKUMAR P, 1989, CELL, V58, P911; BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; GALLAGHER PF, 1989, P NATL ACAD SCI USA, V86, P10044, DOI 10.1073/pnas.86.24.10044; HOO WS, 1993, J IMMUNOL, V150, P4331; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; ROJO JM, 1989, P NATL ACAD SCI USA, V86, P3311, DOI 10.1073/pnas.86.9.3311; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; Scott CA, 1996, J EXP MED, V183, P2087, DOI 10.1084/jem.183.5.2087; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; SYKULEV Y, 1994, P NATL ACAD SCI USA, V91, P11487, DOI 10.1073/pnas.91.24.11487; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TOURVIEILLE B, 1986, SCIENCE, V234, P610, DOI 10.1126/science.3094146; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; UDAKA K, 1993, P NATL ACAD SCI USA, V90, P11271; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; Vignali DAA, 1996, J EXP MED, V183, P2097, DOI 10.1084/jem.183.5.2097; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0	26	268	275	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1996	384	6609					577	581		10.1038/384577a0	http://dx.doi.org/10.1038/384577a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955273				2022-12-01	WOS:A1996VX76900063
J	Bose, S; Weikl, T; Bugl, H; Buchner, J				Bose, S; Weikl, T; Bugl, H; Buchner, J			Chaperone function of Hsp90-associated proteins	SCIENCE			English	Article							HEAT-SHOCK PROTEINS; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; HSP90; RECEPTOR	The Hsp90 heat shock protein of eukaryotic cells regulates the activity of proteins involved in signal transduction pathways and may direct intracellular protein folding in general. Hsp90 performs at least part of its function in a complex with a specific set of partner proteins that include members of the prolyl isomerase family. The properties of the major components of the Hsp90 complex were examined through the use of in vitro protein folding assays. Two of the components, FKBP52 and p23, functioned as mechanistically distinct molecular chaperones. These results suggest the existence of a super-chaperone complex in the cytosol of eukaryotic cells.	UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, D-93040 REGENSBURG, GERMANY	University of Regensburg			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				BOSE S, 1994, BIOCHEM J, V300, P865, DOI 10.1042/bj3000865; BOSE S, UNPUB; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; EHRNSPERGER M, IN PRESS EMBO J; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; JAKOB U, 1995, J BIOL CHEM, V270, P14412, DOI 10.1074/jbc.270.24.14412; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEBEAU MC, 1993, STEROID HORMONE RECE, P261; PRATT WB, 1993, J BIOL CHEM, V268, P21455; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; SCHEIBEL T, UNPUB; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1995, SCI MED, V2, P38; SMITH DF, 1993, STEROID HORMONE RECE, P247; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0	28	311	324	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1996	274	5293					1715	1717		10.1126/science.274.5293.1715	http://dx.doi.org/10.1126/science.274.5293.1715			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939863				2022-12-01	WOS:A1996VW71200062
J	Cook, DG; Peacock, JL; Feyerabend, C; Carey, IM; Jarvis, MJ; Anderson, HR; Bland, JM				Cook, DG; Peacock, JL; Feyerabend, C; Carey, IM; Jarvis, MJ; Anderson, HR; Bland, JM			Relation of caffeine intake and blood caffeine concentrations during pregnancy to fetal growth: Prospective population based study	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT; MATERNAL SMOKING; SERUM COTININE; CONSUMPTION; ALCOHOL	Objectives-To examine the association of plasma caffeine concentrations during pregnancy with fetal growth and to compare this with relations with reported caffeine intake. Design-Prospective population based study. Setting-District general hospital, inner London. Subjects-Women booking for delivery between 1982 and 1984. Stored plasma was available for 1500 women who had provided a blood sample on at least one occasion and for 640 women who had provided. a sample on all three occasions (at booking, 28 weeks, and 36 weeks). Main outcome measure-Birth weight adjusted for gestational age, maternal height, parity, and sex of infant, The exposures of interest were reported caffeine consumption and blood caffeine concentration. Cigarette smoking was assessed by blood cotinine concentration, Results-Caffeine intake showed no changes during pregnancy, but blood caffeine concentrations rose by 75%., Although caffeine intake increased steadily with increasing cotinine concentration above 15 ng/ml, blood caffeine concentrations fell. Caffeine consumption was inversely related to adjusted birth weight, the estimated effect being a 1.3% fall in birth weight for a 1000 mg per week increase in intake (95% confidence interval 0.5% to 2.1%)., The apparent caffeine effect was confined to cigarette smokers, among whom the estimated effect was -1.6%/1000 mg a week (-2.9% to -0.2%) after adjustment for cotinine and -1.3% (-2.7% to 0.1%) after further adjustment for social class and alcohol intake, Adjusted birth weight mas unrelated to blood caffeine concentrations overall (P = 0.09, but a positive coefficient), after adjustment for cotinine (P = 0.73), or among current smokers (P = 0.45). Conclusions-Smokers consume more caffeine than non-smokers. Blood caffeine concentrations during pregnancy are not related to fetal growth, but caffeine intake is negatively associated with birth weight, with this effect being apparent only in smokers. The effect remains of borderline significance after adjustment for other factors. Prudent advice for pregnant women would be to reduce caffeine intake in conjunction with stopping smoking.	NEW CROSS HOSP, MED TOXICOL UNIT, LONDON, ENGLAND; UCL, DEPT EPIDEMIOL & PUBL HLTH, IMPERIAL CANC RES FUND, HLTH BEHAV UNIT, LONDON, ENGLAND	New Cross Hospital; Cancer Research UK; University of London; University College London	Cook, DG (corresponding author), UNIV LONDON ST GEORGES HOSP, SCH MED, DEPT PUBL HLTH SCI, LONDON SW17 0RE, ENGLAND.		Jarvis, Martin J/B-1034-2008; Anderson, Hugh R/A-7417-2016; Carey, Iain/O-6973-2014	Jarvis, Martin J/0000-0001-9238-8038; Carey, Iain/0000-0003-1099-8460; Peacock, Janet/0000-0002-0310-2518; Cook, Derek/0000-0002-9723-5759				ALDRIDGE A, 1981, SEMIN PERINATOL, V5, P310; ALSAMARRAE W, 1975, P NUTR SOC, V34, pA18; BARDY AH, 1993, BRIT J OBSTET GYNAEC, V100, P721, DOI 10.1111/j.1471-0528.1993.tb14262.x; BEAULACBAILLARGEON L, 1987, AM J OBSTET GYNECOL, V157, P1236, DOI 10.1016/S0002-9378(87)80301-0; BLAND JM, 1990, APPL STAT-J ROY ST C, V39, P229; BROOKE OG, 1989, BRIT MED J, V298, P795, DOI 10.1136/bmj.298.6676.795; DLUGOSZ L, 1992, EPIDEMIOL REV, V14, P83, DOI 10.1093/oxfordjournals.epirev.a036093; ESKENAZI B, 1995, AM J PUBLIC HEALTH, V85, P395, DOI 10.2105/AJPH.85.3.395; FENSTER L, 1991, AM J PUBLIC HEALTH, V81, P458, DOI 10.2105/AJPH.81.4.458; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; FORTIER I, 1993, AM J EPIDEMIOL, V137, P931, DOI 10.1093/oxfordjournals.aje.a116763; GRAHAM DM, 1978, NUTR REV, V36, P97, DOI 10.1111/j.1753-4887.1978.tb03717.x; HADDOW JE, 1987, BRIT J OBSTET GYNAEC, V94, P678, DOI 10.1111/j.1471-0528.1987.tb03174.x; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; KRISHNA K, 1978, BRIT J OBSTET GYNAEC, V85, P726, DOI 10.1111/j.1471-0528.1978.tb15591.x; Leviton A, 1996, EPIDEMIOLOGY, V7, P110, DOI 10.1097/00001648-199601000-00022; MCNEILL AD, 1987, BRIT J ADDICT, V82, P1355; Office of Population Censuses and Surveys, 1980, CLASS OCC; PARSONS WD, 1978, CLIN PHARMACOL THER, V24, P40; PEACOCK JL, 1991, J EPIDEMIOL COMMUN H, V45, P159, DOI 10.1136/jech.45.2.159; SHIONO PH, 1993, AM J EPIDEMIOL, V137, P951, DOI 10.1093/oxfordjournals.aje.a116765; Verma R C, 1983, Indian Pediatr, V20, P105	22	61	62	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	1996	313	7069					1358	1362		10.1136/bmj.313.7069.1358	http://dx.doi.org/10.1136/bmj.313.7069.1358			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956700	Green Published			2022-12-01	WOS:A1996VW68500022
J	Kallunki, T; Deng, TL; Hibi, M; Karin, M				Kallunki, T; Deng, TL; Hibi, M; Karin, M			c-jun Can recruit JNK to phosphorylate dimerization partners via specific docking interactions	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAY; ACTIVATED PROTEIN-KINASES; NEGATIVE REGULATOR; AP-1 ACTIVITY; HA-RAS; FOS; TYROSINE; BINDING; TRANSFORMATION; COMPLEXES	Structurally related serine/threonine kinases recognize similar phosphoacceptor peptides in vitro yet in vivo, they phosphorylate distinct substrates. To understand the basis for this specificity, we stud led the interaction between the Jun kinases (JNKs) and Jun proteins. JNKs phosphorylate c-Jun very efficiently, JunD less efficiently, but they do not phosphorylate JunB. Effective JNK substrates require a separate docking site and specificity-conferring residues flanking the phosphoacceptor. The docking site increases the efficiency and specificity of the phosphorylation reaction. JunB has a functional JNK docking site but lacks specificity-conferring residues. Insertion of such residues brings JunB under JNK control. JunD, by contrast, lacks a JNK docking site, but its phosphoacceptor peptide is identical to that of c-Jun. Substrates such as JunD can be phosphorylated by JNK through heterodimerization with docking competent partners. Therefore, heterodimerization can affect the recognition of transcription factors by signal-regulated protein kinases.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, SCH MED, PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA; UNIV FLORIDA, DEPT BIOCHEM & MOL BIOL, GAINESVILLE, FL 32610 USA	University of California System; University of California San Diego; State University System of Florida; University of Florida			Hibi, Masahiko/I-6215-2014	Hibi, Masahiko/0000-0002-9142-4444; Kallunki, Tuula/0000-0002-8571-383X	NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NCI NIH HHS [CA-50528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	42	398	405	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					929	939		10.1016/S0092-8674(00)81999-6	http://dx.doi.org/10.1016/S0092-8674(00)81999-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945519	Bronze			2022-12-01	WOS:A1996VV77400018
J	Wiegers, TA; Keirse, MJNC; vanderZee, J; Berghs, GAH				Wiegers, TA; Keirse, MJNC; vanderZee, J; Berghs, GAH			Outcome of planned home and planned hospital births in low risk pregnancies: Prospective study in midwifery practices in the Netherlands	BRITISH MEDICAL JOURNAL			English	Article							OPTIMALITY CONCEPT	Objective-To investigate the relation between the intended place of birth (home or hospital) and perinatal outcome in women with low risk pregnancies after controlling for parity and social, medical, and obstetric background. Design-Analysis of prospective data from midwives and their clients. Setting-54 midwifery practices in the province of Gelderland, Netherlands. Subjects-97 midwives and 1836 women with low risk pregnancies who had planned to give birth at home or in hospital. Main outcome measure-Perinatal outcome index based on ''maximal result with minimal intervention'' and incorporating 22 items on childbirth, 9 on the condition of the newborn, and 5 on the mother after the birth. Results-There was no relation between the planned place of birth and perinatal outcome in primiparous women when controlling for a favourable or less favourable background. In multiparous women, perinatal outcome was significantly better for planned home births than for planned hospital births, with or without control for background variables. Conclusions-The outcome of planned home births is at least as good as that of planned hospital births in women at low risk receiving midwifery care in the Netherlands.	FLINDERS UNIV S AUSTRALIA,DEPT OBSTET & GYNAECOL,FLINDERS MED CTR,ADELAIDE,SA 5001,AUSTRALIA	Flinders Medical Centre; Flinders University South Australia	Wiegers, TA (corresponding author), NETHERLANDS INST PRIMARY HLTH CARE,POB 1568,NL-3500 BN UTRECHT,NETHERLANDS.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				Carmines E.G., 1979, RELIABILITY VALIDITY, V17, DOI DOI 10.4135/9781412985642; *CENTR BUR STAT, 1993, MAANDBER GEZONDHEID, V12, P19; CRANDON AJ, 1979, J PSYCHOSOM RES, V23, P109, DOI 10.1016/0022-3999(79)90014-X; DAMSTRAWIJMENGA SMI, 1984, J ROY COLL GEN PRACT, V34, P425; ENKIN M, 1995, GUIDE EFFECTIVE CARE, P389; KEIRSE MJN, 1982, EFFECTIVENESS SATISF, P222; KEIRSE MJNC, 1984, LANCET, V1, P1166; MCPHERSON K, 1994, J EPIDEMIOL COMMUN H, V48, P6, DOI 10.1136/jech.48.1.6; PRECHTL HFR, 1980, EARLY HUM DEV, V4, P201; TOUWEN BCL, 1980, EARLY HUM DEV, V4, P207, DOI 10.1016/0378-3782(80)90027-4; TREFFERS PE, 1990, JAMA-J AM MED ASSOC, V264, P2203, DOI 10.1001/jama.264.17.2203; van Teijlingen E, 1987, Midwifery, V3, P178, DOI 10.1016/S0266-6138(87)80038-4; Wiegers TA, 1996, J CLIN EPIDEMIOL, V49, P319, DOI 10.1016/0895-4356(95)00549-8; *ZIEK, 1987, VERL IND 1987 FIN RE	14	118	119	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1996	313	7068					1309	1313						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV153	8942693				2022-12-01	WOS:A1996VV15300027
J	Cohen, JE; Tilman, D				Cohen, JE; Tilman, D			Ecology - Biosphere 2 and biodiversity: The lessons so far	SCIENCE			English	Editorial Material									COLUMBIA UNIV,NEW YORK,NY 10027; UNIV MINNESOTA,ST PAUL,MN 55108	Columbia University; University of Minnesota System; University of Minnesota Twin Cities	Cohen, JE (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.		Tilman, David/ABD-5309-2021					Broecker WS, 1996, GSA TODAY, V6, P1; BURGESS T, BIODIVERSITY WORKING; DEMPSTER WF, 1993, TECH PAP SER SOC AUT; Macilwain C, 1996, NATURE, V380, P275, DOI 10.1038/380275a0; Odum EP, 1996, NATURE, V382, P18, DOI 10.1038/382018a0; Severinghaus J. P., 1994, EOS T AM GEOPHYS UN, V75, P33, DOI DOI 10.1029/94E000285; WOLFGANG L, 1995, SCIENCE, V270, P1111	7	26	28	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1150	1151		10.1126/science.274.5290.1150	http://dx.doi.org/10.1126/science.274.5290.1150			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8966587				2022-12-01	WOS:A1996VT33500039
J	Frisch, M; Hjalgrim, H; Olsen, JH; Melbye, M				Frisch, M; Hjalgrim, H; Olsen, JH; Melbye, M			Risk for subsequent cancer after diagnosis of basal-cell carcinoma - A population-based, epidemiologic study	ANNALS OF INTERNAL MEDICINE			English	Article						carcinoma, basal-cell; melanoma; lymphoma, non-Hodgkin; testicular neoplasms; breast neoplasms	SALIVARY-GLAND CARCINOMA; NON-HODGKINS-LYMPHOMA; SKIN-CANCER; MALIGNANCIES	Background: Considerable debate is taking place over whether patients with basal-cell carcinoma and other skin neoplasms are at increased risk for internal cancer. Objective: To investigate risk for subsequent cancer in patients with basal-cell carcinoma. Design: Population-based cohort study. Setting: Denmark, from 1978 to 1991. Patients: 37 674 patients followed for a maximum of 14 years after a first diagnosis of basal-cell carcinoma. Measurements: The occurrence of subsequent cancer was compared with the expected cancer pattern (which was determined on the basis of national incidence data). Standardized incidence ratios (SIRs), ratios of actual to expected number of cases of cancer, yielded estimates of the relative risk. Results: During 190 945 patient-years of follow-up, 3663 new cases of cancer occurred where only 3245 were expected. As anticipated, malignant melanoma occurred frequently (SIR, 2.64 [95% CI, 2.21 to 3.13]), but patients were also at increased risk for noncutaneous cancer (SIR, 1.19 [CI, 1.13 to 1.24] for men and 1.09 [CI, 1.03 to 1.16] for women). The excess risk for noncutaneous cancer pertained to cancer of the lip (SIR, 2.07), salivary glands (SIR, 2.45), larynx (SIR, 1.41), lung (SIR, 1.40), breast (SIR, 1.13), and kidney (SIR, 1.30) and non-Hodgkin lymphoma (SIR, 1.36). Patients receiving a diagnosis of basal-cell carcinoma before 60 years of age (SIR, 1.26) had a statistically higher risk for developing new cancer (P < 0.01) than did those receiving the diagnosis at 60 years of age or older (SIR, 1.11). This applied to breast cancer (SIR, 1.37 in patients <60 years of age compared with 1.05 in those greater than or equal to 60 years of age), testicular cancer (SIR, 3.52 in patients <60 years of age compared with 0 seen and 1.96 expected in those greater than or equal to 60 years of age), and non-Hodgkin lymphoma (SIR, 2.50 in patients <60 years of age compared with 1.16 in those greater than or equal to 60 years of age). Conclusion: In addition to having an increased risk for new skin cancer, patients with basal-cell carcinoma have an increased risk for noncutaneous cancer at various sites. Increased risks for testicular cancer, breast cancer, and non-Hodgkin lymphoma should be kept in mind, particularly for patients in whom basal-cell carcinoma is diagnosed when they are at a young age.	DANISH CANC SOC, DIV CANC EPIDEMIOL, DK-2100 COPENHAGEN O, DENMARK	Danish Cancer Society	Frisch, M (corresponding author), STATENS SERUM INST, DANISH EPIDEMIOL SCI CTR, 5 ARTILLERIVEJ, DK-2300 COPENHAGEN S, DENMARK.		Hjalgrim, Henrik/AAG-4973-2021; Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; melbye, mads/0000-0001-8264-6785; Olsen, Jorgen Helge/0000-0001-9633-5662				ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; BATSAKIS JG, 1981, CLIN OTOLARYNGOL, V6, P129, DOI 10.1111/j.1365-2273.1981.tb01799.x; Breslow N. E., 1987, STAT METHODS CANC RE, VII, P65; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; CHUTE CG, 1991, JAMA-J AM MED ASSOC, V266, P816, DOI 10.1001/jama.266.6.816; FRISCH M, 1994, AM J EPIDEMIOL, V140, P12, DOI 10.1093/oxfordjournals.aje.a117154; FRISCH M, 1995, AM J EPIDEMIOL, V141, P916, DOI 10.1093/oxfordjournals.aje.a117358; Hakulinen T, 1986, Acta Pathol Microbiol Immunol Scand Suppl, V288, P1; Hartge P, 1996, J NATL CANCER I, V88, P298, DOI 10.1093/jnci/88.5.298; Hunter David J., 1990, Annals of Epidemiology, V1, P13; KARAGAS MR, 1992, JAMA-J AM MED ASSOC, V267, P3305, DOI 10.1001/jama.267.24.3305; LINDELOF B, 1991, J AM ACAD DERMATOL, V25, P245, DOI 10.1016/0190-9622(91)70189-9; PRESTON DS, 1992, NEW ENGL J MED, V327, P1649, DOI 10.1056/NEJM199212033272307; SANDSTROM A, 1984, ACTA RADIOL ONCOL, V23, P227, DOI 10.3109/02841868409136016; SCOTTO J, 1982, CANCER EPIDEMIOL, P996; SPITZ MR, 1985, ANN OTO RHINOL LARYN, V94, P129, DOI 10.1177/000348948509400206; SPITZ MR, 1984, CANCER, V54, P1854, DOI 10.1002/1097-0142(19841101)54:9<1854::AID-CNCR2820540915>3.0.CO;2-1; Storm H H, 1985, Natl Cancer Inst Monogr, V68, P411; STORM HH, 1994, CANC INCIDENCE DENMA; STORM HH, 1991, CANC REGISTRATION PR, P220; TEPPO L, 1985, J NATL CANCER I, V75, P207; World Health Organization, 1976, INT CLASS DIS	22	106	107	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					815	+		10.7326/0003-4819-125-10-199611150-00005	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928988				2022-12-01	WOS:A1996VU52400008
J	SCHACHTMAN, DP; SCHROEDER, JI; LUCAS, WJ; ANDERSON, JA; GABER, RF				SCHACHTMAN, DP; SCHROEDER, JI; LUCAS, WJ; ANDERSON, JA; GABER, RF			EXPRESSION OF AN INWARD-RECTIFYING POTASSIUM CHANNEL BY THE ARABIDOPSIS KAT1 CDNA	SCIENCE			English	Article							GUARD-CELL PROTOPLASTS; PLASMA-MEMBRANE; K+ CHANNELS; ION CHANNELS; SACCHAROMYCES-CEREVISIAE; SODIUM-CHANNEL; PATCH-CLAMP; VICIA-FABA; ANOMALOUS RECTIFICATION; VOLTAGE-DEPENDENCE	Inward-rectifying potassium channels located in the plasma membrane of higher plant and animal cells contribute to cellular homeostasis and excitability. The genes encoding this specific class of K+ channels have not been functionally identified. This report shows that a single messenger RNA transcript from the Arabidopsis thaliana KAT1 complementary DNA confers the functional expression of a hyperpolarization-activated K+ channel in Xenopus oocytes. The channels encoded by KAT1 are highly selective for K+ over other monovalent cations, are blocked by tetraethylammonium and barium, and have a single-channel conductance of 28 +/- 7 picosiemens with 118 millimolar K+ in the bathing solution. These functional characteristics, typical of inward-rectifying K+ channels in eukaryotic cells, demonstrate that KAT1 encodes an inward-rectifying K+ channel.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; UNIV CALIF DAVIS, DEPT BOT, DAVIS, CA 95616 USA	Northwestern University; University of California System; University of California San Diego; University of California System; University of California Davis	SCHACHTMAN, DP (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA.			Schroeder, Julian/0000-0002-3283-5972; Schachtman, Daniel/0000-0003-1807-4369				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; BLATT MR, 1992, J GEN PHYSIOL, V99, P615, DOI 10.1085/jgp.99.4.615; BLOOM AJ, 1986, PLANT PHYSIOL, V81, P67, DOI 10.1104/pp.81.1.67; BUSH DS, 1988, PLANTA, V176, P368, DOI 10.1007/BF00395417; CAO YW, 1992, PLANT CELL, V4, P961, DOI 10.1105/tpc.4.8.961; COLOMBO R, 1991, PLANT PHYSIOL, V97, P1130, DOI 10.1104/pp.97.3.1130; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; EPSTEIN E, 1972, MINERAL NUTRITION PL; FAIRLEYGRENOT KA, 1992, PLANTA, V186, P282, DOI 10.1007/BF00196258; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HAGIWARA S, 1974, J MEMBRANE BIOL, V18, P61, DOI 10.1007/BF01870103; HAGIWARA S, 1978, J PHYSIOL-LONDON, V279, P167, DOI 10.1113/jphysiol.1978.sp012338; HAGIWARA S, 1983, MEMBRANE POTENTIAL D, P61; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HAYNES RJ, 1978, BIOL REV, V53, P465, DOI 10.1111/j.1469-185X.1978.tb00862.x; HEDRICH R, 1989, ANNU REV PLANT PHYS, V40, P539, DOI 10.1146/annurev.pp.40.060189.002543; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KATZ B, 1949, ARCH SCI PHYSIOL, V3, P285; KETCHUM KA, 1989, PLANT PHYSIOL, V89, P1184, DOI 10.1104/pp.89.4.1184; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KOCHIAN LV, 1988, ADV BOT RES, V15, P93; KOURIE J, 1992, PLANT PHYSIOL, V98, P1087, DOI 10.1104/pp.98.3.1087; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LINDAU M, 1986, J GEN PHYSIOL, V88, P349, DOI 10.1085/jgp.88.3.349; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MATSUDA H, 1991, ANNU REV PHYSIOL, V53, P289, DOI 10.1146/annurev.ph.53.030191.001445; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; NEWMAN IA, 1987, PLANT PHYSIOL, V84, P1177, DOI 10.1104/pp.84.4.1177; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PARKER I, 1988, PROC R SOC SER B-BIO, V233, P191, DOI 10.1098/rspb.1988.0018; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; SCHACHTMAN DP, UNPUB; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; SCHROEDER JI, 1988, J GEN PHYSIOL, V92, P667, DOI 10.1085/jgp.92.5.667; SCHROEDER JI, 1991, P NATL ACAD SCI USA, V88, P11583, DOI 10.1073/pnas.88.24.11583; SCHROEDER JI, 1987, P NATL ACAD SCI USA, V84, P4108, DOI 10.1073/pnas.84.12.4108; SCHROEDER JI, 1984, NATURE, V312, P361, DOI 10.1038/312361a0; SCHROEDER JI, 1989, NATURE, V338, P427, DOI 10.1038/338427a0; SENENAC H, 1992, SCIENCE, V256, P663; SLAYMAN CL, 1987, J BIOENERG BIOMEMBR, V19, P1; SUSSMAN MR, 1989, PLANT CELL, V1, P953, DOI 10.1105/tpc.1.10.953; TESTER M, 1990, NEW PHYTOL, V114, P305, DOI 10.1111/j.1469-8137.1990.tb00403.x; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	56	373	390	2	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1992	258	5088					1654	1658		10.1126/science.8966547	http://dx.doi.org/10.1126/science.8966547			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	8966547				2022-12-01	WOS:A1992KA89600039
J	Groves, JT; Ulman, N; Boxer, SG				Groves, JT; Ulman, N; Boxer, SG			Micropatterning fluid lipid bilayers on solid supports	SCIENCE			English	Article							T-CELLS; MEMBRANES; ADHESION	Lithographically patterned grids of photoresist, aluminum oxide, or gold on oxidized silicon substrates were used to partition supported lipid bilayers into micrometer-scale arrays of isolated fluid membrane corrals. Fluorescently labeled lipids were observed to diffuse freely within each membrane corral but were confined by the micropatterned barriers. The concentrations of fluorescent probe molecules in individual corrals were altered by selective photobleaching to create arrays of fluid membrane patches with differing compositions. Application of an electric field parallel to the surface induced steady-state concentration gradients of charged membrane components in the corrals, In addition to producing patches of membrane with continuously varying composition, these gradients provide an intrinsically parallel means of acquiring information about molecular properties such as the diffusion coefficient in individual corrals.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; STANFORD UNIV,DEPT ELECT ENGN,EDWARD L GINZTON LAB,STANFORD,CA 94305	Stanford University; Stanford University			Wunder, Stephanie L/B-5066-2012; Zdilla, Michael J/B-4145-2011	Boxer, Steven/0000-0001-9167-4286				ABBOTT NL, 1992, SCIENCE, V257, P1380, DOI 10.1126/science.257.5075.1380; BAYERL TM, 1990, BIOPHYS J, V58, P357, DOI 10.1016/S0006-3495(90)82382-1; BRIAN AA, 1984, P NATL ACAD SCI-BIOL, V81, P6159, DOI 10.1073/pnas.81.19.6159; CHAN PY, 1991, J CELL BIOL, V115, P245, DOI 10.1083/jcb.115.1.245; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Groves JT, 1996, BIOPHYS J, V71, P2716, DOI 10.1016/S0006-3495(96)79462-6; Groves JT, 1995, BIOPHYS J, V69, P1972, DOI 10.1016/S0006-3495(95)80067-6; JOHNSON SJ, 1991, BIOPHYS J, V59, P289, DOI 10.1016/S0006-3495(91)82222-6; Koenig BW, 1996, LANGMUIR, V12, P1343, DOI 10.1021/la950580r; KUMR A, 1993, APPL PHYS LETT, V63, P2002; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; POO MM, 1977, NATURE, V265, P602, DOI 10.1038/265602a0; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; Salafsky J, 1996, BIOCHEMISTRY-US, V35, P14773, DOI 10.1021/bi961432i; STELZLE M, 1992, BIOPHYS J, V63, P1346, DOI 10.1016/S0006-3495(92)81712-5; TOZEREN A, 1992, J CELL BIOL, V116, P997, DOI 10.1083/jcb.116.4.997; WATTS TH, 1987, ANNU REV IMMUNOL, V5, P461, DOI 10.1146/annurev.immunol.5.1.461; Xia YN, 1996, SCIENCE, V273, P347, DOI 10.1126/science.273.5273.347	18	487	518	1	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					651	653		10.1126/science.275.5300.651	http://dx.doi.org/10.1126/science.275.5300.651			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005848				2022-12-01	WOS:A1997WF07700035
J	Mulcahy, D; Husain, S; Zalos, G; Rehman, A; Andrews, NP; Schenke, WH; Geller, NL; Quyyumi, AA				Mulcahy, D; Husain, S; Zalos, G; Rehman, A; Andrews, NP; Schenke, WH; Geller, NL; Quyyumi, AA			Ischemia during ambulatory monitoring as a prognostic indicator in patients with stable coronary artery disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SILENT-MYOCARDIAL-ISCHEMIA; LEFT-VENTRICULAR FUNCTION; LONG-TERM PROGNOSIS; ST SEGMENT CHANGES; FOLLOW-UP; ANGINA-PECTORIS; MEDICAL THERAPY; BYPASS-SURGERY; HEART-DISEASE; DAILY LIFE	Objective.-To assess long-term prognostic significance of transient ischemia in patients with documented coronary artery disease and stable symptoms and to examine the relation between transient ischemia and the site of angiographic disease progression following acute cardiac events. Design.-Cohort study with a mean+/-SD follow-up of 51.5+/-23.8 months. Setting.--Ambulatory patients with stable coronary artery disease, assigned to medical therapy. Patients.-A total 221 patients (173 men; mean age, 60.8 years) were recruited, Of the 221 patients, 101 (45.7%) had single-vessel, 86 (38.9%) had 2-vessel, and 34 (15.4%) had 3-vessel disease. A total of 135 had a positive exercise test for ischemia, and mean+/-SD resting left ventricular ejection fraction (LVEF) was 49.8%+/-11.4%. Using conventional criteria, patients were prospectively stratified as low risk for continued medical therapy (single-vessel disease, 2-vessel disease with negative exercise test, or LVEF greater than or equal to 40%; n=189 [85.5%]) or high risk for continued medical therapy (multivessel disease with ischemia and/or left ventricular dysfunction; n=32 [14.5%]). Interventions.-Ambulalory ST-segment monitoring, treadmill exercise testing, radionuclide ventriculography, and coronary angiography. Main Outcome Measures.-Demographic, clinical, ambulatory monitoring, treadmill exercise, and left ventricular function variables as independent predictors of acute (cardiac death, myocardial infarction, or unstable angina) or all (including revascularization) cardiac events in the overall and the low-risk population. Results.-None of the clinical or noninvasive measures of ischemia were of prognostic significance in the overall or the low-risk group. The only significant independent predictor of outcome in all patients for all events, including revascularization, was the number of diseased vessels (chi(2)=13.5 [df=1]; P<.001). Exclusion of vessel disease resulted in conventional risk stratification as the most significant predictor of outcome from all events in all patients (chi(2)=10.3 [df=1]; P=.001). In the low-risk group, the number of diseased vessels was the only predictor for all events (chi(2)=4.6; P=.03). For acute cardiac events, none of the variables tested were of prognostic significance. Based on the frequency of events in the low-risk patients, a 2-fold increase in the rate of cardiac events in patients with transient ischemia compared with those without transient ischemia during ambulatory monitoring could be excluded with greater than 85% power and alpha of .05. Of 30 patients suffering acute nonfatal cardiac events during follow-up, angiography was performed in 27, revealing significant progression of coronary disease in 24 (88.8%) and the development of new significant lesions al sites remote from previously significant lesions in 20 (74%) cases. These new lesions were equally likely to occur in those with or without transient ischemia at initial assessment. Conclusions.-Acute cardiac events in predominantly low-risk stable angina patients with confirmed coronary disease are unpredictable, and those more likely to suffer such an event cannot be identified by the detection of ambulatory ischemia. Acute nonfatal cardiac events result predominantly from the development of significant new coronary lesions, not initially severe enough to cause ischemia. Patients categorized as high risk for long-term medical therapy have an increased rate of cardiac events (mainly revascularization) when compared with low-risk patients.	NHLBI, CARDIOL BRANCH, NIH, BETHESDA, MD 20892 USA; NHLBI, OFF BIOSTAT RES, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; AMBROSE JA, 1986, J AM COLL CARDIOL, V7, P472, DOI 10.1016/S0735-1097(86)80455-7; AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; BONOW RO, 1984, NEW ENGL J MED, V311, P1339, DOI 10.1056/NEJM198411223112103; BRUNELLI C, 1989, EUR HEART J, V10, P292, DOI 10.1093/oxfordjournals.eurheartj.a059486; CAMPBELL S, 1986, CIRCULATION, V74, P72, DOI 10.1161/01.CIR.74.1.72; Cox DR., 1984, ANAL SURVIVAL DATA; CREA F, 1987, AM J CARDIOL, V60, P40, DOI 10.1016/0002-9149(87)90981-7; Dargie HJ, 1996, EUR HEART J, V17, P104; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEEDWANIA PC, 1990, CIRCULATION, V81, P748, DOI 10.1161/01.CIR.81.3.748; DETRE KM, 1984, NEW ENGL J MED, V311, P1333; EPSTEIN SE, 1989, NEW ENGL J MED, V321, P320, DOI 10.1056/NEJM198908033210511; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GORLIN R, 1986, CIRCULATION, V74, P6, DOI 10.1161/01.CIR.74.1.6; HACKETT D, 1989, AM J CARDIOL, V63, P1517, DOI 10.1016/0002-9149(89)90018-0; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kay R., 1977, APPL STATIST, V26, P227, DOI 10.2307/2346962; KENNEDY HL, 1990, AM J CARDIOL, V65, P14, DOI 10.1016/0002-9149(90)90019-W; KENT KM, 1982, NEW ENGL J MED, V306, P441, DOI 10.1056/NEJM198202253060801; KUNKES SH, 1980, AM HEART J, V100, P813, DOI 10.1016/0002-8703(80)90061-7; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MOISE A, 1988, AM J CARDIOL, V61, P1255, DOI 10.1016/0002-9149(88)91165-4; MOSS AJ, 1993, JAMA-J AM MED ASSOC, V269, P2379, DOI 10.1001/jama.269.18.2379; MULCAHY D, 1989, J AM COLL CARDIOL, V14, P1166, DOI 10.1016/0735-1097(89)90411-7; MULCAHY D, 1995, EUR HEART J, V16, P317, DOI 10.1093/oxfordjournals.eurheartj.a060913; MULCAHY D, 1988, BRIT HEART J, V60, P417; MULCAHY D, 1992, AM HEART J, V123, P597, DOI 10.1016/0002-8703(92)90495-H; NOBUYOSHI M, 1991, J AM COLL CARDIOL, V18, P904, DOI 10.1016/0735-1097(91)90745-U; PANDULLA C, 1991, J ITAL CARDIOL, V21, P735; PATEL D, 1993, BRIT HEART J, V70, P337; QUYYUMI AA, 1985, BRIT HEART J, V54, P557; QUYYUMI AA, 1993, J AM COLL CARDIOL, V21, P700, DOI 10.1016/0735-1097(93)90103-8; QUYYUMI AA, 1985, BRIT HEART J, V53, P186; QUYYUMI AA, 1992, J AM COLL CARDIOL, V19, P962, DOI 10.1016/0735-1097(92)90279-V; ROCCO MB, 1988, CIRCULATION, V78, P877, DOI 10.1161/01.CIR.78.4.877; ROGERS WJ, 1995, J AM COLL CARDIOL, V26, P594, DOI 10.1016/0735-1097(95)00228-V; *SAS I INC, 1984, P229 SASSTST; TZIVONI D, 1988, AM J CARDIOL, V62, P661, DOI 10.1016/0002-9149(88)91198-8; TZIVONI D, 1989, AM J CARDIOL, V63, P273, DOI 10.1016/0002-9149(89)90329-9; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; YEUNG AC, 1991, CIRCULATION, V83, P1598, DOI 10.1161/01.CIR.83.5.1598	45	31	31	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1997	277	4					318	324		10.1001/jama.277.4.318	http://dx.doi.org/10.1001/jama.277.4.318			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC458	9002495				2022-12-01	WOS:A1997WC45800032
J	Cao, H; Glazebrook, J; Clarke, JD; Volko, S; Dong, XN				Cao, H; Glazebrook, J; Clarke, JD; Volko, S; Dong, XN			The Arabidopsis NPR1 gene that controls systemic acquired resistance encodes a novel protein containing ankyrin repeats	CELL			English	Article							PLANT-DISEASE RESISTANCE; TOBACCO MOSAIC-VIRUS; NF-KAPPA-B; SALICYLIC-ACID; HYDROGEN-PEROXIDE; THALIANA; SIGNAL; TRANSDUCTION; INDUCTION; EXPRESSION	The Arabidopsis NPR1 gene controls the onset of systemic acquired resistance (SAR), a plant immunity, to a broad spectrum of pathogens that is normally established after a primary exposure to avirulent pathogens. Mutants with defects in NPR1 fail to respond to various SAP-inducing treatments, displaying little expression of pathogenesis-related (PR) genes and exhibiting increased susceptibility to infections. NPR1 was cloned using a map-based approach and was found to encode a novel protein containing ankyrin repeats. The lesion in one npr1 mutant allele disrupted the ankyrin consensus sequence, suggesting that these repeats are important for NPR1 function. Furthermore, transformation of the cloned wild-type NPR1 gene into npr1 mutants not only complemented the mutations, restoring the responsiveness to SAP induction with respect to PR-gene expression and resistance to infections, but also rendered the transgenic plants more resistant to infection by P. syringae in the absence of SAP induction.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT MOL BIOL, BOSTON, MA 02114 USA; UNIV MARYLAND, BIOTECHNOL INST, AGR BIOTECHNOL CTR, COLLEGE PK, MD 20742 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University System of Maryland; University of Maryland College Park	Cao, H (corresponding author), DUKE UNIV, DEPT BOT, DEV CELL & MOL BIOL GRP, DURHAM, NC 27708 USA.			Glazebrook, Jane/0000-0001-5167-736X	NIGMS NIH HHS [GM48707] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048707, R01GM048707] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1993, CURRENT PROOTOCOLS M; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BI YM, 1995, PLANT J, V8, P235, DOI 10.1046/j.1365-313X.1995.08020235.x; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; CAO H, 1994, PLANT CELL, V6, P1583, DOI 10.1105/tpc.6.11.1583; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; DELANEY TP, 1994, SCIENCE, V266, P1247, DOI 10.1126/science.266.5188.1247; DELANEY TP, 1995, P NATL ACAD SCI USA, V92, P6602, DOI 10.1073/pnas.92.14.6602; Dellaporta S.L., 1983, PLANT MOL BIOL REP, V1, P19, DOI [10.1007/BF02712670, DOI 10.1007/BF02712670]; DONG XN, 1991, PLANT CELL, V3, P61, DOI 10.1105/tpc.3.1.61; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; Glazebrook J, 1996, GENETICS, V143, P973; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gorlach J, 1996, PLANT CELL, V8, P629, DOI 10.1105/tpc.8.4.629; JEFFERSON RA, 1987, EMBO J, V6, P3901; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KUC J, 1982, BIOSCIENCE, V32, P854, DOI 10.2307/1309008; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LAMB CJ, 1994, CELL, V76, P419, DOI 10.1016/0092-8674(94)90106-6; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; Metraux J. P., 1991, Advances in molecular genetics of plant-microbe interactions. Vol. 1. Proceedings of the 5th international symposium on the molecular genetics of plant-microbe interactions, Interlaken, Switzerland, September 9-14, 1990., P432; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; NEUENSCHWANDER U, 1995, PLANT J, V8, P227, DOI 10.1046/j.1365-313X.1995.08020227.x; PARKER JE, 1993, PLANT J, V4, P821, DOI 10.1046/j.1365-313X.1993.04050821.x; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; RASMUSSEN JB, 1991, PLANT PHYSIOL, V97, P1342, DOI 10.1104/pp.97.4.1342; ROSS AF, 1961, VIROLOGY, V14, P329, DOI 10.1016/0042-6822(61)90318-X; ROSS AF, 1961, VIROLOGY, V14, P340, DOI 10.1016/0042-6822(61)90319-1; Sokal R.R., 1981, BIOMETRY; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; UKNES S, 1992, PLANT CELL, V4, P645, DOI 10.1105/tpc.4.6.645; VANLOON LC, 1970, VIROLOGY, V40, P199, DOI 10.1016/0042-6822(70)90395-8; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WHITE RF, 1979, VIROLOGY, V99, P410, DOI 10.1016/0042-6822(79)90019-9; YALPANI N, 1991, PLANT CELL, V3, P809, DOI 10.1105/tpc.3.8.809	40	1073	1206	12	158	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1997	88	1					57	63		10.1016/S0092-8674(00)81858-9	http://dx.doi.org/10.1016/S0092-8674(00)81858-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019406	Bronze			2022-12-01	WOS:A1997WC56900009
J	Crespo, P; Schuebel, KE; Ostrom, AA; Gutkind, JS; Bustelo, XR				Crespo, P; Schuebel, KE; Ostrom, AA; Gutkind, JS; Bustelo, XR			Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product	NATURE			English	Article							TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; RAS TRANSFORMATION; SIGNALING PATHWAY; SH2 DOMAIN; B-CELLS; T-CELL; RHO	THE oncogenic protein Vav(1,2) harbours a complex array of structural motifs, including leucine-rich, Dbl-homology, pleckstrin-homology, zinc-finger, SH2 and SH3 domains, Upon stimulation by antigens or mitogens, Vav becomes phosphorylated on key tyrosine residues(3-5) and associates with other signalling proteins, including the mitogen receptors(3,4) Zap-70 (ref. 6). Vap-1 (ref. 5) and Slp-76 (ref. 7). Disruption of the vav locus by homologous recombination causes severe defects in signalling by primary antigen receptors, leading to abnormal lymphocyte proliferation and lymphopenia(8,9). Despite the importance of Vav cell signalling, the function of this protein remains unknown, Here we show that tyrosine-phosphorylated Vav, but not the non-phosphorylated protein, catalyses GDP/GTP exchange on Rac-1, a protein implicated in cell proliferation and cytoskeletal organization(10,11), causing this GTPase to switch from its inactive to its active state, Transfection experiments also show that phosphorylation of Vav on tyrosine residues leads to nucleotide exchange on Rac-1 in vivo and stimulates c-Jun kinase, a downstream element in the signalling pathway involving this GTPase, Our results have identified a function for Vav and define a mechanism in which engaged membrane receptors activate its signalling pathway.	SUNY STONY BROOK,SCH MED,DEPT PATHOL,STONY BROOK,NY 11794; SUNY STONY BROOK,UNIV HOSP,STONY BROOK,NY 11794; NIDR,MOL SIGNALLING UNIT,CELLULAR DEV & ONCOL LAB,NIH,BETHESDA,MD 20892; UNIV CANTABRIA,FAC MED,DEPT MOL BIOL,SANTANDER 39011,CANTABRIA,SPAIN	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Universidad de Cantabria			Gutkind, J. Silvio/J-1201-2016; Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010; Gutkind, J. Silvio/A-1053-2009; Crespo, Piero/M-3273-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Crespo, Piero/0000-0003-2825-7783				BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SPANA C, 1993, PROTEIN EXPRES PURIF, V4, P390, DOI 10.1006/prep.1993.1051; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	24	660	666	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					169	172		10.1038/385169a0	http://dx.doi.org/10.1038/385169a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990121				2022-12-01	WOS:A1997WB72800057
J	Soumeral, SB; McLaughlin, TJ; Spiegelman, D; Hertzmark, E; Thibault, G; Goldman, L				Soumeral, SB; McLaughlin, TJ; Spiegelman, D; Hertzmark, E; Thibault, G; Goldman, L			Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	19th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 1996	WASHINGTON, D.C.	Soc Gen Internal Med			CORONARY HEART-DISEASE; CLINICAL-TRIALS; CLAIMS DATA; THERAPY; MEDICAID; MORTALITY; MASSACHUSETTS; SERVICES; QUALITY; DRUGS	Objectives-To study determinants and adverse outcomes (mortality and rehospitalization) of beta-blocker underuse in elderly patients with myocardial infarction; and whether the relative risks (RRs) of survival associated with beta-blocker use were comparable to those reported in the large randomized controlled trials (RCTs). Setting.-New Jersey Medicare population. Design.-Retrospective cohort design using linked Medicare and drug claims data from 1987 to 1992. Patients.-Statewide cohort of 5332 elderly 30-day acute myocardial infarction (AMI) survivors with prescription drug coverage, of whom 3737 were eligible for beta-blockers. Main Outcome Measures.-beta-Blocker and calcium channel blocker use in the first 90 days after discharge and mortality rates and cardiac hospital readmissions over the 2-year period after discharge, controlling for sociodemographic and baseline risk variables. Results.-Only 21% of eligible patients received beta-blocker therapy; this rate remained unchanged from 1987 to 1991. Patients were almost 3 times more likely to receive a new prescription for a calcium channel blocker than for a new beta-blocker after their AMIs. Advanced age and calcium channel blocker use predicted underuse of beta-blockers. Controlling for other predictors of survival, the mortality rate among beta-blocker recipients was 43% less than that for nonrecipients (RR=0.57; 95% confidence interval [CI], 0.47-0.69). Effects on mortality were substantial in all age strata (65-74 years, 75-84 years, and greater than or equal to 85 years) and consistent with the results for elderly subgroups of 2 large RCTs, beta-Blocker recipients were rehospitalized 22% less often than nonrecipients (RR=0.78; 95% CI, 0.67-0.90). Use of a calcium channel blocker instead of a beta-blocker was associated with a doubled risk of death (RR=1.98; 95% CI, 1.44-2.72), not because calcium channel blockers had a demonstrable adverse effect, but because they were substitutes for beta-blockers. Conclusions.-beta-Blockers are underused in elderly AMI survivors, leading to measurable adverse outcomes. These data suggest that the survival benefits of beta-blockade after an AMI may extend to eligible patients older than 75 years, a group that has been excluded from RCTs.	HARVARD PILGRIM HLTH CTR, BOSTON, MA 02215 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA USA	Harvard Pilgrim Health Care; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of California System; University of California San Francisco	Soumeral, SB (corresponding author), HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, 126 BROOKLINE AVE, SUITE 200, BOSTON, MA 02215 USA.				AHRQ HHS [R01 HSO6341, R01 HSO7631] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BRAND DA, 1995, J AM COLL CARDIOL, V26, P1432, DOI 10.1016/0735-1097(95)00362-2; BURRIS JF, 1993, ARCH INTERN MED, V153, P2085, DOI 10.1001/archinte.153.18.2085; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; DAHLOF C, 1991, CIRCULATION, V84, P108; ECCLES M, 1991, BMJ-BRIT MED J, V302, P91, DOI 10.1136/bmj.302.6768.91; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; EPSTEIN AM, 1992, JAMA-J AM MED ASSOC, V268, P2530; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HARRELL FE, 1988, P 12 ANN SAS US GROU, P1107; HARRELL FE, 1987, P 11 ANN SAS US GROU, P823; HORWITZ RI, 1990, AM J MED, V89, P630, DOI 10.1016/0002-9343(90)90182-D; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JANSEN RWMM, 1994, DRUG AGING, V4, P175, DOI 10.2165/00002512-199404030-00001; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KENNEDY HL, 1994, AM J CARDIOL, V74, P674, DOI 10.1016/0002-9149(94)90308-5; KENNEDY HL, 1995, J AM COLL CARDIOL, V26, P547, DOI 10.1016/0735-1097(95)80035-F; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; Lohr K N, 1990, Int J Technol Assess Health Care, V6, P263; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; RAY WA, 1990, ARCH INTERN MED, V150, P2109, DOI 10.1001/archinte.150.10.2109; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; ROOS LL, 1989, STRENGTHS WEAKNESS H; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SIAL SH, 1994, J GEN INTERN MED, V9, P599, DOI 10.1007/BF02600301; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; Temple R, 1990, Int J Technol Assess Health Care, V6, P211; Wennberg J E, 1984, Health Aff (Millwood), V3, P6, DOI 10.1377/hlthaff.3.2.6; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255	44	416	422	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1997	277	2					115	121		10.1001/jama.277.2.115	http://dx.doi.org/10.1001/jama.277.2.115			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WA650	8990335				2022-12-01	WOS:A1997WA65000030
J	Churchill, D; Perry, IJ; Beevers, DG				Churchill, D; Perry, IJ; Beevers, DG			Ambulatory blood pressure in pregnancy and fetal growth	LANCET			English	Article							HYPERTENSION; WEIGHT; RATIO; LIFE	Background Retarded growth in utero has been linked with high blood pressure and other risk factors for cardiovascular disease in adult life. However, the influence on fetal growth of the maternal blood pressure during pregnancy is not well defined. In a prospective study, we examined the relation between maternal ambulatory blood pressure during pregnancy and indices of fetal growth. Methods We studied 209 healthy nulliparous pregnant women referred to an inner-city district general hospital (86% of 244 consecutively referred women who met the study criteria). 24 h ambulatory blood-pressure recordings were obtained in early (median 18 weeks [IQR 17-18]) mid (28 weeks [28]), and late (36 weeks [36]) gestation. Eight infants delivered before 32 weeks' gestation were excluded from the analysis. Findings A 5 mm Hg (1 SD) increase in mean 24 h diastolic blood pressure at 28 weeks' gestation was associated with a 68 g (95% CI 3-132) decrease in birthweight; a similar change in diastolic pressure at 36 weeks' gestation was associated with a 76 g (24-129) decrease in birthweight. These associations were independent of potential confounders (maternal age, height, weight, cigarette smoking, alcohol intake, ethnic origin, pregnancy hypertension syndromes, and preterm birth). Maternal mean 24 h diastolic blood pressure at 28 weeks' gestation was also inversely associated with the infant's ponderal index at birth in multivariate analysis (p=0.06). Higher maternal ambulatory blood pressure at 28 weeks' and 36 weeks' gestation also predicted lower head circumference, although these associations were dependent on birthweight. Associations between ambulatory systolic blood pressure and indices of fetal growth were weak and inconsistent and ambulatory blood pressure at 18 weeks' gestation did not predict fetal growth. Interpretation There is a continuous inverse association between fetal growth and maternal blood pressure, throughout the range seen in normal pregnancy. Maternal blood pressure may be an important confounding factor in the reported associations between fetal growth retardation and adult hypertension and cardiovascular disease.	GOOD HOPE HOSP NHS TRUST, DEPT OBSTET & GYNAECOL, SUTTON COLDFIELD, W MIDLANDS, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT PRIMARY CARE & POPULAT SCI, LONDON, ENGLAND; CITY HOSP, DEPT MED, BIRMINGHAM, W MIDLANDS, ENGLAND	Heart of England NHS Foundation Trust; Good Hope Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Birmingham				Perry, Ivan/0000-0002-4965-9792				Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1992, FETAL INFANT ORIGINS; BARTLEY M, 1994, BMJ-BRIT MED J, V309, P1475, DOI 10.1136/bmj.309.6967.1475; Churchill D, 1996, OBSTET GYNECOL, V88, P455, DOI 10.1016/0029-7844(96)00192-5; COLLEY NV, 1991, BRIT J OBSTET GYNAEC, V98, P524, DOI 10.1111/j.1471-0528.1991.tb10363.x; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; DAVIES AM, 1983, OBSTETRICAL EPIDEMIO, P167; FERRY IJ, 1994, BRIT MED BULL, V50, P246, DOI 10.1093/oxfordjournals.bmb.a072890; FISHER KA, 1981, MEDICINE, V60, P267, DOI 10.1097/00005792-198107000-00002; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; MACGILLIVRAY I, 1969, CLIN SCI, V37, P395; Misra DP, 1996, PAEDIATR PERINAT EP, V10, P244, DOI 10.1111/j.1365-3016.1996.tb00048.x; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PERRY IJ, 1991, BRIT J OBSTET GYNAEC, V98, P241, DOI 10.1111/j.1471-0528.1991.tb13386.x; PERRY IJ, 1995, BMJ-BRIT MED J, V310, P436, DOI 10.1136/bmj.310.6977.436; Shennan A, 1996, LANCET, V347, P139, DOI 10.1016/S0140-6736(96)90338-4; SHENNAN AH, 1993, BRIT J OBSTET GYNAEC, V100, P904, DOI 10.1111/j.1471-0528.1993.tb15104.x; WARD R, 1990, HYPERTENSION PATHOPH, P81; ZINNER SH, 1985, HYPERTENSION, V7, P411, DOI 10.1161/01.HYP.7.3_Pt_1.411	21	108	110	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 4	1997	349	9044					7	10		10.1016/S0140-6736(96)06297-6	http://dx.doi.org/10.1016/S0140-6736(96)06297-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988114				2022-12-01	WOS:A1997WA72500008
J	Hancock, BW; Aitken, M; Radstone, C; Hudson, GV				Hancock, BW; Aitken, M; Radstone, C; Hudson, GV			Why don't cancer patients get entered into clinical trials? Experience of the Sheffield Lymphoma Group's collaboration in British National Lymphoma Investigation studies	BRITISH MEDICAL JOURNAL			English	Article									MIDDLESEX HOSP,BRITISH NATL LYMPHOMA INVEST,LONDON W1N BAA,ENGLAND	University of London; University College London	Hancock, BW (corresponding author), WESTON PK HOSP,DEPT CLIN ONCOL,YORKSHIRE CANC RES CAMPAIGN,SHEFFIELD S10 2SJ,S YORKSHIRE,ENGLAND.							SLEVIN M, 1995, BRIT J CANCER, V71, P1270, DOI 10.1038/bjc.1995.245; SMITH R, 1995, BRIT MED J, V310, P1277; SMYTH JF, 1994, BRIT MED J, V309, P457, DOI 10.1136/bmj.309.6952.457; STILLER CA, 1994, BRIT J CANCER, V70, P352, DOI 10.1038/bjc.1994.306; TANNOCK IF, 1995, BRIT J CANCER, V71, P1134, DOI 10.1038/bjc.1995.221	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					36	37		10.1136/bmj.314.7073.36	http://dx.doi.org/10.1136/bmj.314.7073.36			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB684	9001479	Green Published			2022-12-01	WOS:A1997WB68400024
J	Songyang, Z; Fanning, AS; Fu, C; Xu, J; Marfatia, SM; Chishti, AH; Crompton, A; Chan, AC; Anderson, JM; Cantley, LC				Songyang, Z; Fanning, AS; Fu, C; Xu, J; Marfatia, SM; Chishti, AH; Crompton, A; Chan, AC; Anderson, JM; Cantley, LC			Recognition of unique carboxyl-terminal motifs by distinct PDZ domains	SCIENCE			English	Article							TUMOR-SUPPRESSOR PROTEIN; SEPTATE JUNCTIONS; GENE; BINDING; CLONING; TIGHT; ZO-1; IDENTIFICATION; PEPTIDES; ENCODES	The oriented peptide library technique was used to investigate the peptide-binding specificities of nine PDZ domains. Each PDZ domain selected peptides with hydrophobic residues at the carboxyl terminus. Individual PDZ domains selected unique optimal motifs defined primarily by the carboxyl terminal three to seven residues of the peptides. One family of PDZ domains, including those of the Discs Large protein, selected peptides with the consensus motif Glu-(Ser/Thr)-Xxx-(Val/Ile) (where Xxx represents any ami no acid) at the carboxyl terminus. in contrast, another ami ly of PDZ domains, including those of LIN-2, p55, and Tiam-1, selected peptides with hydrophobic or aromatic side chains at the carboxyl terminal three residues. On the basis of crystal structures of the PSD-95-3 PDZ domain, the specificities observed with the peptide library can be rationalized.	BETH ISRAEL HOSP, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; YALE UNIV, SCH MED, DEPT INTERNAL MED, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA; WASHINGTON UNIV, SCH MED,DEPT PATHOL & MED,CTR IMMUNOL, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; TUFTS UNIV, ST ELIZABETHS MED CTR, DEPT BIOMED RES, TUMOR CELL BIOL LAB, BOSTON, MA 02135 USA; ONYX PHARMACEUT, RICHMOND, CA 94806 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Yale University; Yale University; Howard Hughes Medical Institute; Washington University (WUSTL); St. Elizabeth's Medical Center; Tufts University			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NCI NIH HHS [CA66263] Funding Source: Medline; NIDDK NIH HHS [DK34989] Funding Source: Medline; NIGMS NIH HHS [R01 GM056203] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRECHER A, UNPUB; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hata Y, 1996, J NEUROSCI, V16, P2488; Hoskins R, 1996, DEVELOPMENT, V122, P97; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; KIRN E, 1995, NATURE, V378, P85; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LIPINSKA B, 1990, J BACTERIOL, V172, P1791, DOI 10.1128/jb.172.4.1791-1797.1990; MARFATIA SM, IN PRESS J BIOL CHEM; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; PRASAD R, 1993, CANCER RES, V53, P5624; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SHESTAKOV SV, 1994, J BIOL CHEM, V269, P19354; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; SONGYANG Z, UNPUB; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	1182	1216	0	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 3	1997	275	5296					73	77		10.1126/science.275.5296.73	http://dx.doi.org/10.1126/science.275.5296.73			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974395				2022-12-01	WOS:A1997WA90300051
J	Austrup, F; Vestweber, D; Borges, E; Lohning, M; Brauer, R; Herz, U; Renz, H; Hallmann, R; Scheffold, A; Radbruch, A; Hamann, A				Austrup, F; Vestweber, D; Borges, E; Lohning, M; Brauer, R; Herz, U; Renz, H; Hallmann, R; Scheffold, A; Radbruch, A; Hamann, A			P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues	NATURE			English	Article							HOMING RECEPTOR; MYELOID CELLS; IN-VIVO; EXPRESSION; ANTIGEN; LYMPHOCYTES; TH1	WHEN activated, T helper cells differentiate into one of two subsets, Th1 and Th2, characterized by distinct profiles of cytokine production. Th1 cells activate pro-inflammatory effector mechanisms involved in protection and autoimmunity, whereas Th2 cells induce humoral and allergic responses and downregulate local inflammation(1,2). Apart from differences in the repertoire of cytokines, no phenotypic attributes are established that distinguish the two subsets. Here we show that Th1 cells, but not Th2 cells, are able to bind to P-selectin and E-selectin. Moreover, only Th1 cells can efficiently enter inflamed sites in Th1-dominated models, such as sensitized skin or arthritic joints, but not in a Th2-dominated allergic response, Immigration of Th1 cells into inflamed skin can be blocked by antibodies against P- and E-selectin, These results provide evidence for adhesion mechanisms to distinguish between the two T helper subsets and mediate their differential trafficking, They indicate that selective recruitment is an additional level of regulation for both effector function profile and character of a local immune response.	UNIV HAMBURG, KRANKENHAUS EPPENDORF, MED KLIN, IMMUNOL ABT, D-20246 HAMBURG, GERMANY; UNIV MUNSTER, INST ZELLBIOL, D-48149 MUNSTER, GERMANY; UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY; FRIEDRICH SCHILLER UNIV KLINIKUM, INST PATHOL, D-07740 JENA, GERMANY; HUMBOLDT UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, INST KLIN CHEM & BIOCHEM, D-13353 BERLIN, GERMANY; UNIV ERLANGEN NURNBERG, INST EXPT MED & BINDEGEWEBSFORSCH, D-91054 ERLANGEN, GERMANY	University of Hamburg; University of Munster; University of Cologne; Friedrich Schiller University of Jena; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Erlangen Nuremberg			Scheffold, Alexander/S-2090-2016; Löhning, Max/AAL-2967-2021	Scheffold, Alexander/0000-0002-0626-343X; Löhning, Max/0000-0001-6382-7281; Radbruch, Andreas/0000-0001-5753-0000; Vestweber, Dietmar/0000-0002-3517-732X				ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; Assenmacher M, 1996, EUR J IMMUNOL, V26, P263, DOI 10.1002/eji.1830260141; AUSTRUP F, 1995, EUR J IMMUNOL, V25, P1487, DOI 10.1002/eji.1830250602; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; BRAUER R, 1993, AGENTS ACTIONS, V38, pC95, DOI 10.1007/BF01991149; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; HALLMANN R, 1995, J RHEUAMTOL S101, V24, P107; HAMANN A, 1994, J IMMUNOL, V152, P3282; HAMANN A, 1993, ADHESION LEUCOCYTE H, P109; HAMANN A, 1996, IMMUNOLOGY METHODS M, P1333; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Smith M E, 1980, Monogr Allergy, V16, P203; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2	22	653	670	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 2	1997	385	6611					81	83		10.1038/385081a0	http://dx.doi.org/10.1038/385081a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985251				2022-12-01	WOS:A1997WA73100054
J	John, LCH				John, LCH			''Phlebomania Hancocksia'': Prevalence of a previously undescribed psychomotor disturbance	BRITISH MEDICAL JOURNAL			English	Article							INHIBITION; HEPARIN				John, LCH (corresponding author), ST BARTHOLOMEWS HOSP,DEPT CARDIOTHORAC SURG,LONDON EC1A 7BE,ENGLAND.							JOHN LCH, 1993, ANN THORAC SURG, V56, P899, DOI 10.1016/0003-4975(93)90352-I; JOHN LCH, 1993, J THORAC CARDIOV SUR, V105, P816; JOHN LCH, 1993, ANN THORAC SURG, V55, P1175, DOI 10.1016/0003-4975(93)90029-H	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1620	1620		10.1136/bmj.313.7072.1620	http://dx.doi.org/10.1136/bmj.313.7072.1620			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991011	Green Published			2022-12-01	WOS:A1996VZ81100043
J	Verhulst, J; Onghena, P				Verhulst, J; Onghena, P			Circaseptennial rhythm in ear growth	BRITISH MEDICAL JOURNAL			English	Article													Onghena, Patrick/M-6649-2017	Onghena, Patrick/0000-0002-3986-8312				FULLER WA, 1996, INTRO STATISTICAL TI; Heathcote JA, 1995, BRIT MED J, V311, P1668, DOI 10.1136/bmj.311.7021.1668; *SAS I, 1989, STAT AN SYST VERS 6; Verhulst J, 1996, PSYCHOL REP, V78, P19, DOI 10.2466/pr0.1996.78.1.19; VERHULST J, IN PRESS ANN HUM BIO	5	6	6	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1597	1598		10.1136/bmj.313.7072.1597	http://dx.doi.org/10.1136/bmj.313.7072.1597			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991002	Green Published			2022-12-01	WOS:A1996VZ81100025
J	Deng, GR; Lu, Y; Zlotnikov, G; Thor, AD; Smith, HS				Deng, GR; Lu, Y; Zlotnikov, G; Thor, AD; Smith, HS			Loss of heterozygosity in normal tissue adjacent to breast carcinomas	SCIENCE			English	Article							CHAIN-REACTION PCR; GENETIC ALTERATIONS; CANCER; POLYMORPHISM; CHROMOSOME-17; 17P	Loss of heterozygosity (LOH) was detected in morphologically normal lobules adjacent to breast cancers. The most frequent aberration was at chromosome 3p22-25; of ten cases with this LOH in the carcinoma, six displayed the same LOH in adjacent normal lobules. This suggests that in a subset of sporadic breast cancers, a tumor suppresser gene at 3p22-25 may be important in initiation or early progression of tumorigenesis. Among sixteen breast cancers with LOH at 17p13.1 and five breast cancers with LOH at 11p15.5, one case each displayed the same LOH in adjacent normal lobules. Thus the molecular heterogeneity that characterizes invasive breast cancers may occur at the earliest detectable stages of progression.	CALIF PACIFIC MED CTR,GERALDINE BRUSH CANC RES INST,SAN FRANCISCO,CA 94619; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; NORTHWESTERN UNIV,EVANSTON HOSP,SCH MED,DEPT PATHOL,EVANSTON,IL 60201	California Pacific Medical Center; University of California System; University of California San Francisco; NorthShore University Health System; Northwestern University					NCI NIH HHS [2P50CA58207] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P113, DOI 10.1002/gcc.2870040203; BLOUNT PL, 1994, CANCER RES, V54, P2292; Dairkee SH, 1996, J MAMMARY GLAND BIOL, V1, P139, DOI 10.1007/BF02013638; DENG G, 1994, CANCER RES, V54, P499; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3761, DOI 10.1093/nar/19.13.3761; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3760; GAZDAR AF, 1956, 86 ANN M AM ASS CANC; HARADA Y, 1994, CANCER, V74, P2281, DOI 10.1002/1097-0142(19941015)74:8<2281::AID-CNCR2820740812>3.0.CO;2-I; HILDRETH NG, 1989, NEW ENGL J MED, V321, P1281, DOI 10.1056/NEJM198911093211901; JENSEN RA, 1994, P NATL ACAD SCI USA, V91, P9257, DOI 10.1073/pnas.91.20.9257; LI H, 1992, HUM MOL GENET, V1, P425; MCDANIEL T, 1991, NUCLEIC ACIDS RES, V19, P6969; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; OCONNELL P, 1994, BREAST CANCER RES TR, V32, P5, DOI 10.1007/BF00666201; OLSCHWANG S, 1991, HUM GENET, V86, P369; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P3753, DOI 10.1093/nar/19.13.3753-a; RADFORD DM, 1993, CANCER RES, V53, P2947; SAITO H, 1991, CYTOGENET CELL GENET, V58, P1806; TAKITA K, 1992, CANCER RES, V52, P3914; TOKUNAGA M, 1984, BREAST CANC ATOMIC B, P45; Tsai YC, 1996, CANCER RES, V56, P402; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WELLINGS SR, 1980, PATHOL RES PRACT, V166, P515, DOI 10.1016/S0344-0338(80)80248-2; Zhuang ZP, 1996, CANCER RES, V56, P1961	26	466	489	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2057	2059		10.1126/science.274.5295.2057	http://dx.doi.org/10.1126/science.274.5295.2057			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953032				2022-12-01	WOS:A1996VY97400042
J	Morgentaler, A; Bruning, CO; DeWolf, WC				Morgentaler, A; Bruning, CO; DeWolf, WC			Occult prostate cancer in men with low serum testosterone levels	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIGITAL RECTAL EXAMINATION; SCREENING-TEST; ANTIGEN; ADENOCARCINOMA; ULTRASONOGRAPHY; DIAGNOSIS; CARCINOMA; DENSITY	Objective.-To determine the prevalence of occult prostate cancer in men with low serum total testosterone or free testosterone levels. Design.-Retrospective analysis of a consecutive series of men. Setting.-Academic teaching hospital. Patients.-Seventy-seven men with low total testosterone or free testosterone levels, with normal results of digital rectal examination and prostate-specific antigen (PSA) levels of 4.0 ng/mL or less. The mean age was 58 years. Interventions.-Sextant prostate needle biopsies with ultrasound guidance. Main Outcome Measures.-Results of prostate needle biopsies, transrectal ultrasound, prostate volume, PSA level, PSA density, total and free testosterone levels. Results.-Prostate cancer was identified in 14% (11/77) of the entire group and in 10 men (29%) aged 60 years or older. The median age for men with cancer was 64 years. Histologic examination showed Gleason scores of 6 or 7 for all cancers. No significant differences were noted between the cancer and benign groups with regard to PSA level, PSA density, prostate volume, total testosterone level, or free testosterone level. Conclusions.-A high prevalence of biopsy-detectable prostate cancer was identified in men with low total or free testosterone levels despite normal PSA levels and results of digital rectal examination. These data suggest that (1) digital rectal examination and PSA levels are insensitive indicators of prostate cancer in men with low total or free testosterone levels, and (2) PSA levels may be altered by naturally occurring reductions in serum androgen levels.			Morgentaler, A (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV UROL,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							BEHRE HM, 1994, CLIN ENDOCRINOL, V40, P341; BILLIS A, 1986, UROLOGY, V28, P324, DOI 10.1016/0090-4295(86)90019-1; BRAWER MK, 1995, PROSTATE, V27, P1, DOI 10.1002/pros.2990270102; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; ELLIS WJ, 1994, J UROLOGY, V152, P1520, DOI 10.1016/S0022-5347(17)32460-6; ENGLISH HF, 1986, CANCER RES, V46, P839; Gleason DF, 1977, UROLOGIC PATHOLOGY P; GUESS HA, 1993, UROL CLIN N AM, V20, P627; HAMMERER P, 1992, J UROLOGY, V147, P833, DOI 10.1016/S0022-5347(17)37399-8; JACKSON JA, 1989, ARCH INTERN MED, V149, P2365, DOI 10.1001/archinte.149.10.2365; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; MESHREF AW, 1995, UROLOGY, V45, P972, DOI 10.1016/S0090-4295(99)80117-4; MONATH JR, 1995, UROLOGY, V46, P58, DOI 10.1016/S0090-4295(99)80159-9; MONDA JM, 1995, UROLOGY, V46, P62, DOI 10.1016/S0090-4295(99)80160-5; RUDMAN D, 1994, J AM GERIATR SOC, V42, P522, DOI 10.1111/j.1532-5415.1994.tb04975.x; SEAMAN E, 1993, UROL CLIN N AM, V20, P653; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STAMEY TA, 1989, J UROLOGY, V141, P1088, DOI 10.1016/S0022-5347(17)41177-3; STONE NN, 1994, UROLOGY, V44, P18, DOI 10.1016/S0090-4295(94)80239-4; TENOVER JS, 1992, J CLIN ENDOCR METAB, V75, P1092, DOI 10.1210/jc.75.4.1092; TENOVER JS, 1994, ENDOCRIN METAB CLIN, V23, P877, DOI 10.1016/S0889-8529(18)30073-2; UZZO RG, 1995, UROLOGY, V46, P831, DOI 10.1016/S0090-4295(99)80353-7; VALLANCIEN G, 1991, J UROLOGY, V146, P1308, DOI 10.1016/S0022-5347(17)38076-X	24	195	201	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1996	276	23					1904	1906		10.1001/jama.276.23.1904	http://dx.doi.org/10.1001/jama.276.23.1904			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX522	8968017				2022-12-01	WOS:A1996VX52200039
J	DeRubertis, F; Kadosh, D; Henchoz, S; Pauli, D; Reuter, G; Struhl, K; Spierer, P				DeRubertis, F; Kadosh, D; Henchoz, S; Pauli, D; Reuter, G; Struhl, K; Spierer, P			The histone deacetylase RPD3 counteracts genomic silencing in Drosophila and yeast	NATURE			English	Article							POSITION-EFFECT VARIEGATION; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL STATES; X-CHROMOSOME; ACETYLATION; EXPRESSION; GENE; REPRESSION; TELOMERE; DOMAINS	BOTH position-effect variegation (PEV)(1,2) in Drosophila and telomeric position-effect in yeast (TPE)(3-5) result from the mosaic inactivation of genes relocated next to a block of centromeric heterochromatin or next to telomeres. In many aspects, these phenomena are analogous to other epigenetic silencing mechanisms, such as the control of homeotic gene clusters(6), X-chromosome inactivation(7) and imprinting in mammals(8), and mating-type control in yeast(5), Dominant mutations that suppress or enhance PEV are thought to encode either chromatin proteins or factors that directly affect chromatin structure(1), We have identified an insertional mutation in Drosophila that enhances PEV and reduces transcription of the gene in the eye-antenna imaginal disc, The gene corresponds to that encoding the transcriptional regulator RPD3 in yeast(9,10), and to a human histone deacetylase(11). In yeast, RRD3-deletion strains show enhanced TPE, suggesting a conserved role of the histone deacetylase RPD3 in counteracting genomic silencing, This function of RPD3, which is in contrast to the general correlation between histone acetylation and increased transcription, might be due to a specialized chromatin structure at silenced loci.	UNIV GENEVA,DEPT ZOOL & ANIM BIOL,CH-1211 GENEVA 4,SWITZERLAND; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115; UNIV HALLE WITTENBERG,INST GENET,D-06108 HALLE,GERMANY	University of Geneva; Harvard University; Harvard Medical School; Martin Luther University Halle Wittenberg								APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; Paro R, 1993, CURR OPIN CELL BIOL, V5, P999, DOI 10.1016/0955-0674(93)90084-4; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; RUNDLETT SE, 1996, P NATL ACAD SCI USA, V93, P13723; Seum C, 1996, DEVELOPMENT, V122, P1949; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SOLTER D, 1988, ANNU REV GENET, V22, P127; SUSSEL L, 1995, GENETICS, V141, P873; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1991, J CELL SCI, V99, P13; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4	26	191	194	1	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1996	384	6609					589	591						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955276				2022-12-01	WOS:A1996VX76900066
J	Lesch, KP; Bengel, D; Heils, A; Sabol, SZ; Greenberg, BD; Petri, S; Benjamin, J; Muller, CR; Hamer, DH; Murphy, DL				Lesch, KP; Bengel, D; Heils, A; Sabol, SZ; Greenberg, BD; Petri, S; Benjamin, J; Muller, CR; Hamer, DH; Murphy, DL			Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region	SCIENCE			English	Article							ANGIOTENSIN-CONVERTING ENZYME; UNIFIED BIOSOCIAL THEORY; H-3 PAROXETINE BINDING; MYOCARDIAL-INFARCTION; QUANTITATIVE TRAITS; PERSONALITY-DISORDERS; SEXUAL ORIENTATION; MAJOR DEPRESSION; MARKERS; LINKAGE	Transporter-facilitated uptake of serotonin (5-hydroxytryptamine or 5-HT) has been implicated in anxiety in humans and animal models and is the site of action of widely used uptake-inhibiting antidepressant and antianxiety drugs. Human 5-HT transporter (5-HTT) gene transcription is modulated by a common polymorphism in its upstream regulatory region. The short variant of the polymorphism reduces the transcriptional efficiency of the 5-HTT gene promoter, resulting in decreased 5-HTT expression and 5-HT uptake in lymphoblasts. Association studies in two independent samples totaling 505 individuals revealed that the 5-HTT polymorphism accounts for 3 to 4 percent of total variation and 7 to 9 percent of inherited variance in anxiety-related personality traits in individuals as well as sibships.	NIMH,CLIN SCI LAB,NIH,BETHESDA,MD 20892; NCI,BIOCHEM LAB,NIH,BETHESDA,MD 20892; UNIV WURZBURG,INST HUMAN GENET,D-97074 WURZBURG,GERMANY	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wurzburg	Lesch, KP (corresponding author), UNIV WURZBURG,DEPT PSYCHIAT,FUCHSLEINSTR 15,D-97080 WURZBURG,GERMANY.		Hamer, Dean H/L-1248-2015; Lesch, Klaus-Peter/J-4906-2013; Petri, Susanne/AID-7665-2022	Hamer, Dean H/0000-0002-6211-5781; Lesch, Klaus-Peter/0000-0001-8348-153X; Lagrange, hugues/0000-0002-2180-5284				Altemus M, 1996, AM J MED GENET, V67, P409, DOI 10.1002/(SICI)1096-8628(19960726)67:4<409::AID-AJMG16>3.0.CO;2-N; ANDREWS G, 1990, J AFFECT DISORDERS, V19, P23, DOI 10.1016/0165-0327(90)90005-S; [Anonymous], 1990, PERSONALITY ADULTHOO; ARBUSTINI E, 1995, BRIT HEART J, V74, P584; BEASLEY CM, 1992, PSYCHOPHARMACOLOGY, V107, P1, DOI 10.1007/BF02244958; Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; BENKERT O, 1993, INT CLIN PSYCHOPHARM, V8, P3, DOI 10.1097/00004850-199309001-00001; BERGEMAN CS, 1988, PSYCHOL AGING, V3, P399, DOI 10.1037/0882-7974.3.4.399; BLIER P, 1994, TRENDS PHARMACOL SCI, V15, P220, DOI 10.1016/0165-6147(94)90315-8; BOJA JW, 1994, DOPAMINE RECEPTORS T, P611; CAMBIEN F, 1994, CLIN GENET, V46, P94; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; Cattell R.B., 1946, DESCRIPTION MEASUREM; Cattell RB, 1943, J ABNORM SOC PSYCH, V38, P476, DOI 10.1037/h0054116; CHEEK J, IN PRESS; CHEN HT, 1992, J PHARMACOL TOXICOL, V27, P209, DOI 10.1016/1056-8719(92)90043-Z; Cloninger C.R., 1986, PSYCHIATRIC DEV, V3, P167; CLONINGER CR, 1987, ARCH GEN PSYCHIAT, V44, P573; CLONINGER CR, 1988, PSYCHIAT DEV, V6, P83; COLLIER D, IN PRESS MOL PSYCHIA; Collier DA, 1996, NEUROREPORT, V7, P1675, DOI 10.1097/00001756-199607080-00030; COOK EH, 1994, NEUROREPORT, V5, P1745, DOI 10.1097/00001756-199409080-00014; COSTA PTJ, HDB PERSONALITY INVE; DENBOER JA, 1995, INT CLIN PSYCHOPHARM, V9, P47, DOI 10.1097/00004850-199501004-00007; DIBELLA D, 1995, PSYCHIAT GENET, V5, pS100; Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78; ELSTON RC, 1994, SAGE USERS GUIDE REL; EYSENCK HJ, 1957, HDB ABNORMAL PSYCHOL, P131; FALUDI G, 1994, J PSYCHIATR NEUROSCI, V19, P109; FARAJ BA, 1994, INT J IMMUNOPHARMACO, V16, P561, DOI 10.1016/0192-0561(94)90107-4; FLINT J, 1995, SCIENCE, V269, P1432, DOI 10.1126/science.7660127; FUXE K, 1983, NEUROPHARMACOLOGY, V22, P389, DOI 10.1016/0028-3908(83)90188-0; GARDEMANN A, 1995, CIRCULATION, V92, P2796, DOI 10.1161/01.CIR.92.10.2796; GELERNTER J, 1995, HUM GENET, V95, P677; GEORGE VT, 1987, GENET EPIDEMIOL, V4, P193, DOI 10.1002/gepi.1370040304; Gray J., 1982, NEUROPSYCHOLOGY ANXI, DOI 10.1002/9780470720394.ch2; GRIEBEL G, 1995, PHARMACOL THERAPEUT, V65, P319, DOI 10.1016/0163-7258(95)98597-J; HAMER DH, 1993, SCIENCE, V261, P321, DOI 10.1126/science.8332896; HANDLEY SL, 1995, PHARMACOL THERAPEUT, V66, P103, DOI 10.1016/0163-7258(95)00004-Z; HEATH AC, 1994, J PERS SOC PSYCHOL, V66, P762, DOI 10.1037/0022-3514.66.4.762; Heils A, 1996, J NEUROCHEM, V66, P2621; Heils A, 1995, J NEURAL TRANSM-GEN, V102, P247, DOI 10.1007/BF01281159; Heninger George R., 1995, P471; HENSLER JG, 1994, SYNAPSE, V17, P1, DOI 10.1002/syn.890170102; HU S, 1995, NAT GENET, V11, P248, DOI 10.1038/ng1195-248; IKEN K, 1995, CELL IMMUNOL, V163, P1, DOI 10.1006/cimm.1995.1092; INY LJ, 1994, BIOL PSYCHIAT, V36, P281; KENDLER KS, 1987, ARCH GEN PSYCHIAT, V44, P451; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P863; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LESCH KP, 1994, J NEURAL TRANSM-GEN, V95, P157, DOI 10.1007/BF01276434; LESCH KP, 1995, BIOL PSYCHIAT, V37, P215, DOI 10.1016/0006-3223(94)00147-U; LESCH KP, 1993, J NEURAL TRANSM-GEN, V91, P67, DOI 10.1007/BF01244919; LOEHLIN JC, 1989, AM PSYCHOL, V44, P1285, DOI 10.1037/0003-066X.44.10.1285; MACKINNON A, 1994, HDB DEPRESSION ANXIE, P71; MAJ J, 1992, J NEURAL TRANSM-GEN, V88, P143, DOI 10.1007/BF01244819; MULDER RT, 1994, COMPR PSYCHIAT, V35, P225, DOI 10.1016/0010-440X(94)90195-3; MURPHY DL, 1993, SEROTONIN CELL BIOL, V2, P223; NICK TG, 1995, GENET EPIDEMIOL, V12, P145, DOI 10.1002/gepi.1370120204; Ogilvie AD, 1996, LANCET, V347, P731, DOI 10.1016/S0140-6736(96)90079-3; Ohno T, 1996, METABOLISM, V45, P218, DOI 10.1016/S0026-0495(96)90057-8; OWENS MJ, 1994, CLIN CHEM, V40, P288; PATERSON AH, 1991, GENETICS, V127, P181; PEDERSEN NL, 1988, J PERS SOC PSYCHOL, V55, P950, DOI 10.1037/0022-3514.55.6.950; PLOMIN R, 1994, SCIENCE, V264, P1733, DOI 10.1126/science.8209254; RAMAMOORTHY JD, 1995, J BIOL CHEM, V270, P17189, DOI 10.1074/jbc.270.29.17189; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; SHUEY DL, 1992, TERATOLOGY, V46, P367, DOI 10.1002/tera.1420460407; STUBER CW, 1992, GENETICS, V132, P823; SVRAKIC DM, 1993, ARCH GEN PSYCHIAT, V50, P991; WESTENBERG HG, 1996, ADV NEUROBIOLOGY ANX; WHITAKERAZMITIA P, 1990, ANN NY ACAD SCI, V600, P4; WIGGINS JS, 1992, ANNU REV PSYCHOL, V43, P473, DOI 10.1146/annurev.ps.43.020192.002353	73	3975	4120	7	433	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1527	1531		10.1126/science.274.5292.1527	http://dx.doi.org/10.1126/science.274.5292.1527			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VV775	8929413				2022-12-01	WOS:A1996VV77500048
J	Wang, Q; Stacy, T; Miller, JD; Lewis, AF; Gu, TL; Huang, XM; Bushweller, JH; Bories, JC; Alt, FW; Ryan, G; Liu, PP; WynshawBoris, A; Binder, M; MarinPadilla, M; Sharpe, AH; Speck, NA				Wang, Q; Stacy, T; Miller, JD; Lewis, AF; Gu, TL; Huang, XM; Bushweller, JH; Bories, JC; Alt, FW; Ryan, G; Liu, PP; WynshawBoris, A; Binder, M; MarinPadilla, M; Sharpe, AH; Speck, NA			The CBF beta subunit is essential for CBF alpha 2 (AML1) function in vivo	CELL			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; MOUSE EMBRYO; RUNT DOMAIN; TRANSCRIPTION FACTORS; TARGETED MUTATION; CEREBRAL-CORTEX; CHIMERIC MICE; PROTEIN RBTN2; YOLK-SAC	The CBF beta subunit is the non-DNA-binding subunit of the heterodimeric core-binding factor (CBF). CBF beta associates with DNA-binding CBF alpha subunits and increases their affinity for DNA. Genes encoding the CBF beta subunit (CBFB) and one of the CBF alpha subunits (CBFA2, otherwise known as AML1) are the most frequent targets of chromosomal translocations in acute leukemias in humans. We and others previously demonstrated that homozygous disruption of the mouse Cbfa2 (AML1) gene results in embryonic lethality at midgestation due to hemorrhaging in the central nervous system and blocks fetal liver hematopoiesis. Here we demonstrate that homozygous mutation of the Cbfb gene results in the same phenotype. Our results demonstrate that the CBF beta subunit is required for CBF alpha 2 function in vivo.	DARTMOUTH COLL,DEPT CHEM,HANOVER,NH 03755; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02215; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; DARTMOUTH COLL SCH MED,DEPT ANAT,HANOVER,NH 03755; DARTMOUTH COLL SCH MED,DEPT PATHOL,HANOVER,NH 03755; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Dartmouth College; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Dartmouth College; Dartmouth College; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Wang, Q (corresponding author), DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755, USA.		Bories, Jean-Christophe/L-6952-2017; Liu, Paul/A-7976-2012	Liu, Paul/0000-0002-6779-025X; Bushweller, John/0000-0002-5386-1758	NATIONAL CANCER INSTITUTE [R01CA058343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI039536, R01AI039536] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022897] Funding Source: NIH RePORTER; NCI NIH HHS [CA58343] Funding Source: Medline; NIAID NIH HHS [AI39536-01] Funding Source: Medline; NINDS NIH HHS [NS22897] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRES KH, 1967, Z ZELLFORSCH MIK ANA, V79, P272, DOI 10.1007/BF00369291; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BITTER MA, 1987, HUM PATHOL, V18, P211, DOI 10.1016/S0046-8177(87)80002-3; BOWIE JU, 1989, J BIOL CHEM, V264, P7596; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Golling G, 1996, MOL CELL BIOL, V16, P932; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KRISCH B, 1984, CELL TISSUE RES, V238, P459; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MARINPADILLA M, 1985, J COMP NEUROL, V241, P237, DOI 10.1002/cne.902410210; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; SOLFER SJ, 1994, AM J PATHOL, V144, P60; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; THORNELL A, 1991, J VIROL, V65, P42, DOI 10.1128/JVI.65.1.42-50.1991; TSAL JY, 1994, NATURE, V371, P221; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851	46	532	539	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					697	708		10.1016/S0092-8674(00)81389-6	http://dx.doi.org/10.1016/S0092-8674(00)81389-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929538	hybrid			2022-12-01	WOS:A1996VU03500012
J	Kessler, DA; Barnett, PS; Witt, A; Zeller, MR; Mande, JR; Schultz, WB				Kessler, DA; Barnett, PS; Witt, A; Zeller, MR; Mande, JR; Schultz, WB			The legal and scientific basis for FDA's assertion of jurisdiction over cigarettes and smokeless tobacco	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NICOTINE; SMOKING; DEPENDENCE	On August 28, 1996, the US Food and Drug Administration (FDA) asserted jurisdiction over cigarettes and smokeless tobacco under the Federal Food, Drug, and Cosmetic Act. Under this Act, a product is a ''drug'' or ''device'' subject to FDA jurisdiction if it is ''intended to affect the structure or any function of the body.'' The FDA determined that nicotine in cigarettes and smokeless tobacco does ''affect the structure or any function of the body'' because nicotine causes addiction and other pharmacological effects. The FDA then determined that these pharmacological effects are ''intended'' because (1) a scientific consensus has emerged that nicotine is addictive; (2) recent studies have shown that most consumers use cigarettes and smokeless tobacco for pharmacological purposes, including satisfying their addiction to nicotine; and (3) newly disclosed evidence from the tobacco manufacturers has revealed that the manufacturers know that nicotine causes pharmacological effects, including addiction, and design their products to provide pharmacologically active doses of nicotine. The FDA thus concluded that cigarettes and smokeless tobacco are subject to FDA jurisdiction because they contain a ''drug,'' nicotine, and a ''device'' for delivering this drug to the body.			Kessler, DA (corresponding author), US FDA,DEPT HLTH & HUMAN SERV,5600 FISHERS LN,14-71 PKLN,ROCKVILLE,MD 20857, USA.							*AM MED ASS, 1993, 1993 AMA POL COMP, P35; *AM PSYCH ASS, 1980, DIAGN STAT MAN MENT, P159; Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149; CORRIGALL WA, 1989, PSYCHOPHARMACOLOGY, V99, P473, DOI 10.1007/BF00589894; COTTLER LB, 1993, ADDICTION, V88, P689, DOI 10.1111/j.1360-0443.1993.tb02082.x; *CTR DIS CONTR, 1994, MMWR-MORBID MORTAL W, V43, P745; *CTR DIS CONTR PRE, 1993, MMWR MROB MORTAL WKL, V43, P925; ELLIS C, 1962, SMOKING HLTH POLICY; GOLDING J, 1982, PSYCHOPHYSIOLOGY, V19, P449, DOI 10.1111/j.1469-8986.1982.tb02504.x; HALE KL, 1993, NIDA RES MONOGRAPH, V182; HUGHES JR, 1987, AM J PSYCHIAT, V144, P205; KOZLOWSKI LT, 1989, JAMA-J AM MED ASSOC, V261, P898; MARKS MJ, 1983, J PHARMACOL EXP THER, V226, P817; *MED RES COUNC, 1994, MRC FIELD REV DRUG D, P11; MORRIS W, 1991, AM HERITAGE DICT ENG, P668; NORTON R, 1992, PSYCHOPHARMACOLOGY, V108, P473, DOI 10.1007/BF02247424; NOVOTNY TE, 1989, NATL CANCER I MONOGR, V8, P25; PRITCHARD WS, 1991, PSYCHOPHARMACOLOGY, V104, P485, DOI 10.1007/BF02245654; *ROY SOC CAN HLTH, 1989, COMM REP, pR5; SEVERSON HH, 1993, NIH MONOGRAPH, V2; SPEARS AW, 1981, RECENT ADV TOBACCO S, V7, P22; United States Department of Energy, 1992, SPIT TOB YOUTH, P8; *US DEP HHS OFF SM, 1988, HLTH CONS SMOK NIC A, P7; *US DEP HHS PHS, 1986, HLTH CONS US SMOK TO, P182; *US FDA, 1991, INT AGR CTR DRUG EV; *US FDA, 1996, FED REG         0828, V61; *WHO, 1992, ICD 10 CLASS MENT BE, P76; WOODY GE, 1993, ADDICTION, V88, P1573, DOI 10.1111/j.1360-0443.1993.tb03144.x; 1996, FED REG         0828, V61, P44396	31	28	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					405	409		10.1001/jama.277.5.405	http://dx.doi.org/10.1001/jama.277.5.405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WE771	9010173				2022-12-01	WOS:A1997WE77100031
J	Kawabe, T; Muslin, AJ; Korsmeyer, SJ				Kawabe, T; Muslin, AJ; Korsmeyer, SJ			HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint	NATURE			English	Article							OKADAIC ACID; HOMEOBOX GENE; KINASE; TRANSCRIPTION; MATURATION; REGULATOR; INHIBITOR; ONCOGENE; SYSTEM; TYPE-1	Hox11 is an orphan homeobox gene that controls the genesis of the spleen(1). HOX11 is also oncogenic, having been isolated from a chromosomal breakpoint in human T-cell leukaemia(2-4). Transgenic mice that redirected HOX11 to the thymus demonstrated cell-cycle aberration and progression to malignancy(5). We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells. Inhibition of PP2A can relate the cell cycle and control the activation of maturation-promoting factor in Xenopus oocytes(6). Microinjection of HOX11 into Xenopus oocytes arrested at the G2. phase of the cell cycle promoted progression to the M phase. G2 arrest can be induced by gamma-irradiation, but is eliminated bt expression oi HOX11 within a T-cell line. Thus HOX11 is a cellular oncogene that targets PP2A and PP1, both of which are targets for oncogenic viruses and chemical tumour promoters(7,8). This interaction suggests a mechanism by which a homeobox can alter the cell cycle.	ST LOUIS UNIV,SCH MED,JEWISH HOSP ST LOUIS,HOWARD HUGHES MED INST,DEPT MED & PATHOL,ST LOUIS,MO 63110; ST LOUIS UNIV,SCH MED,JEWISH HOSP ST LOUIS,DIV CARDIOL,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Howard Hughes Medical Institute; Saint Louis University; Barnes-Jewish Hospital; Saint Louis University								BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; CONDIE BG, 1994, NATURE, V370, P304, DOI 10.1038/370304a0; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DUBE ID, 1991, BLOOD, V78, P2996; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FAHRAEUS R, 1994, EMBO J, V13, P6041, DOI 10.1002/j.1460-2075.1994.tb06950.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HATANO M, 1992, CURR OPIN ONCOL S, V4, P24; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KINOSHITA N, 1993, GENE DEV, V7, P10759; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUMAGAI A, 1992, CELL, V70, P138; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; SHIOMI K, 1994, DEVELOPMENT, V120, P1591; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YANG SI, 1991, MOL CELL BIOL, V64, P1988	30	181	186	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1997	385	6615					454	458		10.1038/385454a0	http://dx.doi.org/10.1038/385454a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009195				2022-12-01	WOS:A1997WF00700057
J	Bernstein, BE; Michels, PAM; Hol, WGJ				Bernstein, BE; Michels, PAM; Hol, WGJ			Synergistic effects of substrate-induced conformational changes in phosphoglycerate kinase activation	NATURE			English	Article							SITE-DIRECTED MUTAGENESIS; 3-PHOSPHOGLYCERATE KINASE; MOLECULAR REPLACEMENT; CRYSTAL-STRUCTURE; PROTEIN MODELS; COMPLEX; ENZYME; EVOLUTION; SEQUENCE; BINDING	Phosphoglycerate kinase (PGK), a key enzyme in glycolysis, catalyses the transfer of a phosphoryl-group from 1,3-bis-phosphoglycerate to ADP to form 3-phosphoglycerate and ATP. Despite extensive kinetic and structural investigations over more than two decades, the conformation assumed by this enzyme during catalysis remained unknown. Here we present the 2.8 Angstrom crystal structure of a ternary complex of PGK from Trypanosoma brucei, the causative agent of sleeping sickness. This structure determination relied on a procedure in which fragments containing less than 10% of the scattering mass were successively positioned in the unit cell to obtain phases. The PGK ternary complex exhibits a dramatic dosing of the large cleft between the two domains seen in all previous studies(1-6), thereby bringing the two ligands, 3-phosphoglycerate and ADP into dose proximity. Our results demonstrate that PGK is a hinge-bending enzyme, reveal a novel mechanism in which substrate-induced effects combine synergistically to induce major conformational changes and, to our knowledge, afford the first observation of the PGK active site in a catalytic conformation.	UNIV WASHINGTON, DEPT BIOCHEM, BIOMOL STRUCT CTR, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOL STRUCT, BIOMOL STRUCT CTR, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV CATHOLIQUE LOUVAIN, INT INST CELLULAR & MOL PATHOL, TROP DIS RES UNIT, B-1200 BRUSSELS, BELGIUM; UNIV CATHOLIQUE LOUVAIN, BIOCHEM LAB, B-1200 BRUSSELS, BELGIUM	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Universite Catholique Louvain; Universite Catholique Louvain			Michels, Paul A/A-5637-2009	Michels, Paul A/0000-0003-3726-6104				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANKS RD, 1979, NATURE, V279, P773, DOI 10.1038/279773a0; BLAKE CCF, 1974, J MOL BIOL, V84, P585, DOI 10.1016/0022-2836(74)90118-1; BRUNGER AT, 1992, X PLOR VERSION 3 1; DAVIES GJ, 1994, ACTA CRYSTALLOGR D, V50, P202, DOI 10.1107/S0907444993011138; FOTHERGILLGILMORE LA, 1993, PROG BIOPHYS MOL BIO, V59, P105, DOI 10.1016/0079-6107(93)90001-Z; GRAHAM HC, 1991, EUR J BIOCHEM, V197, P81, DOI 10.1111/j.1432-1033.1991.tb15885.x; HARLOS K, 1992, PROTEINS, V12, P133, DOI 10.1002/prot.340120207; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; May A, 1996, PROTEINS, V24, P292; McPhillips TM, 1996, BIOCHEMISTRY-US, V35, P4118, DOI 10.1021/bi952500o; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILDVAN AS, 1981, PHILOS T ROY SOC B, V293, P65, DOI 10.1098/rstb.1981.0061; MISSET O, 1986, EUR J BIOCHEM, V157, P441, DOI 10.1111/j.1432-1033.1986.tb09687.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OH BH, 1995, ACTA CRYSTALLOGR D, V51, P140, DOI 10.1107/S0907444994010024; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAPPU KM, 1994, ARCH BIOCHEM BIOPHYS, V311, P503, DOI 10.1006/abbi.1994.1268; SCOPES RK, 1978, EUR J BIOCHEM, V85, P503, DOI 10.1111/j.1432-1033.1978.tb12266.x; SHERMAN MA, 1992, PROTEIN SCI, V1, P752, DOI 10.1002/pro.5560010607; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; TOMPA P, 1986, EUR J BIOCHEM, V154, P643, DOI 10.1111/j.1432-1033.1986.tb09446.x; WALKER PA, 1989, EUR J BIOCHEM, V183, P49, DOI 10.1111/j.1432-1033.1989.tb14895.x; WATSON HC, 1982, EMBO J, V1, P1635, DOI 10.1002/j.1460-2075.1982.tb01366.x	29	178	181	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 16	1997	385	6613					275	278		10.1038/385275a0	http://dx.doi.org/10.1038/385275a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000079				2022-12-01	WOS:A1997WC71100054
J	Jang, MS; Cai, EN; Udeani, GO; Slowing, KV; Thomas, CF; Beecher, CWW; Fong, HHS; Farnsworth, NR; Kinghorn, AD; Mehta, RG; Moon, RC; Pezzuto, JM				Jang, MS; Cai, EN; Udeani, GO; Slowing, KV; Thomas, CF; Beecher, CWW; Fong, HHS; Farnsworth, NR; Kinghorn, AD; Mehta, RG; Moon, RC; Pezzuto, JM			Cancer chemopreventive activity of resveratrol, a natural product derived from grapes	SCIENCE			English	Article							CORONARY HEART-DISEASE; TRANS-RESVERATROL; ALCOHOL; WINE; CARCINOGENESIS; CONSUMPTION; PREVENTION; ACTIVATION; STILBENES; MORTALITY	Resveratrol, a phytoalexin found in grapes and other food products, was purified and shown to have cancer chemopreventive activity in assays representing three major stages of carcinogenesis. Resveratrol was found to act as an antioxidant and antimutagen and to induce phase II drug-metabolizing enzymes (anti-initiation activity); it mediated anti-inflammatory effects and inhibited cyclooxygenase and hydroperoxidase functions (antipromotion activity); and it induced human promyelocytic leukemia cell differentiation (antiprogression activity). In addition, it inhibited the development of preneoplastic lesions in carcinogen-treated mouse mammary glands in culture and inhibited tumorigenesis in a mouse skin cancer model. These data suggest that resveratrol, a common constituent of the human diet, merits investigation as a potential cancer chemopreventive agent in humans.	UNIV ILLINOIS,COLL PHARM,DEPT MED CHEM & PHARMACOGNOSY,CHICAGO,IL 60612; UNIV ILLINOIS,DEPT PHARM,CHICAGO,IL 60612; UNIV COMPLUTENSE MADRID,DEPT FARMACOL,E-28040 MADRID,SPAIN; UNIV ILLINOIS,COLL MED,DEPT SURG ONCOL,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Complutense University of Madrid; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Slowing, Karla V/I-1135-2015	Slowing, Karla V/0000-0002-8106-2240; Udeani, George/0000-0001-5797-7849; Kinghorn, A. Douglas/0000-0002-6647-8707	NATIONAL CANCER INSTITUTE [P01CA048112] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA48112] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARICHI H, 1982, CHEM PHARM BULL, V30, P1766; DERCKS W, 1989, PHYSIOL MOL PLANT P, V34, P289; Ector BJ, 1996, AM J ENOL VITICULT, V47, P57; GERHAUSER C, 1995, NAT MED, V1, P260, DOI 10.1038/nm0395-260; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; GOLDBERG DM, 1995, AM J ENOL VITICULT, V46, P159; GOLDBERG DM, 1995, CLIN CHEM, V41, P14; GOLDBERG DM, 1995, CLIN CHIM ACTA, V237, P155, DOI 10.1016/0009-8981(95)06069-P; GOODWIN JS, 1984, AM J MED, V77, P7, DOI 10.1016/S0002-9343(84)80086-8; JAYATILAKE GS, 1993, J NAT PROD, V56, P1805, DOI 10.1021/np50100a021; JEANDET P, 1991, AM J ENOL VITICULT, V42, P41; KIMURA Y, 1985, BIOCHIM BIOPHYS ACTA, V834, P275; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KLATSKY AL, 1994, ALCOHOL CLIN EXP RES, V18, P88, DOI 10.1111/j.1530-0277.1994.tb00886.x; KUDO T, 1980, GANN, V71, P260; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; MANNILA E, 1993, PHYTOCHEMISTRY, V33, P813, DOI 10.1016/0031-9422(93)85280-5; MOON RC, 1990, CHEM BIOL SYNTHETIC, P501; PACEASCIAK CR, 1995, CLIN CHIM ACTA, V235, P207, DOI 10.1016/0009-8981(95)06045-1; PLESCIA OJ, 1975, P NATL ACAD SCI USA, V72, P1848, DOI 10.1073/pnas.72.5.1848; POLLARD M, 1983, CANCER LETT, V21, P57, DOI 10.1016/0304-3835(83)90082-4; PROCHASKA HJ, 1988, ANAL BIOCHEM, V169, P328, DOI 10.1016/0003-2697(88)90292-8; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RomeroPerez AI, 1996, J AGR FOOD CHEM, V44, P2124, DOI 10.1021/jf9507654; SHAMON LA, 1995, ANTICANCER RES, V14, P1775; SHARMA S, 1994, CANCER RES, V54, P5848; SIEMANN EH, 1992, AM J ENOL VITICULT, V43, P49; SLOWING K, 1994, J ETHNOPHARMACOL, V43, P9, DOI 10.1016/0378-8741(94)90110-4; SPORN MB, 1979, FED PROC, V38, P2528; SUH N, 1995, ANTICANCER RES, V15, P233; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; VANDEROUDERAA FJG, 1982, METHOD ENZYMOL, V86, P60; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WATTENBERG LW, 1993, CANCER RES, V53, P5890; WILD D, 1987, CARCINOGENESIS, V8, P541, DOI 10.1093/carcin/8.4.541; ZENSER TV, 1983, J PHARMACOL EXP THER, V227, P545; ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147	37	4066	4436	21	933	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					218	220		10.1126/science.275.5297.218	http://dx.doi.org/10.1126/science.275.5297.218			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985016				2022-12-01	WOS:A1997WC02200040
J	Krude, T; Jackman, M; Pines, J; Laskey, RA				Krude, T; Jackman, M; Pines, J; Laskey, RA			Cyclin/Cdk-dependent initiation of DNA replication in a human cell-free system	CELL			English	Article							PROTEIN-KINASE; S-PHASE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN FIBROBLASTS; CYCLE CONTROL; G(1); TRANSITION; EXPRESSION; INVITRO; NUCLEI	We describe a cell-free system from HeLa cells that initiates DNA replication under cell cycle control. G1 but not G2 phase nuclei initiate replication when coincubated with S phase nuclei in cytosolic extracts from S phase but not from G1 or G2 phase HeLa cells. S phase nuclei or an S phase nuclear extract are required for the initiation of semiconservative DNA replication in G1 nuclei but not for elongation in S phase nuclei. S phase nuclear extract could be replaced by recombinant human cyclins A and E complexed to Cdk2 but not by Cdk2 alone or by human cyclin B1 complexed to CdcP. In S phase cytosol, cyclins A/Cdk2 and E/Cdk2 triggered initiation synergistically.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	University of Cambridge	Krude, T (corresponding author), WELLCOME TRUST CANC RES CAMPAIGN INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.			Krude, Torsten/0000-0002-1842-1933	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELYAEV AS, 1993, NUCLEIC ACIDS RES, V21, P1219, DOI 10.1093/nar/21.5.1219; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HARRIS H, 1966, J CELL SCI, V1, P1; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HEICHMAN KA, 1994, CELL, V79, P577; HEINTZ NH, 1988, MOL CELL BIOL, V8, P1923, DOI 10.1128/MCB.8.5.1923; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; Johnson R. T., 1993, CELL CYCLE PRACTICAL, P1; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Krude T, 1996, J CELL SCI, V109, P309; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; LOHKA MJ, 1983, SCIENCE, V220, P79; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Romanowski P, 1996, TRENDS CELL BIOL, V6, P184, DOI 10.1016/0962-8924(96)10015-5; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WIMMEL A, 1994, ONCOGENE, V9, P995; Wu JR, 1996, SCIENCE, V271, P1270, DOI 10.1126/science.271.5253.1270; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	47	265	271	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					109	119		10.1016/S0092-8674(00)81863-2	http://dx.doi.org/10.1016/S0092-8674(00)81863-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019396	Bronze			2022-12-01	WOS:A1997WC56900014
J	Gostin, LO; Lazzarini, Z; Jones, S; Flaherty, K				Gostin, LO; Lazzarini, Z; Jones, S; Flaherty, K			Prevention of HIV/AIDS and other blood-borne diseases among injection drug users - A national survey on the regulation of syringes and needles	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; COMMUNITY PHARMACIES; EXCHANGE PROGRAM; HIV-INFECTION; UNITED-STATES; SAN-FRANCISCO; RISK BEHAVIOR; AIDS; CONNECTICUT	We report the results of a survey of laws and regulations governing the sale and possession of needles and syringes in the United States and its territories and discuss legal and public health proposals to increase the availability of sterile syringes, as a human immunodeficiency virus (HIV) transmission prevention measure, for persons who continue to inject drugs. Every state, the District of Columbia (DC), and the Virgin islands (VI) have enacted state or local laws or regulations that restrict the sale, distribution, or possession of syringes, Drug paraphernalia laws prohibiting the sale, distribution, and/or possession of syringes known to be used to introduce illicit drugs into the body exist in 47 states, DC, and VI. Syringe prescription laws prohibiting the sale, distribution, and possession of syringes without a valid medical prescription exist in 8 states and VI. Pharmacy regulations or practice guidelines restrict access to syringes in 23 states. We discuss the following legal and public health approaches to improve the availability of sterile syringes to prevent blood-borne disease among injection drug users: (1) clarify the legitimate medical purpose of sterile syringes for the prevention of HIV and other blood-borne infections; (2) modify drug paraphernalia laws to exclude syringes; (3) repeal syringe prescription laws; (4) repeal pharmacy regulations and practice guidelines restricting the sale of sterile syringes; (5) promote professional training of pharmacists, other health professionals, and law enforcement officers about the prevention of blood-borne infections; (6) permit local discretion in establishing syringe exchange programs; and (7) design community programs for safe syringe disposal.	GEORGETOWN JOHNS HOPKINS PROGRAM LAW & PUBL HLTH, WASHINGTON, DC USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA	Johns Hopkins University; Harvard University; Harvard T.H. Chan School of Public Health; Centers for Disease Control & Prevention - USA								*ABA AIDS COORD CO, 1988, AIDS LEG ISS; ALLEN DM, 1992, AM J PUBLIC HEALTH, V82, P541, DOI 10.2105/AJPH.82.4.541; ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259; *AM MED ASS, 1996, PHYS GUID HIV PREV; *AM MED ASS, 1996, INTR DRUG US SYR SUB; BLACK JL, 1986, NEW ENGL J MED, V314, P446; BRUNEAU J, 1996, P 11 INT C AIDS JUL; Burris S, 1996, AM J PUBLIC HEALTH, V86, P1161, DOI 10.2105/AJPH.86.8_Pt_1.1161; *CDCP, 1996, HIV AIDS SURV 1995; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P969; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P849; CELENTANO DD, 1991, AM J PUBLIC HEALTH, V81, P1291, DOI 10.2105/AJPH.81.10.1291; Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P392; CHAISSON RE, 1987, AM J PUBLIC HEALTH, V77, P169, DOI 10.2105/AJPH.77.2.169; CHEEVERS J, 1995, LOS ANGELES TIM 0109, pA1; CHERUBIN CE, 1993, ANN INTERN MED, V119, P1017, DOI 10.7326/0003-4819-119-10-199311150-00009; CLARK C, 1994, SAN DIEGO UNION 0629, pB1; *COMM MED LAW, 1986, LEG NONPR SAL HYP NE; COMPTON WM, 1992, AM J PUBLIC HEALTH, V82, P595, DOI 10.2105/AJPH.82.4.595; CROATTO JP, 1987, AUST J PHARM, V68, P602; DESJARLAIS DC, 1985, NEW ENGL J MED, V313, P1476; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DONOGHOE MC, 1989, AIDS, V3, P267, DOI 10.1097/00002030-198905000-00003; ETTELSON R, 1991, PHARM TIMES, V57, P107; FELDMAN HIV, 1988, NIDA MONOGRAPH, V80; FERNANDEZ MA, 1993, ALEPH, VOL 8, PT 2, P44; FRIEDLAND GH, 1987, NEW ENGL J MED, V317, P1125, DOI 10.1056/NEJM198710293171806; Garfein RS, 1996, AM J PUBLIC HEALTH, V86, P655, DOI 10.2105/AJPH.86.5.655; GLANZ A, 1989, BRIT MED J, V299, P1076, DOI 10.1136/bmj.299.6707.1076; GLEGHORN AA, 1995, J ACQ IMMUN DEF SYND, V10, P97; GOSTIN L, 1991, HARVARD CIVIL RIGHTS, V26, P113; GOSTIN LO, 1993, DIMENSIONS HIV PREVE; GROSECLOSE SL, 1995, J ACQ IMMUN DEF SYND, V10, P82; GRUND JPC, 1995, J ACQ IMMUN DEF SYND, V10, P104, DOI 10.1097/00042560-199509000-00016; HAGAN H, 1991, JAMA-J AM MED ASSOC, V266, P1646, DOI 10.1001/jama.1991.03470120048019; HAHN RA, 1989, JAMA-J AM MED ASSOC, V261, P2677, DOI 10.1001/jama.261.18.2677; HARTGERS C, 1989, AIDS, V3, P571, DOI 10.1097/00002030-198909000-00003; HAVERKOS HW, 1994, J ACQ IMMUN DEF SYND, V7, P741; Heimer R., 1994, AIDS and Public Policy Journal, V9, P59; HOGE P, 1994, SACRAMENTO BEE  1205, pA1; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; JARLAIS DCD, 1988, AM PSYCHOL, V43, P865, DOI 10.1037/0003-066X.43.11.865; JARLAIS DCD, 1994, JAMA-J AM MED ASSOC, V271, P121, DOI 10.1001/jama.271.2.121; KAPLAN EH, 1992, J ACQ IMMUN DEF SYND, V5, P163; Koester S., 1990, International Journal on Drug Policy, V1, P28; KOESTER SK, 1994, HUM ORGAN, V53, P286; LJUNGBERG B, 1991, J ACQ IMMUN DEF SYND, V4, P890; LURIE P, 1993, PUBLIC HLTH IMPACT N, V1; MAGURA S, 1989, AM J PUBLIC HEALTH, V79, P459, DOI 10.2105/AJPH.79.4.459; MUSTO DF, 1987, AM DISEASE ORIGINS N; *NAT COMM AIDS, 1991, TWIN EP SUBST US HIV; NELSON KE, 1991, JAMA-J AM MED ASSOC, V266, P2259, DOI 10.1001/jama.266.16.2259; NEWMEYER JA, 1988, J PSYCHOACTIVE DRUGS, V20, P185, DOI 10.1080/02791072.1988.10524493; NORMAND J, 1995, PREVENTING HIV TRANS; Paone D, 1995, J Am Med Womens Assoc (1972), V50, P109; PASCAL C, 1988, NIDA MONOGRAPH, V80; Prevots DR, 1996, AM J EPIDEMIOL, V143, P733, DOI 10.1093/oxfordjournals.aje.a008807; RICE DP, 1991, PUBLIC HEALTH REP, V106, P280; SINGER M, 1995, J ACQ IMMUN DEF SYND, V10, P104, DOI 10.1097/00042560-199509000-00015; STRYKER J, 1989, J HEALTH POLIT POLIC, V14, P719, DOI 10.1215/03616878-14-4-719; TURNER CF, 1989, AIDS SEXUAL BEHAV IN; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, V2nd; USA Council of State and Territorial Epidemiologists, 1987, Morbidity and Mortality Weekly Report, V36, P1; VALLEROY LA, 1995, J ACQ IMMUN DEF SYND, V10, P73; VEAL GR, 1981, GEORGIA LAW REV, V16, P137; WATTERS JK, 1994, JAMA-J AM MED ASSOC, V271, P115, DOI 10.1001/jama.271.2.115; Zellmer W A, 1994, Am Pharm, VNS34, P48	67	102	102	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1997	277	1					53	62		10.1001/jama.277.1.53	http://dx.doi.org/10.1001/jama.277.1.53			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VZ767	8980211				2022-12-01	WOS:A1997VZ76700030
J	Saah, AJ; Hoover, DR				Saah, AJ; Hoover, DR			''Sensitivity'' and ''specificity'' reconsidered: The meaning of these terms in analytical and diagnostic settings	ANNALS OF INTERNAL MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; IMMUNODEFICIENCY-VIRUS INFECTION; BLOOD MONONUCLEAR-CELLS; TREPONEMA-PALLIDUM; HIV-1 INFECTION; PROVIRAL DNA; AMPLIFICATION; NEUROSYPHILIS; RELIABILITY; CULTURE	Imprecise usage of the terms ''sensitivity'' and ''specificity'' produces confusion in the diagnostic use of sophisticated laboratory test results. ''Analytical sensitivity'' represents the smallest amount of substance in a sample that can accurately be measured by an assay. ''Analytical specificity'' refers to the ability of an assay to measure one particular organism or substance, rather than others, in a sample. An assay's analytical sensitivity and analytical specificity are distinct from that assay's clinical diagnostic sensitivity and diagnostic specificity. ''Diagnostic sensitivity'' is the percentage of persons who have a given disorder who are identified by the assay as positive for the disorder. High analytical sensitivity does not guarantee acceptable diagnostic sensitivity. ''Diagnostic specificity'' is the percentage of persons who do not have a given condition who are identified by the assay as negative for the condition. False-positive reactions occur because of sample contamination and diminish the diagnostic specificity of the assay. The terms ''sensitivity'' and ''specificity'' should be used with the requisite adjectives because the ''diagnostic'' and the ''analytical'' meanings of these terms are very different.			Saah, AJ (corresponding author), JOHNS HOPKINS UNIV, SCH PUBL HLTH, 615 N WOLFE ST, ROOM E6006, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035042] Funding Source: NIH RePORTER; NIAID NIH HHS [U01-AI-35042] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMBRUSTER DA, 1994, CLIN CHEM, V40, P1233; BABU PG, 1993, PCR METH APPL, V3, P63; BOURNIQUE B, 1992, MOL CELL PROBE, V6, P443, DOI 10.1016/0890-8508(92)90040-5; CANDOTTI D, 1991, AIDS, V5, P1003, DOI 10.1097/00002030-199108000-00012; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CLEWLEY JP, 1989, J VIROL METHODS, V25, P179, DOI 10.1016/0166-0934(89)90031-1; COUTLEE F, 1991, MOL CELL PROBE, V5, P241, DOI 10.1016/0890-8508(91)90046-M; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; GARCIAFERRER FJ, 1995, AM J OPHTHALMOL, V119, P7, DOI 10.1016/S0002-9394(14)73807-3; GORDON SM, 1994, NEW ENGL J MED, V331, P1469, DOI 10.1056/NEJM199412013312201; HOROWITZ HW, 1994, NEW ENGL J MED, V331, P1488, DOI 10.1056/NEJM199412013312204; MACGREGOR RR, 1995, CLIN INFECT DIS, V21, P122, DOI 10.1093/clinids/21.1.122; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; NOORDHOEK GT, 1991, J CLIN MICROBIOL, V29, P1976, DOI 10.1128/JCM.29.9.1976-1984.1991; NOORDHOEK GT, 1993, NEW ENGL J MED, V329, P2036, DOI 10.1056/NEJM199312303292713; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; Owens DK, 1996, ANN INTERN MED, V124, P803, DOI 10.7326/0003-4819-124-9-199605010-00004; ROSENTHAL N, 1994, NEW ENGL J MED, V331, P315, DOI 10.1056/NEJM199408043310508; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANCHEZ PJ, 1993, J INFECT DIS, V167, P148, DOI 10.1093/infdis/167.1.148; Tietz N.W., 1985, TXB CLIN CHEM, V1st ed.; TOSSWILL JHC, 1994, LANCET, V343, P1431, DOI 10.1016/S0140-6736(94)92554-2; Vandamme A M, 1994, Verh K Acad Geneeskd Belg, V56, P231; YENI P, 1996, STATUS TRENDS GLOBAL; ZAAIJER HL, 1993, LANCET, V341, P722, DOI 10.1016/0140-6736(93)90488-3	26	153	163	3	43	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					91	94		10.7326/0003-4819-126-1-199701010-00026	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00026			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992938				2022-12-01	WOS:A1997WA16500026
J	VandenAckerveken, G; Marois, E; Bonas, U				VandenAckerveken, G; Marois, E; Bonas, U			Recognition of the bacterial avirulence protein AvrBs3 occurs inside the host plant cell	CELL			English	Article							CAMPESTRIS PV VESICATORIA; T-DNA TRANSFER; NUCLEAR-LOCALIZATION; HYPERSENSITIVE RESPONSE; DISEASE RESISTANCE; GENE AVRBS3; AGROBACTERIUM-TUMEFACIENS; HRP PATHWAY; PLASMID; ELICITOR	The molecular mechanism by which bacterial avirulence genes mediate recognition by resistant host plants has been enigmatic for more than a decade. In this paper we provide evidence that the Xanthomonas campestris pv. vesicatoria avirulence protein AvrBs3 is recognized inside the plant cell. Transient expression of avrBs3 in pepper leaves, using Agrobacterium tumefaciens for gene delivery, results in hypersensitive cell death, specifically on plants carrying the resistance gene Bs3. In addition, for its intracellular recognition, AvrBs3 requires nuclear localization signals that are present in the C-terminal region of the protein. We propose that AvrBs3 is translocated into plant cells via the Xanthomonas Hrp type III secretion system and that nuclear factors are involved in AvrBs3 perception.	CNRS, INST SCI VEGETALES, F-91198 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Van den Ackerveken, Guido/B-8568-2011; Marois, Eric/AAZ-5549-2021; Marois, Eric/H-9246-2016	Van den Ackerveken, Guido/0000-0002-0183-8978; Marois, Eric/0000-0003-4147-3747; Marois, Eric/0000-0003-4147-3747				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARLAT M, 1994, EMBO J, V13, P543, DOI 10.1002/j.1460-2075.1994.tb06292.x; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BONAS U, 1989, MOL GEN GENET, V218, P127, DOI 10.1007/BF00330575; BONAS U, 1993, MOL GEN GENET, V238, P261, DOI 10.1007/BF00279555; BONAS U, 1991, MOL PLANT MICROBE IN, V4, P81, DOI 10.1094/MPMI-4-081; BROWN I, 1993, MOL PLANT MICROBE IN, V6, P376, DOI 10.1094/MPMI-6-376; BUNDOCK P, 1995, EMBO J, V14, P3206, DOI 10.1002/j.1460-2075.1995.tb07323.x; CITOVSKY V, 1992, SCIENCE, V256, P1802, DOI 10.1126/science.1615325; Dangl J L, 1994, Curr Top Microbiol Immunol, V192, P99; DEBLAERE R, 1985, NUCLEIC ACIDS RES, V13, P4777, DOI 10.1093/nar/13.13.4777; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FENSELAU S, 1992, MOL PLANT MICROBE IN, V5, P390, DOI 10.1094/MPMI-5-390; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; Fullner KJ, 1996, J BACTERIOL, V178, P1498, DOI 10.1128/jb.178.6.1498-1504.1996; Fullner KJ, 1996, SCIENCE, V273, P1107, DOI 10.1126/science.273.5278.1107; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Gopalan S, 1996, PLANT CELL, V8, P1095, DOI 10.1105/tpc.8.7.1095; Hakansson S, 1996, MOL MICROBIOL, V20, P593, DOI 10.1046/j.1365-2958.1996.5251051.x; HE SY, 1993, CELL, V73, P1255, DOI 10.1016/0092-8674(93)90354-S; HERBERS K, 1992, NATURE, V356, P172, DOI 10.1038/356172a0; HOWARD EA, 1992, CELL, V68, P109, DOI 10.1016/0092-8674(92)90210-4; ISHII N, 1994, J VIROL, V68, P8209, DOI 10.1128/JVI.68.12.8209-8216.1994; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KANG KI, 1994, P NATL ACAD SCI USA, V91, P340, DOI 10.1073/pnas.91.1.340; KEEN NT, 1991, THEOR APPL GENET, V81, P133, DOI 10.1007/BF00226123; KEEN NT, 1990, MOL PLANT MICROBE IN, V3, P112, DOI 10.1094/MPMI-3-112; KNOOP V, 1991, J BACTERIOL, V173, P7142, DOI 10.1128/jb.173.22.7142-7150.1991; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lacy G. H., 1982, PHYTOPATHOGENIC PROK, V2, P149; LESSL M, 1994, CELL, V77, P321, DOI 10.1016/0092-8674(94)90146-5; Lindsay W P, 1993, Trends Microbiol, V1, P181, DOI 10.1016/0966-842X(93)90088-9; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; Mittler R, 1996, TRENDS MICROBIOL, V4, P10, DOI 10.1016/0966-842X(96)81499-5; MURILLO J, 1994, PLASMID, V31, P275, DOI 10.1006/plas.1994.1029; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; POHLNER J, 1995, MOL MICROBIOL, V17, P1073, DOI 10.1111/j.1365-2958.1995.mmi_17061073.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; Rossi L., 1993, Plant Molecular Biology Reporter, V11, P220, DOI 10.1007/BF02669849; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SORY MP, 1994, MOL MICROBIOL, V14, P583, DOI 10.1111/j.1365-2958.1994.tb02191.x; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; VANCANNEYT G, 1990, MOL GEN GENET, V220, P245, DOI 10.1007/BF00260489; VANDERKROL AR, 1991, PLANT CELL, V3, P667, DOI 10.1105/tpc.3.7.667; VANLAREBEKE G, 1974, NATURE, V252, P169; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; Wengelnik K, 1996, J BACTERIOL, V178, P1061, DOI 10.1128/jb.178.4.1061-1069.1996; YANG YN, 1995, MOL PLANT MICROBE IN, V8, P627, DOI 10.1094/MPMI-8-0627; ZUPAN JR, 1995, PLANT PHYSIOL, V107, P1041, DOI 10.1104/pp.107.4.1041	54	278	310	0	31	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 27	1996	87	7					1307	1316		10.1016/S0092-8674(00)81825-5	http://dx.doi.org/10.1016/S0092-8674(00)81825-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980236	Bronze			2022-12-01	WOS:A1996WA54100018
J	Barthold, SW				Barthold, SW			Globalisation of lyme borreliosis	LANCET			English	Article							BURGDORFERI; CALIFORNIA; DISEASE; TICKS				Barthold, SW (corresponding author), YALE UNIV,SCH MED,COMPARAT MED SECT,NEW HAVEN,CT 06520, USA.							ANDERSON JF, 1990, J WILDLIFE DIS, V26, P1, DOI 10.7589/0090-3558-26.1.1; ANDERSON JF, 1989, J CLIN MICROBIOL, V27, P13, DOI 10.1128/JCM.27.1.13-20.1989; ASSOUS MV, 1994, FEMS MICROBIOL LETT, V121, P93, DOI 10.1111/j.1574-6968.1994.tb07081.x; BROWN RN, 1992, SCIENCE, V256, P1439, DOI 10.1126/science.1604318; Bunikis J, 1996, J CLIN MICROBIOL, V34, P364, DOI 10.1128/JCM.34.2.364-368.1996; DEMAERSCHALCK I, 1995, J CLIN MICROBIOL, V33, P602, DOI 10.1128/JCM.33.3.602-608.1995; DYKHUIZEN DE, 1993, P NATL ACAD SCI USA, V90, P10163, DOI 10.1073/pnas.90.21.10163; FILIPPOVA NA, 1991, MODERN ACAROLOGY, V1, P109; Guttman DS, 1996, J CLIN MICROBIOL, V34, P652, DOI 10.1128/JCM.34.3.652-656.1996; MAUPIN GO, 1994, J INFECT DIS, V170, P636, DOI 10.1093/infdis/170.3.636; NAKAO M, 1992, AM J TROP MED HYG, V47, P505, DOI 10.4269/ajtmh.1992.47.505; ZINGG BC, 1993, J CLIN MICROBIOL, V31, P3109, DOI 10.1128/JCM.31.12.3109-3114.1993	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1603	1604		10.1016/S0140-6736(05)65691-7	http://dx.doi.org/10.1016/S0140-6736(05)65691-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961987	hybrid			2022-12-01	WOS:A1996VX87600006
J	Arancio, O; Kiebler, M; Lee, CJ; LevRam, V; Tsien, RY; Kandel, ER; Hawkins, RD				Arancio, O; Kiebler, M; Lee, CJ; LevRam, V; Tsien, RY; Kandel, ER; Hawkins, RD			Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neurons	CELL			English	Article							CYCLIC-GMP FORMATION; TRANSMITTER RELEASE; SYNAPSES; ENHANCEMENT; DEPRESSION; MECHANISM; MESSENGER; PATHWAY	Nitric oxide (NO) has been proposed to act as a retrograde messenger during long-term potentiation (LTP) in the CA1 region of hippocampus, but the inaccessibility of the presynaptic terminal has prevented a definitive test of this hypothesis. Because both sides of the synapse are accessible in cultured hippocampal neurons, we have used this preparation to investigate the role of NO. We examined LTP following intra- or extracellular application of an NO scavanger, an inhibitor of NO synthase, and a membrane-impermeant NO donor that releases NO only upon photolysis with UV light. Our results indicate that NO is produced in the postsynaptic neuron, travels through the extracellular space, and acts directly in the presynaptic neuron to produce long-term potentiation, supporting the hypothesis that NO acts as a retrograde messenger during LTP.	NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY 10032; HOWARD HUGHES MED INST,NEW YORK,NY 10032; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST 0647,DEPT PHARMACOL,LA JOLLA,CA 92093	New York State Psychiatry Institute; Howard Hughes Medical Institute; University of California System; University of California San Diego	Arancio, O (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032, USA.		arancio, ottavio/AAB-7959-2019	Lee, C Justin/0000-0002-3555-0980; Kiebler, Michael/0000-0002-8850-6297; arancio, ottavio/0000-0001-6335-164X	NIMH NIH HHS [MH50733] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARANCIO O, 1995, NATURE, V376, P74, DOI 10.1038/376074a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BOULTON CL, 1994, EUR J NEUROSCI, V6, P1528, DOI 10.1111/j.1460-9568.1994.tb00543.x; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; EAST SJ, 1990, EUR J PHARMACOL, V184, P311, DOI 10.1016/0014-2999(90)90623-E; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; GORBUNOV NV, 1995, BIOCHEMISTRY-US, V34, P6689, DOI 10.1021/bi00020a014; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; Hawkins RD, 1996, NEURON, V16, P465, DOI 10.1016/S0896-6273(00)80064-1; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; LEVRAM V, 1995, NEURON, V15, P407, DOI 10.1016/0896-6273(95)90044-6; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MAKINGS LR, 1994, J BIOL CHEM, V269, P6282; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; MURPHEY RK, 1994, J NEUROBIOL, V25, P595, DOI 10.1002/neu.480250602; MURPHY KPSJ, 1994, NEUROPHARMACOLOGY, V33, P1375, DOI 10.1016/0028-3908(94)90039-6; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; POPOV S, 1992, J NEUROSCI, V12, P77; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; Vogel A.I., 1989, TXB QUANTITATIVE INO; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	29	304	313	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1025	1035		10.1016/S0092-8674(00)81797-3	http://dx.doi.org/10.1016/S0092-8674(00)81797-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978607	hybrid			2022-12-01	WOS:A1996VY44700008
J	Pasvol, G				Pasvol, G			Malaria and resistance genes - They work in wondrous ways	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM; ALPHA-THALASSEMIA; RED-CELLS; SUSCEPTIBILITY; ERYTHROCYTES				Pasvol, G (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,DEPT INFECT & TROP MED,HARROW HA1 3UJ,MIDDX,ENGLAND.							[Anonymous], 1995, EVOLUTION HEALING NE; CARLSON J, 1994, BLOOD, V84, P3909, DOI 10.1182/blood.V84.11.3909.bloodjournal84113909; FLINT J, 1986, NATURE, V321, P744, DOI 10.1038/321744a0; HALDANE JBS, 1949, 8TH P INT C GEN, P267; HILL AV, 1994, BIOCHEM SOC T, P282; LUZZI GA, 1990, BRIT J HAEMATOL, V74, P519, DOI 10.1111/j.1365-2141.1990.tb06344.x; LUZZI GA, 1991, J EXP MED, V173, P785, DOI 10.1084/jem.173.4.785; NAGEL RL, 1990, BLOOD CELLS, V16, P321; PASVOL G, 1977, NATURE, V270, P171, DOI 10.1038/270171a0; PASVOL G, 1978, NATURE, V274, P701, DOI 10.1038/274701a0; PASVOL G, 1980, BRIT J HAEMATOL, V45, P285, DOI 10.1111/j.1365-2141.1980.tb07148.x; Williams TN, 1996, NATURE, V383, P522, DOI 10.1038/383522a0	12	5	5	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1532	1534		10.1016/S0140-6736(05)66166-1	http://dx.doi.org/10.1016/S0140-6736(05)66166-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950877				2022-12-01	WOS:A1996VX02300005
J	Krapp, HG; Hengstenberg, R				Krapp, HG; Hengstenberg, R			Estimation of self-motion by optic flow processing in single visual interneurons	NATURE			English	Article							BLOWFLY CALLIPHORA-ERYTHROCEPHALA; GIANT VERTICAL CELLS; LOBULA PLATE; DROSOPHILA; DIRECTION; BEHAVIOR; NEURONS; FIELD	HUMANS, animals and some mobile robots use visual motion cues for object detection and navigation in structured surroundings(1-4). Motion is commonly sensed by large arrays of small field movement detectors, each preferring motion in a particular direction(5,6), Self-motion generates distinct 'optic flow fields' in the eyes that depend on the type and direction of the momentary locomotion (rotation, translation)(7). To investigate how the optic flow is processed at the neuronal level, we recorded intracellularly from identified interneurons in the third visual neuropile of the blowfly(8). The distribution of local motion tuning over their huge receptive fields was mapped in detail. The global structure of the resulting 'motion response fields' is remarkably similar to optic flow fields. Thus, the organization of the receptive fields of the so-called VS neurons(9,10) strongly suggests that each of these neurons specifically extracts the rotatory component of the optic flow around a particular horizontal axis. Other neurons are probably adapted to extract translatory flow components. This study shows how complex visual discrimination can be achieved by task-oriented preprocessing in single neurons.	MAX PLANCK INST BIOL CYBERNET, D-72076 TUBINGEN, GERMANY	Max Planck Society								BORST A, 1992, P NATL ACAD SCI USA, V89, P4139, DOI 10.1073/pnas.89.9.4139; BORST A, 1993, VISUAL MOTION ITS RO, P3; COLLETT T, 1993, VISUAL MOTION ITS RO, P239; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1329, DOI 10.1152/jn.1991.65.6.1329; EGELHAAF M, 1989, J OPT SOC AM A, V6, P1070, DOI 10.1364/JOSAA.6.001070; FRANCESCHINI N, 1992, PHILOS T R SOC B, V337, P283, DOI 10.1098/rstb.1992.0106; GEIGER G, 1981, NATURE, V293, P398, DOI 10.1038/293398a0; Gibson J.J., 1950, PERCEPTION VISUAL WO, DOI DOI 10.2307/1419017; GOTZ KG, 1979, BIOL CYBERN, V35, P101, DOI 10.1007/BF00337435; HAUSEN K, 1983, PROC R SOC SER B-BIO, V219, P211, DOI 10.1098/rspb.1983.0068; HAUSEN K, 1993, VISUAL MOTION ITS RO, P203; HENGSTENBERG R, 1982, J COMP PHYSIOL, V149, P179, DOI 10.1007/BF00619212; Hengstenberg R., 1991, Seminars in the Neurosciences, V3, P19, DOI 10.1016/1044-5765(91)90063-T; HENGSTENBERG R, 1982, J COMP PHYSIOL, V149, P163, DOI 10.1007/BF00619211; Hengstenberg R., 1983, Springer Series in Experimental Entomology, V1983, P183; HENGSTENBERG R, 1995, P 4 INT C NEUR, P255; KOENDERINK JJ, 1987, BIOL CYBERN, V56, P247, DOI 10.1007/BF00365219; KRAPP H, 1995, P 4 INT C NEUR, P264; KRAPP HG, IN PRESS VISION RES; KRAPP HG, 1995, THESIS U TUBINGEN; MORRONE MC, 1995, NATURE, V376, P507, DOI 10.1038/376507a0; NAKAYAMA K, 1985, VISION RES, V25, P625, DOI 10.1016/0042-6989(85)90171-3; NAKAYAMA K, 1974, PERCEPTION, V3, P63, DOI 10.1068/p030063; PFLUGFELDER GO, 1995, COMP BIOCHEM PHYS A, V110, P185, DOI 10.1016/0300-9629(94)00159-Q; REICHARDT W, 1987, J COMP PHYSIOL A, V161, P533, DOI 10.1007/BF00603660; SRINIVASAN MV, 1993, BIOL CYBERN, V68, P1299; Strausfeld N.J., 1983, Springer Series in Experimental Entomology, V1983, P132; TANAKA K, 1989, J NEUROPHYSIOL, V62, P626, DOI 10.1152/jn.1989.62.3.626; WARREN WH, 1988, NATURE, V336, P162, DOI 10.1038/336162a0; Wehner R, 1981, HDB SENSORY PHYSL, V6B, P287, DOI DOI 10.1007/978-3642-67868-4	30	270	270	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 5	1996	384	6608					463	466		10.1038/384463a0	http://dx.doi.org/10.1038/384463a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945473				2022-12-01	WOS:A1996VW68700063
J	Dannenberg, AL; McNeil, JG; Brundage, JF; Brockmeyer, R				Dannenberg, AL; McNeil, JG; Brundage, JF; Brockmeyer, R			Suicide and HIV infection - Mortality follow-up of 4147 HIV-seropositive military service applicants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NATIONAL-DEATH-INDEX; SCREENING-PROGRAM; AIDS; RISK; CERTIFICATES; IMPACT	Objective.-To examine the risk of suicide among individuals positive for the human immunodeficiency virus (HIV) following screening for evidence of HIV infection. Prior studies have reported a 7- to 36-fold increased risk of suicide for persons with the acquired immunodeficiency syndrome. Design.-Prospective cohort study. Setting.-Military service applicants from throughout the United States. Main Outcome Measure.-Death from suicide. Methods.-The National Death Index was searched for mortality among 4147 HIV-positive military service applicants and 12437 HIV-negative applicants disqualified from military service due to other medical conditions (matched 1:3 on age, race, sex, and screening date and location) identified by the US Department of Defense between October 1985 and December 1993. Death certificates were obtained from individual states. Identifiers and HIV status of living applicants were known only by the Department of Defense. Results.-The HIV-positive applicants were 92% male, 37% white, and 56% black. Median age was 24 years (range, 17-57 years). Median follow-up time was 70 months (range, 0-99 months). Ten HIV-positive (49 per 100 000 person-years) and 24 HIV-negative applicants (36 per 100 000 person-years) died of suicide (rate ratio [RR], 1.35; 95% confidence interval [CI]= 0.58-2.93). Suicide rates among both HIV-positive (RR, 2.08; 95% CI, 1.00-3.82) and HIV-negative (RR, 1.67; 95% CI, 1.07-2.48) applicants are marginally higher than those for the US general population, after adjustment for age, race, and sex. Time from screening to death was less than 3 months for 3 of 10 HIV-positive and 2 of 24 HIV-negative applicants who died of suicide. Conclusions.-The HIV-positive individuals do not appear to have a significantly increased risk of death from suicide in the months following HIV screening in this study population. Because suicide risk is reported to be greatly increased after symptomatic HIV disease is present, clinicians should consider asking persons with HIV infection about suicide risk factors during both initial counseling and subsequent medical care.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR INJURY RES & POLICY,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD; WALTER REED ARMY MED CTR,WALTER REED ARMY INST RES,DIV PREVENT MED,WASHINGTON,DC 20307; HENRY M JACKSON FDN ADVANCEMENT MIL MED,ROCKVILLE,MD	Johns Hopkins University; Johns Hopkins University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc			Brundage, John/Q-9244-2019		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047756] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH47756] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALFONSO CA, 1994, PSYCHOSOMATICS, V35, P368, DOI 10.1016/S0033-3182(94)71758-8; BURKE DS, 1988, NEW ENGL J MED, V319, P961, DOI 10.1056/NEJM198810133191501; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; *CDC, 1988, MMWR-MORBID MORTAL W, V37, P677; *CDC, 1988, MMWR-MORBID MORTAL W, V37, P779; *CDC, 1988, MMWR-MORBID MORTAL W, V37, P773; CHU SY, 1993, AM J PUBLIC HEALTH, V83, P1429, DOI 10.2105/AJPH.83.10.1429; COPELAND AR, 1993, MED SCI LAW, V33, P21, DOI 10.1177/002580249303300105; COTE TR, 1992, JAMA-J AM MED ASSOC, V268, P2066, DOI 10.1001/jama.268.15.2066; CURB JD, 1985, AM J EPIDEMIOL, V121, P754, DOI 10.1093/aje/121.5.754; FARBEROW NL, 1977, PUBLIC HEALTH REP, V92, P223; FLAVIN D K, 1987, Advances in Alcohol and Substance Abuse, V6, P23; FRIERSON RL, 1988, PSYCHOSOMATICS, V29, P226, DOI 10.1016/S0033-3182(88)72403-2; GALA C, 1992, ACTA PSYCHIAT SCAND, V86, P70, DOI 10.1111/j.1600-0447.1992.tb03229.x; GLASS RM, 1988, JAMA-J AM MED ASSOC, V259, P1369, DOI 10.1001/jama.259.9.1369; HARDY AM, 1987, PUBLIC HEALTH REP, V102, P386; HELMKAMP JC, 1995, MIL MED, V160, P45, DOI 10.1093/milmed/160.2.45; HESSOL NA, 1992, AM J PUBLIC HEALTH, V82, P561, DOI 10.2105/AJPH.82.4.561; KIZER KW, 1988, JAMA-J AM MED ASSOC, V260, P1881, DOI 10.1001/jama.1988.03410130075021; KOCHANEK KD, 1995, MON VITL STAT REP S, V43; LYKETSOS CG, 1995, EPIDEMIOL REV, V17, P152, DOI 10.1093/oxfordjournals.epirev.a036171; MACMAHON B, 1983, AM J PUBLIC HEALTH, V73, P1247, DOI 10.2105/AJPH.73.11.1247; MARZUK P M, 1991, International Review of Psychiatry, V3, P365, DOI 10.3109/09540269109072143; MARZUK PM, 1988, JAMA-J AM MED ASSOC, V259, P1333, DOI 10.1001/jama.259.9.1333; MCKEGNEY FP, 1992, AM J PSYCHIAT, V149, P396; MOYER LA, 1989, AM J EPIDEMIOL, V130, P1024, DOI 10.1093/oxfordjournals.aje.a115403; *NAT CTR HLTH STAT, 1982, DHHS PUBL, V2; *NAT CTR HLTH STAT, 1993, VIT STAT US, V2; Nightingale SL, 1996, JAMA-J AM MED ASSOC, V276, P14; PERRY S, 1990, JAMA-J AM MED ASSOC, V263, P679, DOI 10.1001/jama.263.5.679; PIERCE C, 1987, CLIN PSYCHIAT NEWS, V10, P1; PRIER RE, 1991, HOSP COMMUNITY PSYCH, V42, P619; PUGH K, 1993, AIDS CARE, V5, P391, DOI 10.1080/09540129308258009; RAJS J, 1992, ACTA PSYCHIAT SCAND, V85, P234, DOI 10.1111/j.1600-0447.1992.tb08601.x; RUNDELL JR, 1992, PSYCHOSOMATICS, V33, P24, DOI 10.1016/S0033-3182(92)72017-9; SCHNEIDER SG, 1991, J PERS SOC PSYCHOL, V61, P776, DOI 10.1037/0022-3514.61.5.776; Starace F, 1993, Int J Soc Psychiatry, V39, P64, DOI 10.1177/002076409303900107; VANHAASTRECHT HJA, 1994, AIDS, V8, P1721, DOI 10.1097/00002030-199412000-00013	38	41	43	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1743	1746		10.1001/jama.276.21.1743	http://dx.doi.org/10.1001/jama.276.21.1743			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VV566	8940323				2022-12-01	WOS:A1996VV56600032
J	Gallant, P; Shiio, Y; Cheng, PF; Parkhurst, SM; Eisenman, RN				Gallant, P; Shiio, Y; Cheng, PF; Parkhurst, SM; Eisenman, RN			Myc and max homologs in Drosophila	SCIENCE			English	Article							C-MYC; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; NEOPLASTIC-CELLS; N-MYC; PROTEIN; GENE; DIMERIZATION; FAMILY; ONCOPROTEIN	The proteins encoded by the myc proto-oncogene family are involved in cell proliferation, apoptosis, differentiation, and neoplasia. Myc acts through dimerization with Max to bind DNA and activate transcription. Homologs of the myc and mau genes were cloned from the fruit fly Drosophila melanogaster and their protein products (dMyc and dMax) were shown to heterodimerize, recognize the same DNA sequence as their vertebrate homologs, and activate transcription. The dMyc protein is likely encoded by the Drosophila gene diminutive (dm), a mutation in which results in small body size and female sterility caused by degeneration of the ovaries. These findings indicate a potential role for Myc in germ cell development and set the stage for genetic analysis of Myc and Max.	FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047852] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA47138] Funding Source: Medline; NIGMS NIH HHS [R01GM47852] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ATCHLEY WR, 1995, P NATL ACAD SCI USA, V92, P10217, DOI 10.1073/pnas.92.22.10217; AUSUBEL FM, 1995, CURRENT PROTOCOLS S, V29; Bartel PL, 1993, CELLULAR INTERACTION, P153; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALLANT P, UNPUB; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHERTY CD, UNPUB; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MAGRATH I, 1990, ADV CANCER RES, V55, P134; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARLOR RL, 1986, MOL CELL BIOL, V6, P1129, DOI 10.1128/MCB.6.4.1129; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MODOLELL J, 1983, P NATL ACAD SCI-BIOL, V80, P1678, DOI 10.1073/pnas.80.6.1678; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; MOZER B, 1985, MOL CELL BIOL, V5, P885, DOI 10.1128/MCB.5.4.885; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PARKHURST SM, 1985, CELL, V41, P429, DOI 10.1016/S0092-8674(85)80016-7; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041	48	145	151	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1523	1527		10.1126/science.274.5292.1523	http://dx.doi.org/10.1126/science.274.5292.1523			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929412				2022-12-01	WOS:A1996VV77500047
J	Subramanya, HS; Bird, LE; Brannigan, JA; Wigley, DB				Subramanya, HS; Bird, LE; Brannigan, JA; Wigley, DB			Crystal structure of a DExx box DNA helicase	NATURE			English	Article							REPLICATION PROTEIN PRIA; COLI REP HELICASE; ESCHERICHIA-COLI; RNA HELICASE; BINDING; OVEREXPRESSION; DIMERIZATION; COMPONENT; MUTATIONS; PRIMOSOME	THERE are a wide variety of helicases that unwind helical DNA(1) and RNA substrates(2). The twelve helicases that have been identified in Escherichia coli(1) play a role in almost all cellular processes involving nucleic acids, We have solved the crystal structure of a monomeric form of a DNA helicase from Bacillus stearothermophilus, alone and in a complex with ADP, at 2.5 and 2.9 Angstrom resolution, respectively, The enzyme comprises two domains with a deep cleft running between them, The ATP-binding site, which is situated at the bottom of this cleft, is formed by motifs that are conserved across the superfamily of related helicases, Unexpected structural homology with the DNA recombination protein, RecA, suggests how ATP binding and hydrolysis may drive conformational changes of the enzyme during catalysis, and implies that there is a common mechanism for all helicases.	UNIV OXFORD,MOL BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND; UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of Oxford; University of York - UK				Bird, Louise/0000-0002-9846-5716	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; Egelman EH, 1996, STRUCTURE, V4, P759, DOI 10.1016/S0969-2126(96)00081-0; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; IORDANESCU S, 1993, MOL GEN GENET, V241, P185, DOI 10.1007/BF00280216; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; OPPERMAN T, 1994, J BACTERIOL, V176, P6033; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; STASIAK A, 1988, J MOL BIOL, V202, P659, DOI 10.1016/0022-2836(88)90293-8; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WASHBURN BK, 1993, J BACTERIOL, V175, P341, DOI 10.1128/JB.175.2.341-350.1993; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Yu X, 1995, BIOPHYS J, V69, P2728, DOI 10.1016/S0006-3495(95)80144-X; ZAVITZ KH, 1993, J BIOL CHEM, V268, P4337; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933; ZHU L, 1988, VIROLOGY, V166, P366, DOI 10.1016/0042-6822(88)90507-7	30	382	385	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					379	383		10.1038/384379a0	http://dx.doi.org/10.1038/384379a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934527				2022-12-01	WOS:A1996VV27100055
J	Stiller, CA; Boyle, J				Stiller, CA; Boyle, J			Effect of population mixing and socioeconomic status in England and Wales, 1979-85, on lymphoblastic leukaemia in children	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NON-HODGKINS-LYMPHOMA; CHILDHOOD LEUKEMIA; INFECTIVE BASIS; NUCLEAR SITE; BRITAIN	Objectives-To examine the effects of migration, diversity of migrant origins, commuting, and socioeconomic status on the incidence of acute lymphoblastic leukaemia in childhood. Design-Poisson regression analysis of incidence rates in relation to the variables of interest. Setting-The 403 county districts of England and Wales during 1979-85. Subjects-Children aged under 15 years. Results-There were significant trends in the incidence of lymphoblastic leukaemia at ages 0-4 and 5-9 years with the proportion of children in a district who had recently entered the district. While there was no consistent relation between the proportion of recent incomers in the total population of a district and its incidence rate, the combination of higher migration with greater diversity of origins or distance moved was associated with higher incidence in both age groups. Incidence increased significantly at age 0-4 with the level of employment in a district and at age 5-9 with the proportion of households with access to a car. No significant trends were found with commuting. Conclusions-The results for level of child migration and diversity of total migration provide evidence of an effect of population mi ring on the incidence of childhood leukaemia which is not restricted to areas experiencing the most extreme levels of mixing.	UNIV LEEDS, SCH GEOG, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Leeds	Stiller, CA (corresponding author), UNIV OXFORD, CHILDHOOD CANC RES GRP, S PARKS RD, OXFORD OX2 6HJ, ENGLAND.			Stiller, Charles/0000-0002-3006-7869				ALEXANDER FE, 1993, J PUBLIC HEALTH MED, V15, P9, DOI 10.1093/oxfordjournals.pubmed.a042826; ALEXANDER FE, 1990, LANCET, V336, P1461, DOI 10.1016/0140-6736(90)93176-P; ALEXANDER FE, 1992, BRIT J CANCER, V65, P589, DOI 10.1038/bjc.1992.119; DRAPER GJ, 1991, STUDIES MED POPULATI, V53, P37; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1995, BMJ-BRIT MED J, V310, P763, DOI 10.1136/bmj.310.6982.763; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; KNOX EG, 1992, J EPIDEMIOL COMMUN H, V46, P566, DOI 10.1136/jech.46.6.566; LANGFORD I, 1991, SOC SCI MED, V33, P435, DOI 10.1016/0277-9536(91)90325-7; MCWHIRTER WR, 1982, BRIT J CANCER, V46, P640, DOI 10.1038/bjc.1982.249; Rodrigues L, 1991, STUDIES MED POPULATI, P47; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Stiller CA, 1995, EUR J CANCER, V31A, P2028, DOI 10.1016/0959-8049(95)00428-9; STILLER CA, 1991, OPCS STUDIES MED POP, V53, P7	18	61	61	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	1996	313	7068					1297	1300						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV153	8942689	Green Published			2022-12-01	WOS:A1996VV15300023
J	Riordan, FAI; Thomson, APJ; Sills, JA; Hart, CA				Riordan, FAI; Thomson, APJ; Sills, JA; Hart, CA			Lesson of the week - Who spots the spots? Diagnosis and treatment of early meningococcal disease in children	BRITISH MEDICAL JOURNAL			English	Article							PARENTERAL PENICILLIN; RASH		UNIV LIVERPOOL,INST CHILD HLTH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT MED MICROBIOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool; University of Liverpool								CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; *DEP HLTH NAT MEN, 1994, KNOW MEN SEPT; FARMER G, 1993, BRIT MED J, V307, P127, DOI 10.1136/bmj.307.6896.127-a; GOSSAIN S, 1992, BRIT MED J, V305, P523, DOI 10.1136/bmj.305.6852.523-c; MARZOUK O, 1991, ARCH DIS CHILD, V66, P485, DOI 10.1136/adc.66.4.485; OAKLEY JR, 1979, BRIT MED J, V2, P468, DOI 10.1136/bmj.2.6188.468; RIORDAN FAI, 1995, EUR J PEDIATR, V154, P472; RIORDAN FAI, 1993, ARCH DIS CHILD, V69, P7117; SLACK J, 1982, J ROY COLL PHYS LOND, V16, P40; SORENSEN HT, 1992, J CLIN EPIDEMIOL, V11, P1289; THOMSON AP, 1993, ARCH DIS CHILD, V69, P166, DOI 10.1136/adc.69.1.166; WATKINSON M, 1995, BRIT MED J, V311, P1504; WELSBY PD, 1990, BRIT MED J, V300, P1150, DOI 10.1136/bmj.300.6733.1150	13	52	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1255	1256		10.1136/bmj.313.7067.1255	http://dx.doi.org/10.1136/bmj.313.7067.1255			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939123	Green Published			2022-12-01	WOS:A1996VU20800035
J	Berendes, E; Walter, M; Cullen, P; Prien, T; VanAken, H; Horsthemke, J; Schulte, M; vonWild, K; Scherer, R				Berendes, E; Walter, M; Cullen, P; Prien, T; VanAken, H; Horsthemke, J; Schulte, M; vonWild, K; Scherer, R			Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage	LANCET			English	Article							ANTIDIURETIC-HORMONE; INAPPROPRIATE SECRETION; HYPONATREMIA; HEMORRHAGE; PLASMA	Background Subarachnoid haemorrhage is commonly associated with natriuresis and hyponatraemia. One possible explanation for these features is a defect in the central regulation of renal sodium reabsorption with increased secretion of a natriuretic factor. We investigated whether excess sodium secretion in patients with subarachnoid haemorrhage is related to increased secretion of natriuretic peptides or to the presence of digoxin-like immunoreactive substances. Methods We measured the plasma concentrations of digoxin-like immunoreactive substances (by a fluorescence polarisation immunoassay) and natriuretic peptides, aldosterone, renin, and antidiuretic hormone (by radioimmunoassay) in ten patients with aneurysmal subarachnoid haemorrhage, ten patients undergoing elective craniotomy for cerebral tumours, and 40 healthy controls of similar age and sex distribution. Samples were collected before surgery, 1 h, 4 h, and 12 h after surgery, then daily until 7 days postoperatively in the two groups of patients. Findings All patients with subarachnoid haemorrhage, but none of the tumour patients, showed increased urine output and urinary excretion of sodium (p=0.018 for comparison of means of curves to 7 days). The patients with subarachnoid haemorrhage had much higher plasma concentrations of brain natriuretic peptide (BNP) than controls, on admission (mean 15.1 [SE 3.8] vs 1.6 [1.0] pmol/L, p<0.001) and throughout the study period, accompanied by lower than normal aldosterone concentrations and normal plasma concentrations of atrial and C-type natriuretic peptides (ANP, CNP). The patients with tumours had similar plasma concentrations of ANP, BNP, and CNP to the controls. We did not detect digoxin-like immunoreactive substances in either group of patients. Interpretation Salt-wasting of central origin may induce hyponatraemia in patients with aneurysmal subarachnoid haemorrhage, possibly as a result of increased secretion of BNP with subsequent suppression of aldosterone synthesis.	UNIV MUNSTER,CLEMENSHOSP,KLIN & POLIKLIN ANASTHESIOL & OPERAT INTENS MED,D-4400 MUNSTER,GERMANY; UNIV MUNSTER,CLEMENSHOSP,INST KLIN CHEM & LAB MED,D-4400 MUNSTER,GERMANY; UNIV MUNSTER,CLEMENSHOSP,INST ARTERIOSKLEROSEFORSCH,D-4400 MUNSTER,GERMANY; UNIV MUNSTER,CLEMENSHOSP,NEUROCHIRURG KLIN,D-4400 MUNSTER,GERMANY; UNIV MUNSTER,CLEMENSHOSP,KLIN ANASTHESIOL & OPERAT INTENS MED,D-4400 MUNSTER,GERMANY	University of Munster; University of Munster; University of Munster; University of Munster; University of Munster			Lascola, Christopher D/B-9126-2017	Lascola, Christopher D/0000-0002-8031-782X				AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; BARTTER FC, 1967, AM J MED, V42, P790, DOI 10.1016/0002-9343(67)90096-4; CORT JH, 1954, LANCET, V1, P752; DIRINGER M, 1988, STROKE, V19, P1119, DOI 10.1161/01.STR.19.9.1119; ESPINER EA, 1994, J INTERN MED, V235, P527, DOI 10.1111/j.1365-2796.1994.tb01261.x; GRUBER KA, 1980, NATURE, V287, P743, DOI 10.1038/287743a0; HASAN D, 1990, ANN NEUROL, V27, P106, DOI 10.1002/ana.410270118; IIMURA O, 1993, AM HEART J, V125, P635, DOI 10.1016/0002-8703(93)90215-U; ISOTANI E, 1994, STROKE, V25, P2198, DOI 10.1161/01.STR.25.11.2198; JUUL R, 1990, ACTA NEUROCHIR, V106, P18, DOI 10.1007/BF01809328; KROLL M, 1992, J INTERN MED, V232, P291; LANDOLT AM, 1984, J NEUROSURG, V37, P210; MOTWANI JG, 1993, LANCET, V341, P1109, DOI 10.1016/0140-6736(93)93126-L; OELKERS W, 1989, NEW ENGL J MED, V321, P492, DOI 10.1056/NEJM198908243210802; PETERS JP, 1950, T ASSOC AM PHYSICIAN, V63, P57; RAINE AEG, 1986, NEW ENGL J MED, V315, P533, DOI 10.1056/NEJM198608283150901; SAITO Y, 1989, BIOCHEM BIOPH RES CO, V158, P360, DOI 10.1016/S0006-291X(89)80056-7; SHAMISS A, 1993, EUR J PHARMACOL, V233, P113, DOI 10.1016/0014-2999(93)90356-M; STERNS RH, 1986, NEW ENGL J MED, V314, P1535, DOI 10.1056/NEJM198606123142402; TAKAHASHI K, 1992, PEPTIDES, V13, P121, DOI 10.1016/0196-9781(92)90149-W; WIJDICKS EFM, 1991, STROKE, V22, P1519, DOI 10.1161/01.STR.22.12.1519; YAMAKI T, 1992, ACTA NEUROCHIR, V115, P156, DOI 10.1007/BF01406376	22	267	281	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					245	249		10.1016/S0140-6736(96)08093-2	http://dx.doi.org/10.1016/S0140-6736(96)08093-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014912				2022-12-01	WOS:A1997WD90600012
J	Stewart, M				Stewart, M			Will glycosylated haemoglobin replace the oral glucose-tolerance test?	LANCET			English	Editorial Material											Stewart, M (corresponding author), MED SCH NEWCASTLE UPON TYNE, HUMAN DIABET & METAB RES CTR, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND.							[Anonymous], 1995, DIABETES, V44, P968; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; Kannel W B, 1979, Diabetes Care, V2, P120, DOI 10.2337/diacare.2.2.120; Peters AL, 1996, JAMA-J AM MED ASSOC, V276, P1246, DOI 10.1001/jama.276.15.1246; *WHO, 1985, TECH REP SER WHO, V727	5	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 25	1997	349	9047					223	224		10.1016/S0140-6736(05)64858-1	http://dx.doi.org/10.1016/S0140-6736(05)64858-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014906				2022-12-01	WOS:A1997WD90600006
J	James, P; Pfund, C; Craig, EA				James, P; Pfund, C; Craig, EA			Functional specificity among Hsp70 molecular chaperones	SCIENCE			English	Article							SHOCK COGNATE PROTEIN; PEPTIDE-BINDING; ATPASE; HSC70; BIP; FRAGMENT; REVEALS	Molecular chaperones of the 70-kilodalton heat shock protein (Hsp70) class bind to partially unfolded polypeptide substrates and participate in a wide variety of cellular processes. Differences in peptide-binding specificity among Hsp70s have led to the hypothesis that peptide binding determines specific Hsp70 functions. Protein domains were identified that were required for two separate functions of a yeast Hsp70 family. The peptide-binding domain was not required for either of these specific Hsp70 functions, which suggests that peptide-binding specificity plays little or no role in determining Hsp70 functions in vivo.	UNIV WISCONSIN,DEPT BIOMOL CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CRAIG E, 1995, PROTEIN KINESIS DYNA, V15, P441; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HAUS U, 1993, EMBO J, V12, P3763, DOI 10.1002/j.1460-2075.1993.tb06054.x; HUANG SP, 1993, J BIOL CHEM, V268, P2063; JAMES P, UNPUB; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; Morimoto R. I., 1994, COLD SPRING HARBOR M; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; TSAI MY, 1994, J BIOL CHEM, V269, P5958; WALDRON C, 1977, BIOCHEM J, V168, P409, DOI 10.1042/bj1680409; WANG TF, 1993, J BIOL CHEM, V268, P26049; WIECH H, 1993, J BIOL CHEM, V268, P7414; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZIEGELHOFFER T, UNPUB	23	174	177	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					387	389		10.1126/science.275.5298.387	http://dx.doi.org/10.1126/science.275.5298.387			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994035				2022-12-01	WOS:A1997WC87300046
J	Cool, DR; Normant, E; Shen, FS; Chen, HC; Pannell, L; Zhang, Y; Loh, YP				Cool, DR; Normant, E; Shen, FS; Chen, HC; Pannell, L; Zhang, Y; Loh, YP			Carboxypeptidase E is a regulated secretory pathway sorting receptor: Genetic obliteration leads to endocrine disorders in Cpe(fat) mice	CELL			English	Article							TRANS-GOLGI NETWORK; PITUITARY INTERMEDIATE LOBE; OPIOMELANOCORTIN CONVERTING ENZYME; PRO-OPIOMELANOCORTIN; SECRETOGRANIN-II; DISULFIDE BOND; CHROMOGRANIN-B; PH; PROOPIOMELANOCORTIN; CELLS	A proposed mechanism for sorting secretory proteins into granules for release via the regulated secretory pathway in endocrine-neuroendocrine cells involves binding the proteins to a sorting receptor at the transGolgi network, followed by budding and granule formation. We have identified such a sorting receptor as membrane-associated carboxypeptidase E (CPE) in pituitary Golgi-enriched and secretory granule membranes. CPE specifically bound regulated secretory pathway proteins, including prohormones, but not constitutively secreted proteins. We show that in the Cpe(fat) mutant mouse lacking CPE, the pituitary prohormone, pro-opiomelanocortin, was missorted to the constitutive pathway and secreted in an unregulated manner. Thus, obliteration of CPE, the sorting receptor, leads to multiple endocrine disorders in these genetically defective mice, including hyperproinsulinemia and infertility.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,NIH,BETHESDA,MD 20892; NIDDKD,ANALYT CHEM LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Cool, DR (corresponding author), NICHHD,CELLULAR NEUROBIOL SECT,NIH,BETHESDA,MD 20892, USA.							BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BIRCH NP, 1989, PROTEOLYTIC ENZYMES, P211; BRENNAN SO, 1978, NATURE, V274, P908, DOI 10.1038/274908a0; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CARNELL L, 1994, J CELL BIOL, V127, P693, DOI 10.1083/jcb.127.3.693; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHANDRA S, 1991, J CELL SCI, V100, P747; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; COOL DR, 1994, BIOCHIMIE, V76, P265, DOI 10.1016/0300-9084(94)90156-2; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; ESTIVARIZ FE, 1989, J BIOL CHEM, V264, P17796; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; FRICKER LD, 1988, J CELL BIOCHEM, V38, P279, DOI 10.1002/jcb.240380407; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1983, J BIOL CHEM, V258, P950; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; LOH YP, 1985, FEBS LETT, V184, P40, DOI 10.1016/0014-5793(85)80648-7; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; LOH YP, 1977, J GEN PHYSIOL, V70, P37, DOI 10.1085/jgp.70.1.37; LOH YP, 1984, J BIOL CHEM, V259, P8238; LOH YP, 1985, J BIOL CHEM, V260, P7194; LOH YP, 1981, EUR J CELL BIOL, V26, P177; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NAKANISHI S, 1979, NATURE, V278, P423, DOI 10.1038/278423a0; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; TILDERS FJH, 1975, EXP BRAIN RES, V23, P198; Varlamov O, 1996, J BIOL CHEM, V271, P6077, DOI 10.1074/jbc.271.11.6077; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; WONG SH, 1993, J BIOL CHEM, V268, P22853; YOO SH, 1992, J BIOL CHEM, V267, P11236; ZHOU A, 1993, J BIOL CHEM, V268, P1763	45	374	383	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					73	83		10.1016/S0092-8674(00)81860-7	http://dx.doi.org/10.1016/S0092-8674(00)81860-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019408	Bronze			2022-12-01	WOS:A1997WC56900011
J	Rodionov, VI; Borisy, GG				Rodionov, VI; Borisy, GG			Microtubule treadmilling in vivo	SCIENCE			English	Article							DYNAMIC INSTABILITY; PIGMENT TRANSPORT; FISH MELANOPHORES; LIVING CELLS; CHROMATOPHORES; INVIVO; CENTROSOME; DIRECTION; TURNOVER; POLARITY	In vivo, cytoplasmic microtubules are nucleated and anchored by their minus ends at the centrosome and are believed to turn over by a mechanism termed dynamic instability: depolymerization and repolymerization at their plus ends. In cytoplasmic fragments of fish melanophores, microtubules were shown to detach from their nucleation site and depolymerize from their minus ends. Free microtubules moved toward the periphery by treadmilling-growth at one end and shortening from the opposite end. Frequent release from nucleation sites may be a general properly of centrosomes and permit a minus-end mechanism of microtubule turnover and treadmilling.	UNIV WISCONSIN,MOL BIOL LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Borisy, Gary/0000-0002-0266-8018	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025062, R37GM025062] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25062] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD FJ, 1995, J CELL SCI, V108, P2761; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; FUJII R, 1993, INT REV CYTOL, V143, P191; GYOEVA FK, 1987, J CELL SCI, V88, P649; HAIMO LT, 1994, BIOESSAYS, V16, P727, DOI 10.1002/bies.950161007; KITANISHIYUMURA T, 1987, CELL MOTIL CYTOSKEL, V6, P106; MARGOLIS RL, 1981, NATURE, V293, P705, DOI 10.1038/293705a0; MCBEATH E, 1990, EUR J CELL BIOL, V52, P1; MCNIVEN MA, 1988, J CELL BIOL, V106, P1593, DOI 10.1083/jcb.106.5.1593; MCNIVEN MA, 1986, J CELL BIOL, V103, P1547, DOI 10.1083/jcb.103.4.1547; MCNIVEN MA, 1984, CELL, V37, P753, DOI 10.1016/0092-8674(84)90411-2; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; RODIONOV VI, 1994, J CELL BIOL, V126, P1455, DOI 10.1083/jcb.126.6.1455; RODIONOV VI, UNPUB; SAMMAK PJ, 1987, J CELL BIOL, V104, P395, DOI 10.1083/jcb.104.3.395; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SCHLIWA M, 1983, AM ZOOL, V23, P479; SCHULZE E, 1988, NATURE, V334, P356, DOI 10.1038/334356a0; SCHULZE E, 1987, J CELL BIOL, V104, P277, DOI 10.1083/jcb.104.2.277; SOLTYS BJ, 1985, J CELL BIOL, V100, P1682, DOI 10.1083/jcb.100.5.1682; VOROBJEV IA, 1983, EUR J CELL BIOL, V30, P149; ZHAI Y, 1995, J CELL BIOL, V131, P721, DOI 10.1083/jcb.131.3.721	24	135	137	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					215	218		10.1126/science.275.5297.215	http://dx.doi.org/10.1126/science.275.5297.215			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985015				2022-12-01	WOS:A1997WC02200039
J	DelRio, JA; Heimrich, B; Borrell, V; Forster, E; Drakew, A; Alcantara, S; Nakajima, K; Miyata, T; Ogawa, M; Mikoshiba, K; Derer, P; Frotscher, M; Soriano, E				DelRio, JA; Heimrich, B; Borrell, V; Forster, E; Drakew, A; Alcantara, S; Nakajima, K; Miyata, T; Ogawa, M; Mikoshiba, K; Derer, P; Frotscher, M; Soriano, E			A role for Cajal-Retzius cells and reelin in the development of hippocampal connections	NATURE			English	Article							POSTNATAL MURINE HIPPOCAMPUS; SUBPLATE NEURONS; IN-VITRO; ORGANIZATION; PROTEIN; AXONS; PROJECTIONS; GUIDANCE; TISSUE	DURING development ache nervous system, specific recognition molecules provide the cues necessary for the formation of neural connections, In some regions, guiding cues for axonal pathfinding and target selection are provided by specific cells that exist only transiently during development, such as the floorplate or the cortical subplate(1-4). In the hippocampus, distinct groups of fibres innervate different layers(5). We have tested the hypothesis that transient neurons in the hippocampus(6,7) provide positional information for the targeting of these fibres, Here we report that ablation of Cajal-Retzius cells in organotypic slice cultures of hippocampus prevented the ingrowth of entorhinal but not of commissural afferents. Experiments Inhibiting ReeIin (an extracellular matrix protein expressed by Cajal-Retzius cells) and analysis of reeler mutant mice showed dramatic abnormalities in the development of entorhinal afferents, Thus Cajal-Retzius cells and reelin are essential for the formation of layer-specific hippocampal connections.	UNIV BARCELONA,FAC BIOL,DEPT ANIM & PLANT CELL BIOL,BARCELONA 08028,SPAIN; UNIV FREIBURG,INST ANAT 1,D-79001 FREIBURG,GERMANY; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOL NEUROBIOL LAB,TSUKUBA,IBARAKI 305,JAPAN; KOCHI MED SCH,DEPT PHYSIOL,NANKO KU,KOCHI 783,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; UNIV PARIS 06,DEV NEUROBIOL LAB,F-75005 PARIS,FRANCE	University of Barcelona; University of Freiburg; RIKEN; Kochi University; University of Tokyo; UDICE-French Research Universities; Sorbonne Universite			Soriano, Eduardo/AAB-3216-2019; del rio, jose antonio/L-9232-2014; Mikoshiba, Katsuhiko/N-7943-2015; MIYATA, TAKAKI/I-7066-2014; Nakajima, Kazunori/L-3396-2013; Borrell, Victor/U-1802-2017; Alcantara, Soledad/K-3648-2014; Del Rio Fernandez, Jose A/AAD-1121-2020	Soriano, Eduardo/0000-0002-3204-9285; del rio, jose antonio/0000-0002-5214-4909; Nakajima, Kazunori/0000-0003-1864-9425; Borrell, Victor/0000-0002-7833-3978; Alcantara, Soledad/0000-0003-3313-2715; 				Amaral David G., 1995, P443; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DARCANGELO G, IN PRESS J NEUROSCI; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FROTSCHER M, 1993, P NATL ACAD SCI USA, V90, P10400, DOI 10.1073/pnas.90.21.10400; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GHOSH A, 1992, SCIENCE, V255, P1441, DOI 10.1126/science.1542795; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GUENET JL, 1981, MOUSE NEWS LETT, V41; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; HERMANN K, 1995, P NATL ACAD SCI USA, V92, P11244; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Kennedy Timothy E., 1995, Current Opinion in Neurobiology, V5, P83, DOI 10.1016/0959-4388(95)80091-3; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LI D, 1993, NEUROSCIENCE, V52, P799, DOI 10.1016/0306-4522(93)90530-S; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SONANO E, 1989, J COMP NEUROL, V281, P586; SORIANO E, 1994, J COMP NEUROL, V342, P571, DOI 10.1002/cne.903420406; SORIANO E, 1991, J HISTOCHEM CYTOCHEM, V39, P255, DOI 10.1177/39.3.1671576; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; SUPER H, 1994, J COMP NEUROL, V344, P101, DOI 10.1002/cne.903440108; SUPER H, IN PRESS DEV BRAIN R; VOMOV JJ, 1991, EXP NEUROL, V114, P11	29	383	397	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					70	74		10.1038/385070a0	http://dx.doi.org/10.1038/385070a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985248				2022-12-01	WOS:A1997WA73100051
J	Farrall, M				Farrall, M			Mapping genetic susceptibility to multiple sclerosis	LANCET			English	Editorial Material											Farrall, M (corresponding author), UNIV OXFORD,WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND.							DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; *MULT SCLER GEN GR, 1996, NAT GENET, V13, P469; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Robertson NP, 1996, BRAIN, V119, P449, DOI 10.1093/brain/119.2.449; SADOVNICK AD, 1988, AM J MED GENET, V29, P533, DOI 10.1002/ajmg.1320290310; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; SUAREZ BK, 1994, GENETIC APPROACHES M	9	9	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1674	1675		10.1016/S0140-6736(05)65817-5	http://dx.doi.org/10.1016/S0140-6736(05)65817-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973425				2022-12-01	WOS:A1996VZ76600005
J	Genain, CP; Abel, K; Belmar, N; Villinger, F; Rosenberg, DP; Linington, C; Raine, CS; Hauser, SL				Genain, CP; Abel, K; Belmar, N; Villinger, F; Rosenberg, DP; Linington, C; Raine, CS; Hauser, SL			Late complications of immune deviation therapy in a nonhuman primate	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; T-CELL CLONES; MULTIPLE-SCLEROSIS; OLIGODENDROCYTE GLYCOPROTEIN; DEMYELINATING DISEASES; EXPRESSION; CYTOKINES; INVITRO	The administration of antigens in soluble form can induce antigen-specific immune tolerance and suppress experimental autoimmune diseases, In a marmoset model of multiple sclerosis induced by myelin oligodendrocyte glycoprotein (MOG), marmosets tolerized to MOG were protected against acute disease, but after tolerization treatment a lethal demyelinating disorder emerged. In these animals, MOG-specific T cell proliferative responses were transiently suppressed, cytokine production was shifted from a T helper type 1 (T(H)1) to a T(H)2 pattern, and titers of autoantibodies to MOG were enhanced. Thus, immune deviation can increase concentrations of pathogenic autoantibodies and in some circumstances exacerbate autoimmune disease.	EMORY UNIV,SCH MED,DEPT PATHOL & LAB MED,ATLANTA,GA 30322; MAX PLANCK INST PSYCHIAT,DEPT NEUROIMMUNOL,D-8033 MARTINSRIED,GERMANY; ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10461	Emory University; Max Planck Society; Yeshiva University; Albert Einstein College of Medicine	Genain, CP (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143, USA.		Hauser, Stephen L/J-2978-2016; Linington, Chris/M-4883-2019	Linington, Christopher/0000-0002-0937-9526	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030727, R01NS008952, P01NS011920, P50NS011920] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 30727, NS 08952, NS 11920] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMOR S, 1994, J IMMUNOL, V153, P4349; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; Brosnan CF, 1996, BRAIN PATHOL, V6, P243, DOI 10.1111/j.1750-3639.1996.tb00853.x; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; COMPSTON DAS, 1989, NEUROPATH APPL NEURO, V15, P307, DOI 10.1111/j.1365-2990.1989.tb01231.x; CRITCHFIELD JM, 1994, SCIENCE, V263, P1139, DOI 10.1126/science.7509084; CROSS AH, 1995, J CLIN INVEST, V95, P2783, DOI 10.1172/JCI117982; DALCANTO MC, 1975, J NEUROL SCI, V24, P313, DOI 10.1016/0022-510X(75)90251-8; DEROSBO NK, 1993, J CLIN INVEST, V92, P2602, DOI 10.1172/JCI116875; GARDINIER MV, 1992, J NEUROSCI RES, V33, P177, DOI 10.1002/jnr.490330123; GENAIN CP, 1994, J CLIN INVEST, V94, P1339, DOI 10.1172/JCI117454; Genain CP, 1995, J CLIN INVEST, V96, P2966, DOI 10.1172/JCI118368; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; HILTON AA, 1995, J NEUROCHEM, V65, P309; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; KUCHROO VK, 1993, J IMMUNOL, V151, P4371; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MASSACESI L, 1995, ANN NEUROL, V37, P519, DOI 10.1002/ana.410370415; MILLER A, 1993, J NEUROIMMUNOL, V46, P73, DOI 10.1016/0165-5728(93)90235-Q; MILLER SD, 1994, IMMUNOL TODAY, V15, P356, DOI 10.1016/0167-5699(94)90173-2; MONDINO A, 1996, P NATL ACAD SCI USA, V93, P225; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PANITCH HS, 1980, ARCH NEUROL-CHICAGO, V37, P206, DOI 10.1001/archneur.1980.00500530044005; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PETTINELLI CB, 1981, J IMMUNOL, V127, P1420; PHAMDINH D, 1994, J NEUROCHEM, V63, P2353; POWELL MB, 1990, INT IMMUNOL, V2, P539, DOI 10.1093/intimm/2.6.539; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; Raine C. S., 1983, MULTIPLE SCLEROSIS P, P413; RAINE CS, 1970, J NEUROPATH EXP NEUR, V29, P177, DOI 10.1097/00005072-197004000-00002; Rocken M, 1996, IMMUNOL TODAY, V17, P225, DOI 10.1016/0167-5699(96)80556-1; ROTT O, 1994, EUR J IMMUNOL, V24, P1434, DOI 10.1002/eji.1830240629; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; SCOLDING NJ, 1989, NATURE, V339, P620, DOI 10.1038/339620a0; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SIELING PA, 1993, J IMMUNOL, V150, P5501; TAGA K, 1992, J IMMUNOL, V148, P1143; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; WARREN KG, 1994, ANN NEUROL, V35, P280, DOI 10.1002/ana.410350307; XIAO BG, 1991, J NEUROIMMUNOL, V31, P91, DOI 10.1016/0165-5728(91)90014-X	43	294	300	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2054	2057		10.1126/science.274.5295.2054	http://dx.doi.org/10.1126/science.274.5295.2054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953031				2022-12-01	WOS:A1996VY97400041
J	Hikida, M; Mori, M; Takai, T; Tomochika, K; Hamatani, K; Ohmori, H				Hikida, M; Mori, M; Takai, T; Tomochika, K; Hamatani, K; Ohmori, H			Reexpression of RAG-1 and RAG-2 genes in activated mature mouse B cells	SCIENCE			English	Article							V(D)J RECOMBINATION; BONE-MARROW; EXPRESSION; LYMPHOCYTES; MICE; REARRANGEMENT; RESPONSES; ANTIBODY; RECEPTOR; SYSTEM	Recombination activating genes (RAG-1 and RAG-2), involved in V(D)J rearrangement of immunoglobulin genes, have been thought to be expressed only in immature stages of B-cell development. However, RAG-1 and RAG-2 transcripts were found to be reexpressed in mature mouse B cells after culture with interleukin-4 in association with several different co-stimuli. Reexpression was also detected in draining lymph nodes from immunized mice, RAG-1 and RAG-2 proteins could be detected by immunofluorescence microscopy in the nuclei of B cells cultured in vitro and in the germinal centers of draining lymph nodes. These findings suggest that RAG gene products play a heretofore unsuspected role in mature B cells.	OKAYAMA UNIV,FAC ENGN,DEPT BIOTECHNOL,OKAYAMA 700,JAPAN; OKAYAMA PREFECTURAL UNIV,FAC HLTH & WELF SCI,SOJA,OKAYAMA 71911,JAPAN; OKAYAMA UNIV,FAC PHARMACEUT SCI,OKAYAMA 700,JAPAN; RADIAT EFFECTS RES FDN,HIROSHIMA 732,JAPAN	Okayama University; Okayama Prefectural University; Okayama University; Radiation Effects Research Foundation - Japan								ABE M, 1991, INT IMMUNOL, V3, P105; CHEN C, 1994, J IMMUNOL, V152, P1970; Chen C, 1995, IMMUNITY, V3, P747, DOI 10.1016/1074-7613(95)90064-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; GHIA P, 1995, EUR J IMMUNOL, V25, P3108, DOI 10.1002/eji.1830251118; GOODMAN MG, 1983, J IMMUNOL, V130, P2580; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; HAGMAN J, 1994, CURR OPIN IMMUNOL, V6, P222, DOI 10.1016/0952-7915(94)90095-7; HARUNA K, 1993, CELL IMMUNOL, V151, P52, DOI 10.1006/cimm.1993.1221; Hikida M, 1996, J IMMUNOL, V156, P2730; HIKIDA M, UNPUB; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; MA A, 1992, EMBO J, V11, P2727, DOI 10.1002/j.1460-2075.1992.tb05338.x; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OHMORI H, UNPUB; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SNAPPER CM, 1988, J EXP MED, V167, P183, DOI 10.1084/jem.167.1.183; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; VERKOCZY LK, 1995, J IMMUNOL, V154, P5136; WILSON A, 1994, J EXP MED, V179, P1355, DOI 10.1084/jem.179.4.1355; YAMAMOTO A, 1992, CELL BIOCHEM FUNCT, V10, P71, DOI 10.1002/cbf.290100202	30	191	200	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2092	2094		10.1126/science.274.5295.2092	http://dx.doi.org/10.1126/science.274.5295.2092			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953042				2022-12-01	WOS:A1996VY97400052
J	Huang, BH; Eberstadt, M; Olejniczak, ET; Meadows, RP; Fesik, SW				Huang, BH; Eberstadt, M; Olejniczak, ET; Meadows, RP; Fesik, SW			NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; PROGRAMMED CELL-DEATH; DISTANCE GEOMETRY; TNF RECEPTOR; PROTEINS; APOPTOSIS; INTERACTS; ANTIGEN; BINDING; LIGAND	PROGRAMMED cell death (apoptosis) mediated by the cytokine receptor Fas is critical for the removal of autoreactive T cells(1), the mechanism of immune privilege(2,3), and for maintenance of immune-system homeostasis(4). Signalling of programmed cell death involves the self-association of a conserved cytoplasmic region of Fas called the death domain(5-7) and interaction with another death-domain-containing protein, FADD(8) (also known as MORT1)(9). Although death domains are found in several proteins(10), their three dimensional structure and the manner in which they interact is unknown, Here we describe the solution structure of the Fas death domain, as determined by NMR spectroscopy, The structure consists of six antiparallel, amphipathic a-helices arranged in a novel fold, From the structure and from site-directed mutagenesis, we have identified the region of the death domain involved in self-association and binding to the downstream signalling partner FADD.	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064	Abbott Laboratories								BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, XPLOR 3 1 MANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; DILLON PJ, 1990, BIOTECHNIQUES, V9, P298; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GOLDSTEIN P, 1995, CELL, V84, P185; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HSU H, 1995, CELL, V81, P535; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KIM JS, 1993, PROTEIN SCI, V2, P348; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005	30	310	320	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 19	1996	384	6610					638	641		10.1038/384638a0	http://dx.doi.org/10.1038/384638a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VZ296	8967952				2022-12-01	WOS:A1996VZ29600032
J	Dorman, P; Sandercock, P				Dorman, P; Sandercock, P			TPA within 3 hours of acute ischaemic stroke?	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; HEMORRHAGE; HEMATOMA; TRIAL				Dorman, P (corresponding author), UNIV EDINBURGH, NEUROSCI TRIALS UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135				Adams HP, 1996, STROKE, V27, P1711; Bogousslavsky J, 1996, CEREBROVASC DIS, V6, P315; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; HUNT D, 1992, LANCET, V339, P753; LEVY DE, 1994, STROKE, V25, P291, DOI 10.1161/01.STR.25.2.291; *NAT I NEUR DIS ST, 1995, NEW ENGL J MED, V33, P1581; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; SIX AJ, 1990, AM J CARDIOL, V65, P119, DOI 10.1016/0002-9149(90)90071-8; WARDLAW JM, 1996, COCHRANE DATABASE SY	9	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 14	1996	348	9042					1600	1601		10.1016/S0140-6736(05)65688-7	http://dx.doi.org/10.1016/S0140-6736(05)65688-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961984				2022-12-01	WOS:A1996VX87600003
J	Heringlake, S; Osterkamp, S; Trautwein, C; Tillmann, HL; Boker, K; Muerhoff, S; Mushahwar, IK; Hunsmann, G; Manns, MP				Heringlake, S; Osterkamp, S; Trautwein, C; Tillmann, HL; Boker, K; Muerhoff, S; Mushahwar, IK; Hunsmann, G; Manns, MP			Association between fulminant hepatic failure and a strain of GBV virus C	LANCET			English	Article							RNA; PHOSPHORYLATION; PROTEIN; GENOME; SERUM	Background The GB virus C (GBV-C) and the hepatitis G virus (HGV) have been detected in patients with acute indeterminant hepatitis and post-transfusion hepatitis. However, the role of the new hepatitis viruses in the aetiology of fulminant hepatitis is little understood, We investigated the presence of GBV-C/HGV in patients with fulminant hepatic failure. Methods Serum samples from 22 German patients with fulminant hepatic failure and 106 symptom-free blood donors (controls) were studied for presence of GBV-C RNA by seminested reverse transcriptase PCR. Primer sequences were derived from the published gene sequences of the conserved NS3 region of the GBV-C prototype and the published isolates. Nucleotide and aminoacid sequences of GBV-C-positive isolates, the central RNA, and the published HGV and GBV-C prototype sequences were compared by multiple sequence alignment. We also compared the GBV-C sequences of virus-positive patients who had fulminant hepatic failure with those of 19 patients with chronic hepatitis from our centre, In addition, we searched databases and published papers for further GBV-C helicase sequences in patients with non-fulminant hepatitis. Findings GBV-C RNA was detected in 11 (50%) of the 22 patients with fulminant hepatic failure and in five (4.7%) of 106 control-group blood donors. Among the patients with fulminant hepatic failure, six of seven with fulminant hepatitis B and five of ten with fulminant non-A-E hepatitis were positive for GBV-C RNA. Analysis of nucleic acid sequences showed six mutations at defined positions in all 11 patients with fulminant hepatic failure who were positive for GBV-C, None of-these mutations were found in the five GBV-C-positive control-group blood donors, Of the six nucleotide changes, four caused no aminoacid changes, whereas two mutations at position 100 (G to T) and 102 (T to C) led to an alanine to serine change in the predicted translation product. However, comparison with GBV-C sequences of patients with non-fulminant hepatitis showed that this aminoacid mutation was not specific for fulminant hepatic failure, The sequence-motif containing the six nucleotide mutations detected in all patients with fulminant hepatic failure was found in only two of 19 German patients with chronic hepatitis from our centre, and in only one of 88 GBV-C sequences from non-fulminant patients reported by others. Interpretation The frequency of GBV-C RNA is higher in fulminant hepatic failure than in any other group of patients with hepatitis, particularly in patients with fulminant hepatitis B or fulminant non-A-E hepatitis. A specific strain of GBV-C may occur in serum of German patients with fulminant hepatic failure.	HANNOVER MED SCH, DEPT GASTROENTEROL & HEPATOL, D-30625 HANNOVER, GERMANY; GERMAN PRIMATE CTR, DEPT VIROL & IMMUNOL, GOTTINGEN, GERMANY; ABBOTT LABS, HEPATITIS VIRUS DISCOVERY GRP, N CHICAGO, IL 60064 USA	Hannover Medical School; Deutsches Primatenzentrum (DPZ); Abbott Laboratories								Egawa K, 1996, J MED VIROL, V49, P110, DOI 10.1002/(SICI)1096-9071(199606)49:2&lt;110::AID-JMV7&gt;3.0.CO;2-8; FERAY C, 1993, GASTROENTEROLOGY, V104, P549, DOI 10.1016/0016-5085(93)90425-C; Fiordalisi G, 1996, J INFECT DIS, V174, P181, DOI 10.1093/infdis/174.1.181; HADLER SC, 1984, ANN INTERN MED, V100, P339, DOI 10.7326/0003-4819-100-3-339; Heringlake S, 1996, J HEPATOL, V25, P239, DOI 10.1016/S0168-8278(96)80081-X; KANAI A, 1995, FEBS LETT, V376, P221, DOI 10.1016/0014-5793(95)01283-X; Kao JH, 1996, J INFECT DIS, V174, P410, DOI 10.1093/infdis/174.2.410; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Masuko K, 1996, NEW ENGL J MED, V334, P1485, DOI 10.1056/NEJM199606063342301; MICHITAKA K, 1994, GASTROENTEROLOGY, V106, P1603, DOI 10.1016/0016-5085(94)90417-0; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; Pereira S, 1995, J BIOL CHEM, V270, P30401, DOI 10.1074/jbc.270.51.30401; Sallie R, 1996, LANCET, V347, P1552, DOI 10.1016/S0140-6736(96)90704-7; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; SIMONS JN, IN PRESS INFECT AGEN; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Tsuda F, 1996, J MED VIROL, V49, P248, DOI 10.1002/(SICI)1096-9071(199607)49:3&lt;248::AID-JMV15&gt;3.0.CO;2-8; WIDELL A, 1991, J MED VIROL, V35, P253, DOI 10.1002/jmv.1890350409; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7	21	214	215	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 14	1996	348	9042					1626	1629		10.1016/S0140-6736(96)04413-3	http://dx.doi.org/10.1016/S0140-6736(96)04413-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961994				2022-12-01	WOS:A1996VX87600013
J	Gieseche, J				Gieseche, J			Surveillance of infectious diseases in the European Union	LANCET			English	Editorial Material											Gieseche, J (corresponding author), SWEDISH INST INFECT DIS CONTROL,S-10521 STOCKHOLM,SWEDEN.								0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1534	1534		10.1016/S0140-6736(05)66167-3	http://dx.doi.org/10.1016/S0140-6736(05)66167-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950878				2022-12-01	WOS:A1996VX02300006
J	Mitchell, EA				Mitchell, EA			Co-sleeping and sudden infant death syndrome	LANCET			English	Editorial Material							SMOKING				Mitchell, EA (corresponding author), UNIV AUCKLAND,DEPT PAEDIAT,AUCKLAND,NEW ZEALAND.							Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; LEWIS KW, 1995, J PEDIATR-US, V127, P691, DOI 10.1016/S0022-3476(95)70155-9; MCKENNA JJ, 1993, SLEEP, V16, P263, DOI 10.1093/sleep/16.3.263; MCKENNA JJ, IN PRESS PEDIATRICS; Mitchell E. A., 1995, P266; MITCHELL EA, 1994, NEW ZEAL MED J, V107, P466; MITCHELL EA, 1994, ARCH DIS CHILD, V70, P291, DOI 10.1136/adc.70.4.291; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; SCRAGG R, 1993, BMJ-BRIT MED J, V307, P1312, DOI 10.1136/bmj.307.6915.1312; TUFFNELL CS, 1966, ARCH DIS CHILD, V75, P249	10	11	11	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1466	1466		10.1016/S0140-6736(05)65889-8	http://dx.doi.org/10.1016/S0140-6736(05)65889-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942773				2022-12-01	WOS:A1996VV46300006
J	Li, P; McLeod, M				Li, P; McLeod, M			Molecular mimicry in development: Identification of ste11(+) as a substrate and mei3(+) as a pseudosubstrate inhibitor of ran1(+) kinase	CELL			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; PREMEIOTIC DNA-SYNTHESIS; MATING-TYPE GENES; FISSION YEAST; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATOR; G(1) ARREST; MEIOSIS; SPORULATION; MUTANTS	ran1(+) (pat1(+)) kinase inhibits exit from the mitotic cell cycle and entry into meiosis. Inactivation of ran1(+) by mei3(+) is sufficient to precipitate the entire meiotic developmental program. Here, we show that the ste11(+) transcription factor is a substrate for ran1(+) in vitro and that this reaction is directly inhibited by mei3(+). Sequence comparison reveals that ste11(+) contains two domains homologous to each other and to a domain of mei3(+). Mutagenesis studies reveal that the regions of homology contain substrate specificity determinants. These results identify sequences critical for phosphorylation of ste11(+) by ran1(+) and suggest that mei3(+) employs a pseudosubstrate mechanism for its inhibitory function.			Li, P (corresponding author), SUNY HLTH SCI CTR, DEPT MICROBIOL & IMMUNOL, MORSE INST MOL BIOL & GENET, BROOKLYN, NY 11203 USA.							Alfa C., 1993, EXPT FISSION YEAST; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; DAVEY J, 1994, CURR GENET, V26, P105, DOI 10.1007/BF00313796; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; EGEL R, 1973, MOL GEN GENET, V121, P277, DOI 10.1007/BF00267055; EGEL R, 1974, EXP CELL RES, V88, P127, DOI 10.1016/0014-4827(74)90626-0; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Hardie G., 1995, PROTEIN KINASE FACTS; IINO Y, 1985, P NATL ACAD SCI USA, V82, P2447, DOI 10.1073/pnas.82.8.2447; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; IMAI Y, 1994, GENE DEV, V8, P328, DOI 10.1101/gad.8.3.328; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MCLEOD M, 1988, NATURE, V332, P509, DOI 10.1038/332509a0; NIELSEN O, 1990, EMBO J, V9, P1401, DOI 10.1002/j.1460-2075.1990.tb08255.x; Nielsen Olaf, 1993, Trends in Cell Biology, V3, P60, DOI 10.1016/0962-8924(93)90162-T; NURSE P, 1985, MOL GEN GENET, V198, P497, DOI 10.1007/BF00332946; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; RUSSELL RP, 1993, NATURE, V301, P167; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SIPICZKI M, 1988, MOL GEN GENET, V14, P4712; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WILLER M, 1995, MOL CELL BIOL, V15, P4964; WISNIEWSKI JR, 1994, EUR J BIOCHEM, V225, P687, DOI 10.1111/j.1432-1033.1994.00687.x; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	35	69	71	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					869	880		10.1016/S0092-8674(00)81994-7	http://dx.doi.org/10.1016/S0092-8674(00)81994-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945514	Bronze			2022-12-01	WOS:A1996VV77400013
J	MaloneLee, J				MaloneLee, J			Is detrusor instability and hypertrophy a smooth-muscle disease of the lower urinary tract?	LANCET			English	Editorial Material											MaloneLee, J (corresponding author), UCL HOSP, GERIATR MED CTR, LONDON NW1 0PE, ENGLAND.							BRADING AF, 1994, BRIT J UROL, V73, P3, DOI 10.1111/j.1464-410X.1994.tb07447.x; ELBADAWI A, 1993, J UROLOGY, V150, P1650, DOI 10.1016/S0022-5347(17)35866-4; Hadgu A, 1996, LANCET, V348, P592, DOI 10.1016/S0140-6736(96)05122-7; Khullar V, 1996, BRIT J OBSTET GYNAEC, V103, P904, DOI 10.1111/j.1471-0528.1996.tb09910.x; LIER PK, 1993, NEUROUROL URODYNAM, V12, P308; VANDOORN ESCV, 1995, CURR OPIN OBSTET GYN, V7, P378; Wagg A. S., 1996, Neurourology and Urodynamics, V15, P279	7	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1395	1395		10.1016/S0140-6736(05)67496-X	http://dx.doi.org/10.1016/S0140-6736(05)67496-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937274				2022-12-01	WOS:A1996VU98600004
J	Ericson, J; Morton, S; Kawakami, A; Roelink, H; Jessell, TM				Ericson, J; Morton, S; Kawakami, A; Roelink, H; Jessell, TM			Two critical periods of Sonic Hedgehog signaling required for the specification of motor neuron identify	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; MIDBRAIN DOPAMINERGIC-NEURONS; FLOOR PLATE DIFFERENTIATION; TERMINAL CLEAVAGE PRODUCT; CELL PATTERN; POLARIZING ACTIVITY; FROG EMBRYOS; SPINAL-CORD; INDUCTION; EXPRESSION	Antibodies that block Sonic Hedgehog (SHH) signaling have been used to show that SHH activity is required for the induction of floor plate differentiation by the notochord and independently for the induction of motor neurons by both the notochord and midline neural eels. Motor neuron generation depends on two critical periods of SHH signaling: an early period during which naive neural plate cells are converted into ventralized progenitors and a late period that extends well into S phase of the final progenitor cell division, during which SHH drives the differentiation of ventralized progenitors into motor neurons. The ambient SHH concentration during the late period determines whether ventralized progenitors differentiate into motor neurons or interneurons, thus defining the pattern of neuronal cell types generated in the neural tube.	NAGOYA UNIV, DIV BIOL SCI, NAGOYA, AICHI, JAPAN; UNIV WASHINGTON, DEPT BIOL STRUCT, SEATTLE, WA 98195 USA	Nagoya University; University of Washington; University of Washington Seattle	Ericson, J (corresponding author), COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOL BIOPHYS, NEW YORK, NY 10032 USA.		Kawakami, Atsushi/D-3785-2019	Kawakami, Atsushi/0000-0001-9461-6372; Roelink, Henk/0000-0002-5260-3634; Ericson, Johan/0000-0002-8019-7127				ALTABA AR, 1995, DEV BIOL, V170, P299; ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GURDON JB, 1987, DEVELOPMENT, V99, P285; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; JESSELL TM, 1992, HARVEY LECT, V86, P87; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KIMMEL CB, 1994, DEVELOPMENT, V120, P265; KORZH V, 1993, DEVELOPMENT, V118, P417; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LANGMAN J, 1966, J COMP NEUROL, V127, P399, DOI 10.1002/cne.901270308; LEBER SM, 1990, J NEUROSCI, V10, P2451; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; MARTI E, 1995, DEVELOPMENT, V121, P2537; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1995, CURR OPIN GENET DEV, V5, P499, DOI 10.1016/0959-437X(95)90055-L; PLACZEK M, 1991, DEVELOPMENT, P105; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; Tremblay P, 1996, DEVELOPMENT, V122, P2555; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WICKHAM TJ, 1992, BIOTECHNOL PROGR, V8, P391, DOI 10.1021/bp00017a003; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZECCA M, 1995, DEVELOPMENT, V121, P2265	52	735	766	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1996	87	4					661	673		10.1016/S0092-8674(00)81386-0	http://dx.doi.org/10.1016/S0092-8674(00)81386-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929535	hybrid			2022-12-01	WOS:A1996VU03500009
J	Kuzin, B; Roberts, I; Peunova, N; Enikolopov, G				Kuzin, B; Roberts, I; Peunova, N; Enikolopov, G			Nitric oxide regulates cell proliferation during Drosophila development	CELL			English	Article							NEURONAL NADPH DIAPHORASE; RIBONUCLEOTIDE REDUCTASE; NERVOUS-SYSTEM; SYNTHASE; EXPRESSION; PROTEIN; GROWTH; DEATH; TRANSIENT; CYCLE	Cell division and subsequent programmed cell death in imaginal discs of Drosophila larvae determine the final size of organs and structures of the adult fly. We show here that nitric oxide (NO) is involved in controlling the size of body structures during Drosophila development. We have found that NO synthase (NOS) is expressed at high levels in developing imaginal discs. Inhibition of NOS in larvae causes hypertrophy of organs and their segments in adult flies, whereas ectopic expression of NOS in larvae has the opposite effect. Blocking apoptosis in eye imaginal discs unmasks surplus cell proliferation and results in an increase in the number of ommatidia and component cells of individual ommatidia. These results argue that NO acts as an antiproliferative agent during Drosophila development, controlling the balance between cell proliferation and cell differentiation.	UNIV CAMBRIDGE, DEPT GENET, CAMBRIDGE, ENGLAND; RUSSIAN ACAD SCI, NK KOLTSOV DEV BIOL INST, MOSCOW 117808, RUSSIA	University of Cambridge; Russian Academy of Sciences	Kuzin, B (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.		Enikolopov, Grigori/P-5731-2019; Enikolopov, Grigori N/B-7771-2009	Enikolopov, Grigori/0000-0001-8178-8917; Enikolopov, Grigori N/0000-0001-8178-8917; Kuzin, Boris/0000-0001-9951-1553				BAKER NE, 1992, DEV BIOL, V150, P381, DOI 10.1016/0012-1606(92)90250-K; BLOTTNER D, 1995, HISTOCHEM J, V27, P785; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRYANT PJ, 1984, Q REV BIOL, V59, P387, DOI 10.1086/414040; BRYANT PJ, 1990, J CELL SCI, P169; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; Cohen Stephen M., 1993, P747; COLLINOSDOBY P, 1995, J CELL BIOCHEM, V57, P399, DOI 10.1002/jcb.240570305; CRAMER KS, 1995, J COMP NEUROL, V353, P306, DOI 10.1002/cne.903530211; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DECKER KF, 1995, J GASTROEN HEPATOL, V10, pS12, DOI 10.1111/j.1440-1746.1995.tb01789.x; ELLIS MC, 1993, DEVELOPMENT, V119, P855; FAIN MJ, 1982, DEV BIOL, V92, P247, DOI 10.1016/0012-1606(82)90169-5; Forstermann U, 1995, Adv Pharmacol, V34, P171; Fristrom D., 1993, DEV DROSOPHILA MELAN, P843; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GRAVES BJ, 1982, DEV BIOL, V93, P104, DOI 10.1016/0012-1606(82)90243-3; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HORTELANO S, 1995, HEPATOLOGY, V21, P776; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MISRA S, 1990, CELL, V62, P269, DOI 10.1016/0092-8674(90)90365-L; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULLER U, 1994, EUR J NEUROSCI, V6, P1362, DOI 10.1111/j.1460-9568.1994.tb00327.x; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; ROSKAMS AJ, 1994, NEURON, V13, P289; SCHUBIGER M, 1987, DEV BIOL, V123, P145, DOI 10.1016/0012-1606(87)90436-2; Shaul P W, 1995, Adv Pediatr, V42, P367; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPRADLING AC, 1986, DROSOPHILA PRACTICAL, P60; Thummel CS, 1992, DROS INF SERV, V71, P150; Wang Y, 1995, Adv Pharmacol, V34, P71; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WETTS R, 1995, DEV DYNAM, V202, P215, DOI 10.1002/aja.1002020302; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wolff Tanya, 1993, P1277	51	220	229	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1996	87	4					639	649		10.1016/S0092-8674(00)81384-7	http://dx.doi.org/10.1016/S0092-8674(00)81384-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929533	Bronze			2022-12-01	WOS:A1996VU03500007
J	Collman, JP; Fu, L; Herrmann, PC; Zhang, XM				Collman, JP; Fu, L; Herrmann, PC; Zhang, XM			A functional model related to cytochrome c oxidase and its electrocatalytic four-electron reduction of O-2	SCIENCE			English	Article							PROTON PUMP; DIOXYGEN; ISSUES	A cytochrome c oxidase model that consists of a cobalt(II) porphyrin with a copper(I) triazacyclononane macrocycle fastened on the distal face and an imidazole covalently attached to the proximal face has been synthesized and characterized. Redox titrations with molecular oxygen (O-2) and cobaltocene were carried out, and O-2 was found to bind irreversibly in a 1:1 ratio to the model compound. This O-2 adduct (a bridged peroxide) can be fully reduced to the deoxygenated form with four equivalents of cobaltocene. The model compound was adsorbed on an edge-plane graphite electrode, and rotating ring-disk voltammetry was used to monitor the electrocatalytic reduction of O-2. Four-electron reduction of O-2 was observed at physiological pH.			Collman, JP (corresponding author), STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305, USA.		Zhang, Xumu/K-8746-2013	Zhang, Xumu/0000-0001-5700-0608	NCRR NIH HHS [RR 04122] Funding Source: Medline; NIGMS NIH HHS [5R37 GM-17880-26] Funding Source: Medline; PHS HHS [CHE9123187-A2] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017880] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BLACKMORE RS, 1991, J BIOL CHEM, V266, P19245; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; COLLMAN JP, 1995, INORG CHEM, V34, P1311, DOI 10.1021/ic00110a006; COLLMAN JP, 1994, J AM CHEM SOC, V116, P2681, DOI 10.1021/ja00085a083; COLLMAN JP, 1994, ANGEW CHEM INT EDIT, V33, P1537, DOI 10.1002/anie.199415371; COLLMAN JP, UNPUB; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Jameson GB, 1996, METAL-CONTAINING POLYMERIC MATERIALS, P421; KOUTECKY J, 1958, ZH FIZ KHIM+, V32, P1565; MALMSTROM BG, 1990, ARCH BIOCHEM BIOPHYS, V280, P233, DOI 10.1016/0003-9861(90)90325-S; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; OGURA T, 1993, J AM CHEM SOC, V115, P8527, DOI 10.1021/ja00072a002; OLIVEBERG M, 1992, BIOCHEMISTRY-US, V31, P3560, DOI 10.1021/bi00129a002; PALMER G, 1993, J BIOENERG BIOMEMBR, V25, P145, DOI 10.1007/BF00762856; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; WOODRUFF WH, 1991, P NATL ACAD SCI USA, V88, P2588, DOI 10.1073/pnas.88.6.2588; [No title captured]	20	171	173	4	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					949	951		10.1126/science.275.5302.949	http://dx.doi.org/10.1126/science.275.5302.949			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020071				2022-12-01	WOS:A1997WH38800036
J	Nakano, N; Rooke, R; Benoist, C; Mathis, D				Nakano, N; Rooke, R; Benoist, C; Mathis, D			Positive selection of T cells induced by viral delivery of neopeptides to the thymus	SCIENCE			English	Article							INVARIANT CHAIN; RECEPTOR REPERTOIRE; NEGATIVE SELECTION; ANTIGEN; PEPTIDE; MICE; RECOGNITION; LIGANDS; LYMPHOCYTES; SPECIFICITY	The relation between an antigenic peptide that can stimulate a mature T cell and the natural peptide that promoted selection of this cell in the thymus is still unknown. An experimental system was devised to address this issue in vivo-mice expressing neopeptides in thymic stromal cells after adenovirus-mediated delivery of invariant chain-peptide fusion proteins. In this system, selection of T cells capable of responding to a given antigenic peptide could be promoted by the peptide itself, by closely related analogs lacking agonist and antagonist activity, or by ostensibly unrelated peptides. However, the precise repertoire of T cells selected was dictated by the particular neopeptide expressed.			Nakano, N (corresponding author), UNIV STRASBOURG 1,CU STRASBOURG,INSERM,CNRS,INST GENET & BIOL MOL CELLULAIRE,1 RUE LAURENT FRIES,F-67404 ILLKIRCH GRAFFENS,FRANCE.							ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; CANDEIAS S, 1991, P NATL ACAD SCI USA, V88, P6167, DOI 10.1073/pnas.88.14.6167; CASANOVA JL, 1993, IMMUNOL TODAY, V14, P391, DOI 10.1016/0167-5699(93)90140-G; COCHET M, 1992, EUR J IMMUNOL, V22, P2639, DOI 10.1002/eji.1830221025; EVAVOLD BD, 1995, IMMUNITY, V2, P655, DOI 10.1016/1074-7613(95)90010-1; FINK PJ, 1990, J EXP MED, V172, P139, DOI 10.1084/jem.172.1.139; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; HEDRICK SM, 1988, SCIENCE, V239, P1541, DOI 10.1126/science.2832942; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1995, IMMUNITY, V3, P79, DOI 10.1016/1074-7613(95)90160-4; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; JAMESON SC, 1994, NATURE, V369, P750, DOI 10.1038/369750a0; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; Kaye J, 1991, Semin Immunol, V3, P269; KOOP BF, 1994, GENOMICS, V19, P478, DOI 10.1006/geno.1994.1097; LIANG HE, 1994, EUR J IMMUNOL, V24, P1604, DOI 10.1002/eji.1830240723; Martin WD, 1996, CELL, V84, P543, DOI 10.1016/S0092-8674(00)81030-2; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; NAKANO N, UNPUB; NANDA NK, 1995, J EXP MED, V182, P531, DOI 10.1084/jem.182.2.531; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; Oehen S, 1996, J EXP MED, V183, P2617, DOI 10.1084/jem.183.6.2617; Pawlowski TJ, 1996, EUR J IMMUNOL, V26, P851, DOI 10.1002/eji.1830260419; ROOKE R, UNPUB; SANDERSON S, 1995, P NATL ACAD SCI USA, V92, P7217, DOI 10.1073/pnas.92.16.7217; SCHUMACHER TNM, 1994, IMMUNITY, V1, P721, DOI 10.1016/S1074-7613(94)80013-8; Sebzda E, 1996, J EXP MED, V183, P1093, DOI 10.1084/jem.183.3.1093; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; TOURNE S, 1995, EUR J IMMUNOL, V25, P1851, DOI 10.1002/eji.1830250709; TOURNE S, UNPUB; VANSANTEN HM, 1995, J EXP MED, V181, P787, DOI 10.1084/jem.181.2.787; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	40	98	100	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					678	683		10.1126/science.275.5300.678	http://dx.doi.org/10.1126/science.275.5300.678			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005856				2022-12-01	WOS:A1997WF07700043
J	Moayyedi, P; Carter, AM; Catto, A; Heppell, RM; Grant, PJ; Axon, ATR				Moayyedi, P; Carter, AM; Catto, A; Heppell, RM; Grant, PJ; Axon, ATR			Validation of a rapid whole blood test for diagnosing Helicobacter pylori infection	BRITISH MEDICAL JOURNAL			English	Article							SEROLOGY		UNIV LEEDS,RES SCH MED,UNIT MOL VASC MED,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds	Moayyedi, P (corresponding author), GEN INFIRM,CTR DIGEST DIS,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.		Moayyedi, Paul/M-6178-2014	Moayyedi, Paul/0000-0002-3616-9292; Catto, Andrew/0000-0002-5934-3054				GLUPCZYNSKI Y, 1993, ZBL BAKT-INT J MED M, V280, P150, DOI 10.1016/S0934-8840(11)80951-5; MOAYYEDI P, 1994, LANCET, V344, P1016; SOBALA GM, 1991, LANCET, V338, P94, DOI 10.1016/0140-6736(91)90085-4	3	67	67	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					119	119		10.1136/bmj.314.7074.119	http://dx.doi.org/10.1136/bmj.314.7074.119			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006471	Green Published			2022-12-01	WOS:A1997WC47900025
J	Troop, P				Troop, P			More resources, better survival?	LANCET			English	Editorial Material							CARDIOGENIC-SHOCK; TRIAL				Troop, P (corresponding author), NHS EXECUT ANGLIA & OXFORD,MILTON KEYNES MK14 6QP,BUCKS,ENGLAND.							HOCHMAN JS, 1995, CIRCULATION, V91, P873, DOI 10.1161/01.CIR.91.3.873; HOLMES DR, 1995, J AM COLL CARDIOL, V26, P668, DOI 10.1016/0735-1097(95)00215-P; VANDEWERF F, 1995, JAMA-J AM MED ASSOC, V273, P1586, DOI 10.1001/jama.273.20.1586	3	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					72	72		10.1016/S0140-6736(05)60879-3	http://dx.doi.org/10.1016/S0140-6736(05)60879-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996413				2022-12-01	WOS:A1997WB80000004
J	Davis, S; Aldrich, TH; Jones, PF; Acheson, A; Compton, DL; Jain, V; Ryan, TE; Bruno, J; Radziejewski, C; Maisonpierre, PC; Yancopoulos, GD				Davis, S; Aldrich, TH; Jones, PF; Acheson, A; Compton, DL; Jain, V; Ryan, TE; Bruno, J; Radziejewski, C; Maisonpierre, PC; Yancopoulos, GD			Isolation of Angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning	CELL			English	Article							ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE GENES; VASCULAR ENDOTHELIUM; MOLECULAR-CLONING; TEK; PROTEIN; FAMILY; CELLS; VASCULOGENESIS; ANGIOGENESIS	TIE2 is a receptor-like tyrosine kinase expressed almost exclusively in endothelial cells and early hemopoietic cells and required for the normal development of vascular structures during embryogenesis. We report the identification of a secreted ligand for TIE2, termed Angiopoietin-1, using a novel expression cloning technique that involves intracellular trapping and detection of the ligand in COS cells. The structure of Angiopoietin-1 differs from that of known angiogenic factors or other ligands for receptor tyrosine kinases. Although Angiopoietin-1 binds and induces the tyrosine phosphorylation of TIE2, it does not directly promote the growth of cultured endothelial cells. However, its expression in close proximity with developing blood vessels implicates Angiopoietin-1 in endothelial developmental processes.			Davis, S (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.							Batard P, 1996, BLOOD, V87, P2212, DOI 10.1182/blood.V87.6.2212.bloodjournal8762212; BURROWS FJ, 1994, PHARMACOL THERAPEUT, V64, P155, DOI 10.1016/0163-7258(94)90037-X; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FERRARA N, 1995, ANN NY ACAD SCI, V752, P246, DOI 10.1111/j.1749-6632.1995.tb17435.x; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hashiyama M, 1996, BLOOD, V87, P93; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KAIPAINEN A, 1994, CANCER RES, V54, P6571; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; Luckow VA, 1992, BACULOVIRUS EXPRESSI; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W., 1991, DEV VASCULAR SYSTEM, P58; Rodewald HR, 1996, ONCOGENE, V12, P397; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; ZIEGLER SF, 1993, ONCOGENE, V8, P663	37	1568	1739	0	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1161	1169		10.1016/S0092-8674(00)81812-7	http://dx.doi.org/10.1016/S0092-8674(00)81812-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980223	Bronze			2022-12-01	WOS:A1996WA54100005
J	Fambrough, D; Goodman, CS				Fambrough, D; Goodman, CS			The Drosophila beaten path gene encodes a novel secreted protein that regulates defasciculation at motor axon choice points	CELL			English	Article							GROWTH CONE GUIDANCE; FASCICLIN-II; ADHESION MOLECULE; POLYSIALIC ACID; NEURONAL DEVELOPMENT; GRASSHOPPER EMBRYOS; EXPRESSION; NCAM; MOTONEURONS; OUTGROWTH	In the Drosophila embryo, at specific choice points along the major motor nerves, subsets of motor axons defasciculate and then steer into their muscle target regions. Here we describe the analysis of beaten path (beat), a gene required for the selective defasciculation of motor axons at these choice points. In beat mutant embryos, motor axons fail to defasciculate and bypass their targets. This phenotype is suppressed by mutations in FasII and conn, two genes encoding cell adhesion molecules expressed on motor axons, suggesting that beat provides an antiadhesive function. beat encodes a novel secreted protein that is expressed by motoneurons during outgrowth. Rescue and ectopic expression experiments support the model that Beat protein is secreted by motor axons where it functions to regulate their selective defasciculation at specific choice points.			Fambrough, D (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720, USA.							ASHBURNER M, 1990, GENETICS, V126, P679; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BASTIANI MJ, 1984, J NEUROSCI, V4, P2311; BRAND AH, 1993, DEVELOPMENT, V118, P401; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; GREENINGLOH G, 1991, CELL, V67, P45; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; RAPER JA, 1984, J NEUROSCI, V4, P2329; RUTISHAUSER U, 1991, TRENDS NEUROSCI, V14, P528, DOI 10.1016/0166-2236(91)90006-G; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; TANG J, 1992, NEURON, V8, P1031, DOI 10.1016/0896-6273(92)90125-W; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; XU Y, 1995, NEURAL BIOL SYSTEMS, P128; YANG PF, 1992, J CELL BIOL, V116, P1487, DOI 10.1083/jcb.116.6.1487; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	31	105	105	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1049	1058		10.1016/S0092-8674(00)81799-7	http://dx.doi.org/10.1016/S0092-8674(00)81799-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978609	Bronze			2022-12-01	WOS:A1996VY44700010
J	Thompson, MS				Thompson, MS			Contraceptive implants: Long acting and provider dependent contraception raises concerns about freedom of choice	BMJ-BRITISH MEDICAL JOURNAL			English	Article								David Bromham's editorial on contraceptive implants ignores the wider issues to voice concern that trial by media could limit contraceptive choice by jeopardising research into new methods. However, it is more beneficial to the public for points of conflict to be debated openly. Furthermore, the impetus for research into new contraceptive technology is driven by profit and political motives and is only marginally affected by the media. Implanted contraceptives may increase the choice of contraceptive methods, but they put control of fertility increasingly into the hands of the medical profession. Herein lies their greatest problem: their potential to increase providers' control over clients) choice. There is the danger that certain groups of women may be targeted for their use: in the United States the coercive use of Norplant for mothers receiving welfare benefit has been suggested. Long acting contraceptives are a contraceptive of choice only when they are available without pressure, as part of a wider menu; when instant removal on request is guaranteed; and when there is an open and free flow of information and opinions between users, health professionals, and special interest groups.	UNIV DURHAM, DURHAM DH1 3HP, ENGLAND	Durham University								Bromham DR, 1996, BRIT MED J, V312, P1555, DOI 10.1136/bmj.312.7046.1555; COCKBURN A, 1994, NATION          0725, P116; DUNN CDR, 1993, SCRIPS 1993 REV FERT; FRASER IS, 1989, CONTRACEPTION SCI PR, P109; GARCIA G, 1992, WOMENS PERSPECTIVES, P29; Hardee K., 1994, International Family Planning Perspectives, V20, P59, DOI 10.2307/2133436; HARTMANN B, 1995, REPRODUCTIVE RIGHTS; MORSY S, 1993, NORPLANT HER SKIN, P89; ODLIND V, 1986, ACTA OBSTET GYN SCAN, P15; OLLILA E, 1993, NORPLANT SKIN, P47; WHELAN R, 1992, CHOICES CHILDBEARING; ZIMMERMAN M, 1990, STUD FAMILY PLANN, V21, P92, DOI 10.2307/1966670; 1993, CONTRACEPTIVE TECHNO, V14, P149	13	9	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	1996	313	7069					1393	1395		10.1136/bmj.313.7069.1393	http://dx.doi.org/10.1136/bmj.313.7069.1393			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VW685	8956712	Green Published			2022-12-01	WOS:A1996VW68500039
J	Kouskoff, V; Korganow, AS; Duchatelle, V; Degott, C; Benoist, C; Mathis, D				Kouskoff, V; Korganow, AS; Duchatelle, V; Degott, C; Benoist, C; Mathis, D			Organ-specific disease provoked by systemic autoimmunity	CELL			English	Article							FIBROBLAST-LIKE SYNOVIOCYTES; TUMOR-NECROSIS-FACTOR; CLASS-II MOLECULES; T-CELL; RHEUMATOID-ARTHRITIS; TRANSGENIC MICE; GENE-EXPRESSION; INDUCTION; ANTIGEN; MOUSE	Rheumatoid arthritis (RA) is a chronic joint disease characterized by leukocyte invasion and synoviocyte activation followed by cartilage and bone destruction. Its etiology and pathogenesis are poorly understood. We describe a spontaneous mouse model of this syndrome, generated fortuitously by crossing a T cell receptor (TCR) transgenic line with the NOD strain. All offspring develop a joint disease highly reminiscent of RA in man. The trigger for the murine disorder is chance recognition of a NOD-derived major histocompatibility complex (MHC) class II molecule by the transgenic TCR; progression to arthritis involves CD4+ T, B, and probably myeloid cells. Thus, a joint-specific disease need not arise from response to a joint-specific antigen but can be precipitated by a breakdown in general mechanisms of self-tolerance resulting in systemic self-reactivity. We suggest that human RA develops by an analogous mechanism.	HOP BEAUJON,SERV ANAT PATHOL,F-92110 CLICHY,FRANCE; ULP,INSERM,CNRS,INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)				Korganow, Anne-Sophie/0000-0002-1664-6311				ALVAROGRACIA JM, 1989, J EXP MED, V170, P865, DOI 10.1084/jem.170.3.865; ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; CANDEIAS S, 1991, P NATL ACAD SCI USA, V88, P6167, DOI 10.1073/pnas.88.14.6167; COBBOLD SP, 1990, EUR J IMMUNOL, V20, P2747, DOI 10.1002/eji.1830201232; COLE BC, 1995, MECH MODELS RHEUMATO, P47; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DAVIDAMELINE J, 1996, IN PRESS SELECTION T; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Henderson B., 1995, MECH MODELS RHEUMATO; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IVANOV V, 1993, J IMMUNOL, V151, P4694; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOUSKOFF V, 1995, J IMMUNOL METHODS, V180, P273, DOI 10.1016/0022-1759(95)00002-R; KOUSKOFF V, 1994, THESIS U L PASTEUR S; KRAAL G, 1986, IMMUNOLOGY, V58, P665; MEHINDATE K, 1994, J BIOL CHEM, V269, P32063; MILLER JFAP, 1992, ANNU REV IMMUNOL, V10, P51, DOI 10.1146/annurev.iy.10.040192.000411; MOURAD W, 1992, J EXP MED, V175, P613, DOI 10.1084/jem.175.2.613; NORDLING C, 1992, ARTHRITIS RHEUM, V35, P717, DOI 10.1002/art.1780350619; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; Schmidt D, 1996, J CLIN INVEST, V97, P2027, DOI 10.1172/JCI118638; SCOTET E, 1996, IN PRESS J EXP MED; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; TREDE NS, 1991, J IMMUNOL, V146, P2310; WANG B, 1996, J EXP MED, V183, P1; WICKER LS, 1995, ANNU REV IMMUNOL, V13, P179, DOI 10.1146/annurev.iy.13.040195.001143; WORDSWORTH P, 1992, CURR OPIN IMMUNOL, V4, P766, DOI 10.1016/0952-7915(92)90059-N	33	685	725	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					811	822		10.1016/S0092-8674(00)81989-3	http://dx.doi.org/10.1016/S0092-8674(00)81989-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945509	Bronze			2022-12-01	WOS:A1996VV77400008
J	Thomas, HC; Foster, GR; Sumiya, M; McIntosh, D; Jack, DL; Turner, MW; Summerfield, JA				Thomas, HC; Foster, GR; Sumiya, M; McIntosh, D; Jack, DL; Turner, MW; Summerfield, JA			Mutation of gene for mannose-binding protein associated with chronic hepatitis B viral infection	LANCET			English	Article							MANNAN; ACTIVATION; OPSONIN; ANTIGEN; ALLELE; LEVEL	Background Persistent infection with hepatitis B virus (HBV) affects 350 million people worldwide, and 20-40% of infected patients die of cirrhosis and liver cancer. Little is known about the host factors that determine the variable natural history. Studies have focused on the role of acquired rather than innate immunity. We have investigated the prevalence of mutations in the gene for mannose-binding protein (MBP), which have been associated with susceptibility to bacterial and fungal infections. Methods Mutations in the MBP gene were sought by sequence-specific oligonucleotide hybridisation, site-directed mutagenesis polymerase chain amplification, and direct sequencing in Caucasian and Asian patients with HBV infection, and in HBsAg-negative controls. Findings A mutation in codon 52 of the MBP gene was present in two (11%) of 19 Caucasian patients with acute hepatitis B and nine (27%) of 33 Caucasian patients with chronic hepatitis B, compared with four (4%) of 98 Caucasian controls (p=0.0004). By contrast, the prevalence of the mutation was similar in Asian patients with chronic hepatitis B and in Asian controls (one [5%] of 20 vs two [2%] of 117). Mutations in codon 54 and codon 57 were found in similar proportions of patients and controls. Interpretation These findings show in Caucasian, but not Asian, patients an association of the codon 52 mutation of the MBP gene with persistent HBV infection. They suggest an important role for this gene, or a gene in linkage disequilibrium with MBP, in determining outcome after HBV infection in adult but not neonatal life.	INST CHILD HLTH, IMMUNOBIOL UNIT, LONDON, ENGLAND	University of London; University College London	Thomas, HC (corresponding author), ST MARYS HOSP, IMPERIAL COLL,SCH MED,DEPT MED,LIVER UNIT, QEQM WING, LONDON W2 1PG, ENGLAND.		Thomas, Howard C/A-3152-2009	Foster, Graham/0000-0002-3704-386X				CARMAN WF, 1989, LANCET, V2, P588; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; GERLICH W, 1993, VIRAL HEPATITIS, P93; HARTSHORN KL, 1993, J CLIN INVEST, V91, P1414, DOI 10.1172/JCI116345; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; Lipscombe RJ, 1996, EUR J HUM GENET, V4, P13; MADSEN HO, 1995, J IMMUNOL, V155, P3013; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; MALHOTRA R, 1993, BIOCHEM J, V293, P15, DOI 10.1042/bj2930015; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; MILICH DR, 1990, P NATL ACAD SCI USA, V87, P6599, DOI 10.1073/pnas.87.17.6599; MUNOZ L, 1989, THESIS U LONDON, P89; OHTA M, 1990, J BIOL CHEM, V265, P1980; SHERLOCK S, 1993, VIRAL HEPATITIS, P1; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; SUPER M, 1990, CLIN EXP IMMUNOL, V79, P144; TAYLOR ME, 1989, BIOCHEM J, V262, P763, DOI 10.1042/bj2620763; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; WORDSWORTH BP, 1990, IMMUNOGENETICS, V32, P413	21	110	121	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	1996	348	9039					1417	1419		10.1016/S0140-6736(96)05409-8	http://dx.doi.org/10.1016/S0140-6736(96)05409-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8965590				2022-12-01	WOS:A1996VU98600013
J	Lorenz, RD; McKay, CP; Lunine, JI				Lorenz, RD; McKay, CP; Lunine, JI			Photochemically driven collapse of Titan's atmosphere	SCIENCE			English	Article							SURFACE; MODEL; EQUILIBRIUM; CLIMATE; LIQUID; MARS	Saturn's giant moon Titan has a thick (1.5 bar) nitrogen atmosphere, which has a temperature structure that is controlled by the absorption of solar and thermal radiation by methane, hydrogen, and organic aerosols into which methane is irreversibly converted by photolysis. Previous studies of Titan's climate evolution have been done with the assumption that the methane abundance was maintained against photolytic depletion throughout Titan's history, either by continuous supply from the interior or by buffering by a surface or near surface reservoir. Radiative-convective and radiative-saturated equilibrium models of Titan's atmosphere show that methane depletion may have allowed Titan's atmosphere to cool so that nitrogen, its main constituent, condenses onto the surface, collapsing Titan into a Triton-like frozen state with a thin atmosphere.	NASA,AMES RES CTR,MOFFETT FIELD,CA 94035	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Lorenz, RD (corresponding author), UNIV ARIZONA,DEPT PLANETARY SCI,LUNAR & PLANETARY LAB,TUCSON,AZ 85721, USA.		Lorenz, Ralph D/B-8759-2016	Lorenz, Ralph D/0000-0001-8528-4644				BERTAUX JL, 1983, J GEOPHYS RES-SPACE, V88, P8716, DOI 10.1029/JA088iA11p08716; COUSTENIS A, 1995, ICARUS, V118, P87, DOI 10.1006/icar.1995.1179; DEMOTT SF, 1995, NATURE, V374, P238; DUBOULOZ N, 1989, ICARUS, V82, P81, DOI 10.1016/0019-1035(89)90025-0; ENGEL S, 1995, PLANET SPACE SCI, V43, P1059, DOI 10.1016/0032-0633(95)00044-6; GIERASCH PJ, 1973, J ATMOS SCI, V30, P1502, DOI 10.1175/1520-0469(1973)030<1502:APVATC>2.0.CO;2; GRIFFITH CA, 1991, ICARUS, V93, P362, DOI 10.1016/0019-1035(91)90219-J; KASTING JF, 1991, ICARUS, V94, P1, DOI 10.1016/0019-1035(91)90137-I; KOUVARIS LC, 1991, ICARUS, V91, P112, DOI 10.1016/0019-1035(91)90131-C; LARA LM, 1994, PLANET SPACE SCI, V42, P5, DOI 10.1016/0032-0633(94)90135-X; LEMMON MT, 1995, ICARUS, V113, P27, DOI 10.1006/icar.1995.1003; Lorenz RD, 1995, J GEOPHYS RES-PLANET, V100, P26377, DOI 10.1029/95JE02708; LORENZ RD, 1993, PLANET SPACE SCI, V41, P647, DOI 10.1016/0032-0633(93)90048-7; Lorenz RD, 1996, PLANET SPACE SCI, V44, P1021, DOI 10.1016/0032-0633(95)00139-5; LORENZ RD, 1994, PLANET SPACE SCI, V42, P1, DOI 10.1016/0032-0633(94)90134-1; Lorenz RD, 1996, ICARUS, V122, P79, DOI 10.1006/icar.1996.0110; LUNINE JI, 1985, NATURE, V317, P238, DOI 10.1038/317238a0; LUNINE JI, 1989, ICARUS, V80, P370, DOI 10.1016/0019-1035(89)90147-4; McIlveen R., 1992, FUNDAMENTALS WEATHER; MCKAY CP, 1991, SCIENCE, V253, P1118, DOI 10.1126/science.11538492; MCKAY CP, 1989, ICARUS, V80, P23, DOI 10.1016/0019-1035(89)90160-7; MCKAY CP, 1993, ICARUS, V102, P88, DOI 10.1006/icar.1993.1034; MORRISON D, 1986, SATELLITES, P764; MUHLEMAN DO, 1990, SCIENCE, V248, P975, DOI 10.1126/science.248.4958.975; SAMUELSON RE, 1983, ICARUS, V53, P364, DOI 10.1016/0019-1035(83)90156-2; Smith PH, 1996, ICARUS, V119, P336, DOI 10.1006/icar.1996.0023; THOMPSON WR, 1992, ICARUS, V97, P187, DOI 10.1016/0019-1035(92)90127-S; TOON OB, 1992, ICARUS, V95, P24, DOI 10.1016/0019-1035(92)90188-D; TOUBLANC D, 1995, ICARUS, V113, P2, DOI 10.1006/icar.1995.1002; YUNG YL, 1984, ASTROPHYS J SUPPL S, V55, P465, DOI 10.1086/190963	30	76	76	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					642	644		10.1126/science.275.5300.642	http://dx.doi.org/10.1126/science.275.5300.642			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005844				2022-12-01	WOS:A1997WF07700031
J	Williams, DM; Kasting, JF; Wade, RA				Williams, DM; Kasting, JF; Wade, RA			Habitable moons around extrasolar giant planets	NATURE			English	Article							MARS; ATMOSPHERE; COMPANION; CONSTRAINTS; TITANS	Possible planetary objects have now been discovered(1-9) orbiting nine different main-sequence stars. These companion objects (some of which might actually be brown dwarfs) all have a mass at least half that of Jupiter, and are therefore unlikely to be hospitable to Earth-like Life: jovian planets and brown dwarfs support neither a solid nor a liquid surface near which organisms might dwell. Here we argue that redry moons orbiting these companions could be habitable if the planet-moon system orbits the parent star within the so-called 'habitable zone'(10), where life- supporting liquid water(11) could be present. The companions to the stars 16 Cygni B and 47 Ursae Majoris might satisfy this criterion. Such a moon would, however, need to be large enough (>0.12 Earth masses) to retain a substantial and long-lived atmosphere, and would also need to possess a strong magnetic field in order to prevent its atmosphere from being sputtered away by the constant bombardment of energetic ions from the planet's magnetosphere.	PENN STATE UNIV, DEPT GEOSCI, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Williams, DM (corresponding author), PENN STATE UNIV, DEPT ASTRON & ASTROPHYS, 525 DAVEY LAB, UNIVERSITY PK, PA 16802 USA.		Kasting, James/AAF-6851-2020					Boss AP, 1996, NATURE, V379, P397, DOI 10.1038/379397a0; BRACK A, 1993, ORIGINS LIFE EVOL B, V23, P3, DOI 10.1007/BF01581985; Butler RP, 1996, ASTROPHYS J, V464, pL153, DOI 10.1086/310102; BUTLER RP, UNPUB ASTROPHYS J; CHYBA CF, 1990, NATURE, V343, P129, DOI 10.1038/343129a0; COCHRAN WD, 1991, ASTROPHYS J, V380, pL35; Cochran WD., 1996, B AM ASTRON SOC, V28, P1111; FOX JL, 1993, J GEOPHYS RES-PLANET, V98, P3297, DOI 10.1029/92JE02289; FRANCIS PW, 1982, J GEOPHYS RES, V87, P9881, DOI 10.1029/JB087iB12p09881; Gatewood G., 1996, B AM ASTRON SOC, V28, P885; GRIFFITH CA, 1995, J GEOPHYS RES-PLANET, V100, P16907, DOI 10.1029/95JE01135; Gurnett DA, 1996, NATURE, V384, P535, DOI 10.1038/384535a0; KASS DM, 1995, SCIENCE, V268, P697, DOI 10.1126/science.7732377; KASTING JF, 1988, SCI AM, V258, P90, DOI 10.1038/scientificamerican0288-90; KASTING JF, 1993, ICARUS, V101, P1; Kivelson MG, 1996, NATURE, V384, P537, DOI 10.1038/384537a0; LATHAM DW, 1989, NATURE, V339, P38, DOI 10.1038/339038a0; Lin DNC, 1996, NATURE, V380, P606, DOI 10.1038/380606a0; Marcy GW, 1996, ASTROPHYS J, V464, pL147, DOI 10.1086/310096; MARCY GW, UNPUB ASTROPHYS J; MAYOR M, 1995, NATURE, V378, P355, DOI 10.1038/378355a0; MCELROY MB, 1972, SCIENCE, V175, P443, DOI 10.1126/science.175.4020.443; MCKAY CP, 1991, NATURE, V352, P489, DOI 10.1038/352489a0; Peale S.J, 1977, IAU C 28 PLANETARY S, P87; PEALE SJ, 1979, SCIENCE, V203, P892, DOI 10.1126/science.203.4383.892; PRINN RG, 1981, ASTROPHYS J, V249, P308, DOI 10.1086/159289; Rasio FA, 1996, SCIENCE, V274, P954, DOI 10.1126/science.274.5289.954; ROY AE, 1988, ORBITAL MOTION, P239; Saumon D, 1996, ASTROPHYS J, V460, P993, DOI 10.1086/177027; SOLOMON SC, 1990, J GEOPHYS RES-SOLID, V95, P11073, DOI 10.1029/JB095iB07p11073; STROBEL DF, 1992, ICARUS, V100, P512, DOI 10.1016/0019-1035(92)90114-M; Turcotte DL, 1996, J GEOPHYS RES-PLANET, V101, P4765, DOI 10.1029/95JE02295; TURCOTTE DL, 1982, GEODYNAMICS APPL CON, P137; VANALLEN JA, 1976, JUPITER; WALKER JCG, 1981, J GEOPHYS RES-OCEANS, V86, P9776, DOI 10.1029/JC086iC10p09776; WATSON A, 1978, BIOSYSTEMS, V10, P293, DOI 10.1016/0303-2647(78)90012-6	36	157	158	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1997	385	6613					234	236		10.1038/385234a0	http://dx.doi.org/10.1038/385234a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000072				2022-12-01	WOS:A1997WC71100040
J	Farmer, RDT; Lawrenson, RA; Thompson, CR; Kennedy, JG; Hambleton, IR				Farmer, RDT; Lawrenson, RA; Thompson, CR; Kennedy, JG; Hambleton, IR			Population-based study of risk of venous thromboembolism associated with various oral contraceptives	LANCET			English	Article							PROGESTAGEN; WOMEN	Background Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens. However, confounding and bias in the design of these studies may have affected the findings. The aim of our study was to re-examine the association between risk of VTE and OC use with a different study design and analysis to avoid some of the bias and confounding of the earlier studies. Methods We used computer records of patients from 143 general practices in the UK. The study was based on the medical records of about 540000 women born between 1941 and 1981. All women who had a recorded diagnosis of deep-vein thrombosis, venous thrombosis not otherwise specified, or pulmonary embolus during the study period, and who had been treated with an anticoagulant were identified as potential cases of VTE. We did a cohort analysis to estimate and compare incidence of VTE in users of the main OC preparations, and a nested case-control study to calculate the odds ratios of VTE associated with use of different types of OC, after adjustment for potential confounding factors. In the case-control study, we matched cases to controls by exact year of birth, practice, and current use of OCs. We used a multiple logistic regression model that included body-mass index, number of cycles, change in type of OC prescribed within 3 months of the event, previous pregnancy, and concurrent disease. Findings 85 women met the inclusion criteria for VTE, two of whom were users of progestagen-onyy OCs. Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified. The crude rate of VTE per 10000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol. With all second-generation OCs as the reference, the odds ratios for VTE were 3.49 (1.21-10.12) for desogestrel plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation progestagens. Interpretation The previously reported increase in odds ratio associated with third-generation OCs when compared with second-generation products is likely to have been the result of residual confounding by age. The increased odds ratio associated with products containing 20 mu g ethinyloestradiol and desogestrel compared with the 30 mu g product is biologically implausible, and is likely to be the result of preferential prescribing and, thus, confounding.			Farmer, RDT (corresponding author), UNIV LONDON,CHELSEA & WESTMINSTER HOSP,CHARING CROSS & WESTMINSTER MED SCH,LONDON SW10 9NH,ENGLAND.		Hambleton, Ian/AAP-3519-2020	Hambleton, Ian/0000-0002-5638-9794				ARRIGHI HM, 1994, EPIDEMIOLOGY, V5, P189, DOI 10.1097/00001648-199403000-00009; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; *COMM SAF MED, 1995, COMB OR CONTR THROMB; Farmer R. D. T., 1995, Journal of Obstetrics and Gynaecology (Abingdon), V15, P195, DOI 10.3109/01443619509015499; FORD BL, 1983, INCOMPLETE DATA SAMP, P185; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; HELMRICH SP, 1987, OBSTET GYNECOL, V69, P91; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; Lewis MA, 1996, CONTRACEPTION, V54, P5, DOI 10.1016/0010-7824(96)00112-6; Lidegaard O, 1996, CONTRACEPTION, V53, P135, DOI 10.1016/0010-7824(96)00035-2; Lis Y, 1993, PHARMACOEPIDEM DR S, V2, P51; MACRAE K, 1995, BRIT MED J, V311, P11; Sande IG, 1983, INCOMPLETE DATA SAMP, V3, P334; Spitzer WO, 1996, BRIT MED J, V312, P83; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; VESSEY M, 1986, BRIT MED J, V292, P302; WATT AH, 1995, LANCET, V346, P1430, DOI 10.1016/S0140-6736(95)92446-9; *WHO COLL STUD CAR, 1995, LANCET, V346, P1582; 1995, NATURE, V377, P663	19	288	289	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					83	88		10.1016/S0140-6736(96)07496-X	http://dx.doi.org/10.1016/S0140-6736(96)07496-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996419				2022-12-01	WOS:A1997WB80000010
J	Mahajan, R; Delphin, C; Guan, TL; Gerace, L; Melchior, F				Mahajan, R; Delphin, C; Guan, TL; Gerace, L; Melchior, F			A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2	CELL			English	Article							RNA1 GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; TRANSPORT FACTORS; RCC1 PROTEIN; IMPORT; RAN/TC4; GTP; IDENTIFICATION; ENCODES	We have found that the mammalian Ran GTPase-activating protein RanGAP1 is highly concentrated at the cytoplasmic periphery of the nuclear pore complex (NPC), where it associates with the 358-kDa Ran-GTP-binding protein RanBP2. This interaction requires the ATP-dependent posttranslational conjugation of RanGAP1 with SUMO-1 (for small ubiquitin-related modifier), a novel protein of 101 amino acids that contains low but significant homology to ubiquitin. SUMO-1 appears to represent the prototype for a novel family of ubiquitin-related protein modifiers. Inhibition of nuclear protein import resulting from antibodies directed at NPC-associated RanGAP1 cannot be overcome by soluble cytosolic RanGAP1, indicating that GTP hydrolysis by Ran at RanBP2 is required for nuclear protein import.			Mahajan, R (corresponding author), Scripps Res Inst, DEPT CELL BIOL, 10555 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Melchior, Frauke/E-2014-2014; Christian, Delphin/P-9284-2017	Melchior, Frauke/0000-0001-9546-8797; Christian, Delphin/0000-0003-3240-8695				Bastos R, 1995, INT REV CYTOL, V162B, P257; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DEGREGORI J, 1994, GENE DEV, V8, P265, DOI 10.1101/gad.8.3.265; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Mannen H, 1996, BIOCHEM BIOPH RES CO, V222, P178, DOI 10.1006/bbrc.1996.0717; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; Pante N, 1996, SCIENCE, V273, P1729, DOI 10.1126/science.273.5282.1729; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; SAITOH H, 1995, J BIOL CHEM, V270, P10658, DOI 10.1074/jbc.270.18.10658; Saitoh H, 1996, MOL BIOL CELL, V7, P1319, DOI 10.1091/mbc.7.9.1319; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; SWEET DJ, 1995, TRENDS CELL BIOL, V5, P444, DOI 10.1016/S0962-8924(00)89108-4; TRAGLIA HM, 1989, MOL CELL BIOL, V9, P2989, DOI 10.1128/MCB.9.7.2989; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	45	932	976	2	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1997	88	1					97	107		10.1016/S0092-8674(00)81862-0	http://dx.doi.org/10.1016/S0092-8674(00)81862-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019411	Bronze			2022-12-01	WOS:A1997WC56900013
J	Markram, H; Lubke, J; Frotscher, M; Sakmann, B				Markram, H; Lubke, J; Frotscher, M; Sakmann, B			Regulation of synaptic efficacy by coincidence of postsynaptic APs and EPSPs	SCIENCE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPUS; NEURONS	Activity-driven modifications in synaptic connections between neurons in the neocortex may occur during development and learning. In dual whole-cell voltage recordings from pyramidal neurons, the coincidence of postsynaptic action potentials (APs) and unitary excitatory postsynaptic potentials (EPSPs) was found to induce changes in EPSPs. Their average amplitudes were differentially up- or down-regulated, depending on the precise timing of postsynaptic APs relative to EPSPs. These observations suggest that APs propagating back into dendrites serve to modify single active synaptic connections, depending on the pattern of electrical activity in the pre- and postsynaptic neurons.	MAX PLANCK INST MED RES,ZELLPHYSIOL ABT,D-69120 HEIDELBERG,GERMANY; UNIV FREIBURG,INST ANAT,D-79104 FREIBURG,GERMANY	Max Planck Society; University of Freiburg			Lubke, Joachim/H-8762-2013	Lubke, Joachim/0000-0002-4086-3199				BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; FOX K, 1995, NEURON, V15, P485, DOI 10.1016/0896-6273(95)90136-1; FRIEDLANDER MJ, 1990, J NEUROSCI, V10, P814; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; HEBB DO, 1949, ORG BEHAVIOR; Helmchen F, 1996, BIOPHYS J, V70, P1069, DOI 10.1016/S0006-3495(96)79653-4; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; MARKRAM H, 1995, J PHYSIOL-LONDON, V485, P1; MARKRAM H, IN PRESS J PHYSL; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; SCHILLER J, 1995, J PHYSIOL-LONDON, V487, P583, DOI 10.1113/jphysiol.1995.sp020902; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.ph.55.030193.002025; STANTON PK, 1989, NATURE, V339, P215, DOI 10.1038/339215a0; Stricker C, 1996, J PHYSIOL-LONDON, V490, P443, DOI 10.1113/jphysiol.1996.sp021156; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; TALBOT MJ, 1996, J NEUROPHYSIOL, V70, P2120	19	2603	2665	4	151	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					213	215		10.1126/science.275.5297.213	http://dx.doi.org/10.1126/science.275.5297.213			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985014				2022-12-01	WOS:A1997WC02200038
J	Melbye, M; Wohlfahrt, J; Olsen, JH; Frisch, M; Westergaard, T; HelwegLarsen, K; Andersen, PK				Melbye, M; Wohlfahrt, J; Olsen, JH; Frisch, M; Westergaard, T; HelwegLarsen, K; Andersen, PK			Induced abortion and the risk of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REPRODUCTIVE FACTORS; YOUNG-WOMEN; PREGNANCY; SWEDISH	Background It has been hypothesized that an interrupted pregnancy might increase a woman's risk of breast cancer because breast cells could proliferate without the later protective effect of differentiation. Methods We established a population-based cohort with information on parity and vital status consisting of all Danish women born from April 1, 1935, through March 31, 1978. Through linkage with the National Registry of Induced Abortions, information on the number and dates of induced abortions among those women was combined with information on the gestational age of each aborted fetus. All new cases of breast cancer were identified through linkage with the Danish Cancer Registry. Results In the cohort of 1.5 million women (28.5 million person-years), we identified 370,715 induced abortions among 280,965 women (2.7 million person-years) and 10,246 women with breast cancer. After adjustment for known risk factors, induced abortion was not associated with an increased risk of breast cancer (relative risk, 1.00; 95 percent confidence interval, 0.94 to 1.06). No increases in risk were found in subgroups defined according to age at abortion, parity, time since abortion, or age at diagnosis of breast cancer. The relative risk of breast cancer increased with increasing gestational age of the fetus at the time of the most recent induced abortion: <7 weeks, 0.81 (95 percent confidence interval, 0.58 to 1.13); >12 weeks, 1.38 (1.00 to 1.90) (reference category, 9 to 10 weeks). Conclusions Induced abortions have no overall effect on the risk of breast cancer. (C) 1997, Massachusetts Medical Society.	DANISH CANC REGISTRY, COPENHAGEN, DENMARK; NATL BOARD HLTH, COPENHAGEN, DENMARK		Melbye, M (corresponding author), STATENS SERUM INST, DANISH EPIDEMIOL SCI CTR, DEPT EPIDEMIOL RES, 5 ARTILLERIVEJ, DK-2300 COPENHAGEN S, DENMARK.		Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; Olsen, Jorgen Helge/0000-0001-9633-5662; melbye, mads/0000-0001-8264-6785				ADAMI HO, 1990, BRIT J CANCER, V62, P122, DOI 10.1038/bjc.1990.242; ALBREKTSEN G, 1995, BRIT J CANCER, V72, P480, DOI 10.1038/bjc.1995.359; ANDRIEU N, 1994, CANCER DETECT PREV, V18, P51; BERNSTEIN L, 1985, J NATL CANCER I, V74, P741; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; Brind J, 1996, J EPIDEMIOL COMMUN H, V50, P481, DOI 10.1136/jech.50.5.481; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; CALLE EE, 1995, CANCER CAUSE CONTROL, V6, P460, DOI 10.1007/BF00052187; DALING JR, 1994, JNCI-J NATL CANCER I, V86, P1584, DOI 10.1093/jnci/86.21.1584; EWERTZ M, 1988, BRIT J CANCER, V58, P99, DOI 10.1038/bjc.1988.172; HADJIMICHAEL OC, 1986, BRIT J CANCER, V53, P281, DOI 10.1038/bjc.1986.46; HARRIS BML, 1989, BMJ-BRIT MED J, V299, P1430, DOI 10.1136/bmj.299.6713.1430; HOWE HL, 1989, INT J EPIDEMIOL, V18, P300, DOI 10.1093/ije/18.2.300; KVALE G, 1987, AM J EPIDEMIOL, V126, P831, DOI 10.1093/oxfordjournals.aje.a114720; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; LINDEFORSHARRIS BM, 1991, AM J EPIDEMIOL, V134, P1003, DOI 10.1093/oxfordjournals.aje.a116173; LIPWORTH L, 1995, INT J CANCER, V61, P181, DOI 10.1002/ijc.2910610207; MICHELS KB, 1995, CANCER CAUSE CONTROL, V6, P75, DOI 10.1007/BF00051683; *NAT BOARD HLTH, 1993, VITALSTATISTIK, V1, P36; Newcomb RA, 1996, JAMA-J AM MED ASSOC, V275, P283, DOI 10.1001/jama.275.4.283; PARAZZINI F, 1991, INT J CANCER, V48, P816, DOI 10.1002/ijc.2910480605; PIKE MC, 1981, BRIT J CANCER, V43, P72, DOI 10.1038/bjc.1981.10; ROSENBERG L, 1993, EPIDEMIOL REV, V15, P133, DOI 10.1093/oxfordjournals.epirev.a036097; ROSENBERG L, 1994, J NATL CANCER I, V86, P1569, DOI 10.1093/jnci/86.21.1569; ROSENBERG L, 1988, AM J EPIDEMIOL, V127, P981, DOI 10.1093/oxfordjournals.aje.a114901; ROSENBERG L, 1994, AM J EPIDEMIOL, V140, P856; RUSSO J, 1980, AM J PATHOL, V100, P497; *SAS I, 1992, P229 SAS I; SELLERS TA, 1993, CANCER CAUSE CONTROL, V4, P21, DOI 10.1007/BF00051710; Storm H H, 1991, IARC Sci Publ, P220; Tavani A, 1996, INT J CANCER, V65, P401, DOI 10.1002/(SICI)1097-0215(19960208)65:4<401::AID-IJC1>3.3.CO;2-N	31	158	162	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1997	336	2					81	85		10.1056/NEJM199701093360201	http://dx.doi.org/10.1056/NEJM199701093360201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC481	8988884				2022-12-01	WOS:A1997WC48100001
J	Zhang, N; Zhang, JP; Purcell, KJ; Cheng, Y; Howard, K				Zhang, N; Zhang, JP; Purcell, KJ; Cheng, Y; Howard, K			The Drosophila protein Wunen repels migrating germ cells	NATURE			English	Article							AXON MIGRATIONS; PHENOTYPES; RECEPTOR; ELEGANS	IN Drosophila, germ cells migrate in embryonic development from the lumen of the developing gut towards the overlying mesoderm, where they enter the gonads(1,2). The gene wunen is responsible for guiding the germ cells early in this process(3). Here we report that the protein Wunen has two properties that allow it to use repulsion to guide the germ cells. Wunen can transform a permissive cellular environment into a repulsive one, and is expressed in the gut in a pattern that guides germ cells towards the mesoderm. Wunen shows strong similarity to the enzyme type 2 phosphatidic acid phophatase (PAP2)(4), suggesting that it is involved in lipid metabolism.	ROCHE INST MOL BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA; JACKSON LAB, BAR HARBOR, ME 04609 USA; MERCK SHARP & DOHME RES LABS, DEPT VIRUS & CELL BIOL, W POINT, PA 19486 USA; YALE UNIV, SCH MED, BOYER CTR MOL MED, DEPT CELL BIOL, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, BOYER CTR MOL MED, DEPT BIOL, NEW HAVEN, CT 06536 USA; UNIV NOTRE DAME, DEPT BIOL SCI, NOTRE DAME, IN 46556 USA; UCL, MOL CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND	Roche Holding; Jackson Laboratory; Merck & Company; Yale University; Yale University; University of Notre Dame; University of London; University College London								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROOKMAN JJ, 1992, DEVELOPMENT, V116, P1185; CALLAINI G, 1995, DEV BIOL, V170, P365, DOI 10.1006/dbio.1995.1222; COLAMARINO SA, 1995, CELL, V81, P6521; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FAITH MJ, 1993, MICROBIOL REV, V57, P995; FAN, 1993, J BIOL CHEM, V121, P867; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GRIEG S, 1995, CURR BIOL, V5, P1057; HART AC, 1993, NATURE, V361, P732, DOI 10.1038/361732a0; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; Hofmann K., 1993, BIOL CHEM, V374, P166; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; JAGLARZ MK, 1995, DEVELOPMENT, V121, P3495; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; KOBOYASHI S, 1996, NATURE, V380, P708; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Rabinowitz M, 1941, J MORPHOL, V69, P1, DOI 10.1002/jmor.1050690102; Sonnenblick BP, 1941, P NATL ACAD SCI USA, V27, P484, DOI 10.1073/pnas.27.10.484; TOROK T, 1993, GENETICS, V135, P71; Zhang N, 1996, GENETICS, V143, P1231	23	169	174	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					64	67		10.1038/385064a0	http://dx.doi.org/10.1038/385064a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985246				2022-12-01	WOS:A1997WA73100049
J	McHugh, TJ; Blum, KI; Tsien, JZ; Tonegawa, S; Wilson, MA				McHugh, TJ; Blum, KI; Tsien, JZ; Tonegawa, S; Wilson, MA			Impaired hippocampal representation of space in CA1-specific NMDAR1 knockout mice	CELL			English	Article							LONG-TERM POTENTIATION; CALMODULIN KINASE-II; ASPARTATE RECEPTOR ANTAGONIST; SYNAPTIC PLASTICITY; MUTANT MICE; SELECTIVE IMPAIRMENT; FREQUENCY; BLOCKADE; MEMORY; RATS	To investigate the role of synaptic plasticity in the place-specific firing of the hippocampus, we have applied multiple electrode recording techniques to freely behaving mice with a CA1 pyramidal cell-specific knockout of the NMDAR1 gene. We have discovered that although the CA1 pyramidal cells of these mice retain place-related activity, there is a significant decrease in the spatial specificity of individual place fields. We have also found a striking deficit in the coordinated firing of pairs of neurons tuned to similar spatial locations. Pairs have uncorrelated firing even if their fields overlap. These results demonstrate that NMDA receptor-mediated synaptic plasticity is necessary for the proper representation of space in the CA1 region of the hippocampus.	MIT, CTR LEARNING & MEMORY, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	McHugh, TJ (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		McHugh, Thomas J/A-6693-2010; McHugh, Thomas/M-6159-2019	McHugh, Thomas J/0000-0002-1243-5189; McHugh, Thomas/0000-0002-1243-5189	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER; NINDS NIH HHS [NS32925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; Chen C, 1997, ANNU REV NEUROSCI, V20, P157, DOI 10.1146/annurev.neuro.20.1.157; Chrobak JJ, 1996, J NEUROSCI, V16, P3056; DAVIS S, 1992, J NEUROSCI, V12, P21; EICHENBAUM H, 1988, BEHAV NEUROSCI, V102, P331, DOI 10.1037/0735-7044.102.3.331; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Hertz J, 1991, INTRO THEORY NEURAL; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; MCNAUGHTON BL, 1983, J NEUROSCI METH, V8, P391, DOI 10.1016/0165-0270(83)90097-3; Miller KD, 1996, NEURON, V17, P371, DOI 10.1016/S0896-6273(00)80169-5; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; Paxinos G., 2018, RAT NERVOUS SYSTEM; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; SAUCIER D, 1995, NATURE, V378, P186, DOI 10.1038/378186a0; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; TURRIGIANO G, 1994, SCIENCE, V264, P974, DOI 10.1126/science.8178157; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; YLINEN A, 1995, J NEUROSCI, V15, P30; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	36	444	459	0	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 27	1996	87	7					1339	1349		10.1016/S0092-8674(00)81828-0	http://dx.doi.org/10.1016/S0092-8674(00)81828-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980239	Bronze			2022-12-01	WOS:A1996WA54100021
J	Newport, MJ; Huxley, CM; Huston, S; Hawrylowicz, CM; Oostra, BA; Williamson, R; Levin, M				Newport, MJ; Huxley, CM; Huston, S; Hawrylowicz, CM; Oostra, BA; Williamson, R; Levin, M			A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-MONOCYTES; TUBERCULOSIS INFECTION; MACROPHAGE; ACTIVATION; IDENTIFICATION; RESISTANCE; EXPRESSION; LYMPHOKINE; BINDING; MICE	Background Genetic differences in immune responses may affect susceptibility to mycobacterial infection, but no specific genes have been implicated in humans. We studied four children who had an unexplained genetic susceptibility to mycobacterial infection and who appeared to have inherited the same recessive mutation from a common ancestor. Methods We used microsatellite analysis, immunofluorescence studies, and sequence analysis to study the affected patients, unaffected family members, and normal controls. Results A genome search using microsatellite markers identified a region on chromosome 6q in which the affected children were ail homozygous for eight markers. The gene for interferon-gamma receptor 1 maps to this region. Immunofluorescence studies showed that the receptor was absent on leukocytes from the affected children. Sequence analysis of complementary DNA for the gene for interferon-gamma receptor 1 revealed a point mutation at nucleotide 395 that introduces a stop codon and results in a truncated protein that lacks the transmembrane and cytoplasmic domains. Conclusions Four children with severe mycobacterial infections had a mutation in the gene for interferon-gamma receptor 1 that leads to the absence of receptors on cell surfaces and a functional defect in the up-regulation of tumor necrosis factor a by macrophages in response to interferon-gamma. The interferon-gamma pathway is important in the response to intracellular pathogens such as mycobacteria. (C) 1996, Massachusetts Medical Society.	ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT PEDIAT,LONDON W2 1NY,ENGLAND; ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT BIOCHEM & MOL GENET,LONDON W2 1NY,ENGLAND; ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT IMMUNOL,LONDON W2 1NY,ENGLAND; ERASMUS UNIV ROTTERDAM,DEPT CLIN GENET,NL-3000 DR ROTTERDAM,NETHERLANDS	Imperial College London; Imperial College London; Imperial College London; Erasmus University Rotterdam			Hawrylowicz, Catherine/Q-8483-2017	Hawrylowicz, Catherine/0000-0002-2337-7463; Katsanis, Sara/0000-0002-5044-8765; Newport, Melanie/0000-0002-8946-7525; Levin, Michael/0000-0003-2767-6919				AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BLACKWELL JM, 1989, RES IMMUNOL, V140, P767, DOI 10.1016/0923-2494(89)90029-1; Chan John, 1994, P389; COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621; COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243; DENIS M, 1991, CLIN EXP IMMUNOL, V84, P200, DOI 10.1111/j.1365-2249.1991.tb08149.x; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DSouza S, 1996, CLIN EXP IMMUNOL, V103, P35, DOI 10.1046/j.1365-2249.1996.00904.x; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FINE PEM, 1981, INT J LEPROSY, V49, P437; FLESCH IEA, 1990, INFECT IMMUN, V58, P2675, DOI 10.1128/IAI.58.8.2675-2677.1990; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HOLLAND SM, 1994, NEW ENGL J MED, V330, P1348, DOI 10.1056/NEJM199405123301904; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P4, DOI 10.1164/ajrccm/139.1.4; HOUWEN RHJ, 1994, NAT GENET, V8, P380, DOI 10.1038/ng1294-380; Kallmann Franz J., 1943, AMER REV TUBERC, V47, P549; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; Klein N. J., 1994, Immunology and Infectious Diseases (Oxford), V4, P33; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LEVIN M, 1995, LANCET, V345, P79, DOI 10.1016/S0140-6736(95)90059-4; LEWIS DB, 1990, PEDIATR INFECT DIS J, V9, P642; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; NEWPORT M, 1995, J MED GENET, V32, P904, DOI 10.1136/jmg.32.11.904; ORME IM, 1993, J IMMUNOL, V151, P518; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PFIZENMAIER K, 1988, J IMMUNOL, V141, P856; ROOK GAW, 1986, IMMUNOLOGY, V57, P159; SAMBROOK J, 1989, MOL CLONIG LAB MANUA, V2; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STRICKLAND RW, 1986, J IMMUNOL, V137, P1577; WALKER L, 1981, NATURE, V293, P69, DOI 10.1038/293069a0; WONG GHW, 1983, J IMMUNOL, V131, P788	37	962	993	1	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1996	335	26					1941	1949		10.1056/NEJM199612263352602	http://dx.doi.org/10.1056/NEJM199612263352602			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA160	8960473				2022-12-01	WOS:A1996WA16000002
J	Chen, LM; Hobbie, S; Galan, JE				Chen, LM; Hobbie, S; Galan, JE			Requirement of CDC42 for Salmonella-induced cytoskeletal and nuclear responses	SCIENCE			English	Article							GROWTH-FACTOR-RECEPTOR; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; RAC; TYPHIMURIUM; ACTIVATION; INVASION; RHO; BINDING	The bacterial pathogen Salmonella typhimurium triggers host cell signaling pathways that lead to cytoskeletal and nuclear responses required for pathogenesis. Here, the role of the small guanosine triphosphate (GTP)-binding protein CDC42Hs in these responses was examined. Expression of a dominant interfering mutant of CDG42 (CDC42HsN17) prevented S. typhimurium-induced cytoskeletal reorganization and subsequent macropinocytosis and bacterial internalization into host cells. Cells expressing constitutively active CDC42 (CDC42HsV12) internalized an S. typhimurium mutant unable to trigger host cell responses. Furthermore, expression of CDC42HsN17 prevented S. typhimurium-induced JNK kinase activation. These results indicate that CDC42 is required for bacterial invasion and induction of nuclear responses in host cells.	SUNY STONY BROOK, SCH MED, DEPT MOL GENET & MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052543] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52543] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chen LM, 1996, MOL MICROBIOL, V21, P1101, DOI 10.1046/j.1365-2958.1996.471410.x; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Denoyelle S., SYNTHESIS SAR STUDY; FINLAY BB, 1990, J INFECT DIS, V162, P1096, DOI 10.1093/infdis/162.5.1096; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GALAN JE, 1992, J BACTERIOL, V174, P4338; GALAN JE, 1995, CURR TOP MICROBIOL I, V209, P43; Galan Jorge E., 1994, Trends in Cell Biology, V4, P196, DOI 10.1016/0962-8924(94)90136-8; GARCIADELPORTILLO F, 1994, INFECT IMMUN, V62, P4641, DOI 10.1128/IAI.62.10.4641-4645.1994; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOBBIE S, UNPUB; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JONES BD, 1993, P NATL ACAD SCI USA, V90, P10390, DOI 10.1073/pnas.90.21.10390; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P77; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RUSCHKOWSKI S, 1992, FEMS MICROBIOL LETT, V95, P121; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; VANPUTTEN JPM, 1994, METHOD ENZYMOL, V236, P420; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	38	241	249	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	1996	274	5295					2115	2118		10.1126/science.274.5295.2115	http://dx.doi.org/10.1126/science.274.5295.2115			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953049				2022-12-01	WOS:A1996VY97400059
J	Weidenschilling, SJ; Marzari, F				Weidenschilling, SJ; Marzari, F			Gravitational scattering as a possible origin for giant planets at small stellar distances	NATURE			English	Article							JUPITER; COMPANION; SYSTEMS; DISK	THE recent discoveries(1-4) of massive planetary companions orbiting several solar-type stars pose a conundrum, Conventional models(5,6) for the formation of giant planets (such as Jupiter and Saturn) place such objects at distances of several astronomical units from the parent star, whereas all but one of the new objects are on orbits well inside 1 AU; these planets must therefore have originated at larger distances and subsequently migrated inwards. One suggested migration mechanism invokes tidal interactions between the planet and the evolving circumstellar disk(7). Such a mechanism results in planets with small, essentially circular orbits, which appears to be the case for many of the new planets. But two of the objects have substantial orbital eccentricities, which are difficult to reconcile with a tidal-linkage model, Here we describe an alternative model for planetary migration that can account for these large orbital eccentricities, If a system of three or more giant planets form about a star, their orbits may become unstable as they gain mass by accreting gas from the circumstellar disk; subsequent gravitational encounters among these planets can eject one from the system while placing the others into highly eccentric orbits both closer and farther from the star.	UNIV PADUA,DIPARTIMENTO FIS,I-35131 PADUA,ITALY	University of Padua	Weidenschilling, SJ (corresponding author), PLANETARY SCI INST,SJI,620 N 6TH AVE,TUCSON,AZ 85705, USA.		Marzari, Francesco/X-2440-2019					Beckwith SVW, 1996, NATURE, V383, P139, DOI 10.1038/383139a0; BOSS A, 1995, NATURE, V379, P397; BOSS AP, 1995, SCIENCE, V267, P360, DOI 10.1126/science.267.5196.360; Butler RP, 1996, ASTROPHYS J, V464, pL153, DOI 10.1086/310102; Chambers JE, 1996, ICARUS, V119, P261, DOI 10.1006/icar.1996.0019; Cochran WD., 1996, B AM ASTRON SOC, V28, P1111; Everhart E., 1985, DYNAMICS COMETS THEI, P185; FARINELLA P, 1980, MOON PLANETS, V22, P25, DOI 10.1007/BF00896864; GLADMAN B, 1993, ICARUS, V106, P247, DOI 10.1006/icar.1993.1169; LATHAM DW, 1989, NATURE, V339, P38, DOI 10.1038/339038a0; Lin DNC, 1996, NATURE, V380, P606, DOI 10.1038/380606a0; LISSAUER JJ, 1987, ICARUS, V69, P249, DOI 10.1016/0019-1035(87)90104-7; Marcy GW, 1996, ASTROPHYS J, V464, pL147, DOI 10.1086/310096; MAYOR M, 1995, NATURE, V378, P355, DOI 10.1038/378355a0; POLLACK J, IN PRESS ICARUS; RASIO FA, IN PRESS SCIENCE; TAKEDA H, 1985, PROG THEOR PHYS, V74, P272, DOI 10.1143/PTP.74.272; WARD WR, 1988, ICARUS, V73, P330, DOI 10.1016/0019-1035(88)90103-0; WETHERILL GW, 1994, ASTROPHYS SPACE SCI, V212, P23, DOI 10.1007/BF00984505; WETHERILL GW, 1995, NATURE, V373, P470, DOI 10.1038/373470a0	20	366	368	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 19	1996	384	6610					619	621		10.1038/384619a0	http://dx.doi.org/10.1038/384619a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VZ296	8967949				2022-12-01	WOS:A1996VZ29600026
J	Farwell, B				Farwell, B			Health care in America: An intimate glimpse	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1996	125	12					1005	1006		10.7326/0003-4819-125-12-199612150-00014	http://dx.doi.org/10.7326/0003-4819-125-12-199612150-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX768	8967689				2022-12-01	WOS:A1996VX76800014
J	Leng, GC; Fowkes, FGR; Lee, AJ; Dunbar, J; Housley, E; Ruckley, CV				Leng, GC; Fowkes, FGR; Lee, AJ; Dunbar, J; Housley, E; Ruckley, CV			Use of ankle brachial pressure index to predict cardiovascular events and death: A cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PERIPHERAL ARTERIAL-DISEASE; RISK-FACTORS; CAROTID STENOSIS; HEART-DISEASE; ARM INDEX; MORTALITY; MEN; MORBIDITY; WOMEN	Objective-To determine whether a low ankle brachial pressure index is associated with an increased risk of cardiovascular events and death, and whether the prediction of such events could be improved by including this index. Design-Cohort study. Setting-11 practices in Edinburgh, Scotland. Subjects-1592 men and women aged 55-74 years selected at random from the age-sex registers of 11 general practices and followed up for 5 years. Main outcome measures-Incidence of fatal and non-fatal cardiovascular events and all cause mortality. Results-At baseline 90 (5.7%) of subjects had an ankle brachial pressure index less than or equal to 0.7, 288 (18.2%) had an index less than or equal to 0.9, and 566 (35.6%) less than or equal to 1.0. After five years subjects with an index less than or equal to 0.9 at baseline had an increased risk of non-fatal myocardial infarction (relative risk 1.38, 95% confidence interval 0.88 to 2.16), stroke (1.98, 1.05 to 3.77), cardiovascular death (1.85, 1.15 to 2.97), and all cause mortality (1.58, 1.14 to 2.18) after adjustment for age, sex, coronary disease, and diabetes at baseline. The ability to predict subsequent events was greatly increased by combining the index with other risk factors-for example, hypertensive smokers with normal cholesterol concentrations had a positive predictive value of 25.0%, increasing to 43.8% in subjects with a low index and decreasing to 15.6% in those with a normal index. Conclusion-The ankle brachial pressure index is a good predictor of subsequent cardiovascular events, and improves on predictions by conventional risk factors alone. It is simple and accurate and could be included in routine screening of cardiovascular status.	UNIV EDINBURGH, DEPT PUBL HLTH SCI, WOLFSON UNIT PREVENT PERIPHERAL VASC DIS, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; ROYAL INFIRM EDINBURGH NHS TRUST, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh								CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; DORMANDY J, 1989, J CARDIOVASC SURG, V30, P50; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FOWKES FGR, 1988, J EPIDEMIOL COMMUN H, V42, P128, DOI 10.1136/jech.42.2.128; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; KALLERO KS, 1981, J CHRON DIS, V34, P455, DOI 10.1016/0021-9681(81)90005-9; KANNEL WB, 1987, AM HEART J, V114, P213, DOI 10.1016/0002-8703(87)90964-1; KORNITZER M, 1995, ANGIOLOGY, V46, P211, DOI 10.1177/000331979504600304; KULLER LH, 1995, CIRCULATION, V92, P720, DOI 10.1161/01.CIR.92.4.720; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; OGREN M, 1995, BMJ-BRIT MED J, V310, P1294, DOI 10.1136/bmj.310.6990.1294; OGREN M, 1993, LANCET, V342, P1138, DOI 10.1016/0140-6736(93)92123-B; OURIEL K, 1982, SURGERY, V91, P686; Prineas R.J., 1982, MINNESOTA CODE MANUA; *REG GEN SCOTL, 1993, ANN REP; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; SLEIGHT P, 1991, AM HEART J, V121, P990, DOI 10.1016/0002-8703(91)90609-L; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; VOGT MT, 1993, JAMA-J AM MED ASSOC, V270, P465, DOI 10.1001/jama.270.4.465; VOGT MT, 1993, J AM GERIATR SOC, V41, P523, DOI 10.1111/j.1532-5415.1993.tb01889.x; WIDMER LK, 1986, P 14 WORLD C INT UN, P13; YAO ST, 1969, BRIT J SURG, V56, P676, DOI 10.1002/bjs.1800560910	23	396	408	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 7	1996	313	7070					1440	1444		10.1136/bmj.313.7070.1440	http://dx.doi.org/10.1136/bmj.313.7070.1440			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX612	8973232	Green Published			2022-12-01	WOS:A1996VX61200029
J	Murphy, C; Saffrich, R; Grummt, W; Gournier, H; Rybin, V; Rubino, M; Auvinen, P; Lutcke, A; Parton, RG; Zerial, M				Murphy, C; Saffrich, R; Grummt, W; Gournier, H; Rybin, V; Rubino, M; Auvinen, P; Lutcke, A; Parton, RG; Zerial, M			Endosome dynamics regulated by a Rho protein	NATURE			English	Article							ACTIN STRESS FIBERS; MEMBRANE; ENDOCYTOSIS; GTPASES; CELLS; CDC42; MICROFILAMENTS; CYTOCHALASIN; INHIBITION; FUSION	Vesicular transport is a dynamic process that requires coordinated interactions between membrane and cytoskeleton. The mechanisms and molecules integrating these interactions are unclear. A Rho protein, RhoD, might provide a molecular link between membrane traffic and the cytoskeleton. Activated RhoD causes rearrangements of the actin cytoskeleton and cell surface, and governs early endosome motility and distribution.	EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Murphy, Carol/ABE-4282-2021; Parton, Robert G/C-5673-2009; Auvinen, Petri/D-5044-2009; Auvinen, Petri/AAP-8117-2021	Murphy, Carol/0000-0003-1353-8558; Parton, Robert G/0000-0002-7494-5248; Auvinen, Petri/0000-0002-3947-4778; Saffrich, Rainer/0000-0002-0547-4550				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ALLAN V, 1995, FEBS LETT, V369, P101, DOI 10.1016/0014-5793(95)00615-G; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; CUDMORE S, 1995, NATURE, V378, P636, DOI 10.1038/378636a0; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; JACKMAN MR, 1994, J CELL SCI, V107, P2547; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riezman Howard, 1993, Trends in Cell Biology, V3, P273, DOI 10.1016/0962-8924(93)90056-7; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Sheetz MP, 1996, TRENDS CELL BIOL, V6, P85, DOI 10.1016/0962-8924(96)80993-7; STELZER EHK, 1989, P SOC PHOTOOPT INSTR, V1028, P146; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Wirth JA, 1996, J CELL SCI, V109, P653; YAMASHIRO DJ, 1984, CELL, V37, P389; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	38	192	199	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					427	432		10.1038/384427a0	http://dx.doi.org/10.1038/384427a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945468				2022-12-01	WOS:A1996VW68700052
J	Corne, J				Corne, J			Diffuse panbronchiolitis - A new Japanese export?	LANCET			English	Editorial Material											Corne, J (corresponding author), SOUTHAMPTON GEN HOSP,DEPT MED,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.							Fitzgerald JE, 1996, AM J RESP CRIT CARE, V154, P497, DOI 10.1164/ajrccm.154.2.8756828; FUJII T, 1995, THORAX, V50, P1246, DOI 10.1136/thx.50.12.1246; HOMER RJ, 1995, CHEST, V107, P1176, DOI 10.1378/chest.107.4.1176; HOMMA H, 1983, CHEST, V83, P63, DOI 10.1378/chest.83.1.63; IWATA M, 1994, HUM PATHOL, V25, P357, DOI 10.1016/0046-8177(94)90143-0; NISHIMURA K, 1992, RADIOLOGY, V184, P779, DOI 10.1148/radiology.184.3.1509067; SUGIYAMA Y, 1990, AM REV RESPIR DIS, V141, P1459, DOI 10.1164/ajrccm/141.6.1459	7	14	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1465	1466		10.1016/S0140-6736(05)65888-6	http://dx.doi.org/10.1016/S0140-6736(05)65888-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942772				2022-12-01	WOS:A1996VV46300005
J	Geballe, TR; Oka, T				Geballe, TR; Oka, T			Detection af H-3(+) in interstellar space	NATURE			English	Article							INFRARED-SPECTRUM; H-3+; CLOUDS; GAS; MOLECULES; FEATURES; SEARCH; LINES; CO	THE H-3(+) ion is widely believed to play an important role in interstellar chemistry, by initiating the chains of reactions that lead to the production of many of the complex molecular species observed in the interstellar medium(1-5). The presence of H-3(+) in the interstellar medium was first suggested(6) in 1961, and its infrared spectrum was measured(7) in the laboratory in 1980. But attempts(8-11) to detect it in interstellar space have hitherto proved unsuccessful, Here we report the detection of H-3(+) absorption in the spectra of two molecular clouds. Ali-hough the present results do not permit an accurate determination of the H-3(+) abundances, these ions appear nevertheless to be present in sufficient quantities to drive much of the chemistry in molecular clouds, It should soon be possible to obtain more accurate measurements, and thus better quantify the role of ion-neutral reactions in the chemical evolution of molecular clouds.	UNIV CHICAGO, DEPT CHEM, DEPT ASTRON & ASTROPHYS, CHICAGO, IL 60637 USA; UNIV CHICAGO, ENRICO FERMI INST, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago	Geballe, TR (corresponding author), JOINT ASTRON CTR, UNIV PK, HILO, HI 96720 USA.							AMANO T, 1988, ASTROPHYS J, V329, pL121, DOI 10.1086/185190; ANICICH VG, 1986, ASTROPHYS J SUPPL S, V62, P553, DOI 10.1086/191151; BLACK JH, 1990, ASTROPHYS J, V358, P459, DOI 10.1086/168999; DALGARNO A, 1976, REP PROG PHYS, V39, P573, DOI 10.1088/0034-4885/39/6/002; DROSSART P, 1989, NATURE, V340, P539, DOI 10.1038/340539a0; GEBALLE TR, 1993, ASTROPHYS J, V408, pL109, DOI 10.1086/186843; GEBALLE TR, 1989, ASTROPHYS J, V342, P855, DOI 10.1086/167641; GEBALLE TR, 1985, ASTRON ASTROPHYS, V146, pL6; HERBST E, 1973, ASTROPHYS J, V185, P505, DOI 10.1086/152436; Lee HH, 1996, ASTRON ASTROPHYS SUP, V119, P111, DOI 10.1051/aas:1996232; LEPP S, 1987, ASTROPHYS J, V321, P383, DOI 10.1086/165636; MAILLARD JP, 1995, SPECTROCHIM ACTA A, V51, P1105, DOI 10.1016/0584-8539(94)00014-3; MARTIN DW, 1961, ASTROPHYS J, V134, P1012, DOI 10.1086/147232; MILLER S, 1992, NATURE, V355, P420, DOI 10.1038/355420a0; MILLER S, 1994, CAN J PHYS, V72, P760, DOI 10.1139/p94-100; MITCHELL GF, 1990, ASTROPHYS J, V363, P554, DOI 10.1086/169365; OKA T, 1981, PHILOS T R SOC A, V303, P543, DOI 10.1098/rsta.1981.0223; OKA T, 1980, PHYS REV LETT, V45, P531, DOI 10.1103/PhysRevLett.45.531; Schutte WA, 1996, ASTRON ASTROPHYS, V309, P633; SPITZER L, 1975, ANNU REV ASTRON ASTR, V13, P133, DOI 10.1146/annurev.aa.13.090175.001025; SUZUKI H, 1979, PROG THEOR PHYS, V62, P936, DOI 10.1143/PTP.62.936; TIELENS AGGM, 1991, ASTROPHYS J, V381, P181, DOI 10.1086/170640; TRAFTON LM, 1993, ASTROPHYS J, V405, P761, DOI 10.1086/172404; WATSON WD, 1973, ASTROPHYS J, V183, pL17, DOI 10.1086/181242; WATSON WD, 1976, REV MOD PHYS, V48, P513, DOI 10.1103/RevModPhys.48.513	25	301	304	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 28	1996	384	6607					334	335		10.1038/384334a0	http://dx.doi.org/10.1038/384334a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934516				2022-12-01	WOS:A1996VV27100040
J	Sornson, MW; Wu, W; Dasen, JS; Flynn, SE; Norman, DJ; OConnell, SM; Gukovsky, I; Carriere, C; Ryan, AK; Miller, AP; Zuo, L; Gleiberman, AS; Andersen, B; Beamer, WG; Rosenfeld, MG				Sornson, MW; Wu, W; Dasen, JS; Flynn, SE; Norman, DJ; OConnell, SM; Gukovsky, I; Carriere, C; Ryan, AK; Miller, AP; Zuo, L; Gleiberman, AS; Andersen, B; Beamer, WG; Rosenfeld, MG			Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism	NATURE			English	Article							GENE; EXPRESSION; MICE; DNA; DROSOPHILA; MUTATION; ARISTALESS; FRAGMENTS; SEQUENCE; CONTAINS	The gene apparently responsible for a heritable form of murine pituitary-dependent dwarfism (Ames dwarf, df) has been positionally cloned, identifying a novel, tissue-specific, paired-like homeodomain transcription factor, termed Prophet of Pit-1 (Prop-1). The df phenotype results from an apparent failure of initial determination of the Pit-1 lineage required for production of growth hormone, prolactin or thyroid-stimulating hormone, resulting in dysmorphogenesis and failure to activate Pit-1 gene expression. These results imply that a cascade of tissue-specific regulators is responsible for the determination and differentiation of specific cell lineages in pituitary organogenesis.	UNIV CALIF SAN DIEGO,DEPT & SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT & SCH MED,BIOL GRAD PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT & SCH MED,BIOMED SCI GRAD PROGRAM,LA JOLLA,CA 92093; SEQUANA THERAPEUT INC,LA JOLLA,CA 92037; JACKSON LAB,BAR HARBOR,ME 04609	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Jackson Laboratory				gleiberman, anatoli/0000-0001-8491-0826				Andersen B, 1995, DEV BIOL, V172, P495, DOI 10.1006/dbio.1995.8040; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BARTKE A, 1965, MOUSE NEWSLETT, V32, P52; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BUCKWALTER MS, 1991, GENOMICS, V10, P515, DOI 10.1016/0888-7543(91)90430-M; BUM TC, 1995, GENE, V161, P183; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAMPER SA, 1990, GENOMICS, V8, P586, DOI 10.1016/0888-7543(90)90050-5; CATRON KM, 1995, MOL CELL BIOL, V15, P861; COULY G, 1988, DEVELOPMENT, V103, P101; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Gage PJ, 1996, DEVELOPMENT, V122, P151; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; HEARNE CM, 1991, MAMM GENOME, V1, P273, DOI 10.1007/BF00352339; HEMESZ E, 1996, DEVELOPMENT, V122, P41; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; KENDALL SK, 1995, GENE DEV, V9, P2007, DOI 10.1101/gad.9.16.2007; KEYNES R, 1994, ANNU REV NEUROSCI, V17, P109, DOI 10.1146/annurev.ne.17.030194.000545; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LISITSYN NA, 1994, NAT GENET, V6, P57, DOI 10.1038/ng0194-57; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; Oliver G, 1995, DEVELOPMENT, V121, P4045; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; Schaible R., 1961, Genetics, V46, P896; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SEIDAH NG, 1994, DNA CELL BIOL, V13, P1163, DOI 10.1089/dna.1994.13.1163; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SZETO DP, 1996, P NATL ACAD SCI USA, V15, P7706; THOMAS PQ, 1995, J BIOL CHEM, V270, P3869, DOI 10.1074/jbc.270.8.3869; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; WATANABE YG, 1982, CELL TISSUE RES, V227, P257, DOI 10.1007/BF00210884; WIJNHOLDS J, 1995, DEV BIOL, V171, P73, DOI 10.1006/dbio.1995.1261; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0	48	560	573	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					327	333		10.1038/384327a0	http://dx.doi.org/10.1038/384327a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934515				2022-12-01	WOS:A1996VV27100039
J	Alavanja, MCR; Brownson, RC; Berger, E; Lubin, J; Modigh, C				Alavanja, MCR; Brownson, RC; Berger, E; Lubin, J; Modigh, C			Avian exposure acid risk of lung cancer in women in Missouri: Population based case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NONSMOKING WOMEN; UNITED-STATES; PET BIRDS	Objective-To investigate the association, previously reported in three European studies, between ownership of pet birds and the risk of lung cancer. Design-A population based case-control study with a structured questionnaire administered by telephone. Setting-Missouri, a midwestern state in the United States with a population of about 5 million. Subjects-All newly diagnosed cases of primary lung cancer in women aged 30-84 years in Missouri from 1 January 1993 to 31 January 1994 reported to the state cancer registry were invited to participate (n = 652); and 629 population based controls. Main outcome measures-Odds ratios were computed in relation to whether or not the study subject ever kept pet birds, the type of bird kept, and several measures of intensity or duration of exposure. Odds ratios were adjusted for smoking. Results-The odds ratio (95% confidence interval) for the development of lung cancer associated with keeping pet birds was 0.84 (0.65 to 1.09). The results were similar for the type of pet bird kept, the number of birds kept, the location of the bird in the house, and the duration of ownership. Conclusion-The keeping of pet birds carries no excess risk for the development of lung cancer.	ST LOUIS UNIV, SCH PUBL HLTH, DEPT COMMUNITY MED, ST LOUIS, MO 63108 USA; INFORMAT MANAGEMENT SERV INC, ROCKVILLE, MD 20904 USA; GOTHENBURG UNIV, GOTHENBURG, SWEDEN	Saint Louis University; Information Management Services, Inc.; University of Gothenburg	Alavanja, MCR (corresponding author), NCI, EPIDEMIOL & BIOSTAT PROGRAM, DIV CANC EPIDEMIOL & GENET, EXECUT PLAZA N, ROOM 430, ROCKVILLE, MD 20852 USA.				NCI NIH HHS [CP-95654-13] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALAVANJA MCR, 1992, AM J EPIDEMIOL, V136, P623, DOI 10.1093/oxfordjournals.aje.a116542; ALAVANJA MCR, 1994, J NATL CANCER I, V86, P1829, DOI 10.1093/jnci/86.24.1829; ALAVANJA MCR, 1993, J NATL CANCER I, V85, P1906, DOI 10.1093/jnci/85.23.1906; ALAVANJA MCR, 1995, CANCER CAUSE CONTROL, V6, P209, DOI 10.1007/BF00051792; [Anonymous], 1982, AM J CLIN PATHOL, V77, P123; BLAIR A, 1991, OCCUP MED, V6, P335; BOURNE WRP, 1975, PRACTITIONER, V215, P165; Breslow NE., 1980, IARC SCI PUBLICATION, V32; BROWNSON RC, 1993, CANCER CAUSE CONTROL, V4, P449, DOI 10.1007/BF00050864; BROWNSON RC, 1992, AM J PUBLIC HEALTH, V82, P1525, DOI 10.2105/AJPH.82.11.1525; GARDINER AJS, 1992, BRIT MED J, V305, P989, DOI 10.1136/bmj.305.6860.989; GART JJ, 1970, BIOMETRIKA, V57, P471, DOI 10.1093/biomet/57.3.471; HOLST PA, 1988, BRIT MED J, V297, P1319, DOI 10.1136/bmj.297.6659.1319; KOHLMEIER L, 1992, BMJ-BRIT MED J, V305, P986, DOI 10.1136/bmj.305.6860.986; KOSS IG, 1979, DIAGNOSTIC CYTOLOGY, P6; MARTIN G, 1989, HCFA PUBLICATION, P181; Modigh C, 1996, BMJ-BRIT MED J, V313, P1236, DOI 10.1136/bmj.313.7067.1236; WEINBERG CR, 1991, AM J EPIDEMIOL, V134, P421, DOI 10.1093/oxfordjournals.aje.a116104; WEINBERG CR, 1990, BIOMETRICS, V46, P963, DOI 10.2307/2532441	19	22	22	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	1996	313	7067					1233	1235		10.1136/bmj.313.7067.1233	http://dx.doi.org/10.1136/bmj.313.7067.1233			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939111	Green Published			2022-12-01	WOS:A1996VU20800020
J	Hanein, D; Matlack, KES; Jungnickel, B; Plath, K; Kalies, KU; Miller, KR; Rapoport, TA; Akey, CW				Hanein, D; Matlack, KES; Jungnickel, B; Plath, K; Kalies, KU; Miller, KR; Rapoport, TA; Akey, CW			Oligomeric rings of the Sec61p complex induced by ligands required for protein translocation	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SECRETORY PROTEINS; CONDUCTING CHANNEL; ER-MEMBRANE; YEAST; INSERTION; COMPONENTS; RIBOSOMES; POLYPEPTIDES; TRANSPORT	The heterotrimeric Sec61p complex is a major component of the protein-conducting channel of the endoplasmic reticulum (ER) membrane, associating with either ribosomes or the Sec62/63 complex to perform co- and posttranslational transport, respectively. We show by electron microscopy that purified mammalian and yeast Sec61p complexes in detergent form cylindrical oligomers with a diameter of similar to 85 Angstrom and a central pore of similar to 20 Angstrom. Each oligomer contains 3-4 heterotrimers. Similar ring structures are seen in reconstituted proteoliposomes and native membranes. Oligomer formation by the reconstituted Sec61p complex is stimulated by its association with ribosomes or the Sec62/63p complex. We propose that these cylindrical oligomers represent protein-conducting channels of the ER, formed by ligands specific for co- and posttranslational transport.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY; BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912	Harvard University; Harvard Medical School; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Brown University	Hanein, D (corresponding author), BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02218, USA.			Plath, Kathrin/0000-0001-7796-3372; Akey, Christopher/0000-0002-3059-3121				AKEY CW, 1995, J MOL BIOL, V248, P273, DOI 10.1006/jmbi.1995.0221; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1995, P NATL ACAD SCI USA, V92, P1182, DOI 10.1073/pnas.92.4.1182; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; FRANK J, 1988, J MICROSC-OXFORD, V150, P99, DOI 10.1111/j.1365-2818.1988.tb04602.x; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GIDDINGS TH, 1980, J CELL BIOL, V85, P147, DOI 10.1083/jcb.85.1.147; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NICCHITTA CV, 1995, J CELL BIOL, V129, P957, DOI 10.1083/jcb.129.4.957; OJAKIAN GK, 1977, J CELL BIOL, V72, P530, DOI 10.1083/jcb.72.3.530; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; RAPOPORT TA, 1985, FEBS LETT, V187, P1, DOI 10.1016/0014-5793(85)81202-3; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; STRAMBIODECASTILLIA C, 1995, J CELL BIOL, V131, P19, DOI 10.1083/jcb.131.1.19; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87; [No title captured]	38	275	280	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					721	732		10.1016/S0092-8674(00)81391-4	http://dx.doi.org/10.1016/S0092-8674(00)81391-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929540	hybrid			2022-12-01	WOS:A1996VU03500014
J	Radler, JO; Koltover, I; Salditt, T; Safinya, CR				Radler, JO; Koltover, I; Salditt, T; Safinya, CR			Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes	SCIENCE			English	Article							SYNCHROTRON X-RAY; GENE-THERAPY; PHASE; TRANSFECTION; EXPRESSION; HUMANS	Cationic liposomes complexed with DNA (CL-DNA) are promising synthetically based nonviral carriers of DNA vectors for gene therapy. The solution structure of CL-DNA complexes was probed on length scales from subnanometer to micrometer by synchrotron x-ray diffraction and optical microscopy. The addition of either linear lambda-phage or plasmid DNA to CLs resulted in an unexpected topological transition from liposomes to optically birefringent liquid-crystalline condensed globules. X-ray diffraction of the globules revealed a novel multilamellar structure with alternating lipid bilayer and DNA monolayers. The lambda-DNA chains form a one-dimensional lattice with distinct interhelical packing regimes. Remarkably, in the isoelectric point regime, the lambda-DNA interaxial spacing expands between 24.5 and 57.1 angstroms upon lipid dilution and is indicative of a long-range electrostatic-induced repulsion that is possibly enhanced by chain undulations.	UNIV CALIF SANTA BARBARA, DEPT MAT, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT PHYS, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, BIOCHEM & MOL BIOL PROGRAM, SANTA BARBARA, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara			Rädler, Joachim/AAD-8747-2019	Rädler, Joachim/0000-0002-5846-1489				BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P382, DOI 10.1021/bc00029a002; BLOOMFIELD VA, 1991, BIOPOLYMERS, V31, P1471, DOI 10.1002/bip.360311305; BOLTENHAGEN P, 1992, PHYS REV A, V46, pR1743, DOI 10.1103/PhysRevA.46.R1743; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; DAN N, IN PRESS BIOPHYS J; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P7132, DOI 10.1073/pnas.83.19.7132; FELGNER PL, 1991, NATURE, V349, P351, DOI 10.1038/349351a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GUSTAFSSON J, 1995, BBA-BIOMEMBRANES, V1235, P305, DOI 10.1016/0005-2736(95)80018-B; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; Kamien RD, 1996, PHYS REV E, V53, P650, DOI 10.1103/PhysRevE.53.650; KEMWORTHY AK, 1995, BIOPHYS J, V68, P1921; KOLOVER I, UNPUB; LASIC D, IN PRESS ADV DRUG DE; LIGOURE C, 1993, PHYS REV LETT, V71, P3600, DOI 10.1103/PhysRevLett.71.3600; LIN AL, UNPUB; LIVOLANT F, 1989, NATURE, V339, P724, DOI 10.1038/339724a0; MANNING GS, 1969, J CHEM PHYS, V51, P924, DOI 10.1063/1.1672157; MARSHALL E, 1995, SCIENCE, V269, P1050, DOI 10.1126/science.7652552; MARSHALL E, 1995, SCIENCE, V270, P1751, DOI 10.1126/science.270.5243.1751; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; PODGORNIK R, 1989, MACROMOLECULES, V22, P1780, DOI 10.1021/ma00194a048; RADLER JO, UNPUB; REICH Z, 1994, SCIENCE, V264, P1460, DOI 10.1126/science.8197460; ROUX D, 1988, J PHYS-PARIS, V49, P307, DOI 10.1051/jphys:01988004902030700; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; SAFINYA CR, 1989, NATO ADV SCI I B-PHY, V211, P249; SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718; SELINGER JV, 1991, PHYS REV A, V43, P2922, DOI 10.1103/PhysRevA.43.2922; SINGHAL A, 1994, GENE THERAPEUTICS ME; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; Warriner HE, 1996, SCIENCE, V271, P969, DOI 10.1126/science.271.5251.969; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	38	1244	1293	4	277	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					810	814		10.1126/science.275.5301.810	http://dx.doi.org/10.1126/science.275.5301.810			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012343				2022-12-01	WOS:A1997WG77700054
J	Rees, G; Frackowiak, R; Frith, C				Rees, G; Frackowiak, R; Frith, C			Two modulatory effects of attention that mediate object categorization in human cortex	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; INFERIOR TEMPORAL CORTEX; SHORT-TERM-MEMORY; RHESUS-MONKEY; PREFRONTAL CORTEX; VISUAL-ATTENTION; NEURONAL MECHANISMS; ASSOCIATION CORTEX; PARIETAL CORTEX; FRONTAL-CORTEX	Attentional modulation of cortical activity was examined by varying the rate of visual stimuli in object categorization tasks according to single and conjoined features. Activation of dorsolateral frontal cortex was independent of the stimulus presentation rate and elicited by the participant's attention to conjoined compared with single features. Several cortical regions showed attentionally modulated activity. In inferior temporal cortex, modulation was due to an additional bias signal underlying normal rate-correlated activity, In two other regions (premotor cortex and cerebellum), attention modified the correlation of activity and the stimulus presentation rate, Attentional effects in the human cortex are expressed by at least two physiologically distinct mechanisms acting on spatially distributed areas.			Rees, G (corresponding author), INST NEUROL,WELCOME DEPT COGNIT NEUROL,QUEEN SQ,LONDON WC1N 3BG,ENGLAND.		Frith, Chris D/A-2171-2009; Rees, Geraint/C-1493-2008; Frackowiak, Richard/H-4383-2011; Frackowiak, Richard S/I-1809-2013	Frith, Chris D/0000-0002-8665-0690; Rees, Geraint/0000-0002-9623-7007; Frackowiak, Richard/0000-0002-3151-822X; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allport A., 1987, PERSPECTIVES PERCEPT, P395; BARBAS H, 1988, J COMP NEUROL, V276, P313, DOI 10.1002/cne.902760302; BARBAS H, 1981, J COMP NEUROL, V200, P407, DOI 10.1002/cne.902000309; Broadbent D.E., 1958, PERCEPTION COMMUNICA; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; CHAVIS DA, 1976, BRAIN RES, V117, P369, DOI 10.1016/0006-8993(76)90089-5; CORBETTA M, 1995, SCIENCE, V270, P802, DOI 10.1126/science.270.5237.802; CORBETTA M, 1991, J NEUROSCI, V11, P2383; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DUNCAN J, 1993, PERCEPTION, V22, P1261, DOI 10.1068/p221261; DUNCAN J, 1984, J EXP PSYCHOL GEN, V113, P501, DOI 10.1037/0096-3445.113.4.501; EGLIN M, 1991, CEREB CORTEX, V1, P263; FOX PT, 1985, ANN NEUROL, V17, P303, DOI 10.1002/ana.410170315; FOX PT, 1985, NEUROPHYSIOLOGY, V64, P349; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; FRISTON KJ, 1995, HUMAN BRAIN MAPPING, V2, P165; FUSTER JM, 1985, BRAIN RES, V330, P299, DOI 10.1016/0006-8993(85)90689-4; Harter M. R., 1984, VARIETIES ATTENTION, P293; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; JACOBSON S, 1977, BRAIN RES, V132, P209, DOI 10.1016/0006-8993(77)90417-6; JAMES W, 1976, PRINCIPLES PSYCHOL; JONES E G, 1970, Brain Behavior and Evolution, V93, P793, DOI 10.1093/brain/93.4.793; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; MILLER EK, 1993, J NEUROSCI, V13, P1460; MILLER EK, 1994, SCIENCE, V263, P520, DOI 10.1126/science.8290960; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; Neisser U., 2014, COGNITIVE PSYCHOL; ODRISCOLL GA, 1995, P NATL ACAD SCI USA, V92, P925, DOI 10.1073/pnas.92.3.925; PANDYA DN, 1969, BRAIN RES, V13, P13, DOI 10.1016/0006-8993(69)90141-3; PANDYA DN, 1971, BRAIN RES, V31, P35, DOI 10.1016/0006-8993(71)90632-9; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Paus T, 1996, NEUROPSYCHOLOGIA, V34, P475, DOI 10.1016/0028-3932(95)00134-4; PETRIDES M, 1988, J COMP NEUROL, V273, P52, DOI 10.1002/cne.902730106; PETRIDES M, 1978, NEUROPSYCHOLOGIA, V16, P527, DOI 10.1016/0028-3932(78)90080-5; POSNER MI, 1987, PSYCHOBIOLOGY, V15, P107; POSNER MI, 1994, TRENDS NEUROSCI, V17, P75, DOI 10.1016/0166-2236(94)90078-7; PRAGAY EB, 1987, EXP NEUROL, V96, P481, DOI 10.1016/0014-4886(87)90213-5; PRICE C, 1992, NEUROSCI LETT, V146, P179, DOI 10.1016/0304-3940(92)90072-F; Price CJ, 1996, NEUROIMAGE, V3, P40, DOI 10.1006/nimg.1996.0005; RICHMOND BJ, 1987, J NEUROPHYSIOL, V58, P1292, DOI 10.1152/jn.1987.58.6.1292; RICHMOND BJ, 1982, SOC NEUR ABSTR, V8, P812; SAHGAL A, 1975, NATURE, V257, P672, DOI 10.1038/257672a0; SAKAGAMI M, 1994, EXP BRAIN RES, V97, P423; SELTZER B, 1989, J COMP NEUROL, V281, P97, DOI 10.1002/cne.902810108; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TANAKA K, 1993, SCIENCE, V262, P685, DOI 10.1126/science.8235589; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; Vandenberghe R, 1995, NEUROIMAGE, V2, P306, DOI 10.1006/nimg.1995.1038; VECERA SP, 1994, J EXP PSYCHOL GEN, V123, P146, DOI 10.1037/0096-3445.123.2.146; WEBSTER MJ, 1994, CEREB CORTEX, V4, P470, DOI 10.1093/cercor/4.5.470; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	51	139	142	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					835	838		10.1126/science.275.5301.835	http://dx.doi.org/10.1126/science.275.5301.835			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012351				2022-12-01	WOS:A1997WG77700062
J	Mittrucker, HW; Matsuyama, T; Grossman, A; Kundig, TM; Potter, J; Shahinian, A; Wakeham, A; Patterson, B; Ohashi, PS; Mak, TW				Mittrucker, HW; Matsuyama, T; Grossman, A; Kundig, TM; Potter, J; Shahinian, A; Wakeham, A; Patterson, B; Ohashi, PS; Mak, TW			Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function	SCIENCE			English	Article							IMMUNOGLOBULIN-KAPPA GENE; FACTOR IRF-1; MICE; COMPARTMENT; APOPTOSIS; MEMBER; FAMILY; REGION	Lymphocyte-specific interferon regulatory factor (LSIRF) (now called IRF4) is a transcription factor expressed only in lymphocytes. Mice deficient in IRF4 showed normal distribution of B and T lymphocyes at 4 to 5 weeks of age but developed progressive generalized lymphadenopathy. IRF-4-deficient mice exhibited a profound reduction in serum immunoglobulin concentrations and did not mount detectable antibody responses. T lymphocyte function was also impaired in vivo; these mice could not generate cytotoxic or antitumor responses. Thus, IRF4 is essential for the function and homeostasis of both mature B and mature T lymphocytes.	UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M5G 2C1,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2C1,CANADA; AMGEN INST,TORONTO,ON M5G 2C1,CANADA; NAGASAKI UNIV,FAC MED,DEPT ONCOL,NAGASAKI 852,JAPAN; ONTARIO CANC INST,DEPT ONCOL PATHOL,TORONTO,ON M5G 2C1,CANADA	University of Toronto; University of Toronto; Nagasaki University; University of Toronto; University Toronto Affiliates; University Health Network Toronto				Ohashi, Pamela S./0000-0003-2915-9317				Benatar T, 1996, J EXP MED, V183, P329, DOI 10.1084/jem.183.1.329; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Grossman A, 1996, GENOMICS, V37, P229, DOI 10.1006/geno.1996.0547; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KNEITZ B, 1995, EUR J IMMUNOL, V25, P2572, DOI 10.1002/eji.1830250925; LAMPHIER M, 1994, IMMUNOLOGIST, V2, P167; LEIST TP, 1987, J IMMUNOL, V138, P2278; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; MEYER KB, 1990, NUCLEIC ACIDS RES, V18, P5609, DOI 10.1093/nar/18.19.5609; Mittrucker HW, 1996, J EXP MED, V183, P2481, DOI 10.1084/jem.183.6.2481; MITTRUCKER HW, UNPUB; MOMBAERTS P, 1994, INT IMMUNOL, V6, P1061, DOI 10.1093/intimm/6.7.1061; MOSKOPHIDIS D, 1989, P NATL ACAD SCI USA, V86, P3291, DOI 10.1073/pnas.86.9.3291; Schmits R, 1996, J EXP MED, V183, P1415, DOI 10.1084/jem.183.4.1415; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Yamagata T, 1996, MOL CELL BIOL, V16, P1283	25	455	459	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					540	543		10.1126/science.275.5299.540	http://dx.doi.org/10.1126/science.275.5299.540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999800				2022-12-01	WOS:A1997WE25700047
J	Minn, AJ; Velez, P; Schendel, SL; Liang, H; Muchmore, SW; Fesik, SW; Fill, M; Thompson, CB				Minn, AJ; Velez, P; Schendel, SL; Liang, H; Muchmore, SW; Fesik, SW; Fill, M; Thompson, CB			Bcl-x(L) forms an ion channel in synthetic lipid membranes	NATURE			English	Article							ENDOPLASMIC-RETICULUM; MITOCHONDRIAL-MEMBRANE; NUCLEAR-ENVELOPE; DIPHTHERIA-TOXIN; BCL-2; BILAYERS; TRANSLOCATION; COLICIN-E1; MECHANISM; APOPTOSIS	Bcl-2-related proteins are critical regulators of cell survival that are localized to the outer mitochondrial, outer nuclear and endoplasmic reticulum membranes(1-4). Despite their physiological importance, the biochemical function of Bcl-2-related proteins has remained elusive. The three-dimensional structure of Bcl-x(L), an inhibitor of apoptosis, was recently shown to be similar to the structures of the pore-forming domains of bacterial toxins(5). A key feature of these pore-forming domains is the ability to form ion channels in biological membranes(6,7). Here we demonstrate that Bcl-x(L) shares this functional feature. Like the bacterial toxins, Bcl-X(L) can insert into either synthetic lipid vesicles or planar Lipid bilayers and form an ion-conducting channel. This channel is pH-sensitive and becomes cation-selective at physiological pH. The ion-conducting channel(s) formed by Bcl-x(L) display multiple conductance states that have identical ion selectivity. Together, these data suggest that Bcl-x(L) may maintain cell survival by regulating the permeability of the intracellular membranes to which it is distributed.	LOYOLA UNIV, STRITCH SCH MED, CARDIOVASC INST, DEPT PHYSIOL, MAYWOOD, IL 60153 USA; UNIV CHICAGO, COMM IMMUNOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOL GENET & CELL BIOL, CHICAGO, IL 60637 USA; PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA; ABBOTT LABS, DIV PHARMACEUT DISCOVERY, PROT CRYSTALLOG, ABBOTT PK, IL 60064 USA; ABBOTT LABS, NMR RES, ABBOTT PK, IL 60064 USA; UNIV CHICAGO, GWEN KNAPP CTR LUPUS & IMMUNOL RES, CHICAGO, IL 60637 USA	Loyola University Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago; University of Chicago; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Abbott Laboratories; Abbott Laboratories; University of Chicago				Schendel, Sharon/0000-0002-5062-7261; Minn, Andy/0000-0003-1418-0906				CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; Cramer W.A., 1990, ENERGY TRANSDUCTION; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.bb.24.060195.003143; DAVIDSON VL, 1984, J MEMBRANE BIOL, V79, P105, DOI 10.1007/BF01872115; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; MANNELLA CA, 1992, TRENDS BIOCHEM SCI, V17, P315, DOI 10.1016/0968-0004(92)90444-E; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; PETERSON AA, 1987, J MEMBRANE BIOL, V99, P197, DOI 10.1007/BF01995700; RAYMOND L, 1985, J MEMBRANE BIOL, V84, P173, DOI 10.1007/BF01872215; SLATIN SL, 1990, BIOCHEM BIOPH RES CO, V169, P765, DOI 10.1016/0006-291X(90)90397-6; Tomarev SI, 1996, EUR J BIOCHEM, V235, P449, DOI 10.1111/j.1432-1033.1996.00449.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zakharov SD, 1996, BIOPHYS J, V70, P2774, DOI 10.1016/S0006-3495(96)79847-8; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	29	717	736	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 23	1997	385	6614					353	357		10.1038/385353a0	http://dx.doi.org/10.1038/385353a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002522				2022-12-01	WOS:A1997WD91400054
J	Davin, LB; Wang, HB; Crowell, AL; Bedgar, DL; Martin, DM; Sarkanen, S; Lewis, NG				Davin, LB; Wang, HB; Crowell, AL; Bedgar, DL; Martin, DM; Sarkanen, S; Lewis, NG			Stereoselective bimolecular phenoxy radical coupling by an auxiliary (dirigent) protein without an active center	SCIENCE			English	Article							CONIFERYL ALCOHOL OXIDASE; LIGNIFICATION; LIGNIN; (+)-PINORESINOL; MONOLIGNOLS; LACCASES	The regio- and stereospecificity of bimolecular phenoxy radical coupling reactions, of especial importance in lignin and lignan biosynthesis, are clearly controlled in some manner in vivo; yet in vitro coupling by oxidases, such as laccases, only produce racemic products. In other words, laccases, peroxidases, and comparable oxidases ave unable to control regio- or stereospecificity by themselves and thus some other agent must exist. A 78-kilodalton protein has been isolated that, in the presence of an oxidase or one electron oxidant, effects stereoselective bimolecular phenoxy radical coupling in vitro. Itself lacking a catalytically active (oxidative) center, its mechanism of action is presumed to involve capture of E-coniferyl alcohol-derived free-radical intermediates, with consequent stereoselective coupling to give (+)-pinoresinol.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164; UNIV MINNESOTA,DEPT WOOD & PAPER SCI,KAUFERT LAB,ST PAUL,MN 55108	Washington State University; University of Minnesota System; University of Minnesota Twin Cities				Lewis, Norman/0000-0001-5742-032X; Davin, Laurence/0000-0002-3248-6485				Ayres D., 1990, CHEM PHARM NATURAL P; BAO W, 1993, SCIENCE, V260, P672, DOI 10.1126/science.260.5108.672; BERNARDS MA, 1995, J BIOL CHEM, V270, P7382, DOI 10.1074/jbc.270.13.7382; BRUICE TC, 1980, ACCOUNTS CHEM RES, V13, P256, DOI 10.1021/ar50152a002; BULOCK JD, 1962, J CHEM SOC, P2085, DOI 10.1039/jr9620002085; CAMERON DW, 1967, ORGANIC SUBSTANCES N, V1, P203; Davin L.B., 1995, AN ACAD BRAS CIEN S3, V67, P363; DAVIN LB, 1992, PHYTOCHEMISTRY, V31, P3869, DOI 10.1016/S0031-9422(00)97544-7; DEYAMA T, 1983, CHEM PHARM BULL, V31, P2993; ERDTMAN H, 1939, SVENSK PAPPERSTIDN, V42, P115; FREUDENBERG K, 1958, CHEM BER-RECL, V91, P581, DOI 10.1002/cber.19580910317; FREUDENBERG K, 1959, NATURE, V183, P1152, DOI 10.1038/1831152a0; FREUDENBERG K, 1965, SCIENCE, V148, P595, DOI 10.1126/science.148.3670.595; Gottlieb O. R., 1989, NATURAL PRODUCTS WOO, P439; HARKIN JM, 1973, SCIENCE, V180, P296, DOI 10.1126/science.180.4083.296; HIGUCHI T, 1957, PHYSIOL PLANTARUM, V10, P356, DOI 10.1111/j.1399-3054.1957.tb06958.x; IQBAL J, 1994, CHEM REV, V94, P519, DOI 10.1021/cr00026a008; KOBLITZ H, 1964, NATURE, V204, P199, DOI 10.1038/204199a0; LEWIS NG, 1994, ACS SYM SER, V562, P202; Marmaras VJ, 1996, ARCH INSECT BIOCHEM, V31, P119, DOI 10.1002/(SICI)1520-6327(1996)31:2&lt;119::AID-ARCH1&gt;3.0.CO;2-V; MASON HS, 1955, J AM CHEM SOC, V77, P491, DOI 10.1021/ja01607a087; MIESSNER M, 1991, HELV CHIM ACTA, V74, P1205, DOI 10.1002/hlca.19910740607; NOSE M, 1995, PHYTOCHEMISTRY, V39, P71, DOI 10.1016/0031-9422(95)95268-Y; PARE PW, 1994, TETRAHEDRON LETT, V35, P4731, DOI 10.1016/S0040-4039(00)76953-X; RAGAN MA, 1984, PHYTOCHEMISTRY, V23, P2029, DOI 10.1016/S0031-9422(00)84964-X; SAVIDGE R, 1992, PHYTOCHEMISTRY, V31, P2959, DOI 10.1016/0031-9422(92)83427-Z; STERJIADES R, 1992, PLANT PHYSIOL, V99, P1162, DOI 10.1104/pp.99.3.1162; STERJIADES R, 1993, PLANTA, V190, P75, DOI 10.1007/BF00195678; UDAGAMARANDENIYA P, 1994, ELECTROPHORESIS, V15, P1072, DOI 10.1002/elps.11501501160; USAITIS A, 1994, POLYMER, V35, P4896	30	517	537	9	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					362	366		10.1126/science.275.5298.362	http://dx.doi.org/10.1126/science.275.5298.362			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994027				2022-12-01	WOS:A1997WC87300038
J	Haley, RW; Kurt, TL; Hom, J				Haley, RW; Kurt, TL; Hom, J			Is there a gulf war syndrome? Searching for syndromes by factor analysis of symptoms	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Research Conference on the Gulf War Illness	OCT 26, 1995	CTR DIS CONTROL & PREVENT, ATLANTA, GA		CTR DIS CONTROL & PREVENT		VALIDITY; RELIABILITY; VALIDATION; MODEL; MMPI	Objective.-To search for syndromes in Persian Gulf War veterans. Participants.-Two hundred forty-nine (41%) of the 606 Gulf War veterans of the Twenty-fourth Reserve Naval Mobile Construction Battalion living in 5 south-eastern states participated; 145 (58%) had retired from service, and the rest were still serving in the battalion. Design.-Participants completed a standardized survey booklet measuring the anatomical distributions or characteristics of each symptom, a booklet measuring wartime exposures, and a standard psychological personality assessment inventory. Two-stage factor analysis was used to disentangle ambiguous symptoms and identify syndromes. Main Outcome Measures.-Factor analysis-derived syndromes, Results.-Of 249 participants, 175 (70%) reported having had serious health problems that most attributed to the war, and 74 (30%) reported no serious health problems. Principal factor analysis yielded 6 syndrome factors, explaining 71% of the variance. Dichotomized syndrome indicators identified the syndromes in 63 veterans (25%). Syndromes 1 (''impaired cognition,'' characterized by problems with attention, memory, and reasoning, as well as insomnia, depression, daytime sleepiness, and headaches), 2 (''confusion-ataxia,'' characterized by problems with thinking, disorientation, balance disturbances, vertigo, and impotence), and 3 (''arthro-myo-neuropathy,'' characterized by joint and muscle pains, muscle fatigue, difficulty lifting, and extremity paresthesias) represented strongly clustered symptoms; whereas, syndromes 4 (''phobia-apraxia''), 5 (''fever-adenopathy''), and 6 (''weakness-incontinence'') involved weaker clustering and mostly overlapped syndromes 2 and 3. Veterans with syndrome 2 were 12.5 times (95% confidence interval, 3.5-44.8) more likely to be unemployed than those with no health problems. A psychological profile, found in 48.4% of those with the syndromes, differed from posttraumatic stress disorder, depression, somatoform disorder, and malingering. Conclusion.-These findings support the hypothesis that clusters of symptoms of many Gulf War, veterans represent discrete factor analysis-derived syndromes that appear to reflect a spectrum of neurologic injury involving the central, peripheral, and autonomic nervous systems.	UNIV TEXAS, SW MED CTR, DEPT NEUROL, DALLAS, TX 75235 USA; NEUROPSYCHOL CTR, DALLAS, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Haley, RW (corresponding author), UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DIV EPIDEMIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.		Haley, Robert/P-9026-2014	Haley, Robert/0000-0001-8849-9579				Alfano Dennis P, 1990, Clin Neuropsychol, V4, P69, DOI 10.1080/13854049008401498; ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P111; American Psychiatric Association (Washington), 2000, DSM 4 T DIAGN STAT M; Anastasi A., 1988, PSYCHOL TESTING; [Anonymous], 1994, JAMA, V272, P391; [Anonymous], 1995, Arch Intern Med, V155, P262; BLACK FW, 1974, J CLIN PSYCHOL, V30, P571, DOI 10.1002/1097-4679(197410)30:4<571::AID-JCLP2270300432>3.0.CO;2-W; Cattell R. B., 1978, SCI USE FACTOR ANAL, DOI [DOI 10.1007/978-1-4684-2262-7_5, 10.1007/978-1-4684-2262-7_5]; Cattell RB., 1966, HDB MULTIVARIATE EXP, P174; CERNY BA, 1977, MULTIVAR BEHAV RES, V12, P43, DOI 10.1207/s15327906mbr1201_3; COMREY AL, 1978, J CONSULT CLIN PSYCH, V46, P648, DOI 10.1037/0022-006X.46.4.648; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; *DEF SCI BOARD, 1994, REP DEF SCI BOARD TA; ELLENBERG JH, 1994, STAT MED, V13, P557, DOI 10.1002/sim.4780130518; FINK LA, 1995, AM J PSYCHIAT, V152, P1329, DOI 10.1176/ajp.152.9.1329; Gorsuch R., 1983, FACTOR ANAL; Gould S. J., 1981, MISMEASURE OF MAN; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P231, DOI 10.1001/jama.277.3.231; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P223, DOI 10.1001/jama.277.3.223; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; *I MED MED FOLL AG, 1995, HLTH CONS SERV PERS; Joliffe I T, 1992, Stat Methods Med Res, V1, P69, DOI 10.1177/096228029200100105; KAMARCK TW, 1994, HEALTH PSYCHOL, V13, P471, DOI 10.1037/0278-6133.13.6.471; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; Kleinbaum D, 1982, EPIDEMIOLOGIC RES PR, P194; LEVY A, 1992, Brain Injury, V6, P401, DOI 10.3109/02699059209008136; LINDENMAYER JP, 1995, PSYCHOPATHOLOGY, V28, P22, DOI 10.1159/000284896; MENDELSON G, 1991, THEOR MED, V12, P227, DOI 10.1007/BF00489608; MEYERINK LH, 1988, J CLIN PSYCHOL, V44, P764, DOI 10.1002/1097-4679(198809)44:5<764::AID-JCLP2270440517>3.0.CO;2-Y; Morey, 1996, INTERPRETATIVE GUIDE; Morey L. C., 1991, PERSONALITY ASSESSME; Morey L. C., 1993, 101 ANN M AM PSYCH A; *PERS GULF VET COO, 1994, SUMM ISS IMP HLTH PE; SAS Institute Inc, 1990, SAS STAT US GUID VER, V4; STREINER DL, 1994, CAN J PSYCHIAT, V39, P135, DOI 10.1177/070674379403900303; Taub E, 1995, DIGEST DIS SCI, V40, P2647, DOI 10.1007/BF02220455; *US DEP DEF, 1996, COMPREHENSIVE CLIN E	37	287	292	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1997	277	3					215	222		10.1001/jama.277.3.215	http://dx.doi.org/10.1001/jama.277.3.215			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WB446	9005271				2022-12-01	WOS:A1997WB44600023
J	Pobel, D; Viel, JF				Pobel, D; Viel, JF			Case-control study of leukaemia among young people near La Hague nuclear reprocessing plant: The environmental hypothesis revisited	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD LEUKEMIA INCIDENCE; NON-HODGKINS-LYMPHOMA; WEST CUMBRIA; RADIATION; CHILDREN; CANCER; INSTALLATION; WINDSCALE; CAITHNESS; RESIDENT	Objective: To investigate the association between childhood leukaemia and established risk factors or other factors related to La Hague nuclear waste reprocessing plant. Design: Case-control study. Setting: Area within a 35 km radius of La Hague, Normandy, France. Subjects: Twenty seven cases of leukaemia diagnosed during the period 1978-93 in people aged under 25 years and 192 controls matched for sex, age, place of birth, and residence at time of diagnosis. Main outcome measures: Antenatal and postnatal exposure to x rays and viral infections, occupational exposure of parents (particularly ionising radiation), living conditions, lifestyle of parents and children. Results: Increased trends were found for use of local beaches by mothers and children (P less than or equal to 0.01); relative risks 2.87 (95% confidence intervals 1.05 to 8.72) and 4.49 (1.52 to 15.23) when categories were aggregated in two levels (more or less than once a month). Consumption of local fish and shellfish also showed an increased trend (P 0.01); relative risk 2.66 (0.91 to 9.51) when categories were grouped in two levels (more or less than once a week). A relative risk of 1.18 a year (1.03 to 1.42) was observed for length of residence in a granite-built house or in a granitic area. No association was shown with occupational radiation exposure in parents. Conclusions: There is some convincing evidence in childhood leukaemia of a causal role for environmental radiation exposure from recreational activities on beaches. New methods for identifying the environmental pathways, focusing on marine ecosystems, are warranted.	FAC MED,DEPT PUBL HLTH,BIOSTAT & EPIDEMIOL UNIT,F-25030 BESANCON,FRANCE	Universite de Franche-Comte; CHU Besancon			Viel, Jean-Francois/K-2224-2015	Viel, Jean-Francois/0000-0002-6716-7468				ALEXANDER FE, 1990, LANCET, V335, P1336; BLACK RJ, 1994, J EPIDEMIOL COMMUN H, V48, P232, DOI 10.1136/jech.48.3.232; *COMM MED ASP RAD, 1988, 2 REP INV POSS INCR; *CYT SOFTW, 1995, STATX 3 WIND; *CYT SOFTW, 1993, LOGX; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; DRAPER GJ, 1993, BRIT MED J, V306, P89, DOI 10.1136/bmj.306.6870.89; GARDNER MJ, 1984, LANCET, V1, P216; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; HATCH M, 1990, INT J EPIDEMIOL, V19, P546, DOI 10.1093/ije/19.3.546; HEASMAN MA, 1986, LANCET, V266, P385; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; *IND ADV GROUP, 1984, INV POSS INCR INC CA; KNOX E G, 1988, Journal of Radiological Protection, V8, P9, DOI 10.1088/0952-4746/8/1/302; MCLAUGHLIN JR, 1993, BRIT MED J, V307, P959, DOI 10.1136/bmj.307.6910.959; MULDER YM, 1994, J EPIDEMIOL COMMUN H, V48, P161, DOI 10.1136/jech.48.2.161; *NAT RES COUNC COM, RAD DOS REC EP US; RICHARDSON S, 1995, STAT MED, V14, P2487, DOI 10.1002/sim.4780142116; URQUHART J, 1984, LANCET, V1, P217; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; VIEL JF, 1995, STAT MED, V14, P2459, DOI 10.1002/sim.4780142114; VIEL JF, 1993, CANCER CAUSE CONTROL, V4, P341, DOI 10.1007/BF00051336; VIEL JF, 1990, BRIT MED J, V300, P580, DOI 10.1136/bmj.300.6724.580	24	69	71	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					101	106		10.1136/bmj.314.7074.101	http://dx.doi.org/10.1136/bmj.314.7074.101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006467	Green Published			2022-12-01	WOS:A1997WC47900019
J	Huszar, D; Lynch, CA; FairchildHuntress, V; Dunmore, JH; Fang, Q; Berkemeier, LR; Gu, W; Kesterson, RA; Boston, BA; Cone, RD; Smith, FJ; Campfield, LA; Burn, P; Lee, F				Huszar, D; Lynch, CA; FairchildHuntress, V; Dunmore, JH; Fang, Q; Berkemeier, LR; Gu, W; Kesterson, RA; Boston, BA; Cone, RD; Smith, FJ; Campfield, LA; Burn, P; Lee, F			Targeted disruption of the melanocortin-4 receptor results in obesity in mice	CELL			English	Article							MELANOCYTE-STIMULATING-HORMONE; YELLOW A(VY)/ MICE; MOLECULAR-CLONING; AGOUTI GENE; BODY-WEIGHT; ECTOPIC EXPRESSION; COAT COLOR; MOUSE; PROTEIN; MSH	The melanocortin-4 receptor (MC4-R) is a G protein-coupled, seven-transmembrane receptor expressed in the brain. Inactivation of this receptor by gene targeting results in mice that develop a maturity onset obesity syndrome associated with hyperphagia, hyperinsulinemia, and hyperglycemia. This syndrome recapitulates several of the characteristic features of the agouti obesity syndrome, which results from ectopic expression of agouti protein, a pigmentation factor normally expressed in the skin. Our data identify a novel signaling pathway in the mouse for body weight regulation and support a model in which the primary mechanism by which agouti induces obesity is chronic antagonism of the MC4-R.	OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT PEDIAT, PORTLAND, OR 97201 USA; HOFFMANN LA ROCHE INC, DEPT METAB DIS, NUTLEY, NJ 07110 USA	Oregon Health & Science University; Oregon Health & Science University; Roche Holding	Huszar, D (corresponding author), MILLENNIUM PHARMACEUT INC, 640 MEM DR, CAMBRIDGE, MA 02139 USA.							ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BRAY GA, 1984, INT J OBESITY, V8, P119; BRAY GA, 1987, NUTR REV, V45, P33; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; CARPENTER KJ, 1958, AM J PHYSIOL, V193, P499, DOI 10.1152/ajplegacy.1958.193.3.499; Castle WE, 1941, GENETICS, V26, P177; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; COLEMAN DL, 1977, DIABETOLOGIA, V13, P25, DOI 10.1007/BF00996323; DEWIED D, 1982, PHYSIOL REV, V62, P976, DOI 10.1152/physrev.1982.62.3.976; DICKERSON GE, 1947, SCIENCE, V105, P496, DOI 10.1126/science.105.2732.496-a; DICKIE MM, 1946, J HERED, V37, P365, DOI 10.1093/oxfordjournals.jhered.a105562; DUBUC PU, 1975, HORM METAB RES, V7, P102, DOI 10.1055/s-0028-1095645; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; FAN W, 1997, IN PRESS NATURE; FENG JD, 1987, BRAIN RES BULL, V18, P473, DOI 10.1016/0361-9230(87)90111-0; FERRY WL, 1995, GENETICS, V140, P267; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; FRIGERI LG, 1983, ENDOCRINOLOGY, V113, P2097, DOI 10.1210/endo-113-6-2097; FRIGERI LG, 1988, INT J OBESITY, V12, P305; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1994, BIOCHEM BIOPH RES CO, V200, P1214, DOI 10.1006/bbrc.1994.1580; GANTZ I, 1993, J BIOL CHEM, V268, P8246; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; GRIFFON N, 1994, BIOCHEM BIOPH RES CO, V200, P1007, DOI 10.1006/bbrc.1994.1550; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HESTON WE, 1962, J NATL CANCER I, V29, P197; HRUBY VJ, 1995, J MED CHEM, V38, P3454, DOI 10.1021/jm00018a005; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; JACOBOWITZ DM, 1978, P NATL ACAD SCI USA, V75, P6300, DOI 10.1073/pnas.75.12.6300; JOHNSON PR, 1972, J LIPID RES, V13, P2; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; KLEIN MC, 1985, LIFE SCI, V36, P769, DOI 10.1016/0024-3205(85)90197-3; LABBE O, 1994, BIOCHEMISTRY-US, V33, P4543, DOI 10.1021/bi00181a015; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LIN SY, 1987, HYPERTENSION, V10, P619, DOI 10.1161/01.HYP.10.6.619; LIPTON JM, 1980, PEPTIDES, V1, P15, DOI 10.1016/0196-9781(80)90029-7; Low M.J., 1994, CURR OPIN ENDOCRINOL, V1, P79; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MANNE J, 1995, P NATL ACAD SCI USA, V92, P4721, DOI 10.1073/pnas.92.11.4721; MICHAUD EJ, 1993, GENE DEV, V7, P1203, DOI 10.1101/gad.7.7a.1203; MICHAUD EJ, 1994, P NATL ACAD SCI USA, V91, P2562, DOI 10.1073/pnas.91.7.2562; MICHAUD EJ, 1994, GENE DEV, V8, P1483; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; Mizuno TM, 1996, P NATL ACAD SCI USA, V93, P3434, DOI 10.1073/pnas.93.8.3434; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; MURPHY JV, 1955, J COMP PHYSIOL PSYCH, V48, P47, DOI 10.1037/h0043004; MURPHY MT, 1983, SCIENCE, V221, P192, DOI 10.1126/science.6602381; ODONOHUE TL, 1982, PEPTIDES, V3, P353, DOI 10.1016/0196-9781(82)90098-5; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; SANACORA G, 1990, ENDOCRINOLOGY, V127, P730, DOI 10.1210/endo-127-2-730; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; SEARLE AG, 1968, J HERED, V59, P341, DOI 10.1093/oxfordjournals.jhered.a107739; SHIMIZU H, 1989, LIFE SCI, V45, P543, DOI 10.1016/0024-3205(89)90105-7; Silvers W. K., 1979, COAT COLORS MICE, P6; SILVERS WK, 1955, J EXP ZOOL, V130, P199, DOI 10.1002/jez.1401300203; SOLOMON J, 1973, ENDOCRINOLOGY, V93, P510, DOI 10.1210/endo-93-2-510; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WARBRITTON A, 1994, P SOC EXP BIOL MED, V206, P145, DOI 10.3181/00379727-206-43733; WATSON SJ, 1978, NATURE, V275, P226, DOI 10.1038/275226a0; WOLFF GL, 1971, NATURE-NEW BIOL, V232, P181, DOI 10.1038/newbio232181a0; WOLFF GL, 1986, J HERED, V77, P151, DOI 10.1093/oxfordjournals.jhered.a110206; WOLFF GL, 1987, AM J CLIN NUTR, V45, P168, DOI 10.1093/ajcn/45.1.168; WOLFF GL, 1978, J HERED, V69, P295, DOI 10.1093/oxfordjournals.jhered.a108953; WOLFF GL, 1963, GENETICS, V48, P1041; YEN T T T, 1970, Hormone and Metabolic Research, V2, P200; YEN TT, 1976, BIOCHIM BIOPHYS ACTA, V441, P213, DOI 10.1016/0005-2760(76)90164-8; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; YEN TT, 1976, HORM METAB RES, V8, P159, DOI 10.1055/s-0028-1093672; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	86	2391	2535	4	102	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1997	88	1					131	141		10.1016/S0092-8674(00)81865-6	http://dx.doi.org/10.1016/S0092-8674(00)81865-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019399	Bronze			2022-12-01	WOS:A1997WC56900016
J	Mogami, H; Nakano, K; Tepikin, AV; Petersen, OH				Mogami, H; Nakano, K; Tepikin, AV; Petersen, OH			Ca2+ flow via tunnels in polarized cells: Recharging of apical Ca2+ stores by focal Ca2+ entry through basal membrane patch	CELL			English	Article							PANCREATIC ACINAR-CELLS; CAPACITATIVE CALCIUM-ENTRY; INOSITOL TRISPHOSPHATE; EXOCRINE PANCREAS; ACTIVATION; CHANNELS; SIGNALS; OSCILLATIONS; HEPATOCYTES; MICROSCOPY	Intracellular Ca2+ store depletion induces Ca2+ entry across the plasma membrane, allowing the store to recharge. In our experiments, Ca2+ stores in pancreatic acinar cells were depleted by acetylcholine (ACh) stimulation in Ca2+-free solution. Thereafter, Ca2+ entry was only allowed through a CaCl2-containing pipette attached to the basal membrane. Recharging intracellular Ca2+ stores via a patch pipette occurred without a rise in the cytosolic Ca2+ concentration and depended on the operation of a thapsigargin-sensitive Ca2+ pump. After a period of focal Ca2+ entry, ACh could again evoke a rise in the cytosolic Ca2+ concentration, and this rise always started in the apical secretory pole. Recharging the apical Ca2+ store therefore depends on Ca2+ flow through a tunnel from the basal to the secretory pole, and the endoplasmic reticulum Ca2+ pump is essential for this process.	UNIV LIVERPOOL,PHYSIOL LAB,MRC,SECRETORY CONTROL RES GRP,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool			Petersen, Ole H/E-8708-2010	Petersen, Ole/0000-0002-6998-0380; Tepikin, Alexei/0000-0002-8172-7513				BAUM BJ, 1988, BIOCHEM J, V254, P649, DOI 10.1042/bj2540649; BENNETT DL, 1995, CURR BIOL, V5, P1225, DOI 10.1016/S0960-9822(95)00243-0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Camello P, 1996, J PHYSIOL-LONDON, V490, P585, DOI 10.1113/jphysiol.1996.sp021169; ELLIOTT AC, 1992, PFLUG ARCH EUR J PHY, V422, P245, DOI 10.1007/BF00376209; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; Gerasimenko OV, 1996, PFLUG ARCH EUR J PHY, V432, P1055, DOI 10.1007/s004240050234; Gorelick Frederick S., 1994, P1353; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORBER JKH, 1995, BIOPHYS J, V68, P1687, DOI 10.1016/S0006-3495(95)80346-2; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; Kern Horst F., 1993, P9; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; PETERSEN CCH, 1993, J BIOL CHEM, V268, P22262; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; Petersen OH, 1996, TRENDS NEUROSCI, V19, P411; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PETERSEN OH, 1983, SINGLE CHANNEL RECOR, P425; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; RUKNUDIN A, 1991, J CELL BIOL, V112, P125, DOI 10.1083/jcb.112.1.125; Sasaki S, 1996, PFLUG ARCH EUR J PHY, V432, P538, DOI 10.1007/s004240050167; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMAS AP, 1995, CIBA F SYMP, V188, P18; Thorn P, 1996, EMBO J, V15, P999, DOI 10.1002/j.1460-2075.1996.tb00436.x; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TOESCU EC, 1992, J BIOL CHEM, V267, P23467; TOESCU EC, 1995, J BIOL CHEM, V270, P8528, DOI 10.1074/jbc.270.15.8528; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	39	238	240	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					49	55		10.1016/S0092-8674(00)81857-7	http://dx.doi.org/10.1016/S0092-8674(00)81857-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019404	Bronze			2022-12-01	WOS:A1997WC56900008
J	deNooij, JC; Letendre, MA; Hariharan, IK				deNooij, JC; Letendre, MA; Hariharan, IK			A cyclin-dependent kinase inhibitor, dacapo, is necessary for timely exit from the cell cycle during Drosophila embryogenesis	CELL			English	Article							S-PHASE; NERVOUS-SYSTEM; GENE; MELANOGASTER; EXPRESSION; EMBRYOS; CLONING; DOMAIN; EYE; P57(KIP2)	In a screen for genes that interact with the Rap1 GTPase, we have identified a Drosophila gene, dacapo (dap), which is a member of the p21/p27 family of cdk inhibitors. Unlike mammalian cdk inhibitors studied to dale, dap is essential for normal embryonic development. Dacapo inhibits cyclin-cdk activity in vitro. Overexpressing dap during eye development interferes with cell cycle progression and interacts genetically with the retinoblastoma homolog (Rbf) and cyclin E. dap expression in embryos parallels the exit of cells from the cell cycle. dap mutant embryos delay the normal cell cycle exit during development; many cells complete an additional cycle and subsequently become quiescent. Thus, dap functions during embryogenesis to achieve a precisely timed exit from the cell cycle.			deNooij, JC (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BLDG 149,13TH ST,CHARLESTOWN,MA 02129, USA.							BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAMPOSORTEGA JA, 1993, DEV DROSOPHILA MELAN, P149; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FOE VE, 1989, DEVELOPMENT, V107, P1; Foe Victoria E., 1993, P149; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HARTENSTEIN V, 1987, ROUX ARCH DEV BIOL, V196, P473, DOI 10.1007/BF00399871; HAY BA, 1994, DEVELOPMENT, V120, P2121; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEHNER CF, 1991, COLD SH Q B, V56, P465; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; Murray A., 1993, CELL CYCLE INTRO; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OBRIEN MA, 1994, GENETICS, V137, P121; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PATEL NH, 1994, DROSOPHILA MELANOGAS, P445; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PROKOP A, 1991, DEVELOPMENT, V111, P79; RICHARDSON H, 1995, DEVELOPMENT, V121, P3371; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; Sambrook J., 1989, MOL CLONING LAB MANU; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Williamson A, 1996, ANNU REV CELL DEV BI, V12, P365, DOI 10.1146/annurev.cellbio.12.1.365; XU T, 1993, DEVELOPMENT, V117, P1223; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	47	280	281	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1237	1247		10.1016/S0092-8674(00)81819-X	http://dx.doi.org/10.1016/S0092-8674(00)81819-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980230	Bronze			2022-12-01	WOS:A1996WA54100012
J	Studer, M; Lumsden, A; ArizaMcNaughton, L; Bradley, A; Krumlauf, R				Studer, M; Lumsden, A; ArizaMcNaughton, L; Bradley, A; Krumlauf, R			Altered segmental identity and abnormal migration of motor neurons in mice lacking Hoxb-1	NATURE			English	Article							ZINC-FINGER GENE; MOUSE HINDBRAIN; CRABP-I; EXPRESSION; HOXA-1; TRANSFORMATION; EMBRYOGENESIS; ORGANIZATION; TRANSCRIPTS; PATTERNS	SEGMENTATION of the vertebrate hindbrain into rhombomeres is important for the anterior-posterior arrangement of cranial motor nuclei and efferent nerves'. Underlying this reiterated organization, Hox genes display segmentally restricted domains of expression(2-4), such as expression of Hoxb-1 (refs 5, 6) in rhombomere 4 (r4). Here we report that absence of Hoxb-1 leads to changes in r4 identity. In mutant mouse embryos, molecular markers indicate that patterning of r4 is initiated properly but not maintained. Cellular analysis by DiI tracing reveals that the r4-specific facial branchiomotor (FBM) and contralateral vestibuloacoustic efferent (CVA) neurons are incorrectly specified. In wild-type mice CVA neurons migrate from r4 into the contralateral side(7), and we found in lineage analysis that FBM neurons migrate from r4 into r5. In mutants, motor neurons differentiate but the CVA and FBM neurons fail to migrate into their proper positions. Instead, they form a motor nucleus which migrates atypically, and there is a subsequent loss of the facial motor nerve. These results demonstrate that, as a part of its role in maintaining rhombomere identity, Hoxb-1 is involved in controlling migratory properties of motor neurons in the hindbrain.	NATL INST MED RES,MRC,DIV DEV NEUROBIOL,LONDON NW7 1AA,ENGLAND; UNITED MED & DENT SCH,GUYS HOSP,DEPT DEV NEUROBIOL,LONDON SE1 9RT,ENGLAND; BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030	MRC National Institute for Medical Research; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Baylor College of Medicine; Howard Hughes Medical Institute			Krumlauf, Robb/AAH-5012-2019; Lumsden, Andrew/C-5146-2009; Studer, Michele/P-4580-2016	Krumlauf, Robb/0000-0001-9102-7927; Studer, Michele/0000-0001-7105-2957; Bradley, Allan/0000-0002-2349-8839				ALEXANDRE D, 1996, DEVELOPMENT, V122, P723; Altman J., 1982, DEV CRANIAL NERVE GA; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; FRASCH M, 1995, DEVELOPMENT, V121, P957; HUME CR, 1993, DEVELOPMENT, V119, P1147; HUNT P, 1991, NATURE, V353, P891; Irving C, 1996, DEV BIOL, V173, P26, DOI 10.1006/dbio.1996.0004; Itasaki N, 1996, NEURON, V16, P487, DOI 10.1016/S0896-6273(00)80069-0; KEYNES R, 1994, ANNU REV NEUROSCI, V17, P109, DOI 10.1146/annurev.ne.17.030194.000545; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MADEN M, 1992, MECH DEVELOP, V37, P13, DOI 10.1016/0925-4773(92)90011-8; MARK M, 1993, DEVELOPMENT, V119, P219; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MCKAY I, IN PRESS MOL CELL NE; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; NIETO MA, 1992, DEVELOPMENT, V116, P1137; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; RAMIREZSOLIS R, 1993, GUIDE TECHNIQUES MOU, P885; RUBERTE E, 1992, DEVELOPMENT, V115, P973; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SIMON H, 1993, NEURON, V11, P209, DOI 10.1016/0896-6273(93)90179-U; STUDER M, 1994, SCIENCE, V265, P1728, DOI 10.1126/science.7916164; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	34	336	337	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 19	1996	384	6610					630	634		10.1038/384630a0	http://dx.doi.org/10.1038/384630a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VZ296	8967950				2022-12-01	WOS:A1996VZ29600030
J	Langenberg, M; Hellemons, BSP; vanRee, JW; Vermeer, F; Lodder, J; Schouten, HA; Knottnerus, JA				Langenberg, M; Hellemons, BSP; vanRee, JW; Vermeer, F; Lodder, J; Schouten, HA; Knottnerus, JA			Atrial fibrillation in elderly patients: Prevalence and comorbidity in general practice	BRITISH MEDICAL JOURNAL			English	Article									UNIV MAASTRICHT,DEPT METHODOL & STAT,NL-6200 MD MAASTRICHT,NETHERLANDS; ACAD HOSP MAASTRICHT,DEPT CARDIOL,MAASTRICHT,NETHERLANDS; ACAD HOSP MAASTRICHT,DEPT NEUROL,MAASTRICHT,NETHERLANDS	Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)	Langenberg, M (corresponding author), UNIV MAASTRICHT,DEPT GEN PRACTICE,POB 616,NL-6200 MD MAASTRICHT,NETHERLANDS.		Knottnerus, Andre/F-4866-2013; Knottnerus, Johannes A/A-3829-2009					*ATR FIBR INV, 1994, ARCH INTERN MED, V154, P1449; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; Lip GYH, 1996, BRIT MED J, V312, P175; METSEMAKERS JFM, 1992, BRIT J GEN PRACT, V42, P102; *STROK ED OFF, 1994, STROKE, V25, P1318	5	58	58	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1534	1534		10.1136/bmj.313.7071.1534	http://dx.doi.org/10.1136/bmj.313.7071.1534			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY691	8978233	Green Published			2022-12-01	WOS:A1996VY69100027
J	Hodge, MR; Chun, HJ; Rengarajan, J; Alt, A; Lieberson, R; Glimcher, LH				Hodge, MR; Chun, HJ; Rengarajan, J; Alt, A; Lieberson, R; Glimcher, LH			NF-AT-driven interleukin-4 transcription potentiated by NIP45	SCIENCE			English	Article							CYCLOSPORINE-A; T-CELLS; GENE; IDENTIFICATION; ROLES; AP-1	The induction of cytokine gene transcription is mediated in part by the nuclear factor of activated T cells (NF-AT). Factors involved in the mechanisms of NF-AT-mediated transcription are not well understood. A nuclear factor that interacted with the Rel homology domain (RHD) of NF-ATp was identified with the use of a two-hybrid interaction trap. Designated NIP45 (NF-AT interacting protein), it has minimal similarity to any known genes. Transcripts encoding this factor were enriched in lymphoid tissues and testes. NIP45 synergized with NF-ATp and the proto-oncogene c-Maf to activate the interleukin-4 (IL-4) cytokine promoter; transient overexpression of NIP45 with NF-ATp and c-maf in B lymphoma cells induced measurable endogenous IL-4 protein production. The identification of NIP45 advances our understanding of gene activation of cytokines, critical mediators of the immune response.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School			chun, hyung/AAE-1463-2020; Chun, Hyung/K-1859-2013	Chun, Hyung/0000-0003-3508-2678	NIAID NIH HHS [AI37833] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI037833] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; HODGE M, UNPUB; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; LIEBERSON R, UNPUB; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3	17	124	131	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1903	1905		10.1126/science.274.5294.1903	http://dx.doi.org/10.1126/science.274.5294.1903			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943202				2022-12-01	WOS:A1996VY20000042
J	Serafini, T; Colamarino, SA; Leonardo, ED; Wang, H; Beddington, R; Skarnes, WC; TessierLavigne, M				Serafini, T; Colamarino, SA; Leonardo, ED; Wang, H; Beddington, R; Skarnes, WC; TessierLavigne, M			Netrin-1 is required for commissural axon guidance in the developing vertebrate nervous system	CELL			English	Article							FLOOR PLATE; MOUSE EMBRYO; SONIC-HEDGEHOG; SPINAL-CORD; RAT EMBRYO; C-ELEGANS; EXPRESSION; NEURONS; CELL; CHEMOATTRACTANT	During nervous system development, spinal commissural axons project toward floor plate cells and trochlear motor axons extend away from these cells. Netrin-1, a diffusible protein made by floor plate cells, can attract spinal commissural axons and repel trochlear axons in vitro, but its role in vivo is unknown. Netrin-1 deficient mice exhibit defects in spinal commissural axon projections that are consistent with netrin-1 guiding these axons. Defects in several forebrain commissures are also observed, suggesting additional guidance roles for netrin-1. Trochlear axon projections are largely normal, predicting the existence of additional cues for these axons, and evidence is provided for a distinct trochlear axon chemorepellent produced by floor plate cells. These results establish netrin-1 as a guidance cue that likely collaborates with other diffusible cues to guide axons in vivo.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM CELL & DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; NATL INST MED RES,LAB MAMMALIAN DEV,LONDON NW7 1AA,ENGLAND; UNIV EDINBURGH,BIOTECHNOL & BIOL SCI RES COUNCIL,CTR GENOME RES,EDINBURGH EH3 3JQ,MIDLOTHIAN,SCOTLAND	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; MRC National Institute for Medical Research; University of Edinburgh			Leonardo, Eduardo/AAH-1525-2020	Leonardo, Eduardo/0000-0001-7426-0217				ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BOURRAT F, 1990, J COMP NEUROL, V294, P1, DOI 10.1002/cne.902940102; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; COLAMARINO SA, 1995, ANNU REV NEUROSCI, V18, P497, DOI 10.1146/annurev.ne.18.030195.002433; Culotti JG, 1996, CURR OPIN NEUROBIOL, V6, P81, DOI 10.1016/S0959-4388(96)80012-2; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; EBENS A, 1996, IN PRESS NEURON; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FRITZSCH B, 1995, J NEUROBIOL, V27, P457, DOI 10.1002/neu.480270403; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V2, P61; Hu HY, 1996, NEURON, V16, P933, DOI 10.1016/S0896-6273(00)80116-6; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; PLACZEK M, 1990, DEVELOPMENT, V110, P19; Probst M, 1901, ARCH PSYCHIAT NERVEN, V34, P709, DOI 10.1007/BF02680175; SASAKI H, 1993, DEVELOPMENT, V118, P47; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHIRASAKI R, 1995, NEURON, V14, P961, DOI 10.1016/0896-6273(95)90334-8; SHIRASAKI R, IN PRESS NEURON; SILVER J, 1993, J COMP NEUROL, V328, P415, DOI 10.1002/cne.903280308; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TESSIERLAVIGNE M, 1996, IN PRESS SCIENCE; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WENTWORTH LE, 1984, J COMP NEUROL, V222, P96, DOI 10.1002/cne.902220109	31	1020	1042	1	40	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1001	1014		10.1016/S0092-8674(00)81795-X	http://dx.doi.org/10.1016/S0092-8674(00)81795-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978605	Bronze			2022-12-01	WOS:A1996VY44700006
J	Anker, SD; Coats, AJS				Anker, SD; Coats, AJS			Metabolic, functional, and haemodynamic staging for CHF?	LANCET			English	Editorial Material							HEART-FAILURE; EXERCISE CAPACITY; TRANSPLANTATION				Anker, SD (corresponding author), NATL HEART & LUNG INST,IMPERIAL COLL,LONDON SW3 6LY,ENGLAND.		Coats, Andrew J Stewart/E-4451-2012	Coats, Andrew J Stewart/0000-0002-2771-4260				Coats Andrew J. S., 1994, British Heart Journal, V72, pS36; Haywood GA, 1996, HEART, V75, P455, DOI 10.1136/hrt.75.5.455; MANDAK JS, 1995, J HEART LUNG TRANSPL, V14, P468; MAXWELL AE, 1977, MONOGRAPHS APPL PROB; MUDGE GH, 1993, J AM COLL CARDIOL, V22, P21, DOI 10.1016/0735-1097(93)90812-F; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; STEVENSON LW, 1990, CIRCULATION, V81, P78, DOI 10.1161/01.CIR.81.1.78; STEVENSON WG, 1995, J AM COLL CARDIOL, V26, P1417, DOI 10.1016/0735-1097(95)00341-X; SURVIVAL MJ, 1992, CHEST, V101, pS340; TSUTAMOTO T, 1995, AM J CARDIOL, V76, P803, DOI 10.1016/S0002-9149(99)80231-8	10	36	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1530	1531		10.1016/S0140-6736(05)66163-6	http://dx.doi.org/10.1016/S0140-6736(05)66163-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950874				2022-12-01	WOS:A1996VX02300002
J	Nightingale, SL				Nightingale, SL			Breath test for Helicobacter pylori collection kit approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1710	1710						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940307				2022-12-01	WOS:A1996VV56600009
J	Ekwanzala, M; Pepin, J; Khonde, N; Molisho, S; Bruneel, H; DeWals, P				Ekwanzala, M; Pepin, J; Khonde, N; Molisho, S; Bruneel, H; DeWals, P			In the heart of darkness: Sleeping sickness in Zaire	LANCET			English	Editorial Material									BUR CENT TRYPANOSOMLASE, KINSHASA, DEM REP CONGO; UNIV SHERBROOKE, SHERBROOKE, PQ J1K 2R1, CANADA; FONDS MED TROP, BRUSSELS, BELGIUM	University of Sherbrooke								BRUNEEL H, 1994, ANN SOC BELG MED TR, V74, P203; BURKE J, 1971, Annales des Societes Belges de Medecine Tropicale de Parasitologie et de Mycologie, V51, P465; BURKE J, 1992, MED HYGIENE AFRIQUE; *CTR DIS CONTR PRE, 1995, MMWR-MORBID MORTAL W, V44, P468; Kabeya N.M., 1988, Medecine Tropicale, V48, P277; Khonde N, 1995, T ROY SOC TROP MED H, V89, P607, DOI 10.1016/0035-9203(95)90408-5; NEUJEAN G, 1963, B WORLD HEALTH ORGAN, V28, P797; SCOTT D, 1970, AFRICAN TRYPANOSOMIA; VANHOOF LMJJ, 1947, T ROY SOC TROP MED H, V40, P728	9	67	68	2	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	1996	348	9039					1427	1430		10.1016/S0140-6736(96)06088-6	http://dx.doi.org/10.1016/S0140-6736(96)06088-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937285				2022-12-01	WOS:A1996VU98600017
J	Clegg, CH; Rulffes, JT; Wallace, PM; Haugen, HS				Clegg, CH; Rulffes, JT; Wallace, PM; Haugen, HS			Regulation of an extrathymic T-cell development pathway by oncostatin M	NATURE			English	Article							STEM-CELLS; EXPRESSION; CD4+	MOST Of the T lymphocytes that populate the immune system develop in the thymus before its involution during late adolescence, Therefore, subsequent losses in T cells caused by HIV infection(1), chemotherapy(2) or age related factors(3) can greatly diminish immune responses to new antigenic challenge, Here we report the discovery of a thymus-independent pathway of T-cell development that may provide help for T cell immunodeficiency, We show that expression of an oncostatin M transgene(4) in the early T lineage stimulates a dramatic accumulation of immature and mature T cells in lymph nodes, A functional thymus is not required for this effect as reconstitution of nu/nu mice with transgenic bone marrow stimulated a 500-fold increase in Thy-1(+) lymph node cells and restored immune responsiveness to allogeneic mouse melanoma cells, This lymphopoietic pathway is not unique to transgenic mice because administration of oncostatin M protein produced a similar response in non-transgenic mice, These results identify a new pathway of T-cell development and a potential treatment for T-cell immunodeficiency with oncostatin M.			Clegg, CH (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.							BERNAD A, 1994, IMMUNITY, V1, P725, DOI 10.1016/S1074-7613(94)80014-6; Bruce A. Gregory, 1992, Progress in Growth Factor Research, V4, P157, DOI 10.1016/0955-2235(92)90029-H; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; FRANCESCHI C, 1995, IMMUNOL TODAY, V16, P12, DOI 10.1016/0167-5699(95)80064-6; GEANING DP, 1992, SCIENCE, V255, P1434; KSIELOW P, 1995, ADV IMMUNOL, V58, P87; LI YW, 1994, J IMMUNOL, V153, P421; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MALIK N, 1995, MOL CELL BIOL, V15, P2349; ROCHA B, 1995, CURR OPIN IMMUNOL, V7, P235, DOI 10.1016/0952-7915(95)80008-5; ROEDERER M, 1995, NAT MED, V1, P621, DOI 10.1038/nm0795-621; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SHEN MM, 1994, EMBO J, V13, P1375, DOI 10.1002/j.1460-2075.1994.tb06391.x; Wallace PM, 1995, ANN NY ACAD SCI, V762, P42; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x	16	90	90	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					261	263		10.1038/384261a0	http://dx.doi.org/10.1038/384261a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918875				2022-12-01	WOS:A1996VU38100050
J	Modigh, C; Axelsson, G; Alavanja, M; Andersson, L; Rylander, R				Modigh, C; Axelsson, G; Alavanja, M; Andersson, L; Rylander, R			Pet birds and risk of lung cancer in Sweden: A case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NONSMOKING WOMEN	Objective-To investigate the association between keeping birds and the risk of lung cancer in Sweden. Design-Case-control study based on cases of lung cancer and community controls. Interviews were performed by two nurses specially trained for this project. Setting-Three major referral hospitals located in southwest Sweden. Subjects-All patients aged 75 and under with newly diagnosed lung cancer and of Scandinavian birth who lived in one of 26 municipalities in Gothenburg and Bohus county or Alvsborg county. Potential control subjects matched on county of residence, sex, and closest date of birth were selected from population registries. In the context of a larger case-control study, information on pet birds was obtained from 380 patients with lung cancer (252 men) and 696 controls (433 men). Main outcome measures-Odds ratios for lung cancer in relation to whether or not pet birds were kept and the duration of keeping pet birds. Results-The adjusted odds ratio for ever versus never exposed to pet birds at home was 0.94 (95% confidence interval 0.64 to 1.39) for men and 1.10 (0.64 to 1.90) for women. There was no evidence of a trend for increased risk of lung cancer with duration of bird ownership. Conclusion-Bird keeping does not seem to confer any excess risk of lung cancer to Swedish men or women.	NCI, DIV CANC EPIDEMIOL & GENET, ROCKVILLE, MD 20852 USA; N ALVSBORG GEN HOSP, LUNG CLIN, TROLLHATTAN, SWEDEN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Modigh, C (corresponding author), GOTHENBURG UNIV, DEPT ENVIRONM MED, MEDICINAREGATAN 16, S-41390 GOTHENBURG, SWEDEN.							Alavanja MCR, 1996, BMJ-BRIT MED J, V313, P1233, DOI 10.1136/bmj.313.7067.1233; ALAVANJA MCR, 1992, AM J EPIDEMIOL, V136, P623, DOI 10.1093/oxfordjournals.aje.a116542; ALAVANJA MCR, 1993, J NATL CANCER I, V85, P1906, DOI 10.1093/jnci/85.23.1906; Axelsson G, 1996, INT J EPIDEMIOL, V25, P32, DOI 10.1093/ije/25.1.32; BRITTON J, 1992, BRIT MED J, V305, P970, DOI 10.1136/bmj.305.6860.970; CULTAS DB, 1994, EPIDEMIOLOGY LUNG CA, P299; GARDINER A, 1993, BRIT MED J, V306, P60, DOI 10.1136/bmj.306.6869.60-a; GARDINER AJS, 1992, BRIT MED J, V305, P989, DOI 10.1136/bmj.305.6860.989; General U.S. Surgeon, 1986, HLTH CONS INV SMOK; HOLST PA, 1988, BRIT MED J, V297, P1319, DOI 10.1136/bmj.297.6659.1319; KOHLMEIER L, 1992, BMJ-BRIT MED J, V305, P986, DOI 10.1136/bmj.305.6860.986; KOHLMEIER L, 1993, BRIT MED J, V306, P60, DOI 10.1136/bmj.306.6869.60; MORABIA A, 1993, BRIT MED J, V306, P60, DOI 10.1136/bmj.306.6869.60-b; PERSHAGEN G, 1990, COMPLEX MIXTURES CAN, P240; RAMPEN FHJ, 1993, BRIT MED J, V306, P61, DOI 10.1136/bmj.306.6869.61-a; Speizer FE, 1994, EPIDEMIOLOGY LUNG CA, P131; *STAT EP RES, 1991, EGRET REV 2; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672	18	18	18	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	1996	313	7067					1236	1238		10.1136/bmj.313.7067.1236	http://dx.doi.org/10.1136/bmj.313.7067.1236			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939112	Green Published			2022-12-01	WOS:A1996VU20800021
J	Chen, DF; Schneider, GE; Martinou, JC; Tonegawa, S				Chen, DF; Schneider, GE; Martinou, JC; Tonegawa, S			Bcl-2 promotes regeneration of severed axons in mammalian CNS	NATURE			English	Article							RETINAL GANGLION-CELLS; TRANSGENIC MICE; NERVOUS-SYSTEM; IN-VITRO; DEATH; APOPTOSIS; SURVIVAL; PROTEIN; NEURONS; GROWTH	Most neurons of the mammalian central nervous system (CNS) lose the ability to regenerate severed axons in vivo after a certain point in development(1). At least part of this loss in regenerative potential is intrinsic to neuron(2-4). Although embryonic retinal ganglion cells (RGCs) can grow axons into tectum of any age, most RGCs from older animals fail to extend axons into CNS tissue derived from donors of any age, including the embryonic tectum(2). Here we report that the proto-oncogene bcl-2 plays a key role in this developmental change by promoting the growth and regeneration of retinal axons. This effect does not seem to be an indirect consequence of its well-known anti-apoptotic activity. Another anti-apoptotic drug, ZVAD, supported neuronal survival but did noe promote axon regeneration in culture. This finding could lead to new strategies for the treatment of injuries to the CNS.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; GLAXO INST MOL BIOL SA,CH-1228 GENEVA,SWITZERLAND	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); GlaxoSmithKline	Chen, DF (corresponding author), MIT,HOWARD HUGHES MED INST,CTR LEARNING & MEMORY,CTR CANC RES,CAMBRIDGE,MA 02139, USA.			martinou, Jean-claude/0000-0002-9847-2051				AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; Angelucci A, 1996, J NEUROSCI METH, V65, P101, DOI 10.1016/0165-0270(95)00155-7; AUBERT I, 1995, CURR OPIN NEUROBIOL, V5, P625, DOI 10.1016/0959-4388(95)80068-9; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; CHEN DF, 1995, P NATL ACAD SCI USA, V92, P7287, DOI 10.1073/pnas.92.16.7287; DAVIES AM, 1995, TRENDS NEUROSCI, V18, P355, DOI 10.1016/0166-2236(95)93928-Q; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; DUSART I, 1994, J COMP NEUROL, V347, P211, DOI 10.1002/cne.903470206; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FLETCHER DS, 1995, J INTERF CYTOK RES, V15, P243, DOI 10.1089/jir.1995.15.243; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MERRY DE, 1994, DEVELOPMENT, V120, P301; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; MISANTONE LJ, 1984, J NEUROCYTOL, V13, P449, DOI 10.1007/BF01148334; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PERRY VH, 1983, J COMP NEUROL, V219, P3546; Sagot Y, 1996, J NEUROSCI, V16, P2335; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SHEWAN D, 1995, J NEUROSCI, V15, P2057, DOI 10.1523/JNEUROSCI.15-03-02057.1995; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WANG HG, 1994, ONCOGENE, V9, P2751; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	30	403	439	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1997	385	6615					434	439		10.1038/385434a0	http://dx.doi.org/10.1038/385434a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009190				2022-12-01	WOS:A1997WF00700052
J	Donnan, GA; Darby, DG; Saling, MM				Donnan, GA; Darby, DG; Saling, MM			Identification of brain region for coordinating speech articulation	LANCET			English	Editorial Material											Donnan, GA (corresponding author), AUSTIN & REPATRIAT MED CTR,NEUROSCI CLIN SERV UNIT,HEIDELBERG,VIC 3084,AUSTRALIA.		DONNAN, GEOFFREY A/A-9947-2008	Donnan, Geoffrey/0000-0001-6324-3403				Broca P. A., 1865, B SOC ANTHROPOL PAR, V6, P493; Dronkers NF, 1996, NATURE, V384, P159, DOI 10.1038/384159a0; HUERTA MF, 1993, TRENDS NEUROSCI, V16, P436, DOI 10.1016/0166-2236(93)90069-X; OJEMANN GA, 1978, BRAIN LANG, V6, P239, DOI 10.1016/0093-934X(78)90061-5; OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727; TOGNOLA G, 1980, NEUROPSYCHOLOGIA, V18, P257, DOI 10.1016/0028-3932(80)90122-0	6	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					221	222		10.1016/S0140-6736(05)64855-6	http://dx.doi.org/10.1016/S0140-6736(05)64855-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014903				2022-12-01	WOS:A1997WD90600003
J	Loh, E; Sutton, MSJ; Wun, CCC; Rouleau, JL; Flaker, GC; Gottlieb, SS; Lamas, GA; Moye, LA; Goldhaber, SZ; Pfeffer, MA				Loh, E; Sutton, MSJ; Wun, CCC; Rouleau, JL; Flaker, GC; Gottlieb, SS; Lamas, GA; Moye, LA; Goldhaber, SZ; Pfeffer, MA			Ventricular dysfunction and the risk of stroke after myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TWO-DIMENSIONAL ECHOCARDIOGRAPHY; TERM FOLLOW-UP; DILATED CARDIOMYOPATHY; MURAL THROMBI; HEART-FAILURE; MORTALITY; PREVENTION; MANAGEMENT; CAPTOPRIL; EMBOLISM	Background In patients who have had a myocardial infarction, the long-term risk of stroke and its relation to the extent of left ventricular dysfunction have not been determined. We studied whether a reduced left ventricular ejection fraction is associated with an increased risk of stroke after myocardial infarction and whether other factors such as older age and therapy with anticoagulants, thrombolytic agents, or captopril affect long-term rates of stroke. Methods We performed an observational analysis of prospectively collected data on 2231 patients who had left ventricular dysfunction after acute myocardial infarction who were enrolled in the Survival and Ventricular Enlargement trial. The mean follow-up was 42 months. Risk factors for stroke were assessed by both univariate and multivariate Cox proportional-hazards analysis. Results Among these patients, 103 (4.6 percent) had fatal or nonfatal strokes during the study (rate of stroke per year of follow-up, 1.5 percent). The estimated five-year rate of stroke in all the patients was 8.1 percent. As compared with patients without stroke, patients with stroke were older (mean [+/-SD] age, 63+/-9 years vs. 59+/-11 years; P<0.001) and had lower ejection fractions (29+/-7 percent vs. 31+/-7 percent, P=0.01). Independent risk factors for stroke included a lower ejection fraction (for every decrease of 5 percentage points in the ejection fraction there was an 18 percent increase in the risk of stroke), older age, and the absence of aspirin or anticoagulant therapy. Patients with ejection fractions of less than or equal to 28 percent after myocardial infarction had a relative risk of stroke of 1.86, as compared with patients with ejection fractions of >35 percent (P=0.01). The use of thrombolytic agents and captopril had no significant effect on the risk of stroke. Conclusions During the five years after myocardial infarction, patients have a substantial risk of stroke. A decreased ejection fraction and older age are both independent predictors of an increased risk of stroke. Anticoagulant therapy appears to have a protective effect against stroke after myocardial infarction. (C) 1997, Massachusetts Medical Society.	UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX; MONTREAL HEART INST,MONTREAL,PQ H1T 1C8,CANADA; UNIV MISSOURI HOSP & CLIN,COLUMBIA,MO; UNIV MARYLAND HOSP,BALTIMORE,MD 21201; MT SINAI MED CTR,MIAMI BEACH,FL 33140; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	University of Texas System; University of Texas Health Science Center Houston; Universite de Montreal; University of Missouri System; University of Missouri Columbia; University System of Maryland; University of Maryland Baltimore; Mount Sinai Medical Center; Harvard University; Brigham & Women's Hospital	Loh, E (corresponding author), HOSP UNIV PENN,9 FOUNDERS PAVILION,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				NHLBI NIH HHS [HL-02514] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002514] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, LANCET, V346, P1647; *ANT SEC PREV EV C, 1994, LANCET, V343, P499; ASINGER RW, 1981, NEW ENGL J MED, V305, P297, DOI 10.1056/NEJM198108063050601; BAKER DW, 1994, JAMA-J AM MED ASSOC, V272, P1614, DOI 10.1001/jama.272.20.1614; BEHAR S, 1991, AM J MED, V91, P45, DOI 10.1016/0002-9343(91)90072-6; CAIRNS JA, 1995, CHEST, V108, pS380, DOI 10.1378/chest.108.4_Supplement.380S; CIACCHERI M, 1989, BRIT HEART J, V62, P26; DOMENICUCCI S, 1987, CIRCULATION, V75, P737, DOI 10.1161/01.CIR.75.4.737; DRAPKIN A, 1972, J AMER MED ASSOC, V222, P541, DOI 10.1001/jama.222.5.541; DUNKMAN WB, 1993, CIRCULATION, V87, P94; FRIEDMAN MJ, 1982, AM J MED, V72, P894, DOI 10.1016/0002-9343(82)90848-8; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; HESS DC, 1993, NEUROL CLIN, V11, P399, DOI 10.1016/S0733-8619(18)30160-9; JOHANNESSEN KA, 1984, BRIT HEART J, V51, P533; KEATING EC, 1983, AM J MED, V74, P989, DOI 10.1016/0002-9343(83)90798-2; KOMRAD MS, 1984, NEUROLOGY, V34, P1403, DOI 10.1212/WNL.34.11.1403; KYRLE PA, 1985, THROMB HAEMOSTASIS, V54, P521; LAMAS GA, 1988, AM J CARDIOL, V62, P31, DOI 10.1016/0002-9149(88)91360-4; MAGGIONI A, 1991, BMJ-BRIT MED J, V302, P1428, DOI 10.1136/bmj.302.6790.1428; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; MARTIN R, 1993, J NEUROL NEUROSUR PS, V56, P760, DOI 10.1136/jnnp.56.7.760; *MED RES COUNC, 1969, BRIT MED J, V1, P335; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; Segal J P, 1978, Curr Probl Cardiol, V3, P1, DOI 10.1016/0146-2806(78)90026-9; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; STRATTON JR, 1988, CIRCULATION, V78, P1388, DOI 10.1161/01.CIR.78.6.1388; TANNE D, 1995, AM J CARDIOL, V76, P825, DOI 10.1016/S0002-9149(99)80236-7; THOMPSON PL, 1978, BRIT MED J, V2, P457, DOI 10.1136/bmj.2.6135.457; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; VAITKUS PT, 1993, J AM COLL CARDIOL, V22, P1004, DOI 10.1016/0735-1097(93)90409-T; VISSER CA, 1984, CHEST, V86, P532, DOI 10.1378/chest.86.4.532; WEINREICH DJ, 1984, ANN INTERN MED, V100, P789, DOI 10.7326/0003-4819-100-6-789; 1973, JAMA-J AM MED ASSOC, V225, P724	34	417	428	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1997	336	4					251	257		10.1056/NEJM199701233360403	http://dx.doi.org/10.1056/NEJM199701233360403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE632	8995087				2022-12-01	WOS:A1997WE63200003
J	Sharma, SD; Smith, EM; Hazleman, BL; Jenner, JR				Sharma, SD; Smith, EM; Hazleman, BL; Jenner, JR			Thermographic changes in keyboard operators with chronic forearm pain	BRITISH MEDICAL JOURNAL			English	Article									ADDENBROOKES NHS TRUST,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital	Sharma, SD (corresponding author), RHEUMATOL RES UNIT,BOX 194,CAMBRIDGE CB2 2QQ,ENGLAND.							COHEN ML, 1992, MED J AUSTRALIA, V156, P432, DOI 10.5694/j.1326-5377.1992.tb139853.x; COHEN ML, 1990, PAIN S, V5, pS465; HADLER NM, 1992, J OCCUP ENVIRON MED, V34, P113, DOI 10.1097/00043764-199202000-00009; MILLER MH, 1988, J RHEUMATOL, V15, P1705; ROBERTS WJ, 1986, PAIN, V24, P297, DOI 10.1016/0304-3959(86)90116-8	5	32	32	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					118	118		10.1136/bmj.314.7074.118	http://dx.doi.org/10.1136/bmj.314.7074.118			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006470	Green Published			2022-12-01	WOS:A1997WC47900024
J	Kondo, T; Mori, T; Lebedeva, NV; Aoki, S; Ishiura, M; Golden, SS				Kondo, T; Mori, T; Lebedeva, NV; Aoki, S; Ishiura, M; Golden, SS			Circadian rhythms in rapidly dividing cyanobacteria	SCIENCE			English	Article							GENE-EXPRESSION; CLOCK; LUCIFERASE; REPORTER	The long-standing supposition that the biological clock cannot function in cells that divide more rapidly than the circadian cycle was investigated. During exponential growth in which the generation time was 10 hours, the profile of bioluminescence from a reporter strain of the cyanobacterium Synechococcus (species PCC 7942) matched a model based on the assumption that cells proliferate exponentially and the bioluminescence of each cell oscillates in a cosine fashion. Some messenger RNAs showed a circadian rhythm in abundance during continuous exponential growth with a doubling time of 5 to 6 hours. Thus, the cyanobacterial circadian clock functions in cells that divide three or more times during one circadian cycle.	VANDERBILT UNIV,DEPT BIOL,NASHVILLE,TN 37235; TEXAS A&M UNIV,DEPT BIOL,COLLEGE STN,TX 77843	Vanderbilt University; Texas A&M University System; Texas A&M University College Station	Kondo, T (corresponding author), NAGOYA UNIV,GRAD SCH SCI,DIV BIOL SCI,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN.							Bunning E, 1973, PHYSL CLOCK; BUSTOS SA, 1991, J BACTERIOL, V173, P7525, DOI 10.1128/jb.173.23.7525-7533.1991; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; Edmunds L.N., 1988, CELLULAR MOL BASES B; Ehret C. F, 1970, pUnpaginated; Engelmann W., 1980, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V5, P49; ENSOR MH, 1996, CELL, V84, P677; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; KONDO T, 1994, J BACTERIOL, V176, P1881, DOI 10.1128/jb.176.7.1881-1885.1994; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONDO T, UNPUB; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; LIU Y, 1995, J BACTERIOL, V177, P2080, DOI 10.1128/jb.177.8.2080-2086.1995; LOROS J, 1995, SEMIN NEUROSCI, V7, P3, DOI 10.1016/1044-5765(95)90012-8; Mori T, 1996, P NATL ACAD SCI USA, V93, P10183, DOI 10.1073/pnas.93.19.10183; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; NJUS D, 1974, NATURE, V248, P116, DOI 10.1038/248116a0; Press WH., 1988, NUMERICAL RECIPES C; SCHAEFER MR, 1989, J BACTERIOL, V171, P3973, DOI 10.1128/jb.171.7.3973-3981.1989; Sweeney BM., 1987, RHYTHMIC PHENOMENA P; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	23	120	133	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					224	227		10.1126/science.275.5297.224	http://dx.doi.org/10.1126/science.275.5297.224			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985018				2022-12-01	WOS:A1997WC02200042
J	Roelfsema, PR; Engel, AK; Konig, P; Singer, W				Roelfsema, PR; Engel, AK; Konig, P; Singer, W			Visuomotor integration is associated with zero time-lag synchronization among cortical areas	NATURE			English	Article							OSCILLATORY NEURONAL RESPONSES; CAT VISUAL-CORTEX; MOTOR CORTEX; MONKEY; POTENTIALS; MECHANISMS; COHERENCE; STRIATE	INFORMATION processing in the cerebral cortex invariably involves the activation of millions of neurons that are widely distributed over its various areas, These distributed activity patterns need to be integrated into coherent representational states, A candidate mechanism for the integration and coordination of neuronal activity between different brain regions is synchronization on a fine temporal scale(1-3). In the visual cortex, synchronization occurs selectively between the responses of neurons that represent related features(2-5) and that need to be integrated for the generation of coherent percepts; neurons in other areas of the cerebral cortex also synchronize their discharges(6-10). However, little is known about the patterns and the behavioural correlates of synchrony among widely separated cortical regions, Here we report that synchronization occurs between areas of the visual and parietal cortex, and between areas of the parietal and motor cortex, in the awake cat, When cats responded to a sudden change of a visual pattern, neuronal activity in cortical areas exhibited synchrony without time lags; this synchrony was particularly strong between areas subserving related functions, During reward and inter-trial episodes, zero-time-lag synchrony was lost and replaced by interactions exhibiting large and unsystematic time lags.	NETHERLANDS OPHTHALM RES INST,NL-1100 AC AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,DEPT MED PHYS,NL-1100 AC AMSTERDAM,NETHERLANDS; INST NEUROSCI,SAN DIEGO,CA 92121	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam	Roelfsema, PR (corresponding author), MAX PLANCK INST BRAIN RES,DEUTSCHORDENSTR 46,D-60528 FRANKFURT,GERMANY.		Singer, Wolf/D-6874-2012; anand, amit/A-7222-2009; Engel, Andreas K./AAH-6384-2019; König, Peter/ABB-2380-2020; Roelfsema, Pieter/J-6903-2013; Engel, Andreas K/C-7781-2012	Engel, Andreas K./0000-0003-4899-8466; König, Peter/0000-0003-3654-5267; Roelfsema, Pieter/0000-0002-1625-0034; Engel, Andreas K/0000-0003-4899-8466				Abeles M., 1991, CORTICONICS; BOUYER JJ, 1981, ELECTROEN CLIN NEURO, V51, P244, DOI 10.1016/0013-4694(81)90138-3; BRESSLER SL, 1993, NATURE, V366, P153, DOI 10.1038/366153a0; BUCHWALD NA, 1964, NATURE, V201, P830, DOI 10.1038/201830a0; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FRIEN A, 1994, NEUROREPORT, V5, P2273, DOI 10.1097/00001756-199411000-00017; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; JEANNEROD M, 1995, TRENDS NEUROSCI, V18, P314, DOI 10.1016/0166-2236(95)93921-J; KALASKA JF, 1992, SCIENCE, V255, P1517, DOI 10.1126/science.1549781; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; MITZDORF U, 1985, PHYSIOL REV, V65, P37, DOI 10.1152/physrev.1985.65.1.37; Munk MHJ, 1996, SCIENCE, V272, P271, DOI 10.1126/science.272.5259.271; Munk MHJ, 1995, J NEUROPHYSIOL, V74, P2401, DOI 10.1152/jn.1995.74.6.2401; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; NELSON JI, 1992, VISUAL NEUROSCI, V9, P21, DOI 10.1017/S0952523800006349; NIEOULLON A, 1976, BRAIN RES, V105, P405, DOI 10.1016/0006-8993(76)90590-4; Roelfsema PR, 1996, J COGNITIVE NEUROSCI, V8, P603, DOI 10.1162/jocn.1996.8.6.603; SANES JN, 1993, P NATL ACAD SCI USA, V90, P4470, DOI 10.1073/pnas.90.10.4470; SCANNELL JW, 1995, J NEUROSCI, V15, P1463; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; TUSA RJ, 1978, J COMP NEUROL, V177, P213, DOI 10.1002/cne.901770204; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0	29	793	809	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					157	161		10.1038/385157a0	http://dx.doi.org/10.1038/385157a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990118	Green Submitted			2022-12-01	WOS:A1997WB72800054
J	Brennan, TA; Sox, CM; Burstin, HR				Brennan, TA; Sox, CM; Burstin, HR			Relation between negligent adverse events and the outcomes of medical-malpractice litigation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIABILITY; CLAIMS; RESOLUTION; STANDARD; CARE	Background We have previously shown that in New York State the initiation of malpractice suits correlates poorly with the actual occurrence of adverse events (injuries resulting from medical treatment) and negligence. There is little information on the outcome of such lawsuits, however. To assess the ability of malpractice litigation to make accurate determinations, we studied 51 malpractice suits to identify factors that predict payment to plaintiffs. Methods Among malpractice claims that we reviewed independently in an earlier study, we identified 51 litigated claims and followed them over a 10-year period to determine whether the malpractice insurer had closed the case. We obtained detailed summaries of the cases from the insurers and reviewed the litigation files if the outcome of a case differed from the outcome predicted in our original review. Results Of the 51 malpractice cases, 46 had been closed as of December 31, 1995. Among these cases, 10 of 24 that we originally identified as involving no adverse event were settled for the plaintiffs (mean payment, $28,760), as were 6 of 13 cases classified as involving adverse events but no negligence (mean payment, $98,192) and 5 of 9 cases in which adverse events due to negligence were found in our assess ment (mean payment, $66,944). Seven of eight claims involving permanent disability were settled for the plaintiffs (mean payment, $201,250). In a multivariate analysis, disability (permanent vs. temporary or none) was the only significant predictor of payment (P = 0.03). There was no association between the occurrence of an adverse event due to negligence (P = 0.32) or an adverse event of any type (P = 0.79) and payment. Conclusions Among the malpractice claims we studied, the severity of the patient's disability, not the occurrence of an adverse event or an adverse event due to negligence, was predictive of payment to the plaintiff. (C) 1996, Massachusetts Medical Society.			Brennan, TA (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.			Sox, Colin/0000-0002-0249-9656				BOVBJERG RR, 1995, MED MALPRACTICE PROB; Brennan T., 1996, NEW RULES REGULATION; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BURSTIN HR, 1993, JAMA-J AM MED ASSOC, V270, P1697, DOI 10.1001/jama.270.14.1697; CHENEY FW, 1989, JAMA-J AM MED ASSOC, V261, P1599, DOI 10.1001/jama.261.11.1599; DANZON PM, 1985, MED MALPRACTICE THEO; FARBER HS, 1994, J LEGAL STUD, V23, P777, DOI 10.1086/467945; FARBER HS, 1991, RAND J ECON, V22, P199, DOI 10.2307/2601017; Horwitz J, 1995, HEALTH AFFAIR, V14, P164, DOI 10.1377/hlthaff.14.4.164; KINNEY ED, 1995, J HEALTH POLIT POLIC, V20, P99, DOI 10.1215/03616878-20-1-99; LAWTHERS AG, 1992, J HEALTH POLIT POLIC, V17, P463, DOI 10.1215/03616878-17-3-463; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; PETERSEN SK, 1995, ANN INTERN MED, V122, P462, DOI 10.7326/0003-4819-122-6-199503150-00010; ROSENFIELD H, 1994, SILENT VIOLENCE SILE; SAS Institute, 1990, SAS STAT US GUID VER; SCHWARTZ GT, 1994, UCLA LAW REV, V42, P377; SLOAN FA, 1991, INSURING MED MALPRAC; Sloan Frank A., 1993, SUING MED MALPRACTIC; TARAGIN MI, 1992, ANN INTERN MED, V117, P780, DOI 10.7326/0003-4819-117-9-780; Weiler PC, 1993, MEASURE MALPRACTICE; WEILER PC, 1991, MED MALPR TRIAL; WHITE MJ, 1994, HEALTH AFFAIR, V13, P75, DOI 10.1377/hlthaff.13.4.75	22	269	274	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1996	335	26					1963	1967		10.1056/NEJM199612263352606	http://dx.doi.org/10.1056/NEJM199612263352606			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WA160	8960477	Bronze			2022-12-01	WOS:A1996WA16000006
J	Pryce, AJ; Heatlie, HF; Chapman, SR				Pryce, AJ; Heatlie, HF; Chapman, SR			Buccaling under the pressure: Influence of secondary care establishments on the prescribing of glyceryl trinitrate buccal tablets in primary care	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; SUBLINGUAL NITROGLYCERIN; ANGINA-PECTORIS; WEIGHTINGS; ENGLAND; COSTS; AGE; SEX; PUS	Objective-To determine which characteristics were the best predictors of high rates of prescribing of glyceryl trinitrate buccal tablets. Design-Practice and patient characteristics from 197 practices were examined, and a multiple regression analysis was performed to examine which variables were important in predicting this prescribing. Setting-Former family health services authority (197 practices). Main outcome measure-Volume of prescribing of glyceryl trinitrate buccal tablets. Results-Four variables contributed significantly to a multiple regression model: the catchment area of the secondary care establishment; the number of partners in a practice; the level of practice deprivation; and whether the practice served an urban or a rural area. The model suggests that the most important variable was the catchment area of the secondary care establishment in which the practice was located. Conclusion-Although only the prescribing of short acting glyceryl trinitrate buccal tablets was studied, an impact of this size on primary care prescribing may have extensive implications for all drug expenditure in primary care.	UNIV KEELE,DEPT MED MANAGEMENT,KEELE ST5 5BG,STAFFS,ENGLAND	Keele University								ABRAMS J, 1983, ROYAL SOC MED INT C, V54, P13; *AUD COMM, 1994, 1 AUD COMM; BAKER R, 1995, BRIT J GEN PRACT, V45, P297; BRAY CL, 1991, EUR HEART J, V12, P16; EDWARDS C, 1991, INT J PHARM PRACTICE, V1, P73; HEALEY AT, 1994, HEALTH ECON, V3, P47, DOI 10.1002/hec.4730030107; LAHIRI A, 1989, American Journal of Noninvasive Cardiology, V3, P281; LLOYD DCEF, 1995, BRIT MED J, V311, P991; MCCARTHY M, 1992, BRIT J GEN PRACT, V42, P10; MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318; MORTONJONES TJ, 1993, BRIT MED J, V306, P1244, DOI 10.1136/bmj.306.6887.1244; *NHS EX, 1994, PURCH PRESCR; Office of Population Censuses and Surveys, 1995, MORB STAT GEN PRACT; REICHEK N, 1982, ADV PHARMACOTHERAPY, V1, P143; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; RYDEN L, 1987, EUR HEART J, V8, P995, DOI 10.1093/oxfordjournals.eurheartj.a062377; SCRIVENER G, 1995, BRIT MED J, V311, P163, DOI 10.1136/bmj.311.6998.163; STRICKLANDHODGE B, 1988, J ROY SOC MED, V81, P207, DOI 10.1177/014107688808100407; Townsend P, 1988, HLTH DEPRIVATION INE; *WHO, 1991, GUID DDD; WILSON RPH, 1995, BRIT MED J, V311, P1347, DOI 10.1136/bmj.311.7016.1347	21	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1621	1624		10.1136/bmj.313.7072.1621	http://dx.doi.org/10.1136/bmj.313.7072.1621			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991012	Green Published			2022-12-01	WOS:A1996VZ81100044
J	Wright, DJM; Roberts, AP				Wright, DJM; Roberts, AP			Which doctors die first? Analysis of BMJ obituary columns	BRITISH MEDICAL JOURNAL			English	Article											Wright, DJM (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,LONDON W6 8RF,ENGLAND.							Balarajan R, 1995, Health Trends, V27, P114; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; NIEMI T, 1980, SCAND J SOC MED, V8, P39, DOI 10.1177/140349488000800106; *OFF POP CENC, 1955, MORT SER, P38	4	35	36	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1581	1582		10.1136/bmj.313.7072.1581	http://dx.doi.org/10.1136/bmj.313.7072.1581			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VZ811	8990991	Green Published			2022-12-01	WOS:A1996VZ81100012
J	Tighe, MJ; Kite, P; Fawley, WN; Thomas, D; McMahon, MJ				Tighe, MJ; Kite, P; Fawley, WN; Thomas, D; McMahon, MJ			An endoluminal brush to detect the infected central venous catheter in situ: A pitot study	BRITISH MEDICAL JOURNAL			English	Article							CULTURES		UNIV LEEDS,GEN INFIRM,NUTR SUPPORT SERV,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; UNIV LEEDS,GEN INFIRM,DEPT SURG,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; GEN INFIRM,DEPT MICROBIOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary; University of Leeds; Leeds General Infirmary; University of Leeds; Leeds General Infirmary								MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MUGHAL MM, 1989, BRIT J SURG, V76, P15, DOI 10.1002/bjs.1800760107; PETTIGREW RA, 1985, BRIT J SURG, V72, P52, DOI 10.1002/bjs.1800720121; SHERERTZ RJ, 1990, J CLIN MICROBIOL, V28, P76, DOI 10.1128/JCM.28.1.76-82.1990	4	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1528	1529		10.1136/bmj.313.7071.1528	http://dx.doi.org/10.1136/bmj.313.7071.1528			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY691	8978230	Green Published			2022-12-01	WOS:A1996VY69100023
J	Niu, W; Kim, Y; Tau, G; Heyduk, T; Ebright, RH				Niu, W; Kim, Y; Tau, G; Heyduk, T; Ebright, RH			Transcription activation at class II CAP-dependent promoters: Two interactions between CAP and RNA polymerase	CELL			English	Article							AMP RECEPTOR PROTEIN; ALANINE-SCANNING MUTAGENESIS; ESCHERICHIA-COLI-CRP; ALPHA-SUBUNIT; FUNCTIONAL SUBUNIT; GENE-ACTIVATION; CAMP-CRP; DNA; REGION; IDENTIFICATION	At Class II catabolite activator protein (CAP)-dependent promoters, CAP activates transcription from a DNA site overlapping the DNA site for RNA polymerase. We show that transcription activation at Class II CAP-dependent promoters requires not only the previously characterized interaction between an activating region of CAP and the RNA polymerase a subunit C-terminal domain, but also an interaction between a second, promoter-class-specific activating region of CAP and the RNA polymerase a subunit N-terminal domain. We further show that the two interactions affect different steps in transcription initiation. Transcription activation at Class II CAP-dependent promoters provides a paradigm for understanding how an activator can make multiple interactions with the transcription machinery, each interaction being responsible for a specific mechanistic consequence.	RUTGERS STATE UNIV, WAKSMAN INST, NEW BRUNSWICK, NJ 08855 USA; ST LOUIS UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, ST LOUIS, MO 63104 USA	Rutgers State University New Brunswick; Saint Louis University	Niu, W (corresponding author), RUTGERS STATE UNIV, DEPT CHEM, NEW BRUNSWICK, NJ 08855 USA.		Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NIGMS NIH HHS [GM50514, GM41376, R01 GM041376, R37 GM041376, R01 GM050514] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041376, R01GM050514, R21GM050514, R01GM041376] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATLUNG T, 1991, GENE, V107, P11, DOI 10.1016/0378-1119(91)90291-I; ATTEY A, 1994, NUCLEIC ACIDS RES, V22, P4375, DOI 10.1093/nar/22.21.4375; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; Belyaeva TA, 1996, NUCLEIC ACIDS RES, V24, P2243, DOI 10.1093/nar/24.12.2243; BLATTER E, 1994, PROTEIN EXPRES PURIF, V4, P503; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; Ebright YW, 1996, BIOCONJUGATE CHEM, V7, P380, DOI 10.1021/bc9600168; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; HASAN N, 1994, GENE, V150, P51, DOI 10.1016/0378-1119(94)90856-7; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; IRWIN N, 1987, P NATL ACAD SCI USA, V84, P8315, DOI 10.1073/pnas.84.23.8315; JIN RZ, 1995, J BIOL CHEM, V270, P19213, DOI 10.1074/jbc.270.33.19213; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; NIU W, 1994, J MOL BIOL, V243, P595, DOI 10.1016/0022-2836(94)90034-5; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; SABOURIN D, 1975, J BACTERIOL, V122, P338, DOI 10.1128/JB.122.1.338-340.1975; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; TANG H, 1994, GENE DEV, V8, P3058, DOI 10.1101/gad.8.24.3058; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; TANG H, 1996, IN PRESS METH ENZYMO; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEST D, 1993, MOL MICROBIOL, V10, P789, DOI 10.1111/j.1365-2958.1993.tb00949.x; WILLIAMS R, 1991, NUCLEIC ACIDS RES, V19, P6705, DOI 10.1093/nar/19.24.6705; Williams RM, 1996, NUCLEIC ACIDS RES, V24, P1112, DOI 10.1093/nar/24.6.1112; ZHOU YH, 1994, J MOL BIOL, V243, P603, DOI 10.1016/0022-2836(94)90035-3; ZHOU YH, 1994, EMBO J, V13, P4549, DOI 10.1002/j.1460-2075.1994.tb06776.x; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081; ZHOU YH, 1993, CELL, V73, P375, DOI 10.1016/0092-8674(93)90236-J; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	41	228	236	0	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 13	1996	87	6					1123	1134		10.1016/S0092-8674(00)81806-1	http://dx.doi.org/10.1016/S0092-8674(00)81806-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978616	Bronze, Green Accepted			2022-12-01	WOS:A1996VY44700017
J	Gabbiani, F; Metzner, W; Wessel, R; Koch, C				Gabbiani, F; Metzner, W; Wessel, R; Koch, C			From stimulus encoding to feature extraction in weakly electric fish	NATURE			English	Article							LATERAL-LINE LOBE; JAMMING AVOIDANCE-RESPONSE; GYMNOTIFORM FISH; EIGENMANNIA; NEURONS; ELECTRORECEPTORS; COMMUNICATION; CORTEX; MONKEY	ANIMALS acquire information about sensory stimuli around them and encode it using an analogue or a pulse-based code. Behaviourally relevant features need to be extracted from this representation for further processing. In the electrosensory system of weakly electric fish, single P-type electroreceptor afferents accurately encode the time course of random modulations in electric-field amplitude(1). We applied a stimulus estimation method(2) and a signal-detection method to both P-receptor afferents and their targets, the pyramidal cells in the electrosensory lateral-line lobe. We found that although pyramidal cells do not accurately convey detailed information about the time course of the stimulus, they reliably encode up- and downstrokes of random modulations in electric-field amplitude. The presence of such temporal features is best signalled by short bursts of spikes, probably caused by dendritic processing, rather than by isolated spikes. Furthermore, pyramidal cells outperform P-receptor afferents in signalling the presence of temporal features in the stimulus waveform. We conclude that the sensory neurons are specialized to acquire information accurately with little processing, whereas the following stage extracts behaviourally relevant features, thus performing a nonlinear pattern-recognition task.	UNIV CALIF RIVERSIDE, DEPT BIOL, RIVERSIDE, CA 92521 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California Riverside; University of California System; University of California San Diego	Gabbiani, F (corresponding author), CALTECH, COMPUTAT & NEURAL SYST PROGRAM, DIV BIOL 13974, PASADENA, CA 91125 USA.			Koch, Christof/0000-0001-6482-8067				ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; Anderson T.W., 1984, INTRO MULTIVARIATE S; BAIR W, 1994, J NEUROSCI, V14, P2870; BASTIAN J, 1980, J COMP PHYSIOL, V136, P135, DOI 10.1007/BF00656908; Bastian J., 1986, P577; BASTIAN J, 1991, J COMP PHYSIOL A, V168, P393, DOI 10.1007/BF00199600; BIALEK W, 1991, SCIENCE, V252, P1854, DOI 10.1126/science.2063199; CARR CE, 1982, J COMP NEUROL, V211, P139, DOI 10.1002/cne.902110204; Gabbiani F, 1996, NEURAL COMPUT, V8, P44, DOI 10.1162/neco.1996.8.1.44; Gabbiani F, 1996, NETWORK-COMP NEURAL, V7, P61, DOI 10.1080/0954898X.1996.11978655; Heiligenberg W., 1991, NEURAL NETS ELECT FI; HOPKINS CD, 1988, ANNU REV NEUROSCI, V11, P497, DOI 10.1146/annurev.ne.11.030188.002433; HOPKINS CD, 1976, J COMP PHYSIOL, V111, P171, DOI 10.1007/BF00605531; Jolliffe IT., 1986, PRINCIPAL COMPONENT; KAWASAKI M, 1988, NATURE, V336, P173, DOI 10.1038/336173a0; KRUEGER J, 1991, Trends in Neurosciences, V14, P282; LEHKY SR, 1992, J NEUROSCI, V12, P3568; MALER L, 1994, J COMP NEUROL, V345, P224, DOI 10.1002/cne.903450206; MALER L, 1981, J COMP NEUROL, V195, P87, DOI 10.1002/cne.901950107; MALER L, 1991, J CHEM NEUROANAT, V4, P1, DOI 10.1016/0891-0618(91)90030-G; METZNER W, 1991, J COMP PHYSIOL A, V169, P135, DOI 10.1007/BF00215861; METZNER W, 1993, J NEUROSCI, V13, P1862; Poor H, 1985, INTRO SIGNAL DETECTI; RAUDYS SJ, 1991, IEEE T PATTERN ANAL, V13, P252, DOI 10.1109/34.75512; SHUMWAY CA, 1989, J NEUROSCI, V9, P4388; TURNER RW, 1994, J NEUROSCI, V14, P6453; Turner RW, 1996, J NEUROPHYSIOL, V76, P2364, DOI 10.1152/jn.1996.76.4.2364; Wessel R, 1996, J NEUROPHYSIOL, V75, P2280, DOI 10.1152/jn.1996.75.6.2280; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4; Zakon H.H., 1986, P103	30	183	186	0	28	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 12	1996	384	6609					564	567		10.1038/384564a0	http://dx.doi.org/10.1038/384564a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955269				2022-12-01	WOS:A1996VX76900059
J	Mistry, PK; Wraight, EP; Cox, TM				Mistry, PK; Wraight, EP; Cox, TM			Therapeutic delivery of proteins to macrophages: Implications for treatment of Gaucher's disease	LANCET			English	Article							MANNOSE-TERMINATED GLUCOCEREBROSIDASE; INHERITED ENZYME DEFICIENCY; REPLACEMENT THERAPY; ALGLUCERASE; EFFICACY; TYPE-1; CELLS; CLEARANCE; REGIMEN; LIVER	Background The primary defect in Gaucher's disease, a lysosomal disorder affecting macrophages, is in the activity of glucocerebrosidase. Treatment with exogenous enzyme (modified to increase its affinity for macrophage glycoprotein receptors) aims to restore this activity. However, the fate of the exogenous enzyme in vivo is unknown. We used radiolabelled enzyme to assess macrophage receptor activity for mannosylated ligands in vivo. Methods We examined the uptake and tissue distribution of radiolabelled enzyme molecules by gamma scintigraphy after bolus injection of iodine-123-labelled recombinant or placental enzyme (imiglucerase and alglucerase, respectively) in eight patients with type 1 Gaucher's disease, and in one healthy individual. The metabolism of the tracer enzyme was followed by scintigraphy and by analysis of blood, urine, and faeces. Results The tracer enzyme was rapidly cleared from blood (half-life 4.7 min [SD 1.0]). Concomitantly, there was avid uptake by the liver (about 30% of the injected dose), the spleen (about 15%), and the bone marrow. 40-55% of the tracer was cleared rapidly from the viscera (half-life 1-2 h) and 45-60% was cleared slowly (half-life 34-42 h). The half-life in the bone marrow was 14.1 h. Infusion of alglucerase at dose of 5 U/kg bodyweight normalised acid beta-glucosidase activity of splenic Gaucher's cells in vivo. When the enzyme was administered at a seven-fold higher dose (35 U/kg over 1 h), the receptor-mediated uptake in vivo was saturated, as shown by the increase in blood-clearance half-life of tracer enzyme from 4.5 min to 12 min. Interpretation Avid and saturable uptake of modified glucocerebrosidase was found, which indicates high-affinity targeting to the macrophage system in vivo. The rate of enzyme turnover suggests a rational basis for use of this therapy in treatment of Gaucher's disease.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND; ADDENBROOKES HOSP TRUST,DEPT NUCL MED,CAMBRIDGE,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital								ACHORD DT, 1978, CELL, V15, P269, DOI 10.1016/0092-8674(78)90102-2; BARTON NW, 1993, NEW ENGL J MED, V328, P1564; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BEUTLER E, 1995, MOL MED, V1, P320, DOI 10.1007/BF03401556; Beutler E., 1995, METABOLIC MOL BASES, P2641; Bijsterbosch MK, 1996, EUR J BIOCHEM, V237, P344, DOI 10.1111/j.1432-1033.1996.00344.x; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRADY RO, 1994, BIOCHEM MED METAB B, V52, P1, DOI 10.1006/bmmb.1994.1026; BURNS GF, 1977, J CLIN PATHOL, V30, P981, DOI 10.1136/jcp.30.10.981; COHEN Y, 1994, AM J HEMATOL, V47, P235, DOI 10.1002/ajh.2830470317; DEDUVE C, 1964, FED PROC, V23, P1045; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FIGUEROA ML, 1992, NEW ENGL J MED, V327, P1632, DOI 10.1056/NEJM199212033272304; FURBISH FS, 1981, BIOCHIM BIOPHYS ACTA, V673, P425, DOI 10.1016/0304-4165(81)90474-8; GRABOWSKI GA, 1995, ANN INTERN MED, V122, P33, DOI 10.7326/0003-4819-122-1-199501010-00005; HOLLAK CEM, 1995, LANCET, V345, P1474, DOI 10.1016/S0140-6736(95)91037-9; LENNARTZ MR, 1987, J BIOL CHEM, V262, P9942; MATTHEWS CME, 1957, PHYS MED BIOL, V2, P36, DOI 10.1088/0031-9155/2/1/305; MISTRY PK, 1992, LANCET, V339, P889, DOI 10.1016/0140-6736(92)90928-V; MISTRY PK, 1993, J MED GENET, V30, P889, DOI 10.1136/jmg.30.11.889; MISTRY PK, 1992, Q J MED, V84, P541; MURRAY GJ, 1995, J CELL BIOCHEM, V57, P208, DOI 10.1002/jcb.240570205; MYERS MJ, 1981, BRIT J RADIOL, V54, P1062, DOI 10.1259/0007-1285-54-648-1062; *NIH TECHN ASS PAN, 1996, JAMA-J AM MED ASSOC, V275, P548; PASTORES GM, 1993, BLOOD, V82, P408; PENTCHEV PG, 1975, J MOL MED, V1, P73; RAGHAVAN SS, 1980, AM J HUM GENET, V32, P158; SATO Y, 1993, J CLIN INVEST, V91, P1909, DOI 10.1172/JCI116409; TAYLOR ME, 1993, BIOCHEM SOC T, V21, P468, DOI 10.1042/bst0210468; VANFURTH R, 1992, MONONUCLEAR PHAGOCYTES, P3; WILLEMSEN R, 1995, HISTOCHEM J, V27, P639; ZIMRAN A, 1994, AM J MED, V97, P3, DOI 10.1016/0002-9343(94)90042-6	32	75	99	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1555	1559		10.1016/S0140-6736(96)04451-0	http://dx.doi.org/10.1016/S0140-6736(96)04451-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950883				2022-12-01	WOS:A1996VX02300011
J	Mayford, M; Bach, ME; Huang, YY; Wang, L; Hawkins, RD; Kandel, ER				Mayford, M; Bach, ME; Huang, YY; Wang, L; Hawkins, RD; Kandel, ER			Control of memory formation through regulated expression of a CaMKII transgene	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; II MUTANT MICE; GENE-EXPRESSION; FEAR; RAT; AMYGDALA; LTP; AUTOPHOSPHORYLATION; THREONINE-286	One of the major limitations in the use of genetically modified mice for studying cognitive,, functions is the lack of regional and temporal control of gene function, To overcome these limitations, a forebrain-specific promoter was combined with the tetracycline transactivator system to achieve both regional and temporal control of transgene expression, Expression of an activated calcium-independent form of calcium-calmodulin-dependent dent kinase II (CaMKII) resulted in a loss of hippocampal long-term potentiation in response to 10-hertz stimulation and a deficit in spatial memory, a form of explicit memory, Suppression of transgene expression reversed both the physiological and the memory deficit, When the transgene was expressed at high levels in the lateral amygdala and the striatum but not other forebrain Structures, there was a deficit in fear conditioning, an implicit memory task, that also was reversible Thus, the CaMKII signaling pathway is critical for both explicit and implicit memory storage,in a manner that is independent of its potential role in development.	COLUMBIA UNIV, COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute				Mayford, Mark/0000-0002-9001-5024				BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BLANCHARD DC, 1972, J COMP PHYSIOL PSYCH, V81, P281, DOI 10.1037/h0033521; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CANTERAS NS, 1995, J COMP NEUROL, V360, P213, DOI 10.1002/cne.903600203; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; DAVIS M, 1992, P255; FONG YL, 1989, J BIOL CHEM, V264, P16759; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; KITA H, 1990, J COMP NEUROL, V298, P40, DOI 10.1002/cne.902980104; LEDOUX J E, 1992, P339; LEDOUX JE, 1990, J NEUROSCI, V10, P1062; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141, DOI 10.1016/0959-4388(95)80019-0; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mayford M, 1996, P NATL ACAD SCI USA, V93, P13250, DOI 10.1073/pnas.93.23.13250; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; Neveu D, 1996, NEURON, V16, P619, DOI 10.1016/S0896-6273(00)80081-1; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; QUIRK GJ, 1995, NEURON, V15, P1029, DOI 10.1016/0896-6273(95)90092-6; ROGAN MT, 1995, NEURON, V15, P127, DOI 10.1016/0896-6273(95)90070-5; SCHACTER DL, 1994, MEMORY SYSTEMS BRAIN; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUNYER T, 1990, P NATL ACAD SCI USA, V87, P278, DOI 10.1073/pnas.87.1.278; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002	38	1065	1124	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1996	274	5293					1678	1683		10.1126/science.274.5293.1678	http://dx.doi.org/10.1126/science.274.5293.1678			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939850				2022-12-01	WOS:A1996VW71200049
J	Logan, RPH; Berg, DE				Logan, RPH; Berg, DE			Genetic diversity of Helicobacter pylori	LANCET			English	Editorial Material									WASHINGTON UNIV,SCH MED,DEPT MOL GENET,ST LOUIS,MO 63119	Washington University (WUSTL)	Logan, RPH (corresponding author), UNIV NOTTINGHAM HOSP,DEPT MED,NOTTINGHAM NG7 2UH,ENGLAND.							Akopyants Natalia S., 1996, Gut, V39, pA67; Atherton J. C., 1996, Gut, V39, pA73; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; BUKANOV NO, 1994, MOL MICROBIOL, V11, P509, DOI 10.1111/j.1365-2958.1994.tb00332.x; Censini S., 1996, Gut, V39, pA72; COVER TL, 1995, J CLIN MICROBIOL, V33, P1496, DOI 10.1128/JCM.33.6.1496-1500.1995; Dubois A., 1996, Gut, V39, pA74; Go MF, 1996, J BACTERIOL, V178, P3934, DOI 10.1128/jb.178.13.3934-3938.1996; Hazell S. L., 1996, Gut, V39, pA74; Jiang Q, 1996, MOL MICROBIOL, V20, P833, DOI 10.1111/j.1365-2958.1996.tb02521.x; Kuipers E. J., 1996, Gut, V39, pA10; Tomb J.-F., 1996, Gut, V39, pA3; Tummuru MKR, 1995, MOL MICROBIOL, V18, P867, DOI 10.1111/j.1365-2958.1995.18050867.x	13	57	62	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1462	1463		10.1016/S0140-6736(05)65885-0	http://dx.doi.org/10.1016/S0140-6736(05)65885-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942769				2022-12-01	WOS:A1996VV46300002
J	Manna, AC; Pai, KS; Bussiere, DE; Davies, C; White, SW; Bastia, D				Manna, AC; Pai, KS; Bussiere, DE; Davies, C; White, SW; Bastia, D			Helicase-contrahelicase interaction and the mechanism of termination of DNA replication	CELL			English	Article							BACILLUS-SUBTILIS CHROMOSOME; RIBOSOMAL-RNA GENES; SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; POLAR CONTRAHELICASE; TOPOISOMERASE-IV; ANTIGEN HELICASE; PROTEIN IMPEDES; TERMINUS REGION; FORK MOVEMENT	Termination of DNA replication at a sequence-specific replication terminus is potentiated by the binding of the replication terminator protein (RTP) to the terminus sequence, causing polar arrest of the replicative helicase (contrahelicase activity). Two alternative models have been proposed to explain the mechanism of replication fork arrest. In the first model, the RTP-terminus DNA interaction simply imposes a polar barrier to helicase movement without involving any specific interaction between the helicase and the terminator proteins. The second model proposes that there is a specific interaction between the two proteins, and that the DNA-protein interaction both restricts the fork arrest to the replication terminus and determines the polarity of the process. The evidence presented in this paper strongly supports the second model.	DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710	Duke University			White, Stephen W/N-8164-2018		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI019881] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI19881] Funding Source: Medline; NIGMS NIH HHS [GM-49264] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; AMIN AA, 1992, J BIOL CHEM, V267, P18612; Bastia D., 1996, DNA REPLICATION EUKA, P177; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BLAKELY G, 1991, NEW BIOL, V3, P789; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; BUSSIERE DE, 1995, CELL, V80, P651; CARRIGAN CM, 1991, J MOL BIOL, V222, P197, DOI 10.1016/0022-2836(91)90206-L; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FRANKS AH, 1995, MOL MICROBIOL, V17, P13, DOI 10.1111/j.1365-2958.1995.mmi_17010013.x; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; HERNANDEZ P, 1988, EMBO J, V7, P303, DOI 10.1002/j.1460-2075.1988.tb02813.x; HIASA H, 1994, J BIOL CHEM, V269, P16371; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KAUL S, 1994, P NATL ACAD SCI USA, V91, P11143, DOI 10.1073/pnas.91.23.11143; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KRALICEK AV, 1991, BIOCHEM J, V275, P823, DOI 10.1042/bj2750823; KUEMPEL PL, 1991, NEW BIOL, V3, P799; LANGLEY DB, 1993, MOL MICROBIOL, V10, P771, DOI 10.1111/j.1365-2958.1993.tb00947.x; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LEWIS PJ, 1990, J MOL BIOL, V214, P73, DOI 10.1016/0022-2836(90)90147-E; LEWIS PJ, 1991, RES MICROBIOL, V142, P893, DOI 10.1016/0923-2508(91)90070-Q; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; Manna AC, 1996, P NATL ACAD SCI USA, V93, P3253, DOI 10.1073/pnas.93.8.3253; MARCZALEK J, 1994, J BIOL CHEM, V269, P4883; MARTIN MCS, 1995, J STRUCT BIOL, V114, P167; Meijer WJJ, 1996, MOL MICROBIOL, V19, P1295, DOI 10.1111/j.1365-2958.1996.tb02474.x; MOHANTY BK, 1996, EMBO J, V15, P2520; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; NAKAYAMA N, 1984, J BIOL CHEM, V259, P97; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pai KS, 1996, EMBO J, V15, P3164, DOI 10.1002/j.1460-2075.1996.tb00679.x; Pai KS, 1996, P NATL ACAD SCI USA, V93, P10647, DOI 10.1073/pnas.93.20.10647; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; Ratnakar PVAL, 1996, P NATL ACAD SCI USA, V93, P5522, DOI 10.1073/pnas.93.11.5522; SAHOO T, 1995, J BIOL CHEM, V270, P29138, DOI 10.1074/jbc.270.49.29138; SAHOO T, 1995, EMBO J, V14, P619, DOI 10.1002/j.1460-2075.1995.tb07038.x; SMITH MT, 1994, J MOL BIOL, V241, P335, DOI 10.1006/jmbi.1994.1510; Smith MT, 1996, J MOL BIOL, V260, P54, DOI 10.1006/jmbi.1996.0381; SMITH MT, 1992, J MOL BIOL, V227, P648, DOI 10.1016/0022-2836(92)90214-5; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; YOSHIKAWA H, 1963, P NATL ACAD SCI USA, V49, P559, DOI 10.1073/pnas.49.4.559; YOSHIKAWA H, 1963, P NATL ACAD SCI USA, V49, P806, DOI 10.1073/pnas.49.6.806; YOUNG PA, 1994, J MOL BIOL, V240, P275, DOI 10.1006/jmbi.1994.1444; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297	56	37	38	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					881	891		10.1016/S0092-8674(00)81995-9	http://dx.doi.org/10.1016/S0092-8674(00)81995-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945515	Bronze			2022-12-01	WOS:A1996VV77400014
J	Kitson, J; Raven, T; Jiang, YP; Goeddel, DV; Giles, KM; Pun, KT; Grinham, CJ; Brown, R; Farrow, SN				Kitson, J; Raven, T; Jiang, YP; Goeddel, DV; Giles, KM; Pun, KT; Grinham, CJ; Brown, R; Farrow, SN			A death-domain-containing receptor that mediates apoptosis	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; TNF RECEPTOR; CELL-DEATH; PROTEIN; INTERACTS; FAS; SYSTEM; YEAST	THE cell-killing effects of the cytokines TNF-alpha and Fast are mediated by the distinct cell-surface receptors TNFR1, TNFR2 and Fas (also known as CD95/APO-1), which are all members of a receptor superfamily that is important for regulating cell survival(1-4). The cytoplasmic regions of TNFR1 and Fas contain a conserved 'death' domain which is an essential component of the signal pathway that triggers apoptosis and activation of the transcription factor NF-kappa B (refs 5, 6). Here we report the isolation of a 54K receptor that is a new member of the TNFR superfamily, using the death domain of TNFR1 in a yeast two-hybrid system(7,8). This protein, WSL-1, is most similar to TNFR1 itself, particularly in the death-domain region, The gene wsl-1 is capable of inducing apoptosis when transfected into 3T3 and 293 cells, and can also activate NF-kappa B in 293 cells, Like TNFR1, WSL-1 will homodimerize in yeast. WSL-1 also interacts specifically with the TNFR1-associated molecule TRADD(9). The tissue distribution is very restricted and significantly different from that of Fas and TNFR1.	GLAXO WELLCOME MED RES CTR,CELL BIOL UNIT,STEVENAGE SG1 2NY,HERTS,ENGLAND; TULARIK INC,S SAN FRANCISCO,CA 94080	GlaxoSmithKline				Pun, Tao/0000-0001-5241-2187				Baker SJ, 1996, ONCOGENE, V12, P1; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1994, J BIOL CHEM, V269, P22492; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	22	285	329	3	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					372	375		10.1038/384372a0	http://dx.doi.org/10.1038/384372a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934525				2022-12-01	WOS:A1996VV27100053
J	Tinsley, JM; Potter, AC; Phelps, SR; Fisher, R; Trickett, JI; Davies, KE				Tinsley, JM; Potter, AC; Phelps, SR; Fisher, R; Trickett, JI; Davies, KE			Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene	NATURE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; ORAL SODIUM PHENYLBUTYRATE; MUSCLE-SPECIFIC EXPRESSION; SKELETAL ACTIN GENE; EXTRACELLULAR-MATRIX; FULL-LENGTH; THERAPY; PROTEIN; COMPLEX; MOUSE	DUCHENNE muscular dystrophy (DMD) is a severe, progressive muscle-wasting disease that causes cardiac or respiratory failure(1,2) and results in death at about 20 years of age, Replacement of the missing protein, dystrophin, using myoblast transfer in humans or viral/liposomal delivery in the mouse DMD model is inefficient and short-lived(3,4). One alternative approach to treatment would be to upregulate the closely related protein, utrophin(5,6), which might be able to compensate for the dystrophin deficiency in all relevant muscles(7,8). As a first step to this approach, we have expressed a utrophin transgene at high levels in the dystrophin-deficient mdx mouse. Our results indicate that high expression of the utrophin transgene in skeletal and diaphragm muscle can markedly reduce the dystrophic pathology. These data suggest that systemic upregulation of utrophin in DMD patients may lead to the development of an effective treatment for this devastating disorder.	UNIV OXFORD,DEPT BIOCHEM,GENET LAB,OXFORD OX1 3QU,ENGLAND	University of Oxford								Blake DJ, 1996, BRAIN PATHOL, V6, P37, DOI 10.1111/j.1750-3639.1996.tb00781.x; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; DOVER GJ, 1994, BLOOD, V84, P339; EMERY AEH, 1993, OXFORD MONOGR MED GE, V24; Hoffman EP, 1996, BRAIN PATHOL, V6, P49, DOI 10.1111/j.1750-3639.1996.tb00782.x; HOFFMAN EP, 1994, NAT GENET, V8, P311, DOI 10.1038/ng1294-311; Hogan B., 1986, MANIPULATING MOUSE E; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; MORGAN JE, 1994, HUM GENE THER, V5, P165, DOI 10.1089/hum.1994.5.2-165; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NHUYEN TM, 1991, J CELL BIOL, V155, P1695; PARTRIDGE TA, 1995, BRIT MED BULL, V51, P123, DOI 10.1093/oxfordjournals.bmb.a072942; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; RAFAEL JA, 1994, HUM MOL GENET, V3, P1725, DOI 10.1093/hmg/3.10.1725; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; SHERRATT TG, 1992, BIOCHEM J, V287, P755, DOI 10.1042/bj2870755; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; TINSLEY JM, 1993, NEUROMUSCULAR DISORD, V3, P537, DOI 10.1016/0960-8966(93)90111-V; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; WELLS DJ, 1995, HUM MOL GENET, V4, P1245, DOI 10.1093/hmg/4.8.1245	27	393	417	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					349	353		10.1038/384349a0	http://dx.doi.org/10.1038/384349a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934518				2022-12-01	WOS:A1996VV27100046
J	Cronin, JR; Pizzarello, S				Cronin, JR; Pizzarello, S			Enantiomeric excesses in meteoritic amino acids	SCIENCE			English	Article							REPORTED OPTICAL-ACTIVITY; MURCHISON METEORITE; ALKANOIC ACIDS; BIOMOLECULAR CHIRALITY	Gas chromatographic-mnas spectral analyses of the four stereoisomers of 2-amino-2,3-dimethylpentanoic acid (DL-alpha-methylisoleucine and DL-alpha-methylalloisoleucine) obtained from the Murchison meteorite show that the L enantiomer occurs in excess (7.0 and 9.1%, respectively) in both of the enantiomeric pairs. Similar results were obtained for two other alpha-methyl amino acids, isovaline and alpha-methylnorvaline, although the a hydrogen analogs of these amino acids, alpha-amino-n-butyric acid and norvaline, were found to be racemates. With the exception of alpha-amino-n-butyric acid, these amino acids are either unknown or of limited occurrence in the biosphere. Because carbonaceous chondrites formed 4.5 billion years ago, the results are indicative of an asymmetric influence on organic chemical evolution before the origin of life.			Cronin, JR (corresponding author), ARIZONA STATE UNIV, DEPT CHEM & BIOCHEM, TEMPE, AZ 85287 USA.							BADA JL, 1991, PHILOS T R SOC B, V333, P349, DOI 10.1098/rstb.1991.0084; BADA JL, 1986, NATURE, V319, P314, DOI 10.1038/319314a0; BADA JL, 1983, NATURE, V301, P494, DOI 10.1038/301494a0; BAKER CG, 1952, J AM CHEM SOC, V74, P4701, DOI 10.1021/ja01138a502; BAYER E, 1983, Z NATURFORSCH B, V38, P1281, DOI 10.1515/znb-1983-1019; BONNER WA, 1991, ORIGINS LIFE EVOL B, V21, P59, DOI 10.1007/BF01809580; BONNER WA, 1987, BIOSYSTEMS, V20, P99, DOI 10.1016/0303-2647(87)90025-6; BRUCE DW, 1991, J MATER CHEM, V1, P251, DOI 10.1039/jm9910100251; CAHN RS, 1966, ANGEW CHEM INT EDIT, V5, P385, DOI 10.1002/anie.196603851; CHRISTIE BD, 1987, ANAL CHIM ACTA, V200, P347, DOI 10.1016/S0003-2670(00)83782-4; COOMBES F, 1995, ASTRON ASTROPHYS, V308, P618; Cronin J R, 1983, Adv Space Res, V3, P5, DOI 10.1016/0273-1177(83)90036-4; Cronin J R, 1995, Adv Space Res, V15, P91, DOI 10.1016/S0273-1177(99)80068-4; CRONIN JR, 1993, GEOCHIM COSMOCHIM AC, V57, P4745, DOI 10.1016/0016-7037(93)90197-5; CRONIN JR, 1981, J MOL EVOL, V17, P265, DOI 10.1007/BF01795748; CRONIN JR, 1986, GEOCHIM COSMOCHIM AC, V50, P2419, DOI 10.1016/0016-7037(86)90024-4; CRONIN JR, 1985, GEOCHIM COSMOCHIM AC, V49, P2259, DOI 10.1016/0016-7037(85)90226-1; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; CRONIN JR, 1982, ANAL BIOCHEM, V124, P139, DOI 10.1016/0003-2697(82)90231-7; ENGEL MH, 1982, NATURE, V296, P837, DOI 10.1038/296837a0; ENGEL MH, 1990, NATURE, V348, P47, DOI 10.1038/348047a0; ENGEL MH, 1983, NATURE, V301, P496, DOI 10.1038/301496a0; EPSTEIN S, 1987, NATURE, V326, P477, DOI 10.1038/326477a0; FLORES JJ, 1977, J AM CHEM SOC, V99, P3622, DOI 10.1021/ja00453a018; GELPI E, 1969, J CHROMATOGR SCI, V7, P604, DOI 10.1093/chromsci/7.10.604; Greenberg JM, 1996, AIP CONF PROC, P185; IPSEN J, 1970, BARCROFTS INTRO BIOS; KISUMI M, 1976, J BIOCHEM-TOKYO, V80, P333, DOI 10.1093/oxfordjournals.jbchem.a131281; KVENVOLDEN K, 1970, NATURE, V228, P923, DOI 10.1038/228923a0; KVENVOLDEN KA, 1971, P NATL ACAD SCI USA, V68, P486, DOI 10.1073/pnas.68.2.486; LAWLESS JG, 1971, ANAL BIOCHEM, V44, P473, DOI 10.1016/0003-2697(71)90235-1; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; MacDermott AJ, 1996, CHEMICAL EVOLUTION: PHYSICS OF THE ORIGIN AND EVOLUTION OF LIFE, P373; MEINSCHEIN WG, 1966, SCIENCE, V154, P377, DOI 10.1126/science.154.3747.377; Miao Y., 1994, B AM ASTRON SOC, V26, P906; NAGY BARTHOLOMEW, 1964, NATURE, V202, P228, DOI 10.1038/202228a0; NANDI P, 1953, NATURE, V171, P871; ORO J, 1971, NATURE, V230, P107, DOI 10.1038/230107a0; PELTZER ET, 1978, NATURE, V272, P443, DOI 10.1038/272443a0; POLLOCK GE, 1975, GEOCHIM COSMOCHIM AC, V39, P1571, DOI 10.1016/0016-7037(75)90159-3; RUBENSTEIN E, 1983, NATURE, V306, P118, DOI 10.1038/306118a0; SCHOLLKOPF U, 1987, LIEBIGS ANN CHEM, P399; WALD G, 1957, ANN NY ACAD SCI, V69, P353; Zolensky M., 1988, METEORITES EARLY SOL, P114	44	701	715	1	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					951	955		10.1126/science.275.5302.951	http://dx.doi.org/10.1126/science.275.5302.951			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020072				2022-12-01	WOS:A1997WH38800037
J	Cai, DG; Kleine, M; Kifle, S; Harloff, HJ; Sandal, NN; Marcker, KA; KleinLankhorst, RM; Salentijn, EMJ; Lange, W; Stiekema, WJ; Wyss, U; Grundler, FMW; Jung, C				Cai, DG; Kleine, M; Kifle, S; Harloff, HJ; Sandal, NN; Marcker, KA; KleinLankhorst, RM; Salentijn, EMJ; Lange, W; Stiekema, WJ; Wyss, U; Grundler, FMW; Jung, C			Positional cloning of a gene for nematode resistance in sugar beet	SCIENCE			English	Article							HETERODERA-SCHACHTII RESISTANCE; PLANT-PARASITIC NEMATODES; LEUCINE-RICH REPEAT; BETA-VULGARIS; DISEASE RESISTANCE; PROCUMBENS; SEQUENCE; SECTION; PROTEIN	Hs1(pro-1) locus confers resistance to the beet cyst nematode (Heterodera schachtii Schmidt), a major pest in the cultivation of sugar beet (Beta vulgaris L.). The Hs1(pro-1) gene was cloned with the use of genome-specific satellite markers and chromosomal breakpoint analysis, Expression of the corresponding complementary DNA in a susceptible sugar beet conferred resistance to infection with the beet cyst nematode. The native HS1(pro-1) gene, expressed in roots, encodes a 282-amino acid protein with imperfect leucine-rich repeats and a putative membrane-spanning segment, features similar to those of disease resistance genes previously cloned from higher plants.	CHRISTIAN ALBRECHTS UNIV KIEL,INST CROP SCI & PLANT BREEDING,D-24118 KIEL,GERMANY; AARHUS UNIV,DEPT MOL & STRUCT BIOL,DK-8000 AARHUS,DENMARK; DLO,CTR PLANT BREEDING & REPROD RES,NL-6700 AA WAGENINGEN,NETHERLANDS; CHRISTIAN ALBRECHTS UNIV KIEL,INST PHYTOPATHOL,D-24118 KIEL,GERMANY	University of Kiel; Aarhus University; University of Kiel			Grundler, Florian MW/I-6508-2012	Grundler, Florian M.W./0000-0001-8101-0558				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BRANDES A, 1987, PLANT BREEDING, V99, P56, DOI 10.1111/j.1439-0523.1987.tb01150.x; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; GABRIEL DW, 1990, ANNU REV PHYTOPATHOL, V28, P365, DOI 10.1146/annurev.py.28.090190.002053; GRUNDLER EMW, IN PRESS PHYSL MOL P; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEIJBROEK W, 1988, EUPHYTICA, V38, P121, DOI 10.1007/BF00040182; Heller R, 1996, THEOR APPL GENET, V92, P991, DOI 10.1007/BF00224039; HOLTMANN B, UNPUB; HUSSEY RS, 1989, ANNU REV PHYTOPATHOL, V27, P123, DOI 10.1146/annurev.py.27.090189.001011; JEFFERSON RA, 1987, EMBO J, V6, P3901; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; Jones JDG, 1996, CURR OPIN BIOTECH, V7, P155, DOI 10.1016/S0958-1669(96)80006-1; JUNG C, 1987, PLANT BREEDING, V98, P205, DOI 10.1111/j.1439-0523.1987.tb01118.x; JUNG C, 1992, MOL GEN GENET, V232, P271, DOI 10.1007/BF00280006; KIFLE S, UNPUB; KLEINE M, 1995, THEOR APPL GENET, V90, P399, DOI 10.1007/BF00221982; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kunkel BN, 1996, TRENDS GENET, V12, P63, DOI 10.1016/0168-9525(96)81402-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PAUL H, 1990, EUPHYTICA, V48, P153, DOI 10.1007/BF00037194; SALENTIJN EMJ, 1995, THEOR APPL GENET, V90, P885, DOI 10.1007/BF00222027; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; SAVITSKY H, 1978, CAN J GENET CYTOL, V20, P177, DOI 10.1139/g78-019; SPIEGEL Y, 1995, J NEMATOL, V27, P127; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; TOXOPEUS JH, 1979, P EUCARPIA CRUCIFERA, P151; TRAUT TW, 1994, EUR J BIOCHEM, V229, P9; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YU MH, 1984, EUPHYTICA, V33, P633, DOI 10.1007/BF00021891	35	321	409	2	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					832	834		10.1126/science.275.5301.832	http://dx.doi.org/10.1126/science.275.5301.832			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012350				2022-12-01	WOS:A1997WG77700061
J	Nightingale, SL				Nightingale, SL			Ruminant-to-ruminant feeding ban proposed to reduce risk of transmissible spongiform encephalopathies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1997, FED REGISTER, V62, P551	1	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					370	370						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE771	9010159				2022-12-01	WOS:A1997WE77100006
J	Ali, JA; Lohman, TM				Ali, JA; Lohman, TM			Kinetic measurement of the step size of DNA unwinding by Escherichia coli UvrD helicase	SCIENCE			English	Article							GENE-PRODUCT; REP HELICASE; INDUCED DIMERIZATION; POLYMERASE-I; PROTEIN; MECHANISMS; BINDING; SYSTEM	The kinetic mechanism by which the DNA repair helicase UvrD of Escherichia coli unwinds duplex DNA was examined with the use of a series of oligodeoxynucleotides with duplex regions ranging from 10 to 40 base pairs. Single-turnover unwinding experiments showed distinct lag phases that increased with duplex length because partially unwound DNA intermediate states are highly populated during unwinding. Analysis of these kinetics indicates that UvrD unwinds duplex DNA in discrete steps, with an average ''step size'' of 4 to 5 base pairs (approximately one-half turn of the DNA helix). This suggests an unwinding mechanism in which alternating subunits of the dimeric helicase interact directly with duplex DNA.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)					NIGMS NIH HHS [GM45948, R01 GM045948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali J., UNPUB; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Bjornson KP, 1996, J MOL BIOL, V263, P411, DOI 10.1006/jmbi.1996.0585; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; GILCHRIST CA, 1987, NUCLEIC ACIDS RES, V15, P465, DOI 10.1093/nar/15.2.465; GUTFREUND H, 1995, KINETICS LIFE SCI RE; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MAPLES VF, 1982, P NATL ACAD SCI-BIOL, V79, P5616, DOI 10.1073/pnas.79.18.5616; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; RUNYON GT, 1990, P NATL ACAD SCI USA, V87, P6383, DOI 10.1073/pnas.87.16.6383; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; WONG I, 1992, J BIOL CHEM, V267, P7596; WONG I, 1993, J BIOL CHEM, V268, P20386; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YAMAMOTO Y, 1986, J BIOCHEM-TOKYO, V99, P1579, DOI 10.1093/oxfordjournals.jbchem.a135631	26	228	231	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					377	380		10.1126/science.275.5298.377	http://dx.doi.org/10.1126/science.275.5298.377			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994032				2022-12-01	WOS:A1997WC87300043
J	Russell, NH				Russell, NH			Biology of acute leukaemia	LANCET			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; COLONY-STIMULATING FACTOR; PROGNOSTIC IMPLICATIONS; P53 MUTATIONS; EXPRESSION; GRANULOCYTE; CHEMOTHERAPY; MACROPHAGE	The leukaemias vary in their response to therapy. In acute myeloid leukaemia, for instance, response to therapy is poorer in order than in younger patients. One explanation for this is that in older patients the acute myeloid leukaemia is more likely to have arisen from a pluripotent stem cell than from a lineage-restricted progenitor cell; the former has a high self-renewal capacity, an active drug-efflux pump, and high content of anti-apoptotic proteins, all of which contribute to chemoresistance. Unravelling the biology of the leukaemias should help in the development of novel therapies.	UNIV NOTTINGHAM,DEPT CLIN LAB SCI,NOTTINGHAM NG7 2RD,ENGLAND	University of Nottingham								BEDI A, 1994, BLOOD, V83, P2038; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BOEKHORST PAWT, 1995, LEUKEMIA, V9, P1025; Bonnet D., 1996, British Journal of Haematology, V93, P144; BRADBURY D, 1994, LEUKEMIA, V8, P786; CAMPOS L, 1993, BLOOD, V81, P3091; Campos L, 1996, LEUKEMIA, V10, P434; DELPOETA B, 1996, BLOOD, V87, P1992; DICCIANNI MB, 1994, BLOOD, V84, P3105; DONG F, 1994, P NATL ACAD SCI USA, V91, P4480, DOI 10.1073/pnas.91.10.4480; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; FIALKOW PJ, 1987, NEW ENGL J MED, V317, P468, DOI 10.1056/NEJM198708203170802; GOASGUEN JE, 1993, BLOOD, V81, P2394; GREAVES MF, 1993, BRIT J CANCER, V67, P413, DOI 10.1038/bjc.1993.81; HAASE D, 1995, BLOOD, V86, P2906; HUNTER AE, 1993, BLOOD, V82, P899; JANOSSY G, 1989, LEUKEMIA, V3, P170; KEINANEN M, 1988, NEW ENGL J MED, V318, P1153, DOI 10.1056/NEJM198805053181803; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; MANABE A, 1992, BLOOD, V79, P2370; Marks DI, 1996, BLOOD, V87, P1155, DOI 10.1182/blood.V87.3.1155.bloodjournal8731155; MCCULLOCH EA, 1982, BLOOD, V59, P601; PORWITTMCDONALD, 1996, BLOOD, V87, P1162; SECKERWALKER LM, 1993, LEUKEMIA, V7, P147; SWANSBURY GJ, 1994, CANCER GENET CYTOGEN, V73, P1, DOI 10.1016/0165-4608(94)90174-0; TURHAN AG, 1995, BLOOD, V85, P2154, DOI 10.1182/blood.V85.8.2154.bloodjournal8582154; vanLom K, 1996, BRIT J HAEMATOL, V93, P594, DOI 10.1046/j.1365-2141.1996.d01-1692.x; WATARI K, 1994, BLOOD, V84, P36; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; WILLMAN CL, 1996, LEUKEMIA S, V10, P533	30	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					118	122		10.1016/S0140-6736(96)07185-1	http://dx.doi.org/10.1016/S0140-6736(96)07185-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996433				2022-12-01	WOS:A1997WB80000044
J	Abbott, LF; Varela, JA; Sen, K; Nelson, SB				Abbott, LF; Varela, JA; Sen, K; Nelson, SB			Synaptic depression and cortical gain control	SCIENCE			English	Article							NEOCORTEX	Cortical neurons receive synaptic inputs from thousands of afferents that fire action potentials at rates ranging from less than 1 hertz to more than 200 hertz. Both the number of afferents and their large dynamic range can mask changes in the spatial and temporal pattern of synaptic activity, limiting the ability of a cortical neuron to respond to its inputs. Modeling work based on experimental measurements indicates that short-term depression of intracortical synapses provides a dynamic gain-control mechanism that allows equal percentage rate changes on rapidly and slowly firing afferents to produce equal postsynaptic responses. Unlike inhibitory and adaptive mechanisms that reduce responsiveness to all inputs, synaptic depression is input-specific, reading to a dramatic increase in the sensitivity of a neuron to subtle changes in the firing patterns of its afferents.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University	Abbott, LF (corresponding author), BRANDEIS UNIV,VOLEN CTR,WALTHAM,MA 02254, USA.			Nelson, Sacha/0000-0002-0108-8599				Abbott L. F., 1996, Society for Neuroscience Abstracts, V22, P952; ARONIADOU VA, 1991, BRAIN RES, V562, P136, DOI 10.1016/0006-8993(91)91197-9; Barlow HB, 1989, NEURAL COMPUT, V1, P412, DOI 10.1162/neco.1989.1.3.412; Barlow HB, 1989, NEURAL COMPUT, V1, P295, DOI 10.1162/neco.1989.1.3.295; deCharms RC, 1996, NATURE, V381, P610, DOI 10.1038/381610a0; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; FECHNER GT, 1880, ELEMENTE PSYCHOPHYSI; Gawne TJ, 1996, CEREB CORTEX, V6, P482, DOI 10.1093/cercor/6.3.482; GAWNE TJ, 1993, J NEUROSCI, V13, P2758; Hess G, 1996, J NEUROPHYSIOL, V75, P1765, DOI 10.1152/jn.1996.75.5.1765; MAGLEBY KL, 1982, J GEN PHYSIOL, V80, P613, DOI 10.1085/jgp.80.4.613; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; Nelson S. B., 1993, Society for Neuroscience Abstracts, V19, P629; Nelson S. B., 1996, Society for Neuroscience Abstracts, V22, P952; NELSON SB, 1996, IN PRESS P COMP NEUR; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SOFTKY WR, 1992, NEURAL COMPUT, V4, P643, DOI 10.1162/neco.1992.4.5.643; SOFTKY WR, 1993, J NEUROSCI, V13, P334; Stratford KJ, 1996, NATURE, V382, P258, DOI 10.1038/382258a0; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; TROYER TW, IN PRESS NEURAL COMP; Tsodyks M., 1995, NETWORK, V6, P1; TSODYKS MV, 1996, LECT NOTES COMPUTER, P445; TSODYKS MV, IN PRESS P NATL ACAD; [No title captured]	25	1162	1175	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					220	224						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985017				2022-12-01	WOS:A1997WC02200041
J	Messler, W; Stewart, CB				Messler, W; Stewart, CB			Episodic adaptive evolution of primate lysozymes	NATURE			English	Article							POSITIVE DARWINIAN SELECTION; STOMACH LYSOZYMES; NUCLEOTIDE SUBSTITUTIONS; FOREGUT FERMENTERS; DIVERGENCE; CONVERGENCE; NUMBERS; RATES; GENE	ALTHOUGH the darwinian concept of adaptation was established nearly a century ago, it has been difficult to demonstrate rigorously that the amino-acid differences between homologous proteins from different species have adaptive significance, There are currently two major types of sequence tests for positive darwinian selection on proteins from different species: sequence convergence, and neutral rate violation (reviewed in ref. 1). Lysozymes from the stomachs of cows and langur monkeys, two mammalian species displaying fermentation in the foregut, are an example(2,3) of amino-acid sequence convergence among homologous proteins(4,6). Here we combine tests of neutral rate violation with reconstruction of ancestral sequences to document an episode of positive selection on the lineage leading to the common ancestor of the foregut-fermenting colobine monkeys. This analysis also detected a previously unsuspected adaptive episode on the lineage leading to the common ancestor of the modern hominoid lysozymes. Both adaptive episodes were followed by episodes of negative selection. Thus this approach can detect adaptive and purifying episodes, and localize them to specific lineages during protein evolution.	SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222	State University of New York (SUNY) System; State University of New York (SUNY) Albany								[Anonymous], 1993, MEGA MOL EVOLUTIONAR; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; CHIVERS DJ, 1980, J MORPHOL, V166, P337, DOI 10.1002/jmor.1051660306; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Delson Eric, 1994, P11; DOBSON DE, 1984, J BIOL CHEM, V259, P1607; Endo T, 1996, MOL BIOL EVOL, V13, P685, DOI 10.1093/oxfordjournals.molbev.a025629; Felsenstein J., 1996, PHYLIP PHYLOGENY INF; Gillespie J.H., 1991, CAUSES MOL EVOLUTION; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; IRWIN DM, 1990, J BIOL CHEM, V265, P4944; JOLIES J, 1989, J MOL EVOL, V28, P528; KREITMAN M, 1995, ANNU REV ECOL SYST, V26, P403, DOI 10.1146/annurev.es.26.110195.002155; LEE Y, 1992, BIOL BULL, V182, P97, DOI 10.2307/1542183; Li W-H., 1991, FUNDAMENTALS MOL EVO; LI WH, 1985, MOL BIOL EVOL, V2, P150; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; MADDISON WP, 1994, MACCRADE ANAL PHYLOG; NEI M, 1986, MOL BIOL EVOL, V3, P418; NEI M, 1989, MOL BIOL EVOL, V6, P290; Nei M., 1987, MOL EVOLUTIONARY GEN; STEWART CB, 1987, NATURE, V330, P401, DOI 10.1038/330401a0; STEWART CB, 1987, COLD SPRING HARB SYM, V52, P891, DOI 10.1101/SQB.1987.052.01.097; STEWART CB, 1986, LYSOZYME EVOLUTION O; SWANSON KW, 1991, J MOL EVOL, V33, P418, DOI 10.1007/BF02103133; SWANSON WJ, 1995, P NATL ACAD SCI USA, V92, P4957, DOI 10.1073/pnas.92.11.4957; SWOFFORD DL, IN PRESS PAUP PHYLOG; WOLFE KH, 1993, J MOL EVOL, V37, P441, DOI 10.1007/BF00178874; YANG ZH, 1995, GENETICS, V141, P1641; Yu M, 1996, MOL PHYLOGENET EVOL, V5, P298, DOI 10.1006/mpev.1996.0025	30	336	377	0	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					151	154		10.1038/385151a0	http://dx.doi.org/10.1038/385151a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990116				2022-12-01	WOS:A1997WB72800052
J	Freeman, SM; Ramesh, R; Marrogi, AJ				Freeman, SM; Ramesh, R; Marrogi, AJ			Immune system in suicide-gene therapy	LANCET			English	Editorial Material							REGRESSION				Freeman, SM (corresponding author), TULANE UNIV,SCH MED,DEPT PATHOL,NEW ORLEANS,LA 70112, USA.							CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; FREEMAN SM, 1993, CANCER RES, V53, P5274; FREEMAN SM, 1995, CANCER LETT, V92, P167, DOI 10.1016/0304-3835(95)03771-N; Freeman SM, 1996, SEMIN ONCOL, V23, P31; Freeman SM, 1992, HUM GENE THER, V3, P342; GANGANDEEP S, IN PRESS CANC GENE T; Ramesh R, 1996, EXP HEMATOL, V24, P829; RAMESH R, IN PRESS CANC GENE T; SANTODONATO L, 1996, HUM GENE THER, V7, P10; VILE RG, 1994, CANCER RES, V54, P6228	10	122	134	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					2	3		10.1016/S0140-6736(97)22001-5	http://dx.doi.org/10.1016/S0140-6736(97)22001-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988108				2022-12-01	WOS:A1997WA72500002
J	Dorsky, RI; Chang, WS; Rapaport, DH; Harris, WA				Dorsky, RI; Chang, WS; Rapaport, DH; Harris, WA			Regulation of neuronal diversity in the Xenopus retina by Delta signalling	NATURE			English	Article							CELL-FATE; DROSOPHILA EYE; FROG RETINA; IN-VITRO; NOTCH; DIFFERENTIATION; NEUROGENESIS; EXPRESSION; PHOTORECEPTORS; PROGENITORS	To generate the variety of mature neurons and glia found in the developing retina, the competence of pluripotent progenitor cells to respond to extracellular signals must be controlled. Delta, a ligand of the Notch receptor, is a candidate for regulating progenitor competence on the grounds that activation of the pathway involving Notch and Delta can inhibit cellular differentiation(1-6). Here we test this possibility in the developing Xenopus retina by misexpression of Delta messenger RNA. We find that Delta-misexpressing cells with wild-type neighbours adopt earlier fates, primarily becoming ganglion cells and cone photoreceptors. Progenitors transfected with Delta later in development also produce rod photoreceptors, but not the latest-generated cell types, demonstrating the importance of timing in Delta function. We conclude that Delta signalling in the vertebrate retina is a basic regulatory mechanism that can be used to generate neuronal diversity.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT SURG,DIV ANAT,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; ALTSHULER D, 1992, DEVELOPMENT, V114, P947; AUSTIN CP, 1995, DEVELOPMENT, V121, P3637; BeleckyAdams T, 1996, DEV BIOL, V178, P304, DOI 10.1006/dbio.1996.0220; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; DORSKY RI, 1995, NEURON, V14, P487, DOI 10.1016/0896-6273(95)90305-4; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FUHRMANN S, 1995, DEVELOPMENT, V121, P2695; HARRIS WA, 1992, NEURON, V9, P357, DOI 10.1016/0896-6273(92)90174-C; Heitzler P, 1996, DEVELOPMENT, V122, P161; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HOLT CE, 1990, NEURON, V4, P203, DOI 10.1016/0896-6273(90)90095-W; HUANG S, 1993, J NEUROSCI, V13, P3193; KELLEY MW, 1994, DEVELOPMENT, V120, P2091; KELLEY MW, 1995, DEVELOPMENT, V121, P3777; LAVAIL MM, 1991, J COMP NEUROL, V309, P86, DOI 10.1002/cne.903090107; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; NYE JS, 1994, DEVELOPMENT, V120, P2421; PARKS AL, 1995, MECH DEVELOP, V50, P201, DOI 10.1016/0925-4773(94)00336-L; REH TA, 1989, J NEUROSCI, V9, P4179; REH TA, 1992, J NEUROBIOL, V23, P1067, DOI 10.1002/neu.480230811; REH TA, 1987, J NEUROSCI, V7, P3317; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; Waid D. K., 1995, Society for Neuroscience Abstracts, V21, P529; WATANABE T, 1992, DEVELOPMENT, V114, P899; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732	31	231	236	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					67	70		10.1038/385067a0	http://dx.doi.org/10.1038/385067a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985247				2022-12-01	WOS:A1997WA73100050
J	MAndelboim, O; Davis, DM; Reyburn, HT; ValesGomez, M; Sheu, EG; Pazmany, L; Strominger, JL				MAndelboim, O; Davis, DM; Reyburn, HT; ValesGomez, M; Sheu, EG; Pazmany, L; Strominger, JL			Enhancement of class II-restricted T cell responses by costimulatory NK receptors for class I MHC proteins	SCIENCE			English	Article							NATURAL-KILLER-CELLS; HLA-C MOLECULES; HISTOCOMPATIBILITY COMPLEX; ANTIGEN RECOGNITION; CLONES; P58; RESISTANCE; LYSIS; HETEROGENEITY; LYMPHOCYTES	An important feature of the human immune system is the ability of T cells to respond to small quantities of antigen. Class II major histocompatibility complex (MHC)-restricted T cells that expressed a costimulatory natural killer (NK) cell receptor for class I MHC proteins were cloned. In the presence of low doses of superantigen, the proliferative response of these T cell clones was three- to ninefold greater when the T cells were costimulated by way of the NK receptor. Thus, the action of costimulatory NK receptors on T cells may play a significant role in initiating and sustaining immune responses.			MAndelboim, O (corresponding author), HARVARD UNIV,DEPT MOL & CELLULAR BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Reyburn, Hugh T/B-4338-2009; Valés-Gómez, Mar/F-5351-2012; Vales-Gomez, Mar/ABG-7808-2020; Sheu, Eric/U-2188-2019	Reyburn, Hugh T/0000-0003-2855-1595; Valés-Gómez, Mar/0000-0001-7424-3206; Vales-Gomez, Mar/0000-0001-7424-3206; Sheu, Eric/0000-0003-2707-1768; Mandelboim, Ofer/0000-0002-9354-1855; Davis, Daniel/0000-0002-9182-291X	NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biassoni R, 1996, J EXP MED, V183, P645, DOI 10.1084/jem.183.2.645; BOUSSIOTIS VA, 1994, CURR OPIN IMMUNOL, V6, P797, DOI 10.1016/0952-7915(94)90087-6; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; CICCONE E, 1992, J EXP MED, V175, P709, DOI 10.1084/jem.175.3.709; CICCONE E, 1990, P NATL ACAD SCI USA, V87, P9794, DOI 10.1073/pnas.87.24.9794; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; COLONNA M, 1993, SCIENCE, V260, P1121, DOI 10.1126/science.8493555; DANDREA A, 1995, J IMMUNOL, V155, P2306; DANDREA A, 1996, J EXP MED, V194, P784; FALK CS, 1995, J EXP MED, V182, P1005, DOI 10.1084/jem.182.4.1005; FERRINI S, 1994, EUR J IMMUNOL, V24, P2294, DOI 10.1002/eji.1830241005; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; GUMPERZ JE, 1995, J EXP MED, V181, P1133, DOI 10.1084/jem.181.3.1133; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; Mandelboim O, 1996, J EXP MED, V184, P913, DOI 10.1084/jem.184.3.913; MANDELBOIM O, UNPUB; MILLER JFAP, 1992, ANNU REV IMMUNOL, V10, P51, DOI 10.1146/annurev.iy.10.040192.000411; MINGARI MC, 1995, INT IMMUNOL, V7, P697, DOI 10.1093/intimm/7.4.697; MORETTA A, 1995, J EXP MED, V182, P875, DOI 10.1084/jem.182.3.875; Moretta A, 1996, ANNU REV IMMUNOL, V14, P619, DOI 10.1146/annurev.immunol.14.1.619; NAKAJIMA H, 1995, J IMMUNOL, V155, P4139; Olcese L, 1996, J IMMUNOL, V156, P4531; Pazmany L, 1996, SCIENCE, V274, P792, DOI 10.1126/science.274.5288.792; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; REYBURN HT, UNPUB; SHIMIZU Y, 1989, J IMMUNOL, V142, P3320; SPITS H, 1995, BLOOD, V85, P10; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X	32	88	88	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2097	2100		10.1126/science.274.5295.2097	http://dx.doi.org/10.1126/science.274.5295.2097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953044				2022-12-01	WOS:A1996VY97400054
J	Henningfield, JE; Hariharan, M; Kozlowski, LT				Henningfield, JE; Hariharan, M; Kozlowski, LT			Nicotine content and health risks of cigars	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CIGARETTES; SMOKERS		UNIV MICHIGAN,SCH MED,DEPT PSYCHIAT,ANN ARBOR,MI; PENN STATE UNIV,COLL HLTH & HUMAN DEV,DEPT BIOBEHAV HLTH,UNIVERSITY PK,PA 16802	University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Henningfield, JE (corresponding author), NATL INST DRUG ABUSE,INTRAMURAL RES PROGRAM,BALTIMORE,MD 21224, USA.							BENOWITZ NL, 1994, NEW ENGL J MED, V331, P123, DOI 10.1056/NEJM199407143310212; GOTTSCHO AM, 1988, J ASSOC OFF ANA CHEM, V71, P1110; HARIHARAN M, 1991, CLIN CHEM, V37, P1276; HENNINGFIELD JE, 1994, JAMA-J AM MED ASSOC, V272, P312, DOI 10.1001/jama.272.4.312; Henningfield JE, 1995, TOB CONTROL, V1, P57, DOI DOI 10.1136/TC.4.1.57; HERLING S, 1988, PREV MED, V17, P73, DOI 10.1016/0091-7435(88)90073-4; OCKENE JK, 1987, AM J PUBLIC HEALTH, V77, P1412, DOI 10.2105/AJPH.77.11.1412; PETO R, 1994, MORTALITY SMOKING; *US DHHS, 1983, HLTH CONSEQUENCES SM; *US DHHS, 1984, HLTH CONSEQUENCES SM; *US DHHS, 1982, HLTH CONSEQUENCES SM; *US DHHS, 1988, HLTH CONSEQUENCES SM	12	25	25	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1996	276	23					1857	1858		10.1001/jama.1996.03540230007003	http://dx.doi.org/10.1001/jama.1996.03540230007003			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX522	8967995				2022-12-01	WOS:A1996VX52200002
J	Davies, E; Clarke, C; Hopkins, A				Davies, E; Clarke, C; Hopkins, A			Malignant cerebral glioma .1. Survival, disability, and morbidity after radiotherapy	BRITISH MEDICAL JOURNAL			English	Article							COST-BENEFIT-ANALYSIS; RADIATION-THERAPY; BRAIN; IRRADIATION; MANAGEMENT; TRIAL; ASTROCYTOMAS; SURGERY; GRADE-3; TUMORS	Objective-To describe survival, disability, and morbidity after radiotherapy for malignant glioma. Design-Two year prospective study with home interviews with patients and relatives. Setting-Seven neurosurgical and radiotherapy centres in London. Subjects-105 patients aged 21 to 75: 59 had biopsy; 46 had partial macroscopic resection; 92 received radiotherapy; and 13 received steroids alone. Main outcome measures-Survival, time free from disability, and changes in disability after treatment. Results-Six and 12 month survival for radiotherapy patients was 70% and 39%, respectively. Age, World Health Organisation clinical performance status, extent of surgery, and history of seizures before diagnosis each influenced survival. The Medical Research Council prognostic index was also significantly related to survival. Multivariate analysis showed that initial clinical performance status was the most important component of the index. Most (80%; 49/61) patients with a clinical performance status of 0, 1, or 2 lived at least six months before becoming permanently disabled. Most patients who had initially had a good clinical performance status (0-2) and who were alive six months after radiotherapy (68%; 36/52), however, had experienced either clinical deterioration or severe tiredness after treatment. In 17% (9/52) of these some permanent loss of function remained. These adverse effects were associated with increasing radiotherapy dose. Severely disabled patients (clinical performance status 3 or 4) gained little benefit. Conclusion-Severely disabled patients gain little physical benefit from radiotherapy, whereas those not so disabled may experience considerable adverse effects.	UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL,DIRECTORATE NEUROSURG & CLIN NEUROSCI,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London	Davies, E (corresponding author), ROYAL COLL PHYSICIANS,RES UNIT,LONDON NW1 4LE,ENGLAND.			Davies, Elizabeth/0000-0003-2325-0849				BLEEHEN NM, 1991, BRIT J CANCER, V64, P769, DOI 10.1038/bjc.1991.396; BRADA M, 1989, BRIT J CANCER, V60, P1, DOI 10.1038/bjc.1989.207; BURGER PC, 1987, CANCER, V59, P1617, DOI 10.1002/1097-0142(19870501)59:9<1617::AID-CNCR2820590916>3.0.CO;2-X; CHANG CH, 1983, CANCER, V52, P997, DOI 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2; CHOUCAIR AK, 1990, J NATL CANCER I, V82, P531, DOI 10.1093/jnci/82.6.531; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; Davies E, 1996, BMJ-BRIT MED J, V313, P1512, DOI 10.1136/bmj.313.7071.1512; FAITHFULL S, 1991, J ADV NURS, V16, P936; FREEMAN JE, 1973, BRIT MED J, V4, P523, DOI 10.1136/bmj.4.5891.523; GIBBERD FB, 1983, J NEUROL NEUROSUR PS, V46, P460, DOI 10.1136/jnnp.46.5.460; GREEN SB, 1983, CANCER TREAT REP, V67, P121; HUTTON JL, 1992, J NEUROL NEUROSUR PS, V55, P271, DOI 10.1136/jnnp.55.4.271; KRISTIANSEN K, 1981, CANCER, V47, P649, DOI 10.1002/1097-0142(19810215)47:4<649::AID-CNCR2820470405>3.0.CO;2-W; LEIBEL SA, 1987, J NEUROSURG, V66, P1, DOI 10.3171/jns.1987.66.1.0001; MAHONEY F I, 1965, Md State Med J, V14, P61; MCKERAN RO, 1980, BRAIN TUMOURS SCI BA, P194; MRC Brain Tumour Working Party, 1990, J NEUROONCOL, V9, P47; Nouri F. M., 1987, CLIN REHABIL, V1, P301, DOI DOI 10.1177/026921558700100409; PICKARD JD, 1990, BRIT MED J, V301, P629, DOI 10.1136/bmj.301.6753.629; ROBINSON R, 1993, BRIT MED J, V307, P924, DOI 10.1136/bmj.307.6909.924; *ROYAL COLL PHYS, 1992, STAND ASS SCAL ELD; SHELINE GE, 1980, INT J RADIAT ONCOL, V6, P1215, DOI 10.1016/0360-3016(80)90175-3; Thomas D G, 1989, Br J Neurosurg, V3, P321, DOI 10.3109/02688698909002810; TODD NV, 1987, LANCET, V1, P611; VALK PE, 1991, AM J ROENTGENOL, V156, P689; WALKER MD, 1978, J NEUROSURG, V49, P333, DOI 10.3171/jns.1978.49.3.0333; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; WARA WM, 1991, COMPLICATIONS CANC M; WHITTLE IR, 1991, SURG NEUROL, V36, P106, DOI 10.1016/0090-3019(91)90227-Z; World Health Organization, 1979, HDB REP RES CANC TRE; WROE SJ, 1986, BRIT MED J, V293, P1015, DOI 10.1136/bmj.293.6553.1015	31	42	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1507	1512		10.1136/bmj.313.7071.1507	http://dx.doi.org/10.1136/bmj.313.7071.1507			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY691	8978224	Green Published			2022-12-01	WOS:A1996VY69100016
J	Niessen, LC				Niessen, LC			Pericoronitis as a cause of tonsillitis	LANCET			English	Article											Niessen, LC (corresponding author), TEXAS A&M UNIV,BAYLOR COLL DENT,DEPT PUBL HLTH SCI,DALLAS,TX 75246, USA.							KRUGER GO, 1984, TXB ORAL SURG, P198; MOMBELLI A, 1990, J CLIN PERIODONTOL, V17, P48, DOI 10.1111/j.1600-051X.1990.tb01047.x; NITZAN DW, 1985, J ORAL MAXIL SURG, V43, P510, DOI 10.1016/S0278-2391(85)80029-X; Rajasuo A, 1996, CLIN INFECT DIS, V23, P51, DOI 10.1093/clinids/23.1.51; TOPAZIAN RG, 1994, ORAL MAXILLOFACIAL I, P309; WADE WG, 1991, ORAL MICROBIOL IMMUN, V6, P310, DOI 10.1111/j.1399-302X.1991.tb00499.x	6	3	4	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1602	1603		10.1016/S0140-6736(05)65690-5	http://dx.doi.org/10.1016/S0140-6736(05)65690-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961986				2022-12-01	WOS:A1996VX87600005
J	Bhat, MA; Philp, AV; Glover, DM; Bellen, HJ				Bhat, MA; Philp, AV; Glover, DM; Bellen, HJ			Chromatid segregation at anaphase requires the barren product, a novel chromosome-associated protein that interacts with topoisomerase II	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; DROSOPHILA CYCLIN-A; CELL-CYCLE; NEURONAL PRECURSORS; MITOSIS; MELANOGASTER; GENE; EMBRYOGENESIS; MUTATIONS; PROGRESSION	We have isolated a Drosophila gene, barren (barr), required for sister-chromatid segregation in mitosis. barr encodes a novel protein that is present in proliferating cells and has homologs in yeast and human. Mitotic defects in barr embryos become apparent during cycle 16, resulting in a loss of PNS and CNS neurons. Centromeres move apart at the metaphase-anaphase transition and Cyclin B is degraded, but sister chromatids remain connected, resulting in chromatin bridging. This phenotype is similar to that described in TOP2 mutants in yeast. Barren protein localizes to chromatin throughout mitosis. Colocalization and biochemical experiments indicate that Barren associates with Topoisomerase II throughout mitosis and alters the activity of Topoisomerase II. We propose that this association is required for proper chromosomal segregation by facilitating the decatenation of chromatids at anaphase.	UNIV DUNDEE,DEPT ANAT & PHYSIOL,CRC,CELL CYCLE GENET GRP,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	Bhat, MA (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030, USA.		; BHAT, MANZOOR/S-9273-2018	Bellen, Hugo/0000-0001-5992-5989; BHAT, MANZOOR/0000-0003-0989-1498; Glover, David/0000-0003-0956-0103				AULT JG, 1994, CURR OPIN CELL BIOL, V6, P41, DOI 10.1016/0955-0674(94)90114-7; BELLEN HJ, 1992, GENE DEV, V6, P2125, DOI 10.1101/gad.6.11.2125; BUCHENAU P, 1993, J CELL SCI, V104, P1175; BYERS TJ, 1987, J CELL BIOL, V105, P2103, DOI 10.1083/jcb.105.5.2103; CARMENA M, 1993, J CELL SCI, V105, P41; DANDREA RJ, 1993, MOL BIOL CELL, V4, P1161, DOI 10.1091/mbc.4.11.1161; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; KANIA A, 1995, GENETICS, V139, P1663; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MORIN N, 1994, EMBO J, V13, P4343, DOI 10.1002/j.1460-2075.1994.tb06754.x; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cb.01.110185.001445; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; PHILP AV, 1993, J CELL SCI, V106, P87; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SALZBERG A, 1994, NEURON, V13, P269, DOI 10.1016/0896-6273(94)90346-8; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Stratmann R, 1996, CELL, V84, P25, DOI 10.1016/S0092-8674(00)80990-3; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; WHALEN AM, 1991, J CELL BIOL, V112, P203, DOI 10.1083/jcb.112.2.203; WHITFIELD WGF, 1989, NATURE, V338, P337, DOI 10.1038/338337a0; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; ZIPURSKY SL, 1985, P NATL ACAD SCI USA, V82, P1855, DOI 10.1073/pnas.82.6.1855	44	243	246	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1103	1114		10.1016/S0092-8674(00)81804-8	http://dx.doi.org/10.1016/S0092-8674(00)81804-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978614	Bronze			2022-12-01	WOS:A1996VY44700015
J	Schendel, DE; Berg, CJ; YearginAllsopp, M; Boyle, CA; Decoufle, P				Schendel, DE; Berg, CJ; YearginAllsopp, M; Boyle, CA; Decoufle, P			Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERIVENTRICULAR-INTRAVENTRICULAR HEMORRHAGE; GERMINAL MATRIX HEMORRHAGE; PRETERM INFANTS; POPULATION; PREDICTION; BRAIN; TRENDS; REDUCE; TRIAL	Objective.-To examine the relationship between prenatal magnesium sulfate exposure and the risk for cerebral palsy (CP) or mental retardation (MR) among very low-birth-weight (VLBW; <1500 g) children. Secondarily, to investigate the effect of prenatal magnesium sulfate exposure on VLBW infant mortality. Design.-Cohort study with follow-up to 1 year of age; a subset followed up to 3 to 5 years. Setting.-Twenty-nine Georgia counties, including the Ei-county Atlanta metropolitan area. Participants.-All VLBW births (N=1097) occurring during 2 years (1986-1988); all metropolitan Atlanta VLBW neonates who survived infancy (N=519). Main Outcome Measures.-lnfant mortality as determined from vital statistics records, Development of CP or MR by 3 to 5 years of age among metropolitan Atlanta VLBW survivors as determined from the Metropolitan Atlanta Developmental Disabilities Surveillance Program. Results.-For the entire cohort, there was no association between prenatal magnesium sulfate exposure and infant mortality (adjusted rate ratio, 1.02; 95% confidence interval [CI], 0.83-1.25). Among Atlanta-born survivors, those exposed to magnesium sulfate had a lower prevalence of GP or MR than those not exposed (CP: magnesium sulfate, 0.9%, no magnesium sulfate, 7.7%, crude odds ratio [OR], 0.11, 95% CI, 0.02-0.81; MR: magnesium sulfate, 1.8%, no magnesium sulfate, 5.8%, crude OR, 0.30, 95% CI, 0.07-1.29). Multivariable adjustment had no appreciable effect on the ORs for CP or MR, but the Cls included 1.0. Conclusions.-A reduced risk for CP, and possibly MR, among VLBW children is associated with prenatal magnesium sulfate exposure. The reduced risk for childhood CP or MR does not appear to be due to selective mortality of magnesium sulfate-exposed infants.	CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,DIV BIRTH DEFECTS & DEV DISABIL,ATLANTA,GA; CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,DIV REPROD HLTH,ATLANTA,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								*AM COLL OBST GYN, 1986, TECHN B AM COLL OBST, V91; [Anonymous], 1992, Arch Dis Child, V67, P675; [Anonymous], 1982, EPIDEMIOLOGIC RES; AZIZ K, 1995, PEDIATRICS, V95, P837; BERG CJ, 1994, PAEDIATR PERINAT EP, V8, P53, DOI 10.1111/j.1365-3016.1994.tb00435.x; BHUSHAN V, 1993, PEDIATRICS, V91, P1094; Blair E, 1996, PEDIATRICS, V97, P780; Boyle C A, 1996, MMWR CDC Surveill Summ, V45, P1; COOKE RWI, 1990, ARCH DIS CHILD, V65, P201, DOI 10.1136/adc.65.2.201; COSTELLO AMD, 1988, DEV MED CHILD NEUROL, V30, P711; CUMMINS SK, 1993, J PEDIATR-US, V123, P230, DOI 10.1016/S0022-3476(05)81693-2; ENSDOKKUM MH, 1994, ARCH DIS CHILD-FETAL, V70, pF96, DOI 10.1136/fn.70.2.F96; FLANDERS WD, 1987, J CHRON DIS, V40, P697, DOI 10.1016/0021-9681(87)90106-8; GRAZIANI LJ, 1986, PEDIATRICS, V78, P88; GROOME LJ, 1992, AM J OBSTET GYNECOL, V167, P873, DOI 10.1016/S0002-9378(12)80004-4; Hauth J. C., 1995, American Journal of Obstetrics and Gynecology, V172, P419; HOFFMAN DJ, 1994, BRAIN RES, V644, P144, DOI 10.1016/0006-8993(94)90357-3; JOHNSON M A, 1987, Canadian Medical Association Journal, V136, P1157; JOHNSTON MM, 1990, AM J OBSTET GYNECOL, V163, P743, DOI 10.1016/0002-9378(90)91060-P; KUBAN KCK, 1992, J CHILD NEUROL, V7, P70, DOI 10.1177/088307389200700113; LEVITON A, 1993, PEDIATRICS, V91, P1083; MARRET S, 1995, DEV MED CHILD NEUROL, V37, P473; MCDONALD JW, 1990, NEUROSCI LETT, V109, P234, DOI 10.1016/0304-3940(90)90569-U; MERVIS CA, 1995, PAEDIATR PERINAT EP, V9, P455, DOI 10.1111/j.1365-3016.1995.tb00168.x; MUTCH L, 1992, DEV MED CHILD NEUROL, V34, P547; NELSON KB, 1995, PEDIATRICS, V95, P263; O'Shea M, 1992, Paediatr Perinat Epidemiol, V6, P352, DOI 10.1111/j.1365-3016.1992.tb00775.x; PICKLES CJ, 1989, BRIT J OBSTET GYNAEC, V96, P38, DOI 10.1111/j.1471-0528.1989.tb01574.x; PINTOMARTIN JA, 1995, PEDIATRICS, V95, P249; RANTAKALLIO P, 1985, DEV MED CHILD NEUROL, V27, P655; *SCOTT LOW BIRTHW, 1992, ARCH DIS CHILD, V67, P682; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; VANDEBOR M, 1987, J PERINAT MED, V15, P333, DOI 10.1515/jpme.1987.15.4.333; Volpe J., 1995, NEUROLOGY NEWBORN; WEISGLASKUPERUS N, 1993, PEDIATRICS, V92, P658; WILCOSKY TC, 1985, J CHRON DIS, V38, P849, DOI 10.1016/0021-9681(85)90109-2	36	193	194	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1996	276	22					1805	1810		10.1001/jama.276.22.1805	http://dx.doi.org/10.1001/jama.276.22.1805			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV997	8946900				2022-12-01	WOS:A1996VV99700029
J	Wolozin, B; Iwasaki, K; Vito, P; Ganjei, JK; Lacana, E; Sunderland, T; Zhao, BY; Kusiak, JW; Wasco, V; DAdamio, L				Wolozin, B; Iwasaki, K; Vito, P; Ganjei, JK; Lacana, E; Sunderland, T; Zhao, BY; Kusiak, JW; Wasco, V; DAdamio, L			Participation of Presenilin 2 in apoptosis: Enhanced basal activity conferred by an Alzheimer mutation	SCIENCE			English	Article							AMYLOID PRECURSOR PROTEIN; PROGRAMMED CELL-DEATH; MISSENSE MUTATIONS; ENDOTHELIAL-CELLS; DISEASE; GENE; ACTIVATION	Overexpression of the familial Alzheimer's disease gene Presenilin 2 (PS2) in nerve growth factor-differentiated PC12 cells increased apoptosis induced by trophic factor withdrawal or beta-amyloid. Transfection of antisense PS2 conferred protection against apoptosis induced by trophic withdrawal in nerve growth factor-differentiated or amyloid precursor protein-expressing PC12 cells, The apoptotic cell death induced by PS2 protein was sensitive to pertussis toxin, suggesting that heterotrimeric GTP-binding proteins are involved, A PS2 mutation associated with familial Alzheimer's disease was found to generate a molecule with enhanced basal apoptotic activity, This gain of function might accelerate the process of neurodegeneration that occurs in Alzheimer's disease, leading to the earlier age of onset characteristic a familial Alzheimer's disease.	NIMH,UNIT ALZHEIMER BIOL,CLIN SCI LAB,BETHESDA,MD 20892; NIAID,T CELL MOL BIOL UNIT,CELLULAR & MOL IMMUNOL LAB,BETHESDA,MD 20892; NIA,MOL NEUROBIOL UNIT,BALTIMORE,MD 21224; NINCDS,CELLULAR NEUROBIOL BRANCH,GERONTOL RES CTR,BALTIMORE,MD 21224; HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP E,DEPT NEUROL,GENET & AGING UNIT,CHARLESTOWN,MA 02139; NIH,T CELL MOL BIOL UNIT,CELLULAR & MOL IMMUNOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Harvard University; National Institutes of Health (NIH) - USA			vito, pasquale/ABF-5505-2020	vito, pasquale/0000-0002-5721-7716; D'Adamio, Luciano/0000-0002-9820-4882; D'Adamio, Luciano/0000-0002-2204-9441				BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CIALLELLA JR, 1994, J NEUROSCI RES, V37, P769, DOI 10.1002/jnr.490370611; Dewji NN, 1996, SCIENCE, V271, P159, DOI 10.1126/science.271.5246.159; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GESCHWIND M, 1995, J NEUROCHEM, V65, P292; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KARLINSKY H, 1992, NEUROLOGY, V42, P1445, DOI 10.1212/WNL.42.8.1445; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MESNER PW, 1995, J NEUROSCI, V15, P7357; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yamatsuji T, 1996, EMBO J, V15, P498, DOI 10.1002/j.1460-2075.1996.tb00382.x; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; ZHAO B, 1995, J NEUROSCI RES, V40, P261, DOI 10.1002/jnr.490400215	28	398	412	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1710	1713		10.1126/science.274.5293.1710	http://dx.doi.org/10.1126/science.274.5293.1710			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939861				2022-12-01	WOS:A1996VW71200060
J	Stumpf, G; Domdey, H				Stumpf, G; Domdey, H			Dependence of yeast pre-mRNA 3'-end processing on CFT1: A sequence homolog of the mammalian AAUAAA binding factor	SCIENCE			English	Article							POLYADENYLATION SPECIFICITY FACTOR; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; POLY(A) POLYMERASE; CLEAVAGE; GENE; SITE; SUBUNIT; PROTEIN; IDENTIFICATION	3'-End formation of pre-mRNA in yeast and mammals follows a similar but distinct pathway. In Saccharomyces cerevisiae, the cleavage reaction can be reconstituted by two activities called cleavage factor I and II (CFI and CFII). A CFII component, designated CFT1 (cleavage factor two) was identified by its sequence similarity to the AAUAAA-binding subunit of the mammalian cleavage and polyadenylation specificity factor (CPSF), even though the AAUAAA signal sequence appears to play no rote in yeast pre-mRNA 3' processing. Depletion of a yeast whole-cell extract with antibodies to CFT1 protein abolished cleavage and polyadenylation of pre-mRNAs, Addition of CFII restored cleavage activity, but not polyadenylation. Polyadenylation required the further addition of poly(A) polymerase and polyadenylation factor I, suggesting a close but not necessarily direct association of these two factors with the CFT1 protein.	UNIV MUNICH,GENZENTRUM,INST BIOCHEM,D-81377 MUNICH,GERMANY	University of Munich								BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BILGER A, 1994, GENE DEV, V8, P1106, DOI 10.1101/gad.8.9.1106; BUTLER JS, 1988, SCIENCE, V242, P1270, DOI 10.1126/science.2848317; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GILMARTIN GM, 1995, GENE DEV, V9, P72, DOI 10.1101/gad.9.1.72; GUO ZJ, 1995, MOL CELL BIOL, V15, P5983; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HEIDMANN S, 1994, MOL CELL BIOL, V14, P4633, DOI 10.1128/MCB.14.7.4633; HEIDMANN S, 1992, MOL CELL BIOL, V12, P4215, DOI 10.1128/MCB.12.9.4215; JENNY A, 1995, NUCLEIC ACIDS RES, V23, P2629, DOI 10.1093/nar/23.14.2629; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KESSLER MM, 1995, BIOCHEMISTRY-US, V34, P1750, DOI 10.1021/bi00005a032; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; MOREIRA A, 1995, EMBO J, V14, P3809, DOI 10.1002/j.1460-2075.1995.tb00050.x; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Stumpf G, 1996, MOL CELL BIOL, V16, P2204; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; ZHELKOVSKY AM, 1995, J BIOL CHEM, V270, P26715, DOI 10.1074/jbc.270.44.26715	29	42	43	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1517	1520		10.1126/science.274.5292.1517	http://dx.doi.org/10.1126/science.274.5292.1517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929410				2022-12-01	WOS:A1996VV77500045
J	Walker, PL				Walker, PL			Facing creationist challenges	LANCET			English	Editorial Material											Walker, PL (corresponding author), UNIV CALIF SANTA BARBARA,DEPT ANTHROPOL,SANTA BARBARA,CA 93106, USA.							Lord T, 1993, J COLL SCI TEACH, V22, P353; Newport F., 1993, GALLUP POLL MONTHLY, V336, P24; NUMBERS R, 1995, CHRISTIAN CENTURY, V112, P574; Schmidt K, 1996, SCIENCE, V273, P420, DOI 10.1126/science.273.5274.420	4	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1397	1398		10.1016/S0140-6736(05)67499-5	http://dx.doi.org/10.1016/S0140-6736(05)67499-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937277				2022-12-01	WOS:A1996VU98600007
J	Jia, ZC; DeLuca, CI; Chao, HM; Davies, PL				Jia, ZC; DeLuca, CI; Chao, HM; Davies, PL			Structural basis for the binding of a globular antifreeze protein to ice	NATURE			English	Article							ADSORPTION; MECHANISM; PROGRAM	ANTIFREEZE proteins (AFPs) have the unique ability to adsorb to ice and inhibit its growth(1). Many organisms ranging from fish to bacteria use AFPs to retard freezing or lessen the damage incurred upon freezing and thawing(2-6). The ice-binding mechanism of the long linear alpha-helical type I AFPs has been attributed to their regularly spaced polar residues matching the ice lattice along a pyramidal plane(7,8). In contrast, it is not known how globular antifreeze proteins such as type III AFP that lack repeating ice-binding residues bind to ice. Here we report the 1.25 Angstrom crystal structure of recombinant type III AFP (QAE isoform(9)) from eel pout (Macrozoarces americanus), which reveals a remarkably hat amphipathic ice-binding site where five hydrogen-bonding atoms match two ranks of oxygens on the {10 (1) over bar 0} ice prism plane in the [0001] direction, giving high ice binding affinity and specificity. This binding site, substantiated by the structures and properties of several ice-binding site mutants, suggests that the AFP occupies a niche in the ice surface in which it covers the basal plane while binding to the prism face.			Jia, ZC (corresponding author), QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA.							[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHAO H, 1993, PROTEIN SCI, V2, P1411, DOI 10.1002/pro.5560020906; CHAO H, 1994, PROTEIN SCI, V3, P1760, DOI 10.1002/pro.5560031016; CHAO H, 1994, THESIS QUEENS U; Cheng C.C., 1991, P1; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; Duman J.G., 1991, P94; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; GRIFFITH M, 1992, PLANT PHYSIOL, V100, P593, DOI 10.1104/pp.100.2.593; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; JIA ZC, 1995, PROTEIN SCI, V4, P1236, DOI 10.1002/pro.5560040621; KALLUNGAL JP, 1975, THESIS SYRACUSE U; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; Sheldrick G.M., 1986, SHELXS86 PROGRAM SOL; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; SONNICHSEN FD, 1993, SCIENCE, V259, P1154, DOI 10.1126/science.8438165; SUN XY, 1995, CAN J MICROBIOL, V41, P776, DOI 10.1139/m95-107; UMUTLA ME, 1992, BIOCHIM BIOPHYS ACTA, V1121, P199; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2	26	195	211	4	75	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					285	288		10.1038/384285a0	http://dx.doi.org/10.1038/384285a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918883				2022-12-01	WOS:A1996VU38100058
J	Jousilahti, P; Vartiainen, E; Tuomilehto, J; Puska, P				Jousilahti, P; Vartiainen, E; Tuomilehto, J; Puska, P			Twenty-year dynamics of serum cholesterol levels in the middle-aged population of eastern Finland	ANNALS OF INTERNAL MEDICINE			English	Article						cholesterol; Finland; middle age; dietary fats; cardiovascular diseases	CORONARY HEART-DISEASE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; NORTH KARELIA; LIPOPROTEINS; FRAMINGHAM; MORTALITY; PROJECT; ADULTS	Background: In cross-sectional analyses, serum cholesterol levels differ among different age groups. However, secular time trends in cholesterol levels can be seen across age groups in a population. A birth cohort analysis provides useful information on the combined effect of age and time on changes in serum cholesterol levels. Objective: To analyze the 20-year dynamics of serum total cholesterol levels in relation to age, sex, birth cohort, time period, mortality rate, and changes in the intake of saturated fats. Design: Cross-sectional measurements of serum total cholesterol levels in five independent population surveys done in 1972, 1977, 1982, 1987, and 1992. Setting: Kuopio and North Karelia provinces in eastern Finland. Patients: Random sample of 16 711 men and 17 542 women 25 to 64 years of age. Persons in the oldest birth cohort were born in 1913; persons in the youngest birth cohort were born in 1967. Measurements: Total serum cholesterol levels and daily intake of dietary fat. Results: Between 1972 and 1992, mean cholesterol levels decreased with time in each age group and for both sexes. According to the cross-sectional data, cholesterol levels increased with age and increased more steeply in women than in men. Contrary to these data, cholesterol levels in birth cohorts did not increase with age. Cholesterol levels did not change at all within birth cohorts of women and started to decrease after 45 years of age in birth cohorts of men. Cholesterol levels in the youngest birth cohorts (persons 25 to 29 years of age) entering the study each study year were markedly lower than levels in the same age group in the previous survey of risk factors. Daily intake of saturated fat decreased markedly between 1972 and 1992. Most of this decrease could be explained by change in intake of liquid dairy products and spreadable fats. In both sexes, changes in saturated fat intake were correlated with the time period, whereas the association with age was weak. Conclusions: In this Finnish population, total serum cholesterol levels are more closely associated with birth cohort than with age. Changes in dietary intake of saturated fat over time may account for changes in cholesterol levels. This finding suggests that community-based strategies for preventing cardiovascular disease can affect most of the population.			Jousilahti, P (corresponding author), NATL PUBL HLTH INST, DEPT EPIDEMIIOL & HLTH PROMOT, MANNERHEIMINTIE 166, FIN-00300 HELSINKI, FINLAND.							[Anonymous], COMMUNITY CONTROL CA; EHNHOLM C, 1982, NEW ENGL J MED, V307, P850, DOI 10.1056/NEJM198209303071403; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; FULWOOD R, 1986, DHHS PUBLICATION; GUTZWILLER F, 1985, PREV MED, V14, P482, DOI 10.1016/0091-7435(85)90008-8; HJORTLAND MC, 1976, AM J EPIDEMIOL, V103, P304, DOI 10.1093/oxfordjournals.aje.a112228; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; KEYS A, 1970, CIRCULATION, V41, pI1; Kleemola P, 1994, 1992 DIETARY SURVEY; KOSKINEN EH, 1975, REPORT SOCIAL INSURA; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MENOTTI A, 1993, EUR J EPIDEMIOL, V9, P527, DOI 10.1007/BF00209531; MIETTINEN TA, 1995, NEW ENGL J MED, V333, P1308, DOI 10.1056/NEJM199511163332002; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; NEWSCHAFFER CJ, 1992, AM J EPIDEMIOL, V136, P23, DOI 10.1093/oxfordjournals.aje.a116417; Nissinen A, 1988, Scand J Prim Health Care Suppl, V1, P49; OKAYAMA A, 1993, INT J EPIDEMIOL, V22, P1038, DOI 10.1093/ije/22.6.1038; Pietinen P, 1996, INT J OBESITY, V20, P114; PUSKA P, 1983, BRIT MED J, V287, P1840, DOI 10.1136/bmj.287.6408.1840; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROSSOUW JE, 1986, ATHEROSCLEROSIS, V7; SAS Institute Inc, 1990, SAS STAT US GUID VER, V4; STAMLER J, 1979, CIRCULATION, V60, P1575, DOI 10.1161/01.CIR.60.7.1575; Thelle Dag S., 1995, Current Opinion in Lipidology, V6, P25, DOI 10.1097/00041433-199502000-00006; Thom TJ, 1992, NIH PUBLICATION; UUSITALO U, 1990, FOOD NUTRIENT INTAKE; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; VIIKARI J, 1991, ANN MED, V23, P53, DOI 10.3109/07853899109147931; 1991, WORLD HLTH STAT Q, V44, P48; 1988, J CLIN EPIDEMIOL, V41, P105, DOI [10.1016/0895-4356(88)90084-4, DOI 10.1016/0895-4356(88)90084-4]	34	32	32	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					713	+		10.7326/0003-4819-125-9-199611010-00002	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929004				2022-12-01	WOS:A1996VQ07200002
J	Bentley, DR				Bentley, DR			Genomic sequence information should be released immediately and freely in the public domain	SCIENCE			English	Editorial Material											Bentley, DR (corresponding author), SANGER CTR,WELLCOME TRUST GENOME CAMPUS,HINXTON HALL,CAMBRIDGE CB10 1SA,ENGLAND.							*BAT CTR HUM GEN R, 1996, POL AV PAT HUM GEN D; *BIOIND ASS, 1995, PENT HUM GEN; Marshall E, 1996, SCIENCE, V272, P188, DOI 10.1126/science.272.5259.188; MARSHALL E, 1995, SCIENCE, V267, P783, DOI 10.1126/science.7846520; *NAT SCI COUNC, 1988, MAPP SEQ HUM GEN; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; *WELLC TRUST, 1996, 1 INT STRAT M HUM GE; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; 1996, HUMAN GENOME NEWS, V7	9	42	47	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					533	534		10.1126/science.274.5287.533	http://dx.doi.org/10.1126/science.274.5287.533			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8928006				2022-12-01	WOS:A1996VN91900034
J	Rohr, S; Kucera, JP; Fast, VG; Kleber, AG				Rohr, S; Kucera, JP; Fast, VG; Kleber, AG			Paradoxical improvement of impulse conduction in cardiac tissue by partial cellular uncoupling	SCIENCE			English	Article							PATTERNED GROWTH; TRANSMEMBRANE VOLTAGE; FATTY-ACIDS; HEART; CULTURES; MUSCLE; CELLS; BLOCK; PROPAGATION; EXCITATION	Generally, impulse propagation in cardiac tissue is assumed to be impaired by a reduction of intercellular electrical coupling or by the presence of structural discontinuities. Contrary to this notion, the spatially uniform reduction of electrical coupling induced successful conduction in discontinuous cardiac tissue structures exhibiting unidirectional conduction block. This seemingly paradoxical finding can be explained by a nonsymmetric effect of uncoupling on the current source and the current sink in the preparations used. It suggests that partial cellular uncoupling might prevent the initiation of cardiac arrhythmias that are dependent on the presence of unidirectional conduction block.			Rohr, S (corresponding author), UNIV BERN,DEPT PHYSIOL,BUHLPL 5,CH-3012 BERN,SWITZERLAND.		Rohr, Stephan/B-9166-2008	Rohr, Stephan/0000-0003-4358-7035; Kucera, Jan/0000-0003-0310-6962				Akima H., 1978, ACM Transactions on Mathematical Software, V4, P148, DOI 10.1145/355780.355786; BURT JM, 1991, AM J PHYSIOL, V260, pC439, DOI 10.1152/ajpcell.1991.260.3.C439; CABO C, 1994, CIRC RES, V75, P1014, DOI 10.1161/01.RES.75.6.1014; DAVIDENKO JM, 1992, NATURE, V355, P349, DOI 10.1038/355349a0; FAST VG, 1995, CARDIOVASC RES, V29, P697, DOI 10.1016/0008-6363(96)88643-3; FAST VG, 1995, CARDIOVASC RES, V30, P449, DOI 10.1016/S0008-6363(95)00071-2; JANSE MJ, 1989, PHYSIOL REV, V69, P1049, DOI 10.1152/physrev.1989.69.4.1049; LEGRICE IJ, 1995, AM J PHYSIOL-HEART C, V269, pH571, DOI 10.1152/ajpheart.1995.269.2.H571; MIURA I, 1991, CLIN EXP PHARMACOL P, V18, P259, DOI 10.1111/j.1440-1681.1991.tb01440.x; ROHR S, 1995, J CARDIOVASC ELECTR, V6, P551, DOI 10.1111/j.1540-8167.1995.tb00428.x; ROHR S, 1994, J GEN PHYSIOL, V104, P287, DOI 10.1085/jgp.104.2.287; ROHR S, 1991, CIRC RES, V68, P114, DOI 10.1161/01.RES.68.1.114; SMITH JH, 1991, AM J PATHOL, V139, P801; STREIT J, 1989, J NEUROSCI, V9, P4190; URSELL PC, 1985, CIRC RES, V56, P436, DOI 10.1161/01.RES.56.3.436; VEENSTRA RD, 1984, CIRC RES, V54, P500, DOI 10.1161/01.RES.54.5.500; WINFREE AT, 1987, TIME BREAKS DOWN	17	221	224	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					841	844		10.1126/science.275.5301.841	http://dx.doi.org/10.1126/science.275.5301.841			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012353				2022-12-01	WOS:A1997WG77700064
J	Burton, K; Taylor, DL				Burton, K; Taylor, DL			Traction forces of cytokinesis measured with optically modified elastic substrata	NATURE			English	Article							CONTRACTILE RING; CELL-DIVISION; ANIMAL-CELLS; ACTIN-FILAMENTS; CULTURED-CELLS; MYOSIN; MECHANISM; MOVEMENT; ESTABLISHMENT; DICTYOSTELIUM	Animal cells dividing in culture undergo a dramatic sequence of morphological changes, characterized by cytoskeletal disassembly as cells round up, redistribution of actin, myosins and other cytoplasmic and surface molecules into the cleavage furrow(1-11), and respreading(12), before daughter cells finally separate at the mid-body(13). Knowledge of forces governing these movements is critical to understanding their mechanisms, including whether formation of the cleavage furrow results from increased force generation at the equator(14,15) or relaxation at the poles(16), and whether traction force subsequently mediates cytofission of the intercellular bridge(5,13,17,18). We have quantitatively mapped traction forces in dividing cells, by extending the silicone-rubber substratum method(19) to detect forces of nanonewtons to micro-newtons. We used a new silicone polymer to fabricate substrata whose compliance can be adjusted precisely by ultraviolet irradiation. We show that traction force appears locally at the furrow in the absence of relaxation at the poles during cleavage. Force also rises as connected daughter cells respread and attempt to separate, suggesting that tension contributes to the severing of the intercellular bridge when cytokinesis is completed.	CARNEGIE MELLON UNIV, DEPT BIOL, PITTSBURGH, PA 15213 USA	Carnegie Mellon University	Burton, K (corresponding author), CARNEGIE MELLON UNIV, CTR LIGHT MICROSCOPE IMAGING & BIOTECHNOL, 4400 5TH AVE, PITTSBURGH, PA 15213 USA.			Taylor, D. Lansing/0000-0001-6947-1343				BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BRECKLER J, 1994, CELL MOTIL CYTOSKEL, V29, P312, DOI 10.1002/cm.970290404; Burton K., 1993, Molecular Biology of the Cell, V4, p114A; CAO LG, 1990, J CELL BIOL, V111, P1905, DOI 10.1083/jcb.111.5.1905; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; DeBiasio RL, 1996, MOL BIOL CELL, V7, P1259, DOI 10.1091/mbc.7.8.1259; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; Dembo M, 1996, BIOPHYS J, V70, P2008, DOI 10.1016/S0006-3495(96)79767-9; FIELD CM, 1995, J CELL BIOL, V131, P165, DOI 10.1083/jcb.131.1.165; FISHKIND DJ, 1993, J CELL BIOL, V123, P837, DOI 10.1083/jcb.123.4.837; FISHKIND DJ, 1995, CURR OPIN CELL BIOL, V7, P23, DOI 10.1016/0955-0674(95)80041-7; FUKUI Y, 1991, CELL MOTIL CYTOSKEL, V18, P41, DOI 10.1002/cm.970180105; FUKUI Y, 1993, INT REV CYTOL, V144, P85, DOI 10.1016/S0074-7696(08)61514-4; HARRIS AK, 1980, SCIENCE, V208, P177, DOI 10.1126/science.6987736; HARRIS AK, 1988, METHOD ENZYMOL, V163, P623; HARRIS AK, 1984, J BIOMECH ENG-T ASME, V106, P19, DOI 10.1115/1.3138449; HARRIS AK, 1994, NATO ADV SCI INST SE, V84, P37; HIRAMOTO Y, 1979, CELL MOTILITY MOL OR, P653; MABUCHI I, 1994, J CELL SCI, V107, P1853; MAUPIN P, 1994, J CELL SCI, V107, P3077; MULLINS JM, 1977, J CELL BIOL, V73, P672, DOI 10.1083/jcb.73.3.672; OLIVER T, 1995, CELL MOTIL CYTOSKEL, V31, P225, DOI 10.1002/cm.970310306; Peterson MA, 1996, BIOPHYS J, V71, P657, DOI 10.1016/S0006-3495(96)79266-4; RAPPAPORT R, 1967, SCIENCE, V156, P1241, DOI 10.1126/science.156.3779.1241; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; RAPPAPORT R, 1986, J EXP ZOOL, V240, P55, DOI 10.1002/jez.1402400108; Salmon ED, 1989, CURR OPIN CELL BIOL, V1, P541, DOI 10.1016/0955-0674(89)90018-5; SANGER JM, 1994, CELL MOTIL CYTOSKEL, V27, P26, DOI 10.1002/cm.970270104; SHU HB, 1995, J CELL SCI, V108, P2955; WANG YL, 1994, J CELL BIOL, V127, P963, DOI 10.1083/jcb.127.4.963; WHITE JG, 1983, J THEOR BIOL, V101, P289, DOI 10.1016/0022-5193(83)90342-9	31	256	263	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 30	1997	385	6615					450	454		10.1038/385450a0	http://dx.doi.org/10.1038/385450a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009194				2022-12-01	WOS:A1997WF00700056
J	Wallace, SJ				Wallace, SJ			Nasal benzodiazepines for management of acute childhood seizures?	LANCET			English	Editorial Material							MIDAZOLAM				Wallace, SJ (corresponding author), UNIV WALES HOSP,DEPT PAEDIAT NEUROL,CARDIFF CF4 4XW,S GLAM,WALES.							JAWAD S, 1986, J NEUROL NEUROSUR PS, V49, P1050, DOI 10.1136/jnnp.49.9.1050; Newman M, 1993, J Cardiothorac Vasc Anesth, V7, P615, DOI 10.1016/1053-0770(93)90325-F; ORegan ME, 1996, DEV MED CHILD NEUROL, V38, P1037; REY E, 1991, EUR J CLIN PHARMACOL, V41, P355, DOI 10.1007/BF00314967; SHORVON SD, 1994, STATUS EPILEPTICUS, P213	5	32	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					222	222		10.1016/S0140-6736(05)64856-8	http://dx.doi.org/10.1016/S0140-6736(05)64856-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014904				2022-12-01	WOS:A1997WD90600004
J	Sone, M; Hoshino, M; Suzuki, E; Kuroda, S; Kaibuchi, K; Nakagoshi, H; Saigo, K; Nabeshima, Y; Hama, C				Sone, M; Hoshino, M; Suzuki, E; Kuroda, S; Kaibuchi, K; Nakagoshi, H; Saigo, K; Nabeshima, Y; Hama, C			Still life, a protein in synaptic terminals of Drosophila homologous to GDP-GTP exchangers	SCIENCE			English	Article							GENE; RHO; EXPRESSION; GTPASES; RAC; ORGANIZATION; SPECIFICITY; INVASION; ENCODES; FUSION	The morphology of axon terminals changes with differentiation into mature synapses. A molecule that might regulate this process was identified by a screen of Drosophila mutants for abnormal motor activities. The still life (sif) gene encodes a protein homologous to guanine nucleotide exchange factors, which convert Rho-like guanosine triphosphatases (GTPases) from a guanosine diphosphate-bound inactive state to a guanosine triphosphate-bound active state. The SIF proteins are found adjacent to the plasma membrane of synaptic terminals. Expression of a truncated SIF protein resulted in defects in neuronal morphology and induced membrane ruffling with altered actin localization in human KB cells. Thus, SIF proteins may regulate synaptic differentiation through the organization of the actin cytoskeleton by activating Rho-like GTPases.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DEPT MOL GENET,KODAIRA,TOKYO 187,JAPAN; UNIV TOKYO,GRAD SCH SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,INST MED SCI,DEPT FINE MORPHOL,MINATO KU,TOKYO 108,JAPAN; NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,NARA 63001,JAPAN	National Center for Neurology & Psychiatry - Japan; University of Tokyo; University of Tokyo; Nara Institute of Science & Technology			NAKAGOSHI, Hideki/B-2145-2011; Sone, Masaki/Q-9058-2019	NAKAGOSHI, Hideki/0000-0003-0850-1814; Suzuki, Emiko/0000-0002-4005-0542				BRAND AH, 1993, DEVELOPMENT, V118, P401; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BURNS ME, 1995, CELL, V83, P187, DOI 10.1016/0092-8674(95)90160-4; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; GINIGER E, 1993, ROUX ARCH DEV BIOL, V202, P112, DOI 10.1007/BF00636536; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HART MJ, 1994, J BIOL CHEM, V269, P62; HOSHINO M, 1993, NEURON, V10, P395, DOI 10.1016/0896-6273(93)90329-P; Hoshino M, 1996, DEVELOPMENT, V122, P589; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JOHANSEN J, 1989, J NEUROSCI, V9, P710; Kleiman RJ, 1996, CELL, V85, P461, DOI 10.1016/S0092-8674(00)81245-3; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; MEINERTZHAGEN IA, 1991, J COMP NEUROL, V305, P232, DOI 10.1002/cne.903050206; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; VANBERKUM MFA, 1995, NEURON, V14, P43, DOI 10.1016/0896-6273(95)90239-2; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; YAO KM, 1994, J NEUROCHEM, V63, P41	35	111	114	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					543	547		10.1126/science.275.5299.543	http://dx.doi.org/10.1126/science.275.5299.543			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999801				2022-12-01	WOS:A1997WE25700048
J	Nishina, H; Fischer, KD; Radvanyi, L; Shahinian, A; Hakem, R; Rubie, EA; Bernstein, A; Mak, TW; Woodgett, JR; Penninger, JM				Nishina, H; Fischer, KD; Radvanyi, L; Shahinian, A; Hakem, R; Rubie, EA; Bernstein, A; Mak, TW; Woodgett, JR; Penninger, JM			Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3	NATURE			English	Article							AMINO-TERMINAL KINASES; C-JUN; ACTIVATION; DEFICIENT; CELLS; JNK	Distinct and evolutionarily conserved signal transduction cascades mediate survival or death in response to developmental and environmental cues, The stress-activated protein kinases, or Jun N-terminal kinases (SAPKs/JNKs)(1,2), are activated in response to a variety of cellular stresses such as changes in osmolarity and metabolism, DNA damage, heat shock, ischaemia, or inflammatory cytokines(3-6). Sek1 (JNKK/MKK4) is a direct activator of SAPKs/JNKs in response to environmental stresses or mitogenic factors(7-9). Here we investigate the role of Sek1 in development and apoptosis by deleting sek1 in embryonic stem (ES) cells by homologous recombination, We provide genetic evidence that different stresses utilize distinct signalling pathways for SAPK/JNK activation, sek1(-/-)/rag2(-/-) chimaeric mice have normal numbers of mature T cells but fewer immature CD4(+)CD8(+) thymocytes, The sek1 mutation did not affect the induction of apoptosis in response to environmental stresses in ES and T cells: instead, sek1 protected thymocytes from CD95 (Fas)- and CD3-mediated apoptosis, These data indicate that SEK1 mediates survival signals in T-cell development.	UNIV TORONTO,ONTARIO CANC INST,AMGEN INST,TORONTO,ON M5G 2C1,CANADA; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 2C1,CANADA; UNIV WURZBURG,INST RADIAT & CELL RES,D-97078 WURZBURG,GERMANY; UNIV TORONTO,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO,ON M5G 2C1,CANADA; UNIV TORONTO,ONTARIO CANC INST,DEPT IMMUNOL,TORONTO,ON M5G 2C1,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Wurzburg; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto			Penninger, Josef M/I-6860-2013; Woodgett, Jim/F-1087-2010	Penninger, Josef M/0000-0002-8194-3777; Woodgett, Jim/0000-0003-3731-5797; Hakem, Razqallah/0000-0001-5948-7931				DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Kruisbeek AM, 1996, CURR OPIN IMMUNOL, V8, P233, DOI 10.1016/S0952-7915(96)80062-8; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; POMBO CM, 1994, J BIOL CHEM, V269, P26546; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	20	308	323	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					350	353		10.1038/385350a0	http://dx.doi.org/10.1038/385350a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002521				2022-12-01	WOS:A1997WD91400053
J	Weinstein, JN; Myers, TG; OConnor, PM; Friend, SH; Fornace, AJ; Kohn, KW; Fojo, T; Bates, SE; Rubinstein, LV; Anderson, NL; Buolamwini, JK; vanOsdol, WW; Monks, AP; Scudiero, DA; Sausville, EA; Zaharevitz, DW; Bunow, B; Viswanadhan, VN; Johnson, GS; Wittes, RE; Paull, KD				Weinstein, JN; Myers, TG; OConnor, PM; Friend, SH; Fornace, AJ; Kohn, KW; Fojo, T; Bates, SE; Rubinstein, LV; Anderson, NL; Buolamwini, JK; vanOsdol, WW; Monks, AP; Scudiero, DA; Sausville, EA; Zaharevitz, DW; Bunow, B; Viswanadhan, VN; Johnson, GS; Wittes, RE; Paull, KD			An information-intensive approach to the molecular pharmacology of cancer	SCIENCE			English	Article							TUMOR-CELL-LINES; ANTICANCER DRUG SCREEN; DIFFERENTIAL CYTOTOXICITY DATA; TOPOISOMERASE-II; DISCOVERY SCREEN; SUPPRESSOR GENE; INSTITUTE; P53; TUBULIN; AGENTS	Since 1990, the National Cancer institute (NCI) has screened more than 60,000 compounds against a panel of 60 human cancer cell lines, The 50-percent growth-inhibitory concentration (GI(50)) for any single cell line is simply an index of cytotoxicity or cytostasis, but the patterns of 60 such GI(50) values encode unexpectedly rich, detailed information on mechanisms of drug action and drug resistance. Each compound's pattern is like a fingerprint, essentially unique among the many billions of distinguishable possibilities. These activity patterns are being used in conjunction with molecular structural features of the tested agents to explore the NCI's database of more than 460,000 compounds, and they are providing insight into potential target molecules and modulators of activity in the 60 cell lines, For example, the information is being used to search for candidate anticancer drugs that are not dependent on intact p53 suppressor gene function for their activity. It remains to be seen how effective this information-intensive strategy will be at generating new clinically active agents.	FRED HUTCHINSON CANC RES CTR, NCI, SEATTLE, WA 98105 USA; NCI, DIV CLIN SCI, MED BRANCH, NIH, BETHESDA, MD 20892 USA; NCI, DIV CANC TREATMENT DIAGNOSIS & CTR, CANC THERAPY EVALUAT PROGRAM,BIOMETR RES BRANCH, NIH, BETHESDA, MD 20892 USA; LARGE SCALE BIOL, ROCKVILLE, MD 20850 USA; NCI, FREDERICK CANC RES & DEV CTR, SAIC, FREDERICK, MD 21701 USA; NCI, DEV THERAPEUT PROGRAM, DCTDC, NIH, BETHESDA, MD 20892 USA; NCI, INFORMAT TECHNOL BRANCH,DEV THERAPEUT PROGRAM, DCTDC,NIH, BETHESDA, MD 20892 USA; NCI, GRANTS & CONTRACTS OPERAT BRANCH, DEV THERAPEUT PROGRAM,DCTDC,NIH, BETHESDA, MD 20892 USA; NCI, OFF DIRECTOR, DCTDC, NIH, BETHESDA, MD 20892 USA	Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Weinstein, JN (corresponding author), NCI, DIV BASIC SCI,MOL PHARMACOL LAB,NIH,BLDG 37, ROOM 5C-25, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.		Bates, Susan/AFP-9514-2022; Fornace, Albert J/A-7407-2008; LAIRD, PETER W/G-8683-2012	Fornace, Albert J/0000-0001-9695-085X; Weinstein, John/0000-0001-9401-6908; Rubinstein, Lawrence/0000-0002-9720-9737; LAIRD, PETER W/0000-0001-9117-3641; Myers, Timothy Gene/0000-0002-7059-5906				ALVAREZ M, 1995, J CLIN INVEST, V95, P2205, DOI 10.1172/JCI117910; BAI R, 1991, J BIOL CHEM, V266, P15882; BATES SE, 1995, J CANCER RES CLIN, V121, P495, DOI 10.1007/BF01197759; Boyd M. R., 1989, CANCER PRINCIPLES PR, V3, P1; BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203; BOYD MR, 1992, DEV ONCOL, V68, P11; BUOLAMWINI JK, UNPUB; CHABNER BA, 1994, CANC TREATMENT UPDAT, P10; CHIN KV, 1993, ADV CANCER RES, V60, P157; CLEAVELAND ES, 1995, BIOCHEM PHARMACOL, V49, P947, DOI 10.1016/0006-2952(95)00009-O; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GREVER MR, 1992, SEMIN ONCOL, V19, P622; GUPTA M, 1995, MOL PHARMACOL, V48, P658; Hamel E, 1996, BIOCHEM PHARMACOL, V51, P53, DOI 10.1016/0006-2952(95)02156-6; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Izquierdo MA, 1996, INT J CANCER, V65, P230; JAYARAM HN, 1992, BIOCHEM BIOPH RES CO, V186, P1600, DOI 10.1016/S0006-291X(05)81591-8; Koo HM, 1996, CANCER RES, V56, P5211; KOUTSOUKOS AD, 1994, STAT MED, V13, P719, DOI 10.1002/sim.4780130532; KUO SC, 1993, J MED CHEM, V36, P1146, DOI 10.1021/jm00061a005; LEE JS, 1994, MOL PHARMACOL, V46, P627; LETEURTRE F, 1995, BIOCHEM PHARMACOL, V49, P1283, DOI 10.1016/0006-2952(95)00047-4; LETEURTRE F, 1994, J NATL CANCER I, V86, P1239, DOI 10.1093/jnci/86.16.1239; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARSONI S, 1987, CANCER TREAT REP, V71, P71; MILNE GWA, 1994, J CHEM INF COMP SCI, V34, P1219, DOI 10.1021/ci00021a032; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; Myers T. G., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P299; Myers T. G., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P305; MYERS TG, IN PRESS ELECTROPHOR; OCONNOR PW, UNPUB; PAULL KD, 1992, CANCER RES, V52, P3892; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; PAULL KD, 1993, CANC CHEMOTHERAPEUTI, P1574; PENDYALA L, 1993, CANCER RES, V53, P5970; Scala S., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P325; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; SOLARY E, 1993, BIOCHEM PHARMACOL, V45, P2449, DOI 10.1016/0006-2952(93)90226-M; STINSON SF, 1992, ANTICANCER RES, V12, P1035; VANOSDOL WW, 1994, J NATL CANCER I, V86, P1853, DOI 10.1093/jnci/86.24.1853; WANG SM, 1994, J MED CHEM, V37, P4479, DOI 10.1021/jm00052a007; WEINSTEIN JN, 1994, STEM CELLS, V12, P13, DOI 10.1002/stem.5530120106; WEINSTEIN JN, 1992, SCIENCE, V258, P447, DOI 10.1126/science.1411538; Wilkins MR, 1996, BIOTECHNOL GENET ENG, V13, P19, DOI 10.1080/02648725.1996.10647923; WOSIKOWSKI K, UNPUB; WU L, 1992, CANCER RES, V52, P3029; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	53	989	1038	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 17	1997	275	5298					343	349		10.1126/science.275.5298.343	http://dx.doi.org/10.1126/science.275.5298.343			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994024				2022-12-01	WOS:A1997WC87300035
J	Lyman, SK; Schekman, R				Lyman, SK; Schekman, R			Binding of secretory precursor polypeptides to a translocon subcomplex is regulated by BiP	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PREPRO-ALPHA-FACTOR; CELL-FREE SYSTEM; PROTEIN TRANSLOCATION; SACCHAROMYCES-CEREVISIAE; SIGNAL SEQUENCE; SEC PROTEINS; EUKARYOTIC HOMOLOGS; SEC63P-BIP COMPLEX; ATP HYDROLYSIS	The translocation of a secretory precursor protein across the ER membrane comprises three phases: docking of the precursor at the membrane, insertion into the translocation pore, and exit from the pore into the ER lumen. We demonstrate that Sec62p, Sec71p and Sec72p form a translocon subcomplex that engages secretory precursors at the membrane site of the ER translocation machinery. Binding of a precursor to the subcomplex depends on the presence of an intact signal sequence and occurs only in the absence of ATP. In the presence of ATP, the precursor is released from the subcomplex in a reaction mediated by the lumenal hsp70, BiP. This release reaction, which is specific to BiP and requires interaction between BiP and the DnaJ homolog Sec63p, defines a role for BiP and Sec63p early in the ER translocation process.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026755] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26755] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1988, MOL CELL BIOL, V8, P1915, DOI 10.1128/MCB.8.5.1915; ALLISON DS, 1989, MOL CELL BIOL, V9, P4977, DOI 10.1128/MCB.9.11.4977; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; BRODSKY JL, 1994, BIOL HEAT SHOCK PROT, P85; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; FANG H, 1994, MOL BIOL CELL, V5, P933, DOI 10.1091/mbc.5.9.933; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FELDHEIM D, 1993, MOL BIOL CELL, V4, P931, DOI 10.1091/mbc.4.9.931; FELDHEIM D, 1994, J CELL BIOL, V126, P935, DOI 10.1083/jcb.126.4.935; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HANSEN W, 1988, J CELL BIOL, V106, P1075, DOI 10.1083/jcb.106.4.1075; Hightower L. E, 1994, BIOL HEAT SHOCK PROT, V26, P179; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURIHARA T, 1993, MOL BIOL CELL, V4, P919, DOI 10.1091/mbc.4.9.919; LYMAN SK, 1995, J CELL BIOL, V131, P1163, DOI 10.1083/jcb.131.5.1163; LYMAN SK, IN PRESS GUIDEBOOK M; LYMAN SK, 1996, THESIS U CALIFORNIA; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NELSON MK, 1993, GENETICS, V134, P159; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANZ P, 1989, J CELL BIOL, V108, P2101, DOI 10.1083/jcb.108.6.2101; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WATERS MG, 1986, J BIOL CHEM, V263, P6209; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; WICKNER WT, 1994, SCIENCE, V266, P1197, DOI 10.1126/science.7973701; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2	51	121	125	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					85	96		10.1016/S0092-8674(00)81861-9	http://dx.doi.org/10.1016/S0092-8674(00)81861-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019409	Bronze			2022-12-01	WOS:A1997WC56900012
J	Wolfe, SA; Zhou, P; Dotsch, V; Chen, L; You, A; Ho, SN; Crabtree, GR; Wagner, G; Verdine, GL				Wolfe, SA; Zhou, P; Dotsch, V; Chen, L; You, A; Ho, SN; Crabtree, GR; Wagner, G; Verdine, GL			Unusual Rel-like architecture in the DNA-binding domain of the transcription factor NFATc	NATURE			English	Article							NF-KAPPA-B; FAMILY; SPECIFICITY; ELEMENTS; HOMOLOGY; SUBUNIT; MEMBER	TRANSCRIPTION factors of the NFAT family regulate the production of effector proteins that coordinate the immune response(1). The immunosuppressive drugs FK506 and cyclosporin A (CsA) act by blocking a Ca2+-mediated signalling pathway leading to NFAT. Although FK506 and CsA have enabled human organs to Re transplanted routinely, the toxic side-effects of these drugs limit their usage. This toxicity might be absent in antagonists that target NFAT directly. As a first step in the structure-based search for NFAT antagonists, we now report the identification and solution structure of a 20K domain of NFATc (NFATc-DBD) that is both necessary and sufficient to bind DNA and activate transcription cooperatively. Although the overall fold of the NFATc DNA-hinding domain is related to that of NF-kappa B p50 (refs 2, 3), the two proteins use significantly different strategies for DNA recognition. On the basis of these results, we present a model for the cooperative complex formed between NFAT and the mitogenic transcription factor AP-1 on the interleukin-2 enhancer.	HARVARD UNIV,DEPT CHEM & CHEM BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115; STANFORD UNIV,HOWARD HUGHES MED INST,SCH MED,STANFORD,CA 94305	Harvard University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Stanford University			Zhou, Pei/O-6704-2019; chen, Lin/A-3392-2008; Doetsch, Volker/D-5697-2011	Zhou, Pei/0000-0002-7823-3416; chen, Lin/0000-0003-4798-6199; Dotsch, Volker/0000-0001-5720-212X				BLACKWELL TK, 1994, SCIENCE, V266, P621, DOI 10.1126/science.7939715; CHEN L, 1995, CURR BIOL, V5, P882, DOI 10.1016/S0960-9822(95)00178-3; CHEN L, 1994, THESIS HARVARD U; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LIU J, 1994, P NATL ACAD SCI USA, V91, P908, DOI 10.1073/pnas.91.3.908; MASCARENAS JL, 1993, J AM CHEM SOC, V115, P373, DOI 10.1021/ja00054a068; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Min CH, 1996, J AM CHEM SOC, V118, P6116, DOI 10.1021/ja953658z; MULLER CW, 1995, NATURE, V373, P301; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PENG JW, 1992, J MAGN RESON, V98, P308, DOI 10.1016/0022-2364(92)90135-T; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; SHORTLE D, 1994, J MAGN RESON SER B, V105, P88, DOI 10.1006/jmrb.1994.1106; STAN DB, 1991, CELL, V67, P1231; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; WOLFE SA, 1996, THESIS HARVARD U; [No title captured]	30	88	93	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					172	176		10.1038/385172a0	http://dx.doi.org/10.1038/385172a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990122				2022-12-01	WOS:A1997WB72800058
J	Batchelor, AM; Garthwaite, J				Batchelor, AM; Garthwaite, J			Frequency detection and temporally dispersed synaptic signal association through a metabotropic glutamate receptor pathway	NATURE			English	Article							CEREBELLAR PURKINJE-CELLS; LONG-TERM DEPRESSION; PROTEIN-KINASE-C; CALCIUM TRANSIENTS; CLIMBING FIBER; ACTIVATION; INVITRO; SLICES; INDUCTION; DENDRITES	IN the classical view, a central neuron integrates incoming synaptic information by simple algebraic summation of the resultant bioelectrical signals that coincide in time, The voltage dependence of the NMDA (N-methyl-D-aspartate) type of ionotropic glutamate receptor endows neurons with an additional tool that allows one synaptic input to influence another, providing again, that the two are active simultaneously(1). Here we identify a new mechanism by which non-coincident signals generated by different synaptic inputs are integrated, The device serves to regulate neuronal excitation through G-protein-coupled, metabotropic glutamate receptors (mGluRs)(2) in a powerful and specific manner. We show that, in cerebellar Purkinje cells, a single activation of the climbing-fibre input markedly potentiates mGluR-mediated excitation at parallel-fibre synapses(3). The potentiation results; from a transient rise in cytosolic Ca2+ which is 'memorized' in such a way that it promotes excitation through mGluRs for about two minutes. A Ca2+-transient is also effective if imposed up to two seconds after parallel-fibre stimulation. By allowing temporally and spatially dispersed synaptic signals to be assimilated, this mechanism adds a new element to the computational power of central neurons.	UCL, CRUCIFORM PROJECT, LONDON W1P 9LN, ENGLAND	University of London; University College London			Batchelor, Andrew/C-1174-2008	Batchelor, Andrew/0000-0002-5984-7842				ABE T, 1992, J BIOL CHEM, V267, P13361; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; BATCHELOR AM, 1994, NEUROSCIENCE, V63, P911, DOI 10.1016/0306-4522(94)90558-4; BATCHELOR AM, 1993, NEUROPHARMACOLOGY, V32, P11, DOI 10.1016/0028-3908(93)90124-L; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; Eccles J. C. M., 1967, CEREBELLUM NEURONAL; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; Garthwaite J, 1996, J NEUROSCI METH, V64, P189, DOI 10.1016/0165-0270(95)00133-6; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.neuro.12.1.85; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P171, DOI 10.1113/jphysiol.1980.sp013357; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MARSH SJ, 1995, NEURON, V15, P729, DOI 10.1016/0896-6273(95)90160-4; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MERRILL EG, 1978, J PHYSIOL-LONDON, V284, P127, DOI 10.1113/jphysiol.1978.sp012531; MIYAKAWA H, 1992, J NEUROPHYSIOL, V68, P1178, DOI 10.1152/jn.1992.68.4.1178; ROSS WN, 1987, J PHYSIOL-LONDON, V389, P319, DOI 10.1113/jphysiol.1987.sp016659; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; STAUB C, 1992, EUR J NEUROSCI, V4, P832, DOI 10.1111/j.1460-9568.1992.tb00193.x; SUGIMORI M, 1990, P NATL ACAD SCI USA, V87, P5084, DOI 10.1073/pnas.87.13.5084; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W	25	159	159	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					74	77		10.1038/385074a0	http://dx.doi.org/10.1038/385074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985249				2022-12-01	WOS:A1997WA73100052
J	Monks, CRF; Kupfer, H; Tamir, I; Barlow, A; Kupfer, A				Monks, CRF; Kupfer, H; Tamir, I; Barlow, A; Kupfer, A			Selective modulation of protein kinase C-theta during T-cell activation	NATURE			English	Article							SIGNAL-TRANSDUCTION; B-CELLS; RECEPTOR; MEMBER; FAMILY	EVERY cell contains many families of protein kinases, and may express several structurally related yet genetically distinct kinases of each family. The activity of the serine/threonine protein kinase C (PKC) enzymes(1-2) has long been implicated in T-cell activation(3), but it is not known which members of the PKC family regulate the T-cell response to foreign antigens. The activation of T cells by antigen-presenting cells (APCs) is spatially restricted to their site of contact, where receptors on the T cells engage their counter-receptors on the APCs(4,5). We used this localized engagement to identify, at the single-cell level, intracellular proteins involved in the activation process. By digital immunofluorescence microscopy, we localized six isoforms of PKC in antigen-specific T-cell clones activated by APCs. Surprisingly, only PKC-theta translocated to the site of cell contact. Accordingly, in vitro kinase activity assays of PkC immunoprecipitates from the conjugates of T cells and APCs showed a selective increase in the activity of PKC-theta, indicating that the translocated enzyme is active. Several modes of partial T-cell activation that failed to cause PKC-theta translocation also failed to cause T-cell proliferation, further suggesting the involvement of PKC-theta in T-cell activation.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,DENVER,CO 80262; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Howard Hughes Medical Institute; Yale University								BAIER G, 1993, J BIOL CHEM, V268, P4997; BALER G, 1994, EUR J BIOCHEM, V225, P195; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; CHERWINSKI HM, 1992, J IMMUNOL, V148, P2996; HARWELL L, 1980, J EXP MED, V152, P893, DOI 10.1084/jem.152.4.893; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; KUPFER A, 1990, J MOL CELL IMMUNOL, V4, P317; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; KUPFER A, 1989, J EXP MED, V170, P1697, DOI 10.1084/jem.170.5.1697; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; PODACK ER, 1991, ANNU REV CELL BIOL, V7, P479, DOI 10.1146/annurev.cellbio.7.1.479; ROBLESFLORES M, 1993, BIOCHEM J, V296, P467, DOI 10.1042/bj2960467; ROJO JM, 1989, EUR J IMMUNOL, V19, P2061, DOI 10.1002/eji.1830191114; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAMADA K, 1995, BIOCHEM J, V308, P177, DOI 10.1042/bj3080177; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; YOON ST, 1994, IMMUNITY, V1, P563	20	470	482	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					83	86		10.1038/385083a0	http://dx.doi.org/10.1038/385083a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985252				2022-12-01	WOS:A1997WA73100055
J	MaciasSilva, M; Abdollah, S; Hoodless, PA; Pirone, R; Attisano, L; Wrana, JL				MaciasSilva, M; Abdollah, S; Hoodless, PA; Pirone, R; Attisano, L; Wrana, JL			MADR2 is a substrate of the TGF beta receptor and its phosphorylation is required for nuclear accumulation and signaling	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; MUTATION; COMPLEX; PROTEIN	MAD-related (MADR) proteins are essential intracellular components of TGF beta signaling pathways and are regulated by phosphorylation. Here, we demonstrate that MADR2 and not the related protein DPC4 transiently interacts with the TGF beta receptor and is directly phosphorylated by the complex on C-terminal serines. Interaction of MADR2 with receptors and phosphorylation requires activation of receptor I by receptor II and is mediated by the receptor I kinase. Mutation of the phosphorylation sites generates a dominant negative MADR2 that blocks TGF beta-dependent transcriptional responses, stably associates with receptors, and fails to accumulate in the nucleus in response to TGF beta signaling. Thus, transient association and phosphorylation of MADR2 by the TGF beta receptor is necessary for nuclear accumulation and initiation of signaling.	HOSP SICK CHILDREN, DIV GASTROENTEROL, PROGRAM DEV BIOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DEPT MED GENET & MICROBIOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DEPT ANAT & CELL BIOL, TORONTO, ON M5G 1X8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Wrana, Jeffrey/F-8857-2013	Macias-Silva, Marina/0000-0002-3972-0983; Hoodless, Pamela/0000-0003-1371-0725				Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1996, CANCER SURV, V27, P41; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SMITH DB, 1994, CURRENT PROTOCOL S28, V2; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Ventura F, 1996, J BIOL CHEM, V271, P13931, DOI 10.1074/jbc.271.24.13931; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1996, IN PRESS TRENDS GENE; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	35	636	668	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 27	1996	87	7					1215	1224		10.1016/S0092-8674(00)81817-6	http://dx.doi.org/10.1016/S0092-8674(00)81817-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980228	Bronze			2022-12-01	WOS:A1996WA54100010
J	Tokatlidis, K; Junne, T; Moes, S; Schatz, G; Glick, BS; Kronidou, N				Tokatlidis, K; Junne, T; Moes, S; Schatz, G; Glick, BS; Kronidou, N			Translocation arrest of an intramitochondrial sorting signal next to Tim11 at the inner-membrane import site	NATURE			English	Article							MITOCHONDRIAL INTERMEMBRANE SPACE; PROTEIN IMPORT; PRECURSOR PROTEIN; MATRIX; ATP; BINDING	THE import of proteins from the cytosol into the mitochondrial matrix involves the concerted action of two separate import systems: the TOM system in the outer membrane, and the TIM system in the inner membrane(1,2), Here we report that the inner-membrane system also sorts proteins to the intermembrane space. Some intermembrane-space proteins, such as cytochromes b(2) and c(1), are synthesized with a complex pre-sequence consisting of a positively charged matrix targeting signal followed by an uncharged sequence that acts as sorting signal for the intermembrane space(3). We show that this sorting signal can be efficiently crosslinked to an inner-membrane protein of relative molecular mass 11K after the mature part of the precursor has been sorted to the intermembrane space. The 11K protein, which we term Tim11, is a component of the protein import system in the inner membrane.	UNIV CHICAGO,CUMMINGS LIFE SCI CTR,CHICAGO,IL 60637	University of Chicago	Tokatlidis, K (corresponding author), UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND.			Tokatlidis, Kostas/0000-0001-6295-8183				BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GARTNER F, 1995, EMBO J, V14, P1349; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HUANG ST, 1991, J BIOL CHEM, V266, P21083; JASCUR T, 1992, J BIOL CHEM, V267, P13636; KAUFMANN SH, 1984, EXP CELL RES, V155, P477, DOI 10.1016/0014-4827(84)90208-8; KUBRICH M, 1994, FEBS LETT, V349, P222, DOI 10.1016/0014-5793(94)00670-9; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; PFANNER N, 1995, CURR BIOL, V5, P132; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; PHIL A, 1962, J BIOL CHEM, V237, P1356; RYAN KR, 1993, J BIOL CHEM, V268, P23743; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; TOKATLIDIS K, 1991, FEBS LETT, V282, P205, DOI 10.1016/0014-5793(91)80478-L; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; WACH A, 1994, YEAST, V10, P1791; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	27	55	55	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1996	384	6609					585	588		10.1038/384585a0	http://dx.doi.org/10.1038/384585a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955275				2022-12-01	WOS:A1996VX76900065
J	Blane, D; Hart, CL; Smith, GD; Gillis, CR; Hole, DJ; Hawthorne, VM				Blane, D; Hart, CL; Smith, GD; Gillis, CR; Hole, DJ; Hawthorne, VM			Association of cardiovascular disease risk factors with socioeconomic position during childhood and during adulthood	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BRITISH CIVIL-SERVANTS; BIRTH COHORT; MORTALITY; MEN; PREDICTORS; SCOTLAND; FINLAND; WEIGHT; HEALTH	Objective-To investigate strength of associations between risk factors for cardiovascular disease and socioeconomic position during childhood and adulthood. Design-Cross sectional analysis of status of cardiovascular risk factors and past and present social circumstances. Subjects-5645 male participants in the west of Scotland collaborative study, a workplace screening study. Main outcome measures-Strength of association between each risk factor for cardiovascular disease (diastolic blood pressure, serum cholesterol concentration, level of recreational physical exercise, cigarette smoking, body mass index, and FEV(1) score (forced expiratory volume in one second as percentage of expected value) and social class during childhood (based on father's main occupation) and adulthood (based on own occupation at time of screening). Results-All the measured risk factors were significantly associated with both father's and own social class (P<0.05), apart from exercise and smoking (nut significantly associated with father's social class) and body mass index (not significantly associated with own social class). For all risk factors except body mass index, the regression coefficient of own social class was larger than the regression coefficient of father's social class. The difference between the coefficients was significant for serum cholesterol concentration, cigarette smoking, body mass index, and FEV(1) score (all P<0.001). Conclusions-Subjects) status for behavioural risk factors (exercise and smoking) was associated primarily with current socioeconomic, circumstances, while status for physiological risk factors (serum cholesterol, blood pressure, body mass index, and FEV(1)) was associated to varying extents with both past and present socioeconomic circumstances.	UNIV GLASGOW, DEPT PUBL HLTH, GLASGOW, LANARK, SCOTLAND; UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND; RUCHILL HOSP, W SCOTLAND CANC SURVEILLANCE UNIT, GLASGOW, LANARK, SCOTLAND; UNIV MICHIGAN, DEPT EPIDEMIOL, ANN ARBOR, MI 48109 USA	University of Glasgow; University of Bristol; University of Glasgow; University of Michigan System; University of Michigan	Blane, D (corresponding author), CHARING CROSS & WESTMINSTER MED SCH, ACAD DEPT PSYCHIAT, LONDON W6 8RP, ENGLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				[Anonymous], 1954, SOCIAL MOBILITY BRIT; Armitage P, 1971, STAT METHODS MED RES; ARNESEN E, 1985, J EPIDEMIOL COMMUN H, V39, P210, DOI 10.1136/jech.39.3.210; Barker DJP, 1992, FETAL INFANT ORIGINS; BARTLEY M, 1994, BMJ-BRIT MED J, V309, P1475, DOI 10.1136/bmj.309.6967.1475; BRADDON FFM, 1986, BMJ-BRIT MED J, V293, P299, DOI 10.1136/bmj.293.6542.299; Brunner E, 1996, LANCET, V347, P1008, DOI 10.1016/S0140-6736(96)90147-6; BURR ML, 1980, J EPIDEMIOL COMMUN H, V34, P93, DOI 10.1136/jech.34.2.93; EBIKRYSTON KL, 1989, INT J EPIDEMIOL, V18, P84, DOI 10.1093/ije/18.1.84; Erikson R., 1993, CONSTANT FLUX; FORSDAHL A, 1978, J EPIDEMIOL COMMUN H, V32, P34, DOI 10.1136/jech.32.1.34; FOX AJ, 1976, BRIT J PREVENTATIVE, V9, P180; GLIKSMAN MD, 1995, J EPIDEMIOL COMMUN H, V49, P10, DOI 10.1136/jech.49.1.10; Goldthorpe J., 1980, SOCIAL MOBILITY CLAS; HAWTHORNE VM, 1978, J EPIDEMIOL COMMUN H, V32, P260, DOI 10.1136/jech.32.4.260; HAWTHORNE VM, 1995, SCOT MED J, V40, P102, DOI 10.1177/003693309504000402; Hole DJ, 1996, BRIT MED J, V313, P711; KAPLAN GA, 1990, BRIT MED J, V301, P1121, DOI 10.1136/bmj.301.6761.1121; LEON DA, 1995, J EPIDEMIOL COMMUN H, V49, P5, DOI 10.1136/jech.49.1.5; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; Marshall G., 1988, SOCIAL CLASS MODERN; NOTKOLA V, 1985, SOC SCI MED, V21, P517, DOI 10.1016/0277-9536(85)90035-8; NOTKOLA V, 1985, COMMENTATIONES SCIEN, V29, P15; *OFF POP CENS SURV, 1966, CLASS OCC 1966; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; PAYNE G, 1987, MOBILITY CHANGE MODE; POWER C, 1988, INT J OBESITY, V12, P445; REID I, 1989, SOCIAL CLASS DIFFERE; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; WADSWORTH MEJ, 1985, BRIT MED J, V291, P1534, DOI 10.1136/bmj.291.6508.1534; WOODWARD M, 1992, PREV MED, V21, P136, DOI 10.1016/0091-7435(92)90013-8	33	269	270	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 7	1996	313	7070					1434	1438		10.1136/bmj.313.7070.1434	http://dx.doi.org/10.1136/bmj.313.7070.1434			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX612	8973230	Green Published			2022-12-01	WOS:A1996VX61200026
J	Kantor, DB; Lanzrein, M; Stary, SJ; Sandoval, GM; Smith, WB; Sullivan, BM; Davidson, N; Schuman, EM				Kantor, DB; Lanzrein, M; Stary, SJ; Sandoval, GM; Smith, WB; Sullivan, BM; Davidson, N; Schuman, EM			A role for endothelial NO synthase in LTP revealed by adenovirus-mediated inhibition and rescue	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; LONG-TERM POTENTIATION; SYNAPTIC POTENTIATION; RAT HIPPOCAMPUS; PROTEIN; GENE; ACID; MYRISTOYLATION; INVOLVEMENT; MESSENGER	Pharmacological studies support the idea that nitric oxide (NO) serves as a retrograde messenger during long-term potentiation (LTP) in area CAI of the hippocampus. Mice with a defective form of the gene for neuronal NO synthase (nNOS), however, exhibit normal LTP. The myristoyl protein endothelial NOS (eNOS) is present in the dendrites of CA1 neurons. Recombinant adenovirus vectors containing either a truncated eNOS (a putative dominant negative) or an eNOS fused to a transmembrane protein were used to demonstrate that membrane-targeted eNOS is required for LTP. The membrane localization of eNOS may optimally position the enzyme both to respond to Ca2+ influx and to release NO into the extracellular space during LTP induction.	CALTECH, DIV BIOL 216 76, PASADENA, CA 91125 USA	California Institute of Technology			Schuman, Erin M/D-6204-2011	Kantor, David/0000-0002-0466-1012	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R43NS037292] Funding Source: NIH RePORTER; NINDS NIH HHS [NS37292] Funding Source: Medline; PHS HHS [49176] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BUSCONI L, 1994, J BIOL CHEM, V269, P25016; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; CUMMINGS JA, 1994, NEUROSCI LETT, V176, P110, DOI 10.1016/0304-3940(94)90883-4; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GRIBKOFF VK, 1992, J NEUROPHYSIOL, V68, P639, DOI 10.1152/jn.1992.68.2.639; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HALEY JE, 1993, NEUROSCI LETT, V160, P85, DOI 10.1016/0304-3940(93)90919-C; HALEY JE, IN PRESS LEARN MEM; HELM R, 1995, NATURE, V373, P663; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; KANTOR DB, UNPUB; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; LIU JW, 1994, J BIOL CHEM, V269, P11691; MCILHINNEY RAJ, 1990, J NEUROCHEM, V54, P110, DOI 10.1111/j.1471-4159.1990.tb13289.x; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; PAIGE LA, 1990, BIOCHEMISTRY-US, V29, P10566, DOI 10.1021/bi00498a021; POLLOCK JS, 1992, FEBS LETT, V309, P402, DOI 10.1016/0014-5793(92)80816-Y; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Sakoda T, 1995, MOL CELL BIOCHEM, V152, P143, DOI 10.1007/BF01076076; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; SUKHATME VP, 1985, CELL, V40, P591, DOI 10.1016/0092-8674(85)90207-7; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; WILLIAMS JH, 1993, NEURON, V11, P877, DOI 10.1016/0896-6273(93)90117-A	33	161	166	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1996	274	5293					1744	1748		10.1126/science.274.5293.1744	http://dx.doi.org/10.1126/science.274.5293.1744			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939872				2022-12-01	WOS:A1996VW71200071
J	Kirkpatrick, AF				Kirkpatrick, AF			Role of the USA in shortage of food and medicine in Cuba	LANCET			English	Article							EPIDEMIC	For over 30 years an embargo by the USA has restricted Cuba's ability to purchase foods and medicines. In 1992, the USA enacted the Cuban Democracy Act (CDA), which ''exempted'' the sale of medicines from the embargo. However, the implementation of the CDA's requirements and the intensification of the embargo as a result of the passage of the Helms-Burton Act in March, 1996, have undermined the purpose of the medicine exemption. The resultant lack of food and medicine to Cuba contributed to the worst epidemic of neurological disease this century. The Inter-American Commission on Human Rights of the Organization of American States has informed the US Government that such activities violate international law and has requested that the US take immediate steps to exempt food and medicine from the embargo.			Kirkpatrick, AF (corresponding author), UNIV S FLORIDA,COLL MED,12901 BRUCE B DOWNS BLVD,BOX 59,TAMPA,FL 33612, USA.							*AM PUBL HLTH ASS, 1993, POL SUFF IMP US EMB; *AMN INT, 1995, US HUM RIGHTS VIOL S; BARRAL PE, 1990, 15 YEARS RESULTS PHA; CARTER T, 1995, WASHINGTON TIME 0730; *CUBA NEUR FIELD I, 1995, NEW ENGL J MED, V333, P1176; *HUM RIGHTS WATCH, 1995, CUB IMPR REF; Kirkpatrick AF, 1996, JAMA-J AM MED ASSOC, V275, P1633, DOI 10.1001/jama.1996.03530450023014; MONMANEY T, 1995, LOS ANGELES TIM 1120; *PHARM RES MAN AM, 1994, WORLD CLASS DRUGS OR; REDWOOD H, 1994, PRICE REGULATION PHA; ROMAN GC, 1995, ANN INTERN MED, V122, P530, DOI 10.7326/0003-4819-122-7-199504010-00009; ROMAN GC, 1994, NEUROLOGY, V44, P1784, DOI 10.1212/WNL.44.10.1784; WALTE J, 1995, USA TODAY       0307; 1995, USA TODAY       1025, pA3	14	27	31	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1489	1491		10.1016/S0140-6736(96)07376-X	http://dx.doi.org/10.1016/S0140-6736(96)07376-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942780				2022-12-01	WOS:A1996VV46300013
J	Takagaki, Y; Seipelt, RL; Peterson, ML; Manley, JL				Takagaki, Y; Seipelt, RL; Peterson, ML; Manley, JL			The polyadenylation factor CstF-64 regulates alternative processing of IgM heavy chain pre-mRNA during B cell differentiation	CELL			English	Article							SACCHAROMYCES-CEREVISIAE RNA14; SPLICE SITE SELECTION; 2 MESSENGER-RNAS; SPECIFICITY FACTOR; 3' ENDS; IN-VIVO; BINDING DOMAIN; SR PROTEINS; CLEAVAGE; SUBUNIT	The switch from membrane-bound to secreted-form IgM that occurs during differentiation of B lymphocytes has long been known to involve regulated processing of the heavy chain pre-mRNA. Here, we show that accumulation of one subunit of an essential polyadenylation factor (CstF-64) is specifically repressed in mouse primary B cells and that overexpression of CstF-64 is sufficient to switch heavy chain expression from membrane-bound (mu m) to secreted form (mu s). We further show that CstF-64 is limiting for formation of intact CstF, that CstF has a higher affinity for the pm poly(A) site than for the mu s site, and that the mu m site is stronger in a reconstituted in vitro processing reaction. Our results indicate that CstF-64 plays a key role in regulating IgM heavy chain expression during B cell differentiation.	UNIV KENTUCKY,MED CTR,DEPT MICROBIOL & IMMUNOL,DEPT PATHOL & LAB MED,LEXINGTON,KY 40536	University of Kentucky	Takagaki, Y (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Seipelt-Thiemann, Rebecca/0000-0001-5265-7897; Manley, James/0000-0002-8341-1459; Peterson, Martha/0000-0002-7214-421X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028983] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28983] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALT FW, 1980, CELL, V20, P293, DOI 10.1016/0092-8674(80)90615-7; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BLATTNER FR, 1984, NATURE, V307, P417, DOI 10.1038/307417a0; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEBENEDETTE M, 1991, J IMMUNOL, V147, P2839; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; EDWALDSGILBERT G, 1995, MOL CELL BIOL, V15, P6420; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; Guise J. W., 1989, Immunoglobulin genes., P275; GUISE JW, 1988, J IMMUNOL, V140, P3988; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; MANDART E, 1995, MOL CELL BIOL, V15, P6979; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MANLEY JL, 1982, J MOL BIOL, V159, P581, DOI 10.1016/0022-2836(82)90102-4; MANN KP, 1993, MOL CELL BIOL, V13, P2411, DOI 10.1128/MCB.13.4.2411; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; MITCHELSON A, 1993, GENE DEV, V7, P241, DOI 10.1101/gad.7.2.241; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; OHARE K, 1995, TRENDS GENET, V11, P255, DOI 10.1016/S0168-9525(00)89067-8; PETERSON ML, 1994, MOL CELL BIOL, V14, P7891, DOI 10.1128/MCB.14.12.7891; PETERSON ML, 1986, P NATL ACAD SCI USA, V83, P8883, DOI 10.1073/pnas.83.23.8883; PETERSON ML, 1991, MOL CELL BIOL, V11, P2324, DOI 10.1128/MCB.11.4.2324; PETERSON ML, 1994, HDB B T LYMPHOCYTES, P321; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; WANG J, 1995, RNA, V1, P335; YAN DH, 1995, MOL CELL BIOL, V15, P1901; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	48	321	323	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					941	952		10.1016/S0092-8674(00)82000-0	http://dx.doi.org/10.1016/S0092-8674(00)82000-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945520	hybrid			2022-12-01	WOS:A1996VV77400019
J	vanderWal, G; van der Maas, PJ; Bosma, JM; OnwuteakaPhilipsen, BD; Willems, DL; Haverkate, I; Kostense, PJ				vanderWal, G; van der Maas, PJ; Bosma, JM; OnwuteakaPhilipsen, BD; Willems, DL; Haverkate, I; Kostense, PJ			Evaluation of the notification procedure for physician-assisted death in the Netherlands	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EUTHANASIA	Background In the Netherlands, a notification procedure for physician-assisted death has been in use since 1991. it requires doctors to report each case to the coroner, who in turn notifies the public prosecutor. Ultimately, the Assembly of Prosecutors General decides whether to prosecute. Although physician-assisted death remains technically illegal, doctors are extremely unlikely to be prosecuted if they comply with the requirements for accepted practice. In 1995, the ministers of health and justice commissioned an evaluation to determine the adequacy of the notification procedure. Methods A random sample of 405 physicians were interviewed. We also interviewed 147 physicians who had reported cases of physician-assisted death and 116 coroners, and we reviewed 353 judicial files of reported cases. In addition, we interviewed 48 public prosecutors and reviewed the minutes of the Assembly of Prosecutors General for 1991 to 1995 and all published court decisions from 1981 through 1995. Results in 1995, about 41 percent of all cases of euthanasia and physician-assisted suicide were reported. There were no major differences between reported and unreported cases in terms of the patients' characteristics, clinical conditions, or reasons for the action. Most patients had cancer and were described as suffering ''unbearably'' and ''hopelessly.'' Of the 6324 cases reported during the period from 1991 through 1995, only 13 involved prosecution of the physician. The majority of respondents in the groups interviewed thought that all cases of physician-asssisted death should be reviewed, although most doctors thought the review should be performed by other doctors, and there was substantial concern about the burden associated with the reporting procedure. Conclusions Substantial progress in the oversight of physician-assisted death has been achieved in the Netherlands. The reporting procedure could be more streamlined and less threatening. (C)1996, Massachusetts Medical Society.	VRIJE UNIV AMSTERDAM, INST RES EXTRAMURAL MED, NL-1081 BT AMSTERDAM, NETHERLANDS; VRIJE UNIV AMSTERDAM, DEPT GEN PRACTICE NURSING HOME & SOCIAL MED, NL-1081 BT AMSTERDAM, NETHERLANDS; VRIJE UNIV AMSTERDAM, DEPT EPIDEMIOL & BIOSTAT, NL-1081 BT AMSTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, ROTTERDAM, NETHERLANDS	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam								ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; ANNAS GJ, 1990, JAMA-J AM MED ASSOC, V263, P858, DOI 10.1001/jama.263.6.858; Gardner M, 1989, BRIT MED J; Haverkate I, 1996, JAMA-J AM MED ASSOC, V275, P435, DOI 10.1001/jama.275.6.435; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; van der Maas PJ, 1995, JAMA-J AM MED ASSOC, V273, P1411, DOI 10.1001/jama.273.18.1411; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; VANDERMAAS PJ, 1992, HLTH POLICY, V22; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346	10	160	160	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1706	1711						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV936	8965876				2022-12-01	WOS:A1996VV93600035
J	Tanner, MA; Cech, TR				Tanner, MA; Cech, TR			Joining the two domains of a group I ribozyme to form the catalytic core	SCIENCE			English	Article							COMPARATIVE SEQUENCE-ANALYSIS; GUANOSINE-BINDING-SITE; TERTIARY STRUCTURE; TETRAHYMENA RIBOZYME; RIBONUCLEASE-P; BASE-TRIPLES; TRANSFER-RNA; INTRON; ARCHITECTURE; CLEAVAGE	Self-splicing group I introns, like other large catalytic RNAs, contain structural domains. Although the crystal structure of one of these domains has been determined by x-ray analysis, its connection to the other major domain that contains the guanosine-binding site has not been known. Site-directed mutagenesis and kinetic analysis of RNA splicing were used to identify a base triple in the conserved core of both a cyanobacterial (Anabaena) and a eukaryotic (Tetrahymena) group I intron. This long-range interaction connects a sequence adjacent to the guanosine-binding site with the domain implicated in coordinating the 5' splice site helix, and it thereby contributes to formation of the active site. The resulting five-strand junction, in which a short helix forms base triples with three separate strands in the Tetrahymena intron, reveals exceptionally dense packing of RNA.	UNIV COLORADO, HOWARD HUGHES MED INST, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028039, R01GM028039] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28039] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; COSTA M, 1995, EMBO J, V14, P1276, DOI 10.1002/j.1460-2075.1995.tb07111.x; DOUDNA JA, 1995, RNA, V1, P36; EHRENMAN K, 1986, P NATL ACAD SCI USA, V83, P5875, DOI 10.1073/pnas.83.16.5875; GAUTHERET D, 1995, J MOL BIOL, V248, P27, DOI 10.1006/jmbi.1995.0200; Golden BL, 1996, BIOCHEMISTRY-US, V35, P3754, DOI 10.1021/bi952599z; GREEN R, 1994, J MOL BIOL, V235, P140, DOI 10.1016/S0022-2836(05)80022-1; GUTELL RR, 1996, RIBOSOMAL RNA STRUCT, P111; GUTELL RR, UNPUB; HARRIS ME, 1994, EMBO J, V13, P3953, DOI 10.1002/j.1460-2075.1994.tb06711.x; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; LACKS S, 1966, GENETICS, V53, P207; LAGGERBAUER B, 1994, EMBO J, V13, P2669, DOI 10.1002/j.1460-2075.1994.tb06557.x; Meervelt L. V., 1995, NATURE, V374, P742; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; PAN T, 1995, BIOCHEMISTRY-US, V34, P902, DOI 10.1021/bi00003a024; PRICE JV, 1985, SCIENCE, V228, P719, DOI 10.1126/science.2986286; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P2716, DOI 10.1021/bi00175a047; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; TABAK HF, 1987, CELL, V48, P101, DOI 10.1016/0092-8674(87)90360-6; Tanner MA, 1996, RNA, V2, P74; TANNER MA, UNPUB; Vlieghe D, 1996, SCIENCE, V273, P1702, DOI 10.1126/science.273.5282.1702; WANG JF, 1992, SCIENCE, V256, P526, DOI 10.1126/science.1315076; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747; Zarrinkar PP, 1996, NUCLEIC ACIDS RES, V24, P854, DOI 10.1093/nar/24.5.854; ZAUG AJ, 1993, BIOCHEMISTRY-US, V32, P7946, DOI 10.1021/bi00082a016; ZAUG AJ, 1983, NATURE, V301, P578, DOI 10.1038/301578a0; ZAUG AJ, 1994, BIOCHEMISTRY-US, V33, P14935, DOI 10.1021/bi00253a033; ZHURKIN VB, 1994, J MOL BIOL, V239, P181, DOI 10.1006/jmbi.1994.1362	39	38	39	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 7	1997	275	5301					847	849		10.1126/science.275.5301.847	http://dx.doi.org/10.1126/science.275.5301.847			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012355				2022-12-01	WOS:A1997WG77700066
J	Neugebauer, R; Kline, J; Shrout, P; Skodol, A; OConnor, P; Geller, PA; Stein, Z; Susser, M				Neugebauer, R; Kline, J; Shrout, P; Skodol, A; OConnor, P; Geller, PA; Stein, Z; Susser, M			Major depressive disorder in the 6 months after miscarriage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPONTANEOUS-ABORTION; PERINATAL DEATH; GRIEF; KARYOTYPE; SYMPTOMS	Objective.-To test a priori hypotheses that miscarrying women are at increased risk for a first or recurrent episode of major depressive disorder in the 6 months following loss and that this increased risk is greater for childless women, women with prior reproductive loss, and women aged 35 years or older; and to evaluate whether risk varies by time of gestation or by attitude toward the pregnancy. Design.-Cohort study. Setting.-The miscarriage cohort consisted of women attending a medical center for a spontaneous abortion (n=229); the comparison group was a population-based cohort of women drawn from the community (n=230). Participants.-Miscarriage was defined as the involuntary termination of a nonviable intrauterine pregnancy before 28 completed weeks of gestation. Half of all participants were between 25 and 34 years of age; 40% were white and 35% Hispanic; 55% had more than a high school education. Participants constituted 60% of miscarrying women and 72% of community women who completed the first phase of this cohort study. Main Outcome Measure.-Major depressive disorder was measured using the Diagnostic Interview Schedule. Results.-Risk for an episode of major depressive disorder among miscarrying women in the 6 months following loss was compared with the 6-month risk among community women who had not been pregnant in the preceding year. Among miscarrying women, 10.9% experienced an episode of major depressive disorder, compared with 4.3% of community women. The overall relative risk (RR) for an episode of major depressive disorder for miscarrying women was 2.5 (95% confidence interval [Cl], 1.2-5.1) and was substantially higher for childless women (RR, 5.0; 95% Cl, 1.7-14.4) than for women with children (RR, 1.3; 95% Cl, 0.5-3.5) (P<.06). Among miscarrying women, 72% of cases of major depressive disorder began within the first month after loss; only 20% of community cases started during the comparable period. Among miscarrying women with a history of major depressive disorder, 54% experienced a recurrence. However, RR did not vary significantly by history of prior reproductive loss or by maternal age, nor did risk vary by time of gestation or attitude toward the pregnancy. Conclusions.-Physicians should monitor miscarrying women in the first weeks after reproductive loss, particularly women who are childless or who have a history of major depressive disorder. Where appropriate, supportive counseling or psychopharmacologic treatment should be considered.	COLUMBIA UNIV,FAC MED,GERTRUDE H SERGIEVSKY CTR,NEW YORK,NY; NYU,DEPT PSYCHOL,NEW YORK,NY 10003; COLUMBIA UNIV,FAC MED,DEPT PSYCHIAT,NEW YORK,NY; COLUMBIA UNIV,SCH PUBL HLTH,DIV EPIDEMIOL,NEW YORK,NY; RUSSELL SAGE COLL,DEPT PSYCHOL,TROY,NY	Columbia University; New York University; Columbia University; Columbia University	Neugebauer, R (corresponding author), NEW YORK STATE PSYCHIAT INST & HOSP,DEPT EPIDEMIOL DEV BRAIN DISORDERS,BOX 53,722 W 168TH ST,NEW YORK,NY 10032, USA.		Skodol, Andrew/AAK-9646-2021		NICHD NIH HHS [HD12207, HD15509] Funding Source: Medline; NIMH NIH HHS [MH39581] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039581] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd; ANESHENSEL CS, 1982, PUBLIC OPIN QUART, V46, P110, DOI 10.1086/268703; CLARKE M, 1979, LANCET, V2, P916; *COMM STUD HLTH CO, 1984, BER REACT CONS CAR; Dillman DA, 1978, MAIL TELEPHONE SURVE; EATON WW, 1990, ACTA PSYCHIAT SCAND, V26, P163; FORREST CG, 1982, BRIT MED J, V285, P1475; FRIEDMAN T, 1989, BRIT J PSYCHIAT, V155, P810, DOI 10.1192/bjp.155.6.810; GAREL M, 1992, CONTRACEPT FERTIL S, V20, P75; GRAHAM MA, 1987, AM J OBSTET GYNECOL, V157, P254, DOI 10.1016/S0002-9378(87)80145-X; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HOCHSTIM JR, 1967, J AM STAT ASSOC, V62, P976, DOI 10.2307/2283686; KLINE J, 1995, AM J EPIDEMIOL, V141, P417, DOI 10.1093/oxfordjournals.aje.a117444; KLINE J, 1991, EPIDEMIOLOGY, V2, P409, DOI 10.1097/00001648-199111000-00004; Kline J, 1989, CONCEPTION BIRTH EPI, P43; LAROCHE C, 1984, CAN J PSYCHIAT, V29, P14, DOI 10.1177/070674378402900104; LEINBACH RM, 1982, GERONTOLOGIST, V22, P78, DOI 10.1093/geront/22.1.78; LEPPERT PC, 1984, OBSTET GYNECOL, V64, P119; MYERS JK, 1984, ARCH GEN PSYCHIAT, V41, P959; *NAT CTR HLTH STAT, 1995, 1992 VIT STAT US, V1; NEUGEBAUER R, 1992, AM J OBSTET GYNECOL, V166, P104, DOI 10.1016/0002-9378(92)91839-3; NEUGEBAUER R, 1992, AM J PUBLIC HEALTH, V82, P1332, DOI 10.2105/AJPH.82.10.1332; NICOL MT, 1986, MED J AUSTRALIA, V144, P287, DOI 10.5694/j.1326-5377.1986.tb128375.x; PEPPERS LG, 1980, PSYCHIATRY, V43, P155, DOI 10.1080/00332747.1980.11024061; Prettyman RJ, 1994, J REPROD INFANT PSYC, V12, P37, DOI DOI 10.1080/02646839408408866; RABKIN JG, 1982, HDB STRESS THEORETIC, P566; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ROBINS LN, 1991, PSYCHIAT DISORDERS A; ROBINSON GE, 1994, J REPROD INFANT PSYC, V12, P31, DOI DOI 10.1080/02646839408408865; SEIBEL M, 1980, J REPROD MED, V25, P161; THARPAR AK, 1992, BRIT J GEN PRACT, V42, P94; TOEDTER LJ, 1988, AM J ORTHOPSYCHIAT, V58, P435, DOI 10.1111/j.1939-0025.1988.tb01604.x; TUNALEY JR, 1993, PSYCHOL HEALTH, V8, P369, DOI 10.1080/08870449308401929; VIEDERMAN M, 1995, AM J PSYCHIAT, V152, P1	35	126	128	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					383	388		10.1001/jama.277.5.383	http://dx.doi.org/10.1001/jama.277.5.383			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WE771	9010170				2022-12-01	WOS:A1997WE77100028
J	Elliott, G; OHare, P				Elliott, G; OHare, P			Intercellular trafficking and protein delivery by a herpesvirus structural protein	CELL			English	Article							SIMPLEX VIRUS TYPE-1; FIBROBLAST GROWTH-FACTOR; GLYCOPROTEIN-H; TAT PROTEIN; TEGUMENT PROTEIN; BREFELDIN-A; CELLS; TRANSLOCATION; TRANSPORT; SEQUENCE	We show that the HSV-1 structural protein VP22 has the remarkable property of intercellular transport, which is so efficient that following expression in a subpopulation the protein spreads to every cell in a monolayer, where it concentrates in the nucleus and binds chromatin. VP22 movement was observed both after delivery of DNA by transfection or microinjection and during virus infection. Moreover, we demonstrate that VP22 trafficking occurs via a nonclassical Golgi-independent mechanism. Sensitivity to cytochalasin D treatment suggests that VP22 utilizes a novel trafficking pathway that involves the actin cytoskeleton. In addition, we demonstrate intercellular transport of a VP22 fusion protein after endogenous synthesis or exogenous application, indicating that VP22 may have potential in the field of protein delivery.			Elliott, G (corresponding author), MARIE CURIE RES INST,THE CHART,OXTED RH8 0TL,SURREY,ENGLAND.			O'Hare, Peter/0000-0003-4508-5602				BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BLAHO JA, 1994, J BIOL CHEM, V269, P17401; CAO Y, 1993, J CELL SCI, V104, P77; Cao YH, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037497; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DARGAN D, 1986, VIRAL STRUCTURE, P359; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; ELLIOTT G, 1995, J VIROL, V69, P7932, DOI 10.1128/JVI.69.12.7932-7941.1995; ELLIOTT GD, 1992, J GEN VIROL, V73, P723, DOI 10.1099/0022-1317-73-3-723; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FORRESTER A, 1992, J VIROL, V66, P341, DOI 10.1128/JVI.66.1.341-348.1992; FULLER AO, 1989, J VIROL, V63, P3435, DOI 10.1128/JVI.63.8.3435-3443.1989; GOMPELS U, 1986, VIROLOGY, V153, P230, DOI 10.1016/0042-6822(86)90026-7; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HELLAND DE, 1991, J VIROL, V65, P4547, DOI 10.1128/JVI.65.8.4547-4549.1991; HUTCHINSON L, 1992, J VIROL, V66, P2240, DOI 10.1128/JVI.66.4.2240-2250.1992; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; KRASNEY PA, 1992, CYTOKINE, V4, P134, DOI 10.1016/1043-4666(92)90048-V; Kuchler Karl, 1993, Trends in Cell Biology, V3, P421, DOI 10.1016/0962-8924(93)90030-5; Leslie J, 1996, VIROLOGY, V220, P60, DOI 10.1006/viro.1996.0286; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MENGAUD J, 1996, CELL, V84, P823; PASTAN IH, 1981, SCIENCE, V214, P504, DOI 10.1126/science.6170111; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; PRIOR TI, 1992, BIOCHEMISTRY-US, V31, P3555, DOI 10.1021/bi00129a001; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; RUBARTELLI A, 1995, TRENDS CELL BIOL, V5, P409, DOI 10.1016/S0962-8924(00)89093-5; STENMARK H, 1991, J CELL BIOL, V113, P1025, DOI 10.1083/jcb.113.5.1025	35	857	1160	0	33	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1997	88	2					223	233		10.1016/S0092-8674(00)81843-7	http://dx.doi.org/10.1016/S0092-8674(00)81843-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008163	Bronze			2022-12-01	WOS:A1997WE97000011
J	Tishkoff, DX; Filosi, N; Gaida, GM; Kolodner, RD				Tishkoff, DX; Filosi, N; Gaida, GM; Kolodner, RD			A novel mutation avoidance mechanism dependent on S-cerevisiae RAD27 is distinct from DNA mismatch repair	CELL			English	Article							NUCLEOTIDE EXCISION-REPAIR; SIMPLE REPETITIVE DNA; POLYPOSIS-COLI GENE; SACCHAROMYCES-CEREVISIAE; ADENOMATOUS POLYPOSIS; MICROSATELLITE INSTABILITY; COLORECTAL TUMORS; ESCHERICHIA-COLI; P53 GENE; REPLICATION	Mutations in the S. cerevisiae RAD27 (also called RTH1 or YKL510) gene result in a strong mutator phenotype. In this study we show that the majority of the resulting mutations have a structure in which sequences ranging from 5-108 bp flanked by direct repeats of 3-12 bp are duplicated. Such mutations have not been previously detected at high frequency in the mutation spectra of mutator strains. Epistasis analysis indicates that RAD27 does not play a major role in MSH2-dependent mismatch repair. Mutations in RAD27 cause increased rates of mitotic crossing over and are lethal in combination with mutations in RAD51 and RAD52. These observations suggest that the majority of replication errors that accumulate in rad27 strains are processed by double-strand break repair, while a smaller percentage are processed by a mutagenic repair pathway. The duplication mutations seen in rad27 mutants occur both in human tumors and as germline mutations in inherited human diseases.	DANA FARBER CANC INST,CHARLES A DANA DIV HUMAN CANC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School					NCI NIH HHS [CA06516] Funding Source: Medline; NIAID NIH HHS [AI28691] Funding Source: Medline; NIGMS NIH HHS [GM50006] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1994, GENETICS, V137, P19; BAYES M, 1995, HUM MUTAT, V5, P228, DOI 10.1002/humu.1380050307; BLASZYK H, 1994, LANCET, V343, P1195, DOI 10.1016/S0140-6736(94)92403-1; COTTRELL S, 1992, LANCET, V340, P626, DOI 10.1016/0140-6736(92)92169-G; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; ESPOSITO MS, 1990, CURR GENET, V17, P7, DOI 10.1007/BF00313242; FANG WH, 1993, J BIOL CHEM, V268, P11838; GEITZ RD, 1991, YEAST, V7, P253; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; Greenblatt MS, 1996, CANCER RES, V56, P2130; HAMELIN R, 1994, GASTROENTEROLOGY, V107, P1012, DOI 10.1016/0016-5085(94)90225-9; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; Ivanov EL, 1996, GENETICS, V142, P693; JEGO N, 1993, ONCOGENE, V8, P209; JINKSROBERTSON S, 1993, MOL CELL BIOL, V13, P3937, DOI 10.1128/MCB.13.7.3937; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KATABUCHI H, 1995, CANCER RES, V55, P5556; KENNY MK, 1988, J BIOL CHEM, V263, P9801; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; KUZMINOV A, 1995, BIOESSAYS, V17, P733, DOI 10.1002/bies.950170810; Lea D, 1948, J GENET, V49, P264; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Lovett ST, 1996, P NATL ACAD SCI USA, V93, P7120, DOI 10.1073/pnas.93.14.7120; MANIVASAKAM P, 1995, NUCLEIC ACIDS RES, V23, P2799, DOI 10.1093/nar/23.14.2799; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MCGRATH JA, 1995, PRENATAL DIAG, V15, P647, DOI 10.1002/pd.1970150710; MIYAKI M, 1994, CANCER RES, V54, P3011; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; REENAN RAG, 1992, GENETICS, V132, P975; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STEELE DF, 1992, GENETICS, V132, P9; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; TISHKOFF DX, 1995, GENETICS, V139, P495; Tran HT, 1996, GENETICS, V143, P1579; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; WAGA S, 1994, J BIOL CHEM, V269, P10923; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WILLIAMSON MS, 1985, GENETICS, V110, P609; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	64	393	399	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1997	88	2					253	263		10.1016/S0092-8674(00)81846-2	http://dx.doi.org/10.1016/S0092-8674(00)81846-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008166	Bronze			2022-12-01	WOS:A1997WE97000014
J	Cousens, SN; Vynnycky, E; Zeidler, M; Will, RG; Smith, PG				Cousens, SN; Vynnycky, E; Zeidler, M; Will, RG; Smith, PG			Predicting the CJD epidemic in humans	NATURE			English	Editorial Material									WESTERN GEN HOSP,NATL CJD SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	Cousens, SN (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		smith, peter/ABH-9627-2020	smith, peter/0000-0003-0080-7560				Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; Brookmeyer R, 1996, BIOMETRICS, V52, P781, DOI 10.2307/2533042; BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; *HOUS COMM, 1996, STAT UK SPONG ENC AD; KLITZMAN R L, 1984, Neuroepidemiology, V3, P3, DOI 10.1159/000110837; MARION SA, 1993, STAT MED, V12, P617, DOI 10.1002/sim.4780120702; SARTWELL PE, 1950, AM J HYG, V51, P310, DOI 10.1093/oxfordjournals.aje.a119397; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	10	176	181	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1997	385	6613					197	198		10.1038/385197a0	http://dx.doi.org/10.1038/385197a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000063				2022-12-01	WOS:A1997WC71100018
J	Jenuwein, T; Forrester, WC; FernandezHerrero, LA; Laible, G; Dull, M; Grosschedl, R				Jenuwein, T; Forrester, WC; FernandezHerrero, LA; Laible, G; Dull, M; Grosschedl, R			Extension of chromatin accessibility by nuclear matrix attachment regions	NATURE			English	Article							CHROMOSOMAL LOOP ANCHORAGE; IMMUNOGLOBULIN-MU GENE; LOCUS-CONTROL REGION; TRANSGENIC MICE; ENHANCER; TRANSCRIPTION; SEQUENCES; ELEMENTS; DOMAINS	Transcription of the variable region of the rearranged immunoglobulin mu gene is dependent on an enhancer sequence situated within one of the introns of the gene, Experiments with transgenic mice have shown that activation of the promoter controlling this transcription also requires the matrix-attachment regions (MARs) that flank the intronic enhancer(1), As this mu gene enhancer can establish local areas of accessible chromatin(2), we investigated whether the MARs can extend accessibility to more distal positions, We eliminated interactions between enhancer- and promoter-bound factors by linking mu enhancer/MAR fragments to the binding sites for bacteriophage RNA polymerases that were either dose to or one kilobase distal to the enhancer. The mu enhancer alone mediated chromatin accessibility at the proximal site but required a flanking MAR to confer accessibility upon the distal promoter, This long-range accessibilty correlates with extended demethylation of the gene construct but not with whether it is being actively transcribed, MARs thus collaborate with the mu enhancer to generate an extended domain of accessible chromatin.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; INST MOL PATHOL,A-1030 VIENNA,AUSTRIA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Fernández-Herrero, Luis Ángel/AAA-2583-2021; Fernández, Luis Ángel/D-2713-2009	Fernández-Herrero, Luis Ángel/0000-0001-5920-0638; Fernández, Luis Ángel/0000-0001-5920-0638; Laible, Goetz/0000-0003-1048-2819				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ARONOW BJ, 1995, MOL CELL BIOL, V15, P1123; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; CULLEN BR, 1992, AIDS RES HUM RETROV, V8, P387, DOI 10.1089/aid.1992.8.387; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DILLON N, 1994, CURR OPIN GENET DEV, V4, P260, DOI 10.1016/S0959-437X(05)80053-X; ERNST P, 1995, IMMUNITY, V2, P427, DOI 10.1016/1074-7613(95)90024-1; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FERSTENSTEIN R, 1996, SCIENCE, V271, P1123; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; JENUWEIN T, 1993, GENE DEV, V7, P2016, DOI 10.1101/gad.7.10.2016; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; McArthur M, 1996, EMBO J, V15, P1705, DOI 10.1002/j.1460-2075.1996.tb00516.x; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; YISRAELI J, 1984, DNA METHYLATION BIOC, P353; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	30	219	226	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1997	385	6613					269	272		10.1038/385269a0	http://dx.doi.org/10.1038/385269a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000077				2022-12-01	WOS:A1997WC71100052
J	Welch, MD; Iwamatsu, A; Mitchison, TJ				Welch, MD; Iwamatsu, A; Mitchison, TJ			Actin polymerization is induced by Arp2/3 protein complex at the surface of Listeria monocytogenes	NATURE			English	Article							PROLINE-RICH REGION; END-BOUND INSERTIN; MAMMALIAN-CELLS; BARBED ENDS; FILAMENTS; MOTILITY; PURIFICATION; ACANTHAMOEBA; MOVEMENT; PROFILIN	The pathogenic bacterium Listeria monocytogenes is capable of directed movement within the cytoplasm of infected host cells. Propulsion is thought to be driven by actin polymerization at the bacterial ceil surface(1,2), and moving bacteria leave in their wake a tail of actin filaments(3). Determining the mechanism by which L. monocytogenes polymerizes actin may aid the understanding of how actin polymerization is controlled in the cell. Actin assembly by L. monocytogenes requires the bacterial surface protein ActA(4,5) and protein components present in host cell cytoplasm. We have purified an eight-polypeptide complex that possesses the properties of the host-cell actin polymerization factor. The pure complex is sufficient to initiate ActA-dependent actin polymerization at the surface oft. monocytogenes, and is required to mediate actin tail formation and motility. Two subunits of this protein complex are actin-related proteins (ARPs) belonging to the Arp2 and Arp3 subfamilies. The Arp3 subunit localizes to the surface of stationary bacteria and the tails of motile bacteria in tissue culture cells infected with L. monocytogenes; this is consistent with a role for the complex in promoting actin assembly in vivo. The activity and subunit composition of the Arp2/3 complex suggests that it forms a template that nucleates actin polymerization.	KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA,JAPAN	Kirin Brewery Company Limited	Welch, MD (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143, USA.							BRUNDAGE RA, 1993, P NATL ACAD SCI USA, V90, P11890, DOI 10.1073/pnas.90.24.11890; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Frankel S, 1996, CURR OPIN CELL BIOL, V8, P30, DOI 10.1016/S0955-0674(96)80045-7; GAERTNER A, 1991, J MUSCLE RES CELL M, V12, P27, DOI 10.1007/BF01781171; HIRANO H, 1990, ELECTROPHORESIS, V11, P573, DOI 10.1002/elps.1150110708; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; LEIMEISTERWACHTER M, 1989, INFECT IMMUN, V57, P2350; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; McCollum D, 1996, EMBO J, V15, P6438, DOI 10.1002/j.1460-2075.1996.tb01035.x; MICHAILLE JJ, 1995, GENE, V154, P205, DOI 10.1016/0378-1119(94)00865-P; Moreau V, 1996, J CELL BIOL, V134, P117, DOI 10.1083/jcb.134.1.117; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; RUHNAU K, 1989, J MOL BIOL, V210, P141, DOI 10.1016/0022-2836(89)90296-9; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; SAWIN KE, 1992, J CELL SCI, V101, P303; SCHAIER SR, 1992, METHOD ENZYMOL, V215, P58; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; TANAKA T, 1992, BIOCHEM BIOPH RES CO, V187, P1022, DOI 10.1016/0006-291X(92)91299-6; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	31	479	488	0	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1997	385	6613					265	269		10.1038/385265a0	http://dx.doi.org/10.1038/385265a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000076				2022-12-01	WOS:A1997WC71100051
J	Choo, V				Choo, V			Understanding acute leukaemias	LANCET			English	Editorial Material																		Dolk H, 1997, AM J EPIDEMIOL, V145, P10, DOI 10.1093/oxfordjournals.aje.a009026; Dolk H, 1997, AM J EPIDEMIOL, V145, P1, DOI 10.1093/oxfordjournals.aje.a009025	2	0	0	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					74	74		10.1016/S0140-6736(05)60882-3	http://dx.doi.org/10.1016/S0140-6736(05)60882-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996416				2022-12-01	WOS:A1997WB80000007
J	Ho, YS; Swenson, L; Derewenda, U; Serre, L; Wei, YY; Dauter, Z; Hattori, M; Adachi, T; Aoki, J; Arai, H; Inoue, K; Derewenda, ZS				Ho, YS; Swenson, L; Derewenda, U; Serre, L; Wei, YY; Dauter, Z; Hattori, M; Adachi, T; Aoki, J; Arai, H; Inoue, K; Derewenda, ZS			Brain acetylhydrolase that inactivates platelet-activating factor is a G-protein-like trimer	NATURE			English	Article							DIEKER LISSENCEPHALY GENE; NEURONAL MIGRATION; NERVOUS-SYSTEM; LIS-1 GENE; SUBUNIT; EXPRESSION; MESSENGER; PURIFICATION; PRODUCT	THE platelet-activating factor PAF (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a potent lipid first messenger active in general cell activation, fertilization, inflammatory and allergic reactions, asthma, HIV pathogenesis, carcinogenesis, and apoptosis(1-5). There is substantial evidence that PAF is involved in intracellular signalling, but the pathways are poorly understood. Inactivation of PAF is carried out by specific intra- and extracellular acetylhydrolases(6) (PAF-AHs), a subfamily of phospholipases A2 that remove the sn-2 acetyl group, Mammalian brain contains at least three intracellular isoforms, of which PAF-AH(Ib) is the best characterized(7-9). This isoform contains a heterodimer of two homologous catalytic subunits alpha(1) and alpha(2), each of relative molecular mass 26K, and a non-catalytic 45K beta-subunit, a homologue of the beta-subunit of trimeric G proteins. We now report the crystal structure of the bovine alpha(1) subunit of PAF-AH(Ib) at 1.7 Angstrom resolution in complex with a reaction product, acetate, The tertiary fold of this protein is closely reminiscent of that found in p21(ras) and other GTPases. The active site is made up of a trypsin-like triad of Ser 47, His 195 and Asp 192, Thus, the intact PAF-AH(Ib) molecule is an unusual G-protein-like (alpha(1)/alpha(2))beta trimer.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MOL PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22906; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA; EUROPEAN MOL BIOL LAB,OUTSTN,D-22603 HAMBURG,GERMANY; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT HLTH CHEM,BUNKYO KU,TOKYO 113,JAPAN	University of Virginia; University of Alberta; European Molecular Biology Laboratory (EMBL); University of Tokyo			Hattori, Mitsuharu/F-3859-2010	Hattori, Mitsuharu/0000-0002-0503-4969; Aoki, Junken/0000-0001-9435-1896; SERRE, laurence/0000-0002-6794-1492				ADACHI H, 1995, BIOCHEM BIOPH RES CO, V214, P180, DOI 10.1006/bbrc.1995.2272; BAZAN NG, 1995, NEUROCHEM INT, V26, P435, DOI 10.1016/0197-0186(94)00138-K; BENNETT SAL, 1993, CARCINOGENESIS, V14, P1289, DOI 10.1093/carcin/14.7.1289; DEREWENDA ZS, 1995, J AM CHEM SOC, V117, P2104, DOI 10.1021/ja00112a029; DEREWENDA ZS, 1994, ADV PROTEIN CHEM, V45, P1; ELAZZOUZI B, 1993, BIOCHEM BIOPH RES CO, V190, P320, DOI 10.1006/bbrc.1993.1050; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KUMAR R, 1988, BIOCHIM BIOPHYS ACTA, V963, P375, DOI 10.1016/0005-2760(88)90304-9; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; MIZUGUCHI M, 1995, AM J PATHOL, V147, P1142; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OFLAHERTY JT, 1989, PLATELET ACTIVATING, P117; PANETTA T, 1987, BIOCHEM BIOPH RES CO, V149, P580, DOI 10.1016/0006-291X(87)90407-4; REINER O, 1995, J NEUROSCI, V15, P3730; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; VENABLE ME, 1993, J LIPID RES, V34, P691; WANG DS, 1995, BIOCHEM BIOPH RES CO, V209, P622, DOI 10.1006/bbrc.1995.1545; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	30	160	163	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					89	93		10.1038/385089a0	http://dx.doi.org/10.1038/385089a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985254				2022-12-01	WOS:A1997WA73100057
J	Thompson, DC; Rivara, FP; Thompson, RS				Thompson, DC; Rivara, FP; Thompson, RS			Effectiveness of bicycle safety helmets in preventing head injuries - A case-control study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CYCLE HELMETS; COLLISIONS; AUSTRALIA; CHILDREN; VICTORIA	Objectives.-To examine the protective effectiveness of bicycle helmets in 4 different age groups of bicyclists, in crashes involving motor vehicles, and by helmet type and certification standards. Research Design.-Prospective case-control study Setting.-Emergency departments (EDs) in 7 Seattle, Wash, area hospitals between March 1, 1992, and August 31, 1994. Participants.-Case subjects were all bicyclists treated in EDs for head injuries, all who were hospitalized, and all who died at the scene. Control subjects were bicyclists treated for nonhead injuries. Main Results.-There were 3390 injured bicyclists in the study; 29% of cases and 56% of controls were helmeted. Risk of head injury in helmeted vs unhelmeted cyclists adjusted for age and motor vehicle involvement indicate a protective effect of 69% to 74% for helmets for 3 different categories of head injury: any head injury (odds ratio [OR], 0.31; 95% confidence interval [CI], 0.26-0.37), brain injury (OR, 0.35; 95% CI, 0.25-0.48), or severe brain injury (OR, 0.26; 95% CI, 0.14-0.48). Adjusted ORs for each of 4 age groups (<6 y, 6-12 y, 13-19 y, and greater than or equal to 20 years) indicate similar revels of helmet protection by age (OR range, 0.27-0.40). Helmets were equally effective in crashes involving motor vehicles (OR, 0.31; 95% CI, 0.20-0.48) and those not involving motor vehicles (OR, 0.32; 95% CI, 0.20-0.39). There was no effect modification by age or motor vehicle involvement (P=.7 and P=.3). No significant differences were found for the protective effect of hard-shell, thin-shell, or no-shell helmets (P=.5). Conclusions.-Bicycle helmets, regardless of type, provide substantial protection against head injuries for cyclists or all ages involved in crashes, including crashes involving motor vehicles.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,DEPT PREVENT CARE,SEATTLE,WA 98121	University of Washington; University of Washington Seattle; Group Health Cooperative	Thompson, DC (corresponding author), UNIV WASHINGTON,DEPT PEDIAT,HARBORVIEW INJURY PREVENT & RES CTR,325 9TH AVE,BOX 359960,SEATTLE,WA 98104, USA.							Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BRESLOW NE, 1980, INT AGENCY RES CANC, V32, P190; CAMERON MH, 1994, ACCIDENT ANAL PREV, V26, P325, DOI 10.1016/0001-4575(94)90006-X; COTE TR, 1992, PEDIATRICS, V89, P1216; Henderson M, 1996, EFFECTIVENESS BICYCL; Hillman M, 1993, CYCLE HELMETS CASE; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; MCCARTHY M, 1992, BRIT MED J, V305, P881, DOI 10.1136/bmj.305.6858.881; MCDERMOTT F, 1994, BRIT MED J, V309, P877, DOI 10.1136/bmj.309.6958.877b; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; *NAT CTR HLTH STAT, 1991, DHHS PUBL; PITT WR, 1994, BRIT MED J, V308, P177, DOI 10.1136/bmj.308.6922.177; RIVARA FP, 1994, PEDIATRICS, V93, P567; *SAS I INC, 1989, SASLANG PROC US VERS; SPAITE DW, 1991, J TRAUMA, V31, P1510, DOI 10.1097/00005373-199111000-00008; TEASDALE G, 1974, LANCET, V2, P81; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1974, DOI 10.1001/jama.276.24.1974; THOMPSON DC, 1994, J TRAUMA, V36, P463; THOMPSON DC, IN PRESS INJ PREV; Thompson DC, 1996, EPIDEMIOLOGY SPORTS, P98; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; *TRIAN INC, 1989, TRI CODE 5 0 PERS CO; VULCAN AP, 1992, WORLD J SURG, V16, P389, DOI 10.1007/BF02104437; WACHTEL A, 1994, ITE J, V64, P30; [No title captured]	27	224	225	0	36	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1996	276	24					1968	1973		10.1001/jama.276.24.1968	http://dx.doi.org/10.1001/jama.276.24.1968			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY689	8971066				2022-12-01	WOS:A1996VY68900029
J	Curran, J; Pollard, B				Curran, J; Pollard, B			Beards, academia, and anaesthesia: A controlled study	BRITISH MEDICAL JOURNAL			English	Article									MANCHESTER ROYAL INFIRM,MANCHESTER M13 9WL,LANCS,ENGLAND	University of Manchester	Curran, J (corresponding author), CITY HOSP NOTTINGHAM,NOTTINGHAM NG5 1PB,ENGLAND.							Addis William E., 1954, CATHOLIC DICT; [Anonymous], 2 SAMUEL, V5, P25; BRAUNFALCO O, 1991, DERMATOLOGY, P757; BROWNING DC, 1987, DICT QUOTATIONS PROV; Carcopino J ., 1956, DAILY LIFE ANCIENT R	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1643	1644		10.1136/bmj.313.7072.1643a	http://dx.doi.org/10.1136/bmj.313.7072.1643a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	9011292	Green Published			2022-12-01	WOS:A1996VZ81100053
J	Sheth, BR; Sharma, J; Rao, SC; Sur, M				Sheth, BR; Sharma, J; Rao, SC; Sur, M			Orientation maps of subjective contours in visual cortex	SCIENCE			English	Article							ILLUSORY CONTOURS; RETINOTOPIC ORGANIZATION; CYTOCHROME-OXIDASE; STRIATE CORTEX; CAT; AREA-17; NEURONS; RESPONSES; PATTERNS; KITTENS	Responses to subjective contours in visual cortical areas V1 and V2 in adult cats were investigated by optical imaging of intrinsic signals and single-unit recording. Both V1 and V2 contain maps of the orientation of subjective gratings that have their basis in specific kinds of neuronal responses to subjective orientations. A greater proportion of neurons in V2 than in V1 show a robust response to subjective edges. Through the use of subjective stimuli in which the orientation of the luminance component is invariant, an unmasked V1 response to subjective edges alone can be demonstrated. The data indicate that the processing of subjective contours begins as early as V1 and continues progressively in higher cortical areas.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NEI NIH HHS [EY07023] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBUS K, 1975, EXP BRAIN RES, V24, P159, DOI 10.1007/BF00234061; BONHOEFFER T, 1995, EUR J NEUROSCI, V7, P1973, DOI 10.1111/j.1460-9568.1995.tb00720.x; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BRAVO M, 1988, VISION RES, V28, P861, DOI 10.1016/0042-6989(88)90095-8; DEWEERD P, 1990, BEHAV BRAIN RES, V39, P1, DOI 10.1016/0166-4328(90)90117-W; GREGORY RL, 1972, NATURE, V238, P51, DOI 10.1038/238051a0; GREGORY RL, 1963, NATURE, V199, P678, DOI 10.1038/199678a0; GRINVALD A, 1986, NATURE, V324, P351; GROSOF DH, 1993, NATURE, V365, P550, DOI 10.1038/365550a0; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; HUBEL DH, 1963, J PHYSIOL-LONDON, V165, P559, DOI 10.1113/jphysiol.1963.sp007079; HUMPHREY AL, 1985, J COMP NEUROL, V233, P190, DOI 10.1002/cne.902330204; KAGEYAMA GH, 1986, J COMP NEUROL, V243, P182, DOI 10.1002/cne.902430204; Kanizsa G., 1979, ORG VISION ESSAYS GE, P192; Kanizsa G., 1955, RIV PSICOL, V49, P7; KOENDERINK JJ, 1984, PERCEPTION, V13, P321, DOI 10.1068/p130321; LAMME VAF, 1995, J NEUROSCI, V15, P1605; Leopold DA, 1996, NATURE, V379, P549, DOI 10.1038/379549a0; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P101, DOI 10.1113/jphysiol.1978.sp012490; NELSON S, 1994, SCIENCE, V265, P774, DOI 10.1126/science.8047882; OTSUKA R, 1962, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V203, P212, DOI 10.1007/BF00352744; PAYNE BR, 1990, VISUAL NEUROSCI, V4, P445, DOI 10.1017/S0952523800005204; PRICE DJ, 1985, EXP BRAIN RES, V58, P125; Rao S. C., 1994, Society for Neuroscience Abstracts, V20, P836; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; REDIES C, 1986, EXP BRAIN RES, V61, P469; ROCK I, 1979, PERCEPTION, V8, P665, DOI 10.1068/p080665; Rossi AF, 1996, SCIENCE, V273, P1104, DOI 10.1126/science.273.5278.1104; Schumann F, 1900, Z PSYCHOL PHYSIOL SI, V23, P1; SHERMAN SM, 1982, PHYSIOL REV, V62, P738, DOI 10.1152/physrev.1982.62.2.738; Toth LJ, 1996, P NATL ACAD SCI USA, V93, P9869, DOI 10.1073/pnas.93.18.9869; TUSA RJ, 1979, J COMP NEUROL, V185, P657, DOI 10.1002/cne.901850405; TUSA RJ, 1978, J COMP NEUROL, V177, P213, DOI 10.1002/cne.901770204; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; VONDERHEYDT R, 1989, J NEUROSCI, V9, P1731	35	143	146	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2110	2115		10.1126/science.274.5295.2110	http://dx.doi.org/10.1126/science.274.5295.2110			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953048				2022-12-01	WOS:A1996VY97400058
J	Kurumbail, RG; Stevens, AM; Gierse, JK; McDonald, JJ; Stegeman, RA; Pak, JY; Gildehaus, D; Miyashiro, JM; Penning, TD; Seibert, K; Isakson, PC; Stallings, WC				Kurumbail, RG; Stevens, AM; Gierse, JK; McDonald, JJ; Stegeman, RA; Pak, JY; Gildehaus, D; Miyashiro, JM; Penning, TD; Seibert, K; Isakson, PC; Stallings, WC			Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents	NATURE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN-G/H SYNTHASE; CRYSTAL-STRUCTURE; ASPIRIN	PROSTAGLANDINS and glucocorticoids are potent mediators of inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) exert their effects by inhibition of prostaglandin production. The pharmacological target of NSAIDs is cyclooxygenase (COX, also known as PGH synthase), which catalyses the first committed step in arachidonic-acid metabolism(1,2). Two isoforms of the membrane protein COX are known(3): COX-1, which is constitutively expressed in most tissues, is responsible for the physiological production of prostaglandins(4); and COX-2, which is induced by cytokines, mitogens and endotoxins in inflammatory cells(5), is responsible for the elevated production of prostaglandins during inflammation(6,7). The structure of ovine COX-1 complexed with several NSAIDs has been determined(8-10). Here we report the structures of unliganded murine COX-2 and complexes with flurbiprofen, indomethacin and SC-558, a selective COX-2 inhibitor, determined at 3.0 to 25 Angstrom resolution. These structures explain the structural basis for the selective inhibition of COX-2, and demonstrate some of the conformational changes associated with time-dependent inhibition.	GD SEARLE & CO,SKOKIE,IL 60077	Pfizer	Kurumbail, RG (corresponding author), GD SEARLE & CO,700 CHESTERFIELD PKWY N,ST LOUIS,MO 63198, USA.							BERTENSHAW SR, 1995, BIOORG MED CHEM LETT, V5, P2919, DOI 10.1016/0960-894X(95)00512-R; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; Black WC, 1996, BIOORG MED CHEM LETT, V6, P725, DOI 10.1016/0960-894X(96)00100-X; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DIETZ R, 1988, EUR J BIOCHEM, V171, P320; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GANS KR, 1990, J PHARMACOL EXP THER, V254, P180; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HOOGSTEE.K, 1970, J ORG CHEM, V35, P521, DOI 10.1021/jo00827a057; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KULMACZ RJ, 1985, J BIOL CHEM, V260, P2572; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; Loll PJ, 1996, BIOCHEMISTRY-US, V35, P7330, DOI 10.1021/bi952776w; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MASTENER JL, 1994, P NATL ACAD SCI USA, V91, P3228; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; OTTO JC, 1995, J LIPID MEDIAT CELL, V12, P139, DOI 10.1016/0929-7855(95)00015-I; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SMITH WL, 1994, MET IONS BIOL SYST, V30, P163; VAN JR, 1971, NATURE-NEW BIOL, V231, P232; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046	30	1436	1491	2	124	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 19	1996	384	6610					644	648		10.1038/384644a0	http://dx.doi.org/10.1038/384644a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VZ296	8967954				2022-12-01	WOS:A1996VZ29600034
J	Michels, KB; Trichopoulos, D; Robins, JM; Rosner, BA; Manson, JE; Hunter, DJ; Colditz, GA; Hankinson, SE; Speizer, FE; Willett, WC				Michels, KB; Trichopoulos, D; Robins, JM; Rosner, BA; Manson, JE; Hunter, DJ; Colditz, GA; Hankinson, SE; Speizer, FE; Willett, WC			Birthweight as a risk factor for breast cancer	LANCET			English	Article							BIRTH-WEIGHT; GESTATIONAL-AGE; MAMMARY-GLAND; CARCINOGENESIS; DIFFERENTIATION; SUSCEPTIBILITY; HYPOTHESIS; PATTERNS	Background The mammary gland is largely undifferentiated before birth and may be particularly susceptible to intrauterine influences that could increase the risk of cancer through acceleration of cell proliferation or other pregnancy-related processes. Studies of migrant populations, animal data, and limited epidemiological evidence suggest that breast cancer may originate in utero. In a nested case-control study we assessed whether birthweight and other perinatal factors are associated with risk of breast cancer. Methods This case-control study was nested within the cohorts of the two Nurses' Health Studies. We used self-administered questionnaires to obtain information from the mothers of 582 nurses with. invasive breast cancer and the mothers of 1569 nurses who did not have breast cancer (controls). Information on risk factors for breast cancer during adulthood were obtained from the nurses; multiple logistic regression analysis adjusted for these risk factors. Findings Birthweight was a significant predictor of breast-cancer risk. With women who weighed 4000 g or more at birth as the reference category, the adjusted odds ratios for breast cancer were 0.86 (95% CI 0.59-1.25) for birthweights of 3500-3999 g, 0.68 (0.48-0.97) for birthweights of 3000-3499 g, 0.66 (0.45-0.98) for birthweights of 2500-2999 g, and 0.55 (0.33-0.93) for birthweights below 2500 g (p for trend 0.004). Prematurity was not significantly associated with risk of breast cancer. Interpretation Birthweight is significantly associated with breast-cancer risk, which suggests that intrauterine factors or processes affect the risk of breast cancer in the offspring, High concentrations of pregnancy oestrogens may have an important role in breast carcinogenesis, but other pregnancy hormones or intrauterine factors may also be involved.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; CHANNING LABS,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT MED,DIV PREVENT MED,BOSTON,MA; BRIGHAM & WOMENS HOSP,BOSTON,MA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Michels, KB (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356, CA 55075, CA 50385] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050385, R37CA040356, R01CA040356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adami HO, 1995, MUTAT RES-FUND MOL M, V333, P29, DOI 10.1016/0027-5107(95)00128-X; ANBAZHAGAN R, 1994, EUR J CANCER, V30A, P1, DOI 10.1016/S0959-8049(05)80006-1; BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116; CHA RS, 1994, P NATL ACAD SCI USA, V91, P3749, DOI 10.1073/pnas.91.9.3749; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; COLE P, 1969, LANCET, V1, P604; DALING JR, 1984, J NATL CANCER I, V72, P1039; EKBOM A, 1995, INT J CANCER, V61, P177, DOI 10.1002/ijc.2910610206; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; GERHARD I, 1987, EUR J OBSTET GYN R B, V26, P313, DOI 10.1016/0028-2243(87)90129-8; GERHARD I, 1986, J PERINAT MED, V14, P279, DOI 10.1515/jpme.1986.14.5.279; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; HAENSZEL W, 1968, JNCI-J NATL CANCER I, V40, P43; Hanai A, 1982, Natl Cancer Inst Monogr, V62, P3; JANERICH DT, 1994, MED HYPOTHESES, V43, P105, DOI 10.1016/0306-9877(94)90059-0; LEMARCHAND L, 1988, BRIT J CANCER, V57, P437, DOI 10.1038/bjc.1988.99; MACMAHON B, 1962, J NATL CANCER I, V28, P231; MCFADYEN IR, 1982, BRIT J OBSTET GYNAEC, V89, P994, DOI 10.1111/j.1471-0528.1982.tb04653.x; Petridou E, 1990, Epidemiology, V1, P247, DOI 10.1097/00001648-199005000-00011; Rosner B., 2011, FUNDAMENTALS BIOSTAT, P352; Russo J., 1987, The mammary gland. Development, regulation, and function., P67; RUSSO J, 1980, CANCER RES, V40, P2677; RUSSO J, 1979, AM J PATHOL, V96, P721; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; Sanderson M, 1996, EPIDEMIOLOGY, V7, P34, DOI 10.1097/00001648-199601000-00007; SEIDMAN DS, 1987, BRIT J OBSTET GYNAEC, V94, P731, DOI 10.1111/j.1471-0528.1987.tb03717.x; TIBBLIN G, 1995, EPIDEMIOLOGY, V6, P423, DOI 10.1097/00001648-199507000-00017; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; Troy LM, 1996, INT J EPIDEMIOL, V25, P122, DOI 10.1093/ije/25.1.122; WANG XB, 1994, INT J EPIDEMIOL, V23, P119, DOI 10.1093/ije/23.1.119; ZIEGLER RG, 1993, JNCI-J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819	32	310	314	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1542	1546		10.1016/S0140-6736(96)03102-9	http://dx.doi.org/10.1016/S0140-6736(96)03102-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950880				2022-12-01	WOS:A1996VX02300008
J	Shibata, D; Reale, MA; Lavin, P; Silverman, M; Fearon, ER; Steele, G; Jessup, JM; Loda, M; Summerhayes, IC				Shibata, D; Reale, MA; Lavin, P; Silverman, M; Fearon, ER; Steele, G; Jessup, JM; Loda, M; Summerhayes, IC			The DCC protein and prognosis in colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUPPRESSOR GENE DCC; FLUOROURACIL PLUS LEVAMISOLE; FREQUENT LOSS; ADJUVANT THERAPY; COLON-CANCER; CHROMOSOME 18Q; CARCINOMA GENE; ALLELIC LOSS; EXPRESSION; HETEROZYGOSITY	Background Allelic loss of chromosome 18q predicts a poor outcome in patients with stage II colorectal cancer. Although the specific gene inactivated by this allelic loss has not been elucidated, the DCC (deleted in colorectal cancer) gene is a candidate. We investigated whether the expression of the DCC protein in tumor cells is a prognostic marker in colorectal carcinoma. Methods The expression of DCC was evaluated immunohistochemically in 132 paraffin-embedded samples from patients with curatively resected stage II or III colorectal carcinomas. The Cox proportional-hazards model was used to adjust for covariates including age, sex, tumor site, degree of tumor differentiation, and use of adjuvant therapy. Results The expression of DCC was a strong positive predictive factor for survival in both stage II and stage III colorectal carcinomas. In patients with stage II disease whose tumors expressed DCC, the five-year survival rate was 94.3 percent, whereas in patients with DCC-negative tumors, the survival rate was 61.6 percent (P<0.001). In patients with stage III disease, the respective survival rates were 59.3 percent and 33.2 percent (P = 0.03). Conclusions DCC is a prognostic marker in patients with stage II or stage III colorectal cancer. In stage II colorectal carcinomas, the absence of DCC identifies a subgroup of patients with lesions that behave like stage III cancers. These findings may thus have therapeutic implications in this group of (C) 1996, Massachusetts Medical Society.	HARVARD UNIV, NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT SURG, LAB CANC BIOL, BOSTON, MA 02215 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02215 USA; YALE UNIV, SCH MED, SECT MED ONCOL, NEW HAVEN, CT USA; BOSTON BIOSTAT RES FDN, FRAMINGHAM, MA USA; LAHEY HITCHCOCK MED CTR, DEPT PATHOL, BURLINGTON, MA USA; UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, DIV MED & MOL GENET, ANN ARBOR, MI 48109 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Yale University; Lahey Hospital & Medical Center; University of Michigan System; University of Michigan					NCI NIH HHS [CA-44704] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1984, NEW ENGL J MED, V310, P737; BRABANT G, 1993, CANCER RES, V53, P4987; BREWSTER SF, 1994, J UROLOGY, V151, P1073, DOI 10.1016/S0022-5347(17)35186-8; BREWSTER SF, 1994, BRIT J CANCER, V70, P697, DOI 10.1038/bjc.1994.376; BROWN RW, 1995, MODERN PATHOL, V8, P515; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; Cordon-Cardo C, 1994, Important Adv Oncol, P71; COX DR, 1972, J R STAT SOC B, V34, P187; ENOMOTO T, 1995, BRIT J CANCER, V71, P462, DOI 10.1038/bjc.1995.94; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; FROGGATT NJ, 1995, J CANCER RES CLIN, V121, P7, DOI 10.1007/BF01202723; GAO X, 1993, CANCER RES, V53, P2723; GIMA T, 1994, INT J CANCER, V57, P480, DOI 10.1002/ijc.2910570407; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOHNE MW, 1992, CANCER RES, V52, P2616; IACOPETTA B, 1994, EUR J CANCER, V30A, P664, DOI 10.1016/0959-8049(94)90541-X; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASHIWABA M, 1995, VIRCHOWS ARCH, V426, P441; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; KODNER IJ, 1994, PRINCIPLES SURG, P1191; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; LUMADUE JA, 1995, SURG CLIN N AM, V75, P845, DOI 10.1016/S0039-6109(16)46731-9; MIYAKE K, 1994, LEUKEMIA LYMPHOMA, V16, P13, DOI 10.3109/10428199409114135; MIYAKE K, 1993, BLOOD, V82, P927; MIYAKE S, 1994, CANCER RES, V54, P3007; MOERTEL CG, 1995, J CLIN ONCOL, V13, P2936, DOI 10.1200/JCO.1995.13.12.2936; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; MURTY VVVS, 1994, ONCOGENE, V9, P3227; NARAYANAN R, 1992, ONCOGENE, V7, P553; OCONNELL MJ, 1992, CANCER-AM CANCER SOC, V70, P1732, DOI 10.1002/1097-0142(19920915)70:4+<1732::AID-CNCR2820701614>3.0.CO;2-#; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; REALE MA, 1994, CANCER RES, V54, P4493; SCHECK AC, 1993, CANCER RES, V53, P5605; Shibata David, 1995, Surgical Forum, V46, P526; TURLEY H, 1995, CANCER RES, V55, P5628; UCHINO S, 1992, CANCER RES, V52, P3099; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879	46	238	247	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1996	335	23					1727	1732		10.1056/NEJM199612053352303	http://dx.doi.org/10.1056/NEJM199612053352303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW795	8929264				2022-12-01	WOS:A1996VW79500003
J	Nightingale, SL				Nightingale, SL			Warning on severe renal impairment with use of cidofovir injection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1710	1710						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940307				2022-12-01	WOS:A1996VV56600010
J	Mena, M; Ambrose, BA; Meeley, RB; Briggs, SP; Yanofsky, MF; Schmidt, RJ				Mena, M; Ambrose, BA; Meeley, RB; Briggs, SP; Yanofsky, MF; Schmidt, RJ			Diversification of C-function activity in maize flower development	SCIENCE			English	Article							FLORAL HOMEOTIC GENES; ZEA-MAYS; ARABIDOPSIS; SEPARATION	The Arabidopsis gene AGAMOUS is required for male and female reproductive organ development and for floral determinacy. Reverse genetics allowed the isolation of a transposon-induced mutation in ZAG1, the maize homolog of AGAMOUS. ZAG1 mutants exhibited a loss of determinacy, but the identity of reproductive organs was largely unaffected. This suggested a redundancy in maize sex organ specification that led to the identification and cloning of a second AGAMOUS homolog, ZMM2, that has a pattern of expression distinct from that of ZAG1. C-function organ identity in maize (as defined by the A, B, C model of floral organ development) may therefore be orchestrated by two closely related genes, ZAG1 and ZMM2, with overlapping but nonidentical activities.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOL GENET, LA JOLLA, CA 92093 USA; PIONEER HI BRED INT INC, DEPT BIOTECHNOL RES, JOHNSTON, IA 50131 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; DuPont; Pioneer Hi-Bred International, Inc.			Mena, Montaña/AAB-1153-2019	Mena, Montaña/0000-0001-7521-1644				BENSEN RJ, 1995, PLANT CELL, V7, P75, DOI 10.1105/tpc.7.1.75; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; CHENG PC, 1983, AM J BOT, V70, P450, DOI 10.2307/2443252; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; Davies B, 1994, Results Probl Cell Differ, V20, P235; GOODMAN MM, 1980, GENETICS, V96, P697; HELENTJARIS T, 1989, GENETICS, V118, P6442; KIESSELBACH TA, 1949, U NEBR AGR EXP STN R, V161; MA H, 1994, GENE DEV, V8, P745, DOI 10.1101/gad.8.7.745; MANDEL A, UNPUB; Mena M, 1995, PLANT J, V8, P845, DOI 10.1046/j.1365-313X.1995.8060845.x; MIZUKAMI Y, 1995, PLANT MOL BIOL, V28, P767, DOI 10.1007/BF00042064; Riechmann JL, 1996, P NATL ACAD SCI USA, V93, P4793, DOI 10.1073/pnas.93.10.4793; SCHMIDT RJ, 1993, PLANT CELL, V5, P729, DOI 10.1105/tpc.5.7.729; SIEBURTH LE, 1995, PLANT CELL, V7, P1249, DOI 10.1105/tpc.7.8.1249; THEISSEN G, 1995, GENE, V156, P155, DOI 10.1016/0378-1119(95)00020-7; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WENDEL JF, 1986, THEOR APPL GENET, V72, P178, DOI 10.1007/BF00266990; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123	22	240	258	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1537	1540		10.1126/science.274.5292.1537	http://dx.doi.org/10.1126/science.274.5292.1537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929416				2022-12-01	WOS:A1996VV77500051
J	Nozette, S; Lichtenberg, CL; Spudis, P; Bonner, R; Ort, W; Malaret, E; Robinson, M; Shoemaker, EM				Nozette, S; Lichtenberg, CL; Spudis, P; Bonner, R; Ort, W; Malaret, E; Robinson, M; Shoemaker, EM			The Clementine bistatic radar experiment	SCIENCE			English	Article							OUTER PLANET SATELLITES; GREENLAND ICE-SHEET; COHERENT-BACKSCATTER; MOON; MERCURY; STABILITY; MODEL; POLARIZATION; GANYMEDE; CRATERS	During the Clementine 1 mission, a bistatic radar experiment measured the magnitude and polarization of the radar echo versus bistatic angle, beta, for selected lunar areas. Observations of the lunar south pole yield a same-sense polarization enhancement around beta = 0. Analysis shows that the observed enhancement is localized to the permanently shadowed regions of the lunar south pole. Radar observations of periodically solar-illuminated lunar surfaces, including the north pole, yielded no such enhancement. A probable explanation for these differences is the presence of low-loss volume scatterers, such as water ice, in the permanently shadowed region at the south pole.	USN,RES LAB,WASHINGTON,DC 20375; LUNAR & PLANETARY INST,HOUSTON,TX 77058; PROTASIS INC,ALEXANDRIA,VA 22314; APPL COHERENT TECHNOL,HERNDON,VA 22070; US GEOL SURVEY,FLAGSTAFF,AZ 86001	United States Department of Defense; United States Navy; Naval Research Laboratory; United States Department of the Interior; United States Geological Survey	Nozette, S (corresponding author), USAF,PHILLIPS LAB,SPACE EXPT DIRECTORATE,711 N FAYETTE ST,ALEXANDRIA,VA 22314, USA.							ARNOLD JR, 1979, J GEOPHYS RES, V84, P5659, DOI 10.1029/JB084iB10p05659; BUTLER BJ, 1993, J GEOPHYS RES-PLANET, V98, P15003, DOI 10.1029/93JE01581; CAMPBELL DB, 1978, ICARUS, V34, P254, DOI 10.1016/0019-1035(78)90166-5; ESCHLEMAN VR, 1986, SCIENCE, V234, P587, DOI 10.1126/science.234.4776.587; Eternad S., 1987, PHYS REV LETT, V59, P1420; Evans J.V., 1968, RADAR ASTRONOMY; GOLDSTEIN RM, 1980, SCIENCE, V207, P179, DOI 10.1126/science.207.4427.179; GORODNICHEV EE, 1990, PHYS LETT A, V144, P48, DOI 10.1016/0375-9601(90)90047-R; HAPKE B, 1990, ICARUS, V88, P407, DOI 10.1016/0019-1035(90)90091-M; HAPKE B, 1991, NATURE, V352, P46, DOI 10.1038/352046a0; HARMON JK, 1994, NATURE, V369, P213, DOI 10.1038/369213a0; INGERSOLL AP, 1992, ICARUS, V100, P40, DOI 10.1016/0019-1035(92)90016-Z; MISHCHENKO MI, 1992, ASTROPHYS SPACE SCI, V194, P327, DOI 10.1007/BF00644001; MISHCHENKO MI, 1992, J OPT SOC AM A, V9, P978, DOI 10.1364/JOSAA.9.000978; MISHCHENKO MI, 1992, EARTH MOON PLANETS, V58, P127, DOI 10.1007/BF00054650; MUHLEMAN DO, 1991, SCIENCE, V253, P1508, DOI 10.1126/science.253.5027.1508; NOZETTE S, 1994, SCIENCE, V266, P1835, DOI 10.1126/science.266.5192.1835; OSTRO SJ, 1990, ICARUS, V85, P335, DOI 10.1016/0019-1035(90)90121-O; OSTRO SJ, 1982, SATELLITES JUPITER; PAIGE DA, 1992, SCIENCE, V258, P643, DOI 10.1126/science.258.5082.643; PETERS KJ, 1992, PHYS REV B, V46, P801, DOI 10.1103/PhysRevB.46.801; RIGNOT E, 1995, J GEOPHYS RES-PLANET, V100, P9389, DOI 10.1029/95JE00485; RIGNOT EJ, 1993, SCIENCE, V261, P1710, DOI 10.1126/science.261.5129.1710; SALVAIL JR, 1994, ICARUS, V111, P441, DOI 10.1006/icar.1994.1155; SHOEMAKER EM, 1994, SCIENCE, V266, P1851, DOI 10.1126/science.266.5192.1851; SIMPSON RA, 1993, IEEE T GEOSCI REMOTE, V31, P465, DOI 10.1109/36.214923; SLADE MA, 1992, SCIENCE, V258, P635, DOI 10.1126/science.258.5082.635; Spudis P.D., 1993, GEOLOGY MULTIRING IM; SPUDIS PD, 1994, SCIENCE, V266, P1848, DOI 10.1126/science.266.5192.1848; SPUDIS PD, 1995, LUNAR PLANET SCI, V26, P1339; STACY NJS, 1993, THESIS CORNELL U; Tsang L., 1985, THEORY MICROWAVE REM; WATSON K, 1961, J GEOPHYS RES, V66, P3033, DOI 10.1029/JZ066i009p03033; ZUBER MT, 1994, SCIENCE, V266, P1839, DOI 10.1126/science.266.5192.1839	34	253	274	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1495	1498		10.1126/science.274.5292.1495	http://dx.doi.org/10.1126/science.274.5292.1495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929403	Green Submitted			2022-12-01	WOS:A1996VV77500038
J	Davies, J; Hey, E; Reid, W; Young, G				Davies, J; Hey, E; Reid, W; Young, G			Prospective regional study of planned home births	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; GENERAL-PRACTITIONER; OBSTETRICS; DELIVERY; AUDIT; CARE; UNIT	Objective-To collect data from a cohort of women requesting a home birth and examine the experience and outcome of pregnancy, the indications for hospital transfer, and the attitudes of mothers, midwives, and general practitioners. Design-Follow up study with anonymised postal questionnaires. Setting-Northern Regional Health Authority area. Subjects-The 256 women resident in the Northern region who expected to deliver in 1993 and whose request for a home birth became known to one of the local supervisors of midwives. Limited cross validating information was also collected retrospectively on all other women delivering a baby outside hospital in 1993. Main outcome measures-Rate of and reason for transferred care; maternal, midwifery, and general practitioner views; perinatal outcome. Results-Five women miscarried, leaving 251 in the study. Of these, 142 (57%) delivered at home. There were 17 (7%) caesarean sections but no perinatal deaths. General practitioners had reservations about half of the booking requests. Two thirds of the women thought they had not been offered any option about place of birth, 74 (29%) were referred to hospital for delivery before the onset of labour, and 35 (14%) were referred to hospital during labour. Intrapartum transfers were uneventful, and half the mothers commented spontaneously that they valued having spent even part of their labour at home. Conclusions-Home birth is valued for its family setting. General practitioners' support is sought and influential but uncommon, possibly because of a lack of understanding of the of the midwife and general practitioner.	MED SCH NEWCASTLE UPON TYNE,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; CUMBERLAND INFIRM,CARLISLE CA2 7HY,CUMBERLAND,ENGLAND; TEMPLE SOWERBY,CUMBRIA CA10 1RZ,ENGLAND	Newcastle University - UK	Davies, J (corresponding author), MATERN SURVEY OFF,25 CLAREMONT PL,NEWCASTLE TYNE NE2 4AA,TYNE & WEAR,ENGLAND.							Baird AG, 1996, BRIT MED J, V312, P223; BROWN DJ, 1994, BRIT MED J, V309, P777, DOI 10.1136/bmj.309.6957.777; CAMPBELL R, 1990, BRIT MED J, V301, P1103, DOI 10.1136/bmj.301.6760.1103-c; CAMPBELL R, 1994, TO BE BORN DEBATE EV; CHAMBERLAIN G, 1991, BRIT J OBSTET GYNAEC, V98, P1067, DOI 10.1111/j.1471-0528.1991.tb15355.x; CHAMBERLAIN G, 1994, FUTURE MATERNITY SER, P298; CHAPMAN MG, 1986, BRIT J OBSTET GYNAEC, V93, P182, DOI 10.1111/j.1471-0528.1986.tb07884.x; CUNNINGHAM JD, 1993, SOC SCI MED, V36, P475, DOI 10.1016/0277-9536(93)90409-W; Department of Health, 1993, CHANGING CHILDBIRTH; FORD C, 1991, BRIT MED J, V303, P1517, DOI 10.1136/bmj.303.6816.1517; HUNDLEY VA, 1994, BRIT MED J, V309, P1400, DOI 10.1136/bmj.309.6966.1400; KITZINGER S, 1978, PLACE BIRTH STUDY EN; MACVICAR J, 1993, BRIT J OBSTET GYNAEC, V100, P316, DOI 10.1111/j.1471-0528.1993.tb12972.x; MARSH BT, 1989, BRIT MED J, V298, P1313, DOI 10.1136/bmj.298.6683.1313; MARSH GN, 1985, BRIT MED J, V290, P901, DOI 10.1136/bmj.290.6472.901; MARSH GN, 1989, BRIT MED J, V298, P1077, DOI 10.1136/bmj.298.6680.1077; MARSH GN, 1989, BRIT MED J, V298, P1579, DOI 10.1136/bmj.298.6687.1579; MATTHEWS AEB, 1975, HLTH TRENDS, V7, P69; *NO REG PER MORT S, 1996, BRIT MED J, V313, P1306; O'Brien M, 1978, J R Coll Gen Pract, V28, P460; *OFF NAT STAT, BIRTH STAT; *PER MORT SURV COO, 1991, COLL SURV PER LAT NE; PRENTICE A, 1989, BRIT MED J, V299, P1090, DOI 10.1136/bmj.299.6707.1090; PRENTICE A, 1989, BRIT MED J, V299, P1402; SCHNEIDER D, 1986, SOC SCI MED, V23, P1011, DOI 10.1016/0277-9536(86)90258-3; SHEARER JML, 1985, BRIT MED J, V291, P1478, DOI 10.1136/bmj.291.6507.1478; SODERSTROM B, 1990, CAN MED ASSOC J, V142, P963; Strauss A., 1987, QUALITATIVE ANAL SOC; YOUNG G, 1987, BRIT MED J, V294, P744, DOI 10.1136/bmj.294.6574.744	29	60	60	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1996	313	7068					1302	1306						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV153	8942691				2022-12-01	WOS:A1996VV15300025
J	ChoiLundberg, DL; Lin, Q; Chang, YN; Chiang, YL; Hay, CM; Mohajeri, H; Davidson, BL; Bohn, MC				ChoiLundberg, DL; Lin, Q; Chang, YN; Chiang, YL; Hay, CM; Mohajeri, H; Davidson, BL; Bohn, MC			Dopaminergic neurons protected from degeneration by GDNF gene therapy	SCIENCE			English	Article							NEUROTROPHIC FACTOR; IN-VIVO; ADENOVIRUS VECTORS; SURVIVAL FACTOR; GROWTH-FACTOR; LINE; BRAIN; RAT; 6-HYDROXYDOPAMINE; SYSTEM	Glial cell line-derived neurotrophic factor (GDNF) supports growth and survival of dopaminergic (DA) neurons. A replication-defective adenoviral (Ad) vector encoding human GDNF injected near the rat substantia nigra was found to protect DA neurons from the progressive degeneration induced by the neurotoxin 6-hydroxydopamine (6-OHDA) injected into the striatum, Ad GDNF gene therapy reduced loss of DA neurons approximately threefold 6 weeks after 6-OHDA lesion, as compared with no treatment or injection of Ad lacZ or Ad mGDNF (encoding a biologically inactive deletion mutant GDNF). These results suggest that Ad vector-mediated GDNF gene therapy may slow the DA neuronal cell loss in humans with Parkinson's disease.	UNIV ROCHESTER,DEPT NEUROBIOL & ANAT,ROCHESTER,NY 14642; GENET THERAPY,GAITHERSBURG,MD 20878; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242	University of Rochester; University of Iowa			Choi-Lundberg, Derek L/J-7670-2014	Choi-Lundberg, Derek L/0000-0002-3594-8585	NIA NIH HHS [T32AG00107] Funding Source: Medline; NINDS NIH HHS [NS31957] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000107] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; ANGELOV DN, 1995, GLIA, V13, P113, DOI 10.1002/glia.440130205; Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; BAJOCCHI G, 1993, NAT GENET, V3, P229, DOI 10.1038/ng0393-229; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BOWENKAMP KE, 1995, J COMP NEUROL, V355, P479, DOI 10.1002/cne.903550402; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; BYRNES AP, 1995, NEUROSCIENCE, V66, P1015, DOI 10.1016/0306-4522(95)00068-T; CEPKO C, 1990, NEUROMETHODS, V16, P177; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHOILUNDBERG DL, 1995, DEV BRAIN RES, V85, P80, DOI 10.1016/0165-3806(94)00197-8; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EBENDAL T, 1995, J NEUROSCI RES, V40, P276, DOI 10.1002/jnr.490400217; ENGELE J, 1992, DEV BIOL, V152, P363, DOI 10.1016/0012-1606(92)90143-5; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HOFFER BJ, 1994, NEUROSCI LETT, V182, P107, DOI 10.1016/0304-3940(94)90218-6; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LU B, 1995, HEPATOLOGY, V21, P752, DOI 10.1016/0270-9139(95)90529-4; MOUNT HTJ, 1995, P NATL ACAD SCI USA, V92, P9092, DOI 10.1073/pnas.92.20.9092; OLANOW CW, 1993, J NEURAL TRANSM-GEN, V91, P161, DOI 10.1007/BF01245230; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd ed; RINAMAN L, 1991, NEUROSCIENCE, V44, P765, DOI 10.1016/0306-4522(91)90096-7; SAUER H, 1994, NEUROSCIENCE, V59, P401, DOI 10.1016/0306-4522(94)90605-X; SAUER H, 1995, P NATL ACAD SCI USA, V92, P8935, DOI 10.1073/pnas.92.19.8935; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362	37	530	569	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					838	841		10.1126/science.275.5301.838	http://dx.doi.org/10.1126/science.275.5301.838			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012352				2022-12-01	WOS:A1997WG77700063
J	Tansey, WP; Herr, W				Tansey, WP; Herr, W			Selective use of TBP and TFIIB revealed by a TATA-TBP-TFIIB array with altered specificity	SCIENCE			English	Article							BOX-BINDING-PROTEIN; ACTIVATION DOMAINS; CRYSTAL-STRUCTURE; IN-VIVO	Interaction between the TATA box-binding protein TBP and TFIIB is critical for transcription in vitro. An altered-specificity TBP-TFIIB interaction was rationally designed and linked in sequence to an altered-specificity TATA box-TBP interaction to study how TBP and TFIIB function together to support transcription in human cells. The activity of this altered-specificity TATA-TBP-TFIIB array demonstrated that many activators use the known TBP-TFIIB interaction to stimulate transcription. One activator, however, derived from a glutamine-rich activation domain of Sp1, activated transcription independently of this interaction. These results reveal that selectivity in activator function in vivo can be achieved through differential use of TBP and TFIIB.			Tansey, WP (corresponding author), COLD SPRING HARBOR LAB,1 BUNGTOWN RD,POB 100,COLD SPRING HARBOR,NY 11724, USA.		Herr, Winship/E-6491-2012	Herr, Winship/0000-0002-3606-4546	NCI NIH HHS [CA-13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; STRUBIN M, 1992, CELL, V69, P97; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; TANSEY WP, 1995, P NATL ACAD SCI USA, V92, P10550, DOI 10.1073/pnas.92.23.10550; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TANSEY WP, UNPUB; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X	14	38	39	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					829	831		10.1126/science.275.5301.829	http://dx.doi.org/10.1126/science.275.5301.829			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012349				2022-12-01	WOS:A1997WG77700060
J	Velculescu, VE; Zhang, L; Zhou, W; Vogelstein, J; Basrai, MA; Bassett, DE; Hieter, P; Vogelstein, B; Kinzler, KW				Velculescu, VE; Zhang, L; Zhou, W; Vogelstein, J; Basrai, MA; Bassett, DE; Hieter, P; Vogelstein, B; Kinzler, KW			Characterization of the yeast transcriptome	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; GENE-EXPRESSION; ALPHA-FACTOR; FACTOR PHEROMONE; DNA; SEQUENCE; IDENTIFICATION; HYBRIDIZATION; TERMINATION	We have analyzed the set of genes expressed from the yeast genome, herein called the transcriptome, using serial analysis of gene expression. Analysis of 60,633 transcripts revealed 4,665 genes, with expression levels ranging from 0.3 to over 200 transcripts per cell. Of these genes, 1981 had known functions, while 2684 were previously uncharacterized. The integration of positional information with gene expression data allowed for the generation of chromosomal expression maps identifying physical regions of transcriptional activity and identified genes that had not been predicted by sequence information alone. These studies provide insight into global patterns of gene expression in yeast and demonstrate the feasibility of genome-wide expression studies in eukaryotes.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21231; NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20894	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Velculescu, VE (corresponding author), JOHNS HOPKINS UNIV,SCH MED,PROGRAM HUMAN & GENET & MOL BIOL,BALTIMORE,MD 21231, USA.		Velculescu, Victor/ABF-4846-2020; Vogelstein, Joshua/AAG-5489-2019; Zhang, Lin/A-7389-2009; Basrai, Munira/AAV-4422-2020	Velculescu, Victor/0000-0003-1195-438X; Vogelstein, Joshua/0000-0003-2487-6237; Zhang, Lin/0000-0003-0018-3903; Vogelstein, R. Jacob/0000-0001-8159-9577; Bassett, Douglas/0000-0002-1619-4618	NATIONAL CANCER INSTITUTE [R01CA057345, R01CA035494, R37CA035494, R37CA057345] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCHER JE, 1995, CELL, V82, P425, DOI 10.1016/0092-8674(95)90431-X; BAJWA W, 1988, MOL CELL BIOL, V8, P3439, DOI 10.1128/MCB.8.8.3439; Basrai MA, 1996, MOL CELL BIOL, V16, P2838; BISHOP JO, 1974, NATURE, V250, P199, DOI 10.1038/250199a0; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHAMBERS A, 1989, MOL CELL BIOL, V9, P5516, DOI 10.1128/MCB.9.12.5516; DENIS CL, 1983, J BIOL CHEM, V258, P1165; Dick T, 1996, MOL GEN GENET, V251, P38; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P4932, DOI 10.1128/MCB.9.11.4932; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HEREFORD LM, 1977, CELL, V10, P453, DOI 10.1016/0092-8674(77)90032-0; IRNIGER S, 1994, P NATL ACAD SCI USA, V91, P257, DOI 10.1073/pnas.91.1.257; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; MCALISTER L, 1982, J BIOL CHEM, V257, P7181; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; NGUYEN C, 1995, GENOMICS, V29, P207, DOI 10.1006/geno.1995.1233; NISHIZAWA M, 1989, MOL CELL BIOL, V9, P442, DOI 10.1128/MCB.9.2.442; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHMITT HD, 1983, MOL GEN GENET, V192, P247, DOI 10.1007/BF00327674; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH A, 1983, NUCLEIC ACIDS RES, V11, P4049, DOI 10.1093/nar/11.12.4049; SMITH MM, 1983, J MOL BIOL, V169, P641, DOI 10.1016/S0022-2836(83)80163-6; STJOHN TP, 1979, CELL, V16, P443, DOI 10.1016/0092-8674(79)90020-5; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; [No title captured]; [No title captured]	34	832	1083	13	161	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1997	88	2					243	251		10.1016/S0092-8674(00)81845-0	http://dx.doi.org/10.1016/S0092-8674(00)81845-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008165	hybrid			2022-12-01	WOS:A1997WE97000013
J	Yamanashi, Y; Baltimore, D				Yamanashi, Y; Baltimore, D			Identification of the abl- and rasGAP-associated 62 kDa protein as a docking protein, dok	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEINS; TYROSINE KINASES; SIGNAL TRANSDUCTION; POINT MUTATIONS; BCR-ABL; C-ABL; V-SRC; PHOSPHORYLATION; INSULIN	A 62 kDa protein is highly phosphorylated in many cells containing activated tyrosine kinases. This protein, characterized mainly by its avid association with rasGAP, has proved elusive. Anti-phosphotyrosine antibody was used to purify p62. From peptide sequence, molecular cloning revealed a cDNA encoding a novel protein, p62(dok), with little homology to others but with a prominent set of tyrosines and nearby sequences suggestive of SH2 binding sites. In cells, v-Abl tyrosine kinase binds and strongly phosphorylates p62(dok), which then binds rasGAP. A monoclonal antibody, 2C4, to the rasGAP-associated p62 reacts with p62(dok). Thus, p62(dok) appears to be the long-sought major substrate of many tyrosine kinases.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; UNIV TOKYO, INST MED SCI, MINATO KU, TOKYO 108, JAPAN	Massachusetts Institute of Technology (MIT); University of Tokyo					NCI NIH HHS [CA-51462] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; DARBY C, 1994, J IMMUNOL, V152, P5429; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOLD MR, 1993, J IMMUNOL, V150, P377; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HAWLEY RG, 1994, GENE THER, V1, P136; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; Ishino M, 1995, ONCOGENE, V11, P2331; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; MAA MC, 1994, MOL CELL BIOL, V14, P5466, DOI 10.1128/MCB.14.8.5466; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NEET K, 1995, MOL CELL BIOL, V15, P4908; OGAWA W, 1994, J BIOL CHEM, V269, P29602; Parmar K, 1996, J VIROL, V70, P1009, DOI 10.1128/JVI.70.2.1009-1015.1996; PAWSON T, 1995, NATURE, V373, P477, DOI 10.1038/373477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SANCHEZMARGALET V, 1995, ENDOCRINOLOGY, V136, P316, DOI 10.1210/en.136.1.316; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; ZHOU MM, 1995, NATURE, V92, P7784; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	280	291	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1997	88	2					205	211		10.1016/S0092-8674(00)81841-3	http://dx.doi.org/10.1016/S0092-8674(00)81841-3			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008161	Bronze			2022-12-01	WOS:A1997WE97000009
J	Colman, H; Nabekura, J; Lichtman, JW				Colman, H; Nabekura, J; Lichtman, JW			Alterations in synaptic strength preceding axon withdrawal	SCIENCE			English	Article							FROG NEUROMUSCULAR-JUNCTION; LONG-TERM POTENTIATION; TRANSMITTER RELEASE; SKELETAL-MUSCLE; NERVOUS-SYSTEM; ACETYLCHOLINE; ELIMINATION; INNERVATION; RECEPTORS; SYNAPSES	Permanent removal of axonal input to postsynaptic cells helps shape the pattern of neuronal connections in response to experience, but the process is poorly understood. Intracellular recording from newborn and adult mouse muscle fibers temporarily innervated by two axons showed an increasing disparity in the synaptic strengths of the two inputs before one was eliminated. The connection that survived gained strength by increasing the amount of neurotransmitter released (quantal content), whereas the input that was subsequently removed became progressively weaker, because of a reduction in quantal content and a reduction in quantal efficacy associated with reduced postsynaptic receptor density. Once the synaptic strengths of two inputs began to diverge, complete axonal withdrawal of the weaker input occurred within 1 to 2 days, These experiments provide a link between experience-driven changes in synaptic strength and long-term changes in connectivity in the mammalian nervous system.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Colman, Howard/L-5433-2019		NINDS NIH HHS [NS 34448, NS 20364] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020364, P01NS034448] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBUQUERQUE EX, 1976, EXP NEUROL, V51, P536, DOI 10.1016/0014-4886(76)90179-5; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BALICEGORDON RJ, 1993, NEURON, V11, P801, DOI 10.1016/0896-6273(93)90110-D; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BETZ W, 1977, J PHYSIOL-LONDON, V270, P75, DOI 10.1113/jphysiol.1977.sp011939; BETZ WJ, 1989, J PHYSIOL-LONDON, V418, P25, DOI 10.1113/jphysiol.1989.sp017827; BIXBY JL, 1981, J NEUROCYTOL, V10, P81, DOI 10.1007/BF01181746; BRENNER HR, 1976, J PHYSIOL-LONDON, V260, P159, DOI 10.1113/jphysiol.1976.sp011509; BRENNER HR, 1976, J PHYSIOL-LONDON, V260, P143, DOI 10.1113/jphysiol.1976.sp011508; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; COTMAN CW, 1981, PHYSIOL REV, V61, P684, DOI 10.1152/physrev.1981.61.3.684; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P370, DOI 10.1113/jphysiol.1954.sp005114; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DENNIS MJ, 1981, DEV BIOL, V81, P266, DOI 10.1016/0012-1606(81)90290-6; ELMQVIST D, 1965, J PHYSIOL-LONDON, V177, P463, DOI 10.1113/jphysiol.1965.sp007605; GLAVINOVIC MI, 1987, J NEUROPHYSIOL, V58, P230, DOI 10.1152/jn.1987.58.1.230; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P142, DOI 10.1016/0166-2236(88)90139-7; HARRIS JB, 1979, J PHYSIOL-LONDON, V296, P245, DOI 10.1113/jphysiol.1979.sp013003; HARTZELL HC, 1975, J PHYSIOL-LONDON, V251, P427, DOI 10.1113/jphysiol.1975.sp011102; JANSEN JKS, 1990, PROG NEUROBIOL, V34, P39, DOI 10.1016/0301-0082(90)90025-C; KATZ B, 1973, J PHYSIOL-LONDON, V231, P549, DOI 10.1113/jphysiol.1973.sp010248; KIDOKORO Y, 1980, DEV BIOL, V78, P231, DOI 10.1016/0012-1606(80)90332-2; KIDOKORO Y, 1980, DEV BIOL, V78, P464, DOI 10.1016/0012-1606(80)90347-4; KOMELIUSSEN H, 1976, J NEUROCYTOL, V5, P591; KUNO M, 1971, J PHYSIOL-LONDON, V213, P545, DOI 10.1113/jphysiol.1971.sp009399; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Lichtman Jeff W., 1995, Seminars in Developmental Biology, V6, P195, DOI 10.1016/S1044-5781(06)80029-0; Linden D J, 1993, Curr Opin Neurobiol, V3, P401, DOI 10.1016/0959-4388(93)90133-J; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; MAGLEBY KL, 1975, J PHYSIOL-LONDON, V244, P467, DOI 10.1113/jphysiol.1975.sp010808; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; NEGRETE J, 1972, NATURE-NEW BIOL, V235, P158, DOI 10.1038/newbio235158a0; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; PURVES D, 1980, SCIENCE, V210, P153, DOI 10.1126/science.7414326; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; RICH MM, 1989, J NEUROSCI, V9, P1781, DOI 10.1523/jneurosci.09-05-01781.1989; ROSENTHAL JL, 1977, J PHYSIOL-LONDON, V270, P299, DOI 10.1113/jphysiol.1977.sp011953; SHAW G, 1986, EUR J CELL BIOL, V42, P1; SOHA JM, 1987, DEV BIOL, V123, P136, DOI 10.1016/0012-1606(87)90435-0; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; TAXT T, 1983, ACTA PHYSIOL SCAND, V117, P557, DOI 10.1111/j.1748-1716.1983.tb07226.x	42	214	215	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					356	361		10.1126/science.275.5298.356	http://dx.doi.org/10.1126/science.275.5298.356			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994026				2022-12-01	WOS:A1997WC87300037
J	Gamble, TR; Vajdos, FF; Yoo, SH; Worthylake, DK; Houseweart, M; Sundquist, WI; Hill, CP				Gamble, TR; Vajdos, FF; Yoo, SH; Worthylake, DK; Houseweart, M; Sundquist, WI; Hill, CP			Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CIS-TRANS ISOMERASE; X-RAY STRUCTURE; CYCLOSPORINE-A; PARTICLE FORMATION; BINDING-PROTEIN; HOMOLOG NINAA; SUBSTRATE; COMPLEX; INFECTIVITY	The HIV-1 capsid protein forms the conical core structure at the center of the mature virion. Capsid also binds the human peptidyl prolyl isomerase, cyclophilin A, thereby packaging the enzyme into the virion. Cyclophilin A subsequently performs an essential function in HIV-1 replication, possibly helping to disassemble the capsid core upon infection. We report the 2.36 Angstrom crystal structure of the N-terminal domain of HIV-1 capsid (residues 1-151) in complex with human cyclophilin A. A single exposed capsid loop (residues 85-93) binds in the enzyme's active site, and Pro-90 adopts an unprecedented trans conformation. The structure suggests how cyclophilin A can act as a sequence-specific binding protein and a nonspecific prolyl isomerase. In the crystal lattice, capsid molecules assemble into continuous planar strips. Side by side association of these strips may allow capsid to form the surface of the viral core. Cyclophilin A could then function by weakening the association between capsid strips, thereby promoting disassembly of the viral core.	UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84103	Utah System of Higher Education; University of Utah				Vajdos, Felix/0000-0002-8256-2087				Aberham C, 1996, J VIROL, V70, P3536, DOI 10.1128/JVI.70.6.3536-3544.1996; ANDERSON SK, 1993, P NATL ACAD SCI USA, V90, P542, DOI 10.1073/pnas.90.2.542; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BILLICH A, 1995, J VIROL, V69, P2451, DOI 10.1128/JVI.69.4.2451-2461.1995; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; Braaten D, 1996, J VIROL, V70, P5170, DOI 10.1128/JVI.70.8.5170-5176.1996; Braaten D, 1996, J VIROL, V70, P4220, DOI 10.1128/JVI.70.7.4220-4227.1996; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Colgan J, 1996, J VIROL, V70, P4299, DOI 10.1128/JVI.70.7.4299-4310.1996; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; DORFMAN T, 1993, J VIROL, V67, P6159, DOI 10.1128/JVI.67.10.6159-6169.1993; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FRANKE EK, 1994, J VIROL, V68, P5300, DOI 10.1128/JVI.68.8.5300-5305.1994; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; GELDERBLOM HR, 1992, MEMBRANE INTERACTION, P33; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; HUNTER E, 1994, SEMIN VIROL, V5, P71, DOI 10.1006/smvy.1994.1008; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOWETT JBM, 1992, J GEN VIROL, V73, P3079, DOI 10.1099/0022-1317-73-12-3079; KAKALIS LT, 1994, BIOCHEMISTRY-US, V33, P1495, DOI 10.1021/bi00172a028; KALLEN J, 1992, FEBS LETT, V300, P286, DOI 10.1016/0014-5793(92)80865-E; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KE HM, 1993, P NATL ACAD SCI USA, V90, P3324, DOI 10.1073/pnas.90.8.3324; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MCCLURE MA, 1991, MOL BIOL EVOL, V8, P835; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; MYERS G, 1995, HUMAN RETROVIRUSES A; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REICIN AS, 1995, J VIROL, V69, P642, DOI 10.1128/JVI.69.2.642-650.1995; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHUTKOWSKI M, 1995, BIOCHEMISTRY-US, V34, P13016, DOI 10.1021/bi00040a012; STAMNES M A, 1992, Trends in Cell Biology, V2, P272, DOI 10.1016/0962-8924(92)90200-7; STEINKASSERER A, 1995, J VIROL, V69, P814, DOI 10.1128/JVI.69.2.814-824.1995; SYKES K, 1993, P NATL ACAD SCI USA, V90, P5853, DOI 10.1073/pnas.90.12.5853; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; TRABER R, 1994, ANTIVIR CHEM CHEMOTH, V5, P331, DOI 10.1177/095632029400500507; VONPOBLOTZKI A, 1993, VIROLOGY, V193, P981, DOI 10.1006/viro.1993.1210; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WANG CT, 1993, J VIROL, V67, P4264, DOI 10.1128/JVI.67.7.4264-4273.1993; Weisman R, 1996, EMBO J, V15, P447, DOI 10.1002/j.1460-2075.1996.tb00377.x; WOLFENDEN R, 1991, CHEMTRACTS BIOCH MOL, V2, P52; Zhao YD, 1996, BIOCHEMISTRY-US, V35, P7356, DOI 10.1021/bi9602775; Zhao YD, 1996, BIOCHEMISTRY-US, V35, P7362, DOI 10.1021/bi960278x	60	596	612	3	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1285	1294		10.1016/S0092-8674(00)81823-1	http://dx.doi.org/10.1016/S0092-8674(00)81823-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980234	Bronze			2022-12-01	WOS:A1996WA54100016
J	Mosley, JG; Gibbs, ACC				Mosley, JG; Gibbs, ACC			Premature grey hair and hair loss among smokers: A new opportunity for health education?	BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; BALDNESS		CHRISTIE HOSP,CTR CANC EPIDEMIOL,MANCHESTER M20 4QL,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Mosley, JG (corresponding author), LEIGH INFIRM,LEIGH WN7 1HS,LANCS,ENGLAND.							ARMITAGE P, 1994, STAT METHODS MED RES, P515; BULPITT CJ, 1994, AGING-CLIN EXP RES, V6, P181, DOI 10.1007/BF03324236; LESKO SM, 1993, JAMA-J AM MED ASSOC, V269, P998, DOI 10.1001/jama.269.8.998; MODEL D, 1985, BMJ-BRIT MED J, V291, P1760, DOI 10.1136/bmj.291.6511.1760; SCHNOHR P, 1995, AM HEART J, V130, P1003, DOI 10.1016/0002-8703(95)90201-5	5	49	49	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1616	1616		10.1136/bmj.313.7072.1616	http://dx.doi.org/10.1136/bmj.313.7072.1616			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991008	Green Published			2022-12-01	WOS:A1996VZ81100039
J	Hu, ED; Kim, JB; Sarraf, P; Spiegelman, BM				Hu, ED; Kim, JB; Sarraf, P; Spiegelman, BM			Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR gamma	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; ADIPOSE-TISSUE DEVELOPMENT; TUMOR NECROSIS FACTOR; MYELIN BASIC-PROTEIN; ADIPOCYTE DIFFERENTIATION; SUBSTRATE RECOGNITION; 3T3-L1 ADIPOCYTES; INSULIN-RECEPTORS; ESTROGEN-RECEPTOR	Adipocyte differentiation is an important component of obesity and other metabolic diseases. This process is strongly inhibited by many mitogens and oncogenes. Several growth factors that inhibit fat cell differentiation caused mitogen-activated protein (MAP) kinase-mediated phosphorylation of the dominant adipogenic transcription factor peroxisome proliferator-activated receptor gamma (PPAR gamma) and reduction of its transcriptional activity. Expression of PPAR gamma with a nonphosphorylatable mutation at this site (serine-112) yielded cells with increased sensitivity to ligand-induced adipogenesis and resistance to inhibition of differentiation by mitogens. These results indicate that covalent modification of PPAR gamma by serum and growth factors is a major regulator of the balance between cell growth and differentiation in the adipose cell lineage.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Song, Minsun/I-5701-2015	KIM, Jae Bum/0000-0003-2337-6935	NIDDK NIH HHS [R37DK31405] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDO A, 1992, J BIOL CHEM, V267, P12788; Ausubel F.M., 1995, CURRENT PROTOCOLS MO; BERG M, 1994, CYTOKINE, V6, P425, DOI 10.1016/1043-4666(94)90067-1; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; EXTON JH, 1972, J BIOL CHEM, V247, P3579; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FORMAN BM, 1995, CELL, V83, P813; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HAUNER H, 1995, EUR J CLIN INVEST, V25, P90, DOI 10.1111/j.1365-2362.1995.tb01532.x; HAUNER H, 1990, ENDOCRINOLOGY, V127, P865, DOI 10.1210/endo-127-2-865; HOFMANN C, 1989, J BIOL CHEM, V264, P8606; HORIEIN A, 1995, NATURE, V377, P451; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; HU EX, UNPUB; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Maniatis T, 1989, DECONTAMINATION DILU; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAVRE M, 1989, J CELL BIOL, V109, P1857, DOI 10.1083/jcb.109.4.1857; ONATE SA, 1995, SCIENCE, V270, P1354; RODBELL M, 1964, J BIOL CHEM, V239, P375; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; SERRERO G, 1987, BIOCHEM BIOPH RES CO, V146, P194, DOI 10.1016/0006-291X(87)90710-8; SERRERO G, 1991, P NATL ACAD SCI USA, V88, P3912, DOI 10.1073/pnas.88.9.3912; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SPLEGLEMAN BM, 1996, CELL, V87, P377; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	52	902	927	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2100	2103		10.1126/science.274.5295.2100	http://dx.doi.org/10.1126/science.274.5295.2100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953045				2022-12-01	WOS:A1996VY97400055
J	Forster, R; Mattis, AE; Kremmer, E; Wolf, E; Brem, G; Lipp, M				Forster, R; Mattis, AE; Kremmer, E; Wolf, E; Brem, G; Lipp, M			A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen	CELL			English	Article							PROTEIN-COUPLED RECEPTOR; HUMAN INTERLEUKIN-8 RECEPTOR; PRIMARY IMMUNE-RESPONSE; GERMINAL-CENTERS; FUNCTIONAL EXPRESSION; CD40 LIGAND; MICE; (4-HYDROXY-3-NITROPHENYL)ACETYL; DIFFERENTIATION; RECIRCULATION	We describe the phenotype of gene-targeted mice lacking the putative chemokine receptor BLR1. In normal mice, this receptor is expressed on mature B cells and a subpopulation of T helper cells. Blr1 mutant mice tack inguinal lymph nodes and possess no or only a few phenotypically abnormal Peyer's patches. The migration of lymphocytes into splenic follicles is severely impaired, resulting in morphologically altered primary lymphoid follicles. Furthermore, activated B cells fail to migrate from the T cell-rich zone into B cell follicles of the spleen, and despite high numbers of germinal center founder cells, no functional germinal centers develop in this organ. Our results identify the putative chemokine receptor BLR1 as the first G protein-coupled receptor involved in B cell migration and localization of these cells within specific anatomic compartments.	GSF MUNICH,RES CTR,INST IMMUNOL,D-81377 MUNICH,GERMANY; UNIV MUNICH,CTR GENE,INST MOL ANIM BREEDING,D-81375 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Forster, R (corresponding author), MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY.		Förster, Reinhold/D-6770-2011; Lipp, Martin/G-2235-2010	Forster, Reinhold/0000-0001-6190-7923; Lipp, Martin/0000-0002-0087-2672; Wolf, Eckhard/0000-0002-0430-9510				BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; BRELINSKA R, 1982, CELL TISSUE RES, V226, P155, DOI 10.1007/BF00217090; BURGSTAHLER R, 1995, BIOCHEM BIOPH RES CO, V215, P737, DOI 10.1006/bbrc.1995.2525; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CRAIG SW, 1971, J EXP MED, V134, P188, DOI 10.1084/jem.134.1.188; CYSTER JG, 1995, J EXP MED, V182, P581, DOI 10.1084/jem.182.2.581; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FORSTER R, 1994, BLOOD, V84, P830; FORSTER R, 1993, BIOCHEM BIOPH RES CO, V196, P1496, DOI 10.1006/bbrc.1993.2421; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; GRAY D, 1988, IMMUNOLOGY, V65, P73; GROOM AC, 1990, SPLEEN STRUCTURE FUN, P45; Hedrick JA, 1996, CURR OPIN IMMUNOL, V8, P343, DOI 10.1016/S0952-7915(96)80123-3; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; KAISER E, 1993, EUR J IMMUNOL, V23, P2532, DOI 10.1002/eji.1830231023; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.immunol.12.1.593; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PELLAS TC, 1990, AM J ANAT, V187, P355, DOI 10.1002/aja.1001870405; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SPANGRUDE GJ, 1984, J IMMUNOL, V132, P354; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; VONDERHEIDE RH, 1990, EUR J IMMUNOL, V20, P79, DOI 10.1002/eji.1830200112; Wagner N, 1996, NATURE, V382, P366, DOI 10.1038/382366a0; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	44	904	925	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1037	1047		10.1016/S0092-8674(00)81798-5	http://dx.doi.org/10.1016/S0092-8674(00)81798-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978608	Bronze			2022-12-01	WOS:A1996VY44700009
J	Qian, F; Watnick, TJ; Onuchic, LF; Germino, GG				Qian, F; Watnick, TJ; Onuchic, LF; Germino, GG			The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I	CELL			English	Article							HUMAN ANDROGEN-RECEPTOR; GENETIC-HETEROGENEITY; 2ND GENE; LOCALIZATION; PKD1; CHILDHOOD; MUTATIONS; DELETION; LOCUS	Autosomal dominant polycystic kidney disease (ADPKD) is a common disease and an important cause of renal failure. It is characterized by considerable intrafamilial phenotypic variation and focal cyst formation. To elucidate the molecular basis for these observations, we have developed a novel method for isolating renal cystic epithelia from single cysts and have used it to show that individual renal cysts in ADPKD are monoclonal. Loss of heterozygosity was discovered within a subset of cysts for two closely linked polymorphic markers located within the PKD1 gene. Genetic analysis revealed that it was the normal haplotype that was lost. This study provides a molecular explanation for the focal nature of cyst formation and a probable mechanism whereby mutations cause disease. The high rate at which ''second hits'' must occur to account for the large number of cysts observed suggests that unique structural features of the PKD1 gene may be responsible for its mutability.			Qian, F (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV NEPHROL,720 RUTLAND ST,BALTIMORE,MD 21205, USA.		Onuchic, Luiz Fernando/H-1589-2012	Onuchic, Luiz Fernando/0000-0002-4053-5419; Germino, Gregory/0000-0002-3609-5588	NIDDK NIH HHS [DK48006] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK048006, R01DK048006] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; BLYTH H, 1971, J MED GENET, V8, P257, DOI 10.1136/jmg.8.3.257; BOGDANOVA N, 1995, HUM GENET, V95, P645; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; DEALMEIDA S, 1995, HUM GENET, V96, P83, DOI 10.1007/BF00214191; *EUR POL KIDN DIS, 1994, CELL, V77, P881; EVAN AP, 1992, CYSTIC KIDNEY, P21; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FICK GM, 1993, J AM SOC NEPHROL, V3, P1863; FICK GM, 1994, KIDNEY INT, V45, P1153, DOI 10.1038/ki.1994.153; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GILLILAND DG, 1991, P NATL ACAD SCI USA, V88, P6848, DOI 10.1073/pnas.88.15.6848; HANDLER JS, 1979, P NATL ACAD SCI USA, V76, P4151, DOI 10.1073/pnas.76.8.4151; HUFF V, 1991, AM J HUM GENET, V48, P997; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; IAKOUBOVA OA, 1995, GENOMICS, V26, P107, DOI 10.1016/0888-7543(95)80088-4; *INT POL KIDN DIS, 1995, CELL, V81, P289; KAARIAINEN H, 1987, J MED GENET, V24, P474, DOI 10.1136/jmg.24.8.474; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; NAROD S, 1991, CLIN GENET, V39, P125; Peral B, 1996, HUM MOL GENET, V5, P539, DOI 10.1093/hmg/5.4.539; Peral B, 1996, AM J HUM GENET, V58, P86; PERAL B, 1995, HUM MOL GENET, V4, P569, DOI 10.1093/hmg/4.4.569; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; RAO BS, 1988, NUCLEIC ACIDS RES, V16, P8077, DOI 10.1093/nar/16.16.8077; RAVINE D, 1992, LANCET, V340, P1330, DOI 10.1016/0140-6736(92)92503-8; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; SCHAFER K, 1994, KIDNEY INT, V46, P134, DOI 10.1038/ki.1994.253; SNAREY A, 1994, AM J HUM GENET, V55, P365; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; WILLMAN CL, 1994, NEW ENGL J MED, V331, P154, DOI 10.1056/NEJM199407213310303; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023; ZERRES K, 1993, J MED GENET, V30, P583, DOI 10.1136/jmg.30.7.583; 1995, HUM MOL GENET, V4, P575	38	468	481	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					979	987		10.1016/S0092-8674(00)81793-6	http://dx.doi.org/10.1016/S0092-8674(00)81793-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978603	hybrid			2022-12-01	WOS:A1996VY44700004
J	Lieb, JD; Capowski, EE; Meneely, P; Meyer, BJ				Lieb, JD; Capowski, EE; Meneely, P; Meyer, BJ			DPY-26, a link between dosage compensation and meiotic chromosome segregation in the nematode	SCIENCE			English	Article							UBIQUITOUS PROTEIN FAMILY; CAENORHABDITIS-ELEGANS; SEX DETERMINATION; C-ELEGANS; FISSION YEAST; X-CHROMOSOME; GENE; CONDENSATION; DROSOPHILA; MUTATIONS	The DPY-26 protein is required in the nematode Caenorhabditis elegans for X-chromosome dosage compensation as well as for proper meiotic chromosome segregation. DPY-26 was shown to mediate both processes through its association with chromosomes. in somatic cells, DPY-26 associates specifically with hermaphrodite X chromosomes to reduce their transcript levels, in germ cells, DPY-26 associates with all meiotic chromosomes to mediate its role in chromosome segregation. The X-specific localization of DPY-26 requires two dosage compensation proteins (DPY-27 and DPY-30) and two proteins that coordinately control both sex determination and dosage compensation (SDC-2 and SDC-3).	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	University of California System; University of California Berkeley; Fred Hutchinson Cancer Center				Meyer, Barbara/0000-0002-6530-4588; Lieb, Jason/0000-0001-7601-8061	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007127, R01GM030702, R37GM030702] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24324] Funding Source: Medline; NIGMS NIH HHS [GM30702, R01 GM030702, T32 GM07127] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; CAPOWSKI EE, UNPUB; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Chuang PT, 1996, SCIENCE, V274, P1736, DOI 10.1126/science.274.5293.1736; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; DAWES HM, UNPUB; DELONG L, 1993, GENETICS, V133, P875; EISSENBERG JC, 1990, EUR J CELL BIOL, V50, P170; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HIRAOKA Y, 1990, BIOPHYS J, V57, P321; HODGKIN J, 1993, MOL GEN GENET, V192, P452; HSU DR, 1995, DEVELOPMENT, V121, P3323; HSU DR, 1994, GENETICS, V137, P999; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; KELLUM R, 1995, J CELL SCI, V108, P1419; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; LIEB JD, UNPUB; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NONET ML, 1991, NATURE, V351, P65, DOI 10.1038/351065a0; NUSBAUM C, 1989, GENETICS, V122, P579; PLENEFISCH JD, 1989, GENETICS, V121, P57; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; VILLENEUVE AM, 1987, CELL, V48, P25, DOI 10.1016/0092-8674(87)90352-7; VILLENEUVE AM, 1990, GENETICS, V124, P91	34	100	114	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1732	1736		10.1126/science.274.5293.1732	http://dx.doi.org/10.1126/science.274.5293.1732			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939869				2022-12-01	WOS:A1996VW71200068
J	Ting, CN; Olson, MC; Barton, KP; Leiden, JM				Ting, CN; Olson, MC; Barton, KP; Leiden, JM			Transcription factor GATA-3 is required for development of the T-cell lineage	NATURE			English	Article							THYMOCYTE DIFFERENTIATION; RECEPTOR GENES; MICE LACKING; EXPRESSION; ENHANCER; EMBRYOGENESIS; HEMATOPOIESIS; REARRANGEMENT; PROTOONCOGENE; DISRUPTION	THE zinc-finger transcription factor GATA-3 is expressed in haematopoietic cells and in the developing kidney and nervous system(1-7). Within the haematopoietic lineages, expression of GATA-3 is restricted to thymocytes and T cells. Functionally important GATA-3 binding sites have been identified in multiple T-cell-specific genes(1,6-8). Mice containing homozygous null mutations of the GATA-3 gene die on embryonic day 12, precluding a detailed assessment of the role of GATA-3 in haematopoietic development(9). Here we have used murine embryonic stem (ES) cells containing homozygous mutations in the GATA-3 gene (GATA-3(-/-)) in conjunction with the RAG-2(-/-) (ref. 10) and C57BL/6 complementation systems to study the role of GATA-3 in mammalian haematopoiesis. Our results show that GATA-3(-/-) ES cells can contribute to the development of the mature erythroid, myelomonocytic and B-cell lineages, but fail to give rise to thymocytes or mature peripheral T cells. The differentiation of GATA-3(-/-) T cells is blocked at or before the earliest double-negative (CD4(-)/CD8(-)) stage of thymocyte development, such that the GATA-3(-/-) ES cells are unable to contribute measurably to the double-negative thymocyte population. These findings suggest that GATA-3 is an essential and specific regulator of early thymocyte development.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637	University of Chicago; University of Chicago								ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; Clevers HC, 1996, IMMUNOL TODAY, V17, P336, DOI 10.1016/0167-5699(96)10019-0; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GODFREY DI, 1994, J IMMUNOL, V152, P4783; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; LABASTIE MC, 1995, KIDNEY INT, V47, P1597, DOI 10.1038/ki.1995.223; LABASTIE MC, 1994, GENOMICS, V21, P1, DOI 10.1006/geno.1994.1217; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; MARINE J, 1991, P NATL ACAD SCI USA, V88, P7284, DOI 10.1073/pnas.88.16.7284; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; OOSTERWEGEL M, 1992, DEV IMMUNOL, V3, P1, DOI 10.1155/1992/27903; PADUA RA, 1978, BIOCHEM GENET, V16, P127, DOI 10.1007/BF00484389; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0	30	517	529	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					474	478		10.1038/384474a0	http://dx.doi.org/10.1038/384474a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945476				2022-12-01	WOS:A1996VW68700066
J	Grouard, G; Durand, I; Filgueira, L; Banchereau, J; Liu, YJ				Grouard, G; Durand, I; Filgueira, L; Banchereau, J; Liu, YJ			Dendritic cells capable of stimulating T cells in germinal centres	NATURE			English	Article							AIDS-RELATED LYMPHADENOPATHY; VIRUS-LIKE PARTICLES; RETICULUM CELLS; LYMPHOID-TISSUE; HUMAN BLOOD; B-CELLS; CENTERS; ANTIGEN; INFECTION; LYMPHOCYTES	THE B cells within the germinal centres of lymphoid organs undergo affinity maturation of their antigen receptors, a critical event for antibody memory(1-3). Follicular dendritic cells within the germinal centres retain immune complexes(4-6) that select the developing B cells for which they have a higher affinity(7). We have now identified a subset of CD4(+)CD11c(+)CD3(-) dendritic cells in the germinal centres. These are strong antigen-presenting cells for T cells, but do not co-stimulate CD40-activated B cells, These dendritic cells probably stimulate germinal centre T cells and aid the complicated processes that are required for the generation of memory B cells.	SCHERING PLOUGH CORP,LAB IMMUNOL RES,F-69571 DARDILLY,FRANCE; UNIV ZURICH IRCHEL,DIV CELL BIOL,INST ANAT,CH-8057 ZURICH,SWITZERLAND	Merck & Company; Schering Plough Corporation; University of Zurich			Filgueira, Luis/B-6492-2008	Filgueira, Luis/0000-0002-2266-6650				ARMSTRONG JA, 1984, LANCET, V2, P370; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; CHEN LL, 1978, J CELL BIOL, V77, P148, DOI 10.1083/jcb.77.1.148; CLARK EA, 1994, J IMMUNOL, V153, P2951; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; FULLER KA, 1993, J IMMUNOL, V151, P4505; GORCZYCA W, 1993, LEUKEMIA, V7, P659; GROUARD G, 1995, J IMMUNOL, V155, P3345; INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KIM HS, 1994, J IMMUNOL, V153, P2951; KNAPP W, 1989, LEUCOCYTE TYPING, V4, P183; KOSCO MH, 1988, J IMMUNOL, V140, P354; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LAUSE DB, 1981, CELL TISSUE RES, V218, P557; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, IN PRESS J EXP MED; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; NAIEM M, 1983, J CLIN PATHOL, V36, P167, DOI 10.1136/jcp.36.2.167; NOSSAL GJV, 1968, J EXP MED, V127, P277, DOI 10.1084/jem.127.2.277; ODOHERTY U, 1994, IMMUNOLOGY, V82, P487; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PARWARESCH MR, 1983, J IMMUNOL, V131, P2719; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHIEVER F, 1989, J EXP MED, V169, P2043; TENNERRACZ K, 1985, LANCET, V1, P105; TEW JG, 1989, IMMUNOL TODAY, V10, P229, DOI 10.1016/0167-5699(89)90258-2	32	233	240	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					364	367		10.1038/384364a0	http://dx.doi.org/10.1038/384364a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934523				2022-12-01	WOS:A1996VV27100051
J	Asahara, T; Murohara, T; Sullivan, A; Silver, M; vanderZee, R; Li, T; Witzenbichler, B; Schatteman, G; Isner, JM				Asahara, T; Murohara, T; Sullivan, A; Silver, M; vanderZee, R; Li, T; Witzenbichler, B; Schatteman, G; Isner, JM			Isolation of putative progenitor endothelial cells for angiogenesis	SCIENCE			English	Article							RECEPTOR TYROSINE KINASES; GROWTH-FACTOR; MONOCLONAL-ANTIBODY; PLASMINOGEN-ACTIVATOR; ADHESION MOLECULES; VASCULOGENESIS; HEMATOPOIESIS; EXPRESSION; IDENTIFICATION; LIMB	Putative endothelial cell (EC) progenitors or angioblasts were isolated from human peripheral blood by magnetic bead selection on the basis of cell surface antigen expression. In vitro, these cells differentiated into ECs. In animal models of ischemia, heterologous, homologous, and autologous EC progenitors incorporated into sites of active angiogenesis. These findings suggest that EC progenitors may be useful for augmenting collateral vessel growth to ischemic tissues (therapeutic angiogenesis) and for delivering anti- or pro-angiogenic agents, respectively, to sites of pathologic or utilitarian angiogenesis.	TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT MED CARDIOL, BOSTON, MA 02135 USA; TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT BIOMED RES, BOSTON, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University			Mordwinkin, Nicholas M/A-4347-2010; Asahara, Takayuki/AAH-5990-2021; Witzenbichler, Bernhard/ABC-2525-2021; Murohara, Toyoaki/M-4958-2014		PHS HHS [2824, 53354, 57516] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREWS RG, 1986, BLOOD, V67, P842; BAFFOUR R, 1992, J VASC SURG, V16, P181, DOI 10.1016/0741-5214(92)90106-I; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.immunol.11.1.767; BRUGGER W, 1995, NEW ENGL J MED, V333, P283, DOI 10.1056/NEJM199508033330503; CIVIN CI, 1984, J IMMUNOL, V133, P157; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FINA L, 1990, BLOOD, V75, P2417; FLAMME I, 1992, DEVELOPMENT, V116, P435; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; His W, 1900, ABHANDL KS GES WISS, V22, P171; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; ITO A, 1995, LAB INVEST, V72, P532; KATZ FE, 1985, LEUKEMIA RES, V9, P191, DOI 10.1016/0145-2126(85)90082-7; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Noishiki Y, 1996, NAT MED, V2, P90, DOI 10.1038/nm0196-90; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; PU LQ, 1993, CIRCULATION, V88, P208, DOI 10.1161/01.CIR.88.1.208; RISAU W, 1988, DEVELOPMENT, V102, P471; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SATO Y, 1993, EXP CELL RES, V204, P223, DOI 10.1006/excr.1993.1028; SCHAPER W, 1971, CIRC RES, V28, P671, DOI 10.1161/01.RES.28.6.671; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; Senger DR, 1996, AM J PATHOL, V149, P293; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHI Q, 1994, J VASC SURG, V20, P546, DOI 10.1016/0741-5214(94)90279-8; SOLIGO D, 1991, LEUKEMIA, V5, P1026; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Tschudi MR, 1996, J CLIN INVEST, V98, P899, DOI 10.1172/JCI118872; VANDERZEE R, IN PRESS CIRCULATION; Weiss MJ, 1996, J CLIN INVEST, V97, P591, DOI 10.1172/JCI118454; WU MHD, 1995, J VASC SURG, V21, P862, DOI 10.1016/S0741-5214(05)80019-9; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	37	6839	7817	11	449	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1997	275	5302					964	967		10.1126/science.275.5302.964	http://dx.doi.org/10.1126/science.275.5302.964			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020076				2022-12-01	WOS:A1997WH38800041
J	Marcand, S; Gilson, E; Shore, D				Marcand, S; Gilson, E; Shore, D			A protein-counting mechanism for telomere length regulation in yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; TERMINAL TRANSFERASE; CHROMOSOME STABILITY; RAP1; DNA; IDENTIFICATION; TRANSCRIPTION; LOCALIZATION; TETRAHYMENA; INTERACTS	In the yeast Saccharomyces cerevisiae, telomere elongation is negatively regulated by the telomere repeat-binding protein Rap1p, such that a narrow length distribution of telomere repeat tracts is observed, This length regulation was shown to function independently of the orientation of the telomere repeats. The number of repeats at an individual telomere was reduced when hybrid proteins containing the Rap1p carboxyl terminus were targeted there by a heterologous DNA-binding domain. The extent of this telomere tract shortening was proportional to the number of targeted molecules, consistent with a feedback mechanism of telomere length regulation that can discriminate the precise number of Rap1p molecules bound to the chromosome end.	UNIV GENEVA,DEPT MOL BIOL,CH-1211 GENEVA 4,SWITZERLAND; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; ECOLE NORMALE SUPER LYON,LAB BIO MOL & CELLULAIRE,F-69364 LYON 07,FRANCE; ECOLE NORMALE SUPER LYON,LAB BIOL MOL & CELLULAIRE,CNRS,UMR 49,F-69364 LYON 07,FRANCE	University of Geneva; Columbia University; Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet			Shore, David/F-6240-2015	Shore, David/0000-0002-9859-143X; Marcand, Stephane/0000-0001-5199-1885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040094] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40094] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; Boscheron C, 1996, EMBO J, V15, P2184, DOI 10.1002/j.1460-2075.1996.tb00572.x; BUCK S, 1996, THESIS COLUMBIA U; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GILSON E, 1994, NUCLEIC ACIDS RES, V22, P5310, DOI 10.1093/nar/22.24.5310; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRANDIN N, IN PRESS GENES DEV; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HARDY CFJ, 1991, THESIS COLUMBIA U; HARLEY CB, 1995, TELOMERES, P247; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; Li BB, 1996, GENE DEV, V10, P1310, DOI 10.1101/gad.10.11.1310; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; Liu C, 1996, GENETICS, V143, P81; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; MARCAND S, UNPUB; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; SANDELL LL, 1994, P NATL ACAD SCI USA, V91, P12061, DOI 10.1073/pnas.91.25.12061; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; VANSTEENSEL B, IN PRESS NATURE; WALMSLEY RM, 1985, P NATL ACAD SCI USA, V82, P506, DOI 10.1073/pnas.82.2.506; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WOTTON D, IN PRESS GENES DEV; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	45	427	434	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					986	990		10.1126/science.275.5302.986	http://dx.doi.org/10.1126/science.275.5302.986			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020083				2022-12-01	WOS:A1997WH38800048
J	Zangwill, KM; Schuchat, A; Riedo, FX; Pinner, RW; Koo, DT; Reeves, MW; Wenger, JD				Zangwill, KM; Schuchat, A; Riedo, FX; Pinner, RW; Koo, DT; Reeves, MW; Wenger, JD			School-based clusters of meningococcal disease in the United States - Descriptive epidemiology and a case-control analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEISSERIA-MENINGITIDIS; RISK-FACTORS; OUTBREAK; TRANSMISSION; POPULATION; CLASSROOM; INFECTION; CONTACTS	Objective.-To evaluate the epidemiologic features and risk factors for multiple cases of meningococcal disease in schools. Design.-Population-based prospective evaluation and case-control study of clusters of meningococcal disease that occurred in schools from January 1989 to June 1994. Setting.-Surveillance conducted through state health departments in the United States. Main Outcome Measures.-Descriptive epidemiology of school-based clusters of meningococcal disease and determinants of their occurrence. Results.-We identified 22 clusters of meningococcal disease in 15 states. The estimated incidence of secondary meningococcal disease among schoolchildren aged 5 to 18 years was 2.5 per 100 000 population, a relative risk of 2.3 (95% confidence interval [Cl], 1.6-3.3). The median number of students per cluster was 2 (range, 2-4), Of 30 subsequent cases, 10 (33%) occurred 2 or fewer days after the index case, and 22 (79%) occurred 14 or fewer days after the index case. Among the 8 schools with 2 or more cases, 50% of the additional cases occurred 2 or more days after the Second case. Secondary schools (grades 7 through 12) accounted for 15 (75%) of 20 cluster schools compared with 9 (45%) of 20 matched control schools (P<.05). In 16 (73%) of 22 clusters, interaction between case patients was noted. The index patient in cluster schools was more likely than the controls to have participated in a-school-based group activity 14 or fewer days before illness (matched odds ratio, 7.0; 95% Cl, 0.9-57). Conclusions.-Three quarters of the school clusters occurred in secondary schools, with over 70% of subsequent cases occurring within 2 weeks of the index case. Rapid initiation of a chemoprophylaxis program after 2 cases of meningococcal disease in a school would have potentially prevented 50% of subsequent cases in the clusters described.	CTR DIS CONTROL & PREVENT,CHILDHOOD & RESP DIS BRANCH,NATL CTR INFECT DIS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								ALEXANDER JP, 1993, J INFECT DIS, V167, P1201, DOI 10.1093/infdis/167.5.1201; CHEEK JE, 1995, ARCH PEDIAT ADOL MED, V149, P774, DOI 10.1001/archpedi.1995.02170200064010; COUNTS GW, 1984, REV INFECT DIS, V6, P640; *CTR DIS CONTR, 1985, MMWR-MORBID MORTAL W, V34, P255; *CTR DIS CONTR PRE, 1995, MMWR MORBID MORTAL W, V44, P121; DEWALS P, 1981, J INFECTION, V3, P53, DOI 10.1016/S0163-4453(81)80009-6; FAVOROVA L A, 1975, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, V6, P15; FEIGIN RD, 1982, NEW ENGL J MED, V307, P1255, DOI 10.1056/NEJM198211113072007; GAUNT PN, 1988, J ANTIMICROB CHEMOTH, V21, P489, DOI 10.1093/jac/21.4.489; HARRISON LH, 1991, ARCH INTERN MED, V151, P1005, DOI 10.1001/archinte.151.5.1005; HOGE CW, 1994, AM J EPIDEMIOL, V139, P520, DOI 10.1093/oxfordjournals.aje.a117035; HUDSON PJ, 1986, PEDIATR INFECT DIS J, V5, P213, DOI 10.1097/00006454-198603000-00011; HUME SE, 1992, JAMA-J AM MED ASSOC, V267, P1837; HUME SE, 1992, JAMA-J AM MED ASSOC, V267, P1834; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; Jackson Lisa A., 1993, Morbidity and Mortality Weekly Report, V42, P21; JACOBSON JA, 1976, AM J EPIDEMIOL, V104, P552, DOI 10.1093/oxfordjournals.aje.a112329; *MEN DIS SURV GROU, 1976, JAMA-J AM MED ASSOC, V235, P261; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; MORROW HW, 1990, PEDIATR INFECT DIS J, V9, P394, DOI 10.1097/00006454-199006000-00005; MUNFORD RS, 1994, LANCET, V343, P1275; OLIVARES R, 1992, EUR J EPIDEMIOL, V8, P737, DOI 10.1007/BF00145393; SAS, 1996, SAS STAT SOFTW CHANG; SCHWARTZ B, 1989, CLIN MICROBIOL REV, V2, pS118, DOI 10.1128/CMR.2.Suppl.S118-S124.1989; SCHWARTZ B, 1988, LANCET, V1, P1239; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; WANG JF, 1993, J INFECT DIS, V167, P1320, DOI 10.1093/infdis/167.6.1320	27	60	62	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					389	395		10.1001/jama.277.5.389	http://dx.doi.org/10.1001/jama.277.5.389			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE771	9010171				2022-12-01	WOS:A1997WE77100029
J	Shu, LJ; Nesheim, JC; Kauffmann, K; Munck, E; Lipscomb, JD; Que, L				Shu, LJ; Nesheim, JC; Kauffmann, K; Munck, E; Lipscomb, JD; Que, L			An (Fe2O2)-O-IV diamond core structure for the key intermediate Q of methane monooxygenase	SCIENCE			English	Article							METHYLOCOCCUS-CAPSULATUS-BATH; RIBONUCLEOTIDE REDUCTASE; MAGNETIC-PROPERTIES; CATALYTIC CYCLE; DIIRON CENTER; HYDROXYLASE; COMPONENT; OXIDATION; CLUSTER; PURIFICATION	A new paradigm for oxygen activation is required for enzymes such as methane monooxygenase (MMO), for which catalysis depends on a nonheme diiron center instead of the more familiar Fe-porphyrin cofactor. On the basis of precedents from synthetic diiron complexes, a high-valent Fe-2(mu-O)(2) diamond core has been proposed as the key oxidizing species for MMO and other nonheme diiron enzymes such as ribonucleotide reductase and fatty acid desaturase. The presence of a single short Fe-O bond (1.77 angstroms) per Fe atom and an Fe-Fe distance of 2.46 angstroms in MMO reaction intermediate Q, obtained from extended x-ray absorption fine structure and Mossbauer analysis, provides spectroscopic evidence that the diiron center in Q has an (Fe2O2)-O-IV, diamond core.	UNIV MINNESOTA,DEPT CHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,CTR MET BIOCATALYSIS,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; CARNEGIE MELLON UNIV,DEPT CHEM,PITTSBURGH,PA 15213	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Carnegie Mellon University				Lipscomb, John/0000-0002-8158-5594	NIGMS NIH HHS [GM-22701, GM-08277, GM-40466, R01 GM040466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040466, T32GM008277, R01GM022701] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG JM, 1982, IRON SULFUR PROTEINS, P3; COLBY J, 1978, BIOCHEM J, V171, P461, DOI 10.1042/bj1710461; COLLINS TJ, 1990, J AM CHEM SOC, V112, P5637, DOI 10.1021/ja00170a037; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DEWITT JG, 1995, INORG CHEM, V34, P2505, DOI 10.1021/ic00114a007; DONG YH, 1995, J AM CHEM SOC, V117, P2778, DOI 10.1021/ja00115a013; Dong YH, 1996, ANGEW CHEM INT EDIT, V35, P618, DOI 10.1002/anie.199606181; DONG YH, 1995, J AM CHEM SOC, V117, P11377, DOI 10.1021/ja00150a051; ELANGO N, IN PRESS PROTEIN SCI; FOX BG, 1989, J BIOL CHEM, V264, P10023; Halfen JA, 1996, SCIENCE, V271, P1397, DOI 10.1126/science.271.5254.1397; Kim K, 1996, J AM CHEM SOC, V118, P4914, DOI 10.1021/ja9604370; KURTZ DM, 1990, CHEM REV, V90, P585, DOI 10.1021/cr00102a002; LEE SK, 1993, J BIOL CHEM, V268, P21569; LEE SK, 1993, J AM CHEM SOC, V115, P6450, DOI 10.1021/ja00067a086; LIU KE, 1995, J AM CHEM SOC, V117, P4997, DOI 10.1021/ja00122a032; LIU KE, 1995, J AM CHEM SOC, V117, P10174, DOI 10.1021/ja00146a002; LIU KE, 1995, ADV INORG CHEM RAD, V42, P263; LIU Y, 1995, J BIOL CHEM, V270, P24662, DOI 10.1074/jbc.270.42.24662; MAHAPATRA S, 1995, J AM CHEM SOC, V117, P8865, DOI 10.1021/ja00139a026; Nesheim JC, 1996, BIOCHEMISTRY-US, V35, P10240, DOI 10.1021/bi960596w; Ookubo T, 1996, J AM CHEM SOC, V118, P701, DOI 10.1021/ja953705n; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; PECORARO VL, 1994, CHEM REV, V94, P807, DOI 10.1021/cr00027a012; PENNERHAHN JE, 1986, J AM CHEM SOC, V108, P7819, DOI 10.1021/ja00284a054; Que L, 1996, ACCOUNTS CHEM RES, V29, P190, DOI 10.1021/ar950146g; RANDALL CR, 1995, INORG CHEM, V34, P1036, DOI 10.1021/ic00109a007; REDDY KR, 1994, INORG CHEM, V33, P428, DOI 10.1021/ic00081a008; RiggsGelasco PJ, 1996, J AM CHEM SOC, V118, P2387, DOI 10.1021/ja9504496; ROE AL, 1984, J AM CHEM SOC, V106, P1676, DOI 10.1021/ja00318a021; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; ROSENZWEIG AC, 1995, CHEM BIOL, V2, P409, DOI 10.1016/1074-5521(95)90222-8; SCARROW RC, 1987, J AM CHEM SOC, V109, P7857, DOI 10.1021/ja00259a039; Shu LJ, 1996, J BIOL INORG CHEM, V1, P297, DOI 10.1007/s007750050057; SHU LJ, 1995, BIOCHEMISTRY-US, V34, P6649, DOI 10.1021/bi00020a010; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; YACHANDRA VK, 1993, SCIENCE, V260, P675, DOI 10.1126/science.8480177; ZANG Y, 1995, J AM CHEM SOC, V117, P1169, DOI 10.1021/ja00108a050	38	527	534	4	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					515	518		10.1126/science.275.5299.515	http://dx.doi.org/10.1126/science.275.5299.515			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999792				2022-12-01	WOS:A1997WE25700039
J	Ahlgren, U; Pfaff, SL; Jessell, TM; Edlund, T; Edlund, H				Ahlgren, U; Pfaff, SL; Jessell, TM; Edlund, T; Edlund, H			Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells	NATURE			English	Article							ENDOCRINE PANCREAS; PROTEIN ISL-1; INSULIN GENE; HOMEODOMAIN; NEURONS; POLYPEPTIDE; EXPRESSION; ELEGANS; LINEAGE	The mammalian pancreas is a specialized derivative of the primitive gut endoderm and controls many homeostatic functions through the activity of its component exocrine acinar and endocrine islet cells. The LIM homeodomain protein ISL1 is expressed in all classes of islet cells in the adult(1,2) and its expression in the embryo is initiated soon after the islet cells have left the cell cycle. ISL1 is also expressed in mesenchymal cells that surround the dorsal but not ventral evagination of the gut endoderm, which together comprise the pancreatic anlagen. To define the role of ISL1 in the development of the pancreas, we have now analysed acinar and islet cell differentiation in mice deficient in ISL1 function(3). Dorsal pancreatic mesenchyme does not form in ISL1-mutant embryos and there is an associated failure of exocrine cell differentiation in the dorsal but not the ventral pancreas. There is also a complete loss of differentiated islet cells. Exocrine, but not endocrine, cell differentiation in the dorsal pancreas can be rescued in vitro by provision of mesenchyme derived from wild-type embryos. These results indicate that ISL1, by virtue of its requirement for the formation of dorsal mesenchyme, is necessary for the development of the dorsal exocrine pancreas, and also that ISL1 function in pancreatic endodermal cells is required for the generation of all endocrine islet cells.	UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN; COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOL BIOPHYS,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Umea University; Columbia University; Howard Hughes Medical Institute				Edlund, Helena/0000-0002-3553-7348; Ahlgren, Ulf/0000-0001-5923-8572				Ahlgren U, 1996, DEVELOPMENT, V122, P1409; ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GOLOSOW N, 1962, DEV BIOL, V4, P242, DOI 10.1016/0012-1606(62)90042-8; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KUANG J, 1989, P NATL ACAD SCI USA, V86, P4982, DOI 10.1073/pnas.86.13.4982; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LUNDGREN FE, 1995, DEVELOPMENT, V121, P1769; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Offield MF, 1996, DEVELOPMENT, V122, P983; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Pictet R., 1972, HDB PHYSIOLOGY     7, V1, P25; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; UPCHURCH BH, 1994, DEVELOPMENT, V120, P245; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2	22	551	578	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1997	385	6613					257	260		10.1038/385257a0	http://dx.doi.org/10.1038/385257a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000074				2022-12-01	WOS:A1997WC71100049
J	Foreman, KE; Friborg, J; Kong, WP; Woffendin, C; Polverini, PJ; Nickoloff, BJ; Nabel, GJ				Foreman, KE; Friborg, J; Kong, WP; Woffendin, C; Polverini, PJ; Nickoloff, BJ; Nabel, GJ			Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; EPSTEIN-BARR-VIRUS; DNA-SEQUENCES; HIRT SUPERNATANT; HIV; INFECTION; EPIDEMIOLOGY; CELLS	Background Although unique DNA sequences related to gammaherpesviruses have been found in Kaposi's sarcoma lesions, it is uncertain whether this DNA encodes a virus that is able to reproduce. Methods We isolated and propagated a filterable agent whose DNA sequences were found to be identical to those of the Kaposi's sarcoma-associated herpesvirus (KSHV). We obtained early-passage spindle cells from skin lesions of patients with the acquired immunodeficiency syndrome (AIDS) who had Kaposi's sarcoma and cultured them with cells of the human embryonal-kidney epithelial-cell line 293. We characterized the virus according to its effects on cellular morphology and viral replication and its appearance on electron microscopy. Results KSHV was cytotoxic to 293 cells and was detected by the polymerase chain reaction (PCR) in infected cells but not uninfected ones. Cytotoxicity and positive PCR signals were consistently maintained with viral titers of 1 million per milliliter or higher for about 20 serial infections of 293 cells. The viral copy number was relatively low (1 to 10 copies per cell). Viral replication was confirmed by Southern blot analysis of DNA isolated from the enriched nuclear fraction of infected cells and by a semiquantitative PCR using dilutions of the lysates of infected cells to detect the 233-bp viral DNA fragment originally described in association with Kaposi's lesions. Electron microscopy revealed herpesvirus-like particles in about 1 percent of cells from infected cultures, as compared with none in cells from uninfected cultures. Conclusions A herpesvirus with DNA sequences identical to those of KSHV can be propagated from skin lesions of patients with AIDS-associated Kaposi's sarcoma. (C) 1997, Massachusetts Medical Society.	UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,MSRBI,DEPT INTERNAL MED & BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT ORAL PATHOL,ANN ARBOR,MI 48109; LOYOLA UNIV,MED CTR,DEPT PATHOL,CARDINAL BERNARDIN CANC CTR,SKIN DIS RES LABS,MAYWOOD,IL 60153	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Loyola University Chicago			Polverini, Peter/AAJ-8392-2020		NCI NIH HHS [CA70057, CA64416] Funding Source: Medline; NIAMS NIH HHS [AR40488] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064416, R01CA070057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; APOLLONI A, 1994, VIROLOGY, V202, P978, DOI 10.1006/viro.1994.1422; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, EUR J CANCER, V27, P1057, DOI 10.1016/0277-5379(91)90281-H; BERAL V, 1991, CANCER SURV, V10, P5; BERAL V, 1992, CANCER SURV, V12, pA225; Boshoff C, 1996, Lancet, V348, P138; Boshoff C, 1996, LANCET, V347, P338, DOI 10.1016/S0140-6736(96)90524-3; CAO M, 1989, J INVEST DERMATOL, V92, P391, DOI 10.1111/1523-1747.ep12277232; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COEN DM, 1992, CURRENT PROTOCOLS MO, V2; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; EIZURU Y, 1984, J CLIN MICROBIOL, V20, P1012, DOI 10.1128/JCM.20.5.1012-1014.1984; Finesmith Tina H., 1994, International Journal of Dermatology, V33, P755, DOI 10.1111/j.1365-4362.1994.tb00983.x; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; HUANG TQ, 1993, ARCH DERMATOL, V129, P1622; HUANG YQ, 1993, ARCH DERMATOL, V129, P1291, DOI 10.1001/archderm.129.10.1291; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; JOACHIM HL, 1995, CANCER, V75, P1376; JONES K, 1995, J EXP MED, V182, P1213, DOI 10.1084/jem.182.5.1213; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; LEBBE C, 1995, LANCET, V345, P1180, DOI 10.1016/S0140-6736(95)91011-5; LENHOFF RJ, 1994, J VIROL, V68, P4565, DOI 10.1128/JVI.68.7.4565-4571.1994; LIN JC, 1995, LANCET, V346, P1601, DOI 10.1016/S0140-6736(95)91931-7; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; NAIDU YM, 1994, P NATL ACAD SCI USA, V91, P5281, DOI 10.1073/pnas.91.12.5281; PATER MM, 1976, VIROLOGY, V75, P481, DOI 10.1016/0042-6822(76)90046-5; RADY PL, 1995, LANCET, V345, P1339, DOI 10.1016/S0140-6736(95)92538-4; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; SAADU A, 1993, CLIN EXP IMMUNOL, V91, P50, DOI 10.1111/j.1365-2249.1993.tb03352.x; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; YANG J, 1994, J IMMUNOL, V152, P361	37	150	157	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1997	336	3					163	171		10.1056/NEJM199701163360302	http://dx.doi.org/10.1056/NEJM199701163360302			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC266	8988896				2022-12-01	WOS:A1997WC26600002
J	Petrie, J; Small, M; Connell, J				Petrie, J; Small, M; Connell, J			''Glitazones'', a prospect for non-insulin-dependent diabetes	LANCET			English	Editorial Material							EXPRESSION		W GLASGOW HOSP UNIV NHS TRUST,GLASGOW,LANARK,SCOTLAND	University of Glasgow	Petrie, J (corresponding author), UNIV GLASGOW,WESTERN INFIRM,DEPT MED & THERAPEUT,GLASGOW G11 6NT,LANARK,SCOTLAND.							Berger M, 1996, DIABETOLOGIA, V39, P873, DOI 10.1007/BF03035774; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; IBRAHIMI A, 1994, MOL PHARMACOL, V46, P1070; Iwamoto Y, 1996, DIABETIC MED, V13, P365, DOI 10.1002/(SICI)1096-9136(199604)13:4<365::AID-DIA19>3.0.CO;2-M; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; OSTREGA D, 1995, DIABETES, V44, P437, DOI 10.2337/diabetes.44.4.437; PETRIE JR, 1994, DRUGS, V47, P701, DOI 10.2165/00003495-199447050-00001; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; STEVENSON RW, 1990, DIABETES, V39, P1218, DOI 10.2337/diabetes.39.10.1218; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118	10	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					70	71		10.1016/S0140-6736(97)22002-7	http://dx.doi.org/10.1016/S0140-6736(97)22002-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996411				2022-12-01	WOS:A1997WB80000002
J	Choquet, D; Felsenfeld, DP; Sheetz, MP				Choquet, D; Felsenfeld, DP; Sheetz, MP			Extracellular matrix rigidity causes strengthening of integrin-cytoskeleton linkages	CELL			English	Article							LOCOMOTING CELLS; TYROSINE PHOSPHORYLATION; TRACTION FORCES; GROWTH CONE; FIBRONECTIN; DOMAIN; REARRANGEMENT; FIBROBLASTS; ATTACHMENT; EXPRESSION	To move forward, migrating cells must generate traction forces through surface receptors bound to extracellular matrix molecules coupled to a rigid structure. We investigated whether cells sample and respond to the rigidity of the anchoring matrix. Movement of beads coated with fibronectin or an anti-integrin antibody was restrained with an optical trap on fibroblasts to mimic extracellular attachment sites of different resistance. Cells precisely sense the restraining force on fibronectin beads and respond by a localized, proportional strengthening of the cytoskeleton linkages, allowing stronger force to be exerted on the integrins. This strengthening was absent or transient with antibody beads, but restored with soluble fibronectin. Hence, ligand binding site occupancy was required. Finally, phenylarsine oxide inhibited strengthening of cytoskeletal linkages, indicating a role for dephosphorylation. Thus, the strength of integrin-cytoskeleton linkages is dependent on matrix rigidity and on its biochemical composition. Matrix rigidity may, therefore, serve as a guidance cue in a process of mechanotaxis.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University			Ladoux, Benoit/A-9879-2013; Choquet, Daniel/K-7893-2018; Choquet, Daniel/E-4203-2013	Choquet, Daniel/0000-0003-4726-9763; 				ASHKIN A, 1992, BIOPHYS J, V61, P569, DOI 10.1016/S0006-3495(92)81860-X; CARNEMOLLA B, 1992, J BIOL CHEM, V267, P24689; CROWLEY E, 1995, J CELL BIOL, V131, P525, DOI 10.1083/jcb.131.2.525; DALTON SL, 1992, J BIOL CHEM, V267, P8186; DEMBO M, 1981, J CELL BIOL, V91, P528, DOI 10.1083/jcb.91.2.528; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; HALLIDAY NL, 1995, EXP CELL RES, V217, P109, DOI 10.1006/excr.1995.1069; HARRIS AK, 1981, NATURE, V290, P249, DOI 10.1038/290249a0; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; KIMIZUKA F, 1991, J BIOL CHEM, V266, P3045; KUCIK DF, 1991, J CELL BIOL, V114, P1029, DOI 10.1083/jcb.114.5.1029; Kuo S C, 1992, Trends Cell Biol, V2, P116, DOI 10.1016/0962-8924(92)90016-G; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE J, 1994, J CELL BIOL, V127, P1957, DOI 10.1083/jcb.127.6.1957; Lin CH, 1996, NEURON, V16, P769, DOI 10.1016/S0896-6273(00)80097-5; LIN CH, 1995, NEURON, V14, P763, DOI 10.1016/0896-6273(95)90220-1; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MANDEVILLE JTH, 1996, IN PRESS J LEUKOC BI; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; OLIVER T, 1995, CELL MOTIL CYTOSKEL, V31, P225, DOI 10.1002/cm.970310306; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; ROMER LH, 1992, COLD SPRING HARB SYM, V57, P193, DOI 10.1101/SQB.1992.057.01.024; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SATO M, 1987, ARTERIOSCLEROSIS, V7, P276, DOI 10.1161/01.ATV.7.3.276; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; Sheetz Michael P., 1994, Seminars in Cell Biology, V5, P149, DOI 10.1006/scel.1994.1019; SHIRINSKY VP, 1989, J CELL BIOL, V109, P331, DOI 10.1083/jcb.109.1.331; Simmons RM, 1996, BIOPHYS J, V70, P1813, DOI 10.1016/S0006-3495(96)79746-1; SIMS JR, 1992, J CELL SCI, V103, P1215; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; STOPAK D, 1985, P NATL ACAD SCI USA, V82, P2804, DOI 10.1073/pnas.82.9.2804; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; WANG N, 1994, BIOPHYS J, V66, P2181, DOI 10.1016/S0006-3495(94)81014-8; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; ZHELEV DV, 1995, BIOPHYS J, V68, P2004, DOI 10.1016/S0006-3495(95)80377-2	46	991	1009	2	93	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					39	48		10.1016/S0092-8674(00)81856-5	http://dx.doi.org/10.1016/S0092-8674(00)81856-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019403	Bronze			2022-12-01	WOS:A1997WC56900007
J	Zapun, A; Petrescu, SM; Rudd, PM; Dwek, RA; Thomas, DY; Bergeron, JJM				Zapun, A; Petrescu, SM; Rudd, PM; Dwek, RA; Thomas, DY; Bergeron, JJM			Conformation-independent binding of monoglucosylated ribonuclease B to calnexin	CELL			English	Article							HISTOCOMPATIBILITY COMPLEX-MOLECULES; HIGH MANNOSE OLIGOSACCHARIDES; PROTEIN DISULFIDE-ISOMERASE; ENDOPLASMIC-RETICULUM; GLYCOPROTEIN GLUCOSYLTRANSFERASE; RAT-LIVER; LINKED OLIGOSACCHARIDES; UDP-GLC; ASSOCIATION; RECOGNITION	Calnexin is a membrane protein of the endoplasmic reticulum that associates transiently with newly synthesized N-linked glycoproteins in vivo. Using defined components, the binding of ribonuclease B (RNase B) Man(7)-Man(9) glycoforms to the luminal domain of calnexin was observed in vitro only if RNase B was monoglucosylated. Binding was independent of the conformation of the glycoprotein. Calnexin protected monoglucosylated RNase B from the action of glucosidase II and PNGase F but not from that of Endo H, which completely released the protein from calnexin. These observations directly demonstrate that calnexin can act exclusively as a lectin.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,GENET GRP,MONTREAL,PQ H4P 2R2,CANADA; UNIV OXFORD,DEPT BIOCHEM,OXFORD GLYCOBIOL INST,OXFORD OX1 3QU,ENGLAND; INST BIOCHEM,BUCHAREST 77700,ROMANIA; MCGILL UNIV,DEPT BIOL,MONTREAL,PQ H3A 1B1,CANADA	National Research Council Canada; University of Oxford; Romanian Academy of Sciences; Institute of Biochemistry, Bucharest; McGill University	Zapun, A (corresponding author), MCGILL UNIV,DEPT ANAT & CELL BIOL,MONTREAL,PQ H3A 2B2,CANADA.		Petrescu, Stefana M/I-9240-2012; Petrescu, Stefana/AAJ-9505-2021; Bergeron, John/AAW-1893-2021; Thomas, David/M-7661-2017	Petrescu, Stefana M/0000-0002-4047-0811; Petrescu, Stefana/0000-0002-4047-0811; Thomas, David/0000-0002-8854-762X; Zapun, Andre/0000-0001-8953-4399				ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BALOW JP, 1995, J BIOL CHEM, V270, P29025, DOI 10.1074/jbc.270.48.29025; BRADA D, 1984, EUR J BIOCHEM, V141, P149, DOI 10.1111/j.1432-1033.1984.tb08169.x; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; CARRENO BM, 1995, J IMMUNOL, V154, P5173; CHU FK, 1986, J BIOL CHEM, V261, P172; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; DATEMA R, 1982, P NATL ACAD SCI-BIOL, V79, P6787, DOI 10.1073/pnas.79.22.6787; GRAFL R, 1987, J BIOL CHEM, V262, P10624; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARODI AJ, 1984, J BIOL CHEM, V259, P6351; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RUDD PM, 1994, BIOCHEMISTRY-US, V33, P17, DOI 10.1021/bi00167a003; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SUH KS, 1989, J CELL BIOL, V108, P811, DOI 10.1083/jcb.108.3.811; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WANG FFC, 1977, J BIOL CHEM, V252, P8358; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WATANABE D, 1994, J BIOL CHEM, V269, P7744; WILLIAMS RL, 1987, J BIOL CHEM, V262, P16020; YEO KT, 1989, BIOCHEM BIOPH RES CO, V161, P1013, DOI 10.1016/0006-291X(89)91344-2; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	43	174	178	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					29	38		10.1016/S0092-8674(00)81855-3	http://dx.doi.org/10.1016/S0092-8674(00)81855-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019402	Bronze			2022-12-01	WOS:A1997WC56900006
J	Keeling, MJ; Grenfell, BT				Keeling, MJ; Grenfell, BT			Disease extinction and community size: Modeling the persistence of measles	SCIENCE			English	Article							CHAOS; DYNAMICS; EPIDEMIC; COMPLEXITY; CHANCE	A basic issue in ecology is the relation between extinction and population size. One of the dearest manifestations of a population threshold for extinction is the critical community size below which infections like measles do not persist. The current generation of stochastic models overestimates the observed critical community size for measles, generating much less persistence of infection than is observed. The inclusion of a more biologically realistic model for the duration of infection produced a much closer fit to the actual critical community size and explains previously undescribed high-frequency oscillations in measles incidence.			Keeling, MJ (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.		Keeling, Matt J/J-9280-2012	Keeling, Matt J/0000-0003-4639-4765	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; Anderson R M, 1984, IMA J Math Appl Med Biol, V1, P233; ARON JL, 1984, J THEOR BIOL, V110, P665, DOI 10.1016/S0022-5193(84)80150-2; Bailey N.T.J., 1975, MATH THEORY INFECT D; BAILEY NTJ, 1956, BIOMETRIKA, V43, P15; BARTLETT MS, 1960, J R STAT SOC SER A-G, V123, P37, DOI 10.2307/2343186; BARTLETT MS, 1957, J R STAT SOC SER A-G, V120, P48, DOI 10.2307/2342553; BLACK FL, 1966, J THEOR BIOL, V11, P207, DOI 10.1016/0022-5193(66)90161-5; BOLKER B, 1995, PHILOS T R SOC B, V348, P309, DOI 10.1098/rstb.1995.0070; BOLKER B, 1993, IMA J MATH APPL MED, V10, P83; BOLKER BM, 1993, P ROY SOC B-BIOL SCI, V251, P75, DOI 10.1098/rspb.1993.0011; Burnet M., 1972, NATURAL HIST INFECT; Cliff A., 1981, SPATIAL DIFFUSION HI; ENGBERT R, 1994, CHAOS SOLITON FRACT, V4, P1147, DOI 10.1016/0960-0779(94)90028-0; FERGUSON NM, 1996, PREPRINT; FINE PEM, 1982, INT J EPIDEMIOL, V11, P5, DOI 10.1093/ije/11.1.5; Grenfell B T, 1995, Stat Methods Med Res, V4, P160, DOI 10.1177/096228029500400205; GRENFELL BT, 1995, P ROY SOC B-BIOL SCI, V259, P97, DOI 10.1098/rspb.1995.0015; GRENFELL BT, 1992, J ROY STAT SOC B MET, V54, P383; GRENFELL BT, 1994, PHILOS T R SOC A, V348, P515, DOI 10.1098/rsta.1994.0108; GROSSMAN Z, 1980, THEOR POPUL BIOL, V18, P204, DOI 10.1016/0040-5809(80)90050-7; HOPPENSTEADT F, 1974, J FRANKLIN I, V297, P325, DOI 10.1016/0016-0032(74)90037-4; KEELING MJ, 1996, PREPRINT; Lloyd AL, 1996, J THEOR BIOL, V179, P1, DOI 10.1006/jtbi.1996.0042; MAY RM, 1984, MATH BIOSCI, V72, P83, DOI 10.1016/0025-5564(84)90063-4; MOLLISON D, 1984, NATURE, V310, P224, DOI 10.1038/310224a0; MOLLISON D, 1991, MATH BIOSCI, V107, P255, DOI 10.1016/0025-5564(91)90009-8; OLSEN LF, 1990, SCIENCE, V249, P499, DOI 10.1126/science.2382131; Schenzle D, 1984, IMA J Math Appl Med Biol, V1, P169; SIMPSON REH, 1952, LANCET, V263, P549; Soper HE, 1929, J R STAT SOC, V92, P34, DOI 10.2307/2341437	31	305	308	0	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 3	1997	275	5296					65	67		10.1126/science.275.5296.65	http://dx.doi.org/10.1126/science.275.5296.65			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974392				2022-12-01	WOS:A1997WA90300048
J	Bito, H; Deisseroth, K; Tsien, RW				Bito, H; Deisseroth, K; Tsien, RW			CREB phosphorylation and dephosphorylation: A Ca2(+)- and stimulus duration-dependent switch for hippocampal gene expression	CELL			English	Article							PROTEIN-KINASE-IV; LONG-TERM-MEMORY; CAMP-RESPONSIVE ELEMENT; C-FOS TRANSCRIPTION; RAT-BRAIN; SOMATOSTATIN GENE; BINDING PROTEIN; MUTANT MICE; CALMODULIN; NEURONS	While changes in gene expression are critical for many brain functions, including long-term memory, little is known about the cellular processes that mediate stimulus-transcription coupling at central synapses. In studying the signaling pathways by which synaptic inputs control the phosphorylation state of cyclic AMP-responsive element binding protein (CREB) and determine expression of CRE-regulated genes, we found two important Ca2+/calmodulin (CaM)-regulated mechanisms in hippocampal neurons: a CaM kinase cascade involving nuclear CaMKIV and a calcineurin-dependent regulation of nuclear protein phosphatase 1 activity. Prolongation of the synaptic input on the time scale of minutes, in part by an activity-induced inactivation of calcineurin, greatly extends the period over which phospho-CREB levels are elevated, thus affecting induction of downstream genes.			Bito, H (corresponding author), STANFORD UNIV,BECKMAN CTR,SCH MED,DEPT MOL & CELLULAR PHYSIOL,STANFORD,CA 94305, USA.		Bito, Haruhiko/A-8635-2008	Bito, Haruhiko/0000-0001-6315-9594				ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bennett PC, 1996, BRAIN RES, V730, P107; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; BROCKE L, 1995, J NEUROSCI, V15, P6797; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CURRAN T, 1995, J NEUROBIOL, V26, P403, DOI 10.1002/neu.480260312; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; DEZAZZO J, 1995, TRENDS NEUROSCI, V18, P212, DOI 10.1016/0166-2236(95)93905-D; DUGAN LL, 1995, J NEUROSCI, V15, P6377; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; ITO T, 1994, ARCH BIOCHEM BIOPHYS, V312, P278, DOI 10.1006/abbi.1994.1310; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Klee C.B., 1988, CALMODULIN, P225; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LIU FC, 1996, IN PRESS NEURON, V17; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUOKA N, 1995, NEUROSCIENCE, V66, P617, DOI 10.1016/0306-4522(94)00628-I; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141, DOI 10.1016/0959-4388(95)80019-0; Nagao M, 1995, MUTAT RES-FUND MOL M, V333, P173, DOI 10.1016/0027-5107(95)00143-3; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; OUIMET CC, 1995, P NATL ACAD SCI USA, V92, P3396, DOI 10.1073/pnas.92.8.3396; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; PAYLOR R, 1994, BRAIN RES, V651, P275, DOI 10.1016/0006-8993(94)90707-2; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; SAKAGAMI H, 1993, MOL BRAIN RES, V19, P215, DOI 10.1016/0169-328X(93)90029-O; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; STEMMER PM, 1995, FEBS LETT, V374, P237, DOI 10.1016/0014-5793(95)01095-V; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; VALLEJO M, 1995, MOL CELL BIOL, V15, P415, DOI 10.1128/MCB.15.1.415; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; XIE HJ, 1995, J IMMUNOL, V154, P1717; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; YOSHIDA K, 1995, J NEUROCHEM, V65, P1499; Zhang W, 1996, J EXP MED, V183, P413, DOI 10.1084/jem.183.2.413	73	943	963	0	47	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1203	1214		10.1016/S0092-8674(00)81816-4	http://dx.doi.org/10.1016/S0092-8674(00)81816-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980227	Bronze			2022-12-01	WOS:A1996WA54100009
J	Mizzen, CA; Yang, XJ; Kokubo, T; Brownell, JE; Bannister, AJ; OwenHughes, T; Workman, J; Wang, L; Berger, SL; Kouzarides, T; Nakatani, Y; Allis, CD				Mizzen, CA; Yang, XJ; Kokubo, T; Brownell, JE; Bannister, AJ; OwenHughes, T; Workman, J; Wang, L; Berger, SL; Kouzarides, T; Nakatani, Y; Allis, CD			The TAF(II)250 subunit of TFIID has histone acetyltransferase activity	CELL			English	Article							RNA-POLYMERASE-II; TATA-BOX-BINDING; TRANSCRIPTION FACTOR; NUCLEOSOMAL DNA; FACILITATED BINDING; ACETYLATION; CHROMATIN; GENE; ACTIVATION; INITIATION	The transcription initiation factor TFIID is a multimeric protein complex composed of TATA box-binding protein (TBP) and many TBP-associated factors (TAF(II)s). TAF(II)s are important cofactors that mediate activated transcription by providing interaction sites for distinct activators. Here, we present evidence that human TAF(II)250 and its homologs in Drosophila and yeast have histone acetyltransferase (HAT) activity in vitro. HAT activity maps to the central, most conserved portion of dTAF(II)230 and yTAF(II)130. The HAT activity of dTAF(II)230 resembles that of yeast and human GCN5 in that it is specific for histones H3 and H4 in vitro. Our findings suggest that targeted histone acetylation at specific promoters by TAF(II)250 may be involved in mechanisms by which TFIID gains access to transcriptionally repressed chromatin.	UNIV ROCHESTER, DEPT BIOL, ROCHESTER, NY 14627 USA; NICHHD, LAB MOL GROWTH REGULAT, NIH, BETHESDA, MD 20892 USA; UNIV CAMBRIDGE, WELLCOME CRC INST, CAMBRIDGE CB2 1QR, ENGLAND; PENN STATE UNIV, DEPT BIOCHEM & MOL BIOL, UNIVERSITY PK, PA 16802 USA; WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; NARA INST SCI & TECHNOL, NARA 63001, JAPAN	University of Rochester; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Cambridge; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; The Wistar Institute; Nara Institute of Science & Technology				Owen-Hughes, Tom/0000-0002-0618-8185; Kouzarides, Tony/0000-0002-8918-4162; Berger, Shelley/0000-0001-5398-4400; Bannister, Andrew/0000-0002-6312-4436	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053512, R37GM053512] Funding Source: NIH RePORTER; NIGMS NIH HHS [NIH-GM53512] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BAUER WR, 1994, J MOL BIOL, V236, P685, DOI 10.1006/jmbi.1994.1180; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Candau R, 1996, MOL CELL BIOL, V16, P593; CANDAU R, 1997, IN PRESS EMBO J; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; GODDE JS, 1995, NUCLEIC ACIDS RES, V23, P4557, DOI 10.1093/nar/23.22.4557; HAYASHIDA T, 1994, GENE, V141, P267; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/0968-0004(96)10043-8; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LOIDL P, 1994, CHROMOSOMA, V103, P441; Lu L, 1996, J BIOL CHEM, V271, P18920, DOI 10.1074/jbc.271.31.18920; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Nakatani Y, 1996, J BIOL CHEM, V271, P6575, DOI 10.1074/jbc.271.12.6575; NISHIKAWA J, 1997, IN PRESS P NATL ACAD; NORTON VG, 1990, J BIOL CHEM, V265, P19848; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OLINS AL, 1976, NUCLEIC ACIDS RES, V3, P3271, DOI 10.1093/nar/3.12.3271; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; PRUZAN R, 1992, NUCLEIC ACIDS RES, V20, P5705, DOI 10.1093/nar/20.21.5705; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/S0968-0004(96)10050-5; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; Roth SY, 1996, TRENDS CELL BIOL, V6, P371, DOI 10.1016/0962-8924(96)20032-7; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WANG L, 1997, IN PRESS MOL CELL BI; WEINZIERL RO, 1993, NATURE, V262, P511; WOLFFE AP, 1994, CURR OPIN GENET DEV, V4, P245, DOI 10.1016/S0959-437X(05)80051-6; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	70	618	628	0	17	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 27	1996	87	7					1261	1270		10.1016/S0092-8674(00)81821-8	http://dx.doi.org/10.1016/S0092-8674(00)81821-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980232	hybrid			2022-12-01	WOS:A1996WA54100014
J	Ryner, LC; Goodwin, SF; Castrillon, DH; Anand, A; Villella, A; Baker, BS; Hall, JC; Taylor, BJ; Wasserman, SA				Ryner, LC; Goodwin, SF; Castrillon, DH; Anand, A; Villella, A; Baker, BS; Hall, JC; Taylor, BJ; Wasserman, SA			Control of male sexual behavior and sexual orientation in Drosophila by the fruitless gene	CELL			English	Article							NERVOUS-SYSTEM; DNA-BINDING; MELANOGASTER; DIFFERENTIATION; MUSCLE; PROTEINS; METAMORPHOSIS; EXPRESSION; DOUBLESEX; COURTSHIP	Sexual orientation and courtship behavior in Drosophila are regulated by fruitless (fru), the first gene in a branch of the sex-determination hierarchy functioning specifically in the central nervous system (CNS). The phenotypes of new fru mutants encompass nearly all aspects of male sexual behavior. Alternative splicing of fru transcripts produces sex-specific proteins belonging to the BTB-ZF family of transcriptional regulators. The sex-specific fru products are produced in only about 500 of the 10(5) neurons that comprise the CNS. The properties of neurons expressing these fru products suggest that fru specifies the fates or activities of neurons that carry out higher order control functions to elicit and coordinate the activities comprising male courtship behavior.	BRANDEIS UNIV, DEPT BIOL, WALTHAM, MA 02254 USA; UNIV TEXAS, SW MED CTR, DEPT MOL BIOL & ONCOL, DALLAS, TX 75235 USA; OREGON STATE UNIV, DEPT ZOOL, CORVALLIS, OR 97331 USA	Brandeis University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Oregon State University	Ryner, LC (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.			Goodwin, Stephen/0000-0002-0552-4140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021473] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033352] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-21473] Funding Source: Medline; NINDS NIH HHS [NS-33352] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; BELOTE JM, 1987, P NATL ACAD SCI USA, V84, P8026, DOI 10.1073/pnas.84.22.8026; BREEDLOVE SM, 1994, ANNU REV PSYCHOL, V45, P389, DOI 10.1146/annurev.psych.45.1.389; BREEDLOVE SM, 1992, J NEUROSCI, V12, P4133; BURROWS M, 1992, TRENDS NEUROSCI, V15, P226, DOI 10.1016/0166-2236(92)90040-F; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; Burtis KC, 1993, CURR OPIN CELL BIOL, V5, P1006, DOI 10.1016/0955-0674(93)90085-5; CASTRILLON DH, 1993, GENETICS, V135, P489; Dauwalder B, 1996, P NATL ACAD SCI USA, V93, P9004, DOI 10.1073/pnas.93.17.9004; DIANTONIO A, 1993, J NEUROSCI, V13, P4924; EMERY IF, 1994, DEVELOPMENT, V120, P3275; GAILEY DA, 1991, DEVELOPMENT, V113, P879; GREENSPAN RJ, 1995, SCI AM, V272, P74; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; HAMBLENCOYLE M, 1989, J NEUROGENET, V5, P229, DOI 10.3109/01677068909066210; HEISENBERG M, 1995, J NEUROSCI, V15, P1951, DOI 10.1523/JNEUROSCI.15-03-01951.1995; HEISENBERG M, 1994, CENTRAL BRAIN FUNCTI, P61; Hing ALY, 1996, J NEUROBIOL, V30, P454; HU S, 1995, NAT GENET, V11, P248, DOI 10.1038/ng1195-248; HU S, 1995, GENE DEV, V9, P2936, DOI 10.1101/gad.9.23.2936; Ito H, 1996, P NATL ACAD SCI USA, V93, P9687, DOI 10.1073/pnas.93.18.9687; KULKARNI SJ, 1987, GENETICS, V115, P461; LAWRENCE PA, 1986, CELL, V45, P505, DOI 10.1016/0092-8674(86)90282-5; LEVAY S, 1996, QUEER SCI; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MATSUO N, 1995, J BIOL CHEM, V270, P28216, DOI 10.1074/jbc.270.47.28216; MCKEOWN M, 1994, DEV GENET, V15, P201, DOI 10.1002/dvg.1020150302; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PERKINS A, 1995, HORM BEHAV, V29, P31, DOI 10.1006/hbeh.1995.1003; PIRROTTA V, 1986, DROSOPHILA PRACTICAL; READ D, 1992, MECH DEVELOP, V38, P183, DOI 10.1016/0925-4773(92)90052-L; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; RYNER LC, 1995, CELL, V81, P483, DOI 10.1016/0092-8674(95)90069-1; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Segade F, 1996, FEBS LETT, V387, P152, DOI 10.1016/0014-5793(96)00496-6; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; SWAAB DF, 1995, TRENDS NEUROSCI, V18, P264, DOI 10.1016/0166-2236(95)93913-I; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TAYLOR BJ, 1995, DEVELOPMENT, V121, P3079; TAYLOR BJ, 1994, DEV GENET, V15, P275, DOI 10.1002/dvg.1020150309; TAYLOR BJ, 1992, GENETICS, V132, P179; Villella A, 1996, GENETICS, V143, P331; VONKALM L, 1994, EMBO J, V13, P3505, DOI 10.1002/j.1460-2075.1994.tb06657.x; ZHANG SD, 1995, P NATL ACAD SCI USA, V92, P5525, DOI 10.1073/pnas.92.12.5525	46	388	395	3	72	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 13	1996	87	6					1079	1089		10.1016/S0092-8674(00)81802-4	http://dx.doi.org/10.1016/S0092-8674(00)81802-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978612	Bronze			2022-12-01	WOS:A1996VY44700013
J	Sheen, J				Sheen, J			Ca2+-dependent protein kinases and stress signal transduction in plants	SCIENCE			English	Article							STOMATAL GUARD-CELLS; ABSCISIC-ACID; ARABIDOPSIS-THALIANA; GENE-EXPRESSION; MOLECULAR RESPONSES; PROMOTER ACTIVITY; SEED MATURATION; LOW-TEMPERATURE; OSMOTIC-STRESS; SALT STRESS	Stress responses in plants involve changes in the transcription of specific genes. The constitutively active mutants of two related Ca2+-dependent protein kinases (CDPK1 and CDPK1a) activate a stress-inducible promoter, bypassing stress signals. Six other plant protein kinases, including two distinct CDPKs, fail to mimic this stress signaling, The activation is abolished by a CDPK1 mutation in the kinase domain and diminished by a constitutively active protein phosphatase 2C that is capable of blocking responses to the stress hormone abscisic acid. A variety of functions are mediated by different CDPKs. CDPK1 and CDPK1a may be positive regulators controlling stress signal transduction in plants.	MASSACHUSETTS GEN HOSP, DEPT MOL BIOL, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital	Sheen, J (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA.							ANDERBERG RJ, 1992, P NATL ACAD SCI USA, V89, P10183, DOI 10.1073/pnas.89.21.10183; ARMSTRONG F, 1995, P NATL ACAD SCI USA, V92, P9520, DOI 10.1073/pnas.92.21.9520; ASSMANN SM, 1993, ANNU REV CELL BIOL, V9, P345, DOI 10.1146/annurev.cb.09.110193.002021; BAKER SS, 1994, PLANT MOL BIOL, V24, P701, DOI 10.1007/BF00029852; Bethke Paul C., 1995, P298; BRAAM J, 1992, P NATL ACAD SCI USA, V89, P3213, DOI 10.1073/pnas.89.8.3213; BRAY EA, 1993, PLANT PHYSIOL, V103, P1035, DOI 10.1104/pp.103.4.1035; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CHANDLER PM, 1994, ANNU REV PLANT PHYS, V45, P113, DOI 10.1146/annurev.pp.45.060194.000553; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; CHRISTENSEN AH, 1992, PLANT MOL BIOL, V18, P675, DOI 10.1007/BF00020010; Daugherty C.J., 1994, ARABIDOPSIS, P769; DEVETTEN NC, 1995, PLANT J, V7, P589, DOI 10.1046/j.1365-313X.1995.7040589.x; ESTRUCH JJ, 1994, P NATL ACAD SCI USA, V91, P8837, DOI 10.1073/pnas.91.19.8837; FINKELSTEIN RR, 1993, MOL GEN GENET, V238, P401, DOI 10.1007/BF00291999; FINKELSTEIN RR, 1994, ARABIDOPSIS, P523; GIRAUDAT J, 1994, PLANT MOL BIOL, V26, P1557, DOI 10.1007/BF00016490; GOSTI F, 1995, MOL GEN GENET, V246, P10, DOI 10.1007/BF00290128; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HARPER JF, 1994, BIOCHEMISTRY-US, V33, P7267, DOI 10.1021/bi00189a031; HATTORI T, 1995, PLANT J, V7, P913, DOI 10.1046/j.1365-313X.1995.07060913.x; HATTORI T, 1992, GENE DEV, V6, P609, DOI 10.1101/gad.6.4.609; HOECKER U, 1995, GENE DEV, V9, P2459, DOI 10.1101/gad.9.20.2459; HOLAPPA LD, 1995, PLANT PHYSIOL, V108, P1203, DOI 10.1104/pp.108.3.1203; Jefferson RA., 1987, PLANT MOL BIOL REP, V5, P387, DOI DOI 10.1007/BF02667740; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KNIGHT CD, 1995, PLANT CELL, V7, P499, DOI 10.1105/tpc.7.5.499; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Lu GH, 1996, PLANT CELL, V8, P847, DOI 10.1105/tpc.8.5.847; LUEHRSEN KR, 1992, METHOD ENZYMOL, V216, P397; MCAINSH MR, 1992, PLANT CELL, V4, P1113, DOI 10.2307/3869479; MCCARTY DR, 1995, ANNU REV PLANT PHYS, V46, P71, DOI 10.1146/annurev.pp.46.060195.000443; MENKENS AE, 1995, TRENDS BIOCHEM SCI, V20, P506, DOI 10.1016/S0968-0004(00)89118-5; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; MINET M, 1992, PLANT J, V2, P417; MONROY AF, 1995, PLANT CELL, V7, P321, DOI 10.1105/tpc.7.3.321; Nakagawa H, 1996, PLANT J, V9, P217, DOI 10.1046/j.1365-313X.1996.09020217.x; NAMBARA E, 1995, DEVELOPMENT, V121, P629; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; PARK YS, 1993, PLANT MOL BIOL, V22, P615, DOI 10.1007/BF00047402; PLA M, 1993, PLANT MOL BIOL, V21, P259, DOI 10.1007/BF00019942; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; ROCK CD, 1994, CURR BIOL, V4, P1013, DOI 10.1016/S0960-9822(00)00229-3; SCHROEDER JI, 1991, PLANT CELL, V3, P555, DOI 10.2307/3869184; SHEEN J, 1993, EMBO J, V12, P3497, DOI 10.1002/j.1460-2075.1993.tb06024.x; SHEEN J, UNPUB; SHEN QX, 1995, PLANT CELL, V7, P295, DOI 10.1105/tpc.7.3.295; SKRIVER K, 1990, PLANT CELL, V2, P503, DOI 10.1105/tpc.2.6.503; STRAUB PF, 1994, PLANT MOL BIOL, V26, P617, DOI 10.1007/BF00013748; SUEN KL, 1991, PLANT MOL BIOL, V17, P581, DOI 10.1007/BF00037045; TAYLOR JE, 1995, PLANT J, V7, P129, DOI 10.1046/j.1365-313X.1995.07010129.x; THOMAS JC, 1993, PLANT PHYSIOL, V103, P1299, DOI 10.1104/pp.103.4.1299; THOMAS TL, 1993, PLANT CELL, V5, P1401, DOI 10.1105/tpc.5.10.1401; THOMASHOW MF, 1994, ARABIDOPSIS, P807, DOI DOI 10.1101/0.807-834; TREWAVAS A, 1994, PLANT MOL BIOL, V26, P1329, DOI 10.1007/BF00016478; URAO T, 1994, MOL GEN GENET, V244, P331, DOI 10.1007/BF00286684; URAO T, 1994, PLANT PHYSIOL, V105, P1461, DOI 10.1104/pp.105.4.1461; WARD JM, 1994, PLANT CELL, V6, P669; Xu DP, 1996, PLANT PHYSIOL, V110, P249, DOI 10.1104/pp.110.1.249; YAMAGUCHISHINOZAKI K, 1994, PLANT CELL, V6, P251, DOI 10.1105/tpc.6.2.251	65	454	550	4	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 13	1996	274	5294					1900	1902		10.1126/science.274.5294.1900	http://dx.doi.org/10.1126/science.274.5294.1900			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943201				2022-12-01	WOS:A1996VY20000041
J	Duina, AA; Chang, HCJ; Marsh, JA; Lindquist, S; Gaber, RF				Duina, AA; Chang, HCJ; Marsh, JA; Lindquist, S; Gaber, RF			A cyclophilin function in Hsp90-dependent signal transduction	SCIENCE			English	Article							HEAT-SHOCK PROTEINS; STEROID-RECEPTOR; SACCHAROMYCES-CEREVISIAE; PROGESTERONE-RECEPTOR; GLUCOCORTICOID RECEPTOR; CYCLOSPORINE-A; HOMOLOG NINAA; HSP90; BINDING; DOMAIN	Cpr6 and Cpr7, the Saccharomyces cerevisiae homologs of cyclophilin-40 (CyP-40), were shown to form complexes with Hsp90, a protein chaperone that functions in several signal transduction pathways, Deletion of CPR7 caused severe growth defects when combined with mutations that decrease the amount of Hsp90 or Sti1, another component of the Hsp90 chaperone machinery. The activities of two heterologous Hsp90-dependent signal transducers expressed in yeast, glucocorticoid receptor and pp60(v-src) kinase, were adversely affected by cpr7 null mutations. These results suggest that CyP-40 cyclophilins play a general role in Hsp90-dependent signal transduction pathways under normal growth conditions.	NORTHWESTERN UNIV,DEPT BIOCHEM MOL BIOL & CELL BIOL,EVANSTON,IL 60208; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	Northwestern University; Howard Hughes Medical Institute; University of Chicago			Foreman, Hui-Chen (Jane)/GMW-4448-2022	Foreman, Hui-Chen (Jane)/0000-0001-9640-9780	NIGMS NIH HHS [GM45739, GM25874] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025874, R37GM025874, R01GM045739] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CHANG H, UNPUB; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CHANG HCJ, IN PRESS MOL CELL BI; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Duina AA, 1996, YEAST, V12, P943, DOI 10.1002/(SICI)1097-0061(199608)12:10<943::AID-YEA997>3.0.CO;2-3; DUINA AA, UNPUB; FREEMAN BC, 1996, EMBO J, V12, P2969; FREEMAN BC, 1996, SCIENCE, V274; GARABEDIAN MJ, 1992, MOL BIOL CELL, V3, P1245, DOI 10.1091/mbc.3.11.1245; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HINKO A, 1993, ENDOCRINOLOGY, V133, P1511, DOI 10.1210/en.133.4.1511; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; MILAD M, 1995, MOL ENDOCRINOL, V9, P838, DOI 10.1210/me.9.7.838; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RENOIR JM, 1995, P NATL ACAD SCI USA, V92, P4977, DOI 10.1073/pnas.92.11.4977; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	36	184	190	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1713	1715		10.1126/science.274.5293.1713	http://dx.doi.org/10.1126/science.274.5293.1713			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939862				2022-12-01	WOS:A1996VW71200061
J	Peyroche, A; Paris, S; Jackson, CL				Peyroche, A; Paris, S; Jackson, CL			Nucleotide exchange on ARF mediated by yeast Gea1 protein	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; GUANINE-NUCLEOTIDE; GOLGI-APPARATUS; TRANSPORT; COATOMER; ENCODES; VACUOLE; MUTANT; GENES	THE ADP-ribosylation factor ARF is a small GTP-binding protein that is involved in the transport of vesicles between the endoplasmic reticulum (ER) and Golgi complex and within the Golgi complex itself(1-4), ARF cycles between inactive and membrane-associated active forms as a result of exchange of bound GDP for GTP; the GTP-bound form is an essential participant in the formation of transport vesicles(4). This nucleotide exchange is inhibited by the fungal metabolite brefeldin A (BFA)(5,6), Here we identify a protein (Gea1) from Saccharomyces cerevisiae that is a component of a complex possessing guanine-nucleotide-exchange activity for ARF: We show that the activity of the complex is sensitive to brefeldin A and that Gea1 function is necessary for ER-Golgi transport in vivo, Gea1 contains a domain that is similar to a domain of Sec7, a protein necessary for intra-Golgi transport. We propose that Gea1 and ARNO, a human protein with a homologous Sed domain(7), are members of a new family of ARF guanine-nucleotide exchange factors.	CEA SACLAY,DEPT BIOL CELLULAIRE & MOL,SERV BIOCHIM & GENET MOL,F-91191 GIF SUR YVETTE,FRANCE; CNRS,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			PEYROCHE, Anne/C-5548-2014; Jackson, Catherine/A-3421-2013; Jackson, Catherine/T-5688-2019	PEYROCHE, Anne/0000-0002-8808-8785; Jackson, Catherine/0000-0002-0843-145X; 				BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; DASCHER C, 1994, J BIOL CHEM, V269, P1437; Deitz SB, 1996, MOL CELL BIOL, V16, P3275; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; FRANZUSOFF A, 1992, NATURE, V355, P173, DOI 10.1038/355173a0; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FUJIMURA K, 1993, MOL GEN GENET, V241, P280, DOI 10.1007/BF00284679; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; JACKSON CL, 1994, GENETICS, V137, P423; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; ZAGULSKI M, 1995, YEAST, V11, P1179, DOI 10.1002/yea.320111208	28	231	235	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					479	481		10.1038/384479a0	http://dx.doi.org/10.1038/384479a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945477				2022-12-01	WOS:A1996VW68700067
J	Fainzilber, M; Smit, AB; Syed, NI; Wildering, WC; Hermann, PM; vanderSchors, RC; Jimenez, C; Li, KW; vanMinnen, J; Bulloch, AGM; Ibanez, CF; Geraerts, WPM				Fainzilber, M; Smit, AB; Syed, NI; Wildering, WC; Hermann, PM; vanderSchors, RC; Jimenez, C; Li, KW; vanMinnen, J; Bulloch, AGM; Ibanez, CF; Geraerts, WPM			CRNF, a molluscan neurotrophic factor that interacts with the p75 neurotrophin receptor	SCIENCE			English	Article							NERVE GROWTH-FACTOR; LYMNAEA-STAGNALIS; NEURONS; EVOLUTIONARY; EXPRESSION; FAMILY; SNAIL; NGF	A 13.1-kilodalton protein, cysteine-rich neurotrophic factor (CRNF), was purified from the mollusk Lymnaea stagnalis by use of a binding assay on the p75 neurotrophin receptor. CRNF bound to p75 with nanomolar affinity but was not similar in sequence to neurotrophins or any other known gene product. CRNF messenger RNA expression was highest in adult foot subepithelial cells; in the central nervous system, expression was regulated by lesion. The factor evoked neurite outgrowth and modulated calcium currents in pedal motor neurons. Thus, CRNF may be involved in target-derived trophic support for motor neurons and could represent the prototype of another family of p75 ligands.	VRIJE UNIV AMSTERDAM,INST NEUROSCI,GRAD SCH NEUROSCI,NL-1081 HV AMSTERDAM,NETHERLANDS; UNIV CALGARY,NEUROSCI RES GRP,CALGARY,AB T2N 4N1,CANADA	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Vrije Universiteit Amsterdam; University of Calgary	Fainzilber, M (corresponding author), KAROLINSKA INST,MOL NEUROBIOL LAB,DEPT NEUROSCI,BERZELIUS LABS BLDG,DOKTORSRINGEN 12A,S-17177 STOCKHOLM,SWEDEN.		Smit, August B/E-8410-2011	Fainzilber, Mike/0000-0001-8173-8557				BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARBACID M, 1994, J NEUROBIOL, V25, P1373; BARDE YA, 1994, J NEUROBIOL, V25, P1329, DOI 10.1002/neu.480251102; Bothwell M, 1996, SCIENCE, V272, P506, DOI 10.1126/science.272.5261.506; BULLOCH AGM, UNPUB; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; Fisher Robert J., 1994, Current Opinion in Biotechnology, V5, P389, DOI 10.1016/0958-1669(94)90047-7; GOODMAN CS, 1994, CELL, V78, P353, DOI 10.1016/0092-8674(94)90413-8; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; GOTZ R, 1992, J NEUROCHEM, V59, P432, DOI 10.1111/j.1471-4159.1992.tb09389.x; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; IBANEZ CF, 1995, LIFE DEATH NERVOUS S; JACKSON AR, 1995, CELL TISSUE RES, V281, P507, DOI 10.1007/s004410050446; JIMENEZ CR, 1994, J NEUROCHEM, V62, P404; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; KORSCHING S, 1993, J NEUROSCI, V13, P2739; MAROIS R, 1990, J NEUROBIOL, V21, P1053, DOI 10.1002/neu.480210710; RIDGWAY RL, 1991, J NEUROBIOL, V22, P377, DOI 10.1002/neu.480220406; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; SYED NI, 1989, COMP BIOCHEM PHYS A, V93, P633, DOI 10.1016/0300-9629(89)90024-8; SYED NI, 1992, NEURON, V8, P767, DOI 10.1016/0896-6273(92)90097-W; SYED NI, 1990, SCIENCE, V250, P282, DOI 10.1126/science.2218532; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; Wildering WC, 1995, J NEUROPHYSIOL, V74, P2778, DOI 10.1152/jn.1995.74.6.2778	26	71	72	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1540	1543		10.1126/science.274.5292.1540	http://dx.doi.org/10.1126/science.274.5292.1540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929417				2022-12-01	WOS:A1996VV77500052
J	Liu, ZG; Baskaran, R; LeaChou, ET; Wood, LD; Chen, Y; Karin, M; Wang, JYJ				Liu, ZG; Baskaran, R; LeaChou, ET; Wood, LD; Chen, Y; Karin, M; Wang, JYJ			Three distinct signalling responses by murine fibroblasts to genotoxic stress	NATURE			English	Article							ABL TYROSINE KINASE; ACTIVATED PROTEIN-KINASES; C-ABL; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; PHOSPHORYLATION; DOMAIN; TRANSDUCTION; AGENTS	GENOTOXIC stress triggers signalling pathways that mediate either the protection or killing of affected cells, Whereas induction of p53 involves events in the cell nucleus(1), the activation of transcription factors AP-1 and NF-kappa B by ultraviolet radiation is mediated through membrane-associated signalling proteins, ruling out a nuclear signal(2-6), An early event in AP-1 induction by ultraviolet radiation is activation of Jun kinases (JNKs)(3,7), which mediate the induction of the immediate-early genes c-jun and c-fos(7-13). The JNKs have also been proposed to mediate the apoptopic response to genotoxins(14). The non-receptor tyrosine kinase c-Abl is also activated by genotoxic stress(15,16), To understand the relationship between these events, we compared the activation of p53, JNK and c-Abl by several DNA-damaging agents in murine fibroblasts. We found that whereas p53 was induced by every genotoxic stimulus tested, c-Abl was activated by most stimuli except ultraviolet irradiation and JNK was strongly stimulated only by ultraviolet light and the alkylating agent methyl methanesulphonate. Activation of JNK by this alkylating agent was normal in c-Abl-null cells but was reduced in c-Src-null cells, Unlike p53 induction, c-Abl activation occurs in the S phase of the cell cycle and does not affect cell proliferation, These findings show that signals generated by genotoxins are transduced by multiple, independent pathways. Only p53 appears to be a universal sensor of genotoxic stress.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Wood, Laura/ABF-1531-2020		NCI NIH HHS [R01 CA043054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1996, MOL CELL BIOL, V16, P3361; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KHARBANDA S, 1995, J BIOL CHEM, V270, P30178; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; ROSETTE CL, IN PRESS SCIENCE; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	30	340	344	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					273	276		10.1038/384273a0	http://dx.doi.org/10.1038/384273a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918879				2022-12-01	WOS:A1996VU38100054
J	Zheng, B; Han, SH; Zhu, Q; Goldsby, R; Kelsoe, G				Zheng, B; Han, SH; Zhu, Q; Goldsby, R; Kelsoe, G			Alternative pathways for the selection of antigen-specific peripheral T cells	NATURE			English	Article							GERMINAL-CENTERS; IN-VIVO; B-CELLS; RECEPTOR; DEATH; APOPTOSIS; ANTIBODIES; IMMUNITY; INVIVO; NUR77	IN the thymus, maturing lymphocytes receive activation signals mediated by the T-cell antigen receptor (TCR) that either promote clonal survival (positive selection) or induce apoptosis (negative selection), This balance between life and death is mirrored by the sensitivity of cortical thymocytes to apoptotic death induced by antibodies against the CD3 component of the TCR signal-transduction complex, bacterial superantigens that bind to the TCR beta-chain, and corticosteroids(1-3). In contrast, mature peripheral T cells are positively activated by anti-CD3 antibody or superantigens and are resistant to steroid-induced death(4,5). Here we show that in splenic germinal centres, T cells regain thymocyte-like sensitivity to TCR- and steroid-induced apoptosis and undergo antigen-driven positive and negative selection, T-cell responses elsewhere in the spleen are unaccompanied by programmed cell death, Our observations define a new differentiation pathway for peripheral T cells and suggest that germinal centres induce a lymphocyte phenotype necessary for the maintenance of self-tolerance.	UNIV MARYLAND, SCH MED, DEPT MICROBIOL & IMMUNOL, BALTIMORE, MD 21201 USA; AMHERST COLL, DEPT BIOL, AMHERST, MA 01002 USA	University System of Maryland; University of Maryland Baltimore; Amherst College			Goldsby, Robert/O-8363-2019					COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; FULLER KA, 1993, J IMMUNOL, V151, P4505; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GUBRANSONJUDGE A, 1996, EUR J IMMUNOL, V26, P1830; HEDRICK SM, 1988, ADV IMMUNOL, V43, P193; HEDRICK SM, 1988, SCIENCE, V239, P1541, DOI 10.1126/science.2832942; JACOB J, 1993, J EXP MED, V178, P1293, DOI 10.1084/jem.178.4.1293; JAMESON SC, 1991, J IMMUNOL, V147, P3185; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; KELSOE G, 1993, CURR OPIN IMMUNOL, V5, P418, DOI 10.1016/0952-7915(93)90062-W; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; MCHEYZERWILLIAMS MG, 1993, J EXP MED, V178, P295, DOI 10.1084/jem.178.1.295; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; PUTLEN AM, 1988, NATURE, V335, P796; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SURTH CD, 1994, NATURE, V372, P100; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WINOTO A, 1986, NATURE, V324, P679, DOI 10.1038/324679a0; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; WYLIE AH, 1989, NATURE, V284, P555; Zheng B, 1996, J EXP MED, V184, P1083, DOI 10.1084/jem.184.3.1083; ZHENG B, 1994, NATURE, V372, P556, DOI 10.1038/372556a0	29	77	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	1996	384	6606					263	266		10.1038/384263a0	http://dx.doi.org/10.1038/384263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918876				2022-12-01	WOS:A1996VU38100051
J	Cornuz, J; Pearson, SD; Creager, MA; Cook, EF; Goldman, L				Cornuz, J; Pearson, SD; Creager, MA; Cook, EF; Goldman, L			Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article						thrombophlebitis; ultrasonography, Doppler duplex; comorbidity; neoplasms; physical examination	VEIN THROMBOSIS; OCCULT CANCER; DIAGNOSIS	Background: The relation between thrombosis and cancer is well documented, but the clinical evaluation appropriate for detecting underlying cancer in patients with deep venous thrombosis remains unknown. Objectives: To 1) determine the appropriate initial evaluation for cancer in patients with idiopathic deep venous thrombosis and 2) estimate the incidence of subsequently diagnosed cancer in patients who were not found to have cancer when deep venous thrombosis was diagnosed. Design: Retrospective cohort study. Setting: Urban, tertiary care teaching hospital. Patients: 986 consecutive patients (637 women and 349 men; mean age +/- SD, 53 +/- 17 years) who had no risk factors for venous disease and had venous ultrasonography because idiopathic deep venous thrombosis was suspected. Measurements: Initial clinical evaluation was assessed by using chart review. The incidence of cancer at a median of 34 months after diagnosis of deep venous thrombosis was obtained through hospital chart review (38%), computerized record extraction (54%), mailed questionnaires (6%), telephone interviews (1%), or a death registry (1%). Results: Deep venous thrombosis was diagnosed in 142 patients (14%); 136 of the 142 were hospitalized. Cancer was diagnosed in 16 of these 136 patients (12%) during the index hospitalization. All 16 of these patients had one or more abnormalities on at least one of the four components of the clinical examination: history, physical examination, basic laboratory testing, or chest radiography. The probability of detecting cancer increased as the number of findings suggestive of cancer on the four components of the clinical evaluation increased. Cancer was diagnosed in none of the 56 patients with deep venous thrombosis who did not have findings on the clinical evaluation. The probability of cancer-free survival during follow-up (median, 34 months) was similar in patients with (3 of 122 [2.5%]) and without (23 of 844 [2.7%]) deep venous thrombosis and in the age- and sex-matched U.S. population. Conclusions: A clinical evaluation that includes a comprehensive medical history, physical examination, routine laboratory testing, and chest radiography seems to be appropriate for detecting cancer in these patients. Additional testing should be guided by any abnormalities detected by this clinical evaluation.	HARVARD COMMUNITY HLTH PLAN, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02215 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DIV GEN MED, CLIN EPIDEMIOL SECT, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOVASC, VASC DIAGNOST LAB, BOSTON, MA 02115 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California San Francisco	Cornuz, J (corresponding author), UNIV LAUSANNE HOSP, DEPT INTERNAL MED, BUGNON AVE, CH-1011 LAUSANNE, SWITZERLAND.				NHLBI NIH HHS [HL02663] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADERKA D, 1986, CANCER, V57, P1846, DOI 10.1002/1097-0142(19860501)57:9<1846::AID-CNCR2820570925>3.0.CO;2-3; ANLYAN WG, 1956, JAMA-J AM MED ASSOC, V161, P964, DOI 10.1001/jama.1956.62970100002009a; Bounameaux H, 1988, Vasa Suppl, V25, P1; CORNUZ J, 1995, RADIOLOGY, V197, P434; *EARL DET BRANC, 1987, WORK GUID EARL CANC; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR, P39; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; GRIFFIN MR, 1987, ARCH INTERN MED, V147, P1907, DOI 10.1001/archinte.147.11.1907; HIRSCH DR, 1993, PREVENTION VENOUS TH, P485; LEVINE M, 1990, SEMIN ONCOL, V17, P160; Miller A B, 1993, J Public Health Policy, V14, P403, DOI 10.2307/3342875; MILLER AB, 1993, CANCER PRINCIPLES PR, P564; MONREAL M, 1991, CANCER, V67, P541, DOI 10.1002/1097-0142(19910115)67:2<541::AID-CNCR2820670237>3.0.CO;2-J; NORDSTROM M, 1994, BRIT MED J, V308, P891, DOI 10.1136/bmj.308.6933.891; OCONNOR NTJ, 1984, POSTGRAD MED J, V60, P275, DOI 10.1136/pgmj.60.702.275; POLAK JF, 1991, CHEST, V99, pS165, DOI 10.1378/chest.99.4.165S; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; PRINS MH, 1994, ARCH INTERN MED, V154, P1310, DOI 10.1001/archinte.154.12.1310; RICKLES FR, 1983, BLOOD, V62, P14; RIES LAG, 1994, NIH PUB; ROSE SC, 1990, RADIOLOGY, V175, P639, DOI 10.1148/radiology.175.3.2188293; ROSNER B, 1990, FUNDAMENTALS BIOSTAT, P458; SILVERSTEIN RL, 1992, NEW ENGL J MED, V327, P1163, DOI 10.1056/NEJM199210153271611; SIMONS GR, 1995, AM J MED, V99, P43, DOI 10.1016/S0002-9343(99)80103-X; SOX HC, 1994, NEW ENGL J MED, V330, P1589, DOI 10.1056/NEJM199406023302208; YUCEL EK, 1991, RADIOLOGY, V179, P443, DOI 10.1148/radiology.179.2.2014289	26	113	123	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					785	+		10.7326/0003-4819-125-10-199611150-00001	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928984				2022-12-01	WOS:A1996VU52400004
J	Freeman, M				Freeman, M			Reiterative use of the EGF receptor triggers differentiation of all cell types in the Drosophila eye	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN TYROSINE KINASE; DORSAL-VENTRAL AXIS; FAINT-LITTLE-BALL; SIGNAL TRANSDUCTION; MAP KINASE; PC12 CELLS; PHOTORECEPTOR CELLS; IMAGINAL DISKS; FATE DECISIONS	The Drosophila eye has contributed much to our knowledge of cell differentiation. This understanding has primarily come from the study of the R7 photoreceptor; much less is known about the development of the other classes of photoreceptor or the nonneuronal cone or pigment cells. I have used a dominant-negative form of the Drosophila epidermal growth factor receptor (DER) to show that this receptor tyrosine kinase (RTK) is required for the differentiation of all these cell types, and I have also shown that DER is sufficient to trigger their development. DER is even required in R7, where it can replace Sevenless, another RTK. These results broaden our view of eye development to include the whole ommatidium and suggest that reiterative activation of DER is critical for triggering the differentiation of all cell types.			Freeman, M (corresponding author), MRC,MOL BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.			Freeman, Matthew/0000-0003-0410-5451				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BAKER NE, 1992, DEV BIOL, V150, P381, DOI 10.1016/0012-1606(92)90250-K; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BAUMANN P, 1993, DEVELOPMENT, V119, P65; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CLIFFORD RJ, 1989, GENETICS, V123, P771; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; ELLIS MC, 1993, DEVELOPMENT, V119, P855; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FREEMAN M, 1994, DEVELOPMENT, V120, P2297; FREEMAN M, 1992, DEVELOPMENT, V116, P335; FREEMAN M, 1994, MECH DEVELOP, V48, P25, DOI 10.1016/0925-4773(94)90003-5; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; Golembo M, 1996, DEVELOPMENT, V122, P223; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAY BA, 1994, DEVELOPMENT, V120, P2121; HEBERLEIN U, 1993, DEV BIOL, V160, P51, DOI 10.1006/dbio.1993.1285; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KOLODKIN AL, 1994, DEVELOPMENT, V120, P1731; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; RAZ E, 1992, DEVELOPMENT, V114, P113; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; ROGGE R, 1992, P NATL ACAD SCI USA, V89, P5271, DOI 10.1073/pnas.89.12.5271; RUOHOLABAKER H, 1993, CELL, V73, P953, DOI 10.1016/0092-8674(93)90273-S; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; SAWAMOTO K, 1994, DEV BIOL, V164, P267, DOI 10.1006/dbio.1994.1197; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STURTEVANT MA, 1994, DEVELOPMENT, V120, P2593; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TIO M, 1994, MECH DEVELOP, V48, P13, DOI 10.1016/0925-4773(94)90002-7; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; VASSIN H, 1987, EMBO J, V6, P3433; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WOLFF T, 1991, DEVELOPMENT, V113, P825; XU T, 1993, DEVELOPMENT, V117, P1223; ZAK NB, 1992, DEV BIOL, V149, P448, DOI 10.1016/0012-1606(92)90299-V; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	68	677	683	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					651	660		10.1016/S0092-8674(00)81385-9	http://dx.doi.org/10.1016/S0092-8674(00)81385-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929534	Bronze			2022-12-01	WOS:A1996VU03500008
J	Bao, JX; Kandel, ER; Hawkins, RD				Bao, JX; Kandel, ER; Hawkins, RD			Involvement of pre- and postsynaptic mechanisms in posttetanic potentiation at Aplysia synapses	SCIENCE			English	Article							POST-TETANIC POTENTIATION; TERM SYNAPTIC PLASTICITY; SPONTANEOUS TRANSMITTER RELEASE; DISSOCIATED CELL-CULTURE; MOTOR NEURON SYNAPSES; SENSORIMOTOR SYNAPSES; SENSORY NEURONS; NERVE-TERMINALS; NITRIC-OXIDE; CALCIUM	Posttetanic potentiation (PTP) is a common form of short-term synaptic plasticity that is generally thought to be entirely presynaptic. Consistent with that idea, PTP of evoked excitatory postsynaptic potentials at Aplysia sensory/motor neuron synapses in cell culture was reduced by presynaptic injection of a slow calcium chelator and was accompanied by an increase in the frequency but not the amplitude of spontaneous excitatory postsynaptic potentials. However, PTP was also reduced by postsynaptic injection of a rapid calcium chelator or postsynaptic hyperpolarization. Thus, PTP at these synapses is likely to involve a postsynaptic induction mechanism in addition to the known presynaptic mechanisms.	COLUMBIA UNIV, COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA; NEW YORK STATE PSYCHIAT INST & HOSP, NEW YORK, NY 10032 USA; HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; New York State Psychiatry Institute; Howard Hughes Medical Institute					NIMH NIH HHS [MH 26212] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH026212] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADLER EM, 1991, J NEUROSCI, V11, P1496; ANWYL R, 1989, BRAIN RES, V503, P148, DOI 10.1016/0006-8993(89)91716-2; ATWOOD HL, 1986, INT REV NEUROBIOL, V28, P275, DOI 10.1016/S0074-7742(08)60111-7; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; CASTELLUCCI VF, 1974, P NATL ACAD SCI USA, V71, P5004, DOI 10.1073/pnas.71.12.5004; CLAMANN HP, 1989, J NEUROPHYSIOL, V61, P403, DOI 10.1152/jn.1989.61.2.403; CLARK GA, 1984, P NATL ACAD SCI-BIOL, V81, P2577, DOI 10.1073/pnas.81.8.2577; CONNOR JA, 1986, J PHYSIOL-LONDON, V375, P625, DOI 10.1113/jphysiol.1986.sp016137; DALE N, 1993, P NATL ACAD SCI USA, V90, P7163, DOI 10.1073/pnas.90.15.7163; DALE N, 1990, J PHYSIOL-LONDON, V421, P203, DOI 10.1113/jphysiol.1990.sp017941; DELANEY KR, 1989, J NEUROSCI, V9, P3558; ELIOT LS, 1994, J NEUROSCI, V14, P3280; ELIOT LS, 1994, J NEUROSCI, V14, P368; EPSTEIN R, 1970, J PHYSIOL-LONDON, V209, P1; Feng T.P., 1941, CHINESE J PHYSIOL, V16, P341; FROST WN, 1987, THESIS COLUMBIA U NE, P113; GRIFFITH WH, 1990, J NEUROPHYSIOL, V63, P491, DOI 10.1152/jn.1990.63.3.491; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; KRETZ R, 1982, P NATL ACAD SCI-BIOL, V79, P5430, DOI 10.1073/pnas.79.17.5430; LIN XY, 1994, P ROY SOC B-BIOL SCI, V255, P113, DOI 10.1098/rspb.1994.0016; LIN XY, 1994, P ROY SOC B-BIOL SCI, V255, P215, DOI 10.1098/rspb.1994.0031; LO YJ, 1994, J NEUROSCI, V14, P4694; MAGLEBY KL, 1975, J PHYSIOL-LONDON, V245, P183, DOI 10.1113/jphysiol.1975.sp010840; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MARTIN AR, 1964, J PHYSIOL-LONDON, V175, P17, DOI 10.1113/jphysiol.1964.sp007500; MURPHEY RK, 1994, J NEUROBIOL, V25, P595, DOI 10.1002/neu.480250602; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; SCHACHER S, 1983, J NEUROSCI, V3, P2403; SCHACHER S, 1990, J NEUROSCI, V10, P3286; SCHACHER S, 1985, J NEUROSCI, V5, P2028; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; WALTERS ET, 1984, BRAIN RES, V293, P377, DOI 10.1016/0006-8993(84)91247-2; WAZIRI R, 1969, J NEUROPHYSIOL, V32, P509, DOI 10.1152/jn.1969.32.4.509; YUSTE R, 1995, NEURON, V14, P7, DOI 10.1016/0896-6273(95)90236-8; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUCKER RS, 1994, NETH J ZOOL, V44, P495	37	87	90	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1997	275	5302					969	973		10.1126/science.275.5302.969	http://dx.doi.org/10.1126/science.275.5302.969			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020078				2022-12-01	WOS:A1997WH38800043
J	Ewbank, JJ; Barnes, TM; Lakowski, B; Lussier, M; Bussey, H; Hekimi, S				Ewbank, JJ; Barnes, TM; Lakowski, B; Lussier, M; Bussey, H; Hekimi, S			Structural and functional conservation of the Caenorhabditis elegans timing gene clk-1	SCIENCE			English	Article							C-ELEGANS; SACCHAROMYCES-CEREVISIAE; MUTATIONS; OPERONS; COMMON	Mutations in the Caenorhabditis elegans gene clk-1 affect biological timing and extend longevity. The gene clk-1 was identified, and the cloned gene complemented the clk-1 phenotypes and restored normal longevity. The CLK-1 protein was found to be conserved among eukaryotes, including humans, and structurally similar to the yeast metabolic regulator Cat5p (also called Coq7p). These proteins contain a tandem duplication of a core 82-residue domain. clk-1 complemented the phenotype of cat5/coq7 null mutants, demonstrating that clk-1 and CAT5/COQ7 share biochemical function and that clk-1 acts at the level of cellular physiology.	MCGILL UNIV,DEPT BIOL,MONTREAL,PQ H3A 1B1,CANADA	McGill University			Ewbank, Jonathan J/G-4948-2010	Ewbank, Jonathan J/0000-0002-1257-6862				Barnes TM, 1996, J NEUROCHEM, V67, P46; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BLUMENTHAL T, 1995, TRENDS GENET, V11, P132, DOI 10.1016/S0168-9525(00)89026-5; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CAMPISI J, 1996, CELL, V86, P9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Creighton TE, 1993, PROTEINS STRUCTURES; Eeckman FH, 1995, METHOD CELL BIOL, V48, P583; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gems D, 1996, NATURE, V379, P723, DOI 10.1038/379723a0; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HEKIMI S, 1995, GENETICS, V141, P1351; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; Jonassen T, 1996, ARCH BIOCHEM BIOPHYS, V330, P285, DOI 10.1006/abbi.1996.0255; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LAKOWSKI B, UNPUB; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Mello C, 1995, METHOD CELL BIOL, V48, P451; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; PROFT M, 1995, MOL GEN GENET, V246, P367, DOI 10.1007/BF00288610; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1995, 3 INT C INT SYST MOL, P314; ROST B, 1995, PROTEIN FOLDS DISTAN, P132; SCHOLER A, 1994, MOL CELL BIOL, V14, P3613, DOI 10.1128/MCB.14.6.3613; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WONG A, 1995, GENETICS, V139, P1247; WONG A, 1994, THESIS MCGILL U MONT; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0; [No title captured]; [No title captured]	34	258	276	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					980	983		10.1126/science.275.5302.980	http://dx.doi.org/10.1126/science.275.5302.980			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020081				2022-12-01	WOS:A1997WH38800046
J	Wong, JY; Kuhl, TL; Israelachvili, JN; Mullah, N; Zalipsky, S				Wong, JY; Kuhl, TL; Israelachvili, JN; Mullah, N; Zalipsky, S			Direct measurement of a tethered ligand-receptor interaction potential	SCIENCE			English	Article							LIPOSOMES; CHAINS; FORCES; CELLS	Many biological recognition interactions involve ligands and receptors that are tethered rather than rigidly bound on a cell surface. A surface forces apparatus was used to directly measure the force-distance interaction between a polymer-tethered ligand and its receptor. At separations near the fully extended tether length, the ligands rapidly lock onto their binding sites, pulling the ligand and receptor together. The measured interaction potential and its dynamics can be modeled with standard theories of polymer and colloidal interactions.	SEQUUS PHARMACEUT,MENLO PK,CA 94025		Wong, JY (corresponding author), UNIV CALIF SANTA BARBARA,DEPT CHEM ENGN,SANTA BARBARA,CA 93106, USA.		Wong, Joyce Y/F-3732-2011; Wong, Joyce Y./AAF-5759-2019	Wong, Joyce Y/0000-0002-3526-6381; Wong, Joyce Y./0000-0002-3526-6381	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334, F32GM017876] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 47334, GM17876] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN TM, 1995, BBA-BIOMEMBRANES, V1237, P99, DOI 10.1016/0005-2736(95)00085-H; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BLUME G, 1993, BIOCHIM BIOPHYS ACTA, V1149, P180, DOI 10.1016/0005-2736(93)90039-3; Cevc G, 1987, PHOSPHOLIPID BILAYER; DeFrees SA, 1996, J AM CHEM SOC, V118, P6101, DOI 10.1021/ja954122g; EVANS E, IN PRESS BIOPHYS J; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; Israelachvili J., 1992, INTERMOLECULAR SURFA; KUHL TL, 1994, BIOPHYS J, V66, P1479, DOI 10.1016/S0006-3495(94)80938-5; LECKBAND DE, 1992, SCIENCE, V255, P1419, DOI 10.1126/science.1542789; LECKBAND DE, 1994, BIOCHEMISTRY-US, V33, P4611, DOI 10.1021/bi00181a023; LEE RJ, 1994, J BIOL CHEM, V269, P3198; MARRA J, 1986, METHOD ENZYMOL, V127, P353; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; Uster PS, 1996, FEBS LETT, V386, P243, DOI 10.1016/0014-5793(96)00452-8; ZALIPSKY S, 1995, BIOCONJUGATE CHEM, V6, P705, DOI 10.1021/bc00036a008; ZALIPSKY S, 1994, FEBS LETT, V353, P71, DOI 10.1016/0014-5793(94)01013-7	18	220	229	0	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					820	822		10.1126/science.275.5301.820	http://dx.doi.org/10.1126/science.275.5301.820			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012346				2022-12-01	WOS:A1997WG77700057
J	Downie, AB; Mulligan, J; Stratford, RJ; Betts, PR; Voss, LD				Downie, AB; Mulligan, J; Stratford, RJ; Betts, PR; Voss, LD			Are short normal children at a disadvantage? The Wessex growth study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SHORT STATURE	Objective: To examine whether short stature through childhood represents a disadvantage at around 12 years. Design: Longitudinal non-intervention study of the physical and psychological development of children recruited from the community in 1986-7 after entry into primary school at age 5-6 years; this is the second psychometric assessment made in 1994-5 after entry into secondary school at age 11-13 years. Setting: Southampton and Winchester health districts. Subjects: 106 short normal children (<3rd centile for height when recruited) and 119 controls of average stature (10th-90th centile). Main outcome measures: Psychometric measures of cognitive development, self concept development, behaviour, and locus of control. Results: The short children did not differ significantly from the control children on measures of self esteem (19.4 v 20.2), self perception (104.2 v 102.4), parents' perception (46.9 v 47.0), or behaviour (6.8 v 5.3). The short children achieved significantly lower scores on measures of intelligence quotient (IQ) (102.6 v 108.6; P<0.005), reading attainment (44.3 v 47.9; P<0.002), and basic number skills (40.2 v 43.5; P<0.003) and displayed less internalisation of control (16.6 v 14.3; P<0.001) and less satisfaction with their height (P<0.0001). More short than control children, however,came fi-om working class homes (P<0.05). Social class was a better predictor than height of all measures except that of body satisfaction Attainment scores were predicted by class and IQ together rather than by height Height accounted for some of the variance in IQ and locus of control scores. Conclusions: These results provide only limited support for the hypothesis that short children are disadvantaged, at least up until 11-13 years old. Social class seems to have more influence than height on children's psychological development.	SOUTHAMPTON GEN HOSP, UNIV HOSP TRUST, DEPT CHILD HLTH, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND; UNIV SOUTHAMPTON, DEPT PSYCHOL, SOUTHAMPTON SO17 1BJ, HANTS, ENGLAND; SOUTHAMPTON UNIV HOSP TRUST, DEPT PAEDIAT, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND	University of Southampton; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust								ALLEN KD, 1993, CHILD HEALTH CARE, V22, P61; Battle J, 1981, CULTURE FREE SELF ES; DOWDNEY L, 1995, INT J METHOD PSYCH, V5, P29; Downie AB, 1996, ARCH DIS CHILD, V75, P32, DOI 10.1136/adc.75.1.32; Elliot C. D., 1983, BRIT ABILITY SCALES; Harter S., 1985, SELF PERCEPTION PROF; Hoare P, 1993, Eur Child Adolesc Psychiatry, V2, P19, DOI 10.1007/BF02098827; HOLMES CS, 1982, CHILD CARE HLTH DEV, V8, P327, DOI 10.1111/j.1365-2214.1982.tb00293.x; LAW CM, 1987, ARCH DIS CHILD, V62, P855, DOI 10.1136/adc.62.8.855; *MARK RES SOC, 1991, OCC GROUP JOB DICT; NOWICKI S, 1973, J CONSULT CLIN PSYCH, V40, P148, DOI 10.1037/h0033978; RUTTER M, 1967, J CHILD PSYCHOL PSYC, V8, P1, DOI 10.1111/j.1469-7610.1967.tb02175.x; SANDBERG DE, 1994, PEDIATRICS, V94, P832; SCARTH LG, 1994, GROWTH STATURE ADAPT, P107; SIEGEL PT, 1994, GROWTH STATURE ADAPT, P123; SIEGEL PT, 1990, PSYCHONEUROENDOCRINO, P40; SKUSE D, 1994, ACTA PAEDIATR, V83, P11, DOI 10.1111/j.1651-2227.1994.tb13413.x; STABLER B, 1991, ACTA PAEDIATR SCAND, P9; STABLER B, 1987, GROWTH ABNORMALITIES, P255; TANNER JM, 1956, ARCH DIS CHILD, V31, P372, DOI 10.1136/adc.31.159.372; TANNER JM, 1966, ARCH DIS CHILD, V41, P454, DOI 10.1136/adc.41.219.454; VOSS L, 1989, ACTA PAEDIATR SCAND, P65; VOSS LD, 1992, BMJ-BRIT MED J, V305, P1400, DOI 10.1136/bmj.305.6866.1400; VOSS LD, 1994, GROWTH STATURE ADAPT, P47; WEINBERG WA, 1974, J PEDIATR-US, V85, P482, DOI 10.1016/S0022-3476(74)80449-X; YOUNG-HYMAN D, 1986, P27; YOUNGHYMAN DL, 1990, PSYCHONEUROENDOCRINO, P40	27	106	107	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 11	1997	314	7074					97	100		10.1136/bmj.314.7074.97	http://dx.doi.org/10.1136/bmj.314.7074.97			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WC479	9006466	Green Published			2022-12-01	WOS:A1997WC47900018
J	Rennie, AN				Rennie, AN			Prevalence of arm movements in patients with coronary heart disease: Case-control study	BRITISH MEDICAL JOURNAL			English	Article																		RENNIE AN, 1972, BRIT MED J, V1, P380, DOI 10.1136/bmj.1.5796.380-a; ROTH PJ, 1981, J ENG MED, V10, P79	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					122	122		10.1136/bmj.314.7074.122	http://dx.doi.org/10.1136/bmj.314.7074.122			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006473	Green Published			2022-12-01	WOS:A1997WC47900027
J	Reynolds, F; Crowhurst, JA				Reynolds, F; Crowhurst, JA			Opioids in labour - No analgesic effect	LANCET			English	Editorial Material							PAIN		QUEEN CHARLOTTES & CHELSEA HOSP,LONDON W6 0XG,ENGLAND	Imperial College London	Reynolds, F (corresponding author), ST THOMAS HOSP,DEPT ANAESTHET,LONDON SE1 7EH,ENGLAND.							Chamberlain G, 1993, PAIN ITS RELIEF CHIL; HOLDCROFT A, 1974, J OBSTET GYN BR COMM, V81, P603; MOORE J, 1993, EFFECTS BABY MATERNA, P148; MORGAN BM, 1982, LANCET, V2, P808; NORVELL KT, 1987, PAIN, V31, P77, DOI 10.1016/0304-3959(87)90008-X; Olofsson C, 1996, Int J Obstet Anesth, V5, P176, DOI 10.1016/S0959-289X(96)80028-8; Olofsson C, 1996, BRIT J OBSTET GYNAEC, V103, P968, DOI 10.1111/j.1471-0528.1996.tb09545.x; PAECH MJ, 1991, ANAESTH INTENS CARE, V19, P393, DOI 10.1177/0310057X9101900316; Ranta P, 1994, Int J Obstet Anesth, V3, P193, DOI 10.1016/0959-289X(94)90067-1; REYNOLDS F, 1989, BRIT MED J, V299, P751, DOI 10.1136/bmj.299.6702.751; WIENER PC, 1977, BRIT MED J, V2, P228, DOI 10.1136/bmj.2.6081.228	11	22	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					4	5		10.1016/S0140-6736(05)62156-3	http://dx.doi.org/10.1016/S0140-6736(05)62156-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988111				2022-12-01	WOS:A1997WA72500005
J	Hull, HF				Hull, HF			Vaccines - Pax polio	SCIENCE			English	Editorial Material											Hull, HF (corresponding author), WHO,GLOBAL PROGRAMME VACCINES & IMMUNIZAT,CH-1211 GENEVA 27,SWITZERLAND.							BART KJ, 1996, WHO, V74, P35; HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4; MORRIS W, 1978, AM HERITAGE DICT ENG, P833; 1995, WKLY EPIDEMIOL REC, V71, P189	4	11	11	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					40	41		10.1126/science.275.5296.40	http://dx.doi.org/10.1126/science.275.5296.40			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8999534				2022-12-01	WOS:A1997WA90300037
J	Cockerill, FR; MacDonald, KL; Thompson, RL; Roberson, F; Kohner, PC; BesserWiek, J; Manahan, JM; Musser, JM; Schlievert, PM; Talbot, J; Frankfort, B; Steckelberg, JM; Wilson, WR; Osterholm, MT; Abbott, JA; Badley, AD; Dale, JC; Dylla, BL; Holley, KE; Jacobsen, RA; Leavelle, DE; Osmon, DR; Uhl, JR; Vetter, EA; Anderson, EA; Clare, JG; Forfang, JC; Hedberg, CW; Korlath, JA; Rainbow, JI; Edmonson, L; Lovgren, M; Olstad, S				Cockerill, FR; MacDonald, KL; Thompson, RL; Roberson, F; Kohner, PC; BesserWiek, J; Manahan, JM; Musser, JM; Schlievert, PM; Talbot, J; Frankfort, B; Steckelberg, JM; Wilson, WR; Osterholm, MT; Abbott, JA; Badley, AD; Dale, JC; Dylla, BL; Holley, KE; Jacobsen, RA; Leavelle, DE; Osmon, DR; Uhl, JR; Vetter, EA; Anderson, EA; Clare, JG; Forfang, JC; Hedberg, CW; Korlath, JA; Rainbow, JI; Edmonson, L; Lovgren, M; Olstad, S			An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SHOCK-LIKE SYNDROME; GROUP-A STREPTOCOCCI; SCARLET FEVER TOXIN; MOLECULAR CHARACTERIZATION; EPIDEMIOLOGIC ANALYSIS; CHANGING EPIDEMIOLOGY; RHEUMATIC-FEVER; PYOGENES; INFECTIONS; BACTEREMIA	Objectives.-To determine if a common strain of group A streptococcus was responsible for an outbreak of invasive streptococcal disease in southeastern Minnesota and to determine whether this strain was prevalent among residents of this area during the outbreak who either had streptococcal pharyngitis or were asymptomatic streptococcal carriers. Design.-Pharyngeal culture survey and case-contact evaluation. Setting.-Three adjacent counties in southeastern Minnesota defined as the outbreak area. Outbreak period, January 1 through March 31, 1995. Patients.-Seven patients with invasive streptococcal infection, 1249 patients (adults and children) with sore throat who resided in the outbreak area, children from an elementary school located in 1 community where the majority of invasive cases occurred, and 896 students from 3 schools located in Minnesota counties outside the outbreak area. Measurements.-Pulsed-field gel electrophores is (DNA fingerprinting) of group A streptococcal isolates obtained from patients with invasive disease, throat swabs of patients with sore throat, and throat swabs of asymptomatic school-aged children. Results.-All patients with outbreak-associated invasive disease had group A streptococcal isolates that were indistinguishable by pulsed-field gel electrophoresis. Additional testing showed that these isolates carried significant virulence factors including pyrogenic exotoxin A and streptococcal superantigen. Five of these 7 patients with invasive disease had underlying medical conditions; 4 developed toxic shock syndrome and died (case fatality, 57%). The outbreak-associated group A streptococcal clone was found in 69 (26.5%) of the 260 patients with sore throat from whom group A streptococcus was isolated. The frequency of the outbreak done among pharyngeal carriers from the 3 schools outside the outbreak area was significantly less (range, 0%-10%) than in children from the school in the outbreak area (78%; relative risk, 29; 95% confidence interval, 11.1-78. 1; P<.001). Four of the 7 patients with outbreak-associated disease had contact with children who attended the school in the outbreak area, Conclusions.-A single clone of group A streptococcus was responsible for 7 cases of invasive streptococcal disease during an outbreak in Minnesota and for a significant number of pharyngitis cases that also occurred during the outbreak invasive disease occurred most frequently in persons with underlying medical conditions. This outbreak was also associated with increased carriage rates of the invasive streptococcal clone among community school-aged children, Cases of invasive group A streptococcal infection may therefore reflect the tip of the iceberg with regard to the burden of colonization of a specific invasive streptococcal clone in a community.	MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,DIV INFECT DIS,ROCHESTER,MN 55905; MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,MINNEAPOLIS,MN 55414; MINNESOTA DEPT HLTH,CLIN LAB SECT,MINNEAPOLIS,MN 55414; INTERSTATE CLIN & ZUMBROTA COMMUNITY HOSP,ZUMBROTA,MN 55992; BAYLOR COLL MED,DEPT PATHOL,SECT MOL PATHOBIOL,HOUSTON,TX 77030; UNIV MINNESOTA,DEPT MICROBIOL,MINNEAPOLIS,MN 55455; PROV LAB PUBL HLTH,NATL CTR STREPTOCOCCUS,EDMONTON,AB,CANADA; OLMSTED PUBL HLTH DEPT,ROCHESTER,MN	Mayo Clinic; Minnesota Department of Health (MHD); Minnesota Department of Health (MHD); Baylor College of Medicine; University of Minnesota System; University of Minnesota Twin Cities	Cockerill, FR (corresponding author), MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,DIV MICROBIOL,HILTON 4,ROCHESTER,MN 55905, USA.		badley, andrew d/O-9022-2014	Schlievert, Patrick/0000-0001-8314-9369	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL036611, R01HL036611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033119] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36611] Funding Source: Medline; NIAID NIH HHS [AI-33119] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUERBACH SB, 1992, ARCH INTERN MED, V152, P1017, DOI 10.1001/archinte.152.5.1017; BARTTER T, 1988, ARCH INTERN MED, V148, P1421, DOI 10.1001/archinte.148.6.1421; BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106; CHOMARAT M, 1990, EUR J CLIN MICROBIOL, V9, P901, DOI 10.1007/BF01967508; CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; Davies HD, 1996, NEW ENGL J MED, V335, P547, DOI 10.1056/NEJM199608223350803; DERMODY TS, 1995, CLIN INFECT DIS, V20, P1333; DRABICK JJ, 1989, NEW ENGL J MED, V321, P1545, DOI 10.1056/NEJM198911303212212; FRANCIS J, 1988, Q J MED, V68, P603; GAWORZEWSKA E, 1988, EPIDEMIOL INFECT, V100, P257, DOI 10.1017/S095026880006739X; GIVNER LB, 1991, J PEDIATR-US, V118, P341, DOI 10.1016/S0022-3476(05)82144-4; Griffith F, 1934, J HYG-CAMBRIDGE, V34, P542, DOI 10.1017/S0022172400043308; HANSMAN D, 1989, NEW ENGL J MED, V321, P1546; HARBAUGH MP, 1993, MOL MICROBIOL, V8, P981, DOI 10.1111/j.1365-2958.1993.tb01642.x; HAUSER AR, 1991, J CLIN MICROBIOL, V29, P1562, DOI 10.1128/JCM.29.8.1562-1567.1991; HENRICHSEN J, 1992, ZBL BAKT S, V22, P8; HOGE CW, 1993, JAMA-J AM MED ASSOC, V269, P384, DOI 10.1001/jama.269.3.384; JOHNSON DR, 1992, J INFECT DIS, V166, P374, DOI 10.1093/infdis/166.2.374; KAPUR V, 1993, MICROB PATHOGENESIS, V15, P327, DOI 10.1006/mpat.1993.1083; KISKA DL, 1995, 95 GEN M AM SOC MICR; Kline JB, 1996, INFECT IMMUN, V64, P861, DOI 10.1128/IAI.64.3.861-869.1996; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; Maslow Joel N., 1993, P563; MAXTED WR, 1973, J MED MICROBIOL, V6, P83, DOI 10.1099/00222615-6-1-83; MIRANDA AG, 1991, J CLIN MICROBIOL, V29, P2752, DOI 10.1128/JCM.29.12.2752-2757.1991; MOSES AE, 1995, CLIN INFECT DIS, V20, P1393, DOI 10.1093/clinids/20.5.1393; MURRAY BE, 1990, J CLIN MICROBIOL, V28, P2059, DOI 10.1128/JCM.28.9.2059-2063.1990; MUSSER JM, 1993, J INFECT DIS, V167, P337, DOI 10.1093/infdis/167.2.337; MUSSER JM, 1991, P NATL ACAD SCI USA, V88, P2668, DOI 10.1073/pnas.88.7.2668; MUSSER JM, 1995, INFECT IMMUN, V63, P994, DOI 10.1128/IAI.63.3.994-1003.1995; MUSSER JM, 1992, J CLIN MICROBIOL, V30, P600, DOI 10.1128/JCM.30.3.600-603.1992; MUSSER JM, 1994, ARCH PATHOL LAB MED, V118, P128; NELSON K, 1991, J EXP MED, V174, P1271, DOI 10.1084/jem.174.5.1271; REDA KB, 1994, INFECT IMMUN, V62, P1867, DOI 10.1128/IAI.62.5.1867-1874.1994; ROTTA J, 1971, J EXP MED, V134, P1298, DOI 10.1084/jem.134.5.1298; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; STEVENS DL, 1995, EMERG INFECT DIS, V1, P69, DOI 10.3201/eid0103.950301; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STEVENS DL, 1992, CLIN INFECT DIS, V14, P2, DOI 10.1093/clinids/14.1.2; STROMBERG A, 1991, J INFECT DIS, V164, P595, DOI 10.1093/infdis/164.3.595; TALKINGTON DF, 1993, INFECT IMMUN, V61, P3369, DOI 10.1128/IAI.61.8.3369-3374.1993; WHEELER MC, 1991, JAMA-J AM MED ASSOC, V266, P533, DOI 10.1001/jama.266.4.533; *WORK GROUP SEV ST, 1993, JAMA-J AM MED ASSOC, V269, P390	43	135	137	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1997	277	1					38	43		10.1001/jama.277.1.38	http://dx.doi.org/10.1001/jama.277.1.38			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ767	8980208				2022-12-01	WOS:A1997VZ76700027
J	Suri, C; Jones, PF; Patan, S; Bartunkova, S; Maisonpierre, PC; Davis, S; Sato, TN; Yancopoulos, GD				Suri, C; Jones, PF; Patan, S; Bartunkova, S; Maisonpierre, PC; Davis, S; Sato, TN; Yancopoulos, GD			Requisite role of Angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis	CELL			English	Article							ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE GENES; NEUREGULIN RECEPTOR; CARDIAC DEVELOPMENT; MOLECULAR-CLONING; VASCULAR SYSTEM; MICE LACKING; CELL LINEAGE; EXPRESSION; TEK	Vascular endothelial growth factor (VEGF), which acts via members of a family of endothelial-specific receptor tyrosine kinases, is the only factor that has been shown definitively to play a role in the formation of the embryonic vasculature. Only one other family of receptor tyrosine kinases, comprising TIE1 and TIE2, is largely endothelial cell specific. We have recently cloned a ligand for TIE2, termed Angiopoietin-1. Here we show that mice engineered to lack Angiopoietin-1 display angiogenic deficits reminiscent of those previously seen in mice lacking TIE2, demonstrating that Angiopoietin-1 is a primary physiologic ligand for TIE2 and that it has critical in vivo angiogenic actions that are distinct from VEGF and that are not reflected in the classic in vitro assays used to characterize VEGF. Angiopoietin-1 seems to play a crucial role in mediating reciprocal interactions between the endothelium and surrounding matrix and mesenchyme.	BETH ISRAEL HOSP,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215; MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Suri, C (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.							BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; Batard P, 1996, BLOOD, V87, P2212, DOI 10.1182/blood.V87.6.2212.bloodjournal8762212; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FERRARA N, 1995, ANN NY ACAD SCI, V752, P246, DOI 10.1111/j.1749-6632.1995.tb17435.x; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hashiyama M, 1996, BLOOD, V87, P93; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Patan S, 1996, MICROVASC RES, V51, P80, DOI 10.1006/mvre.1996.0009; Patan S, 1996, MICROVASC RES, V51, P260, DOI 10.1006/mvre.1996.0025; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W., 1991, DEV VASCULAR SYSTEM, P58; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; ZIEGLER SF, 1993, ONCOGENE, V8, P663	37	2228	2376	0	50	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1171	1180		10.1016/S0092-8674(00)81813-9	http://dx.doi.org/10.1016/S0092-8674(00)81813-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980224	Bronze			2022-12-01	WOS:A1996WA54100006
J	Han, SH; Zheng, B; Schatz, DG; Spanopoulou, E; Kelsoe, G				Han, SH; Zheng, B; Schatz, DG; Spanopoulou, E; Kelsoe, G			Neoteny in lymphocytes: Rag1 and Rag2 expression in germinal center B cells	SCIENCE			English	Article							PRIMARY IMMUNE-RESPONSE; V(D)J RECOMBINATION; SOMATIC DIVERSIFICATION; FOLLICULAR LYMPHOMA; CHROMOSOMAL TRANSLOCATION; RECIPROCAL PARTNERS; PEANUT AGGLUTININ; GENE CONVERSION; CHAIN GENE; ANTIGEN	The products of the Rag1 and Rag2 genes drive genomic V(D)J rearrangements that assemble functional immunoglobulin and T cell antigen receptor genes. Expression of the Rag genes has been thought to be limited to developmentally immature lymphocyte populations that in normal adult animals are primarily restricted to the bone marrow and thymus. Abundant RAGI and RAG2 protein and messenger RNA was detected in the activated B cells that populate murine splenic and Peyer's patch germinal centers. Germinal center B cells thus share fundamental characteristics of immature lymphocytes, raising the possibility that antigen-dependent secondary V(D)J rearrangements modify the peripheral antibody repertoire.	UNIV MARYLAND,SCH MED,DEPT MICROBIOL & IMMUNOL,BALTIMORE,MD 21201; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06520; MT SINAI CANC CTR,NEW YORK,NY 10021	University System of Maryland; University of Maryland Baltimore; Howard Hughes Medical Institute; Yale University; Icahn School of Medicine at Mount Sinai			Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032524, R01AI024335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010207] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32524, AI24335] Funding Source: Medline; NIA NIH HHS [AG10207] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BECKER RS, 1990, CELL, V63, P987, DOI 10.1016/0092-8674(90)90502-6; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; Chen C, 1995, IMMUNITY, V3, P747, DOI 10.1016/1074-7613(95)90064-0; CLEARY ML, 1986, CELL, V44, P97, DOI 10.1016/0092-8674(86)90488-5; COICO RF, 1983, J IMMUNOL, V131, P2254; COTTER F, 1990, BLOOD, V76, P131; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; GIACHINO C, 1995, J EXP MED, V181, P1245, DOI 10.1084/jem.181.3.1245; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; GRAY D, 1993, J EXP MED, V177, P999; HAN SH, 1995, J EXP MED, V182, P1635, DOI 10.1084/jem.182.6.1635; HAN SH, 1995, J IMMUNOL, V155, P556; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HODES R, COMMUNICATION; JACOB J, 1993, J EXP MED, V178, P1293, DOI 10.1084/jem.178.4.1293; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KELSOE G, 1980, J EXP MED, V151, P289, DOI 10.1084/jem.151.2.289; Kelsoe G, 1995, ADV IMMUNOL, V60, P267, DOI 10.1016/S0065-2776(08)60587-8; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; KNIGHT KL, 1990, CELL, V60, P963, DOI 10.1016/0092-8674(90)90344-E; LANZAVECCHIA A, COMMUNITY; LAZLO G, 1993, J IMMUNOL, V150, P5252; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; LEVY R, 1987, IMMUNOL REV, V96, P43, DOI 10.1111/j.1600-065X.1987.tb00508.x; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIN WC, 1995, IMMUNOL TODAY, V16, P279, DOI 10.1016/0167-5699(95)80182-0; LINTON PJ, 1992, EUR J IMMUNOL, V22, P1293, DOI 10.1002/eji.1830220526; LINTON PJ, 1989, CELL, V59, P1049, DOI 10.1016/0092-8674(89)90761-7; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; MILLER C, 1995, J EXP MED, V181, P1319, DOI 10.1084/jem.181.4.1319; Miller Carla, 1994, Aging Immunology and Infectious Disease, V5, P249; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; RADIC MZ, 1993, J EXP MED, V177, P116; REISNER Y, 1979, P NATL ACAD SCI USA, V76, P447, DOI 10.1073/pnas.76.1.447; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; REYNAUD CA, 1995, CELL, V80, P115, DOI 10.1016/0092-8674(95)90456-5; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; SKLAR J, 1984, NEW ENGL J MED, V311, P20, DOI 10.1056/NEJM198407053110104; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; WEINSTEIN PD, 1991, INT IMMUNOL, V3, P1253, DOI 10.1093/intimm/3.12.1253; WEINSTEIN PD, 1994, IMMUNITY, V1, P647, DOI 10.1016/1074-7613(94)90036-1; WU HY, 1995, SCAND J IMMUNOL, V42, P52, DOI 10.1111/j.1365-3083.1995.tb03625.x; ZELENETZ AD, 1992, J EXP MED, V176, P1137, DOI 10.1084/jem.176.4.1137; Zheng B, 1996, J EXP MED, V184, P1083, DOI 10.1084/jem.184.3.1083; ZHENG B, UNPUB; ZHENG B, IN PRESS NATURE	57	244	247	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2094	2097		10.1126/science.274.5295.2094	http://dx.doi.org/10.1126/science.274.5295.2094			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953043				2022-12-01	WOS:A1996VY97400053
J	Clark, IA; AlYaman, FM; Cowden, WB; Rockett, KA				Clark, IA; AlYaman, FM; Cowden, WB; Rockett, KA			Does malarial tolerance, through nitric oxide, explain the low incidence of autoimmune disease in tropical Africa?	LANCET			English	Article							FALCIPARUM MALARIA; MACROPHAGES; SUPPRESSION; LIPOPOLYSACCHARIDE; IMMUNITY; PATHWAY	Autoimmune disease is generally rare in tropical rural populations. Plasma concentrations of nitrite plus nitrate (reactive nitrogen intermediates), reflecting high nitric-oxide production somewhere in the body, can be high in patients who have cerebral malaria, but even higher in symptom-free parasitised individuals, who are termed malaria-tolerant. We propose that the nitric oxide causing high serum levels of reactive nitrogen intermediates in malaria-tolerant individuals is generated in macrophages during the establishment and maintenance of malarial tolerance, and makes autoimmune disease rare in many tropical rural populations by minimising proliferation of autoreactive T cells. Conversely, innately low levels of nitric-oxide generation in these populations, selected by malarial disease in tropical areas, could rationalise their high frequency of autoimmune disease and hypertension when living in western societies.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,CANBERRA,ACT 2601,AUSTRALIA; JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND	Australian National University; John Curtin School of Medical Research; University of Oxford	Clark, IA (corresponding author), AUSTRALIAN NATL UNIV,SCH LIFE SCI,DIV BIOCHEM & MOL BIOL,CANBERRA,ACT 0200,AUSTRALIA.		Clark, Ian A./K-2069-2012					ALYAMAN F, IN PRESS T R SOC TRO; AlYaman FM, 1996, T ROY SOC TROP MED H, V90, P270, DOI 10.1016/S0035-9203(96)90243-6; Anstey NM, 1996, J EXP MED, V184, P557, DOI 10.1084/jem.184.2.557; BATE CAW, 1990, IMMUNOLOGY, V70, P315; CLARK IA, 1992, LANCET, V340, P894, DOI 10.1016/0140-6736(92)93295-X; FAHMI H, 1995, INFECT IMMUN, V63, P1863, DOI 10.1128/IAI.63.5.1863-1869.1995; GREENWOO.BM, 1968, LANCET, V2, P380; ISOBE KI, 1992, INFECT IMMUN, V60, P4832, DOI 10.1128/IAI.60.11.4832-4837.1992; JOHNSON AE, 1995, ARTHRITIS RHEUM, V38, P551, DOI 10.1002/art.1780380415; Kitchen S. F., 1949, MALARIOLOGY, V2, P966; Kremsner PG, 1996, T ROY SOC TROP MED H, V90, P44, DOI 10.1016/S0035-9203(96)90476-9; MILLS CD, 1991, J IMMUNOL, V146, P2719; MURRAY HW, 1992, J INFECT DIS, V165, P513, DOI 10.1093/infdis/165.3.513; NUSSLER AK, 1994, J INFECT DIS, V169, P1418, DOI 10.1093/infdis/169.6.1418; POWELL RD, 1972, P HELM SOC WASH, V39, P51; ROCKETT KA, 1994, PARASITE IMMUNOL, V16, P243, DOI 10.1111/j.1365-3024.1994.tb00346.x; ROJAS A, 1993, BIOCHEM BIOPH RES CO, V191, P441, DOI 10.1006/bbrc.1993.1237; RUBENSTEIN M, 1965, P SOC EXP BIOL MED, V118, P238; RUTLEDGE DR, 1994, DRUGS, V47, P914, DOI 10.2165/00003495-199447060-00005; Ruuls SR, 1996, CLIN EXP IMMUNOL, V103, P467; SCAMMELL TE, 1996, AM J PHYSIOL, V40, pR333; STERNBERG J, 1992, EUR J IMMUNOL, V22, P2741, DOI 10.1002/eji.1830221041; TAYLOR DW, 1978, AM J TROP MED HYG, V27, P738, DOI 10.4269/ajtmh.1978.27.738; VONMULLER CS, 1978, EUR J IMMUNOL, V8, P771, DOI 10.1002/eji.1830081104; WEINBERG JB, 1995, BLOOD, V86, P1184; WILLIAMSON WA, 1978, LANCET, V1, P1328; ZIEGLERHEITBROCK HWL, 1995, J INFLAMM, V45, P13; ZINGARELLI B, 1995, SHOCK, V3, P102, DOI 10.1097/00024382-199503020-00004	28	36	38	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1492	1494		10.1016/S0140-6736(96)07342-4	http://dx.doi.org/10.1016/S0140-6736(96)07342-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942781				2022-12-01	WOS:A1996VV46300014
J	Jenny, A; MinvielleSebastia, L; Preker, PJ; Keller, W				Jenny, A; MinvielleSebastia, L; Preker, PJ; Keller, W			Sequence similarity between the 73-kilodalton protein of mammalian CPSF and a subunit of yeast polyadenylation factor I	SCIENCE			English	Article							PRE-MESSENGER-RNA; SPECIFICITY FACTOR; POLY(A) POLYMERASE; CLEAVAGE; 3'-END; CLONING; PURIFICATION; GENE	The 3' ends of most eukaryotic messenger RNAs are generated by endonucleolytic cleavage and polyadenylation. In mammals, the cleavage and polyadenylation specificity factor (CPSF) plays a central role in both steps of the processing reaction. Here, the cloning of the 73-kilodalton subunit of CPSF is reported. Sequence analyses revealed that a yeast protein (Ysh1) was highly similar to the 73-kD polypeptide. Ysh1 constitutes a new subunit of polyadenylation factor I (PFI), which has a role in yeast pre-mRNA 3'-end formation. This finding was unexpected because in contrast to CPSF, PFI is only required for the polyadenylation reaction. These results contribute to the understanding of how 3'-end processing factors may have evolved.	UNIV BASEL,BIOZENTRUM,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND	University of Basel			Minvielle-Sebastia, Lionel/M-7154-2014					ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; BARABINO SML, UNPUB; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHANFREAU G, COMMUNICATION; CHANFREAU G, UNPUB; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; GUO ZJ, 1995, MOL CELL BIOL, V15, P5983; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; JENNY A, 1995, NUCLEIC ACIDS RES, V23, P2629, DOI 10.1093/nar/23.14.2629; JENNY A, UNPUB; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; Noble SM, 1996, GENETICS, V143, P67; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PARK EC, 1992, P NATL ACAD SCI USA, V89, P1249, DOI 10.1073/pnas.89.4.1249; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; PREKER PJ, UNPUB; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; Sambrook J., 1989, MOL CLONING; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; VARSHAVSKY A, 1996, COLD SPRING HARB SYM, V60, P461; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J	31	94	98	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1514	1517		10.1126/science.274.5292.1514	http://dx.doi.org/10.1126/science.274.5292.1514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929409				2022-12-01	WOS:A1996VV77500044
J	Eng, C; Clayton, D; Schuffenecker, I; Lenoir, G; Cote, G; Gagel, RF; vanAmstel, HKP; Lips, CJM; Nishisho, I; Takai, SI; Marsh, DJ; Robinson, BG; FrankRaue, K; Raue, F; Xue, FY; Noll, WW; Romei, C; Pacini, F; Fink, M; Niederle, B; Zedenius, J; Nordenskjold, M; Komminoth, P; Hendy, GN; Gharib, H; Thibodeau, SN; Lacroix, A; Frilling, A; Ponder, BAJ; Mulligan, LM				Eng, C; Clayton, D; Schuffenecker, I; Lenoir, G; Cote, G; Gagel, RF; vanAmstel, HKP; Lips, CJM; Nishisho, I; Takai, SI; Marsh, DJ; Robinson, BG; FrankRaue, K; Raue, F; Xue, FY; Noll, WW; Romei, C; Pacini, F; Fink, M; Niederle, B; Zedenius, J; Nordenskjold, M; Komminoth, P; Hendy, GN; Gharib, H; Thibodeau, SN; Lacroix, A; Frilling, A; Ponder, BAJ; Mulligan, LM			The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 - International RET mutation consortium analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; MEN 2A; PROTOONCOGENE MUTATIONS; HIRSCHSPRUNG DISEASE; POINT MUTATION; FMTC; FAMILIES	Objective.-Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant disorder. The 3 recognized subtypes include MEN 2A, characterized by medullary thyroid carcinoma (MTC), pheochromocytoma (pheo), and hyperparathyroidism (HPT); MEN 2B, by MTC, pheo, and characteristic stigmata; and familial MTC (FMTC), by the presence of MTC only. The purpose of this study was to establish the relationship between specific mutations and the presence of certain disease features in MEN 2 which could help in clinical decision making. Design.-Correlative survey study of 477 MEN 2 families. Setting.-Eighteen tertiary referral centers worldwide. Patients.-A total of 477 independent MEN 2 families. Main Outcome Measures.-Association between the position and type of germline mutation in the RET proto-oncogene and the presence or absence of MTC, pheo, HPT, and/or other features in a family. Results.-There is a statistically significant association between the presence of any mutation at a specific position (codon 634) and the presence of pheo and HPT. The presence of a specific mutation, CGC at codon 634, has yet to be associated with FMTC, Conversely, mutations at codons 768 and 804 are thus far seen only with FMTC, while codon 918 mutation is MEN 2B-specific. Rare families with both MEN 2 and Hirschsprung disease were found to have MEN 2-specific codon mutations. Patients with Hirschsprung disease presenting with such mutations should be monitored for the possible development of MEN 2 tumors. Conclusions.-This consortium analysis suggests that genotype-phenotype correlations do exist and, if made reliably absolute, could prove useful in the future in clinical management with respect to screening, surveillance, and prophylaxis, as well as provide insight into the genetic effects of particular mutations.	QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON K7L 3N6,CANADA; UNIV CAMBRIDGE,CANC RES CAMPAIGN,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 1TN,ENGLAND; UNIV CAMBRIDGE,INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE CB2 1TN,ENGLAND; INT AGCY RES CANC,F-69372 LYON,FRANCE; UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX; UNIV UTRECHT,DEPT INTERNAL MED,UTRECHT,NETHERLANDS; UNIV UTRECHT,CLIN GENET CTR,UTRECHT,NETHERLANDS; OSAKA UNIV,SCH MED,DEPT MED GENET,OSAKA,JAPAN; UNIV SYDNEY,ROYAL N SHORE HOSP,KOLLING INST MED RES,MOL GENET UNIT,ST LEONARDS,NSW 2065,AUSTRALIA; UNIV HEIDELBERG,DEPT INTERNAL MED 1,HEIDELBERG,GERMANY; DARTMOUTH HITCHCOCK MED CTR,DEPT PATHOL,LEBANON,NH 03766; UNIV PISA,INST ENDOCRINOL,PISA,ITALY; UNIV VIENNA,DEPT SURG,A-1010 VIENNA,AUSTRIA; KAROLINSKA HOSP,DEPT MOL MED,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT SURG,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT CLIN GENET,S-10401 STOCKHOLM,SWEDEN; UNIV ZURICH,DEPT PATHOL,CH-8006 ZURICH,SWITZERLAND; ROYAL VICTORIA HOSP,CALCIUM RES LAB,MONTREAL,PQ H3A 1A1,CANADA; MAYO CLIN,DIV ENDOCRINOL,ROCHESTER,MN; HOP HOTEL DIEU,CTR RECH,MONTREAL,PQ,CANADA; UNIV HAMBURG,DEPT SURG,HAMBURG,GERMANY; QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON,CANADA	Queens University - Canada; CRUK Cambridge Institute; University of Cambridge; MRC Biostatistics Unit; University of Cambridge; World Health Organization; International Agency for Research on Cancer (IARC); University of Texas System; UTMD Anderson Cancer Center; Utrecht University; Utrecht University; Osaka University; Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; Ruprecht Karls University Heidelberg; Dartmouth College; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Pisa; University of Vienna; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; University of Zurich; McGill University; Royal Victoria Hospital; Mayo Clinic; Universite de Montreal; University of Hamburg; Queens University - Canada; Queens University - Canada	Eng, C (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,DIV CANC EPIDEMIOL & CONTROL,44 BINNEY ST,BOSTON,MA 02115, USA.		Lacroix, Andre/AAI-5645-2020; Marsh, Deborah J/I-1491-2014; Raue, Friedhelm/ABD-6150-2021	Marsh, Deborah J/0000-0001-5899-4931; Raue, Friedhelm/0000-0002-7700-1648; Eng, Charis/0000-0002-3693-5145; Niederle, Bruno/0000-0001-8107-4068; Nordenskjold, Magnus/0000-0002-4974-425X				ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BOLINO A, 1995, ONCOGENE, V10, P2415; BORST MJ, 1995, SURGERY, V117, P386, DOI 10.1016/S0039-6060(05)80057-1; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1995, CLIN ENDOCRINOL, V43, P123, DOI 10.1111/j.1365-2265.1995.tb01903.x; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENG C, IN PRESS HUM MUTAT; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; FRILLING A, 1992, H FORD HOSP MED J, V40, P233; GAGEL RF, 1989, ANN INTERN MED, V111, P802, DOI 10.7326/0003-4819-111-10-802; GARDNER E, 1994, HUM MOL GENET, V3, P1771, DOI 10.1093/hmg/3.10.1771; Hofstra R. M. W., 1994, American Journal of Human Genetics, V55, pA60; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KOMMINOTH P, 1995, CANCER, V76, P479; Komminoth P, 1996, J CLIN ENDOCR METAB, V81, P2041, DOI 10.1210/jc.81.6.2041; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; Marsh DJ, 1996, CLIN ENDOCRINOL, V44, P213, DOI 10.1046/j.1365-2265.1996.505292.x; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; MULLIGAN LM, 1995, J INTERN MED, V238, P343, DOI 10.1111/j.1365-2796.1995.tb01208.x; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Noorani HZ, 1996, AM J HUM GENET, V59, P301; Okamoto E, 1967, J PEDIATR SURG, V2, P437; Pausova Z, 1996, J CLIN ENDOCR METAB, V81, P2711, DOI 10.1210/jc.81.7.2711; PONDER BAJ, 1988, Q J MED, V67, P299; Reynolds Lucinda F., 1995, Current Opinion in Pediatrics, V7, P702; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SCHIMKE RN, 1968, NEW ENGL J MED, V279, P1, DOI 10.1056/NEJM196807042790101; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; THAKKER RV, 1988, CLIN ENDOCRINOL META, V28, P1031; VERDY M, 1982, J PEDIATR GASTR NUTR, V1, P603, DOI 10.1097/00005176-198212000-00027; ZEDENIUS J, 1995, J CLIN ENDOCR METAB, V80, P3088, DOI 10.1210/jc.80.10.3088	35	854	883	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1575	1579		10.1001/jama.276.19.1575	http://dx.doi.org/10.1001/jama.276.19.1575			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT025	8918855				2022-12-01	WOS:A1996VT02500030
J	Bowman, RJC; Bennett, HGB; Houston, CA; Aitchison, TC; Dutton, GN				Bowman, RJC; Bennett, HGB; Houston, CA; Aitchison, TC; Dutton, GN			Waiting times for and attendance at paediatric ophthalmology outpatient appointments	BRITISH MEDICAL JOURNAL			English	Article									GLASGOW EYE INFIRM,GLASGOW G3 8JE,LANARK,SCOTLAND; UNIV GLASGOW,DEPT STAT,GLASGOW G12 8AG,LANARK,SCOTLAND	University of Glasgow	Bowman, RJC (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,TENNENT INST OPHTHALMOL,GLASGOW G11 6NT,LANARK,SCOTLAND.							ALPERT JJ, 1964, PEDIATRICS, V34, P127; CARSTAIRS V, 1992, DEPRIVATION HLTH SCO; MCCARRON PG, 1994, BRIT MED J, V309, P1481, DOI 10.1136/bmj.309.6967.1481	3	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1244	1244		10.1136/bmj.313.7067.1244	http://dx.doi.org/10.1136/bmj.313.7067.1244			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939117	Green Published			2022-12-01	WOS:A1996VU20800026
J	MasucciMagoulas, L; Goldberg, IJ; Bisgaier, CL; Serajuddin, H; Francone, OL; Breslow, JL; Tall, AR				MasucciMagoulas, L; Goldberg, IJ; Bisgaier, CL; Serajuddin, H; Francone, OL; Breslow, JL; Tall, AR			A mouse model with features of familial combined hyperlipidemia	SCIENCE			English	Article							SERUM TRIGLYCERIDE LEVELS; APOLIPOPROTEIN-A-I; AIV GENE-CLUSTER; TRANSGENIC MICE; PLASMA-LIPOPROTEINS; LPL GENE; CHOLESTEROL; HYPERTRIGLYCERIDEMIA; EXPRESSION; POLYMORPHISMS	Familial combined hyperlipidemia (FCHL) is a common inherited lipid disorder, affecting 1 to 2 percent of the population in Westernized societies. Individuals with FCHL have large quantities of very low density lipoprotein (VLDL) and low density lipoprotein (LDL) and develop premature coronary heart disease. A mouse model displaying some of the features of FCHL was created by crossing mice carrying the human apolipoprotein C-III (APOC3) transgene with mice deficient in the LDL receptor. A synergistic interaction between the apolipoprotein C-III and the LDL receptor defects produced large quantities of VLDL and LDL and enhanced the development of atherosclerosis. This mouse model may provide clues to the origin of human FCHL.	COLUMBIA UNIV,DEPT MED,NEW YORK,NY 10032; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,DEPT VASC & CARDIAC DIS,ANN ARBOR,MI 48105; PFIZER INC,DIV CENT RES,DEPT METAB DIS,GROTON,CT 06340; ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021	Columbia University; Pfizer; Pfizer; Rockefeller University			Tall, Alan/AAT-8528-2021; Breslow, Jan L/B-7544-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006, P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 21006, HL 54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AAITOSETALA K, 1992, J CLIN INVEST, V90, P1889; AaltoSetala K, 1996, J LIPID RES, V37, P1802; AGELLON LB, 1991, J BIOL CHEM, V266, P10796; BABIRAK SP, 1992, ARTERIOSCLER THROMB, V12, P1176, DOI 10.1161/01.ATV.12.10.1176; BRUNS GAP, 1984, ARTERIOSCLEROSIS, V4, P97, DOI 10.1161/01.ATV.4.2.97; BRUNZELL JD, 1983, J LIPID RES, V24, P147; BRUNZELL JD, 1984, ARTERIOSCLEROSIS, V4, P79, DOI 10.1161/01.ATV.4.2.79; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CHIESA G, 1993, J CLIN INVEST, V32, P23747; CULLEN P, 1994, ARTERIOSCLER THROMB, V14, P1233, DOI 10.1161/01.ATV.14.8.1233; DallingaThie GM, 1996, J LIPID RES, V37, P136; DAMMERMAN M, 1993, P NATL ACAD SCI USA, V90, P4562, DOI 10.1073/pnas.90.10.4562; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; FIELDING CJ, 1995, J LIPID RES, V36, P211; GAGNE E, 1994, ARTERIOSCLER THROMB, V14, P1250, DOI 10.1161/01.ATV.14.8.1250; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GRUNDY SM, 1987, ARTERIOSCLEROSIS, V7, P203; Haubenwallner S, 1995, J LIPID RES, V36, P2541; HAYDEN MR, 1987, AM J HUM GENET, V40, P421; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; ISHIBASHI S, 1994, J CLIN INVEST, V92, P833; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JI ZS, 1994, J BIOL CHEM, V269, P2764; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; KIEFT KA, 1991, J LIPID RES, V32, P859; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SCHACHTER NS, 1996, J CLIN INVEST, V98, P846; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; VENKATESAN S, 1993, ARTERIOSCLER THROMB, V13, P1110, DOI 10.1161/01.ATV.13.7.1110; WOJCIECHOWSKI AP, 1991, NATURE, V349, P161, DOI 10.1038/349161a0; XU CF, 1994, CLIN GENET, V46, P385; YANG WS, 1995, P NATL ACAD SCI USA, V92, P4462, DOI 10.1073/pnas.92.10.4462; ZENG Q, 1994, HUM GENET, V95, P371	34	111	112	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					391	394		10.1126/science.275.5298.391	http://dx.doi.org/10.1126/science.275.5298.391			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994037				2022-12-01	WOS:A1997WC87300048
J	Gu, Y; Kuida, K; Tsutsui, H; Ku, G; Hsiao, K; Fleming, MA; Hayashi, N; Higashino, K; Okamura, H; Nakanishi, K; Kurimoto, M; Tanimoto, T; Flavell, RA; Sato, V; Harding, MW; Livingston, DJ; Su, MSS				Gu, Y; Kuida, K; Tsutsui, H; Ku, G; Hsiao, K; Fleming, MA; Hayashi, N; Higashino, K; Okamura, H; Nakanishi, K; Kurimoto, M; Tanimoto, T; Flavell, RA; Sato, V; Harding, MW; Livingston, DJ; Su, MSS			Activation of interferon-gamma inducing factor mediated by interleukin-1 beta converting enzyme	SCIENCE			English	Article							ENDOTOXIC-SHOCK; POLY(ADP-RIBOSE) POLYMERASE; IMMUNE-RESPONSE; MICE DEFICIENT; GRANZYME-B; PROTEASE; APOPTOSIS; INDUCTION; CYTOKINE; CELLS	The interleukin-1 beta (IL-1 beta) converting enzyme (ICE) processes the inactive IL-IP precursor to the proinflammatory cytokine. ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export. Lipopolysaccharide-activated ICE-deficient (ICE(-/-)) Kupffer cells synthesized the IGIF precursor but failed to process it into the active form. Interferon-gamma and IGIF were diminished in the sera of ICE(-/-) mice exposed to Propionibacterium acnes and lipopolysaccharide. The lack of multiple proinflammatory cytokines in ICE(-/-) mice may account for their protection from septic shock.	TOKYO METROPOLITAN INST MED SCI,TOKYO 113,JAPAN; HYOGO MED UNIV,NISHINOMIYA,HYOGO,JAPAN; HAYASHIBARA CO INC,HAYASHIBARA BIOCHEM LABS,OKAYAMA,JAPAN; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Tokyo Metropolitan Institute of Medical Science; Hyogo College of Medicine; University of Hyogo; Hayashibara Biochemical Laboratories, Inc.; Howard Hughes Medical Institute; Yale University	Gu, Y (corresponding author), VERTEX PHARMACEUT INC,130 WAVERLY ST,CAMBRIDGE,MA 02139, USA.			Tsutsui, Hiroko/0000-0001-7928-4875				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BELARDELLI F, 1995, APMIS, V103, P161, DOI 10.1111/j.1699-0463.1995.tb01092.x; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Gu Y, 1996, J BIOL CHEM, V271, P10816, DOI 10.1074/jbc.271.18.10816; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; KU G, UNPUB; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARGOLIS N, UNPUB; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OKAMURA H, 1995, INFECT IMMUN, V63, P3966, DOI 10.1128/IAI.63.10.3966-3972.1995; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; QUILL H, 1987, J IMMUNOL, V138, P3704; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; Tsuji  N., UNPUB; TSUTSUI H, 1992, HEPATO-GASTROENTEROL, V39, P553; Ushio S, 1996, J IMMUNOL, V156, P4274; ZHENG H, 1995, IMMUNITY, V3, P9, DOI 10.1016/1074-7613(95)90154-X	33	986	1071	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					206	209		10.1126/science.275.5297.206	http://dx.doi.org/10.1126/science.275.5297.206			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8999548				2022-12-01	WOS:A1997WC02200036
J	Penton, A; Selleck, SB; Hoffmann, FM				Penton, A; Selleck, SB; Hoffmann, FM			Regulation of cell cycle synchronization by decapentaplegic during Drosophila eye development	SCIENCE			English	Article							G2-M TRANSITION; GENE-PRODUCT; DPP; HEDGEHOG; PROTEIN; ENCODES; COMPARTMENT; EXPRESSION; SCHNURRI; PATTERN	In the developing Drosophila eye, differentiation is coordinated with synchronized progression through the cell cycle. Signaling mediated by the transforming growth factor-beta-related gene decapentaplegic (dpp) was required for the synchronization of the cell cycle but not for cell fate specification. DPP may affect cell cycle synchronization by promoting cell cycle progression through the G(2)-M phases. This synchronization is critical for the precise assembly of the eye.	UNIV WISCONSIN,SCH MED,MCARDLE LAB CANC RES,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,GENET LAB,MADISON,WI 53706; UNIV ARIZONA,ARIZONA RES LABS,DIV NEUROBIOL,TUCSON,AZ 85721; UNIV ARIZONA,DEPT MOL & CELLULAR BIOL,TUCSON,AZ 85721	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Arizona; University of Arizona				Hoffmann, F. Michael/0000-0002-2770-9656				ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BROWN NL, 1991, DEVELOPMENT, V113, P1245; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FISCHERVIZE JA, 1994, DEVELOPMENT, V120, P2609; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; Jackson SG, UNPUB; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; Milan M, 1996, P NATL ACAD SCI USA, V93, P640, DOI 10.1073/pnas.93.2.640; NAKATO H, 1995, DEVELOPMENT, V121, P3687; PENTON A, UNPUB; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; STAEHLINGHAMPTON K, 1995, DEVELOPMENT, V121, P3393; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; WOLFF T, 1993, DEV DROSOPHILA MELAN, V2, P1277; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	29	70	71	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					203	206		10.1126/science.275.5297.203	http://dx.doi.org/10.1126/science.275.5297.203			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985012				2022-12-01	WOS:A1997WC02200035
J	Graham, SM; Daley, HM; Ngwira, B				Graham, SM; Daley, HM; Ngwira, B			Finger clubbing and HIV infection in Malawian children	LANCET			English	Article											Graham, SM (corresponding author), UNIV MALAWI,COLL MED,DEPT PAEDIAT,BLANTYRE 3,MALAWI.			Graham, Stephen/0000-0003-3525-2294				REEVE PA, 1987, THORAX, V42, P986, DOI 10.1136/thx.42.12.986	1	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					31	31		10.1016/S0140-6736(05)62164-2	http://dx.doi.org/10.1016/S0140-6736(05)62164-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988127				2022-12-01	WOS:A1997WA72500021
J	Oliver, JD; vanderWal, FJ; Bulleid, NJ; High, S				Oliver, JD; vanderWal, FJ; Bulleid, NJ; High, S			Interaction of the thiol-dependent reductase ERp57 with nascent glycoproteins	SCIENCE			English	Article							PHOSPHOLIPASE-C-ALPHA; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; QUALITY-CONTROL; PROTEINS; CALNEXIN; ASSOCIATION; FORM; CALRETICULIN; DEGRADATION	Calnexin and calreticulin interact specifically with newly synthesized glycoproteins in the endoplasmic reticulum (ER) and function as molecular chaperones. The carbohydrate-specific interactions between ER components and glycoproteins synthesized in isolated canine pancreatic microsomes were analyzed using a cross-linking approach. A carbohydrate-dependent interaction between newly synthesized glycoproteins, the thiol-dependent reductase ERp57, and either calnexin or calreticulin was identified. The interaction between ERp57 and the newly synthesized glycoproteins required trimming of the N-linked oligosaccharide side chain. Thus, it is likely that ERp57 functions as part of the glycoprotein-specific quality control machinery operating in the lumen of the ER.	UNIV MANCHESTER,SCH BIOL SCI,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester				Bulleid, Neil/0000-0002-9839-5279; van der Wal, Fimme/0000-0002-6859-1252; High, Stephen/0000-0002-4532-8152				ABRIOLA C, 1905, J CELL BIOL, V130, P771; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BULLEID NJ, 1990, BIOCHEM J, V268, P777, DOI 10.1042/bj2680777; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARLOW E, 1988, NTIBODIES LAB MANUAL; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIRANO N, 1994, BIOCHEM BIOPH RES CO, V204, P375, DOI 10.1006/bbrc.1994.2469; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KLAPPA P, 1995, EUR J BIOCHEM, V232, P755, DOI 10.1111/j.1432-1033.1995.755zz.x; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; Oliver JD, 1996, J BIOL CHEM, V271, P13691, DOI 10.1074/jbc.271.23.13691; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; SRIVASTAVA SP, 1993, BIOCHEM BIOPH RES CO, V193, P971, DOI 10.1006/bbrc.1993.1720; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; URADE R, 1992, J BIOL CHEM, V267, P15152	25	334	340	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					86	88		10.1126/science.275.5296.86	http://dx.doi.org/10.1126/science.275.5296.86			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974399				2022-12-01	WOS:A1997WA90300055
J	Andreotti, AH; Bunnell, SC; Feng, S; Berg, LJ; Schreiber, SL				Andreotti, AH; Bunnell, SC; Feng, S; Berg, LJ; Schreiber, SL			Regulatory intramolecular association in a tyrosine kinase of the Tec family	NATURE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; SH3 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; GENE; PROTEIN; BINDING; EXPRESSION; PEPTIDES; INTERLEUKIN-2; SPECTROSCOPY	THE T-cell-specific tyrosine kinase Itk is a member of the Tec family of non-receptor tyrosine kinases(1-7), and is required for signalling through the T-cell antigen receptor (TCR)(8). The role of Itk in TCR Signalling and the manner in which Itk activity is regulated are not well understood. Substrate binding and enzymatic activity of the structurally related Src kinases are regulated by an intramolecular interaction between the Src-homology-2 (SH2) domain and a phosphotyrosine(9,10). Although Itk also contains SH3, SH2 and tyrosine kinase domains, it lacks the corresponding regulatory phosphorylation site, and therefore must be regulated by an alternative mechanism. The proline-rich sequence adjacent to the SH3 domain of Tec family kinases contains an SH3 ligand, potentially allowing a different intramolecular interaction. By using multidimensional nuclear magnetic resonance we have determined the structure of a fragment of Itk, confirming that these domains interact intramolecularly. Formation of this intramolecular SH3-ligand complex prevents the Itk SH3 domain and proline-rich region from interacting with their respective protein ligands, Sam68 and Grb-2. We believe that this structure represents the first example of an intramolecular interaction between an SH3 domain and a proline-rich ligand, and has implications for the regulation of Tec family kinases.	HARVARD UNIV, HOWARD HUGHES MED INST, DEPT CHEM & CHEM BIOL, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University; Howard Hughes Medical Institute; Harvard University				Bunnell, Stephen/0000-0001-6887-0828				Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; BRUNGER AT, 1992, XPLOR 3 1; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHEN JK, 1994, BIOORG MED CHEM LETT, V4, P1755, DOI 10.1016/S0960-894X(00)80375-3; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; MANO H, 1993, ONCOGENE, V8, P417; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANAKA N, 1993, FEBS LETT, V324, P1, DOI 10.1016/0014-5793(93)81520-A; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	30	229	235	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 2	1997	385	6611					93	97		10.1038/385093a0	http://dx.doi.org/10.1038/385093a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985255				2022-12-01	WOS:A1997WA73100058
J	Kang, JM; Rebek, J				Kang, JM; Rebek, J			Acceleration of a Diels-Alder reaction by a self-assembled molecular capsule	NATURE			English	Article							MICELLAR CATALYSIS	THE interior of cage-like molecules can be considered to provide a new phase of matter(1,2), in which it becomes possible to stabilize reactive intermediates(3) and to observe new forms of stereoisomerism(4). Cage-like molecular complexes that self-assemble through weak intermolecular forces are dynamic species(5,6), encapsulating guest molecules reversibly. They can persist over timescales ranging from microseconds to hours, long enough for chemical processes to take place within them. Here we report the acceleration of a Diels-Alder reaction bg encapsulation of the reactants in a self-assembling molecular capsule(7,8). Although product inhibition (lack of dissociation) prevents the system from showing true catalytic behaviour, there is clear evidence for a rate increase of over two orders of magnitude owing to the effective enhancement of concentration inside the capsule.	Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA; MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA	Scripps Research Institute; Massachusetts Institute of Technology (MIT)								BRAUN R, 1986, TETRAHEDRON LETT, V27, P1285, DOI 10.1016/S0040-4039(00)84239-2; BRESLOW R, 1988, J AM CHEM SOC, V110, P5613, DOI 10.1021/ja00225a003; BRESLOW R, 1983, TETRAHEDRON LETT, V24, P1901, DOI 10.1016/S0040-4039(00)81801-8; CRAM DJ, 1991, ANGEW CHEM INT EDIT, V30, P1024, DOI 10.1002/anie.199110241; GAREL L, 1993, ANGEW CHEM INT EDIT, V32, P1169, DOI 10.1002/anie.199311691; GRIECO PA, 1983, TETRAHEDRON LETT, V24, P1897, DOI 10.1016/S0040-4039(00)81800-6; Grieco PA, 1996, J AM CHEM SOC, V118, P2095, DOI 10.1021/ja9531992; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; Kang JM, 1996, NATURE, V382, P239, DOI 10.1038/382239a0; KELLY TR, 1990, TETRAHEDRON LETT, V31, P3381, DOI 10.1016/S0040-4039(00)97402-1; Kirby A.J., 1980, ADV PHYS ORG CHEM, V17, P183; MCCURDY A, 1992, J AM CHEM SOC, V114, P10314, DOI 10.1021/ja00052a031; MEISSNER R, IN PRESS J AM CHEM S; MEISSNER RS, 1995, SCIENCE, V270, P1485, DOI 10.1126/science.270.5241.1485; MOCK WL, 1989, J ORG CHEM, V54, P5302, DOI 10.1021/jo00283a024; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; SHERMAN JC, 1989, J AM CHEM SOC, V111, P4527, DOI 10.1021/ja00194a074; SINGH VK, 1988, SYNTHETIC COMMUN, V18, P567, DOI 10.1080/00397918808064013; TIMMERMAN P, 1994, ANGEW CHEM INT EDIT, V33, P2345, DOI 10.1002/anie.199423451; Valdes C, 1995, J AM CHEM SOC, V117, P12733, DOI 10.1021/ja00156a010; WALTER CJ, 1993, J CHEM SOC CHEM COMM, P459; WYLER R, 1993, ANGEW CHEM INT EDIT, V32, P1699, DOI 10.1002/anie.199316991	22	479	482	3	121	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 2	1997	385	6611					50	52		10.1038/385050a0	http://dx.doi.org/10.1038/385050a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985245				2022-12-01	WOS:A1997WA73100044
J	Rice, PA; Yang, SW; Mizuuchi, K; NAsh, HA				Rice, PA; Yang, SW; Mizuuchi, K; NAsh, HA			Crystal structure of an IHF-DNA complex: A protein-induced DNA u-turn	CELL			English	Article							INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; BINDING PROTEINS; ADENINE TRACT; MINOR-GROOVE; HU PROTEIN; SITES; LATTICE; MUTANTS; RECOMBINATION	Integration host factor (IHF) is a small heterodimeric protein that specifically binds to DNA and functions as an architectural factor in many cellular processes in prokaryotes. Here, we report the crystal structure of IHF complexed with 35 bp of DNA. The DNA is wrapped around the protein and bent by >160 degrees, thus reversing the direction of the helix axis within a very short distance. Much of the bending occurs at two large kinks where the base stacking is interrupted by intercalation of a proline residue. IHF contacts the DNA exclusively via the phosphodiester backbone and the minor groove and relies heavily on indirect readout to recognize its binding sequence. One such readout involves a six-base A tract, providing evidence for the importance of a narrow minor groove.	NIMH,MOL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Rice, PA (corresponding author), NIDDK,MOL BIOL LAB,NIH,BETHESDA,MD 20892, USA.							BERMAN HM, 1994, CURR OPIN STRUC BIOL, V4, P345, DOI 10.1016/S0959-440X(94)90102-3; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; *DAR LAB, 1979, CCP4 SERC UK DAR LAB; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; DIGABRIELE AD, 1993, J MOL BIOL, V231, P1024, DOI 10.1006/jmbi.1993.1349; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GOODMAN SD, 1992, P NATL ACAD SCI USA, V89, P11910, DOI 10.1073/pnas.89.24.11910; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GOOSEN N, 1995, MOL MICROBIOL, V16, P1, DOI 10.1111/j.1365-2958.1995.tb02386.x; GRANSTON AE, 1993, J MOL BIOL, V234, P45, DOI 10.1006/jmbi.1993.1562; HALES LM, 1994, BIOCHIMIE, V76, P1030, DOI 10.1016/0300-9084(94)90027-2; HALES LM, 1994, J BACTERIOL, V176, P2999, DOI 10.1128/JB.176.10.2999-3006.1994; Hales LM, 1996, NUCLEIC ACIDS RES, V24, P1780, DOI 10.1093/nar/24.9.1780; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; Lavoie BD, 1996, CELL, V85, P761, DOI 10.1016/S0092-8674(00)81241-6; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE EC, 1992, EMBO J, V11, P305, DOI 10.1002/j.1460-2075.1992.tb05053.x; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Luisi B., 1995, DNA PROTEIN STRUCTUR, P1; MENGERITSKY G, 1993, J MOL BIOL, V231, P646, DOI 10.1006/jmbi.1993.1316; Minor W., 1993, XDISPLAYF PROGRAM; MIRZABEKOV AD, 1979, P NATL ACAD SCI USA, V76, P1118, DOI 10.1073/pnas.76.3.1118; MOLINALOPEZ JA, 1994, J BIOL CHEM, V269, P25419; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; Nash Howard A., 1996, P149; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NUNESDUBY SE, 1995, J MOL BIOL, V253, P228, DOI 10.1006/jmbi.1995.0548; Oberto J, 1996, J BACTERIOL, V178, P293, DOI 10.1128/jb.178.1.293-297.1996; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Parekh BS, 1996, P NATL ACAD SCI USA, V93, P1173, DOI 10.1073/pnas.93.3.1173; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PEREZMARTIN J, 1994, J BIOL CHEM, V269, P22657; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROTH A, 1994, BIOCHIMIE, V76, P917, DOI 10.1016/0300-9084(94)90016-7; SCHULTZ SC, 1990, J MOL BIOL, V213, P159, DOI 10.1016/S0022-2836(05)80128-7; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; STOFER E, 1994, BIOPOLYMERS, V34, P337, DOI 10.1002/bip.360340305; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; SUZUKI M, 1995, NUCLEIC ACIDS RES, V23, P2083, DOI 10.1093/nar/23.12.2083; Suzuki M, 1996, NUCLEIC ACIDS RES, V24, P2767, DOI 10.1093/nar/24.14.2767; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; TOUSSAINT B, 1994, BIOCHIMIE, V76, P951, DOI 10.1016/0300-9084(94)90020-5; VIS H, 1995, J MOL BIOL, V254, P692, DOI 10.1006/jmbi.1995.0648; WANG SQ, 1995, BIOCHEMISTRY-US, V34, P13082, DOI 10.1021/bi00040a020; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; YANG SW, 1994, P NATL ACAD SCI USA, V91, P12183, DOI 10.1073/pnas.91.25.12183; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; ZULIANELLO L, 1995, J BIOL CHEM, V270, P17902, DOI 10.1074/jbc.270.30.17902	66	655	676	1	39	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1295	1306		10.1016/S0092-8674(00)81824-3	http://dx.doi.org/10.1016/S0092-8674(00)81824-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980235	Bronze			2022-12-01	WOS:A1996WA54100017
J	McCormick, J				McCormick, J			Sloth	BRITISH MEDICAL JOURNAL			English	Article											McCormick, J (corresponding author), TRINITY COLL DUBLIN,DEPT COMMUNITY HLTH & GEN PRACTICE,DUBLIN 2,IRELAND.							MCCORMICK JS, 1988, LANCET, V2, P26; 1966, OXFORD DICT QUOTATIO	2	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1596	1596		10.1136/bmj.313.7072.1596	http://dx.doi.org/10.1136/bmj.313.7072.1596			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991000	Green Published			2022-12-01	WOS:A1996VZ81100023
J	Bonn, D				Bonn, D			Surfactants and babies: Slippery little things	LANCET			English	News Item																		1996, DRUGS, V51, P226	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1650	1650		10.1016/S0140-6736(05)65703-0	http://dx.doi.org/10.1016/S0140-6736(05)65703-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8984309				2022-12-01	WOS:A1996VX87600032
J	Scheffzek, K; Lautwein, A; Kabsch, W; Ahmadian, MR; Wittinghofer, A				Scheffzek, K; Lautwein, A; Kabsch, W; Ahmadian, MR; Wittinghofer, A			Crystal structure of the GTPase-activating domain of human p120GAP and implications for the interaction with Ras	NATURE			English	Article							TYPE-1 NF1 GENE; PROTEIN; MECHANISM; GAP; HYDROLYSIS; NEUROFIBROMIN; P21; DIFFERENTIATION; MUTAGENESIS; STIMULATION	RAS-RELATED GTP-binding proteins function as molecular switches which cycle between GTP-bound 'on'- and GDP-bound 'off'-states(1), GTP hydrolysis is the common timing mechanism that mediates the return from the 'on' to the 'off'-state, It is usually slow but can be accelerated by orders of magnitude upon interaction with GTPase-activating proteins (GAPs). In the case of Ras, a major regulator of cellular growth, point mutations are found in approximately 30% of human tumours which render the protein unable to hydrolyse GTP, even in the presence of Ras-GAPs, The first structure determination of a GTPase-activating protein reveals the catalytically active fragment of the Ras-specific p120GAP (ref. 2), GAP-334, as an elongated, exclusively helical protein which appears to represent a novel protein fold, The molecule consists of two domains, one of which contains all the residues conserved among different GAPs for Ras. From the location of conserved residues around a shallow groove in the central domain we can identify the site of interaction with Ras-GTP. This leads to a model for the interaction between Ras and GAP that satisfies numerous biochemical and genetic data on this important regulatory process.	MAX PLANCK INST MOL PHYSIOL, D-44139 DORTMUND, GERMANY; MAX PLANCK INST MED RES, D-69120 HEIDELBERG, GERMANY	Max Planck Society; Max Planck Society								Ahmadian MR, 1996, J BIOL CHEM, V271, P16409, DOI 10.1074/jbc.271.27.16409; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; BRUNGER TA, 1992, XPLOR VERSION 3 1; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; GUTMANN DH, 1993, ONCOGENE, V8, P761; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HETTICH L, 1994, CANCER RES, V54, P5438; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; Miao WY, 1996, J BIOL CHEM, V271, P15322, DOI 10.1074/jbc.271.26.15322; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MON S, 1995, J BIOL CHEM, V270, P28834; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; Morcos P, 1996, MOL CELL BIOL, V16, P2496; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NISHI T, 1991, ONCOGENE, V6, P1555; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Parrini MC, 1996, EMBO J, V15, P1107, DOI 10.1002/j.1460-2075.1996.tb00448.x; POULLET P, 1994, MOL CELL BIOL, V14, P815, DOI 10.1128/MCB.14.1.815; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; REY I, 1994, ONCOGENE, V9, P685; RUBINFELD B, 1991, INT J PEPT PROT RES, V38, P47; SCHEFFZEK K, IN PRESS PROTEINS ST; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YODERHILL J, 1995, J BIOL CHEM, V270, P27615, DOI 10.1074/jbc.270.46.27615	35	137	141	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 12	1996	384	6609					591	596		10.1038/384591a0	http://dx.doi.org/10.1038/384591a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955277				2022-12-01	WOS:A1996VX76900067
J	Erickson, JC; Hollopeter, G; Palmiter, RD				Erickson, JC; Hollopeter, G; Palmiter, RD			Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y	SCIENCE			English	Article							GENE-PRODUCT; MOUSE; RATS; HYPOTHALAMUS; PROTEIN; RNA	The obesity syndrome of ob/ob mice results from lack of leptin, a hormone released by fat cells that acts in the brain to suppress feeding and stimulate metabolism. Neuropeptide Y (NPY) is a neuromodulator implicated in the control of energy balance and is overproduced in the hypothalamus of ob/ob mice. To determine the role of NPY in the response to leptin deficiency, ob/ob mice deficient for NPY were generated. In the absence of NPY, ob/ob mice are less obese because of reduced food intake and increased energy expenditure, and are less severely affected by diabetes, sterility, and somatotropic defects, These results suggest that NPY is a central effector of leptin deficiency.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Barash IA, 1996, ENDOCRINOLOGY, V137, P3144, DOI 10.1210/en.137.7.3144; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CATZEFLIS C, 1993, ENDOCRINOLOGY, V132, P224, DOI 10.1210/en.132.1.224; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; LANE PW, 1954, J HERED, V45, P56, DOI 10.1093/oxfordjournals.jhered.a106439; LARSON BA, 1976, ENDOCRINOLOGY, V98, P139, DOI 10.1210/endo-98-1-139; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Pierroz DD, 1996, ENDOCRINOLOGY, V137, P3, DOI 10.1210/en.137.1.3; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; SHEHAB FF, 1996, NAT GENET, V12, P318; Smith FJ, 1996, NATURE, V382, P307, DOI 10.1038/382307a0; Stanley B.G., 1993, BIOL NEUROPEPTIDE RE, P457, DOI [10.1007/978-1-59259-465-8_11, DOI 10.1007/978-1-59259-465-8_11]; STANLEY BG, 1986, PEPTIDES, V7, P1189; STEIN DT, 1995, INT J OBESITY, V19, P804; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; WILDING JPH, 1993, ENDOCRINOLOGY, V132, P1939, DOI 10.1210/en.132.5.1939; ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	35	707	727	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1704	1707		10.1126/science.274.5293.1704	http://dx.doi.org/10.1126/science.274.5293.1704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939859				2022-12-01	WOS:A1996VW71200058
J	Wengler, GS; Lanfranchi, A; Frusca, T; Verardi, R; Neva, A; Brugnoni, D; Giliani, S; Fiorini, M; Mella, P; Guandalini, F; Mazzolari, E; Pecorelli, S; Notarangelo, LD; Porta, F; Ugazio, AG				Wengler, GS; Lanfranchi, A; Frusca, T; Verardi, R; Neva, A; Brugnoni, D; Giliani, S; Fiorini, M; Mella, P; Guandalini, F; Mazzolari, E; Pecorelli, S; Notarangelo, LD; Porta, F; Ugazio, AG			In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI)	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; STEM-CELLS; RECIPIENTS; GENE	Background X-linked severe combined immunodeficiency (SCIDXI) is an inherited immune defect which leads to death in infancy from severe infections. The defect is caused by mutations of the IL-2RG gene that encodes for the common gamma chain shared by several cytokine receptors. The disease is characterised by lack of T and NK cells with normal numbers of B cells. SCIDXI can be cured by bone marrow transplantation (BMT) or prevented by abortion after prenatal diagnosis. Methods A male fetus was diagnosed as having SCIDXI by molecular, immunophenotypic, and functional analyses. The fetus was injected intraperitoneally under ultrasound guidance with CD34 haematopoietic progenitor cells purified from paternal bone marrow and T-cell depleted by E resetting. Chimerism analysis was by HLA-DQ alpha typing and gamma-chain staining on cord blood. Findings A healthy 3.6 kg boy was delivered by caesarean section at 38 weeks of gestation with no clinical or laboratory signs of graft-versus-host disease. Engraftment of donor-derived CD2 cells was found at birth, At 3.5 months of age the infant is well and his T-cell counts and function are normal. Interpretation In-utero transplantation of haematopoietic progenitor cells allowed immune reconstitution of a fetus with SCIDXI and may be an alternative to elective abortion. Our report should encourage applications of this method to other inherited disorders curable by BMT.	UNIV BRESCIA,DEPT GYNAECOL,I-25124 BRESCIA,ITALY; UNIV BRESCIA,INST CLIN IMMUNOL,I-25124 BRESCIA,ITALY; UNIV BRESCIA,INST CHEM,I-25124 BRESCIA,ITALY	University of Brescia; University of Brescia; University of Brescia	Wengler, GS (corresponding author), UNIV BRESCIA,DEPT PAEDIAT,I-25124 BRESCIA,ITALY.		Brugnoni, Duilio/AAG-9425-2019; Giliani, Silvia/AAX-8843-2020; Ugazio, Alberto/AAA-6092-2020	Brugnoni, Duilio/0000-0001-9420-9961; Giliani, Silvia/0000-0001-8137-4642; 	Telethon [A.042] Funding Source: Medline	Telethon(Fondazione Telethon)		Blau CA, 1996, NAT MED, V2, P161, DOI 10.1038/nm0296-161; BLAZAR BR, 1995, BLOOD, V86, P4353, DOI 10.1182/blood.V86.11.4353.bloodjournal86114353; BLAZAR BR, 1995, BLOOD, V85, P833, DOI 10.1182/blood.V85.3.833.bloodjournal853833; BORDIGNON C, 1995, NATURE, V270, P470; CLARK PA, 1995, HUM GENET, V96, P427; Cowan MJ, 1996, BONE MARROW TRANSPL, V17, P1157; DURANDY A, 1985, ARCH FR PEDIATR, V42, P163; Flake A. W., 1995, Blood, V86, p125A; Friedrich W, 1993, Immunodeficiency, V4, P315; Gelfand E W, 1983, Birth Defects Orig Artic Ser, V19, P65; HARRISON MR, 1989, LANCET, V2, P425; MCKINNON S, 1995, BLOOD, V86, P1261; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOTARANGELO LD, 1993, DEV PHYSIOPATH CLIN, V4, P109; REISNER Y, 1983, P NATL ACAD SCI USA, V79, P6047; SLAVIN S, 1992, BONE MARROW TRANSPL, V9, P189; SROUR EF, 1993, BLOOD, V82, P3333; Sutherland DR, 1996, EXP HEMATOL, V24, P795; TOURAINE JL, 1987, THYMUS, V10, P75; Vossen J M, 1993, Immunodeficiency, V4, P311; WENGLER GS, 1993, J IMMUNOL, V150, P700; WENGLER GS, 1995, SCIENCE, V86, P3648	22	190	192	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1484	1487		10.1016/S0140-6736(96)09392-0	http://dx.doi.org/10.1016/S0140-6736(96)09392-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942778				2022-12-01	WOS:A1996VV46300011
J	Grunewald, A; Lankheet, MJM				Grunewald, A; Lankheet, MJM			Orthogonal motion after-effect illusion predicted by a model of cortical motion processing	NATURE			English	Article							TRANSPARENT MOTION; AREA MT; PERCEPTION; DIRECTION; INTEGRATION; MOVEMENT; PATTERNS; ADAPTATION; COHERENCE; NEURONS	THE motion after-effect occurs after prolonged viewing of motion; a subsequent stationary scene is perceived as moving in the opposite direction(1,2). This illusion Is thought to arise because motion is represented by the differential activities of populations of cortical neurons toned to opposite directions; fatigue in one population leads to an imbalance that favours the opposite direction once the stimulus ceases(3). Following adaptation to multiple directions of motion, the after-effect is unidirectional(4-6), indicating that motion signals are integrated across all directions. Yet humans can perceive several directions of motion simultaneously(7-10). The question therefore arises as to how the visual system can perform both sharp segregation and global integration of motion signals, Here me show in computer simulations that this can occur if excitatory interactions between different directions are sharply tuned while inhibitory interactions are broadly tuned, Our model predicts that adaptation to simultaneous motion in opposite directions will lead to an orthogonal motion after-effect. This prediction was confirmed in psychophysical experiments, Thus, broadly tuned inhibitory interactions are likely to be important in the integration and segregation of motion signals. These interactions may occur in the cortical area MT, which contains motion-sensitive neurons with properties similar to those required by our model(11-14).	MAX PLANCK INST BIOL CYBERNET,D-72076 TUBINGEN,GERMANY; UNIV UTRECHT,DEPT COMPARAT PHYSIOL,NL-3584 CH UTRECHT,NETHERLANDS; UNIV UTRECHT,HELMHOLTZ INST,NL-3584 CH UTRECHT,NETHERLANDS	Max Planck Society; Utrecht University; Utrecht University	Grunewald, A (corresponding author), CALTECH,DIV BIOL,MAIL CODE 216-76,PASADENA,CA 91125, USA.							Addams J, 1834, LONDON EDINBURGH PHI, V5, P373, DOI [10.1080/14786443408648481, DOI 10.1080/14786443408648481]; ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; BRADDICK O, 1993, TRENDS NEUROSCI, V16, P263, DOI 10.1016/0166-2236(93)90179-P; BRADLEY DC, 1995, NATURE, V373, P609, DOI 10.1038/373609a0; CLARKE PGH, 1977, VISION RES, V17, P1243, DOI 10.1016/0042-6989(77)90164-X; GIASCHI D, 1993, J NEUROPHYSIOL, V70, P2024, DOI 10.1152/jn.1993.70.5.2024; GROSSBERG S, 1972, Mathematical Biosciences, V15, P253, DOI 10.1016/0025-5564(72)90038-7; GROSSBERG S, 1976, BIOL CYBERN, V23, P121, DOI 10.1007/BF00344744; Grunewald A, 1996, ADV NEUR IN, V8, P837; Heeger DJ, 1996, P NATL ACAD SCI USA, V93, P623, DOI 10.1073/pnas.93.2.623; HINS E, 1992, P NATL ACAD SCI USA, V89, P9025; Hiris E, 1996, VISUAL NEUROSCI, V13, P187, DOI 10.1017/S0952523800007227; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; MATHER G, 1980, PERCEPTION, V9, P379, DOI 10.1068/p090379; MINGOLLA E, 1992, VISION RES, V32, P1015, DOI 10.1016/0042-6989(92)90003-2; MULLIGAN JB, 1993, VISION RES, V33, P2021, DOI 10.1016/0042-6989(93)90025-R; NAKAYAMA K, 1985, VISION RES, V25, P625, DOI 10.1016/0042-6989(85)90171-3; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; QIAN N, 1994, J NEUROSCI, V14, P7357; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; STONER GR, 1990, NATURE, V344, P153, DOI 10.1038/344153a0; SUTHERLAND NS, 1961, Q J EXP PSYCHOL, V13, P222, DOI 10.1080/17470216108416498; TOOTELL RBH, 1995, NATURE, V375, P139, DOI 10.1038/375139a0; VANDOORN AJ, 1985, PERCEPTION, V14, P209, DOI 10.1068/p140209; VERSTRATEN FAJ, 1994, VISION RES, V34, P349, DOI 10.1016/0042-6989(94)90093-0; VERSTRATEN FAJ, 1994, VISION RES, V34, P1149, DOI 10.1016/0042-6989(94)90297-6; WATAMANIUK SNJ, 1989, VISION RES, V29, P47, DOI 10.1016/0042-6989(89)90173-9; Wohlgemuth A., 1911, AFTER EFFECT SEEN MO, V1	29	62	62	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					358	360		10.1038/384358a0	http://dx.doi.org/10.1038/384358a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934521				2022-12-01	WOS:A1996VV27100049
J	Nelson, RG; Bennett, PH; Beck, GJ; Tan, M; Knowler, WC; Mitch, WE; Hirschman, GH; Myers, BD				Nelson, RG; Bennett, PH; Beck, GJ; Tan, M; Knowler, WC; Mitch, WE; Hirschman, GH; Myers, BD			Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OVERT NEPHROPATHY; ALBUMIN EXCRETION; NEPHROTIC HUMANS; PROTEINURIA; SELECTIVITY; PREVALENCE; DIET	Background Non-insulin-dependent diabetes mellitus (NIDDM) is a major cause of end-stage renal disease. However, the course and determinants of renal failure in this type of diabetes have not been clearly defined. Methods We studied glomerular function at intervals of 6 to 12 months for 4 years in 194 Pima Indians selected to represent different stages in the development and progression of diabetic renal disease. Initially, 31 subjects had normal glucose tolerance, 29 had impaired glucose tolerance, 30 had newly diagnosed diabetes, and 104 had had diabetes for five years or more; of these 104, 20 had normal albumin excretion, 50 had microalbuminuria, and 34 had macroalbuminuria. The glomerular filtration rate, renal plasma flow, urinary albumin excretion, and blood pressure were measured at each examination. Results Initially, the mean (+/-SE) glomerular filtration rate was 143+/-7 ml per minute in subjects with newly diagnosed diabetes, 155+/-7 ml per minute in those with microalbuminuria, and 124+/-7 ml per minute in those with macroalbuminuria; these values were 16 percent, 26 percent, and 1 percent higher, respectively, than in the subjects with normal glucose tolerance (123+/-4 ml per minute). During four years of follow-up, the glomerular filtration rate increased by 18 percent in the subjects who initially had newly diagnosed diabetes (P=0.008); the rate declined by 3 percent in those with microalbuminuria at base line (P=0.29) and by 35 percent in those with macroalbuminuria (P<0.001). Higher base-line blood pressure predicted increasing urinary albumin excretion (P=0.006), and higher base-line urinary albumin excretion predicted a decline in the glomerular filtration rate (P<0.001). The initial glomerular filtration rate did not predict worsening albuminuria. Conclusions The glomerular filtration rate is elevated at the onset of NIDDM and remains so while normal albumin excretion or microalbuminuria persists. it declines progressively after the development of macroalbuminuria. (C)1996, Massachusetts Medical Society.	CLEVELAND CLIN FDN,DEPT BIOSTAT & EPIDEMIOL,DIABET RENAL DIS STUDY DATA COORDINATING CTR,CLEVELAND,OH 44195; EMORY UNIV,SCH MED,DIV RENAL,ATLANTA,GA 30322; NIDDKD,DIV KIDNEY UROL & HEMATOL DIS,CHRON RENAL DIS PROGRAM,BETHESDA,MD; NIDDKD,PHOENIX EPIDEMIOL & CLIN RES BRANCH,PHOENIX,AZ; STANFORD UNIV,SCH MED,DIV NEPHROL,STANFORD,CA 94305	Cleveland Clinic Foundation; Emory University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Stanford University			Bennett, Peter/AAH-9605-2021; Nelson, Robert G/B-1470-2012		NIDDK NIH HHS [N01-DK-6-2285, N01-DK-7-2291] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK062285, N01DK072291] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHANG RLS, 1975, BIOPHYS J, V15, P861, DOI 10.1016/S0006-3495(75)85862-0; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; DEEN WM, 1985, AM J PHYSIOL, V249, pF374, DOI 10.1152/ajprenal.1985.249.3.F374; DRUMOND MC, 1994, J CLIN INVEST, V94, P1187, DOI 10.1172/JCI117435; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; HOSTETTER TH, 1981, KIDNEY INT, V19, P410, DOI 10.1038/ki.1981.33; KNOWLER WC, 1978, AM J EPIDEMIOL, V108, P497, DOI 10.1093/oxfordjournals.aje.a112648; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MENARD L, 1980, CLIN CHEM, V26, P1598; MYERS BD, 1995, KIDNEY INT, V47, P1781, DOI 10.1038/ki.1995.246; NAKAMURA Y, 1988, DIABETES, V37, P1202, DOI 10.2337/diabetes.37.9.1202; NELSON RG, 1991, ARCH INTERN MED, V151, P1761, DOI 10.1001/archinte.151.9.1761; NELSON RG, 1995, DIABETES CARE, V18, P182, DOI 10.2337/diacare.18.2.182; NELSON RG, 1989, DIABETOLOGIA, V32, P870, DOI 10.1007/BF00297452; NELSON RG, 1988, DIABETOLOGIA, V31, P730, DOI 10.1007/BF00274774; NELSON RG, 1991, ACTA DIABETOL, V28, P143, DOI 10.1007/BF00579717; PAGTALUNAN ME, 1994, J AM SOC NEPHROL, V5, P381; PARVING HH, 1992, KIDNEY INT, V41, P758, DOI 10.1038/ki.1992.118; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; VASQUEZ B, 1984, DIABETOLOGIA, V26, P127, DOI 10.1007/BF00281119; World Health Organization, 1985, WHO TECH REP SER, V727, P7; [No title captured]	25	365	373	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1636	1642		10.1056/NEJM199611283352203	http://dx.doi.org/10.1056/NEJM199611283352203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV936	8929360				2022-12-01	WOS:A1996VV93600003
J	Scully, R; Chen, JJ; Plug, A; Xiao, YH; Weaver, D; Feunteun, J; Ashley, T; Livingston, DM				Scully, R; Chen, JJ; Plug, A; Xiao, YH; Weaver, D; Feunteun, J; Ashley, T; Livingston, DM			Association of BRCA1 with Rad51 in mitotic and meiotic cells	CELL			English	Article							CANCER SUSCEPTIBILITY GENE; DNA STRAND EXCHANGE; OVARIAN-CANCER; BREAST-CANCER; FAMILIAL BREAST; SCHIZOSACCHAROMYCES-POMBE; SYNAPTONEMAL COMPLEXES; CHROMOSOME SYNAPSIS; PROTEIN; MUTATIONS	BRCA1 immunostaining reveals discrete, nuclear foci during S phase of the cell cycle. Human Rad51, a homolog of bacterial RecA, behaves similarly. The two proteins were found to colocalize in vivo and to coimmunoprecipitate. BRCA1 residues 758-1064 alone formed Rad51-containing complexes in vitro. Rad51 is also specifically associated with developing synaptonemal complexes in meiotic cells, and BRCA1 and Rad51 were both detected on asynapsed (axial) elements of human synaptonemal complexes. These findings suggest a functional interaction between BRCA1 and RadB1 in the meiotic and mitotic cell cycles, which, in turn, suggests a role for BRCA1 in the control of recombination and of genome integrity.	YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06520 USA; INST GUSTAVE ROUSSY, CNRS, F-94805 VILLEJUIF, FRANCE	Yale University; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Scully, R (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, 44 BINNEY ST, BOSTON, MA 02115 USA.		Scully, Ralph/F-5008-2013; Feunteun, Jean/AAZ-1267-2020	Feunteun, Jean/0000-0003-1212-9189				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ASHLEY T, 1995, CHROMOSOMA, V104, P19, DOI 10.1007/s004120050088; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BENTLEY NJ, 1996, IN PRESS EMBO J; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Carr AM, 1996, SCIENCE, V271, P314, DOI 10.1126/science.271.5247.314; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; CLAUS EB, 1991, AM J HUM GENET, V48, P232; EASTON DF, 1993, AM J HUM GENET, V52, P678; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Feunteun J, 1996, BBA-REV CANCER, V1242, P177, DOI 10.1016/0304-419X(95)00016-9; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.biophys.20.1.539; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAMMERS JHM, 1994, MOL CELL BIOL, V14, P1137, DOI 10.1128/MCB.14.2.1137; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOENS PB, 1987, J CELL BIOL, V105, P93, DOI 10.1083/jcb.105.1.93; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NAROD SA, 1991, LANCET, V338, P82; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; Peters AHFM, 1997, CHROMOSOME RES, V5, P66, DOI 10.1023/A:1018445520117; Plug AW, 1996, P NATL ACAD SCI USA, V93, P5920, DOI 10.1073/pnas.93.12.5920; RADDING CM, 1991, J BIOL CHEM, V266, P5355; Rao VN, 1996, ONCOGENE, V12, P523; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/0968-0004(96)10036-0; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Shao NS, 1996, ONCOGENE, V13, P1; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; Tashiro S, 1996, ONCOGENE, V12, P2165; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILSON CA, 1996, IN PRESS ONCOGENE; Zabludoff SD, 1996, ONCOGENE, V13, P649	76	1272	1300	0	67	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1997	88	2					265	275		10.1016/S0092-8674(00)81847-4	http://dx.doi.org/10.1016/S0092-8674(00)81847-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008167	hybrid			2022-12-01	WOS:A1997WE97000015
J	Ozonoff, DM				Ozonoff, DM			Fields of controversy	LANCET			English	Editorial Material											Ozonoff, DM (corresponding author), BOSTON UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,BOSTON,MA 02130, USA.			Ozonoff, David/0000-0002-4281-4171				FEYCHTING M, 1994, EPIDEMIOLOGY, V5, P501; MOULDER JE, 1996, IEEE ENG MED BIOL, V4, P31; *NAT RES COUNC, 1996, POSS HLTH EFF EXP RE; POOLE C, 1996, IEEE ENG MED BIOL, V4, P41; Verkasalo PK, 1996, BRIT MED J, V313, P1047, DOI 10.1136/bmj.313.7064.1047; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					74	74		10.1016/S0140-6736(05)60881-1	http://dx.doi.org/10.1016/S0140-6736(05)60881-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996415	hybrid			2022-12-01	WOS:A1997WB80000006
J	Songaila, A; Wampler, EJ; Cowie, LL				Songaila, A; Wampler, EJ; Cowie, LL			A high deuterium abundance in the early Universe	NATURE			English	Article							CLOUDS	INTERGALACTIC gas clouds at high redshifts have element abundances that are close to primordial, The ratio of deuterium to hydrogen (D/H) within such clouds-which is determined from absorption lines in the spectra of more distant quasars that lie along the same line of sight-provides the best estimate of the density of baryons (Omega(B)) in the Universe. Previous estimates of D/H in the early Universe have yielded values that differ by about an order of magnitude(1-7), with the lower values(6,7) implying a high density of baryons that may be difficult to reconcile with both estimates of the primordial abundances of other light elements (especially He-4) and the known number of light neutrinos(8-10). The accuracy of such D/H determinations is heavily dependent on the inferred column density of neutral hydrogen in the absorbing clouds, Here we report an independent measurement of the neutral hydrogen column density in the cloud towards the quasar Q1937 - 1009, for which one of the low D/H values was derived(6). Our measurement requires a substantial revision to the D/H value reported previously; we obtain a lower limit of D/H > 4 x 10(-5) for this cloud, which implies Omega(B) < 0.016 for a Hubble constant of 100 km s(-1) Mpc(-1). This reduced upper limit for the baryon density relieves any conflict with standard Big Bang nucleosynthesis(6).	NATL ASTRON OBSERV,MITAKA,TOKYO 181,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ)	Songaila, A (corresponding author), UNIV HAWAII,INST ASTRON,2680 WOODLAWN DR,HONOLULU,HI 96822, USA.							BURLES S, UNPUB SCIENCE; CARSWELL RF, 1994, MON NOT R ASTRON SOC, V268, pL1, DOI 10.1093/mnras/268.1.L1; FIELDS BD, 1996, NEW ASTRON, V1, P77; HATA N, IN PRESS PHYS REV D; MADAU P, STSC1085 SPAC TEL SC; PRESS WH, 1993, ASTROPHYS J, V414, P64, DOI 10.1086/173057; Rugers M, 1996, ASTRON J, V111, P2135, DOI 10.1086/117949; Rugers M, 1996, ASTROPHYS J, V459, pL1, DOI 10.1086/309931; SONGAILA A, 1994, NATURE, V368, P599, DOI 10.1038/368599a0; STEIGMAN G, IN PRESS CRISIS CONF; Tytler D, 1996, NATURE, V381, P207, DOI 10.1038/381207a0; TYTLER D, IN PRESS ORIGIN MATT; Wampler EJ, 1996, ASTRON ASTROPHYS, V316, P33; Wampler EJ, 1996, NATURE, V383, P308, DOI 10.1038/383308a0	14	64	64	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					137	139		10.1038/385137a0	http://dx.doi.org/10.1038/385137a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990115	Green Submitted			2022-12-01	WOS:A1997WB72800046
J	Chehab, FF; Mounzih, K; Lu, RH; Lim, ME				Chehab, FF; Mounzih, K; Lu, RH; Lim, ME			Early onset of reproductive function in normal female mice treated with leptin	SCIENCE			English	Article							WEIGHT	Numerous studies have revealed an association between nutritional status, adiposity, and reproductive maturity. The role of leptin, a hormone secreted from adipose tissue, in the onset of reproductive function was investigated. Normal prepubertal female mice injected with leptin grew at a slower rate than controls as a result of the hormone's thinning effects, but they reproduced up to 9 days earlier than controls and showed earlier maturation of the reproductive tract. These results suggest that leptin acts as a signal triggering puberty, thus supporting the hypothesis that fat accumulation enhances maturation of the reproductive tract.			Chehab, FF (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT LAB MED,505 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [HLS 53762] Funding Source: Medline; NIDDK NIH HHS [DK 07636] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007636] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; FRISCH RE, 1980, FED PROC, V39, P2395; FRISCH RE, 1974, SCIENCE, V185, P949, DOI 10.1126/science.185.4155.949; FRISCH RE, 1970, SCIENCE, V169, P397, DOI 10.1126/science.169.3943.397; FRISCH RE, 1980, NEW ENGL J MED, V303, P17, DOI 10.1056/NEJM198007033030105; FRISCH RE, 1975, P NATL ACAD SCI USA, V72, P4172, DOI 10.1073/pnas.72.10.4172; JOHNSTON FE, 1971, SCIENCE, V174, P1148, DOI 10.1126/science.174.4014.1148; KENNEDY GC, 1957, J ENDOCRINOL, V16, P9, DOI 10.1677/joe.0.0160009; KENNEDY GC, 1963, J PHYSIOL-LONDON, V166, P408, DOI 10.1113/jphysiol.1963.sp007112; KENNEDY GC, 1963, J PHYSIOL-LONDON, V166, P395, DOI 10.1113/jphysiol.1963.sp007111; ZACHARIA.L, 1970, AM J OBSTET GYNECOL, V108, P833, DOI 10.1016/0002-9378(70)90552-1	11	666	710	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					88	90		10.1126/science.275.5296.88	http://dx.doi.org/10.1126/science.275.5296.88			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974400				2022-12-01	WOS:A1997WA90300056
J	Lambert, H				Lambert, H			Popular therapeutics and medical preferences in rural north India	LANCET			English	Editorial Material							SYSTEMS; PERSPECTIVE				Lambert, H (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							BANERJI D, 1973, EC POLIT WKLY, V8, P2261; Beals A., 1980, ASIAN MED SYSTEMS, P194; CHAVUNDUKA GL, 1986, PROFESSIONALIZATION; KLEINMAN A, 1980, COMP STUDIES HLTH SY, V3, P71; Kleinman A., 1980, COMP STUDIES HLTH SY; LAMBERT H, 1992, SOC SCI MED, V34, P1069, DOI 10.1016/0277-9536(92)90280-4; LAMBERT H, IN PRESS W MED CONTE; LAST M, 1981, SOC SCI MED-MED ANTH, V15, P387, DOI 10.1016/0160-7987(81)90064-8; LAST M, 1991, MED ANTHR CONT THEOR, P349; LESLIE C, 1980, SOC SCI MED-MED ANTH, V14, P191, DOI 10.1016/0160-7987(80)90044-7; LESLIE C, 1980, ASIAN MED SYSTEMS; LESLIE CM, 1992, PATHS ASIAN MED KNOW, P3; NICHTER M, 1980, SOC SCI MED-MED ANTH, V14, P225, DOI 10.1016/0160-7987(80)90048-4; NICHTER M, 1989, ANTHR INT HLTH S ASI; PRESS I, 1980, SOC SCI MED-MED ANTH, V14, P45, DOI 10.1016/0160-7987(80)90040-X; WAXLERMORRISON NE, 1988, SOC SCI MED, V27, P531, DOI 10.1016/0277-9536(88)90377-2; WORSLEY P, 1982, ANNU REV ANTHROPOL, V11, P315, DOI 10.1146/annurev.an.11.100182.001531; Zimmerman Francis, 1987, JUNGLE AROMA MEATS E	18	24	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1706	1709		10.1016/S0140-6736(96)07135-8	http://dx.doi.org/10.1016/S0140-6736(96)07135-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973437				2022-12-01	WOS:A1996VZ76600017
J	Smith, V; Chou, KN; Lashkari, D; Botstein, D; Brown, PO				Smith, V; Chou, KN; Lashkari, D; Botstein, D; Brown, PO			Functional analysis of the genes of yeast chromosome V by genetic footprinting	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; SECRETORY PATHWAY; PROTEIN; ENCODES; MUTANTS; EXPRESSION; SYNTHETASE; SUBFAMILY; COMPLEX	Genetic footprinting was used to assess the phenotypic effects of Ty1 transposon insertions in 268 predicted genes of chromosome V of Saccharomyces cerevisiae. When seven selection protocols were used, Ty1 insertions in more than half the genes tested (157 of 268) were found to result in a detectable reduction in fitness. Results could not be obtained for fewer than 3 percent of the genes tested (7 of 268). Previously known mutant phenotypes were confirmed, and, for about 30 percent of the genes, new mutant phenotypes were identified.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University					NHGRI NIH HHS [1PO1 HG00205-05] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000205] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BOONCHIRD C, 1991, MOL GEN GENET, V226, P154, DOI 10.1007/BF00273599; BRANDRISS MC, 1979, J BACTERIOL, V138, P816, DOI 10.1128/JB.138.3.816-822.1979; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; DIETRICH F, IN PRESS NATURE; ELLEDGE J, 1990, GENE DEV, V4, P4740; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; GUELIN E, 1994, YEAST, V10, P1389, DOI 10.1002/yea.320101016; HARRINGTON A, 1993, MOL MICROBIOL, V9, P545; IRIE K, 1994, MOL CELL BIOL, V14, P3150, DOI 10.1128/MCB.14.5.3150; KIM YJ, 1994, J CELL BIOL, V127, P1381, DOI 10.1083/jcb.127.5.1381; MASSELOT M, 1975, MOL GEN GENET, V139, P121, DOI 10.1007/BF00264692; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; MCNEIL JB, 1994, J BIOL CHEM, V269, P9155; MITCHELL AP, 1984, MOL CELL BIOL, V4, P2767, DOI 10.1128/MCB.4.12.2767; MITCHELL AP, 1984, MOL CELL BIOL, V4, P2758, DOI 10.1128/MCB.4.12.2758; MOEHLE CM, 1987, GENETICS, V115, P255; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NASS G, 1976, MOL GEN GENET, V147, P39, DOI 10.1007/BF00337933; OHMEN JD, 1988, NUCLEIC ACIDS RES, V16, P10783, DOI 10.1093/nar/16.22.10783; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PRAKASH S, 1977, GENETICS, V87, P229; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH V, 1995, P NATL ACAD SCI USA, V92, P6479, DOI 10.1073/pnas.92.14.6479; THIAGALINGAM S, 1995, P NATL ACAD SCI USA, V92, P6062, DOI 10.1073/pnas.92.13.6062; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568	31	193	214	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2069	2074		10.1126/science.274.5295.2069	http://dx.doi.org/10.1126/science.274.5295.2069			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953036				2022-12-01	WOS:A1996VY97400046
J	Kannus, P; Parkkari, J; Niemi, S; Palvanen, M				Kannus, P; Parkkari, J; Niemi, S; Palvanen, M			Epidemiology of osteoporotic ankle fractures in elderly persons in Finland	ANNALS OF INTERNAL MEDICINE			English	Article							AGE-ADJUSTED INCIDENCE; HIP-FRACTURES; RISK; PREVENTION; WOMEN	Background: Although osteoporotic or minimal trauma fractures among elderly persons are a major public health problem worldwide, epidemiologic information on these fractures is limited. Objective: To determine the current trend in the number and incidence of osteoporotic ankle fractures in the elderly. A fracture was defined as osteoporotic only if it occurred as a result of minimal trauma in a person 60 years of age or older. Design: National hospital discharge register. Setting: Finland, a country with approximately 5 million inhabitants. Participants: All patients 60 years of age or older who were admitted to hospitals in Finland for primary treatment of first osteoporotic ankle fracture in 1970 to 1972, 1974, 1975, 1978 to 1980, 1983 to 1985, 1988 to 1989, and 1991 to 1994. Measurements: The number and the age-specific and age-adjusted incidence of osteoporotic ankle fractures in each year of the study. Results: For the study period, the number and incidence (per 100 000 persons) of osteoporosis-related ankle fractures in Finnish persons 60 years of age or older increased considerably (370 and 57, respectively, in 1970 compared with 1243 and 130, respectively, in 1994). The age-adjusted incidence of these fractures also increased in women, from 66 in 1970 to 162 in 1994, and in men, from 38 in 1970 to 82 in 1994. Conclusion: The number of osteoporotic ankle fractures in Finland is increasing at a rate that cannot be explained simply by demographic changes. Vigorous preventive measures are needed to control the increasing burden of this type of fracture.			Kannus, P (corresponding author), UKK INST HLTH PROMOT RES, KAUPINPUISTONKATU 1, FIN-33500 TAMPERE, FINLAND.							Aro S, 1990, Duodecim, V106, P1443; BENGNER U, 1986, ACTA ORTHOP SCAND, V57, P35, DOI 10.3109/17453678608993211; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; DALY PJ, 1987, ACTA ORTHOP SCAND, V58, P539, DOI 10.3109/17453678709146395; GREENSPAN SL, 1994, JAMA-J AM MED ASSOC, V271, P128, DOI 10.1001/jama.271.2.128; JONES G, 1994, OSTEOPOROSIS INT, V4, P277, DOI 10.1007/BF01623352; KANNUS P, 1995, LANCET, V346, P50, DOI 10.1016/S0140-6736(95)92679-8; LAURITZEN JB, 1993, OSTEOPOROSIS INT, V3, P127, DOI 10.1007/BF01623273; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; LUTHJE P, 1995, ACTA ORTHOP SCAND, V66, P245; MELTON LJ, 1993, BONE, V14, pS1; MELTON LJ, 1981, CLIN ORTHOP RELAT R, V155, P43; MeltonIII L. J., 1988, OSTEOPOROSIS ETIOLOG, P133; OBRANT KJ, 1989, CALCIFIED TISSUE INT, V44, P157, DOI 10.1007/BF02556558; *OFF STAT FINL, 1994, STRUCT POP VIT STAT, P1970; PARKKARI J, 1994, CALCIFIED TISSUE INT, V55, P342, DOI 10.1007/BF00299311; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; ROSE SH, 1982, CLIN ORTHOP RELAT R, V168, P24; Salmela R, 1987, SAIRAALA, V49, P480; Thorngren K G, 1994, Disabil Rehabil, V16, P119	20	60	64	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1996	125	12					975	978		10.7326/0003-4819-125-12-199612150-00007	http://dx.doi.org/10.7326/0003-4819-125-12-199612150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX768	8967708				2022-12-01	WOS:A1996VX76800008
J	Sirrenberg, C; Bauer, MF; Guiard, B; Neupert, W; Brunner, M				Sirrenberg, C; Bauer, MF; Guiard, B; Neupert, W; Brunner, M			Import of carrier proteins into the mitochondrial Inner membrane mediated by Tim22	NATURE			English	Article							ADP-ATP CARRIER; TRANSLOCATION; COMPLEX; HSP70; BIOGENESIS; ENCODES; SYSTEM; MATRIX	TRANSLOCATION of mitochondrial preproteins across the inner membrane is facilitated by the TIM machinery(1-8). Tim34 binds to matrix targeting signals and initiates membrane potential-dependent import(8). Tim23 and Tim17 are constituents of a translocation channel across the inner membrane(6). Tim44 is associated with this channel at the matrix side(6), and Tim44 recruits mitochondrial Hsp70 and its co-chaperone Mge1, which drive protein translocation into the matrix using ATP as an energy source(9-14). Tim22 is a new component of the import machinery of mitochondria, which shares sequence similarity with both Tim23 and Tim17. Here we report that Tim22 is required for the import of proteins of the mitochondrial ADP/ATP carrier (AAC) family into the inner membrane. Members of the yeast AAC family are synthesized without matrix targeting signals(15,16). Tim22 is in an assembly of high relative molecular mass that is distinct from the Tim23-Tim17 complex(6). Import of proteins of the AAC family is independent of Tim23, and import of matrix targeting signals containing preproteins is independent of Tim22.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY; UNIV PARIS 06,CNRS,CTR MOL GENET,F-91190 GIF SUR YVETTE,FRANCE	University of Munich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay				Brunner, Michael/0000-0001-9798-3047				Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BLOM J, 1996, EUR J BIOCHEM, V232, P309; DAYHOFF MO, ATLAS PROTEIN SEQUEN, V5, P342; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KLINGENBERG M, 1978, BIOCHIM BIOPHYS ACTA, V503, P193, DOI 10.1016/0005-2728(78)90182-2; KOLBE HVJ, 1984, J BIOL CHEM, V259, P9115; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MAARSE AC, 1994, FEBS LETT, V349, P215, DOI 10.1016/0014-5793(94)00669-5; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x; ZARA V, 1991, EUR J BIOCHEM, V198, P405, DOI 10.1111/j.1432-1033.1991.tb16029.x; ZIMMERMAN R, 1979, EUR J BIOCHEM, V99, P247, DOI 10.1111/j.1432-1033.1979.tb13251.x	26	257	261	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1996	384	6609					582	585		10.1038/384582a0	http://dx.doi.org/10.1038/384582a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955274				2022-12-01	WOS:A1996VX76900064
J	Trivier, E; DeCesare, D; Jacquot, S; Pannetier, S; Zackai, E; Young, I; Mandel, JL; SassoneCorsi, P; Hanauer, A				Trivier, E; DeCesare, D; Jacquot, S; Pannetier, S; Zackai, E; Young, I; Mandel, JL; SassoneCorsi, P; Hanauer, A			Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome	NATURE			English	Article							RIBOSOMAL S6 KINASE; PROTEIN-KINASES; C-FOS; EXPRESSION; SEQUENCE; DOMAINS; GENE; LOCALIZATION; CLONING; FAMILY	THE Coffin-Lowry syndrome (CLS), an X-linked disorder, is characterized by severe psychomotor retardation, facial and digital dysmorphisms, and progressive skeletal deformations(1). Genetic linkage analysis mapped the CLS locus to an interval of 2-3 megabases at Xp22.2. The gene coding for Rsk-2, a member of the growth-factor-regulated protein kinases, maps within the candidate interval, and was tested as a candidate gene for CLS. Initial screening for mutations in the gene for Rsk-2 in 76 unrelated CLS patients revealed one intragenic deletion, a nonsense, two splice site, and two missense mutations. The two missenses affect sites critical for the function of Rsk-2. The mutated Rsk-2 proteins were found to be inactive in a S6 kinase assay. These findings provide direct evidence that abnormalities in the MAPK/RSK signalling pathway cause Coffin-Lowry syndrome.	ULP,CNRS,INSERM,INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,CLIN GENET CTR,PHILADELPHIA,PA 19104; CITY HOSP NOTTINGHAM,CTR MED GENET,NOTTINGHAM NG5 1PB,ENGLAND	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Nottingham University Hospital NHS Trust; Nottingham City Hospital								ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BIANCALANA V, 1994, GENOMICS, V22, P617, DOI 10.1006/geno.1994.1435; BIRD H, 1995, AM J MED GENET, V59, P512, DOI 10.1002/ajmg.1320590420; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BJORBAEK C, 1995, DIABETES, V44, P90, DOI 10.2337/diabetes.44.1.90; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHONCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HANAUER A, 1988, AM J MED GENET, V30, P523, DOI 10.1002/ajmg.1320300154; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; Trump D, 1996, HUM GENET, V97, P60; WASSARMAN DA, 1994, GENE, V144, P309, DOI 10.1016/0378-1119(94)90396-4; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YOUNG ID, 1988, J MED GENET, V25, P344, DOI 10.1136/jmg.25.5.344; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	22	320	328	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1996	384	6609					567	570		10.1038/384567a0	http://dx.doi.org/10.1038/384567a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955270				2022-12-01	WOS:A1996VX76900060
J	Modan, B; Gak, E; SadeBruchim, RB; HirshYechezkel, G; Theodor, L; Lubin, F; BenBaruch, G; Beller, U; Fishman, A; Dgani, R; Menczer, J; Papa, M; Friedman, E				Modan, B; Gak, E; SadeBruchim, RB; HirshYechezkel, G; Theodor, L; Lubin, F; BenBaruch, G; Beller, U; Fishman, A; Dgani, R; Menczer, J; Papa, M; Friedman, E			High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST; FAMILIES; GENE	Objective.-To determine the role of BRCA1 185delAG mutation in ovarian carcinogenesis. Design.-Genetic testing of a subset of cases from an ongoing study of ovarian cancer and of controls. Setting.-A community-based case-control incidence study. Subjects.-Seventy-nine patients with ovarian cancer, 62 hospitalized women without cancer (controls), and 120 healthy women participating in a fragile X screening program (also controls), examined for the presence of germline BRCA1 185delAG mutation. Main Outcome Measures.-Polymerase chain reaction-amplified BRCA1 exon 2 fragments generated from patients' and controls' blood samples, analyzed by heteroduplex gel shift assay and direct sequence analyses. Results.-The 185delAG mutation was detected in 38.9% (7/18) of ovarian cancer patients with familial history, and 13.1% (8/61) of family history-negative ovarian cancer cases. Only 1 carrier was detected among the 120 healthy controls, and none in the hospital controls. A significant difference in mutation carrier rates between family history-negative cases and control groups of 120 and 62 subjects was identified (Fisher exact test, P=.001 and P=.003, respectively). The median age (+/-SE) at disease diagnosis was tower among both familial and family history-negative mutation carriers, as compared with mutation-negative, family history-negative cases-50 (+/-1.4) vs 60.5 (+/-3.5) years old, respectively (hazard ratio, 1.68; 95% confidence interval, 0.94-3.01). Conclusions.-Our data are preliminary but suggest that BRCA1 185delAG germline mutation is frequent in Israeli ovarian cancer patients, irrespective of family history, and may confer an early-onset phenotype of ovarian cancer.	CHAIM SHEBA MED CTR,ONCOGENET UNIT,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,DEPT SURG,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,GYNECOL ONCOL UNIT,IL-52621 TEL HASHOMER,ISRAEL; TEL AVIV UNIV,STANLEY STEYER INST CANC EPIDEMIOL & RES,IL-69978 TEL AVIV,ISRAEL; SHAARE ZEDEK MED CTR,JERUSALEM,ISRAEL; KAPLAN MED CTR,KEFAR SAVA,ISRAEL; EDITH WOLFSON MED CTR,HOLON,ISRAEL	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Kaplan Medical Center	Modan, B (corresponding author), CHAIM SHEBA MED CTR,DEPT CLIN EPIDEMIOL,IL-52621 TEL HASHOMER,ISRAEL.				NCI NIH HHS [CA 61126-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061126] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Muto MG, 1996, CANCER RES, V56, P1250; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; STRUEWING JP, 1993, AM J HUM GENET, V67, P1; SYVANEN AC, 1989, FEBS LETT, V258, P71, DOI 10.1016/0014-5793(89)81618-7; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TONIN P, 1995, AM J HUM GENET, V57, P189	14	57	57	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1996	276	22					1823	1825		10.1001/jama.276.22.1823	http://dx.doi.org/10.1001/jama.276.22.1823			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV997	8946903				2022-12-01	WOS:A1996VV99700032
J	Chuang, PT; Lieb, JD; Meyer, BJ				Chuang, PT; Lieb, JD; Meyer, BJ			Sex-specific assembly of a dosage compensation complex on the nematode X chromosome	SCIENCE			English	Article							UBIQUITOUS PROTEIN FAMILY; CAENORHABDITIS-ELEGANS; C-ELEGANS; SMC FAMILY; GENE; CONDENSATION; SEGREGATION; EXPRESSION; DEFINES; DPY-30	In nematodes, flies, and mammals, dosage compensation equalizes X-chromosome gene expression between the sexes through chromosome-wide regulatory mechanisms that function in one sex to adjust the levels of X-linked transcripts. Here, a dosage compensation complex was identified in the nematode Caenorhabditis elegans that reduces transcript levels from the two X chromosomes in hermaphrodites, This complex contains at least four proteins, including products of the dosage compensation genes dpy-26 and dpy-27. Specific localization of the complex to the hermaphrodite X chromosomes is conferred by XX-specific regulatory genes that coordinately control both sex determination and dosage compensation.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley				Lieb, Jason/0000-0001-7601-8061; Meyer, Barbara/0000-0002-6530-4588	NIGMS NIH HHS [T32 GM07127, GM30702, R01 GM030702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030702, T32GM007127, R37GM030702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; CHUANG PT, UNPUB; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; DAWES HM, UNPUB; DELONG L, 1993, GENETICS, V133, P875; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HODGKIN J, 1983, MOL GEN GENET, V192, P452, DOI 10.1007/BF00392190; HSU DR, 1995, DEVELOPMENT, V121, P3323; HSU DR, 1994, GENETICS, V137, P999; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NONET ML, 1991, NATURE, V351, P65, DOI 10.1038/351065a0; NUSBAUM C, 1989, GENETICS, V122, P579; PLENEFISCH JD, 1989, GENETICS, V121, P57; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; SAITOH N, 1995, BIOESSAYS, V17, P759, DOI 10.1002/bies.950170905; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; VILLENEUVE AM, 1987, CELL, V48, P25, DOI 10.1016/0092-8674(87)90352-7; VILLENEUVE AM, 1990, GENETICS, V124, P91	27	81	94	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1736	1739		10.1126/science.274.5293.1736	http://dx.doi.org/10.1126/science.274.5293.1736			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939870				2022-12-01	WOS:A1996VW71200069
J	Liang, R; Yan, L; Loebach, J; Ge, M; Uozumi, Y; Sekanina, K; Horan, N; Gildersleeve, J; Thompson, C; Smith, A; Biswas, K; Still, WC; Kahne, D				Liang, R; Yan, L; Loebach, J; Ge, M; Uozumi, Y; Sekanina, K; Horan, N; Gildersleeve, J; Thompson, C; Smith, A; Biswas, K; Still, WC; Kahne, D			Parallel synthesis and screening of a solid phase carbohydrate library	SCIENCE			English	Article							SUPPORTED SOLUTION SYNTHESIS; INFLUENZA-VIRUS; CHEMICAL LIBRARIES; DRUG DISCOVERY; GENERAL-METHOD; OLIGOSACCHARIDES; GLYCOSYLATION; AGGLUTINATION; ERYTHROCYTES; RECOGNITION	A solid phase carbohydrate library was synthesized and screened against Bauhinia purpurea lectin. The library, which contains approximately 1300 di- and trisaccharides, was synthesized with chemical encoding on TentaGel resin so that each bead contained a single carbohydrate. Two ligands that bind more tightly to the lectin than Gal-beta-1,3-GalNAc (the known ligand) have been identified. The strategy outlined can be used to identify carbohydrate-based ligands for any receptor; however, because the derivatized beads mimic the polyvalent presentation of cell surface carbohydrates, the screen may prove especially valuable for discovering new compounds that bind to proteins participating in cell adhesion.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544; COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Princeton University; Columbia University			Gildersleeve, Jeffrey/N-3392-2014; Uozumi, Yasuhiro/A-7841-2016	Gildersleeve, Jeffrey/0000-0002-3744-6423; Uozumi, Yasuhiro/0000-0001-6805-3422				BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; DANISHEFSKY SJ, 1993, SCIENCE, V260, P1307, DOI 10.1126/science.8493573; DOUGLAS SP, 1995, J AM CHEM SOC, V117, P2116, DOI 10.1021/ja00112a035; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Frechet J. M., 1980, POLYM SUPPORTED REAC, P407; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; GLICK GD, 1991, J AM CHEM SOC, V113, P4701, DOI 10.1021/ja00012a060; GORDON EM, 1994, J MED CHEM, V37, P1385, DOI 10.1021/jm00036a001; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; Hunt JA, 1996, J AM CHEM SOC, V118, P9998, DOI 10.1021/ja962128f; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P10779, DOI 10.1073/pnas.91.23.10779; Kanie O, 1995, ANGEW CHEM INT EDIT, V34, P2720; Kiessling LL, 1996, CHEM BIOL, V3, P71, DOI 10.1016/S1074-5521(96)90280-X; KINGERYWOOD JE, 1992, J AM CHEM SOC, V114, P7303, DOI 10.1021/ja00044a057; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEE YC, 1995, ACCOUNTS CHEM RES, V28, P321, DOI 10.1021/ar00056a001; Mortell KH, 1996, J AM CHEM SOC, V118, P2297, DOI 10.1021/ja953574q; NESTLER HP, 1994, J ORG CHEM, V59, P4723, DOI 10.1021/jo00096a008; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; Osawa T, 1978, Methods Enzymol, V50, P367; Rademann J, 1996, TETRAHEDRON LETT, V37, P3989, DOI 10.1016/0040-4039(96)00763-0; ROY R, 1995, TETRAHEDRON LETT, V36, P4377, DOI 10.1016/0040-4039(95)00817-V; ROY R, 1988, CARBOHYD RES, V177, pC1, DOI 10.1016/0008-6215(88)85068-7; SCHNAAR RL, 1978, J BIOL CHEM, V253, P7940; SCHUSTER M, 1994, J AM CHEM SOC, V116, P1135, DOI 10.1021/ja00082a047; SHARON N, 1993, SCI AM, V268, P82, DOI 10.1038/scientificamerican0193-82; SPALTENSTEIN A, 1991, J AM CHEM SOC, V113, P686, DOI 10.1021/ja00002a053; SPEVAK W, 1993, J AM CHEM SOC, V115, P1146, DOI 10.1021/ja00056a047; Thompson LA, 1996, CHEM REV, V96, P555, DOI 10.1021/cr9402081; TOSHIMA K, 1993, CHEM REV, V93, P1503, DOI 10.1021/cr00020a006; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VERDUYN R, 1993, RECL TRAV CHIM PAY B, V112, P464; WU AM, 1980, ARCH BIOCHEM BIOPHYS, V204, P622, DOI 10.1016/0003-9861(80)90074-0; YAN L, 1994, J AM CHEM SOC, V116, P6953, DOI 10.1021/ja00094a067	35	266	456	1	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1520	1522		10.1126/science.274.5292.1520	http://dx.doi.org/10.1126/science.274.5292.1520			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929411				2022-12-01	WOS:A1996VV77500046
J	Ogryzko, VV; Schiltz, RL; Russanova, V; Howard, BH; Nakatani, Y				Ogryzko, VV; Schiltz, RL; Russanova, V; Howard, BH; Nakatani, Y			The transcriptional coactivators p300 and CBP are histone acetyltransferases	CELL			English	Article							NUCLEAR-PROTEIN CBP; E1A; SEQUENCE; CREB; DNA; NUCLEOSOME; ALIGNMENT; ADAPTER; FAMILY	p300/CBP is a transcriptional adaptor that integrates signals from many sequence-specific activators via direct interactions. Various cellular and viral factors target p300/CBP to modulate transcription and/or cell cycle progression. One such factor, the cellular p300/CBP associated factor (PCAF), possesses intrinsic histone acetyltransferase activity. Here, we demonstrate that p300/CBP is not only a transcriptional adaptor but also a histone acetyltransferase. p300/CBP represents a novel class of acetyltransferases in that it does not have the conserved motif found among various other acetyltransferases. p300/CBP acetylates all four core histones in nucleosomes. These observations suggest that p300/CBP acetylates nucleosomes in concert with PCAF.			Ogryzko, VV (corresponding author), NICHHD,LAB MOL GROWTH REPROD,NIH,BETHESDA,MD 20892, USA.		Ogryzko, Vasily/M-6665-2015	Ogryzko, Vasily/0000-0002-8548-1389				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; LU L, 1996, RGFGIGS IS AMINO ACI, V271, P18920; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; ONATE SA, 1995, SCIENCE, V270, P1354; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RAMAKRISHNAN V, 1994, CURR OPIN STRUC BIOL, V4, P44, DOI 10.1016/S0959-440X(94)90058-2; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; SHIMAMURA A, 1989, J BIOL CHEM, V264, P14524; SONG CZ, 1995, J BIOL CHEM, V270, P23263, DOI 10.1074/jbc.270.40.23263; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/0092-8674(93)90673-E; WANG HGH, 1993, J VIROL, V67, P4804, DOI 10.1128/JVI.67.8.4804-4813.1993; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	42	2328	2379	6	106	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					953	959		10.1016/S0092-8674(00)82001-2	http://dx.doi.org/10.1016/S0092-8674(00)82001-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945521	Bronze			2022-12-01	WOS:A1996VV77400020
J	Wilhelmi, LK; Preuss, D				Wilhelmi, LK; Preuss, D			Self-sterility in Arabidopsis due to defective pollen tube guidance	SCIENCE			English	Article							MOLECULAR MECHANISMS; GROWTH; INCOMPATIBILITY; GLYCOPROTEIN; PLANTS; GENE	In flowering plants, a series of cell-cell interactions govern the delivery of sperm to the ovules through precise guidance of pollen tubes. Two Arabidopsis genes, POP2 and POP3, were found that mediate pollen tube guidance and are critical for self-fertility in diploid reproductive cells. The pop2 and pop3 mutations exhibited genetic redundancy: Self-sterility occurred only when male and female tissues were defective in both genes. This phenotype resembles that found in many self-incompatible species.	UNIV CHICAGO, DEPT MOL GENET & CELL BIOL, CHICAGO, IL 60637 USA	University of Chicago								BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; CHEUNG AY, 1995, CELL, V82, P383, DOI 10.1016/0092-8674(95)90427-1; Dodds PN, 1996, CELL, V85, P141, DOI 10.1016/S0092-8674(00)81090-9; FOOTE HCC, 1994, P NATL ACAD SCI USA, V91, P2265, DOI 10.1073/pnas.91.6.2265; GOODMAN CS, 1994, CELL, V78, P353, DOI 10.1016/0092-8674(94)90413-8; HILL JP, 1987, AM J BOT, V74, P988, DOI 10.2307/2443938; HISCOCK SJ, 1995, PLANTA, V196, P367, DOI 10.1007/BF00201397; HULSKAMP M, 1995, PLANT CELL, V7, P57, DOI 10.1105/tpc.7.1.57; KANDASAMY MK, 1994, DEVELOPMENT, V120, P3405; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; LIPKE PN, 1992, MICROBIOL REV, V56, P180, DOI 10.1128/MMBR.56.1.180-194.1992; LORD EM, 1992, DEV BIOL, V153, P16, DOI 10.1016/0012-1606(92)90088-X; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; MO YY, 1992, P NATL ACAD SCI USA, V89, P7213, DOI 10.1073/pnas.89.15.7213; NASRALLAH JB, 1994, SCIENCE, V266, P1505, DOI 10.1126/science.266.5190.1505; NIYOGI KK, 1993, PLANT CELL, V5, P1011, DOI 10.1105/tpc.5.9.1011; PREUSS D, 1993, GENE DEV, V7, P974, DOI 10.1101/gad.7.6.974; PRUITT RE, 1994, ARABIDOPSIS, P467; SEAVEY SR, 1986, BOT REV, V52, P195, DOI 10.1007/BF02861001; TAYLOR LP, 1992, J HERED, V83, P11, DOI 10.1093/oxfordjournals.jhered.a111149	20	74	79	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1535	1537		10.1126/science.274.5292.1535	http://dx.doi.org/10.1126/science.274.5292.1535			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929415				2022-12-01	WOS:A1996VV77500050
J	Skinner, JA; Cohen, AT				Skinner, JA; Cohen, AT			Amputation for premature peripheral atherosclerosis: Do young patients do better	LANCET			English	Editorial Material							ADULTS; LIMB		UNIV LONDON KINGS COLL HOSP,DEPT MED,LONDON SE5 9RS,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Skinner, JA (corresponding author), WHIPPS CROSS HOSP & CHEST CLIN,DEPT ORTHOPAED,LONDON E11 1NR,ENGLAND.			Skinner, John/0000-0002-1901-9057				*ANT TRIAL COLL, 1994, BMJ-BRIT MED J, V308, P159; BODILY KC, 1983, AM J SURG, V146, P280, DOI 10.1016/0002-9610(83)90391-4; DASILVA E, 1980, OCCLUSIVE PERIPHERAL; EDMONDSON RA, 1994, LANCET, V344, P914, DOI 10.1016/S0140-6736(94)92269-1; Greant P, 1990, Ann Vasc Surg, V4, P288; HANSEN ME, 1995, SURGERY, V118, P834, DOI 10.1016/S0039-6060(05)80273-9; Olsen P S, 1988, Eur J Vasc Surg, V2, P15, DOI 10.1016/S0950-821X(88)80101-4; PAIROLERO PC, 1984, J VASC SURG, V1, P459, DOI 10.1067/mva.1984.avs0010459; VALENTINE RJ, 1995, J VASC SURG, V21, P296, DOI 10.1016/S0741-5214(95)70270-9; Valentine RJ, 1996, SURGERY, V119, P487, DOI 10.1016/S0039-6060(96)80255-8	10	9	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1396	1396		10.1016/S0140-6736(05)67497-1	http://dx.doi.org/10.1016/S0140-6736(05)67497-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937275				2022-12-01	WOS:A1996VU98600005
J	Slaper, H; Velders, GJM; Daniel, JS; deGruijl, FR; vanderLeun, JC				Slaper, H; Velders, GJM; Daniel, JS; deGruijl, FR; vanderLeun, JC			Estimates of ozone depletion and skin cancer incidence to examine the Vienna Convention achievements	NATURE			English	Article							ULTRAVIOLET; UV; RADIATION; RISK; INDUCTION; SUNLIGHT; CLOUDS	DEPLETION of the ozone layer has been observed on a global scale(1), and is probably related to halocarbon emissions, Ozone depletion increases the biologically harmful solar ultraviolet radiation reaching the surface of the Earth, which leads to a variety of adverse effects, including an increase in the incidence of skin cancer. The 1985 Vienna Convention provided the framework for international restrictions on the production of ozone-depleting substances, The consequences of such restrictions have not yet been assessed in terms of effects avoided. Here we present a new method of estimating future excess skin cancer risks which is used to compare effects of a 'no restrictions' scenario with two restrictive scenarios specified under the Vienna Convention: the Montreal Protocol, and the much stricter Copenhagen Amendments, The no-restrictions and Montreal Protocol scenarios produce a runaway increase in skin cancer incidence, up to a quadrupling and doubling, respectively, by the year 2100. The Copenhagen Amendments scenario leads to an ozone minimum around the year 2000, and a peak relative increase in incidence of skin cancer of almost 10% occurring 60 years later. These results demonstrate the importance of the international measures agreed upon under the Vienna Convention.	NATL INST PUBL HLTH & ENVIRONM,AIR RES LAB,NL-3720 BA BILTHOVEN,NETHERLANDS; NOAA,AERON LAB,BOULDER,CO 80303; UNIV UTRECHT,INST DERMATOL,NL-3508 GA UTRECHT,NETHERLANDS	Netherlands National Institute for Public Health & the Environment; National Oceanic Atmospheric Admin (NOAA) - USA; Utrecht University	Slaper, H (corresponding author), NATL INST PUBL HLTH & ENVIRONM,RADIAT RES LAB,POB 1,NL-3720 BA BILTHOVEN,NETHERLANDS.		Daniel, John S/D-9324-2011; Velders, Guus/H-1204-2013	Velders, Guus/0000-0002-6597-7088				*ALT FLUOR ENV ACC, 1993, PROD SAL ATM REL FLU; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; BORDEWIJK JA, 1995, GEOPHYS RES LETT, V22, P2151, DOI 10.1029/95GL01506; DANIEL JS, 1995, J GEOPHYS RES-ATMOS, V100, P1271, DOI 10.1029/94JD02516; DEGRUIJL FR, 1994, HEALTH PHYS, V67, P319, DOI 10.1097/00004032-199410000-00001; DEGRUIJL FR, 1993, CANCER RES, V53, P53; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; DEWINTER R, 1995, 722201005 RIVM; GALLAGHER RP, 1995, ARCH DERMATOL, V131, P157, DOI 10.1001/archderm.131.2.157; *HLTH COUNC NETH, 1994, UV RAD SUNL; HOLMAN CD, 1984, JNCI-J NATL CANCER I, V73, P75; KERR RA, 1995, SCIENCE, V270, P376; KRICKER A, 1994, NATURE, V368, P594, DOI 10.1038/368594b0; LONGSTRETH JD, 1987, UAEPA400187001D; LUBIN D, 1995, NATURE, V377, P710, DOI 10.1038/377710a0; MADRONICH S, 1993, NATURE, V366, P23, DOI 10.1038/366023a0; MCKENZIE RL, 1995, WMO REP, V37, pCH9; SCOTTO J, 1981, NIH PUBLICATION; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; SLAPER H, 1995, GEOPHYS RES LETT, V22, P2721, DOI 10.1029/95GL02824; SLAPER H, 1986, PHOTODERMATOLOGY, V3, P271; SLAPER H, 1987, THESIS UTRECHT U; SLAPER H, 1992, 749202001 RIVM; VELDERS GJM, 1995, 722201006 RIVM; VITASA BC, 1990, CANCER, V65, P2611; World Meteorological Organization, 1992, 25 WMO; World Meteorological Organization, 1995, 37 WMO; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	28	178	182	1	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					256	258		10.1038/384256a0	http://dx.doi.org/10.1038/384256a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918873				2022-12-01	WOS:A1996VU38100048
J	Starr, JM; Inch, S; Cross, S; Deary, IJ; MacLennan, WJ				Starr, JM; Inch, S; Cross, S; Deary, IJ; MacLennan, WJ			Blood pressure and mortality in healthy old people: The r shaped curve	BRITISH MEDICAL JOURNAL			English	Article							ELDERLY PATIENTS; MANAGEMENT; HYPERTENSION		UNIV EDINBURGH,DEPT GERIATR MED,EDINBURGH EH4 2DN,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PSYCHOL,EDINBURGH EH4 2DN,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh			Starr, John/C-8951-2011; Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X				BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; FOTHERBY MD, 1992, BMJ-BRIT MED J, V305, P750, DOI 10.1136/bmj.305.6856.750; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; Starr J.M., 1996, EPIDEMIOLOGY OLD AGE; STARR JM, 1993, J AM GERIATR SOC, V41, P753, DOI 10.1111/j.1532-5415.1993.tb07466.x	5	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1243	1244		10.1136/bmj.313.7067.1243	http://dx.doi.org/10.1136/bmj.313.7067.1243			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VU208	8939116	Green Published, Green Submitted			2022-12-01	WOS:A1996VU20800025
J	Castilla, LH; Wijmenga, C; Wang, Q; Stacy, T; Speck, NA; Eckhaus, M; MarinPadilla, M; Collins, FS; WynshawBoris, A; Liu, PP				Castilla, LH; Wijmenga, C; Wang, Q; Stacy, T; Speck, NA; Eckhaus, M; MarinPadilla, M; Collins, FS; WynshawBoris, A; Liu, PP			Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11	CELL			English	Article							ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; MYOSIN HEAVY-CHAIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; RECEPTOR-DELTA-ENHANCER; TRANSCRIPTION FACTOR; ERYTHROID DEVELOPMENT; MICE LACKING; AML1 GENE; C-MYB	The fusion oncogene CBFB-MYH11 is generated by a chromosome 16 inversion in human acute myeloid leukemia subtype M4Eo. Mouse embryonic stem (ES) cells heterozygous for this oncogene were generated by inserting part of the human MYH11 cDNA into the mouse Cbfb gene through homologous recombination (knock-in). Chimeric mice were leukemia free, but the ES cells with the knocked-in Cbfb-MYH11 gene did not contribute to their hematopoietic tissues. Mouse embryos heterozygous for Cbfb-MYH11 lacked definitive hematopoiesis and developed multiple fatal hemorrhages around embryonic day 12.5. This phenotype is very similar to that resulting from homozygous deletions of either Cbfb or Cbfa2 (AML1), consistent with a dominant negative function of the Cbfb-MYH11 fusion oncogene. An impairment of primitive hematopoiesis was also observed, however, suggesting a possible additional function of Cbfb-MYH11.	NIH,NATL CTR HUMAN GENOME RES,LAB GENET DIS RES,BETHESDA,MD 20892; NIH,NATL CTR RES RESOURCES,VET RESOURCES PROGRAM,BETHESDA,MD 20892; DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755; DARTMOUTH COLL SCH MED,DEPT PATHOL,HANOVER,NH 03755	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; Dartmouth College; Dartmouth College	Castilla, LH (corresponding author), NIH,NATL CTR HUMAN GENOME RES,LAB GENE TRANSFER,BETHESDA,MD 20892, USA.		Wijmenga, Cisca/D-2173-2009; Liu, Paul/A-7976-2012; Wijmenga, Cisca/AAE-7719-2019	Liu, Paul/0000-0002-6779-025X; Wijmenga, Cisca/0000-0002-5635-1614	NCI NIH HHS [CA58343] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE SC, 1993, ONCOGENE, V8, P809; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DIGGS LW, 1954, MORPHOLOGY BLOOD CEL; Eaves C, 1995, ATLAS HUMAN HEMATOPO; Frank R, 1995, ONCOGENE, V11, P2667; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; MARLTON P, 1995, BLOOD, V85, P772, DOI 10.1182/blood.V85.3.772.bloodjournal853772; MATSUOKA R, 1993, AM J MED GENET, V46, P61, DOI 10.1002/ajmg.1320460110; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	41	242	249	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					687	696		10.1016/S0092-8674(00)81388-4	http://dx.doi.org/10.1016/S0092-8674(00)81388-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929537	hybrid			2022-12-01	WOS:A1996VU03500011
J	Hill, LN				Hill, LN			My not-so-near-death experience	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Hill, LN (corresponding author), AMER EMBASSY, APO, AP 96440 USA.								0	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					855	857		10.7326/0003-4819-125-10-199611150-00012	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928995				2022-12-01	WOS:A1996VU52400015
J	Mombaerts, P; Wang, F; Dulac, C; Chao, SK; Nemes, A; Mendelsohn, M; Edmondson, J; Axel, R				Mombaerts, P; Wang, F; Dulac, C; Chao, SK; Nemes, A; Mendelsohn, M; Edmondson, J; Axel, R			Visualizing an olfactory sensory map	CELL			English	Article							ODORANT RECEPTOR EXPRESSION; MITRAL TUFTED CELLS; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; BULB; MOUSE; NEURONS; ORGANIZATION; EPITHELIUM; MOLECULES	We have developed a genetic approach to visualize axons from olfactory sensory neurons expressing a given odorant receptor, as they project to the olfactory bulb. Neurons expressing a specific receptor project to only two topographically fixed loci among the 1800 glomeruli in the mouse olfactory bulb. Our data provide direct support for a model in which a topographic map of receptor activation encodes odor quality in the olfactory bulb. Receptor swap experiments suggest that the olfactory receptor plays an instructive role in the guidance process but cannot be the sole determinant in the establishment of this map. This genetic approach may be more broadly applied to visualize the development and plasticity of projections in the mammalian nervous system.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOL BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute; Columbia University				Axel, Richard/0000-0002-3141-4076; Dulac, Catherine/0000-0001-5024-5418	NCI NIH HHS [5 PO1 CA23767] Funding Source: Medline; NIMH NIH HHS [5 P50 MH 50733] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; BUIAKOVA OI, 1994, GENOMICS, V20, P452, DOI 10.1006/geno.1994.1200; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FARBMAN AI, 1980, DEV BIOL, V74, P205, DOI 10.1016/0012-1606(80)90062-7; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; KATOH K, 1993, J NEUROPHYSIOL, V70, P2161, DOI 10.1152/jn.1993.70.5.2161; KAUER JS, 1987, BRAIN RES, V418, P255, DOI 10.1016/0006-8993(87)90093-X; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; LANCET D, 1982, P NATL ACAD SCI-BIOL, V79, P670, DOI 10.1073/pnas.79.2.670; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; Mombaerts P, 1996, CURR OPIN NEUROBIOL, V6, P481, DOI 10.1016/S0959-4388(96)80053-5; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROYET JP, 1988, J COMP NEUROL, V270, P559, DOI 10.1002/cne.902700409; SAUER B, 1990, New Biologist, V2, P441; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STROTMANN J, 1995, EUR J NEUROSCI, V7, P492, DOI 10.1111/j.1460-9568.1995.tb00345.x; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Woolsey T.A., 1990, P461	41	1538	1560	8	132	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					675	686		10.1016/S0092-8674(00)81387-2	http://dx.doi.org/10.1016/S0092-8674(00)81387-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929536	hybrid			2022-12-01	WOS:A1996VU03500010
J	Rampino, N; Yamamoto, H; Ionov, Y; Li, Y; Sawai, H; Reed, JC; Perucho, M				Rampino, N; Yamamoto, H; Ionov, Y; Li, Y; Sawai, H; Reed, JC; Perucho, M			Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype	SCIENCE			English	Article							REPEATED SEQUENCES REVEAL; TUMOR-SUPPRESSOR P53; CELL-DEATH; COLORECTAL TUMORIGENESIS; BINDING-PROTEIN; DNA-DAMAGE; INSTABILITY; RECEPTOR; EXPRESSION; MECHANISM	Cancers of the microsatellite mutator phenotype (MMP) show exaggerated genomic instability at simple repeat sequences. More than 50 percent (21 out of 41) of human MMP(+) colon adenocarcinomas examined were found to have frameshift mutations in a tract of eight deoxyguanosines [(G)(8)] within BAX, a gene that promotes apoptosis. These mutations were absent in MMP tumors and were significantly less frequent in (G), repeats from other genes. Frameshift mutations were present in both BAX alleles in some MMP(+) colon tumor cell lines and in primary tumors. These results suggest that inactivating BAX mutations are selected for during the progression of colorectal MMP(+) tumors and that the wild-type BAX gene plays a suppressor role in a p53-independent pathway for colorectal carcinogenesis.	BURNHAM INST,LA JOLLA CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute				Perucho, Manuel/0000-0002-2169-2662	NCI NIH HHS [CA63585, CA38579] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038579, R37CA063585, R01CA063585] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Casares S, 1995, ONCOGENE, V11, P2303; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KASTAN MB, 1991, CANCER RES, V51, P6304; KIM HG, 1994, AM J PATHOL, V145, P148; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KOLLURI R, 1991, NUCLEIC ACIDS RES, V19, P4771, DOI 10.1093/nar/19.17.4771; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Krajewski S, 1996, ANAL BIOCHEM, V236, P221, DOI 10.1006/abio.1996.0160; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOEB LA, 1994, CANCER RES, V54, P5059; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; Malkhosyan S, 1996, MUTAT RES-DNAGING G, V316, P249, DOI 10.1016/S0921-8734(96)90007-7; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MEIJERINK JPP, 1995, LEUKEMIA, V9, P1828; MIYASHITA T, 1995, CELL, V80, P293; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERUCHO M, 1994, COLD SPRING HARB SYM, V59, P339, DOI 10.1101/SQB.1994.059.01.038; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	34	1170	1201	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					967	969		10.1126/science.275.5302.967	http://dx.doi.org/10.1126/science.275.5302.967			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020077				2022-12-01	WOS:A1997WH38800042
J	Simioni, P; Prandoni, P; Lensing, AWA; Scudeller, A; Sardella, C; Prins, MH; Villalta, S; Dazzi, F; Girolami, A				Simioni, P; Prandoni, P; Lensing, AWA; Scudeller, A; Sardella, C; Prins, MH; Villalta, S; Dazzi, F; Girolami, A			The risk of recurrent venous thromboembolism in patients with an Arg(506)->Gln mutation in the gene for factor V (factor V Leiden)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVATED PROTEIN-C; DEEP-VEIN THROMBOSIS; POOR ANTICOAGULANT RESPONSE; COAGULATION-FACTOR-V; RESISTANCE; DIAGNOSIS; THROMBOPHILIA	Background A recently discovered mutation in coagulation factor V (Arg(506)-->Gln, referred to as factor V Leiden), which results in resistance to activated protein C, is found in approximately one fifth of patients with venous thromboembolism. However, the risk of recurrent thromboembolism in heterozygous carriers of this genetic abnormality is unknown. Methods We searched for factor V Leiden in 251 unselected patients with a first episode of symptomatic deep-vein thrombosis diagnosed by venography. The patients were followed prospectively for a mean of 3.9 years to determine the frequency of recurrent venous thrombosis and pulmonary embolism. Results Factor V Leiden was found in 41 of the patients (16.3 percent; 95 percent confidence interval, 11.8 to 20.9 percent). The cumulative incidence of recurrent venous thromboembolism after follow-up of up to eight years was 39.7 percent (95 percent confidence interval, 22.8 to 56.5 percent) among carriers of the mutation, as compared with 18.3 percent (95 percent confidence interval, 12.3 to 24.3 percent) among patients without the mutation (hazard ratio, 2.4; 95 percent confidence interval, 1.3 to 4.5; P<0.01). Conclusions The risk of recurrent thromboembolic events is significantly higher in carriers of factor V Leiden than in patients without this abnormality. Large trials assessing the risk-benefit ratio of long-term anticoagulation in carriers of the mutation who have had a first episode of venous thromboembolism are indicated. (C) 1997, Massachusetts Medical Society.	UNIV AMSTERDAM, ACAD MED CTR, CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA, NL-1105 AZ AMSTERDAM, NETHERLANDS; UNIV HOSP PADUA, INST MED SEMEIOT, PADUA, ITALY; UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN EPIDEMIOL, NL-1105 AZ AMSTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Amsterdam; Academic Medical Center Amsterdam			Dazzi, Francesco/ABD-6171-2021; Simioni, Paolo/AAC-5416-2022; SIMIONI, PAOLO/AAC-5438-2022	Dazzi, Francesco/0000-0003-2407-236X; SIMIONI, PAOLO/0000-0002-6744-383X				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; GIROLAMI A, 1993, BRIT J HAEMATOL, V85, P521; GRIFFIN JH, 1993, BLOOD, V82, P1989; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HIRSH J, 1993, HEMOSTASIS THROMBOSI, P1322; HUISMAN MV, 1988, ARCH INTERN MED, V148, P681, DOI 10.1001/archinte.148.3.681; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LENSING AWA, 1992, THROMB HAEMOSTASIS, V68, P245; LENSING AWA, 1993, HEMOSTASIS THROMBOSI, P1297; PABINGER I, 1992, BLOOD COAGUL FIBRIN, V3, P547, DOI 10.1097/00001721-199210000-00005; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Rintelen C, 1996, THROMB HAEMOSTASIS, V75, P229; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TRIPLETT DA, 1995, THROMB RES, V78, P1, DOI 10.1016/0049-3848(95)00001-1; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8	22	323	327	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1997	336	6					399	403		10.1056/NEJM199702063360602	http://dx.doi.org/10.1056/NEJM199702063360602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF859	9010145	Green Published			2022-12-01	WOS:A1997WF85900002
J	Perkins, ND; Felzien, LK; Betts, JC; Leung, KY; Beach, DH; Nabel, GJ				Perkins, ND; Felzien, LK; Betts, JC; Leung, KY; Beach, DH; Nabel, GJ			Regulation of NF-kappa B by cyclin-dependent kinases associated with the p300 coactivator	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RNA-POLYMERASE-II; LONG TERMINAL REPEAT; CELL-CYCLE; DNA-BINDING; E1A-ASSOCIATED P300; HUMAN FIBROBLASTS; GENE-EXPRESSION; PROTEIN P300; G(1) ARREST	The nuclear factor kappa B (NF-kappa B) transcription factor is responsive to specific cytokines and stress and is often activated in association with cell damage and growth arrest in eukaryotes. NF-kappa B is a heterodimeric protein, typically composed of 50- and 65-kilodalton subunits of the Rel family, of which RelA(p65) stimulates transcription of diverse genes. Specific cyclin-dependent kinases (CDKs) were found to regulate transcriptional activation by NF-kappa B through interactions with the coactivator p300. The transcriptional activation domain of RelA(p65) interacted with an amino-terminal region of p300 distinct from a carboxyl-terminal region of p300 required for binding to the cyclin E-Cdk2 complex. The CDK inhibitor p21 or a dominant negative Cdk2,which inhibited p300-associated cyclin E-Cdk2 activity, stimulated kappa B-dependent gene expression which was also enhanced by expression of p300 in the presence of p21. The interaction of NF-kappa B and CDKS through the p300 and CBP coactivators provides a mechanism for the coordination of transcriptional activation with cell cycle progression.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109; COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029179] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI29179] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BANERJEE AC, 1994, ONCOGENE, V9, P1733; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ECK SL, 1993, MOL CELL BIOL, V13, P6530, DOI 10.1128/MCB.13.10.6530; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Janknecht R, 1996, ONCOGENE, V12, P1961; JIANG HP, 1994, ONCOGENE, V9, P3397; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI Y, 1994, ONCOGENE, V9, P2261; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIN WC, 1991, BIOTECHNIQUES, V11, P344; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MICHIELI P, 1994, CANCER RES, V54, P3391; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Muraoka M, 1996, ONCOGENE, V12, P1565; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PARKER SF, IN PRESS J VIROL; PERKINS N, UNPUB; PERKINS ND, 1994, J VIROL, V68, P6820, DOI 10.1128/JVI.68.10.6820-6823.1994; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cellbio.10.1.405; SONG CZ, 1995, J VIROL, V69, P2907, DOI 10.1128/JVI.69.5.2907-2911.1995; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; THEVENIN C, 1990, New Biologist, V2, P793; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VENTURA AM, 1990, P NATL ACAD SCI USA, V87, P1310, DOI 10.1073/pnas.87.4.1310; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389	65	659	682	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					523	527		10.1126/science.275.5299.523	http://dx.doi.org/10.1126/science.275.5299.523			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999795				2022-12-01	WOS:A1997WE25700042
J	Montoya, G; Svensson, C; Luirink, J; Sinning, I				Montoya, G; Svensson, C; Luirink, J; Sinning, I			Crystal structure of the NG domain from the signal-recognition particle receptor FtsY	NATURE			English	Article							ESCHERICHIA-COLI; GTP HYDROLYSIS; MOLECULAR SWITCH; PROTEIN MODELS; RAS PROTEIN; RESOLUTION; MECHANISM; SUBUNIT; PROGRAM; SRP	Newly synthesized proteins destined either for secretion or incorporation into membranes are targeted to the membrane translocation machinery by a ubiquitous system consisting of a signal recognition particle (SRP) and its receptor(1,2). Both the SRP receptor and the protein within the SRP that binds the signal sequence contain GTPases(3,4). These two proteins, together with the RNA component of the SRP, form a complex(5-7) and thereby regulate each other's GTPase activity(8). Here we report the structure of the GTPase-containing portion of FtsY, the functional homologue of the SRP receptor of Escherichia coli(9), at 2.2 Angstrom resolution without bound nucleotide. This so-called NG domain displays similarities to the Ras-related GTPases, as well as features unique to the SRP-type GTPases(10), such as a separate aminoterminal domain, an insertion within the p21(ras) (Ras) effector domain(11), and a wide-open GTP-binding region. The structure explains the low affinity of FtsY for GTP, and suggests rearrangements that may occur on nucleotide binding. It also identifies regions potentially involved in the transmission of signals between domains and in interactions with regulatory proteins.	EUROPEAN MOL BIOL LAB, STRUCT BIOL PROGRAMME, D-69117 HEIDELBERG, GERMANY; BIOCTR AMSTERDAM, INST MOL BIOL SCI, DEPT MICROBIOL, NL-1081 HV AMSTERDAM, NETHERLANDS	European Molecular Biology Laboratory (EMBL); University of Amsterdam			Sinning, Irmgard/A-2982-2010; Luirink, Joen/AAB-8658-2021					Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNGER TA, 1993, XPLOR VERSION 3 1; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, 1990, AM CRYST ASS 40 AN M; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSTERS R, 1995, FEBS LETT, V372, P253, DOI 10.1016/0014-5793(95)00997-N; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MONTOYA G, IN PRESS PROTEINS ST; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; Schmidt G, 1996, ONCOGENE, V12, P87; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650	30	181	184	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 23	1997	385	6614					365	368		10.1038/385365a0	http://dx.doi.org/10.1038/385365a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002525				2022-12-01	WOS:A1997WD91400057
J	Atchison, RE; Gosling, J; Monteclaro, FS; Franci, C; Digilio, L; Charo, IF; Goldsmith, MA				Atchison, RE; Gosling, J; Monteclaro, FS; Franci, C; Digilio, L; Charo, IF; Goldsmith, MA			Multiple extracellular elements of CCR5 and HIV-1 entry: Dissociation from response to chemokines	SCIENCE			English	Article							EXPRESSION; INFECTION; RECEPTOR; CLONING	The human beta-chemokine receptor CCR5 is an important cofactor for entry of human immunodeficiency virus-type 1 (HIV-1), The murine form of CCR5, despite its 82 percent identity to the human form, was not functional as an HIV-1 coreceptor. HIV-1 entry function could be reconstituted by fusion of various individual elements derived from the extracellular region of human CCR5 onto murine CCR5. Analysis of chimeras containing elements from human CCR5 and human CCR2B suggested that a complex structure rather than single contact sites is responsible for facilitation of viral entry, Further, certain chimeras lacking the domains necessary to signal in response to their natural chemokine ligands retained vigorous HIV-1 coreceptor activity.	UNIV CALIF SAN FRANCISCO,SCH MED,GLADSTONE INST VIROL & IMMUNOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,SCH MED,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes					NHLBI NIH HHS [HL52773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; ATCHSION R, UNPUB; Boring L, 1996, J BIOL CHEM, V271, P7551, DOI 10.1074/jbc.271.13.7551; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DENG H, 1996, SCIENCE, V272, P1955; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FRANCI C, 1995, J IMMUNOL, V154, P6511; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GOLDSMITH MA, 1995, J VIROL, V69, P4112, DOI 10.1128/JVI.69.7.4112-4121.1995; GOSLING J, UNPUB; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LORES P, 1992, AIDS RES HUM RETROV, V8, P2063, DOI 10.1089/aid.1992.8.2063; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MONTECLARO FS, UNPUB; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g	22	274	284	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1924	1926		10.1126/science.274.5294.1924	http://dx.doi.org/10.1126/science.274.5294.1924			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943208				2022-12-01	WOS:A1996VY20000048
J	Bulaj, ZJ; Griffen, LM; Jorde, LB; Edwards, CQ; Kushner, JP				Bulaj, ZJ; Griffen, LM; Jorde, LB; Edwards, CQ; Kushner, JP			Clinical and biochemical abnormalities in people heterozygous for hemochromatosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HLA-LINKED HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; IDIOPATHIC HEMOCHROMATOSIS; ANCESTRAL HAPLOTYPE; IRON OVERLOAD; UNITED-STATES; ASSOCIATION; EXPRESSION; POPULATION; PREVALENCE	Background Ten percent of whites are heterozygous for the HLA-linked hemochromatosis mutation. We performed a cross-sectional analysis of 1058 genotyped heterozygotes to define the effects of age and sex on the phenotype. Methods The heterozygous genotype was assigned to 505 male and 553 female members of 202 pedigrees, each with an HLA-typed homozygous proband. We measured serum iron, transferrin saturation, and ferritin in all heterozygotes and in 321 genetically normal subjects (unaffected family members or spouses of family members). Liver biopsies were performed in a subgroup of heterozygotes. Results The mean serum iron concentrations and transferrin-saturation values were higher in heterozygotes than in normal subjects and did not increase with age. Initial transferrin-saturation levels exceeding the threshold associated with the homozygous genotype were found in 4 percent of male and 8 percent of female heterozygotes. The geometric mean serum ferritin concentration was higher in heterozygotes than in normal subjects and increased with age. Higher-than-normal values were found in 20 percent of male and 8 percent of female heterozygotes. The clinical and biochemical expression of hemochromatosis was more marked in heterozygotes with paternally transmitted mutations than in those with maternally transmitted mutations. Liver-biopsy abnormalities were generally associated with alcohol abuse, hepatitis, or porphyria cutanea tarda. Conclusions The phenotype of persons heterozygous for hemochromatosis differs from that of normal subjects, but complications due to iron overload alone in these heterozygotes are extremely rare. (C) 1996, Massachusetts Medical Society.	UNIV UTAH,SCH MED,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132; LATTER DAY ST HOSP,SALT LAKE CITY,UT 84143; UNIV UTAH,SCH MED,DIV HEMATOL ONCOL,DEPT INTERNAL MED,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020630] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00064] Funding Source: Medline; NIDDK NIH HHS [DK 20630] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS PC, 1994, AM J HEMATOL, V45, P146, DOI 10.1002/ajh.2830450210; BALAN V, 1994, GASTROENTEROLOGY, V107, P453, DOI 10.1016/0016-5085(94)90171-6; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BASSETT ML, 1981, HEPATOLOGY, V1, P120, DOI 10.1002/hep.1840010206; BUITING K, 1995, NAT GENET, V10, P249, DOI 10.1038/ng0695-249c; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; CARTWRIGHT GE, 1980, J CLIN INVEST, V65, P989, DOI 10.1172/JCI109785; CARTWRIGHT GE, 1979, NEW ENGL J MED, V301, P175, DOI 10.1056/NEJM197907263010402; COOK JD, 1986, BLOOD, V68, P726; COOK JD, 1982, SEMIN HEMATOL, V19, P6; CRAWFORD DHG, 1995, AM J HUM GENET, V57, P362; DADONE MM, 1982, AM J CLIN PATHOL, V78, P196, DOI 10.1093/ajcp/78.2.196; EDWARDS CQ, 1989, GASTROENTEROLOGY, V97, P972, DOI 10.1016/0016-5085(89)91506-0; EDWARDS CQ, 1977, NEW ENGL J MED, V297, P7, DOI 10.1056/NEJM197707072970102; EDWARDS CQ, 1982, CLIN HAEMATOL, V11, P411; EDWARDS CQ, 1981, PROG HEMATOL, V12, P43; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; EDWARDS CQ, 1981, BLOOD, V58, P844; EDWARDS CQ, 1990, AM J MED SCI, V300, P245, DOI 10.1097/00000441-199010000-00009; EDWARDS CQ, 1993, WINTROBES CLIN HEMAT, V1, P872; FARGION S, 1986, AM J CLIN PATHOL, V86, P645, DOI 10.1093/ajcp/86.5.645; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; JAZWINSKA EC, 1995, AM J HUM GENET, V56, P428; MARGARITTEJEANNIN P, 1995, AM J HUM GENET, V56, P1080; MCLAREN CE, 1995, BLOOD, V86, P2021, DOI 10.1182/blood.V86.5.2021.bloodjournal8652021; MCMAHON FJ, 1995, AM J HUM GENET, V56, P1277; RAHACHOWDHURY R, 1995, J MED GENET, V32, P446, DOI 10.1136/jmg.32.6.446; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAY JG, 1976, DHEW PUBL NIH; SCHEUER PJ, 1962, J PATHOL BACTERIOL, V84, P53, DOI 10.1002/path.1700840107; SIMON M, 1977, NEW ENGL J MED, V297, P1017, DOI 10.1056/NEJM197711102971901; SIMON M, 1987, AM J HUM GENET, V41, P89; VALBERG LS, 1980, GASTROENTEROLOGY, V79, P884; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2	35	259	262	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 12	1996	335	24					1799	1805		10.1056/NEJM199612123352403	http://dx.doi.org/10.1056/NEJM199612123352403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW683	8943161				2022-12-01	WOS:A1996VW68300003
J	Freeman, BC; Toft, DO; Morimoto, RI				Freeman, BC; Toft, DO; Morimoto, RI			Molecular chaperone machines: Chaperone activities of the cyclophilin Cyp-40 and the steroid aporeceptor-associated protein p23	SCIENCE			English	Article							HEAT-SHOCK PROTEINS; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; SIGNAL-TRANSDUCTION; HSP90; BINDING; HSP70; DNAK; IDENTIFICATION; HETEROCOMPLEX	Molecular chaperones are essential proteins that participate in the regulation of steroid receptors in eukaryotes. The steroid aporeceptor complex contains the molecular chaperones Hsp90 and Hsp70, p48, the cyclophilin Cyp-40, and the associated proteins p23 and p60. In vitro folding assays showed that Cyp-40 and p23 functioned as molecular chaperones in a manner similar to that of Hsp90 or Hsp70. Although neither Cyp-40 nor p23 could completely refold an unfolded substrate, both proteins interacted with the substrate to maintain a nonnative folding-competent intermediate. Thus, the steroid aporeceptor complexes have multiple chaperone components that maintain substrates in an intermediate folded state.	NORTHWESTERN UNIV, RICE INST BIOMED RES, DEPT BIOCHEM MOL BIOL & CELL BIOL, EVANSTON, IL 60208 USA; MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOL BIOL, ROCHESTER, MN 55905 USA	Northwestern University; Mayo Clinic					NIGMS NIH HHS [GM38109] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038109, R01GM038109] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BOHEN SP, 1995, J BIOL CHEM, V270, P29433, DOI 10.1074/jbc.270.49.29433; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FREEMAN BC, UNPUB; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cellbio.9.1.601; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HEITMAN J, 1992, NEW BIOL, V4, P448; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOHFELD J, 1995, CELL, V83, P589; HUTCHISON KA, 1992, J BIOL CHEM, V267, P3190; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; SMITH DF, 1995, SCI MED, V2, P38; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; [No title captured]	34	286	290	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1996	274	5293					1718	1720		10.1126/science.274.5293.1718	http://dx.doi.org/10.1126/science.274.5293.1718			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939864				2022-12-01	WOS:A1996VW71200063
J	Asbury, D; Boggis, CRM; Sheals, D; Threlfall, AG; Woodman, CBJ				Asbury, D; Boggis, CRM; Sheals, D; Threlfall, AG; Woodman, CBJ			NHS breast screening programme: Is the high incidence of interval cancers inevitable?	BRITISH MEDICAL JOURNAL			English	Article									CHRISTIE HOSP NHS TRUST,CTR CANC EPIDEMIOL,MANCHESTER M20 4QL,LANCS,ENGLAND; WITHINGTON HOSP,MANCHESTER BREAST SCREENING SERV,MANCHESTER M20 0PT,LANCS,ENGLAND; ROYAL ALBERT EDWARD INFIRM,WIGAN BREAST SCREENING SERV,WIGAN WN1 2NN,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; University of Manchester								Day N, 1995, J Med Screen, V2, P180; FIELD S, 1995, BRIT MED J, V310, P203, DOI 10.1136/bmj.310.6974.203; FRISELL J, 1992, BREAST CANCER RES TR, V24, P11, DOI 10.1007/BF01832353; PEETERS PHM, 1989, BRIT J CANCER, V59, P929, DOI 10.1038/bjc.1989.196; WOODMAN CBJ, 1995, BRIT MED J, V310, P224, DOI 10.1136/bmj.310.6974.224	5	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1996	313	7069					1369	1370		10.1136/bmj.313.7069.1369	http://dx.doi.org/10.1136/bmj.313.7069.1369			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956704	Green Published			2022-12-01	WOS:A1996VW68500026
J	Raine, R; Streetly, A; Daves, AM				Raine, R; Streetly, A; Daves, AM			Variation in local policies and guidelines for cholesterol management: National survey	BRITISH MEDICAL JOURNAL			English	Article									UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Raine, R (corresponding author), LAMBETH SOUTHWARK & LEWISHAM HLTH AUTHOR,DIRECTORATE PUBL HLTH & HLTH POLICY,LONDON SE1 7NT,ENGLAND.			Raine, Rosalind/0000-0003-0904-749X				[Anonymous], 1994, EFF HLTH CAR B; Pharoah PDP, 1996, BMJ-BRIT MED J, V312, P1443, DOI 10.1136/bmj.312.7044.1443; *U LEEDS, 1993, EFF HLTH CAR B, V6	3	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1996	313	7069					1368	1369		10.1136/bmj.313.7069.1368	http://dx.doi.org/10.1136/bmj.313.7069.1368			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956703	Green Published			2022-12-01	WOS:A1996VW68500025
J	Brojatsch, J; Naughton, J; Rolls, MM; Zingler, K; Young, JAT				Brojatsch, J; Naughton, J; Rolls, MM; Zingler, K; Young, JAT			CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukosis sarcoma viruses and mediates apoptosis	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; UNINTEGRATED VIRAL-DNA; DENSITY-LIPOPROTEIN RECEPTOR; DEATH DOMAIN; ENVELOPE GLYCOPROTEIN; MOLECULAR-CLONING; FAS ANTIGEN; T-CELLS; INFECTION	Viral envelope (Env)-receptor interactions have been implicated in the cell death associated with infection by subgroups B and D avian leukosis-sarcoma viruses (ALVs). A chicken protein, CAR1, was identified that permitted infection of mammalian cells by these viral subgroups. CAR1 bound to a viral Env fusion protein, comprising an ALV-B surface Env protein and the Fc region of an immunoglobulin, indicating that it is a specific Viral receptor. CAR1 contains two extracellular cysteine-rich domains characteristic of the TNFR family and a cytoplasmic region strikingly similar to the death domain of TNFR1 and Pas, implicating this receptor in cell killing. Chicken embryo fibroblasts susceptible to ALV-B infection and transfected quail QT6 cells expressing CAR1 underwent apoptosis in response to the Env-lg fusion protein, demonstrating that this cytopathic ALV receptor can mediate cell death.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	Brojatsch, J (corresponding author), HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOL GENET, BOSTON, MA 02115 USA.		Rolls, Melissa/G-6402-2014	Rolls, Melissa/0000-0002-5021-4360; Young, John/0000-0003-1824-2561; brojatsch, jurgen/0000-0002-7424-365X	NATIONAL CANCER INSTITUTE [R01CA070810, R29CA062000, R01CA062000] Funding Source: NIH RePORTER; NCI NIH HHS [CA62000, CA70810] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1992, SHORIT PROTOCOLS MOL; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; BELANGER C, 1995, J VIROL, V69, P1019; BERGERON L, 1992, J VIROL, V66, P5777, DOI 10.1128/JVI.66.10.5777-5787.1992; BEUTLER B, 1994, ANN NY ACAD SCI, V730, P118, DOI 10.1111/j.1749-6632.1994.tb44244.x; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOVA CA, 1988, J VIROL, V62, P75, DOI 10.1128/JVI.62.1.75-83.1988; Cao J, 1996, J VIROL, V70, P1340, DOI 10.1128/JVI.70.3.1340-1354.1996; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHAPMAN BS, 1995, FEBS LETT, V374, P216, DOI 10.1016/0014-5793(95)01113-S; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; CONNOLLY L, 1994, J VIROL, V68, P2760, DOI 10.1128/JVI.68.4.2760-2764.1994; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; DONAHUE PR, 1991, J VIROL, V65, P4461, DOI 10.1128/JVI.65.8.4461-4469.1991; DORNER AJ, 1986, CELL, V45, P365, DOI 10.1016/0092-8674(86)90322-3; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HAAKFRENDSCHO M, 1993, IMMUNOLOGY, V79, P594; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KESHET E, 1979, J VIROL, V31, P376, DOI 10.1128/JVI.31.2.376-388.1979; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LASTER SM, 1988, J IMMUNOL, V141, P2629; LAURENTCRAWFORD AG, 1993, J GEN VIROL, V74, P2619, DOI 10.1099/0022-1317-74-12-2619; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; LU YY, 1994, J VIROL, V68, P390, DOI 10.1128/JVI.68.1.390-399.1994; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; PAQUETTE Y, 1989, P NATL ACAD SCI USA, V86, P3896, DOI 10.1073/pnas.86.10.3896; PAUZA CD, 1990, J EXP MED, V172, P1035, DOI 10.1084/jem.172.4.1035; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PITTI RM, 1994, MOL IMMUNOL, V31, P1345, DOI 10.1016/0161-5890(94)90053-1; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RESNICKROGUEL N, 1989, J VIROL, V63, P4325, DOI 10.1128/JVI.63.10.4325-4330.1989; RIEDEL N, 1988, P NATL ACAD SCI USA, V85, P2758, DOI 10.1073/pnas.85.8.2758; ROBINSON HL, 1990, J VIROL, V64, P4836, DOI 10.1128/JVI.64.10.4836-4841.1990; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHREIBER M, 1994, VIROLOGY, V204, P692, DOI 10.1006/viro.1994.1585; Siliciano RF, 1996, CURR TOP MICROBIOL, V205, P159; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SOMASUNDARAN M, 1987, J VIROL, V61, P3114, DOI 10.1128/JVI.61.10.3114-3119.1987; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; STUMPH WE, 1981, NUCLEIC ACIDS RES, V9, P5383, DOI 10.1093/nar/9.20.5383; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEISS RA, 1995, CELL, V82, P531, DOI 10.1016/0092-8674(95)90024-1; WEISS RA, 1993, RETROVIRIDAE, V2, P1; WELLER SK, 1981, J VIROL, V39, P713, DOI 10.1128/JVI.39.3.713-721.1981; WELLER SK, 1980, J VIROL, V33, P494, DOI 10.1128/JVI.33.1.494-506.1980; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YOUNG JAT, 1993, J VIROL, V67, P1811, DOI 10.1128/JVI.67.4.1811-1816.1993; Zingler K, 1996, J VIROL, V70, P7510, DOI 10.1128/JVI.70.11.7510-7516.1996; ZINGLER K, 1995, J VIROL, V69, P4261, DOI 10.1128/JVI.69.7.4261-4266.1995	67	215	241	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					845	855		10.1016/S0092-8674(00)81992-3	http://dx.doi.org/10.1016/S0092-8674(00)81992-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945512	Bronze			2022-12-01	WOS:A1996VV77400011
J	Zecca, M; Basler, K; Struhl, G				Zecca, M; Basler, K; Struhl, G			Direct and long-range action of a wingless morphogen gradient	CELL			English	Article							POLARITY GENE ARMADILLO; PROTEIN-KINASE-A; DROSOPHILA EMBRYO; SIGNALING PATHWAY; PATTERN-FORMATION; SHAGGY ZESTE-WHITE-3; LIMB DEVELOPMENT; DISC DEVELOPMENT; DORSAL PROTEIN; IMAGINAL DISC	Wingless (Wg), a founding member of the Wingless/Int-1 (Wnt) family of secreted proteins, acts as a short-range inducer and as a long-range organizer during Drosophila development. Here, we determine the consequences of ectopically expressing (i) a wild-type form of Wg, (ii) a membrane-tethered form of Wg, and (iii) a constitutively active form of the cytosolic protein Armadillo (Arm), which normally acts to transduce Wg, and we compare them with the effects of removing endogenous Wg or Arm activity. Our results indicate that wild-type Wg acts at long range, up-regulating the transcription of particular target genes as a function of concentration and distance from secreting cells. In contrast, tethered Wg and Arm have only short-range or autonomous effects, respectively, on the transcription of these genes. We interpret these findings as evidence that Wg can act directly and at long range as a gradient morphogen during normal development.	COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Zecca, M (corresponding author), UNIV ZURICH, INST ZOOL, WINTERTHURERSTR 190, CH-8057 ZURICH, SWITZERLAND.			Basler, Konrad/0000-0003-3534-1529				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1992, DEV BIOL, V152, P263, DOI 10.1016/0012-1606(92)90134-3; BOULIANNE GL, 1991, EMBO J, V10, P2975, DOI 10.1002/j.1460-2075.1991.tb07848.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRONNER G, 1991, MECH DEVELOP, V35, P205, DOI 10.1016/0925-4773(91)90019-3; BRYANT PJ, 1970, DEV BIOL, V22, P389, DOI 10.1016/0012-1606(70)90160-0; CARROLL SB, 1994, SCIENCE, V265, P109, DOI 10.1126/science.7912449; CASANOVA J, 1995, GENE DEV, V9, P2539, DOI 10.1101/gad.9.20.2539; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; COUSO JP, 1994, DEVELOPMENT, V120, P621; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; Dietrich U, 1984, J Neurogenet, V1, P315, DOI 10.3109/01677068409107094; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; LAWRENCE PA, 1996, IN PRESS DEVELOPMENT; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MCMAHON AP, 1989, DEVELOPMENT, V107, P161; Morgan T.H., 1897, ROUX ARCH DEV BIOL, V5, P570; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann CJ, 1996, DEVELOPMENT, V122, P1781; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; Roelink H, 1996, CURR OPIN NEUROBIOL, V6, P33, DOI 10.1016/S0959-4388(96)80006-7; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SLACK JMW, 1987, TRENDS BIOCHEM SCI, V12, P200, DOI 10.1016/0968-0004(87)90094-6; Spemann H., 1938, EMBRYONIC DEV INDUCT; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TREISMAN JE, 1995, DEVELOPMENT, V121, P3519; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; VINCENT JP, 1994, TRENDS GENET, V10, P383, DOI 10.1016/0168-9525(94)90040-X; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; WILDER EL, 1995, DEVELOPMENT, V121, P477; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; Wilson EB, 1925, CELL DEV INHERITANCE; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; XU T, 1993, DEVELOPMENT, V117, P1223; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZECCA M, 1995, DEVELOPMENT, V121, P2265	69	624	630	1	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					833	844		10.1016/S0092-8674(00)81991-1	http://dx.doi.org/10.1016/S0092-8674(00)81991-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945511	Green Accepted, hybrid			2022-12-01	WOS:A1996VV77400010
J	Barron, SL; Blain, P; Bullough, CHW; Carney, T; Gomersall, R; Herve, J; Hey, EN; Irani, A; Johnson, FS; Lamb, W; Lowry, MF; Lawson, JB; Layton, R; Morris, D; Morrell, P; Parsons, L; Reid, W; Ryall, A; Thomson, R; Platt, MW; Welch, RG; Wright, C; West, S; Wyllie, J; Young, G				Barron, SL; Blain, P; Bullough, CHW; Carney, T; Gomersall, R; Herve, J; Hey, EN; Irani, A; Johnson, FS; Lamb, W; Lowry, MF; Lawson, JB; Layton, R; Morris, D; Morrell, P; Parsons, L; Reid, W; Ryall, A; Thomson, R; Platt, MW; Welch, RG; Wright, C; West, S; Wyllie, J; Young, G			Collaborative survey of perinatal loss in planned and unplanned home births	BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL BIRTHS; DELIVERIES; SAFETY; PLACE	Objective-To document the outcome of planned and unplanned births outside hospital. Design-Confidential review of every pregnancy ending in stillbirth or neonatal death in which plans had been made for home delivery, irrespective of where delivery eventually occurred, The review was part of a sustained collaborative survey of all perinatal deaths. Setting-Northern Regional Health Authority area. Subjects-All 558 691 registered births to women normally resident in the former Northern Regional Health Authority area during 1981-94. Main outcome measure-Perinatal death. Results-The estimated perinatal mortality during 1981-94 among women booked for a home birth was 14 deaths in 2888 births. This was less than half that among all women in the region. Only three of the 14 women delivered outside hospital. Independent review suggested that two of the 14 deaths might have been averted by different management. Both births occurred in hospital, and in only one was management before admission of the mother judged inappropriate. Perinatal loss to the 64 women who booked for hospital delivery but delivered outside and to the 67 women who delivered outside hospital without ever making arrangements to receive professional care during labour accounted for the high perinatal mortality (134 deaths in 3466 deliveries) among all births outside hospital. Conclusions-The perinatal hazard associated with planned home birth in the few women who exercised this option (<1%) was low and mostly unavoidable. Health authorities purchasing maternity care need to address the much greater hazard associated with unplanned delivery outside hospital.	MATERN SURVEY OFF,NEWCASTLE TYNE NE2 4AA,TYNE & WEAR,ENGLAND									Anderson RE, 1995, J NURSE-MIDWIFERY, V40, P483, DOI 10.1016/0091-2182(95)00051-8; ATAULLAH I, 1990, COLLABORATIVE SURVEY; BARRON SL, 1977, BRIT J OBSTET GYNAEC, V84, P401, DOI 10.1111/j.1471-0528.1977.tb12614.x; CAMPBELL R, 1984, BRIT MED J, V289, P721, DOI 10.1136/bmj.289.6447.721; CAMPBELL R, 1994, TO BE BORN DEBATE EV; CAPLAN M, 1985, PUBLIC HEALTH, V99, P307, DOI 10.1016/S0033-3506(85)80066-4; COLE SK, 1995, J PUBLIC HEALTH MED, V17, P17; Davies J, 1996, BRIT MED J, V313, P1302; Department of Health, 1993, CHANGING CHILDBIRTH; DURAND AM, 1992, AM J PUBLIC HEALTH, V82, P450, DOI 10.2105/AJPH.82.3.450; FORD C, 1991, BRIT MED J, V303, P1517, DOI 10.1136/bmj.303.6816.1517; GLASIER A, 1992, BRIT MED J, V305, P476, DOI 10.1136/bmj.305.6851.476-c; HAFNEREATON C, 1994, J HEALTH POLIT POLIC, V19, P813, DOI 10.1215/03616878-19-4-813; HOFF GA, 1985, HASTINGS CENT REP, V15, P19, DOI 10.2307/3563065; HOLDSWORTH JE, 1989, BRIT MED J, V298, P1177, DOI 10.1136/bmj.298.6681.1177-b; *HOUS COMM HLTH CO, 1992, MAT SERV 2 REP SESS; JOHNSON M, 1992, BRIT MED J, V305, P255, DOI 10.1136/bmj.305.6847.255; LILFORD RJ, 1987, BRIT MED J, V295, P1298, DOI 10.1136/bmj.295.6609.1298; *MARK OP RES I, 1993, RES STUD COND DEP HL; MORGAN BM, 1984, BRIT J OBSTET GYNAEC, V91, P624, DOI 10.1111/j.1471-0528.1984.tb04820.x; MURPHY JF, 1984, BRIT MED J, V288, P1429, DOI 10.1136/bmj.288.6428.1429; *NHS MAN EX, 1994, EL949 NHS MAN EX; *NO REG HLTH AUTH, 1984, BRIT MED J, V288, P717; O'Brien M, 1978, J R Coll Gen Pract, V28, P460; Settatree RS, 1996, BRIT MED J, V312, P756; Shepperdson B, 1983, Health Visit, V56, P405; TAYLOR A, 1986, J ROY COLL GEN PRACT, V36, P157; TEW M, 1990, CHANGING CHILDBIRTH; TYSON H, 1991, BIRTH-ISS PERINAT C, V18, P14, DOI 10.1111/j.1523-536X.1991.tb00047.x; Woodcock H C, 1994, Midwifery, V10, P125, DOI 10.1016/0266-6138(94)90042-6	30	34	35	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1996	313	7068					1306	1309						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VV153	8942692				2022-12-01	WOS:A1996VV15300026
J	Baxter, GF; Sumeray, MS; Walker, JM				Baxter, GF; Sumeray, MS; Walker, JM			Infarct size and magnesium: Insights into LIMIT-2 and ISIS-4 from experimental studies	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; INTERVENTION-TRIAL LIMIT-2; INTRAVENOUS-MAGNESIUM; SULFATE; ARRHYTHMIAS; MODEL; REPERFUSION; THERAPY; HEART		UNIV LONDON SCH MED, LONDON WC1E 6DB, ENGLAND	University of London	Baxter, GF (corresponding author), UCL HOSP, DEPT ACAD & CLIN CARDIOL, HATTER INST, LONDON WC1E 6DB, ENGLAND.			Baxter, Gary/0000-0002-7887-6841; Walker, John Malcolm/0000-0002-8559-7218				ABRAHAM AS, 1987, ARCH INTERN MED, V147, P753, DOI 10.1001/archinte.147.4.753; BARROS LFM, 1995, INT J CARDIOL, V48, P3, DOI 10.1016/0167-5273(94)02208-Z; CEREMUZYNSKI L, 1989, AM HEART J, V118, P1333, DOI 10.1016/0002-8703(89)90027-6; CHANG C, 1985, J AM COLL CARDIOL, V5, P2622; CHRISTENSEN CW, 1995, CIRCULATION, V92, P2617, DOI 10.1161/01.CIR.92.9.2617; COLLINS R, 1995, LANCET, V345, P669; FELDSTEDT M, 1991, EUR HEART J, V12, P1215, DOI 10.1093/eurheartj/12.11.1215; FELDSTEDT M, 1988, European Heart Journal, V9, P226; HAIGNEY MCP, 1995, CIRCULATION, V92, P2190, DOI 10.1161/01.CIR.92.8.2190; HERZOG WR, 1995, CIRCULATION, V92, P2622, DOI 10.1161/01.CIR.92.9.2622; LEOR J, 1995, AM J CARDIOL, V75, P1292, DOI 10.1016/S0002-9149(99)80787-5; Morton B C, 1984, Magnesium, V3, P346; MORTON BC, 1981, MAGNESIUM-B, V1, P192; MORTON BC, 1984, MAGNESIUM-B, V4, P133; RASMUSSEN HS, 1986, LANCET, V1, P234; RASMUSSEN HS, 1988, CLIN CARDIOL, V11, P377, DOI 10.1002/clc.4960110604; SHATTOCK MJ, 1987, J AM COLL NUTR, V6, P27; SHECHTER M, 1990, AM J CARDIOL, V66, P271, DOI 10.1016/0002-9149(90)90834-N; SHECHTER M, 1995, AM J CARDIOL, V75, P391; SMITH LF, 1986, INT J CARDIOL, V12, P175, DOI 10.1016/0167-5273(86)90239-1; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; WOODS KL, 1994, LANCET, V343, P816, DOI 10.1016/S0140-6736(94)92024-9; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; WOODS KL, 1991, BRIT J CLIN PHARMACO, V32, P3, DOI 10.1111/j.1365-2125.1991.tb05605.x	24	32	32	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1424	1426		10.1016/S0140-6736(96)07281-9	http://dx.doi.org/10.1016/S0140-6736(96)07281-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937284				2022-12-01	WOS:A1996VU98600016
J	Wagner, JM; McKinney, WP; Carpenter, JL				Wagner, JM; McKinney, WP; Carpenter, JL			Does this patient have appendicitis?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE ABDOMINAL-PAIN; RIGHT LOWER QUADRANT; PHYSICAL-EXAMINATION; ACUTE ABDOMEN; DECISION-MAKING; SCORING SYSTEM; DIAGNOSTIC-ACCURACY; PRACTICAL SCORE; HISTORY-TAKING; APPENDECTOMY	Appendicitis is a common cause of abdominal pain for which prompt diagnosis is rewarded by a marked decrease in morbidity and mortality. The history and physical examination are at least as accurate as any laboratory modality in diagnosing or excluding appendicitis. Those signs and symptoms most helpful in diagnosing or excluding appendicitis are reviewed. The presence of a positive psoas sign, fever, or migratory pain to the right lower quadrant suggests an increased likelihood of appendicitis. Conversely, the presence of vomiting before pain makes appendicitis unlikely. The lack of the classic migration of pain, right lower quadrant pain, guarding, or fever makes appendicitis less likely, This article reviews the literature evaluating the operating characteristics of the most useful elements of the history and physical examination for the diagnosis of appendicitis.			Wagner, JM (corresponding author), UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.			Wagner, James/0000-0001-9903-6588				ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; ALVARADO A, 1986, ANN EMERG MED, V15, P557, DOI 10.1016/S0196-0644(86)80993-3; ANTEBY SO, 1975, ANN SURG, V181, P484, DOI 10.1097/00000658-197504000-00022; AVORN J, 1991, ARCH INTERN MED, V151, P694, DOI 10.1001/archinte.151.4.694; BALSANO N, 1990, Emergency Medicine Clinics of North America, V8, P399; BARR D, 1991, WORLD J SURG, V15, P526, DOI 10.1007/BF01675654; BERRY J, 1984, ANN SURG, V200, P567, DOI 10.1097/00000658-198411000-00002; BJERKE K, 1986, GUT, V27, P667, DOI 10.1136/gut.27.6.667; BOND GR, 1990, ANN EMERG MED, V19, P1014; BONGARD F, 1985, AM J SURG, V150, P90, DOI 10.1016/0002-9610(85)90015-7; BRAZAITIS MP, 1993, MED CLIN N AM, V77, P939; BREWER RJ, 1976, AM J SURG, V131, P219, DOI 10.1016/0002-9610(76)90101-X; Britt H, 1994, Aust Fam Physician, V23, P375; BUGLIOSI TF, 1990, ANN EMERG MED, V19, P1383, DOI 10.1016/S0196-0644(05)82602-2; BUSCHARD K, 1973, ACTA CHIR SCAND, V139, P293; CHANG FC, 1973, AM J SURG, V126, P752, DOI 10.1016/S0002-9610(73)80063-7; CHRISTIAN F, 1992, ANN ROY COLL SURG, V74, P281; DAVIES AH, 1991, BRIT J SURG, V78, P1178, DOI 10.1002/bjs.1800781010; DEDOMBAL FT, 1993, POSTGRAD MED J, V69, pS94; DEDOMBAL FT, 1991, DIAGNOSIS ACUTE ABDO, V2, P1; DIXON JM, 1991, BRIT MED J, V302, P386, DOI 10.1136/bmj.302.6773.386; DOMBAL FTD, 1974, BRIT MED J, V1, P376, DOI 10.1136/bmj.1.5904.376; ESKELINEN M, 1995, SCAND J GASTROENTERO, V30, P349, DOI 10.3109/00365529509093289; ESKELINEN M, 1994, INT J BIOMED COMPUT, V36, P239, DOI 10.1016/0020-7101(94)90059-0; FENYO G, 1982, AM J SURG, V143, P751, DOI 10.1016/0002-9610(82)90052-6; FENYO G, 1974, ACTA CHIR SCAND, V140, P396; FENYO G, 1987, ACTA CHIR SCAND, V153, P545; FRANZ MG, 1995, AM SURGEON, V61, P40; GAMAL R, 1990, AM J SURG, V159, P589, DOI 10.1016/S0002-9610(06)80073-5; HAMPTON JR, 1975, BRIT MED J, V2, P486, DOI 10.1136/bmj.2.5969.486; HENNINGTON MH, 1991, ANN SURG, V214, P61; HOUGHTON A, 1988, GASTROINTEST ENDOSC, V34, P489, DOI 10.1016/S0016-5107(88)71451-0; HOWIE JGR, 1966, LANCET, V2, P1334; IRVIN TT, 1989, BRIT J SURG, V76, P1121, DOI 10.1002/bjs.1800761105; IZBICKI JR, 1992, EUR J SURG, V158, P227; Jerman R P, 1969, Br J Clin Pract, V23, P466; JESS P, 1981, AM J SURG, V141, P232, DOI 10.1016/0002-9610(81)90164-1; JOHN H, 1993, WORLD J SURG, V17, P243, DOI 10.1007/BF01658936; JOHNSON JE, 1986, ARCH INTERN MED, V146, P937, DOI 10.1001/archinte.146.5.937; JONES PF, 1990, BRIT J SURG, V77, P365, DOI 10.1002/bjs.1800770404; KANG WM, 1989, SURGERY, V167, P187; KOLLIAS J, 1994, AUST NZ J SURG, V64, P830, DOI 10.1111/j.1445-2197.1994.tb04558.x; LAVELLE SM, 1990, INT J BIOMED COMPUT, V26, P203, DOI 10.1016/0020-7101(90)90043-T; LEWIS FR, 1975, ARCH SURG-CHICAGO, V110, P677; LIDDINGTON MI, 1991, BRIT J SURG, V78, P795, DOI 10.1002/bjs.1800780710; LIM HK, 1992, AM J ROENTGENOL, V159, P539, DOI 10.2214/ajr.159.3.1503019; LIN J, 1990, AM J MED, V89, P377, DOI 10.1016/0002-9343(90)90353-F; LOPEZNAVIDAD A, 1990, REV INFECT DIS, V12, P297; MAXWELL JM, 1991, AM SURGEON, V57, P282; MITTELPUNKT A, 1966, SURGERY, V60, P971; MORGAN DL, 1995, ANN EMERG MED, V25, P140; NADLER S, 1990, DIGEST DIS SCI, V35, P603, DOI 10.1007/BF01540408; NARDONE DA, 1988, SOUTH MED J, V81, P770, DOI 10.1097/00007611-198806000-00019; NAUTA RJ, 1986, AM J SURG, V151, P746, DOI 10.1016/0002-9610(86)90057-7; NEUTRA RR, 1978, MED CARE, V16, P956, DOI 10.1097/00005650-197811000-00006; OHMANN C, 1995, EUR J SURG, V161, P273; ORIENT JM, 1985, MED DECIS MAKING, V5, P77, DOI 10.1177/0272989X8500500116; OWENS BJ, 1978, ANN SURG, V187, P392, DOI 10.1097/00000658-197804000-00008; PELTOKALLIO P, 1970, ARCH SURG-CHICAGO, V100, P140; PETERSON MC, 1992, WESTERN J MED, V156, P163; POOLE GV, 1990, SOUTH MED J, V83, P771, DOI 10.1097/00007611-199007000-00013; PUTNAM TC, 1990, SURG GYNECOL OBSTET, V170, P527; PUYLAERT JBCM, 1987, NEW ENGL J MED, V317, P666, DOI 10.1056/NEJM198709103171103; RAMIREZ JM, 1994, BRIT J SURG, V81, P680, DOI 10.1002/bjs.1800810516; SACKETT KL, 1991, CLIN EPIDEMIOLOGY BA, V2, P173; SARFATI MR, 1993, AM J SURG, V166, P660, DOI 10.1016/S0002-9610(05)80675-0; SCHROCK TR, 1996, GASTROINTESTINAL DIS, P1339; SCHRODER DM, 1993, AM SURGEON, V59, P541; SCHWARTZ SI, 1987, NEW ENGL J MED, V317, P703, DOI 10.1056/NEJM198709103171109; SHEN GK, 1991, ARCH SURG-CHICAGO, V126, P569; SILEN W, 1987, COPES EARLY DIAGNOSI, V17, P1; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; STANILAND JR, 1972, BMJ-BRIT MED J, V3, P393, DOI 10.1136/bmj.3.5823.393; TAOUREL P, 1992, GASTROINTEST RADIOL, V17, P287, DOI 10.1007/BF01888571; TEICHER I, 1983, ANN SURG, V198, P753, DOI 10.1097/00000658-198312000-00014; TODD BS, 1993, MED INFORM, V18, P255, DOI 10.3109/14639239309025314; WADE DS, 1993, ARCH SURG-CHICAGO, V128, P1039; Wasson J H, 1981, Med Decis Making, V1, P215, DOI 10.1177/0272989X8100100302; WHITE JJ, 1975, AM SURGEON, V41, P793; WHITWORTH CM, 1988, SURG GYNECOL OBSTET, V167, P187; WIENER S, 1976, JAMA-J AM MED ASSOC, V236, P852, DOI 10.1001/jama.236.7.852; WILSON DH, 1977, BRIT J SURG, V64, P250, DOI 10.1002/bjs.1800640407	83	188	192	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1589	1594		10.1001/jama.276.19.1589	http://dx.doi.org/10.1001/jama.276.19.1589			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT025	8918857				2022-12-01	WOS:A1996VT02500032
J	Vinetz, JM; Glass, GE; Flexner, CE; Mueller, P; Kaslow, DC				Vinetz, JM; Glass, GE; Flexner, CE; Mueller, P; Kaslow, DC			Sporadic urban leptospirosis	ANNALS OF INTERNAL MEDICINE			English	Article						Leptospira interrogans; leptospirosis; urban population; rats; polymerase chain reaction	RISK-FACTORS; ROCHALIMAEA	Background: Surprisingly, many inner-city residents have antibodies to Leptospira interrogans. The manner in which these persons acquire this organism in the absence of recognized occupational, recreational, or epidemic risk factors is not known. Objective: To study the epidemiology of patients with leptospirosis who acquired L. interrogans in inner-city Baltimore, Maryland. Design: Epidemiologic investigation. Setting: Inner-city university hospital. Patients: Three inner-city residents who developed leptospirosis. Measurements: Trapping rats in alleys where the patients may have acquired L. interrogans; polymerase chain reaction (PCR) analysis of patient serum and cerebrospinal fluid specimens and rat tissues to determine the presence of leptospiral DNA; and serologic testing of serum from patients and rats by microagglutination assay to confirm L. interrogans infection. Results: Three patients developed leptospirosis after probable percutaneous exposure to rat (Rattus norvegicus) urine in Baltimore alleys. A PCR assay detected L. interrogans DNA in samples of body fluid obtained from the first two patients at presentation (one in cerebrospinal fluid, the other in serum). Results of PCR done on serum drawn from the third patient after antibiotic therapy began were negative. A microagglutination test showed that all patients had high levels of antibodies to the L. interrogans serogroup Icterohaemorrhagiae. In 19 of 21 rats that were trapped in the alleys where the patients had sustained lacerations before illness developed, kidney or brain tissues were positive by PCR for the presence of L. interrogans. Conclusions: A population was discovered to be at risk for acquiring L. interrogans: urban residents who are sporadically exposed to rat urine in the inner city. Inner-city rats often carry L. interrogans. Polymerase chain reaction can quickly establish the diagnosis of leptospirosis and is useful for epidemiologic study. An endemic substrate for the transmission of the organism is present in inner-city Baltimore. Leptospirosis may become increasingly recognized in deteriorating inner cities in which rat populations are expanding.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT MOL MICROBIOL & IMMUNOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21287 USA; NIH, BETHESDA, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA	Vinetz, JM (corresponding author), NIAID, PARASIT DIS LAB, 9000 ROCKVILLE PIKE, BLDG 4, ROOM 126, BETHESDA, MD 20892 USA.			Vinetz, Joseph/0000-0001-8344-2004				BABUDIERI B, 1958, ANN NY ACAD SCI, V70, P393, DOI 10.1111/j.1749-6632.1958.tb35398.x; CACCIAPUOTI B, 1994, EUR J EPIDEMIOL, V10, P173, DOI 10.1007/BF01730367; CHILDS JE, 1992, AM J PUBLIC HEALTH, V82, P597, DOI 10.2105/AJPH.82.4.597; COLE JR, 1973, APPL MICROBIOL, V25, P976, DOI 10.1128/AEM.25.6.976-980.1973; DEMERS RY, 1983, J FAM PRACTICE, V17, P1007; DRANCOURT M, 1995, NEW ENGL J MED, V332, P419, DOI 10.1056/NEJM199502163320702; EDWARDS GA, 1964, MEDICINE, V39, P117; FARR RW, 1995, CLIN INFECT DIS, V21, P1, DOI 10.1093/clinids/21.1.1; FEIGIN RD, 1973, ANN INTERN MED, V79, P777, DOI 10.7326/0003-4819-79-6-777; GRAVEKAMP C, 1993, J GEN MICROBIOL, V139, P1691, DOI 10.1099/00221287-139-8-1691; HEATH CW, 1965, NEW ENGL J MED, V273, P857, DOI 10.1056/NEJM196510142731606; MERIEN F, 1995, J INFECT DIS, V172, P281, DOI 10.1093/infdis/172.1.281; MORSE SS, 1995, EMERG INFECT DIS, V1, P7, DOI 10.3201/eid0101.950102; RELMAN DA, 1995, NEW ENGL J MED, V332, P463, DOI 10.1056/NEJM199502163320710; SASAKI DM, 1993, AM J TROP MED HYG, V48, P35, DOI 10.4269/ajtmh.1993.48.35; SPACH DH, 1995, NEW ENGL J MED, V332, P424, DOI 10.1056/NEJM199502163320703; STARR L, 1992, BIOTECHNIQUES, V13, P612; TORTEN M, 1994, HDB ZOONOSES A, P245; Zaki SR, 1996, LANCET, V347, P535, DOI 10.1016/S0140-6736(96)91167-8; 1972, MMWR-MORBID MORTAL W, V21, P401; 1994, MMWR-MORBID MORTAL W, V42, P36; 1995, MMWR-MORBID MORTAL W, V44, P841	22	170	175	0	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					794	+		10.7326/0003-4819-125-10-199611150-00002	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928985				2022-12-01	WOS:A1996VU52400005
J	Benhamou, Y; Katlama, C; Lunel, F; Coutellier, A; Dohin, E; Hamm, N; Tubiana, R; Herson, S; Poynard, T; Opolon, P				Benhamou, Y; Katlama, C; Lunel, F; Coutellier, A; Dohin, E; Hamm, N; Tubiana, R; Herson, S; Poynard, T; Opolon, P			Effects of lamivudine on replication of hepatitis B virus in HIV-infected men	ANNALS OF INTERNAL MEDICINE			English	Article						hepatitis B; human immunodeficiency; virus infections; lamivudine; virus replication; comorbidity	HUMAN-IMMUNODEFICIENCY-VIRUS; CHRONIC ACTIVE HEPATITIS; ALPHA-INTERFERON; SURVIVAL; CARRIERS; EFFICACY; INVITRO; THERAPY; TRIAL	Background: Therapy for hepatitis B virus (HBV) infection is still unsatisfactory, particularly in patients who are co-infected with the human immunodeficiency virus (HIV). Lamivudine, a retroviral inhibitor, has been shown to have activity against HBV replication in vitro, in animal models, and in studies of immunocompetent persons. Objective: To assess the efficacy of lamivudine in inhibiting HBV replication during a 12-month period in patients with both HBV and HIV infection. Design: Prospective, open study. Setting: University hospital. Patients: 40 consecutive patients (39 men and 1 woman) infected with both HIV and HBV. All had progressive HIV disease; were refractory to or unable to tolerate therapies other than lamivudine; and received lamivudine, 600 mg/d or 600 mg/d followed by 300 mg/d, as therapy for HIV disease. Measurements: Serum concentrations of HBV DNA were assessed every 2 months by using molecular hybridization. Polymerase chain reaction (PCR) for HBV DNA was done at baseline and was done at months 2, 6, and 12 only if the HBV DNA concentration was less than 5 pg/mL. Results: Two groups were retrospectively identified at baseline: patients with high HBV replication (serum HBV DNA concentrations >5 pg/mL) (n = 30) and patients with low HBV replication (serum HBV DNA concentrations <5 pg/mL) (n = 10). After 12 months of treatment, 26 of 27 patients (96.3% [95% Cl, 81% to 99.9%]) who had had high HBV replication at baseline had serum HBV DNA concentrations less than 5 pg/mL. However, PCR could still detect HBV DNA in serum in 11.5% (Cl, 2% to 30%) of these patients. Among patients who had had low HBV replication at baseline, the results of PCR for serum HBV DNA became negative in the 6 patients who had had a positive result on PCR at baseline. No serious adverse events occurred during treatment. Conclusion: Although this study was not a randomized, blinded trial, it suggests that lamivudine is active against HBV replication in men infected with both HBV and HIV.	GRP HOSP PITIE SALPETRIERE, SERV MALAD INFECT, F-75651 PARIS 13, FRANCE; HOP LA PITIE SALPETRIERE, VIROL LAB, F-75651 PARIS 13, FRANCE; HOP LA PITIE SALPETRIERE, SERV MED INTERNE, F-75651 PARIS 13, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Benhamou, Y (corresponding author), GRP HOSP PITIE SALPETRIERE, SERV HEPATOGASTROENTEROL, 47 BLVD HOP, F-75651 PARIS 13, FRANCE.		françoise, lunel/B-7273-2015; Poynard, Thierry/C-1355-2010	françoise, lunel/0000-0002-1856-0300; Poynard, Thierry/0000-0002-3726-7230; Poynard, Thierry/0000-0002-2050-640X				[Anonymous], 1992, MMWR Recomm Rep, V41, P1; ANTINORI S, 1993, J HEPATOL, V18, P255, DOI 10.1016/S0168-8278(05)80254-5; ASHMAN C, 1994, 6 INT S VIR HEP MADR, P65; BROOK MG, 1989, HEPATOLOGY, V10, P761, DOI 10.1002/hep.1840100502; BROOK MG, 1988, VIRAL HEPATITIS LIVE, P906; CHANG CN, 1992, J BIOL CHEM, V267, P22414; CHOSSEGROS P, 1993, GASTROENTEROLOGY, V104, pA888; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P202, DOI 10.1128/AAC.36.1.202; DEJONGH FE, 1992, GASTROENTEROLOGY, V103, P1630, DOI 10.1016/0016-5085(92)91188-A; DIANZANI F, 1993, GUT, V34, pS74, DOI 10.1136/gut.34.2_Suppl.S74; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; FRIED MW, 1992, HEPATOLOGY, V20, pA209; GARCIA F, 1995, J CLIN MICROBIOL, V33, P413, DOI 10.1128/JCM.33.2.413-415.1995; KANE MA, 1993, GUT, V34, pS10, DOI 10.1136/gut.34.2_Suppl.S10; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KROGSGAARD K, 1987, HEPATOLOGY, V7, P37, DOI 10.1002/hep.1840070109; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; MARCELLIN P, 1989, HEPATOLOGY, V10, P328, DOI 10.1002/hep.1840100313; MARCELLIN P, 1989, NEW ENGL J MED, V321, P1758; MCDONALD JA, 1987, HEPATOLOGY, V7, P719, DOI 10.1002/hep.1840070417; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; MONNO L, 1988, VIRAL HEPATITIS LIVE, P205; PERRILLO RP, 1986, ANN INTERN MED, V105, P382, DOI 10.7326/0003-4819-105-3-382; RUSTGI VK, 1984, ANN INTERN MED, V101, P795, DOI 10.7326/0003-4819-101-6-795; Taylor PE, 1988, VIRAL HEPATITIS LIVE, P198; TYRRELL DL, 1993, CLIN INVEST MED S4, V16, P877; VANLEEUWEN R, 1995, J INFECT DIS, V171, P1166, DOI 10.1093/infdis/171.5.1166; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; WONG DKH, 1995, GASTROENTEROLOGY, V108, P165, DOI 10.1016/0016-5085(95)90021-7	31	135	137	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					705	+		10.7326/0003-4819-125-9-199611010-00001	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929003				2022-12-01	WOS:A1996VQ07200001
J	Zamponi, GW; Bourinet, E; Nelson, D; Nargeot, J; Snutch, TP				Zamponi, GW; Bourinet, E; Nelson, D; Nargeot, J; Snutch, TP			Crosstalk between G proteins and protein kinase C mediated by the calcium channel alpha(1) subunit	NATURE			English	Article							CA2+ CHANNELS; SYNAPTIC TRANSMISSION; N-TYPE; SUBCELLULAR-DISTRIBUTION; RECEPTOR INHIBITION; SYMPATHETIC NEURONS; BETA-SUBUNIT; K+ CHANNEL; MODULATION; RAT	The modulation of voltage-dependent Ca2+ channels at presynaptic nerve terminals is an important factor in the control of neurotranmitter release and synaptic efficacy, Some terminals contain multiple Ca2+-channel subtypes (N and P/Q)(1-3), which are differentially regulated by G-protein activation(4-8) and by protein kinase C (PKC)-dependent phosphorylation(9-11). Regulation of channel activity by crosstalk between second messenger pathways has been reported(12,13), although the molecular mechanisms underlying crosstalk have not been described. Here we show that crosstalk occurs at the level of the presynaptic Ca2+-channel complex. The alpha(1) subunit domain I-II linker, which connects the first and second transmembrane domains, contributes to the PKC-dependent upregulation of channel activity, while G-protein-dependent inhibition occurs through binding of G beta gamma to two sites in the I-II linker, Crosstalk results from the PKC-dependent phosphorylation of one of the G beta gamma binding sites which antagonizes G beta gamma-induced inhibition. The results provide a mechanism for the highly regulated and dynamic control of neurotransmitter release that depends on bite integration of multiple presynaptic signals.	UNIV BRITISH COLUMBIA, BIOTECHNOL LAB, VANCOUVER, BC V6T 1Z3, CANADA; CNRS, CRBM, F-34033 MONTPELLIER, FRANCE	University of British Columbia; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Snutch, Terrance P/L-3464-2019	Snutch, Terrance P/0000-0001-5182-1296; Nargeot, Joel/0000-0003-2893-5636; bourinet, emmanuel/0000-0001-8021-0419; Zamponi, Gerald W./0000-0002-0644-9066				BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; CAMPBELL V, 1995, J PHYSIOL-LONDON, V485, P365, DOI 10.1113/jphysiol.1995.sp020735; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; DASCAL N, 1995, P NATL ACAD SCI USA, V92, P6758, DOI 10.1073/pnas.92.15.6758; DEWAARD M, NATURE; DOLPHIN AC, 1995, EXP PHYSIOL, V80, P1; DOLPHIN AC, 1986, J PHYSIOL-LONDON, V373, P47, DOI 10.1113/jphysiol.1986.sp016034; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; RHIM H, 1994, J NEUROSCI, V14, P7608; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; ZHU Y, 1994, J NEUROPHYSIOL, V72, P1549, DOI 10.1152/jn.1994.72.4.1549	27	391	401	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 30	1997	385	6615					442	446		10.1038/385442a0	http://dx.doi.org/10.1038/385442a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009192				2022-12-01	WOS:A1997WF00700054
J	Benador, D; Benador, N; Slosman, D; Mermillod, B; Girardin, E				Benador, D; Benador, N; Slosman, D; Mermillod, B; Girardin, E			Are younger children at highest risk of renal sequelae after pyelonephritis?	LANCET			English	Article							URINARY-TRACT INFECTION; SCINTIGRAPHY; REFLUX	Background The general belief about the relation between risk of renal sequelae after pyelonephritis and age is that infants are at highest risk and children older than 5 years at tower risk. This assumption has led to differences in treatment based on age. The aim of this prospective study was to investigate the occurrence of renal lesions in children aged 0-16 years. Methods Between May, 1994, and January, 1996, all children aged 0-16 years who were admitted to our department with a diagnosis of probable pyelonephritis and a positive urine culture were included in this prospective study. All patients received antibiotics for 7-21 days. During the acute phase of urinary-tract infection, scintigraphy with technetium-99m-dimercaptosuccinic acid (DMSA) and ultrasonography were done. Voiding cystourethrography was undertaken at least 6 weeks after the end of antibiotic treatment. When scintigraphy showed renal parenchymal lesions, repeat scintigraphy was done after at least 2 months to assess the progression of renal lesions. For the analysis, children were grouped by age according to presumed risk of renal sequelae after pyelonephritis: high risk (<1 year), moderate risk (1-5 years), low risk (>5 years). Findings 201 patients were enrolled in the study (119 <1 year, 47 aged 1-5 years, 35 >5 years). During the acute phase of urinary-tract infection, renal lesions were found in 66 (55%) infants under 1 year, in 37 (79%) children aged 1-5 years, and in 24 (69%) children older than 5 years. Of these 127 children, 108 underwent repeat scintigraphy after an average of 3 months (50 <1 year, 36 aged 1-5 years, 22 >5 years). Overall, renal scars were found on repeat scintigraphy in 20 (40%) infants under 1 year, in 31 (86%) children aged 1-5 years, and in 14 (64%) children older than 5 years. 38 (36%) of these 65 patients had vesicoureteric reflux. Among 88 children who had a first documented urinary-tract infection and underwent repeat scintigraphy, renal scars were found in 20 (43%) under 1 year, in 26 (84%) aged 1-5 years, and in eight (80%) older than 5 years. Interpretation This study did not confirm the conventional view that the risk of renal scars after pyelonephritis diminishes with age, We believe that ail children, irrespective of age, will benefit from any measure that prevents the development of renal sequelae.	HOP CANTONAL GENEVA,DEPT RADIOL,CH-1211 GENEVA 14,SWITZERLAND; HOP CANTONAL GENEVA,DEPT INFORMAT,CH-1211 GENEVA 14,SWITZERLAND	University of Geneva; University of Geneva	Benador, D (corresponding author), HOP CANTONAL GENEVA,DEPT PAEDIAT,CH-1211 GENEVA 14,SWITZERLAND.			Girardin, Eric/0000-0002-5443-3640				BENADOR D, 1994, J PEDIATR-US, V124, P17, DOI 10.1016/S0022-3476(94)70248-9; CHABAN C, 1995, INFECT UROL, V8, P114; FRASER IR, 1995, CLIN NEPHROL, V43, P159; GLAUSER MP, 1987, PEDIATR NEPHROL, V1, P615, DOI 10.1007/BF00853599; GLEESON FV, 1991, ARCH DIS CHILD, V66, P1282, DOI 10.1136/adc.66.11.1282; GOLDRAICH NP, 1989, PEDIATR NEPHROL, V3, P1, DOI 10.1007/BF00859614; GORDON I, 1995, LANCET, V346, P489, DOI 10.1016/S0140-6736(95)91328-9; HAYCOCK GB, 1986, ARCH DIS CHILD, V61, P1155, DOI 10.1136/adc.61.12.1155; HOBERMAN A, 1993, J PEDIATR-US, V123, P17, DOI 10.1016/S0022-3476(05)81531-8; JACOBSON SH, 1989, BMJ-BRIT MED J, V299, P703, DOI 10.1136/bmj.299.6701.703; JAKOBSSON B, 1992, ARCH DIS CHILD, V67, P1338, DOI 10.1136/adc.67.11.1338; MARTINELL J, 1995, PEDIATR NEPHROL, V9, P131, DOI 10.1007/BF00860724; MERRICK MV, 1980, BRIT J RADIOL, V53, P544, DOI 10.1259/0007-1285-53-630-544; OIBING H, 1992, J UROLOGY, V148, P1653; PATEL K, 1993, PEDIATR RADIOL, V23, P506, DOI 10.1007/BF02012131; RUSHTON HG, 1992, J UROLOGY, V148, P1726, DOI 10.1016/S0022-5347(17)37014-3; SMELLIE J, 1975, KIDNEY INT, V8, P565; SMELLIE JM, 1985, BRIT MED J, V290, P1957, DOI 10.1136/bmj.290.6486.1957; SPENCER JR, 1986, UROL CLIN N AM, V13, P661	19	149	154	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					17	19		10.1016/S0140-6736(96)06126-0	http://dx.doi.org/10.1016/S0140-6736(96)06126-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988117				2022-12-01	WOS:A1997WA72500011
J	Lane, ME; Sauer, K; Wallace, K; Jan, YN; Lehner, CF; Vaessin, H				Lane, ME; Sauer, K; Wallace, K; Jan, YN; Lehner, CF; Vaessin, H			Dacapo, a cyclin-dependent kinase inhibitor, stops cell proliferation during Drosophila development	CELL			English	Article							DNA-SYNTHESIS; POTENTIAL MEDIATOR; P21; EXPRESSION; CDK; DIFFERENTIATION; EMBRYOGENESIS; GENE; P21(CIP1); PROTEIN	Most cell types in multicellular eukaryotes exit from the mitotic cell cycle before terminal differentiation. We show that the dacapo gene is required to arrest the epidermal cell proliferation at the correct developmental stage during Drosophila embryogenesis. dacapo encodes an inhibitor of cyclin E/cdk2 complexes with similarity to the vertebrate Cip/Kip inhibitors. dacapo is transiently expressed beginning late in the G2 phase preceding the terminal division (mitosis 16). Mutants unable to express the inhibitor fail to arrest cell proliferation after mitosis 16 and progress through an extra division cycle. Conversely, premature dacapo expression in transgenic embryos results in a precocious G1 arrest.	MAX PLANCK GESELL,FRIEDRICH MIESCHER LAB,D-72076 TUBINGEN,GERMANY; OHIO STATE UNIV,DEPT MOL GENET,CTR NEUROBIOTECHNOL,COLUMBUS,OH 43210; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Eberhard Karls University of Tubingen; Max Planck Society; University System of Ohio; Ohio State University; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Wallace, Kenneth/0000-0001-7897-6984; Jan, Yuh Nung/0000-0003-1367-6299				BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chen IT, 1996, ONCOGENE, V12, P595; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FINLEY RL, 1996, JP NATL ACAD SCI US, V93, P3011; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HEBERLEIN U, 1995, CELL, V81, P987, DOI 10.1016/S0092-8674(05)80003-0; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; JIANG HP, 1994, ONCOGENE, V9, P3397; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SAUER K, 1996, IN PRESS MOL BIOL CE; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SMITH AV, 1991, DEVELOPMENT, V112, P997; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	49	276	276	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1225	1235		10.1016/S0092-8674(00)81818-8	http://dx.doi.org/10.1016/S0092-8674(00)81818-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980229	Bronze			2022-12-01	WOS:A1996WA54100011
J	Davies, E; Clarke, C; Hopkins, A				Davies, E; Clarke, C; Hopkins, A			Malignant cerebral glioma .2. Perspectives of patients and relatives on the value of radiotherapy	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; CANCER-PATIENTS; BAD-NEWS; CHEMOTHERAPY; PREFERENCES; COMMUNICATE; HEALTHY; TRIAL	Objective-To explore the experiences patients and relatives after the diagnosis treatment of malignant cerebral glioma. Design-Two year prospective study with home interviews, Setting-Six neurosurgery and radiotherapy centres in London, Subjects-75 patients and 66 close relatives interviewed at diagnosis, 58 patients interviewed after radiotherapy, and 27 interviewed after recurrence, Main outcome measures-Awareness of likely prognosis, distress, dissatisfaction with radiotherapy and perception of severe problems in everyday life, Results-As they began radiotherapy most patients understood that they suffered from a brain tumour (95%; 71/75), but only one quarter (19/75) seemed fully aware of the poor prognosis. Others were unaware (43%; 32/75) or only partly aware (32%; 24/75), The more aware patients were more distressed. Relatives were three times more Likely to be aware of the prognosis (67%; 44/66) and were more distressed, Although 39% (29/75) of patients initially made negative comments about radiotherapy, only 17% (13/75) were completely dissatisfied, The decision to accept radiotherapy could be discussed directly with 19 fully aware patients, Twelve found radiotherapy acceptable if it were medically advised or if it improved survival. Assessed by their own reports of problems only 40% of patients achieved a period of stability or remission, yet dissatisfaction with treatment did not increase. Conclusion-Most patients with malignant glioma initially seemed unaware or only partly aware of the poor prognosis. Relatives were more aware, more distressed, and often concerned to protect patients from full awareness, which made it difficult to explore with patients directly the possible trade off between quality and length of life, Conceptualising the question as a rational choice ignores the social and emotional context of life threatening disease.	UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL, DIRECTORATE NEUROSURG & CLIN NEUROSCI, LONDON EC1A 7BE, ENGLAND	University of London; Queen Mary University London	Davies, E (corresponding author), ROYAL COLL PHYSICIANS, RES UNIT, LONDON NW1 4LE, ENGLAND.			Davies, Elizabeth/0000-0003-2325-0849				BLEEHEN NM, 1991, BRIT J CANCER, V64, P769, DOI 10.1038/bjc.1991.396; BREETVELT IS, 1991, SOC SCI MED, V32, P981, DOI 10.1016/0277-9536(91)90156-7; BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491; Brown G., 1978, SOCIAL ORIGINS DEPRE; BROWN GW, 1966, HUM RELAT, V19, P241, DOI 10.1177/001872676601900301; CASSILETH BR, 1984, NEW ENGL J MED, V311, P506, DOI 10.1056/NEJM198408233110805; Davies E, 1996, BRIT MED J, V313, P1507, DOI 10.1136/bmj.313.7071.1507; DAVIES E, 1993, NEUROLOGICAL REHABIL, P535; EBRAHIM S, 1995, SOC SCI MED, V41, P1383, DOI 10.1016/0277-9536(95)00116-O; FALLOWFIELD L, 1995, PSYCHO-ONCOLOGY, V4, P197, DOI 10.1002/pon.2960040305; FALLOWFIELD L, 1993, LANCET, V341, P476, DOI 10.1016/0140-6736(93)90219-7; Glaser B.G., 1966, AWARENESS DYING; *GOV COMM, 1992, CHOIC HLTH CAR; Hinton J, 1972, DYING; KREITLER S, 1993, SOC SCI MED, V36, P547, DOI 10.1016/0277-9536(93)90415-Z; KUBLERROSS E, 1992, DEATH DYING; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; MAGUIRE P, 1988, BRIT MED J, V297, P972, DOI 10.1136/bmj.297.6654.972; MAGUIRE P, 1988, BRIT MED J, V297, P907, DOI 10.1136/bmj.297.6653.907; MCGEE HM, 1991, PSYCHOL MED, V21, P749, DOI 10.1017/S0033291700022388; OBOYLE CA, 1992, LANCET, V339, P1088, DOI 10.1016/0140-6736(92)90673-Q; OCONNOR AM, 1989, J CLIN EPIDEMIOL, V42, P119, DOI 10.1016/0895-4356(89)90085-1; Office of Population Censuses and Surveys, 1991, STAND OCC CLASS; ROSSER R, 1992, MEASURES QUALITY LIF, P81; ROSSER RM, 1990, MEASURING OUTCOMES M, P1; *ROYAL COLL PHYS, 1995, SETT PRIOR NHS FRAM; Salander P, 1996, SOC SCI MED, V42, P985, DOI 10.1016/0277-9536(95)00204-9; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; WALKER MD, 1978, J NEUROSURG, V49, P333, DOI 10.3171/jns.1978.49.3.0333; Williams A, 1992, MEASURES QUALITY LIF, P21; World Health Organisation, 1979, HDB REP RES CANC TRE	31	58	58	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 14	1996	313	7071					1512	1516		10.1136/bmj.313.7071.1512	http://dx.doi.org/10.1136/bmj.313.7071.1512			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VY691	8978225	Green Published			2022-12-01	WOS:A1996VY69100017
J	Koyama, H; Raines, EW; Bornfeldt, KE; Roberts, JM; Ross, R				Koyama, H; Raines, EW; Bornfeldt, KE; Roberts, JM; Ross, R			Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors	CELL			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; CYCLIN-DEPENDENT KINASES; EXTRACELLULAR-MATRIX; CELL-CYCLE; SIGNALING PATHWAYS; GROWTH; RAPAMYCIN; ACTIVATION; EXPRESSION; INTEGRIN	Arterial smooth muscle cells (SMCs) are arrested in the G1 phase of the cell cycle on polymerized type I collagen fibrils, while monomer collagen supports SMC proliferation. Cyclin E-associated kinase and cyclin-dependent kinase 2 (cdk2) phosphorylation are inhibited on polymerized collagen, and levels of the cdk2 inhibitors p27(Kip1) p21(Cip1/Waf1) increased compared with SMCs on monomer collagen. p27(Kip1) associates with the cyclin E-cdk2-p21(Cip1/Waf1) complex in SMCs on polymerized collagen. Monovalent blocking antibodies to alpha 2 integrins, integrins that mediate adhesion to both forms of collagen, mimic these effects on monomer collagen. Furthermore, polymerized collagen rapidly suppresses p70 S6 kinase, a possible regulator of p27(Kip1). Thus, fibrillar collagen specifically regulates early integrin signaling that may lead to up-regulation of cdk2 inhibitors and inhibition of SMC proliferation.	FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	Koyama, H (corresponding author), UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195, USA.		Koyama, Hidenori/AAU-2346-2020; Bornfeldt, Karin/AAI-2241-2019	Koyama, Hidenori/0000-0001-7930-2228; Bornfeldt, Karin/0000-0001-9208-6523	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ALBERS MW, 1993, J BIOL CHEM, V268, P22825; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COULTER A, 1983, J IMMUNOL METHODS, V59, P199, DOI 10.1016/0022-1759(83)90031-5; CYBULSKY AV, 1993, AM J PHYSIOL, V264, pC323, DOI 10.1152/ajpcell.1993.264.2.C323; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HANSEN LK, 1994, MOL BIOL CELL, V5, P967, DOI 10.1091/mbc.5.9.967; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MARTIN GR, 1990, PEPTIDE GROWTH FACTO, P463; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORICE WG, 1993, J BIOL CHEM, V268, P22737; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P50755; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; REKHTER MD, 1995, AM J PATHOL, V147, P668; RHUDY RW, 1988, J CELL PHYSIOL, V137, P185, DOI 10.1002/jcp.1041370123; SCHOR SL, 1980, J CELL SCI, V41, P159; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SKINNER MP, 1994, AM J PATHOL, V145, P1070; SPORN MB, 1990, PEPTIDE GROWTH FACTO, P3; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	45	442	451	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1069	1078		10.1016/S0092-8674(00)81801-2	http://dx.doi.org/10.1016/S0092-8674(00)81801-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978611	Bronze			2022-12-01	WOS:A1996VY44700012
J	Blanas, E; Carbone, FR; Allison, J; Miller, JFAP; Heath, WR				Blanas, E; Carbone, FR; Allison, J; Miller, JFAP; Heath, WR			Induction of autoimmune diabetes by oral administration of autoantigen	SCIENCE			English	Article							COLLAGEN-INDUCED ARTHRITIS; MYELIN BASIC-PROTEIN; CD8(+) T-CELLS; II COLLAGEN; VIRUS-INFECTION; NOD MICE; TOLERANCE; INSULIN; SUPPRESSION; ANTIGEN	An antigen administered orally can induce immunological tolerance to a subsequent challenge with the same antigen. Evidence has been provided for the efficacy of this approach in the treatment of human autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. However, oral administration of autoantigen in mice was found to induce a cytotoxic T lymphocyte response that could lead to the onset of autoimmune diabetes. Thus, feeding autoantigen can cause autoimmunity, which suggests that caution should be used when applying this approach to the treatment of human autoimmune diseases.	WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA; ALFRED HOSP, MONASH MED SCH, PRAHRAN, VIC 3181, AUSTRALIA	Walter & Eliza Hall Institute; Florey Institute of Neuroscience & Mental Health; Monash University			Carbone, Francis/ABF-2141-2020	Heath, William/0000-0001-9670-259X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029385] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-29385] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRETT SP, 1995, EUR J IMMUNOL, V25, P2686, DOI 10.1002/eji.1830250943; Bennett S. N. L., UNPUB; BERGEROT I, 1994, J AUTOIMMUN, V7, P655, DOI 10.1006/jaut.1994.1050; BITAR DM, 1988, CELL IMMUNOL, V112, P364, DOI 10.1016/0008-8749(88)90305-X; BLANAS E, UNPUB; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CHALLACOMBE SJ, 1980, J EXP MED, V152, P1459, DOI 10.1084/jem.152.6.1459; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; GARSIDE P, 1995, INT IMMUNOL, V7, P501, DOI 10.1093/intimm/7.3.501; HANCOCK WW, 1995, AM J PATHOL, V147, P1193; HARRISON LC, 1995, MOL MED, V1, P722, DOI 10.1007/BF03401887; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; HEATH WR, 1995, J IMMUNOL, V155, P2339; HEHMKE B, 1995, DIABETES, V44, P1414, DOI 10.2337/diabetes.44.12.1414; HIGGINS PJ, 1988, J IMMUNOL, V140, P440; Hogan B., 1986, MANIPULATING MOUSE E; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; ITOH N, 1993, J CLIN INVEST, V92, P2313, DOI 10.1172/JCI116835; Ke Y, 1996, J IMMUNOL, V156, P916; KHARE SD, 1995, J IMMUNOL, V155, P3653; LAMONT AG, 1989, IMMUNOLOGY, V66, P595; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; NAGLERANDERSON C, 1986, P NATL ACAD SCI USA, V83, P7443, DOI 10.1073/pnas.83.19.7443; NUSSENBLATT RB, 1990, J IMMUNOL, V144, P1689; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; THOMPSON HSG, 1986, CLIN EXP IMMUNOL, V64, P581; THOMPSON HSG, 1990, IMMUNOL TODAY, V11, P396; TITUS RG, 1981, INT ARCH ALLER A IMM, V65, P323, DOI 10.1159/000232772; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; VAZ NM, 1977, J ALLERGY CLIN IMMUN, V60, P110, DOI 10.1016/0091-6749(77)90035-5; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; ZHANG ZJ, 1992, FASEB J, V6, pA1693; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	35	220	246	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1996	274	5293					1707	1709		10.1126/science.274.5293.1707	http://dx.doi.org/10.1126/science.274.5293.1707			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939860				2022-12-01	WOS:A1996VW71200059
J	vanVreeswijk, C; Sompolinsky, H				vanVreeswijk, C; Sompolinsky, H			Chaos in neuronal networks with balanced excitatory and inhibitory activity	SCIENCE			English	Article							NEURAL NETWORK; NOISE	Neurons in the cortex of behaving animals show temporally irregular spiking patterns. The origin of this irregularity and its implications for neural processing are unknown. The hypothesis that the temporal variability in the firing of a neuron results from an approximate balance between its excitatory and inhibitory inputs was investigated theoretically, Such a balance emerges naturally in large networks of excitatory and inhibitory neuronal populations that are sparsely connected by relatively strong synapses. The resulting state is characterized by strongly chaotic dynamics, even when the external inputs to the network are constant in time. Such a network exhibits a linear response, despite the highly nonlinear dynamics of single neurons, and reacts to changing external stimuli on time scales much smaller than the integration time constant of a single neuron.	HEBREW UNIV JERUSALEM,CTR NEURAL COMPUTAT,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	vanVreeswijk, C (corresponding author), HEBREW UNIV JERUSALEM,RACAH INST PHYS,IL-91904 JERUSALEM,ISRAEL.		Sompolinsky, Haim/ABB-8398-2021					ABELES M, UNPUB; AMIT DJ, IN PRESS CEREB CORTE; BELL A, 1994, SOC NEUR ABSTR, V20, P1527; BURNS BD, 1976, PROC R SOC SER B-BIO, V194, P211, DOI 10.1098/rspb.1976.0074; Bush PC, 1991, NEURAL COMPUT, V3, P19, DOI 10.1162/neco.1991.3.1.19; DERRIDA B, 1987, EUROPHYS LETT, V4, P167, DOI 10.1209/0295-5075/4/2/007; DOUGLAS RJ, 1991, TRENDS NEUROSCI, V14, P286, DOI 10.1016/0166-2236(91)90139-L; HANSEL D, 1992, PHYS REV LETT, V68, P718, DOI 10.1103/PhysRevLett.68.718; HANSEL D, 1996, J COMPUT NEUROSCI, V3, P5; Holt GR, 1996, J NEUROPHYSIOL, V75, P1806, DOI 10.1152/jn.1996.75.5.1806; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; Shadlen M N, 1995, Curr Opin Neurobiol, V5, P248, DOI 10.1016/0959-4388(95)80033-6; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; Softky W R, 1995, Curr Opin Neurobiol, V5, P239, DOI 10.1016/0959-4388(95)80032-8; SOFTKY WR, 1993, J NEUROSCI, V13, P334; SOMPOLINSKY H, 1988, PHYS REV LETT, V61, P259, DOI 10.1103/PhysRevLett.61.259; TSODYKS MV, 1995, NETWORK-COMP NEURAL, V6, P111, DOI 10.1088/0954-898X/6/2/001	17	1058	1064	6	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1724	1726						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939866				2022-12-01	WOS:A1996VW71200065
J	Wiertz, EJHJ; Tortorella, D; Bogyo, M; Yu, J; Mothes, W; Jones, TR; Rapoport, TA; Ploegh, HL				Wiertz, EJHJ; Tortorella, D; Bogyo, M; Yu, J; Mothes, W; Jones, TR; Rapoport, TA; Ploegh, HL			Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction	NATURE			English	Article							CLASS-I MOLECULES; LIGHT-CHAINS; DEGRADATION; TRANSLOCATION; COMPLEX; EXPRESSION; COMPARTMENT; INHIBITORS; PATHWAY; PEPTIDE	The human cytomegalovirus genome encodes proteins that trigger destruction of newly synthesized major histocompatibility complex (MHC) class I molecules. The human cytomegalovirus gene US2 specifies a product capable of dislocating MHC class I molecules from the endoplasmic reticulum to the cytosol and delivering them to the proteasome. This process involves the Sec61 complex, in what appears to be a reversal of the reaction by which it translocates nascent chains into the endoplasmic reticulum.	MIT, CTR CANC RES, DEPT BIOL, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; WYETH AYERST RES, INFECT DIS SECT, DEPT MOL BIOL, PEARL RIVER, NY 10965 USA	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Pfizer				Bogyo, Matthew/0000-0003-3753-4412; Tortorella, Domenico/0000-0003-0961-3535				BACALLAO R, 1994, J CELL SCI, V107, P3301; BEERSMA MFC, 1993, J IMMUNOL, V151, P4455; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; BIJLMAKERS MJE, 1993, EUR J IMMUNOL, V23, P1305, DOI 10.1002/eji.1830230618; BONIFACINO JS, 1994, MODERN CELL BIOL CEL, V15, P137; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CIECHANOVER AJ, 1994, CELLULAR PROTEOLYTIC, P3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; KIM HJ, 1995, J VIROL, V69, P2565, DOI 10.1128/JVI.69.4.2565-2573.1995; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MAUDSLEY DJ, 1991, IMMUNOL TODAY, V12, P429, DOI 10.1016/0167-5699(91)90013-J; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PARHAM P, 1979, J IMMUNOL, V123, P342; PEYRIERAS N, 1983, EMBO J, V2, P823, DOI 10.1002/j.1460-2075.1983.tb01509.x; PLOEGH HL, 1979, P NATL ACAD SCI USA, V76, P2273, DOI 10.1073/pnas.76.5.2273; PLOEGH HL, 1995, CURRENT PROTOCOLS PR; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; RIVETT AJ, 1993, BIOCHEM J, V291, P1; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753	50	920	942	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 5	1996	384	6608					432	438		10.1038/384432a0	http://dx.doi.org/10.1038/384432a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945469				2022-12-01	WOS:A1996VW68700053
J	Nightingale, SL				Nightingale, SL			New spinal fusion devices approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1710	1710						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940307				2022-12-01	WOS:A1996VV56600007
J	Zook, HA; Grun, E; Baguhl, M; Hamilton, DP; Linkert, G; Liou, JC; Forsyth, R; Phillips, JL				Zook, HA; Grun, E; Baguhl, M; Hamilton, DP; Linkert, G; Liou, JC; Forsyth, R; Phillips, JL			Solar wind magnetic field bending of Jovian dust trajectories	SCIENCE			English	Article							JUPITER; EJECTION; GALILEO	From September 1991 to October 1992, the cosmic dust detector on the Ulysses spacecraft recorded 11 short bursts, or streams, of dust. These dust grains emanated from the jovian system, and their trajectories were strongly affected by solar wind magnetic field forces. Analyses of the on-board measurements of these fields, and of stream approach directions, show that stream-associated dust grain masses are of the order of 10(-18) gram and dust grain velocities exceed 200 kilometers per second. These masses and velocities are, respectively, about 10(3) times less massive and 5 to 10 times faster than earlier reported.	MAX PLANCK INST KERNPHYS,D-69029 HEIDELBERG,GERMANY; UNIV MARYLAND,DEPT ASTRON,COLLEGE PK,MD 20742; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,BLACKETT LAB,LONDON SW7 2BZ,ENGLAND; LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545	Max Planck Society; University System of Maryland; University of Maryland College Park; Imperial College London; United States Department of Energy (DOE); Los Alamos National Laboratory	Zook, HA (corresponding author), NASA,LYNDON B JOHNSON SPACE CTR,HOUSTON,TX 77058, USA.							BAGUHI M, 1994, PLANET SPACE SCI, V41, P1085; BALOGH A, 1993, GEOPHYS RES LETT, V20, P2331, DOI 10.1029/93GL02621; BARNE SJ, 1993, GEOPHYS RES LETT, V20, P2323; GOLLER JR, 1989, PLANET SPACE SCI, V37, P1197, DOI 10.1016/0032-0633(89)90014-7; GRUN E, 1995, PLANET SPACE SCI, V43, P971, DOI 10.1016/0032-0633(94)00233-H; GRUN E, 1993, NATURE, V362, P428, DOI 10.1038/362428a0; GRUN E, 1995, PLANET SPACE SCI, V43, P941, DOI 10.1016/0032-0633(94)00232-G; GRUN E, 1992, SCIENCE, V257, P1550, DOI 10.1126/science.11538054; Grun E, 1996, SCIENCE, V274, P399, DOI 10.1126/science.274.5286.399; Grun E, 1996, NATURE, V381, P395, DOI 10.1038/381395a0; HAMILTON DP, 1993, NATURE, V364, P695, DOI 10.1038/364695a0; HORANYI M, 1993, NATURE, V363, P144, DOI 10.1038/363144a0; MARIANI F, 1990, PHYSICS INNER HELIOS, P99; ZOOK HA, 1996, P 150 C INT ASTR UN, V104, P23	14	75	75	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1501	1503		10.1126/science.274.5292.1501	http://dx.doi.org/10.1126/science.274.5292.1501			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929405				2022-12-01	WOS:A1996VV77500040
J	Wary, KK; Mainiero, F; Isakoff, SJ; Marcantonio, EE; Giancotti, FG				Wary, KK; Mainiero, F; Isakoff, SJ; Marcantonio, EE; Giancotti, FG			The adaptor protein Shc couples a class of integrins to the control of cell cycle progression	CELL			English	Article							HUMAN-ENDOTHELIAL CELLS; FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; MEMBRANE DOMAINS; DIFFERENTIATION; FIBRONECTIN; EXPRESSION; RECEPTOR; CAVEOLIN	We provide evidence that a class of integrins combines with the adaptor She and thereby with Grb2. Coimmunoprecipitation and mutagenesis experiments indicate that the recruitment of She is specified by the extracellular or transmembrane domain of integrin cu subunit and suggest that this process is mediated by caveolin. Mutagenesis and dominant-negative inhibition studies reveal that She is necessary and sufficient for activation of the MAP kinase pathway in response to integrin ligation. Mitogens and She-activating integrins cooperate to promote transcription from the Fos serum response element and transit through G1. In contrast, adhesion mediated by integrins not linked to She results in cell cycle arrest and apoptosis even in presence of mitogens. These findings indicate that the association of specific integrins with She regulates cell survival and cell cycle progression.	NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016; NYU,SCH MED,SACKLER INST GRAD BIOMED SCI,NEW YORK,NY 10016; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	New York University; New York University; New York University; Columbia University			Isakoff, Steven/ABE-3566-2020	Wary, Kishore/0000-0001-8851-8565; Mainiero, Fabrizio/0000-0002-7136-9839	NATIONAL CANCER INSTITUTE [R37CA058976, P30CA016087, R01CA058976] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044585] Funding Source: NIH RePORTER; NCI NIH HHS [CA-58976, CA-16087] Funding Source: Medline; NIGMS NIH HHS [GM-44585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BRIESEWITZ R, 1993, MOL BIOL CELL, V4, P593, DOI 10.1091/mbc.4.6.593; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONFORTI G, 1989, BLOOD, V73, P1576; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIANCOTTI FG, 1994, METHOD ENZYMOL, V245, P297; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1996, IN PRESS DEV BIOL; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KEM A, 1994, J BIOL CHEM, V269, P22811; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pullan S, 1996, J CELL SCI, V109, P631; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; Vuori K, 1996, MOL CELL BIOL, V16, P2606; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	48	633	642	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					733	743		10.1016/S0092-8674(00)81392-6	http://dx.doi.org/10.1016/S0092-8674(00)81392-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929541	hybrid			2022-12-01	WOS:A1996VU03500015
J	Nightingale, SL				Nightingale, SL			Fertility drug shortage over	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					370	370						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE771	9010159				2022-12-01	WOS:A1997WE77100007
J	Franke, TF; Kaplan, DR; Cantley, LC; Toker, A				Franke, TF; Kaplan, DR; Cantley, LC; Toker, A			Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate	SCIENCE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; TARGET; KINASE	The regulation of the serine-threonine kinase Akt by lipid products of phosphoinositide 3-kinase (PI 3-kinase) was investigated. Akt activity was found to correlate with the amount of phosphatidylinositol-3,4-bisphosphate (PtdIns-3,4-P-2) in vivo, and synthetic PtdIns-3,4-P-2 activated Akt both in vitro and in vivo. Binding of PtdIns-3,4-P-2 occurred within the Akt pleckstrin homology (PH) domain and facilitated dimerization of Akt. Akt mutated in the PH domain was not activated by PI 3-kinase in vivo or by PtdIns-3,4-P-2 in vitro, and it was impaired in binding to PtdIns-3,4-P-2. Examination of the binding to other phosphoinositides revealed that they bound to the Akt PH domain with much lower affinity than did PtdIns-3,4-P-2 and failed to increase Akt activity. Thus, Akt is apparently regulated by the direct interaction of PtdIns-3,4-P-2 with the Akt PH domain.	MCGILL UNIV,MONTREAL NEUROL INST,MONTREAL,PQ H3A 2B4,CANADA; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT CELL BIOL,DIV SIGNAL TRANSDUCTION,BOSTON,MA 02115	McGill University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Franke, TF (corresponding author), NCI,ABL BASIC RES PROGRAM,FREDERICK CANC RES FACIL & DEV CTR,FREDERICK,MD 21702, USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIGMS NIH HHS [GM41890, R01 GM041890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041890, R01GM041890] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DERMAN MP, IN PRESS J BIOL CHEM; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRANKE TF, UNPUB; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304	18	1294	1319	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					665	668		10.1126/science.275.5300.665	http://dx.doi.org/10.1126/science.275.5300.665			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005852				2022-12-01	WOS:A1997WF07700039
J	Wiener, M; Freymann, D; Ghosh, P; Stroud, RM				Wiener, M; Freymann, D; Ghosh, P; Stroud, RM			Crystal structure of colicin Ia	NATURE			English	Article							PORE-FORMING DOMAIN; ESCHERICHIA-COLI; OUTER-MEMBRANE; HELICAL HAIRPIN; CHANNEL; RECEPTOR; PROTEIN; TRANSPORT; GENE; PURIFICATION	The ion-channel forming colicins A, B, E1, Ia, Ib and N all kill bacterial cells selectively by co-opting bacterial active-transport pathways and forming voltage-gated ion conducting channels across the plasma membrane of the target bacterium(1,2). The crystal structure of colicin Ia reveals a molecule 210 Angstrom long with three distinct functional domains arranged along a backbone of two extraordinarily long alpha-helices. A central domain at the bend of the hairpin-like structure mediates specific recognition and binding to an outer-membrane receptor(3). A second domain mediates translocation across the outer membrane via the TonB transport pathway(4); the TonB-box(5) recognition element of colicin Ia is on one side of three 80 Angstrom-long helices arranged as a helical sheet. A third domain is made up of 10 alpha-helices which form a voltage-activated and voltage-gated ion conducting channel across the plasma membrane of the target cell. The two 160 Angstrom-long alpha-helices that link the receptor-binding domain to the other domains enable the colicin Ia molecule to span the periplasmic space and contact both the outer and plasma membranes simultaneously during function(6,7).	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS S964,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco			Stroud, Rhonda M./C-5503-2008	Stroud, Rhonda M./0000-0001-5242-8015; Freymann, Douglas/0000-0002-5231-8841				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BATY D, 1988, MOL MICROBIOL, V2, P807, DOI 10.1111/j.1365-2958.1988.tb00092.x; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; BENEDETTI H, 1991, J MOL BIOL, V217, P429, DOI 10.1016/0022-2836(91)90747-T; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1016/0168-6445(95)00003-U; BRUNDEN KR, 1984, J BIOL CHEM, V259, P190; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.bb.24.060195.003143; DUCHE D, 1995, J BACTERIOL, V177, P4935, DOI 10.1128/jb.177.17.4935-4939.1995; GHOSH P, 1993, J MEMBRANE BIOL, V134, P85; GHOSH P, 1994, NAT STRUCT BIOL, V1, P597, DOI 10.1038/nsb0994-597; JEANTEUR D, 1994, J MOL BIOL, V235, P898, DOI 10.1006/jmbi.1994.1047; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KONISKY J, 1970, J BIOL CHEM, V245, P2972; LAKEY JH, 1993, J MOL BIOL, V230, P1055, DOI 10.1006/jmbi.1993.1218; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEDUC M, 1985, J BACTERIOL, V161, P627, DOI 10.1128/JB.161.2.627-635.1985; MEL SF, 1993, BIOCHEMISTRY-US, V32, P9473, DOI 10.1021/bi00087a027; MENDE J, 1990, MOL MICROBIOL, V4, P1523, DOI 10.1111/j.1365-2958.1990.tb02063.x; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; NAU CD, 1989, J BACTERIOL, V171, P1041, DOI 10.1128/jb.171.2.1041-1047.1989; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; Qiu XQ, 1996, J GEN PHYSIOL, V107, P313, DOI 10.1085/jgp.107.3.313; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; SCHRAMM E, 1987, J BACTERIOL, V169, P3350, DOI 10.1128/jb.169.7.3350-3357.1987; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; STROUD R, 1995, CURR OPIN STRUC BIOL, V5, P514, DOI 10.1016/0959-440X(95)80037-9	30	221	226	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1997	385	6615					461	464		10.1038/385461a0	http://dx.doi.org/10.1038/385461a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009197				2022-12-01	WOS:A1997WF00700059
J	OReilly, MS; Boehm, T; Shing, Y; Fukai, N; Vasios, G; Lane, WS; Flynn, E; Birkhead, JR; Olsen, BR; Folkman, J				OReilly, MS; Boehm, T; Shing, Y; Fukai, N; Vasios, G; Lane, WS; Flynn, E; Birkhead, JR; Olsen, BR; Folkman, J			Endostatin: An endogenous inhibitor of angiogenesis and tumor growth	CELL			English	Article							ENDOTHELIAL-CELL PROLIFERATION; LEWIS-LUNG-CARCINOMA; POTENT INHIBITOR; IN-VIVO; DOMAINS; THROMBOSPONDIN-1; IDENTIFICATION; SUPPRESSION; CHEMOKINE; FRAGMENT	We previously identified the angiogenesis inhibitor angiostatin. Using a similar strategy, we have identified endostatin, an angiogenesis inhibitor produced by hemangioendothelioma. Endostatin is a 20 kDa C-terminal fragment of collagen XVIII. Endostatin specifically inhibits endothelial proliferation and potently inhibits angiogenesis and tumor growth. By a novel method of sustained release, E. coli-derived endostatin was administered as a nonrefolded suspension. Primary tumors were regressed to dormant microscopic lesions. Immunohistochemistry revealed blocked angiogenesis accompanied by high proliferation balanced by apoptosis in tumor cells. There was no toxicity. Together with angiostatin data, these findings validate a strategy for identifying endogenous angiogenesis inhibitors, suggest a theme of fragments of proteins as angiogenesis inhibitors, and demonstrate dormancy therapy.	CHILDRENS HOSP, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELLULAR BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, HARVARD MICROCHEM FACIL, CAMBRIDGE, MA 02115 USA; OSTEOARTHRIT SCI INC, CAMBRIDGE, MA 02139 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University					NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040711, P01HL033014] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA45548] Funding Source: Medline; NHLBI NIH HHS [HL33014, HL 40711] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; CHEN C, 1995, CANCER RES, V55, P4230; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; Folkman J, 1985, Important Adv Oncol, P42; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOLKMAN J, 1996, P NATL ACAD SCI USA, V93, P2002; Gately S, 1996, CANCER RES, V56, P4887; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; GROSS JL, 1983, P NATL ACAD SCI-BIOL, V80, P2623, DOI 10.1073/pnas.80.9.2623; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; HORI A, 1991, CANCER RES, V51, P6180; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; NELSON J, 1995, CANCER RES, V55, P3772; NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003; OBESO J, 1990, LAB INVEST, V63, P259; OH SP, 1994, P NATL ACAD SCI USA, V91, P4229, DOI 10.1073/pnas.91.10.4229; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; REHN M, 1994, P NATL ACAD SCI USA, V91, P4234, DOI 10.1073/pnas.91.10.4234; SAGE EH, 1995, J CELL BIOCHEM, V57, P127, DOI 10.1002/jcb.240570113; SAKAMOTO N, 1991, CANCER RES, V51, P903; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TEICHER BA, 1994, INT J CANCER, V57, P920, DOI 10.1002/ijc.2910570624; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581	41	3682	4176	1	175	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1997	88	2					277	285		10.1016/S0092-8674(00)81848-6	http://dx.doi.org/10.1016/S0092-8674(00)81848-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008168	Bronze			2022-12-01	WOS:A1997WE97000016
J	Semaw, S; Renne, P; Harris, JWK; Feibel, CS; Bernor, RL; Fesseha, N; Mowbray, K				Semaw, S; Renne, P; Harris, JWK; Feibel, CS; Bernor, RL; Fesseha, N; Mowbray, K			2.5-million-year-old stone tools from Gona, Ethiopia	NATURE			English	Article							PLIOCENE HOMINIDS; TURKANA BASIN; LAKE TURKANA; TIME-SCALE; HADAR; KENYA; MA	The Oldowan Stone tool industry was named for 1.8-million-year-old (Mpr) artefacts found near the bottom of Olduvai Gorge, Tanzania. Subsequent archaeological research in the Omo (Ethiopia) and Turkana (Kenya) also yielded stone tools dated to 2.3 Myr. Palaeoanthropological investigations in the Hadar region of the Awash Valley of Ethiopia(1), revealed Oldowan assemblages in the adjacent Gona River drainage(2). We conducted held work in the Gona study area of Ethiopia between 1992 and 1994 which resulted in additional archaeological discoveries as well as radioisotopic age control and a magnetic polarity stratigraphy of the Gona sequence. These occurrences are now securely dated between 2.6-2.5 Myr. The stone tools are thus the oldest known artefacts from anywhere in the world The artefacts show surprisingly sophisticated control of stone fracture mechanics, equivalent to much younger Oldowan assemblages of Early Pleistocene age. This indicates an unexpectedly long period of technological stasis in the Oldowan.	BERKELEY GEOCHRONOL CTR,BERKELEY,CA 94709; HOWARD UNIV,COLL MED,DEPT ANAT,LAB PALEOBIOL,WASHINGTON,DC 20059	Berkeley Geochronolgy Center; Howard University	Semaw, S (corresponding author), RUTGERS STATE UNIV,DEPT ANTHROPOL,DOUGLASS CAMPUS,NEW BRUNSWICK,NJ 08903, USA.		Klein, Richard G/B-5910-2009; Semaw, Sileshi/M-7021-2018	Semaw, Sileshi/0000-0001-8377-8288; Renne, Paul/0000-0003-1769-5235				ASFAW B, 1992, NATURE, V360, P732, DOI 10.1038/360732a0; Chavaillon J., 1976, EARLIEST MAN ENV LAK, P565; CORVINUS G, 1976, ANTHROPOLOGIE, V80, P315; DEINO A, 1990, J GEOPHYS RES-SOLID, V95, P8453, DOI 10.1029/JB095iB06p08453; DEMENOCAL PB, 1995, SCIENCE, V270, P53, DOI 10.1126/science.270.5233.53; Dominguez-Rodrigo M., 1996, COMPLUTUM, V7, P7; Gowlett J.A.J., 1986, STONE AGE PREHISTORY, p243e260; Harris J.W.K., 1983, AFR ARCHAEOL REV, V1, P3, DOI DOI 10.1007/BF01116770; HARRIS JWK, 1989, NYAME AKUMA, V31, P19; HILL A, 1992, NATURE, V355, P719, DOI 10.1038/355719a0; ISAAC GL, 1976, EARLIEST MAN ENV LAK, P552; ISAACS GL, 1974, NATURE, V249, P624, DOI 10.1038/249624a0; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P373, DOI 10.1002/ajpa.1330570402; KIBUNJIA M, 1994, J HUM EVOL, V27, P159, DOI 10.1006/jhev.1994.1040; KIMBEL WH, 1994, NATURE, V368, P449, DOI 10.1038/368449a0; Leakey M.D., 1971, OLDUVAI GORGE; MCDOUGALL I, 1992, GEOPHYS RES LETT, V19, P2349, DOI 10.1029/92GL02714; Merrick H.V., 1976, EARLIEST MAN ENV LAK, P574; Piperno M., 1989, P189; RENNE P, 1993, GEOPHYS RES LETT, V20, P1067, DOI 10.1029/93GL00733; ROCHE H, 1977, CR ACAD SCI D NAT, V284, P1871; TOTH N, 1985, J ARCHAEOL SCI, V12, P101, DOI 10.1016/0305-4403(85)90056-1; Vrba E.S., 1988, P405; WALKER A, 1986, NATURE, V322, P517, DOI 10.1038/322517a0; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0	25	374	386	3	66	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					333	336		10.1038/385333a0	http://dx.doi.org/10.1038/385333a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WD914	9002516				2022-12-01	WOS:A1997WD91400048
J	Stanley, EF; Mirotznik, RR				Stanley, EF; Mirotznik, RR			Cleavage of syntaxin prevents G-protein regulation of presynaptic calcium channels	NATURE			English	Article							CHICK CILIARY GANGLION; ACETYLCHOLINE-RELEASE; SENSORY NEURONS; GIANT SYNAPSE; N-TYPE; CURRENTS; SYNAPTOTAGMIN; MODULATION; INHIBITION	Neurotransmitter release into the synapse is stimulated by calcium influx through ion channels that are closely associated with the transmitter release sites(1,2). This link may involve the membrane protein syntaxin, which is known to be associated with the release sites and to bind to the calcium channels(3,4). There is evidence that presynaptic calcium channels are downregulated by second messenger pathways involving G proteins(5,6). Here we use the patch-clamp technique to test whether calcium current is regulated by G proteins in a vertebrate presynaptic nerve terminal(7), and whether this regulation is affected by the Linkage to syntaxin. The calcium current in the nerve terminal showed typical G-protein-mediated changes in amplitude and activation kinetics which were reversed by a preceding depolarization. These effects of the G protein were virtually eliminated if syntaxin was I first cleaved with botulinum toxin CI. Our findings indicate that this sensitivity of the current to modulation by G proteins requires the association of the presynaptic calcium channel with elements of the transmitter release site, which may ensure that channels tethered at release sites(2,8) are preferentially regulated by the G-protein second messenger pathway.			Stanley, EF (corresponding author), NINCDS, SYNAPT MECH SECT, NIH, BLD 36, RM 5A25, BETHESDA, MD 20892 USA.							BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; DOLPHIN AC, 1995, EXP PHYSIOL, V80, P1; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; GRASSI F, 1989, NEUROSCI LETT, V105, P113, DOI 10.1016/0304-3940(89)90021-9; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Kee Y, 1996, J NEUROSCI, V16, P1975; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MARCHETTI C, 1989, BIOPHYS J, V56, P1267, DOI 10.1016/S0006-3495(89)82774-2; MOCHIDA S, 1995, NEUROSCIENCE, V65, P905, DOI 10.1016/0306-4522(94)00508-3; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; ROSSETTO O, 1994, NATURE, V372, P415, DOI 10.1038/372415a0; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SCOTT RH, 1986, NEUROSCI LETT, V69, P59, DOI 10.1016/0304-3940(86)90414-3; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SHIAVO G, 1994, ANN NY ACAD SCI, V710, P65; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; STANLEY EF, 1991, ANN NY ACAD SCI, V635, P70, DOI 10.1111/j.1749-6632.1991.tb36482.x; STANLEY EF, 1991, J NEUROSCI, V11, P985; STANLEY EF, 1989, BRAIN RES, V505, P341, DOI 10.1016/0006-8993(89)91465-0; STANLEY EF, 1991, NEURON, V7, P585, DOI 10.1016/0896-6273(91)90371-6; STANLEY EF, 1993, NEURON, V11, P1007, DOI 10.1016/0896-6273(93)90214-C; Williamson LC, 1996, J BIOL CHEM, V271, P7694, DOI 10.1074/jbc.271.13.7694; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; YAWO H, 1993, J PHYSIOL-LONDON, V460, P153, DOI 10.1113/jphysiol.1993.sp019464; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	29	153	156	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 23	1997	385	6614					340	343		10.1038/385340a0	http://dx.doi.org/10.1038/385340a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002518				2022-12-01	WOS:A1997WD91400050
J	Haley, RW; Hom, J; Roland, PS; Bryan, WW; VanNess, PC; Bonte, FJ; Devous, MD; Matthews, D; Fleckenstein, JL; Wians, FH; Wolfe, GI; Kurt, TL				Haley, RW; Hom, J; Roland, PS; Bryan, WW; VanNess, PC; Bonte, FJ; Devous, MD; Matthews, D; Fleckenstein, JL; Wians, FH; Wolfe, GI; Kurt, TL			Evaluation of neurologic function in gulf war veterans - A blinded case-control study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BRAIN; POSTUROGRAPHY	Objective.-To determine whether Gulf War-related illnesses are associated with central or peripheral nervous system dysfunction. Design.-Nested case-control study. Participants.-Twenty-three veterans with factor analysis-derived syndromes (the cases), 10 well veterans deployed to the Gulf War (the deployed controls), and 10 well veterans not deployed to the Gulf War (the nondeployed controls), Method.-With investigators blinded to group identities, participants underwent objective neurophysiological, audiovestibular, neuroradiological, neuropsychological, and blood tests. Main Outcome Measures.-Evidence of neurologic dysfunction. Results.-Compared with the 20 controls, the 23 cases had significantly more neuropsychological evidence of brain dysfunction on the Halstead Impairment Index (P=.01), greater interside asymmetry of the wave I to wave III interpeak latency of brain stem auditory evoked potentials (P=.02), greater interocular asymmetry of nystagmic velocity on rotational testing, increased asymmetry of saccadic Velocity (P=.04), more prolonged interpeak latency of the lumbar-to-cerebral peaks on posterior tibial somatosensory evoked potentials (on right side, P=.03, and on the left side, P=.005), and diminished nystagmic velocity after caloric stimulation bilaterally (P values range from .02 to .04). Cases (n=5) with syndrome 1 (''impaired cognition'') were the most impaired on brain stem auditory evoked potentials (P=.005); those (n=13) with syndrome 2 (''confusion-ataxia'') were the most impaired on the Halstead Impairment Index (P=.006), rotational testing (P=.01), asymmetry of saccadic velocity (P=.03), and somatosensory evoked potentials (P less than or equal to.01); and those (n=5) with syndrome 3 (''arthro-myo-neuropathy'') were the most impaired on caloric stimulation (P less than or equal to.01). Conclusions.-The 3 factor-derived syndromes identified among Gulf War veterans appear to represent variants of a generalized injury to the nervous system.	UNIV TEXAS,SW MED CTR,DEPT OTOLARYNGOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT NEUROL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT RADIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235; NEUROPSYCHOL CTR,DALLAS,TX	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Haley, RW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV EPIDEMIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Wolfe, Gil/AAO-2786-2020; Haley, Robert/P-9026-2014	Roland, Peter/0000-0003-4152-7346; Haley, Robert/0000-0001-8849-9579				AbouDonia MB, 1996, J TOXICOL ENV HEALTH, V48, P35, DOI 10.1080/009841096161456; AbouDonia MB, 1996, FUND APPL TOXICOL, V34, P201, DOI 10.1006/faat.1996.0190; ATLAS SW, 1993, J COMPUT ASSIST TOMO, V17, pS1, DOI 10.1097/00004728-199301001-00001; BALOH RW, 1983, CLIN NEUROPHYSIOLOGY; BONTE FJ, 1993, RADIOLOGY, V186, P361, DOI 10.1148/radiology.186.2.8421735; CHIAPPA KH, 1990, EVOKED POTENTIALS CL; DEBLEECKER JL, 1992, CLIN NEUROL NEUROSUR, V94, P93, DOI 10.1016/0303-8467(92)90065-B; DIFABIO RP, 1995, PHYS THER, V75, P290, DOI 10.1093/ptj/75.4.290; ELIAS MF, 1993, J GERONTOL, V48, pP278, DOI 10.1093/geronj/48.6.P278; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P231, DOI 10.1001/jama.277.3.231; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P215, DOI 10.1001/jama.277.3.215; HALL JW, 1992, HDB AUDITORY EVOKED, P350; Jacobson GP., 1993, HDB BALANCE FUNCTION; Jamal GA, 1996, J NEUROL NEUROSUR PS, V60, P449, DOI 10.1136/jnnp.60.4.449; Kleinbaum D. G., 1982, EPIDEMIOLOGIC RES PR, P62; KLEINBAUM DG, 1988, APPLIED REGRESSION A; KRISS A, 1993, EVOKED POTENTIALS CL, P1; LIPP M, 1994, J OTOLARYNGOL, V23, P177; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P403; PAIGE GD, 1989, ACTA OTO-LARYNGOL, V108, P1, DOI 10.3109/00016488909107385; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; REITAN RM, 1993, HALSTEADREITAN NEURO; ROLAND PS, 1995, TRAUMATIC BRAIN INJU, P131; RUNGE VM, 1995, TOP MAGN RESON IMAG, V7, P158; SAHA GB, 1994, SEMIN NUCL MED, V24, P324, DOI 10.1016/S0001-2998(05)80022-4; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P75; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P124; SEQUEIRA W, 1994, CLIN EXP RHEUMATOL, V12, P325; Snedecor GW, 1980, STAT METHODS; *US DEP DEF, 1996, COMPR CLIN EV PROGR; Wechsler, 2012, WECHSLER ADULT INTEL, DOI 10.1037/t15169-000	32	179	182	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1997	277	3					223	230		10.1001/jama.277.3.223	http://dx.doi.org/10.1001/jama.277.3.223			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB446	9005272				2022-12-01	WOS:A1997WB44600024
J	Rotenberg, A; Mayford, M; Hawkins, RD; Kandel, ER; Muller, RU				Rotenberg, A; Mayford, M; Hawkins, RD; Kandel, ER; Muller, RU			Mice expressing activated CaMKII lack low frequency LTP and do not form stable place cells in the CA1 region of the hippocampus	CELL			English	Article							SPATIAL FIRING PATTERNS; FREELY-BEHAVING RATS; COMPLEX-SPIKE CELLS; MOVING RATS; ENVIRONMENT; UNITS	To relate different forms of synaptic plasticity to the formation and maintenance of place cells in the hippocampus, we have recorded place cells in freely behaving, transgenic mice that express a mutated Ca2+-independent form of CaM Kinase II. These mice have normal long-term potentiation (LTP) at 100 Hz, but they lack LTP in response to stimulation at 5-10 Hz and are impaired on spatial memory tasks. In these transgenic mice, the place cells in the CA1 region have three important differences from those of wild types: they are less common, less precise, and less stable. These findings suggest that LTP in the 5-10 Hz range may be important for the maintenance of place-field stability and that this stability may be essential for the storage of spatial memory.	COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, NEW YORK STATE PSYCHIAT INST, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University; New York State Psychiatry Institute	Rotenberg, A (corresponding author), SUNY HLTH SCI CTR, DEPT PHYSIOL, DOWNSTATE MED CTR, BOX 31, BROOKLYN, NY 11203 USA.			Mayford, Mark/0000-0002-9001-5024				BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BLISS TV, 1973, J PHYSL, V232, P2331; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bostock E, 1991, Hippocampus, V1, P193, DOI 10.1002/hipo.450010207; EICHENBAUM H, 1989, J NEUROSCI, V9, P2764; HILL AJ, 1978, EXP NEUROL, V62, P282, DOI 10.1016/0014-4886(78)90058-4; Kubie J. L., 1992, Society for Neuroscience Abstracts, V18, P1062; KUBIE JL, 1990, J NEUROSCI, V10, P1110; KUBIE JL, 1984, PHYSIOL BEHAV, V32, P115, DOI 10.1016/0031-9384(84)90080-5; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MULLER RU, 1987, J NEUROSCI, V7, P1951; MULLER RU, 1989, J NEUROSCI, V9, P4101; MULLER RU, 1987, J NEUROSCI, V7, P1935; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; OLTON DS, 1978, PHYSIOL BEHAV, V20, P597, DOI 10.1016/0031-9384(78)90252-4; QUIRK GJ, 1992, J NEUROSCI, V12, P1945; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; SCHACTER DL, 1994, MEMORY SYSTEMS BRAIN; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHARP PE, 1995, J NEUROSCI, V15, P173; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Taube JS, 1995, HIPPOCAMPUS, V5, P569, DOI 10.1002/hipo.450050608; THOMPSON LT, 1989, J NEUROSCI, V9, P2382; THOMPSON LT, 1990, BRAIN RES, V509, P299, DOI 10.1016/0006-8993(90)90555-P; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	28	186	188	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 27	1996	87	7					1351	1361		10.1016/S0092-8674(00)81829-2	http://dx.doi.org/10.1016/S0092-8674(00)81829-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980240	hybrid			2022-12-01	WOS:A1996WA54100022
J	Gudjonsson, B				Gudjonsson, B			Critical look at resection for pancreatic cancer	LANCET			English	Editorial Material											Gudjonsson, B (corresponding author), MED CLIN,ALFHEIMUM 74,IS-104 REYKJAVIK,ICELAND.							BRAMHALL SR, 1995, BRIT J SURG, V82, P111, DOI 10.1002/bjs.1800820137; BRENNAN MF, 1994, ANN SURG, V220, P436, DOI 10.1097/00000658-199410000-00003; Conlon KC, 1996, ANN SURG, V223, P273, DOI 10.1097/00000658-199603000-00007; GALLITANO A, 1968, CANCER-AM CANCER SOC, V22, P939, DOI 10.1002/1097-0142(196811)22:5<939::AID-CNCR2820220507>3.0.CO;2-E; GUDJONSSON B, 1995, J AM COLL SURGEONS, V181, P483; Nagakawa T, 1996, CANCER, V77, P640, DOI 10.1002/(SICI)1097-0142(19960215)77:4<640::AID-CNCR9>3.0.CO;2-K; YEO CJ, 1995, ANN SURG, V221, P721, DOI 10.1097/00000658-199506000-00011	7	8	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1676	1676		10.1016/S0140-6736(05)65818-7	http://dx.doi.org/10.1016/S0140-6736(05)65818-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973426				2022-12-01	WOS:A1996VZ76600006
J	Nathwani, D; Davey, P				Nathwani, D; Davey, P			Intravenous antimicrobial therapy in the community: Underused, inadequately resourced, or irrelevant to health care in Britain?	BRITISH MEDICAL JOURNAL			English	Article							PARENTERAL ANTIBIOTICS; PROMOTE QUALITY; HOME TREATMENT; INFECTIONS; FEASIBILITY; MANAGEMENT; INSURANCE; SECONDARY; ECONOMY; 1990S	The NHS Executive is keen to promote ''hospital at home'' services in Britain, as part of its philosophy of keeping more care in the community and also to relieve the increasing demand for hospital beds. One such service is the provision of intravenous antimicrobial therapy in the community. Yet, compared with the United States, where home or outpatient intravenous antimicrobial therapy programmes are well developed, experience in Britain and Europe is limited, reflecting a difference in cultural attitudes and healthcare structures between the two continents. Only a few units in Britain currently run home intravenous antimicrobial therapy programmes, and several issues need to be addressed if more treatment is to be provided outside hospital. These include an assessment of the need for community intravenous antibiotic treatment and which patient groups many benefit. The main motive for community intravenous treatment should be better patient care and not simply a reduction in healthcare costs. At present the pace of change is being set by a few clinical enthusiasts and by commercial organisations, whereas the NHS deserves a more organised strategy for purchasing treatment with intravenous antibiotics in the community.	KINGS CROSS HOSP,INFECT & IMMUNODEFICIENCY SERV,DUNDEE DD3 8EA,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CLIN PHARMACOL,MED MONITORING UNIT,DUNDEE DD1 9SY,SCOTLAND	University of Dundee								ANTONISKIS A, 1978, WESTERN J MED, V128, P203; Bakker W, 1993, Ned Tijdschr Geneeskd, V137, P2486; BALINSKY W, 1989, AM J MED, V87, P301, DOI 10.1016/S0002-9343(89)80155-X; COULTER A, 1995, BRIT MED J, V311, P1447, DOI 10.1136/bmj.311.7018.1447; CRAIG WA, 1993, HOSP PRACT, V28, P16, DOI 10.1080/21548331.1993.11442930; CRUMP BJ, 1995, BRIT MED J, V310, P509, DOI 10.1136/bmj.310.6978.509; Davey PG, 1996, J ANTIMICROB CHEMOTH, V37, P623, DOI 10.1093/jac/37.3.623; DONABEDIAN A, 1966, MILBANK Q, V4, P155; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; FINCH R, 1995, HOME OUTPATIENT MANA; GILL S, 1993, BR J NURSING, V3, P767; GRAHAM DR, 1993, INFECT DIS CLIN PRAC, V2, P158; HALLS GA, 1993, J ANTIMICROB CHEMOTH, V31, P985, DOI 10.1093/jac/31.6.985; Kayley J, 1996, J ANTIMICROB CHEMOTH, V37, P1023, DOI 10.1093/jac/37.5.1023; KOHLER JA, 1991, POSTGRADUATE UPDATE, V42, P950; KRAVITZ GR, 1993, HOSP PRACT, V28, P21, DOI 10.1080/21548331.1993.11442931; KUNKEL MJ, 1993, HOSP PRACT, V28, P33, DOI 10.1080/21548331.1993.11442933; LOWSON K, 1993, CLIN MANAGEMENT, V2, P8; MALIK IA, 1995, AM J MED, V98, P224, DOI 10.1016/S0002-9343(99)80367-2; MILKOVICH G, 1995, INT J ANTIMICROB AG, V5, P27, DOI 10.1016/0924-8579(94)00049-Z; NATHWANI D, 1995, HOSP UPDATE, V21, P2; *NHS MAN EX, 1995, EL955 NHSME; NOLET B, 1993, INFECT DIS CLIN PRAC, V3, P225; Parker S E, 1992, Pharmacoeconomics, V1, P103, DOI 10.2165/00019053-199201020-00007; POSTEMA CA, 1995, INT J ANTIMICROB AG, V5, P39, DOI 10.1016/0924-8579(94)00055-Y; RUBINSTEIN E, 1993, HOSP FORMUL, V28, P46; SCHRIJVERS G, 1995, INT J ANTIMICROB AG, V5, P45, DOI 10.1016/0924-8579(94)00056-Z; SHAUGHNESSY PW, 1989, QUALITY CARE INDICAT; SIMMONS B, 1990, INFECT CONT HOSP EP, V11, P362; Thickson N D, 1993, Pharmacoeconomics, V3, P220, DOI 10.2165/00019053-199303030-00005; WELCH J, 1990, GENITOURIN MED, V66, P460	32	17	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1541	1543		10.1136/bmj.313.7071.1541	http://dx.doi.org/10.1136/bmj.313.7071.1541			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY691	8978235	Green Published			2022-12-01	WOS:A1996VY69100029
J	Song, LZ; Hobaugh, MR; Shustak, C; Cheley, S; Bayley, H; Gouaux, JE				Song, LZ; Hobaugh, MR; Shustak, C; Cheley, S; Bayley, H; Gouaux, JE			Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore	SCIENCE			English	Article							BETA-SHEET BARRELS; FORMING PROTEIN; MACROMOLECULAR CRYSTALLOGRAPHY; LIPID BILAYER; KEY RESIDUES; TOXIN GENE; AUREUS; MEMBRANE; CHANNEL; OLIGOMERIZATION	The structure of the Staphylococcus aureus alpha-hemolysin pore has been determined to 1.9 Angstrom resolution. Contained within the mushroom-shaped homo-oligomeric heptamer is a solvent-filled channel, 100 Angstrom in length, that runs along the sevenfold axis and ranges from 14 Angstrom to 46 Angstrom in diameter. The lytic, transmembrane domain comprises the lower half of a 14-strand antiparallel beta barrel, to which each protomer contributes two beta strands, each 65 Angstrom long. The interior of the beta barrel is primarily hydrophilic, and the exterior has a hydrophobic belt 28 Angstrom wide. The structure proves the heptameric subunit stoichiometry of the alpha-hemolysin oligomer, shows that a glycine-rich and solvent-exposed region of a water-soluble protein can self-assemble to form a transmembrane pore of defined structure, and provides insight into the principles of membrane interaction and transport activity of beta barrel pore-forming toxins.	WORCESTER FDN BIOMED RES,SHREWSBURY,MA 01545	Worcester Foundation for Biomedical Research	Song, LZ (corresponding author), UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.		Gouaux, Eric/Y-4370-2019	Gouaux, Eric/0000-0002-8549-2360; Bayley, Hagan/0000-0003-2499-6116				ALOUF JE, 1991, SURCEBOOK BACTERIAL; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Bayley H, 1995, BIOORG CHEM, V23, P340, DOI 10.1006/bioo.1995.1023; BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BRICOGNE G, 1974, ACTA CRYSTALLOGR A, VA 30, P395, DOI 10.1107/S0567739474010722; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FRANKS NP, 1976, J MOL BIOL, V100, P345, DOI 10.1016/S0022-2836(76)80067-8; FUREY W, IN PRESS METHODS ENZ; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; HAUSER H, 1981, BIOCHIM BIOPHYS ACTA, V650, P21, DOI 10.1016/0304-4157(81)90007-1; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; HOBAUGH MR, UNPUB; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOUTHALL NT, UNPUB; JURSCH R, 1994, INFECT IMMUN, V62, P2249, DOI 10.1128/IAI.62.6.2249-2256.1994; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KASIANOWICZ JJ, 1995, BIOPHYS J, V69, P94, DOI 10.1016/S0006-3495(95)79879-4; KORCHEV YE, 1995, J MEMBRANE BIOL, V143, P143; KRASILNIKOV OV, 1988, GEN PHYSIOL BIOPHYS, V7, P467; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNASASTRY M, 1994, FEBS LETT, V356, P66, DOI 10.1016/0014-5793(94)01240-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI J, 1992, CURR OPIN STRUC BIOL, V2, P545; MCLACHLAN AD, 1979, J MOL BIOL, V128, P49, DOI 10.1016/0022-2836(79)90308-5; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MENESTRINA G, 1986, J MEMBRANE BIOL, V90, P177, DOI 10.1007/BF01869935; MENZIES BE, 1994, INFECT IMMUN, V62, P1843, DOI 10.1128/IAI.62.5.1843-1847.1994; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MURZIN AG, 1994, J MOL BIOL, V236, P1382, DOI 10.1016/0022-2836(94)90065-5; MURZIN AG, 1994, J MOL BIOL, V236, P1369, DOI 10.1016/0022-2836(94)90064-7; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PASTOR RW, 1991, P NATL ACAD SCI USA, V88, P892, DOI 10.1073/pnas.88.3.892; PAUPTIT RA, 1991, J STRUCT BIOL, V107, P136, DOI 10.1016/1047-8477(91)90017-Q; PEITSCH M C, 1991, Current Opinion in Cell Biology, V3, P710, DOI 10.1016/0955-0674(91)90045-Z; ROSSMAN MG, 1963, ACTA CRYSTALLOGR, V16, P39, DOI 10.1107/S0365110X63000062; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SONG L, 1996, METHOD ENZYMOL, V276, P60; SURGENOR DM, 1974, RED BLOOD CELL, V1; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; TOMITA T, 1992, J BIOL CHEM, V267, P13391; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; VALEVA A, 1995, BBA-BIOMEMBRANES, V1236, P213, DOI 10.1016/0005-2736(95)00060-G; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; WALKER B, 1994, PROTEIN ENG, V7, P655, DOI 10.1093/protein/7.5.655; WALKER B, 1995, PROTEIN ENG, V8, P491, DOI 10.1093/protein/8.5.491; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WARD RJ, 1992, J STRUCT BIOL, V109, P129, DOI 10.1016/1047-8477(92)90044-B; WARD RJ, 1994, BIOCHEMISTRY-US, V33, P7477, DOI 10.1021/bi00189a056; WATANABE M, 1987, BIOCHIM BIOPHYS ACTA, V898, P257, DOI 10.1016/0005-2736(87)90065-4; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41	61	1889	2004	10	440	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1859	1866		10.1126/science.274.5294.1859	http://dx.doi.org/10.1126/science.274.5294.1859			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943190				2022-12-01	WOS:A1996VY20000030
J	Gissler, M; Hemminki, E; Lonnqvist, J				Gissler, M; Hemminki, E; Lonnqvist, J			Suicides after pregnancy in Finland, 1987-94: Register linkage study	BRITISH MEDICAL JOURNAL			English	Article							POSTNATAL DEPRESSION; THERAPEUTIC-ABORTION; MATERNAL MORTALITY; COMPLICATIONS; WOMEN	Objective-To determine rates of suicide associated with pregnancy by the type of pregnancy. Design-Register linkage study. information on suicides in women of reproductive age was Linked with the Finnish birth, abortion, and hospital discharge registers to find out how many women who committed suicide had had a completed pregnancy during her last year of life. Setting-Nationwide data from Finland. Subjects-Women who committed suicide in 1987-94. Results-There were 73 suicides associated with pregnancy, representing 5.4% of all suicides in women in this age group. The mean annual suicide rate was 11.3 per 100 000. The suicide rate associated with birth was significantly lower (5.9) and the rates associated with miscarriage (18.1) and induced abortion (34.7) were significantly higher than in the population. The risk associated with birth was higher among teenagers and that associated with abortion was increased in all age groups. Women who had committed a suicide tended to come from lower social classes and were more Likely to be unmarried than other women who had had a completed pregnancy. Conclusions-The increased risk of suicide after an induced abortion indicates either common risk factors for both or harmful effects of induced abortion on mental health.	NATL RES & DEV CTR WEL & HLTH STAKES,HLTH SERV RES UNIT,HELSINKI 00531,FINLAND; NATL PUBL HLTH INST,DEPT MENTAL HLTH,SF-00300 HELSINKI,FINLAND	Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare	Gissler, M (corresponding author), NATL RES & DEV CTR WEL & HLTH STAKES,UNIT STAT REGISTERS & INFORMAT SYST,POB 220,HELSINKI 00531,FINLAND.			Gissler, Mika/0000-0001-8254-7525				ADLER NE, 1992, AM PSYCHOL, V47, P1194, DOI 10.1037/0003-066X.47.10.1194; [Anonymous], 1992, INT STAT CLASS DIS R, V1-3; APPLEBY L, 1991, BRIT MED J, V302, P137, DOI 10.1136/bmj.302.6769.137; BOUVIERCOLLE MH, 1991, INT J EPIDEMIOL, V20, P717, DOI 10.1093/ije/20.3.717; Brown S, 1994, MISSING VOICES EXPER; COX JL, 1993, BRIT J PSYCHIAT, V163, P27, DOI 10.1192/bjp.163.1.27; GISSLER M, 1995, SCAND J SOC MED, V23, P75, DOI 10.1177/140349489502300113; GISSLER M, 1996, INT J EPIDEMIOL, V2, P376; GREER HS, 1976, BRIT J PSYCHIAT, V128, P74, DOI 10.1192/bjp.128.1.74; HEDEGAARD M, 1993, BMJ-BRIT MED J, V307, P234, DOI 10.1136/bmj.307.6898.234; Heikkinen ME, 1995, BRIT J PSYCHIAT, V167, P747, DOI 10.1192/bjp.167.6.747; HOGBERG U, 1994, OBSTET GYNECOL, V84, P240; Keskimaki I, 1991, INT J HLTH SCI, V2, P15, DOI DOI 10.1177/1403494812456637; KLEINER GJ, 1984, SUICIDE PREGNANCY, P23; Lonnqvist Jouko, 1977, SUICIDE HELSINKI EPI; MURRAY D, 1995, BRIT J PSYCHIAT, V166, P595, DOI 10.1192/bjp.166.5.595; SCOTT D, 1992, CHILD ABUSE NEGLECT, V16, P345, DOI 10.1016/0145-2134(92)90044-R; STACK JM, 1990, EARLY PREGNANCY FAIL, P212; *STAT FINL, 1989, DEATH CAUS 1987 1994; STEIN A, 1989, BRIT MED J, V298, P1073, DOI 10.1136/bmj.298.6680.1073; SURTEES PG, 1983, BRIT J PSYCHIAT, V142, P238, DOI 10.1192/bjp.142.3.238; WHO, 1995, WORLD HLTH STAT ANN; ZOLESE G, 1992, BRIT J PSYCHIAT, V160, P742, DOI 10.1192/bjp.160.6.742	23	145	149	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1996	313	7070					1431	1434		10.1136/bmj.313.7070.1431	http://dx.doi.org/10.1136/bmj.313.7070.1431			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VX612	8973229	Green Published			2022-12-01	WOS:A1996VX61200025
J	Grunwald, DJ				Grunwald, DJ			A Fin-de-Siecle achievement: Charting new waters in vertebrate biology	SCIENCE			English	Editorial Material							DROSOPHILA-MELANOGASTER; LARVAL CUTICLE; ZYGOTIC LOCI; EMBRYONIC INDUCTION; FLOOR PLATE; ZEBRAFISH; MUTATIONS; CHROMOSOME; PATTERN				Grunwald, DJ (corresponding author), UNIV UTAH,DEPT HUMAN GENET,ECCLES INST HUMAN GENET,SALT LAKE CITY,UT 84112, USA.							Abdelilah S, 1996, DEVELOPMENT, V123, P217; Baier H, 1996, DEVELOPMENT, V123, P415; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; Brand M, 1996, DEVELOPMENT, V123, P129; Brand M, 1996, DEVELOPMENT, V123, P179; BUMCROT DA, 1995, CURR BIOL, V5, P612, DOI 10.1016/S0960-9822(95)00123-0; Chen JN, 1996, DEVELOPMENT, V123, P293; Currie PD, 1996, NATURE, V382, P452, DOI 10.1038/382452a0; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; Driever W, 1996, DEVELOPMENT, V123, P37; FurutaniSeiki M, 1996, DEVELOPMENT, V123, P229; Granato M, 1996, DEVELOPMENT, V123, P399; Haffter P, 1996, DEVELOPMENT, V123, P1; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; Halpern ME, 1995, DEVELOPMENT, V121, P4257; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; Hammerschmidt M, 1996, DEVELOPMENT, V123, P143; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; Heisenberg CP, 1996, DEVELOPMENT, V123, P191; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; Jiang YJ, 1996, DEVELOPMENT, V123, P205; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; Kane DA, 1996, DEVELOPMENT, V123, P57; Kane DA, 1996, DEVELOPMENT, V123, P47; Karlstrom RO, 1996, DEVELOPMENT, V123, P427; Kelsh RN, 1996, DEVELOPMENT, V123, P369; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KIMMEL CB, 1989, NATURE, V337, P358, DOI 10.1038/337358a0; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Knapik EW, 1996, DEVELOPMENT, V123, P451; Malicki J, 1996, DEVELOPMENT, V123, P275; Malicki J, 1996, DEVELOPMENT, V123, P263; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; Mullins MC, 1996, DEVELOPMENT, V123, P81; Neuhauss SCF, 1996, DEVELOPMENT, V123, P357; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Odenthal J, 1996, DEVELOPMENT, V123, P391; Odenthal J, 1996, DEVELOPMENT, V123, P103; OPITZ JM, 1994, AM J MED GENET, V49, P14, DOI 10.1002/ajmg.1320490105; Pack M, 1996, DEVELOPMENT, V123, P321; Piotrowski T, 1996, DEVELOPMENT, V123, P345; Placzek M, 1996, CURR BIOL, V6, P526, DOI 10.1016/S0960-9822(02)00533-X; POSTLETHWAIT JH, 1994, SCIENCE, V264, P699, DOI 10.1126/science.8171321; PYERITZ RE, 1989, AM J MED GENET, V34, P124, DOI 10.1002/ajmg.1320340120; Ransom DG, 1996, DEVELOPMENT, V123, P311; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Schier AF, 1996, DEVELOPMENT, V123, P165; Schilling TF, 1996, DEVELOPMENT, V123, P329; SMITH DW, 1988, RECOGNIZABLE PATTERN; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; SOLNICAKREZEL L, 1994, GENETICS, V136, P1401; SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67; Stainier DYR, 1996, DEVELOPMENT, V123, P285; Stemple DL, 1996, DEVELOPMENT, V123, P117; Trowe T, 1996, DEVELOPMENT, V123, P439; vanEeden FJM, 1996, DEVELOPMENT, V123, P255; vanEeden FJM, 1996, DEVELOPMENT, V123, P153; WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143; WEINSTEIN BW, 1986, DEVELOPMENT, V123, P303; Whitfield TT, 1996, DEVELOPMENT, V123, P241; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158	62	25	25	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1634	1635		10.1126/science.274.5293.1634	http://dx.doi.org/10.1126/science.274.5293.1634			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8984632				2022-12-01	WOS:A1996VW71200040
J	Metcalf, JV; Mitchison, HC; Palmer, JM; Jones, DE; Bassendine, MF; James, OFW				Metcalf, JV; Mitchison, HC; Palmer, JM; Jones, DE; Bassendine, MF; James, OFW			Natural history of early primary biliary cirrhosis	LANCET			English	Article							MITOCHONDRIAL AUTO-ANTIGENS; DISEASE; AUTOANTIBODIES; IDENTIFICATION; PROGNOSIS; SURVIVAL	Background In 1986, we reported a group of 29 patients who were positive in serum for antimitochondrial antibody (AMA), the disease-specific marker for primary biliary cirrhosis (PBC), but who had normal liver function test results and no symptoms of liver disease. However, liver histology was diagnostic or compatible with PBC in 24 patients and normal in only two. The aims of this 10-year follow-up study were to establish whether patients with AMA have very early PBC, to assess the outlook for such patients, and to follow the progression of the disease. Methods All patients were assessed every year at our PBC clinic: records were reviewed, cause of death verified when applicable, and current clinical and biochemical data collected, including repeat liver histology as indicated. Serum samples from the original study were located. Original and follow-up serum samples were tested by ELISA for E2 components of pyruvate dehydrogenase complex and 2-oxoglutarate dehydrogenase complex. Findings Five patients died during follow-up; no deaths were attributable to liver disease. Median follow-up of patients who survived was 17.8 years (range 11.0-23.9) from first-detected AMA to the last follow-up review. Overall, 22 (76%) developed symptoms of PBC and 24 (83%) had liver function tests persistently showing cholestasis. Repeat liver biopsy samples were obtained from ten patients; among these patients PBC progressed from Scheuer grade 1 to grade 2 in two and from grade 1 to grade 3 in two. No patient developed clinically apparent cirrhosis. ELISA of baseline serum samples from 27 patients was positive in 21, all of whom had original liver histology compatible with or diagnostic of PBC. Of the six patients who tested negative, only one had an original liver biopsy sample that was compatible with PBC. Interpretation This study confirms that before the advent of any clinical or biomedical indications, individuals positive for AMA do have PBC. This finding extends the natural history of PBC back in some cases for many years. What determines the eventual progression to biochemically and clinically apparent disease is not yet understood. During our study no patient developed clinically apparent portal hypertension or cirrhosis. Thus, although the finding of a solitary persistently raised AMA is confirmation of a diagnosis of PBC, patients with AMA but no other signs or symptoms of PBC seem to have slow progression of the disease.	UNIV NEWCASTLE UPON TYNE,SCH CLIN MED SCI,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; CITY HOSP SUNDERLAND NHS TRUST,SUNDERLAND,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; Sunderland Royal Hospital					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALASUBRAMANIAM K, 1990, GASTROENTEROLOGY, V98, P1567, DOI 10.1016/0016-5085(90)91091-J; BERG PA, 1992, DIGEST DIS, V10, P85, DOI 10.1159/000171347; CHRISTENSEN E, 1993, GASTROENTEROLOGY, V105, P1865, DOI 10.1016/0016-5085(93)91086-W; FUSSEY SPM, 1988, P NATL ACAD SCI USA, V85, P8654, DOI 10.1073/pnas.85.22.8654; HESELTINE L, 1990, GASTROENTEROLOGY, V99, P1786, DOI 10.1016/0016-5085(90)90488-M; JEFFREY GP, 1990, J GASTROEN HEPATOL, V5, P639, DOI 10.1111/j.1440-1746.1990.tb01118.x; LEHMANN AB, 1985, GERONTOLOGY, V31, P186, DOI 10.1159/000212701; LONG RG, 1977, GASTROENTEROLOGY, V72, P1104; MAHL TC, 1994, J HEPATOL, V20, P707, DOI 10.1016/S0168-8278(05)80139-4; MITCHISON HC, 1986, HEPATOLOGY, V6, P1279, DOI 10.1002/hep.1840060609; MITCHISON HC, 1990, GASTROENTEROLOGY, V99, P778, DOI 10.1016/0016-5085(90)90968-7; MUTIMER DJ, 1989, HEPATOLOGY, V10, P403, DOI 10.1002/hep.1840100402; NYBERG A, 1989, SCAND J GASTROENTERO, V24, P57, DOI 10.3109/00365528909092240; PALMER JM, 1993, CLIN SCI, V85, P289, DOI 10.1042/cs0850289; Portmann B. C., 1994, P477; ROLL J, 1983, NEW ENGL J MED, V301, P1; YEAMAN SJ, 1988, LANCET, V1, P1067	17	328	361	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1399	1402		10.1016/S0140-6736(96)04410-8	http://dx.doi.org/10.1016/S0140-6736(96)04410-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937278				2022-12-01	WOS:A1996VU98600009
J	Schuler, GD; Boguski, MS; Hudson, TJ; Hui, L; Ma, J; Castle, AB; Wu, X; Silva, J; Nusbaum, HC; Birren, BB; Slonim, DK; Rozen, S; Stein, LD; Page, D; Lander, ES; Stewart, EA; Aggarwal, A; Bajorek, E; Brady, S; Chu, A; Fang, N; Hadley, D; Harris, M; Hussain, S; Maratukulam, A; Perkins, S; Piercy, M; Qin, F; Reif, T; Sanders, C; She, X; Sun, WL; Tabar, P; Voyticky, S; Mader, C; McKusick, KB; Fan, JB; Cowles, S; Quackenbush, J; Vollrath, D; Myers, RM; Cox, DR; Butler, A; Clee, C; Dibling, T; East, C; Edwards, C; Garrett, C; Green, L; Harrison, P; Hicks, A; Holloway, E; Ranby, S; MacGilvery, A; Mungall, A; Peck, A; Wilmer, T; Soderlund, C; Rice, K; Dunham, I; Bentley, D; Deloukas, P; Gyapay, G; Chiannilkulchai, N; Fizames, C; Bentolila, S; Duprat, S; VegaCzarny, N; Muselet, D; Drouot, N; Morissette, J; Weissenbach, J; Morissette, J; James, MR; White, RE; Thangarajah, T; LouisDitSully, C; Day, PJR; Goodfellow, PN; Schmitt, K; Walter, NAR; Berry, R; Iorio, KR; Sikela, JM; Polymeropoulos, MH; Torres, R; Ide, SE; Dehejia, A; Houlgatte, R; Auffray, C; Adams, MD; Phillips, C; Brandon, R; Sandusky, M; Venter, JC; Seki, N; Nagase, T; Ishikawa, K; Nomura, N; RodriguezTome, P; Matise, TC; Lee, WY; Swanson, KA; Hudson, JR				Schuler, GD; Boguski, MS; Hudson, TJ; Hui, L; Ma, J; Castle, AB; Wu, X; Silva, J; Nusbaum, HC; Birren, BB; Slonim, DK; Rozen, S; Stein, LD; Page, D; Lander, ES; Stewart, EA; Aggarwal, A; Bajorek, E; Brady, S; Chu, A; Fang, N; Hadley, D; Harris, M; Hussain, S; Maratukulam, A; Perkins, S; Piercy, M; Qin, F; Reif, T; Sanders, C; She, X; Sun, WL; Tabar, P; Voyticky, S; Mader, C; McKusick, KB; Fan, JB; Cowles, S; Quackenbush, J; Vollrath, D; Myers, RM; Cox, DR; Butler, A; Clee, C; Dibling, T; East, C; Edwards, C; Garrett, C; Green, L; Harrison, P; Hicks, A; Holloway, E; Ranby, S; MacGilvery, A; Mungall, A; Peck, A; Wilmer, T; Soderlund, C; Rice, K; Dunham, I; Bentley, D; Deloukas, P; Gyapay, G; Chiannilkulchai, N; Fizames, C; Bentolila, S; Duprat, S; VegaCzarny, N; Muselet, D; Drouot, N; Morissette, J; Weissenbach, J; Morissette, J; James, MR; White, RE; Thangarajah, T; LouisDitSully, C; Day, PJR; Goodfellow, PN; Schmitt, K; Walter, NAR; Berry, R; Iorio, KR; Sikela, JM; Polymeropoulos, MH; Torres, R; Ide, SE; Dehejia, A; Houlgatte, R; Auffray, C; Adams, MD; Phillips, C; Brandon, R; Sandusky, M; Venter, JC; Seki, N; Nagase, T; Ishikawa, K; Nomura, N; RodriguezTome, P; Matise, TC; Lee, WY; Swanson, KA; Hudson, JR			Genome maps .7. The human transcript map	SCIENCE			English	Article									WHITEHEAD INST,CTR GENOME RES,CAMBRIDGE,MA 02142; STANFORD HUMAN GENOME CTR,STANFORD,CA; SANGER CTR,CAMBRIDGE,ENGLAND; CNRS,GENETHON,EVRY,FRANCE; CHU LAVAL,CTR RECH,LAVAL,PQ,CANADA; WELLCOME TRUST CTR HUMAN GENET,OXFORD,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CB2 1TN,ENGLAND; UNIV COLORADO,HLTH SCI CTR,DENVER,CO; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; CNRS,GENEXPRESS,VILLEJUIF,FRANCE; INST GENOM RES,ROCKVILLE,MD; KAZUSA DNA RES INST,KISARAZU,JAPAN; EUROPEAN MOL BIOL LAB OUTSTN,EUROPEAN BIOINFORMAT INST,CAMBRIDGE,ENGLAND; ROCKEFELLER UNIV,NEW YORK,NY; RES GENET,HUNTSVILLE,AL	Massachusetts Institute of Technology (MIT); Whitehead Institute; Stanford University; Wellcome Trust Sanger Institute; Centre National de la Recherche Scientifique (CNRS); Laval University; University of Oxford; Wellcome Centre for Human Genetics; University of Cambridge; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Centre National de la Recherche Scientifique (CNRS); J. Craig Venter Institute; Kazusa DNA Research Institute; European Molecular Biology Laboratory (EMBL); Rockefeller University	Schuler, GD (corresponding author), NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20894, USA.		Deloukas, Panos/B-2922-2013; Houlgatte, Remi/P-3020-2017; Mungall, Andrew J./U-7067-2018; Rozen, Steven G./J-5939-2013	Deloukas, Panos/0000-0001-9251-070X; Mungall, Andrew J./0000-0002-0905-2742; Slonim, Donna/0000-0003-3357-437X; Rozen, Steven G./0000-0002-4288-0056				RES GENETICS RESOURC, V3, P1	1	32	32	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					547	558						12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8928009				2022-12-01	WOS:A1996VN91900039
J	Jacobson, DR; Pastore, RD; Yaghoubian, R; Kane, I; Gallo, G; Buck, FS; Buxbaum, JN				Jacobson, DR; Pastore, RD; Yaghoubian, R; Kane, I; Gallo, G; Buck, FS; Buxbaum, JN			Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SENILE SYSTEMIC AMYLOIDOSIS; CLINICAL-SIGNIFICANCE; LIVER-TRANSPLANTATION; POLYNEUROPATHY; FREQUENCY; HEART; GENE; PCR; POPULATION; AUTOPSY	Background After the age of 60, isolated cardiac amyloidosis is four times more common among blacks than whites in the United States; 3.9 percent of blacks are heterozygous for an amyloidogenic allele of the normal serum carrier protein transthyretin in which isoleucine is substituted for valine at position 122 (Ile 122). We hypothesized that the high prevalence of transthyretin lie 122 is at least partially responsible for the increased frequency of senile cardiac amyloidosis among blacks. Methods Paraffin blocks of cardiac tissue were obtained from an earlier study of 52,370 autopsies in Los Angeles and were examined by immunohistochemical and DNA analyses. Samples were available from 32 of 55 blacks and 20 of 78 whites over 60 years of age with isolated cardiac amyloidosis and from two control groups (228 cases). Results Transthyretin amyloidosis was identified in 31 of the 32 cardiac-tissue samples from the black patients and in 19 of the 20 samples from the white patients. Six of the 26 analyzable DNA samples (23 percent) from the black patients and none of the 19 samples from the white patients were heterozygous for the lie 122 variant, Four of 125 DNA samples obtained at autopsy (3.2 percent) from a second, more recent, age-matched cohort of blacks without amyloidosis at the same institution were heterozygous for the transthyretin lie 122 allele. On reexamination the cardiac tissue from these four patients contained small amounts of amyloid not detected at the initial autopsies. All subjects with the lie 122 variant had ventricular amyloid. Conclusions The assessment of elderly black patients with unexplained heart disease should include a consideration of transthyretin amyloidosis, particularly that related to the lie 122 allele. (C)1997, Massachusetts Medical Society.	VET AFFAIRS MED CTR, RES SERV, NEW YORK, NY 10010 USA; NYU, SCH MED, DEPT MED, NEW YORK, NY USA; NYU, SCH MED, DEPT PATHOL, NEW YORK, NY USA; UNIV SO CALIF, LOS ANGELES CTY MED CTR, DEPT PATHOL, LOS ANGELES, CA 90033 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); New York University; New York University; University of Southern California					PHS HHS [34900] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALMEIDA MD, 1991, BIOCHIM BIOPHYS ACTA, V1097, P224; Alves Isabel L., 1993, Journal of Rheumatology, V20, P185; [Anonymous], 1993, Bull World Health Organ, V71, P105; BARTALENA L, 1992, THYROID, V2, P237, DOI 10.1089/thy.1992.2.237; Beneke R, 1908, BEITR PATHOL ANAT AL, V44, P362; Benson MD, 1996, AMYLOID, V3, P44, DOI 10.3109/13506129609014354; BUCK FS, 1989, MODERN PATHOL, V2, P372; CHRISTMANSON L, 1991, FEBS LETT, V281, P177, DOI 10.1016/0014-5793(91)80387-I; COELHO T, 1994, J MED GENET, V31, P293, DOI 10.1136/jmg.31.4.293; GALLO G, 1988, MODERN PATHOL, V1, P453; GALLO GR, 1986, CLIN IMMUNOL IMMUNOP, V39, P479, DOI 10.1016/0090-1229(86)90175-3; GERTZ MA, 1985, AM J CARDIOL, V55, P1645, DOI 10.1016/0002-9149(85)90995-6; GOREVIC PD, 1989, J CLIN INVEST, V83, P836, DOI 10.1172/JCI113966; GRATEAU G, 1993, CLIN GENET, V43, P143, DOI 10.1111/j.1399-0004.1993.tb04439.x; Greer C E, 1991, PCR Methods Appl, V1, P46; GRIFFITHS BE, 1982, THORAX, V37, P711, DOI 10.1136/thx.37.9.711; GUSTAVSSON A, 1995, LAB INVEST, V73, P703; HODKINSON HM, 1977, Q J MED, V46, P381; HUSBY G, 1992, J INTERN MED, V232, P511, DOI 10.1111/j.1365-2796.1992.tb00626.x; Jacobson D R, 1991, Adv Hum Genet, V20, P69; JACOBSON DR, 1990, AM J HUM GENET, V47, P127; Jacobson DR, 1996, HUM GENET, V98, P236, DOI 10.1007/s004390050199; JACOBSON DR, 1992, AM J HUM GENET, V50, P195; JACOBSON DR, 1991, AM J HUM GENET, V49, P192; JACOBSON DR, 1994, HUM MUTAT, V3, P254, DOI 10.1002/humu.1380030313; JACOBSON DR, 1994, AMYLOID AMYLOIDOSIS, P474; JACOBSON DR, 1991, ADV HUM GENET, V20, P309; JACOBSON DR, IN PRESS TEXAS HEART; JONES RS, 1950, ARCH PATHOL, V50, P366; KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889; Kwok S, 1990, PCR PROTOCOLS GUIDE, P142; KYLE RA, 1994, AMYLOID AMYLOIDOSIS, P648; LIE JT, 1988, MAYO CLIN PROC, V63, P552, DOI 10.1016/S0025-6196(12)64885-X; MILLS NE, 1995, J NATL CANCER I, V87, P1056, DOI 10.1093/jnci/87.14.1056; NAVIDI W, 1992, AM J HUM GENET, V50, P347; NICHOLS WC, 1991, J LAB CLIN MED, V117, P175; *PHS, 1991, DHHS PUBL, P46; POMERANCE A, 1991, CARDIOVASC PATHOL, P155; RUBINOW A, 1981, CIRCULATION, V63, P1285, DOI 10.1161/01.CIR.63.6.1285; RUSSELL C, 1996, OFFICIAL GUIDE RACIA, P71; SARAIVA MJM, 1990, SCAND J IMMUNOL, V32, P341, DOI 10.1111/j.1365-3083.1990.tb02928.x; Skinner M, 1996, AM J MED, V100, P290, DOI 10.1016/S0002-9343(97)89487-9; SKINNER M, 1994, ANN INTERN MED, V120, P133, DOI 10.7326/0003-4819-120-2-199401150-00006; SMITH TJ, 1984, MAYO CLIN PROC, V59, P547, DOI 10.1016/S0025-6196(12)61493-1; Soyka J, 1876, PRAG MED WOCHENSCH, V1, P165; SUHR OB, 1995, TRANSPLANTATION, V60, P933, DOI 10.1097/00007890-199511150-00009; WRIGHT JR, 1975, J AM GERIATR SOC, V23, P97, DOI 10.1111/j.1532-5415.1975.tb00968.x; WRIGHT JR, 1969, MEDICINE, V48, P39, DOI 10.1097/00005792-196901000-00002	48	390	415	1	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1997	336	7					466	473		10.1056/NEJM199702133360703	http://dx.doi.org/10.1056/NEJM199702133360703			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG776	9017939	Bronze			2022-12-01	WOS:A1997WG77600003
J	Barrett, T; Xiao, B; Dodson, EJ; Dodson, G; Ludbrook, SB; Nurmahomed, K; Gamblin, SJ; Musacchio, A; Smerdon, SJ; Eccleston, JF				Barrett, T; Xiao, B; Dodson, EJ; Dodson, G; Ludbrook, SB; Nurmahomed, K; Gamblin, SJ; Musacchio, A; Smerdon, SJ; Eccleston, JF			The structure of the GTPase-activating domain from p50rhoGAP	NATURE			English	Article							PROTEIN; BINDING; RHO; BCR; REGION	Members of the Rho family of small G proteins transduce signals from plasma-membrane receptors and control cell adhesion, motility and shape by actin cytoskeleton formation(1-4), They also activate other kinase cascades, Like all other GTPases, Rho proteins act as molecular switches, with an active GTP-bound form and an inactive GDP-bound form(5), The active conformation is promoted by guanine-nucleotide exchange factors, and the inactive state by GTPase-activating proteins (GAPs) which stimulate the intrinsic GTPase activity of small G proteins(6), Rho-specific GAP domains are found in a wide variety of large, multi-functional proteins(7), Here we report the crystal structure of an active 242-residue C-terminal fragment of human p50rhoGAP(8), The structure is an unusual arrangement of nine alpha-helices, the core of which includes a four-helix bundle, Residues conserved across the rhoGAP family are largely confined to one face of this bundle, which may be an interaction site for target G protein, In particular, we propose that Arg 85 and Asn 194 are involved in binding G proteins and enhancing GTPase activity.	NATL INST MED RES, LONDON NW7 1AA, ENGLAND; UNIV YORK, DEPT CHEM, YORK YO1 5DD, N YORKSHIRE, ENGLAND; CHILDRENS HOSP, MOL MED LAB, BOSTON, MA 02115 USA	MRC National Institute for Medical Research; University of York - UK; Harvard University; Boston Children's Hospital				Smerdon, Stephen/0000-0001-5688-8465; Musacchio, Andrea/0000-0003-2362-8784				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LIFSHITZ B, 1988, ONCOGENE, V2, P113; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1994, J CELL SCI, P127; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	22	94	102	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 30	1997	385	6615					458	461		10.1038/385458a0	http://dx.doi.org/10.1038/385458a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009196				2022-12-01	WOS:A1997WF00700058
J	Preziosi, MP; Yam, A; Ndiaye, M; Simaga, A; Simondon, F; Wassilak, SGF				Preziosi, MP; Yam, A; Ndiaye, M; Simaga, A; Simondon, F; Wassilak, SGF			Practical experiences in obtaining informed consent for a vaccine trial in rural Africa	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ETHICS		INST FRANCAIS RECH SCI DEV & COOPERAT,DAKAR,SENEGAL; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA				Simondon, Francois/0000-0003-0395-1314				AABY P, 1993, AM J EPIDEMIOL, V138, P746, DOI 10.1093/oxfordjournals.aje.a116912; ANGELL M, 1988, NEW ENGL J MED, V319, P1081, DOI 10.1056/NEJM198810203191608; BARRY M, 1988, NEW ENGL J MED, V319, P1083, DOI 10.1056/NEJM198810203191609; BRANDON S, 1991, J ROY SOC MED, V84, P575; *COM CONS NAT ETH, 1993, 41 COM CONS NAT ETH; DICKINSON RE, 1991, CLIMATIC CHANGE, V19, P175, DOI 10.1007/BF00142224; FREEMAN TR, 1992, FAM PRACT, V9, P36, DOI 10.1093/fampra/9.1.36; HOFFMASTER B, 1992, SOC SCI MED, V35, P1421, DOI 10.1016/0277-9536(92)90045-R; *I SUP SAN, 1995, 11 INT S PERT VACC T; IJSSELMUIDEN CB, 1992, NEW ENGL J MED, V326, P830, DOI 10.1056/NEJM199203193261212; Levine R J, 1991, Law Med Health Care, V19, P207; LYNOE N, 1991, BRIT MED J, V303, P610, DOI 10.1136/bmj.303.6803.610; MEISEL A, 1992, ARTHRITIS RHEUM, V35, P1264, DOI 10.1002/art.1780351104; MILLER B, 1992, AM BOOK REV, V14, P7; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P771, DOI 10.1016/0895-4356(91)90129-W; SIMONDON F, 1994, 34 INT C ANT AG CHEM, P188; Singer P A, 1990, J Clin Ethics, V1, P95; SPAETH GL, 1992, OPHTHALMIC SURG LAS, V23, P648; *WHO, 1982, PROP INT GUID BIOM R; *WHO, 1993, WHO GUID GOOD CLIN P; World Health Organization, 1993, INT ETH GUID BIOM RE	21	62	63	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1997	336	5					370	373		10.1056/NEJM199701303360511	http://dx.doi.org/10.1056/NEJM199701303360511			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG233	9011793				2022-12-01	WOS:A1997WG23300011
J	Arvanitakis, L; GerasRaaka, E; Varma, A; Gershengorn, MC; Cesarman, E				Arvanitakis, L; GerasRaaka, E; Varma, A; Gershengorn, MC; Cesarman, E			Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation	NATURE			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; KAPOSIS-SARCOMA; DNA-SEQUENCES; GENE-EXPRESSION; CHEMOKINES; CYTOKINES; SAIMIRI; CLONING	Kaposi's sarcoma-associated herpesvirus (KSHV, also known as human herpesvirus 8, or HHV 8) is a virus that is consistently present in Kaposi's sarcoma(1,2) and in primary-effusion (body-cavity-based) lymphomas(3), malignancies that occur frequently, but not exclusively in AIDS patients. KSHV is a gamma herpesvirus with homology to herpesvirus Saimiri and Epstein-Barr virus(1,4), both of which can transform lymphocytes(5). Cloning of a KSHV genome fragment revealed the presence of an open reading frame encoding a putative G-protein-coupled receptor(6) that is homologous to a G-protein-coupled receptor encoded by herpesvirus Saimiri(7,8) and to human interleukin-8 receptors(9,10). Here we show that the KSHV G-protein-coupled receptor is a bona fide signalling receptor which has constitutive (agonist-independent) activity in the phosphoinositide-inositoltrisphosphate-protein kinase C pathway. Furthermore, the KSHV G-protein-coupled receptor stimulates cellular proliferation, making it a candidate viral oncogene.	CORNELL UNIV MED COLL,DEPT MED,DIV MOL MED,NEW YORK,NY 10021; CORNELL UNIV MED COLL,DEPT PATHOL,NEW YORK,NY 10021	Cornell University; Cornell University								AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Alblas J, 1996, EMBO J, V15, P3351, DOI 10.1002/j.1460-2075.1996.tb00700.x; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; DOTTO GP, 1985, NATURE, V318, P472; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; ERDOS G, 1995, J CELL PHYSIOL, V164, P404, DOI 10.1002/jcp.1041640221; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LOYTER A, 1982, P NATL ACAD SCI-BIOL, V79, P422, DOI 10.1073/pnas.79.2.422; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; NUSSENZVEIG DR, 1994, J BIOL CHEM, V269, P28123; Roizman B, 1996, FIELDS VIROLOGY, P2221; SANDE JV, 1995, J CLIN ENDOCR METAB, V80, P2577; SCHADLOW VC, 1992, MOL BIOL CELL, V3, P941, DOI 10.1091/mbc.3.8.941; SCIACCA FL, 1994, J IMMUNOL, V153, P4816; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	28	529	554	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					347	350		10.1038/385347a0	http://dx.doi.org/10.1038/385347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002520				2022-12-01	WOS:A1997WD91400052
J	Hardingham, GE; Chawla, S; Johnson, CM; Bading, H				Hardingham, GE; Chawla, S; Johnson, CM; Bading, H			Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression	NATURE			English	Article							C-FOS; HIPPOCAMPAL-NEURONS; NERVOUS-SYSTEM; ACTIVATION; KINASE; SERUM; TRANSCRIPTION; STIMULATION; SEQUENCES; PATHWAYS	Calcium entry into neuronal cells through voltage or ligand-gated ion channels triggers neuronal affinity-dependent gene expression critical for adaptive changes in the nervous system(1-5). Cytoplasmic calcium transients are often accompanied by an increase in the concentration of nuclear calcium(6-9), but the functional significance of such spatially distinct calcium signals is unknown. Here we show that gene expression is differentially controlled by nuclear and cytoplasmic calcium signals which enable a single second messenger to generate diverse transcriptional responses, We used nuclear microinjection of a nondiffusible calcium chelator to block increases in nuclear, but not cytoplasmic, calcium concentrations following activation of L-type voltage-gated calcium channels, We showed that increases in nuclear calcium concentration control calcium-activated gene expression mediated by the cyclic-AMP-response element (CRE), and demonstrated that the CRE-binding protein CREB can function as a nuclear calcium-responsive transcription factor. A second signalling pathway, activating transcription through the serum-response element (SRE), is triggered by a rise in cytoplasmic calcium and does not require an increase in nuclear calcium.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology				Johnson, Claire/0000-0003-4428-3594; Hardingham, Giles/0000-0002-7629-5314				ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRCH BD, 1992, P NATL ACAD SCI USA, V89, P7978, DOI 10.1073/pnas.89.17.7978; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MINTA A, 1989, J BIOL CHEM, V264, P8171; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; OMALLEY DM, 1994, J NEUROSCI, V14, P5741; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SEGAL M, 1992, J PHYSIOL-LONDON, V448, P655, DOI 10.1113/jphysiol.1992.sp019063; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; WORLEY PE, 1994, J NEUROSCI, V13, P4776; ZHENG W, 1991, MOL PHARMACOL, V40, P734	27	626	649	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1997	385	6613					260	265		10.1038/385260a0	http://dx.doi.org/10.1038/385260a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000075				2022-12-01	WOS:A1997WC71100050
J	Doney, K; Leisenring, W; Storb, R; Appelbaum, FR				Doney, K; Leisenring, W; Storb, R; Appelbaum, FR			Primary treatment of acquired aplastic anemia: Outcomes with bone marrow transplantation and immunosuppressive therapy	ANNALS OF INTERNAL MEDICINE			English	Article						outcome and process assessment (health care); anemia, aplastic; bone marrow transplantation; immunosuppression; age factors	VERSUS-HOST DISEASE; ANTITHYMOCYTE GLOBULIN ATG; HLA-HAPLOIDENTICAL MARROW; COLONY-STIMULATING FACTOR; ANTI-THYMOCYTE GLOBULIN; SAA WORKING PARTY; RANDOMIZED TRIAL; ANTILYMPHOCYTE GLOBULIN; MALIGNANT-TUMORS; GRAFT	Background: Both immunosuppressive therapy and bone marrow transplantation are accepted treatments for patients with aplastic anemia. Choosing one of these therapies for a given patient depends not only on donor availability but also on such factors as patient age. Objective: io compare survival rates and long-term complications after bone marrow transplantation or immunosuppressive therapy in patients with acquired aplastic anemia and to identify prognostic factors associated with improved survival. Design: Center-based, retrospective analysis. Setting: Referral center for patients with aplastic anemia. Patients: 395 patients with acquired aplastic anemia. Intervention: Bone marrow transplant from an HLA-identical, related donor or immunosuppressive therapy. Measurements: Kaplan-Meier survival curves, results of log-rank tests, and cumulative incidence curves. Results: Of 168 bone marrow transplant recipients, 89% had sustained engraftment. Forty-six patients developed grade II to IV acute graft-versus-host disease, and 68 developed chronic graft-versus-host disease that required therapy. Of 227 patients who received immunosuppressive therapy, 44% achieved a complete, partial, or minimal response. Fifty-four percent died or had no response to therapy. Actuarial survival at 15 years was 69% for bone marrow transplant recipients and 38% for patients receiving immunosuppressive therapy (P < 0.001). Improved survival was associated with having bone marrow transplantation as primary therapy, being younger, having no transfusion before transplantation, and having a higher absolute neutrophil count. Disease duration, year of therapy, sex, refractoriness to platelet transfusions, and previous treatment with androgens or corticosteroids did not significantly affect survival. Conclusions: Data from this center suggest that bone marrow transplantation may be preferred for younger patients with acquired aplastic anemia who have matched, related donors. Long-term survival is excellent for patients who respond to either form of therapy.	SEATTLE VET ADM MED CTR, SEATTLE, WA USA		Doney, K (corresponding author), UNIV WASHINGTON, FRED HUTCHINSON CANC RES CTR,SCH MED,DIV CLIN RES, 1124 COLUMBIA ST, M-120, SEATTLE, WA 98104 USA.				NCI NIH HHS [CA 18221, CA 15704] Funding Source: Medline; NHLBI NIH HHS [HL 36444] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA015704, P01CA018221] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036444] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACIGALUPO A, 1995, BLOOD, V85, P1348, DOI 10.1182/blood.V85.5.1348.bloodjournal8551348; BACIGALUPO A, 1988, BRIT J HAEMATOL, V70, P177, DOI 10.1111/j.1365-2141.1988.tb02460.x; CAMITTA B, 1983, BLOOD, V62, P883; CAMITTA BM, 1976, BLOOD, V48, P63; CRUMP M, 1992, AM J MED, V92, P596, DOI 10.1016/0002-9343(92)90776-8; DEEG HJ, 1985, TRANSPLANTATION, V40, P162, DOI 10.1097/00007890-198508000-00011; DEEG HJ, 1986, TRANSPLANT P, V18, P791; DONEY K, 1987, EXP HEMATOL, V15, P239; DONEY K, 1984, BLOOD, V63, P342; DONEY K, 1992, BLOOD, V79, P2566; DONEY K, 1993, BRIT J HAEMATOL, V85, P182, DOI 10.1111/j.1365-2141.1993.tb08665.x; DONEY KC, 1981, EXP HEMATOL, V9, P829; DONEY KC, 1981, AM J HEMATOL, V11, P1, DOI 10.1002/ajh.2830110102; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KENNEDY MS, 1985, AM J MED, V78, P978, DOI 10.1016/0002-9343(85)90221-9; MARSH JCW, 1987, BLOOD, V70, P1046; PAQUETTE RL, 1995, BLOOD, V85, P283, DOI 10.1182/blood.V85.1.283.bloodjournal851283; PEPE MS, 1993, BRIT J HAEMATOL, V83, P602, DOI 10.1111/j.1365-2141.1993.tb04697.x; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SOCIE G, 1991, BLOOD, V78, P277; STORB R, 1994, BLOOD, V83, P2749; STORB R, 1980, ANN INTERN MED, V92, P30, DOI 10.7326/0003-4819-92-1-30; STORB R, 1982, BLOOD, V59, P236; STORB R, 1986, BLOOD, V68, P119; STORB R, 1994, BLOOD, V84, P941, DOI 10.1182/blood.V84.3.941.941; SULLIVAN KM, 1991, SEMIN HEMATOL, V28, P250; SULLIVAN KM, 1988, BLOOD, V72, P546; SULLIVAN KM, 1988, BLOOD, V72, P555; TICHELLI A, 1988, BRIT J HAEMATOL, V69, P413, DOI 10.1111/j.1365-2141.1988.tb02382.x	30	128	135	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1997	126	2					107	+		10.7326/0003-4819-126-2-199701150-00003	http://dx.doi.org/10.7326/0003-4819-126-2-199701150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD298	9005744				2022-12-01	WOS:A1997WD29800005
J	Haley, RW; Kurt, TL				Haley, RW; Kurt, TL			Self-reported exposure to neurotoxic chemical combinations in the Gulf War - A cross-sectional epidemiologic study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Research Conference on the Gulf War Illness	OCT 26, 1995	CTR DIS CONTROL & PREVENT, ATLANTA, GA		CTR DIS CONTROL & PREVENT		INDUCED DELAYED POLYNEUROPATHY; NERVE AGENTS; PYRIDOSTIGMINE; ORGANOPHOSPHORUS; SOMAN; PRETREATMENT; NEUROPATHY; SARIN; ANTAGONISM; PROTECTION	Objective.-To identify risk factors of factor analysis-derived Gulf War-related syndromes. Design.-A cross-sectional survey. Participants.-A total of 249 Gulf War veterans from the Twenty-fourth Reserve Naval Mobile Construction Battalion. Data Collection.-Participants completed standardized booklets measuring self-reported wartime exposures and present symptoms. Main Outcome Measures.-Associations of factor analysis-derived syndromes with risk factors for chemical interactions that inhibit butyrylcholinesterase and neuropathy target esterase. Results.-Risk of syndrome 1 (''impaired cognition'') was greater in veterans who reported wearing flea collars during the war (5 of 20, 25%) than in those who never wore them (7 of 229, 3%; relative risk [RR], 8.7; 95% confidence interval [CI], 3.0-24.7; P<.001). Risk of syndrome 2 (''confusion-ataxia'') increased with a scale of advanced adverse effects from pyridostigmine bromide (chi(2) for trend, P<.001), was greater among veterans who believed they had been involved in chemical weapons exposure (18 of 108, 17%) than in those who did not (3 of 141, 2%; RR, 7.8; 95% CI, 2.3-25.9; P<.001), and was increased in veterans who had been in a sector of far northeastern Saudi Arabia on the fourth day of the air war (6 of 21, 29%) than in those who had not been (15 of 228, 7%; RR, 4.3; 95% CI, 1.9-10.0; P=.004). Effects of perceived chemical weapons exposure and advanced adverse effects from pyridostigmine were synergistic (Rothman S, 5.3; 95% CI, 1.04-26.7), Risk of syndrome 3 (''arthro-myo-neuropathy'') increased with an index of frequency and amount of government-issued insect repellent containing 75% DEET (N,N-diethyl-m-toluamide) in ethanol applied during the war (chi(2) for trend, P<.001) and with advanced adverse effects from pyridostigmine (chi(2) for trend, P<.001). Conclusion.-Some Gulf War Veterans may have delayed, chronic neurotoxic syndromes from wartime exposure to combinations of chemicals that inhibit butyrylcholinesterase and neuropathy target esterase.			Haley, RW (corresponding author), UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DIV EPIDEMIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.		Haley, Robert/P-9026-2014	Haley, Robert/0000-0001-8849-9579				AbouDonia MB, 1996, J TOXICOL ENV HEALTH, V48, P35, DOI 10.1080/009841096161456; AbouDonia MB, 1996, FUND APPL TOXICOL, V34, P201, DOI 10.1006/faat.1996.0190; ABOUDONIA MB, 1990, ANNU REV PHARMACOL, V30, P405, DOI 10.1146/annurev.pa.30.040190.002201; [Anonymous], 1994, JAMA, V272, P391; BAKER DB, 1988, ARCH ENVIRON HEALTH, V43, P325; BOULDIN TW, 1979, AM J PATHOL, V94, P241; BROOMFIELD CA, 1991, J PHARMACOL EXP THER, V259, P633; CAPODICASA E, 1991, ARCH TOXICOL, V65, P150, DOI 10.1007/BF02034943; Cattell R. B., 1978, SCI USE FACTOR ANAL, DOI [DOI 10.1007/978-1-4684-2262-7_5, 10.1007/978-1-4684-2262-7_5]; COOK JE, 1992, MIL MED, V157, P250, DOI 10.1093/milmed/157.5.250; DEBLEECKER JL, 1992, CLIN NEUROL NEUROSUR, V94, P93, DOI 10.1016/0303-8467(92)90065-B; *DEF SCI BOARD, 1994, REP DEF SCI BOARD TA; DIRNHUBER P, 1978, J PHARM PHARMACOL, V30, P419, DOI 10.1111/j.2042-7158.1978.tb13278.x; DOCTOR BP, 1993, CHEM-BIOL INTERACT, V87, P285, DOI 10.1016/0009-2797(93)90056-5; DUFFY FH, 1979, TOXICOL APPL PHARM, V47, P161, DOI 10.1016/0041-008X(79)90083-8; DUNN MA, 1989, JAMA-J AM MED ASSOC, V262, P649, DOI 10.1001/jama.262.5.649; ECOBICHON DJ, 1994, PESTICIDES NEUROLOGI, P171; Goldberg J, 1992, Ann Epidemiol, V2, P841, DOI 10.1016/1047-2797(92)90078-5; GORDON JJ, 1983, ARCH TOXICOL, V52, P71, DOI 10.1007/BF00354767; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P223, DOI 10.1001/jama.277.3.223; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P215, DOI 10.1001/jama.277.3.215; Hayes W.J., 1991, HDB PESTICIDE TOXICO; HOGAN MD, 1978, AM J EPIDEMIOL, V108, P60; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; Husain K., 1995, Indian Journal of Physiology and Pharmacology, V39, P47; HUSAIN K, 1993, J APPL TOXICOL, V13, P143, DOI 10.1002/jat.2550130212; *I MED MED FOLL UP, 1995, HLTH CONS SERV PERS; IDSON B, 1975, J PHARM SCI-US, V64, P901, DOI 10.1002/jps.2600640604; Jamal GA, 1996, J NEUROL NEUROSUR PS, V60, P449, DOI 10.1136/jnnp.60.4.449; JOHNSON MK, 1970, BIOCHEM J, V120, P523, DOI 10.1042/bj1200523; JOHNSON MK, 1987, TRENDS PHARMACOL SCI, V8, P174, DOI 10.1016/0165-6147(87)90161-1; KAPLAN JG, 1993, NEUROLOGY, V43, P2193, DOI 10.1212/WNL.43.11.2193; KEELER JR, 1991, JAMA-J AM MED ASSOC, V266, P693, DOI 10.1001/jama.266.5.693; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P284; KOPLOVITZ I, 1992, FUND APPL TOXICOL, V18, P102, DOI 10.1016/0272-0590(92)90201-R; La Du BN, 1992, PHARMACOGENETICS DRU, P51; LEESHALEY PR, 1992, PERCEPT MOTOR SKILL, V75, P531, DOI 10.2466/PMS.75.5.531-544; LOTTI M, 1992, CRIT REV TOXICOL, V21, P465, DOI 10.3109/10408449209089884; MANTEL N, 1959, J NATL CANCER I, V22, P719; *MICR HEALTHC SERV, 1995, POISINDEX CD ROM VER; MILLER SA, 1993, PHARMACOL BIOCHEM BE, V44, P343, DOI 10.1016/0091-3057(93)90472-6; MORGAN JP, 1978, ARCH NEUROL-CHICAGO, V35, P530, DOI 10.1001/archneur.1978.00500320050011; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P403; MOUNT ME, 1991, VET HUM TOXICOL, V33, P19; OSIMITZ TG, 1995, J AM MOSQUITO CONTR, V11, P274; PETTY CS, 1958, AM J MED, V24, P467, DOI 10.1016/0002-9343(58)90332-2; POPE CN, 1990, J TOXICOL ENV HEALTH, V31, P261, DOI 10.1080/15287399009531455; RICHARDSON RJ, 1992, ORGANOPHOSPHATES CHE, P299; ROBBINS PJ, 1986, J TOXICOL ENV HEALTH, V18, P503, DOI 10.1080/15287398609530891; ROSENSTOCK L, 1991, LANCET, V338, P223, DOI 10.1016/0140-6736(91)90356-T; ROTHMAN KJ, 1976, AM J EPIDEMIOL, V103, P506, DOI 10.1093/oxfordjournals.aje.a112252; RUMMEL RJ, 1970, APPLIED FACTOR ANAL; SABRI MI, 1980, EXPT CLIN NEUROTOXIC, P206; SAS Institute Inc, 1990, SAS STAT US GUID VER, V4; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SAVAGE EP, 1988, ARCH ENVIRON HEALTH, V43, P38, DOI 10.1080/00039896.1988.9934372; SHARABI Y, 1991, ISRAEL J MED SCI, V27, P656; SIDELL FR, 1992, ANN EMERG MED, V21, P865, DOI 10.1016/S0196-0644(05)81036-4; SIDELL FR, 1974, CLIN TOXICOL, V7, P1; Smith MI, 1930, PUBLIC HEALTH REP, V45, P2509, DOI 10.2307/4579816; Snedecor GW, 1980, STAT METHODS; SPIEGELBERG U, 1961, WERHRDIENST GESUNDHE, V3; Stockholm International Peace Research Institute, 1975, DEL TOX EFF CHEM WAR; TAUBES G, 1995, SCIENCE, V269, P164, DOI 10.1126/science.7618077; *US SEN, 1994, US CHEM BIOL WARF RE; WENGER B, 1993, AVIAT SPACE ENVIR MD, V64, P905; WILLEMS JL, 1984, ARCH TOXICOL, V55, P76, DOI 10.1007/BF00316591; WINDHEUSER JJ, 1982, J PHARM SCI-US, V71, P1211, DOI 10.1002/jps.2600711107	69	269	274	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1997	277	3					231	237		10.1001/jama.277.3.231	http://dx.doi.org/10.1001/jama.277.3.231			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WB446	9005273				2022-12-01	WOS:A1997WB44600025
J	Castillo, J; Davalos, A; Noya, M				Castillo, J; Davalos, A; Noya, M			Progression of ischaemic stroke and excitotoxic aminoacids	LANCET			English	Article							FOCAL CEREBRAL-ISCHEMIA; GLUTAMATE; PROGNOSIS; RELEASE; INJURY	Background Mechanisms involved in progression of stroke are little understood. Studies in animals have shown an association between neuronal death mediated by excitatory aminoacids and deterioration in focal cerebral ischaemia. We looked for an association between concentrations of glutamate and glycine in plasma and cerebrospinal fluid (CSF) and early progression in a prospective study of 128 patients with acute ischaemic stroke. Methods Of 556 consecutive admissions to our emergency unit, 128 eligible patients with ischaemic stroke were included in our study. Blood and CSF samples were taken within the first 24 h from stroke onset when cerebral oedema had been excluded on a previous cranial computed tomography. Ischaemic stroke was judged to be in progression if the Canadian stroke scale score (1.5=maximum neurological deficit, 10=no deficit) fell by 1 or more points during the first 48 h after inclusion. Glutamate and glycine concentrations in plasma and CSF were measured by high-performance liquid chromatography. The effect of plasma and CSF glutamate concentrations on progression was analysed by logistic regression. Findings 43 (33.6%) patients had progressing ischaemic stroke. Concentrations of glutamate and glycine in plasma and CSF were higher in patients with progressing stroke than in those with stable cerebral infarcts (p<0.0001). There was a significant linear correlation between CSF and plasma concentrations of glutamate (r=0.79, p<0.001). The positive predictive value of a plasma glutamate concentration of more than 200 mu mol/L for progression of ischaemic stroke was 97% (95% CI 85-100). Glutamate concentrations of more than 200 mu mol/L in plasma and of more than 8.2 mu mol/L in CSF were independently and significantly associated with progression of neurological deficit (26.1 [6.9-98.6] and 40.9 [7.6-220], respectively). Interpretation Early neurological progression of acute ischaemic stroke is associated with high concentrations of glutamate in blood and CSF. Measurement of plasma glutamate may be useful for the early detection of those patients with acute stroke who will deteriorate during 48 h after onset.	HOSP DOCTOR JOSEP TRUETA, NEUROL SECT, GIRONA 17007, SPAIN; CLIN UNIV, HOSP GEN GALICIA, DEPT NEUROL, SANTIAGO DE COMPOSTELA, SPAIN	Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Complexo Hospitalario Universitario de Santiago de Compostela				Castillo, Jose/0000-0002-6685-3001				ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; ASPLUND K, 1992, CEREBROVASC DIS, V2, P317, DOI 10.1159/000109037; ASPLUND K, 1993, THROMBOLYTIC THERAPY, V2, P119; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BAKER CJ, 1995, NEUROSURGERY, V36, P994, DOI 10.1227/00006123-199505000-00016; BRITTON M, 1985, STROKE, V16, P629, DOI 10.1161/01.STR.16.4.629; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; CASTILLO J, 1994, CEREBROVASC DIS, V4, P66, DOI 10.1159/000108454; COTE R, 1986, STROKE, V17, P731, DOI 10.1161/01.STR.17.4.731; DAVALOS A, 1990, NEUROLOGY, V40, P1865, DOI 10.1212/WNL.40.12.1865; DAVALOS A, 1995, STROKE, V26, P2233, DOI 10.1161/01.STR.26.12.2233; DELZOPPO GJ, 1994, CEREBROVAS BRAIN MET, V6, P47; GAUTIER JC, 1985, STROKE, V16, P729, DOI 10.1161/01.STR.16.4.729; HOSSMANN KA, 1994, BRAIN PATHOL, V4, P23; HOSSMANN KA, 1994, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1994, P239; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; JORGENSEN HS, 1994, LANCET, V344, P156; KEMP JA, 1993, TRENDS PHARMACOL SCI, V14, P20, DOI 10.1016/0165-6147(93)90108-V; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MATSUMOTO K, 1993, J CEREBR BLOOD F MET, V13, P586, DOI 10.1038/jcbfm.1993.76; MYSEROS JS, 1995, NY ACAD SCI, V765, P262; OLLENSCHLAGER G, 1989, SCAND J CLIN LAB INV, V49, P773, DOI 10.3109/00365518909091556; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; ROBERT C, 1991, COMPUT BIOMED RES, V24, P514, DOI 10.1016/0010-4809(91)90037-W; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SAGE JI, 1984, STROKE, V15, P46, DOI 10.1161/01.STR.15.1.46; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; TAKAGI K, 1993, J CEREBR BLOOD F MET, V13, P575, DOI 10.1038/jcbfm.1993.75; TOMINAGA T, 1993, ALCOHOL ALCOHOLISM, V28, P103, DOI 10.1093/alcalc/28.Supplement_1A.103; TONI D, 1995, ARCH NEUROL-CHICAGO, V52, P670, DOI 10.1001/archneur.1995.00540310040014	32	277	289	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 11	1997	349	9045					79	83		10.1016/S0140-6736(96)04453-4	http://dx.doi.org/10.1016/S0140-6736(96)04453-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996418				2022-12-01	WOS:A1997WB80000009
J	Liu, S; Siegel, PZ; Brewer, RD; Mokdad, AH; Sleet, DA; Serdula, M				Liu, S; Siegel, PZ; Brewer, RD; Mokdad, AH; Sleet, DA; Serdula, M			Prevalence of alcohol-impaired driving - Results from a national self-reported survey of health behaviors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK FACTOR SURVEILLANCE	Objective.-To estimate how frequently adults in the United States drive while impaired by alcohol. Design.-Telephone survey. Setting-The 49 states (and the District of Columbia) that participated in the Behavioral Risk Factor Surveillance System (BRFSS) in 1993. Participants.-A total of 102 263 noninstitutionalized adults aged 18 years or older. Main Outcome Measures.-The percentage of respondents who reported alcohol-impaired driving; number of episodes of alcohol-impaired driving per 1 000 adult population; and total number of episodes of alcohol-impaired driving-each by age, sex, race, level of education, and state. Results.-Overall, 2.5% of adults reported an estimated 123 million episodes of alcohol-impaired driving in 1993, This corresponds to 655 episodes of alcohol-impaired driving for each 1000 adults (range among states per 1000 adults, 165-1550). Alcohol-impaired driving was most frequent among men aged 21 to 34 years (1739 episodes per 1 000 adults) and was nearly as frequent among men aged 18 to 20 years (1623 episodes per 1000 adults), despite legislation in all states that prohibited the sale of alcohol to persons younger than age 21 years in 1993. Conclusions.-Alcohol-impaired driving is common even among underage persons. Strict enforcement of laws that discourage alcohol-impaired driving is needed along with community and patient education to reduce the prevalence of alcohol-impaired driving and prevent injuries and deaths from alcohol-related motor vehicle crashes. Data From the BRFSS, an ongoing source of national and state-specific data on the number of episodes of alcohol-impaired driving, are potentially useful for monitoring trends and evaluating the effect of future efforts to reduce alcohol-impaired driving.	CTR DIS CONTROL & PREVENT,DIV UNINTENT INJURY PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341; CTR DIS CONTROL,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,DIV NUTR & PHYS ACT,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,DIV ADULT & COMMUNITY HLTH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Liu, Simin/I-3689-2014; Liu, Simin/GSN-4159-2022	Liu, Simin/0000-0003-2098-3844; 				ANDA RF, 1986, JAMA-J AM MED ASSOC, V256, P3213, DOI 10.1001/jama.1986.03380230037007; Brewer R D, 1995, Arch Fam Med, V4, P499, DOI 10.1001/archfami.4.6.499; *BUR CENS, 1992, 1990 CENS POP HOUS S; CHERPITEL CJ, 1995, ANN EMERG MED, V26, P158, DOI 10.1016/S0196-0644(95)70146-X; *CTR DIS CONTR, 1992, US CHRON DIS DAT HDB; *CTR DIS CONTR PRE, 1993, MMWR MORB MORT WKLY, V43, P443; *CTR DIS CONTR PRE, 1993, MMWR MORB MORT WKLY, V42, P905; *CTR DIS CONTR PRE, 1995, MMWR MORB MORT WKLY, V44; *CTR DIS CONTR PRE, 1994, MMWR MORB MORT WKLY, V43, P759; *FED BUR INV, 1994, UN CRIM REP US 1993; FELL JC, 1989, HEALTH EDUC QUART, V16, P335, DOI 10.1177/109019818901600303; GENTILELLO LM, 1995, JAMA-J AM MED ASSOC, V274, P1043, DOI 10.1001/jama.274.13.1043; Gentry E M, 1985, Am J Prev Med, V1, P9; MAULL KI, 1984, JAMA-J AM MED ASSOC, V252, P1880, DOI 10.1001/jama.252.14.1880; *NAT CTR HLTH STAT, 1994, US DEPT HHS PUBL; *NAT HIGHW TRAFF S, 1995, TRAFF SAF FACTS 1994; *PUBL HLTH SERV, 1994, US DEPT HHS PUBL; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; *RES TRIANGL I, 1989, SURV DAT AN SUDAAN V; Siegel P Z, 1991, MMWR CDC Surveill Summ, V40, P1; Siegel Paul Z, 1993, Morbidity and Mortality Weekly Report, V42, P23; SMITH PF, 1989, HEALTH EDUC QUART, V16, P345, DOI 10.1177/109019818901600304; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, V2nd; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513	24	78	79	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1997	277	2					122	125		10.1001/jama.277.2.122	http://dx.doi.org/10.1001/jama.277.2.122			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA650	8990336				2022-12-01	WOS:A1997WA65000031
J	Abulrahi, HA; Bohlega, EA; Fontaine, RE; AlSeghayer, SM; AlRuwais, AA				Abulrahi, HA; Bohlega, EA; Fontaine, RE; AlSeghayer, SM; AlRuwais, AA			Plasmodium falciparum malaria transmitted in hospital through heparin locks	LANCET			English	Article								Background After a community investigation had implicated hospital admission as a shared feature of a cluster of acute Plasmodium falciparum malaria (AFM) cases in Riyadh, Saudi Arabia, we began an in-hospital investigation to determine the method of transmission. Methods We investigated all AFM patients admitted to one paediatric hospital for any reason from December, 1991, to April, 1992. We classified AFM as locally acquired (LAFM) if during the month before AFM onset the patient had not visited a malarious area, and as hospital acquired (HAFM) if the LAFM patient had been admitted to hospital during that month. We compared exposures of HAFM cases with those of other patients sampled from the same wards. We observed nursing practices and investigated by anonymous questionnaire how nurses administered parenteral drugs. Findings Of 21 LAFM cases, 20 (95%) had a previous hospital admission (exposure admission) compared with 15 (25%) of 61 other patients (p<0.001; chi(2) test). During the exposure admission, all HAFM patients had occupied the same room as, or a room adjacent to, an AFM patient; 14 (23%) of 60 other patients occupied the same room or rooms adjacent to an AFM patient (p<0.001, chi(2)). 90% of HAFM patients received infusions through a heparin lock during the exposure admission, compared with 49% of 120 general patients (p<0.001, chi(2)). 10% of nurses admitted to using one syringe for more than one heparin lock and 50% filled syringes with enough heparin for three to ten heparin locks. Interpretation P falciparum was transmitted between patients when single syringes were used on heparin locks of sequential patients. This practice would easily transmit other blood-borne agents.	MINIST HLTH,SAUDI ARABIAN FIELD EPIDEMIOL TRAINING PROGRAM,RIYADH 11442,SAUDI ARABIA; MINIST HLTH,GEN DIRECTORATE INFECT & PARASIT DIS,MALARIA DEPT,RIYADH 11442,SAUDI ARABIA; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,DIV INT HLTH,ATLANTA,GA	Ministry of Health - Saudi Arabia; Ministry of Health - Saudi Arabia; Centers for Disease Control & Prevention - USA								Dean A. G., 1990, EPI INFO VERSION 5 W; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.2307/2332323; KEMPEN P M, 1989, Anesthesiology (Hagerstown), V71, pA948, DOI 10.1097/00000542-198909001-00948; LETTAU LA, 1991, INFECT CONT HOSP EP, V12, P111, DOI 10.1086/646297; NAVARRO P, 1987, Boletin de la Oficina Sanitaria Panamericana, V102, P476; ROSENBERG A D, 1989, Anesthesiology (Hagerstown), V71, pA949, DOI 10.1097/00000542-198909001-00949; 1990, MMWR-MORBID MORTAL W, V39, P426; 1990, MMWR-MORBID MORTAL W, V39, P433	9	51	53	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					23	25		10.1016/S0140-6736(96)03508-8	http://dx.doi.org/10.1016/S0140-6736(96)03508-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988119				2022-12-01	WOS:A1997WA72500013
J	daSilveira, CM; Salisbury, DM; deQuadros, CA				daSilveira, CM; Salisbury, DM; deQuadros, CA			Measles vaccination and Guillain-Barre syndrome	LANCET			English	Article								Background Guillain-Barre syndrome (GBS) has been associated with several infectious agents, and the possibility that the disorder may be caused by vaccination has been raised. We compared the numbers of cases of GBS observed immediately after mass measles vaccination campaigns with the numbers that would be expected from baseline rates, to assess whether there is a causal relation between measles vaccination and GBS. Methods We analysed data on 2296 cases of GBS reported to the Poliomyelitis Eradication Surveillance System of the Pan American Health Organization as cases of suspected poliomyelitis. These cases occurred among 73 million immunised children aged 9 months to 15 years in Argentina, Brazil, Chile, and Colombia, between January, 1990, and December, 1994. These children were targeted for mass measles vaccination compaigns (each lasting 1 month) in 1992 and 1993. The frequency of GBS cases observed during the Vaccination campaigns or the next 42 days (the latent period) was compared with that during the rest of the study period, with the assumption of a Poisson distribution. Findings The average annual incidence of GBS was 0.62 per 100 000 children aged 1-14 years. The number of cases that would be expected within any 72-day period would therefore be 92. The average observed number of cases during latent periods after measles vaccination was 97. The probability that 97 or more cases would occur during a period with an expected number of 92 was 0.31. Interpretation The average annual rates of GBS by age-group for the 5 years analysed were consistent with previous data; thus we are confident that the surveillance system is sufficiently sensitive. There was no statistically significant association between measles vaccination and GBS. If there is any causal relation, the number of GBS cases due to measles vaccination was so small that data from the vaccination of more than 70 million children were not sufficient to detect a rise in the number of observed GBS cases beyond the expected number.	DEPT HLTH,LONDON SE1 8UG,ENGLAND; PAN AMER HLTH ORG,WASHINGTON,DC	Pan American Health Organization								[Anonymous], 1978, Ann Neurol, V3, P565; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; Awong IE, 1996, ANN PHARMACOTHER, V30, P173, DOI 10.1177/106002809603000212; Cutts F, 1996, BRIT MED J, V312, P589; DEQUADROS CA, 1991, PEDIATR INFECT DIS J, V10, P222, DOI 10.1097/00006454-199103000-00011; deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224; Korinthenberg R, 1996, ARCH DIS CHILD, V74, P281, DOI 10.1136/adc.74.4.281; KOSKI CL, 1986, AM FAM PHYSICIAN, V34, P198; Lasky T, 1996, NEUROEPIDEMIOLOGY, V15, P57, DOI 10.1159/000109890; LILIENFELD AM, 1980, OBSERVATIONAL STUDIE, V2, P226; *MED CONTR AG, 1995, CURR PROB PHARMACOVI, V21, P9; *PAN AM HLTH ORG, 1988, 6 PAHO SPEC PROGR VA, P1; STRATTON KR, 1994, ADVERSE EVENTS ASS C, P34; STRATTON KR, 1994, ADVERSE EVENTS ASS C, P118	14	34	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					14	16						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988116				2022-12-01	WOS:A1997WA72500010
J	Tsien, JZ; Chen, DF; Gerber, D; Tom, C; Mercer, EH; Anderson, DJ; Mayford, M; Kandel, ER; Tonegawa, S				Tsien, JZ; Chen, DF; Gerber, D; Tom, C; Mercer, EH; Anderson, DJ; Mayford, M; Kandel, ER; Tonegawa, S			Subregion- and cell type-restricted gene knockout in mouse brain	CELL			English	Article							LONG-TERM POTENTIATION; II MUTANT MICE; RECEPTOR ANTAGONIST; KINASE; RECOMBINATION; NEURONS; SYSTEM; LTP	Using the phage P1-derived Cre/loxP recombination system, we have developed a method to create mice in which the deletion (knockout) of virtually any gene of interest is restricted to a subregion or a specific cell type in the brain such as the pyramidal cells of the hippocampal CA1 region. The Cre/loxP recombination-based gene deletion appears to require a certain level of Cre protein expression. The brain subregional restricted gene knockout should allow a more precise analysis of the impact of a gene mutation on animal behaviors.	CALTECH,DIV BIOL,HOWARD HUGHES MED INST,PASADENA,CA 91125; COLUMBIA UNIV,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	California Institute of Technology; Howard Hughes Medical Institute; Columbia University; Howard Hughes Medical Institute	Tsien, JZ (corresponding author), MIT,CTR CANC RES,HOWARD HUGHES MED INST,CTR LEARNING & MEMORY,DEPT BIOL,CAMBRIDGE,MA 02139, USA.		Mercer, Eric H/AAX-6173-2021	Mercer, Eric H/0000-0002-6737-765X; Mayford, Mark/0000-0002-9001-5024	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER; NINDS NIH HHS [NS32925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGEVINE JAY B., 1965, EXP NEUROL SUPPL, V2, P1; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CAPECCHI MR, 1994, SCI AM, V270, P52, DOI 10.1038/scientificamerican0394-52; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DAVIS S, 1992, J NEUROSCI, V12, P21; ECCLES JC, 1953, PRINCIPLES NEUROPHYS; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GU M, 1994, SCIENCE, V265, P103; HEBB DO, 1949, ORG BEHAVIOR; Hogan B., 1986, MANIPULATING MOUSE E; Joyner Alexandra L., 1994, Current Opinion in Neurobiology, V4, P37, DOI 10.1016/0959-4388(94)90029-9; KALDERON D, 1984, CELL, V39, P449; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; LASKO M, 1992, P NATL ACAD SCI USA, V89, P6232; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MAYFORD M, 1996, IN PRESS SCIENCE; MAYFORD M, 1996, IN PRESS P NATL ACAD; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; OBERDICK J, 1990, SCIENCE, V248, P223, DOI 10.1126/science.2109351; POKORNY J, 1981, BRAIN RES BULL, V7, P113, DOI 10.1016/0361-9230(81)90075-7; POKORNY J, 1981, BRAIN RES BULL, V7, P121, DOI 10.1016/0361-9230(81)90076-9; Sambrook J., 1989, MOL CLONING LAB MANU; Saucier D, 1996, BEHAV NEUROSCI, V110, P103, DOI 10.1037/0735-7044.110.1.103; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STANFIELD BB, 1979, J COMP NEUROL, V185, P423, DOI 10.1002/cne.901850303; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; WEI JJ, 1991, I CHUAN HSUEH PAO, V18, P320; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543	31	921	947	0	55	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1317	1326		10.1016/S0092-8674(00)81826-7	http://dx.doi.org/10.1016/S0092-8674(00)81826-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980237	hybrid			2022-12-01	WOS:A1996WA54100019
J	Adams, WL; Barry, KL; Fleming, MF				Adams, WL; Barry, KL; Fleming, MF			Screening for problem drinking in older primary care patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MIDDLE-AGED WOMEN; ALCOHOL-CONSUMPTION; CAGE QUESTIONNAIRE; BREAST-CANCER; ELDERLY PEOPLE; BLOOD-PRESSURE; UNITED-STATES; LONG-TERM; FOLLOW-UP; PREVALENCE	Objectives.-To describe potentially hazardous alcohol use among elderly patients in the primary care setting and to assess the widely used CAGE questionnaire (cut down, annoyed by criticism, guilty about drinking, eye-opener drinks) as a tool for detecting self-reported heavy and binge drinking among these patients. Design.-Cross-sectional study. Setting.-The offices of 88 primary care physicians at 21 sites in southeastern Wisconsin. Patients.-A total of 5065 consecutive consenting patients older than 60 years. Measures.-A previously validated self-administered questionnaire that included beverage-specific questions about the quantity and frequency of regular drinking in the last 3 months, the number of episodes of binge drinking (6 drinks per occasion), and the CAGE questionnaire. Results.-Fifteen percent of men and 12% of women regularly drank in excess of limits recommended by the National Institute of Alcohol Abuse and Alcoholism (>7 drinks per week for women and >14 drinks per week for men). Nine percent of men and 2% of women reported regularly consuming more than 21 drinks per week. When we administered the CAGE questionnaire, 9% of men and 3% of women screened positive for alcohol abuse within 3 months. The CAGE performed poorly in detecting heavy or binge drinkers; fewer than half were CAGE positive when the standard cutoff of 2 positive answers was used. Conclusions.-Alcohol consumption in excess of recommended limits is common among elderly outpatients. The CAGE questionnaire alone is insufficient to detect such drinking. Asking questions on the quantity and frequency of drinking in addition to administering the CAGE increases the number of problem drinkers detected.	MED COLL WISCONSIN,MILWAUKEE,WI 53226; UNIV WISCONSIN,MADISON,WI	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008512] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA08512-02S1] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ADAMS WL, 1993, JAMA-J AM MED ASSOC, V270, P1222, DOI 10.1001/jama.270.10.1222; ADAMS WL, 1990, J AM GERIATR SOC, V38, P211, DOI 10.1111/j.1532-5415.1990.tb03493.x; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; ANDA RF, 1988, JAMA-J AM MED ASSOC, V260, P2529, DOI 10.1001/jama.260.17.2529; BARNES GM, 1979, J AM GERIATR SOC, V27, P244, DOI 10.1111/j.1532-5415.1979.tb06125.x; BOHN MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; BUCHSBAUM DG, 1991, ALCOHOL ALCOHOLISM, V26, P215, DOI 10.1093/oxfordjournals.alcalc.a045103; BUCHSBAUM DG, 1992, J AM GERIATR SOC, V40, P662, DOI 10.1111/j.1532-5415.1992.tb01956.x; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; CRIQUI MH, 1981, HYPERTENSION, V3, P557, DOI 10.1161/01.HYP.3.5.557; DEITZ D, 1994, ALCOHOL HEALTH RES W, V18, P162; DUFOUR M, 1995, ANNU REV MED, V46, P123, DOI 10.1146/annurev.med.46.1.123; EKERDT DJ, 1989, J STUD ALCOHOL, V50, P347, DOI 10.15288/jsa.1989.50.347; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FELSON DT, 1988, AM J EPIDEMIOL, V128, P1102; FILLMORE KM, 1987, BRIT J ADDICT, V82, P77; FLEMING MF, 1991, ALCOHOL ALCOHOLISM, V26, P81; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GLYNN RJ, 1985, AM J PUBLIC HEALTH, V75, P1413, DOI 10.2105/AJPH.75.12.1413; GOODWIN JS, 1987, AM J PUBLIC HEALTH, V77, P173, DOI 10.2105/AJPH.77.2.173; HELZER JE, 1991, PSYCHIAT DISORDERS A, P81; HEMENWAY D, 1988, AM J PUBLIC HEALTH, V78, P1554, DOI 10.2105/AJPH.78.12.1554; HERNANDEZAVILA M, 1991, AM J CLIN NUTR, V54, P157, DOI 10.1093/ajcn/54.1.157; HOLBROOK TL, 1990, AM J EPIDEMIOL, V132, P902, DOI 10.1093/oxfordjournals.aje.a115733; ILIFFE S, 1991, AGE AGEING, V20, P120, DOI 10.1093/ageing/20.2.120; JONES TV, 1993, J GEN INTERN MED, V8, P674, DOI 10.1007/BF02598284; KAGAN A, 1981, CIRCULATION, V64, P27; KLATSKY AL, 1986, CIRCULATION, V73, P628, DOI 10.1161/01.CIR.73.4.628; KRISTENSON H, 1983, ALCOHOL CLIN EXP RES, V7, P203, DOI 10.1111/j.1530-0277.1983.tb05441.x; LONGNECKER MP, 1995, ALCOHOL, V12, P87, DOI 10.1016/0741-8329(94)00088-3; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; MAGRUDERHABIB K, 1986, HOSP COMMUNITY PSYCH, V37, P1251; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MYERS JK, 1984, ARCH GEN PSYCHIAT, V41, P959; *NAT RES COUNC, 1995, NUTR REQ LAB AN, P1; SCHATZKIN A, 1994, CANCER, V74, P1101, DOI 10.1002/1097-0142(19940801)74:3+<1101::AID-CNCR2820741519>3.0.CO;2-X; STEINWEG DL, 1993, AM J MED, V94, P520, DOI 10.1016/0002-9343(93)90088-7; STINSON FS, 1989, ALCOHOL HEALTH RES W, V13, P80; TEMPLE MT, 1989, BRIT J ADDICT, V84, P889; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P575; USDA and HHS, 1990, NUTR YOUR HLTH DIET; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; WERCH CE, 1989, INT J ADDICT, V24, P859, DOI 10.3109/10826088909047316; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902	45	161	162	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1996	276	24					1964	1967						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VY689	8971065				2022-12-01	WOS:A1996VY68900028
J	Vieira, AV; Lamaze, C; Schmid, SL				Vieira, AV; Lamaze, C; Schmid, SL			Control of EGF receptor signaling by clathrin-mediated endocytosis	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE; MUTANT; CELLS; DYNAMIN; PHOSPHORYLATION; RECRUITMENT; BINDING; SITES; SHC	Epidermal growth factor receptor (EGFR) signaling was analyzed in mammalian cells conditionally defective for receptor-mediated endocytosis. EGF-dependent cell proliferation was enhanced in endocytosis-defective cells. However, early EGF-dependent signaling events were not uniformly up-regulated. A subset of signal transducers required the normal endocytic trafficking of EGFR for full activation. Thus, endocytic trafficking of activated EGFR plays a critical role not only in attenuating EGFR signaling but also in establishing and controlling specific signaling pathways.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Lamaze, Christophe/M-4912-2017	, A. Vieira/0000-0002-8906-1293; LAMAZE, Christophe/0000-0001-5430-2707; Schmid, Sandra/0000-0002-1690-7024	NATIONAL CANCER INSTITUTE [P01CA058689, R01CA069099] Funding Source: NIH RePORTER; NCI NIH HHS [CA58689, CA69099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gotoh N, 1995, ONCOGENE, V11, P2525; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P5730; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASUI H, 1991, CANCER RES, V51, P6170; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHPETNER H, 1996, J CELL BIOL, V132, P595; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VIEIRA AJS, UNPUB; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1991, J BIOL CHEM, V266, P11083	34	789	801	2	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2086	2089		10.1126/science.274.5295.2086	http://dx.doi.org/10.1126/science.274.5295.2086			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953040				2022-12-01	WOS:A1996VY97400050
J	Bose, HS; Sugawara, T; Strauss, JF; Miller, WL				Bose, HS; Sugawara, T; Strauss, JF; Miller, WL			The pathophysiology and genetics of congenital lipoid adrenal hyperplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIDE-CHAIN CLEAVAGE; ACUTE REGULATORY PROTEIN; LEYDIG TUMOR-CELLS; GONADAL DEVELOPMENT; COS-1 CELLS; MITOCHONDRIAL; EXPRESSION; PATIENT; P450SCC; GENES	Background Congenital lipoid adrenal hyperplasia results in severe impairment of steroid biosynthesis in the adrenal glands and gonads that is manifested both in utero and postnatally. We recently found mutations in the gene for the steroidogenic acute regulatory protein in four patients with this syndrome, but it was not clear whether all patients have such mutations or why there is substantial clinical variation in these patients. Methods We directly sequenced the gene for steroidogenic acute regulatory protein in 15 patients with congenital lipoid adrenal hyperplasia from 10 countries. Identified mutations were confirmed and recreated in expression vectors, transfected into cultured cells, and assayed for the presence and activity of steroidogenic acute regulatory protein. Results Fifteen different mutations in the gene for steroidogenic acute regulatory protein were found in 14 patients; the mutation Gln258Stop was found in 80 percent of affected alleles from Japanese and Korean patients, and the mutation Arg182Leu was found in 78 percent of affected alleles from Palestinian patients. We developed diagnostic tests for these and eight other mutations. Thirteen of the 15 mutations were in exons 5, 6, or 7, and all rendered the steroidogenic acute regulatory protein inactive in functional assays. Some mutants with amino acid replacements were capable of normal mitochondrial processing, indicating that the activity of steroidogenic acute regulatory protein is not associated with its translocation into mitochondria. Steroidogenic cells lacking the protein retained low levels of steroidogenesis. This explains the secretion of some steroid hormones by the ovaries after puberty before affected cells accumulate large amounts of cholesterol esters. Conclusions The congenital lipoid adrenal hyperplasia phenotype is the result of two separate events, an initial genetic toss of steroidogenesis that is dependent on steroidogenic acute regulatory protein and a subsequent loss of steroidogenesis that is independent of the protein due to cellular damage from accumulated cholesterol esters.	UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV PENN,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104	University of California System; University of California San Francisco; University of Pennsylvania			Miller, Walter L/J-3696-2012		NIDDK NIH HHS [DK37922, DK42154] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037922, R01DK042154] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARKANE F, 1996, P NATL ACAD SCI USA, V93, P13731; CAMACHO AM, 1968, J CLIN ENDOCR METAB, V28, P153, DOI 10.1210/jcem-28-2-153; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; DEGENHART HJ, 1972, ACTA ENDOCRINOL-COP, V71, P513; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; Fukami M., 1995, CLIN PEDIAT ENDOCRIN, V4, P39, DOI [10.1297/cpe.4.39, DOI 10.1297/CPE.4.39]; Hall PF, 1995, J STEROID BIOCHEM, V55, P601, DOI 10.1016/0960-0760(95)00211-1; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; HATANO O, 1994, DEVELOPMENT, V120, P2787; HAUFFA BP, 1985, CLIN ENDOCRINOL, V23, P481, DOI 10.1111/j.1365-2265.1985.tb01107.x; KIRKLAND RT, 1973, J CLIN ENDOCR METAB, V36, P488, DOI 10.1210/jcem-36-3-488; KOIZUMI S, 1977, CLIN CHIM ACTA, V77, P301; KONDO T, 1986, JPN J PEDIAT S, V34, P1223; KONDO T, 1993, CLIN ENDOCRINOL S, V41, P163; KONDO T, 1986, CLIN ENDOCRINOL, V34, P322; LIN D, 1993, GENOMICS, V18, P643, DOI 10.1016/S0888-7543(05)80367-2; LIN D, 1991, J CLIN INVEST, V88, P1955, DOI 10.1172/JCI115520; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Matsuo N., 1994, HORM RES S, V41, P106; MATTESON KJ, 1986, ENDOCRINOLOGY, V118, P1296, DOI 10.1210/endo-118-4-1296; MESIANO S, 1993, J CLIN ENDOCR METAB, V77, P1184, DOI 10.1210/jc.77.5.1184; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MULLER J, 1991, HORM RES, V36, P203, DOI 10.1159/000182162; PRADER A, 1955, Helv Paediatr Acta, V10, P397; SAENGER P, 1995, J CLIN ENDOCR METAB, V80, P200, DOI 10.1210/jc.80.1.200; SAENGER P, 1993, J STEROID BIOCHEM, V45, P87, DOI 10.1016/0960-0760(93)90127-I; SAKAI Y, 1994, J CLIN ENDOCR METAB, V79, P1198, DOI 10.1210/jc.79.4.1198; SANDISON AT, 1955, ARCH DIS CHILD, V30, P538, DOI 10.1136/adc.30.154.538; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; TEE MK, 1995, HUM MOL GENET, V4, P2299, DOI 10.1093/hmg/4.12.2299; TOAFF ME, 1982, ENDOCRINOLOGY, V111, P1785, DOI 10.1210/endo-111-6-1785; VOUTILAINEN R, 1986, J CLIN ENDOCR METAB, V63, P1145, DOI 10.1210/jcem-63-5-1145; ZUBER MX, 1988, P NATL ACAD SCI USA, V85, P699, DOI 10.1073/pnas.85.3.699	37	443	459	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1996	335	25					1870	1878		10.1056/NEJM199612193352503	http://dx.doi.org/10.1056/NEJM199612193352503			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX874	8948562				2022-12-01	WOS:A1996VX87400003
J	Sutherland, D; Samakovlis, C; Krasnow, MA				Sutherland, D; Samakovlis, C; Krasnow, MA			Branchless encodes a Drosophila FGF homolog that controls tracheal cell migration and the pattern of branching	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; RECEPTOR HOMOLOG; MOUSE LUNG; BREATHLESS; MORPHOGENESIS; EXPRESSION; FIBROBLAST; TARGET	The molecular basis for patterning of complex organ structures like the lung and insect tracheal system is unknown. Here, we describe the Drosophila gene branchless (bnl) and demonstrate that it is a key determinant of the tracheal branching pattern. bnl is required for tracheal branching and is expressed dynamically in clusters of cells surrounding the developing tracheal system at each position where a new branch will form and grow out. Localized misexpression of bnl can direct branch formation and outgrowth to new positions. Generalized misexpression activates later programs of tracheal gene expression and branching, resulting in massive networks of branches. bnl encodes a homolog of mammalian fibroblast growth factors (FGFs) and appears to function as a ligand for the breathless receptor tyrosine kinase, an FGF receptor homolog expressed on developing tracheal cells. The results suggest that this FGF pathway specifies the tracheal branching pattern by guiding tracheal cell migration during primary branch formation and then activating later programs of finer branching at the ends of growing primary branches.			Sutherland, D (corresponding author), STANFORD UNIV,SCH MED,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305, USA.							ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; AYRES MD, 1994, VIROLOGY, V202, P586, DOI 10.1006/viro.1994.1380; BRAND AH, 1993, DEVELOPMENT, V118, P401; DEVORE DL, 1995, CELL, V83, P611, DOI 10.1016/0092-8674(95)90101-9; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPODAROWICZ D, 1979, EXP EYE RES, V28, P501, DOI 10.1016/0014-4835(79)90038-1; Guillemin K, 1996, DEVELOPMENT, V122, P1353; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; KRATOCHWIL K, 1969, DEV BIOL, V20, P46, DOI 10.1016/0012-1606(69)90004-9; LEE T, IN PRESS GENES DEV; Lindsley D.L., 1992, GENOME DROSOPHILA ME; Manning Gerards, 1993, P609; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MCFARLANE S, 1995, NEURON, V15, P1017, DOI 10.1016/0896-6273(95)90091-8; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MURPHY AM, 1995, DEVELOPMENT, V121, P2255; NOGAWA H, 1995, DEVELOPMENT, V121, P1015; ONEILL JW, 1994, BIOTECHNIQUES, V17, P874; PERRIMON N, 1991, DEV GENET, V12, P238, DOI 10.1002/dvg.1020120309; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; REICHMANFRIED M, 1995, MECH DEVELOP, V52, P265, DOI 10.1016/0925-4773(95)00407-R; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; Rudnick D, 1933, J EXP ZOOL, V66, P125, DOI 10.1002/jez.1400660106; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Sambrook J., 1989, MOL CLONING LAB MANU; Simonet WS, 1995, P NATL ACAD SCI USA, V92, P12461, DOI 10.1073/pnas.92.26.12461; SPOONER BS, 1970, J EXP ZOOL, V175, P445, DOI 10.1002/jez.1401750404; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; TADERERA JV, 1967, DEV BIOL, V16, P489, DOI 10.1016/0012-1606(67)90061-9; TAUB M, 1990, P NATL ACAD SCI USA, V87, P4002, DOI 10.1073/pnas.87.10.4002; TERRANOVA VP, 1985, J CELL BIOL, V101, P2330, DOI 10.1083/jcb.101.6.2330; THOMAS KA, 1993, NEUROTROPHIC FACTORS, P285; Thompson DW., 1917, GROWTH FORM, DOI [10.5962/bhl.title.11332, DOI 10.5962/BHL.TITLE.11332]; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	36	502	511	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1091	1101		10.1016/S0092-8674(00)81803-6	http://dx.doi.org/10.1016/S0092-8674(00)81803-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978613	Bronze			2022-12-01	WOS:A1996VY44700014
J	Kaiser, RI; Ochsenfeld, C; HeadGordon, M; Lee, YT; Suits, AG				Kaiser, RI; Ochsenfeld, C; HeadGordon, M; Lee, YT; Suits, AG			A combined experimental and theoretical study on the formation of interstellar C3H isomers	SCIENCE			English	Article							NEUTRAL-NEUTRAL REACTIONS; GAUSSIAN-BASIS SETS; ATOMIC CARBON; MOLECULES; CLOUDS; CHEMISTRY; IRC+10216; ENVELOPE; RATES; BEAM	The reaction of ground-state carbon atoms with acetylene was studied under single-collision conditions in crossed beam experiments to investigate the chemical dynamics of forming cyclic and linear C3H isomers (c-C3H and l-C3H, respectively) in interstellar environments via an atom-neutral reaction. Combined state-of-the-art ab initio calculations and experimental identification of the carbon-hydrogen exchange channel to both isomers classify this reaction as an important alternative to ion-molecule encounters to synthesize C3H radicals in the interstellar medium. These findings strongly correlate with astronomical observations and explain a higher [c-C3H]/[l-C3H] ratio in the dark cloud TMC-1 than in the carbon star IRC+10216.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV CHEM SCI, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kaiser, RI (corresponding author), UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA.		Ochsenfeld, Christian/E-8021-2015; Head-Gordon, Martin/AAR-4028-2020; Lee, Yuan-Tseh/F-7914-2012	Ochsenfeld, Christian/0000-0002-4189-6558; 				[Anonymous], 1991, MODERN MOL PHOTOCHEM; BETTENS RPA, 1995, ASTROPHYS J, V443, P664, DOI 10.1086/175558; CLARY DC, 1994, ASTROPHYS J, V422, P416, DOI 10.1086/173737; CLARY DC, 1993, J CHEM SOC FARADAY T, V89, P2185, DOI 10.1039/ft9938902185; DUNNING TH, 1989, J CHEM PHYS, V90, P1007, DOI 10.1063/1.456153; ENTENNMANN EA, 1986, THESIS HARVARD U; HERBST E, 1994, MON NOT R ASTRON SOC, V268, P335, DOI 10.1093/mnras/268.2.335; HERBST E, 1990, ASTRON ASTROPHYS, V233, P177; HERBST E, 1973, ASTROPHYS J, V185, P505, DOI 10.1086/152436; HERBST E, 1984, ASTROPHYS J, V285, P618, DOI 10.1086/162538; HERBST E, 1976, CHEM PHYS LETT, V42, P54, DOI 10.1016/0009-2614(76)80550-7; KAISER RI, 1995, J CHEM PHYS, V103, P10395, DOI 10.1063/1.469877; Kaiser RI, 1996, J CHEM PHYS, V105, P8705, DOI 10.1063/1.472652; Kaiser RI, 1995, REV SCI INSTRUM, V66, P5405, DOI 10.1063/1.1146061; Kanada M, 1996, J CHEM PHYS, V104, P2192, DOI 10.1063/1.471811; KEENE J, 1993, ASTROPHYS J, V415, pL131, DOI 10.1086/187050; LEE YT, 1969, REV SCI INSTRUM, V40, P1402, DOI 10.1063/1.1683809; LEE YT, 1987, SCIENCE, V236, P793, DOI 10.1126/science.236.4803.793; Levine R.D., 1987, MOL REACTION DYNAMIC; LIAO Q, 1995, ASTROPHYS J, V444, P694, DOI 10.1086/175642; MILLAR TJ, 1994, ASTRON ASTROPHYS, V288, P561; MILLER WB, 1967, DISCUSS FARADAY SOC, P108, DOI 10.1039/df9674400108; MILLER WB, 1967, DISCUSS FARADAY SOC, V44, P291; RAGHAVACHARI K, 1989, CHEM PHYS LETT, V157, P479, DOI 10.1016/S0009-2614(89)87395-6; ROBINSON MS, 1995, J AM CHEM SOC, V117, P6766, DOI 10.1021/ja00130a017; SCHAFER A, 1992, J CHEM PHYS, V97, P2571, DOI 10.1063/1.463096; Seburg R. A., 1995, ANGEW CHEM, V107, P2198, DOI DOI 10.1002/ANGE.19951071826; SMITH D, 1992, CHEM REV, V92, P1580; STANTON JF, 1995, CHEM PHYS LETT, V237, P20, DOI 10.1016/0009-2614(95)00270-E; STANTON JF, 1992, INT J QUANTUM CHEM, P879; WATTS JD, 1992, CHEM PHYS LETT, V200, P1, DOI 10.1016/0009-2614(92)87036-O; WINNEWISSER G, 1987, TOP CURR CHEM, P121	32	153	153	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1508	1511		10.1126/science.274.5292.1508	http://dx.doi.org/10.1126/science.274.5292.1508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929407				2022-12-01	WOS:A1996VV77500042
J	Moran, JV; Holmes, SE; Naas, TP; DeBerardinis, RJ; Boeke, JD; Kazazian, HH				Moran, JV; Holmes, SE; Naas, TP; DeBerardinis, RJ; Boeke, JD; Kazazian, HH			High frequency retrotransposition in cultured mammalian cells	CELL			English	Article							HUMAN TRANSPOSABLE ELEMENT; PRIMED REVERSE TRANSCRIPTION; RNA-POLYMERASE-III; OPEN-READING-FRAME; LINE-I ELEMENT; L1 ELEMENT; INDICATOR GENE; TARGET DNA; SACCHAROMYCES-CEREVISIAE; INSERTIONAL MUTAGENESIS	We previously isolated two human L1 elements (L1.2 and LRE2) as the progenitors of disease-producing insertions. Here, we show these elements can actively retrotranspose in cultured mammalian cells. When stably expressed from an episome in HeLa cells, both elements retrotransposed into a Variety of chromosomal locations at a high frequency. The retrotransposed products resembled endogenous L1 insertions, since they were variably 5' truncated, ended in poly(A) tracts, and were flanked by target-site duplications or short deletions. Point mutations in conserved domains of the L1.2-encoded proteins reduced retrotransposition by 100- to 1000-fold. Remarkably, L1.2 also retrotransposed in a mouse cell line, suggesting a potential role for L1-based vectors in random insertional mutagenesis.	UNIV PENN, SCH MED, DEPT GENET, PHILADELPHIA, PA 19104 USA; JOHNS HOPKINS UNIV, DEPT MOL BIOL & GENET, SCH MED, BALTIMORE, MD 21205 USA	University of Pennsylvania; Johns Hopkins University			Naas, Thierry/O-3999-2018	Naas, Thierry/0000-0001-9937-9572				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARKHIPOVA IR, 1995, NUCLEIC ACIDS RES, V23, P4480, DOI 10.1093/nar/23.21.4480; BELFORT M, 1993, SCIENCE, V262, P1009, DOI 10.1126/science.7694364; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; Boeke JD, 1991, CURR OPIN CELL BIOL, V3, P502, DOI 10.1016/0955-0674(91)90079-E; BUREAU TE, 1994, CELL, V77, P479, DOI 10.1016/0092-8674(94)90210-0; BURKE WD, 1987, MOL CELL BIOL, V7, P2221, DOI 10.1128/MCB.7.6.2221; BURTON FH, 1986, J MOL BIOL, V187, P291, DOI 10.1016/0022-2836(86)90235-4; CONWAY L, 1985, P NATL ACAD SCI USA, V82, P3949, DOI 10.1073/pnas.82.12.3949; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; CURCIO MJ, 1991, P NATL ACAD SCI USA, V88, P936, DOI 10.1073/pnas.88.3.936; DEMERS GW, 1986, MOL BIOL EVOL, V3, P179; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; DOMBROSKI BA, 1994, MOL CELL BIOL, V14, P4485, DOI 10.1128/MCB.14.7.4485; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; EVANS JP, 1991, P NATL ACAD SCI USA, V88, P8792, DOI 10.1073/pnas.88.19.8792; FANNING T, 1987, NUCLEIC ACIDS RES, V15, P2251, DOI 10.1093/nar/15.5.2251; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; FREEMAN JD, 1994, BIOTECHNIQUES, V17, P47; HATTORI M, 1986, NATURE, V321, P625, DOI 10.1038/321625a0; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; HEIDMANN T, 1988, P NATL ACAD SCI USA, V85, P2219, DOI 10.1073/pnas.85.7.2219; Hohjoh H, 1996, EMBO J, V15, P630, DOI 10.1002/j.1460-2075.1996.tb00395.x; HOLMES SE, 1992, J BIOL CHEM, V267, P19765; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; HOLMES SE, 1994, THESIS J HOPKINS U B; JENSEN S, 1991, EMBO J, V10, P1927, DOI 10.1002/j.1460-2075.1991.tb07719.x; JENSEN S, 1994, BIOCHEM BIOPH RES CO, V202, P111, DOI 10.1006/bbrc.1994.1900; KATZIR N, 1985, P NATL ACAD SCI USA, V82, P1054, DOI 10.1073/pnas.82.4.1054; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; Kohrman DC, 1996, J BIOL CHEM, V271, P17576, DOI 10.1074/jbc.271.29.17576; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; KUROSE K, 1995, NUCLEIC ACIDS RES, V23, P3704, DOI 10.1093/nar/23.18.3704; LEIBOLD DM, 1990, P NATL ACAD SCI USA, V87, P6990, DOI 10.1073/pnas.87.18.6990; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; LUAN DD, 1995, MOL CELL BIOL, V15, P3882; Maestre J, 1995, EMBO J, V14, P6333, DOI 10.1002/j.1460-2075.1995.tb00324.x; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MIKI Y, 1992, CANCER RES, V52, P643; MINAKAMI R, 1992, NUCLEIC ACIDS RES, V20, P3139, DOI 10.1093/nar/20.12.3139; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; MULHARDT C, 1994, NEURON, V13, P1003, DOI 10.1016/0896-6273(94)90265-8; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; PELISSON A, 1991, P NATL ACAD SCI USA, V88, P4907, DOI 10.1073/pnas.88.11.4907; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCOTT A F, 1987, Genomics, V1, P113, DOI 10.1016/0888-7543(87)90003-6; SINGER MF, 1993, GENE, V135, P183, DOI 10.1016/0378-1119(93)90064-A; SWAIN A, 1992, SCIENCE, V255, P841, DOI 10.1126/science.1371365; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; Takahara T, 1996, HUM MOL GENET, V5, P989, DOI 10.1093/hmg/5.7.989; TANAKA I, 1995, FEBS LETT, V376, P146, DOI 10.1016/0014-5793(95)01262-2; TCHENIO T, 1993, EMBO J, V12, P1487, DOI 10.1002/j.1460-2075.1993.tb05792.x; USDIN K, 1989, J BIOL CHEM, V264, P15681; WOODSAMUELS P, 1989, GENOMICS, V4, P290, DOI 10.1016/0888-7543(89)90332-7; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6; [No title captured]	62	756	775	1	22	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					917	927		10.1016/S0092-8674(00)81998-4	http://dx.doi.org/10.1016/S0092-8674(00)81998-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945518	hybrid			2022-12-01	WOS:A1996VV77400017
J	Oshima, M; Dinchuk, JE; Kargman, SL; Oshima, H; Hancock, B; Kwong, E; Trzaskos, JM; Evans, JF; Taketo, MM				Oshima, M; Dinchuk, JE; Kargman, SL; Oshima, H; Hancock, B; Kwong, E; Trzaskos, JM; Evans, JF; Taketo, MM			Suppression of intestinal polyposis in Apc(Delta 716) knockout mice by inhibition of cyclooxygenase 2 (COX-2)	CELL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; PROSTAGLANDIN-G/H SYNTHASE; HUMAN COLON-CANCER; EPITHELIAL-CELLS; MAJOR MODIFIER; APC GENE; ASPIRIN; EXPRESSION; NEOPLASIA	Two cyclooxygenase isozymes catalyze conversion of arachidonic acid to prostaglandin H-2: constitutive COX-1 and inducible COX-2. To assess the role of COX-2 in colorectal tumorigenisis, we determined the effects of COX-2 gene (Ptgs2) knockouts and a novel COX-2 inhibitor on Apc(Delta 716) knockout mice, a model of human familial adenomatous polyposis. A Ptgs2 null mutation reduced the number and size of the intestinal polyps dramatically. Furthermore, treating Apc(Delta 716) mice with a novel COX-2 inhibitor reduced the polyp number more significantly than with sulindac, which inhibits both isoenzymes. These results provide direct genetic evidence that COX-2 plays a key role in tumorigenesis and indicate that COX-2-selective inhibitors can be a novel class of therapeutic agents for colorectal polyposis and cancer.	BANYU TSUKUBA RES INST MERCK, TSUKUBA, IBARAKI 30033, JAPAN; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA; MERCK FROSST CTR THERAPEUT RES, POINTE CLAIRE, PQ H9R 4P8, CANADA; UNIV TOKYO, FAC PHARMACEUT SCI, DEPT BIOMED GENET, BUNKYO KU, TOKYO 113, JAPAN	Merck & Company; DuPont; Merck & Company; University of Tokyo			Oshima, Masanobu/F-9958-2014	Oshima, Masanobu/0000-0002-3304-0004; Oshima, Hiroko/0000-0001-6855-4008; Hancock, Bruno/0000-0003-4387-2389				Boolbol SK, 1996, CANCER RES, V56, P2556; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HORII A, 1992, CANCER RES, V52, P3231; KARGMAN S, 1996, IN PRESS BIOCH PHARM; KARGMAN SL, 1995, CANCER RES, V55, P2556; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEE SH, 1992, J BIOL CHEM, V267, P25934; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MARNETT LJ, 1992, CANCER RES, V52, P5575; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; OSHIMA M, 1995, CARCINOGENESIS, V16, P2605, DOI 10.1093/carcin/16.11.2605; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Oshima M, 1996, MOL CARCINOGEN, V15, P11, DOI 10.1002/(SICI)1098-2744(199601)15:1<11::AID-MC3>3.0.CO;2-V; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RAO CV, 1995, CANCER RES, V55, P1464; REDDY BS, 1993, CARCINOGENESIS, V14, P1493, DOI 10.1093/carcin/14.8.1493; RIGAS B, 1993, J LAB CLIN MED, V122, P518; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WILLIAMS CW, 1996, GASTROENTEROLOGY, V110, P1134; XIE WL, 1992, DRUG DEVELOP RES, V25, P249, DOI 10.1002/ddr.430250402	39	2137	2242	0	84	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					803	809		10.1016/S0092-8674(00)81988-1	http://dx.doi.org/10.1016/S0092-8674(00)81988-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945508	Bronze			2022-12-01	WOS:A1996VV77400007
J	Parada, CA; Roeder, RG				Parada, CA; Roeder, RG			Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain	NATURE			English	Article							TRANSCRIPTION FACTOR TFIIH; BASAL TRANSCRIPTION; ELONGATION; KINASE; INITIATION; BINDING; COMPLEX; VP16	THE protein Tat is encoded by the HIV-1 genome and is essential for viral replication because of its activation of viral transcription. Tat enhances the ability of RNA polymerase II (Pol II) to move long distances down the DNA through a poorly understood mechanism that involves its binding the to the 5' end of the nascent HIV-1 transcript(1-5), It has been suggested(6-10) that the stimulation of transcript elongation by conventional DNA-binding activators may involve phosphorylation of the carboxy-terminal domain (CTD) of Pol II by the transcription factor TFIIH11-13 through the associated CAK kinase(14-16). Here we show that Tat-enhanced HIV-1 transcription in vitro requires both TFIIH and the CTD of Pol II, In addition, Tat, through its activation domain, both interacts with a functional TFIIH-containing complex and stimulates phosphorylation of a CTD-containing substrate by the TFIIH kinase. Under conditions that jointly restrict transcriptional elongation(5,17) and TFIIH-mediated CTD phosphorylation, Tat stimulates both these activities. Furthermore, RNA synthesis is required for Tat to stimulate phosphorylation of the CTD when it is part of an initiation complex, as expected from Tat's interaction with viral transcripts(1). Thus, stimulation of Pol II elongation by Tat may involve direct effects on TFIIH-mediated CTD phosphorylation.	ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021	Rockefeller University								BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; Blair WS, 1996, EMBO J, V15, P1658, DOI 10.1002/j.1460-2075.1996.tb00511.x; Blau J, 1996, MOL CELL BIOL, V16, P2044; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Herrmann CH, 1996, NUCLEIC ACIDS RES, V24, P501, DOI 10.1093/nar/24.3.501; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; Jiang Y, 1996, MOL CELL BIOL, V16, P1614; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MADORE SJ, 1993, J VIROL, V67, P3703, DOI 10.1128/JVI.67.7.3703-3711.1993; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; PARADA CA, 1995, J BIOL CHEM, V270, P2274, DOI 10.1074/jbc.270.5.2274; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; Wu-Baer Foon, 1996, Journal of Biological Chemistry, V271, P4201, DOI 10.1074/jbc.271.8.4201; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x	30	237	240	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					375	378		10.1038/384375a0	http://dx.doi.org/10.1038/384375a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934526				2022-12-01	WOS:A1996VV27100054
J	van der Maas, PJ; vanderWal, G; Haverkate, I; deGraaff, CLM; Kester, JGC; OnwuteakaPhilipsen, BD; vanderHeide, A; Bosma, JM; Willems, DL				van der Maas, PJ; vanderWal, G; Haverkate, I; deGraaff, CLM; Kester, JGC; OnwuteakaPhilipsen, BD; vanderHeide, A; Bosma, JM; Willems, DL			Euthanasia, physician-assisted suicide, and other medical practices involving the end of life in the Netherlands, 1990-1995	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ATTITUDES	Background In 1991 a new procedure for reporting physician-assisted deaths was introduced in the Netherlands that led to a tripling in the number of reported cases. In 1995, as part of an evaluation of this procedure, a nationwide study of euthanasia and other medical practices concerning the end of life was begun that was identical to a study conducted in 1990. Methods We conducted two studies, the first involving interviews with 405 physicians (general practitioners, nursing home physicians, and clinical specialists) and the second involving questionnaires mailed to the physicians attending 6060 deaths that were identified from death certificates. The response rates were 89 percent and 77 percent, respectively. Results Among the deaths studied, 2.3 percent of those in the interview study and 2.4 percent of those in the death-certificate study were estimated to have resulted from euthanasia, and 0.4 percent and 0.2 percent, respectively, resulted from physician-assisted suicide. In 0.7 percent of cases, life was ended without the explicit, concurrent request of the patient. Pain and symptoms were alleviated with doses of opioids that may have shortened life in 14.7 to 19.1 percent of cases, and decisions to withhold or withdraw life-prolonging treatment were made in 20.2 percent. Euthanasia seems to have increased in incidence since 1990, and the ending of life without the patient's explicit request seems to have decreased slightly. For each type of medical decision except those in which life-prolonging treatment was withheld or withdrawn, cancer was the most frequently reported diagnosis. Conclusions Since the notification procedure was introduced, end-of-life decision making in the Netherlands has changed only slightly, in an anticipated direction. Close monitoring of such decisions is possible, and we found no signs of an unacceptable increase in the number of decisions or of less careful decision making. (C)1996, Massachusetts Medical Society.	VRIJE UNIV AMSTERDAM, INST RES EXTRAMURAL MED, AMSTERDAM, NETHERLANDS; STAT NETHERLANDS, VOORBURG, NETHERLANDS	Vrije Universiteit Amsterdam	van der Maas, PJ (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.							BLACK AL, 1996, JAMA-J AM MED ASSOC, V275, P919; Bokhove J., 1996, BALANS REKENONDERWIJ; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Folker AP, 1996, BIOETHICS, V10, P233, DOI 10.1111/j.1467-8519.1996.tb00122.x; Heinisch O., 1963, SAMPLING TECHNIQUES, V7, P203, DOI [10.1002/bimj.19650070312, DOI 10.1002/BIMJ.19650070312]; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; *ROYAL DUTCH MED A, 1995, POS PAP EUTH; STEVENS CA, 1994, J MED ETHICS, V20, P41, DOI 10.1136/jme.20.1.41; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERMAAS PJ, 1992, HLTH POLICY, V22; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332	14	386	386	1	59	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1699	1705		10.1056/NEJM199611283352227	http://dx.doi.org/10.1056/NEJM199611283352227			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VV936	8929370	Green Published, Bronze			2022-12-01	WOS:A1996VV93600034
J	Tyson, JE; Younes, N; Verter, J; Wright, LL				Tyson, JE; Younes, N; Verter, J; Wright, LL			Viability, morbidity, and resource use among newborns of 501- to 800-g birth weight	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAGNOSIS-RELATED GROUPS; NEONATAL INTENSIVE-CARE; EXTREMELY PREMATURE; GESTATIONAL-AGE; INFANTS BORN; MORTALITY; OUTCOMES; SEVERITY; CHILDREN; NETWORK	Objectives.-To assess risk factors affecting viability and analyze the effects of mechanical ventilation (MV) on neonatal outcome and resource use among extremely premature infants. Design.-Inception cohort study. Setting.-Neonatal intensive care units of the 12-center National Institute of Child Health and Human Development Neonatal Research Network. Participants.-A total of 1126 infants with a birth weight of 501 to 800 g born in network centers between January 1, 1994, and December 31, 1995. Main Outcome Measures.-Observed survival; maximum estimated survival (assuming the same survival among infants who died without MV as among infants in the same risk category who received MV); observed and maximum estimated survival without severe brain injury (either interventricular echodensity with ventricular dilation or parenchymal echodensity); hospital stay; resource investment. Results.-Overall mortality was 43%; mortality in infants without MV was 93%, A total of 15% of ail the infants died without MV. Females, small-for-gestational-age infants, and infants whose mothers received antenatal steroids had an advantage in survival with MV equivalent to an increase in birth weight of 90 g, 57 g, and 67 g, respectively, The corresponding advantage of these infants in survival without severe brain injury was 107 g, 97 g, and 64 g, respectively, Females in the lowest birth-weight group were more likely to die without MV than were larger males with a similar estimated likelihood of survival with MV. Mean hospital stay was 115 days for the survivors, values much greater than the 17.9-day standard for 501- to 800-g survivors under the diagnosis related group system. Resource investment was considerable (127 hospital days per survivor and 148 days per survivor without severe brain injury), but, like outcome, varied markedly between risk categories. Had MV been used for all infants who died, we estimate a substantial increase in resource use and a maximum of 8 additional survivors (no more than 6 without severe brain injury per 100 infants with a birth weight of 501 to 800 g. Conclusions.-Although recommendations to initiate or forgo MV for extremely premature infants have often focused on 1 factor(birth weight or gestational age), multiple factors should be considered. Other factors being equal, our analyses support use of MV for females at a minimum birth weight approximately 100 g lower than that for males. The current diagnosis related group reimbursement system can be expected to compromise resources for 501- to 800-g infants who would benefit from MV. Such care entails considerable resource use, although the cost per life-year gained is likely to be considerably less than that for many adults given intensive care. Our findings can be used to facilitate more appropriate treatment decisions, determine adequate resources, and better inform the debate about the benefits and burdens of intensive care for extremely premature newborns.	GEORGE WASHINGTON UNIV, CTR BIOSTAT, WASHINGTON, DC USA; NICHHD, BETHESDA, MD 20892 USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; UNIV CINCINNATI, CINCINNATI, OH USA; EMORY UNIV, ATLANTA, GA 30322 USA; INDIANA UNIV, SCH MED, INDIANAPOLIS, IN USA; UNIV NEW MEXICO, ALBUQUERQUE, NM 87131 USA; STANFORD UNIV, STANFORD, CA 94305 USA; WAYNE STATE UNIV, DETROIT, MI USA; BROWN UNIV, WOMEN & INFANTS HOSP, PROVIDENCE, RI USA; YALE UNIV, NEW HAVEN, CT USA	George Washington University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Case Western Reserve University; University System of Ohio; University of Cincinnati; Emory University; Indiana University System; Indiana University-Purdue University Indianapolis; University of New Mexico; Stanford University; Wayne State University; Brown University; Women & Infants Hospital Rhode Island; Yale University	Tyson, JE (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PEDIAT, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.				NICHD NIH HHS [2U01 HD 19897, 1U10 HD 21373] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD021373] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD019897] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN AC, 1994, CAN MED ASSOC J, V151, P547; ALLEN MC, 1993, NEW ENGL J MED, V329, P1597, DOI 10.1056/NEJM199311253292201; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ARBUCKLE TE, 1989, CAN MED ASSOC J, V140, P157; ARRAS JD, 1987, CONT ISSUES FETAL NE, V3, P151; AVERY GB, 1987, CLIN PERINATOL, V14, P361, DOI 10.1016/S0095-5108(18)30770-X; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; BALLARD JL, 1991, J PEDIATR-US, V119, P417, DOI 10.1016/S0022-3476(05)82056-6; BAQUET D, 1995, NY TIMES        0305, P1; BERKI SE, 1987, PEDIATRICS, V79, P874; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; BREGMAN J, 1992, CLIN PERINATOL, V19, P673, DOI 10.1016/S0095-5108(18)30451-2; BUCHANAN N, 1987, MED J AUSTRALIA, V147, P184, DOI 10.5694/j.1326-5377.1987.tb133354.x; COHEN IL, 1993, JAMA-J AM MED ASSOC, V269, P1025, DOI 10.1001/jama.269.8.1025; *COMM FET NEWB AM, 1995, PEDIATRICS, V5, P974; *COMM FET NEWB AM, 1971, STAND REC HOSP CAR N; CONSTANTINE NA, 1987, J PEDIATR-US, V110, P921, DOI 10.1016/S0022-3476(87)80416-X; Donovan EF, 1996, PEDIATR RES, V39, P1220; DOYLE LW, 1989, AM J DIS CHILD, V143, P223, DOI 10.1001/archpedi.1989.02150140117032; FANAROFF AA, 1995, AM J OBSTET GYNECOL, V173, P1423, DOI 10.1016/0002-9378(95)90628-2; Frader JE, 1996, PEDIATRICS, V98, P149; HACK M, 1991, PEDIATRICS, V87, P587; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; HACK M, 1993, NEW ENGL J MED, V329, P1649, DOI 10.1056/NEJM199311253292210; HANLEY JA, 1982, DIAGN RADIOL, V149, P29; HARRISON H, 1993, PEDIATRICS, V92, P643; HORBAR JD, 1995, FUTURE CHILD, V5, P139, DOI 10.2307/1602512; HORBAR JD, 1993, CRIT CARE MED, V21, P12, DOI 10.1097/00003246-199301000-00008; IMERSHEIN AW, 1992, PEDIATRICS, V89, P56; JONES R, 1995, PEDIATRICS, V96, P897; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; KRAYBILL EN, 1988, J PEDIATR-US, V113, P327, DOI 10.1016/S0022-3476(88)80273-7; LICHTIG LK, 1989, PEDIATRICS, V84, P49; MILNER RDG, 1974, J OBSTET GYN BR COMM, V81, P956; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; PHIBBS CS, 1986, PEDIATRICS, V78, P829; POLAND RL, 1985, PEDIATRICS, V76, P104; QUINN MW, 1993, LANCET, V342, P324, DOI 10.1016/0140-6736(93)91472-X; RICHARDSON DK, 1993, PEDIATRICS, V91, P969; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P117; SAIGAL S, 1994, J PEDIATR-US, V125, P418, DOI 10.1016/S0022-3476(05)83289-5; Saigal S, 1996, JAMA-J AM MED ASSOC, V276, P453, DOI 10.1001/jama.276.6.453; SCHAPIRA DV, 1993, JAMA-J AM MED ASSOC, V269, P783, DOI 10.1001/jama.269.6.783; SCHWARTZ LS, 1991, GEN HOSP PSYCHIAT, V13, P19, DOI 10.1016/0163-8343(91)90005-H; SIMON NP, 1994, CLIN PERINATOL, V21, P411, DOI 10.1016/S0095-5108(18)30353-1; SINCLAIR JC, 1995, PAEDIATR PERINAT EP, V9, P373, DOI 10.1111/j.1365-3016.1995.tb00157.x; STRONG C, 1987, CONT ISSUES FETAL NE, V3, P187; TARNOWMORDI W, 1990, BRIT MED J, V300, P1611, DOI 10.1136/bmj.300.6740.1611; TORRANCE GW, 1982, OPER RES, V30, P1043, DOI 10.1287/opre.30.6.1043; TYSON J, 1995, FUTURE CHILD, V5, P197, DOI 10.2307/1602515; TYSON J, 1992, Pediatric Research, V31, p26A; VOLPE J, 1995, NEUROLOGY NEWBORN, P427; WATTS JK, 1995, PAEDIATR PERINAT EP, V9, P375; YOUNG EWD, 1990, AM J DIS CHILD, V144, P549, DOI 10.1001/archpedi.1990.02150290043023; 1991, FED REG         0830, V56, P43292; [No title captured]; 1995, PAEDIATR PERINAT EP, V9, P370	58	116	117	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1996	276	20					1645	1651		10.1001/jama.276.20.1645	http://dx.doi.org/10.1001/jama.276.20.1645			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VU209	8922450				2022-12-01	WOS:A1996VU20900031
J	Srinivasan, U; Leonard, N; Jones, E; Kasarda, DD; Weir, DG; OFarrelly, C; Feighery, C				Srinivasan, U; Leonard, N; Jones, E; Kasarda, DD; Weir, DG; OFarrelly, C; Feighery, C			Absence of oats toxicity in adult coeliac disease	BRITISH MEDICAL JOURNAL			English	Article							CELIAC-DISEASE		ST JAMES HOSP,DEPT IMMUNOL,DUBLIN 8,IRELAND; ST JAMES HOSP,DEPT HISTOPATHOL,DUBLIN 8,IRELAND; USDA,ALBANY,CA 94710; ST JAMES HOSP,DEPT GASTROENTEROL,DUBLIN 8,IRELAND; TRINITY COLL DUBLIN,DUBLIN,IRELAND; ST VINCENTS HOSP,EDUC & RES CTR,DUBLIN 4,IRELAND	Trinity College Dublin; Trinity College Dublin; United States Department of Agriculture (USDA); Trinity College Dublin; Trinity College Dublin; University College Dublin				O'Farrelly, Cliona/0000-0002-0616-2874				FEIGHERY C, 1991, EUR J GASTROEN HEPAT, V3, P119; JANATUINEN EK, 1995, NEW ENGL J MED, V333, P1033, DOI 10.1056/NEJM199510193331602; LEIGH RJ, 1985, SCAND J GASTROENTERO, V20, P715, DOI 10.3109/00365528509089201; LOCKHART HB, 1978, OATS CHEM TECHNOLOGY, P153; MEEUWISSE GW, 1970, ACTA PAEDIATR SCAND, V59, P461	5	107	110	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1996	313	7068					1300	1301						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV153	8942690	Green Published			2022-12-01	WOS:A1996VV15300024
J	Katz, DA; Griffith, JL; Beshansky, JR; Selker, HP				Katz, DA; Griffith, JL; Beshansky, JR; Selker, HP			The use of empiric clinical data in the evaluation of practice guidelines for unstable angina	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; ACUTE CARDIAC ISCHEMIA; CORONARY-CARE-UNIT; MEDICAL-PRACTICE GUIDELINES; PREDICTIVE INSTRUMENT; CHEST PAIN; PROSPECTIVE MULTICENTER; HEART-DISEASE; EMERGENCY; PECTORIS	Objective.-To determine the applicability to emergency department (ED) clinical practice of a nationally disseminated practice guideline on the disposition of patients with a diagnosis of unstable angina, and to determine the potential impact of the guideline on hospital admissions and demand for intensive care beds. Design.-Application of guideline criteria for ED disposition decisions to a validation sample derived from a prospective clinical trial. Setting.-Five hospitals, including 2 urban general teaching hospitals, 2 urban tertiary care university hospitals, and 1 suburban university-affiliated community hospital. Patients.-A consecutive sample of 457 patients who presented with symptoms suggestive of acute cardiac ischemia and who had ''unstable angina'' or ''rule out unstable angina'' diagnosed by ED physicians. Greater than 90% of eligible patients were enrolled in the clinical trial, follow-up data sufficient for assignment of a definitive diagnosis were obtained for 99% of subjects. Main outcome Measures.-Acute myocardial infarction and unstable angina, based on blind review of initial and follow-up clinical data, including cardiac enzyme levels and electrocardiograms. After completion of the trial, without knowledge of final diagnosis or outcome, the investigators classified patients into risk groups specified by the unstable angina guideline. Results.-Of subjects with an ED diagnosis of unstable angina, only 6% (n=28) met the guideline's criteria corresponding to low risk for adverse events and were therefore suitable for discharge directly to home. Fifty-four percent (n=247) mel the intermediate-risk criteria; 40% (n=182) met the high-risk criteria and were identified as requiring admission to an intensive care unit. Actual ED disposition differed from guideline recommendations in 2 major areas: only 4% (1/28) of low-risk patients were discharged to home with outpatient follow-up, and only 40% (72/182) of high-risk patients were admitted to an intensive care unit. Conclusions.-Although the guideline was intended to reduce hospitalization by identifying a low-risk group, the small size of this group among ED patients suggests that little reduction in hospitalization can be expected. Indeed, the guideline may increase demand for the limited number of intensive care beds to accommodate patients with unstable angina considered high-risk but currently placed elsewhere. These results emphasize the need to use empiric data from target clinical settings to assess the likely actual impact of guidelines on clinical care prior to national dissemination.	TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DEPT MED, DIV CLIN DECIS MAKING, BOSTON, MA 02111 USA; TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DEPT MED, DIV CLIN CARE RES, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University				Katz, David/0000-0001-5348-6532	AHRQ HHS [R01-HS07360] Funding Source: Medline; NLM NIH HHS [LM7092] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007360] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007092] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ATKINS J, 1995, AM J EMERG MED, V13, P188; AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; BERTINI G, 1991, Journal of Emergency Medicine, V9, P57, DOI 10.1016/0736-4679(91)90589-8; BRAUNWALD E, 1994, CLIN PRACTICE GUIDEL, V10; CALIFF RM, 1988, J AM COLL CARDIOL, V11, P20, DOI 10.1016/0735-1097(88)90160-X; CALVIN JE, 1995, JAMA-J AM MED ASSOC, V273, P136; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CANNON CP, 1995, AM J CARDIOL, V75, P977, DOI 10.1016/S0002-9149(99)80707-3; CANTRILL S, 1992, EMERG MED CLIN N AM, V8, P507; COHEN M, 1991, AM J CARDIOL, V67, P1368, DOI 10.1016/0002-9149(91)90467-Y; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Field MJ, 1992, GUIDELINES CLIN PRAC; FUCHS R, 1981, JAMA-J AM MED ASSOC, V246, P2037, DOI 10.1001/jama.246.18.2037; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRAVES E, 1993, NATL CTR HLTH STAT S, V13; GRIJSEELS EWM, 1995, EUR HEART J, V16, P325; JAYES RL, 1992, J GEN INTERN MED, V7, P387, DOI 10.1007/BF02599153; KARCZ A, 1990, ANN EMERG MED, V19, P865, DOI 10.1016/S0196-0644(05)81559-8; KARLSON BW, 1993, CLIN CARDIOL, V16, P397, DOI 10.1002/clc.4960160506; MCCARTHY BD, 1990, J GEN INTERN MED, V5, P365, DOI 10.1007/BF02600409; MCDONALD C, 1994, CLIN PRACTICE GUIDEL, P71; MCNUTT RA, 1988, MED DECIS MAKING, V8, P90, DOI 10.1177/0272989X8800800204; NATTEL S, 1980, CAN MED ASSOC J, V122, P180; PEARSON SD, 1994, J GEN INTERN MED, V9, P241, DOI 10.1007/BF02599648; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; RIZIK DG, 1995, AM J CARDIOL, V75, P993, DOI 10.1016/S0002-9149(99)80710-3; SARASIN FP, 1994, J GEN INTERN MED, V9, P187, DOI 10.1007/BF02600122; SAS, 2021, SAS PROC KAPP COEFF; Selker H. P., 1995, Journal of Investigative Medicine, V43, p497A; SELKER HP, 1987, JAMA-J AM MED ASSOC, V257, P1181, DOI 10.1001/jama.257.9.1181; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SELKER HP, 1993, AM J CARDIOL, V71, P339, DOI 10.1016/0002-9149(93)90802-J; VANDERDOES E, 1976, HEART B, V7, P91; WHITE LD, 1990, J AM COLL CARDIOL, V16, P304, DOI 10.1016/0735-1097(90)90577-C	35	60	62	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1568	1574						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT025	8918854				2022-12-01	WOS:A1996VT02500029
J	Tanaka, E; Alter, HJ; Nakatsuji, Y; Shih, JWK; Kim, JP; Matsumoto, A; Kobayashi, M; Kiyosawa, K				Tanaka, E; Alter, HJ; Nakatsuji, Y; Shih, JWK; Kim, JP; Matsumoto, A; Kobayashi, M; Kiyosawa, K			Effect of hepatitis G virus infection on chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; NON-B-HEPATITIS; NON-A; ANTIBODY; THERAPY; RNA; GENOTYPES	Objective: To clarify the effect of hepatitis G virus (HGV) infection on chronic hepatitis C. Design: Retrospective study. Setting: University hospital in Matsumoto, Japan. Patients: 189 randomly selected patients with histologically proven chronic hepatitis C, including 101 patients receiving interferon-alpha. Measurements: Serum levels of HGV RNA were measured by reverse-transcription polymerase chain reaction. Clinical features, including liver histologic findings, hepatitis C virus (HCV) markers, and response of HCV to interferon-alpha were compared between HGV RNA-positive and HGV RNA-negative patients. Results: 21 of 189 (11%) patients with chronic hepatitis C were positive for HCV RNA. On average, patients with HGV RNA were younger than those without HCV RNA (mean age +/- SD, 46.6 +/- 13.0 years and 51.7 +/- 10.7 years, respectively); other demographic and clinical features were similar. The HCV genotype and HCV RNA level were distributed similarly between patients with and those without HCV infection. Ten of 101 patients with chronic hepatitis C who received interferon-alpha were positive for HCV RNA. The rate of sustained HCV response to intepferon-alpha: in patients with HGV infection (30%) was similar to that in patients without HGV infection (36%). The HGV RNA level decreased during therapy in all 9 patients in whom this value was measured. However, only 2 of these patients had a sustained HGV response after discontinuation of therapy. Conclusions: Patients who only had HCV infection did not differ from patients with HCV and HGV co-infection in clinical presentation, HCV RNA level, or response of HCV to interferon-alpha therapy. Thus, HCV infection had no apparent influence on the clinical or virologic course of HCV, infection. Hepatitis G virus was uniformly sensitive to interferon-alpha therapy, but only a few patients had a sustained virologic response.	NIH, DEPT TRANSFUS MED, BETHESDA, MD 20852 USA; SHINSHU UNIV, SCH MED, DEPT INTERNAL MED 2, MATSUMOTO, NAGANO 390, JAPAN; GENELABS TECHNOL INC, REDWOOD CITY, CA 94063 USA	National Institutes of Health (NIH) - USA; Shinshu University								ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1995, J VIRAL HEPATITIS, V2, P121, DOI 10.1111/j.1365-2893.1995.tb00017.x; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X; FONG TL, 1991, HEPATOLOGY, V14, P64, DOI 10.1002/hep.1840140111; Jeffers L. J., 1995, Hepatology, V22, p182A, DOI 10.1016/0270-9139(95)94452-4; KAKLAMANI E, 1991, JAMA-J AM MED ASSOC, V265, P1974, DOI 10.1001/jama.265.15.1974; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; MATSUMOTO A, 1994, DIGEST DIS SCI, V39, P1273, DOI 10.1007/BF02093793; NAKATSUJI Y, IN PRESS J VIRAL HEP; OINNEN J, 1996, SCIENCE, V271, P505; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; PONTISSO P, 1993, GASTROENTEROLOGY, V105, P1529, DOI 10.1016/0016-5085(93)90161-5; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1002/hep.1840190538; Tanaka E, 1996, HEPATOLOGY, V23, P1330, DOI 10.1002/hep.510230606; TANAKA E, 1991, J MED VIROL, V33, P117, DOI 10.1002/jmv.1890330210; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	18	175	176	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					740	743		10.7326/0003-4819-125-9-199611010-00007	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929008				2022-12-01	WOS:A1996VQ07200006
J	Roberts, WM; Estrov, Z; Ouspenskaia, MV; Johnston, DA; McClain, KL; Zipf, TF				Roberts, WM; Estrov, Z; Ouspenskaia, MV; Johnston, DA; McClain, KL; Zipf, TF			Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; ACUTE MYELOID-LEUKEMIA; CLINICAL-SIGNIFICANCE; FOLLOW-UP; DISEASE; CHILDREN; PERSISTENCE; THERAPY; CELLS; CHEMOTHERAPY	Background Complete remission of B-precursor acute lymphoblastic leukemia (ALL) has traditionally been defined as the near absence of lymphoblasts in a light-microscopical examination of stained bone marrow smears, but a patient in remission may still harbor up to 10(10) leukemia cells. We investigated whether there is a relation between the outcome of treatment and submicroscopic evidence of residual disease. Methods We conducted a prospective study of patients during a first clinical remission using a quantitative polymerase-chain-reaction (PCR) assay capable of detecting 1 viable leukemia cell among 200,000 normal marrow mononuclear cells and a clonogenic blast-colony assay. Bone marrow specimens from 24 children were sequentially evaluated during a five-year period, and the results were compared with the clinical outcome. Results Seven patients relapsed and 17 remained in remission 2 to 35 months after the completion of treatment. The levels of residual leukemia-cell DNA in the two groups were significantly different (P<0.001; 95 percent confidence interval for the difference in the mean log-transformed ratio of leukemia-cell DNA to normal bone marrow-cell DNA, 0.38 to 1.28). Autoregression analyses identified trends for individual patients that were associated with relapse. Despite continued remission in 17 patients, evidence of residual leukemia was detected by PCR in 15 and by both PCR and blast-colony assays in 7. Conclusions Molecular signs of residual leukemia can persist up to 35 months after the cessation of chemotherapy in children with ALL in remission. This suggests that eradication of all leukemia cells may not be a prerequisite for cure. (C) 1997, Massachusetts Medical Society.	UNIV TEXAS,MD ANDERSON CANCER CTR,DIV PEDIAT,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOIMMUNOTHERAPY,DIV MED,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOMATH,HOUSTON,TX 77030; BAYLOR COLL MED,TEXAS CHILDRENS CANC CTR,HOUSTON,TX 77030; BAYLOR COLL MED,SERV HEMATOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine				McClain, Kenneth/0000-0003-0725-6263	NATIONAL CANCER INSTITUTE [P30CA016672, K08CA001546] Funding Source: NIH RePORTER; NCI NIH HHS [CA01546, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTRAM CR, 1993, CLIN CHIM ACTA, V217, P75, DOI 10.1016/0009-8981(93)90239-Z; BENNETT JM, 1981, BRIT J HAEMATOL, V47, P553, DOI 10.1111/j.1365-2141.1981.tb02684.x; BRADSTOCK KF, 1995, LEUKEMIA LYMPHOMA, V18, P1, DOI 10.3109/10428199509064917; CAMPANA D, 1995, BLOOD, V85, P1416, DOI 10.1182/blood.V85.6.1416.bloodjournal8561416; CHANG KS, 1993, ONCOGENE, V8, P983; DEANE M, 1990, EUR J IMMUNOL, V20, P2209, DOI 10.1002/eji.1830201009; ESTROV Z, 1986, NEW ENGL J MED, V315, P538, DOI 10.1056/NEJM198608283150902; ESTROV Z, 1994, LEUKEMIA, V8, P46; GALE RP, 1991, LANCET, V338, P1315, DOI 10.1016/0140-6736(91)92604-Z; GEORGE SL, 1979, NEW ENGL J MED, V300, P269, DOI 10.1056/NEJM197902083000601; ITO Y, 1994, LEUKEMIA LYMPHOMA, V16, P57, DOI 10.3109/10428199409114140; ITO Y, 1993, J CLIN ONCOL, V11, P546, DOI 10.1200/JCO.1993.11.3.546; Jurlander J, 1996, BLOOD, V88, P2183, DOI 10.1182/blood.V88.6.2183.bloodjournal8862183; KWOK S, 1989, NATURE, V339, P490; MONTAGNA D, 1995, CANCER RES, V55, P3835; NIZET Y, 1991, BRIT J HAEMATOL, V79, P205, DOI 10.1111/j.1365-2141.1991.tb04523.x; NIZET Y, 1993, BLOOD, V82, P1618; NUCIFORA G, 1993, BLOOD, V82, P712; OUSPENSKAIA MV, 1995, LEUKEMIA, V9, P321; PINKEL D, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P211; POTTER MN, 1993, BRIT J HAEMATOL, V83, P412, DOI 10.1111/j.1365-2141.1993.tb04665.x; PUI CH, 1991, J CLIN ONCOL, V9, P1341, DOI 10.1200/JCO.1991.9.8.1341; ROBERTS WM, 1995, CYTOKINES MOL THER, V1, P65; Roberts WM, 1996, LEUKEMIA LYMPHOMA, V20, P181, DOI 10.3109/10428199609051607; SHAHANGIAN S, 1989, CLIN CHEM, V35, P972; SKIPPER H E, 1964, Cancer Chemother Rep, V35, P1; Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18; Wu NH, 1996, PEDIATR HEMAT ONCOL, V13, P257, DOI 10.3109/08880019609030825; YAMADA M, 1990, NEW ENGL J MED, V323, P448, DOI 10.1056/NEJM199008163230705	29	162	166	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1997	336	5					317	323		10.1056/NEJM199701303360501	http://dx.doi.org/10.1056/NEJM199701303360501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG233	9011783				2022-12-01	WOS:A1997WG23300001
J	Itzhaki, RF; Lin, WR; Shang, DH; Wilcock, GK; Faragher, B; Jamieson, GA				Itzhaki, RF; Lin, WR; Shang, DH; Wilcock, GK; Faragher, B; Jamieson, GA			Herpes simplex virus type 1 in brain and risk of Alzheimer's disease	LANCET			English	Article							APOLIPOPROTEIN-E; REACTIVATION; ASSOCIATION; ETIOLOGY; DNA; PCR	Background The apolipoprotein E epsilon 4 (APOE-epsilon 4) allele is a risk factor for Alzheimer's disease (AD), but it is neither essential nor sufficient for development of the disease. Other factors-genetic or environmental-must therefore have a role. By means of a PCR we have detected herpes simplex virus type 1 (HSV1) in latent form in brains of elderly people with and without AD. We have postulated that limited reactivation of the virus causes more damage in AD patients than in elderly people without AD because of a difference in the hosts. We now report the APOE genotypes of AD patients and non-AD sufferers with and without HSV1 in brain. Methods DNA was extracted from 84 samples of brain from 46 AD patients (39 temporal lobe, 39 frontal lobe, three hippocampus) and from 75 samples of brain from 44 non-AD elderly people (33 temporal lobe, 36 frontal lobe, six hippocampus). PCR amplification was used to detect HSV1 thymidine kinase gene and the host APOE gene. Findings By multiple logistic regression, the APOE-epsilon 4 allele frequency was significantly higher in the patients positive for HSV1 in brain than in the HSV1-negative AD group, the HSV1-positive non-AD group, or the HSV1-negative non-AD group (52.8% vs 10.0%, 3.6%, and 6.3%, respectively). The odds ratio for APOE-epsilon 4 in the HSV1-positive AD group compared with HSV1-negative non-AD group was 16.8 (95% CI 3.61-77.8) and in the HSV1-negative AD group, 1.67 (0.21-13.4). We also compared APOE genotypes of 40 people who had recurrent cold sores and 33 non-sufferers; the APOE-epsilon 4 allele frequencies were 36% and 9%, respectively (p<0.0001). Interpretation These findings suggest that the combination of HSV1 in brain and carriage of an APOE-epsilon 4 allele is a strong risk factor for AD, whereas either of these features alone does not increase the risk of AD. The findings in people with cold sores support our hypothesis that APOE-epsilon 4 and HSV1 together are damaging in the nervous system.	FRENCHAY HOSP,DEPT CARE ELDERLY,BRISTOL BS16 1LE,AVON,ENGLAND; UNIV MANCHESTER,DEPT MED BIOPHYS,MED STAT RES SUPPORT UNIT,MANCHESTER M13 9PL,LANCS,ENGLAND	University of Manchester	Itzhaki, RF (corresponding author), UNIV MANCHESTER,INST SCI & TECHNOL,DEPT OPTOMETRY & VIS SCI,MOL NEUROBIOL LAB,MANCHESTER M60 1QD,LANCS,ENGLAND.							BALL UJ, 1982, CANAD J NEUROL SCI, V9, P303; BARINGER JR, 1994, ANN NEUROL, V36, P823, DOI 10.1002/ana.410360605; BEYER CF, 1989, CURR EYE RES, V8, P1287, DOI 10.3109/02713688909013908; BLYTH WA, 1984, IMMUNOBIOLOGY HERPES, P10; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; CAULEY JA, 1993, GENET EPIDEMIOL, V10, P27, DOI 10.1002/gepi.1370100104; ESIRI MM, 1982, J NEUROL NEUROSUR PS, V45, P759, DOI 10.1136/jnnp.45.8.759; Gordon L, 1996, CLIN DIAGN VIROL, V6, P33, DOI 10.1016/0928-0197(95)00203-0; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; Itzhaki R., 1993, ALZHEIMERS DIS ADV C, P97; ITZHAKI RF, 1994, MOL NEUROBIOL, V9, P1, DOI 10.1007/BF02816099; JAMIESON GA, 1991, J MED VIROL, V33, P224, DOI 10.1002/jmv.1890330403; JAMIESON GA, 1992, J PATHOL, V167, P365, DOI 10.1002/path.1711670403; JI ZS, 1994, J BIOL CHEM, V269, P2764; KLAPPER PE, 1984, J NEUROL NEUROSUR PS, V47, P1247, DOI 10.1136/jnnp.47.11.1247; Lin WR, 1995, BIOCHEM SOC T, V23, pS594, DOI 10.1042/bst023594s; Lin WR, 1996, MOL CHEM NEUROPATHOL, V28, P135, DOI 10.1007/BF02815215; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; ROBERTS GW, 1986, J NEUROL NEUROSUR PS, V49, P216, DOI 10.1136/jnnp.49.2.216; SALDANHA J, 1986, J NEUROL NEUROSUR PS, V49, P613, DOI 10.1136/jnnp.49.6.613; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; TANAKA S, 1994, J GEN VIROL, V75, P2691, DOI 10.1099/0022-1317-75-10-2691; Tyler KL, 1995, NEUROLOGY, V45, P2246, DOI 10.1212/WNL.45.12.2246; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; WILCOCK GK, 1989, J NEUROL NEUROSUR PS, V52, P693, DOI 10.1136/jnnp.52.6.693	26	457	465	0	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					241	244		10.1016/S0140-6736(96)10149-5	http://dx.doi.org/10.1016/S0140-6736(96)10149-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014911				2022-12-01	WOS:A1997WD90600011
J	Classen, DC; Pestotnik, SL; Evans, RS; Lloyd, JF; Burke, JP				Classen, DC; Pestotnik, SL; Evans, RS; Lloyd, JF; Burke, JP			Adverse drug events in hospitalized patients - Excess length of stay, extra costs, and attributable mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED ILLNESS; SURVEILLANCE; INFORMATION; ADMISSIONS; INFECTIONS; SERVICES; SYSTEM	Objective.-To determine the excess length of stay, extra costs, and mortality attributable to adverse drug events (ADEs) in hospitalized patients. Design.-Matched case-control study. Setting.-The LDS Hospital, a tertiary care health care institution. Patients.-All patients admitted to LDS Hospital from January 1, 1990, to December 31, 1993, were eligible. Cases were defined as patients with ADEs that occurred during hospitalization; controls were selected according to matching variables in a stepwise fashion. Methods.-Controls were matched to cases on primary discharge diagnosis related group (DRG), age, sex, acuity, and year of admission; varying numbers of controls were matched to each case. Matching was successful for 71% of the cases, leading to 1580 cases and 20197 controls. Main Outcome Measures.-Crude and attributable mortality, crude and attributable length of stay, and cost of hospitalization. Results.-ADEs complicated 2.43 per 100 admissions to the LDS Hospital during the study period. The crude mortality rates for the cases and matched controls were 3.5% and 1.05%, respectively (P<.001). The mean length of hospital stay significantly differed between the cases and matched controls (7.69 vs 4.46 days; P<.001) as did the mean cost of hospitalization ($10 010 vs $5355; P<.001). The extra length of hospital stay attributable to an ADE was 1.74 days (P<.001). The excess cost of hospitalization attributable to an ADE was $2013 (P<.001). A linear regression analysis for length of stay and cost controlling for all matching variables revealed that the occurrence of an ADE was associated with increased length of stay of 1.91 days and an increased cost of $2262 (P<.001). In a similar logistic regression analysis for mortality, the increased risk of death among patients experiencing an ADE was 1.88 (95% confidence interval, 1.54-2.22; P<.001). Conclusion.-The attributable lengths of stay and costs of hospitalization for ADEs are substantial. An ADE is associated with a significantly prolonged length of stay, increased economic burden, and an almost 2-fold increased risk of death.			Classen, DC (corresponding author), LATTER DAY ST HOSP, DEPT CLIN EPIDEMIOL, 8TH AVE & C ST, SALT LAKE CITY, UT 84143 USA.							BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BERWICK DM, 1994, JAMA-J AM MED ASSOC, V272, P797, DOI 10.1001/jama.272.10.797; Bloom B S, 1988, Am J Med, V84, P20, DOI 10.1016/0002-9343(88)90250-1; CARANASOS GJ, 1974, JAMA-J AM MED ASSOC, V228, P713, DOI 10.1001/jama.228.6.713; CHRISCHILLES EA, 1992, ANN INTERN MED, V117, P634, DOI 10.7326/0003-4819-117-8-634; CLASSEN D, 1993, THESIS U UTAH SALT L; Classen D C, 1992, Hosp Pharm, V27, P776; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; CLASSEN DC, 1992, HOSP PHARM, V27, P776; Classen DC, 1992, HOSP PHARM, V27, P783; CLUFF LE, 1975, MAJOR PROBLEMS INTER, V5; COLLEY CA, 1993, J GEN INTERN MED, V8, P278, DOI 10.1007/BF02600099; DAVIS RB, 1995, MED CARE, V33, P906, DOI 10.1097/00005650-199509000-00003; Evans R S, 1993, Proc Annu Symp Comput Appl Med Care, P161; Evans R S, 1992, Proc Annu Symp Comput Appl Med Care, P437; Evans R S, 1995, Proc Annu Symp Comput Appl Med Care, P651; EVANS RS, 1986, JAMA-J AM MED ASSOC, V256, P1007, DOI 10.1001/jama.256.8.1007; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; HALEY RW, 1991, AM J MED, V91, pS32, DOI 10.1016/0002-9343(91)90341-T; HALEY RW, 1992, HOSP INFECT, P507; *INT HLTH CAR INC, 1987, STAND COST MAN US GU; JICK H, 1974, NEW ENGL J MED, V291, P824, DOI 10.1056/NEJM197410172911605; JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; KNOX RA, 1995, BOSTON GLOBE    0323, P1; KUPERMAN G, 1990, HELP SYSTEM DYNAMIC; *LDS HOSP, 1990, NURS CAR MAN; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Lovett R B, 1991, J Pediatr Oncol Nurs, V8, P122, DOI 10.1177/104345429100800305; MELMON KL, 1971, NEW ENGL J MED, V284, P1361; MEYER D, 1978, GRASP PATIENT INFORM; MILLER RR, 1974, ARCH INTERN MED, V134, P219, DOI 10.1001/archinte.134.2.219; PESTOTNIK SL, 1993, ANN PHARMACOTHER, V27, P497, DOI 10.1177/106002809302700418; POLISSAR L, 1982, MED CARE, V20, P959, DOI 10.1097/00005650-198209000-00008; PORTER J, 1977, JAMA-J AM MED ASSOC, V237, P879, DOI 10.1001/jama.237.9.879; Powe NR, 1995, CONTROL CLIN TRIALS, V16, P377, DOI 10.1016/S0197-2456(95)00075-5; PRINCE BS, 1992, AM J HOSP PHARM, V49, P1696, DOI 10.1093/ajhp/49.7.1696; SCHNEIDER PJ, 1995, AM J HEALTH-SYST PH, V52, P2415, DOI 10.1093/ajhp/52.21.2415; SLOAN FA, 1993, MED CARE, V31, P851, DOI 10.1097/00005650-199310000-00001; TALLEY RB, 1974, JAMA-J AM MED ASSOC, V229, P1043, DOI 10.1001/jama.1974.03230460011003; VANRUISWYK J, 1990, NURS MANAG, V23, P44; WHALEN KL, 1990, CRIT CARE MED, V18, P505, DOI 10.1097/00003246-199005000-00009	42	1278	1335	2	53	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1997	277	4					301	306		10.1001/jama.277.4.301	http://dx.doi.org/10.1001/jama.277.4.301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC458	9002492				2022-12-01	WOS:A1997WC45800029
J	Pich, EM; Pagliusi, SR; Tessari, M; TalabotAyer, D; vanHuijsduijnen, RH; Chiamulera, C				Pich, EM; Pagliusi, SR; Tessari, M; TalabotAyer, D; vanHuijsduijnen, RH; Chiamulera, C			Common neural substrates for the addictive properties of nicotine and cocaine	SCIENCE			English	Article							RAT NUCLEUS-ACCUMBENS; REINFORCEMENT; RECEPTORS; DOPAMINE; BRAIN; EXPRESSION; INJECTIONS; INDUCTION; PROTEINS; NEURONS	Regional brain activation was assessed by mapping of Fos-related protein expression in rats trained to self-administration of intravenous nicotine and cocaine. Both drugs produced specific overlapping patterns of activation in the shell and the core of the nucleus accumbens, medial prefrontal cortex, and medial caudate areas, but not in the amygdala. Thus, the reinforcing properties of cocaine and nicotine map on selected structures of the terminal fields of the mesocorticolimbic dopamine system, supporting the idea that common substrates for these addictive drugs exist.	GLAXO WELLCOME SPA,MED RES CTR,I-37100 VERONA,ITALY	GlaxoSmithKline	Pich, EM (corresponding author), GLAXO WELLCOME RES & DEV LTD,GENEVA BIOMED RES INST,CH-1228 GENEVA,SWITZERLAND.		Chiamulera, Cristiano/C-4917-2015; van Huijsduijnen, Rob A.M. Hooft/B-3653-2009	Chiamulera, Cristiano/0000-0001-5076-8518; van Huijsduijnen, Rob A.M. Hooft/0000-0002-2261-9424				BECKERANDRE M, 1992, EUR J BIOCHEM, V206, P401, DOI 10.1111/j.1432-1033.1992.tb16940.x; CAINE SB, 1994, J PHARMACOL EXP THER, V270, P209; CALABRESI P, 1989, BRIT J PHARMACOL, V98, P135, DOI 10.1111/j.1476-5381.1989.tb16873.x; CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149; CORRIGALL WA, 1989, PSYCHOPHARMACOLOGY, V99, P473, DOI 10.1007/BF00589894; DICHIARA G, 1995, DRUG ALCOHOL DEPEN, V38, P95, DOI 10.1016/0376-8716(95)01118-I; FISCHMAN MW, 1982, FED PROC, V41, P241; FLEMMER DD, 1989, PHARMACOL BIOCHEM BE, V34, P261, DOI 10.1016/0091-3057(89)90309-2; GOEDERS NE, 1983, SCIENCE, V221, P773, DOI 10.1126/science.6879176; HENNINGFIELD JE, 1983, PHARMACOL BIOCHEM BE, V19, P887, DOI 10.1016/0091-3057(83)90099-0; HOPE B, 1992, P NATL ACAD SCI USA, V89, P5764, DOI 10.1073/pnas.89.13.5764; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; JAFFE J H, 1979, National Institute on Drug Abuse Research Monograph, P4; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MORGANJI, 1991, ANN REV N EUROSCI, V14, P421; NISELL M, 1994, SYNAPSE, V16, P36, DOI 10.1002/syn.890160105; PANG Y, 1993, MOL BRAIN RES, V20, P162, DOI 10.1016/0169-328X(93)90122-6; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; REN T, 1992, BRAIN RES BULL, V29, P589, DOI 10.1016/0361-9230(92)90127-J; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; STOLERMAN IP, 1995, PSYCHOPHARMACOLOGY, V117, P2, DOI 10.1007/BF02245088; SWANSON LW, 1992, BRAIN BAMPS STRUCTUR; TESSARI M, 1995, PSYCHOPHARMACOLOGY, V121, P282, DOI 10.1007/BF02245640; YANG XM, 1992, PHARMACOL BIOCHEM BE, V41, P643, DOI 10.1016/0091-3057(92)90386-T; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291; ZOLI M, 1990, NEUROCHEM INT, V16, P383, DOI 10.1016/0197-0186(90)90002-B	27	271	274	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					83	86						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974398				2022-12-01	WOS:A1997WA90300054
J	Chen, SY; Yang, AG; Chen, JD; Kute, T; King, CR; Collier, J; Cong, YP; Yao, CP; Huang, XF				Chen, SY; Yang, AG; Chen, JD; Kute, T; King, CR; Collier, J; Cong, YP; Yao, CP; Huang, XF			Potent antitumour activity of a new class of tumour-specific killer cells	NATURE			English	Article							PSEUDOMONAS EXOTOXIN; PROTO-ONCOGENE; HUMAN-BREAST; ANTIBODY; EXPRESSION; CANCER; LYMPHOCYTES; MELANOMA; THERAPY; VECTORS	Two approaches to the antibody-directed targeting of toxic or cytolytic activity and augmentation of cellular immune responses have been explored For tumour immunotherapy, but so far success has been limited(1-3). Obstacles facing immunotherapy are the limited accessibility of antibodies or antibody conjugates to solid tumours and the difficulty in obtaining tumour-specific cytotoxic lymphocytes(4-7). Here we generate a new class of tumour-specific killer cells by genetically modifying lymphocytes to produce and secrete a targeted toxin against an oncoprotein overexpressed on breast and other tumour cells, The transduced lymphocytes were shown to have potent and selective cytotoxicity to tumours in culture and nude mouse models, The potent in vivo antitunour activity is probably a result of the migration of the lymphocytes to tumours as a targeted toxin carrier, and production and accumulation of the targeted toxins inside tumours as a producer. Our approach, which has features of both antibody-directed and cell-mediated immunotherapy, may have application in a gene therapy context.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR COMPREHENS CANC,DEPT PATHOL,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR COMPREHENS CANC,DEPT COMPARAT MED,WINSTON SALEM,NC 27157; GEORGETOWN UNIV,VINCENT T LOMBARDI CANC RES CTR,DEPT BIOCHEM,WASHINGTON,DC 20007; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Georgetown University; Harvard University; Harvard Medical School	Chen, SY (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR COMPREHENS CANC,DEPT CANC BIOL,WINSTON SALEM,NC 27157, USA.							BATRA JK, 1992, P NATL ACAD SCI USA, V89, P5867, DOI 10.1073/pnas.89.13.5867; CHEN SY, 1995, GENE THER, V2, P116; CHEN SY, 1994, P NATL ACAD SCI USA, V91, P5932, DOI 10.1073/pnas.91.13.5932; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; CULVER K, 1991, P NATL ACAD SCI USA, V88, P3155, DOI 10.1073/pnas.88.8.3155; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; JOHNSON RA, 1982, APPLIED MULTIVARIATE, P226; KASPRZYK PG, 1992, CANCER RES, V52, P2771; King CR, 1996, SEMIN CANCER BIOL, V7, P79; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1992, CURR TOP MICROBIOL, V158, P1; OSBORNE CK, 1985, CANCER RES, V45, P584; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PEREZ P, 1985, NATURE, V316, P354, DOI 10.1038/316354a0; POTTER CRD, 1989, HISTOPATHOLOGY, V15, P351; PRESS MF, 1990, ONCOGENE, V5, P953; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; SHOCKLEY TR, 1992, CANCER RES, V52, P357; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; YANG A, IN PRESS NATURE BIOT	27	61	79	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					78	80		10.1038/385078a0	http://dx.doi.org/10.1038/385078a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985250				2022-12-01	WOS:A1997WA73100053
J	Thompson, DC; Nunn, ME; Thompson, RS; Rivara, FP				Thompson, DC; Nunn, ME; Thompson, RS; Rivara, FP			Effectiveness of bicycle safety helmets in preventing serious facial injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FRACTURES	Objective.-To assess the effectiveness of helmets in preventing facial injuries. Design.-Case-control study between March 1, 1992, and August 31, 1994. Setting.-Seven Seattle, Wash, area hospitals including the regional trauma center and a large staff-model health maintenance organization. Patients.-Cases were patients with serious facial injury, ie, fractures or lacerations; controls were patients who had injuries other than facial. Minor facial injuries were excluded to avoid ascertainment bias in those seeking care for serious injuries to other areas. Results.-Serious facial injuries occurred to 700 (20.7%) patients. Helmets were used by 47% of cases and 57% of controls. After adjusting for age, sex, speed, and surface, we found that helmets reduced the risk of injury to the upper face (odds ratio [OR], 0.36; 95% confidence interval [CI], 0.26-0.49) and middle face (OR, 0.35; 95% CI, 0.24-0.50) but had no significant effect on serious injury to the lower face (OR, 0.88; 95% CI, 0.72-1.07). Conclusions.-Bicycle helmets offer substantial protection for the upper and mid face in addition to their known protection against head injuries. Helmets do not appear to offer any protection for the lower face.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT DENT PUBL HLTH SCI,SEATTLE,WA; GRP HLTH COOPERAT PUGET SOUND,DEPT PREVENT CARE,SEATTLE,WA 98121	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative	Thompson, DC (corresponding author), UNIV WASHINGTON,DEPT PEDIAT,HARBORVIEW INJURY PREVENT & RES CTR,325 9TH AVE,BOX 359960,SEATTLE,WA 98104, USA.							ATON CHC, 1996, MED J AUSTRALIA, V165, P249; BRESLOW NE, 1980, INT AGENCY RES CANC, V32, P190; Grimard G, 1995, Inj Prev, V1, P21, DOI 10.1136/ip.1.1.21; Henderson M, 1995, EFFECTIVENESS BICYCL; LINDQVIST C, 1986, INT J ORAL MAX SURG, V15, P12, DOI 10.1016/S0300-9785(86)80005-9; MYALL RWT, 1987, PEDIATRICS, V79, P639; Myall RWT, 1994, CONTROVERSIES ORAL M, V17, P191; Sosin DM, 1996, PEDIATRICS, V98, P868; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; Thompson DC, 1996, EPIDEMIOLOGY SPORTS, P98; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101	12	99	102	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1996	276	24					1974	1975		10.1001/jama.276.24.1974	http://dx.doi.org/10.1001/jama.276.24.1974			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY689	8971067				2022-12-01	WOS:A1996VY68900030
J	Tucker, KL; Mahnken, B; Wilson, PWF; Jacques, P; Selhub, J				Tucker, KL; Mahnken, B; Wilson, PWF; Jacques, P; Selhub, J			Folic acid fortification of the food supply - Potential benefits and risks for the elderly population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COBALAMIN DEFICIENCY; PERNICIOUS-ANEMIA; PLASMA HOMOCYSTEINE; FOLATE; HYPERHOMOCYSTEINEMIA; VITAMIN-B12; QUESTIONNAIRE; MACROCYTOSIS; PREVALENCE; DIAGNOSIS	Objective.-To estimate the potential benefits and risks of food folic acid fortification for an elderly population, Benefits are expected through the improvement of folate and homocysteine status, but there is also a risk of masking or precipitating clinical manifestations related to vitamin B-12 deficiency with increasing exposure to folic acid. Design.-Cross-sectional analysis, with projected change at various levels of folic acid fortification. Setting.-Participants in the Framingham Heart Study original cohort. Participants.-A total of 747 subjects aged 67 to 96 years who both completed usable food frequency questionnaires and had blood concentrations of B vitamins and homocysteine measured. Main Outcome Measures.-Projected blood folate and homocysteine concentrations and combined high folate intake and low plasma vitamin B-12 concentration. Results.-Percentages of this elderly population with folate intake below 400 mu g/d are projected to drop from 66% at baseline to 49% with 140 mu g of folate per 100 g of cereal-grain product, to 32% with 280 mu g, to 26% with 350 mu g, and to 11% with 700 mu g. Percentages with elevated homocysteine concentrations (>14 mu mol/L) are projected to drop from 26% at baseline to 21% with 140 mu g of folate per 100 g, to 17% with 280 mu g, to 16% with 350 mu g, and to 12% with 700 mu g. Without fortification, the prevalence of combined high folate intake (>1000 mu g/d) and low plasma vitamin B-12 concentration (<185 pmol/L [<250 pg/mL]) was 0.1%. This is projected to increase to 0.4% with folate fortification levels of 140 to 350 mu g/100 g and to 3.4% with 700 mu g. Conclusion.-The evidence suggests that, at the level of 140 mu g/100 g of cereal-grain product mandated by the Food and Drug Administration, the benefits of folate fortification, through projected decreases in homocysteine level and heart disease risk, greatly outweigh the expected risks, However, quantification of the actual risks associated with vitamin B-12 deficiency remains elusive. Before higher levels of folio acid fortification are implemented, further research is needed to better understand the clinical course of various forms of Vitamin B-12 deficiency, to measure the potential effect of high folate intake on this course, and to identify cost-effective approaches to the identification and treatment of all forms of vitamin B-12 deficiency.	NHLBI, FRAMINGHAM MASS HEART STUDY, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Tucker, KL (corresponding author), TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, 711 WASHINGTON ST, BOSTON, MA 02111 USA.		Tucker, Katherine L/A-4545-2010; Wilson, Peter W.F./J-2455-2016	Tucker, Katherine/0000-0001-7640-662X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN RH, 1990, AM J HEMATOL, V34, P90, DOI 10.1002/ajh.2830340204; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; BALDWIN JN, 1961, NEW ENGL J MED, V264, P1339, DOI 10.1056/NEJM196106292642604; BORCH K, 1984, SCAND J GASTROENTERO, V19, P154, DOI 10.1080/00365521.1984.12005702; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; CARMEL R, 1988, ARCH INTERN MED, V148, P1712, DOI 10.1001/archinte.148.8.1712; *CDCP, 1993, POSITION PAPER FOLIC; CHOSY JJ, 1962, AM J CLIN NUTR, V10, P349; CRANE NT, 1995, AM J PUBLIC HEALTH, V85, P660, DOI 10.2105/AJPH.85.5.660; DAWBER T. R., 1957, AMER JOUR PUBL HEALTH, V47, P4, DOI 10.2105/AJPH.47.4_Pt_2.4; DICKINSON CJ, 1995, QJM-INT J MED, V88, P357; ELLISON ABC, 1960, JAMA-J AM MED ASSOC, V173, P240, DOI 10.1001/jama.1960.03020210020006; FDA, 1993, FED REG         1014, V58, P53254; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANKEN DG, 1994, J INHERIT METAB DIS, V17, P159, DOI 10.1007/BF00735426; GLUECK CJ, 1995, AM J CARDIOL, V75, P132, DOI 10.1016/S0002-9149(00)80061-2; HEALTON EB, 1991, MEDICINE, V70, P229, DOI 10.1097/00005792-199107000-00001; HERBERT V, 1988, ARCH INTERN MED, V148, P1705, DOI 10.1001/archinte.148.8.1705; JACOBS DS, 1990, LAB TEST HDB; JACQUES PF, 1993, AM J CLIN NUTR, V57, P182, DOI 10.1093/ajcn/57.2.182; JOOSTEN E, 1993, AM J CLIN NUTR, V58, P468, DOI 10.1093/ajcn/58.4.468; LANDGREN F, 1995, J INTERN MED, V237, P381, DOI 10.1111/j.1365-2796.1995.tb01190.x; LEDERLE FA, 1991, JAMA-J AM MED ASSOC, V265, P94, DOI 10.1001/jama.265.1.94; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; LINDENBAUM J, 1994, AM J CLIN NUTR, V60, P2, DOI 10.1093/ajcn/60.1.2; *MN NUTR DAT SYST, 1995, FOOD DAT VERS 9 NUTR; PEDERSEN AB, 1969, ACTA MED SCAND, V185, P449; ROMANO PS, 1995, AM J PUBLIC HEALTH, V85, P667, DOI 10.2105/AJPH.85.5.667; ROSS JF, 1948, BLOOD, V3, P68, DOI 10.1182/blood.V3.1.68.68; RUSSELL RM, 1992, AM J CLIN NUTR, V55, P1203; *SAS I INC, 1989, SAS STAT VERS 6 08; SAVAGE D, 1994, BRIT J HAEMATOL, V86, P844, DOI 10.1111/j.1365-2141.1994.tb04840.x; SAVAGE DG, 1995, BAILLIERE CLIN HAEM, V8, P657, DOI 10.1016/S0950-3536(05)80225-2; SCOTT JM, 1981, LANCET, V2, P337; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STABLER SP, 1990, BLOOD, V76, P871; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TAMURA T, 1990, CLIN CHEM, V36, P1993; UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; VANDENBERG M, 1994, J VASC SURG, V20, P933, DOI 10.1016/0741-5214(94)90230-5; WILLETT WC, 1987, J AM DIET ASSOC, V87, P43; 1996, FED REG         0305, V61, P8781	48	140	143	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1996	276	23					1879	1885		10.1001/jama.276.23.1879	http://dx.doi.org/10.1001/jama.276.23.1879			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX522	8968013				2022-12-01	WOS:A1996VX52200035
J	Sicinski, P; Donaher, JL; Geng, Y; Parker, SB; Gardner, H; Park, MY; Robker, RL; Richards, JS; McGinnis, LK; Biggers, JD; Eppig, JJ; Bronson, RT; Elledge, SJ; Weinberg, RA				Sicinski, P; Donaher, JL; Geng, Y; Parker, SB; Gardner, H; Park, MY; Robker, RL; Richards, JS; McGinnis, LK; Biggers, JD; Eppig, JJ; Bronson, RT; Elledge, SJ; Weinberg, RA			Cyclin DZ is an FSH responsive gene involved in gonadal cell proliferation and oncogenesis	NATURE			English	Article							HUMAN BREAST-CANCER; EXPRESSION; D1; ORGANIZATION; TUMORS	THE D type cyclins (D1, D2 and D3) are critical governors of the cell-cycle clock apparatus during the G1 phase of the mammalian cell cycle. These three D-type cyclins are expressed in overlapping, apparently redundant fashion in the proliferating tissues(1,2). To investigate why mammalian cells need three distinct D-type cyclins, we have generated mice bearing a disrupted cyclin D2 gene by using gene targeting in embryonic stem cells. Cyclin D2-deficient females are sterile owing to the inability of ovarian granulosa cells to proliferate normally in response to follicle-stimulating hormone (FSH), whereas mutant males display hypoplastic testes. In ovarian granulosa cells, cyclin D2 is specifically induced by FSH via a cycllc-AMP dependent pathway, indicating that expression of the various D-type cyclins is under control of distinct intracellular signalling pathways. The hypoplasia seen in cyclin D2(-/-) ovaries and testes prompted us to examine human cancers deriving from corresponding tissues. We find that some human ovarian and testicular tumours contain high levels of cyclin D2 messenger RNA.	MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; JACKSON LAB, BAR HARBOR, ME 04609 USA; TUFTS UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH VET MED, BOSTON, MA 02111 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Scripps Research Institute; Harvard University; Harvard Medical School; Jackson Laboratory; Tufts University; Tufts University			McGinnis, Lynda/AAG-7484-2020	McGinnis, Lynda/0000-0001-7910-9655; Robker, Rebecca/0000-0002-1538-4604				Ausubel F.M., 1995, CURRENT PROTOCOLS MO; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BOLAND NI, 1994, J REPROD FERTIL, V101, P369, DOI 10.1530/jrf.0.1010369; BOSL GJ, 1989, J NATL CANCER I, V81, P1874; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Desjardins C, 1993, CELL MOL BIOL TESTIS; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FITZPATRICK SL, 1991, ENDOCRINOLOGY, V129, P1452, DOI 10.1210/endo-129-3-1452; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Hogan B., 2014, MANIPULATING MOUSE E; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JOHNSON LD, 1995, J REPROD FERTIL, V104, P277, DOI 10.1530/jrf.0.1040277; Nakayama H, 1996, DEV GROWTH DIFFER, V38, P141, DOI 10.1046/j.1440-169X.1996.t01-1-00003.x; OBRIEN MJ, 1993, METHODS TOXICOL, V38, P128; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PETERS G, 1994, J CELL SCI, P89; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SULJKERBUIJK RF, 1993, CANCER GENET CYTOGEN, V101, P85	22	573	579	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 5	1996	384	6608					470	474		10.1038/384470a0	http://dx.doi.org/10.1038/384470a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945475				2022-12-01	WOS:A1996VW68700065
J	AgueroRosenfeld, ME; Horowitz, HW; Wormser, GP; McKenna, DF; Nowakowski, J; Munoz, J; Dumler, JS				AgueroRosenfeld, ME; Horowitz, HW; Wormser, GP; McKenna, DF; Nowakowski, J; Munoz, J; Dumler, JS			Human granulocytic ehrlichiosis: A case series from a medical center in New York state	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES	Background: Human granulocytic ehrlichiosis (HGE) is a newly described illness Objective: To describe the clinical and laboratory features of Design: Case series. Setting: Tertiary care facility in New York State. Patients: is adult patients with HGE. Measurements: Epidemiologic, clinical, and laboratory features; treatment; and outcome of patients with HGE. Results: Patients presented with such symptoms as fever (94%) and myalgia or arthralgia (78%). Thirteen patients (71%) recalled being bitten by a tick before onset of symptoms. Leukopenia or thrombocytopenia was seen in 82% of patients, and abnormal liver enzyme levels were seen in 81%. Results of polymerase chain reaction were positive in 9 of 12 patients (75%); morulae were seen in 3 of 12 patients (25%); and the agent that causes HGE was cultured from 2 patients. All but one patient (94%) developed antibodies to Ehrlichia equi. Five patients (28%) were briefly hospitalized, and none died. All patients were successfully treated with doxycycline. Conclusions: The illness associated with HGE in these patients from the northeastern United States was more mild than that originally described in reports of HGE in the midwestern United States.			AgueroRosenfeld, ME (corresponding author), WESTCHESTER CTY MED CTR, CLIN LABS, ROOM 1J-11A, VALHALLA, NY 10595 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043135, R01AR041508] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR41508, R01-AR43135] Funding Source: Medline; PHS HHS [U50/CCU210280] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bakken JS, 1996, JAMA-J AM MED ASSOC, V275, P199, DOI 10.1001/jama.275.3.199; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; DUMLER JS, 1995, J CLIN MICROBIOL, V33, P1098, DOI 10.1128/JCM.33.5.1098-1103.1995; EDELMAN DC, 1996, MOL DIAGN, V1, P41; FISHBEIN DB, 1994, ANN INTERN MED, V120, P736, DOI 10.7326/0003-4819-120-9-199405010-00003; Goodman JL, 1996, NEW ENGL J MED, V334, P209, DOI 10.1056/NEJM199601253340401; HARDALO CJ, 1995, CLIN INFECT DIS, V21, P910, DOI 10.1093/clinids/21.4.910; Horowitz HW, 1996, NEUROLOGY, V46, P1026, DOI 10.1212/WNL.46.4.1026; Nadelman RB, 1996, AM J MED, V100, P502, DOI 10.1016/S0002-9343(95)99915-9; PETERSEN LR, 1989, J INFECT DIS, V159, P562, DOI 10.1093/infdis/159.3.562; TELFORD SR, 1995, ANN INTERN MED, V123, P277, DOI 10.7326/0003-4819-123-4-199508150-00006; Wormser GP, 1996, LANCET, V347, P981, DOI 10.1016/S0140-6736(96)91475-0; 1995, MMWR-MORBID MORTAL W, V44, P593	13	155	159	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1996	125	11					904	908		10.7326/0003-4819-125-11-199612010-00006	http://dx.doi.org/10.7326/0003-4819-125-11-199612010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV541	8967671				2022-12-01	WOS:A1996VV54100006
J	Agulnick, AD; Taira, M; Breen, JJ; Tanaka, T; Dawid, IB; Westphal, H				Agulnick, AD; Taira, M; Breen, JJ; Tanaka, T; Dawid, IB; Westphal, H			Interactions of the LIM-domain-binding factor Ldb1 with LIM homeodomain proteins	NATURE			English	Article							GENE; ORGANIZER; MUSCLE; XENOPUS; XLIM-1; ZYXIN	THE LIM homeodomain (LIM-HD) proteins, which contain two tandem LIM domains followed by a homeodomain, are critical transcriptional regulators of embryonic development(1-5). The LIM domain is a conserved cysteine-rich zinc-binding motif found in LIM-HD and LMO (rhombotin or Ttg) proteins, cytoskeletal components, LIM kinases and other proteins(1). LIM domains are protein-protein interaction motifs(1), can binding of LIM-HD proteins to DNA(6,7) and can negatively regulate LIM-HD protein function(8). How LIM domains exert these regulatory effects is not known. We have now isolated a new LIM-domain-binding factor, LdB1, on the basis of tis ability to interact with the LIM-HD protein Lhx1 (Lim1)(9). High-affinity binding by Ldb1 requires paired LIM domains and is restricted to the related subgroup of LIM domains found in LIM-HD and LMO proteins. The highly conserved Xenopus Lbd protein XLbd1, interacts with Xlim-1, the Xenopus orthologue of Lhx1. When injected into Xenopus embryos, XLbd1 (or Lbd1) can synergize with Xlim-1 in the formation of partial secondary axes and in activation of the genes encoding goosecoid (gsc), chordin, NCAM and XCG7, demonstrating a functional as well as a physical interaction between the two proteins.	NICHHD,GENET MOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Agulnick, AD (corresponding author), NICHHD,LAB MAMMALIAN GENES & DEV,NIH,BETHESDA,MD 20892, USA.							ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HARPER JW, 1993, CELL, V75, P805; Karavanov AA, 1996, INT J DEV BIOL, V40, P453; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; NUNOUE K, 1995, ONCOGENE, V11, P701; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; TAIRA M, 1995, TRENDS GENET, V11, P431, DOI 10.1016/S0168-9525(00)89139-8; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	23	284	295	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					270	272		10.1038/384270a0	http://dx.doi.org/10.1038/384270a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918878				2022-12-01	WOS:A1996VU38100053
J	Greisman, HA; Pabo, CO				Greisman, HA; Pabo, CO			A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites	SCIENCE			English	Article							BINDING-SPECIFICITY; CRYSTAL-STRUCTURE; TRANSCRIPTION FACTORS; RECOGNITION; SEQUENCES; RULES; REVEALS; COMPLEX; DESIGN; PHAGE	A method is described for selecting DNA-binding proteins that recognize desired sequences. The protocol involves gradually extending a new zinc finger protein across the desired 9- or 10-base pair target site, adding and optimizing one finger at a time. This procedure was tested with a TATA box, a p53 binding site, and a nuclear receptor element, and proteins were obtained that bind with nanomolar dissociation constants and discriminate effectively (greater than 20,000-fold) against nonspecific DNA. This strategy may provide important information about protein-DNA recognition as well as powerful tools for biomedical research.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Wilson, Matthew H/K-3193-2013					BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; CHENG C, 1995, J MOL BIOL, V251, P1, DOI 10.1006/jmbi.1995.0410; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1994, P NATL ACAD SCI USA, V91, P11099, DOI 10.1073/pnas.91.23.11099; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DESJARLAIS JR, 1992, PROTEINS, V13, P272; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; GREISMAN HA, 1997, THEIS MIT CAMBRIDGE; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; Kim CA, 1996, NAT STRUCT BIOL, V3, P940, DOI 10.1038/nsb1196-940; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; NEKLUDOVA L, COMMUNICATION; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; Rebar EJ, 1996, METHOD ENZYMOL, V267, P129; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; SUZUKI M, 1994, NUCLEIC ACIDS RES, V22, P3397, DOI 10.1093/nar/22.16.3397; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; TAYLOR WE, 1995, BIOCHEMISTRY-US, V34, P3222, DOI 10.1021/bi00010a011; THUKRAL SK, 1992, MOL CELL BIOL, V12, P2784, DOI 10.1128/MCB.12.6.2784; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344; ZIFF EB, 1978, CELL, V15, P1463, DOI 10.1016/0092-8674(78)90070-3; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	35	314	416	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					657	661		10.1126/science.275.5300.657	http://dx.doi.org/10.1126/science.275.5300.657			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005850				2022-12-01	WOS:A1997WF07700037
J	Garred, P; Madsen, HO; Balslev, U; Hofmann, B; Pedersen, C; Gerstoft, J; Svejgaard, A				Garred, P; Madsen, HO; Balslev, U; Hofmann, B; Pedersen, C; Gerstoft, J; Svejgaard, A			Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN GENE; NULL ALLELES; RECOGNITION; CD4; POLYMORPHISM; ASSOCIATION; ACTIVATION; MUTATIONS; FREQUENCY	Background Low serum concentrations of mannose-binding lectin (MBL) are associated with increased susceptibility to recurrent infection. Three variant alleles in the MBL gene (B, C, and D), cause low serum concentrations of the protein. We investigated whether variant alleles of MBL affect susceptibility to infection with HIV and progression of AIDS. Methods Between 1983 and 1986, all men who attended two clinics in Copenhagen for HIV screening were invited to take part in our study. We investigated the prevalence of variant alleles of MBL (detected by PCR) and assessed the prognostic value of these alleles and the corresponding serum MBL concentrations (measured by ELISA) in 96 homosexual men with HIV infection and in two control groups (123 healthy adults and 36 HIV-negative homosexual men at high risk of HIV infection because of their sexual behaviour). Follow-up was for up to 10 years. Findings Eight (8%) of the HIV-infected men were homozygous for the variant MBL alleles compared with one (0.8%) of the healthy controls (p=0.005) and none of the high-risk homosexual controls (p=0.05). We found no significant association between MBL genotype and time from first positive HIV test to progression of AIDS (p=0.8). However, in the 61 HIV-infected men who developed AIDS, the median survival time was significantly shorter after the AIDS diagnosis for men who were carriers of the variant alleles (both homozygous and heterozygous) than for men homozygous for the normal MBL allele (11 [IQR 4-21] vs 18 months [9-44], p=0.007). Among men who developed AIDS, there was a significant difference in survival time between those with serum MBL concentrations below the lower quartile, those within the IQR, and those above the upper quartile (p=0.02). Multivariate analysis showed that men who developed AIDS and had low serum concentrations had an increased rate of rapid independently of CD4 T-cell counts at AIDS diagnosis. Interpretation Our findings suggest that homozygous carriers of variant MBL alleles are at increased risk of HIV infection, either directly or indirectly because of increased susceptibility to coinfections. These alleles are also associated with a significantly shorter survival time after a diagnosis of AIDS.	RIGSHOSP, DEPT MED M, DK-2200 COPENHAGEN, DENMARK; HVIDOVRE UNIV HOSP, DEPT INFECT DIS, COPENHAGEN, DENMARK	Rigshospitalet; University of Copenhagen; University of Copenhagen	Garred, P (corresponding author), RIGSHOSP, DEPT CLIN IMMUNOL, TISSUE TYPING LAB, SECT 7631, DK-2200 COPENHAGEN, DENMARK.		Madsen, Hans O/Q-2035-2015	Madsen, Hans O/0000-0001-5551-4787; Garred, Peter/0000-0002-2876-8586				Bradbury J, 1996, LANCET, V348, P463, DOI 10.1016/S0140-6736(05)64540-0; CAMERON PU, 1990, HUM IMMUNOL, V29, P282, DOI 10.1016/0198-8859(90)90042-N; CAMERON PU, 1988, BRIT MED J, V296, P1627, DOI 10.1136/bmj.296.6637.1627; CHILDS RA, 1989, BIOCHEM J, V262, P131, DOI 10.1042/bj2620131; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; GARRED P, 1992, CLIN EXP IMMUNOL, V90, P517; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; GARRED P, 1992, EUR J IMMUNOGENET, V19, P403, DOI 10.1111/j.1744-313X.1992.tb00083.x; GARREDD P, 1995, LANCET, V346, P1630; HAURUM JS, 1993, AIDS, V7, P1307, DOI 10.1097/00002030-199310000-00002; HENTGES F, 1992, CLIN EXP IMMUNOL, V88, P237, DOI 10.1111/j.1365-2249.1992.tb03067.x; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; LARKIN M, 1989, AIDS, V3, P793, DOI 10.1097/00002030-198912000-00003; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADSEN HO, 1995, J IMMUNOL, V155, P3013; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; NIELSEN SL, 1995, CLIN EXP IMMUNOL, V100, P219; ROBINSON WE, 1990, VIROLOGY, V175, P600, DOI 10.1016/0042-6822(90)90449-2; SADLON TA, 1994, IMMUNOL CELL BIOL, V72, P461, DOI 10.1038/icb.1994.70; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SASTRY K, 1993, CURR OPIN IMMUNOL, V5, P59, DOI 10.1016/0952-7915(93)90082-4; SENALDI G, 1995, J INFECTION, V31, P145, DOI 10.1016/S0163-4453(95)92185-0; SNOWDEN N, 1995, LANCET, V346, P1629, DOI 10.1016/S0140-6736(95)91963-5; STEEL CM, 1988, LANCET, V1, P1185; Stoiber H, 1996, J EXP MED, V183, P307, DOI 10.1084/jem.183.1.307; Sullivan BL, 1996, J IMMUNOL, V157, P1791; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; SUPER M, 1989, LANCET, V2, P1236; SVEJGAARD A, 1995, AIDS RES EC LEVEL, P288; TAYLOR ME, 1989, BIOCHEM J, V262, P763, DOI 10.1042/bj2620763; VANEMMERIK LC, 1994, CLIN EXP IMMUNOL, V97, P411	36	323	344	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 25	1997	349	9047					236	240		10.1016/S0140-6736(96)08440-1	http://dx.doi.org/10.1016/S0140-6736(96)08440-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014910				2022-12-01	WOS:A1997WD90600010
J	McCracken, S; Fong, N; Yankulov, K; Ballantyne, S; Pan, GH; Greenblatt, J; Patterson, SD; Wickens, M; Bentley, DL				McCracken, S; Fong, N; Yankulov, K; Ballantyne, S; Pan, GH; Greenblatt, J; Patterson, SD; Wickens, M; Bentley, DL			The C-terminal domain of RNA polymerase II couples mRNA processing to transcription	NATURE			English	Article							MAMMALIAN NUCLEI; GLOBIN GENE; POLYADENYLATION; INITIATION; PROTEIN; SITE; SUBUNIT; INVITRO; INTRON; SIGNAL	Messenger RNA is produced by RNA polymerase II (pol II) transcription, followed by processing of the primary transcript. Transcription, splicing, and cleavage-polyadenylation can occur independently in vitro, but we demonstrate here that these processes are intimately linked in vivo. We show that the carboxy-terminal domain (CTD) of the pol II large subunit is required for efficient RNA processing. Splicing, processing of the 3' end and termination of transcription downstream of the poly(A) site, are all inhibited by truncation of the CTD. We found that the cleavage-polyadenylation factors CPSF and CstF specifically bound to CTD affinity columns and copurified with pol II in a high-molecular-mass complex. Our demonstration of an association between the CTD and 3'-processing factors, considered together with reports of a similar interaction with splicing factors(1,2), suggests that an mRNA 'factory' exists which carries out coupled transcription, splicing and cleavage-polyadenylation of mRNA precursors.	AMGEN INST,TORONTO,ON M5G 2C1,CANADA; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5G 1L6,CANADA; AMGEN INC,DEPT PROT STRUCT,THOUSAND OAKS,CA 91320	University of Wisconsin System; University of Wisconsin Madison; University of Toronto; University of Toronto; Amgen				Bentley, David/0000-0002-8414-4647; Yankulov, Krassimir/0000-0001-9440-9234				BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; Blau J, 1996, MOL CELL BIOL, V16, P2044; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GREENLEAF AL, 1993, TRENDS BIOCHEM SCI, V18, P117, DOI 10.1016/0968-0004(93)90016-G; Jenny A, 1996, SCIENCE, V274, P1514, DOI 10.1126/science.274.5292.1514; LIEBER A, 1989, NUCLEIC ACIDS RES, V17, P8485, DOI 10.1093/nar/17.21.8485; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MATTAJ IW, 1994, NATURE, V372, P727, DOI 10.1038/372727a0; MIFFLIN RC, 1991, J BIOL CHEM, V266, P19593; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NESIC D, 1993, MOL CELL BIOL, V13, P3359, DOI 10.1128/MCB.13.6.3359; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; Schul W, 1996, EMBO J, V15, P2883, DOI 10.1002/j.1460-2075.1996.tb00649.x; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; SMALE ST, 1985, MOL CELL BIOL, V5, P5352; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WEST ML, 1995, GENETICS, V140, P1223; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHANG GH, 1994, NATURE, V372, P809	30	735	745	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					357	361		10.1038/385357a0	http://dx.doi.org/10.1038/385357a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002523				2022-12-01	WOS:A1997WD91400055
J	LopezIlasaca, M; Crespo, P; Pellici, PG; Gutkind, JS; Wetzker, R				LopezIlasaca, M; Crespo, P; Pellici, PG; Gutkind, JS; Wetzker, R			Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma	SCIENCE			English	Article							DEPENDENT ACTIVATION; KINASE; COMPLEXES	The tyrosine kinase class of receptors induces mitogen-activated protein kinase (MAPK) activation through the sequential interaction of the signaling proteins Grb2, Sos, Ras, Raf, and MEK. Receptors coupled to heterotrimeric guanine triphosphate-binding protein (G protein) stimulate MAPK through G(beta gamma) subunits, but the subsequent intervening molecules are still poorly defined. Overexpression of phosphoinositide 3-kinase gamma (PI3K gamma) in COS-7 cells activated MAPK in a G(beta gamma)-dependent fashion, and expression of a catalytically inactive mutant of PI3K gamma abolished the stimulation of MAPK by G(beta gamma) or in response to stimulation of muscarinic (m2) G protein-coupled receptors. Signaling from PI3K gamma to MAPK appears to require a tyrosine kinase, Shc, Grb2, Sos, Ras, and Raf. These findings indicate that PI3K gamma mediates G(beta gamma)-dependent regulation of the MAPK signaling pathway.	NIDR,MOL SIGNALING UNIT,ORAL & PHARYNGEAL CANC BRANCH,NATL INST HLTH,BETHESDA,MD 20892; UNIV JENA,FAC MED,MAX PLANCK UNIT MOL CELL BIOL,D-07747 JENA,GERMANY; UNIV PERUGIA,MONTELUCE POLICLIN,MOL BIOL LAB,IST MED INTERNA & SCI ONCOL,I-20141 MILAN,ITALY	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Friedrich Schiller University of Jena; Max Planck Society; University of Perugia			Gutkind, J. Silvio/J-1201-2016; Wetzker, Reinhard/AAD-8713-2019; Gutkind, J. Silvio/A-1053-2009; Crespo, Piero/M-3273-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Crespo, Piero/0000-0003-2825-7783				Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FERBY I, 1996, J BIOL CHEM, V271, P2799; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; LOPEZILASACA M, UNPUB; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SALCINI AE, 1994, ONCOGENE, V9, P2827; SCHLEFFER B, 1996, J BIOL CHEM, V271, P10329; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Zhang SY, 1996, J BIOL CHEM, V271, P20208, DOI 10.1074/jbc.271.33.20208	22	616	626	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					394	397		10.1126/science.275.5298.394	http://dx.doi.org/10.1126/science.275.5298.394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994038				2022-12-01	WOS:A1997WC87300049
J	Kalmijn, S; Feskens, EJM; Launer, LJ; Kromhout, D				Kalmijn, S; Feskens, EJM; Launer, LJ; Kromhout, D			Longitudinal study of the effect of apolipoprotein e4 allele on the association between education and cognitive decline in elderly men	BRITISH MEDICAL JOURNAL			English	Article							ALZHEIMERS-DISEASE				Kalmijn, S (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CHRON DIS & ENVIRONM EPIDEMIOL,POB 1,NL-3720 BA BILTHOVEN,NETHERLANDS.		Kromhout, Daan/A-8566-2014; Feskens, Edith/ABI-1446-2020; Feskens, Edith JM/A-3757-2012	Feskens, Edith/0000-0001-5819-2488; 				FESKENS EJM, 1994, BRIT MED J, V309, P1202, DOI 10.1136/bmj.309.6963.1202; KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; SWAAB DF, 1991, NEUROBIOL AGING, V12, P317, DOI 10.1016/0197-4580(91)90008-8; WHITE L, 1994, J CLIN EPIDEMIOL, V47, P363, DOI 10.1016/0895-4356(94)90157-0	5	17	18	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					34	35		10.1136/bmj.314.7073.34	http://dx.doi.org/10.1136/bmj.314.7073.34			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB684	9001477	Green Published			2022-12-01	WOS:A1997WB68400022
J	Nakamura, A; Amikura, R; Mukai, M; Kobayashi, S; Lasko, PF				Nakamura, A; Amikura, R; Mukai, M; Kobayashi, S; Lasko, PF			Requirement for a noncoding RNA in Drosophila polar granules for germ cell establishment	SCIENCE			English	Article							LARGE RIBOSOMAL-RNA; XENOPUS-OOCYTES; MESSENGER-RNA; POSTERIOR DETERMINANT; VEGETAL CORTEX; MATERNAL GENE; EMBRYOS; PLASM; LOCALIZATION; PROTEIN	In Drosophila embryos, germ cell formation is induced by specialized cytoplasm at the posterior of the egg, the pole plasm. Pole plasm contains polar granules, organelles in which maternally produced molecules required for germ cell formation are assembled. An untranslatable RNA, called Polar granule component (Pgc), was identified and found to be localized in polar granules. Most pole cells in embryos produced by transgenic females expressing antisense Pge RNA failed to complete migration and to populate the embryonic gonads, and females that developed from these embryos often had agametic ovaries. These results support an essential role for Pge RNA in germline development.	MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 1B1, CANADA; UNIV TSUKUBA, INST BIOL SCI, GENE EXPT CTR, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, CTR TSUKUBA ADV RES ALLIANCE, TSUKUBA, IBARAKI 305, JAPAN	McGill University; University of Tsukuba; University of Tsukuba			Lasko, Paul/C-6761-2014; Nakamura, Akira/V-6869-2019	Lasko, Paul/0000-0002-4037-3501; Nakamura, Akira/0000-0001-6506-9146				Amikura R, 1996, DEV GROWTH DIFFER, V38, P489, DOI 10.1046/j.1440-169X.1996.t01-4-00005.x; AMIKURA R, 1993, DEV GROWTH DIFFER, V35, P617; AMIKURA R, UNPUB; ASHBURNER M, 1990, DROSOPHILA CODON TAB; BARDSLEY A, 1993, DEVELOPMENT, V119, P207; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; Breitwieser W, 1996, GENE DEV, V10, P2179, DOI 10.1101/gad.10.17.2179; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAVENER DR, 1993, ATLAS DROSOPHILA GEN, P359; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVRIES GE, 1992, J BACTERIOL, V174, P5346, DOI 10.1128/JB.174.16.5346-5353.1992; EDDY EM, 1975, INT REV CYTOL, V43, P229; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; Grunert S, 1996, CURR OPIN GENET DEV, V6, P395, DOI 10.1016/S0959-437X(96)80059-1; HAY B, 1988, DEVELOPMENT, V103, P625; IKENISHI K, 1986, DEV GROWTH DIFFER, V28, P563; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; JONGENS TA, 1994, GENE DEV, V8, P2123, DOI 10.1101/gad.8.18.2123; KLOC M, 1994, SCIENCE, V265, P1101, DOI 10.1126/science.7520603; KLOC M, 1993, SCIENCE, V262, P1712, DOI 10.1126/science.7505061; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; KOBAYASHI S, 1989, DEVELOPMENT, V107, P733; KOBAYASHI S, 1994, INT J DEV BIOL, V38, P193; KOBAYASHI S, 1993, SCIENCE, V260, P1521, DOI 10.1126/science.7684857; LANTZ V, 1992, DEVELOPMENT, V115, P75; LAVOIE C, 1994, J BIOL CHEM, V269, P14625; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; MAHOWALD AP, 1971, J EXP ZOOL, V176, P329, DOI 10.1002/jez.1401760308; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MAHOWALD AP, 1971, DEV BIOL, V24, P37, DOI 10.1016/0012-1606(71)90045-5; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; NAKAMURA A, UNPUB; Rongo C, 1996, TRENDS GENET, V12, P102, DOI 10.1016/0168-9525(96)81421-1; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; St Johnston Daniel, 1993, P325; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; SUGIYAMA S, 1990, ROUX ARCH DEV BIOL, V198, P402, DOI 10.1007/BF00376159; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thummel CS, 1992, DROS INF SERV, V71, P150; TIAN SS, 1994, J BIOL CHEM, V269, P28478; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WILLIAMS MA, 1971, DEV BIOL, V25, P568, DOI 10.1016/0012-1606(71)90006-6	48	157	159	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	1996	274	5295					2075	2079		10.1126/science.274.5295.2075	http://dx.doi.org/10.1126/science.274.5295.2075			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953037				2022-12-01	WOS:A1996VY97400047
J	Scott, WG; Murray, JB; Arnold, JRP; Stoddard, BL; Klug, A				Scott, WG; Murray, JB; Arnold, JRP; Stoddard, BL; Klug, A			Capturing the structure of a catalytic RNA intermediate: The hammerhead ribozyme	SCIENCE			English	Article							CLEAVAGE REACTION; ENZYME; OLIGORIBONUCLEOTIDES; MECHANISM	The crystal structure of an unmodified hammerhead RNA in the absence of divalent metal ions has been solved, and it was shown that this ribozyme can cleave itself in the crystal when divalent metal ions are added. This biologically active RNA fold is the same as that found previously for two modified hammerhead ribozymes. Addition of divalent cations at low pH makes it possible to capture the uncleaved RNA in metal-bound form. A conformational intermediate, having an additional Mg(II) bound to the cleavage-site phosphate, was captured by freeze-trapping the RNA at an active pH prior to cleavage. The most significant conformational changes were limited to the active site of the ribozyme, and the changed conformation requires only small additional movements to reach a proposed transition-state.	UNIV LEEDS,DEPT BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	University of Leeds; Fred Hutchinson Cancer Center	Scott, WG (corresponding author), MRC,MOL BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.			Scott, William/0000-0002-9273-3564	NIGMS NIH HHS [GM-49857] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amiri KMA, 1996, J MOL BIOL, V261, P125, DOI 10.1006/jmbi.1996.0446; BASSI GS, 1995, NAT STRUCT BIOL, V2, P45, DOI 10.1038/nsb0195-45; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; BRUNGER AT, 1993, XPLOR 3 1 SYSTEM CRY; DAHM S, 1993, BIOCHEMISTRY-US, V32, P13010; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HERTEL KJ, 1995, BIOCHEMISTRY-US, V34, P1744, DOI 10.1021/bi00005a031; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P145; McKay DB, 1996, RNA, V2, P395; MOFFAT K, 1995, CURR OPIN STRUC BIOL, V5, P656, DOI 10.1016/0959-440X(95)80059-X; MURRAY JB, 1994, ANAL BIOCHEM, V218, P177, DOI 10.1006/abio.1994.1157; MURRAY JB, 1995, BIOCHEM J, V311, P487, DOI 10.1042/bj3110487; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; Scott WG, 1996, TRENDS BIOCHEM SCI, V21, P220; SCOTT WG, 1995, J MOL BIOL, V250, P327, DOI 10.1006/jmbi.1995.0380; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SIGURDSSON ST, 1995, RNA, V1, P575; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; TUSHL T, 1994, SCIENCE, V266, P785; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VANTOL H, 1990, NUCLEIC ACIDS RES, V18, P1971, DOI 10.1093/nar/18.8.1971; YANG JH, 1990, BIOCHEMISTRY-US, V29, P11156, DOI 10.1021/bi00503a002; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	27	409	417	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2065	2069		10.1126/science.274.5295.2065	http://dx.doi.org/10.1126/science.274.5295.2065			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953035	Green Submitted			2022-12-01	WOS:A1996VY97400045
J	Telling, GC; Parchi, P; DeArmond, SJ; Cortelli, P; Montagna, P; Gabizon, R; Mastrianni, J; Lugaresi, E; Gambetti, P; Prusiner, SB				Telling, GC; Parchi, P; DeArmond, SJ; Cortelli, P; Montagna, P; Gabizon, R; Mastrianni, J; Lugaresi, E; Gambetti, P; Prusiner, SB			Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity	SCIENCE			English	Article							FATAL FAMILIAL INSOMNIA; CREUTZFELDT-JAKOB-DISEASE; TRANSMISSIBLE MINK ENCEPHALOPATHY; GERSTMANN-STRAUSSLER SYNDROME; DNA POLYMORPHISM; TRANSGENIC MICE; AGENT-STRAIN; SCRAPIE; MOUSE; GENE	The fundamental event in prion diseases seems to be a conformational change in cellular prion protein (PrPC) whereby it is converted into the pathologic isoform PrPSc. In fatal familial insomnia (FFI), the protease-resistant fragment of PrPSc after deglycosylation has a size of 19 kilodaltons, whereas that from other inherited and sporadic prion diseases is 21 kilodaltons. Extracts from the brains of FFI patients transmitted disease to transgenic mice expressing a chimeric human-mouse PrP gene about 200 days after inoculation and induced formation of the 19-kilodalton PrPSc fragment, whereas extracts from the brains of familiar and sporadic Creutzfeldt-Jakob disease patients produced the 21-kilodalton PrPSc fragment in these mice. The results presented indicate that the conformation of PrPSc functions as a template in directing the formation of nascent PrPSc and suggest a mechanism to explain strains of prions where diversity is encrypted in the conformation of PrPSc.	UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; HEBREW UNIV JERUSALEM,HADASSAH MED CTR,DEPT NEUROL,IL-91120 JERUSALEM,ISRAEL; UNIV BOLOGNA,DEPT NEUROL,I-40123 BOLOGNA,ITALY; CASE WESTERN RESERVE UNIV,DEPT PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Bologna; Case Western Reserve University; University of California System; University of California San Francisco			Cortelli, Pietro/K-6063-2016; Telling, Glenn C/G-1217-2019; Parchi, Piero/L-9833-2015	Telling, Glenn C/0000-0002-6294-1805; Parchi, Piero/0000-0002-9444-9524; Cortelli, Pietro/0000-0002-3633-8818	NINDS NIH HHS [NS07219] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J GEN VIROL, V73, P329, DOI 10.1099/0022-1317-73-2-329; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BRUCE ME, 1976, NEUROPATH APPL NEURO, V2, P471, DOI 10.1111/j.1365-2990.1976.tb00521.x; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; CARP RI, 1991, J GEN VIROL, V72, P293, DOI 10.1099/0022-1317-72-2-293; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; DEARMOND S, UNPUB; DEARMOND SJ, 1993, P NATL ACAD SCI USA, V90, P6449, DOI 10.1073/pnas.90.14.6449; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; FRASER H, 1973, J COMP PATHOL, V83, P29, DOI 10.1016/0021-9975(73)90024-8; GABIZON R, 1993, AM J HUM GENET, V33, P828; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; GAMBETTI P, 1995, BRAIN PATHOL, V5, P43, DOI 10.1111/j.1750-3639.1995.tb00576.x; GELLING GC, 1995, CELL, V83, P79; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; MANETTO V, 1992, NEUROLOGY, V42, P312, DOI 10.1212/WNL.42.2.312; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; Meggendorfer F, 1930, Z GESAMTE NEUROL PSY, V128, P337, DOI 10.1007/BF02864269; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; MURAMOTO T, 1992, AM J PATHOL, V140, P1411; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PARCHI P, 1995, ANN NEUROL, V38, P21, DOI 10.1002/ana.410380107; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Pergami P, 1996, ANAL BIOCHEM, V236, P63, DOI 10.1006/abio.1996.0132; PETERSEN RB, 1992, NEUROLOGY, V42, P1859, DOI 10.1212/WNL.42.10.1859; PETERSEN RB, 1996, J BIOL CHEM, V271; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SCOTT M, UNPUB; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; TATEISHI J, 1995, NATURE, V376, P434, DOI 10.1038/376434a0; TELLING G, UNPUB; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	53	703	722	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2079	2082		10.1126/science.274.5295.2079	http://dx.doi.org/10.1126/science.274.5295.2079			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953038				2022-12-01	WOS:A1996VY97400048
J	Baumgartner, S; Littleton, JT; Broadie, K; Bhat, MA; Harbecke, R; Lengyel, JA; ChiquetEhrismann, R; Prokop, A; Bellen, HJ				Baumgartner, S; Littleton, JT; Broadie, K; Bhat, MA; Harbecke, R; Lengyel, JA; ChiquetEhrismann, R; Prokop, A; Bellen, HJ			A Drosophila neurexin is required for septate junction and blood-nerve barrier formation and function	CELL			English	Article							TUMOR-SUPPRESSOR PROTEIN; ALPHA-LATROTOXIN RECEPTOR; DISKS; TIGHT; HOMOLOG; ZO-1; SYNAPTOTAGMIN; CLONING; GENE; MELANOGASTER	Septate and tight junctions are thought to seal neighboring cells together and to function as barriers between epithelial cells. We have characterized a novel member of the neurexin family, Neurexin IV (NRX), which is localized to septate junctions (SJs) of epithelial and glial cells. NRX is a transmembrane protein with a cytoplasmic domain homologous to glycophorin C, a protein required for anchoring protein 4.1 in the red blood cell. Absence of NRX results in mislocalization of Coracle, a Drosophila protein 4.1 homolog, at SJs and causes dorsal closure defects similar to those observed in coracle mutants. nrx mutant embryos are paralyzed, and electrophysiological studies indicate that the rack of NRX in glial-glial SJs causes a breakdown of the blood-brain barrier. Electron microscopy demonstrates that nrx mutants lack the ladder-like intercellular septa characteristic of pleated SJs (pSJs). These studies identify NRX as the first transmembrane protein of SJ and demonstrate a requirement for NRX in the formation of septate-junction septa and intercellular barriers.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND; UNIV CALIF LOS ANGELES,DEPT MOL CELL & DEV BIOL,LOS ANGELES,CA 90095	Friedrich Miescher Institute for Biomedical Research; Baylor College of Medicine; Howard Hughes Medical Institute; University of Cambridge; University of California System; University of California Los Angeles			Baumgartner, Stefan/A-5879-2011; BHAT, MANZOOR/S-9273-2018	Baumgartner, Stefan/0000-0001-5320-8321; Prokop, Andreas/0000-0001-8482-3298; BHAT, MANZOOR/0000-0003-0989-1498; Bellen, Hugo/0000-0001-5992-5989; Littleton, J. Troy/0000-0001-5576-2887	NICHD NIH HHS [HD09948] Funding Source: Medline; Wellcome Trust Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009948] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AULD VJ, 1995, CELL, V81, P757, DOI 10.1016/0092-8674(95)90537-5; BIEBER AJ, 1994, DROSOPHILA MELANOGAS, P683; Bock G., 1987, JUNCTIONAL COMPLEXES; BROADIE K, 1994, P NATL ACAD SCI USA, V91, P10727, DOI 10.1073/pnas.91.22.10727; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; BROADIE KS, 1993, J NEUROSCI, V13, P144; BRODY LC, 1995, GENOMICS, V25, P2328; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; FEHON RG, 1994, DEVELOPMENT, V120, P545; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; FRISTROM DK, 1982, J CELL BIOL, V94, P77, DOI 10.1083/jcb.94.1.77; Grawe F, 1996, DEVELOPMENT, V122, P951; Hata Y, 1996, J NEUROSCI, V16, P2488; HOOGWERF AM, 1988, GENETICS, V118, P665; HOYLE G, 1952, NATURE, V169, P281, DOI 10.1038/169281a0; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JUANG JL, 1992, CELL TISSUE RES, V270, P95, DOI 10.1007/BF00381884; KIRKPATRICK C, 1995, CURR OPIN GENET DEV, V5, P56, DOI 10.1016/S0959-437X(95)90054-3; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; LANE LJ, 1980, ADV INSECT PHYSL, P35; LANE NJ, 1977, J CELL SCI, V26, P175; LANE NJ, 1991, FORM FUNCTION ZOOLOG, P87; Lewis E., 1968, DROSOPHILA INFO SERV, V43, P193; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LOCKE M, 1965, J CELL BIOL, V25, P166, DOI 10.1083/jcb.25.1.166; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Lux S. E, 1995, BLOOD PRINCIPLES PRA; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; Prokop A, 1996, NEURON, V17, P617, DOI 10.1016/S0896-6273(00)80195-6; Prokop Andreas, 1993, P33; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; SEECOT RL, 1942, P NATL ACAD SCI USA, V69, P565; TEPASS U, 1994, DEV BIOL, V161, P563, DOI 10.1006/dbio.1994.1054; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; Woods D F, 1993, J Cell Sci Suppl, V17, P171; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; 1994, NUCLEIC ACIDS RES, V22, P3456	48	333	335	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1059	1068		10.1016/S0092-8674(00)81800-0	http://dx.doi.org/10.1016/S0092-8674(00)81800-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978610	Bronze			2022-12-01	WOS:A1996VY44700011
J	Caprara, MG; Lehnert, V; Lambowitz, AM; Westhof, E				Caprara, MG; Lehnert, V; Lambowitz, AM; Westhof, E			A tyrosyl-tRNA synthetase recognizes a conserved tRNA-like structural motif in the group I intron catalytic core	CELL			English	Article							TRANSFER-RNA-SYNTHETASE; PROTEIN; MITOCHONDRIA; INVOLVEMENT; CEREVISIAE; REQUIRES; DOMAIN	The Neurospora crassa mitochondrial (mt) tyrosyl-tRNA synthetase (CYT-18 protein) functions in splicing group I introns, in addition to aminoacylating tRNA(Tyr). Here, we compared the CYT-18 binding sites in the N. crassa mt LSU and ND1 introns with that in N. crassa mt tRNA(Tyr) by constructing three-dimensional models based on chemical modification and RNA footprinting data. Remarkably, superimposition of the CYT-18 binding sites in the model structures revealed an extended three-dimensional overlap between the tRNA and the group I intron catalytic core. Our results provide insight into how an RNA-splicing factor can evolve from a cellular RNA-binding protein. Further, the structural similarities between group I introns and tRNAs are consistent with an evolutionary relationship and suggest a general mechanism for the evolution of complex catalytic RNAs.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210; CNRS,INST BIOL MOL & CELLULAIRE,F-67084 STRASBOURG,FRANCE	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Caprara, MG (corresponding author), OHIO STATE UNIV,DEPT MOL GENET,COLUMBUS,OH 43210, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037951, R01GM037951] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37951] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; BEDOUELLE H, 1993, BIOCHIMIE, V75, P1099, DOI 10.1016/0300-9084(93)90009-H; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRENNAN T, 1976, NUCLEIC ACIDS RES, V3, P3235, DOI 10.1093/nar/3.11.3235; BURKE JM, 1986, CELL, V45, P167, DOI 10.1016/0092-8674(86)90380-6; Caprara MG, 1996, J MOL BIOL, V257, P512, DOI 10.1006/jmbi.1996.0182; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CHERNIACK AD, 1990, CELL, V62, P745, DOI 10.1016/0092-8674(90)90119-Y; DERRICK WB, 1993, NUCLEIC ACIDS RES, V21, P4948, DOI 10.1093/nar/21.21.4948; DOCKBREGEON AC, 1989, J MOL BIOL, V206, P707, DOI 10.1016/0022-2836(89)90578-0; FELDEN B, 1994, J MOL BIOL, V235, P508, DOI 10.1006/jmbi.1994.1010; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; GUO Q, 1982, GENE DEV, V6, P1537; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; JAEGER L, 1991, J MOL BIOL, V221, P1153, DOI 10.1016/0022-2836(91)90925-V; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAMPER U, 1992, MOL CELL BIOL, V12, P499; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; MASSIRE C, 1994, J MOL GRAPHICS, V12, P201, DOI 10.1016/0263-7855(94)80088-X; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; Myers CA, 1996, J MOL BIOL, V262, P87, DOI 10.1006/jmbi.1996.0501; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; Saldanha R, 1996, J MOL BIOL, V261, P23, DOI 10.1006/jmbi.1996.0439; SALDANHA RJ, 1995, BIOCHEMISTRY-US, V34, P1275, DOI 10.1021/bi00004a022; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SHERMAN JM, 1992, NUCLEIC ACIDS RES, V20, P2847, DOI 10.1093/nar/20.11.2847; SIBLER AP, 1986, FEBS LETT, V194, P131, DOI 10.1016/0014-5793(86)80064-3; STEIN A, 1976, BIOCHEMISTRY-US, V15, P160, DOI 10.1021/bi00646a025; WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7; Zarrinkar PP, 1996, NAT STRUCT BIOL, V3, P432, DOI 10.1038/nsb0596-432; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848	36	84	87	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1135	1145		10.1016/S0092-8674(00)81807-3	http://dx.doi.org/10.1016/S0092-8674(00)81807-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978617	Bronze			2022-12-01	WOS:A1996VY44700018
J	Zhang, L; Rzigalinski, BA; Ellis, EF; Satin, LS				Zhang, L; Rzigalinski, BA; Ellis, EF; Satin, LS			Reduction of voltage-dependent Mg2+ blockade of NMDA current in mechanically injured neurons	SCIENCE			English	Article							CONCUSSIVE BRAIN INJURY; EXCITATORY AMINO-ACIDS; D-ASPARTIC ACID; CHANNELS; ANTAGONISTS; RECEPTORS; RELEASE; CULTURE; CELLS	Activation of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors is implicated in the pathophysiology of traumatic brain injury. Here, the effects of mechanical injury on the voltage-dependent magnesium (Mg2+) block of NMDA currents in cultured rat cortical neurons were examined. Stretch-induced injury was found to reduce the Mg2+ blockade, resulting in significantly larger ionic currents and increases in intracellular free calcium (Ca2+) concentration after NMDA stimulation of injured neurons. The Mg2+ blockade was partially restored by increased extracellular Mg2+ concentration or by pretreatment with the protein kinase C inhibitor calphostin C. These findings could account for the secondary pathological changes associated with traumatic brain injury.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298	Virginia Commonwealth University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027214] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07537-14] Funding Source: Medline; NINDS NIH HHS [NS 27214] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BULLOCK R, 1994, INTRACRANIAL PRESSUR, P264; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HERRINGTON J, 1994, PULSE CONTROL V 4 3; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PERSSON K, 1995, AM J PHYSIOL-CELL PH, V269, pC1018, DOI 10.1152/ajpcell.1995.269.4.C1018; Schreiber D., 1995, P 1995 INT RES C BIO, P233; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1	26	187	197	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1921	1923		10.1126/science.274.5294.1921	http://dx.doi.org/10.1126/science.274.5294.1921			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943207				2022-12-01	WOS:A1996VY20000047
J	Shuker, SB; Hajduk, PJ; Meadows, RP; Fesik, SW				Shuker, SB; Hajduk, PJ; Meadows, RP; Fesik, SW			Discovering high-affinity ligands for proteins: SAR by NMR	SCIENCE			English	Article							ATOMIC-STRUCTURE; DRUG DESIGN; BINDING; COMPLEX; SPECTROSCOPY; FKBP-FK506; INHIBITORS; PROGRAM; FK506	A nuclear magnetic resonance (NMR)-based method is described in which small organic molecules that bind to proximal subsites of a protein are identified, optimized, and linked together to produce high-affinity ligands. The approach is called ''SAR by NMR'' because structure-activity relationships (SAR) are obtained from NMR. With this technique, compounds with nanomolar affinities for the FK506 binding protein were rapidly discovered by tethering two ligands with micromolar affinities. The method reduces the amount of chemical synthesis and time required for the discovery of high-affinity ligands and appears particularly useful in target-directed drug research.	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064	Abbott Laboratories								Allen KN, 1996, J PHYS CHEM-US, V100, P2605, DOI 10.1021/jp952516o; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/BF00124387; BRUNGER AT, 1992, XPLOR 3 1 MANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; ECKER DJ, 1995, BIO-TECHNOL, V13, P351, DOI 10.1038/nbt0495-351; EISEN MB, 1994, PROTEINS, V19, P199, DOI 10.1002/prot.340190305; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; HAUSKE JR, 1992, J MED CHEM, V35, P4284, DOI 10.1021/jm00101a005; HOLT DA, 1993, J AM CHEM SOC, V115, P9925, DOI 10.1021/ja00075a008; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MEADOWS RP, 1993, BIOCHEMISTRY-US, V32, P754, DOI 10.1021/bi00054a004; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; ROTSTEIN SH, 1993, J MED CHEM, V36, P1700, DOI 10.1021/jm00064a003; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VERLINDE CLMJ, 1992, J COMPUT AID MOL DES, V6, P131, DOI 10.1007/BF00129424; WANG GT, 1994, BIOORG MED CHEM LETT, V4, P1161, DOI 10.1016/S0960-894X(01)80248-1; WERNER S, Patent No. 17356	22	1635	1809	11	327	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1531	1534		10.1126/science.274.5292.1531	http://dx.doi.org/10.1126/science.274.5292.1531			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929414				2022-12-01	WOS:A1996VV77500049
J	Schieber, RA; BrancheDorsey, CM; Ryan, GW; Rutherford, GW; Stevens, JA; ONeil, J				Schieber, RA; BrancheDorsey, CM; Ryan, GW; Rutherford, GW; Stevens, JA; ONeil, J			Risk factors for injuries from in-line skating and the effectiveness of safety gear	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Of the estimated 22.5 million people participating in in-line skating in the United States in 1995, about 100,000 were sufficiently injured to require emergency department care. We investigated the effectiveness of wrist guards, elbow pads, knee pads, and helmets in preventing skating injuries. Methods We used data from the 91 hospital emergency departments participating in the National Electronic Injury Surveillance System, a national probability sample of randomly selected hospitals with 24-hour emergency departments. Injured in-line skaters who sought medical attention between December 1992 and July 1993 were interviewed by telephone. We conducted a case-control study of skaters who injured their wrists, elbows, knees, or heads as compared with skaters with injuries to other parts of their bodies. Results Of 206 eligible injured subjects, 161 (78 percent) were interviewed. Wrist injuries were the most common (32 percent); 25 percent of all injuries were wrist fractures. Seven percent of injured skaters wore all the types of safety gear; 46 percent wore none. Forty-five percent wore knee pads, 33 percent wrist guards, 28 percent elbow pads, and 20 percent helmets. The odds ratio for wrist injury, adjusted for age and sex, for those who did not wear wrist guards, as compared with those who did, was 10.4 (95 percent confidence interval, 2.9 to 36.9). The odds ratio for elbow injury, adjusted for the number of lessons skaters had had and whether or not they performed trick skating, was 9.5 (95 percent confidence interval, 2.6 to 34.4) for those who did not wear elbow pads. Nonuse of knee pads was associated with a nonsignificant increase in the risk of knee injury (crude odds ratio, 2.2; 95 percent confidence interval, 0.7 to 7.2). The effectiveness of helmets could not be assessed. Conclusions Wrist guards and elbow pads are effective in protecting in-line skaters against injuries. (C)1996, Massachusetts Medical Society.	CONSUMER PROD SAFETY COMMISS,DIRECTORATE EPIDEMIOL & HLTH SCI,WASHINGTON,DC		Schieber, RA (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,MAILSTOP K-63,4770 BUFORD HWY,NE,ATLANTA,GA 30341, USA.							Agresti A., 1990, CATEGORICAL DATA ANA, pXV; *AM SPORTS DAT, 1996, AM SPORTS AN SUMM RE; CALLE SC, 1994, AM J PUBLIC HEALTH, V84, P675, DOI 10.2105/AJPH.84.4.675; *CONS PROD SAF COM, 1991, SAF COMM WARNS HAZ I; *CONS PROD SAF COM, 1992, NEISS SAMPL DES IMPL; FRANKEL LR, 1982, DEFINITION RESPONSE; HELLER D, 1993, HAZARD, V10, P11; *INT INL SKAT ASS, 1992, GUID EST INL SKAT TR; *NAT EL INJ SURV S, 1996, CONS PROD SAF COMM; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; SCHIEBER RA, 1994, JAMA-J AM MED ASSOC, V271, P1856, DOI 10.1001/jama.271.23.1856; Schlesselman J.J., 1982, CASE CONTROL STUDIES; Shah BV, 1996, SUDAAN USERS MANUAL; *SHUG RES, 1992, INL SKAT FOC GROUP S; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; ULLIS K, 1979, NEW ENGL J MED, V301, P1350; 1995, MMWR-MORBID MORTAL W, V44, P1	17	117	118	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1630	1635		10.1056/NEJM199611283352202	http://dx.doi.org/10.1056/NEJM199611283352202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV936	8929359				2022-12-01	WOS:A1996VV93600002
J	Blondel, M; Mann, C				Blondel, M; Mann, C			G2 cyclins are required for the degradation of G1 cyclins in yeast	NATURE			English	Article							UBIQUITIN-CONJUGATING ENZYME; B-TYPE CYCLINS; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PROTEIN-KINASE; BUDDING YEAST; S-PHASE; PROTEOLYSIS; INHIBITOR; TURNOVER	PROGRESSION Of the eukaryotic cell cycle is controlled by cyclin-dependent kinases (CDKs)(1). Cdc28, the budding yeast homologue of Cdc2 (Cdk1), is required for both the G1/S and G2/M transitions of the cell cycle(2), The functional specificity of the Cdc28 kinase is determined by its association with G1 or G2 cyclins. Alternation of cell cycle phases is thus mainly due to mechanisms that ensure that one cyclin family succeeds another, Here we show that the G2 cyclins Clb1, Clb2, Clb3 and Clb4 are required for the proteolysis of the G1 cyclins Cln1 and Cln2, providing a mechanism for coupling synthesis of G2 cyclins with the disappearance of G1 cyclins. Our data indicate that this pathway involves the Ubc9 ubiquitin-conjugating enzyme(3). The Cdc34 ubiquitin-conjugating activity(4) may function redundantly with Ubc9, or it may only be involved in Cln1,2 turnover through its role in promoting the degradation of Sic1, a specific inhibitor of Cdc28-Clb complexes(5).	CEA SACLAY,SERV BIOCHIM & GENET MOL,F-91191 GIF SUR YVETTE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay			Blondel, Marc/AAJ-9049-2020	Blondel, Marc/0000-0003-4897-2995; Mann, Carl/0000-0001-7212-1512				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Koch C, 1996, GENE DEV, V10, P129, DOI 10.1101/gad.10.2.129; KUHNE C, 1993, EMBO J, V12, P3437, DOI 10.1002/j.1460-2075.1993.tb06018.x; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	29	35	37	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					279	282		10.1038/384279a0	http://dx.doi.org/10.1038/384279a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918881				2022-12-01	WOS:A1996VU38100056
J	Yu, XM; Askalan, R; Keil, GJ; Salter, MW				Yu, XM; Askalan, R; Keil, GJ; Salter, MW			NMDA channel regulation by channel-associated protein tyrosine kinase Src	SCIENCE			English	Article							RECEPTOR SUBUNITS; RAT HIPPOCAMPUS; FAMILY; NEURONS; PHOSPHORYLATION; PLASTICITY; GLUTAMATE; PP60C-SRC; CURRENTS; DOMAIN	The N-methyl-D-aspartate (NMDA) receptor mediates synaptic transmission and plasticity in the central nervous system (CNS) and is regulated by tyrosine phosphorylation. In membrane patches excised from mammalian central neurons, the endogenous tyrosine kinase Src was shown to regulate the activity of NMDA channels. The action of Src required a sequence [Src(40-58)] within the noncatalytic, unique domain of Src. In addition, Src coprecipitated with NMDA receptor proteins. Finally, endogenous Src regulated the function of NMDA receptors at synapses. Thus, NMDA receptor regulation by Src may be important in development, plasticity, and pathology in the CNS.	UNIV TORONTO,HOSP SICK CHILDREN,DEPT PHYSIOL,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; Boxall AR, 1996, NEURON, V16, P805, DOI 10.1016/S0896-6273(00)80100-2; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; DEKONINCK Y, 1994, J NEUROPHYSIOL, V71, P1218; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P495; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; GIBB AJ, 1992, J PHYSIOL-LONDON, V456, P143, DOI 10.1113/jphysiol.1992.sp019331; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU XQ, 1993, ONCOGENE, V8, P1119; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; PERNEY TM, 1993, SEMIN NEUROSCI, V5, P135; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SALTER MW, 1994, J NEUROSCI, V14, P1563, DOI 10.1523/JNEUROSCI.14-03-01563.1994; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; SORIANO P, 1991, Cell, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wang YT, 1996, P NATL ACAD SCI USA, V93, P1721, DOI 10.1073/pnas.93.4.1721; YU X, UNPUB	35	536	559	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					674	678		10.1126/science.275.5300.674	http://dx.doi.org/10.1126/science.275.5300.674			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005855				2022-12-01	WOS:A1997WF07700042
J	DeWaard, M; Liu, HY; Walker, D; Scott, VES; Gurnett, CA; Campbell, KP				DeWaard, M; Liu, HY; Walker, D; Scott, VES; Gurnett, CA; Campbell, KP			Direct binding of G-protein beta gamma complex to voltage-dependent calcium channels	NATURE			English	Article							CA2+ CHANNELS; N-TYPE; NEUROTRANSMITTER INHIBITION; SYNAPTIC TRANSMISSION; SYMPATHETIC NEURONS; ALPHA-SUBUNITS; CURRENTS; MODULATION; EXPRESSION; CLONING	Voltage-dependent Ca2+ channels play a central role in controlling neurotransmitter release at the synapse(1,2). They can be inhibited by certain G-protein-coupled receptors, acting by a pathway intrinsic to the membrane(3-6). Here we show that this inhibition results from a direct interaction between the G-protein beta gamma complex and the pore-forming alpha(1) subunits of several types of these channels(7). The interaction is mediated by the cytoplasmic linker connecting the first and second transmembrane repeats. Within this linker, binding occurs both in the alpha(1) interaction domain (AID)(8), which also mediates the interaction between the alpha(1) and beta subunits of tbe channel, and in a second downstream sequence. Further analysis of the binding site showed that several amino-terminal residues in the AID are critical for G beta gamma binding, defining a site distinct from the carboxy-terminal residues shown to be essential for binding the beta-subunit of the Ca2+ channel(9). Mutation of an arginine residue within the N-terminal motif abolished beta gamma binding and rendered the channel refractory to G-protein modulation when expressed in Xenopus oocytes, showing that the interaction is indeed responsible for G-protein-dependent modulation of Ca2+ channel activity.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,PROGRAM NEUROSCI,IOWA CITY,IA 52242; FAC MED NORD,INST JEAN ROCHE,INSERM,U464,F-13916 MARSEILLE 20,FRANCE	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			De Waard, Michel/G-7406-2014	De Waard, Michel/0000-0002-2782-9615; Gurnett, Christina/0000-0001-9129-315X; Campbell, Kevin/0000-0003-2066-5889; Walker, Denise/0000-0003-1534-1679				BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BOLAND LM, 1993, J NEUROSCI, V13, P516; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; CAMPBELL V, 1995, J PHYSIOL-LONDON, V485, P365, DOI 10.1113/jphysiol.1995.sp020735; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; DELCOUR AH, 1993, SCIENCE, V259, P980, DOI 10.1126/science.8094902; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; DOLPHIN AC, 1986, J PHYSIOL-LONDON, V373, P47, DOI 10.1113/jphysiol.1986.sp016034; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HIRNING LD, 1990, BRAIN RES, V532, P120, DOI 10.1016/0006-8993(90)91751-2; HOLZ GG, 1989, J NEUROSCI, V9, P657; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; KASAI H, 1992, J PHYSIOL-LONDON, V448, P189, DOI 10.1113/jphysiol.1992.sp019036; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NEER EJ, 1994, METHOD ENZYMOL, V237, P226; OLATE J, 1990, FEBS LETT, V268, P27, DOI 10.1016/0014-5793(90)80964-K; PLUMMER MR, 1991, J NEUROSCI, V11, P2339; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Yassin M, 1996, BIOCHEM BIOPH RES CO, V220, P453, DOI 10.1006/bbrc.1996.0426; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0	30	309	314	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1997	385	6615					446	450						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009193				2022-12-01	WOS:A1997WF00700055
J	Ulbrandt, ND; Newitt, JA; Bernstein, HD				Ulbrandt, ND; Newitt, JA; Bernstein, HD			The E-coli signal recognition particle is required for the insertion of a subset of inner membrane proteins	CELL			English	Article							ESCHERICHIA-COLI; 4.5S RNA; SEQUENCE RECOGNITION; ALKALINE-PHOSPHATASE; ALPHA-SUBUNIT; GENE; TOPOLOGY; EXPORT; RIBONUCLEOPROTEIN; RECEPTOR	E. coli homologs of the signal recognition particle (SRP) and its receptor are essential for viability, but their role in protein export is unclear. To elucidate their function, we devised a genome-wide screen to identify genes that encode SRP substrates. Inhibition of the SRP pathway sharply blocked the membrane insertion of several polytopic inner membrane proteins (IMPs) that were predicted to be SRP substrates, but had a smaller effect on the insertion of other IMPs and no significant effect on preprotein translocation. Our results suggest that whereas most E. coli preproteins and some IMPs can utilize SRP-independent targeting pathways effectively, the structural features of a subset of IMPs have required the conservation of an SRP-based targeting machinery.			Ulbrandt, ND (corresponding author), NIDDKD, GENET & BIOCHEM BRANCH, NIH, BETHESDA, MD 20892 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN HD, 1993, P NATL ACAD SCI USA, V90, P5229, DOI 10.1073/pnas.90.11.5229; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; ICHO T, 1985, J BIOL CHEM, V260, P2078; INOUYE H, 1981, J BACTERIOL, V146, P668, DOI 10.1128/JB.146.2.668-675.1981; Izard JW, 1996, J BIOL CHEM, V271, P21579, DOI 10.1074/jbc.271.35.21579; JOHNSSON N, 1994, EMBO J, V13, P2686, DOI 10.1002/j.1460-2075.1994.tb06559.x; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; Kroll ES, 1996, GENETICS, V143, P95; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MIZUSAWA S, 1982, GENE, V20, P317, DOI 10.1016/0378-1119(82)90200-1; MURPHY CK, 1996, ESCHERICHIA COLI SAL, P967; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SEOL WG, 1993, J BACTERIOL, V175, P565, DOI 10.1128/JB.175.2.565-567.1993; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P7740, DOI 10.1093/nar/16.15.7740; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; TRAXLER B, 1992, J BIOL CHEM, V267, P5339; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87	47	291	295	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1997	88	2					187	196		10.1016/S0092-8674(00)81839-5	http://dx.doi.org/10.1016/S0092-8674(00)81839-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008159	Bronze			2022-12-01	WOS:A1997WE97000007
J	Bezrukov, SM; Vodyanoy, I				Bezrukov, SM; Vodyanoy, I			Stochastic resonance in non-dynamical systems without response thresholds	NATURE			English	Article							NOISE	The addition of noise to a system can sometimes improve its ability to transfer information reliably. This phenomenon-known as stochastic resonance-was originally proposed to account for periodicity in the Earth's ice ages', but has now been shown to occur in many systems in physics and biology(2-4). Recent experimental and theoretical work has shown that the simplest system exhibiting 'stochastic resonance' consists of nothing more than signal and noise with a threshold-triggered device (when the signal plus noise exceeds the threshold, the system responds momentarily, then relaxes to equilibrium to await the next triggering event)(4-6). Here we introduce a class of non-dynamical and threshold-free systems that also exhibit stochastic resonance. We present and analyse a general mathematical model for such systems, in which a sequence of pulses is generated randomly with a probability (per unit time) that depends exponentially on an input. When this input is a sine-wave masked by additive noise, we observe an increase in the output signal-to-noise ratio as the level of noise increases. This result shows that stochastic resonance can occur in a broad class of thermally driven physico-chemical systems, such as semiconductor p-n junctions, mesoscopic electronic devices and voltage-dependent ion channels(7), in which reaction rates are controlled by activation barriers.	ST PETERSBURG NUCL PHYS INST, GATCHINA 188530, RUSSIA; OFF NAVAL RES EUROPE, LONDON NW1 5TH, ENGLAND; UCL, LONDON, ENGLAND	National Research Centre - Kurchatov Institute; Petersburg Nuclear Physics Institute; University of London; University College London	Bezrukov, SM (corresponding author), NIH, DIV COMP RES & TECHNOL, BETHESDA, MD USA.							BENEDICT RR, 1976, ELECT SCI ENG, P80; BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; BEZRUKOV SM, 1995, NATURE, V378, P362, DOI 10.1038/378362a0; Bulsara AR, 1996, PHYS TODAY, V49, P39, DOI 10.1063/1.881491; COX DR, 1955, J ROY STAT SOC B, V17, P129; COX DR, 1996, STAT ANAL SERIES EVE, P28; GINGL Z, 1995, EUROPHYS LETT, V29, P191, DOI 10.1209/0295-5075/29/3/001; Glasstone S., 1941, THEORY RATE PROCESSE, P1; HILLE B, 1992, IONIC CHANNELS EXCIT, P47; JUNG P, 1995, PHYS LETT A, V207, P93, DOI 10.1016/0375-9601(95)00636-H; LECAR H, 1971, BIOPHYS J, V11, P1048, DOI 10.1016/S0006-3495(71)86277-X; MOSS F, 1994, INT J BIFURCAT CHAOS, V4, P1383, DOI 10.1142/S0218127494001118; NYE JF, 1976, PHYSICAL PROPERTIES, P236; REZNIKOV M, 1995, PHYS REV LETT, V75, P3340, DOI 10.1103/PhysRevLett.75.3340; Rice SO, 1954, SELECTED PAPERS NOIS, P133; WIESENFELD K, 1994, PHYS REV LETT, V72, P2125, DOI 10.1103/PhysRevLett.72.2125; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0	17	214	219	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					319	321		10.1038/385319a0	http://dx.doi.org/10.1038/385319a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002515				2022-12-01	WOS:A1997WD91400043
J	Anand, AC; Reddy, PS; Salprasad, GS; Kher, SK				Anand, AC; Reddy, PS; Salprasad, GS; Kher, SK			Does non-dysenteric intestinal amoebiasis exist?	LANCET			English	Article							IRRITABLE-BOWEL-SYNDROME; ENTAMOEBA-HISTOLYTICA; INVASIVE AMEBIASIS; MORPHOLOGY; ADHERENCE; DIAGNOSIS	Background Chronic abdominal pain and frequent bowel disturbance are common symptoms experienced by more than 15% of apparently healthy people. In areas endemic for Entamoeba histolytica infection, these symptoms are often diagnosed as non-dysenteric intestinal amoebiasis even though no causal relation between such symptoms and E histolytica has been established and clinical presentation of non-dysenteric intestinal amoebiasis and irritable bowel syndrome (IBS) is not distinct. This study was done to assess the clinical significance of E histolytica infection in causation of such symptoms. Methods Patients with symptoms suggestive of non-dysenteric intestinal amoebiasis were recruited from a survey to assess the prevalence of abdominal symptoms in the general population (group A; n=78) and from medical outpatient clinics (group B; n=66). Participants who had symp toms as well as symptom-free controls (group C; n=100) were clinically examined and underwent stool examination, amoebic serology, colonoscopic examination, histopathological examination of colonoscopic biopsy samples, and a trial of antiamoebic therapy (only for participants with symptoms) with metronidazole and mebendazole. Findings There were no significant differences between the 144 patients with symptoms and the 100 symptom-free controls in the proportion with E histolytica in stools (26 [18%] vs 18 [18%]), serological evidence of E histolytica infection (61 [42%] vs 41 [41%]), colonoscopic abnormalities (five of 66 vs one of 33), or histopathological abnormalities (36 [49%] of 73 vs ten [30%] of 33). Cyst positive and cyst-negative individuals showed no significant difference in serological evidence of E histolytic infection, histological abnormalities, or response to therapeutic trial with metronidazole. A diagnosis of IBS was suggested on the basis of consensus criteria and Kruis diagnostic index in 127 of 144 patients with symptoms. The diagnosis of non-dysenteric intestinal amoebiasis could be made in only one patient, who had relapse of symptoms within 6 weeks of antiamoebic therapy and therefore the relapse did not meet criteria for the diagnosis of non-dysenteric intestinal amoebiasis. More than 60% of cyst-positive as well as cyst-negative patients with symptoms showed either complete or partial response to treatment strategy for IBS. Interpretation Chronic bowel symptoms, such as pain in abdomen and frequent bowel disturbance, have no association with either past or present infection with E histolytica. Most patients with such symptoms are likely to have IBS. The clinical entity of non-dysenteric intestinal amoebiasis, if it exists, must be extremely rare.	ARMED FORCES MED COLL, DEPT PATHOL, PUNE 411040, MAHARASHTRA, INDIA; ARMED FORCES MED COLL, DEPT SOCIAL & PREVENT MED, PUNE 411040, MAHARASHTRA, INDIA; ARMED FORCES MED COLL, DEPT MICROBIOL, PUNE 411040, MAHARASHTRA, INDIA	Armed Forces Medical College; Armed Forces Medical College; Armed Forces Medical College	Anand, AC (corresponding author), ARMED FORCES MED COLL, DEPT MED, PUNE 411040, MAHARASHTRA, INDIA.		Anand, Anil C/E-4704-2017; Anand, Anil/AAM-5028-2020	Anand, Anil C/0000-0001-7105-1540; Anand, Anil/0000-0001-7105-1540				ABRAHAM P, 1991, INDIAN J GASTROENT S, V10, pA2; Bordie A K, 1972, J Indian Med Assoc, V58, P451; Drossman D., 1990, GASTR INT, V3, P159; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; GILAT T, 1972, DIG DIS, V17, P37; JALAN N, 1988, NATL MED J INDIA, V1, P128; Kamath P S, 1991, Indian J Gastroenterol, V10, P59; KESSEL JF, 1965, AM J TROP MED HYG, V14, P540, DOI 10.4269/ajtmh.1965.14.540; KINGHAM JGC, 1991, GUT, V32, P234, DOI 10.1136/gut.32.3.234; KRUIS W, 1984, GASTROENTEROLOGY, V87, P1; LYNN RB, 1993, NEW ENGL J MED, V329, P1940, DOI 10.1056/NEJM199312233292608; MADAN S, 1981, INDIAN J PEDIATR, V49, P327; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MATHAN MM, 1985, GUT, V26, P710, DOI 10.1136/gut.26.7.710; MATHUR A, 1966, J INDIAN MED ASSOC, V46, P651; MILLER MJ, 1951, T ROY SOC TROP MED H, V45, P131, DOI 10.1016/S0035-9203(51)90704-3; NANDA R, 1984, LANCET, V2, P301; OSEASOHN RO, 1956, GASTROENTEROLOGY, V31, P246; RAVDIN JI, 1994, GUT, V35, P1018, DOI 10.1136/gut.35.8.1018; RAVDIN JI, 1990, J INFECT DIS, V162, P768, DOI 10.1093/infdis/162.3.768; SAPRO JJ, 1939, AM J TROP MED HYG, V19, P497; SCHAPIRO M M, 1959, Mil Med, V124, P196; SCHUSTER MM, 1993, GASTROINTESTINAL DIS, P917; VARIYAM EP, 1989, DIGEST DIS SCI, V34, P732, DOI 10.1007/BF01540345; WHITEHEAD R, 1975, DIGESTION, V13, P129, DOI 10.1159/000197701; *WHO, 1981, WHO TECHN REP SER, V666, P8; *WHO, 1969, WHO TECHN REP SER, V421, P1; 1985, LANCET, V1, P732	28	27	31	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 11	1997	349	9045					89	92		10.1016/S0140-6736(96)06121-1	http://dx.doi.org/10.1016/S0140-6736(96)06121-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996420				2022-12-01	WOS:A1997WB80000011
J	Fan, W; Boston, BA; Kesterson, RA; Hruby, VJ; Cone, RD				Fan, W; Boston, BA; Kesterson, RA; Hruby, VJ; Cone, RD			Role of melanocortinergic neurons in feeding and the agouti obesity syndrome	NATURE			English	Article							MELANOCYTE-STIMULATING-HORMONE; MESSENGER-RNA; ALPHA-MELANOTROPIN; MOLECULAR-CLONING; NEUROPEPTIDE-Y; RECEPTOR; GENE; MOUSE; EXPRESSION; BRAIN	DOMINANT alleles at the agouti locus (A) cause an obesity syndrome in the mouse, as a consequence of ectopic expression of the agouti peptide(1-6). This peptide, normally only found in the skin, is a high-affinity antagonist of the melanocyte-stimulating hormone receptor (MC1-R)(7), thus explaining the inhibitory effect of agouti on eumelanin pigment synthesis, The agouti peptide is also an antagonist of the hypothalamic melanocortin-4 receptor (MC4-R)(7-9). To test the hypothesis that agouti causes obesity by antagonism of hypothalamic melanocortin receptors(7), we identified cyclic melanocortin analogues(10) that are potent agonists or antagonists of the neural MC3 (refs 11, 12) and MC4 receptors. Intracerebroventricular administration of the agonist, MTII, inhibited feeding in four models of hyperphagia: fasted C57BL/6J, ob/ob, and A(Y) mice, and mice injected with neuropeptide Y. Co-administration of the specific melanocortin antagonist and agouti-mimetic SHU9119 completely blocked this inhibition. Furthermore, administration of SHU9119 significantly enhanced nocturnal feeding, or feeding stimulated by a prior fast. Our data show that melanocortinergic neurons exert a tonic inhibition of feeding behaviour. Chronic disruption of this inhibitory signal is a likely explanation of the agouti obesity syndrome.	OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT PEDIAT, PORTLAND, OR 97201 USA; UNIV ARIZONA, DEPT CHEM, TUCSON, AZ 85721 USA	Oregon Health & Science University; Oregon Health & Science University; University of Arizona								ALOBEIDI F, 1989, J MED CHEM, V32, P2555, DOI 10.1021/jm00132a010; BERGENDAHL M, 1992, NEUROENDOCRINOLOGY, V56, P913, DOI 10.1159/000126324; BRADY LS, 1990, NEUROENDOCRINOLOGY, V52, P441, DOI 10.1159/000125626; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1993, J BIOL CHEM, V268, P8246; HRUBY VJ, 1995, J MED CHEM, V38, P3454, DOI 10.1021/jm00018a005; HUSZAR D, IN PRESS CELL; JACOBOWITZ DM, 1978, P NATL ACAD SCI USA, V75, P6300, DOI 10.1073/pnas.75.12.6300; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KESTERSAN RA, UNPUB MOL ENDOCRINOL; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; Kucera GT, 1996, DEV BIOL, V173, P162, DOI 10.1006/dbio.1996.0014; LAURSEN SE, 1986, J PHARMACOL METHOD, V16, P355, DOI 10.1016/0160-5402(86)90038-0; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; PENY WL, 1995, GENETICS, V140, P267; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; STEINER RA, 1994, J NEUROENDOCRINOL, V6, P603, DOI 10.1111/j.1365-2826.1994.tb00625.x; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; WATSON SJ, 1978, NATURE, V275, P226, DOI 10.1038/275226a0; WILDING JPH, 1993, ENDOCRINOLOGY, V132, P1939, DOI 10.1210/en.132.5.1939; WILSON BD, 1995, HUM MOL GENET, V4, P223, DOI 10.1093/hmg/4.2.223; WOLFF GL, 1963, GENETICS, V48, P1041	28	1607	1694	1	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 9	1997	385	6612					165	168		10.1038/385165a0	http://dx.doi.org/10.1038/385165a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990120				2022-12-01	WOS:A1997WB72800056
J	Luban, J				Luban, J			Absconding with the chaperone: Essential cyclophilin-gag interaction in HIV-1 virions	CELL			English	Review							PROTEIN; BINDS		COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University	Luban, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,701 W 168TH ST,NEW YORK,NY 10032, USA.			Luban, Jeremy/0000-0001-5650-4054				Aberham C, 1996, J VIROL, V70, P3536, DOI 10.1128/JVI.70.6.3536-3544.1996; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; Braaten D, 1996, J VIROL, V70, P5170, DOI 10.1128/JVI.70.8.5170-5176.1996; Dorfman T, 1996, J VIROL, V70, P5751, DOI 10.1128/JVI.70.9.5751-5757.1996; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	16	113	118	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1157	1159		10.1016/S0092-8674(00)81811-5	http://dx.doi.org/10.1016/S0092-8674(00)81811-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980222	hybrid			2022-12-01	WOS:A1996WA54100004
J	Baldock, C; Rafferty, JB; Sedelnikova, SE; Baker, PJ; Stuitje, AR; Slabas, AR; Hawkes, TR; Rice, DW				Baldock, C; Rafferty, JB; Sedelnikova, SE; Baker, PJ; Stuitje, AR; Slabas, AR; Hawkes, TR; Rice, DW			A mechanism of drug action revealed by structural studies of enoyl reductase	SCIENCE			English	Article							ESCHERICHIA-COLI; MYCOBACTERIUM-TUBERCULOSIS; DIHYDROFOLATE-REDUCTASE; CRYSTAL-STRUCTURES; TRANSITION-STATE; AREA DETECTOR; PROGRAM; DIFFRACTOMETER; ANALOGS; BINDING	Enoyl reductase (ENR), an enzyme involved in fatty acid biosynthesis, is the target for antibacterial diazaborines and the front-line antituberculosis drug isoniazid. Analysis of the structures of complexes of Escherichia coli ENR with nicotinamide adenine dinucleotide and either thienodiazaborine or benzodiazaborine revealed the formation of a covalent bond between the 2' hydroxyl of the nicotinamide ribose and a boron atom in the drugs to generate a tight, noncovalently bound bisubstrate analog. This analysis has implications for the structure-based design of inhibitors of ENR, and similarities to other oxidoreductases suggest that mimicking this molecular linkage may have generic applications in other areas of medicinal chemistry.	UNIV SHEFFIELD,DEPT MOL BIOL & BIOTECHNOL,KREBS INST BIOMOL RES,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; VRIJE UNIV AMSTERDAM,BIOCTR AMSTERDA,INST MOL BIOL STUDIES IMBW,DEPT GENET,NL-1081 HV AMSTERDAM,NETHERLANDS; UNIV DURHAM,DEPT BIOL SCI,DURHAM DH1 3LE,ENGLAND; ZENECA AGROCHEM,JEALOTTS HILL RES STN,DEPT EXPLORATORY PLANT SCI,BRACKNELL RG12 6EY,BERKS,ENGLAND	University of Sheffield; Vrije Universiteit Amsterdam; Durham University			Liu, Shih/Q-1672-2019; Heterocycles, BoronNitrogen/Q-1699-2019	Rafferty, John/0000-0003-1183-7474; Baker, Patrick/0000-0003-1995-5643; Baldock, Clair/0000-0003-3497-1959				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BALDOCK C, IN PRESS ACTA CRYSTA; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; BERGLER H, 1994, J BIOL CHEM, V269, P5493; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; Bull HG, 1996, J AM CHEM SOC, V118, P2359, DOI 10.1021/ja953069t; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; Cole Stewart T., 1994, Trends in Microbiology, V2, P411, DOI 10.1016/0966-842X(94)90621-1; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; ESNOUF R, COMMUNICATION; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GRASSBERGER MA, 1984, J MED CHEM, V27, P947, DOI 10.1021/jm00374a003; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HOGENAUER G, 1981, NATURE, V293, P662, DOI 10.1038/293662a0; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KATER MM, 1994, PLANT MOL BIOL, V25, P771, DOI 10.1007/BF00028873; KLEYWEGT GJ, 1993, ESF CCP4 NEWSL, P56; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1992, CCP4 ESF EACBM NEWSL; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; RAFFERTY JB, 1995, STRUCTURE, V3, P927, DOI 10.1016/S0969-2126(01)00227-1; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; Taillefumier C, 1996, BIOORG MED CHEM LETT, V6, P615, DOI 10.1016/0960-894X(96)00077-7; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; ZHONG S, 1991, J AM CHEM SOC, V113, P9429, DOI 10.1021/ja00025a001	30	212	224	3	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2107	2110		10.1126/science.274.5295.2107	http://dx.doi.org/10.1126/science.274.5295.2107			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953047				2022-12-01	WOS:A1996VY97400057
J	Friederich, PW; Sanson, BJ; Simioni, P; Zanardi, S; Huisman, MV; Kindt, I; Prandoni, P; Buller, HR; Girolami, A; Prins, MH				Friederich, PW; Sanson, BJ; Simioni, P; Zanardi, S; Huisman, MV; Kindt, I; Prandoni, P; Buller, HR; Girolami, A; Prins, MH			Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: Implications for prophylaxis	ANNALS OF INTERNAL MEDICINE			English	Article						thrombophlebitis; pregnancy complications, hematologic; protein C; protein S deficiency; antithrombins	ANTITHROMBIN-III DEFICIENCY; DEEP-VEIN THROMBOSIS; PROTEIN-C DEFICIENCY; CONGENITAL DEFICIENCY; MATERNAL MORTALITY; HEPARIN-THERAPY; PREVENTION; PUERPERIUM; FAMILIES; SURGERY	Background: It has been reported that women with an inherited deficiency of antithrombin, protein C, or protein S have an increased risk for developing venous thromboembolic disease during pregnancy and the postpartum period. However, because the available data on risk are flawed, it is difficult to define a rational, efficacious, and safe policy about prophylaxis for venous thromboembolism in these women. Objective: To determine the frequency of venous thromboembolism during pregnancy and the postpartum period in women with heritable deficiencies of anticoagulant factors. Design: Retrospective cohort study. Setting: University outpatient clinics in the Netherlands and Italy. Participants: 129 otherwise asymptomatic female family members of patients with a history of venous thromboembolism and an established deficiency of antithrombin, protein C, or protein S. Measurements: Medical history, with specific attention to episodes of venous thromboembolism and obstetric history, was taken. The anticoagulant factor status of the study participants was determined. if a patient had an episode of venous thromboembolism, subsequent pregnancies in that patient were not analyzed. Results: Of the 129 women who participated in the study, 60 had anticoagulant factor deficiency and 69 did not. In the nondeficient group, 198 pregnancies occurred; 1 of these (0.5%) was complicated by an episode of venous thromboembolism during the postpartum period. In the deficient group, 169 pregnancies occurred; 7 of these (4.1%) were complicated by an episode of venous thromboembolism during the third trimester of pregnancy (2 pregnancies [1.2%]) and the postpartum period (5 pregnancies [3.0%]). The risk for venous thromboembolism was increased eightfold in deficient women compared with nondeficient women (hazard ratio, 8.0 [95% CI, 1.2 to 184]). Conclusions: Anticoagulant factor-deficient women have an increased risk for venous thromboembolism during pregnancy and the postpartum period. Although data from an appropriate randomized clinical trial are lacking, the frequency of venous thromboembolism seen in deficient women might justify the use of anticoagulative prophylaxis during the third trimester of pregnancy and the postpartum period.	UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, NL-1105 AZ AMSTERDAM, NETHERLANDS; UNIV PADUA, IST SEMEIOT MED, I-35100 PADUA, ITALY; UNIV AMSTERDAM, ACAD MED CTR, CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA, NL-1105 AZ AMSTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Padua; University of Amsterdam; Academic Medical Center Amsterdam			Simioni, Paolo/AAC-5416-2022; SIMIONI, PAOLO/AAC-5438-2022	SIMIONI, PAOLO/0000-0002-6744-383X				AARO LA, 1966, OBSTET GYNECOL, V28, P553; AIACH M, 1995, THROMB HAEMOSTASIS, V74, P81; ALLAART CF, 1995, BRIT MED J, V311, P910; ANDERSON DR, 1991, THROMB HAEMOSTASIS, V65, P248; BARBOUR LA, 1994, AM J OBSTET GYNECOL, V170, P862, DOI 10.1016/S0002-9378(94)70299-3; BLONDELHILL E, 1992, THROMB RES, V65, P193, DOI 10.1016/0049-3848(92)90239-7; BROEKMANS AW, 1983, NEW ENGL J MED, V309, P340, DOI 10.1056/NEJM198308113090604; COMP PC, 1986, BLOOD, V68, P881; CONARD J, 1990, THROMB HAEMOSTASIS, V63, P319; CONARD J, 1987, THROMB HAEMOSTASIS, V58, P39; DAHLMAN TC, 1993, AM J OBSTET GYNECOL, V168, P1265, DOI 10.1016/0002-9378(93)90378-V; DESTEFANO V, 1994, THROMB HAEMOSTASIS, V71, P799; DOUGLAS AS, 1990, SCOT MED J, V35, P108, DOI 10.1177/003693309003500406; EVARTS CM, 1971, J BONE JOINT SURG AM, VA 53, P1271, DOI 10.2106/00004623-197153070-00002; GALLUS AS, 1973, NEW ENGL J MED, V288, P545, DOI 10.1056/NEJM197303152881103; GINSBERG JS, 1992, THROMB HAEMOSTASIS, V67, P519; GIROLAMI A, 1990, ACTA HAEMATOL-BASEL, V84, P162; GONZALEZ R, 1985, THROMB RES, V39, P637, DOI 10.1016/0049-3848(85)90245-2; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HELLGREN M, 1982, GYNECOL OBSTET INVES, V14, P127, DOI 10.1159/000299460; HULL RD, 1990, ANN INTERN MED, V112, P663, DOI 10.7326/0003-4819-112-9-663; KAUNITZ AM, 1985, OBSTET GYNECOL, V65, P605; KIERKEGAARD A, 1983, ACTA OBSTET GYN SCAN, V62, P239, DOI 10.3109/00016348309155799; MALM J, 1988, BRIT J HAEMATOL, V68, P437, DOI 10.1111/j.1365-2141.1988.tb04232.x; NEERHOF MG, 1993, AM J PERINAT, V10, P311, DOI 10.1055/s-2007-994748; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; ROSENDAAL FR, 1991, LANCET, V337, P260, DOI 10.1016/0140-6736(91)90867-O; SACHS BP, 1987, NEW ENGL J MED, V316, P667, DOI 10.1056/NEJM198703123161105; TREFFERS PE, 1983, INT J GYNECOL OBSTET, V21, P327, DOI 10.1016/0020-7292(83)90024-3; VANDENBELT AG, IN PRESS CLIN APPL H; VILLASAN.U, 1965, AM J OBSTET GYNECOL, V93, P142, DOI 10.1016/0002-9378(65)90308-X; WEENINK GH, 1982, THROMB RES, V26, P281, DOI 10.1016/0049-3848(82)90293-6	33	194	199	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1996	125	12					955	+		10.7326/0003-4819-125-12-199612150-00003	http://dx.doi.org/10.7326/0003-4819-125-12-199612150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX768	8967705				2022-12-01	WOS:A1996VX76800005
J	Bonten, MJM; Hayden, MK; Nathan, C; vanVoorhis, J; Matushek, M; Slaughter, S; Rice, T; Weinstein, RA				Bonten, MJM; Hayden, MK; Nathan, C; vanVoorhis, J; Matushek, M; Slaughter, S; Rice, T; Weinstein, RA			Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci	LANCET			English	Article							HIGH-LEVEL RESISTANCE; STREPTOCOCCUS-FAECALIS; NOSOCOMIAL INFECTION; FAECIUM BACTEREMIA; RISK-FACTORS; D-ALANINE; GENTAMICIN; OUTBREAK	Background Vancomycin-resistant enterococci (VRE) have emerged as nosocomial pathogens during the past 5 years, but little is known about the epidemiology of VRE. We investigated colonisation of patients and environmental contamination with VRE in an endemic setting to assess the importance of different sources of colonisation. Methods Between April 12, and May 29, 1995, cultures from body sites (rectum, groin, arm, oropharynx, trachea, and stomach) and from environmental surfaces (bedrails, drawsheet, blood-pressure cuff, urine containers, and enteral feed) were obtained dairy from ail newly admitted Ventilated patients in our medical intensive-care unit (MICU). Rectal cultures were obtained from all nonventilated patients in the MICU. Strain types of VRE were determined by pulsed-field gel electrophoresis. Findings There were 97 admissions of 92 patients, of whom 38 required mechanical ventilation. Colonisation with VRE on admission was more common in Ventilated than in non-ventilated patients (nine [24%] vs three [6%], p<0.05). Of the nine ventilated patients colonised with VRE on admission, one acquired a new strain of VRE in the MICU. Of the 29 ventilated patients who were not colonised with VRE on admission, 12 (41%) acquired VRE in the MICU. The median time to acquisition of VRE was 5 days (interquartile range 3-8). Of the 13 Ventilated patients who acquired VRE, 11 (85%) were colonised with VRE by cross-colonisation, VRE were isolated from 157 (12%) of 1294 environmental cultures. The rooms of 13 patients were contaminated with VRE, but only three (23%) of these patients subsequently acquired colonisation with VRE. Pulsed-field gel electrophoresis of 262 isolates showed 20 unique strain types of VRE. Interpretation Frequent colonisation with VRE on MICU admission and subsequent cross-colonisation are important factors in the endemic spread of VRE, Persistent VRE colonisation in the gastrointestinal tract and on the skin, the presence of multiple-strain types of VRE, and environmental contamination may all contribute to the spread of VRE.	COOK CTY HOSP,DIV INFECT DIS,CHICAGO,IL 60612; RUSH MED COLL,CHICAGO,IL 60612	John H Stroger Junior Hospital Cook County; Rush University				Hayden, Mary/0000-0002-4603-8501				BINGEN EH, 1991, J CLIN MICROBIOL, V29, P1888, DOI 10.1128/JCM.29.9.1888-1892.1991; BOYCE JM, 1994, J CLIN MICROBIOL, V32, P1148, DOI 10.1128/JCM.32.5.1148-1153.1994; BRISSONNOEL A, 1990, ANTIMICROB AGENTS CH, V34, P924, DOI 10.1128/AAC.34.5.924; CDC, 1993, MMWR-MORBID MORTAL W, V42, P597; CHOW JW, 1993, J CLIN MICROBIOL, V31, P1609, DOI 10.1128/JCM.31.6.1609-1611.1993; DUTKAMALEN S, 1992, GENE, V112, P53, DOI 10.1016/0378-1119(92)90302-6; EDMOND MB, 1995, CLIN INFECT DIS, V20, P1126, DOI 10.1093/clinids/20.5.1126; EVERS S, 1993, GENE, V124, P143, DOI 10.1016/0378-1119(93)90779-3; GOERING RV, 1993, INFECT CONT HOSP EP, V14, P595; HANDWERGER S, 1993, CLIN INFECT DIS, V16, P750, DOI 10.1093/clind/16.6.750; LIVORNESE LL, 1992, ANN INTERN MED, V117, P112, DOI 10.7326/0003-4819-117-2-112; MONTECALVO MA, 1994, ANTIMICROB AGENTS CH, V38, P1363, DOI 10.1128/AAC.38.6.1363; MORRIS JG, 1995, ANN INTERN MED, V123, P250, DOI 10.7326/0003-4819-123-4-199508150-00002; MURRAY BE, 1990, J CLIN MICROBIOL, V28, P2059, DOI 10.1128/JCM.28.9.2059-2063.1990; NASHKIN CA, 1995, INFECT CONT HOSP EP, V16, P577; *NAT COMM CLIN LAB, 1993, M2A3 NAT COMM CLIN L; National Committee for Clinical Laboratory standards, 1993, M7A3 NAT COMM CLIN L; NAVARRO F, 1994, ANTIMICROB AGENTS CH, V38, P1788, DOI 10.1128/AAC.38.8.1788; RHINEHART E, 1990, NEW ENGL J MED, V323, P1814, DOI 10.1056/NEJM199012273232606; Slaughter S, 1996, ANN INTERN MED, V125, P448, DOI 10.7326/0003-4819-125-6-199609150-00004; SWENSON JM, 1993, P 33 INT C ANT AG CH, P263; UTTLEY AHC, 1988, LANCET, V1, P57; UTTLEY AHC, 1989, EPIDEMIOL INFECT, V103, P173, DOI 10.1017/S0950268800030478; ZERVOS MJ, 1987, ANN INTERN MED, V106, P687, DOI 10.7326/0003-4819-106-5-687; ZERVOS MJ, 1986, J INFECT DIS, V153, P1075, DOI 10.1093/infdis/153.6.1075	25	278	294	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1615	1619		10.1016/S0140-6736(96)02331-8	http://dx.doi.org/10.1016/S0140-6736(96)02331-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961991				2022-12-01	WOS:A1996VX87600010
J	English, M; New, L; Peshu, N; Marsh, K				English, M; New, L; Peshu, N; Marsh, K			Video assessment of simple respiratory signs	BRITISH MEDICAL JOURNAL			English	Article							MALARIA		KEMRI,KILIFI UNIT,CLIN RES CTR,KILIFI,KENYA					English, Michael/0000-0002-7427-0826				ENGLISH M, 1995, ARCH DIS CHILD, V72, P334, DOI 10.1136/adc.72.4.334; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; TAYLOR TE, 1993, Q J MED, V86, P99; World Health Organization, 1990, AC RESP INF CHILDR C	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1527	1528		10.1136/bmj.313.7071.1527	http://dx.doi.org/10.1136/bmj.313.7071.1527			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY691	8978229	Green Published			2022-12-01	WOS:A1996VY69100022
J	Lieberman, D; Sleisenger, MH				Lieberman, D; Sleisenger, MH			Is it time to recommend screening for colorectal cancer?	LANCET			English	Editorial Material							MORTALITY		UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco	Lieberman, D (corresponding author), OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97207, USA.							Allison JE, 1996, NEW ENGL J MED, V334, P155, DOI 10.1056/NEJM199601183340304; LIEBERMAN DA, 1995, VA COOPERATIVE S DEC; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; Wagner JL, 1996, PREVENTION EARLY DET, P321; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	6	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1463	1464		10.1016/S0140-6736(05)65886-2	http://dx.doi.org/10.1016/S0140-6736(05)65886-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942770				2022-12-01	WOS:A1996VV46300003
J	Sakai, S; Miyauchi, T; Kobayashi, M; Yamaguchi, I; Goto, K; Sugishita, Y				Sakai, S; Miyauchi, T; Kobayashi, M; Yamaguchi, I; Goto, K; Sugishita, Y			Inhibition of myocardial endothelin pathway improves long-term survival in heart failure	NATURE			English	Article							PULMONARY-HYPERTENSION; INFARCTION; RATS; LOCALIZATION; RECEPTOR; POTENT	OCCLUSION Of the diseased coronary artery in humans causes acute myocardial infarction, survivors of which have a high risk for the development of chronic heart failure(1). Cardiac myocytes and vascular endothelial cells produce endothelin-1 (refs 2-4), which increases the contractility of cardiac muscle and of vascular smooth muscle cells(2,3,5). Endothelin-1 also exerts long-term effects such as myocardial hypertrophy, and causes cellular injury in cardiac myocytes(3,5-7). Production of endothelin-l is markedly increased in the myocardium of rats with heart failure, and acute application of an endothelin-receptor antagonist decreases myocardial contractility in such rats, indicating that myocardial endothelin-1 may help to support contractility of the failing heart(8). But we report here that the upregulated myocardial endothelin system may contribute to the progression of chronic heart failure, because long-term treatment with an endothelin-receptor antagonist greatly improved the survival of rats with chronic heart failure, This beneficial effect was accompanied by significant amelioration of left ventricular dysfunction and prevention of ventricular remodelling, in which there is usually an increase in the ventricular mass and cavity enlargement of the ventricle.	UNIV TSUKUBA,INST CLIN MED,DEPT INTERNAL MED,DIV CARDIOVASC,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST BASIC MED SCI,DEPT PHARMACOL,TSUKUBA,IBARAKI 305,JAPAN; BANYU PHARMACEUT CO LTD,TSUKUBA RES INST,TSUKUBA,IBARAKI 30033,JAPAN	University of Tsukuba; University of Tsukuba; Merck & Company; Novartis								GOTO K, 1995, NATURE, V375, P539, DOI 10.1038/375539a0; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; ISHIKAWA S, 1995, J THORAC CARDIOV SUR, V110, P271, DOI 10.1016/S0022-5223(05)80036-4; KATZ AM, 1986, CIRCULATION, V73, P184; KOBAYASHI M, 1995, ACTA HISTOCHEM CYTOC, V28, P129, DOI 10.1267/ahc.28.129; KOWSKI W, 1995, LANCET, V346, P732; Melillo G, 1996, CIRCULATION, V93, P1447, DOI 10.1161/01.CIR.93.7.1447; MIYAUCHI T, 1993, CIRC RES, V73, P887, DOI 10.1161/01.RES.73.5.887; MIYAUCHI T, 1989, LANCET, V2, P53, DOI 10.1016/S0140-6736(89)90303-6; MOLENAAR P, 1993, CIRC RES, V72, P526, DOI 10.1161/01.RES.72.3.526; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PFEFFER JM, 1995, ANNU REV PHYSIOL, V57, P805, DOI 10.1146/annurev.ph.57.030195.004105; PFEFFER MA, 1979, CIRC RES, V44, P503, DOI 10.1161/01.RES.44.4.503; PFEFFER MA, 1995, ANNU REV MED, V46, P455, DOI 10.1146/annurev.med.46.1.455; PRASAD MR, 1991, BIOCHEM BIOPH RES CO, V174, P952, DOI 10.1016/0006-291X(91)91511-A; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; Sakai S, 1996, CIRCULATION, V93, P1214, DOI 10.1161/01.CIR.93.6.1214; STEWART DJ, 1992, CIRCULATION, V85, P510, DOI 10.1161/01.CIR.85.2.510; SUZUKI T, 1993, BIOCHEM BIOPH RES CO, V191, P823, DOI 10.1006/bbrc.1993.1291; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YORIKANE R, 1993, FEBS LETT, V332, P31, DOI 10.1016/0014-5793(93)80476-B; YORIKANE R, 1990, JPN J PHARMACOL, V53, P259, DOI 10.1254/jjp.53.259	22	527	536	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					353	355		10.1038/384353a0	http://dx.doi.org/10.1038/384353a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934519				2022-12-01	WOS:A1996VV27100047
J	Tajbakhsh, S; Rocancourt, D; Buckingham, M				Tajbakhsh, S; Rocancourt, D; Buckingham, M			Muscle progenitor cells failing to respond to positional cues adopt non-myogenic fates in myf-5 null mice	NATURE			English	Article							SKELETAL-MUSCLE; REGULATORY GENE; MOUSE; DIFFERENTIATION; INACTIVATION; PROTEIN; EMBRYO; MYOD; LIMB	MICE that have mutations in both myogenic transcription factors Myf-5 and MyoD totally lack skeletal muscle fibres and their precursor myoblasts(1), whereas with either mutation alone, muscle is present(2,3). Skeletal muscle in the vertebrate body is derived from epithelial somites that respond to environmental signals to form the dorsal epithelial dermomyotome (dermis, muscle) and ventral mesenchymal sclerotome (axial skeleton, ribs)(4,5). The first muscle, the myotome, forms centrally in the somite, when only myf-5 is programming myogenesis. By targeting the nlacZ reporter gene into the myf-5 locus, we demonstrate that beta-galactosidase(+) muscle progenitor cells are present in the dermomyotome of myf-5 null embryos, and that they undergo a normal epithelial-mesenchymal transition; however, they migrate aberrantly. Dorsally, they accumulate under the ectoderm and express a non-muscle dermal marker, Dermo-1, Ventrally, beta-galactosidase(+) cells also fail to localize correctly, express a cartilage marker scleraxis, and are subsequently found in ribs, Therefore Myf-5 protein is necessary for cells to respond correctly to positional cues in the embryo and to adopt their myogenic fate, In its absence, muscle progenitors, having activated myf-5, remain multipotent and differentiate into other semitic derivatives according to their local environment.			Tajbakhsh, S (corresponding author), INST PASTEUR,DEPT MOL BIOL,CNRS,URA 1947,UNITE GENET MOL DEV,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							BOBER E, 1994, DEVELOPMENT, V120, P3073; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; COSSU G, 1995, P NATL ACAD SCI USA, V92, P2254, DOI 10.1073/pnas.92.6.2254; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; GODSAVE SF, 1991, DEVELOPMENT, V111, P523; Grass S, 1996, DEVELOPMENT, V122, P141; GURDON JB, 1988, NATURE, V336, P772, DOI 10.1038/336772a0; Hay ED, 1993, CURR OPIN CELL BIOL, V5, P1029, DOI 10.1016/0955-0674(93)90088-8; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; OTT MO, 1991, DEVELOPMENT, V111, P1097; Pownall ME, 1996, DEVELOPMENT, V122, P1475; RONG PM, 1992, DEVELOPMENT, V115, P657; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; Tajbakhsh S, 1995, DEVELOPMENT, V121, P4077; Tajbakhsh S, 1996, DEV DYNAM, V206, P291, DOI 10.1002/(SICI)1097-0177(199607)206:3<291::AID-AJA6>3.0.CO;2-D; TAJBAKHSH S, 1994, P NATL ACAD SCI USA, V91, P747, DOI 10.1073/pnas.91.2.747; TAJBAKHSH S, 1995, TRENDS GENET, V11, P42, DOI 10.1016/S0168-9525(00)88994-5; TOSNEY KW, 1994, DEV BIOL, V163, P389, DOI 10.1006/dbio.1994.1157; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Yang XM, 1996, DEVELOPMENT, V122, P2163	27	241	248	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					266	270		10.1038/384266a0	http://dx.doi.org/10.1038/384266a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918877				2022-12-01	WOS:A1996VU38100052
J	Harrington, L; McPhail, T; Mar, V; Zhou, W; Oulton, R; Bass, MB; Arruda, I; Robinson, MO				Harrington, L; McPhail, T; Mar, V; Zhou, W; Oulton, R; Bass, MB; Arruda, I; Robinson, MO			A mammalian telomerase-associated protein	SCIENCE			English	Article							TETRAHYMENA-TELOMERASE; RNA TEMPLATE; SECONDARY STRUCTURE; IMMORTAL CELLS; NUCLEAR RNAS; YEAST; ELONGATION; VECTORS; RIBONUCLEOPROTEIN; SENESCENCE	The telomerase ribonucleoprotein catalyzes the addition of new telomeres onto chromosome ends. A gene encoding a mammalian telomerase homolog called TP1 (telomerase-associated protein 1) was identified and cloned. TP1 exhibited extensive amino acid similarity to the Tetrahymena telomerase protein p80 and was shown to interact specifically with mammalian telomerase RNA. Antiserum to TP1 immunoprecipitated telomerase activity from cell extracts,suggesting that TP1 is associated with telomerase in vivo. The identification of TP1 suggests that telomerase-associated proteins are conserved from ciliates to humans.	AMGEN INC, AMGEN EST PROGRAM, THOUSAND OAKS, CA 91320 USA	Amgen	Harrington, L (corresponding author), UNIV TORONTO, ONTARIO CANC INST, AMGEN INST, DEPT MED BIOPHYS, 620 UNIV AVE, TORONTO, ON M5G 2C1, CANADA.			Robinson, Murray/0000-0003-4462-0685				ARES M, 1986, CELL, V47, P49, DOI 10.1016/0092-8674(86)90365-X; ARRUDA I, UNPUB; AUTEXIER C, 1995, GENE DEV, V9, P2227, DOI 10.1101/gad.9.18.2227; Autexier C, 1996, EMBO J, V15, P5928, DOI 10.1002/j.1460-2075.1996.tb00979.x; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Avilion AA, 1996, CANCER RES, V56, P645; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DEUTSCHER SL, 1988, P NATL ACAD SCI USA, V85, P9479, DOI 10.1073/pnas.85.24.9479; DING SW, 1989, VIROLOGY, V172, P555, DOI 10.1016/0042-6822(89)90198-0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GILLEY D, 1995, GENE DEV, V9, P2214, DOI 10.1101/gad.9.18.2214; GOOD PD, 1994, GENE, V151, P209, DOI 10.1016/0378-1119(94)90658-0; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HARPER JW, 1993, CELL, V75, P805; HARRINGTON L, 1995, J BIOL CHEM, V270, P8893, DOI 10.1074/jbc.270.15.8893; Kaiser C., 1994, METHODS YEAST GENETI; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEGRAIN P, 1994, NUCLEIC ACIDS RES, V22, P3241, DOI 10.1093/nar/22.15.3241; Lendvay TS, 1996, GENETICS, V144, P1399; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; MCCORMICKGRAHAM M, 1995, NUCLEIC ACIDS RES, V23, P1091, DOI 10.1093/nar/23.7.1091; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TENDAM E, 1991, NUCLEIC ACIDS RES, V19, P6951; TOLLERVEY D, 1983, CELL, V35, P753, DOI 10.1016/0092-8674(83)90108-3; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAUG AJ, 1995, RNA, V1, P363; ZHOU WJ, UNPUB	49	614	664	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1997	275	5302					973	977		10.1126/science.275.5302.973	http://dx.doi.org/10.1126/science.275.5302.973			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020079				2022-12-01	WOS:A1997WH38800044
J	Smiley, ST; Kaplan, MH; Grusby, MJ				Smiley, ST; Kaplan, MH; Grusby, MJ			Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells	SCIENCE			English	Article							II-DEFICIENT MICE; NK1.1(+) T-CELLS; IN-VIVO; THYMOCYTES; CD1; CD4(+); IL-4; CD4+; EXPRESSION; MOLECULES	A lymphocyte population that expresses surface markers found on T cells and natural killer (NK) cells secretes large amounts of interleukin-4 (IL-4) immediately after T cell receptor ligation. These NK-like T cells are thus thought to be important for the initiation of type 2 T helper cell (T(H)2) responses. CD1-deficient mice were found to lack this lymphocyte subset, but they could nevertheless mount a protypical T(H)2 response; after immunization with antibody to immunoglobulin D (IgD), CD1-deficient mice produced IgE. Thus, although dependent on CD1 for their development, IL-4-secreting NK-like T cells are not required for T(H)2 responses.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School					PHS HHS [R01 A140171] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; BALK SP, 1991, J IMMUNOL, V146, P768; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; BENDELAC A, 1995, J EXP MED, V182, P2091, DOI 10.1084/jem.182.6.2091; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; BRADBURY A, 1988, EMBO J, V7, P3081, DOI 10.1002/j.1460-2075.1988.tb03173.x; Brown DR, 1996, J EXP MED, V184, P1295, DOI 10.1084/jem.184.4.1295; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; COLES MC, 1994, J EXP MED, V180, P395, DOI 10.1084/jem.180.1.395; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; MACDONALD HR, 1995, J EXP MED, V182, P633, DOI 10.1084/jem.182.3.633; SEDER RA, 1992, J IMMUNOL, V148, P1652; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; YOSHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P11931, DOI 10.1073/pnas.92.25.11931; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845; Zhang Y, 1996, J EXP MED, V184, P1507, DOI 10.1084/jem.184.4.1507; ZLOTNIK A, 1992, J IMMUNOL, V149, P1211	28	427	437	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					977	979		10.1126/science.275.5302.977	http://dx.doi.org/10.1126/science.275.5302.977			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020080				2022-12-01	WOS:A1997WH38800045
J	Chaimanee, Y; Suteethorn, V; Jaeger, JJ; Ducrocq, S				Chaimanee, Y; Suteethorn, V; Jaeger, JJ; Ducrocq, S			A new Late Eocene anthropoid primate from Thailand	NATURE			English	Article							EARLY OLIGOCENE; DISCOVERY; SULTANATE; PROVINCE; ORIGINS; OMAN	The fossil record of anthropoid primates from the Middle Eocene of South Asia is so far restricted to two genera (Pondaungia cotteri Pilgrim, 1937 and Amphipithecus mogaungensis Colbert, 1937 from the Eocene Pondaung deposits of Burma) whose anthropoid status and phylogenetic position have long been under debate(1-6) because they represent the oldest highly derived fossil primates of anthropoid grade. Moreover, several new African taxa(7-10), some of which are even older, have been recently included in the suborder Anthropoidea, suggesting an African origin for this group. Conversely, new fossil primates recently discovered in China (Eosimias) have been related to the most primitive representatives of Anthropoidea, alternatively suggesting an Asian origin and a probable Asian radiation centre(11). We report here the discovery of a new anthropoid from the Thai Late Eocene locality of Krabi(12,13), which displays several additional anthropoid characters with regard to those of the Eocene Burmese genera. This species, which is about the size of the Fayum Aegyptopithecus, can be related to the Burmese forms, and it further provides strong additional evidence for a southeast Asian evolutionary centre for anthropoids.	UNIV MONTPELLIER 2,INST SCI EVOLUT,CNRS,UMR 5554,F-34095 MONTPELLIER 5,FRANCE; DEPT MINERAL RESOURCES,GEOL SURVEY DIV,PALEONTOL SECT,BANGKOK 10400,THAILAND	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Department of Mineral Resources - Thailand			Klein, Richard G/B-5910-2009	chaimanee, yaowalak/0000-0002-8432-3880				Beard KC, 1996, SCIENCE, V272, P82, DOI 10.1126/science.272.5258.82; BEARD KC, 1991, AM J PHYS ANTHROPOL, V85, P159, DOI 10.1002/ajpa.1330850205; CHOW M, 1961, VERTEBRAT PALASIATIC, V1, P1; CIOCHON RL, 1985, SCIENCE, V229, P756, DOI 10.1126/science.229.4715.756; Ciochon Russell L., 1994, P143; Ducrocq S, 1995, J SOUTHE ASIAN EARTH, V12, P65, DOI 10.1016/0743-9547(95)00021-6; DUCROCQ S, 1995, J HUM EVOL, V28, P477, DOI 10.1006/jhev.1995.1035; Ducrocq Stephane, 1995, Neues Jahrbuch fuer Geologie und Palaeontologie Monatshefte, V6, P355; GINGERICH PD, 1980, AM J PHYS ANTHROPOL, V52, P231; Gingerich Philip D., 1994, P163; GODINOT M, 1992, NATURE, V357, P324, DOI 10.1038/357324a0; Godinot Marc, 1994, P235; Holroyd Patricia A., 1994, P297; HUSSAIN S T, 1978, Proceedings of the Koninklijke Nederlandse Akademie van Wetenschappen Series B Physical Sciences, V81, P74; Jaeger J.-J., 1985, EVOLUTIONARY RELATIO, P567; Kay Richard F., 1994, P361; Legendre S., 1989, Muenchner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V16, P1; MAW B, 1979, NATURE, V282, P65, DOI 10.1038/282065a0; SIMONS EL, 1992, P NATL ACAD SCI USA, V89, P10743, DOI 10.1073/pnas.89.22.10743; SIMONS EL, 1971, NATURE, V232, P489, DOI 10.1038/232489a0; SIMONS EL, 1995, SCIENCE, V268, P1885, DOI 10.1126/science.7604261; SIMONS EL, 1991, INT J PRIMATOL, V1, P163; Simons Elwyn L., 1994, P179; SZALAY FS, 1972, NATURE, V236, P179, DOI 10.1038/236179a0; SZALAY FS, 1970, NATURE, V227, P355, DOI 10.1038/227355a0; THOMAS H, 1991, J HUM EVOL, V20, P33, DOI 10.1016/0047-2484(91)90044-V; THOMAS H, 1989, GEOBIOS-LYON, V22, P101, DOI 10.1016/S0016-6995(89)80091-9; Vianey-Liaud Monique, 1994, Palaeovertebrata (Montpellier), V23, P93; Zdansky O., 1930, Palaeontologia Sinica, V6C, P1	29	83	86	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1997	385	6615					429	431		10.1038/385429a0	http://dx.doi.org/10.1038/385429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WF007	9009188				2022-12-01	WOS:A1997WF00700050
J	Fine, MJ; Auble, TE; Yealy, DM; Hanusa, BH; Weissfeld, LA; Singer, DE; Coley, CM; Marrie, TJ; Kapoor, WN				Fine, MJ; Auble, TE; Yealy, DM; Hanusa, BH; Weissfeld, LA; Singer, DE; Coley, CM; Marrie, TJ; Kapoor, WN			A prediction rule to identify low-risk patients with community-acquired pneumonia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-TRACT INFECTIONS; REQUIRING HOSPITALIZATION; ANTIMICROBIAL THERAPY; MEDISGROUPS; MORTALITY; ADMISSION; ETIOLOGY; DECISION; STAY	Background There is considerable variability in rates of hospitalization of patients with community-acquired pneumonia, in part because of physicians' uncertainty in assessing the severity of illness at presentation. Methods From our analysis of data on 14,199 adult inpatients with community-acquired pneumonia, we derived a prediction rule that stratifies patients into five classes with respect to the risk of death within 30 days. The rule was validated with 1991 data on 38,039 inpatients and with data on 2287 inpatients and outpatients in the Pneumonia Patient Outcomes Research Team (PORT) cohort study. The prediction rule assigns points based on age and the presence of coexisting disease, abnormal physical findings (such as a respiratory rate of greater than or equal to 30 per minute or a temperature of greater than or equal to 40 degrees C), and abnormal laboratory findings (such as a pH <7.35, a blood urea nitrogen concentration greater than or equal to 30 mg per deciliter [11 mmol per liter] or a sodium concentration <130 mmol per liter) at presentation. Results There were no significant differences in mortality in each of the five risk classes among the three cohorts. Mortality ranged from 0.1 to 0.4 percent for class I patients (P=0.22), from 0.6 to 0.7 percent for class II (P=0.67), and from 0.9 to 2.8 percent for class III (P=0.12). Among the 1575 patients in the three lowest risk classes in the Pneumonia PORT cohort, there were only seven deaths, of which only four were pneumonia-related. The risk class was significantly associated with the risk of subsequent hospitalization among those treated as outpatients and with the use of intensive care and the number of days in the hospital among inpatients. Conclusions The prediction rule we describe accurately identifies the patients with community-acquired pneumonia who are at low risk for death and other adverse outcomes. This prediction rule may help physicians make more rational decisions about hospitalization for patients with pneumonia. (C) 1997, Massachusetts Medical Society.	UNIV PITTSBURGH,GRAD SCH PUBL HLTH,DEPT EMERGENCY MED,PITTSBURGH,PA; UNIV PITTSBURGH,GRAD SCH PUBL HLTH,DEPT BIOSTAT,PITTSBURGH,PA; MASSACHUSETTS GEN HOSP,MED SERV,GEN INTERNAL MED UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA; VICTORIA GEN HOSP,DEPT MED,DIV INFECT DIS,HALIFAX,NS B3H 2Y9,CANADA; DALHOUSIE UNIV,HALIFAX,NS,CANADA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Dalhousie University; University of Victoria; Dalhousie University					AHRQ HHS [R01HS-06468] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BARTLETT JG, 1995, NEW ENGL J MED, V333, P1618, DOI 10.1056/NEJM199512143332408; BRESLOW N. E., 1980, STATISTICAL METHODS; BREWSTER AC, 1985, INQUIRY-J HEALTH CAR, V22, P377; Coley C. M., 1996, JGIM, V11, P45; Coley CM, 1996, ARCH INTERN MED, V156, P1565, DOI 10.1001/archinte.156.14.1565; COLLET D, 1994, MODELLING SURVIVAL D, P85; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; DANS PE, 1984, ARCH INTERN MED, V144, P1392, DOI 10.1001/archinte.144.7.1392; EHRENKRANZ NJ, 1992, INFECT CONT HOSP EP, V13, P21, DOI 10.2307/30146964; FARR BM, 1991, ANN INTERN MED, V115, P428, DOI 10.7326/0003-4819-115-6-428; FINE MJ, 1990, AM J MED, V89, P713, DOI 10.1016/0002-9343(90)90211-U; FINE MJ, 1990, AM J MED, V88, pN1; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; FINE MJ, 1995, J GEN INTERN MED, V10, P359, DOI 10.1007/BF02599830; FINE MJ, 1993, AM J MED, V94, P153, DOI 10.1016/0002-9343(93)90177-Q; FINE MJ, IN PRESS ARCH INTERN; GARIBALDI RA, 1985, AM J MED, V78, P32, DOI 10.1016/0002-9343(85)90361-4; GENTRY LO, 1992, AM REV RESPIR DIS, V145, P31, DOI 10.1164/ajrccm/145.1.31; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KURASHI NY, 1992, THORAX, V47, P115, DOI 10.1136/thx.47.2.115; LAFORCE FM, 1985, AM J MED, V78, P52, DOI 10.1016/0002-9343(85)90364-X; Lave JR, 1996, J GEN INTERN MED, V11, P415, DOI 10.1007/BF02600189; MARRIE TJ, 1989, REV INFECT DIS, V11, P586; McCormick D., 1996, JGIM, V11, P80; MCMAHON LF, 1989, MED CARE, V27, P623, DOI 10.1097/00005650-198906000-00005; MCNEIL BJ, 1975, NEW ENGL J MED, V293, P211, DOI 10.1056/NEJM197507312930501; MOHER D, 1992, CAN MED ASSOC J, V146, P511; ORTQVIST A, 1990, EUR RESPIR J, V3, P1105; PALADINO JA, 1991, AM J MED, V91, P462, DOI 10.1016/0002-9343(91)90181-V; RAMIREZ JA, 1995, ARCH INTERN MED, V155, P1273, DOI 10.1001/archinte.155.12.1273; Roos N P, 1988, Health Care Financ Rev, V9, P53; SELKER HP, 1993, AM J CARDIOL, V71, P339, DOI 10.1016/0002-9149(93)90802-J; THOMAS JW, 1986, EVALUATION ALTERNATI, V1, P1; Wasson JH, 1996, JAMA-J AM MED ASSOC, V275, P641, DOI 10.1001/jama.275.8.641; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEINGARTEN SR, 1994, CHEST, V105, P1109, DOI 10.1378/chest.105.4.1109; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; *WHO, 1977, MAN INT STAT CLASS D; WYATT JC, 1995, BMJ-BRIT MED J, V311, P1539, DOI 10.1136/bmj.311.7019.1539; 1995, HLTH CARE FINANC REV, V16; 1987, Q J MED, V62, P195	44	3218	3382	2	83	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1997	336	4					243	250		10.1056/NEJM199701233360402	http://dx.doi.org/10.1056/NEJM199701233360402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE632	8995086				2022-12-01	WOS:A1997WE63200002
J	Hiom, K; Gellert, M				Hiom, K; Gellert, M			A stable RAG1-RAG2-DNA complex that is active in V(D)J Cleavage	CELL			English	Article							BROKEN DNA-MOLECULES; MOUSE THYMOCYTES; STRAND TRANSFER; CODING ENDS; RECOMBINATION; MECHANISM; SEQUENCE; REARRANGEMENT; INTEGRATION; INITIATION	The RAG1 and RAG2 proteins initiate V(D)J recombination by making specific double-strand DNA breaks at recombination signal sequences. We show here that RAG1 and RAG2 bind specifically to this sequence, forming a stable protein-DNA complex. The complex requires the conserved heptamer and nonamer motifs of the recombination signal as well as both the RAG1 and RAG2 proteins. This complex is able to either nick or form hairpins at the V(D)J signal sequence, depending on the divalent cation present. A complex trapped using Ca2+ is subsequently active when transferred to Mg2+ or Mn2+. After cleavage, the complex is destabilized and the RAG proteins dissociate. We term this early precursor in the V(D)J recombination reaction a ''stable cleavage complex.''			Hiom, K (corresponding author), NIDDKD,MOL BIOL LAB,NIH,BETHESDA,MD 20892, USA.		Hiom, Kevin/B-4374-2009					BOUBNOV NV, 1995, NUCLEIC ACIDS RES, V23, P1060, DOI 10.1093/nar/23.6.1060; Craig NL, 1996, SCIENCE, V271, P1512, DOI 10.1126/science.271.5255.1512; Cuomo CA, 1996, MOL CELL BIOL, V16, P5683; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; EZEKIEL UR, 1995, IMMUNITY, V2, P381, DOI 10.1016/1074-7613(95)90146-9; GELLERT M, 1992, ANNU REV GENET, V22, P425; GERSTEIN RM, 1993, GENE DEV, V7, P1459, DOI 10.1101/gad.7.7b.1459; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; Roman CAJ, 1996, P NATL ACAD SCI USA, V93, P2333, DOI 10.1073/pnas.93.6.2333; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	30	169	170	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					65	72		10.1016/S0092-8674(00)81859-0	http://dx.doi.org/10.1016/S0092-8674(00)81859-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019407	Bronze			2022-12-01	WOS:A1997WC56900010
J	Dalton, CB; Austin, CC; Sobel, J; Hayes, PS; Bibb, WF; Graves, LM; Swaminathan, B; Proctor, ME; Griffin, PM				Dalton, CB; Austin, CC; Sobel, J; Hayes, PS; Bibb, WF; Graves, LM; Swaminathan, B; Proctor, ME; Griffin, PM			An outbreak of gastroenteritis and fever due to Listeria monocytogenes in milk	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTILOCUS ENZYME ELECTROPHORESIS; FIELD GEL-ELECTROPHORESIS; EPIDEMIC LISTERIOSIS; CHOCOLATE MILK; FOOD; INCUBATION; GROWTH; ADULTS	Background After an outbreak of gastroenteritis and fever among persons who attended a picnic in Illinois, chocolate milk served at the picnic was found to be contaminated with Listeria monocytogenes. Methods In investigating this outbreak, we interviewed the people who attended the picnic about what they ate and their symptoms. Surveillance for invasive listeriosis was initiated in the states that receive milk from the implicated dairy. Stool and milk samples were cultured for L. monocytogenes. Serum samples were tested for IgG antibody to listeriolysin O. Results Forty-five persons had symptoms that met the case definition for illness due to L. monocytogenes, and cultures of stool from 11 persons yielded the organism. Illness in the week after the picnic was associated with the consumption of chocolate milk. The most common symptoms were diarrhea (present in 79 percent of the cases) and fever (72 percent). Four persons were hospitalized. The median incubation period for infection was 20 hours (range, 9 to 32), and persons who became ill had elevated levels of antibody to listeriolysin O. Isolates from stool specimens from patients who became ill after the picnic, from sterile sites in three additional patients identified by surveillance, from the implicated chocolate milk, and from a tank drain at the dairy were all serotype 1/2b and were indistinguishable on multilocus enzyme electrophoresis, ribotyping, and DNA macrorestriction analysis. Conclusions L. monocytogenes is a cause of gastroenteritis with fever, and sporadic cases of invasive listeriosis may be due to unrecognized outbreaks caused by contaminated food. (C) 1997, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT,FOODBORNE & DIARRHEAL DIS BRANCH,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA; ILLINOIS DEPT PUBL HLTH,DIV INFECT DIS,SPRINGFIELD,IL 62761; WISCONSIN DEPT HLTH & SOCIAL SERV,BUR PUBL HLTH,MADISON,WI	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								*ASS OFF AN CHEM I, 1992, BACT AN MAN; BERCHE P, 1990, LANCET, V335, P624, DOI 10.1016/0140-6736(90)90411-W; BIBB WF, 1990, APPL ENVIRON MICROB, V56, P2133, DOI 10.1128/AEM.56.7.2133-2141.1990; BROSCH R, 1994, APPL ENVIRON MICROB, V60, P2584, DOI 10.1128/AEM.60.7.2584-2592.1994; BROSCH R, 1991, RES MICROBIOL, V142, P667, DOI 10.1016/0923-2508(91)90080-T; BULA CJ, 1995, CLIN INFECT DIS, V20, P66, DOI 10.1093/clinids/20.1.66; *CYT SOFTW CORP, 1995, STATX 3 WIND; DEAN AG, 1994, EPIINFO VERSION 6 02; DONNELLY CW, 1986, J FOOD PROTECT, V49, P994, DOI 10.4315/0362-028X-49.12.994; DONNELLY CW, 1986, J FOOD PROTECT, V49, P1002; FARBER JM, 1991, J CLIN MICROBIOL, V29, P2606, DOI 10.1128/JCM.29.11.2606-2608.1991; FARBER JM, 1991, MICROBIOL REV, V55, P476, DOI 10.1128/MMBR.55.3.476-511.1991; FARBER JM, 1991, MICROBIOL REV, V55, P752; FLEMING DW, 1985, NEW ENGL J MED, V312, P404, DOI 10.1056/NEJM198502143120704; Gholizadeh Y, 1996, J CLIN MICROBIOL, V34, P1391, DOI 10.1128/JCM.34.6.1391-1395.1996; GRAVES LM, 1994, J CLIN MICROBIOL, V32, P2936, DOI 10.1128/JCM.32.12.2936-2943.1994; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; MATAR GM, 1992, RES MICROBIOL, V143, P489, DOI 10.1016/0923-2508(92)90095-6; MCCLAIN D, 1988, J ASSOC OFF ANA CHEM, V71, P660; MIETTINEN A, 1990, J CLIN MICROBIOL, V28, P340, DOI 10.1128/JCM.28.2.340-343.1990; NIEMAN RE, 1980, REV INFECT DIS, V2, P207; PINNER RW, 1992, JAMA-J AM MED ASSOC, V267, P2046, DOI 10.1001/jama.267.15.2046; PROCTOR ME, 1995, APPL ENVIRON MICROB, V61, P3177, DOI 10.1128/AEM.61.8.3177-3179.1995; RIEDO FX, 1994, J INFECT DIS, V170, P693, DOI 10.1093/infdis/170.3.693; ROSENOW EM, 1987, J FOOD PROTECT, V50, P452, DOI 10.4315/0362-028X-50.6.452; SALAMINA G, 1993, 33 INT C ANT AG CHEM; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHUCHAT A, 1991, CLIN MICROBIOL REV, V4, P169, DOI 10.1128/CMR.4.2.169-183.1991; SCHUCHAT A, 1991, CLIN MICROBIOL REV, V4, P396, DOI 10.1128/CMR.4.3.396-.1991; SCHWARTZ B, 1989, J INFECT DIS, V159, P680, DOI 10.1093/infdis/159.4.680; Seeliger H.P.R., 1979, METHOD MICROBIOL, V13, P31, DOI [10.1016/S0580-9517(08)70372-6, DOI 10.1016/S0580-9517(08)70372-6]; Vanderzant C, 1992, COMPENDIUM METHODS M; WEAVER RE, 1989, ISOLATION IDENTIFICA, P39; WELLS JG, 1983, J CLIN MICROBIOL, V18, P512, DOI 10.1128/JCM.18.3.512-520.1983	34	379	406	0	26	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1997	336	2					100	105		10.1056/NEJM199701093360204	http://dx.doi.org/10.1056/NEJM199701093360204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC481	8988887				2022-12-01	WOS:A1997WC48100004
J	Cairns, BR; Lorch, Y; Li, Y; Zhang, MC; Lacomis, L; ErdjumentBromage, H; Tempst, P; Du, J; Laurent, B; Kornberg, RD				Cairns, BR; Lorch, Y; Li, Y; Zhang, MC; Lacomis, L; ErdjumentBromage, H; Tempst, P; Du, J; Laurent, B; Kornberg, RD			RSC, an essential, abundant chromatin-remodeling complex	CELL			English	Article							RNA-POLYMERASE-II; YEAST SWI/SNF COMPLEX; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME DISRUPTION; MULTISUBUNIT COMPLEX; NUCLEAR-PROTEIN; PHO5 PROMOTER; GENE-PRODUCTS; HUMAN HOMOLOG	A novel 15-subunit complex with the capacity to remodel the structure of chromatin, termed RSC, has been isolated from S. cerevisiae on the basis of homology to the SWI/SNF complex. At least three RSC subunits are related to SWI/SNF polypeptides: Sth1p, Rsc6p, and Rsc8p are significantly similar to Swi2/Snf2p, Swp73p, and Swi3p, respectively, and were identified by mass spectrometric and sequence analysis of peptide fragments. Like SWI/SNF, RSC exhibits a DNA-dependent ATPase activity stimulated by both free and nucleosomal DNA and a capacity to perturb nucleosome structure. RSC is, however, at least 10-fold more abundant than SWI/SNF complex and is essential for mitotic growth. Contrary to a report for SWI/SNF complex, no association of RSC (nor of SWI/SNF complex) with RNA polymerase II holoenzyme was detected.	STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, STANFORD, CA 94305 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOL BIOL, NEW YORK, NY 10021 USA; SUNY HLTH SCI CTR, DEPT MICROBIOL & IMMUNOL, BROOKLYN, NY 11203 USA	Stanford University; Memorial Sloan Kettering Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center				Erdjument-Bromage, Hediye/0000-0003-0224-3594	NCI NIH HHS [5 P30 CA08748] Funding Source: Medline; NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; ESTRUCH F, 1990, MOL CELL BIOL, V10, P2544, DOI 10.1128/MCB.10.6.2544; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HAPPEL AM, 1991, GENETICS, V128, P69; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LORCH Y, 1992, GENE DEV, V6, P2282, DOI 10.1101/gad.6.12a.2282; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NEIGEBORN L, 1984, GENETICS, V108, P845; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SIKORSKI RS, 1989, GENETICS, V122, P19; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TREICH I, 1995, MOL CELL BIOL, V15, P4240; TSUCHIYA E, 1992, EMBO J, V11, P4017, DOI 10.1002/j.1460-2075.1992.tb05495.x; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; WANG W, 1996, GENE DEV, V10, P2177; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S	55	573	595	0	19	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 27	1996	87	7					1249	1260		10.1016/S0092-8674(00)81820-6	http://dx.doi.org/10.1016/S0092-8674(00)81820-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980231	Bronze			2022-12-01	WOS:A1996WA54100013
J	Butler, DK; Yasuda, LE; Yao, MC				Butler, DK; Yasuda, LE; Yao, MC			Induction of large DNA palindrome formation in yeast: Implications for gene amplification and genome stability in eukaryotes	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; INVERTED DUPLICATION; HAMSTER-CELLS; RIBOSOMAL DNA; TETRAHYMENA-PYRIFORMIS; RESISTANT LEISHMANIA; REPLICATION ORIGIN; CHROMOSOME LOSS; REPEATS; DELETION	Many amplified genes, including some oncogenes, are organized as large inverted repeats. How such giant palindromes are generated remains largely unknown. Recent studies of a palindrome in the ciliate Tetrahymena suggest a novel mechanism that requires chromosome breakage next to short inverted repeats. The prevalence of short inverted repeats in eukaryotic genomes raises the interesting possibility that this process may occur widely as a response to chromosome damage. Here we demonstrate that in Saccharomyces cerevisiae, large DNA palindromes are formed efficiently, probably by intramolecular recombination, when a double-strand break is introduced next to short inverted repeats. These results suggest a general mechanism for large palindromic DNA formation and reveal an important new source of genome instability resulting from chromosome breakage at selective sites.			Butler, DK (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013293] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01NIHGM26210] Funding Source: Medline; NIGMS NIH HHS [F32 GM13293, F32 GM1434] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEVERLEY SM, 1984, CELL, V38, P431, DOI 10.1016/0092-8674(84)90498-7; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BUTLER DK, 1995, MOL CELL BIOL, V15, P7117; CARROLL SM, 1987, MOL CELL BIOL, V7, P1740, DOI 10.1128/MCB.7.5.1740; CARROLL SM, 1988, MOL CELL BIOL, V8, P1525, DOI 10.1128/MCB.8.4.1525; COCKBURN AF, 1978, CHROMOSOMA, V70, P19, DOI 10.1007/BF00292212; DORSEY M, 1992, GENETICS, V132, P943; ENGBERG J, 1976, J MOL BIOL, V104, P455, DOI 10.1016/0022-2836(76)90281-3; Fan QC, 1996, MOL CELL BIOL, V16, P1267; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; FORD M, 1985, P NATL ACAD SCI USA, V82, P3370, DOI 10.1073/pnas.82.10.3370; FRIED M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P143, DOI 10.1016/0167-4781(91)90095-4; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; Grondin K, 1996, MOL CELL BIOL, V16, P3587; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HYRIEN O, 1988, EMBO J, V7, P407, DOI 10.1002/j.1460-2075.1988.tb02828.x; KAFATOS FC, 1985, TRENDS GENET, V1, P301, DOI 10.1016/0168-9525(85)90119-2; KARRER KM, 1976, J MOL BIOL, V104, P421, DOI 10.1016/0022-2836(76)90280-1; KOSHLAND D, 1987, CELL, V48, P801, DOI 10.1016/0092-8674(87)90077-8; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; KUNES S, 1990, GENETICS, V124, P67; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; MA C, 1988, MOL CELL BIOL, V8, P2316, DOI 10.1128/MCB.8.6.2316; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; NALBANTOGLU J, 1986, NUCLEIC ACIDS RES, V14, P8361, DOI 10.1093/nar/14.21.8361; OUELLETTE M, 1991, EMBO J, V10, P1009, DOI 10.1002/j.1460-2075.1991.tb08035.x; RAGHURAMAN MK, 1994, GENE DEV, V8, P554, DOI 10.1101/gad.8.5.554; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH KA, 1992, P NATL ACAD SCI USA, V89, P5427, DOI 10.1073/pnas.89.12.5427; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; VOGT VM, 1976, J MOL BIOL, V106, P567, DOI 10.1016/0022-2836(76)90252-7; WALTON JD, 1986, CELL, V46, P857, DOI 10.1016/0092-8674(86)90067-X; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WINDLE BE, 1992, MUTAT RES, V276, P199, DOI 10.1016/0165-1110(92)90009-X; YASUDA LF, 1991, CELL, V67, P505, DOI 10.1016/0092-8674(91)90525-4	39	69	70	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1115	1122		10.1016/S0092-8674(00)81805-X	http://dx.doi.org/10.1016/S0092-8674(00)81805-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978615	Bronze			2022-12-01	WOS:A1996VY44700016
J	Ryan, K; Garrett, N; Mitchell, A; Gurdon, JB				Ryan, K; Garrett, N; Mitchell, A; Gurdon, JB			Eomesodermin, a key early gene in Xenopus mesoderm differentiation	CELL			English	Article							MAJOR DEVELOPMENTAL TRANSITION; MYOD EXPRESSION; BRACHYURY GENE; EARLY RESPONSE; VEGETAL CELLS; EARLY EMBRYOS; ACTIN GENES; INDUCTION; HOMOLOG; TRANSCRIPTION	Eomesodermin (Eomes) is a novel Xenopus T-domain gene. In normal development, it is expressed in mesodermal cells in a ventral-to-dorsal gradient of increasing concentration. It reaches its peak expression 1-2 hr before any other known panmesodermal gene. It is strongly inducible by normal vegetal cells and by mesoderm-inducing factors. Ectopic expression of Eomes in animal caps induces the transcription of nearly all mesodermal genes in a concentration-dependent way. Overexpression of Eomes dorsalizes ventral mesoderm, inducing gsc and changing cell fate to muscle and notochord. Blocking the function of Eomes causes gastrulation arrest and defective mesoderm-dependent gene activation. We propose that Eomes fulfills an essential function in initiating mesoderm differentiation and in determining mesodermal cell fate.			Ryan, K (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 1QR, ENGLAND.			GURDON, JOHN/0000-0002-5621-3799				ALTABA ARI, 1992, DEVELOPMENT, V116, P81; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BOLCE ME, 1993, DEV BIOL, V160, P413, DOI 10.1006/dbio.1993.1317; Bracket J., 1977, Current Topics Dev Biol, V11, P133, DOI 10.1016/S0070-2153(08)60745-0; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; BULFONE A, 1995, NEURON, V15, P63, DOI 10.1016/0896-6273(95)90065-9; CARNAC G, 1996, IN PRESS DEVELOPMENT; CASCIO S, 1987, DEVELOPMENT, V100, P297; CASCIO S, 1986, UCLA S MOL CELL BIOL, V51, P195; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; Conlon FL, 1996, DEVELOPMENT, V122, P2427; Culling C. F. A., 1963, HDB HISTOPATHOLOGICA; CUNLIFFE V, 1994, EMBO J, V13, P349, DOI 10.1002/j.1460-2075.1994.tb06268.x; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1994, J BIOL CHEM, V269, P6259; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GERHART JC, 1989, DEVELOPMENT S, V109, P37; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; GURDON JB, 1992, SEMIN DEV BIOL, V3, P255; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Holland PWH, 1995, DEVELOPMENT, V121, P4283; HOPWOOD ND, 1991, DEVELOPMENT, V111, P551; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; ISAACS HV, 1992, DEVELOPMENT, V114, P711; JONES EA, 1987, DEVELOPMENT, V101, P557; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; KRIEG PA, 1991, METHODS GENE TECHNOL, V1, P35; LEMAIRE P, 1993, CR ACAD SCI III-VIE, V316, P938; LEMAIRE P, 1994, DEVELOPMENT, V120, P1191; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1977, Current Topics Dev Biol, V11, P115, DOI 10.1016/S0070-2153(08)60744-9; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Pasteels J. J., 1964, Advances in Morphogenesis, V3, P363; RAO Y, 1994, GENE DEV, V8, P939, DOI 10.1101/gad.8.8.939; ReemKalma Y, 1995, P NATL ACAD SCI USA, V92, P12141, DOI 10.1073/pnas.92.26.12141; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1985, DIFFERENTIATION, V29, P109, DOI 10.1111/j.1432-0436.1985.tb00302.x; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; STENNARD F, 1996, IN PRESS DEVELOPMENT; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WAKEFIELD L, 1983, EMBO J, V2, P1613, DOI 10.1002/j.1460-2075.1983.tb01632.x; WORMINGTON WM, 1983, DEV BIOL, V99, P248, DOI 10.1016/0012-1606(83)90273-7	69	210	215	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 13	1996	87	6					989	1000		10.1016/S0092-8674(00)81794-8	http://dx.doi.org/10.1016/S0092-8674(00)81794-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978604	Bronze			2022-12-01	WOS:A1996VY44700005
J	Chardin, P; Paris, S; Antonny, B; Robineau, S; BeraudDufour, S; Jackson, CL; Chabre, M				Chardin, P; Paris, S; Antonny, B; Robineau, S; BeraudDufour, S; Jackson, CL; Chabre, M			A human exchange factor for ARF contains Sec7- and pleckstrin-homology domains	NATURE			English	Article							ADP-RIBOSYLATION FACTOR; GUANINE-NUCLEOTIDE; BREFELDIN-A; BINDING-SITE; PROTEIN; APPARATUS; ENCODES; CELL	THE small G protein ARF1 is involved in the coating of vesicles that bud from the Golgi compartments(1,2). Its activation is controlled by as-yet unidentified guanine-nucleotide exchange factors(3,4). Gea1, the first ARF exchange factor to be discovered in yeast(5), is a large protein containing a domain of homology with Sec7, another yeast protein that is also involved in secretion(6) Here we characterized a smaller human protein (relative molecular mass 47K) named ARNO, which contains a central Sec7 domain that promotes guanine-nucleotide exchange on ARF1. ARNO also contains an amino-terminal coiled-coil motif and a carboxy-terminal pleckstrin-homology (PH) domain. The PH domain mediates an enhancement of ARNO exchange activity by negatively charged phospholipid vesicles supplemented with phosphatidylinositol bisphosphate. The exchange activity of ARNO is not inhibited by brefeldin A, an agent known to block vesicular transport and inhibit the exchange activity on ARF1 in cell extracts(7,8). This suggests that a regulatory component which is sensitive to brefeldin A associates with ARNO in vivo, possibly through the amino-terminal coiled-coil. We propose that other proteins with a Sec7 domain regulate different members of the ARF family.	CEA SACLAY,SERV BIOCHIM & GENET MOL,F-91191 GIF SUR YVETTE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay	Chardin, P (corresponding author), CNRS,INST PHARMACOL MOL & CELLULAIRE,660 ROUTE LUCIOLES,F-06560 VALBONNE,FRANCE.		Jackson, Catherine/T-5688-2019; Jackson, Catherine/A-3421-2013; Antonny, Bruno/ABH-7434-2020; BERAUD-DUFOUR, Sophie/M-4641-2016	Jackson, Catherine/0000-0002-0843-145X; Antonny, Bruno/0000-0002-9166-8668; BERAUD-DUFOUR, Sophie/0000-0002-0062-6842				ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; PORFIRI E, 1994, J BIOL CHEM, V269, P2262; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x	19	406	418	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					481	484		10.1038/384481a0	http://dx.doi.org/10.1038/384481a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945478				2022-12-01	WOS:A1996VW68700068
J	Kotzbauer, PT; Lampe, PA; Heuckeroth, RO; Golden, JP; Creedon, DJ; Johnson, EM; Milbrandt, J				Kotzbauer, PT; Lampe, PA; Heuckeroth, RO; Golden, JP; Creedon, DJ; Johnson, EM; Milbrandt, J			Neurturin, a relative of glial-cell-line-derived neurotrophic factor	NATURE			English	Article							MIDBRAIN DOPAMINERGIC-NEURONS; NERVE GROWTH-FACTOR; IN-VIVO; SYMPATHETIC NEURONS; SURVIVAL FACTOR; MOTOR-NEURONS; GDNF; DEATH; SYSTEM	THE normal development of the vertebrate nervous system entails the death of 30-70% of the neurons originally generated in most neuronal populations(1), This naturally occurring cell death is regulated by specific neurotrophic factors that promote neuronal survival and which are produced in limiting quantities by target cells, glial cells and neurons. These factors are also of potential utility as therapeutic agents for neurodegenerative diseases(2). Here we describe the purification and cloning of a new neurotrophic factor, identified on the basis of its ability to support the survival of sympathetic neurons in culture, This factor, neurturin, is structurally related to glial-cell-line-derived neurotrophic factor (GDNF)(3). These factors can each activate the MAP kinase signalling pathway in cultured sympathetic neurons and support the survival of sympathetic neurons, as well as of sensory neurons of the nodose and dorsal root ganglia, Thus, neurturin and GDNF together now define a new family of neurotrophic factors.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Lampe, Patricia/AAH-9545-2020	Milbrandt, Jeffrey/0000-0002-5477-7689; Golden, Judith/0000-0002-5168-8525; Heuckeroth, Robert/0000-0002-3282-1765				BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BORNSTEIN MB, 1958, LAB INVEST, V7, P134; BOWENKAMP KE, 1995, J COMP NEUROL, V355, P479, DOI 10.1002/cne.903550402; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAY ML, 1990, J BIOL CHEM, V265, P15253; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; HEFTI F, 1994, J NEUROBIOL, V25, P1418, DOI 10.1002/neu.480251109; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOFFER BJ, 1994, NEUROSCI LETT, V182, P107, DOI 10.1016/0304-3940(94)90218-6; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOTZBAUER PT, 1994, NEURON, V12, P763, DOI 10.1016/0896-6273(94)90329-8; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; OPPENHEIM RW, 1992, J NEUROBIOL, V23, P1111, DOI 10.1002/neu.480230903; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; ZUM AD, 1994, NEUROREPORT, V6, P113	30	619	681	1	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					467	470		10.1038/384467a0	http://dx.doi.org/10.1038/384467a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945474				2022-12-01	WOS:A1996VW68700064
J	Yamagata, K; Oda, N; Kaisaki, PJ; Menzel, S; Furuta, H; Vaxillaire, M; Southam, L; Cox, RD; Lathrop, GM; Boriraj, VV; Chen, XN; Cox, NJ; Oda, Y; Yano, H; LeBeau, MM; Yamada, S; Nishigori, H; Takeda, J; Fajans, SS; Hattersley, AT; Iwasaki, N; Hansen, T; Pedersen, O; Polonsky, KS; Turner, RC; Velho, G; Chevre, JC; Froguel, P; Bell, GI				Yamagata, K; Oda, N; Kaisaki, PJ; Menzel, S; Furuta, H; Vaxillaire, M; Southam, L; Cox, RD; Lathrop, GM; Boriraj, VV; Chen, XN; Cox, NJ; Oda, Y; Yano, H; LeBeau, MM; Yamada, S; Nishigori, H; Takeda, J; Fajans, SS; Hattersley, AT; Iwasaki, N; Hansen, T; Pedersen, O; Polonsky, KS; Turner, RC; Velho, G; Chevre, JC; Froguel, P; Bell, GI			Mutations in the hepatocyte nuclear factor-1 alpha gene in maturity-onset diabetes of the young (MODY3)	NATURE			English	Article							CHROMOSOME 12Q; HNF1; LOCALIZATION; HNF-1-ALPHA; MELLITUS; SUBTYPE; CELL	THE disease non-insulin-dependent (type 2) diabetes mellitus (NIDDM) is characterized by abnormally high blood glucose resulting from a relative deficiency of insulin(1). It affects about 2% of the world's population and treatment of diabetes and its complications are an increasing health-care burden(2). Genetic factors are important in the aetiology of NIDDM, and linkage studies are starting to Localize some of the genes that influence the development of this disorder(3). Maturity-onset diabetes of the young (MODY), a single-gene disorder responsible for 2-5% of NIDDM, is characterized by autosomal dominant inheritance and an age of onset of 25 years or younger(4-6). MODY genes have been localized to chromosomes 7, 12 and 20 (refs 5, 7, 8) and clinical studies indicate that mutations in these genes are associated with abnormal patterns of glucose-stimulated insulin secretion(1,9). The gene on chromosome 7 (MODY2) encodes the glycolytic enzyme glucokinase(5) which plays a key role in generating the metabolic signal for insulin secretion and in integrating hepatic glucose uptake. Here we show that subjects with the MODY3-form of NIDDM have mutations in the gene encoding hepatocyte nuclear factor-1 alpha (HNF-1 alpha, which is encoded by the gene TCF1). HNF-1 alpha is a transcription factor that helps in the tissue-specific regulation of the expression of several liver genes(10,11) and also functions as a weak transactivator of the rat insulin-I gene(12).	UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND; INST PASTEUR,CNRS,EP10,F-59019 LILLE,FRANCE; GUNMA UNIV,INST MOL & CELLULAR REGULAT,MAEBASHI,GUMMA 371,JAPAN; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV EXETER,POSTGRAD MED SCH,DEPT VASC MED & DIABET RES,EXETER EX2 5AX,DEVON,ENGLAND; TOKYO WOMENS MED COLL,CTR DIABET,TOKYO 162,JAPAN; STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK; RADCLIFFE INFIRM,DIABET RES LABS,OXFORD OX2 6HE,ENGLAND; HOP ST LOUIS,INSERM,U358,F-75010 PARIS,FRANCE	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Oxford; Wellcome Centre for Human Genetics; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Gunma University; University of Michigan System; University of Michigan; University of Exeter; Tokyo Women's Medical University; Steno Diabetes Center; Radcliffe Infirmary; University of Oxford; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Velho, Gilberto/Q-6724-2017; Pedersen, Oluf/AAG-8015-2020; FROGUEL, Philippe/O-6799-2017; Menzel, Stephan/U-6906-2019; Chevre, Jean-Claude/C-3943-2015	Velho, Gilberto/0000-0001-8811-363X; FROGUEL, Philippe/0000-0003-2972-0784; Chevre, Jean-Claude/0000-0002-5329-5231; Menzel, Stephan/0000-0002-1590-9108; Hattersley, Andrew/0000-0001-5620-473X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BACH I, 1992, NUCLEIC ACIDS RES, V20, P4199, DOI 10.1093/nar/20.16.4199; BACH I, 1990, GENOMICS, V8, P155, DOI 10.1016/0888-7543(90)90238-P; BACH I, 1993, EMBO J, V12, P4229, DOI 10.1002/j.1460-2075.1993.tb06107.x; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BYME MM, 1996, AM J PHYSIOL, V270, pE572; Byrne MM, 1996, DIABETES, V45, P1503, DOI 10.2337/diabetes.45.11.1503; CHUMAKOV IM, 1995, NATURE, V377, P175; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HORLEIN A, 1993, BIOL CHEM H-S, V374, P419, DOI 10.1515/bchm3.1993.374.7-12.419; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Kenny S.J., 1995, NIH PUBLICATION, P47; KOM B, 1992, HUM MOL GENET, V1, P235; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LEDERMANN HM, 1995, LANCET, V345, P648, DOI 10.1016/S0140-6736(95)90548-0; LESAGE S, 1995, DIABETES, V44, P1243, DOI 10.2337/diabetes.44.10.1243; Mahtani MM, 1996, NAT GENET, V14, P90, DOI 10.1038/ng0996-90; McCarty D, 1994, DIABETES 1994 2010 G; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MENZEL S, 1995, DIABETES, V44, P1408, DOI 10.2337/diabetes.44.12.1408; POLONSKY KS, 1995, DIABETES, V44, P705, DOI 10.2337/diabetes.44.6.705; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; VAXILLAIRE M, 1995, NAT GENET, V9, P418, DOI 10.1038/ng0495-418; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	30	950	981	0	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					455	458		10.1038/384455a0	http://dx.doi.org/10.1038/384455a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945470	Green Submitted			2022-12-01	WOS:A1996VW68700060
J	Feng, QH; Moran, JV; Kazazian, HH; Boeke, JD				Feng, QH; Moran, JV; Kazazian, HH; Boeke, JD			Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition	CELL			English	Article							GROUP-II INTRON; YEAST MITOCHONDRIAL-DNA; PRIMED REVERSE TRANSCRIPTION; HUMAN TRANSPOSABLE ELEMENT; ESCHERICHIA-COLI-CELLS; REPAIR ENZYME HAP1; MAURICEVILLE PLASMID; KINETOPLAST DNA; EXONUCLEASE-III; RIBONUCLEASE-H	Human L1 elements are highly abundant poly(A) (non-LTR) retrotransposons whose second open reading frame (ORF2) encodes a reverse transcriptase (RT). We have identified an endonuclease (EN) domain at the L1 ORF2 N-terminus that is highly conserved among poly(A) retrotransposons and resembles the apurinic/apyrimidinic (AP) endonucleases. Purified L1 EN protein (L1 ENp) makes 5'-PO4, 3'-OH nicks in supercoiled plasmids, shows no preference for AP sites, and preferentially cleaves sequences resembling L1 in vivo target sequences. Mutations in conserved amino acid residues of L1 EN abolish its nicking activity and eliminate L1 retrotransposition. We propose that L1 EN cleaves the target site for L1 insertion and primes reverse transcription.	JOHNS HOPKINS UNIV,DEPT MOL BIOL & GENET,SCH MED,BALTIMORE,MD 21205; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104	Johns Hopkins University; University of Pennsylvania					NCI NIH HHS [CA-16519] Funding Source: Medline; NIGMS NIH HHS [GM-45398] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABAD P, 1989, P NATL ACAD SCI USA, V86, P8887, DOI 10.1073/pnas.86.22.8887; BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; BARZILAY G, 1995, NAT STRUCT BIOL, V2, P561, DOI 10.1038/nsb0795-561; BOEKE JD, 1996, IN PRESS RETROVIRUSE; BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; BUCHETON A, 1984, CELL, V38, P153, DOI 10.1016/0092-8674(84)90536-1; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; DOMBROSKI BA, 1994, MOL CELL BIOL, V14, P4485, DOI 10.1128/MCB.14.7.4485; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; DROLET M, 1994, J BIOL CHEM, V269, P2068; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; HOHJOH H, 1990, NUCLEIC ACIDS RES, V18, P4099, DOI 10.1093/nar/18.14.4099; Hohjoh H, 1996, EMBO J, V15, P630, DOI 10.1002/j.1460-2075.1996.tb00395.x; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; KINSEY JA, 1990, GENETICS, V126, P317; KITCHIN PA, 1986, J BIOL CHEM, V261, P1302; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; LEHMAN IR, 1974, SCIENCE, V186, P790; LILLY DMJ, 1981, NUCLEIC ACIDS RES, V9, P1271, DOI 10.1093/nar/9.6.1271; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; LUAN DD, 1995, MOL CELL BIOL, V15, P3882; Maniatis T., 1982, MOL CLONING; MARTIN F, 1995, J MOL BIOL, V247, P49, DOI 10.1006/jmbi.1994.0121; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MIKI Y, 1992, CANCER RES, V52, P643; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; OEFNER C, 1986, J MOL BIOL, V192, P605, DOI 10.1016/0022-2836(86)90280-9; PETTIJOHN DE, 1980, P NATL ACAD SCI-BIOL, V77, P1331, DOI 10.1073/pnas.77.3.1331; PRICE PA, 1975, J BIOL CHEM, V250, P1981; ROBERTS RJ, 1994, BIOSCIENCE REP, V14, P103, DOI 10.1007/BF01240243; SCHWARZSOMMER Z, 1987, EMBO J, V6, P3873, DOI 10.1002/j.1460-2075.1987.tb02727.x; SCOTT A F, 1987, Genomics, V1, P113, DOI 10.1016/0888-7543(87)90003-6; SHIMAMOTO T, 1995, J BACTERIOL, V177, P264, DOI 10.1128/jb.177.1.264-267.1995; SINDEN RR, 1980, CELL, V21, P773, DOI 10.1016/0092-8674(80)90440-7; SINDEN RR, 1981, P NATL ACAD SCI-BIOL, V78, P224, DOI 10.1073/pnas.78.1.224; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; STELLWAGEN NC, 1983, BIOCHEMISTRY-US, V22, P6186, DOI 10.1021/bi00295a023; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J; WANG H, 1993, J BIOL CHEM, V268, P18951; WEISS B, 1976, J BIOL CHEM, V251, P1896; WOODSAMUELS P, 1989, GENOMICS, V4, P290, DOI 10.1016/0888-7543(89)90332-7; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; Yang J, 1996, NATURE, V381, P332, DOI 10.1038/381332a0; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	58	828	851	2	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					905	916		10.1016/S0092-8674(00)81997-2	http://dx.doi.org/10.1016/S0092-8674(00)81997-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945517	hybrid			2022-12-01	WOS:A1996VV77400016
J	Neumann, S; Doubell, TP; Leslie, T; Woolf, CJ				Neumann, S; Doubell, TP; Leslie, T; Woolf, CJ			Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons	NATURE			English	Article							NERVE GROWTH-FACTOR; RAT SPINAL-CORD; SUBSTANCE-P; DORSAL HORN; RECEPTOR ACTIVATION; FACTOR CONTRIBUTES; MESSENGER-RNAS; INJURY; REFLEX; SENSITIZATION	PAIN is normally evoked only by stimuli that are sufficiently intense to activate high-threshold A delta and C sensory fibres, which relay the signal tp the spinal cord, Peripheral inflammation leads to profoundly increased pain sensitivity: noxious stimuli generate a greater response and stimuli that are normally innocuous Elicit pain. Inflammation increases the sensitivity of the peripheral terminals of A delta and C fibres at the site of inflammation(1). It also increases the excitability of spinal cord neurons(2,3), which now amplify all sensory inputs including the normally innocuous tactile stimuli that are conveyed by low-threshold A beta fibres. This central sensitization has been attributed to the enhanced activity of C fibers(4), which increase the excitability of their postsynaptic targets by releasing glutamate and the neuropeptide substance P5-7. Here we show that inflammation results in A beta fibres also acquiring the capacity to increase the excitability of spinal cord neurons. This is due fa a phenotypic switch in a subpopulation of these fibres so that they, like C-fibres, now express substance P. A beta fibres thus appear to contribute to inflammatory hypersensitivity by switching their phenotype to one resembling pain fibres, thereby enhancing synaptic transmission in the spinal cord and exaggerating the central response to innocuous stimuli.			Neumann, S (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.		Woolf, Clifford/A-9784-2010	doubell, timothy/0000-0003-1054-5592				AVERILL S, 1995, EUR J NEUROSCI, V7, P1484, DOI 10.1111/j.1460-9568.1995.tb01143.x; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; DONNERER J, 1992, NEUROSCIENCE, V49, P693, DOI 10.1016/0306-4522(92)90237-V; FITZGERALD M, 1985, BRAIN RES, V332, P131, DOI 10.1016/0006-8993(85)90396-8; HEATH MJS, 1994, J NEUROPHYSIOL, V72, P1192, DOI 10.1152/jn.1994.72.3.1192; LESLIE TA, 1995, NEUROSCIENCE, V67, P753, DOI 10.1016/0306-4522(95)00101-N; LEWIN GR, 1994, EUR J NEUROSCI, V6, P1903, DOI 10.1111/j.1460-9568.1994.tb00581.x; MA QP, 1995, J PHYSIOL-LONDON, V486, P769, DOI 10.1113/jphysiol.1995.sp020852; Ma QP, 1996, PAIN, V67, P97, DOI 10.1016/0304-3959(96)03105-3; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; MCMAHON SB, 1995, NAT MED, V1, P774, DOI 10.1038/nm0895-774; NOGUCHI K, 1995, J NEUROSCI, V15, P7633; Reeh PW, 1994, CELLULAR MECH SENSOR, V79, P119; ROBERTSON B, 1991, J NEUROCYTOL, V20, P387, DOI 10.1007/BF01355535; THOMPSON SWN, 1990, EUR J NEUROSCI, V2, P638, DOI 10.1111/j.1460-9568.1990.tb00453.x; THOMPSON SWN, 1994, J NEUROSCI, V14, P3672; TOREBJORK HE, 1992, J PHYSIOL-LONDON, V448, P765, DOI 10.1113/jphysiol.1992.sp019069; URBAN L, 1984, BRAIN RES, V290, P336, DOI 10.1016/0006-8993(84)90952-1; VERGE VMK, 1995, J NEUROSCI, V15, P2081, DOI 10.1523/JNEUROSCI.15-03-02081.1995; WARDEN MK, 1988, J COMP NEUROL, V272, P90, DOI 10.1002/cne.902720107; WOOLF CJ, 1986, J NEUROSCI, V6, P1433; WOOLF CJ, 1990, J NEUROSCI, V10, P2717; WOOLF CJ, 1994, PAIN, V58, P141, DOI 10.1016/0304-3959(94)90195-3; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; WOOLF CJ, 1987, J COMP NEUROL, V261, P105, DOI 10.1002/cne.902610109; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; WOOLF CJ, 1994, NEUROSCIENCE, V62, P327, DOI 10.1016/0306-4522(94)90366-2; XU XJ, 1992, EUR J PHARMACOL, V216, P337, DOI 10.1016/0014-2999(92)90428-7	28	426	438	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					360	364		10.1038/384360a0	http://dx.doi.org/10.1038/384360a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934522				2022-12-01	WOS:A1996VV27100050
J	Elder, AG; ODonnell, B; McCruden, EAB; Symington, IS; Carman, WF				Elder, AG; ODonnell, B; McCruden, EAB; Symington, IS; Carman, WF			Incidence and recall of influenza in a cohort of Glasgow healthcare workers during the 1993-4 epidemic: Results of serum testing and questionnaire	BRITISH MEDICAL JOURNAL			English	Article									UNIV GLASGOW,INST VIROL,GLASGOW G11 5JR,LANARK,SCOTLAND; STOBHILL NHS TRUST,GLASGOW OCCUPAT HLTH,GLASGOW G1 1JA,LANARK,SCOTLAND; W GLASGOW HOSP UNIV NHS TRUST,DEPT CLIN MICROBIOL,GLASGOW,LANARK,SCOTLAND	University of Glasgow; University of Glasgow								*ADV COMM IMM PRAC, 1994, MMWR            0421, P44; FLEMING DM, 1995, BRIT MED J, V311, P290, DOI 10.1136/bmj.311.7000.290; *JOINT COMM VACC I, 1992, IMM INF DIS; POTTER J, IN PRESS J INF DIS; WOOD JM, 1994, VACCINE, V12, P167, DOI 10.1016/0264-410X(94)90056-6	5	171	189	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1241	1242		10.1136/bmj.313.7067.1241	http://dx.doi.org/10.1136/bmj.313.7067.1241			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939114	Green Published			2022-12-01	WOS:A1996VU20800023
J	Fletcher, CF; Lutz, CM; OSullivan, TN; Shaughnessy, JD; Hawkes, R; Frankel, WN; Copeland, NG; Jenkins, NA				Fletcher, CF; Lutz, CM; OSullivan, TN; Shaughnessy, JD; Hawkes, R; Frankel, WN; Copeland, NG; Jenkins, NA			Absence epilepsy in tottering mutant mice is associated with calcium channel defects	CELL			English	Article							TYROSINE-HYDROXYLASE GENE; PROGRAMMED CELL-DEATH; CA2+ CHANNELS; INTRACELLULAR CALCIUM; SELECTIVE INCREASE; CENTRAL NEURONS; PURKINJE-CELLS; SPIKE-WAVE; MOUSE; EXPRESSION	Mutations at the mouse tottering (tg) locus cause a delayed-onset, recessive neurological disorder resulting in ataxia, motor seizures, and behavioral absence seizures resembling petit mal epilepsy in humans. A more severe allele, leaner (tg(la)), also shows a slow, selective degeneration of cerebellar neurons. By positional cloning, we have identified an alpha(1A) voltage-sensitive calcium channel gene that is mutated in tg and tg(la) mice. The alpha(1A) gene is widely expressed in the central nervous system with prominent, uniform expression in the cerebellum. alpha(1A) expression does not mirror the localized pattern of cerebellar degeneration observed in tg(la) mice, providing evidence for regional differences in biological function of alpha(1A) channels. These studies define the first mutations in a mammalian central nervous system-specific voltage-sensitive calcium channel and identify the first gene involved in absence epilepsy.	JACKSON LAB,BAR HARBOR,ME 04609; UNIV CALGARY,FAC MED,DEPT ANAT,CALGARY,AB T2N 4N1,CANADA; UNIV CALGARY,FAC MED,NEUROSCI RES GRP,CALGARY,AB T2N 4N1,CANADA	Jackson Laboratory; University of Calgary; University of Calgary	Fletcher, CF (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702, USA.		Hawkes, Richard/F-7971-2011					ADACHI K, 1975, IRCS (International Research Communications System) Medical Science Library Compendium, V3, P329; ANDERSON VE, 1991, GENETIC STRATEGIES E, P89; ANNEGERS JF, 1991, GENETIC STRATEGIES E, P139; AUSTIN MC, 1992, MOL BRAIN RES, V15, P227, DOI 10.1016/0169-328X(92)90113-P; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHAUDHARI N, 1992, J BIOL CHEM, V267, P25636; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; CHRISTAKOS S, 1987, METHOD ENZYMOL, V139, P534; de Curtis M, 1994, Funct Neurol, V9, P307; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; GALLI C, 1995, J NEUROSCI, V15, P1172; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GREEN MC, 1962, J HERED, V53, P79; Green MC., 1989, GENETIC VARIANTS STR, P12; HAUSER JF, 1991, GENETIC STRATEGIES E, P45; HAWKES R, 1991, PROG NEUROBIOL, V36, P309, DOI 10.1016/0301-0082(91)90004-K; HECKROTH JA, 1994, BRAIN RES, V658, P93, DOI 10.1016/S0006-8993(09)90014-2; HELLAR AH, 1983, EPILEPSIA, V2, P25; HERRUP K, 1982, NEUROSCIENCE, V7, P2185, DOI 10.1016/0306-4522(82)90129-4; HESS EJ, 1991, NEURON, V6, P123, DOI 10.1016/0896-6273(91)90127-L; HILLE B, 1992, IONIC CHANNELS EXCIT, P83; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KATER SB, 1991, J NEUROSCI, V11, P891; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KOELLER DM, 1995, GENOMICS, V28, P508, DOI 10.1006/geno.1995.1182; KOH JY, 1992, BRAIN RES, V587, P233, DOI 10.1016/0006-8993(92)91002-V; KRAWCZAK M, 1992, HUM GENET, V90, P41; LENNON VA, 1995, NEW ENGL J MED, V332, P1467, DOI 10.1056/NEJM199506013322203; LEVITT P, 1981, P NATL ACAD SCI-BIOL, V78, P4630, DOI 10.1073/pnas.78.7.4630; LIMBRICK DD, 1995, BRAIN RES, V690, P145, DOI 10.1016/0006-8993(95)00552-2; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; LLINAS RR, 1989, ANN NY ACAD SCI, V560, P103, DOI 10.1111/j.1749-6632.1989.tb24084.x; MARESCAUX C, 1992, J NEURAL TRANSM-SUPP, V35, P37; MEIER H, 1971, J HERED, V62, P297, DOI 10.1093/oxfordjournals.jhered.a108176; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Nishimura Y, 1975, ADV NEUROL SCI, V19, P670; NOEBELS JL, 1979, SCIENCE, V204, P1334, DOI 10.1126/science.572084; NOEBELS JL, 1984, NATURE, V310, P409, DOI 10.1038/310409a0; NOEBELS JL, 1984, ANN NEUROL, V16, pS18, DOI 10.1002/ana.410160705; ORRENIUS S, 1994, J NEURAL TRANSM-SUPP, V43, P1; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; PTACEK LJ, 1994, CELL, V77, P863; QIAN F, 1995, GENOMICS, V28, P66, DOI 10.1006/geno.1995.1107; QIAO XX, 1991, BRAIN RES, V555, P43, DOI 10.1016/0006-8993(91)90857-R; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; ROSS ME, 1990, P NATL ACAD SCI USA, V87, P4189, DOI 10.1073/pnas.87.11.4189; RYAN SG, 1995, NAT GENET, V10, P4, DOI 10.1038/ng0595-4; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SNEAD OC, 1995, ANN NEUROL, V37, P146, DOI 10.1002/ana.410370204; Spitzer Nicholas C., 1994, Current Opinion in Neurobiology, V4, P70, DOI 10.1016/0959-4388(94)90034-5; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TANG SQ, 1993, J BIOL CHEM, V268, P13026; TESSAROLLO L, 1995, METHOD ENZYMOL, V254, P419; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; URADE Y, 1991, P NATL ACAD SCI USA, V88, P1069, DOI 10.1073/pnas.88.3.1069; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P; Volsen SG, 1995, MOL BRAIN RES, V34, P271, DOI 10.1016/0169-328X(95)00234-J; Wheeler DB, 1995, PROG BRAIN RES, V105, P65; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P3075; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	68	600	614	0	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					607	617		10.1016/S0092-8674(00)81381-1	http://dx.doi.org/10.1016/S0092-8674(00)81381-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929530	Bronze			2022-12-01	WOS:A1996VU03500004
J	Dudek, H; Datta, SR; Franke, TF; Birnbaum, MJ; Yao, RJ; Cooper, GM; Segal, RA; Kaplan, DR; Greenberg, ME				Dudek, H; Datta, SR; Franke, TF; Birnbaum, MJ; Yao, RJ; Cooper, GM; Segal, RA; Kaplan, DR; Greenberg, ME			Regulation of neuronal survival by the serine-threonine protein kinase Akt	SCIENCE			English	Article							GROWTH-FACTOR-I; MOLECULAR-CLONING; MAP KINASE; C-AKT; INSULIN; ACTIVATION; IDENTIFICATION; SYSTEM; RAS; INHIBITION	A signaling pathway was delineated by which insulin-like growth factor 1 (IGF-1) promotes the survival of cerebellar neurons. IGF-1 activation of phosphoinositide 3-kinase (PI3-K) triggered the activation of two protein kinases, the serine-threonine kinase Akt and the p70 ribosomal protein S6 kinase (p70(S6K)). Experiments with pharmacological inhibitors, as well as expression of wild-type and dominant-inhibitory forms of Akt, demonstrated that Akt but not p70(S6K) mediates PI3-K-dependent survival. These findings suggest that in the developing nervous system, Akt is a critical mediator of growth factor-induced neuronal survival.	CHILDRENS HOSP,DEPT NEUROL,DIV NEUROSCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; MCGILL UNIV,MONTREAL NEUROL INST,MONTREAL,PQ H3A 2B4,CANADA; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV SIGNAL TRANSDUCTION,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT NEUROL,BOSTON,MA 02115; DANA FARBER CANC INST,DIV MOL GENET,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; McGill University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Pennsylvania; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute				Birnbaum, Morris/0000-0001-9972-8680; Datta, Sandeep/0000-0002-8068-3862	NATIONAL CANCER INSTITUTE [R01CA018689, R01CA043855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039519] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA18689, R01 CA43855] Funding Source: Medline; NIDDK NIH HHS [DK39519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED NN, 1993, ONCOGENE, V8, P1957; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BLENIS J, 1987, J BIOL CHEM, V262, P14373; BORASIO GD, 1989, NEURON, V2, P1087; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CARSON MJ, 1993, NEURON, V10, P729, DOI 10.1016/0896-6273(93)90173-O; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DEPABLO F, 1995, TRENDS NEUROSCI, V18, P143, DOI 10.1016/0166-2236(95)93892-2; DUDEK HJ, UNPUB; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRANKE TF, UNPUB; GALLI C, 1995, J NEUROSCI, V15, P1172; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; GRAVEL C, 1987, J NEUROSCI METH, V21, P145, DOI 10.1016/0165-0270(87)90112-9; Heidenreich KA, 1996, J BIOL CHEM, V271, P9891, DOI 10.1074/jbc.271.17.9891; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Nobes CD, 1996, NEUROSCIENCE, V70, P1067, DOI 10.1016/0306-4522(95)00420-3; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Schulz JB, 1996, J NEUROSCI, V16, P4696; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; TORRESALEMAN I, 1994, J NEUROSCI RES, V39, P117, DOI 10.1002/jnr.490390202; WHITE MF, 1994, J BIOL CHEM, V269, P1; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	41	2120	2194	2	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					661	665		10.1126/science.275.5300.661	http://dx.doi.org/10.1126/science.275.5300.661			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005851				2022-12-01	WOS:A1997WF07700038
J	Wyszynski, M; Lin, J; Rao, A; Nigh, E; Beggs, AH; Craig, AM; Sheng, M				Wyszynski, M; Lin, J; Rao, A; Nigh, E; Beggs, AH; Craig, AM; Sheng, M			Competitive binding of alpha-actinin and calmodulin to the NMDA receptor	NATURE			English	Article							POSTSYNAPTIC DENSITY FRACTION; TUMOR-SUPPRESSOR PROTEIN; RAT-BRAIN; SUBUNIT; CHANNEL; MEMBRANE; NEURONS; CLONING; DOMAIN	The mechanisms by which neurotransmitter receptors are immobilized at postsynaptic sites in neurons are largely unknown. The activity of NMDA (N-methyl-D-aspartate) receptors is mechano-sensitive(1) and dependent on the integrity of actin(2), suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton, alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95, alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain. Intriguingly, NR1-alpha-actinin binding is directly antagonized by Ca2+/calmodulin. Thus alpha-actinin may play a role in both the localization of NMDA receptors and their modulation by Ca2+.	MASSACHUSETTS GEN HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT NEUROBIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801; CHILDRENS HOSP,DIV GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Illinois System; University of Illinois Urbana-Champaign; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Craig, Ann Marie/M-2054-2014	Sheng, Morgan/0000-0002-8703-5366; Beggs, Alan/0000-0001-8818-0568				BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; ISHII T, 1993, J BIOL CHEM, V268, P2836; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MILLER SG, 1985, J BIOL CHEM, V260, P9039; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1996, J NEUROSCI, V16, P2157; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q	27	508	523	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1997	385	6615					439	442		10.1038/385439a0	http://dx.doi.org/10.1038/385439a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009191				2022-12-01	WOS:A1997WF00700053
J	Song, ZW; McCall, K; Steller, H				Song, ZW; McCall, K; Steller, H			DCP-1, a Drosophila cell death protease essential for development	SCIENCE			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; POLY(ADP-RIBOSE) POLYMERASE; IL-1-BETA-CONVERTING ENZYME; GENE CED-3; CYSTEINE PROTEASES; MOLECULAR-CLONING; MAMMALIAN HOMOLOG; NERVOUS-SYSTEM; MICE DEFICIENT; APOPTOSIS	Apoptosis, a form of cellular suicide, involves the activation of CED-3-related cysteine proteases (caspases), The regulation of caspases by apoptotic signals and the precise mechanism by which they kill the cell remain unknown. In Drosophila, different death-inducing stimuli induce the expression of the apoptotic activator reaper. Cell killing by reaper and two genetically linked apoptotic activators, hid and grim, requires caspase activity. A Drosophila caspase, named Drosophila caspase-1 (DCP-1), was identified and found to be structurally and biochemically similar to Caenorhabditis elegans CED-3. Loss of zygotic DCP-1 function in Drosophila caused larval lethality and melanotic tumors, showing that this gene is essential for normal development.	MIT,DEPT BRAIN & COGNIT SCI,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)								ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ameisen JC, 1996, SCIENCE, V272, P1278, DOI 10.1126/science.272.5266.1278; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDEZALNEMR.T, 1994, J BIOL CHEM, V269, P30764; Fraser Andrea, 1993, COMMUNICATION; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LIPKE JA, 1996, J BIOL CHEM, V271, P1825; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; ROBINOW S, 1993, DEVELOPMENT, V119, P1251; Song Z., UNPUB; SPARROW J, 1978, GENETICS BIOL DROSOP; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STELLER H, 1994, NEURON, V13, P1269, DOI 10.1016/0896-6273(94)90413-8; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATSON KL, 1991, DEV GENET, V12, P173, DOI 10.1002/dvg.1020120302; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; XUE D, 1996, GENE DEV, V10, P1973; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHOU L, 1995, CURR BIOL, V5, P784, DOI 10.1016/S0960-9822(95)00155-2	61	250	259	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					536	540		10.1126/science.275.5299.536	http://dx.doi.org/10.1126/science.275.5299.536			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999799				2022-12-01	WOS:A1997WE25700046
J	Li, LM; Li, X; Francke, U; Cohen, SN				Li, LM; Li, X; Francke, U; Cohen, SN			The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer	CELL			English	Article							MULTIPLE SIGNAL-TRANSDUCTION; CELL LUNG-CANCER; OVARIAN-CANCER; FREQUENT LOSS; ALLELIC LOSS; HETEROZYGOSITY; IDENTIFICATION; DNA; CLONING; REGIONS	Recent work has identified a mouse gene (tsg101) whose inactivation in fibroblasts results in cellular transformation and the ability to produce metastatic tumors in nude mice. Here, we report that the human homolog, TSG101, which we isolated and mapped to chromosome 11, bands 15.1-15.2, a region proposed to contain tumor suppressor gene(s), is mutated at high frequency in human breast cancer. In 7 of 15 uncultured primary human breast carcinomas, intragenic deletions were shown in TSG101 genomic DNA and transcripts by gel and sequence analysis, and mutations affecting two TSG101 alleles were identified in four of these cancers. No TSG101 defects were found in matched normal breast tissue from the breast cancer patients. These findings strongly implicate TSG101 mutations in human breast cancer.	STANFORD UNIV,DEPT GENET,SCH MED,STANFORD,CA 94305; STANFORD UNIV,HOWARD HUGHES MED INST,SCH MED,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University					NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000298] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00298] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; Baffa R, 1996, CANCER RES, V56, P268; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; BOOTH PM, 1994, GENE, V146, P303, DOI 10.1016/0378-1119(94)90310-7; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BREWSTER SF, 1994, BRIT J CANCER, V70, P697, DOI 10.1038/bjc.1994.376; BYRNE JA, 1993, GENE CHROMOSOME CANC, V8, P104, DOI 10.1002/gcc.2870080207; CHEN LC, 1992, J NATL CANCER I, V84, P506, DOI 10.1093/jnci/84.7.506; COWELL JK, 1993, BRIT J CANCER, V67, P1259, DOI 10.1038/bjc.1993.235; DERRY JMJ, 1995, GENOMICS, V30, P361, DOI 10.1006/geno.1995.0031; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; FERTIPASSANTONOPOULOU A, 1991, CANCER GENET CYTOGEN, V51, P183, DOI 10.1016/0165-4608(91)90130-M; FONG KM, 1994, GENE CHROMOSOME CANC, V10, P183, DOI 10.1002/gcc.2870100306; FRANCKE U, 1986, COLD SPRING HARB SYM, V51, P855, DOI 10.1101/SQB.1986.051.01.099; FRANCKE U, 1994, CYTOGENET CELL GENET, V65, P206, DOI 10.1159/000133633; FULTS D, 1992, GENOMICS, V14, P799, DOI 10.1016/S0888-7543(05)80191-0; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1277; KARNIK P, 1995, HUM MOL GENET, V4, P1889, DOI 10.1093/hmg/4.10.1889; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KONDO M, 1994, ONCOGENE, V9, P3063; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; LI X, 1993, GENOMICS, V18, P667, DOI 10.1016/S0888-7543(05)80371-4; LI X, 1995, CYTOGENET CELL GENET, V68, P185, DOI 10.1159/000133910; LI X, 1995, CYTOGENET CELL GENET, V71, P301, DOI 10.1159/000134132; LICHY JH, 1992, CELL GROWTH DIFFER, V3, P541; LOTHE RA, 1993, GENE CHROMOSOME CANC, V7, P96, DOI 10.1002/gcc.2870070206; LUDWIG CU, 1991, INT J CANCER, V49, P661, DOI 10.1002/ijc.2910490506; MACKAY J, 1988, BRIT J CANCER, V58, P710, DOI 10.1038/bjc.1988.295; MARKLUND U, 1993, J BIOL CHEM, V268, P25671; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Miyagi Mutsuko, 1992, Human Molecular Genetics, V1, P705, DOI 10.1093/hmg/1.9.705; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; NEGRINI M, 1995, CANCER RES, V55, P3003; Phillips KK, 1996, CANCER RES, V56, P1222; PRESTI JC, 1991, CANCER RES, V51, P5405; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROOS G, 1993, LEUKEMIA, V7, P1538; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P10080; SELLAR GC, 1994, GENOMICS, V19, P221, DOI 10.1006/geno.1994.1051; SMITH RC, 1995, J UROLOGY, V153, P1684, DOI 10.1016/S0022-5347(01)67504-9; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; TAKITA K, 1992, GENOMICS, V13, P1296, DOI 10.1016/0888-7543(92)90049-X; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; WEITZEL JN, 1994, GYNECOL ONCOL, V55, P245, DOI 10.1006/gyno.1994.1285; WINQVIST R, 1995, CANCER RES, V55, P2660; WINQVIST R, 1993, CANCER RES, V53, P4486; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; ZHANG RD, 1991, INVAS METAST, V11, P204	57	129	147	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					143	154		10.1016/S0092-8674(00)81866-8	http://dx.doi.org/10.1016/S0092-8674(00)81866-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019400	Bronze			2022-12-01	WOS:A1997WC56900017
J	Shirakawa, T; Enomoto, T; Shimazu, S; Hopkin, JM				Shirakawa, T; Enomoto, T; Shimazu, S; Hopkin, JM			The inverse association between tuberculin responses and atopic disorder	SCIENCE			English	Article							SKIN-TEST REACTIVITY; ASTHMA; IMMUNITY; PREVALENCE; HYPERSENSITIVITY; INDUCTION; CHILDREN; CELLS	Human immune responses are heterogeneous and may involve antagonism between T helper (T-H) lymphocyte subsets and their cytokines. Atopy is characterized by immediate immunoglobulin E (IgE)-mediated hypersensitivity to agents such as dust mites and pollen, and it underlies the increasingly prevalent disorder asthma. Among Japanese schoolchildren, there was a strong inverse association between delayed hypersensitivity to Mycobacterium tuberculosis and atopy. Positive tuberculin responses predicted a lower incidence of asthma, lower serum IgE levels, and cytokine profiles biased toward T(H)1 type. Exposure and response to M. tuberculosis may, by modification of immune profiles, inhibit atopic disorder.	CHURCHILL HOSP, OSLER CHEST UNIT, LUNG RES LAB, OXFORD OX3 7LJ, ENGLAND; WAKAYAMA MED CTR, JAPANESE RED CROSS SOC, DEPT OTOLARYNGOL, WAKAYAMA, JAPAN; NATL WAKAYAMA HOSP, DEPT PEDIAT, WAKAYAMA, JAPAN	University of Oxford								Aebischer I, 1996, ADV IMMUNOL, V61, P341, DOI 10.1016/S0065-2776(08)60871-8; Baker RW, 1996, QJM-INT J MED, V89, P387; BRUCE IN, 1993, Q J MED, V86, P425; Burnet M., 1972, NATURAL HIST INFECT; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CARBALLIDO JM, 1992, EUR J IMMUNOL, V22, P1357, DOI 10.1002/eji.1830220605; COOPER AM, 1995, IMMUNOLOGY, V84, P423; DOLL R, 1992, AM J PUBLIC HEALTH, V82, P933, DOI 10.2105/AJPH.82.7.933; DONCKIER V, 1994, J IMMUNOL, V153, P2361; FEARONDT, 1996, SCIENCE, V270, P50; FINE PEM, 1994, LANCET, V344, P1245, DOI 10.1016/S0140-6736(94)90748-X; GALBRAITH NS, 1972, BMJ-BRIT MED J, V1, P647, DOI 10.1136/bmj.1.5801.647; GRANGE JM, 1996, Q J MED, V89, P387; Holt PG, 1996, TOXICOL LETT, V86, P205, DOI 10.1016/0378-4274(96)03692-2; Hopkin JM, 1995, PEDIAT ALLERG IMM-UK, V6, P139, DOI 10.1111/j.1399-3038.1995.tb00273.x; ISHIZAKA K, 1971, Clinical Allergy, V1, P9, DOI 10.1111/j.1365-2222.1971.tb02444.x; *JAP MIN HLTH WELF, 1995, TRENDS HLTH WELF JAP; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021; LARSEN FS, 1993, MONOGR ALLERGY, V31, P9; MACKANESS GB, 1974, J EXP MED, V139, P1540, DOI 10.1084/jem.139.6.1540; MORRISONSMITH J, 1981, POSTGRAD MED J, V57, P774, DOI 10.1136/pgmj.57.674.774; OETTINGER T, 1995, INFECT IMMUN, V63, P4613, DOI 10.1128/IAI.63.12.4613-4618.1995; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; SHIRAKAWA T, 1993, ALLERGY, V48, P177, DOI 10.1111/j.1398-9995.1993.tb00710.x; SHIRAKAWA T, IN PRESS EUR J EPIDE; SPRINGETT VH, 1988, J EPIDEMIOL COMMUN H, V42, P370, DOI 10.1136/jech.42.4.370; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x; Wichmann HE, 1996, CLIN EXP ALLERGY, V26, P621, DOI 10.1111/j.1365-2222.1996.tb00587.x; XU LX, 1994, INT IMMUNOL, V6, P515, DOI 10.1093/intimm/6.4.515; YOUMANS GP, 1975, AM REV RESPIR DIS, V111, P109	33	1057	1137	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 3	1997	275	5296					77	79		10.1126/science.275.5296.77	http://dx.doi.org/10.1126/science.275.5296.77			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974396				2022-12-01	WOS:A1997WA90300052
J	Loefler, IJP				Loefler, IJP			Microbes, chemotherapy, evolution, and folly	LANCET			English	Article											Loefler, IJP (corresponding author), NAIROBI HOSP,ARGWINGS KODNEK RD,POB 47964,NAIROBI,KENYA.								0	24	25	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1703	1704		10.1016/S0140-6736(96)12006-7	http://dx.doi.org/10.1016/S0140-6736(96)12006-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973435				2022-12-01	WOS:A1996VZ76600015
J	Frankel, S; Elwood, P; Sweetnam, P; Yarnell, J; Smith, GD				Frankel, S; Elwood, P; Sweetnam, P; Yarnell, J; Smith, GD			Birthweight, body-mass index in middle age, and incident coronary heart disease	LANCET			English	Article							BIRTH-WEIGHT; RISK	Background Several studies have shown a relation between fetal development, as shown by birthweight, and later coronary heart disease. This study investigated whether this relation is predominantly the consequence of early life exposures, or can best be explained in terms of an interaction between influences in early life and in adulthood. Methods This prospective study in Caerphilly, South Wales, included 1258 men, aged 45-59 at initial screening, who were able to provide birthweight data. These men are from an initial cohort of 2512 men, from whom information has been obtained in a series of examinations since 1979 on health-related behaviours, incidence of coronary heart disease, and risk factors. The main outcome measure was fatal and non-fatal coronary heart disease during 10 years of follow-up. Findings Higher birthweight was related to lower risk of coronary heart disease during the follow-up period: coronary heart disease occurred in 46 (11.6%) men in the lowest birthweight tertile, 44 (12.0%) of those in the middle tertile, and 38 (9.1%) of those in the highest tertile (p=0.03). Stratification of the cohort by body-mass index (BMI) revealed a significant interaction such that the inverse association between birthweight and risk of coronary heart disease was restricted to men in the top tertile of BMI (interaction test p=0.048 adjusted for age, and p=0.012 fully adjusted). Within the top BMI tertile, coronary heart disease occurred in 19 (16.4%) of men in the lowest birthweight tertile, 13 (12.6%) of those in the middle tertile, and 13 (7.5%) of those in the highest tertile (p=0.0005). These associations were not changed substantially by adjustment for age, father's social class, own social class, marital status, fibrinogen and cholesterol concentrations, systolic blood pressure, and smoking history. Interpretation The association between birthweight and risk of coronary heart disease cannot be explained by associations with childhood or adulthood socioeconomic status. Nor do conventional risk factors for coronary heart disease in adulthood account for the association. However, there is an important interaction between birthweight and BMI such that the increased risk of coronary heart disease associated with low birthweight is restricted to people who have high BMI in adulthood. Risk of coronary heart disease seems to be defined by the combined effect of early-life and later-life exposures.	UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND; LLANDOUGH HOSP, EPIDEMIOL UNIT, MRC, PENARTH, S GLAM, WALES; QUEENS UNIV BELFAST, DEPT EPIDEMIOL & PUBL HLTH, BELFAST, ANTRIM, NORTH IRELAND	University of Bristol; Queens University Belfast			Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARTLEY M, 1994, BMJ-BRIT MED J, V309, P1475, DOI 10.1136/bmj.309.6967.1475; FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91; Frankel S, 1996, PUBLIC HEALTH, V110, P139, DOI 10.1016/S0033-3506(96)80066-7; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; POND WG, 1985, J NUTR, V115, P179, DOI 10.1093/jn/115.2.179; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; RICHEDWARDS J, 1995, AM J EPIDEMIOL, V141, pS78; ROTHWELL PM, 1994, LANCET, V343, P731, DOI 10.1016/S0140-6736(94)91610-1; YARNELL JWG, 1992, EUR HEART J, V13, P1602, DOI 10.1093/oxfordjournals.eurheartj.a060111	10	345	353	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 30	1996	348	9040					1478	1480		10.1016/S0140-6736(96)03482-4	http://dx.doi.org/10.1016/S0140-6736(96)03482-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942776				2022-12-01	WOS:A1996VV46300009
J	Colgan, DF; Murthy, KGK; Prives, C; Manley, JL				Colgan, DF; Murthy, KGK; Prives, C; Manley, JL			Cell-cycle related regulation poly(A) polymerase by phosphorylation	NATURE			English	Article							XENOPUS-LAEVIS OOCYTES; MESSENGER-RNA; DEPENDENT KINASES; MATURATION; EXPRESSION; CLEAVAGE	THE poly(A) tail found on almost all eukaryotic messenger RNAs(1,2) is important in enhancing translation initiation and determining mRNA stability(3,4). Control of poly(A)-tail synthesis thus has the potential to be a key regulatory step in gene expression and is indeed known to be important during early development in many organisms(5). To study a possible basis for such regulation, we examined phosphorylation of poly(A) polymerase (PAP) by p34(cdc2)/cyclin B (maturation/mitosis-promoting factor, MPF). We show here that PAP can be phosphorylated in vivo and in vitro by MPF. Consistent with this, PAP becomes hyperphosphorylated both during meiotic maturation of Xenopus laevis oocytes and in HeLa cells arrested at M phase, times in the cell-cycle when MPF is known to be active(6,7). We show further that hyperphosphorylation by MPF dramatically reduces the activity of purified PAP, and that PAP isolated from mitotic HeLa cells is similarly inhibited by hyperphosphorylation. This repression probably contributes to the well established reductions in poly(A)(+) RNA and/or protein synthesis known to occur in M-phase cells(8-15).	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University				Manley, James/0000-0002-8341-1459				BALLANTYNE S, 1995, RNA, V1, P64; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DAMBROUGH C, 1979, DEV BIOL, V71, P323; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; KANKI JP, 1991, DEV BIOL, V146, P198, DOI 10.1016/0012-1606(91)90460-K; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAWLOWSKI PJ, 1974, DEV BIOL, V40, P71, DOI 10.1016/0012-1606(74)90108-0; PRIVES C, 1991, METHOD CELL BIOL, V36, P185; RAABE T, 1994, MOL CELL BIOL, V14, P2946, DOI 10.1128/MCB.14.5.2946; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; SAGATA N, 1980, DEV BIOL, V77, P431, DOI 10.1016/0012-1606(80)90486-8; SLATER DW, 1972, NATURE, V240, P333, DOI 10.1038/240333a0; STEWARD DL, 1968, SCIENCE, V161, P791, DOI 10.1126/science.161.3843.791; THURESSON AC, 1994, P NATL ACAD SCI USA, V91, P979, DOI 10.1073/pnas.91.3.979; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WILT FH, 1977, CELL, V11, P673, DOI 10.1016/0092-8674(77)90084-8; Zhao WQ, 1996, MOL CELL BIOL, V16, P2378	30	133	135	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	1996	384	6606					282	285		10.1038/384282a0	http://dx.doi.org/10.1038/384282a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918882				2022-12-01	WOS:A1996VU38100057
J	Kellett, JM				Kellett, JM			An ethical dilemma - A nurse is suspended	BRITISH MEDICAL JOURNAL			English	Article								A day hospital sister was suspended and given a final formal warning for obeying the request of her consultant to give a patient tranquillising medication in disguise. Though a disciplinary inquiry exonerated the consultant, the action on the nurse has not been rescinded. This case questions the authority of the multidisciplinary team and the role of nursing managers. We asked two geriatricians and forensic scientists to comment on the case.			Kellett, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT GERIATR MED,LONDON SW17 0RE,ENGLAND.								0	25	25	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1249	1250		10.1136/bmj.313.7067.1249	http://dx.doi.org/10.1136/bmj.313.7067.1249			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939119	Green Published			2022-12-01	WOS:A1996VU20800029
J	Sattler, M; Liang, H; Nettesheim, D; Meadows, RP; Harlan, JE; Eberstadt, M; Yoon, HS; Shuker, SB; Chang, BS; Minn, AJ; Thompson, CB; Fesik, SW				Sattler, M; Liang, H; Nettesheim, D; Meadows, RP; Harlan, JE; Eberstadt, M; Yoon, HS; Shuker, SB; Chang, BS; Minn, AJ; Thompson, CB; Fesik, SW			Structure of Bcl-x(L)-Bak peptide complex: Recognition between regulators of apoptosis	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CELL-DEATH; BCL-2; PROTEINS; HETERODIMERIZATION; DISTINCT; DOMAINS; C-13; BH1; BAX	Heterodimerization between members of the Bcl-2 family of proteins is a key event in the regulation of programmed cell death. The molecular basis for heterodimer formation was investigated by determination of the solution structure of a complex between the survival protein Bcl-x(L) and the death-promoting region of the Bcl-2-related protein Bak. The structure and binding affinities of mutant Bak peptides indicate that the Bak peptide adopts an amphipathic or helix that interacts with Bcl-x(L) through hydrophobic and electrostatic interactions. Mutations in full-length Bak that disrupt either type of interaction inhibit the ability of Bak to heterodimerize with Bcl-x(L).	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOL GENET,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CELL BIOL,CHICAGO,IL 60637	Abbott Laboratories; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago			Sattler, Michael/A-2407-2012; Yoon, Ho Sup/A-2193-2011; Sattler, Michael/C-1169-2010	Sattler, Michael/0000-0002-1594-0527; Yoon, Ho Sup/0000-0002-8243-3904; Minn, Andy/0000-0003-1418-0906	NCI NIH HHS [R37 CA48023] Funding Source: Medline; PHS HHS [P01 A135294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA048023] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD JM, 1995, ONCOGENE, V11, P1921; BRUNGER AT, 1992, X PLOR VERSION 3 1; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHANG BC, UNPUB; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; EBERSTADT M, UNPUB; GRZESIEK S, 1994, J BIOMOL NMR, V4, P871; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	23	1236	1359	0	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					983	986		10.1126/science.275.5302.983	http://dx.doi.org/10.1126/science.275.5302.983			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020082				2022-12-01	WOS:A1997WH38800047
J	Carpino, N; Wisniewski, D; Strife, A; Marshak, D; Kobayashi, R; Stillman, B; Clarkson, B				Carpino, N; Wisniewski, D; Strife, A; Marshak, D; Kobayashi, R; Stillman, B; Clarkson, B			p62(dok): A constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; SIGNAL-TRANSDUCTION; KINASE-ACTIVITY; KIT-LIGAND; C-ABL; BINDING; DOMAINS; SRC; P62; DIFFERENTIATION	Characteristic of chronic myelogenous leukemia (CML) is the presence of the chimeric p210(bcr-abl) protein possessing elevated protein tyrosine kinase activity relative to normal c-abl tyrosine kinase. Hematopoietic progenitors isolated from CML patients in the chronic phase contain a constitutively tyrosine-phosphorylated protein that migrates at 62 kDa by SDS-PAGE and associates with the p120 ras GTPase-activating protein (GAP). We have purified p62(dok) from a hematopoietic cell line expressing p210(bcr-abl). p62(dok) is a novel protein with features of a signaling molecule. Association of p62(dok) with GAP correlates with its tyrosine phosphorylation. p62(dok) is rapidly tyrosine-phosphorylated upon activation of the c-Kit receptor, implicating it as a component of a signal transduction pathway downstream of receptor tyrosine kinases.	SUNY STONY BROOK, PROGRAM MOL & CELLULAR BIOL, STONY BROOK, NY 11794 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; Memorial Sloan Kettering Cancer Center	Carpino, N (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091	NCI NIH HHS [5P01 CA64593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; CHUNG SW, 1995, ONCOGENE, V10, P1261; CLARKSON B, 1993, LEUKEMIA, V7, P1683; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DALEY GQ, 1991, ADV CANCER RES, V57, P151; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GARRELS J, 1993, METHOD ENZYMOL, V100, P411; GROFFEN J, 1991, CHRONIC MYELOGENOUS, P181; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KOZMA LM, 1991, METHOD ENZYMOL, V201, P28; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEET K, 1995, MOL CELL BIOL, V15, P4908; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STRIFE A, 1993, CANCER RES, V53, P401; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; Wisniewski D, 1996, LEUKEMIA, V10, P229; WISNIEWSKI D, 1994, LEUKEMIA, V8, P688; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	40	335	370	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1997	88	2					197	204		10.1016/S0092-8674(00)81840-1	http://dx.doi.org/10.1016/S0092-8674(00)81840-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008160	hybrid			2022-12-01	WOS:A1997WE97000008
J	Maiti, S; Shear, JB; Williams, RM; Zipfel, WR; Webb, WW				Maiti, S; Shear, JB; Williams, RM; Zipfel, WR; Webb, WW			Measuring serotonin distribution in live cells with three-photon excitation	SCIENCE			English	Article							BASOPHILIC LEUKEMIA-CELLS; MAST-CELLS; FLUORESCENCE; MICROSCOPY; SURFACE; PROTEINS; GRANULES	Tryptophan and serotonin were imaged with infrared illumination by three-photon excitation (3PE) of their native ultraviolet (UV) fluorescence. This technique, established by 3PE cross section measurements of tryptophan and the monoamines serotonin and dopamine, circumvents the limitations imposed by photodamage, scattering, and indiscriminate background encountered in other UV microscopies. Three-dimensionally resolved images are presented along with measurements of the serotonin concentration (similar to 50 mM) and content (up to similar to 5 X 10(8) molecules) of individual secretory granutes.	CORNELL UNIV, SCH APPL & ENGN PHYS, ITHACA, NY 14853 USA	Cornell University			Webb, Watt W./B-5905-2011	Williams, Rebecca/0000-0002-1391-5846	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR007719, P41RR004224] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07719, RR04224] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BONIFACINO JS, 1989, J CELL SCI, V92, P701; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; DEMATTEIS MA, 1991, J BIOL CHEM, V266, P10452; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DEYOUNG MB, 1987, ARCH BIOCHEM BIOPHYS, V254, P222, DOI 10.1016/0003-9861(87)90098-1; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GARRIS PA, 1994, J PHYSIOL-LONDON, V478, P239, DOI 10.1113/jphysiol.1994.sp020246; GUILD JB, IN PRESS APPL OPT; LIU G, 1995, NEUROPHARMACOLOGY, V34, P1407, DOI 10.1016/0028-3908(95)00143-T; MAO SY, 1995, BIOCHEMISTRY-US, V34, P1968, DOI 10.1021/bi00006a018; Mertz J, 1995, OPT LETT, V20, P2532, DOI 10.1364/OL.20.002532; Miyake K, 1995, J CELL BIOL, V131, P1737, DOI 10.1083/jcb.131.6.1737; OLIVER JM, 1988, PROG ALLERGY, V42, P185; PHILLIPS DM, 1985, J ULTRA MOL STRUCT R, V90, P105, DOI 10.1016/0889-1605(85)90120-X; Ryan TA, 1996, P NATL ACAD SCI USA, V93, P5567, DOI 10.1073/pnas.93.11.5567; SINGH S, 1964, PHYS REV LETT, V12, P612, DOI 10.1103/PhysRevLett.12.612; SPUDICH A, 1995, P NATL ACAD SCI USA, V92, P6976, DOI 10.1073/pnas.92.15.6976; TAMIR H, 1982, J CELL BIOL, V93, P638, DOI 10.1083/jcb.93.3.638; TAN WH, 1995, ANAL CHEM, V67, P2575, DOI 10.1021/ac00111a013; TEALE FWJ, 1957, BIOCHEM J, V65, P476, DOI 10.1042/bj0650476; THOMAS JL, 1994, J CELL BIOL, V125, P795, DOI 10.1083/jcb.125.4.795; WILLIAMS RM, 1994, FASEB J, V8, P804, DOI 10.1096/fasebj.8.11.8070629; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; Xu C, 1996, J OPT SOC AM B, V13, P481, DOI 10.1364/JOSAB.13.000481; Zerby SE, 1996, BRAIN RES, V712, P1, DOI 10.1016/0006-8993(95)01383-0	26	367	387	8	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 24	1997	275	5299					530	532		10.1126/science.275.5299.530	http://dx.doi.org/10.1126/science.275.5299.530			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999797				2022-12-01	WOS:A1997WE25700044
J	Menard, R; Sultan, AA; Cortes, C; Altszuler, R; vanDijk, MR; Janse, CJ; Waters, AP; Nussenzweig, RS; Nussenzweig, V				Menard, R; Sultan, AA; Cortes, C; Altszuler, R; vanDijk, MR; Janse, CJ; Waters, AP; Nussenzweig, RS; Nussenzweig, V			Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes	NATURE			English	Article							PLASMODIUM-BERGHEI; ANOPHELES-STEPHENSI; THROMBOSPONDIN; EXPRESSION; PARASITE; CELL; TRANSFECTION; HEPATOCYTES	Malaria parasites undergo a sporogonic cycle in the mosquito vector, Sporozoites, the form of the parasite injected into the host during a bloodmeal, develop inside oocysts in the insect midgut, then migrate to and eventually invade the salivary glands, The circumsporozoite protein (CS), one of the major proteins synthesized by salivary gland sporozoites', is a surface-associated molecule which is important in sporozoite infectivity to the host(2). Here, by gene targeting, we created Plasmodium berghei lines in which the single-copy CS gene was disrupted, The CS(-) and wild-type parasites produced similar numbers of oocysts of comparable size in the mosquito midgut, In the CS(-) oocysts, however, sporozoite formation was profoundly inhibited. CS therefore appears to have a pleiotropic role and to be vital for malaria parasites in both the vector and the host: in mosquitoes, CS is essential for sporozoite development within oocysts, and in the vertebrate host it promotes sporozoite attachment to hepatocytes(3-7).	NYU,MED CTR,DEPT MED & MOL PARASITOL,NEW YORK,NY 10016; LEIDEN UNIV,DEPT PARASITOL,NL-2300 RC LEIDEN,NETHERLANDS	New York University; Leiden University; Leiden University - Excl LUMC	Menard, R (corresponding author), NYU MED CTR,KAPLAN CANC CTR,DEPT PATHOL,MICHAEL HEIDELBERGER DIV IMMUNOL,NEW YORK,NY 10016, USA.		Waters, Andy P/C-9377-2009	Waters, Andy P/0000-0001-8900-2982; Janse, Chris J/0000-0002-6410-6205; Cortes, Claudio/0000-0003-2870-0028				ARAKAWA RS, 1992, J PROTOZOOL, V39, P333; BOULANGER N, 1995, PARASITOL RES, V81, P58, DOI 10.1007/BF00932418; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CERAMI C, 1994, J EXP MED, V179, P695, DOI 10.1084/jem.179.2.695; EICHINGER DJ, 1986, MOL CELL BIOL, V6, P3965, DOI 10.1128/MCB.6.11.3965; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; GOONEWARDENE R, 1993, P NATL ACAD SCI USA, V90, P5234, DOI 10.1073/pnas.90.11.5234; HAMILTON AJ, 1988, PARASITOLOGY, V96, P273, DOI 10.1017/S0031182000058273; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; NAGASAWA H, 1988, EXP PARASITOL, V66, P27, DOI 10.1016/0014-4894(88)90047-1; NUSSENZWEIG V, 1985, CELL, V42, P401, DOI 10.1016/0092-8674(85)90093-5; OSAKI LS, 1983, CELL, V34, P815; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; POSTHUMA G, 1988, EUR J CELL BIOL, V46, P18; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; SIMONETTI AB, 1993, J EUKARYOT MICROBIOL, V40, P569, DOI 10.1111/j.1550-7408.1993.tb06109.x; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; VANDERBERG J, 1967, J PROTOZOOL, V14, P82, DOI 10.1111/j.1550-7408.1967.tb01452.x; VANDIJK MR, 1995, SCIENCE, V268, P1358, DOI 10.1126/science.7761856; vanDijk MR, 1996, SCIENCE, V271, P662, DOI 10.1126/science.271.5249.662; WALLIKER D, 1983, MOL BIOL PARASITES, P53; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; YOSHIDA N, 1981, J EXP MED, V154, P1225, DOI 10.1084/jem.154.4.1225	26	232	239	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					336	340		10.1038/385336a0	http://dx.doi.org/10.1038/385336a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002517				2022-12-01	WOS:A1997WD91400049
J	Lesar, TS; Briceland, L; Stein, DS				Lesar, TS; Briceland, L; Stein, DS			Factors related to errors in medication prescribing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; HOSPITALIZED-PATIENTS; PREVENTABILITY; SYSTEMS; DOCTORS	Objective.-To quantify the type and frequency of identifiable factors associated with medication prescribing errors. Design and Setting.-Systematic evaluation of every third prescribing error detected and averted by pharmacists in a 631-bed tertiary care teaching hospital between July 1, 1994, and June 30, 1995. Each error was concurrently evaluated for the potential to result in adverse patient consequences. Each error was retrospectively evaluated by a physician and 2 pharmacists and a factor likely related to the error was identified. Participants.--All physicians prescribing medications during the study period and all staff pharmacists involved in the routine review of medication orders. Main Outcome Measures.-Frequency of association of factors likely related to medication errors in general and specific to medication classes and prescribing services (needed for medical, pediatric, obstetric-gynecologic, surgical, or emergency department patients); and potential consequences of errors for negative patient outcomes. Results.-A total of 2103 errors thought to have potential clinical importance were detected during the 1-year study period. The overall rate of errors was 3.99 errors per 1000 medication orders, and the error rate varied among medication classes and prescribing services. A total of 696 errors met study criteria (ie, errors with the potential for adverse patient effects) and were evaluated for a likely related factor. The most common specific factors associated with errors were decline in renal or hepatic function requiring alteration of drug therapy (97 errors: 13.9%), patient history of allergy to the same medication class (84 errors, 12.1%): using the wrong drug name, dosage form, or abbreviation (total of 79 errors, 11.4%, for both brand name and generic name orders), incorrect dosage calculations (77 errors, 11.1%), and atypical or unusual and critical dosage frequency considerations (75 errors, 10.8%). The most common groups of factors associated with errors were those related to knowledge and the application of knowledge regarding drug therapy (209 errors, 30%); knowledge and use of knowledge regarding patient fac tors that affect drug therapy (203 errors, 29.2%); use of calculations, decimal points, or unit and rate expression factors (122 errors, 17.5%); and nomenclature factors (incorrect drug name, dosage form, or abbreviation) (93 errors, 13.4%). Conclusions.-Several easily identified factors are associated with a large proportion of medication prescribing errors. By improving the focus of organizational, technological, and risk management educational and training efforts using the factors commonly associated with prescribing errors, risk to patients from adverse drug events should be reduced.	ALBANY COLL PHARM, DEPT PHARM PRACTICE, ALBANY, NY USA; ALBANY MED COLL, DIV MED, ALBANY, NY 12208 USA	Albany College of Pharmacy & Health Sciences; Albany Medical College	Lesar, TS (corresponding author), ALBANY MED CTR HOSP, DEPT PHARM, 43 NEW SCOTLAND AVE, ALBANY, NY 12208 USA.							*AM MED ASS, 1994, AMA BOARD TRUST REP; [Anonymous], 1992, Am J Hosp Pharm, V49, P640; Attilio RM, 1996, HOSP PHARM, V31, P17; BALDWIN L, 1995, BRIT MED J, V310, P1154, DOI 10.1136/bmj.310.6988.1154; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1994, J AM MED INFORM ASSN, V1, P404, DOI 10.1136/jamia.1994.95153428; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BEERS MH, 1990, J AM GERIATR SOC, V38, P1183, DOI 10.1111/j.1532-5415.1990.tb01496.x; BJORNSON DC, 1993, AM J HOSP PHARM, V50, P1875, DOI 10.1093/ajhp/50.9.1875; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; DAVIS N, 1987, MED ABBREVIATIONS 55; FOLLI HL, 1987, PEDIATRICS, V79, P718; HAIG GM, 1991, AM J HOSP PHARM, V48, P1457, DOI 10.1093/ajhp/48.7.1457; JICK H, 1977, AM J MED, V62, P514, DOI 10.1016/0002-9343(77)90406-5; KIRCHBAUM DW, 1988, DICP ANN PHARMAC, V22, P981; KOREN G, 1994, J CLIN PHARMACOL, V34, P1043, DOI 10.1002/j.1552-4604.1994.tb01978.x; LANDIS SJ, 1990, CAN MED ASSOC J, V143, P611; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LEAPE LL, 1995, AM J HEALTH-SYST PH, V52, P379, DOI 10.1093/ajhp/52.4.379; LEBELLE MJ, 1993, CAN MED ASSOC J, V149, P941; Lesar T S, 1994, Hosp Pharm, V29, P935; Lesar TS, 1996, ANN PHARMACOTHER, V30, P31, DOI 10.1177/106002809603000105; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; LESAR TS, 1992, ANN INTERN MED, V117, P537, DOI 10.7326/0003-4819-117-6-537_2; LOMAESTRO BM, 1992, JAMA-J AM MED ASSOC, V268, P2031, DOI 10.1001/jama.1992.03490150083021; LOMAESTRO BM, 1994, ANN INTERN MED, V121, P818, DOI 10.7326/0003-4819-121-10-199411150-00034; MCKENNEY JM, 1979, AM J HOSP PHARM, V36, P1691, DOI 10.1093/ajhp/36.12.1691; MEYERSOHN MB, 1992, APPL PHARMACOKINETIC, P1; Potts MJ, 1996, ARCH PEDIAT ADOL MED, V150, P748, DOI 10.1001/archpedi.1996.02170320094016; Preston SL, 1995, ANN PHARMACOTHER, V29, P1202, DOI 10.1177/106002809502901202; ROLFE S, 1995, BRIT MED J, V310, P1173, DOI 10.1136/bmj.310.6988.1173; VITILLO JA, 1991, DICP ANN PHARMAC, V25, P1388, DOI 10.1177/106002809102501221	35	466	481	0	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1997	277	4					312	317		10.1001/jama.277.4.312	http://dx.doi.org/10.1001/jama.277.4.312			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC458	9002494				2022-12-01	WOS:A1997WC45800031
J	Patel, BD; Parekh, SR				Patel, BD; Parekh, SR			Absence of rigor mortis in Indian childhood cirrhosis	LANCET			English	Article									BAI JERBAI WADLA HOSP CHILDREN,MUMBAI,INDIA; INST CHILD HLTH,MUMBAI,INDIA; SETH GS MED COLL,MUMBAI,INDIA	Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital								PATEL BD, 1974, INDIAN PEDIATR, V11, P19; Sen B, 1887, INDIAN MED GAZETTE, V22, P338; SUSHRUTA, 1952, UTTAR TANTRA, pCH27; TSUNEO S, 1976, FORENSIC SCI, V8, P207; WILLIAM B, 1970, TXB PATHOLOGY, P44	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					100	101		10.1016/S0140-6736(05)60883-5	http://dx.doi.org/10.1016/S0140-6736(05)60883-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996425				2022-12-01	WOS:A1997WB80000016
J	Bochkarev, A; Pfuetzner, RA; Edwards, AM; Frappier, L				Bochkarev, A; Pfuetzner, RA; Edwards, AM; Frappier, L			Structure of the single-stranded-DNA-binding domain of replication protein A bound to DNA	NATURE			English	Article							CRYSTAL-STRUCTURE; GENE-V; REFINEMENT	THE single-stranded-DNA-binding proteins (SSBs) are essential fur DNA function in prokaryotic and eukaryotic cells, mitochondria, phages and viruses(1,2). The structures of four SSBs have been solved(3-7), but the molecular details of the interaction of SSBs with DNA remain speculative. We report here the crystal structure at 2.4 Angstrom resolution of the single-stranded-DNA-binding domain of human replication protein A (RPA) bound to DNA. Replication protein a is a heterotrimeric SSB that is highly conserved in eukaryotes. The largest subunit, RPA70, binds to single-stranded (ss)DNA(8,9) and mediates interactions with many cellular and viral proteins(10). The DNA-binding domain, which ties in the middle of RPA70, comprises two structurally homologous subdomains oriented in tandem. The ssDNA lies in a channel that extends from one subdomain lo the other. The structure of each RPA70 subdomain is similar to those of the bacteriophage SSBs, indicating that the mechanism of ssDNA-binding is conserved.	MCMASTER UNIV,INST MOL BIOL & BIOTECHNOL,CANC RES GRP,HAMILTON,ON L8N 3Z5,CANADA	McMaster University				Edwards, Aled/0000-0002-4782-6016				ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; BARWELL JA, 1995, J BIOL CHEM, V270, P20556, DOI 10.1074/jbc.270.35.20556; Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FOLKERS PJM, 1994, J MOL BIOL, V236, P229, DOI 10.1006/jmbi.1994.1132; FOLMER RHA, 1995, EMBO J, V14, P4132, DOI 10.1002/j.1460-2075.1995.tb00087.x; FUREY W, IN PRESS METH ENZYMO; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P5586, DOI 10.1021/bi9526995; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KOMBERG A, 1992, DNA REPLICATION; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; PFUETZNER RA, IN PRESS J BIOL CHEM; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61	24	473	485	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					176	181		10.1038/385176a0	http://dx.doi.org/10.1038/385176a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990123				2022-12-01	WOS:A1997WB72800059
J	Duan, H; Dixit, VM				Duan, H; Dixit, VM			RAIDD is a new 'death' adaptor molecule	NATURE			English	Article							PROGRAMMED CELL-DEATH; C-ELEGANS; PROTEIN; GENE; INTERACTS; APOPTOSIS; ENCODES; DOMAIN; FAS	THE effector arm of the the cell-death pathway is composed of cysteine proteases belonging to the ICE/CED-3 family(1,2). In metazoan cells these exist as inactive polypeptide precursors (zymogens), each composed of a prodomain, which is cleaved to activate the protease, and a large and small catalytic subunit. The coupling of these 'death' proteases to signalling pathways is probably mediated by adaptor molecules that contain protein-protein interaction motifs such as the death domain(1). Were we describe such an adaptor molecule, RAIDD, which has an unusual bipartite architecture comprising a carboxy-terminal death domain that binds to the homologous domain in RIP, a serine/threonine kinase component of the death pathway(3,4). The amino-terminal domain is surprisingly homologous with the sequence of the prodomain of two ICE/CED-3 family members, human ICH-1 (ref. 5) and Caenorhabditis elegans CED-3 (ref. 6). This similar region mediates the binding of RAIDD to ICH-1 and CED-3, serving as a direct link to the death proteases, indicating that the prodomain may, through homophilic interactions, determine the specificity of binding of ICE/CED-3 zymogens to regulatory adaptor molecules. Finally, alternations in the sequence of the N-terminal domain that are equivalent to inactivating mutations in the C. elegans ced-3 gene(7,8) prevent homophilic binding, highlighting the potentially primordial nature of this interaction.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326				CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; Sambrook J., 1989, MOL CLONING LAB MANU; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	16	454	482	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					86	89		10.1038/385086a0	http://dx.doi.org/10.1038/385086a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985253	Green Published			2022-12-01	WOS:A1997WA73100056
J	Tsien, JZ; Huerta, PT; Tonegawa, S				Tsien, JZ; Huerta, PT; Tonegawa, S			The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory	CELL			English	Article							LONG-TERM POTENTIATION; II MUTANT MICE; TARGETED DISRUPTION; PERFORANT PATH; DENTATE GYRUS; AREA CA1; RAT; NEURONS; IMPAIRMENT; BLOCKADE	We have produced a mouse strain in which the deletion of the NMDAR1 gene is restricted to the CA1 pyramidal cells of the hippocampus by using a new and general method that allows CA1-restricted gene knockout. The mutant mice grow into adulthood without obvious abnormalities. Adult mice lack NMDA receptor-mediated synaptic currents and long-term potentiation in the CA1 synapses and exhibit impaired spatial memory but unimpaired nonspatial learning. Our results strongly suggest that activity-dependent modifications of CA1 synapses, mediated by NMDA receptors, play an essential role in the acquisition of spatial memories.			Tsien, JZ (corresponding author), MIT,CTR CANC RES,HOWARD HUGHES MED INST,CTR LEARNING & MEMORY,DEPT BIOL,CAMBRIDGE,MA 02139, USA.			Huerta, Patricio/0000-0003-0270-2308	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER; NINDS NIH HHS [NS32925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BUTCHER SP, 1991, EXP BRAIN RES, V83, P521; Cain DP, 1996, BEHAV NEUROSCI, V110, P86, DOI 10.1037/0735-7044.110.1.86; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN C, 1997, IN PRESS ANN REV NEU; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; de No RL, 1934, J PSYCHOL NEUROL, V46, P113; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EMPSON RM, 1995, J PHYSIOL-LONDON, V484, P707, DOI 10.1113/jphysiol.1995.sp020697; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HANSE E, 1992, EUR J NEUROSCI, V4, P1191, DOI 10.1111/j.1460-9568.1992.tb00144.x; HEBB DO, 1949, ORG BEHAVIOR; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; HESTRIN S, 1996, EXCITATORY AMINO ACI, P53; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; HUERTA PT, 1995, NEURON, V15, P1053, DOI 10.1016/0896-6273(95)90094-2; Huerta PT, 1996, NEUROREPORT, V7, P1685, DOI 10.1097/00001756-199607080-00032; KAWASE E, 1994, INT J DEV BIOL, V38, P385; KOLB B, 1994, CEREB CORTEX, V6, P664; KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957; LEDERMANN B, 1991, EXP CELL RES, V197, P254, DOI 10.1016/0014-4827(91)90430-3; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Morris RGM, 1991, LONG TERM POTENTIATI, P267; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NostenBertrand M, 1996, NATURE, V379, P826, DOI 10.1038/379826a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; POKORNY J, 1981, BRAIN RES BULL, V7, P113, DOI 10.1016/0361-9230(81)90075-7; POKORNY J, 1981, BRAIN RES BULL, V7, P121, DOI 10.1016/0361-9230(81)90076-9; Rawlins J.N.P., 1996, EXCITATORY AMINO ACI, P275; Sakmann Bert, 1995, P199; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Squire L.R., 1987, MEMORY BRAIN; STANFIELD BB, 1979, J COMP NEUROL, V185, P423, DOI 10.1002/cne.901850303; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	54	1346	1410	4	159	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1327	1338		10.1016/S0092-8674(00)81827-9	http://dx.doi.org/10.1016/S0092-8674(00)81827-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980238	Bronze			2022-12-01	WOS:A1996WA54100020
J	Holm, S; Evans, M				Holm, S; Evans, M			Product names, proper claims? More ethical issues in the marketing of drugs	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To analyse the explicit or implicit claims embodied in the proprietary names of pharmaceutical products. Design-Linguistic and ethical analysis of proprietary names of pharmaceutical products marketed in the UK and in Denmark. Results and conclusions-A number of drugs have names that allude to their indication or actions. Such names may be problematic, however, because they often promise more than the drug can deliver. Taking into account, firstly, the type of allusion and its degree of sophistication, and, secondly, the seriousness of the indication may help in identifying the most problematic drug names.	UNIV COLL SWANSEA,CTR PHILOSOPHY & HLTH CARE,SWANSEA SA2 8PP,W GLAM,WALES	Swansea University	Holm, S (corresponding author), UNIV COPENHAGEN,DEPT MED PHILOSOPHY & CLIN THEORY,DK-2200 COPENHAGEN N,DENMARK.			Holm, Soren/0000-0002-7200-5607				ARONSON JK, 1994, BRIT MED J, V308, P1140, DOI 10.1136/bmj.308.6937.1140; *BRIT MED ASS ROYA, 1995, BRIT NAT FORM; FABER J, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92954-Z; JACK DB, 1991, BRIT MED J, V303, P1606, DOI 10.1136/bmj.303.6817.1606; *LAEG FORL, 1995, LAEG MED; MCNULTY H, 1979, BRIT MED J, V2, P836, DOI 10.1136/bmj.2.6194.836; Spigset Olav, 1995, Tidsskrift for den Norske Laegeforening, V115, P380	7	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1627	1629		10.1136/bmj.313.7072.1627	http://dx.doi.org/10.1136/bmj.313.7072.1627			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991014	Green Published			2022-12-01	WOS:A1996VZ81100046
J	Strassman, AM; Raymond, SA; Burstein, R				Strassman, AM; Raymond, SA; Burstein, R			Sensitization of meningeal sensory neurons and the origin of headaches	NATURE			English	Article							SAGITTAL SINUS; TRIGEMINOVASCULAR SYSTEM; THALAMIC NEURONS; STIMULATION; MIGRAINE; CAT; ARTERY; RAT; BRADYKININ; MECHANISMS	THE headaches that accompany certain intracranial pathologies (such as meningitis, subarachnoid haemorrhage and tumour) have been considered to result from mechanical or chemical stimulation of pain-sensitive structures of the intracranial meninges(1,2). Although the recurrent headache of migraine is of unknown origin and is not accompanied by an identifiable pathology, it shares with intracranial headaches features that suggest an exaggerated intracranial mechanosensititivity (worsening of the pain by coughing, breath-holding or sudden head movement(1,3)). One possible basis for such symptoms would be a sensitization of meningeal afferents to mechanical stimuli. Previous studies of neuronal responses to meningeal stimulation have focused primarily on cells in the central portion of the trigeminal pathway, and have not investigated the possible occurrence of sensitization(4-12). We have recorded the activity of primary afferent neurons in the rat trigeminal ganglion that innervate the dural venous sinuses. Chemical stimulation of their dural receptive fields with inflammatory mediators both directly excited the neurons and enhanced their mechanical sensitivity, such that they were strongly activated by mechanical stimuli that initially had evoked little or no response, These properties of meningeal afferents (chemosensitivity and sensitization) may contribute to the intracranial mechanical hypersensitivity that is characteristic of some types of clinically occurring headaches, and may also contribute to the throbbing pain of migraine.	HARVARD UNIV,SCH MED,DEPT ANESTHESIA,BOSTON,MA 02115; HARVARD UNIV,INST MED,DEPT NEUROBIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT ANESTHESIA,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard University; Brigham & Women's Hospital	Strassman, AM (corresponding author), BETH ISRAEL DEACONESS MED CTR,DEPT ANESTHESIA & CRIT CARE,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							ANDRES KH, 1987, ANAT EMBRYOL, V175, P289, DOI 10.1007/BF00309843; BAKER DG, 1980, J PHYSIOL-LONDON, V306, P519, DOI 10.1113/jphysiol.1980.sp013412; BLAU JN, 1981, CEPHALALGIA, V1, P143, DOI 10.1046/j.1468-2982.1981.0103143.x; Burstein R., 1996, Society for Neuroscience Abstracts, V22, P864; DALEY ML, 1995, IEEE T BIO-MED ENG, V42, P420, DOI 10.1109/10.376137; DAVIS KD, 1988, J NEUROPHYSIOL, V59, P648, DOI 10.1152/jn.1988.59.2.648; DAVIS KD, 1993, J NEUROPHYSIOL, V69, P1071, DOI 10.1152/jn.1993.69.4.1071; DAVIS KD, 1988, BRAIN RES, V446, P401, DOI 10.1016/0006-8993(88)90902-X; DAVIS KD, 1988, BRAIN RES, V454, P89, DOI 10.1016/0006-8993(88)90806-2; DOSTROVSKY JO, 1991, CAN J PHYSIOL PHARM, V69, P652, DOI 10.1139/y91-097; FRIBERG L, 1991, LANCET, V338, P13, DOI 10.1016/0140-6736(91)90005-A; GOADSBY PJ, 1993, ANN NEUROL, V33, P48, DOI 10.1002/ana.410330109; Graham JR, 1938, ARCH NEURO PSYCHIATR, V39, P737, DOI 10.1001/archneurpsyc.1938.02270040093005; IVERSEN HK, 1990, LANCET, V336, P837, DOI 10.1016/0140-6736(90)92339-J; KAUBE H, 1992, CEPHALALGIA, V12, P133, DOI 10.1046/j.1468-2982.1992.1203133.x; LAMBERT GA, 1991, CEPHALALGIA, V11, P75, DOI 10.1046/j.1468-2982.1991.1102075.x; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; MARTIN JB, 1991, HARRISONS PRINCIPLES, P108; MOSKOWITZ MA, 1993, CEREBROVAS BRAIN MET, V5, P159; Orr Edward L., 1995, Society for Neuroscience Abstracts, V21, P1858; Penfield W, 1940, ARCH NEURO PSYCHIATR, V44, P43, DOI 10.1001/archneurpsyc.1940.02280070051003; SCHAIBLE HG, 1988, J PHYSIOL-LONDON, V403, P91, DOI 10.1113/jphysiol.1988.sp017240; STEEN KH, 1992, J NEUROSCI, V12, P86; STRASSMAN A, 1986, BRAIN RES, V379, P242, DOI 10.1016/0006-8993(86)90777-8; STRASSMAN AM, 1994, J NEUROSCI, V14, P3725; THOMSEN LL, 1995, CEPHALALGIA, V15, P109, DOI 10.1046/j.1468-2982.1995.015002109.x; Wolff H. G., 1963, HEADACHE OTHER HEAD; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; ZAGAMI AS, 1991, NEUROSCI LETT, V121, P187, DOI 10.1016/0304-3940(91)90681-I; ZAGAMI AS, 1990, EXP BRAIN RES, V81, P552, DOI 10.1007/BF02423504	30	491	513	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1996	384	6609					560	564		10.1038/384560a0	http://dx.doi.org/10.1038/384560a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955268				2022-12-01	WOS:A1996VX76900058
J	Albertini, JJ; Lyman, GH; Cox, C; Yeatman, T; Balducci, L; Ku, NN; Shivers, S; Berman, C; Wells, K; Rapaport, D; Shons, A; Horton, J; Greenberg, H; Nicosia, S; Clark, R; Cantor, A; Reintgen, DS				Albertini, JJ; Lyman, GH; Cox, C; Yeatman, T; Balducci, L; Ku, NN; Shivers, S; Berman, C; Wells, K; Rapaport, D; Shons, A; Horton, J; Greenberg, H; Nicosia, S; Clark, R; Cantor, A; Reintgen, DS			Lymphatic mapping and sentinel node biopsy in the patient with breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; EARLY-STAGE MELANOMA; MALIGNANT-MELANOMA; DISSECTION; METASTASES; MANAGEMENT; CARCINOMA; LYMPHADENECTOMY; MICROMETASTASES	Objectives.-To identify the sentinel lymph node(s) (SLN[s]) (the first node[s] draining the primary tumor in the regional lymphatic basin) in patients with invasive breast cancer and to test the hypothesis that the histologic characteristics of the SLN predict the histologic characteristics of the remaining lymph nodes in the axilla. Design.-A prospective trial. Participants.-Sixty-two patients with newly diagnosed invasive breast cancers. Intervention.-Patients underwent intraoperative lymphatic mapping using a combination of a vital blue dye and filtered technetium-labeled sulfur colloid. The SLN was identified and removed, followed by a definitive cancer operation, including a complete axillary node dissection. Main Outcome Measure The metastatic distribution in the axilla was determined in patients with occult nodal disease. Results.-The SLN was successfully identified in 57 (92%) of 62 patients using the 2 lymphatic mapping procedures. After focalization, 18 patients (32%) were found to have metastatic disease, and the SLN tested positive in all 18 patients. There were no ''skip'' metastases, defined as an SLN that tested negative with higher nodes that tested positive. In 12 (67%) of 18 patients with metastatic disease, the SLN was the only site of disease. The metastatic distribution significantly favored SLN involvement. Among subjects with discordant nodal involvement, the probability of observing the distribution of SLN involvement by chance is very small (P<.001). Conclusions.-This study confirms that lymphatic mapping is technically possible in the patient with breast cancer and that the histologic characteristics of the SLN probably reflect the histologic characteristics of the rest of the axillary lymph nodes. The procedure also allows the pathologist to focus the histologic examination on 1 or 2 nodes, potentially increasing the yield of positive dissections and the accuracy of staging.	UNIV S FLORIDA,H LEE MOFFITT CANC CTR & RES INST,COMPREHENS BREAST CANC PROGRAM,TAMPA,FL 33612	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida			Lyman, Gary H/K-5227-2019; Shivers, Steve/E-6438-2013; Shivers, Steven/AAE-9288-2022	Lyman, Gary H/0000-0002-0823-8086; Shivers, Steve/0000-0001-9538-4016; 	NCI NIH HHS [R21 CA66553-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA066553] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertini JJ, 1996, ANN SURG, V223, P217, DOI 10.1097/00000658-199602000-00016; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; BALCH CM, 1993, ANN SURG, V217, P207; Baxter N, 1996, ANN SURG ONCOL, V3, P235, DOI 10.1007/BF02306277; BONADONNA G, 1989, J CLIN ONCOL, V7, P1380, DOI 10.1200/JCO.1989.7.10.1380; CADY B, 1994, CANCER, V73, P505, DOI 10.1002/1097-0142(19940201)73:3<505::AID-CNCR2820730302>3.0.CO;2-B; DEWAR JA, 1987, INT J RADIAT ONCOL, V13, P475, DOI 10.1016/0360-3016(87)90060-5; FIELDS KK, 1996, J CLIN ONCOL, V6, P1868; FRAZIER TG, 1977, AM J SURG, V133, P697, DOI 10.1016/0002-9610(77)90156-8; GARDNER B, 1993, ANN SURG, V218, P270, DOI 10.1097/00000658-199309000-00006; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; GREENSON JK, 1994, CANCER-AM CANCER SOC, V73, P563, DOI 10.1002/1097-0142(19940201)73:3<563::AID-CNCR2820730311>3.0.CO;2-D; HAAGENSEN CD, 1977, INT J RADIAT ONCOL, V2, P975, DOI 10.1016/0360-3016(77)90198-5; HAINSWORTH PJ, 1993, BRIT J SURG, V80, P459, DOI 10.1002/bjs.1800800417; HOLLANDER M, 1973, NONPARAMETRIC STATIS; *INT LUDW BREAST C, 1990, LANCET, V335, P1565; IVENS D, 1992, BRIT J CANCER, V66, P136, DOI 10.1038/bjc.1992.230; KRAG DN, 1995, ARCH SURG-CHICAGO, V130, P654; KRAG DN, 1993, SURG ONCOL, V2, P335, DOI 10.1016/0960-7404(93)90064-6; LIN PP, 1993, J CLIN ONCOL, V11, P1536, DOI 10.1200/JCO.1993.11.8.1536; Maehara Y, 1996, SURGERY, V119, P397, DOI 10.1016/S0039-6060(96)80138-3; MORENO JG, 1992, CANCER RES, V52, P6110; Morrow M, 1996, ANN SURG ONCOL, V3, P233, DOI 10.1007/BF02306276; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; MOSS TJ, 1991, NEW ENGL J MED, V324, P219, DOI 10.1056/NEJM199101243240403; Nathanson SD, 1996, ANN SURG ONCOL, V3, P329, DOI 10.1007/BF02305661; NICASTRI GR, 1991, SURG GYNECOL OBSTET, V172, P457; NICOSIA S V, 1991, Acta Cytologica, V35, P609; Noguchi S, 1996, AM J PATHOL, V148, P649; RECHT A, 1995, CANCER, V76, P1491, DOI 10.1002/1097-0142(19951101)76:9<1491::AID-CNCR2820760902>3.0.CO;2-8; REINTGEN D, 1994, ANN SURG, V220, P759, DOI 10.1097/00000658-199412000-00009; ROSS MI, 1993, SEMIN SURG ONCOL, V9, P219; SCHOENFELD A, 1994, CANCER RES, V54, P2986; SILVERSTEIN MJ, 1994, CANCER-AM CANCER SOC, V73, P664, DOI 10.1002/1097-0142(19940201)73:3<664::AID-CNCR2820730326>3.0.CO;2-S; SILVERSTEIN MJ, 1987, CANCER, V59, P1819, DOI 10.1002/1097-0142(19870515)59:10<1819::AID-CNCR2820591023>3.0.CO;2-V; SPRINGALL RJ, 1990, J PATHOL, V160, P174; THOMPSON JF, 1995, MELANOMA RES, V5, P255, DOI 10.1097/00008390-199508000-00008; TROJANI M, 1987, BRIT J CANCER, V55, P303, DOI 10.1038/bjc.1987.59; VERONESI U, 1987, CANCER, V59, P682, DOI 10.1002/1097-0142(19870215)59:4<682::AID-CNCR2820590403>3.0.CO;2-Z; WANEBO HJ, 1984, ANN SURG, V199, P569, DOI 10.1097/00000658-198405000-00012; WANG XN, 1994, ANN SURG, V220, P768, DOI 10.1097/00000658-199412000-00010	41	1028	1065	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1996	276	22					1818	1822		10.1001/jama.276.22.1818	http://dx.doi.org/10.1001/jama.276.22.1818			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV997	8946902				2022-12-01	WOS:A1996VV99700031
J	Nightingale, SL				Nightingale, SL			Protease inhibitor charts available	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1710	1710						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940307				2022-12-01	WOS:A1996VV56600008
J	King, RA; BanikMaiti, S; Jin, DJ; Weisberg, RA				King, RA; BanikMaiti, S; Jin, DJ; Weisberg, RA			Transcripts that increase the processivity and elongation rate of RNA polymerase	CELL			English	Article							ESCHERICHIA-COLI RNA; TERMINATION EFFICIENCY; PHAGE-LAMBDA; PAUSE SITE; ANTITERMINATION; PROTEIN; RHO; PHAGE-HK022; PROMOTERS; HAIRPIN	Transcripts encoded by the cis-acting antitermination sites (put sites) of lambdoid phage HK022 promote readthrough of downstream transcription terminators. Proper conformation of the transcripts is essential for activity, since put mutations that prevent the formation of predicted RNA stems prevented antitermination, and suppressor mutations that restore the stems restored antitermination. Antitermination does not appear to require proteins other than RNA polymerase, since put-dependent readthrough of multiple sequential terminators was observed in a purified transcription system consisting of template, polymerase, substrates, and buffer. Transcription of put also increased the elongation rate of polymerase, very likely by suppressing pausing. A mutation that alters the zinc-finger region of the beta' subunit of polymerase specifically prevented the put-dependent increases in terminator readthrough and elongation rate. The simplicity of HK022 antitermination contrasts with that of other known antitermination pathways. We propose that the central effector is a transcript that directly alters the elongation properties of RNA polymerase.	NICHHD,SECT MICROBIAL GENET,GENET MOL LAB,NIH,BETHESDA,MD 20892; NCI,MOL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BUROVA E, 1995, J BACTERIOL, V177, P1388, DOI 10.1128/jb.177.5.1388-1392.1995; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHATTOPADHYAY S, 1995, P NATL ACAD SCI USA, V92, P4061, DOI 10.1073/pnas.92.9.4061; CLERGET M, 1995, J MOL BIOL, V248, P768, DOI 10.1006/jmbi.1995.0259; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; DEVITO J, 1994, P NATL ACAD SCI USA, V91, P8660, DOI 10.1073/pnas.91.18.8660; FRIEDMAN DI, 1995, MOL MICROBIOL, V18, P191, DOI 10.1111/j.1365-2958.1995.mmi_18020191.x; GOLIGER JA, 1989, J MOL BIOL, V205, P331, DOI 10.1016/0022-2836(89)90344-6; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GRUNDY FJ, 1993, CELL, V74, P475, DOI 10.1016/0092-8674(93)80049-K; GUSTIN KE, 1993, BIOTECHNIQUES, V14, P22; INNIS MA, 1990, PCR PROTOCOLS; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; MENZEL R, 1989, ANAL BIOCHEM, V181, P40, DOI 10.1016/0003-2697(89)90391-6; Miller JH., 1972, EXPT MOL GENETICS; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; MOTT JE, 1985, EMBO J, V4, P1887, DOI 10.1002/j.1460-2075.1985.tb03865.x; NURDLER E, 1996, SCIENCE, V273, P211; OBERTO J, 1989, J MOL BIOL, V207, P675, DOI 10.1016/0022-2836(89)90237-4; OBERTO J, 1993, J MOL BIOL, V229, P368, DOI 10.1006/jmbi.1993.1040; POWELL BS, 1994, NUCLEIC ACIDS RES, V22, P5765, DOI 10.1093/nar/22.25.5765; POWELL BS, 1994, NUCLEIC ACIDS RES, V23, P1278; Rees WA, 1996, P NATL ACAD SCI USA, V93, P342, DOI 10.1073/pnas.93.1.342; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; ROBERTS JW, 1995, REGULATION GENE EXPR, P27; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Silhavy T.J., 1984, EXPT GENE FUSIONS; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; STUEBER D, 1982, EMBO J, V1, P1399, DOI 10.1002/j.1460-2075.1982.tb01329.x; TELESNITSKY APW, 1989, J MOL BIOL, V205, P315, DOI 10.1016/0022-2836(89)90343-4; VOGEL U, 1995, J BIOL CHEM, V270, P18335, DOI 10.1074/jbc.270.31.18335; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	36	47	47	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					893	903		10.1016/S0092-8674(00)81996-0	http://dx.doi.org/10.1016/S0092-8674(00)81996-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945516	Bronze			2022-12-01	WOS:A1996VV77400015
J	Craig, AD; Reiman, EM; Evans, A; Bushnell, MC				Craig, AD; Reiman, EM; Evans, A; Bushnell, MC			Functional imaging of an illusion of pain	NATURE			English	Article							COLD; VIBRATION; PRIMATE; NEURONS; CORTEX; BLOCK; INPUT	TOUCHING warm and cool bars that are spatially interlaced produces a painful burning sensation resembling that caused by intense, noxious cold. We demonstrated previously that this thermal grill illusion can be explained as an unmasking phenomenon that reveals the central inhibition of pain by thermosensory integration(1). In order to localize this unmasking in the human brain, we have used positron emission tomography (PET) to compare the cortical activation patterns evoked by the thermal grill and by cool, warm, noxious cold and noxious heat stimuli. The thermal grill illusion produces activation in the anterior cingulate cortex, whereas its component warm and cool stimuli do not. This area is also activated bq noxious heat or cold. Thus, increased activity in the anterior cingulate cortex appears to be selectively associated with the perception of thermal pain. Disruption of thermosensory and pain integration may account for the central pain syndrome that can occur after stroke damage.	GOOD SAMARITAN REG MED CTR, POSITRON EMISS TOMOG CTR, PHOENIX, AZ 85006 USA; UNIV ARIZONA, DEPT PSYCHIAT, TUCSON, AZ 85721 USA; MCGILL UNIV, MONTREAL NEUROL INST, MCCONNELL BRAIN IMAGING CTR, POSITRON IMAGING LABS, MONTREAL, PQ H3A 2B4, CANADA; UNIV MONTREAL, CTR RECH SCI NEUROL, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, FAC MED DENT, DEPT STOMATOL, MONTREAL, PQ H3C 3J7, CANADA	University of Arizona; McGill University; Universite de Montreal; Universite de Montreal	Craig, AD (corresponding author), BARROW NEUROL INST, DIV NEUROBIOL, 350 W THOMAS RD, PHOENIX, AZ 85013 USA.							BINI G, 1984, PAIN, V18, P239, DOI 10.1016/0304-3959(84)90819-4; BOGOUSSLAVSKY J, 1988, NEUROLOGY, V38, P837, DOI 10.1212/WNL.38.6.837; BOIVIE J, 1989, PAIN, V37, P173, DOI 10.1016/0304-3959(89)90128-0; BOIVIE J, 1991, SYMP PAIN R, P65; Bushnell M. C., 1995, Society for Neuroscience Abstracts, V21, P1637; Casey KL, 1996, J NEUROPHYSIOL, V76, P571, DOI 10.1152/jn.1996.76.1.571; COGHILL RC, 1994, J NEUROSCI, V14, P4095; Craig A. D., 1995, Society for Neuroscience Abstracts, V21, P1165; Craig A. D, 1996, SOMESTHESIS NEUROBIO, P27; CRAIG AD, 1994, NATURE, V372, P770, DOI 10.1038/372770a0; CRAIG AD, 1994, SCIENCE, V265, P252, DOI 10.1126/science.8023144; CRAIG AD, 1991, EXP BRAIN RES, V85, P470; CRAIG AD, 1996, SOC NEUR ABSTR, V22, P11; EVANS AC, 1991, J CEREBR BLOOD F MET, V11, pA69, DOI 10.1038/jcbfm.1991.40; FRUHSTORFER H, 1984, PAIN, V20, P355, DOI 10.1016/0304-3959(84)90112-X; Head H, 1911, BRAIN, V34, P102, DOI 10.1093/brain/34.2-3.102; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; KENSHALO DR, 1982, PAIN, V12, P141, DOI 10.1016/0304-3959(82)90190-7; LAMOTTE RH, 1982, BRAIN RES, V244, P279, DOI 10.1016/0006-8993(82)90086-5; OCHOA JL, 1994, BRAIN, V117, P185, DOI 10.1093/brain/117.1.185; OSGOOD PF, 1990, BRAIN RES, V507, P11, DOI 10.1016/0006-8993(90)90514-C; RELMAN EM, 1996, NEW ENGL J MED, V334, P752; SCHMAHMANN JD, 1992, ARCH NEUROL-CHICAGO, V49, P1032, DOI 10.1001/archneur.1992.00530340048017; SIKES RW, 1992, J NEUROPHYSIOL, V68, P1720, DOI 10.1152/jn.1992.68.5.1720; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; VANHOESEN GW, 1996, NEUROBIOLOGY CINGULA, P249; WAHREN LK, 1989, PAIN, V38, P313, DOI 10.1016/0304-3959(89)90218-2; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; YARNITSKY D, 1990, BRAIN, V113, P893, DOI 10.1093/brain/113.4.893	30	409	421	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	1996	384	6606					258	260		10.1038/384258a0	http://dx.doi.org/10.1038/384258a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918874				2022-12-01	WOS:A1996VU38100049
J	Yamashita, YM; Nakaseko, Y; Samejima, I; Kumada, K; Yamada, H; Michaelson, D; Yanagida, M				Yamashita, YM; Nakaseko, Y; Samejima, I; Kumada, K; Yamada, H; Michaelson, D; Yanagida, M			20S cyclosome complex formation and proteolytic activity inhibited by the cAMP/PKA pathway	NATURE			English	Article							FISSION YEAST; GENE; UBIQUITIN; PROTEIN; MITOSIS; SPINDLE; ASPERGILLUS; REGULATOR; ANAPHASE; MUTATION	THE 20S cyclosome complex (also known as the anaphase-promoting complex) has ubiquitin ligase activity and is required for mitotic cyclin destruction(1-3) and sister chromatid separation(4,5). The formation and activation of the 20S cyclosome complex is regulated by an unknown mechanism. Here we show that Cut4 (ref. 6) is an essential component of the cyclosome in fission yeast. Cut4 shares sequence similarity with BimE, a protein that regulates mitosis in Aspergillus nidulans(7-9). Mutations in cut4 result In hypersensitivity to cyclic AMP and to stress-inducing heavy metals, inhibition of the onset of anaphase, disruption of the 20S complex, and inhibition of mitotic cyclin ubiquitination, These phenotypes are fully suppressed by cAMP phosphodiesterase and the protein kinase A (PKA) regulatory subunit and weakly suppressed by Sti1 (an activator of the Hsp70 and Hsp90 chaperones(10,11)), Suppression correlates with the amount of 20S complex, indicating that cyclosome formation and activation is inhibited by the cAMP/PKA pathway.	KYOTO UNIV,GRAD SCH SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University				Yamada, Hiroshi/0000-0002-0536-5581; Yamashita, Yukiko/0000-0001-5541-0216				CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; DEVOTI J, 1991, EMBO J, V10, P3759, DOI 10.1002/j.1460-2075.1991.tb04945.x; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; ISHII T, IN PRESS EMBO J; JAMES SW, 1995, J CELL SCI, V108, P3495; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; MACNEIL SA, 1993, CELL CYCLE PRACTICAL, P93; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MOCHIZUKI N, 1992, MOL GEN GENET, V233, P17, DOI 10.1007/BF00587556; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAMEJIMA I, 1994, J CELL BIOL, V127, P1665; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; STARBORG M, 1994, J BIOL CHEM, V269, P24133; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4	26	140	144	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					276	279		10.1038/384276a0	http://dx.doi.org/10.1038/384276a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918880				2022-12-01	WOS:A1996VU38100055
J	Orth, B; Frei, R; Itin, PH; Rinaldi, MG; Speck, B; Gratwohl, A; Widmer, AF				Orth, B; Frei, R; Itin, PH; Rinaldi, MG; Speck, B; Gratwohl, A; Widmer, AF			Outbreak of invasive mycoses caused by Paecilomyces lilacinus from a contaminated skin lotion	ANNALS OF INTERNAL MEDICINE			English	Article						Paecilomyces lilacinus; mycoses; immunocompromised host; opportunistic infections	BONE-MARROW TRANSPLANTATION; SOLID-ORGAN TRANSPLANTATION; SPECIES INFECTIONS; FUNGAL INFECTION; PATIENT; NEUTROPENIA; CELLULITIS; CANCER	Background: Invasive mycoses are an important cause of illness and death in immunocompromised patients. Infections with molds other than aspergilli have been increasingly seen in patients with hematologic cancers, but epidemics of these infections have not yet been reported. Objective: To describe an outbreak of invasive mycoses with Paecilomyces lilacinus in severely neutropenic patients. Design: An outbreak investigation. Setting: The hematology-oncology isolation and bone marrow transplantation unit of the University Hospital, Basel, Switzerland. Patients: 25 consecutive patients admitted between 17 August 1993 (the date of the first manifestation of P. lilacinus infection) and 31 October 1993 (when the unit was closed). Measurements: Clinical and microbiological data, including histologic findings; cultures from several patient sites; and environmental examinations of potential airborne, parenteral, enteric, and horizontal routes of transmission. Infections were defined by the isolation of P. lilacinus from clinically evident skin eruptions. Results: 12 of the 25 patients (48%) were infected or colonized. Nine patients (36%), including all bone marrow transplant recipients, had documented invasive P. lilacinus infections. All 9 infected patients had papular, pustular, or necrotic skin eruptions. Two patients with severe graft-versus-host disease died with refractory fungal disease; 1 also had microbiologically documented endophthalmitis and kidney infiltrates. Seven affected patients no longer had P. lilacinus after recovery of bone marrow function. The organism was resistant in vitro to amphotericin B, itraconazole, and fluconazole. Patients did not respond clinically to these agents. The outbreak was ultimately traced to a contaminated, commercially available, pharmaceutically prepared skin lotion. The outbreak ended after the skin lotion was recalled and has not recurred after a follow-up period of 2 years. Conclusion: Contaminated skin lotion is a potential cause of opportunistic fungal infections in immunocompromised hosts. Paecilomyces lilacinus is a common saprophytic mold that can cause, by direct cutaneous inoculation, invasive infections associated with illness and death.	UNIV BASEL HOSP, DIV CLIN EPIDEMIOL, CH-4031 BASEL, SWITZERLAND; UNIV BASEL HOSP, DEPT LAB MED, BACTERIOL LAB, CH-4031 BASEL, SWITZERLAND; UNIV BASEL HOSP, DEPT DERMATOL, CH-4031 BASEL, SWITZERLAND; UNIV BASEL HOSP, DIV HEMATOL, CH-4031 BASEL, SWITZERLAND; UNIV BASEL HOSP, DIV CLIN EPIDEMIOL, CH-4031 BASEL, SWITZERLAND; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78284 USA	University of Basel; University of Basel; University of Basel; University of Basel; University of Basel; University of Texas System; University of Texas Health San Antonio								ABDELHAFEZ AII, 1990, J BASIC MICROB, V30, P3; ANAISSIE E, 1992, CLIN INFECT DIS, V14, pS43, DOI 10.1093/clinids/14.Supplement_1.S43; BENEDICT LM, 1992, CLIN INFECT DIS, V15, P17, DOI 10.1093/clinids/15.1.17; Bernacer M., 1992, Medical Microbiology Letters, V1, P207; BODEY GP, 1993, CLIN INFECT DIS, V17, P705, DOI 10.1093/clinids/17.4.705; CASTRO LGM, 1990, J MED VET MYCOL, V28, P15; DOEBBELING BN, 1988, ANN INTERN MED, V109, P394, DOI 10.7326/0003-4819-109-5-394; ESPINELINGROFF A, 1995, ANTIMICROB AGENTS CH, V39, P314, DOI 10.1128/AAC.39.2.314; GORDON MA, 1984, SABOURAUDIA, V22, P109; JADE KB, 1986, ARCH DERMATOL, V122, P1169, DOI 10.1001/archderm.122.10.1169; Merz William G., 1995, P709; MORSE LJ, 1967, NEW ENGL J MED, V277, P472, DOI 10.1056/NEJM196708312770906; NELSON PE, 1994, CLIN MICROBIOL REV, V7, P479, DOI 10.1128/CMR.7.4.479-504.1994; OPAL SM, 1986, J INFECT DIS, V153, P634, DOI 10.1093/infdis/153.3.634; PANDEY A, 1990, MYCOSES, V33, P116, DOI 10.1111/myc.1990.33.3.116; PASSWEG J, 1994, SCHWEIZ MED WSCHR, V124, P62; PAYA CV, 1993, CLIN INFECT DIS, V16, P677, DOI 10.1093/clind/16.5.677; PETERSEN FB, 1992, BONE MARROW TRANSPL, V10, P83; PETTIT TH, 1980, ARCH OPHTHALMOL-CHIC, V98, P1025, DOI 10.1001/archopht.1980.01020031015002; PIZZO PA, 1993, NEW ENGL J MED, V328, P1323; RAPER KB, 1949, MANUAL PENICILLIA, P284; RILEY DK, 1994, AM J MED, V97, P509, DOI 10.1016/0002-9343(94)90345-X; SACHS MK, 1990, ARCH INTERN MED, V150, P1907, DOI 10.1001/archinte.150.9.1907; SHTAYEH MSA, 1996, MYCOPATHOLOGIA, V106, P95; SPECK B, 1992, TRANSPLANT P, V24, P88; SUPPARATPINYO K, 1992, CLIN INFECT DIS, V14, P871, DOI 10.1093/clinids/14.4.871; TAKAYASU S, 1977, ARCH DERMATOL, V113, P1687, DOI 10.1001/archderm.113.12.1687; TAN TQ, 1992, J CLIN MICROBIOL, V30, P2479, DOI 10.1128/JCM.30.9.2479-2483.1992; VARTIVARIAN SE, 1993, CLIN INFECT DIS, V17, pS487, DOI 10.1093/clinids/17.Supplement_2.S487; VOLNA F, 1990, Ceskoslovenska Epidemiologie Mikrobiologie Imunologie, V39, P315; WILLIAMSON PR, 1992, CLIN INFECT DIS, V14, P1023, DOI 10.1093/clinids/14.5.1023; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; ZIMMERLI W, 1991, BLOOD, V77, P393	33	83	90	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					799	+		10.7326/0003-4819-125-10-199611150-00003	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928986				2022-12-01	WOS:A1996VU52400006
